TAB-4996 157267605 Interleukin-27 Producing B-Cell Population and Uses Thereof NEI Collaboration, Ear, Nose, & Throat, Immunology, Licensing, Neurology, Therapeutics Collaboration Ear Nose & Throat Immunology Licensing Neurology Therapeutics Jin Choi, Charles Egwuagu <h2>Summary:&nbsp;</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host disease (GVHD), multiple sclerosis (MS) and transplant rejection.</p> <h2>Description of Technology:&nbsp;</h2> <p>Autoimmune diseases in which the immune system attacks the body&#39;s own tissues or organs include: graft-vs-host disease (GVHD), age-related macular degeneration (AMD), multiple sclerosis (MS), uveitis and encephalomyelitis. &nbsp;These diseases can result in blindness, paralysis, and significant morbidity impacting quality of life. &nbsp;In GVHD, the allogeneic transplant views the recipient&rsquo;s body as foreign, and the transplant attacks the body. &nbsp;Uveitis is comprised of a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology. &nbsp;Similarly, autoimmune processes contribute significantly to the progression of retinal degeneration associated with AMD. &nbsp;MS is caused in part by immune cells that attack and/or destroy neurons, thereby interfering with normal neurological function. Steroids and monoclonal antibodies are temporarily effective therapies; serious adverse effects preclude their prolonged use. Therefore, an unmet need remains for safe, effective long-term therapies for autoimmune disorders.</p> <p>The invention consists of an isolated population of mammal cells comprising about 75 % or higher B-1a regulatory cells and methods of preparation of such cell populations. i27-Bregs have distinct advantages over &nbsp;systemic administration of interleukin-27 (IL-27) since the latter is costly to synthesize and rapidly degrades in the body. i27-Bregs provide several therapeutic advantages over current standard of care: &nbsp;(i) self-renewal after administration and thereby sustained IL-27 production in host tissues; (ii) reprograms recipient lymphocytes into Bregs and Tregs (regulatory T cells) (iii) effective suppression of the host&rsquo;s overreactive immune system; (iv) no requirement of prior activation, providing a potential therapeutic advantage over other disease-specific cell therapies. Immune system suppression by i27-Bregs administration can also be used in conjunction with solid organ or allogenic cell transplants to reduce potentially fatal transplant rejection.&nbsp;</p> <p>This technology is available for development under a license for the above-mentioned disorders. Inventors at the National Eye Institute are interested in participating under a CRADA collaboration to further develop the technology toward clinical applications or will assist to transfer the technological know-how for licensing. &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Cell therapy for severe CNS autoimmune disease, GVHD, transplants, encephalomyelitis, or multiple sclerosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Can be co-administered with other currently approved therapies currently&nbsp;</li> <li>No FDA approved B cell therapy for the treatment of auto immune disease</li> <li>Self-renewing</li> <li>Excreted interleukins following administration provide a longer-lasting effect than currently approved monoclonal antibody therapies</li> <li>Potentially fewer side effects since IL-27 extended release avoids the systemic administration of monoclonal antibodies or immunosuppressive drugs</li> <li>Ex-vivo preparation can be further genetically modified to enhance efficacy</li> <li>Activation not required to inhibit autoimmunity</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations to advance the production and uses of IL-27 producing B-regulatory cells (i27-Bregs) for autoimmune disorders, including but not limited to, graft-versus-host disease (GVHD), age-related macular degeneration (AMD); and transplant rejection. 2024-07-23 2026-04-16 2026-06-05 2024-07-23 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-036-2012 157267704 Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464) https://pubmed.ncbi.nlm.nih.gov/34782464/ <a href="https://pubmed.ncbi.nlm.nih.gov/34782464/">Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464)</a> 157267612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157267616 Choi, Jin National Eye Institute (NEI) NEI Choi, Jin (NEI) 2 157267612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157267616 Choi, Jin National Eye Institute (NEI) NEI Choi, Jin (NEI) 2 157267608 A Novel IL-27-producing Innate B-1a Cell Population Regulates Neuroinflammation And Confers Protection against Severe CNS Autoimmune Diseases E-070-2019-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 157267711 E-070-2019-0 E-070-2019-0-US-01 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF PRV US 62/863,054 Abandoned US <br />Provisional (PRV) 62/863,054<br />Filed on 2019-06-18<br />Status: Abandoned 157267716 E-070-2019-0 E-070-2019-0-PCT-02 INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/038368 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/038368<br />Filed on 2020-06-18<br />Status: Expired 162862740 E-070-2019-0 E-070-2019-0-AU-03 INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF National Stage Australia 2020295470 2020295470 Issued Australia <br />National Stage 2020295470<br />Filed on 2020-06-18<br />Status: Issued 162862741 E-070-2019-0 E-070-2019-0-CA-04 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage Canada 3143998 Pending Canada <br />National Stage 3143998<br />Filed on 2020-06-18<br />Status: Pending 162862742 E-070-2019-0 E-070-2019-0-EP-05 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage European Patent 20736554.5 Pending European Patent <br />National Stage 20736554.5<br />Filed on 2020-06-18<br />Status: Pending 162862743 E-070-2019-0 E-070-2019-0-JP-06 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage Japan 7662543 2021-575486 Issued Japan <br />National Stage 2021-575486<br />Filed on 2021-12-17<br />Status: Issued 162862744 E-070-2019-0 E-070-2019-0-US-07 INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF National Stage US 17/620,248 Pending US <br />National Stage 17/620,248<br />Filed on 2021-12-17<br />Status: Pending 162862745 E-070-2019-0 E-070-2019-0-JP-08 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Japan 2025-061994 Pending Japan <br />Divisional (DIV) 2025-061994<br />Filed on 2025-04-03<br />Status: Pending 165287369 E-070-2019-0 E-070-2019-0-CA-10 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Canada In Preparation Canada <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 165287503 E-070-2019-0 E-070-2019-0-AU-09 INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF DIV Australia 2026200686 Pending Australia <br />Divisional (DIV) 2026200686<br />Filed on 2026-01-30<br />Status: Pending 167740801 E-070-2019-0 E-070-2019-0-JP-11 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Japan In Preparation Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation TAB-5103 167680344 Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells NIAID Application, Diagnostics, ResearchProducts, Therapeutics Application Diagnostics ResearchProducts Therapeutics Angela DeVico, Patricia Korty, Ethan Shevach <p>Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.</p> <p><br /> Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.</p> <p><br /> The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.</p> <p>&nbsp;</p> <ul> <li> Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos. </li> <li> Detection of both mouse and human Eos, enabling application to human research. </li> <li> Precise detection and measurement of Treg cells in diverse sample types. </li> </ul> <ul> <li> Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov. 2026-06-01 2026-06-03 2026-06-03 2026-06-03 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167681122 Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838) Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838) 167680373 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 167680411 DeVico, Angela NIAID - DIR NIAID DeVico, Angela (NIAID) 2 167680417 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 3 167680373 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 167680411 DeVico, Angela NIAID - DIR NIAID DeVico, Angela (NIAID) 2 167680417 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 3 167680347 Anti-mouse Ikzf4 (Eos) Monoclonal Antibody E-104-2025-0 Research Material National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.">yogikala.prabhu@nih.gov</a><br> TAB-5101 167599021 Human-Bovine Reassortant Rotavirus Vaccine NIAID TherapeuticArea, Vaccines TherapeuticArea Vaccines Robert Chanock (Estate), Yasutaka Hoshino, Albert Kapikian (Estate Of) <p>Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.</p> <p>Researchers at NIAID&rsquo;s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.</p> <p>These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.</p> <p>&nbsp;</p> <ul> <li> Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature. </li> <li> No low-grade, transient fever observed compared with prior candidates. </li> <li> Flexible reassortant design that may support addition of newly important rotavirus serotypes. </li> </ul> <ul> <li> Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov. 2026-05-27 2026-05-28 2026-05-28 2026-05-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167599438 Kapikian (Estate Of), Albert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kapikian (Estate Of), Albert (NIAID) 1 167599455 Chanock (Estate), Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chanock (Estate), Robert (NIAID) 2 167599463 Hoshino, Yasutaka National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hoshino, Yasutaka (NIAID) 3 167599438 Kapikian (Estate Of), Albert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kapikian (Estate Of), Albert (NIAID) 1 167599455 Chanock (Estate), Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chanock (Estate), Robert (NIAID) 2 167599463 Hoshino, Yasutaka National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hoshino, Yasutaka (NIAID) 3 167599024 Multivalent Human-Bovine Rotavirus Vaccine E-015-1998-0 Filing authorized NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.">elizabeth.pitts@nih.gov</a><br> 167599028 E-015-1998-0 E-015-1998-0-US-01 Multivalent Human-Bovine Rotavirus Vaccine PRV US 60/094,425 Abandoned US <br />Provisional (PRV) 60/094,425<br />Filed on 1998-07-28<br />Status: Abandoned 167599029 E-015-1998-0 E-015-1998-0-PCT-02 Multivalent Human-Bovine Rotavirus Vaccine PCT Patent Cooperation Treaty PCT/US1999/017036 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/017036<br />Filed on 1999-07-27<br />Status: Expired 167599030 E-015-1998-0 E-015-1998-0-US-10 Multivalent Human-Bovine Rotavirus Vaccine National Stage US 7,932,074 09/743,338 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932074">7,932,074</a><br />Filed on 2001-01-04<br />Status: Expired 167599031 E-015-1998-0 E-015-1998-0-AU-06 Multivalent Human-Bovine Rotavirus Vaccine National Stage Australia 759123 53221/99 Expired Australia <br />National Stage 53221/99<br />Filed on 1999-07-27<br />Status: Expired 167599032 E-015-1998-0 E-015-1998-0-BR-11 Multivalent Human-Bovine Rotavirus Vaccine National Stage Brazil PI9912485-8 PI9912485-8 Expired Brazil <br />National Stage PI9912485-8<br />Filed on 1999-07-27<br />Status: Expired 167599033 E-015-1998-0 E-015-1998-0-CA-07 Multivalent Human-Bovine Rotavirus Vaccine National Stage Canada 2336875 2336875 Expired Canada <br />National Stage 2336875<br />Filed on 1999-07-27<br />Status: Expired 167599034 E-015-1998-0 E-015-1998-0-CN-03 Multivalent Human-Bovine Rotavirus Vaccine National Stage China ZL99810311.X 99810311.X Expired China <br />National Stage 99810311.X<br />Filed on 1999-07-27<br />Status: Expired 167599035 E-015-1998-0 E-015-1998-0-EP-08 Multivalent Human-Bovine Rotavirus Vaccine National Stage European Patent 1100537 99938819.2 Expired European Patent <br />National Stage 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599036 E-015-1998-0 E-015-1998-0-IN-04 Multivalent Human-Bovine Rotavirus Vaccine National Stage India 243453 IN/PCT/2001/0106/CHE Expired India <br />National Stage IN/PCT/2001/0106/CHE<br />Filed on 1999-07-27<br />Status: Expired 167599037 E-015-1998-0 E-015-1998-0-JP-09 Multivalent Human-Bovine Rotavirus Vaccine National Stage Japan 4414095 2000-562050 Expired Japan <br />National Stage 2000-562050<br />Filed on 1999-07-27<br />Status: Expired 167599038 E-015-1998-0 E-015-1998-0-KR-05 Multivalent Human-Bovine Rotavirus Vaccine National Stage South Korea 10-0688434 10-2001-7001236 Expired South Korea <br />National Stage 10-2001-7001236<br />Filed on 1999-07-27<br />Status: Expired 167599040 E-015-1998-0 E-015-1998-0-DE-12 Multivalent Human-Bovine Rotavirus Vaccine EP Germany 69929443.6 99938819.2 Expired Germany <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599041 E-015-1998-0 E-015-1998-0-FR-13 Multivalent Human-Bovine Rotavirus Vaccine EP France 1100537 99938819.2 Expired France <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599042 E-015-1998-0 E-015-1998-0-GB-14 Multivalent Human-Bovine Rotavirus Vaccine EP United Kingdom 1100537 99938819.2 Expired United Kingdom <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599043 E-015-1998-0 E-015-1998-0-IE-15 Multivalent Human-Bovine Rotavirus Vaccine EP Ireland 1100537 99938819.2 Expired Ireland <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599044 E-015-1998-0 E-015-1998-0-IT-16 Multivalent Human-Bovine Rotavirus Vaccine EP Italy 1100537 99938819.2 Expired Italy <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599045 E-015-1998-0 E-015-1998-0-CN-17 Multivalent Human-Bovine Rotavirus Vaccine DIV China ZL200810090397.2 200810090397.2 Expired China <br />Divisional (DIV) 200810090397.2<br />Filed on 2008-04-11<br />Status: Expired 167599047 E-015-1998-0 E-015-1998-0-JP-19 Multivalent Human-Bovine Rotavirus Vaccine DIV Japan 2009-148918 Abandoned Japan <br />Divisional (DIV) 2009-148918<br />Filed on 2009-06-23<br />Status: Abandoned TAB-5100 167551551 Human antibodies with anti-lymphocyte specificities and lytic activity NIAID Antibodies, Application, TherapeuticArea Antibodies Application TherapeuticArea Ainhoa Perez-Diez, Irini Sereti <p>&nbsp; &nbsp; &nbsp; &nbsp;Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.</p> <p>&nbsp; &nbsp; &nbsp; &nbsp;By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.</p> <ul> <li>First fully human IgM antibody that binds to and kills B cells</li> <li>Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response</li> <li>B-cell death observed at concentrations as low as 0.01Nm</li> <li>Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates</li> </ul> <ul> <li>Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov. 2026-05-21 2026-05-21 2026-05-21 2026-05-21 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167551741 Perez-Diez, Ainhoa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Perez-Diez, Ainhoa (NIAID) 1 167551745 Sereti, Irini NIAID - DIR NIAID Sereti, Irini (NIAID) 2 167551741 Perez-Diez, Ainhoa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Perez-Diez, Ainhoa (NIAID) 1 167551745 Sereti, Irini NIAID - DIR NIAID Sereti, Irini (NIAID) 2 167551554 Human antibodies with anti-lymphocyte specificities and lytic activity linked to ICL. E-025-2025-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.">benjamin.hurley@nih.gov</a><br> 167551560 E-025-2025-0 E-025-2025-0-US-01 MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE PRV US 63/787,190 Expired US <br />Provisional (PRV) 63/787,190<br />Filed on 2025-04-11<br />Status: Expired 167551561 E-025-2025-0 E-025-2025-0-PC-01 MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2026/022767 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/022767<br />Filed on 2026-04-08<br />Status: Pending TAB-3924 147157204 Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Lakshmi Balagopalan, Katherine McIntire, Lawrence Samelson, Chang Yi <p>T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.</p> <p>Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.</p> <p>The <a href="https://ccr.cancer.gov/Laboratory-of-Cellular-and-Molecular-Biology" rel="nofollow">Laboratory of Cellular and Molecular Biology</a>, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.</p> <h2>Competitive Advantages:</h2> <ul><li>Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via: <ul><li>Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation</li> <li>Directly triggering the downstream signaling cascade could cause more potent activation of T cells </li> <li>LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion </li> <li>Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable </li> </ul></li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of hematological malignancies and solid tumors</li> <li>Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy</li> </ul> 2019-06-28 2025-04-22 2020-05-19 2026-05-19 2019-06-28 CAP, CAR, Chimeric Adaptor Protein, chimeric antigen receptor, Immunotherapy, LAT, Linker for Activation of T cells, Samelson, T cell False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-05-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-159-2009 147162087 Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps https://www.ncbi.nlm.nih.gov/pubmed/30655520 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30655520">Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps</a> 147162165 Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation https://www.ncbi.nlm.nih.gov/pubmed/29789604 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29789604">Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation</a> 167504673 Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728) https://pubmed.ncbi.nlm.nih.gov/39042728/ <a href="https://pubmed.ncbi.nlm.nih.gov/39042728/">Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)</a> 147162882 Yi, Chang NIH - NCI Yi, Chang 1 147162881 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147162883 McIntire, Katherine NIH - NCI NCI McIntire, Katherine (NCI) 3 147162880 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 4 147162882 Yi, Chang NIH - NCI Yi, Chang 1 147162881 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147162883 McIntire, Katherine NIH - NCI NCI McIntire, Katherine (NCI) 3 147162880 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 4 147158213 Recombinant Molecule Containing LAT For Use In T Cell Immunotherapy E-210-2018-0 Filing authorized NCI 147162560 Chimeric Adaptor Proteins (CAPs) For Improved T-Cell Immunotherapy E-210-2018-1 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147161195 E-210-2018-0 E-210-2018-0-PCT-02 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2020/022752 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/022752<br />Filed on 2020-03-13<br />Status: Expired 147165286 E-210-2018-0 E-210-2018-0-US-01 RECOMBINANT MOLECULES CONTAINING LINKER FOR ACTIVATION OF T CELLS AND THEIR USE IN IMMUNOTHERAPY PRV US 62/819,386 Abandoned US <br />Provisional (PRV) 62/819,386<br />Filed on 2019-03-15<br />Status: Abandoned 147165287 E-210-2018-0 E-210-2018-0-EP-03 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY National Stage European Patent 20718061.3 Pending European Patent <br />National Stage 20718061.3<br />Filed on 2020-03-13<br />Status: Pending 147165288 E-210-2018-0 E-210-2018-0-CN-04 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY National Stage China 202080021582.5 Pending China <br />National Stage 202080021582.5<br />Filed on 2020-03-13<br />Status: Pending 147165289 E-210-2018-0 E-210-2018-0-HK-05 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY EP Hong Kong 62022051308.4 Pending Hong Kong <br />European patent (EP) 62022051308.4<br />Filed on 2020-03-13<br />Status: Pending 147165291 E-210-2018-1 E-210-2018-1-US-01 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY CIP US 17/475,810 Pending US <br />Continuation in Part (CIP) 17/475,810<br />Filed on 2021-09-15<br />Status: Pending 147165292 E-210-2018-1 E-210-2018-1-PCT-02 Chimeric adaptor and kinase signaling proteins and their use in immunotherapy PCT Patent Cooperation Treaty PCT/US2022/076358 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/076358<br />Filed on 2022-09-13<br />Status: Expired 147173698 CAP 147173699 CAR 147173701 Chimeric Adaptor Protein 147173702 chimeric antigen receptor 147173703 Immunotherapy 147173704 LAT 147173706 Linker for Activation of T cells 147173708 Samelson 147173709 T cell TAB-4435 147157730 Levonorgestrel Butanoate Formulation and Methods Relating Thereto NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Diana Blithe, Ken Chen, Jia-Hwa Fang, Min Lee, Eduardo Ruiz <h2>Summary:</h2> <p>The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.</p> <h2>Description of Technology:</h2> <p>This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese &ndash; increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.&nbsp;</p> <p>Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.&nbsp;&nbsp;</p> <p>Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.&nbsp;&nbsp;</p> <p>NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Injectable contraceptive use by humans</li> <li>Use in the treatment of progestin-related diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Safer for women with high-risk conditions</li> <li>Self-subcutaneous and reversible injectable</li> <li>Long-lasting contraceptive effects</li> <li>Increased stability relative to previous formulations</li> <li>Amenable to large-scale manufacture relative to previous formulations</li> <li>Estrogen free contraceptive</li> <li>Progestin only self-injectable contraceptive</li> </ul> 2022-02-24 2026-04-30 2022-02-24 2026-05-18 2022-02-23 Blithe, CONTRACEPTIVE, INJECTABLE, LB, Lee, Levonorgestrel, Levonorgestrel Butanoate, LNG, National Institute of Child Health and Human Development, NICHD, Steroidal Progestin False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-24 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147164730 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147164729 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147164731 Fang, Jia-Hwa SRI International Fang, Jia-Hwa 3 147164732 Ruiz, Eduardo SRI International Ruiz, Eduardo 4 147164733 Chen, Ken SRI International Chen, Ken 5 147164730 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147164729 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147164731 Fang, Jia-Hwa SRI International Fang, Jia-Hwa 3 147164732 Ruiz, Eduardo SRI International Ruiz, Eduardo 4 147164733 Chen, Ken SRI International Chen, Ken 5 147158168 Levonorgestrel Prodrug Formulation And Methods Relating Thereto E-184-2021-0 Filing authorized NICHD, SRI International 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto&body=Please send me information about technology [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto&body=Please send me information about technology [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147161163 E-184-2021-0 E-184-2021-0-US-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PRV US 63/289,965 Expired US <br />Provisional (PRV) 63/289,965<br />Filed on 2021-12-15<br />Status: Expired 147168900 E-184-2021-0 E-184-2021-0-PCT-02 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PCT Patent Cooperation Treaty PCT/US2022/052704 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/052704<br />Filed on 2022-12-13<br />Status: Expired 167305206 E-184-2021-0 E-184-2021-0-IN-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage India 202417045561 Pending India <br />National Stage 202417045561<br />Filed on 2024-06-13<br />Status: Pending 147173251 Blithe 147173252 CONTRACEPTIVE 147173253 INJECTABLE 147173255 LB 147173256 Lee 147173257 Levonorgestrel 147173259 Levonorgestrel Butanoate 147173261 LNG 147173262 National Institute of Child Health and Human Development 147173263 NICHD 147173265 Steroidal Progestin TAB-5094 166511676 Novel malaria vaccine candidates comprising engineered nanoparticles NIAID Collaboration Sought, ResearchProducts, TherapeuticArea, Vaccines Collaboration Sought ResearchProducts TherapeuticArea Vaccines Thayne Dickey, Vu Nguyen, Dashuang Shi, Niraj Tolia <p>Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5&rsquo;-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.</li> </ul> <ul> <li>Malaria vaccinology</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov. 2026-03-19 2026-05-14 2026-05-14 2026-03-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 166527395 Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y) https://pubmed.ncbi.nlm.nih.gov/41420060/ <a href="https://pubmed.ncbi.nlm.nih.gov/41420060/">Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)</a> 166511805 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) Tolia, Niraj 1 166511821 Shi, Dashuang NIAID Shi, Dashuang (NIAID) 2 166511842 Nguyen, Vu National Institute of Allergy and Infectious Diseases (NIAID/NIH) Nguyen, Vu 3 166512001 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 4 166511805 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) Tolia, Niraj 1 166511821 Shi, Dashuang NIAID Shi, Dashuang (NIAID) 2 166511842 Nguyen, Vu National Institute of Allergy and Infectious Diseases (NIAID/NIH) Nguyen, Vu 3 166512001 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 4 166511679 Novel malaria vaccine candidates comprising engineered nanoparticles E-182-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIH - NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.">benjamin.hurley@nih.gov</a><br> 166511684 E-182-2024-0 E-182-2024-0-US-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PRV US 63/695,288 Expired US <br />Provisional (PRV) 63/695,288<br />Filed on 2024-09-16<br />Status: Expired 166511685 E-182-2024-0 E-182-2024-0-PC-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2025/046419 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/046419<br />Filed on 2025-09-15<br />Status: Pending TAB-5049 162271101 A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions NIAID Application, Collaboration, Collaboration Sought, Immunology, Infectious Disease, Licensing, Materials Available, Research Materials, Sequences, Therapeutics, Vaccines Application Collaboration Collaboration Sought Immunology Infectious Disease Licensing Materials Available Research Materials Sequences Therapeutics Vaccines Patrick Duffy, Jonathan Renn <p>The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.</p> <p>The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:</p> <ul> <li>The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.</li> <li>The artificial immunogens retained structured transmission blocking epitopes.</li> </ul> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.</li> <li>Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.</li> </ul> <ul> <li>This technology could be used alone or in combination with existing malaria vaccines. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023. 2025-05-08 2026-05-14 2026-05-14 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162271181 Duffy, Patrick NIAID - DIR NIAID Duffy, Patrick (NIAID) 1 162271185 Renn, Jonathan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Renn, Jonathan (NIAID) 2 162271181 Duffy, Patrick NIAID - DIR NIAID Duffy, Patrick (NIAID) 1 162271185 Renn, Jonathan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Renn, Jonathan (NIAID) 2 162271104 A Novel Strategy To Produce 6-cys Proteins Based On Pfs230D1 Domain Fusions E-086-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.">benjamin.hurley@nih.gov</a><br> 162271153 E-086-2023-0 E-086-2023-0-US-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE PRV US 63/617,717 Expired US <br />Provisional (PRV) 63/617,717<br />Filed on 2024-01-04<br />Status: Expired 162271154 E-086-2023-0 E-086-2023-0-PC-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE PCT Patent Cooperation Treaty PCT/US2025/010325 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/010325<br />Filed on 2025-01-03<br />Status: Pending 166735919 E-086-2023-0 E-086-2023-0-IN-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage India In Preparation India <br />National Stage None<br />Filed on None<br />Status: In Preparation 166735995 E-086-2023-0 E-086-2023-0-US-02 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 166736025 E-086-2023-0 E-086-2023-0-EP-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-4981 155111852 Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization NIAID Infectious Disease, Vaccines Infectious Disease Vaccines Palak Patel, Niraj Tolia <p>This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology&rsquo;s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.</p> <ul> <li>No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates</li> </ul> <ul> <li>Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-09 2026-05-14 2026-05-14 2024-11-12 Design, FALCIPARUM, Malaria, PLASMODIUM, Structure-based False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 155122907 Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023 Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023 155122699 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155122722 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 2 155122699 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155122722 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 2 155111855 Novel malaria vaccine candidates comprising a stabilized designs of AMA1 and RON2 antigens E-096-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.">benjamin.hurley@nih.gov</a><br> 155111948 E-096-2023-0 E-096-2023-0-US-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PRV US 63/524,522 Expired US <br />Provisional (PRV) 63/524,522<br />Filed on 2023-06-30<br />Status: Expired 156351084 E-096-2023-0 E-096-2023-0-PC-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PCT Patent Cooperation Treaty PCT/US2024/035244 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/035244<br />Filed on 2024-06-24<br />Status: Expired 155154090 Malaria 155154109 PLASMODIUM 155154113 FALCIPARUM 155154263 Structure-based 155154272 Design TAB-4980 155110980 Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Thayne Dickey, Carole Long, Kazutoyo Miura, Palak Patel, Niraj Tolia <p>This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite&#39;s immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.</p> <ul> <li>This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.</li> </ul> <ul> <li>This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-09 2026-05-14 2026-05-14 2024-11-12 antibodies, ANTIGENS, Enhanced, Immunotherapy, Malaria, monoclonal, MSP1 False False Pre-clinical True 37470483 Website Abstract 155111531 Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3 Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3 155111249 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155111332 Dickey, Thayne NIH - NIAID NIAID Dickey, Thayne (NIAID) 2 155111348 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 3 155111357 Miura, Kazutoyo NIH - NIAID NIAID Miura, Kazutoyo (NIAID) 4 155111372 Long, Carole NIH - NIAID NIAID Long, Carole (NIAID) 5 155111249 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155111332 Dickey, Thayne NIH - NIAID NIAID Dickey, Thayne (NIAID) 2 155111348 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 3 155111357 Miura, Kazutoyo NIH - NIAID NIAID Miura, Kazutoyo (NIAID) 4 155111372 Long, Carole NIH - NIAID NIAID Long, Carole (NIAID) 5 155110983 Novel Compositions Of Matter Comprising Stabilized MSP1 Malaria Antigens And High Affinity Anti-MSP1 Human Monoclonal Antibodies And Their Use E-154-2022-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.">benjamin.hurley@nih.gov</a><br> 155111222 E-154-2022-0 E-154-2022-0-US-01 METHOD OF IMMUNOFOCUSING AN IMMUNE RESPONSE PRV US 63/369,909 Expired US <br />Provisional (PRV) 63/369,909<br />Filed on 2022-07-29<br />Status: Expired 155111223 E-154-2022-0 E-154-2022-0-PC-01 METHOD OF IMMMUNOFOCUSING AN IMMUNE RESPONSE PCT Patent Cooperation Treaty PCT/US2023/070926 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/070926<br />Filed on 2023-07-25<br />Status: Expired 155111074 antibodies 155111081 ANTIGENS 155111085 MSP1 155111092 Malaria 155111112 monoclonal 155111140 Immunotherapy 155111176 Enhanced TAB-4978 155044855 Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology NIAID Antibodies, Collaboration, Infectious Disease, Vaccines Antibodies Collaboration Infectious Disease Vaccines Thayne Dickey, Niraj Tolia <p>The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.</p> <ul> <li> The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.</li> </ul> <ul> <li> This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-04 2026-05-14 2026-05-14 2024-11-12 Malaria Vaccine, Pfs48/45, proteins, Stabilized False False Preclinical Research True 37470483 Website Abstract 155046595 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tolia, Niraj (NIAID) 1 155046603 Dickey, Thayne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dickey, Thayne (NIAID) 2 155046595 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tolia, Niraj (NIAID) 1 155046603 Dickey, Thayne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dickey, Thayne (NIAID) 2 155044858 Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use E-030-2023-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.">benjamin.hurley@nih.gov</a><br> 155050145 E-030-2023-0 E-030-2023-0-US-01 Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use PRV US 63/476,897 Expired US <br />Provisional (PRV) 63/476,897<br />Filed on 2022-12-22<br />Status: Expired 155050149 E-030-2023-0 E-030-2023-0-PC-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2023/085849 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/085849<br />Filed on 2023-12-22<br />Status: Expired 161727281 E-030-2023-0 E-030-2023-0-IN-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage India 202517060138 Pending India <br />National Stage 202517060138<br />Filed on 2025-06-24<br />Status: Pending 161727321 E-030-2023-0 E-030-2023-0-US-02 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage US 19/142,034 Pending US <br />National Stage 19/142,034<br />Filed on 2025-06-20<br />Status: Pending 161727556 E-030-2023-0 E-030-2023-0-EP-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage European Patent 23848442.2 Pending European Patent <br />National Stage 23848442.2<br />Filed on 2025-07-04<br />Status: Pending 155049175 Pfs48/45 155049189 proteins 155049198 Stabilized 155049276 Malaria Vaccine TAB-3522 114097382 Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use NIAID Collaboration Collaboration Thayne Dickey, Niraj Tolia Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.</li> <li>Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.</li> <li>Computational method of designing vaccine antigens.</li> </ul> <ul> <li>Novel SARS-CoV-2 vaccine.</li> <li>Improved SARS-CoV-2 diagnostics using stabilized antigens.</li> <li>Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; <a href="mailto:peter.tung@nih.gov.">peter.tung@nih.gov</a>. 2022-03-30 2026-05-14 2026-05-14 2022-03-30 ANTIGENS, Compositions, COMPRISING, CORONAVIRUS, Matter, Novel, Stabilized, Their False True True NIHTT 37470483 Website Abstract 114172677 Dickey TH, et al. https://pubmed.ncbi.nlm.nih.gov/34013270/ <a href="https://pubmed.ncbi.nlm.nih.gov/34013270/">Dickey TH, et al.</a> 114110541 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 0 114110542 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110542 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110541 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 0 114102633 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use E-045-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.">benjamin.hurley@nih.gov</a><br> 114169303 E-045-2021-0 E-045-2021-0-PCT-02 COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2022/070744 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/070744<br />Filed on 2022-02-18<br />Status: Expired 114169304 E-045-2021-0 E-045-2021-0-US-01 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use PRV US 63/200,194 Abandoned US <br />Provisional (PRV) 63/200,194<br />Filed on 2021-02-19<br />Status: Abandoned 114152824 Their 114152825 ANTIGENS 114152826 CORONAVIRUS 114152827 Stabilized 114152828 COMPRISING 114152829 Matter 114152830 Compositions 114152831 Novel TAB-3459 114097328 Novel VAR2CSA Immunogens and Methods of Use Thereof NIAID Collaboration Collaboration Rui Ma, Niraj Tolia The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease. <ul><li>Strain-transcending immunogens for vaccination</li> <li>Improved immunogen production through expression of key protein regions</li></ul> The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents. <br /><br /> <ul><li>Placental malaria vaccine</li> <li>CSA-binding proteins for cancer therapeutics</li></ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; <a hef="mailto:Peter.Tung@nih.gov">Peter Tung@nih.gov</a>. 2022-04-01 2026-05-14 2026-05-14 2022-01-13 Against, CANCER, COMPOSITION, COMPRISING, Diagnostics, IMMUNOGENS, Malaria, Matter, Placental, PROTECT, proteins, That, therapeutics, Used False True True NIHTT 37470483 Website Abstract 114110245 Ma, Rui NIAID - VRC NIAID Ma, Rui (NIAID) 0 114110246 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110246 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110245 Ma, Rui NIAID - VRC NIAID Ma, Rui (NIAID) 0 114102572 New Composition Of Matter Comprising Immunogens That Will Protect Against Placental Malaria, And Proteins That Can Be Used For Cancer Diagnostics And Therapeutics E-021-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.">benjamin.hurley@nih.gov</a><br> 114169183 E-021-2021-0 E-021-2021-0-US-01 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PRV US 63/115,729 Abandoned US <br />Provisional (PRV) 63/115,729<br />Filed on 2020-11-19<br />Status: Abandoned 114169184 E-021-2021-0 E-021-2021-0-PCT-02 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2021/059941 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059941<br />Filed on 2021-11-18<br />Status: Expired 114152318 COMPOSITION 114152319 Matter 114152320 COMPRISING 114152321 IMMUNOGENS 114152322 That 114152323 PROTECT 114152324 Against 114152325 Placental 114152326 Malaria 114152327 proteins 114152328 Used 114152329 CANCER 114152330 Diagnostics 114152331 therapeutics TAB-5099 167270778 Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Sanghyun (Peter) Kim, Steven Rosenberg <div> <div> <div class="msocomtxt" id="_com_2"> <h2>Summary:&nbsp;</h2> <p>Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.</p> <p>This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation&ndash;serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.</p> <p>The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Solid tumors expressing p53 or KRAS mutations</li> <li>Hematologic malignancies</li> <li>Melanoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Versatile platform for inducible cytokine regulation</li> <li>Superior survival in mouse models compared with TCR-only T-cells</li> <li>Enhanced tumor cell killing and long-term survival in murine models</li> <li>Decreased IL-12&ndash;associated toxicity</li> <li>Maintenance of higher IL-12 expression&nbsp;</li> <li>Improved sensitivity to lenalidomide-mediated degradation</li> </ul> </div> </div> </div> Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs). 2026-05-14 2026-05-14 2026-05-14 2026-05-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 167271215 Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344 Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344 167270829 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 167270833 Kim, Sanghyun (Peter) NCI - CCR NCI Kim, Sanghyun (Peter) (NCI) 2 167270829 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 167270833 Kim, Sanghyun (Peter) NCI - CCR NCI Kim, Sanghyun (Peter) (NCI) 2 167270784 Drug-regulatable, inducible expression of membrane-bound interleukin 12 for use in adoptive cell therapy. E-217-2023-0 Filing authorized National Cancer Institute (NCI), Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 167270791 E-217-2023-0 E-217-2023-0-US-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PRV US 63/652,871 Expired US <br />Provisional (PRV) 63/652,871<br />Filed on 2024-05-29<br />Status: Expired 167270792 E-217-2023-0 E-217-2023-0-PC-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PCT Patent Cooperation Treaty PCT/US2025/031121 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/031121<br />Filed on 2025-05-28<br />Status: Pending TAB-3391 114097279 Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Kevin Ashley, Mark Boeniger, Eric Esswein Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less). <br /><br /> Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin. <br/<br /> This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead. <br /><br /> <ul> <li>Safe for use on skin</li> <li>Quick and easy to use</li> <li>Portable and convenient to use wherever lead is present</li> <li>Effectively removes Pb ions from the skin to less than the limit of identification</li> <li>Can be used to complement other lead detection methods</li> <li>Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above</li> </ul> <ul> <li>Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day</li> <li>Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms</li> <li>Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint</li> <li>Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk</li> <li>Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))<li> <li>May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof </li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2020-02-13 CDC Docket Import, CDC Docket Import CDC Prosecuting, contamination, Listed LPM Surabian as of 4/15/2015, MECHANICAL, METAL, Methods, NIOSH-DSHEFS, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REMOVAL, SURFACES, VEXXXX, VPXXXX, WGXXXX, WIPES, WMXXXX, XIXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-336-2013-0 114172557 Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9) https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Off <a href="https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Off ">Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)</a> 114172558 Esswein EJ, et al. http://dx.doi.org/10.1520/JAI103527 <a href="http://dx.doi.org/10.1520/JAI103527 ">Esswein EJ, et al.</a> 114172559 NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm <a href="https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm">NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way</a> 114172560 NIOSH. (2018). Workplace Safety and Health Topics https://www.cdc.gov/niosh/topics/lead/default.html <a href="https://www.cdc.gov/niosh/topics/lead/default.html">NIOSH. (2018). Workplace Safety and Health Topics</a> 114110055 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110056 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114110054 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110054 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110055 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110056 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114102523 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES E-221-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.">yogikala.prabhu@nih.gov</a><br> 114168962 E-221-2013-0 E-221-2013-0-US-01 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES ORD US 7,604,997 11/039,178 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7604997 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7604997">7,604,997</a><br />Filed on 2005-01-18<br />Status: Issued 114168963 E-221-2013-0 E-221-2013-0-PCT-02 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES PCT Patent Cooperation Treaty PCT/US2006/001515 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US2006/001515<br />Filed on 2006-01-17<br />Status: Abandoned 114128288 YFXXXX 114128289 VEXXXX 114128290 VPXXXX 114128291 WGXXXX 114128292 WMXXXX 114128293 XIXXXX 114151725 WIPES 114151726 Methods 114151727 REMOVAL 114151728 METAL 114151729 contamination 114151730 SURFACES 114151731 CDC Docket Import 114151732 CDC Docket Import CDC Prosecuting 114151733 NIOSH-DSHEFS 114151734 Listed LPM Surabian as of 4/15/2015 114151735 Pre LPM working set 20150418 114151736 Post LPM Assignment Set 20150420 114151737 MECHANICAL TAB-3392 114097280 Handwipe Disclosing Method for Detecting the Presence of Lead CDC Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Collaboration Dental Endocrinology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Research Materials Kevin Ashley, Mark Boeniger, Eric Esswein Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination. <br /><br /> US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used). <br /><br /> This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead. <br /><br /> <ul> <li>Safe for use on skin</li> <li>Quick and easy to use</li> -<li>Portable and can be used during field evaluations</li> <li>Can be used wherever lead is present</li> <li>Simple color change readout indicates the presence of lead on a surface</li> <li>Lead concentration can be inferred by degree of color shift</li> <li>Can be used to guide and evaluate lead removal methods</li> </ul> <ul> <li>Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead</li> <li>Informing employers and workers on potential lead contamination and exposure</li> <li> Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods</li> <li>Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools <li>Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel</li> <li>Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2020-02-13 CDC Docket Import, CDC Docket Import CDC Prosecuting, Contaminant, Contaminated, contamination, DEFENSE, Detection, detection system, DEVICE, DISCLOSING, firearm, firearm safety, firearms, HANDWIPE, LEAD, lead test, Listed LPM Surabian as of 4/15/2015, MECHANICAL, Method, military, NIOSH, NIOSH-DSHEFS, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRESENCE, SAFETY, VEXXXX, VPXXXX, WCXXXX, WGXXXX, WHXXXX, WIPE, WIPES, WORKER, WORKER safety, YDXXXX, YEXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-221-2013-0 114172561 Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28. https://www.sciencedirect.com/science/article/pii/S1871553209000796 <a href="https://www.sciencedirect.com/science/article/pii/S1871553209000796">Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.</a> 114172562 Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4). https://www.astm.org/DIGITAL_LIBRARY/JOURNALS/JAI/PAGES/JAI103390.htm <a href="https://www.astm.org/DIGITAL_LIBRARY/JOURNALS/JAI/PAGES/JAI103390.htm ">Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).</a> 114172563 Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9). https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Of <a href="https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Of">Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).</a> 114172564 Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5). https://www.researchgate.net/publication/239522749_Handwipe_method_for_removing_lead_from_skin <a href="https://www.researchgate.net/publication/239522749_Handwipe_method_for_removing_lead_from_skin">Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).</a> 114172565 NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way! https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm <a href="https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm">NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!</a> 114172566 NIOSH. (2018). Workplace Safety and Health Topics: Lead. https://www.cdc.gov/niosh/topics/lead/default.html <a href="https://www.cdc.gov/niosh/topics/lead/default.html">NIOSH. (2018). Workplace Safety and Health Topics: Lead.</a> 114172567 NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH. https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf <a href="https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf">NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.</a> 114110058 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110059 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114110057 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110057 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110058 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110059 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114102524 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD E-336-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead . Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .">yogikala.prabhu@nih.gov</a><br> 114168964 E-336-2013-0 E-336-2013-0-US-01 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD PRV US 60/049,352 Abandoned US <br />Provisional (PRV) 60/049,352<br />Filed on 1997-06-11<br />Status: Abandoned 114168965 E-336-2013-0 E-336-2013-0-PCT-02 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD PCT Patent Cooperation Treaty PCT/US1998/011776 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/011776<br />Filed on 1998-06-08<br />Status: Expired 114168966 E-336-2013-0 E-336-2013-0-US-06 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD National Stage US 6,248,593 09/458,152 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6248593 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6248593">6,248,593</a><br />Filed on 1999-12-09<br />Status: Expired 114128308 YEXXXX 114128309 YFXXXX 114128310 VEXXXX 114128311 YDXXXX 114128312 VPXXXX 114128313 WCXXXX 114128314 WGXXXX 114128315 WHXXXX 114151738 HANDWIPE 114151739 DISCLOSING 114151740 Method 114151741 PRESENCE 114151742 LEAD 114151743 CDC Docket Import 114151744 CDC Docket Import CDC Prosecuting 114151745 NIOSH-DSHEFS 114151746 NIOSH 114151747 WIPE 114151748 WIPES 114151749 SAFETY 114151750 lead test 114151751 Detection 114151752 detection system 114151753 Contaminant 114151754 Contaminated 114151755 contamination 114151756 OSHA 114151757 WORKER 114151758 WORKER safety 114151759 Occupational health 114151760 firearm 114151761 firearms 114151762 firearm safety 114151763 DEFENSE 114151764 military 114151765 DEVICE 114151766 Listed LPM Surabian as of 4/15/2015 114151767 Pre LPM working set 20150418 114151768 Post LPM Assignment Set 20150420 114151769 MECHANICAL TAB-4924 153511466 Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring CDC Diagnostics, Licensing, Occupational Safety and Health Diagnostics Licensing Occupational Safety and Health Pramod Kulkarni, Orthodoxia Zervaki <p>&shy;Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred. </p> <p><br /> CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications. </p> <ul> <li>Near real-time and continuous automatic measurement of aerosol and bioaerosol</li> <li> Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity</li> <li> High sample throughput collection </li> <li>- Allows space-saving and miniature designs for easy integration into portable instruments</li> <li> Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results</li> </ul> <ul> <li> Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures</li> <li> Air pollution studies and particulate matter monitoring</li> <li> Environmental and occupational personal exposure monitoring</li> <li> Evaluation of engineering controls</li> <li> Occupational safety and health</li> <li>Monitoring/public health surveillance</li> </ul> The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330. 2024-03-04 2026-05-14 2026-05-14 2024-03-06 Biodefense, ENVIRONMENTAL, MINING, MONITORING, Occupational health, QUALITY CONTROL, RESEARCH TOOL False False Early-stage In situ data available True 52406769 Prototype 52406769 37470483 Website Abstract E-291-2016-0 E-205-2013-0 E-163-2013-0 E-026-2014-0 E-146-2013-0 153512476 Zheng, L. et al. (DOI 10.1080/02786826.2016.1224804) Zheng, L. et al. (DOI 10.1080/02786826.2016.1224804) 153512484 Zheng, L. et al. (DOI 10.1016/j.jaerosci.2016.11.007) Zheng, L. et al. (DOI 10.1016/j.jaerosci.2016.11.007) 153512732 Zheng, L. et al. (DOI 10.1021/acs.analchem.9b02178) Zheng, L. et al. (DOI 10.1021/acs.analchem.9b02178) 153512740 Zervaki, O., et al. (DOI 10.1016/j.jaerosci.2023.106235) Zervaki, O., et al. (DOI 10.1016/j.jaerosci.2023.106235) 153511651 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 153511674 Zervaki, Orthodoxia CDC - NIOSH CDC Zervaki, Orthodoxia (CDC) 2 153511651 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 153511674 Zervaki, Orthodoxia CDC - NIOSH CDC Zervaki, Orthodoxia (CDC) 2 153511469 Methods For High Sample Throughput Collection And Trace Chemical Analysis Of Aerosols Using Laser And Optical Spectroscopies E-173-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.">yogikala.prabhu@nih.gov</a><br> 155749516 E-173-2021-0 E-173-2021-0-JP-01 METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES National Stage Japan 2024-544936 Pending Japan <br />National Stage 2024-544936<br />Filed on 2024-07-29<br />Status: Pending 155749555 E-173-2021-0 E-173-2021-0-US-02 METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES National Stage US 18/832,139 Pending US <br />National Stage 18/832,139<br />Filed on 2024-07-23<br />Status: Pending 153542682 Biodefense 153542729 ENVIRONMENTAL 153542755 MINING 153542805 MONITORING 153542866 Occupational health 153542900 QUALITY CONTROL 153542943 RESEARCH TOOL TAB-3151 114097101 Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Shirley Robertson, Deborah Sammons, Jerome Smith Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology. <ul> <li>Near real-time results</li> <li>Can be used in various locations, on surfaces, and on protective equipment</li> <li>Simple to use</li> <li>Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers</li> </ul> <ul> <li>Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies</li> <li>Kits can be used to assess decontamination procedures</li> <li>Kits can be used to assess protective equipment and closed system drug-transfer devices</li> <li>Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces</li> </ul> The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at <a href="mailto:keg2@cdc.gov">keg2@cdc.gov</a> or 1-513-533-8686. Foreign counterpart patent applications in Europe and Japan. 2022-03-27 2026-05-14 2026-05-14 2017-08-24 AE1BXX, AE2XXX, AE3XXX, Anti-neoplastic, CANCER, CANCER CHEMOTHERAPY, CANCEROUS, CB5XXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDXXXX, Contaminant, Contaminants, Contaminated, contamination, CXXXXX, Detection, detection system, Direct, DRUGS, Kits, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DART, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reading, SAFE, SAFETY, Surface, TOXIC, Toxicity, TOXIGENIC, TOXINS, VCXXXX, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, XHXXXX, XIXXXX, YBXXXX, YEXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171896 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25293722 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25293722">Smith JP</a> 114172342 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25379615 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25379615">Smith JP</a> 114172343 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25956418 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25956418">Smith JP</a> 114109302 Sammons, Deborah CDC Sammons, Deborah (CDC) 0 114109304 Robertson, Shirley CDC Robertson, Shirley (CDC) 0 114109303 Smith, Jerome CDC - NIOSH CDC Smith, Jerome (CDC) 1 114109303 Smith, Jerome CDC - NIOSH CDC Smith, Jerome (CDC) 1 114109302 Sammons, Deborah CDC Sammons, Deborah (CDC) 0 114109304 Robertson, Shirley CDC Robertson, Shirley (CDC) 0 114102303 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs E-162-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.">yogikala.prabhu@nih.gov</a><br> 114168338 E-162-2013-0 E-162-2013-0-US-01 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs PRV US 61/672,059 Abandoned US <br />Provisional (PRV) 61/672,059<br />Filed on 2012-07-16<br />Status: Abandoned 114168339 E-162-2013-0 E-162-2013-0-PCT-02 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs PCT Patent Cooperation Treaty PCT/US2013/050688 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/050688<br />Filed on 2013-07-16<br />Status: Expired 114168340 E-162-2013-0 E-162-2013-0-US-03 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs ORD US 10,782,308 13/943,430 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10782308 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10782308">10,782,308</a><br />Filed on 2013-07-16<br />Status: Issued 114127316 AE3XXX 114127317 CDXXXX 114127318 CXXXXX 114127319 AE1BXX 114127320 AE2XXX 114127321 CB5XXX 114127322 VCXXXX 114127323 VPXXXX 114127324 WCXXXX 114127325 WFXXXX 114127326 WGXXXX 114127327 WIXXXX 114127328 WMXXXX 114127329 XIXXXX 114127330 XHXXXX 114127331 YEXXXX 114127332 YBXXXX 114149251 Direct 114149252 Surface 114149253 Detection 114149254 Reading 114149255 Kits 114149256 contamination 114149257 Anti-neoplastic 114149258 DRUGS 114149259 CDC Docket Import 114149260 CDC Docket Import CDC Prosecuting 114149261 NIOSH-DART 114149262 CANCER 114149263 CANCER CHEMOTHERAPY 114149264 CANCEROUS 114149265 NIOSH 114149266 Contaminants 114149267 Contaminated 114149268 Contaminant 114149269 detection system 114149270 OSHA 114149271 TOXIC 114149272 Toxicity 114149273 TOXINS 114149274 TOXIGENIC 114149275 SAFETY 114149276 SAFE 114149277 Occupational health 114149278 WORKER 114149279 WORKER safety 114149280 Listed LPM Surabian as of 4/15/2015 114149281 Pre LPM working set 20150418 114149282 Post LPM Assignment Set 20150420 TAB-3250 114097184 Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Pramod Kulkarni, Lina Zheng Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement. <ul> <li>Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings</li> <li>Enables elemental analysis of aerosols in near real-time</li> <li>Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources</li> </ul> <ul> <li>Air pollution studies and particulate matter monitoring</li> <li>Environmental and occupational personal exposure monitoring</li> <li> Evaluation of engineering controls</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a>. 2022-03-27 2026-05-14 2026-05-14 2018-02-13 AEROSOLS, analysis, Atmospheric, DART, Discharge, Elemental, Emission, Glow, NIOSH-DART, SPECTROSCOPY, VBXXXX, VPXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, XGXXXX, XIXXXX, YAXXXX, YFXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-205-2013-0 E-163-2013-0 114172457 Zheng L, et al. https://www.ncbi.nlm.nih.gov/pubmed/28513144 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28513144">Zheng L, et al.</a> 114109633 Zheng, Lina CDC - NIOSH CDC Zheng, Lina (CDC) 0 114109632 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114109632 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114109633 Zheng, Lina CDC - NIOSH CDC Zheng, Lina (CDC) 0 114102410 Elemental Analysis Of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy E-291-2016-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.">yogikala.prabhu@nih.gov</a><br> 114168555 E-291-2016-0 E-291-2016-0-US-01 Elemental Analysis of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy PRV US 62/484,300 Abandoned US <br />Provisional (PRV) 62/484,300<br />Filed on 2017-04-11<br />Status: Abandoned 114168599 E-291-2016-0 E-291-2016-0-PCT-02 SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY PCT Patent Cooperation Treaty PCT/US2018/027105 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/027105<br />Filed on 2018-04-11<br />Status: Expired 114168923 E-291-2016-0 E-291-2016-0-US-05 SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY National Stage US 16/500,925 Abandoned US <br />National Stage 16/500,925<br />Filed on 2019-10-04<br />Status: Abandoned 114127769 YAXXXX 114127770 YFXXXX 114127771 VBXXXX 114127772 VPXXXX 114127773 WAXXXX 114127774 WCXXXX 114127775 WEXXXX 114127776 WFXXXX 114127777 WGXXXX 114127778 XGXXXX 114127779 XIXXXX 114150447 Elemental 114150448 analysis 114150449 AEROSOLS 114150450 Atmospheric 114150451 Glow 114150452 Discharge 114150453 Emission 114150454 SPECTROSCOPY 114150455 DART 114150456 NIOSH-DART TAB-3272 114097205 Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Materials Available, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Materials Available Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Gerry Boss, Nicole Fry, Lee Greenawald, Michael Sailor A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.<br /><br /> The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm. <ul> <li>Technology senses and removes particles</li> <li>Ability to monitor several ligands (molecules that bind with others) at once<li> <li>An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters</li> <li>To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions</li> <li> Not based on electrochemical technology</li> <li>Apparatus is added to gas canisters</li> <li>Light weight and inexpensive</li> <li> Uses a light source and mini spectrometer</li> <li>Uses color and/or audible detection</li> </ul> <ul> <li>Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters</li> <li> Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions</li> <li>Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2018-06-06 Based, Canisters, Cobinamide, ENCAPSULATED, GAS, Listed LPM Surabian as of 4/15/2015, MATERIALS, NIOSH-NPPTL, NPPTL, optical, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REMOVAL, Respirator, Sensing, SILICA, TOXIC, VBXXXX, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, YBXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172490 Greenawald LA, et al. https://www.ncbi.nlm.nih.gov/pubmed/26213448. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26213448.">Greenawald LA, et al.</a> 114109705 Boss, Gerry University of California, San Diego Boss, Gerry 0 114109706 Fry, Nicole University of California, San Diego Fry, Nicole 0 114109707 Sailor, Michael University of California, San Diego Sailor, Michael 0 114109704 Greenawald, Lee CDC - NIOSH CDC Greenawald, Lee (CDC) 1 114109704 Greenawald, Lee CDC - NIOSH CDC Greenawald, Lee (CDC) 1 114109705 Boss, Gerry University of California, San Diego Boss, Gerry 0 114109706 Fry, Nicole University of California, San Diego Fry, Nicole 0 114109707 Sailor, Michael University of California, San Diego Sailor, Michael 0 114102434 Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters E-144-2015-0 Closed Centers for Disease Control and Prevention (CDC), University of California, San Diego 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.">yogikala.prabhu@nih.gov</a><br> 114168626 E-144-2015-0 E-144-2015-0-US-01 Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters PRV US 62/016,565 Abandoned US <br />Provisional (PRV) 62/016,565<br />Filed on 2014-06-24<br />Status: Abandoned 114168627 E-144-2015-0 E-144-2015-0-US-02 Cobinamide-Based Materials For Optical Sensing And Gas Removal ORD US 14/748,163 Abandoned US <br />Ordinary Patent (ORD) 14/748,163<br />Filed on 2015-06-23<br />Status: Abandoned 114127898 YBXXXX 114127899 YFXXXX 114127900 VBXXXX 114127901 VPXXXX 114127902 WCXXXX 114127903 WEXXXX 114127904 WFXXXX 114127905 WGXXXX 114127906 WMXXXX 114150727 NIOSH-NPPTL 114150728 Cobinamide 114150729 ENCAPSULATED 114150730 SILICA 114150731 Based 114150732 MATERIALS 114150733 optical 114150734 Sensing 114150735 TOXIC 114150736 GAS 114150737 REMOVAL 114150738 Respirator 114150739 Canisters 114150740 NPPTL 114150741 Listed LPM Surabian as of 4/15/2015 114150742 Pre LPM working set 20150418 114150743 Post LPM Assignment Set 20150420 TAB-3304 114097228 Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Thomas Bobick, Douglas Cantis, Herbert Edgell, Eugene McKenzie Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work. <br /><br /> CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability. <ul> <li>A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction</li> <li> Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through</li> <li>Roof bracket can provide worker support when moving up-slope while installing roofing shingles</li> <li>Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off</li> </ul> <ul> <li>May be used widely throughout the residential and commercial construction building industry</li> <li>May be used to safeguard roof workers</li> <li>May be useful to do-it-yourself (DIY) home improvers</li> </ul> The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2018-07-05 BARRICADE, BRACKET, CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructing, Construction, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DSR, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAFETY, System, THEREIN, VPXXXX, WGXXXX, WMXXXX, WORKER, WORKER safety, XIXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-141-2013-0 114172509 Bobick-TG, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20030149&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20030149&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=1&RecNo=1&View=f&">Bobick-TG, et al.</a> 114172510 Bobick T, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20033870&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20033870&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick T, et al.</a> 114172511 Bobick-TG, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20039599&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20039599&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick-TG, et al.</a> 114172512 Bobick-TG, el al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20046510&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20046510&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick-TG, el al.</a> 114109785 McKenzie, Eugene CDC - NIOSH CDC McKenzie, Eugene (CDC) 0 114109786 Bobick, Thomas CDC - NIOSH CDC Bobick, Thomas (CDC) 0 114109787 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114109784 Cantis, Douglas CDC - NIOSH CDC Cantis, Douglas (CDC) 1 114109784 Cantis, Douglas CDC - NIOSH CDC Cantis, Douglas (CDC) 1 114109785 McKenzie, Eugene CDC - NIOSH CDC McKenzie, Eugene (CDC) 0 114109786 Bobick, Thomas CDC - NIOSH CDC Bobick, Thomas (CDC) 0 114109787 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114102464 BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN E-450-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.">yogikala.prabhu@nih.gov</a><br> 114168679 E-450-2013-0 E-450-2013-0-US-01 BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN ORD US 7,509,702 11/257,472 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7509702 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7509702">7,509,702</a><br />Filed on 2005-10-24<br />Status: Issued 114128019 YFXXXX 114128020 VPXXXX 114128021 WGXXXX 114128022 WMXXXX 114128023 XIXXXX 114151125 BARRICADE 114151126 System 114151127 BRACKET 114151128 THEREIN 114151129 CDC Docket Import 114151130 CDC Docket Import CDC Prosecuting 114151131 NIOSH-DSR 114151132 NIOSH 114151133 SAFETY 114151134 WORKER 114151135 WORKER safety 114151136 Occupational health 114151137 Construction 114151138 Constructing 114151139 Listed LPM Surabian as of 4/15/2015 114151140 Pre LPM working set 20150418 114151141 Post LPM Assignment Set 20150420 TAB-2825 114097004 Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise CDC Cardiology, Computational models/software, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Chucri Kardous This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.<br /><br /> The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss. <ul> <li>This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.</li> </ul> <ul> <li>Assessment of potentially hazardous levels of impulse noise</li> <li>Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades</li> <li>Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA5XXX, AAXXXX, AC1XXX, AC2XXX, ADXXXX, AE1BXX, AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Exposure, firearm, firearm safety, IMPULSE, MONITORING, NIOSH, NIOSH-DART, NOISE, Occupational health, SAFETY, Sampling, System, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, XJXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172150 Kardous CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/12851012 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12851012">Kardous CA, et al.</a> 114172151 Kardous CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15238316 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15238316">Kardous CA, et al.</a> 114172152 Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013. http://www.cdc.gov/niosh/surveyreports/pdfs/349-11a.pdf <a href="http://www.cdc.gov/niosh/surveyreports/pdfs/349-11a.pdf">Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.</a> 114172153 Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85. http://dx.doi.org/10.1016/j.apacoust.2004.11.007 <a href="http://dx.doi.org/10.1016/j.apacoust.2004.11.007">Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.</a> 114108736 Kardous, Chucri CDC - NIOSH CDC Kardous, Chucri (CDC) 1 114108736 Kardous, Chucri CDC - NIOSH CDC Kardous, Chucri (CDC) 1 114102162 System For Monitoring Exposure To Impulse Noise E-225-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.">yogikala.prabhu@nih.gov</a><br> 114167812 E-225-2013-0 E-225-2013-0-US-01 System For Monitoring Exposure To Impulse Noise PRV US 60/487,449 Abandoned US <br />Provisional (PRV) 60/487,449<br />Filed on 2003-07-14<br />Status: Abandoned 114167813 E-225-2013-0 E-225-2013-0-PCT-02 System For Monitoring Exposure To Impulse Noise PCT Patent Cooperation Treaty PCT/US2004/022499 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/022499<br />Filed on 2004-07-13<br />Status: Expired 114167814 E-225-2013-0 E-225-2013-0-US-03 System For Monitoring Exposure To Impulse Noise National Stage US 7,401,519 10/564,860 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7401519 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7401519">7,401,519</a><br />Filed on 2006-01-11<br />Status: Expired 114126187 AXXXXX 114126188 AAXXXX 114126189 AA5XXX 114126190 AC2XXX 114126191 AC1XXX 114126192 ADXXXX 114126193 AEXXXX 114126194 AE1XXX 114126195 AE2XXX 114126196 AE3XXX 114126197 AE2BXX 114126198 AE1BXX 114126199 VPXXXX 114126200 WCXXXX 114126201 WFXXXX 114126202 WGXXXX 114126203 WIXXXX 114126204 WMXXXX 114126205 XDXXXX 114126206 XIXXXX 114126207 XJXXXX 114126208 YEXXXX 114147425 System 114147426 MONITORING 114147427 Exposure 114147428 IMPULSE 114147429 NOISE 114147430 CDC Docket Import 114147431 CDC Docket Import CDC Prosecuting 114147432 NIOSH-DART 114147433 NIOSH 114147434 Occupational health 114147435 SAFETY 114147436 Sampling 114147437 firearm 114147438 firearm safety TAB-2826 114097005 Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Software / Apps Christopher Pan, Bryan Wimer, Shengke Zeng CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury. PEAS is a noninvasive, real-time, instrument-based system. Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis. During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time. The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message. Additionally, the smart phone stores the sent text message for archiving and further data analysis. <ul> <li>No comparable technology currently exists in the marketplace</li> <li>Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm</li> <li>Portable; approximately the size of a mobile phone and uses comparable technology</li> </ul> <ul> <li>Safety officers within the environmental, safety, and health departments of public and private entities</li> <li>Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking</li> <li>Workers' well-being concern groups</li> <li>Insurers and workers' compensation operations</li> <li>Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA1XXX, AA4XXX, AAXXXX, AE1BXX, AE1CXX, AE1XXX, AE2AXX, AE2BXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AFXXXX, AG3XXX, AGXXXX, apparatus, ASSESSING, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Conditions, Injured, Injuries, INJURY, LEAD, Likely, lumbar, Method, MOBILE, MOBILES, MUSCLE, Muscles, MUSCULAR, musculoskeletal, NIOSH, NIOSH-DSR, Occupational health, PERSONAL, Personalized, Portable, SAFE, Safely, SAFETY, System, VMXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, WORKERS, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YAXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108738 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 0 114108739 Zeng, Shengke CDC - DIR CDC Zeng, Shengke (CDC) 0 114108737 Pan, Christopher CDC - NIOSH CDC Pan, Christopher (CDC) 1 114108737 Pan, Christopher CDC - NIOSH CDC Pan, Christopher (CDC) 1 114108738 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 0 114108739 Zeng, Shengke CDC - DIR CDC Zeng, Shengke (CDC) 0 114102163 Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries E-168-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.">yogikala.prabhu@nih.gov</a><br> 114167816 E-168-2013-0 E-168-2013-0-US-01 Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries PRV US 61/599,525 Abandoned US <br />Provisional (PRV) 61/599,525<br />Filed on 2012-02-16<br />Status: Abandoned 114167817 E-168-2013-0 E-168-2013-0-US-02 SYSTEM AND METHOD TO PREDICT AND AVOID MUSCULOSKELETAL INJURIES ORD US 8,942,662 13/768,290 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8942662 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8942662">8,942,662</a><br />Filed on 2013-02-15<br />Status: Issued 114126209 AXXXXX 114126210 AAXXXX 114126211 AA1XXX 114126212 AA4XXX 114126213 AEXXXX 114126214 AE1XXX 114126215 AE1BXX 114126216 AE1CXX 114126217 AE2XXX 114126218 AE2AXX 114126219 AE2BXX 114126220 AE3XXX 114126221 AE4XXX 114126222 AFXXXX 114126223 AGXXXX 114126224 AG3XXX 114126225 VMXXXX 114126226 VPXXXX 114126227 WBXXXX 114126228 WCXXXX 114126229 WFXXXX 114126230 WGXXXX 114126231 WMXXXX 114126232 XDXXXX 114126233 XIXXXX 114126234 XHXXXX 114126235 YAXXXX 114126236 WIXXXX 114126237 XJXXXX 114126238 YEXXXX 114126239 YFXXXX 114147439 Portable 114147440 System 114147441 Method 114147442 ASSESSING 114147443 Conditions 114147444 Likely 114147445 LEAD 114147446 musculoskeletal 114147447 Injuries 114147448 CDC Docket Import 114147449 CDC Docket Import CDC Prosecuting 114147450 NIOSH-DSR 114147451 NIOSH 114147452 WORKER 114147453 WORKER safety 114147454 WORKERS 114147455 Occupational health 114147456 SAFE 114147457 SAFETY 114147458 Safely 114147459 MUSCLE 114147460 MUSCULAR 114147461 Muscles 114147462 Injured 114147463 INJURY 114147464 PERSONAL 114147465 Personalized 114147466 MOBILE 114147467 MOBILES 114147468 apparatus 114147469 lumbar TAB-2827 114097006 Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications CDC Cardiology, Consumer Products, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Stephen Hudock, Ova Johnston, Steven Wurzelbacher This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.<br /><br /> This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity. <ul> <li>Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity</li> <li>Device is extremely portable</li> <li>Easily attaches to a user's lower leg; allows for unhindered movement and ambulation</li> <li>Device automatically moves with the user; no manual readjustments or manipulations are required</li> <li>Durable and nonflammable</li> <li>Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces</li> </ul> <ul> <li>Knee pain, low-back pain alleviation and prevention</li> <li>Improved workplace ergonomics</li> <li>Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce</li> <li>Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-29 AB1XXX, AB3GXX, AB3XXX, AE2BXX, AE2XXX, AE4XXX, AEXXXX, AFXXXX, ARTHRITIS, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Knee, Kneel-sit, LABOR, MINING, NIOSH, NIOSH-DART, OSHA, OSTEOARTHRITIS, SAFETY, SUPPORT, VAXXXX, VMXXXX, VPXXXX, Wearable, WEXXXX, WGXXXX, WMXXXX, WORK, WORKER, WORKER safety, WORKERS, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108741 Johnston, Ova CDC - DIR CDC Johnston, Ova (CDC) 0 114108742 Hudock, Stephen CDC - NIOSH CDC Hudock, Stephen (CDC) 0 114108740 Wurzelbacher, Steven CDC - NIOSH CDC Wurzelbacher, Steven (CDC) 1 114108740 Wurzelbacher, Steven CDC - NIOSH CDC Wurzelbacher, Steven (CDC) 1 114108741 Johnston, Ova CDC - DIR CDC Johnston, Ova (CDC) 0 114108742 Hudock, Stephen CDC - NIOSH CDC Hudock, Stephen (CDC) 0 114102164 Wearable Kneel-sit Support Device E-261-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.">yogikala.prabhu@nih.gov</a><br> 114167818 E-261-2013-0 E-261-2013-0-PCT-02 Wearable Kneel-sit Support Device PCT Patent Cooperation Treaty PCT/US2002/016790 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/016790<br />Filed on 2002-05-28<br />Status: Expired 114167819 E-261-2013-0 E-261-2013-0-US-01 Wearable Kneel-sit Support Device PRV US 60/300,315 Abandoned US <br />Provisional (PRV) 60/300,315<br />Filed on 2001-06-22<br />Status: Abandoned 114167820 E-261-2013-0 E-261-2013-0-US-03 Wearable Kneel-sit Support Device National Stage US 7,152,919 10/481,532 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7152919 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7152919">7,152,919</a><br />Filed on 2003-12-19<br />Status: Abandoned 114126240 AXXXXX 114126241 AB1XXX 114126242 AB3XXX 114126243 AB3GXX 114126244 AEXXXX 114126245 AE2XXX 114126246 AE2BXX 114126247 AE4XXX 114126248 AFXXXX 114126249 VAXXXX 114126250 VMXXXX 114126251 VPXXXX 114126252 WEXXXX 114126253 WGXXXX 114126254 WMXXXX 114126255 XIXXXX 114126256 XDXXXX 114126257 YFXXXX 114126258 YEXXXX 114147470 Wearable 114147471 Kneel-sit 114147472 SUPPORT 114147473 DEVICE 114147474 CDC Docket Import 114147475 CDC Docket Import CDC Prosecuting 114147476 NIOSH-DART 114147477 NIOSH 114147478 SAFETY 114147479 Knee 114147480 WORK 114147481 WORKER 114147482 WORKER safety 114147483 WORKERS 114147484 ARTHRITIS 114147485 OSTEOARTHRITIS 114147486 LABOR 114147487 OSHA 114147488 MINING TAB-2890 114097051 Mobile Instrumentation for the Detection and Sampling of Aerosol Particles CDC Diagnostics, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Research Materials Therapeutics Vaccines Gregory Deye, Pramod Kulkarni Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.<br /><br /> CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter < 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation. <ul> <li>Cost-effective</li> <li>Offers overall reduction of measurement time</li> <li>Requires minimal power to operate</li> <li>Mobile, wearable</li> <li>Space-saving miniature systems as small as 1" x 1" x 3"</li> </ul> <ul> <li>Condensation particle detectors</li> <li>Particle size magnification systems</li> <li>Microfluidic devices for sampling, detection, and growth of hazardous particles</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-11-14 AEROSOL, APPLICATIONS, EXCHANGE, Growth, MEMBRANES, NIOSH-DART, PARTICLE, PERSONAL, Proton, Sampling, SYSTEMS, VBXXXX, VEXXXX, WAXXXX, WCXXXX, WGXXXX, WIXXXX, XDXXXX, XIXXXX, YFXXXX False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-146-2013-0 114108911 Deye, Gregory CDC - NIOSH CDC Deye, Gregory (CDC) 0 114108912 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108912 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108911 Deye, Gregory CDC - NIOSH CDC Deye, Gregory (CDC) 0 114102221 Aerosol Particle Growth Systems For Personal Sampling Applications Using Proton Exchange Membranes E-026-2014-0 Filing authorized Centers for Disease Control and Prevention (CDC), Regents of the University of Minnesota 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.">yogikala.prabhu@nih.gov</a><br> 114161376 E-026-2014-0 E-026-2014-0-US-05 Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes National Stage US 10,583,410 15/325,986 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583410 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583410">10,583,410</a><br />Filed on 2015-07-20<br />Status: Issued 114163079 E-026-2014-0 E-026-2014-0-PCT-02 Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes PCT Patent Cooperation Treaty PCT/US2015/041142 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/041142<br />Filed on 2015-07-20<br />Status: Expired 114167996 E-026-2014-0 E-026-2014-0-US-01 AEROSOL PARTICLE GROWTH SYSTEMS FOR PERSONAL SAMPLING APPLICATIONS USING POLYMER ELECTROLYTE MEMBRANES PRV US 62/026,559 Abandoned US <br />Provisional (PRV) 62/026,559<br />Filed on 2014-07-18<br />Status: Abandoned 114126677 VBXXXX 114126678 VEXXXX 114126679 WAXXXX 114126680 WCXXXX 114126681 WGXXXX 114126682 WIXXXX 114126683 XDXXXX 114126684 XIXXXX 114126685 YFXXXX 114147921 AEROSOL 114147922 PARTICLE 114147923 Growth 114147924 SYSTEMS 114147925 PERSONAL 114147926 Sampling 114147927 APPLICATIONS 114147928 Proton 114147929 EXCHANGE 114147930 MEMBRANES 114147931 NIOSH-DART TAB-2939 114097090 Emergency Maritime Battery Charger CDC Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Chelsea Woodward Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.<br /><br /> Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts. <ul> <li>Charging system is configured to be powered by wave action.</li> <li>Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.</li> <li>Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.</li> </ul> <ul> <li>Battery charger that can be used on personal or commercial boats.</li> <li>Maritime battery charger that can be used for specialized rescue vessels.</li> </ul> Patent protection is not being pursued for this technology. 2022-03-27 2026-05-14 2026-05-14 2015-05-19 Battery, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, Charger/maintainer, EMERGENCY, FISH, Listed LPM Surabian as of 4/15/2015, Maritime, NIOSH, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAFE, SAFETY, VPXXXX, WGXXXX, WIXXXX, WORK, WORKER safety, XDXXXX, XIXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114109045 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114109045 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114102274 Emergency Maritime Battery Charger/maintainer E-567-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.">yogikala.prabhu@nih.gov</a><br> 114127039 VPXXXX 114127040 WGXXXX 114127041 WIXXXX 114127042 XDXXXX 114127043 XIXXXX 114127044 YAXXXX 114127045 YFXXXX 114148362 EMERGENCY 114148363 Maritime 114148364 Battery 114148365 Charger/maintainer 114148366 CDC Docket Import 114148367 CDC Docket Import CDC Prosecuting 114148368 NIOSH 114148369 WORK 114148370 WORKER safety 114148371 SAFETY 114148372 SAFE 114148373 Occupational health 114148374 FISH 114148375 CDCRM 114148376 Listed LPM Surabian as of 4/15/2015 114148377 Pre LPM working set 20150418 114148378 Post LPM Assignment Set 20150420 TAB-2940 114097091 Swing-Away Winch Cathead Guard CDC Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Chelsea Woodward Shrimp boat operators use two trawl retrieval mechanisms mounted on the same winch frame. The main spools are used in the first operation; the shrimpers stand within inches of rotating cathead drums and guide incoming wire rope onto the main spools. Second, lazy lines are wrapped multiple times around each of the two spinning catheads (horizontal beams that raise and secure the anchor). Lastly, the guarding ends are pulled by the operators to cinch the rope to the rotating spool aiding trawl retrieval, but poses a hazard for operators to get entangled in the spinning cathead spools.<br /><br /> Researchers at NIOSH have developed guarding devices to protect shrimp boat winch operators from being entangled in the continuously spinning cathead spools. The mechanical guards feature a swinging functionality covering the catheads after the main trawl operations, allowing access to the normal operation of the catheads. <ul> <li>Swing-away mechanism of cathead guard protects operators from becoming entangled in spinning cathead spools.</li> <li>Designed specifically to address safety issues with industry winch protocols.</li> </ul> <ul> <li>Protective guards used to protect shrimp boat operators from being entangled in cathead spools.</li> <li>Cathead guards used to protect operators in the mining, oil, and gas industries where cathead winch spools are used.</li> <li>Guards can be used in boating industry to protect operators of anchor windlasses.</li> </ul> Patent protection is not being pursued for this technology. 2022-03-27 2026-05-14 2026-05-14 2015-05-19 Cathead, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, Guard, Listed LPM Surabian as of 4/15/2015, Maritime, NIOSH, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Swing-Away, VPXXXX, WGXXXX, WINCH, WIXXXX, WORKER, WORKER safety, XDXXXX, XIXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> </li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109046 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114109046 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114102275 Swing-Away Winch Cathead Guard E-568-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard.">yogikala.prabhu@nih.gov</a><br> 114127046 VPXXXX 114127047 WGXXXX 114127048 WIXXXX 114127049 XDXXXX 114127050 XIXXXX 114127051 YAXXXX 114127052 YFXXXX 114148379 Swing-Away 114148380 WINCH 114148381 Cathead 114148382 Guard 114148383 CDC Docket Import 114148384 CDC Docket Import CDC Prosecuting 114148385 NIOSH 114148386 WORKER 114148387 WORKER safety 114148388 Occupational health 114148389 Maritime 114148390 CDCRM 114148391 Listed LPM Surabian as of 4/15/2015 114148392 Pre LPM working set 20150418 114148393 Post LPM Assignment Set 20150420 TAB-2816 114096995 Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Vaccines Philip Efthimion, Pramod Kulkarni This CDC developed technology entails a novel method of near real-time elemental analysis of aerosols by corona assisted microwave induced plasma spectroscopy (CAMPS).<br /><br /> Analysis of elemental composition of aerosol particles holds significant implications for environmental and workplace pollution monitoring. Various plasma based analytical techniques, including laser-induced breakdown spectroscopy (LIBS) and spark-induced breakdown spectroscopy (SIBS), have been successfully used for multi-elemental analyses in solids, liquids, and gases, including aerosols. However, the characterization of fine and ultrafine aerosols using these techniques is particularly challenging due to small plasma volume, miniscule sample mass, and inferior sampling statistics, often leading to poor detection limits and precision.<br /><br /> This technology utilizes a microwave plasma-based detection system for aerosol analysis that features increased microplasma lifetime, repeatability, and stability over currently-available pulsed microplasma-based methods. This system produces microplasma lifetimes in the range of 5 to 50 milliseconds, a duration that is orders of magnitude larger than lifetimes for laser-induced or spark plasmas, as well as larger plasma volumes, which together are expected to provide improved detection limits over currently-available techniques. <ul> <li>Makes it possible to conduct accurate, near-real-time measurement of the elemental composition of aerosols in industrial and ambient atmospheres</li> <li>Corona field stabilizes the microwave plasma and results in repeatable plasma formation</li> <li>Larger size of CAMPS plasma provides sufficient plasma volume which can lead to complete ablation of deposited aerosol in the tip of the electrode</li> <li>Longer duration of CAMPS plasma (~10-50 ms) allows longer integration time which results in signal enhancement</li> </ul> <ul> <li>Elemental quantification of aerosols in near real-time</li> <li>Air pollution studies, Particulate Matter monitoring</li> <li>Hazardous materials exposure determinations and identification</li> <li>Biodefense, chemical-defense, homeland-security applications</li> <li>Environmental and occupational epidemiology</li> <li>Evaluation of engineering controls</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-15 CDC Docket Import, CDC Docket Import CDC Prosecuting, Microelectrode-Assisted, Microwave-Induced, NIOSH-DART, PLASMA, SPECTROSCOPY, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-205-2013-0 114108712 Efthimion, Philip Efthimion, Philip 0 114108711 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108711 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108712 Efthimion, Philip Efthimion, Philip 0 114102149 Microelectrode-Assisted Microwave-Induced Plasma Spectroscopy E-163-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Envimetrics, LLC 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy.">yogikala.prabhu@nih.gov</a><br> 114167783 E-163-2013-0 E-163-2013-0-US-01 Microelectrode-Assisted Microwave-Induced Plasma Spectroscopy PRV US 61/652,593 Abandoned US <br />Provisional (PRV) 61/652,593<br />Filed on 2012-05-02<br />Status: Abandoned 114167784 E-163-2013-0 E-163-2013-0-US-02 Electrode-Assisted Microwave-Induced Plasma Spectroscopy ORD US 9,091,597 13/804,512 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9091597 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9091597">9,091,597</a><br />Filed on 2013-03-14<br />Status: Issued 114126002 VBXXXX 114126003 VJXXXX 114126004 VKXXXX 114126005 VLXXXX 114126006 VOXXXX 114126007 VPXXXX 114126008 WAXXXX 114126009 WBXXXX 114126010 WCXXXX 114126011 WEXXXX 114126012 WFXXXX 114126013 WGXXXX 114126014 WHXXXX 114126015 WIXXXX 114126016 WMXXXX 114126017 XDXXXX 114126018 XHXXXX 114126019 XIXXXX 114126020 YEXXXX 114126021 YFXXXX 114147256 Microelectrode-Assisted 114147257 Microwave-Induced 114147258 PLASMA 114147259 SPECTROSCOPY 114147260 CDC Docket Import 114147261 CDC Docket Import CDC Prosecuting 114147262 NIOSH-DART TAB-2817 114096996 Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis CDC Computational models/software, Consumer Products, Diagnostics, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Computational models/software Consumer Products Diagnostics Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Michael Flemmer, Ramesh Gali, Jennifer Hornsby-Myers, Larry Lee, Sidney Soderholm This CDC-developed technology describes an automated system for monitoring worker hazard exposures by recording data about where and when hazards occur in a workplace or other environment. This allows the hazards to be avoided and harmful exposures and risks reduced. This field-tested technology consists of an integrated, hand-held electronics instrument and software system that will precisely correlate multiple exposure levels with position coordinates of the user and features real-time data acquisition.<br /><br /> Workers in many outdoor occupations move about frequently during a typical day of work. Certain workers, such as agricultural and construction workers, are particularly mobile. This exposure monitoring system combines geographical location with real-time sensors and outputs the information to a user-friendly interface. By linking worker location throughout the workday to exposure levels from real-time monitors, Local Positioning System (LPS) units (with integrated software processing of data) identify and document where to direct hazard exposure analysis and control efforts. Post-processing of LPS data enables researchers, regulatory inspectors, and industry safety and health personnel to map exposure intensity and location, reveal hot spots to identify sources, and provide exposure intensity distributions to increase workplace safety. <ul> <li>Correlates real-time position and real-time condition data for multiple commercial/industrial applications</li> <li>An add-on capability for any sensor(s) when measurement of a location is also useful</li> <li>System is highly customizable and can be easily adapted for additional monitoring of noise, dust, gases, and vapor, heat stress, etc. exposures</li> <li>Automated system provides greater efficiency and greater feedback than video monitoring systems</li> <li>An integrated alarm will alert users to potential hazards</li> </ul> <ul> <li>Collection, analysis and display of mutual, real-time conditional and 3-dimensional position data</li> <li>Outdoor occupational exposure assessment with various real-time sensors/monitors (e.g., HAZMAT crews, safety inspection, etc.)</li> <li>Solid state "bread crumbs" allowing a person or machine to retrace their path</li> <li>Tracking of objects, animals or people, including sensing of their internal condition or environmental conditions</li> <li>Environmental pollution source-point monitoring and investigation</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-15 apparatus, ASSESSING, CDC Docket Import, CDC Docket Import CDC Prosecuting, Conditions, Method, System, VBXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172138 Lee LA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15986055 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15986055">Lee LA, et al.</a> 114108714 Soderholm, Sidney CDC - NIOSH CDC Soderholm, Sidney (CDC) 0 114108715 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108716 Hornsby-Myers, Jennifer CDC - NIOSH CDC Hornsby-Myers, Jennifer (CDC) 0 114108717 Gali, Ramesh CDC - NIOSH CDC Gali, Ramesh (CDC) 0 114108713 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108713 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108714 Soderholm, Sidney CDC - NIOSH CDC Soderholm, Sidney (CDC) 0 114108715 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108716 Hornsby-Myers, Jennifer CDC - NIOSH CDC Hornsby-Myers, Jennifer (CDC) 0 114108717 Gali, Ramesh CDC - NIOSH CDC Gali, Ramesh (CDC) 0 114102150 Method, Apparatus, And System For Assessing Conditions E-144-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis.">yogikala.prabhu@nih.gov</a><br> 114167785 E-144-2013-0 E-144-2013-0-US-01 Method, Apparatus, And System For Assessing Conditions ORD US 7,191,097 10/815,111 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7191097 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7191097">7,191,097</a><br />Filed on 2004-03-31<br />Status: Abandoned 114126022 VBXXXX 114126023 WAXXXX 114126024 WCXXXX 114126025 WEXXXX 114126026 WFXXXX 114126027 WGXXXX 114126028 WIXXXX 114126029 WMXXXX 114126030 XDXXXX 114126031 XHXXXX 114126032 XIXXXX 114126033 XJXXXX 114126034 YEXXXX 114126035 YFXXXX 114147263 Method 114147264 apparatus 114147265 System 114147266 ASSESSING 114147267 Conditions 114147268 CDC Docket Import 114147269 CDC Docket Import CDC Prosecuting TAB-2823 114097002 Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Equipment Research Materials Software / Apps Therapeutics Vaccines Prasson Diwakar, Pramod Kulkarni This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-real time measurements with superior accuracy and precision. The APU is designed to be small, low-pressure drop unit for its use in a battery-operated, hand-portable instrumentation.<br /><br /> The design significantly improves accuracy and precision of measurements relative to existing methods. The APU can be integrated with a microplasma source (such as a laser-induced plasma) and the optical spectrometer to obtain elemental composition of aerosol particles. The unique features of this invention allow: i) semi-continuous or near-real-time measurement of elemental composition of aerosol particles, ii) measurement with high accuracy, precision, and repeatability, iii) collection of particles using electrostatic principles, iv) higher flow rates with smaller pumps because of a very low pressure drop, v) reliable calibration of the system, vi) easy miniaturization for portable instruments, and vii) lower detection limits, as needed, by increasing the particle collection time and/or sampling flow rate. <ul> <li>This APU allows accurate, near-real-time measurement of the elemental composition of aerosol particles in industrial and ambient atmospheres</li> <li>Can be readily miniaturized and integrated into existing portable plasma, Raman, or IR spectroscopy instruments to allow on-site, semi-continuous measurement of aerosol particles</li> <li>Provides lower detection limits compared to earlier technology, as needed, by increasing the particle collection time and/or sampling flow rate</li> </ul> <ul> <li>Personal exposure measurements of metals</li> <li>Air pollution studies</li> <li>Elemental quantification in near real-time</li> <li>Hazardous materials exposure determinations and identification</li> <li>Biodefense, chemical-defense applications</li> <li>Environmental and occupational epidemiology</li> <li>Evaluation of engineering controls</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-21 AA2XXX, AA3AXX, AA3B5X, AA3CXX, AA3XXX, AC1XXX, AC3XXX, AC4XXX, AC6XXX, ACXXXX, ADXXXX, AE2AXX, AE2XXX, AE3XXX, AE4XXX, AEROSOL, AEXXXX, AG1XXX, ANALYSER, ANALYSES, analysis, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DAXXXX, DEVICE, DXXXXX, IA5XXX, IDXXXX, Method, NIOSH, NIOSH-DART, OID-NCIRD-DVD, optical, PLASMA, SPECTROSCOPY, TECHNIQUE, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XGXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-163-2013-0 114108733 Diwakar, Prasson CDC - NIOSH CDC Diwakar, Prasson (CDC) 0 114108732 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108732 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108733 Diwakar, Prasson CDC - NIOSH CDC Diwakar, Prasson (CDC) 0 114102157 Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy E-205-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), TKC Global 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques.">yogikala.prabhu@nih.gov</a><br> 114167801 E-205-2013-0 E-205-2013-0-US-01 Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy ORD US 8,970,840 13/315,372 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8970840 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8970840">8,970,840</a><br />Filed on 2011-12-09<br />Status: Issued 114126103 AXXXXX 114126104 AA2XXX 114126105 AA3XXX 114126106 AA3AXX 114126107 AA3B5X 114126108 AA3CXX 114126109 ACXXXX 114126110 AC1XXX 114126111 AC3XXX 114126112 AC4XXX 114126113 AC6XXX 114126114 ADXXXX 114126115 AEXXXX 114126116 AE2XXX 114126117 AE2AXX 114126118 AE3XXX 114126119 AE4XXX 114126120 AG1XXX 114126121 DXXXXX 114126122 DAXXXX 114126123 IA5XXX 114126124 IDXXXX 114126125 VBXXXX 114126126 VJXXXX 114126127 VKXXXX 114126128 VLXXXX 114126129 VOXXXX 114126130 VPXXXX 114126131 WAXXXX 114126132 WBXXXX 114126133 WCXXXX 114126134 WEXXXX 114126135 WFXXXX 114126136 WGXXXX 114126137 WIXXXX 114126138 WMXXXX 114126139 XDXXXX 114126140 XFXXXX 114126141 XGXXXX 114126142 XHXXXX 114126143 XIXXXX 114126144 YEXXXX 114126145 YFXXXX 114147358 Method 114147359 apparatus 114147360 AEROSOL 114147361 analysis 114147362 optical 114147363 SPECTROSCOPY 114147364 CDC Docket Import 114147365 CDC Docket Import CDC Prosecuting 114147366 OID-NCIRD-DVD 114147367 NIOSH-DART 114147368 NIOSH 114147369 PLASMA 114147370 ANALYSES 114147371 ANALYSER 114147372 DEVICE 114147373 TECHNIQUE TAB-2824 114097003 Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Equipment Research Materials Software / Apps Therapeutics Vaccines David Frazer, Jeffrey Reynolds CDC researchers have developed a novel acoustic whole body plethysmograph (AWBP) that allows measurement of tidal volume in lab animals, independent of gas compression in the lung. This system provides particular advantages over the traditional whole body plethysmograph (WBP) when measuring model animals with increased gas compression due to increased airway resistance or increased acceleration in the breathing pattern.<br /><br /> Measurement of tidal volume in conscious, unrestrained mice has traditionally been performed using WBP. An animal is placed in a chamber where pressure changes due to respiration are observed, which are then related to tidal volume. Although the effects of gas compression on the WBP signal of normal mice may be negligible, gas compression in mice with altered breathing pattern and/or increased airway resistance can produce significant errors in the measurement of tidal volume. A major advantage of this novel AWBP technology is the ability to measure the tidal volume signal independent of gas compression. This is particularly useful when measuring mice that have been exposed to a respiratory irritant or toxin that increases airway resistance or the frequency content of the breathing pattern. Further, with slight hardware and software modifications the system may also be used to measure specific airway resistances. <ul> <li>System allows fast, efficient, noninvasive measurement of lab animal pulmonary function for numerous inhalation, toxicology research studies</li> <li>Measures tidal volume signal independent of gas compression, increasing accuracy when gathering data from animals with altered breathing patterns and/or elevated airway resistance</li> <li>System operates at a fixed frequency, and automatically tracks the change in sound amplitude as a function of time due to change in lung volume</li> </ul> <ul> <li>Measurement of tidal volume, respiratory rate, and other breath rate parameters of laboratory animals</li> <li>Research and animal modeling tool for in vivo pulmonary investigations of therapeutics efficacy and studying certain infectious diseases </li> <li>Particularly useful when measuring animals exposed to a respiratory irritant or toxin that increases either airway resistance or the frequency</li> <li>Noninvasive measurement of specific airway resistance and restrictions in an unrestrained animal</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA2XXX, AA5XXX, AAXXXX, AC1XXX, AC2XXX, AC3XXX, AC6XXX, Acoustic, ACXXXX, ADXXXX, AE1BXX, AE1XXX, AE3XXX, AE4XXX, AEXXXX, ANIMAL, Animal Model, ANIMAL welfare, ASTHMA, Breath, BREATHING, CDC Docket Import, CDC Docket Import CDC Prosecuting, DDXXXX, DEVICE, DEXXXX, DXXXXX, FUNCTION, IA3XXX, IA5XXX, ICXXXX, IDXXXX, LUNG, lung cancer, Lung Disease, LUNGS, Lung-Targeted, Measuring, NIOSH, NIOSH-HELD, Plethysmograph, Pulmonary, Pulmonary edema, PULMONARY FIBROSIS, research, RESEARCH TOOL, RESPIRABLE, Respiration, respiratory, Respiratory Diseases, respiratory INFECTION, Tool, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YCXXXX, YEXXXX, YFXXXX False True <ul> <li>In vivo data available (animal)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> <ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172147 Reynolds JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/16897419 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16897419">Reynolds JS, et al.</a> 114172148 Reynolds JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/18450981 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18450981">Reynolds JS, et al.</a> 114172149 Daubenspeck JA , et al. http://www.ncbi.nlm.nih.gov/pubmed/17962574 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17962574">Daubenspeck JA , et al.</a> 114108735 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108734 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 1 114108734 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 1 114108735 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114102161 Acoustic Plethysmograph For Measuring Pulmonary Function E-290-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function.">yogikala.prabhu@nih.gov</a><br> 114167810 E-290-2013-0 E-290-2013-0-US-01 Acoustic Plethysmograph For Measuring Pulmonary Function PRV US 60/958,537 Abandoned US <br />Provisional (PRV) 60/958,537<br />Filed on 2007-07-06<br />Status: Abandoned 114167811 E-290-2013-0 E-290-2013-0-US-02 Acoustic Plethysmograph For Measuring Pulmonary Function ORD US 8,328,729 12/168,829 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8328729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8328729">8,328,729</a><br />Filed on 2009-01-08<br />Status: Abandoned 114126147 AA2XXX 114126148 AAXXXX 114126149 AA5XXX 114126150 ACXXXX 114126151 AC1XXX 114126152 AC2XXX 114126153 AC3XXX 114126154 AC6XXX 114126155 ADXXXX 114126156 AEXXXX 114126157 AE3XXX 114126158 AE1XXX 114126159 AE1BXX 114126160 AE4XXX 114126161 DXXXXX 114126162 DDXXXX 114126163 DEXXXX 114126164 IA3XXX 114126165 IA5XXX 114126166 ICXXXX 114126167 IDXXXX 114126168 VBXXXX 114126169 VJXXXX 114126170 VKXXXX 114126171 VLXXXX 114126172 VOXXXX 114126173 WAXXXX 114126174 WBXXXX 114126175 WCXXXX 114126176 WGXXXX 114126177 WIXXXX 114126178 XDXXXX 114126179 XHXXXX 114126180 XIXXXX 114126181 XJXXXX 114126182 YCXXXX 114126183 YEXXXX 114126184 YFXXXX 114126185 VPXXXX 114126186 WMXXXX 114147394 Acoustic 114147395 Plethysmograph 114147396 Measuring 114147397 Pulmonary 114147398 FUNCTION 114147399 CDC Docket Import 114147400 CDC Docket Import CDC Prosecuting 114147401 NIOSH-HELD 114147402 NIOSH 114147403 Tool 114147404 ANIMAL welfare 114147405 Animal Model 114147406 ANIMAL 114147407 research 114147408 RESEARCH TOOL 114147409 DEVICE 114147410 Breath 114147411 BREATHING 114147412 LUNG 114147413 lung cancer 114147414 Lung Disease 114147415 Lung-Targeted 114147416 LUNGS 114147417 ASTHMA 114147418 PULMONARY FIBROSIS 114147419 Pulmonary edema 114147420 RESPIRABLE 114147421 Respiration 114147422 respiratory 114147423 Respiratory Diseases 114147424 respiratory INFECTION TAB-2786 114096965 Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan CDC Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Consumer Products Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials John Bevan, Curtis Clark, Wayne Howie, Jennifer Lincoln, Lewis Martin, Robert Mckibbin, Gregory Miller, Todd Ruff, Chelsea Woodward This CDC-developed invention entails a system of electrical and hydraulic circuits used to stop a rotating winch in an emergency. Amongst other locations, one stop switch can be positioned on a capstan winch horn. This location makes it available to a victim entangled in rope being retrieved on a gypsy drum. As designed, the stop circuit could be used with an electrically, hydraulically or pneumatically operated winch. A variant of this safety system has been successfully tested on a purse seining fishing vessel in Alaskan waters. <ul> <li>Complies with numerous international safety regulations requiring winches, drums and capstans to have a master on/off switch in easy reach for worker safety</li> <li>Can be packaged as a ‘retrofit kit’ for integration with current commercial winch/drum usage</li> </ul> <ul> <li>Retrofitting existing winches for additional safety and adherence to possible future regulations</li> <li>Specifically designed and tested for the marine/fishing industries</li> <li>Applications in mining, construction, forestry, and/or off-road automotive industries</li> <li>Workers' well-being concern groups</li> <li>Insurers of fishing vessels; also mining, construction and forestry operations</li> <li>Manufacturers of cable reel trailers and wire-drawing machinery</li> </ul> Research Tool – Patent protection is not being pursued for this technology. Research Tools – Patent protection is not being pursued for these technologies. 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AE1CXX, AE1XXX, AE2BXX, AE2XXX, AE4XXX, AEXXXX, AFXXXX, AG3XXX, AGXXXX, AXXXXX, CABLE, CABLES, capstan, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, DEVICE, ELECTRO/HYDRAULIC, EMERGENCY, FISH, Maritime, NIOSH, Occupational health, RXXXXX, SAFETY, Stop, SWITCH, Switches, SWITCHING, System, WEXXXX, WFXXXX, WGXXXX, WINCH, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-504-2013-0 E-567-2013-0 E-568-2013-0 E-643-2013-0 114108596 Bevan, John CDC - NIOSH CDC Bevan, John (CDC) 0 114108597 Miller, Gregory CDC - NIOSH CDC Miller, Gregory (CDC) 0 114108598 Ruff, Todd CDC - NIOSH CDC Ruff, Todd (CDC) 0 114108599 Howie, Wayne CDC - NIOSH CDC Howie, Wayne (CDC) 0 114108600 Lincoln, Jennifer CDC - NIOSH CDC Lincoln, Jennifer (CDC) 0 114108602 Martin, Lewis CDC - NIOSH CDC Martin, Lewis (CDC) 0 114108603 Mckibbin, Robert CDC - NIOSH CDC Mckibbin, Robert (CDC) 0 114108604 Clark, Curtis CDC - NIOSH CDC Clark, Curtis (CDC) 0 114108601 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114108601 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114108596 Bevan, John CDC - NIOSH CDC Bevan, John (CDC) 0 114108597 Miller, Gregory CDC - NIOSH CDC Miller, Gregory (CDC) 0 114108598 Ruff, Todd CDC - NIOSH CDC Ruff, Todd (CDC) 0 114108599 Howie, Wayne CDC - NIOSH CDC Howie, Wayne (CDC) 0 114108600 Lincoln, Jennifer CDC - NIOSH CDC Lincoln, Jennifer (CDC) 0 114108602 Martin, Lewis CDC - NIOSH CDC Martin, Lewis (CDC) 0 114108603 Mckibbin, Robert CDC - NIOSH CDC Mckibbin, Robert (CDC) 0 114108604 Clark, Curtis CDC - NIOSH CDC Clark, Curtis (CDC) 0 114102111 ELECTRO/HYDRAULIC EMERGENCY STOP DEVICE FOR A WINCH E-355-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan.">yogikala.prabhu@nih.gov</a><br> 114125655 AXXXXX 114125656 AEXXXX 114125657 AE1XXX 114125658 AE2XXX 114125659 AE1CXX 114125660 AE2BXX 114125661 AE4XXX 114125662 AFXXXX 114125663 AGXXXX 114125664 AG3XXX 114125665 RXXXXX 114125666 WEXXXX 114125667 WFXXXX 114125668 WGXXXX 114125669 WMXXXX 114125670 XDXXXX 114125671 XIXXXX 114125672 YEXXXX 114125673 YFXXXX 114146805 ELECTRO/HYDRAULIC 114146806 EMERGENCY 114146807 Stop 114146808 DEVICE 114146809 WINCH 114146810 CDC Docket Import 114146811 CDC Docket Import CDC Prosecuting 114146812 NIOSH 114146813 SAFETY 114146814 Occupational health 114146815 Maritime 114146816 FISH 114146817 capstan 114146818 CABLE 114146819 CABLES 114146820 System 114146821 SWITCH 114146822 SWITCHING 114146823 Switches 114146824 CDCRM TAB-2788 114096967 Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Donald Tuchman This CDC-developed invention pertains to a novel dust monitor filter that is specially constructed of organic materials for spectrometric analysis, ultimately allowing for detection and accurate quantification of a particular chosen analyte (e.g., crystalline silica/quartz dust that may lead to silicosis).<br /><br /> For miners, the risk of lung disease increases with the extent of dust exposure, and coal worker's pneumoconiosis (aka, black lung disease) and silicosis are still dangers routinely faced by those in the industry. Expectedly, both the concentration and the composition of airborne particulate matter present in mining environments are points of regulatory concern. For some time, collecting airborne dust samples and subsequent determination of quartz content have been integral for assessing mine worker exposure and demonstrating compliance with US Federal regulations.<br /><br /> Unfortunately, highly accurate spectrometric detection and quantification of particulate exposure has not always been possible. Generally, the filters used in existing oscillating microbalances (such as the TEOM® monitor) have been specially designed to for hydrophobicity, in order to retain as little moisture as possible on the filter. These specialized hydrophobic filters (and/or their mounting components) contain inorganic compounds that cannot be readily subjected to thermal or chemical destruction - a necessary first step of many instrumental analytical methods, such as spectroscopy.<br /><br /> This CDC-developed filter consists of entirely ashable material, making it ideal for spectrometric analysis and rapid exposure assessment. As an example, this dust monitor filter can be made entirely of organic materials and designed for quick, easy ashing that will not produce interference with the spectroscopic characteristics of the chosen analyte(s). Further, filter ashing can be carried out by a variety of methods: thermal ashing, microwave ashing, low temperature ashing, or chemical destruction. <ul> <li>Novel dust-monitoring instrument capable of providing near rapid particulate exposure information to miners/users</li> <li>Improves upon older technology by allowing for accurate detection and quantification of chosen analyte(s) and, unlike other filters, does not produce overlap or interfere with spectroscopic analysis</li> <li>Filter can be easily ashed for analysis by thermal ashing, microwave ashing, low temperature ashing, or chemical destruction</li> </ul> <ul> <li>Personal dust monitors worn wherever dust exposure levels and the presence of potentially injurious materials is evaluated</li> <li>Occupationally-mandated pneumoconiosis, asbestosis and/or silicosis prevention and monitoring programs, for complying with safety regulations</li> <li>Miners' wellness concern groups and insurance companies</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AAXXXX, AC1XXX, AC3XXX, ACXXXX, AE1XXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AIRBORNE, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERIZING, COAL, DUST, Dust collector, Methods, MINE, MINER, MINING, MONITOR, NIOSH, NIOSH-PRL, PARTICULATES, VPXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YAXXXX, YBXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172100 Tuchman DP. http://www.ncbi.nlm.nih.gov/pubmed/18449405 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18449405">Tuchman DP.</a> 114108607 Tuchman, Donald CDC - NIOSH CDC Tuchman, Donald (CDC) 1 114108607 Tuchman, Donald CDC - NIOSH CDC Tuchman, Donald (CDC) 1 114102113 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES E-312-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels.">yogikala.prabhu@nih.gov</a><br> 114167693 E-312-2013-0 E-312-2013-0-PCT-02 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES PCT Patent Cooperation Treaty PCT/US2006/023166 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/023166<br />Filed on 2006-06-14<br />Status: Expired 114167694 E-312-2013-0 E-312-2013-0-US-01 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES PRV US 60/691,564 Abandoned US <br />Provisional (PRV) 60/691,564<br />Filed on 2005-06-17<br />Status: Abandoned 114167695 E-312-2013-0 E-312-2013-0-US-03 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES National Stage US 7,947,503 11/922,381 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947503 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947503">7,947,503</a><br />Filed on 2007-12-14<br />Status: Abandoned 114125693 AXXXXX 114125694 AAXXXX 114125695 ACXXXX 114125696 AC1XXX 114125697 AC3XXX 114125698 AEXXXX 114125699 AE1XXX 114125700 AE2XXX 114125701 AE3XXX 114125702 AE4XXX 114125703 WCXXXX 114125704 WEXXXX 114125705 WFXXXX 114125706 WGXXXX 114125707 WMXXXX 114125708 XDXXXX 114125709 XIXXXX 114125710 VPXXXX 114125711 WBXXXX 114125712 YAXXXX 114125713 YBXXXX 114125742 YEXXXX 114125743 YFXXXX 114146853 MONITOR 114146854 Methods 114146855 CHARACTERIZING 114146856 AIRBORNE 114146857 PARTICULATES 114146858 CDC Docket Import 114146859 CDC Docket Import CDC Prosecuting 114146860 NIOSH-PRL 114146861 NIOSH 114146862 MINE 114146863 MINER 114146864 MINING 114146865 COAL 114146866 DUST 114146867 Dust collector TAB-2789 114096968 Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Therapeutics Bean Chen, David Frazer, Walter McKinney This invention pertains to a CDC developed sonic aerosol generator that provides a controllable, stable concentration of particulate aerosol over a long period of time for aerosol exposure studies. Specifically, <em>in situ</em> testing data indicate uniform aerosol stability can be maintainable for greater than 30 hours at concentrations of 15 mg/m<sup>3</sup> or more. Additionally, the technology was specifically developed for, and validated in, animal studies assessing exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been suggested that workers may be at risk for exposure to nanosized particles during the manufacture, handling, and cleanup of engineered nanomaterials. Compared to other technologies, this CDC aerosol generator is particularly helpful when used for generating high testing concentrations of MWCNT aerosols that more accurately represent particulate levels that may be seen in a workplace environment. <ul> <li>Fully automated system with integrated feedback control for optimized stability in testing</li> <li>Maintains concentration of aerosols for >30 hours at concentrations of 15 mg/cubic meter or more</li> <li>Capable of generating high concentrations of aerosols that more accurately represent the levels seen in a workplace environment</li> <li>System insures that each run produces a constant particle concentration, air flow, pressure, temperature and humidity within a testing chamber</li> </ul> <ul> <li>Studying the size and shape of the aerosolized particles produced from simple vibrations of bulk material</li> <li>Toxicological investigations and risk assessment of aerosol exposures, especially those related to nanoparticle manufacturing</li> <li>Any aerosolization application where the aggregating “bird's nest” tendencies of airborne multi-walled carbon nanotubes must be overcome</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AC1DXX, AC1XXX, AC4XXX, ACXXXX, AE1BXX, AE1XXX, AE2BXX, AE3XXX, AEROSOL, AEXXXX, AG2XXX, AG3XXX, AGXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, ENVIRONMENTAL, environmental health, GENERATOR, nanotechnology, Nanotube, NIOSH, NIOSH-HELD, PARTICULATE, TOXICOLOGICAL, TOXICOLOGY, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, WORK, WORKER safety, XDXXXX, XGXXXX, XIXXXX, XJXXXX, YBXXXX, YCXXXX, YEXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172101 McKinney W, et al. http://www.ncbi.nlm.nih.gov/pubmed/19555230 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19555230">McKinney W, et al.</a> 114172102 Porter DW, et al. http://www.ncbi.nlm.nih.gov/pubmed/22881873 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22881873">Porter DW, et al.</a> 114172103 Porter DW, et al. http://www.ncbi.nlm.nih.gov/pubmed/19857541 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19857541">Porter DW, et al.</a> 114172104 Chen BT, et al. http://www.ncbi.nlm.nih.gov/pubmed/23033994 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23033994">Chen BT, et al.</a> 114108609 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108610 Chen, Bean CDC - NIOSH CDC Chen, Bean (CDC) 0 114108608 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108608 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108609 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108610 Chen, Bean CDC - NIOSH CDC Chen, Bean (CDC) 0 114102114 Aerosol Generator E-156-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities.">yogikala.prabhu@nih.gov</a><br> 114167696 E-156-2013-0 E-156-2013-0-US-01 Aerosol Generator PRV US 61/237,945 Abandoned US <br />Provisional (PRV) 61/237,945<br />Filed on 2009-08-28<br />Status: Abandoned 114167697 E-156-2013-0 E-156-2013-0-US-02 Aerosol Generator ORD US 8,875,702 12/871,453 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8875702 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8875702">8,875,702</a><br />Filed on 2010-08-30<br />Status: Abandoned 114167923 E-156-2013-0 E-156-2013-0-US-03 Aerosol Generator DIV US 14/473,324 Abandoned US <br />Divisional (DIV) 14/473,324<br />Filed on 2014-08-29<br />Status: Abandoned 114125714 AXXXXX 114125715 ACXXXX 114125716 AC4XXX 114125717 AC1XXX 114125718 AC1DXX 114125719 AEXXXX 114125720 AE1XXX 114125721 AE1BXX 114125722 AE3XXX 114125723 AE2BXX 114125724 AGXXXX 114125725 AG2XXX 114125726 AG3XXX 114125727 VPXXXX 114125728 WCXXXX 114125729 WFXXXX 114125730 WGXXXX 114125731 WHXXXX 114125732 WIXXXX 114125733 WMXXXX 114125734 XDXXXX 114125735 XGXXXX 114125736 XIXXXX 114125737 XJXXXX 114125738 YBXXXX 114125739 YCXXXX 114125740 YEXXXX 114125741 YFXXXX 114146868 AEROSOL 114146869 GENERATOR 114146870 CDC Docket Import 114146871 CDC Docket Import CDC Prosecuting 114146872 NIOSH-HELD 114146873 Nanotube 114146874 TOXICOLOGICAL 114146875 TOXICOLOGY 114146876 DEVICE 114146877 NIOSH 114146878 WORK 114146879 WORKER safety 114146880 ENVIRONMENTAL 114146881 environmental health 114146882 nanotechnology 114146883 PARTICULATE TAB-2793 114096972 Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Michael Breitenstein, John Snawder CDC/NIOSH scientists have developed an effective point-source control for silica-containing dusts that can be generated from machinery on sites where hydraulic fracturing is occurring. The CDC/NIOSH mini-baghouse retrofit assembly is a bolt-on control designed to contain silica-containing respirable dusts generated during refill operations of sand movers during hydraulic fracturing.<br /><br /> In the U.S., most new oil and gas wells are hydraulically fractured to enhance well production. Most hydraulic fracturing operations have 2-5 sand movers on-site that transfer thousands to millions of pounds of silica sand during each stage of fracturing. While a variety of passive and active controls are currently available (or have been proposed) to limit release of silica-containing dusts, the CDC/NIOSH mini-baghouse retrofit assembly was designed to fill a unique need for a control. The retrofit to equipment can be made in the field, uses existing energy inherent in the system and is relatively simple and effective. CDC/NIOSH field research has shown that risks for exposure to respirable silica arise from at least 8 points of dust generation and that a variety of controls (engineering, administrative and personal protective equipment) are needed to control exposures. Use of the mini-baghouse retrofit technology is intended to limit release of respirable silica from thief hatches on top of the sand movers, enhancing workplace health and safety. <ul> <li>Designed for in-field retrofitting “thief hatches” of existing machinery</li> <li>Uses energy inherent in the pneumatic transfer of sand</li> <li>Provides a passive sand-mover-mounted control for silica release at hydraulic fracturing operations</li> </ul> <ul> <li>Controlling occupational exposure to respirable crystalline silica, particularly during work involving transfer of sand into sand movers on hydraulic fracturing sites</li> <li>In-field retrofits of currently operating heavy equipment (e.g., sand movers)</li> <li>Limiting visible dust emissions from sand moving equipment</li> <li>Reducing respirable crystalline silica dust emissions to enhance compliance with OSHA PEL for silica</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2015-10-14 3/25/2014 -- designated as "Remove" per BHurley/CDC TTO: abstract contains inaccuracies and will be replaced at a later date... --ecr 4/16/2014 -- received updated abstract; okay to post now... --ecr AE1XXX, AE2XXX, AE3XXX, AEXXXX, AGXXXX, apparatus, AXXXXX, Baghouse, CDC Docket Import, CDC Docket Import CDC Prosecuting, CONTROL, CONTROLING, Crystalline, DEVICE, DUST, Dust collector, ENVIRONMENT, ENVIRONMENTAL, environmental health, Equipment, Fracturing, HYDRAULIC, LARGE, Methods, MINE, MINER, Mini, MINING, Movers, MULTIPLE, NIOSH, NIOSH-DSHEFS, Occupational health, PARTICULATE, Release, RESPIRABLE, Respiration, Respirator, Retrofit, SAND, SILICA, SILICOSIS, SYSTEMS, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172133 Esswein EJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/23679563 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23679563">Esswein EJ, et al.</a> 114108622 Breitenstein, Michael CDC - NIOSH CDC Breitenstein, Michael (CDC) 0 114108623 Snawder, John CDC - NIOSH CDC Snawder, John (CDC) 0 114108622 Breitenstein, Michael CDC - NIOSH CDC Breitenstein, Michael (CDC) 0 114108623 Snawder, John CDC - NIOSH CDC Snawder, John (CDC) 0 114102118 Multiple Mini Baghouse Retrofit For Control Of Respirable Crystalline Silica Release From Hydraulic Fracturing Sand Movers E-291-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment.">yogikala.prabhu@nih.gov</a><br> 114162543 E-291-2013-0 E-291-2013-0-US-03 SYSTEMS AND METHODS FOR CONTROLLING PARTICULATE RELEASE FROM LARGE EQUIPMENT DIV US 9,669,345 14/992,963 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9669345 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9669345">9,669,345</a><br />Filed on 2016-01-11<br />Status: Abandoned 114167705 E-291-2013-0 E-291-2013-0-US-01 SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT PRV US 61/673,658 Abandoned US <br />Provisional (PRV) 61/673,658<br />Filed on 2012-07-19<br />Status: Abandoned 114167706 E-291-2013-0 E-291-2013-0-US-02 SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT ORD US 13/802,265 Abandoned US <br />Ordinary Patent (ORD) 13/802,265<br />Filed on 2013-03-13<br />Status: Abandoned 114125774 AXXXXX 114125775 AEXXXX 114125776 AE1XXX 114125777 AE2XXX 114125778 AE3XXX 114125779 AGXXXX 114125780 WCXXXX 114125781 WEXXXX 114125782 WFXXXX 114125783 WGXXXX 114125784 WMXXXX 114125785 XDXXXX 114125786 XIXXXX 114125787 YFXXXX 114125788 YEXXXX 114125939 VPXXXX 114146928 SYSTEMS 114146929 Methods 114146930 CONTROLING 114146931 PARTICULATE 114146932 Release 114146933 LARGE 114146934 Equipment 114146935 Retrofit 114146936 Baghouse 114146937 Mini 114146938 MULTIPLE 114146939 CONTROL 114146940 RESPIRABLE 114146941 Crystalline 114146942 SILICA 114146943 HYDRAULIC 114146944 Fracturing 114146945 SAND 114146946 Movers 114146947 CDC Docket Import 114146948 CDC Docket Import CDC Prosecuting 114146949 NIOSH-DSHEFS 114146950 NIOSH 114146951 MINING 114146952 MINE 114146953 MINER 114146954 DEVICE 114146955 apparatus 114146956 Occupational health 114146957 ENVIRONMENT 114146958 ENVIRONMENTAL 114146959 environmental health 114146960 DUST 114146961 SILICOSIS 114146962 Dust collector 114146963 Respiration 114146964 Respirator TAB-2761 114096940 Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Psychiatry/Mental Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Carlyn Collins, MariBeth Gagnon, James Lange, Tommy Lee, Roger Taylor Micro-Screen is a CDC developed software program designed to capture images and archive and display a compiled image(s) from a portion of a microscope slide in real time. This program allows for the re-creation of larger images that are constructed from individual microscopic fields captured in up to five focal planes and two magnifications. This program may be especially useful for the creation of data archives for diagnostic and teaching purposes and for tracking histological changes during disease progression. <ul> <li>Readily adaptable to other microscopic disciplines</li> <li>Automated imaging and display provides increased cost efficiency and improves objectivity of analysis and testing</li> <li>Can be used to develop a database of standards or reference images for a variety of pathologies and/or applied microscopy concerns</li> </ul> <ul> <li>Medical/cytology training, education and certification</li> <li>All aspects of applied microscopy/histology, microbial smears, hematology, parasitology, etc.</li> <li>Clinical diagnostics</li> <li>Basic and applied biology lab research</li> <li>Forensic analysis</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AA3AXX, AA3B6X, AA3CXX, AA3XXX, AC2XXX, AC3XXX, Acquisition, ACXXXX, AD2XXX, AD3XXX, ADXXXX, Automated, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositing, DISPLAY, Image, MICROSCOPIC, OID-NCPDCID-DLS, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VNXXXX, VOXXXX, VPXXXX, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XHXXXX, XJXXXX, YBXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172053 Taylor RN, et al. http://www.ncbi.nlm.nih.gov/pubmed/10578977 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10578977">Taylor RN, et al.</a> 114108510 Taylor, Roger CDC - DIR CDC Taylor, Roger (CDC) 0 114108511 Lange, James CDC - DIR CDC Lange, James (CDC) 0 114108512 Lee, Tommy CDC - DIR CDC Lee, Tommy (CDC) 0 114108513 Collins, Carlyn CDC - DIR CDC Collins, Carlyn (CDC) 0 114108509 Gagnon, MariBeth CDC - DIR CDC Gagnon, MariBeth (CDC) 1 114108509 Gagnon, MariBeth CDC - DIR CDC Gagnon, MariBeth (CDC) 1 114108510 Taylor, Roger CDC - DIR CDC Taylor, Roger (CDC) 0 114108511 Lange, James CDC - DIR CDC Lange, James (CDC) 0 114108512 Lee, Tommy CDC - DIR CDC Lee, Tommy (CDC) 0 114108513 Collins, Carlyn CDC - DIR CDC Collins, Carlyn (CDC) 0 114102081 Automated Microscopic Image Acquisition, Compositing, And Display E-228-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis.">yogikala.prabhu@nih.gov</a><br> 114167617 E-228-2013-0 E-228-2013-0-US-01 Automated Microscopic Image Acquisition, Compositing, And Display PRV US 60/248,948 Abandoned US <br />Provisional (PRV) 60/248,948<br />Filed on 2000-11-14<br />Status: Abandoned 114167618 E-228-2013-0 E-228-2013-0-US-02 Automated Microscopic Image Acquisition, Compositing, And Display ORD US 7,027,628 10/001,268 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7027628 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7027628">7,027,628</a><br />Filed on 2001-11-13<br />Status: Expired 114167619 E-228-2013-0 E-228-2013-0-US-03 Automated Microscopic Image Acquisition, Compositing, And Display CON US 7,305,109 11/345,863 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7305109 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7305109">7,305,109</a><br />Filed on 2006-02-01<br />Status: Expired 114125183 AXXXXX 114125184 ACXXXX 114125185 AC2XXX 114125186 AC3XXX 114125187 ADXXXX 114125188 AD2XXX 114125189 AD3XXX 114125190 AA3XXX 114125191 AA3AXX 114125192 AA3CXX 114125193 AA3B6X 114125194 VAXXXX 114125195 VBXXXX 114125196 VCXXXX 114125197 VDXXXX 114125198 VEXXXX 114125199 VFXXXX 114125200 VGXXXX 114125201 VHXXXX 114125202 VIXXXX 114125203 VJXXXX 114125204 VKXXXX 114125205 VLXXXX 114125206 VMXXXX 114125207 VNXXXX 114125208 VOXXXX 114125209 VPXXXX 114125210 WBXXXX 114125211 WIXXXX 114125212 WMXXXX 114125213 XDXXXX 114125214 XFXXXX 114125215 XHXXXX 114125216 XJXXXX 114125217 YBXXXX 114125218 YEXXXX 114146447 Automated 114146448 MICROSCOPIC 114146449 Image 114146450 Acquisition 114146451 Compositing 114146452 DISPLAY 114146453 CDC Docket Import 114146454 CDC Docket Import CDC Prosecuting 114146455 OID-NCPDCID-DLS TAB-2762 114096941 Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Harry Dobroski, Steven Page, Jon Volkwein This CDC developed dust detector tube is designed to provide inexpensive, short-term, time weighted average dust exposure data feedback directly to device users. This invention operates upon a conventional gas detector tube platform and can be used with any low volume pump that can electronically measure pump back pressure. The device consists of three sections: the first defines the size of the dust and removes moisture, the second uses a filter whose pressure differential corresponds with cumulative dust loading, and a final section employs a pressure transducer.<br /><br /> Current methods require expensive instantaneous and short-term monitors or gravimetric filters that must be carefully pre- and post-weighed to determine the average dust exposure of a user's work-shift. This novel dust dosimeter fills the need for an inexpensive short-term determination of personal dust exposure aiding in the assessment and preservation of worker respiratory health. <ul> <li>Provides inexpensive, short-term assessment of personal dust exposure</li> <li>Gas detector tube platform makes commercialization of this instrument quite simple and efficient for related manufacturers/distributors</li> <li>Standardizing detection platforms increases cost-efficiency (especially for smaller companies) as the same pump can be used to measure both dust and gas</li> </ul> <ul> <li>Dust, gas and particulate detector/dosimeter manufacturers</li> <li>Industry applications where worker-exposure to dust will be a concern, especially mining, construction and demolition fields</li> <li>Worker health and safety, related insurance agency concerns</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, AG3XXX, AGXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DETECTOR, DEVICE, DUST, Enviromental, environmental health, MINING, MONITOR, NIOSH, NIOSH-PRL, Occupational health, OSHA, Protection, SAMPLER, Tube, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WORKER, WORKER safety, XDXXXX, XHXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172054 Volkwein JC, et al. http://www.ncbi.nlm.nih.gov/pubmed/10712071 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10712071">Volkwein JC, et al.</a> 114108515 Dobroski, Harry CDC - NIOSH CDC Dobroski, Harry (CDC) 0 114108516 Page, Steven CDC - NIOSH CDC Page, Steven (CDC) 0 114108514 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 1 114108514 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 1 114108515 Dobroski, Harry CDC - NIOSH CDC Dobroski, Harry (CDC) 0 114108516 Page, Steven CDC - NIOSH CDC Page, Steven (CDC) 0 114102082 Dust Detector Tube E-238-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform.">yogikala.prabhu@nih.gov</a><br> 114167620 E-238-2013-0 E-238-2013-0-PCT-02 Dust Detector Tube PCT Patent Cooperation Treaty PCT/US1998/013267 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/013267<br />Filed on 1998-06-26<br />Status: Expired 114167621 E-238-2013-0 E-238-2013-0-US-01 Dust Detector Tube PRV US 60/052,719 Abandoned US <br />Provisional (PRV) 60/052,719<br />Filed on 1997-07-03<br />Status: Abandoned 114167622 E-238-2013-0 E-238-2013-0-US-03 Dust Detector Tube ORD US 6,401,520 09/467,934 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6401520 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6401520">6,401,520</a><br />Filed on 1999-12-21<br />Status: Expired 114125219 AXXXXX 114125220 AEXXXX 114125221 AE1XXX 114125222 AE2XXX 114125223 AE2BXX 114125224 AE3XXX 114125225 AGXXXX 114125226 AG3XXX 114125227 WCXXXX 114125228 WEXXXX 114125229 WFXXXX 114125230 WGXXXX 114125231 VPXXXX 114125232 XDXXXX 114125233 XHXXXX 114125234 YEXXXX 114146456 DUST 114146457 DETECTOR 114146458 Tube 114146459 CDC Docket Import 114146460 CDC Docket Import CDC Prosecuting 114146461 NIOSH-PRL 114146462 NIOSH 114146463 OSHA 114146464 MINING 114146465 WORKER 114146466 WORKER safety 114146467 Occupational health 114146468 DEVICE 114146469 MONITOR 114146470 Enviromental 114146471 environmental health 114146472 SAMPLER 114146473 Protection TAB-2774 114096953 Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Materials Software / Apps Therapeutics David Frazer, Kimberly Friend, William Goldsmith, Walter McKinney, Jeffrey Reynolds This CDC developed auscultatory training apparatus includes a database of prerecorded physiological sounds (e.g., lung, bowel, or heart sounds) stored on a computer for playback. Current teaching tools, which utilize previously recorded sounds, suffer from the disadvantage that playback environments cause considerable distortion and errors in sound reproduction. For example, to those trainees using such systems, the reproduced respiratory sounds do not “sound” as if they are being generated by a live patient. Moreover, the aforementioned playback distortions often make it difficult for the listener to hear and interpret the subtleties of a recorded respiratory maneuver.<br /><br /> This device includes a software program that allows a user to select prerecorded sounds for playback. The program will also generate an inverse model of the playback system in the form of a digital filter. The inverse model processes a selected sound to cancel the distortions of the playback system so the sound is accurately reproduced. The program also permits the extraction of a specific sound component from a prerecorded sound so only the extracted sound component is audible during playback. In addition to the obvious role of a teaching tool for medical professionals, this invention could have applications as a diagnostic screening and/or telemedicine tool. <ul> <li>Accurate, realistic reproduction of in situ physiological sounds</li> <li>Apparatus features noise-cancelling filter to eliminate ambient distortion artifacts during playback</li> <li>Device is extremely portable</li> <li>Allows for isolation and playback of specific elements of a recording</li> </ul> <ul> <li>Auscultatory training for health care professionals</li> <li>Telemedicine tool</li> <li>Diagnostic screening comparison and control</li> </ul> International patent application pending (Canada) 2022-03-27 2026-05-14 2026-05-14 2014-02-07 AA3B6X, AA3BXX, AA3XXX, AAXXXX, AB4XXX, ACXXXX, ADXXXX, AFXXXX, Auscultatory, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, IA1XXX, IA5XXX, IAXXXX, IB1FXX, IB4XXX, ICXXXX, IDXXXX, IXXXXX, NIOSH-HELD, System, TRAINING, VDXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XIXXXX, XJXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-245-2013-0 114172068 Goldsmith WT, et al. http://www.ncbi.nlm.nih.gov/pubmed/19876736 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19876736">Goldsmith WT, et al.</a> 114172069 Abaza AA, et al. http://www.ncbi.nlm.nih.gov/pubmed/19930559 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19930559">Abaza AA, et al.</a> 114108555 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 0 114108556 Friend, Kimberly CDC - NIOSH CDC Friend, Kimberly (CDC) 0 114108557 Goldsmith, William CDC - NIOSH CDC Goldsmith, William (CDC) 0 114108558 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108554 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108554 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108555 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 0 114108556 Friend, Kimberly CDC - NIOSH CDC Friend, Kimberly (CDC) 0 114108557 Goldsmith, William CDC - NIOSH CDC Goldsmith, William (CDC) 0 114108558 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114102096 Auscultatory Training System E-283-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds.">yogikala.prabhu@nih.gov</a><br> 114167653 E-283-2013-0 E-283-2013-0-US-01 Auscultatory Training System PRV US 60/287,941 Abandoned US <br />Provisional (PRV) 60/287,941<br />Filed on 2001-04-30<br />Status: Abandoned 114167654 E-283-2013-0 E-283-2013-0-US-02 Auscultatory Training System ORD US 7,209,796 10/135,964 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7209796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7209796">7,209,796</a><br />Filed on 2002-04-29<br />Status: Expired 114125443 AXXXXX 114125444 AAXXXX 114125445 ACXXXX 114125446 ADXXXX 114125447 AB4XXX 114125448 AA3XXX 114125449 AA3BXX 114125450 AA3B6X 114125451 AFXXXX 114125452 IXXXXX 114125453 IAXXXX 114125454 IA1XXX 114125455 IA5XXX 114125456 ICXXXX 114125457 IDXXXX 114125458 IB1FXX 114125459 IB4XXX 114125460 VDXXXX 114125461 VOXXXX 114125462 VPXXXX 114125463 WBXXXX 114125464 WFXXXX 114125465 WHXXXX 114125466 WIXXXX 114125467 WMXXXX 114125468 XDXXXX 114125469 XFXXXX 114125470 XIXXXX 114125471 XJXXXX 114125472 YEXXXX 114125473 YFXXXX 114146610 Auscultatory 114146611 TRAINING 114146612 System 114146613 CDC Docket Import 114146614 CDC Docket Import CDC Prosecuting 114146615 NIOSH-HELD TAB-2781 114096960 Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures CDC Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health Consumer Products Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Charles Litton, William Schiffbauer, Jon Volkwein This technology pertains to monitors for measuring the mass concentration of ambient particulate matter in an atmosphere containing both larger/coarser (e.g., respirable dust) and smaller/finer (sub-micrometer particles such as diesel particulate matter - DPM) particulate mixtures. The monitoring device can be configured for operation with a controller unit adapted to ionization sensor and/or light-scattering modules. The controller translates the sensor output signal into a quantifiable value, determining mass concentration of particulate matter within the ionization chamber. For example, practical applications of this monitor/analysis technology would easily extend to use in mining operations (where both DPM and respirable dust exist in abundance), industrial manufacturing facilities, and anywhere that frequent or extended exposure to fuel-combustion exhaust or airborne pollution is a concern. Further, by virtue of its ability to distinguish “fire smoke” from other aerosols that may be present, the device also has significant potential for use in early-warning fire detection. <ul> <li>Inexpensive and simple to implement</li> <li>Device provides continuous, simultaneous, and independent measurement of both respirable dust and diesel particulate matter (DPM) mass concentrations</li> <li>Previous particulate counting technologies are both expensive and cannot provide accurate quantification of coarse/fine aerosol mixtures, concentrations</li> </ul> <ul> <li>Airborne particle monitor for mining and industrial manufacturing operations</li> <li>Addressing emissions control standards and regulations</li> <li>Early-warning fire detection in locations where traditional smoke-detector use is impractical</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-28 AE1BXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, ANALYZING, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Ionization, Light-scattering, Methods, NIOSH-PRL, PARTICLES, SENSORS, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108580 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 0 114108581 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 0 114108579 Litton, Charles CDC - NIOSH CDC Litton, Charles (CDC) 1 114108579 Litton, Charles CDC - NIOSH CDC Litton, Charles (CDC) 1 114108580 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 0 114108581 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 0 114102106 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors E-240-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures.">yogikala.prabhu@nih.gov</a><br> 114167678 E-240-2013-0 E-240-2013-0-US-01 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors PRV US 60/369,537 Abandoned US <br />Provisional (PRV) 60/369,537<br />Filed on 2002-04-01<br />Status: Abandoned 114167679 E-240-2013-0 E-240-2013-0-US-02 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors ORD US 6,965,240 10/401,980 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6965240 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6965240">6,965,240</a><br />Filed on 2003-03-27<br />Status: Abandoned 114125587 AXXXXX 114125588 AEXXXX 114125589 AE2XXX 114125590 AE2BXX 114125591 AE1BXX 114125592 AE3XXX 114125593 WCXXXX 114125594 WEXXXX 114125595 WFXXXX 114125596 WGXXXX 114125597 WMXXXX 114125598 XDXXXX 114125599 XIXXXX 114125600 YEXXXX 114125601 YFXXXX 114146739 apparatus 114146740 Methods 114146741 ANALYZING 114146742 PARTICLES 114146743 Light-scattering 114146744 SENSORS 114146745 Ionization 114146746 CDC Docket Import 114146747 CDC Docket Import CDC Prosecuting 114146748 NIOSH-PRL TAB-2739 114096918 Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Oncology Ophthalmology Research Equipment Research Materials Therapeutics Jeffrey Fedan, Yi Jing, Michael Van Scott CDC and collaborative researchers have developed a device allowing for simultaneous measurement of smooth muscle contractile/relaxant activity and transepithelial potential difference (Vt) [or short circuit currents (Isc)] and resistance (Rt) within an intact airway <em>in vitro</em>. Investigation of the underlying mechanisms of lung diseases, such as asthma or cystic fibrosis, involves understanding the roles of airway smooth muscle and epithelium. Smooth muscle is involved in the control of the airway diameter; epithelium regulates the ionic composition of the liquid lining the airways through electrogenic ion transport and releases factors that regulate the ability of smooth muscle to contract.<br /><br /> This invention allows for the measurement and study of pulmonary diseases under conditions retaining normal spatial relationships between all the cell types and an unmanipulated/undistorted tracheal airway wall. Further, the device permits evaluation of epithelial functional integrity using pharmacological techniques. Agents can be separately added to the lumen, where they must first cross the epithelium to reach the smooth muscle, or to the outside of the airway, where there is no hindrance of said agents to the muscle. The invention also permits the effective <em>in vitro</em> screening of the effects of agents and drugs on airway epithelium and smooth muscle within the same preparation. <ul> <li>Allows simultaneous measurement of transepithelial potential difference, transepithelial resistance, smooth muscle activity and changes in tracheal diameter</li> <li>In vitro analysis of trachea or tracheal segments retaining native, in situ structure</li> <li>Pharmacological agents may be added separately to the lumen for screening purposes</li> <li>First and only such "single-preparation" device allowing for such broad array of data output</li> </ul> <ul> <li>Investigations into physiological mechanisms of airway diseases, such as cystic fibrosis and asthma</li> <li>Screening of drugs and therapeutic compounds directed to complex, multi-tissue type matrices</li> <li>Biomedical research exploring pharmacology-physiology integration</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-27 AA2XXX, AAXXXX, AC4XXX, AC5XXX, ACXXXX, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERISTICS, ICXXXX, IDXXXX, INTACT, IXXXXX, Measuring, Method, PHYSIOLOGICAL, Trachea, Vitro, VPXXXX, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, YAXXXX, YBXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172021 JIng Y, et. al. http://www.ncbi.nlm.nih.gov/pubmed/18835555 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18835555">JIng Y, et. al.</a> 114108448 Jing, Yi CDC - NIOSH CDC Jing, Yi (CDC) 0 114108449 Van Scott, Michael East Carolina University Van Scott, Michael 0 114108447 Fedan, Jeffrey CDC - NIOSH CDC Fedan, Jeffrey (CDC) 1 114108447 Fedan, Jeffrey CDC - NIOSH CDC Fedan, Jeffrey (CDC) 1 114108448 Jing, Yi CDC - NIOSH CDC Jing, Yi (CDC) 0 114108449 Van Scott, Michael East Carolina University Van Scott, Michael 0 114102057 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro E-246-2013-0 Closed Centers for Disease Control and Prevention (CDC), East Carolina University 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro.">yogikala.prabhu@nih.gov</a><br> 114167534 E-246-2013-0 E-246-2013-0-US-02 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro ORD US 7,907,999 11/655,635 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7907999 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7907999">7,907,999</a><br />Filed on 2007-01-19<br />Status: Abandoned 114167538 E-246-2013-0 E-246-2013-0-US-01 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro PRV US 60/762,465 Abandoned US <br />Provisional (PRV) 60/762,465<br />Filed on 2006-01-25<br />Status: Abandoned 114124780 AXXXXX 114124781 AAXXXX 114124782 AA2XXX 114124783 ACXXXX 114124784 AC4XXX 114124785 AC5XXX 114124786 IXXXXX 114124787 ICXXXX 114124788 IDXXXX 114124790 VPXXXX 114124791 WBXXXX 114124792 WIXXXX 114124793 WMXXXX 114124794 XDXXXX 114124795 XHXXXX 114124796 YAXXXX 114124797 YBXXXX 114124798 YEXXXX 114124799 YFXXXX 114146197 apparatus 114146198 Method 114146199 Measuring 114146200 PHYSIOLOGICAL 114146201 CHARACTERISTICS 114146202 INTACT 114146203 Trachea 114146204 Vitro 114146205 CDC Docket Import 114146206 CDC Docket Import CDC Prosecuting TAB-2758 114096933 Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement CDC Cardiology, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Renguang Dong, Thomas McDowell, Christopher Warren, Daniel Welcome, Bryan Wimer CDC researchers have developed an improved dynamometer device and method for measuring maximum hand grip force or grip-strength. Human test subjects were used in conducting experiments to evaluate the handle and to assess the measurement method. In contrast to the currently used "Jamar handle" grip strength dynamometer devices, the cylindrical handle proved to be able to determine the overall grip strength for a subject, as well as show the grip force distribution around the circumference of the handle. The cylindrical dynamometer handle is accurate with less than 4% error, and it demonstrates that the measurement is independent of the loading position along the handle. For real-world applications, the device can be used to help diagnose the musculoskeletal disorders of the hand, monitor the recovery progress after hand surgery or injury, and collect grip strength data for tool and machine design. Compared to currently used "Jamar" grip test devices: <ul> <li>Cylindrical handle shape more comparable with real-world/workplace machinery</li> <li>Improved comfort</li> <li>Cylindrical meter assesses the total grip force, together with the friction force and torque</li> <li>Grip force distributed at the different parts of the hand can be measured with cylindrical meter - important information for the diagnosis of hand disorders</li> </ul> <ul> <li>Useful for engineering functional design and ergonomic considerations for developing new tools and machinery</li> <li>Monitoring post-operative, post-stroke rehabilitation</li> <li>Diagnosis of carpel tunnel syndrome, musculoskeletal disorders and hand-arm vibration syndrome</li> <li>Training feedback for grip-strength focused athletes - climbing, gymnastics, rugby, martial arts, etc.</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AA1XXX, AA2XXX, AA4BXX, AA4XXX, AAXXXX, AB1XXX, AFXXXX, ASSESSMENT, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Configuration, Dynamometer, GRIP, HAND, Improved, NIOSH-HELD, Strength, VAXXXX, VEXXXX, VPXXXX, WBXXXX, WGXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172051 Wimer B, et al. http://www.ncbi.nlm.nih.gov/pubmed/19250853 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19250853">Wimer B, et al.</a> 114108501 Welcome, Daniel CDC - NIOSH CDC Welcome, Daniel (CDC) 0 114108502 Warren, Christopher CDC - NIOSH CDC Warren, Christopher (CDC) 0 114108503 McDowell, Thomas CDC - NIOSH CDC McDowell, Thomas (CDC) 0 114108504 Dong, Renguang CDC - NIOSH CDC Dong, Renguang (CDC) 0 114108500 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 1 114108500 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 1 114108501 Welcome, Daniel CDC - NIOSH CDC Welcome, Daniel (CDC) 0 114108502 Warren, Christopher CDC - NIOSH CDC Warren, Christopher (CDC) 0 114108503 McDowell, Thomas CDC - NIOSH CDC McDowell, Thomas (CDC) 0 114108504 Dong, Renguang CDC - NIOSH CDC Dong, Renguang (CDC) 0 114102078 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT E-143-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement.">yogikala.prabhu@nih.gov</a><br> 114167611 E-143-2013-0 E-143-2013-0-US-01 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT PRV US 61/175,473 Abandoned US <br />Provisional (PRV) 61/175,473<br />Filed on 2009-05-05<br />Status: Abandoned 114167612 E-143-2013-0 E-143-2013-0-US-02 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT ORD US 8,240,202 12/773,420 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8240202 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8240202">8,240,202</a><br />Filed on 2010-05-04<br />Status: Abandoned 114125132 AXXXXX 114125133 AAXXXX 114125134 AA1XXX 114125135 AA4XXX 114125136 AA4BXX 114125137 AA2XXX 114125138 AB1XXX 114125139 AFXXXX 114125140 XDXXXX 114125141 WBXXXX 114125142 WGXXXX 114125143 XIXXXX 114125144 VAXXXX 114125145 VEXXXX 114125146 VPXXXX 114125147 YEXXXX 114125148 YFXXXX 114146407 HAND 114146408 Dynamometer 114146409 Improved 114146410 Configuration 114146411 GRIP 114146412 Strength 114146413 ASSESSMENT 114146414 CDC Docket Import 114146415 CDC Docket Import CDC Prosecuting 114146416 NIOSH-HELD TAB-2757 114096937 Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Hongwei Hsiao, John Powers, Peter Simeonov Improper positioning of an extension ladder frequently results in "ladder slide-outs," which are the most common cause of ladder-fall scenarios. This invention relates to an extension ladder positioning indicator which is easily installed in a ladder rung; provides multiple cues (visual, sound, and vibration) for rapidly identifying and positioning correct ladder inclination.<br /><br /> CDC-NIOSH researchers found that this technology improved accuracy and efficiency of ladder positioning for both "experienced" and "novice" ladder users, as compared to the "no instruction" method and the standard anthropometric method, and that it was also significantly faster than the bubble indicator method. When properly implemented, this effective and easy to use ladder positioning indicator will reduce the risk of extension ladder slipping and tipping and, ultimately, will reduce the number of fall incidents and injuries – benefitting construction workers, employers, contractors and workplace insurers. <ul> <li>Direct, multimodal user feedback reduces the time for accurate, safe ladder positioning compared to bubble-level indicator, anthropometric and sight- based ladder-positioning methods</li> <li>Visual, auditory and tactile feedback provide increased efficient-setup and safety</li> <li>Technology can be incorporated as an attachable, device which may be affixed to a ladder or integrated as an app for a mobile/tablet device</li> <li>Automated feedback ensures ladders are angled to OSHA and ANSI safety specifications</li> </ul> <ul> <li>Retrofitting existing ladders to provide automated, multisensory feedback for improved compliance with OSHA and ANSI ladder-angle safety guidelines</li> <li>Ladder manufacturing companies</li> <li>Construction contractors, retailers and insurers</li> <li>Training tool to aid worker safety education and adherence</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 advanced ladder technology, AE1XXX, AE2AXX, AE2BXX, AE2XXX, AEXXXX, AFXXXX, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, INDICATOR, LADDER, MULTIMODAL, NIOSH, NIOSH-DSR, Positioning, SAFETY, VPXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172050 Simeonov P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23177178 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23177178">Simeonov P, et al.</a> 114108498 Hsiao, Hongwei CDC - NIOSH CDC Hsiao, Hongwei (CDC) 0 114108499 Powers, John CDC - NIOSH CDC Powers, John (CDC) 0 114108497 Simeonov, Peter CDC - NIOSH CDC Simeonov, Peter (CDC) 1 114108497 Simeonov, Peter CDC - NIOSH CDC Simeonov, Peter (CDC) 1 114108498 Hsiao, Hongwei CDC - NIOSH CDC Hsiao, Hongwei (CDC) 0 114108499 Powers, John CDC - NIOSH CDC Powers, John (CDC) 0 114102077 Multimodal Indicator Safety Device For Ladder Positioning E-141-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency.">yogikala.prabhu@nih.gov</a><br> 114167610 E-141-2013-0 E-141-2013-0-US-01 Multimodal Indicator Safety Device For Ladder Positioning ORD US 8,167,087 12/400,233 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8167087 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8167087">8,167,087</a><br />Filed on 2009-03-09<br />Status: Issued 114125118 AXXXXX 114125119 AEXXXX 114125120 AE1XXX 114125121 AE2XXX 114125122 AE2BXX 114125123 AE2AXX 114125124 AFXXXX 114125125 VPXXXX 114125126 WGXXXX 114125127 WMXXXX 114125128 XDXXXX 114125129 XIXXXX 114125130 YEXXXX 114125131 YFXXXX 114146395 MULTIMODAL 114146396 INDICATOR 114146397 SAFETY 114146398 DEVICE 114146399 LADDER 114146400 Positioning 114146401 CDC Docket Import 114146402 CDC Docket Import CDC Prosecuting 114146403 NIOSH-DSR 114146404 advanced ladder technology 114146405 apparatus 114146406 NIOSH TAB-2759 114096938 Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Michael Flemmer, Larry Lee This CDC developed physiologic sampling pump (PSP) overcomes shortcomings of previous devices by the use of calibrated valves in conjunction with a constant speed pump. This novel approach obviates typical PSP inertia that inherently limits system response, functionality and accuracy. All prior PSP designs have attempted to follow a user's breathing pattern by changing pump speed, thereby altering sampling rate. In that approach, pump inertia will limit system response and function due to the time required to adjust speed. Additionally, variable pump speeds often produce size selective sampling errors at low flow rates.<br /><br /> Performance of this PSP is not degraded by pump inertia or low flow size selective sampling errors. This design maintains a consistent pump speed, controlling PSP sampling rate with calibrated valves that redirect air flow almost instantaneously. In situ device testing demonstrated that when this air-flow valve is properly integrated into a sampling head, response time of the PSP is essentially mutually exclusive of the magnitude of changes in the effective flow, facilitating consistently small error in sampling performance regardless of user-exertion scenario. <ul> <li>Allows for air sampling to be modulated to follow breathing rate</li> <li>Design obviates the sluggishness inherent in prior art physiologic sampling pumps (PSPs) caused by variable pump speed effect on sampling rate</li> <li>Improved accuracy compared to earlier PSPs, irrelevant of user-exertion scenarios</li> <li>Follows inhalation on a breath-by-breath basis</li> </ul> <ul> <li>Air sampling device manufacturers</li> <li>Assessing airborne hazard exposures for workplace safety</li> <li>Industrial hygiene programs</li> <li>Respiration monitoring device for patients</li> <li>Aerobic training system for athletes</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 BREATHING, Capable, CDC Docket Import, CDC Docket Import CDC Prosecuting, NIOSH-HELD, PHYSIOLOGIC, PSP, PUMP, RAPID, RESPONSE, Sampling, UNIVERSAL, VBXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172052 Lee L, et al. http://www.ncbi.nlm.nih.gov/pubmed/19436860 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436860">Lee L, et al.</a> 114108506 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108505 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108505 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108506 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114102079 A Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing E-169-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate.">yogikala.prabhu@nih.gov</a><br> 114167613 E-169-2013-0 E-169-2013-0-US-01 Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing PRV US 61/145,777 Abandoned US <br />Provisional (PRV) 61/145,777<br />Filed on 2010-01-20<br />Status: Abandoned 114167614 E-169-2013-0 E-169-2013-0-US-02 Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing ORD US 8,459,098 12/690,550 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8459098 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8459098">8,459,098</a><br />Filed on 2010-01-20<br />Status: Issued 114125149 VBXXXX 114125150 VPXXXX 114125151 WAXXXX 114125152 WBXXXX 114125153 WCXXXX 114125154 WEXXXX 114125155 WFXXXX 114125156 WGXXXX 114125157 WMXXXX 114125158 XDXXXX 114125159 XIXXXX 114125160 YEXXXX 114125161 YFXXXX 114146417 UNIVERSAL 114146418 PHYSIOLOGIC 114146419 Sampling 114146420 PUMP 114146421 PSP 114146422 Capable 114146423 RAPID 114146424 RESPONSE 114146425 BREATHING 114146426 CDC Docket Import 114146427 CDC Docket Import CDC Prosecuting 114146428 NIOSH-HELD TAB-2760 114096939 Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines William King, Jonathan Szalajda This CDC invention entails methods and apparatuses for <em>in situ</em> testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. Applying this phenomena to occupational health and safety, CDC researchers have developed novel ultrasonics technology to identify and quantify respirator seal leakage in real-time. Small, low power consuming, and inexpensive apparatuses and methods for generating and detecting ultrasound may be easily obtained and customized for a given respirator and/or application.<br /><br /> By correlating user activity to seal sensor data, a precise understanding and awareness of respirator integrity may be obtained. When coupled with a subject alarm, these integrated values can immediately alert a user when a threshold of environmental exposure has been reached. Such real-time feedback will be invaluable to users in dangerous occupational activities, such as firefighters, biodefense and chemical spill first responders, mining applications, etc. Additionally, this invention possesses immense value for respirator mask manufacturers and workplace training programs for employees engaged in mandatory respirator usage applications. <ul> <li>Small, low power consuming, and inexpensive apparatuses and methods may be employed</li> <li>Real-time monitoring and feedback greatly diminish risk of user exposure to environmental hazards</li> </ul> <ul> <li>Manufacturers of respirators, leakage assessment devices and applied ultrasonic technology</li> <li>Regulators of respiratory protection plans</li> <li>Biohazard, biodefense and hazardous chemical handling and disposal</li> <li>Surgery/hospital training and use</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AE2XXX, AE3XXX, AEROSOL, AEROSOLS, AEXXXX, AXXXXX, Biodefense, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Devices, MASK, NIOSH-NPPTL, Preventative, PROCESS, Protection, Respirator, respiratory, SAFETY, Situ, TESTING, ultrasonic, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108508 Szalajda, Jonathan CDC - NIOSH CDC Szalajda, Jonathan (CDC) 0 114108507 King, William CDC - NIOSH CDC King, William (CDC) 1 114108507 King, William CDC - NIOSH CDC King, William (CDC) 1 114108508 Szalajda, Jonathan CDC - NIOSH CDC Szalajda, Jonathan (CDC) 0 114102080 Ultrasonic In Situ Respiratory Mask Testing Process And Mask E-174-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities.">yogikala.prabhu@nih.gov</a><br> 114167615 E-174-2013-0 E-174-2013-0-US-01 Ultrasonic In Situ Respiratory Mask Testing Process And Mask PRV US 61/329,846 Abandoned US <br />Provisional (PRV) 61/329,846<br />Filed on 2012-04-30<br />Status: Abandoned 114167616 E-174-2013-0 E-174-2013-0-US-02 Ultrasonic In Situ Respiratory Mask Testing Process And Mask ORD US 8,573,199 13/098,980 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8573199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8573199">8,573,199</a><br />Filed on 2011-05-02<br />Status: Abandoned 114125162 AEXXXX 114125163 AXXXXX 114125164 AE2XXX 114125165 AE3XXX 114125166 VBXXXX 114125167 VJXXXX 114125168 VKXXXX 114125169 VLXXXX 114125170 VOXXXX 114125171 VPXXXX 114125172 WAXXXX 114125173 WCXXXX 114125174 WEXXXX 114125175 WFXXXX 114125176 WGXXXX 114125177 WIXXXX 114125178 WMXXXX 114125179 XDXXXX 114125180 XIXXXX 114125181 YEXXXX 114125182 YFXXXX 114146429 ultrasonic 114146430 Situ 114146431 respiratory 114146432 MASK 114146433 TESTING 114146434 PROCESS 114146435 CDC Docket Import 114146436 CDC Docket Import CDC Prosecuting 114146437 NIOSH-NPPTL 114146438 AEROSOLS 114146439 AEROSOL 114146440 Preventative 114146441 Protection 114146442 SAFETY 114146443 Devices 114146444 DEVICE 114146445 Biodefense 114146446 Respirator TAB-2698 114096879 Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Thomas Reid, Millie Schafer This invention relates to detecting <em>Histoplasma capsulatum</em> by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by <em>H. capsulatum</em>, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.<br /><br /> Test samples may originate from the environment (soil, for example), where <em>H. capsulatum</em> spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of <em>H. capsulatum</em> in a sample using a nested, or two-stage, PCR assay. <ul> <li>Rapid and precise</li> <li>Cost-effective</li> <li>Easily adapted for H. capsulatum detection kits</li> <li>Can positively identify small sample sizes of as few as 10 spores</li> <li>High-throughput capable</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Occupational health and safety screening for workers who may encounter bird or bat waste</li> <li>Screening biological or soil samples for the presence of fungal pathogens</li> <li>Environment testing for immunocompromised patients</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2013-12-23 AA5XXX, AAXXXX, AIDS, assay, Avian, AXXXXX, CAPSULATUM, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA1XXX, DAXXXX, DETECTING, Detection, diagnostic, DXXXXX, FUNGAL, FUNGI, fungus, HISTOPLASMA, Histoplasmosis, HIV, Method, NESTED, NIOSH-DART, Nucleic, nucleic acid, NUCLEIC ACID DETECTION, PATHOGEN, PATHOGENIC, PATHOGENS, PCR, PCR ASSAY, RAPID, SENSITIVE, VKXXXX, VOXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, XHXXXX, XIXXXX, YBXXXX, Zoo, Zoonotic False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-293-2013-0 E-332-2013-0 E-232-2013-0 E-335-2013-0 114171964 Reid TM, Schafer MP. https://www.ncbi.nlm.nih.gov/pubmed/10441199 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10441199">Reid TM, Schafer MP.</a> 114171965 CDC Fact Sheet: Histoplasmosis https://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109FS.pdf <a href="https://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109FS.pdf">CDC Fact Sheet: Histoplasmosis</a> 114108324 Reid, Thomas CDC - NIOSH CDC Reid, Thomas (CDC) 0 114108325 Schafer, Millie CDC - NIOSH CDC Schafer, Millie (CDC) 1 114108325 Schafer, Millie CDC - NIOSH CDC Schafer, Millie (CDC) 1 114108324 Reid, Thomas CDC - NIOSH CDC Reid, Thomas (CDC) 0 114102008 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM E-313-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples.">yogikala.prabhu@nih.gov</a><br> 114167422 E-313-2013-0 E-313-2013-0-US-01 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM PRV US 60/082,477 Abandoned US <br />Provisional (PRV) 60/082,477<br />Filed on 1998-04-21<br />Status: Abandoned 114167423 E-313-2013-0 E-313-2013-0-PCT-02 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM PCT Patent Cooperation Treaty PCT/US1999/008731 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/008731<br />Filed on 1999-04-20<br />Status: Expired 114167424 E-313-2013-0 E-313-2013-0-US-05 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM National Stage US 6,469,156 09/673,298 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469156">6,469,156</a><br />Filed on 2001-01-12<br />Status: Expired 114124145 AXXXXX 114124146 AAXXXX 114124147 AA5XXX 114124148 DXXXXX 114124149 DAXXXX 114124150 DA1XXX 114124151 VKXXXX 114124152 VOXXXX 114124153 VPXXXX 114124154 WBXXXX 114124155 WCXXXX 114124156 WFXXXX 114124157 WGXXXX 114124158 WIXXXX 114124159 WMXXXX 114124160 XCXXXX 114124161 XEXXXX 114124162 XHXXXX 114124163 XIXXXX 114124164 YBXXXX 114145731 RAPID 114145732 SENSITIVE 114145733 Method 114145734 DETECTING 114145735 HISTOPLASMA 114145736 CAPSULATUM 114145737 nucleic acid 114145738 Nucleic 114145739 fungus 114145740 FUNGI 114145741 FUNGAL 114145742 PATHOGENS 114145743 CDC Docket Import 114145744 CDC Docket Import CDC Prosecuting 114145745 NIOSH-DART 114145746 PATHOGENIC 114145747 PATHOGEN 114145748 AIDS 114145749 HIV 114145750 Detection 114145751 diagnostic 114145752 assay 114145753 PCR ASSAY 114145754 PCR 114145755 Avian 114145756 Zoonotic 114145757 Zoo 114145758 Histoplasmosis 114145759 CDC 114145760 NUCLEIC ACID DETECTION 114145761 NESTED TAB-2709 114096888 Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis CDC Antibodies, Cardiology, Consumer Products, Dental, Dermatology, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Materials, Therapeutics Antibodies Cardiology Consumer Products Dental Dermatology Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Materials Therapeutics Donald Beezhold, Victor Johnson, Tinashe Ruwona, Detlef Schmechel, Paul Siegel CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge. <br /><br /> This invention is a cost-effective, objective alternative for clinical assessment of occupational/environmental dNCO exposure in patient samples. These antibodies may also provide for passive-immunization and prevention of allergic contact dermatitis and/or asthma that can result from extended dermal exposure to dNCO contaminated surfaces and vapors. Further, the present technology allows for high-throughput testing of workplace dNCO air, fabric and working-surface contamination. <ul> <li>Ready for use in high-throughput immuno-histochemistry biomarker detection assays and kits.</li> <li>Two sandwich ELISAs have been developed and validated using human samples.</li> <li>Monitoring is currently performed by elaborate analytical chemical assays; this technology is more rapid and cost effective for dNCO exposure/contamination assessment.</li> <ul> <li>Occupational/environmental safety biomonitoring of polyurethane-worker/user exposure to diisocyanates(dNCOs).</li> <li>Clinical diagnostic use.</li> <li>dNCO-induced allergy/asthma prevention by passive immunization</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AAXXXX, AC5XXX, ACXXXX, AE2AXX, AE2CXX, AE2XXX, AE3XXX, AEXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, CONJUGATES, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IDXXXX, Isocyanate, IXXXXX, Methods, NIOSH-HELD, Relating, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> </li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171975 Lemons AR, et al. http://www.ncbi.nlm.nih.gov/pubmed/24012971 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24012971">Lemons AR, et al.</a> 114171976 Ruwona TB, et al. http://www.ncbi.nlm.nih.gov/pubmed/20568997 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20568997">Ruwona TB, et al.</a> 114171977 Ruwona TB, et al. http://www.ncbi.nlm.nih.gov/pubmed/21878336 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21878336">Ruwona TB, et al.</a> 114108359 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 0 114108360 Ruwona, Tinashe CDC - NIOSH CDC Ruwona, Tinashe (CDC) 0 114108361 Schmechel, Detlef CDC - NIOSH CDC Schmechel, Detlef (CDC) 0 114108362 Johnson, Victor CDC - NIOSH CDC Johnson, Victor (CDC) 0 114108358 Siegel, Paul CDC - NIOSH CDC Siegel, Paul (CDC) 1 114108358 Siegel, Paul CDC - NIOSH CDC Siegel, Paul (CDC) 1 114108359 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 0 114108360 Ruwona, Tinashe CDC - NIOSH CDC Ruwona, Tinashe (CDC) 0 114108361 Schmechel, Detlef CDC - NIOSH CDC Schmechel, Detlef (CDC) 0 114108362 Johnson, Victor CDC - NIOSH CDC Johnson, Victor (CDC) 0 114102018 Methods And Compositions Relating To Isocyanate Conjugates E-189-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis.">yogikala.prabhu@nih.gov</a><br> 114167449 E-189-2013-0 E-189-2013-0-US-01 Methods And Compositions Relating To Isocyanate Conjugates PRV US 61/104,429 Abandoned US <br />Provisional (PRV) 61/104,429<br />Filed on 2008-10-10<br />Status: Abandoned 114167450 E-189-2013-0 E-189-2013-0-US-02 Methods And Compositions Relating To Isocyanate Conjugates ORD US 8,828,667 12/577,241 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828667 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828667">8,828,667</a><br />Filed on 2009-10-12<br />Status: Issued 114124262 IXXXXX 114124263 IAXXXX 114124264 IA2XXX 114124265 IA3XXX 114124266 IA5XXX 114124267 IDXXXX 114124268 AAXXXX 114124269 ACXXXX 114124270 AC5XXX 114124271 AEXXXX 114124272 AE2XXX 114124273 AE2CXX 114124274 AE2AXX 114124275 AE3XXX 114124276 VPXXXX 114124277 WCXXXX 114124278 WFXXXX 114124279 WGXXXX 114124280 WIXXXX 114124281 WJXXXX 114124282 WMXXXX 114124283 XAXXXX 114124284 XCXXXX 114124285 XIXXXX 114124286 YAXXXX 114124287 YBXXXX 114145861 Methods 114145862 Compositions 114145863 Relating 114145864 Isocyanate 114145865 CONJUGATES 114145866 CDC Docket Import 114145867 CDC Docket Import CDC Prosecuting 114145868 NIOSH-HELD TAB-2710 114096889 Warning System for Mobile Machinery Hazardous Zones CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Carl Ganoe, William Schiffbauer This invention relates to a warning system designed to protect individuals working near hazardous machinery. The system consists of a proximity-warning transmitter mounted to hazardous machinery and a receiver, worn by a worker, capable of detecting the transmitter signal. This worker-safety system can incorporate visual alerts and audible alerts. It also allows automatic shutdown of machinery upon receiver activation and may be particularly useful in the mining industry. <ul> <li>Easy transmitter installation</li> <li>Signal can be adjusted for an audio or visual "warning zone alert" and a proximal "imminent danger zone alert"</li> </ul> <ul> <li>Auxiliary safety equipment for heavy machinery</li> <li>Occupational health and safety</li> <li>Mining worker safety</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AE1CXX, AE1XXX, AE2BXX, AE2XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, HAZARDOUS, Machine, MOBILE, NIOSH-PRL, VPXXXX, WARNING, WEXXXX, WFXXXX, WGXXXX, WMXXXX, Working, XDXXXX, XIXXXX, YEXXXX, YFXXXX, ZONE False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114171978 Schiffbauer WH. http://www.ncbi.nlm.nih.gov/pubmed/10519790 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10519790">Schiffbauer WH.</a> 114108364 Ganoe, Carl CDC - NIOSH CDC Ganoe, Carl (CDC) 0 114108363 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 1 114108363 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 1 114108364 Ganoe, Carl CDC - NIOSH CDC Ganoe, Carl (CDC) 0 114102019 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING E-239-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones.">yogikala.prabhu@nih.gov</a><br> 114167451 E-239-2013-0 E-239-2013-0-US-01 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING SYSTEM ORD US 5,939,986 08/733,846 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5939986 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5939986">5,939,986</a><br />Filed on 1996-10-18<br />Status: Expired 114167452 E-239-2013-0 E-239-2013-0-US-02 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING DIV US 09/575,475 Abandoned US <br />Divisional (DIV) 09/575,475<br />Filed on 2000-05-19<br />Status: Abandoned 114124288 AXXXXX 114124289 AEXXXX 114124290 AE1XXX 114124291 AE1CXX 114124292 AE2XXX 114124293 AE2BXX 114124295 VPXXXX 114124296 WEXXXX 114124297 WFXXXX 114124298 WGXXXX 114124299 WMXXXX 114124300 XDXXXX 114124301 XIXXXX 114124302 YEXXXX 114124303 YFXXXX 114145869 MOBILE 114145870 Machine 114145871 HAZARDOUS 114145872 Working 114145873 ZONE 114145874 WARNING 114145875 CDC Docket Import 114145876 CDC Docket Import CDC Prosecuting 114145877 NIOSH-PRL TAB-2711 114096890 Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Therapeutics Vaccines Teh-Hsun Chen, Herbert Edgell, Jyoti Keswani This invention consists of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. The apparatus not only separates out aerosols from the atmosphere, but also serves as a collection tube for aerosol particles. Through its unique design, this CDC-developed apparatus is able to use the centrifugal force of the air flow on aerosolized particles forcing them to separate by size. Since the sample is collected directly in a microcentrifuge tube, in situ analysis of the ambient particulates can be performed. Analysis may include, but is not limited to, PCR, immunoassay analysis, microscopic spore counting, and counting colony-forming units. The device should also have many additional uses for environmental surveillance and occupational health applications. <ul> <li>Rapid, on-site sampling and analysis.</li> <li>Alternative to surface-sampling and culturing for aerosolized biological agents.</li> <li>Superior extraction efficiency compared to filters, impingers, and impactors.</li> <li>Real-world testing demonstrated device's ability to collect airborne mold and mycotoxins, pollen and pollen fragments, airborne dust particulates, as well as airborne influenza virus in a hospital environment.</li> </ul> <ul> <li>Analysis of ambient air particulates</li> <li>Environmental surveillance</li> <li>Occupational safety monitoring</li> <li>Biodefense</li> <li>Long-term exposure assessment</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AA2XXX, AA4XXX, AAXXXX, AE1XXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AFXXXX, AIR, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Method, NIOSH-HELD, Sampling, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114171265 Chen BT, et al. http://dx.doi.org/10.1080/027868290511218 <a href="http://dx.doi.org/10.1080/027868290511218">Chen BT, et al.</a> 114171266 Macher JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18720289 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18720289">Macher JM, et al.</a> 114171267 Macher JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18780236 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18780236">Macher JM, et al.</a> 114171268 Su WC, et al. http://www.ncbi.nlm.nih.gov/pubmed/22833144 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22833144">Su WC, et al.</a> 114171269 Wang CH, et al. http://www.ncbi.nlm.nih.gov/pubmed/25799419 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25799419">Wang CH, et al.</a> 114171979 Lindsley WG, et al. http://www.ncbi.nlm.nih.gov/pubmed/17075620 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17075620">Lindsley WG, et al.</a> 114171980 Blachere FM, et al. http://www.ncbi.nlm.nih.gov/pubmed/19453416 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19453416">Blachere FM, et al.</a> 114171981 Lindsley WG, et al. http://www.ncbi.nlm.nih.gov/pubmed/21152051 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21152051">Lindsley WG, et al.</a> 114171982 Cao G, et al. http://www.ncbi.nlm.nih.gov/pubmed/21975583 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21975583">Cao G, et al.</a> 114171983 CDC-NIOSH Cyclone Bioaerosol Sampler webpage http://www.cdc.gov/niosh/topics/aerosols/biosampler.html <a href="http://www.cdc.gov/niosh/topics/aerosols/biosampler.html">CDC-NIOSH Cyclone Bioaerosol Sampler webpage</a> 114172037 NIOSH Personal Bioaerosol Cyclone Sampler video http://youtu.be/YHC0hw-DQTc <a href="http://youtu.be/YHC0hw-DQTc">NIOSH Personal Bioaerosol Cyclone Sampler video</a> 114108366 Keswani, Jyoti CDC - NIOSH CDC Keswani, Jyoti (CDC) 0 114108367 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114108365 Chen, Teh-Hsun CDC - NIOSH CDC Chen, Teh-Hsun (CDC) 1 114108365 Chen, Teh-Hsun CDC - NIOSH CDC Chen, Teh-Hsun (CDC) 1 114108366 Keswani, Jyoti CDC - NIOSH CDC Keswani, Jyoti (CDC) 0 114108367 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114102020 AIR SAMPLING DEVICE AND METHOD OF USE E-244-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size.">yogikala.prabhu@nih.gov</a><br> 114167453 E-244-2013-0 E-244-2013-0-PCT-02 AIR SAMPLING DEVICE AND METHOD OF USE PCT Patent Cooperation Treaty PCT/US2004/032378 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/032378<br />Filed on 2004-10-01<br />Status: Expired 114167454 E-244-2013-0 E-244-2013-0-US-01 AIR SAMPLING DEVICE AND METHOD OF USE PRV US 60/512,252 Abandoned US <br />Provisional (PRV) 60/512,252<br />Filed on 2003-10-17<br />Status: Abandoned 114167455 E-244-2013-0 E-244-2013-0-US-03 AIR SAMPLING DEVICE AND METHOD OF USE National Stage US 7,370,543 10/575,048 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7370543 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7370543">7,370,543</a><br />Filed on 2006-04-04<br />Status: Abandoned 114167456 E-244-2013-0 E-244-2013-0-US-04 AIR SAMPLING DEVICE AND METHOD OF USE DIV US 8,205,511 12/152,156 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8205511 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8205511">8,205,511</a><br />Filed on 2008-05-12<br />Status: Abandoned 114124294 AXXXXX 114124304 AEXXXX 114124305 AE1XXX 114124306 AE2XXX 114124307 AE3XXX 114124308 AE4XXX 114124309 AFXXXX 114124310 AAXXXX 114124311 AA2XXX 114124312 AA4XXX 114124315 VBXXXX 114124316 VJXXXX 114124317 VKXXXX 114124318 VLXXXX 114124319 VOXXXX 114124320 WAXXXX 114124321 WBXXXX 114124322 WCXXXX 114124323 WEXXXX 114124324 WFXXXX 114124325 WGXXXX 114124326 WMXXXX 114124327 XDXXXX 114124328 XHXXXX 114124329 XIXXXX 114124330 YEXXXX 114124331 YFXXXX 114145878 AIR 114145879 Sampling 114145880 DEVICE 114145881 Method 114145882 CDC Docket Import 114145883 CDC Docket Import CDC Prosecuting 114145884 NIOSH-HELD TAB-2728 114096908 Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Pramod Kulkarni, Chaolong Qi This CDC developed invention is a novel device for a miniature, nonradioactive bipolar charger to electrically charge aerosol particles for use in personal and portable aerosol instrumentation. Such devices are an integral component of aerosol instruments employing electrical mobility-based techniques. Current, commercial state-of-the-art mobility instruments employ aerosol chargers using radioactivity to achieve bipolar particle charging and, therefore, are not suitable for field-portable instruments. Due to strict regulatory restrictions on use of radioactive materials, these radioactive chargers also tend to be too bulky for use in compact aerosolization instruments. <p>This invention circumvents these two critical drawbacks by eliminating radioactivity and miniaturizing overall unit size (1x0.75 x 0.5 inch). Other unique aspects of the invention entail elimination of the need for additional air flows (other than the aerosol sample flow), minimal power consumption, a low per-unit cost, and simplicity of operation. In all, excellent transmission efficiency, steady-state charging characteristics and the miniature size make this bipolar particle charger well-suited for integration with portable or personal aerosol instrumentation.</p> <ul> <li>Non-radioactive; no associated regulatory or transportation issues</li> <li>Low-cost and requires very little power to operate</li> <li>Additional air flows other than sample airflow are unnecessary</li> <li>Unit is small (1x0.75x0.5in;2.54x1.91x1.27cm) and highly portable</li> <li>Eliminates a major barrier for reliable aerosol sampling using "bipolar charger + differential mobility analyzer + condensation particle detector" scheme in a compact device</li> </ul> <ul> <li>Personal and portable aerosol instrumentation</li> <li>Component of field-use device for determining workplace/environmental exposure to ultrafine aerosols and airborne nanoparticles</li> <li>Tool for environmental/occupational health, toxicology, workplace control evaluations and hazard identification involving aerosol exposure</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-20 AA2XXX, AA4BXX, AAXXXX, AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEROSOL, AEXXXX, AFXXXX, AGXXXX, AXXXXX, BIPOLAR, CDC Docket Import, CDC Docket Import CDC Prosecuting, Charger, NIOSH-DART, NON-RADIOACTIVE, PARTICLES, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108415 Qi, Chaolong CDC - NIOSH CDC Qi, Chaolong (CDC) 0 114108414 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108414 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108415 Qi, Chaolong CDC - NIOSH CDC Qi, Chaolong (CDC) 0 114102044 Non-Radioactive Bipolar Charger For Aerosol Particles E-146-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation.">yogikala.prabhu@nih.gov</a><br> 114167500 E-146-2013-0 E-146-2013-0-US-01 Non-Radioactive Bipolar Charger For Aerosol Particles ORD US 8,611,066 13/315,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8611066 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8611066">8,611,066</a><br />Filed on 2011-12-09<br />Status: Issued 114124558 AXXXXX 114124559 AAXXXX 114124560 AEXXXX 114124561 AFXXXX 114124562 AGXXXX 114124563 AE1XXX 114124564 AE2XXX 114124565 AE2BXX 114124566 AE3XXX 114124567 AA2XXX 114124568 AA4BXX 114124569 VBXXXX 114124570 VJXXXX 114124571 VKXXXX 114124572 VLXXXX 114124573 VOXXXX 114124574 VPXXXX 114124575 WAXXXX 114124576 WBXXXX 114124577 WCXXXX 114124578 WFXXXX 114124579 WGXXXX 114124580 WIXXXX 114124581 WMXXXX 114124582 XDXXXX 114124583 XIXXXX 114124584 YEXXXX 114146051 BIPOLAR 114146052 NON-RADIOACTIVE 114146053 Charger 114146054 AEROSOL 114146055 PARTICLES 114146056 CDC Docket Import 114146057 CDC Docket Import CDC Prosecuting 114146058 NIOSH-DART TAB-2614 114096808 Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus) CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Daniel Lewis, Detlef Schmechel <p>CDC NIOSH researchers have developed a simple and rapid detection technique for <em>Stachybotrys chartarum</em> (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in <em>Stachybotrys chartarum</em>. These antibodies can be used in immunologic detection assays to detect and possibly quantify <em>Stachybotrys chartarum</em> in environmental samples, and to our knowledge, they do not cross react with other fungi. The presence of mold in indoor environments has been associated with adverse health effects such as infections (in immunocompromised people) or allergies. Individuals with asthma or those with weaker immune systems can be affected more by mold exposure. Accurate detection methods are needed to measure mold contamination. Traditional methods for monitoring of molds are based on sample cultivation and microscopic analysis which can be time and labor intensive, and require expert classification skills. Immunoassays can potentially overcome these limitations and have been successfully developed for numerous biological aerosols. For more information on <em>Stachybotrys chartarum</em> and other molds, visit CDC&rsquo;s fact page:<a href="http://www.cdc.gov/mold/stachy.htm" target="_blank">&nbsp;www.cdc.gov/mold/stachy.htm</a>.</p> <ul> <li>Simple, rapid, and specific detection of <em>Stachybotrys chartarum</em></li> <li>Easily adaptable for kit format</li> <li>Less labor-intensive than spore counting or culturing</li> <li>Adaptable for high sample volumes (or throughputs) being processed</li> <li>Potential use in proteomics chip for screening multiple pathogens simultaneously</li> </ul> <ul> <li>Detection of <em>Stachybotrys chartarum</em> antigens in contaminated building materials or field environments with a color-changing dipstick assay</li> <li>Occupational health and home safety</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2016-06-16 5/19/2016 -- per email from Karen Surabian, CDC is requesting that abstract be temporarily removed from the OTT website... --ecr 6/15/2016 -- updated abstract received from Karen Surabian, designated as Add... --ecr AE2CXX, AE2XXX, AE3XXX, AEXXXX, Against, antibodies, DA1XXX, FUNGI, Methods, monoclonal, Their, VKXXXX, VOXXXX, WCXXXX, WFXXXX, WGXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YBXXXX, YEXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108064 Lewis, Daniel CDC - NIOSH CDC Lewis, Daniel (CDC) 0 114108063 Schmechel, Detlef CDC - DIR CDC Schmechel, Detlef (CDC) 1 114108063 Schmechel, Detlef CDC - DIR CDC Schmechel, Detlef (CDC) 1 114108064 Lewis, Daniel CDC - NIOSH CDC Lewis, Daniel (CDC) 0 114101932 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE E-224-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus). Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus).">yogikala.prabhu@nih.gov</a><br> 114167199 E-224-2013-0 E-224-2013-0-PCT-02 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE PCT Patent Cooperation Treaty PCT/US2002/025493 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/025493<br />Filed on 2002-08-09<br />Status: Expired 114167200 E-224-2013-0 E-224-2013-0-US-01 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE PRV US 60/311,458 Abandoned US <br />Provisional (PRV) 60/311,458<br />Filed on 2001-08-10<br />Status: Abandoned 114167201 E-224-2013-0 E-224-2013-0-US-03 ANTIBODIES AGAINST STACHYBOTRYS CHARTARUM AND METHODS FOR THEIR USE National Stage US 7,368,256 10/483,921 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7368256 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7368256">7,368,256</a><br />Filed on 2004-01-14<br />Status: Expired 114121876 DA1XXX 114121877 VKXXXX 114121878 VOXXXX 114121879 WCXXXX 114121880 WFXXXX 114121881 WGXXXX 114121905 WMXXXX 114121906 XAXXXX 114121907 XCXXXX 114121908 XIXXXX 114121909 YBXXXX 114121910 YEXXXX 114123580 AE3XXX 114123581 AEXXXX 114123582 AE2CXX 114123586 AE2XXX 114144856 monoclonal 114144857 antibodies 114144858 Against 114144859 FUNGI 114144860 Methods 114144861 Their TAB-2623 114096817 Generation of Artificial Mutation Controls for Diagnostic Testing CDC Cardiology, Computational models/software, Consumer Products, Dental, Dermatology, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Neurology, Oncology, Ophthalmology, Pulmonology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Dermatology Diagnostics Endocrinology Immunology Infectious Disease Licensing Neurology Oncology Ophthalmology Pulmonology Research Materials Software / Apps Therapeutics Laurina Williams This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls has proven to be a major obstacle to the advancement of clinical molecular genetic testing, validation, quality control (QC), quality assurance (QA), and required proficiency testing. This method provides a consistent and renewable source of positive control material, as well as an alternative to patient-derived mutation-positive samples. <ul> <li>Positive controls can be included in new kits or packaged with pre-existing assays</li> <li>Increased accuracy in diagnosis compared to current controls</li> <li>Consistent and renewable source for high-quality controls containing mutations of interest</li> </ul> <ul> <li>Generation of positive controls for molecular genetic tests, particularly for tests to detect cystic fibrosis</li> </ul> Various international patent applications pending or issued. 2022-10-19 2026-05-14 2026-05-14 2013-08-23 AA1XXX, AA5XXX, AA6XXX, AAXXXX, ARTIFICIAL, AXXXXX, CA1AXX, CA1CXX, CA1XXX, CAXXXX, controls, CXXXXX, diagnostic, GAXXXX, GCXXXX, GXXXXX, IA1BXX, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IXXXXX, MUTATION, NA2XXX, OA2XXX, TESTING, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX False True </ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108095 Williams, Laurina CDC - DIR CDC Williams, Laurina (CDC) 0 114108095 Williams, Laurina CDC - DIR CDC Williams, Laurina (CDC) 0 114101941 Artificial Mutation Controls For Diagnostic Testing E-255-2013-0 Closed Centers for Disease Control and Prevention (CDC), University of California, Los Angeles (UCLA) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing.">yogikala.prabhu@nih.gov</a><br> 114167219 E-255-2013-0 E-255-2013-0-PCT-02 Artificial Mutation Controls For Diagnostic Testing PCT Patent Cooperation Treaty PCT/US2005/008108 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/008108<br />Filed on 2005-03-11<br />Status: Expired 114167220 E-255-2013-0 E-255-2013-0-US-01 Artificial Mutation Controls For Diagnostic Testing PRV US 60/552,979 Abandoned US <br />Provisional (PRV) 60/552,979<br />Filed on 2004-03-11<br />Status: Abandoned 114167221 E-255-2013-0 E-255-2013-0-US-08 Artificial Mutation Controls For Diagnostic Testing National Stage US 8,603,745 10/598,589 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603745 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603745">8,603,745</a><br />Filed on 2006-09-05<br />Status: Abandoned 114123649 AXXXXX 114123650 AAXXXX 114123651 AA1XXX 114123652 AA5XXX 114123653 AA6XXX 114123654 CXXXXX 114123655 CAXXXX 114123656 CA1XXX 114123657 CA1AXX 114123658 CA1CXX 114123659 GAXXXX 114123660 GXXXXX 114123661 GCXXXX 114123662 IXXXXX 114123663 IAXXXX 114123664 IA1BXX 114123665 IA3XXX 114123666 IA2XXX 114123667 IA5XXX 114123668 NA2XXX 114123669 OA2XXX 114125360 VPXXXX 114125361 WBXXXX 114125362 WHXXXX 114125363 WIXXXX 114125364 WMXXXX 114125365 XBXXXX 114125366 XCXXXX 114125367 XEXXXX 114125368 YAXXXX 114125369 YBXXXX 114144941 ARTIFICIAL 114144942 MUTATION 114144943 controls 114144944 diagnostic 114144945 TESTING TAB-5085 164394726 Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions NCI Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Diagnostics Immunology Infectious Disease Licensing Oncology Therapeutics Swati Choksi, Zheng-gang Liu, Yeon-Ji Park, PeiXing Wan <h2>Summary:</h2> <p>Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions,<span style="font-size:11.0pt"> and others.&nbsp;&nbsp;&nbsp; </span></p> <h2>Description of Technology:</h2> <p><span style="font-size:11.0pt">Investigators at the National Cancer Institute (NCI) have identified and therapeutically validated a distinctive, disease-restricted driver of thrombosis: soluble tissue factor (sTF). sTF is generated through proteolytic cleavage during inflammatory cell death.</span></p> <p><span style="font-size:11.0pt">Mechanistically, the researchers demonstrated that sTF generation is not limited to necroptosis but represents a conserved outcome of multiple inflammatory cell death pathways, including pyroptosis and NETtosis.</span></p> <p><span style="font-size:11.0pt">Pathological thrombosis remains a leading cause of morbidity and mortality in sepsis, cancer, autoimmune diseases, viral infections, and inflammatory disorders. Current anticoagulant and thrombosis treatments options such as Heparins and Warfarin are effective at reducing clot formation, but act indiscriminately on the coagulation cascade, disrupt normal hemostasis, and are associated with significant bleeding risk. Current thrombosis diagnostics, D-dimer, a fibrin degradation byproduct, is a late stage marker that lacks sensitivity. This invention provides an alternative for early detection based on sTF that is more sensitive and specific. </span></p> <p><span style="font-size:11.0pt">To selectively target this mechanism, the team developed novel humanized monoclonal antibodies (e.g., 58B3 and 56E5) that specifically recognize human soluble tissue factor (hsTF), but not full-length membrane-bound tissue factor (flTF). This selectivity preserves physiological hemostasis while inhibiting pathological coagulation.</span></p> <p><span style="font-size:11.0pt">In vivo validation using human samples of various clinical diseases demonstrated that administration of sTF-specific antibodies prevents fibrinogen depletion and reduces thrombin&ndash;antithrombin (TAT) complex elevation, effectively normalizing coagulation parameters. These results establish proof of concept that selective sTF neutralization can block pathological thrombosis without systemic anticoagulation.</span></p> <p><span style="font-size:11.0pt">By establishing sTF as a unifying mechanistic link between inflammatory cell death and thrombosis across sepsis, cancer, infection, autoimmune disease, cardiovascular disorders, and metabolic inflammation, this antibody platform represents a first-in-class strategy to selectively inhibit pathological coagulation while preserving normal hemostasis. The approach offers a safer, more precise therapeutic and diagnostic alternative to conventional anticoagulants.</span></p> <p><span style="font-size:11.0pt">The humanized monoclonal antibodies, as well as methods of using sTF as a target for diagnosis, treatment and prevention of thrombosis and associated diseases are available for licensing or collaborative development to advance clinical translation. Partnership opportunities include preclinical optimization, clinical development, and diagnostic assay co-development.</span></p> <h2>Potential Commercial Applications:</h2> <ul> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection and monitoring of sTF in plasma.</span></span></span><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection and monitoring of thrombosis, </span>much more sensitive and specific test than the currently used D-dimer test<span style="font-size:11.0pt">.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Basis for diagnostic kits such as ELISA and point-of-care assays.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection of DVT and PE with radiolabeled anti-sTF antibody in combination with ultrasound /CT scan </span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use </span><span style="font-size:11.0pt">for sepsis-associated thrombosis.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for cancer-associated thrombosis.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use viral infection&ndash;associated thrombosis. </span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use autoimmune disorders.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use cardiovascular inflammatory diseases.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use </span><span style="font-size:11.0pt">for acute lung injury including <span style="background-color:white"><span style="color:#0a0a0a">Acute Respiratory Distress Syndrome ARD.</span></span></span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for metabolic and vascular inflammatory diseases</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for high efficient inhibition of thrombosis with anti-sTF-based bispecific antibodies. </span></span></span></li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Selective targeting of pathological soluble tissue factor (sTF).</li> <li>Preservation of normal hemostasis.</li> <li>Potential for long-acting biologic prevention.</li> <li>Specific mechanism-based intervention tied to inflammatory cell death.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for developing diagnostic, prognostic, preventative and therapeutic development of sTF. NCI is seeking collaborators with Access to clinical samples of thrombosis, and with experience of in vivo detection of thrombosis (e.g. DVT) in patients with current tools. Also seeking collaborators with experience in developing bi-specific antibodies. 2025-09-29 2026-05-12 2026-05-07 2026-05-12 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-05-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 164395085 Wan, P., Choksi, S., Park, YJ. et al. Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. Cell Res 35, 840–858 (2025). https://doi.org/10.1038/s41422-025-01167-8 Wan, P., Choksi, S., Park, YJ. et al. Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. Cell Res 35, 840–858 (2025). https://doi.org/10.1038/s41422-025-01167-8 167182477 Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022 Jan;8(1):21-27. doi: 10.1016/j.trecan.2021.09.003. Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022 Jan;8(1):21-27. doi: 10.1016/j.trecan.2021.09.003. 164394956 Liu, Zheng-gang NIH - NCI NCI Liu, Zheng-gang (NCI) 1 164394984 Choksi, Swati NIH - NCI NCI Choksi, Swati (NCI) 2 164395025 Wan, PeiXing NIH - NCI NCI Wan, PeiXing (NCI) 3 167182419 Park, Yeon-Ji NIH - NCI NCI Park, Yeon-Ji (NCI) 4 164394956 Liu, Zheng-gang NIH - NCI NCI Liu, Zheng-gang (NCI) 1 164394984 Choksi, Swati NIH - NCI NCI Choksi, Swati (NCI) 2 164395025 Wan, PeiXing NIH - NCI NCI Wan, PeiXing (NCI) 3 167182419 Park, Yeon-Ji NIH - NCI NCI Park, Yeon-Ji (NCI) 4 164394729 The soluble Tissue Factor generated by necroptosis-triggered shedding of the cell surface TF is responsible for septic shock and viral infection-induced thrombosis E-263-2023-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), NCI - CCR, NIH - NCI 83683663 Cremesti, Aida aida.cremesti@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB aida.cremesti@nih.gov?subject=Web Inquiry on [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions&body=Please send me information about technology [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cremesti, Aida<br><a href="mailto:aida.cremesti@nih.gov?subject=Web Inquiry on [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions&body=Please send me information about technology [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">aida.cremesti@nih.gov</a><br> 164394734 E-263-2023-0 E-263-2023-0-US-01 HUMANIZED ANTIBODIES SPECIFIC AGAINST SOLUBLE TISSUE FACTOR PRV US 63/783,685 Expired US <br />Provisional (PRV) 63/783,685<br />Filed on 2025-04-04<br />Status: Expired 166015111 E-263-2023-0 E-263-2023-0-PC-01 SOLUBLE TISSUE FACTOR, A NOVEL TARGET, AND ANTIBODIES, FOR DIAGNOSIS, PREVENTION AND TREATMENT OF THROMBOSIS AND RELATED CONDTIONS PCT Patent Cooperation Treaty PCT/US2026/022285 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/022285<br />Filed on 2026-04-03<br />Status: Pending TAB-3930 147157210 Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Lin-kun An, Christophe Marchand, Yves Pommier <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics. &nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that plays a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates the antiproliferative activity of TOP2 inhibitors. This suggest that combination therapies consisting of TDP2 and TOP2 inhibitors have a synergistic effect on tumor tissues. Therefore, TDP2 represents a promising anti-cancer pharmacological target as a monotherapy or part of a combination therapy.</p> <p>The NCI investigators and their collaborators have discovered a series of novel furoquinolinedione derivatives as specific TDP2 inhibitors that could act as anti-cancer therapeutics alone and/or potentiate the pharmacological action of TOP2 inhibitors. Systematic structure-activity relationship studies were conducted and demonstrated that several furoquinolinedione derivatives had TDP2 inhibitory activity in the low micromolar or submicromolar range and act in a dose-dependent manner. Further, enzyme-based assays showed the furoquinolinedione derivatives are specific to TDP2 and showed no inhibitory activity against TDP1 and TOP1.</p> <p>NCI is seeking licensees to further develop this family of compounds as anti-cancer agents. &nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Standalone cancer therapeutic</li> <li>Part of a combination cancer therapeutic with other drugs, such as TOP2 inhibitors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential first-in-class drug (novel mechanism of action and novel composition of matter)</li> <li>Selective inhibition of TDP2</li> <li>Can be used alone or in combination with TOP2 inhibitors</li> <li>Synergistic effect to boost the efficacy of TOP2 inhibitors (decrease effective dosage, minimize side effects)</li> <li>Potential for use across many cancer types</li> </ul> Researchers at the NCI seek licensing for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics 2017-10-23 2026-05-11 2026-01-13 2026-05-11 2017-10-23 CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-01-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162094 Yang, H., et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. (PMID 33839584) https://pubmed.ncbi.nlm.nih.gov/33839584/ <a href="https://pubmed.ncbi.nlm.nih.gov/33839584/">Yang, H., et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. (PMID 33839584)</a> 147162172 Yu, L.-M., et al. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2). (PMID 29677635). https://pubmed.ncbi.nlm.nih.gov/29677635/ <a href="https://pubmed.ncbi.nlm.nih.gov/29677635/">Yu, L.-M., et al. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2). (PMID 29677635).</a> 147162905 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 1 147162906 An, Lin-kun Lin-Kun An (SYSU) An, Lin-kun 2 147162904 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147162905 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 1 147162906 An, Lin-kun Lin-Kun An (SYSU) An, Lin-kun 2 147162904 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147158307 Furoquinolinedione Derivatives As Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Inhibitors E-275-2014-0 Filing authorized NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer&body=Please send me information about technology [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer&body=Please send me information about technology [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147161252 E-275-2014-0 E-275-2014-0-CA-04 Furoquinolinedione As Inhibitors Of TDP2 National Stage Canada 2973484 2973484 Issued Canada <br />National Stage 2973484<br />Filed on 2016-01-08<br />Status: Issued 147165346 E-275-2014-0 E-275-2014-0-US-01 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 PRV US 62/100,968 Abandoned US <br />Provisional (PRV) 62/100,968<br />Filed on 2015-01-08<br />Status: Abandoned 147165347 E-275-2014-0 E-275-2014-0-PCT-02 Furoquinolinedione As Inhibitors Of TDP2 PCT Patent Cooperation Treaty PCT/US2016/012672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/012672<br />Filed on 2016-01-08<br />Status: Expired 147165348 E-275-2014-0 E-275-2014-0-AU-03 Furoquinolinedione As Inhibitors Of TDP2 National Stage Australia 2016205137 2016205137 Issued Australia <br />National Stage 2016205137<br />Filed on 2016-01-08<br />Status: Issued 147165349 E-275-2014-0 E-275-2014-0-EP-05 Furoquinolinedione As Inhibitors Of TDP2 National Stage European Patent 3242881 16703001.4 Issued European Patent <br />National Stage 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165350 E-275-2014-0 E-275-2014-0-US-06 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 National Stage US 10,906,914 15/542,560 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10906914 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10906914">10,906,914</a><br />Filed on 2017-07-10<br />Status: Issued 147165351 E-275-2014-0 E-275-2014-0-CN-07 Furoquinolinedione As Inhibitors Of TDP2 National Stage China ZL201680014742.7 201680014742.7 Issued China <br />National Stage 201680014742.7<br />Filed on 2016-01-08<br />Status: Issued 147165352 E-275-2014-0 E-275-2014-0-DE-08 Furoquinolinedione As Inhibitors Of TDP2 EP Germany 3242881 16703001.4 Issued Germany <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165353 E-275-2014-0 E-275-2014-0-FR-09 Furoquinolinedione As Inhibitors Of TDP2 EP France 3242881 16703001.4 Issued France <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165354 E-275-2014-0 E-275-2014-0-GB-10 Furoquinolinedione As Inhibitors Of TDP2 EP United Kingdom 3242881 16703001.4 Issued United Kingdom <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165355 E-275-2014-0 E-275-2014-0-CN-11 Furoquinolinedione As Inhibitors Of TDP2 DIV China ZL202110013140.2 202110013140.2 Issued China <br />Divisional (DIV) 202110013140.2<br />Filed on 2016-01-08<br />Status: Issued 147165356 E-275-2014-0 E-275-2014-0-US-12 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 CON US 11,999,747 17/146,327 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999747 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999747">11,999,747</a><br />Filed on 2021-01-11<br />Status: Issued 147174535 CANCER 147174537 Combination Therapies 147174538 Pommier 147174539 therapeutic 147174541 Topoisomerase 2 (TOP2) 147174543 Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors TAB-4990 157143819 Suppression Of Uveitis By A STAT3 Single Domain Antibody NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Neurology, Therapeutics Application Collaboration Ear Nose & Throat Licensing Neurology Therapeutics Charles Egwuagu, Sunanda Singh <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis.</p> <h2>Description of Technology:</h2> <p>&nbsp;Uveitis is caused by inflammation in the eye that causes pain and reduce vision in affected patients. Rates of uveitis in the United States occurs 1 in every 200 people with eye-related irritation. Permanent damage, such as vision loss, occurs if uveitis goes untreated. Prolonged use of drugs that help treat chronic uveitis, such as periocular or intravitreal corticosteroid injections, can cause serious side-effects such as glaucoma. Therefore, finding alternative treatments for uveitis is an imperative.&nbsp;</p> <p>Signal transducers and activators of transcription-3 (STAT3) regulates the differentiation of pathogenic Th17 lymphocyte cells implicated in several autoimmune diseases. Genetically modified mice incapable of inducing Th17 cells are resistant to developing uveitis. Therefore, targeting the STAT3 pathway required for the differentiation and expansion of Th17 cells has been proposed as a potential therapy for mitigating uveitis. However, the major impediment to therapeutically target intracellular proteins &ndash; such as STAT3 &ndash; is the inability to deliver inhibitors inside cells.&nbsp;</p> <p>Scientists at the NEI have discovered a novel STAT3-specific nanobody (SBT-100) that can cross the blood-retina-barrier (BRB), inhibit pathogenic Th17 lymphocytes and suppress experimental autoimmune uveitis (EAU). The antibody&rsquo;s small size, rapid clearance from the blood and sequence similarity with mammalian STAT3 render SBT-100 non-immunogenic. These factors provide important advantages for its therapeutic use not only for chronic uveitis, but also for inflammatory diseases like multiple sclerosis.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for uveitis</li> <li>Therapeutic for multiple sclerosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Non-immunogenic compared to current uveitis treatments</li> <li>Novel STAT3-specific nanobody</li> <li>Crosses the blood-retina-barrier (BRB)</li> <li>Rapid blood clearance</li> <li>Sequence similarity with mammalian STAT3</li> <li>Potential multi-use for central nervous system autoimmune diseases and other autoinflammatory diseases</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a STAT3 antibody that can suppress uveitis. 2024-07-17 2026-04-16 2026-05-06 2024-07-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157173612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157173719 Singh, Sunanda Singh Biotechnology, LLC Singh, Sunanda 2 157173612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157173719 Singh, Sunanda Singh Biotechnology, LLC Singh, Sunanda 2 157143822 STAT3-specific Single Domain Nanobody Inhibits Expansion Of Pathogenic Th17 Responses And Suppresses Uveitis In Mice E-164-2021-0 Filing authorized National Eye Institute (NEI), Singh Biotechnology LLC 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody&body=Please send me information about technology [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody&body=Please send me information about technology [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 157175301 E-164-2021-0 E-164-2021-0-US-01 SINGLE DOMAIN ANTIBODY INHIBITS EXPANSION OF PATHOGENIC TH17 RESPONSES AND SUPPRESSION OF UVEITIS PRV US 63/219,161 Abandoned US <br />Provisional (PRV) 63/219,161<br />Filed on 2021-07-07<br />Status: Abandoned 160175629 E-164-2021-0 E-164-2021-0-US-03 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY ORD US 17/859,861 Pending US <br />Ordinary Patent (ORD) 17/859,861<br />Filed on 2022-07-07<br />Status: Pending 160175634 E-164-2021-0 E-164-2021-0-JP-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage Japan 2024-525189 Pending Japan <br />National Stage 2024-525189<br />Filed on 2024-01-05<br />Status: Pending 160175639 E-164-2021-0 E-164-2021-0-MX-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage Mexico MX/a/2024/000309 Pending Mexico <br />National Stage MX/a/2024/000309<br />Filed on 2024-01-04<br />Status: Pending 160175644 E-164-2021-0 E-164-2021-0-EP-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage European Patent 22838435.0 Pending European Patent <br />National Stage 22838435.0<br />Filed on 2024-02-05<br />Status: Pending 163826768 E-164-2021-0 E-164-2021-0-PCT-02 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY PCT Patent Cooperation Treaty PCT/US2022/036420 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/036420<br />Filed on 2022-07-07<br />Status: Expired 167147419 E-164-2021-0 E-164-2021-0-US-04 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY CON US 19/662,470 Pending US <br />Continuation (CON) 19/662,470<br />Filed on 2026-04-29<br />Status: Pending TAB-1977 114096197 qPCR Assay for Detection of JC Virus NINDS Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Eugene Major, Caroline Ryschkewitsch JC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. For example, more than five percent (5%) of AIDS patients develop PML. Additionally, these conditions include, but are not limited to, cancers such as leukemias and lymphomas, organ transplants such as kidney, heart and autoimmune conditions with treatment that modulates the immune system such as Multiple Sclerosis (MS), rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. The finding of JCV DNA in the patients with neurological symptoms of PML is a diagnostic criterion and is needed to confirm the diagnosis of PML to rule out other neurological conditions. <br><br> This technology describes a qPCR assay that utilizes viral DNA standards and testing samples to detect the presence of the JC viral genome in patients' cerebrospinal fluid and blood, blood products, and tissue samples from biopsy or autopsy. Assay is sensitive, reproducible and highly specific because the amount JCV DNA in cerebrospinal fluid or blood or blood product samples may be very small. Development of JC Virus (JCV) diagnostics, calibration of existing JCV assays. Research Material -- patent protection is not being pursued for this technology Available for licensing. 2022-03-08 2024-10-28 2026-05-01 2009-07-02 assay, DA4BXX, DA4XXX, DAXXXX, DDXXXX, Detection, DEXXXX, DNA, DXXXXX, JC, Proficiency, Progressive multifocal leukoencephalopathy, QPCR, Samples', STANDARDS, Systemic lupus erythematosus, test, virus False True Materials and assay have been developed and tested. True NIHTT 37470483 Website Abstract 114170863 ML Landry et al. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. J Clin Virol. 2008 Oct;43(2):247-249. http://www.ncbi.nlm.nih.gov/pubmed/18701345?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18701345?dopt">ML Landry et al. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. J Clin Virol. 2008 Oct;43(2):247-249.</a> 114170864 C Ryschkewitsch et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods. 2004 Nov;121(2):217-221. http://www.ncbi.nlm.nih.gov/pubmed/15381359?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15381359?dopt">C Ryschkewitsch et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods. 2004 Nov;121(2):217-221.</a> 114170865 T Yousry et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924-933. http://www.ncbi.nlm.nih.gov/pubmed/16510746?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16510746?dopt">T Yousry et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924-933.</a> 114106668 Ryschkewitsch, Caroline NINDS NINDS Ryschkewitsch, Caroline (NINDS) 0 114106667 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114106667 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114106668 Ryschkewitsch, Caroline NINDS NINDS Ryschkewitsch, Caroline (NINDS) 0 114099880 QPCR Assay For Detection Of JC Virus With DNA Standards And Test Proficiency Samples' E-152-2009-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-1977] qPCR Assay for Detection of JC Virus&body=Please send me information about technology [TAB-1977] qPCR Assay for Detection of JC Virus. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-1977] qPCR Assay for Detection of JC Virus&body=Please send me information about technology [TAB-1977] qPCR Assay for Detection of JC Virus.">susan.ano@nih.gov</a><br> 114120364 DDXXXX 114120365 DAXXXX 114120366 DA4XXX 114120367 DA4BXX 114120368 DEXXXX 114120369 DXXXXX 114138091 QPCR 114138092 assay 114138093 Detection 114138094 JC 114138095 virus 114138096 DNA 114138097 STANDARDS 114138098 test 114138099 Proficiency 114138100 Samples' 114156827 Systemic lupus erythematosus 114156828 Progressive multifocal leukoencephalopathy TAB-5054 162400945 Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma NINDS Licensing, Neurology, Oncology, Therapeutics Licensing Neurology Oncology Therapeutics Sadhana Jackson <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)&mdash;the tightly sealed network of brain blood vessel cells that normally blocks most drugs&mdash;from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible &ldquo;molecular doorway&rdquo; that lets cancer medicines such as liposomal doxorubicin (Doxil&reg;) reach tumors in the central nervous system (CNS). In rodent models of malignant glioma, co-administration of angubindin-1 increased drug penetration into the brain, cut tumor volume, and significantly prolonged survival compared with chemotherapy alone. The opening of the BBB is short-lived and spatially restricted, minimizing exposure of healthy brain tissue and avoiding the hardware, ultrasound, or high-dose osmotic agents required by competing methods.</span></span></span></p> <ul> <li>Peptide-based, systemic administration—no invasive devices or focused ultrasound, lowering clinical complexity and cost.</li> <li>Transient, selective BBB permeability (< hours) preserves barrier integrity post-treatment and limits off-target toxicity.</li> <li>Validated in vivo efficacy with improved survival; platform readily pairs with small-molecule drugs, antibodies, or gene/cell therapies targeting CNS diseases.</li> </ul> <ul> <li>Adjunct to standard-of-care chemotherapy for glioblastoma and other high-grade gliomas.</li> <li>Enabling delivery of emerging biologics (e.g., CAR-T cells, antibody–drug conjugates, gene therapies) to the brain.</li> <li>Enhancing uptake of CNS imaging or diagnostic agents for more accurate tumor visualization and monitoring.</li> </ul> 2025-05-13 2025-06-13 2026-04-30 2025-06-13 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162400962 Jackson, Sadhana NINDS NINDS Jackson, Sadhana (NINDS) 1 162400962 Jackson, Sadhana NINDS NINDS Jackson, Sadhana (NINDS) 1 162400948 Angubindin-1 treatment against malignant glioma E-018-2024-0 Filing authorized NIH - NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma&body=Please send me information about technology [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma&body=Please send me information about technology [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma.">olufunmilola.olufemi@nih.gov</a><br> 162400953 E-018-2024-0 E-018-2024-0-PCT-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA PCT Patent Cooperation Treaty PCT/US2023/079547 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/079547<br />Filed on 2023-11-13<br />Status: Expired 166152782 E-018-2024-0 E-018-2024-0-US-01 COMBINATION OF ANGUBINDIN-1 ABD CHEMOTHERAPY FOR THE TREATMENT OF CNS MALIGNANCIES National Stage US 19/586,174 Pending US <br />National Stage 19/586,174<br />Filed on 2026-05-08<br />Status: Pending 166152811 E-018-2024-0 E-018-2024-0-EP-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-3973 147157254 Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Joo Lee, Eytan Ruppin <h2>Description of Technology:</h2> <p>The use of tumor transcriptomics for precision oncology has made significant advances, mainly by identifying cancer driver genes or actionable mutations for treatment with targeted therapies.&nbsp; However, this strategy misses out on broader genetic interactions that could reveal additional biologically testable biomarkers for therapy response prediction and inform the selection of more effective drugs for targeted treatment.</p> <p>Scientists at the National Cancer Institute (NCI) have developed SELECT, a computational, precision-oncology framework that uses the tumor&rsquo;s whole transcriptome to identify synthetic lethal and synthetic rescue genetic interactions.&nbsp; These genetic interactions provided actional information predicting therapeutic response in 28 of 35 published targeted and immunotherapy trials from 10 different cancer types. Also, it was predictive of patients&rsquo; response in 80 % of these clinical trials.&nbsp; SELECT, an excellent tool in developing new targeted therapies or enhancing patient stratification in transcriptomic multi-arm trials, is available for co-development or licensing opportunity.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Patient stratification in clinical trials&nbsp;</li> <li>Identifying new actionable drug targets and treatments&nbsp;</li> <li>Analysis of genetic interactions that can provide actionable information for selecting effective treatment options for cancer patient</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Predictive accuracy of patients&rsquo; response in many treatment options, including chemotherapy, targeted drugs and immunotherapy</li> <li>Predictive accuracy of patients&rsquo; response across cancer types</li> <li>Enhancing patient stratification for clinical trials and improved therapeutic strategies</li> <li>Increasing the number of patients that could benefit from precision-based treatments</li> </ul> 2021-11-19 2026-04-24 2021-11-19 2026-04-30 2021-11-19 Genetic Interactions, Patient Stratification, Precision Diagnostics, Precision Oncology, Ruppin, Synthetic Lethality, Transcriptome False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162079 PUBLICATION: Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. (PMID 33857424) https://pubmed.ncbi.nlm.nih.gov/33857424/ <a href="https://pubmed.ncbi.nlm.nih.gov/33857424/">PUBLICATION: Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. (PMID 33857424)</a> 167039304 Sahu AD, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30858180/CAPTION: 30858180 Sahu AD, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30858180/CAPTION: 30858180 167072741 Lee JS, et al. Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment. (PMID 29959327) https://pubmed.ncbi.nlm.nih.gov/29959327/ <a href="https://pubmed.ncbi.nlm.nih.gov/29959327/">Lee JS, et al. Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment. (PMID 29959327)</a> 147163087 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147163088 Lee, Joo NIH - NCI Lee, Joo 2 147163087 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147163088 Lee, Joo NIH - NCI Lee, Joo 2 147158081 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome E-150-2020-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome&body=Please send me information about technology [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome&body=Please send me information about technology [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161108 E-150-2020-0 E-150-2020-0-US-01 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome PRV US 63/107,737 Abandoned US <br />Provisional (PRV) 63/107,737<br />Filed on 2020-10-30<br />Status: Abandoned 147165637 E-150-2020-0 E-150-2020-0-PCT-02 Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome PCT Patent Cooperation Treaty PCT/US2021/057229 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/057229<br />Filed on 2021-10-29<br />Status: Expired 147165638 E-150-2020-0 E-150-2020-0-US-02 Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome National Stage US 18/250,816 Pending US <br />National Stage 18/250,816<br />Filed on 2023-04-27<br />Status: Pending 147172374 Genetic Interactions 147172375 Patient Stratification 147172377 Precision Diagnostics 147172378 Precision Oncology 147172379 Ruppin 147172381 Synthetic Lethality 147172382 Transcriptome TAB-3970 147157250 Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo NICHD Collaboration, Diagnostics, Licensing, Neurology Collaboration Diagnostics Licensing Neurology Peter Basser, Dan Benjamini, Diego Iacono <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of multidimensional MRI-based methods.</p> <h2>Description of Technology:</h2> <p>Traumatic brain injury (TBI) represents a major medical, social and economic concern worldwide due to significant mortality &ndash; especially among younger populations &ndash; and long-term disabilities. Various pathological brain lesions (e.g., intracerebral bleedings, necrotic-ischemic lesions, tissue avulsion) are produced by impacting mechanical forces. Among these, diffuse axonal injury (DAI) is one of the most significant brain lesions typically associated with trauma. However, DAI is not necessarily linked with TBI exposure. Therefore, the term &ldquo;traumatic axonal injury (TAI)&rdquo; is commonly used. TAI is a specific form of DAI.</p> <p>Multidimensional MRI-based methods permit identification and categorization of brain specimens to identify sub-voxel tissue components specific to traumatic axon injury or other lesions. Lower dimensional MR spectral data is acquired and processed to provide multidimensional MR data of higher dimensions. One or more spectral ranges are selected that define signatures for brain injury. Evaluation of the multidimensional MR data in these ranges is used to locate voxels associated with brain injury. The invention pertains to noninvasive methods of assessing nervous system injury, particularly TBI &ndash; both mild and severe. A unique TAI multidimensional spectral signature can be measured and used to generate biomarker images closely following amyloid precursor protein (&ldquo;APP&rdquo;) histopathology: APP-positive areas scale with multidimensional TAI biomarker intensity and negative APP corresponds to reduced or absent MRI signal. This specificity of the multidimensional TAI biomarkers permit so-called &ldquo;noninvasive histology.&rdquo; One or more T1-T2-MD ranges can be identified and specifically linked to TAI microscopic tissue alterations. T1, T2 and diffusion dynamics can be different in fixed compared with living tissue. Therefore, different T1-T2-MD ranges can be selected for fixed and living tissues.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnosis and assessment of patients with TBI</li> <li>Noninvasive histology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Noninvasive diagnostic technique</li> <li>Provides substantially more discrete data than prior methodologies</li> <li>Produces measurements with high specificity</li> <li>Unique TAI multidimensional spectral signatures can be measured and used to generate biomarker images</li> </ul> 2022-01-05 2026-04-23 2022-01-05 2026-04-30 2022-01-05 Amyloid Precursor Protein, Be, DAI, Diffuse Axonal Injury, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, MULTIDIMENSIONAL, NICHD, TAI, TBI, Traumatic Axonal Injury, Traumatic Brain Injury False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162279 Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.73737 : Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.737374 <a href=": Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.737374">Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.73737</a> 167039252 Benjamini D, et al. Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain. .PUBLICATIONS HREF: https://doi.org/10.3389/fphy.2021.737374CAPTION: PMID 25838374 https://doi.org/10.1093/brain/awaa447 <a href="https://doi.org/10.1093/brain/awaa447">Benjamini D, et al. Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain. .PUBLICATIONS HREF: https://doi.org/10.3389/fphy.2021.737374CAPTION: PMID 25838374</a> 147163078 Benjamini, Dan NICHD NIA Benjamini, Dan (NIA) 1 147163077 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163079 Iacono, Diego NINDS NINDS Iacono, Diego (NINDS) 3 147163078 Benjamini, Dan NICHD NIA Benjamini, Dan (NIA) 1 147163077 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163079 Iacono, Diego NINDS NINDS Iacono, Diego (NINDS) 3 147158172 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo E-185-2020-0 Filing authorized Henry M. Jackson Foundation (HJF), NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo&body=Please send me information about technology [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo&body=Please send me information about technology [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161166 E-185-2020-0 E-185-2020-0-US-01 MULTIDIMENSIONAL MRI SIGNATURE FOR SPECIFIC DETECTION OF TRAUMATIC BRAIN INJURY IN VIVO PRV US 63/061,105 Abandoned US <br />Provisional (PRV) 63/061,105<br />Filed on 2020-08-04<br />Status: Abandoned 147165625 E-185-2020-0 E-185-2020-0-PCT-02 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo PCT Patent Cooperation Treaty PCT/US2021/041663 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/041663<br />Filed on 2021-07-14<br />Status: Expired 147165626 E-185-2020-0 E-185-2020-0-US-03 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo National Stage US 12,343,132 18/019,725 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12343132 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12343132">12,343,132</a><br />Filed on 2023-02-03<br />Status: Issued 147173292 Amyloid Precursor Protein 147173294 Be 147173296 DAI 147173298 Diffuse Axonal Injury 147173299 Eunice Kennedy Shriver National Institute of Child Health an 147173300 Magnetic Resonance Imaging 147173301 MRI 147173302 MULTIDIMENSIONAL 147173303 NICHD 147173305 TAI 147173306 TBI 147173308 Traumatic Axonal Injury 147173309 Traumatic Brain Injury TAB-4424 147157719 Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Donald Caldwell, Anna Love, Jennifer Prescher, Martin Schnermann, Zi Wei Yao <h2>Summary:</h2> <p>Researchers at UCI and NCI seek licensing to adopt new applications for a family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.&nbsp;</p> <h2>Description of Technology:</h2> <p>Bioluminescence imaging with luciferin-luciferase pairs is a well-established technique for tracking cells and other biological features in animal models. Bioluminescent is a chemical process which does not require an external input for excitation. Bioluminescent imaging is often limited to monitoring single processes in vivo due to the lack of distinguishable probes. Additionally, existing probes typically operate with light in the visible range, which is highly scattered and exhibits poor tissue penetration.&nbsp;</p> <p>To address these issues, researchers at UCI and NCI synthesized a new family of coumarin-based luciferins (CouLuc) with complementary mutant enzymes that exhibit far-red to near-infrared emission. This novel shift in emission opens the possibility of pairing with commercial luciferin-luciferase probes to form multicomponent systems. Additionally, far-red to near-infrared emission enables imaging at greater depths in live animals. Based on commercial courmarin precursors, these CouLuc scaffolds can be prepared in a straightforward two-step sequence. The resulting CouLuc with luciferase mutants provides stable substrate-selective luciferases with robust light emission. Overall, these probes are poised to advance the scope of bioluminescence imaging to more complex biological problems.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Live animal imaging&nbsp;</li> <li>Multicomponent imaging when combined with commercial luciferin-luciferase pairs</li> <li>Enhanced bioluminescence imaging</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Distinct from existing luciferin-luciferase pair due to their emission of far-red to near-red light</li> <li>Superior tissue penetration&nbsp;</li> <li>Greater depth and resolution&nbsp;&nbsp;</li> <li>Enhancement of a variety of current bioluminescence imaging applications</li> <li>Ability to quickly produce significant quantities of the novel CouLucs probes</li> </ul> 2021-09-23 2026-04-24 2021-11-05 2026-04-30 2021-09-23 CouLuc, Luciferases, Luciferins, Near-infrared, NIR, Optical Imaging, Schnermann False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161919 Yao Z, et al. Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging. (PMID) Yao Z, et al. Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging. (PMID) 147164697 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147164698 Caldwell, Donald NCI - CCR NCI Caldwell, Donald (NCI) 2 147164699 Prescher, Jennifer University of California, Irvine Prescher, Jennifer 3 147164700 Yao, Zi Wei University of California, Irvine Yao, Zi Wei 4 147164701 Love, Anna University of California, Irvine Love, Anna 5 147164697 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147164698 Caldwell, Donald NCI - CCR NCI Caldwell, Donald (NCI) 2 147164699 Prescher, Jennifer University of California, Irvine Prescher, Jennifer 3 147164700 Yao, Zi Wei University of California, Irvine Yao, Zi Wei 4 147164701 Love, Anna University of California, Irvine Love, Anna 5 147157997 Coumarin Luciferins And Mutant Luciferases For Bioluminescence Imaging E-105-2021-0 Filing authorized NCI, University of California, Irvine 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging&body=Please send me information about technology [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging&body=Please send me information about technology [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161047 E-105-2021-0 E-105-2021-0-US-01 COUMARIN LUCIFERINS FOR BIOLUMINESCENCE IMAGING PRV US 63/184,432 Abandoned US <br />Provisional (PRV) 63/184,432<br />Filed on 2021-05-05<br />Status: Abandoned 147171520 CouLuc 147171521 Luciferases 147171522 Luciferins 147171523 Near-infrared 147171524 NIR 147171526 Optical Imaging 147171528 Schnermann TAB-4516 151706972 Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease NHLBI Licensing, Plasmids/Vectors, Therapeutics Licensing Plasmids/Vectors Therapeutics Juan Haro Mora, John Tisdale, Naoya Uchida <p>This technology includes efficient lentiviral gene delivery system for both guide RNA and Cas9 endonuclease as a method to cure sickle cell disease. Gene correction is an ideal gene therapy strategy for hereditary disease, including sickle cell disease. To deliver both guide RNA and Cas9 endonuclease into target cells, we used HIV-l based lentiviral vector system, which allows for efficient gene delivery in various cells, including hematopoietic stem cells and ES/1PS cells in this system, transgene expression cassettes can be integrated into genomic DNA in target cells, which results in long‐ term transgene expression. Out data demonstrate that Cas9/CypA fusion proteins can be delivered with lentiviral particles, and the Cas9 fusion proteins have an endonuclease function to induce GFP DNA double strand break.</p> In this system, much smaller size of viral genome is packaged in lentiviral particles, which should allow for more efficient gene/protein delivery with lentiviral vectors. ln addition, site-specific DNA break can be induced for a short term only, which should allow for safer genome editing by reduction of DNA damage in target cells. Perform gene correction in the β-globin gene and/or BCL11lA gene knock-down in hematopoietic stem cells to induce fetal hemoglobin expression to cure sickle cell disease. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-04-30 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706979 Uchida, Naoya University of Tokyo Uchida, Naoya 1 151706983 Haro Mora, Juan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haro Mora, Juan (NHLBI) 2 151707087 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 3 151706979 Uchida, Naoya University of Tokyo Uchida, Naoya 1 151706983 Haro Mora, Juan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haro Mora, Juan (NHLBI) 2 151707087 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 3 151706975 Development Of Lentiviral Protein Delivery System For RNA-guided Genome Editing E-165-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease&body=Please send me information about technology [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease&body=Please send me information about technology [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease.">vk5q@nih.gov</a><br> 157755526 E-165-2015-0 E-165-2015-0-US-01 LENTIVIRAL PROTEIN DELIVERY SYSTEM FOR RNA-GUIDED GENOME EDITING PRV US 62/236,223 Abandoned US <br />Provisional (PRV) 62/236,223<br />Filed on 2015-10-02<br />Status: Abandoned TAB-4468 150736756 Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies NCI Application, Cardiology, Collaboration, Licensing, Neurology, Oncology, Therapeutics Application Cardiology Collaboration Licensing Neurology Oncology Therapeutics Shalini Oberdoerffer, Sarah Schiffers <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for engineered chimeric snoRNA guides that recruit NAT10 to a specific target and cause directed acetylation of the target. They could be used to treat haploinsufficiency-associated disorders or diseases.</p> <h2>Description of Technology:&nbsp;</h2> <p>Haploinsufficiency (HI) is the loss of one allele of a gene. The resultant loss in associated protein expression/function is insufficient for a normal phenotype and manifests in a myriad of diseases. Such diseases include: [1] congenital malformations (e.g., eye defects, cleft lip/palate, etc.), [2] neurodevelopmental disorders (e.g., autism spectrum disorders, epilepsy, schizophrenia, etc.) and [3] disorders of maintenance and self-renewal. This latter category includes cancer predisposition syndromes, obesity, maturity onset diabetes of the young, and autoimmune disorders. In total, over 300 known human haploinsufficiencies exist. However, no therapies exist which can target these HIs without unbalanced protein expression and deleterious side effects.</p> <p>Scientists at the NCI engineered chimeric small nucleolar (snoRNA) guides that recruit the enzyme NAT10 to a target transcript. The NAT10 enzyme acetylates specific cytidines in RNA, including at the ac4C site, through association with these snoRNA guides. In mRNA, ac4C modulates the level of protein produced per mRNA template, manifesting in moderate increases in net protein levels. For HI-related disorders or diseases, moderate increases in protein production alleviate disease phenotypes without the potential side effects of more substantial over-expression and protein production. The inventors developed a proof-of-principle snoRNA guide that recruits NAT10 to the target transcript GAPDH mRNA. The snoRNA was delivered into HeLa cells through incorporation into a minigene vector. Recovery of GAPDH transcripts and mass spectrometry confirmed successful targeted acetylation in these cells. This invention of directed acetylation through engineered snoRNA adapters would be useful for the treatment of haploinsufficiencies where moderate protein expression can lead to alleviation of disease phenotype.</p> <p>The NCI is looking for research co-development partners and/or licensees to help develop these engineered chimeric snoRNA guides into clinically relevant therapeutics for the treatment of a variety of haploinsufficiencies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <p>Patient-specific, RNA-targeting therapy for haploinsufficiencies such as:</p> <ul> <li>Congenital malformations</li> <li>Neurodevelopmental disorders&nbsp;</li> <li>Cancer</li> <li>Autoimmune Lymphoproliferative Syndrome (ALPS)</li> <li>Myelodysplastic Syndrome (MDS)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially fewer and less severe side-effects compared with current gene therapy technology</li> <li>More moderate changes of protein expression&nbsp;</li> <li>Promotion of endogenous protein biosynthesis<br /> &nbsp;</li> </ul> 2023-10-10 2026-04-30 2026-04-30 2023-10-11 False False Basic (Target ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 150757256 Oberdoerffer, Shalini Laboratory of Receptor Biology and Gene Expression NCI Oberdoerffer, Shalini (NCI) 1 150757272 Schiffers, Sarah National Cancer Institute (NCI) NCI Schiffers, Sarah (NCI) 2 150757256 Oberdoerffer, Shalini Laboratory of Receptor Biology and Gene Expression NCI Oberdoerffer, Shalini (NCI) 1 150757272 Schiffers, Sarah National Cancer Institute (NCI) NCI Schiffers, Sarah (NCI) 2 150736762 Directed Acetylation Of Cytidine In Cellular MRNA Through Engineered SnoRNA Adapters For The Treatment Of Haploinsufficiencies E-017-2023-0 Filing authorized Laboratory of Receptor Biology and Gene Expression, NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies&body=Please send me information about technology [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies&body=Please send me information about technology [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 150894306 E-017-2023-0 E-017-2023-0-US-01 Directed acetylation of mRNA through engineered snoRNA adapters PRV US 63/423,714 Expired US <br />Provisional (PRV) 63/423,714<br />Filed on 2022-11-08<br />Status: Expired TAB-4466 149818526 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging NEI Collaboration, Ear, Nose, & Throat, Licensing, Software / Apps, TherapeuticArea Collaboration Ear Nose & Throat Licensing Software / Apps TherapeuticArea Catherine Cukras, Wathudurage De Silva <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images.</p> <h2>Description of Technology:</h2> <p>The present disclosure generally relates a method of automatically detecting ellipsoid zone (EZ) loss in spectral domain optical coherence tomography (SD-OCT) imaging. EZ band represents outer segments of photoreceptors in the retina, and its loss reflects a deterioration of the photoreceptors. EZ loss has been proposed to be evidence of progression of several retinal degenerative diseases including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus erythematosus, Sj&ouml;gren&rsquo;s syndrome, and rheumatoid arthritis. One of the major side-effects that can occur in long-term users of HCQ, is EZ loss that can result in retinal toxicity and permanent damage to photoreceptors and retinal pigment epithelium (RPE), eventually leading to irreversible loss of central vision. The American Academy of Ophthalmology (AAO) recommends two main screening modalities including SD-OCT imaging and functional tests such as visual fields with the goal of recognizing early definitive signs of HCQ-induced retinal toxicity to prevent vision loss. Although this side-effect is estimated to occur in 7.5% of patients taking the drug for more than 10 years, we currently have no treatment for this serious side effect that tends to continue even after the cessation of the drug.</p> <p>Researchers at the NEI have developed a method that can automatically detect and quantitate EZ loss in SD-OCT images immediately after image acquisition. The method includes a deep learning framework with a two-step approach. In the first stage, the method detects and annotates EZ loss regions in individual OCT B-scans. A 2D map is constructed twice in a dual architecture to enhance robustness, where horizontal and vertical slices extracted from the 3D image are trained separately. The second stage of the model operates on these two 2D maps and estimates the final EZ loss map representing the 3D OCT volume. Compared to other screening methods, the algorithm demonstrated excellent performance in diagnosing toxicity even as a stand-alone test, with an F1 score, a measure of test accuracy, of 0.91. This indicates the utility of the tool in assisting with screening for toxicity in an automatic, accurate, time-effective, cost-effective, and objective manner. Addition of this methodology onto current SD-OCT screening could assist the clinician in making diagnostic and treatment decisions immediately after SD-OCT acquisitions.</p> <p>Protected claims for this invention include the method of detecting and outlining the region of EZ loss directly from acquired OCT images, associated algorithms, and the device containing these algorithms and capabilities. This technology is available for licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li style="margin-left:8px">Methodology to integrate with SD-OCT imaging for screening applications for different retinal degeneration diseases</li> <li style="margin-left:8px">Implementation of this automatic algorithm also in screening outside of ophthalmology offices (OCTs become more ubiquitous in internal medicine settings)</li> <li style="margin-left:8px">Quantitative data produced from the algorithms could provide surrogate end points for use in clinical trials and interventional studies aimed at halting progression of degenerative changes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li style="margin-left:8px">Accurate and robust method: Provides excellent performance in diagnosing toxicity as a stand-alone test and compared to qualitative inspection of SD-OCT images</li> <li style="margin-left:8px">Time-efficient (can evaluate SD-OCT volumes): Fully automatic and available within seconds after SD-OCT acquisition</li> <li style="margin-left:8px">Objective: Performs as well as human grading in eyes that demonstrate even small amounts of EZ loss</li> <li style="margin-left:8px">Does not require segmentation of intact layers, avoiding failures in cases of layer deterioration</li> <li style="margin-left:8px">Does not require a large number of training examples, useful for rare diseases</li> </ul> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image435.png" style="height:391px; width:1042px" /></p> <p><br /> &emsp;</p> 2023-09-20 2026-04-30 2026-04-30 2023-10-05 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 150109557 De Silva T, et al. Deep Learning-Based Automatic Detection of Ellipsoid Zone Loss in Spectral-Domain OCT for Hydroxychloroquine Retinal Toxicity Screening (PMID 36246938) https://pubmed.ncbi.nlm.nih.gov/36246938/ <a href="https://pubmed.ncbi.nlm.nih.gov/36246938/">De Silva T, et al. Deep Learning-Based Automatic Detection of Ellipsoid Zone Loss in Spectral-Domain OCT for Hydroxychloroquine Retinal Toxicity Screening (PMID 36246938)</a> 150044076 De Silva, Wathudurage National Eye Institute (NEI) De Silva, Wathudurage 3 150044080 Cukras, Catherine Division of Epidemiology and Clinical Application NEI Cukras, Catherine (NEI) 4 150044076 De Silva, Wathudurage National Eye Institute (NEI) De Silva, Wathudurage 3 150044080 Cukras, Catherine Division of Epidemiology and Clinical Application NEI Cukras, Catherine (NEI) 4 149818530 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging E-194-2021 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging&body=Please send me information about technology [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging&body=Please send me information about technology [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 150655563 E-194-2021 E-194-2021-0-US-01 SYSTEMS AND METHODS TO AUTOMATICALLY DETECT HYDROXYCHLOROQUINE-INDUCED RETINAL TOXICITY IN SD-OCT IMAGING PRV US 63/241,823 Abandoned US <br />Provisional (PRV) 63/241,823<br />Filed on 2021-09-08<br />Status: Abandoned 150655571 E-194-2021 E-194-2021-0-PCT-02 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging PCT Patent Cooperation Treaty PCT/US2022/076135 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/076135<br />Filed on 2022-09-08<br />Status: Expired 164119729 E-194-2021 E-194-2021-0-CA-03 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage Canada 3230840 Pending Canada <br />National Stage 3230840<br />Filed on 2024-03-01<br />Status: Pending 164119730 E-194-2021 E-194-2021-0-AU-04 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage Australia 2022344259 Pending Australia <br />National Stage 2022344259<br />Filed on 2024-02-22<br />Status: Pending 164119731 E-194-2021 E-194-2021-0-US-05 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage US 18/690,130 Pending US <br />National Stage 18/690,130<br />Filed on 2024-03-07<br />Status: Pending 164119732 E-194-2021 E-194-2021-0-EP-06 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage European Patent 22789416.9 Pending European Patent <br />National Stage 22789416.9<br />Filed on 2024-03-08<br />Status: Pending TAB-4448 147157743 National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program NCI Cardiology, Licensing, Neurology, Oncology, Software / Apps Cardiology Licensing Neurology Oncology Software / Apps <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a novel computer program performing radiation dose calculations for diagnostic and therapeutic nuclear medicine.</p> <h2>Description of Technology:</h2> <p>Nuclear medicine is the second largest source of medical radiation exposure to the general population after computed tomography imaging. Imaging modalities utilizing nuclear medicine produce a more detailed view of internal structure and function and are most commonly used to diagnose diseases such as heart disease, Alzheimer&rsquo;s and brain disorders. They are used to visualize tumors, abscesses due to infection or abnormalities in abdominal organs. When using radionuclides for diagnosis or therapy in nuclear medicine, it is critical to accurately estimate unintended dose to organs at risk surrounding tumors or of therapeutic or imaging interest. It is impossible to experimentally measure organ dose. Traditionally, computational approaches were used for this purpose, requiring a series of computational human phantoms and an extensive amount of computer simulation. However, existing model-based organ dose estimation tools rely on simplified human anatomy models or commercial programs.</p> <p>To address these challenges, Dr. Choonsik Lee from the NCI created a radiation dose-calculation tool for nuclear medicine imaging modalities based on more sophisticated human anatomy models. A comprehensive library of photon and electron specific absorbed fractions (SAF) were first calculated for multiple combinations of source and target regions within a series of pediatric and adult computational human phantoms matching the International Commission on Radiological Protection (ICRP)&#39;s reference data. These were combined with a Monte Carlo radiation transport code. Then, a library of S values was derived from these SAFs and the nuclear decay data from ICRP Publication 107. Finally, a graphical user interface, named the National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM), was created to facilitate the dosimetry process. Approximately 13 million S values were derived from 2 million SAFs computed. A comprehensive library of biokinetic data were extracted from multiple up-to-date international reports and implemented into NCINM.&nbsp;</p> <p>The NCI seeks licensees for this technology who are interested in using NCINM, including their implementation within existing commercial solutions for patient dose monitoring.&nbsp;Applications of the NCINM program include computation of absorbed doses for use in radiation epidemiologic studies and patient dose monitoring in nuclear medicine.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Patient radiation dose monitoring in nuclear medicine imaging modalities</li> <li>Radiation epidemiologic studies</li> <li>Components can be incorporated with NCIDose software into a commercial platform: NCINM program, computational human phantom series (human anatomy models, electronic files), organ dose factor library (tabulated numbers)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easy implementation within existing commercial solutions</li> <li>Most advanced pediatric and adult computational phantoms</li> <li>Intuitive user interface</li> <li>Software can run on Macintosh, Windows, and LINUX operating systems</li> </ul> Researchers at the NCI seek licensing for a novel computer program that performs radiation dose calculations for diagnostic and therapeutic nuclear medicine. 2023-05-14 2026-04-30 2023-05-14 2026-04-30 2023-05-14 • National Cancer Institute Dosimetry System for Nuclear Med, Dosimetry, Lee, NCINM, Nuclear Medicine, Radiation, Radiation Dosing, SAF, Specific Absorbed Fraction False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-05-14 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-082-2016 E-127-2023 147162076 Villoing D, et al. NCINM: organ dose calculator for patients undergoing nuclear medicine procedures. https://pubmed.ncbi.nlm.nih.gov/33444241/ <a href="https://pubmed.ncbi.nlm.nih.gov/33444241/">Villoing D, et al. NCINM: organ dose calculator for patients undergoing nuclear medicine procedures.</a> 155750754 National Cancer Institute Dosimetry System For Nuclear Medicine (NCINM) Computer Program E-125-2019-0 Closed NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program&body=Please send me information about technology [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program&body=Please send me information about technology [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171904 • National Cancer Institute Dosimetry System for Nuclear Med 147171905 Dosimetry 147171906 Lee 147171907 NCINM 147171909 Nuclear Medicine 147171910 Radiation 147171911 Radiation Dosing 147171913 SAF 147171915 Specific Absorbed Fraction TAB-4419 147157714 Device for Simulating Explosive Blast and Imaging Biological Specimens NICHD Collaboration, Licensing, Medical Devices, Neurology, Non-Medical Devices Collaboration Licensing Medical Devices Neurology Non-Medical Devices Sergey Bezrukov, Paul Blank, Kim Lee Mcafee, Rea Ravin, Alex Steinkamp, Joshua Zimmerberg <h2>Summary:</h2> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.</p> <h2>Description of Technology:</h2> <p>Traumatic brain injury (TBI) is a major health problem.&nbsp; Between 3.2 and 5.3 million people live with long-term disabilities resulting from TBI, and thus, contribute to the need to develop therapies that treat TBI-induced cellular damage. Researchers at the National Institute of Child Health and Human Development (NICHD) have developed a device that simulates the pressure waves resulting from explosions. This invention can be used to study the in vitro effects of shock waves on cells in culture and could be used to determine the effects of potential treatments for TBI in an in vitro cellular model. The device consists of a source of compressed gas connected to a chamber containing cells. Cells can be derived from central nervous system (CNS) tissue, muscle, etc. The effects of the release of the compressed gas (blast) on the cells can be monitored in real time in a microscope or other imaging device.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Investigate the cellular effects of pressure waves in an in vitro model</li> <li>Use to screen for potential agents to treat traumatic brain injury (TBI)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Allows for the real-time study of a blast effect on in vitro cellular models</li> <li>Allows for testing of potential therapies of traumatic brain injury in an in vitro model.&nbsp;</li> </ul> 2018-09-05 2026-04-30 2021-01-26 2026-04-30 2018-09-05 Central Nervous System, CNS, explosive blast, National Institute of Child Health and Human Development, NICHD, SIMULATOR, TBI, Traumatic Brain Injury, Zimmerberg False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164680 Ravin, Rea NIH - NICHD NIBIB Ravin, Rea (NIBIB) 1 147164678 Blank, Paul NIH - NICHD NICHD Blank, Paul (NICHD) 2 147164681 Steinkamp, Alex NIH - NICHD NICHD Steinkamp, Alex (NICHD) 3 147164677 Zimmerberg, Joshua NIH - NICHD NICHD Zimmerberg, Joshua (NICHD) 4 147164679 Bezrukov, Sergey NIH - NICHD NICHD Bezrukov, Sergey (NICHD) 5 147164682 Mcafee, Kim Lee NIH - NICHD Mcafee, Kim Lee 6 147164680 Ravin, Rea NIH - NICHD NIBIB Ravin, Rea (NIBIB) 1 147164678 Blank, Paul NIH - NICHD NICHD Blank, Paul (NICHD) 2 147164681 Steinkamp, Alex NIH - NICHD NICHD Steinkamp, Alex (NICHD) 3 147164677 Zimmerberg, Joshua NIH - NICHD NICHD Zimmerberg, Joshua (NICHD) 4 147164679 Bezrukov, Sergey NIH - NICHD NICHD Bezrukov, Sergey (NICHD) 5 147164682 Mcafee, Kim Lee NIH - NICHD Mcafee, Kim Lee 6 147157918 A Device To Simulate Explosive Blast For Use In Real Time Imaging Of Cells And Tissue. E-068-2012-0 Filing authorized NICHD 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens&body=Please send me information about technology [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens&body=Please send me information about technology [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147168806 E-068-2012-0 E-068-2012-0-US-01 Device for Simulating Explosive Blast And Imaging Biological Specimen PRV US 61/590,209 Abandoned US <br />Provisional (PRV) 61/590,209<br />Filed on 2012-01-24<br />Status: Abandoned 147168807 E-068-2012-0 E-068-2012-0-US-02 Device For Simulating Explosive Blast And Imaging Biological Specimen ORD US 9,217,698 13/748,410 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9217698 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9217698">9,217,698</a><br />Filed on 2013-01-23<br />Status: Issued 147170708 Central Nervous System 147170709 CNS 147170710 explosive blast 147170711 National Institute of Child Health and Human Development 147170712 NICHD 147170713 SIMULATOR 147170714 TBI 147170715 Traumatic Brain Injury 147170717 Zimmerberg TAB-4417 147157712 Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Eytan Ruppin, Alejandro Schaffer, Sanju Sinha, Rahulsimham Vegesna <h2>Summary:</h2> <p>The NCI is currently seeking research co-development partners for this first-in-kind computational method that is predictive of therapeutic response based on clonal SC gene expression of tumors.</p> <h2>Description of Technology:</h2> <p>Tailoring the best treatments to cancer patients remains a highly important endeavor in the oncology field. However, personalized treatment courses are challenging to determine, and technologies or methods that can successfully be employed for precision oncology are lacking.</p> <p>Researchers at the NCI have built a new method for guiding cancer patient therapy based on single cell transcriptomics data of their tumors. This precision oncology data science and software framework is termed PERsonalized single-Cell Expression-based Planning for Treatments In ONcology (PERCEPTION). It capitalizes on recent, matched bulk and single-cell transcriptome profiles sourced from large-scale cell-line drug screenings and builds treatment response models from patient single-cell (SC) tumor transcriptomes. As a proof-of-concept, PERCEPTION has been shown to successfully predict response to monotherapy and combination therapy based on SC-expression profiles, in screenings of standard cancer cell lines and patient-tumor-derived cell lines. It has also successfully identified responders to a combination therapy based on tumor SC-expression data from recent multiple myeloma and breast cancer clinical trials. Further, it has discovered the development of treatment resistance to five standard tyrosine kinase inhibitors in a recent SC dataset obtained from lung cancer patients undergoing treatment. PERCEPTION is the first technology to demonstrate that SC gene expression can provide a framework to predict effective targeted therapies for individual cancer patients in a data-driven manner.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tool for personalized identification of effective patient therapies (precision oncology) based on single cell transcriptomics data of their tumors</li> <li>Tool for discovery of new drug combinations for specific cancer types and sub-types</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First software of its kind that aims to tailor the best treatments to cancer patients based on single cell transcriptomics data of their tumors&nbsp; &nbsp; &nbsp;</li> <li>Has proof-of-concept retrospective validations in patient clinical trial data where PERCEPTION performed better than published state-of-the-art single-cell-based and bulk-based predictors&nbsp; &nbsp; &nbsp;</li> <li>Useful for companies focused on single cell sequencing or interested in the single cell domain</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a new method for guiding cancer patient therapy based on single cell transcriptomics data of their tumors. 2023-06-06 2026-04-30 2023-06-06 2026-04-30 2023-06-06 Cancer Prognosis, Cancer Treatment Resistance, COMPUTATIONAL, Precision Oncology, Ruppin, Single Cell, Single Cell Screening, Single Cell Transcriptomics, Transcriptomics, Tumor Response False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-06-06 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161872 Sinha. S, et al. 2022. bioRxiv. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors. https://doi.org/10.1101/2022.01.11.475728 <a href="https://doi.org/10.1101/2022.01.11.475728">Sinha. S, et al. 2022. bioRxiv. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.</a> 147164668 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147164670 Sinha, Sanju NCI - CCR NCI Sinha, Sanju (NCI) 2 147164671 Vegesna, Rahulsimham NCI - CCR NCI Vegesna, Rahulsimham (NCI) 3 147164669 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 4 147164668 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147164670 Sinha, Sanju NCI - CCR NCI Sinha, Sanju (NCI) 2 147164671 Vegesna, Rahulsimham NCI - CCR NCI Vegesna, Rahulsimham (NCI) 3 147164669 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 4 147157874 PERsonalized Single-Cell Expression-based Planning For Treatments In ONcology (PERCEPTION) Software E-051-2022-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors&body=Please send me information about technology [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors&body=Please send me information about technology [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147168799 E-051-2022-0 E-051-2022-0-US-01 PREDICTING PATIENT TREATMENT RESPONSE AND RESISTANCE VIA SINGLE CELL TRANSCRIPTOMICS OF THEIR TUMORS PRV US 63/298,045 Expired US <br />Provisional (PRV) 63/298,045<br />Filed on 2022-01-10<br />Status: Expired 147168800 E-051-2022-0 E-051-2022-0-PCT-02 Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of their Tumors PCT Patent Cooperation Treaty PCT/US2023/060416 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/060416<br />Filed on 2023-01-10<br />Status: Expired 147170332 Cancer Prognosis 147170334 Cancer Treatment Resistance 147170335 COMPUTATIONAL 147170337 Precision Oncology 147170338 Ruppin 147170340 Single Cell 147170342 Single Cell Screening 147170344 Single Cell Transcriptomics 147170346 Transcriptomics 147170348 Tumor Response TAB-4123 147157405 Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response NCI Collaboration, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Infectious Disease Licensing Oncology Vaccines Barbara Felber, George Pavlakis <h2>Description of Technology:</h2> <p>The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).&nbsp;<br /> Previous studies by NCI determined that regions of the polypeptides Gag and Env are both essential to the core structure and envelope of the HIV-1 virus. Co-administration of DNA expressing Gag and Env elicits a protective immune response and reduces infection burden.&nbsp;&nbsp;This current technology relates to earlier technology from the same inventors describing the identification of the conserved elements (CE) within HIV-1 p24Gag. Specifically, the inventors demonstrated that priming with p24gag CE followed by vaccination with either a full-length p55gag DNA plasmid or p24gag CE DNA together with full-length p55gag DNA increased the CE responses compared to vaccination with p24CE DNA alone.&nbsp;&nbsp;</p> <p>The current invention expands upon the earlier technology, combining DNA and RNA vaccination strategies to induce an effective HIV immune response.&nbsp;&nbsp;The inventors demonstrated that administration of gag mRNA/LNP efficiently boosted both humoral and cellular responses in rhesus macaques previously immunized by a Gag DNA-based vaccine. Furthermore, the mRNA/LNP as booster vaccination induced more potent cytotoxic T cell responses than using mRNA as prime. Overall, this invention describes a heterologous prime/boost regimen including a DNA prime followed by mRNA boost vaccination with the same or similar immunogens &ndash; resulting in optimal levels of humoral and cellular immune response. The use of a mRNA booster to stimulate DNA primed immunity may be broadly applicable as a vaccination strategy for other infectious diseases and cancer.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Prophylactic and therapeutic vaccines for HIV</li> <li>Prophylactic and therapeutic vaccines for&nbsp;infectious diseases</li> <li>Prophylactic and therapeutic vaccines for cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses key hurdle faced by current HIV vaccines: sequence diversity of HIV and immunodominance of specific epitopes</li> <li>Induces optimal cellular and humoral responses</li> <li>Reduces infectious burden</li> <li>Potential vaccine strategy applicable to other non-HIV diseases, such as cancer</li> <li>In vivo validation of vaccine strategy in non-human primates (rhesus macaques)</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for development of a RNA/DNA combination vaccine against infectious diseases (ex: HIV, SARS-CoV-2) or cancer 2023-07-04 2026-04-24 2023-07-05 2026-04-29 2023-07-04 CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-07-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-087-2015 E-132-2012 147162002 Valentin A, et al. 2022. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. (PMID: 35935984) https://pubmed.ncbi.nlm.nih.gov/35935984/ <a href="https://pubmed.ncbi.nlm.nih.gov/35935984/">Valentin A, et al. 2022. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. (PMID: 35935984)</a> 147163589 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147163588 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147163589 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147163588 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147158103 Immunogens And Methods To Improve Vaccine Immune Response E-158-2022-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response&body=Please send me information about technology [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response&body=Please send me information about technology [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161119 E-158-2022-0 E-158-2022-0-US-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE PRV US 63/358,919 Expired US <br />Provisional (PRV) 63/358,919<br />Filed on 2022-07-07<br />Status: Expired 147166705 E-158-2022-0 E-158-2022-0-PC-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE PCT Patent Cooperation Treaty PCT/US2023/069057 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/069057<br />Filed on 2023-06-26<br />Status: Expired 147172586 CANCER VACCINE 147172587 DNA vaccine 147172588 ENV 147172589 Felber 147172590 GAG 147172591 HIV 147172592 Infectious Disease 147172593 Nci 147172594 Pavlakis 147172596 RNA Vaccine 147172597 SARS-CoV-2 147172598 Vaccine TAB-4122 147157404 Development and Characterization of the SLC46A3 Knockout Mouse Line NCI Endocrinology, Licensing, Oncology, Research Materials Endocrinology Licensing Oncology Research Materials Frank Gonzalez, Jung-Hwan Kim, Sun Hee Yim <h2>Summary:</h2> <p>The NCI is seeking licensees for the SLC46A3 knockout mouse line.</p> <h2>Description of Technology:</h2> <p>Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as SLC46A3 knockout cells and animal models are required.</p> <p>Researchers at the National Cancer Institute (NCI) have developed an SLC46A3 knockout mouse line and demonstrated that TCDD-induced hepatic triglyceride accumulation was significantly reduced in the knockout mice compared to the wild type mice. This reduction in triglyceride accumulation was more pronounced when the mice were fed a high fat diet. The SLC46A3 knockout mouse line is therefore an effective tool to study TCDD-induced lipid accumulation, liver toxicity and nonalcoholic fatty liver disease. As SLC46A3 gene and protein are also associated with other diseases such as breast cancer, prostate cancer, liver cancer, papilloma, glioma, obesity, and SARS, this knockout mouse line may have wide applicability.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Drug screening and development against various diseases such as nonalcoholic fatty liver disease, obesity, liver cancer, SARS, breast cancer, prostate cancer, papilloma, glioma</li> <li>Research tool to study SLC46A3&rsquo;s role in hepatic lipid accumulation or as a solute carrier of the Major Facilitator Superfamily (MFS)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The only known SLC46A knockout mouse line available</li> <li>Effective research tool to study TCDD-mediated liver toxicity leading to nonalcoholic fatty liver disease&nbsp;</li> </ul> 2021-07-14 2026-04-24 2021-07-14 2026-04-29 2021-07-14 2, 3, 7, 8-tetracholodibenzo-p-dioxin, Gonzalez, hepatocellular carcinoma, Knockout Mouse, Liver cancer, Major Facilitator Superfamily, MFS, Nonalcoholic fatty liver disease, OBESITY, SLC46A3, Solute Carrier Family, TCDD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-07-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162426 Kim JH, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. (PMID 33436590) https://pubmed.ncbi.nlm.nih.gov/33436590/ <a href="https://pubmed.ncbi.nlm.nih.gov/33436590/">Kim JH, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. (PMID 33436590)</a> 147163585 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 1 147163586 Yim, Sun Hee NIH - NCI Yim, Sun Hee 2 147163587 Kim, Jung-Hwan NIH - NCI Kim, Jung-Hwan 3 147163585 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 1 147163586 Yim, Sun Hee NIH - NCI Yim, Sun Hee 2 147163587 Kim, Jung-Hwan NIH - NCI Kim, Jung-Hwan 3 147158087 Development And Characterization Of Teh SLC46A3 Knockout Mouse Line E-152-2021-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line&body=Please send me information about technology [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line&body=Please send me information about technology [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147172441 2 147172442 3 147172443 7 147172445 8-tetracholodibenzo-p-dioxin 147172447 Gonzalez 147172448 hepatocellular carcinoma 147172450 Knockout Mouse 147172451 Liver cancer 147172453 Major Facilitator Superfamily 147172455 MFS 147172457 Nonalcoholic fatty liver disease 147172458 OBESITY 147172459 SLC46A3 147172461 Solute Carrier Family 147172463 TCDD TAB-3980 147157261 Polymer-Cast Inserts for Cell Histology and Microscopy NCI Collaboration, Dermatology, Immunology, Infectious Disease, Licensing, Research Materials Collaboration Dermatology Immunology Infectious Disease Licensing Research Materials Thu Nguyen, Ralph Parchment <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for polymer-cast inserts for cell histology and microscopy; a system for high throughput three-dimensional (3D) cell culture and screening microscopy.</p> <h2>Description of Technology:</h2> <p>Three-dimensional (3D) cell cultures systems are important for studying cell biology because they provide <em>in vivo-</em>like microenvironments more physiologically relevant than two-dimensional (2D) culture systems. In 3D culture systems, cells are grown in culture matrixes and turn into spheroids and organoids later processed for downstream analysis by microscopy and histology techniques. The processing of 3D cultures for analysis by microscopy or histology is laborious and time-consuming due to incompatibility of the 3D culture vessels and the microscopy and pathology blocks. Therefore, it is not amenable to high-throughput analysis.</p> <p>NCI scientists developed polymer-cast inserts for cell histology and microscopy (PICHAM), made of soft biocompatible polymer compatible with immunofluorescence microscopy. The technology encompasses fixation for paraffin embedding and sectioning, into which an array of vertical wells were bored to harbor cells in culture in the form of spheroids, organoids or other tissue replicas. A PICHAM is cast as a rectangular cuboid designed and fabricated with dimensions to precisely fit into standard histology cassettes. It is envisioned to provide a one-piece system that allows a seamless transition from 3D culture to high-throughput histopathology and microscopy analysis of spheroids and organoids. Due to the compatibility of PICHAMs with both cell culture and histopathology processes, it will eliminate a major roadblock in high throughput processing of 3D cell cultures for microscopy and histopathology analyses.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for cell biology</li> <li>Growing 3D cell cultures for histology and microscopy analysis</li> <li>High-throughput processing of 3D cell cultures for microscopy and histopathology analysis&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Minimizes processing of 3D cell cultures for histopathology analysis</li> <li>Saves time by reducing processes and eliminating manual steps</li> <li>Enables high-throughput microscopy and histopathology analysis of 3D cultures</li> <li>Minimizes disruptions of 3D cell cultures during processing</li> <li>Compatibility with both 3D cell culture vessels and histopathology cassettes reduces supplies required</li> </ul> 2021-06-12 2026-04-24 2021-06-14 2026-04-29 2021-06-11 3D Cell Culture, high-throughput screening, Histology, Histopathology, MICROSCOPY, Organoids, Parchment, Polymer-cast, Spheroids False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-14 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162164 Huang H, et al. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. (PMID 23527204) https://pubmed.ncbi.nlm.nih.gov/23527204/ <a href="https://pubmed.ncbi.nlm.nih.gov/23527204/">Huang H, et al. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. (PMID 23527204)</a> 147163107 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 1 147163108 Nguyen, Thu NIH - NCI Nguyen, Thu 2 147163107 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 1 147163108 Nguyen, Thu NIH - NCI Nguyen, Thu 2 147158192 Polymer-cast Inserts For Cell Histology And Microscopy (PICHAMs) - A System For High Throughput 3D Cell Culture And Screening Micro_scopy E-196-2018-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy&body=Please send me information about technology [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy&body=Please send me information about technology [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161181 E-196-2018-0 E-196-2018-0-US-01 INSERT FOR PREPARING CELL CULTURE CHAMBERS PRV US 63/058,794 Abandoned US <br />Provisional (PRV) 63/058,794<br />Filed on 2020-07-30<br />Status: Abandoned 147165678 E-196-2018-0 E-196-2018-0-PCT-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS PCT Patent Cooperation Treaty PCT/US2021/043930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/043930<br />Filed on 2021-07-30<br />Status: Expired 147165679 E-196-2018-0 E-196-2018-0-US-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS National Stage US 18/018,762 Pending US <br />National Stage 18/018,762<br />Filed on 2023-01-30<br />Status: Pending 147173485 3D Cell Culture 147173486 high-throughput screening 147173487 Histology 147173488 Histopathology 147173489 MICROSCOPY 147173490 Organoids 147173492 Parchment 147173493 Polymer-cast 147173494 Spheroids TAB-5050 162271610 Broadly neutralizing influenza hemagglutinin stem-directed antibodies NIAID Antibodies, Application, Collaboration, Collaboration Sought, Immunology, Infectious Disease, Licensing, Materials Available, Therapeutics, Vaccines Antibodies Application Collaboration Collaboration Sought Immunology Infectious Disease Licensing Materials Available Therapeutics Vaccines Sarah Andrews, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Grace Mantus, Julie Raab <p>In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance and are useful for only a limited post-infection period. &nbsp;&nbsp;&nbsp;</p> <p>The highly conserved epitopes in the stem region of the influenza hemagglutinin (HA) protein are ideal targets for new vaccines, as they elicit broadly neutralizing antibodies. In light of this, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) cloned and expressed HA stem-specific monoclonal antibodies (mAbs) from B cells isolated from human participants in influenza vaccine clinical trials. Four mAbs exhibited particularly potent neutralizing profiles against H1N1 strains, three exhibited very strong neutralization profiles against H3N2 strains, and two exhibited a good neutralization profile across all subtypes tested. These mAbs may help to substantially reduce global influenza disease burden given their potential to become effective therapeutic and prophylactic agents against a broad range of H1N1 and H3N2 influenza strains.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>Greater neutralization potency against H1N1 and H3N2 strains than observed for other high-profile candidates tested in phase II clinical trials</li> </ul> <ul> <li>Prophylactic or therapeutic strategies against influenza infection</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Wade Green at 301-761-7505, or wade.green@nih.gov, and reference E-026-2024. 2025-05-08 2025-05-08 2026-04-29 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162272045 Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 2023;15:eade4976. https://doi.org/10.1126/scitranslmed.ade4976 <a href="https://doi.org/10.1126/scitranslmed.ade4976">Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 2023;15:eade4976.</a> 162272059 Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem–specific human B cells. Sci. Transl. Med. 2025;17:eadr8373. https://doi.org/10.1126/scitranslmed.adr8373 <a href="https://doi.org/10.1126/scitranslmed.adr8373">Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem–specific human B cells. Sci. Transl. Med. 2025;17:eadr8373.</a> 162271755 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 1 162271768 Mantus, Grace NIAID - VRC NIAID Mantus, Grace (NIAID) 2 162271782 Chopde, Ankita NIAID - VRC NIAID Chopde, Ankita (NIAID) 3 162271793 Creanga, Adrian NIAID - VRC NIAID Creanga, Adrian (NIAID) 4 162271809 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 5 162271837 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 6 162271842 Raab, Julie University of Colorado NIAID Raab, Julie (NIAID) 7 162271755 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 1 162271768 Mantus, Grace NIAID - VRC NIAID Mantus, Grace (NIAID) 2 162271782 Chopde, Ankita NIAID - VRC NIAID Chopde, Ankita (NIAID) 3 162271793 Creanga, Adrian NIAID - VRC NIAID Creanga, Adrian (NIAID) 4 162271809 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 5 162271837 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 6 162271842 Raab, Julie University of Colorado NIAID Raab, Julie (NIAID) 7 162271613 Broadly neutralizing influenza hemagglutinin stem-directed antibodies E-026-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - VRC, NIAID - VRC 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies&body=Please send me information about technology [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies&body=Please send me information about technology [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies.">wade.green@nih.gov</a><br> 162271618 E-026-2024-0 E-026-2024-0-US-01 Broadly neutralizing influenza hemagglutinin stem-directed antibodies PRV US 63/605,374 Expired US <br />Provisional (PRV) 63/605,374<br />Filed on 2023-12-01<br />Status: Expired 162271619 E-026-2024-0 E-026-2024-0-PC-01 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES PCT Patent Cooperation Treaty PCT/US2024/057131 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/057131<br />Filed on 2024-11-22<br />Status: Expired 167038722 E-026-2024-0 E-026-2024-0-US-02 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES National Stage US 19/591,653 Pending US <br />National Stage 19/591,653<br />Filed on 2026-05-28<br />Status: Pending 167038787 E-026-2024-0 E-026-2024-0-EP-01 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-3949 147157229 Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Chi-Ping Day, Hejiao English, Mitchell Ho, Dan Li, Glenn Merlino <h2>Description of Technology:</h2> <p>Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.&nbsp; PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1 negatively regulates T cell-mediated immune responses. It has been suggested that disrupting the PD-L1/PD-1 signaling pathway can be used to treat cancers. The aberrant expression of PD-L1 on multiple tumor types supports this suggestion. As a result, PD-L1 represents a strong target for the development of new anti-cancer therapeutics.&nbsp;</p> <p>Researchers at the NCI&rsquo;s Laboratory of Molecular Biology have isolated three anti-PD-L1 single domain antibodies (also known as nanobodies), B2, A11, and F5 that target PD-L1. These nanobodies can be used either as independent agents or as the targeting domain in chimeric antigen receptors (CARs), antibody drug conjugates (ADCs), recombinant immunotoxins (RITs), and bispecific antibodies. Significantly, CARs using these antibodies has shown potent in vitro and in vivo killing against PD-L1 positive tumors, including liver and triple-negative breast cancer, strongly supporting that these candidates may be further developed as therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Therapeutics against PD-L1-expressing cancers, including liver, bladder, pancreatic, prostate, gastric and triple-negative breast cancer</li> <li>Diagnostic agent for detection and monitoring levels of PD-L1-expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>These anti-PD-L1 nanobodies have an advantage, due to their small size, to potentially bind to epitopes unavailable to more conventional antibodies</li> <li>Cross-species reactivity in mouse and human</li> <li>Combination of B2 and hYP7 CARs in T cells improves lysis of liver cancer cells in mice compared to either CAR alone</li> <li>CARs using the B2 single domain antibody are available for immediate testing</li> </ul> 2021-07-14 2026-04-29 2021-08-05 2026-04-29 2021-08-05 adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-136-2012 147162983 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162982 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147162986 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147162984 English, Hejiao NIH - NCI NCI English, Hejiao (NCI) 4 147162985 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 5 147162983 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162982 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147162986 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147162984 English, Hejiao NIH - NCI NCI English, Hejiao (NCI) 4 147162985 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 5 153379661 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors E-118-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors&body=Please send me information about technology [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors&body=Please send me information about technology [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161068 E-118-2021-0 E-118-2021-0-US-01 CROSS SPECIES SINGLE DOMAIN ANTIBODIES TARGETING PD-L1 FOR TREATING SOLID TUMORS PRV US 63/208,755 Abandoned US <br />Provisional (PRV) 63/208,755<br />Filed on 2021-06-09<br />Status: Abandoned 147165506 E-118-2021-0 E-118-2021-0-PCT-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors PCT Patent Cooperation Treaty PCT/US2022/032378 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/032378<br />Filed on 2022-06-06<br />Status: Expired 153379665 E-118-2021-0 E-118-2021-0-CA-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage Canada 3216228 Pending Canada <br />National Stage 3216228<br />Filed on 2023-10-04<br />Status: Pending 153379666 E-118-2021-0 E-118-2021-0-AU-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage Australia 2022291120 Pending Australia <br />National Stage 2022291120<br />Filed on 2023-11-01<br />Status: Pending 153379667 E-118-2021-0 E-118-2021-0-CN-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage China 202280041531.8 Pending China <br />National Stage 202280041531.8<br />Filed on 2023-12-08<br />Status: Pending 153379668 E-118-2021-0 E-118-2021-0-US-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage US 18/567,990 Pending US <br />National Stage 18/567,990<br />Filed on 2023-12-07<br />Status: Pending 153379669 E-118-2021-0 E-118-2021-0-EP-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage European Patent 22738126.6 Pending European Patent <br />National Stage 22738126.6<br />Filed on 2023-10-18<br />Status: Pending 147171812 adoptive cell therapy 147171814 Chimeric Antigen Receptor T Cells 147171815 HO 147171816 ICI 147171818 Immune Checkpoint Inhibitor 147171819 Immunotherapy 147171820 NANOBODY 147171821 PD-L1 147171822 phage display 147171824 Programed Death-Ligand 147171825 Single Domain Antibody TAB-3004 114096419 Gene Therapy for Niemann-Pick Disease Type C NHGRI Collaboration, Endocrinology, Neurology, Therapeutics Collaboration Endocrinology Neurology Therapeutics Randy Chandler, William ("Bill") Pavan, Charles Venditti Investigators at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) are seeking collaborators to further develop gene therapy to treat Niemann-Pick Disease Type C (NPC). NPC is a rare, autosomal recessive, neurodegenerative disease. Approximately 95% of patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking. Mutations of NPC1 cause intracellular accumulation of unesterified cholesterol in late endosomal/lysosomal structures and marked accumulation of glycosphingolipids, especially in neuronal tissue. Thus, NPC patients generally present with hepatosplenomegaly (enlargement of liver and spleen) and neurological degeneration.<br /><br /> NHGRI investigators have generated adeno-associated viral (AAV) constructs that are able to correct cellular defects of certain cholesterol storage disease or disorders, such as NPC, in vivo. <ul> <li>Optimized components of the vectors (e.g., specific promoters).</li> <li>Shown to work in animal (murine) models.</li> </ul> <ul> <li>Potential for successful gene therapy for patients with NPC.</li> <li>Can lead to similar approaches for treating other cholesterol storage disorders.</li> </ul> NHGRI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these gene therapy vectors. For collaboration opportunities please contact Anna Solowiej at the email address above. 2022-03-08 2026-04-28 2026-04-28 2016-04-18 Adeno-associated, C, Disease, Gene, Listed LPM Contreras as of 4/15/2015, NIEMANN-PICK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THERAPY, treatment, TYPE, VEXXXX, VHXXXX, viral, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114107080 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114107081 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114107079 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114107079 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114107080 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114107081 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114101516 Adeno-associated Viral Gene Therapy As A New Treatment For Niemann-Pick Disease Type C E-185-2014-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C.">anna.solowiej@nih.gov</a><br> 114164810 E-185-2014-0 E-185-2014-0-PCT-02 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder PCT Patent Cooperation Treaty PCT/US2016/026524 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/026524<br />Filed on 2016-04-07<br />Status: Expired 114166393 E-185-2014-0 E-185-2014-0-US-01 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER PRV US 62/144,702 Abandoned US <br />Provisional (PRV) 62/144,702<br />Filed on 2015-04-08<br />Status: Abandoned 114168403 E-185-2014-0 E-185-2014-0-US-04 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER National Stage US 15/565,065 Abandoned US <br />National Stage 15/565,065<br />Filed on 2016-04-07<br />Status: Abandoned 114169057 E-185-2014-0 E-185-2014-0-US-12 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER DIV US 12,201,658 17/033,166 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12201658 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12201658">12,201,658</a><br />Filed on 2020-09-25<br />Status: Issued 166893950 E-185-2014-0 E-185-2014-0-EP-06 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder National Stage European Patent 3280451 16717228.7 Issued European Patent <br />National Stage 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893955 E-185-2014-0 E-185-2014-0-CA-05 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder National Stage Canada 2982129 Pending Canada <br />National Stage 2982129<br />Filed on 2016-04-07<br />Status: Pending 166893960 E-185-2014-0 E-185-2014-0-DE-07 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Germany 3280451 16717228.7 Issued Germany <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893965 E-185-2014-0 E-185-2014-0-ES-08 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Spain 3280451 16717228.7 Issued Spain <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893970 E-185-2014-0 E-185-2014-0-FR-09 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP France 3280451 16717228.7 Issued France <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893975 E-185-2014-0 E-185-2014-0-GB-10 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP United Kingdom 3280451 16717228.7 Issued United Kingdom <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893980 E-185-2014-0 E-185-2014-0-IT-11 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Italy 3280451 16717228.7 Issued Italy <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893987 E-185-2014-0 E-185-2014-0-US-02 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER CON US 18/976,790 Pending US <br />Continuation (CON) 18/976,790<br />Filed on 2024-12-11<br />Status: Pending 114121791 VEXXXX 114121792 VHXXXX 114121793 WJXXXX 114121794 XEXXXX 114137443 Listed LPM Contreras as of 4/15/2015 114137444 Pre LPM working set 20150418 114137445 Post LPM Assignment Set 20150420 114140967 Adeno-associated 114140968 viral 114140969 Gene 114140970 THERAPY 114140971 treatment 114140972 NIEMANN-PICK 114140973 Disease 114140974 TYPE 114140975 C TAB-3848 146937956 Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc) NHGRI Therapeutics Therapeutics William Gahl, Marjan Huizing, Enriko Klootwijk, Eirini (Irini) Manoli <p>N-acetylmannosamine (ManNAc) is a small uncharged physiological molecule that crosses membranes readily and is the natural precursor of intracellular sialic acid synthesis. NHGRI investigators discovered that ManNAc can be used for therapeutic purposes, including treating certain kidney diseases (e.g., those involving abnormal levels of protein in the urine and/or blood in the urine), resulting primarily or secondarily from hyposialylation (deficiency of sialic acid). Notably, ManNAc can also potentially be used to treat diabetic nephropathy.</p> <p>ManNAc therapy is given orally and shows long-term safety and biochemical efficacy, consistent with its mechanism of action in humans.</p> <p>Thus, the following fields of use are available for licensing: Treating <strong>kidney disorders</strong> due to hyposialylation of the glomerular basement membrane (GBM), including but not limited to minimal change disease glomerulopathy (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and diabetic nephropathy in humans with oral formulations of N-acetyl mannosamine (ManNAc) or derivative.</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/huizing_et_al_graphical_abstract__tto_21apr2026.jpg" style="height:720px; width:1280px" /></p> <ul> <li>ManNAc is easy to administer to patients (oral administration).</li> <li>Long-term ManNAc administration has been shown to be safe and well-tolerated in humans.</li> <li>This technology includes many issued patents in the U.S, Canada, Europe, Japan, and Israel for these indications.</li> <li>Extensive published and unpublished preclinical data for these kidney indications is available.</li> <li>A Phase I clinical trial of ManNAc in subjects with primary glomerular diseases has been completed with positive results.</li> <li> A Phase II study in subjects with primary focal segmental glomerulosclerosis is ongoing.</li> <li>A clinical study in diabetic nephropathy is in planning stages.</li> </ul> The National Human Genome Research Institute (NHGRI) is seeking statements of capability or interest from parties interested in collaborating on further developing and commercializing this technology for proteinuric kidney diseases, including diabetic nephropathy. For collaboration opportunities, please contact Anna Solowiej at the email address provided above. 2023-07-19 2026-04-28 2026-04-28 2023-07-27 2023-07-26 False True Phase I completed. True 72159140 Clinical Phase II 72159140 37470483 Website Abstract E-217-2007-0 146938360 Huizing et al., "Rationale and design for Phase 1 study of N-acetylmannosamine for primary glomerular diseases," Kidney International Reports (2019) 4, 1454-1452 https://pubmed.ncbi.nlm.nih.gov/31701055/ <a href="https://pubmed.ncbi.nlm.nih.gov/31701055/">Huizing et al., "Rationale and design for Phase 1 study of N-acetylmannosamine for primary glomerular diseases," Kidney International Reports (2019) 4, 1454-1452</a> 166979020 Huizing et al., “Phase 1 Study of Oral N-Acetylmannosamine in Primary Podocytopathies,” Kidney International Reports (2025) 11, 103758 https://pmc.ncbi.nlm.nih.gov/articles/PMC12861195/ <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12861195/">Huizing et al., “Phase 1 Study of Oral N-Acetylmannosamine in Primary Podocytopathies,” Kidney International Reports (2025) 11, 103758</a> 146938169 Huizing, Marjan National Human Genome Research Institute (NHGRI) NHGRI Huizing, Marjan (NHGRI) 1 146938174 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 2 146938314 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 3 146938332 Klootwijk, Enriko National Human Genome Research Institute (NHGRI) Klootwijk, Enriko 4 146938169 Huizing, Marjan National Human Genome Research Institute (NHGRI) NHGRI Huizing, Marjan (NHGRI) 1 146938174 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 2 146938314 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 3 146938332 Klootwijk, Enriko National Human Genome Research Institute (NHGRI) Klootwijk, Enriko 4 146937959 Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids E-217-2007-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc)&body=Please send me information about technology [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc). Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc)&body=Please send me information about technology [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc).">anna.solowiej@nih.gov</a><br> TAB-3429 114097303 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus NIAID Licensing Licensing Ursula Buchholz, Peter Collins, Jason Gorman, Wing-pui Kong, Peter Kwong, John Mascola, Li Ou, Guillaume Stewart-Jones, Yaroslav Tsybovsky, Baoshan Zhang, Tongqing Zhou Human metapneumovirus (hMPV) infections have been shown as a common cause of upper and lower respiratory diseases such as bronchiolitis and pneumonia in young children, the elderly, and other immunocompromised individuals. Studies show that infections by the non-segmented negative strand RNA virus begin with attachment and entry of viral glycoproteins that mediate fusion with host cellular membranes. Like for the human respiratory syncytial virus (hRSV), a viral entry is initiated by the fusion (F) protein. Given its role in hMPV entry, the F protein has thus been a target for eliciting neutralizing antibodies and development of novel protein-based therapeutic vaccines.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed improved recombinant human metapneumovirus (hMPV) F proteins stabilized in the prefusion conformation that can elicit potent neutralizing antibodies against infection. Double and triple stabilized candidates were designed with inter-and intraprotomer disulfide mutations that increase protein production and show improved antigenic recognition by prefusion-specific antibodies. These second-generation immunogens constitute an improvement over the first generation constructs and are characterized by additional stabilization that results in optimal neutralization responses.<br /><br /> The second-generation stabilized prefusion hMPV F immunogens may be an ideal vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. ... <ul> <li>There are no approved vaccines or therapeutics against the second leading cause of pediatric viral lower respiratory tract infection in infants and young children</li> <li>Second-generation hMPV F immunogens induce higher titer neutralizing responses than first-generation versions in mice</li> </ul> <ul> <li>A promising vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults</li> </ul> </li> <li>Second-generation hMPV F immunogens induce higher titer neutralizing responses than first-generation versions in mice</li> </ul> 2022-10-25 2026-04-27 2026-04-27 2021-01-26 F, Fusion, GLYCOPROTEIN, Human, IMMUNOGENS, Metapneumovirus, Prefusion-Stabilized, Vaccine False True True NIHTT 37470483 Website Abstract 114172594 Liu, P., et al https://pubmed.ncbi.nlm.nih.gov/23761661/ <a href="https://pubmed.ncbi.nlm.nih.gov/23761661/">Liu, P., et al</a> 114172595 Battles, M. B., et al https://pubmed.ncbi.nlm.nih.gov/29142300/ <a href="https://pubmed.ncbi.nlm.nih.gov/29142300/">Battles, M. B., et al</a> 114110156 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110157 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110158 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110159 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114110160 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110161 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114110162 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114110163 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110164 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110165 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114110155 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110155 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110156 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110157 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110158 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110159 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114110160 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110161 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114110162 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114110163 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110164 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110165 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114102552 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus E-131-2019-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus&body=Please send me information about technology [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus&body=Please send me information about technology [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus.">wade.green@nih.gov</a><br> 114168285 E-131-2019-0 E-131-2019-0-PCT-02 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2021/029988 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/029988<br />Filed on 2021-04-29<br />Status: Expired 114169092 E-131-2019-0 E-131-2019-0-US-01 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE PRV US 63/017,581 Abandoned US <br />Provisional (PRV) 63/017,581<br />Filed on 2020-04-29<br />Status: Abandoned 114169666 E-131-2019-0 E-131-2019-0-US-06 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE National Stage US 17/919,733 Pending US <br />National Stage 17/919,733<br />Filed on 2022-10-18<br />Status: Pending 114152011 Prefusion-Stabilized 114152012 Fusion 114152013 F 114152014 GLYCOPROTEIN 114152015 Vaccine 114152016 IMMUNOGENS 114152017 Human 114152018 Metapneumovirus TAB-3342 114097257 Fusion Glycoprotein Vaccine for Human Metapneumovirus NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Ursula Buchholz, Peter Collins, Davide Corti, Michael Joyce, Peter Kwong, Antonio Lanzavecchia, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation.<br /><br /> Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>No human metapneumovirus vaccine is currently available</li> </ul> <ul> <li>Vaccine for prevention of human metapneumovirus infection</li> </ul> Vaccine for prevention of human metapneumovirus infection 2022-04-12 2026-04-27 2026-04-27 2018-10-29 DC5XXX, Fusion, GLYCOPROTEIN, HMPV, Metapneumovirus, Prefusion, respiratory, Respiratory Diseases, respiratory INFECTION, Respiratory Syncytial Virus, Structure-based, Vaccine False True True NIHTT 37470483 Website Abstract 114109955 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109956 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109957 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109958 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109959 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109960 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109961 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109962 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114109954 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109954 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109955 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109956 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109957 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109958 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109959 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109960 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109961 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109962 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114102500 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus E-260-2014-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus&body=Please send me information about technology [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus&body=Please send me information about technology [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus.">wade.green@nih.gov</a><br> 114168779 E-260-2014-0 E-260-2014-0-US-01 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus PRV US 62/096,744 Abandoned US <br />Provisional (PRV) 62/096,744<br />Filed on 2014-12-24<br />Status: Abandoned 114168780 E-260-2014-0 E-260-2014-0-PCT-02 Recombinant Metapneumovirus F Proteins and Their Use PCT Patent Cooperation Treaty PCT/IB2015/059991 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2015/059991<br />Filed on 2015-12-24<br />Status: Expired 114168781 E-260-2014-0 E-260-2014-0-US-04 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE National Stage US 10,420,834 15/539,640 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420834 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420834">10,420,834</a><br />Filed on 2017-06-23<br />Status: Issued 114168782 E-260-2014-0 E-260-2014-0-EP-03 Recombinant Metapneumovirus F Proteins and Their Use National Stage European Patent 15831073.0 Pending European Patent <br />National Stage 15831073.0<br />Filed on 2015-12-24<br />Status: Pending 114168920 E-260-2014-0 E-260-2014-0-US-05 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE DIV US 11,027,007 16/578,748 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11027007 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11027007">11,027,007</a><br />Filed on 2019-09-23<br />Status: Issued 114169126 E-260-2014-0 E-260-2014-0-US-06 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE DIV US 11,786,591 17/334,505 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786591 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786591">11,786,591</a><br />Filed on 2021-05-18<br />Status: Issued 114128216 DC5XXX 114151489 Metapneumovirus 114151490 Vaccine 114151491 GLYCOPROTEIN 114151492 Fusion 114151493 Structure-based 114151494 HMPV 114151495 Prefusion 114151496 Respiratory Diseases 114151497 respiratory INFECTION 114151498 respiratory 114151499 Respiratory Syncytial Virus TAB-3336 114097252 Substitutions-Modified Prefusion RSV F Proteins and Their Use NIAID Licensing Licensing Ulrich Baxa, Man Chen, Aliaksandr Druz, Ivelin Georgiev, Barney Graham, Michael Joyce, Wing-pui Kong, Peter Kwong, John Mascola, Li Ou, Marie Pancera, Emily Rundlet, Mallika Sastry, Cinque Soto, Guillaume Stewart-Jones, Paul Thomas, Yaroslav Tsybovsky, Joseph Van Galen, Yongping Yang, Baoshan Zhang The respiratory syncytial virus (RSV) fusion (F) glycoprotein is the primary target of neutralizing antibodies. The F glycoprotein exists in at least two conformations, a meta-stable prefusion state, and an extremely stable postfusion state. Both states share several epitopes targeted by neutralizing antibodies, but it has been demonstrated that the prefusion conformation of F contains at least one epitope not present in the postfusion conformation. Natural infection results in neutralizing antibodies that are primarily directed against the prefusion conformation of F, not its postfusion conformation. The instability of the prefusion form of F has hindered both its characterization and its use as a vaccine antigen.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases have overcome technical obstacles to produce a homogeneous, soluble RSV F glycoprotein vaccine which is stabilized in the prefusion conformation and has improved stability and immunogenicity compared to the native protein. Additionally, several modifications were introduced to remove the requirement for furin during production, resulting in an increase in expression levels of the immunogen. Stability of the immunogen was increased 20-fold as compared to DS-CAV1 (a prefusion-stabilized RSV F glycoprotein vaccine candidate that is currently being assessed in clinical trials) upon incubation at 60 ºC. In mice, these immunogens elicited neutralization titers that were 2 to 5-fold higher than DS-CAV1.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Increased stability compared to the current leading RSV vaccine candidate (DS-Cav1).</li> <li>Elicits increased neutralization titers in mice.</li> </ul> <ul> <li>Vaccine: RSV vaccine for human use.</li> <li>Probe: B cell-sorting probe to isolate potent neutralizing monoclonal antibodies.</li> <li>Diagnostics: To assess the titer of prefusion-specific antibodies in sera.</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2018-10-17 COVALENT, DS-Cav1, IMPROVEMENTS, LEADING, Neutralizing, Prefusion, proteins, protomer, RSV F, Stabilization, Thermostability, TITERS, Trimeric False True True NIHTT 37470483 Website Abstract E-081-2013-0 114172542 Joyce MG, et al. http://www.nature.com/articles/nsmb.3267 <a href="http://www.nature.com/articles/nsmb.3267">Joyce MG, et al.</a> 114109901 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114109903 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109904 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109905 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114109906 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109907 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109908 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109909 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109910 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109911 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109912 Rundlet, Emily NIAID - DIR NIAID Rundlet, Emily (NIAID) 0 114109913 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109914 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109915 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114109916 Soto, Cinque NIAID - VRC Soto, Cinque 0 114109917 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109918 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109919 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109920 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109902 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109902 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109901 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114109903 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109904 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109905 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114109906 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109907 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109908 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109909 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109910 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109911 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109912 Rundlet, Emily NIAID - DIR NIAID Rundlet, Emily (NIAID) 0 114109913 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109914 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109915 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114109916 Soto, Cinque NIAID - VRC Soto, Cinque 0 114109917 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109918 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109919 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109920 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114102490 Single-chain Covalent Trimeric Prefusion RSV F Proteins That Elicit Neutralizing Titers In Mice Four To Five-fold Higher And Display Substantially Higher Thermostability Than The Current Leading Candidate DS-Cav1 E-064-2016-0 Filing authorized NIAID 114102491 Single-chain Covalent Trimeric Prefusion RSV F Proteins That Elicit Neutralizing Titers In Mice Four To Five-fold Higher And Display Substantially Higher Thermostability Than The Current Leading Candidate DS-Cav1 E-064-2016-1 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use&body=Please send me information about technology [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use&body=Please send me information about technology [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use.">sabrina.hafiz@nih.gov</a><br> 114168764 E-064-2016-0 E-064-2016-0-US-01 RSV F Immunogens and Their Use PRV US 62/314,946 Expired US <br />Provisional (PRV) 62/314,946<br />Filed on 2016-03-29<br />Status: Expired 114168765 E-064-2016-1 E-064-2016-1-PCT-01 RSV F IMMUNOGENS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2017/024714 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/024714<br />Filed on 2017-03-29<br />Status: Expired 114168766 E-064-2016-1 E-064-2016-1-US-07 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE National Stage US 11,174,292 16/089,993 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11174292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11174292">11,174,292</a><br />Filed on 2018-09-28<br />Status: Issued 114169139 E-064-2016-1 E-064-2016-1-US-08 PREFUSION RSV F PROTEINS AND THEIR USE CON US 11,878,998 17/524,380 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11878998 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11878998">11,878,998</a><br />Filed on 2021-11-11<br />Status: Issued 114151403 COVALENT 114151404 Prefusion 114151405 proteins 114151406 Neutralizing 114151407 IMPROVEMENTS 114151408 Trimeric 114151409 TITERS 114151410 Thermostability 114151411 LEADING 114151412 DS-Cav1 114151413 RSV F 114151414 Stabilization 114151415 protomer TAB-2717 114096896 Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason Gorman, Barney Graham, Michael Joyce, Masaru Kanekiyo, Peter Kwong, Jason McLellan, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization with pre F may elicit an immune response superior to the response generated by postfusion F.<br /><br /> NIH researchers have engineered pre F to expose an antigenic site 0, which is targeted by extremely potent RSV neutralizing antibodies. Structure-based design yielded several stabilized variants of pre F that maintained exposure of antigenic site 0 when subjected to extremes of pH, osmolality and temperature.<br /><br /> Preclinical in vivo data on stabilized pre F is available. Immunization of mice and macaques with antigenic site 0 stabilized pre F variants elicited high levels of RSV specific neutralizing activity. <ul> <li>Vaccine stably exposes antigenic site in RSV F that permits generation of potent RSV neutralizing antibodies.</li> <li>There is currently no RSV vaccine on the market.</li> </ul> <ul> <li>Vaccine for Respiratory Syncytial Virus</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2014-01-16 CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX False True <ul> <li>Pre-clinical</li> </li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171986 McLellan JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/23618766 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23618766">McLellan JS, et al.</a> 114171987 McLellan JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/24179220 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24179220">McLellan JS, et al.</a> 114103548 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114103549 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114103550 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114103551 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114104949 Srivatsan, Sanjay NIAID - VRC NIAID Srivatsan, Sanjay (NIAID) 0 114105607 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114105761 Chen, Lei NIAID - VRC NIAID Chen, Lei (NIAID) 0 114106323 Soto, Cinque NIAID - VRC Soto, Cinque 0 114106377 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114108383 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114108384 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108385 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114108386 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108387 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114108628 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114108673 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114108674 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114108675 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114108676 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114108382 McLellan, Jason NIAID - VRC NIAID McLellan, Jason (NIAID) 1 114108382 McLellan, Jason NIAID - VRC NIAID McLellan, Jason (NIAID) 1 114103548 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114103549 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114103550 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114103551 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114104949 Srivatsan, Sanjay NIAID - VRC NIAID Srivatsan, Sanjay (NIAID) 0 114105607 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114105761 Chen, Lei NIAID - VRC NIAID Chen, Lei (NIAID) 0 114106323 Soto, Cinque NIAID - VRC Soto, Cinque 0 114106377 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114108383 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114108384 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108385 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114108386 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108387 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114108628 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114108673 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114108674 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114108675 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114108676 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114100250 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-5 Filing authorized NIAID 114100654 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-4 Filing authorized NIAID 114102027 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-0 Filing authorized NIAID 114102028 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-1 Filing authorized NIAID 114102029 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-2 Filing authorized NIAID 114102030 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-3 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine&body=Please send me information about technology [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine&body=Please send me information about technology [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine.">wade.green@nih.gov</a><br> 114161993 E-081-2013-5 E-081-2013-5-US-01 PREFUSION RSV F PROTEINS AND THEIR USE ORD US 9,738,689 14/207,372 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738689 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738689">9,738,689</a><br />Filed on 2014-03-12<br />Status: Issued 114165078 E-081-2013-4 E-081-2013-4-US-12 Prefusion RSV F Proteins and Their Use National Stage US 10,017,543 14/776,651 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017543 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017543">10,017,543</a><br />Filed on 2015-09-14<br />Status: Issued 114167467 E-081-2013-0 E-081-2013-0-US-01 Prefusion RSV F Proteins and Their Use PRV US 61/780,910 Expired US <br />Provisional (PRV) 61/780,910<br />Filed on 2013-03-13<br />Status: Expired 114167468 E-081-2013-1 E-081-2013-1-US-01 PREFUSION RSV F PROTEINS AND THEIR USE PRV US 61/798,389 Expired US <br />Provisional (PRV) 61/798,389<br />Filed on 2013-03-15<br />Status: Expired 114167469 E-081-2013-2 E-081-2013-2-US-01 Prefusion RSV F Proteins And Their Use PRV US 61/857,613 Expired US <br />Provisional (PRV) 61/857,613<br />Filed on 2013-07-23<br />Status: Expired 114167470 E-081-2013-3 E-081-2013-3-US-01 PREFUSION RSV F PROTEINS AND THEIR USE PRV US 61/863,909 Expired US <br />Provisional (PRV) 61/863,909<br />Filed on 2013-08-09<br />Status: Expired 114168005 E-081-2013-4 E-081-2013-4-PCT-01 Prefusion RSV F Proteins And Their Use PCT COMB Patent Cooperation Treaty PCT/US2014/026714 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/026714<br />Filed on 2014-03-13<br />Status: Expired 114168303 E-081-2013-5 E-081-2013-5-US-02 PREFUSION RSV F PROTEINS AND THEIR USE DIV US 10,858,400 15/633,578 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10858400 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10858400">10,858,400</a><br />Filed on 2017-06-26<br />Status: Issued 114168678 E-081-2013-4 E-081-2013-4-US-13 PREFUSION RSV F PROTEINS AND THEIR USE CON US 11,130,785 16/025,858 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11130785 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11130785">11,130,785</a><br />Filed on 2018-07-02<br />Status: Issued 114169164 E-081-2013-4 E-081-2013-4-US-19 PREFUSION RSV F PROTEINS AND THEIR USE CON US 17/478,533 Abandoned US <br />Continuation (CON) 17/478,533<br />Filed on 2021-09-17<br />Status: Abandoned 114124377 DC5BXX 114124378 DXXXXX 114124379 DCXXXX 114124380 DC5XXX 114124381 VLXXXX 114124382 YCXXXX 114145938 Vaccine 114145939 Stabilization 114145940 RSV 114145941 GLYCOPROTEIN 114145942 PrefusionConformation 114145943 Structure-based 114147144 F 114147145 Prefusion 114147146 CONFORMATION 114148542 Listed LPM Thalhammer-Reyero as of 4/15/2015 114148543 Pre LPM working set 20150418 114148544 Post LPM Assignment Set 20150420 TAB-3130 114095545 Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection NIAID Licensing Licensing Davide Corti, Barney Graham, Antonio Lanzavecchia, Julie Ledgerwood, Sabue Mulangu, Jean-Jacques Muyembe-Tamfun, Daphne Stanley, Nancy Sullivan, John Trefry Ebola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114 for treatment and prevention of EBOV infection. Because there are very few treatments available to treat or prevent EBOV infection, there is a great need to develop effective pre- and post- exposure therapeutics before another outbreak occurs.<br /><br /> Preclinical efficacy studies demonstrate that monoclonal antibodies can effectively prevent EBOV infection or reverse EVD, in non-human primates. Strikingly, mAb114 protected infected monkeys when administered as late as 6 days after infection. mAb114 has a favorable pharmacokinetic profile, making it a promising potential therapeutic. Clinical trials to test the efficacy of mAb114 in humans are projected for 2018. It is anticipated that mAb114 can be used to prevent EBOV infection and EVD both pre- and post-exposure.<br /><br /> Development Stage<br /> First-in-human trials to start in 2018. <ul> <li>Single Antibody</li> <li>Single-shot option</li> <li>Delayed Treatment (>5 days)</li> <li>Good Half-life</li> <li>Highly Stable</li> <li>Easy to manufacture</li> </ul> <ul> <li>Therapeutic - to treat or prevent infection by EBOV</li> <li>Diagnostic - to detect EBOV infection</li> <li>Research reagent</li> </ul> 2022-03-08 2026-04-27 2026-04-27 2021-05-12 antibodies, Ebola, Ebolavirus, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, monoclonal, Neutralize, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, THEREOF, USES, virus False True True NIHTT 37470483 Website Abstract 114172320 Corti D, et al. https://www.ncbi.nlm.nih.gov/pubmed/26917593 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26917593">Corti D, et al.</a> 114172321 Misasi J, et al. https://www.ncbi.nlm.nih.gov/pubmed/26917592 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26917592">Misasi J, et al.</a> 114110191 Mulangu, Sabue NIAID - VRC NIAID Mulangu, Sabue (NIAID) 0 114110200 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114110201 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114110202 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110203 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114110204 Trefry, John USAMRIID/WR Trefry, John 0 114110205 Stanley, Daphne NIAID - VRC NIAID Stanley, Daphne (NIAID) 0 114110206 Muyembe-Tamfun, Jean-Jacques NIAID - VRC NIAID Muyembe-Tamfun, Jean-Jacques (NIAID) 0 114110192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110191 Mulangu, Sabue NIAID - VRC NIAID Mulangu, Sabue (NIAID) 0 114110200 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114110201 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114110202 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110203 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114110204 Trefry, John USAMRIID/WR Trefry, John 0 114110205 Stanley, Daphne NIAID - VRC NIAID Stanley, Daphne (NIAID) 0 114110206 Muyembe-Tamfun, Jean-Jacques NIAID - VRC NIAID Muyembe-Tamfun, Jean-Jacques (NIAID) 0 114102563 Novel Monoclonal Antibodies To Ebolavirus Glycoprotein E-045-2015-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID, USAMRIID/WR 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection&body=Please send me information about technology [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection&body=Please send me information about technology [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection.">wade.green@nih.gov</a><br> 114169119 E-045-2015-0 E-045-2015-0-EP-06 Neutralizing Antibodies to Ebola Virus Glycoprotein and Their Use DIV European Patent 3875481 21158309.1 Abandoned European Patent <br />Divisional (DIV) 21158309.1<br />Filed on 2015-11-13<br />Status: Abandoned 114169120 E-045-2015-0 E-045-2015-0-EP-03 Neutralizing Antibodies to Ebola Virus Glycoprotein and Their Use National Stage European Patent 3218397 15797815.6 Issued European Patent <br />National Stage 15797815.6<br />Filed on 2015-11-13<br />Status: Issued 114169121 E-045-2015-0 E-045-2015-0-US-04 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE National Stage US 10,160,795 15/526,661 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160795 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160795">10,160,795</a><br />Filed on 2017-05-12<br />Status: Issued 114169122 E-045-2015-0 E-045-2015-0-US-05 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE CON US 10,273,288 16/190,676 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273288 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273288">10,273,288</a><br />Filed on 2018-11-14<br />Status: Issued 114149028 monoclonal 114149029 Novel 114149030 antibodies 114149031 Ebolavirus 114149032 GLYCOPROTEIN 114149033 Listed LPM Thalhammer-Reyero as of 4/15/2015 114149034 Pre LPM working set 20150418 114149035 Post LPM Assignment Set 20150420 114149036 That 114149037 Neutralize 114149038 Ebola 114149039 virus 114149040 USES 114149041 THEREOF TAB-3424 114097298 Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection NIAID Licensing Licensing Joseph Francica, Robert Seder, Rachel Vistein, Lawrence Wang Malaria is a major disease caused by a parasite transmitted through the bite of infected female mosquitoes. Globally, an estimated 214 million cases of malaria and 438,000 deaths from malaria occur annually, with chidren in African and South Asian regions being most vulnerable. Approximately 1,500-2,000 cases of malaria are reported in the United States each year, mostly in returning travelers from malaria- endemic countries. Among the international travelers, military personnel, diplomats, pregnant women, children and older individuals with weakened immune systems are more likely to be at risk of malaria infection and mortality.<br /><br /> Currently, there is no licensed vaccine against Plasmodium falciparum, the deadliest species of malaria parasites. Antibodies can prevent malaria infection by binding to sporozoites, the infectious form of P. falciparum that is transmitted to humans by the bites of infected mosquitoes. The major target of anti-sporozoite antibodies is the P. falciparum circumsporozoite protein (PfCSP), an abundant surface protein on sporozoites that is essential for infecting liver cells, which is the critical step for initiating a productive infection. PfCSP is comprised of an N-terminal domain, a central region and the C-terminal region.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have isolated a new neutralizing recombinant human monoclonal antibody, L9, from a protected volunteer immunized with whole Plasmodium falciparum sporozoites. L9 is notable for targeting PfCSP, the immunodominant immunogen that coats the surface of the sporozoite, specifically the Plasmodium infectious form injected into the human host by the mosquito. Also, in vivo studies in a mouse model of malaria infection demonstrated that L9 is more potent than CIS43, another antimalarial mAb, at preventing malaria infection.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>L9 may represent a more attractive passive vaccine candidate to advance through clinical testing and could yield a product superior to other vaccine candidates due to potency and preferential binding to unique epitopes on PfCSP.</li> <li>L9 may result in more durable protection than other vaccine candidates.</li> </ul> <ul> <li>A passive vaccine candidate to prevent and eradicate malaria.</li> </ul> 2022-03-08 2026-04-27 2026-04-27 2020-11-13 ANTIBODY, Human, Identification, Infection, Malaria, monoclonal, Potently, PREVENTS, That False True True NIHTT 37470483 Website Abstract 114172588 Wang, LT, et al. https://pubmed.ncbi.nlm.nih.gov/32946741/ <a href="https://pubmed.ncbi.nlm.nih.gov/32946741/">Wang, LT, et al.</a> 114110137 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 0 114110138 Vistein, Rachel NIAID - VRC NIAID Vistein, Rachel (NIAID) 0 114110139 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 0 114110136 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 1 114110136 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 1 114110137 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 0 114110138 Vistein, Rachel NIAID - VRC NIAID Vistein, Rachel (NIAID) 0 114110139 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 0 114102546 Identification of a new human monoclonal antibody that more potently prevents malaria infection E-087-2019-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection&body=Please send me information about technology [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection&body=Please send me information about technology [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection.">polung.yang@nih.gov</a><br> 114169069 E-087-2019-0 E-087-2019-0-US-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PRV US 62/842,590 Abandoned US <br />Provisional (PRV) 62/842,590<br />Filed on 2019-05-03<br />Status: Abandoned 114169070 E-087-2019-0 E-087-2019-0-PCT-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2020/031345 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/031345<br />Filed on 2020-05-04<br />Status: Expired 114169182 E-087-2019-0 E-087-2019-0-US-03 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE National Stage US 12,269,872 17/608,381 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269872 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269872">12,269,872</a><br />Filed on 2021-11-02<br />Status: Issued 114151964 Identification 114151965 Human 114151966 monoclonal 114151967 ANTIBODY 114151968 That 114151969 Potently 114151970 PREVENTS 114151971 Malaria 114151972 Infection TAB-3382 114097272 Recombinant Nipah F Proteins and Their Use NIAID Licensing Licensing Barney Graham, Rebecca Loomis, John Mascola, Guillaume Stewart-Jones Nipah virus is an emerging pathogenic paramyxovirus responsible for sporadic and isolated outbreaks of severe respiratory and neurologic disease in Southern Asia. As a zoonotic virus, disease can manifest in both animals and human with indigenous fruit bats acting as natural reservoirs of the virus. The effects of viral infection vary from acute respiratory distress to fatal encephalitis. There are currently no approved therapeutics or vaccines against the virus, and growing concerns that this highly pathogenic infection has the potential to cause larger epidemics capable of inflicting significant mortality burden.<br /><br /> Like the RSV fusion (F) glycoprotein, the Nipah fusion glycoprotein is a target of neutralizing antibodies that mediate protection against infection. Previous studies of prefusion-stabilized F glycoproteins from pneumoviruses and other paramyxoviruses (e.g. RSV and PIVs) have shown they elicit higher titers of neutralizing antibodies in both animals and humans than post-fusion F proteins.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) designed disulfide, cavity-filling and other mutations that stabilize the Nipah F glycoprotein in the prefusion conformation and bind prefusion-specific antibodies. These mutations also increase protein expression yields up to 50-fold making the recombinant proteins easy to manufacture and amenable to the use of genetic immunization using nucleic acid or vector-based applications.<br /><br /> The stabilized prefusion state of the Nipah F glycoprotein may be an ideal vaccine immunogen to elicit broad potent Nipah neutralizing antibodies. First and second generation prefusion molecules have been designed and tested in small animals and results (immunogenicity and stability) appear promising.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. Nipah prefusion F design has the following features compared to wild-type fusion glycoprotein:<br /><br /> <ul> <li>Robust stabilization</li> <li>Up to 50-fold increase in expression yields, making the recombinant proteins easy to manufacture</li> <li>Potential to link the recombinant glycoprotein to nanoparticles or oligomerization peptides</li> </ul> <ul> <li>Vaccine - to elicit potent neutralizing antibodies against the Nipah Env glycoprotein</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2019-08-21 F, nipah, proteins, recombinant, Their False True True NIHTT 37470483 Website Abstract 114110035 Loomis, Rebecca NIAID - DIR Loomis, Rebecca 0 114110036 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110037 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110034 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110034 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110035 Loomis, Rebecca NIAID - DIR Loomis, Rebecca 0 114110036 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110037 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114102517 Recombinant Nipah F Proteins And Their Use E-050-2018-0 Filing authorized NIAID, University of Texas 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3382] Recombinant Nipah F Proteins and Their Use&body=Please send me information about technology [TAB-3382] Recombinant Nipah F Proteins and Their Use. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3382] Recombinant Nipah F Proteins and Their Use&body=Please send me information about technology [TAB-3382] Recombinant Nipah F Proteins and Their Use.">bbailey@mail.nih.gov</a><br> 114168905 E-050-2018-0 E-050-2018-0-US-01 NIPAH VIRUS IMMUNOGENS AND THEIR USE PRV US 62/714,230 Abandoned US <br />Provisional (PRV) 62/714,230<br />Filed on 2018-08-03<br />Status: Abandoned 114168906 E-050-2018-0 E-050-2018-0-PCT-02 Nipah Virus Immunogens And Their Use PCT Patent Cooperation Treaty PCT/US2019/045110 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/045110<br />Filed on 2019-08-05<br />Status: Expired 114169089 E-050-2018-0 E-050-2018-0-US-07 NIPAH VIRUS IMMUNOGENS AND THEIR USE National Stage US 11,890,339 17/261,828 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890339">11,890,339</a><br />Filed on 2021-01-20<br />Status: Issued 114151635 recombinant 114151636 nipah 114151637 F 114151638 proteins 114151639 Their TAB-4079 147157361 Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Keli Agama, Lin-kun An, Evgeny Kiselev, Yves Pommier, Azhar Ravji <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered together, demonstrate enhanced anti-tumor efficacy.</p> <h2>Description of Technology:&nbsp;</h2> <p>Topoisomerase 1B (TOP1) is an enzyme that relieves DNA torsional strain through the formation of transient TOP1-DNA covalent cleavage complexes (TOP1ccs) and is an attractive target for anti-cancer therapeutics. TOP1 inhibitors &ndash; such as camptothecin (CPT) &ndash; stabilize TOP1ccs, which ultimately leads to cell death. TOP1 inhibitors have long been recognized as anti-cancer agents and are used clinically. However, existing TOP1 inhibitor CPT, is limited by toxicity, chemical instability, poor solubility, and potential drug resistance via efflux mechanisms. Moreover, CPT directly competes with tyrosyl-DNA phosphodiesterase 1 (TDP1), which is an enzyme that repairs TOP1cc-induced cell damage. As such, this complicates CPT&rsquo;s effectiveness. Overall, there is ongoing interest in finding non-CPT compounds targeting TOP1 and/or TDP1 for cancer therapy.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) and their collaborators have identified a range of oxynitidine derivatives that inhibit TOP1 and/or TDP1. These compounds represent a promising alternative to CPT. These oxynitidine derivatives have demonstrated potent TOP1 inhibition at nanomolar concentrations and effectively induce DNA damage and apoptosis in cancer cell lines. Additionally, some derivatives showed synergistic effects when used in combination with CPT. In vivo studies using xenograft mouse models of colon and breast cancer cells indicated that these derivatives (1) were generally well-tolerated and safe and (2) caused dose-dependent reduction in tumor weight. Crucially, these derivatives exhibit a significantly lower likelihood of eliciting drug resistance due to reduced susceptibility to drug efflux mechanisms. Overall, this research highlights a new class of compounds with potential for enhanced therapeutic efficacy and improved tolerability compared to traditional CPT-based therapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>TOP1 and TDP1 inhibitors for treating various cancers</li> <li>Combinatorial drug treatment options to boost anti-tumor potency</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel chemotype for TOP1 and TDP1 inhibitors</li> <li>Can potentially be used synergistically with existing therapeutics such as CPT</li> <li>Limited number of chemotypes reported as TDP1 inhibitors provides good commercial potential given finite competition</li> <li>These compounds may overcome the limitations of CPT, especially chemical instability and diarrhea</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of oxynitidine derivatives as new TOP1 and TDP1 inhibitors for treating cancer. 2020-11-30 2026-04-24 2024-09-13 2026-04-24 2020-11-30 Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2024-09-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-199-2010 147162124 Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. https://pubmed.ncbi.nlm.nih.gov/30336023/ <a href="https://pubmed.ncbi.nlm.nih.gov/30336023/">Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.</a> 158187906 Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. (PMID: 30336023) Tang W-L, et al. Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. (PMID: 31176097) https://pubmed.ncbi.nlm.nih.gov/30336023/ <a href="https://pubmed.ncbi.nlm.nih.gov/30336023/">Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. (PMID: 30336023) Tang W-L, et al. Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. (PMID: 31176097)</a> 158268568 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 158268572 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 158268597 Agama, Keli NCI - CCR NCI Agama, Keli (NCI) 3 158268726 Kiselev, Evgeny NCI - CCR NCI Kiselev, Evgeny (NCI) 4 158268738 Ravji, Azhar Developmental Therapeutics Branch Ravji, Azhar 5 158268568 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 158268572 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 158268597 Agama, Keli NCI - CCR NCI Agama, Keli (NCI) 3 158268726 Kiselev, Evgeny NCI - CCR NCI Kiselev, Evgeny (NCI) 4 158268738 Ravji, Azhar Developmental Therapeutics Branch Ravji, Azhar 5 147158159 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-0 Filing authorized NCI, Sun Yat-sen University 147162552 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-1 Filing authorized NCI, Sun Yat-sen University 147162553 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-2 Filing authorized NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer&body=Please send me information about technology [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer&body=Please send me information about technology [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147161157 E-181-2018-0 E-181-2018-0-CN-01 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents ORD China 201810827467.1 Abandoned China <br />Ordinary Patent (ORD) 201810827467.1<br />Filed on 2018-07-25<br />Status: Abandoned 147166374 E-181-2018-1 E-181-2018-1-US-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) PRV US 62/732,885 Abandoned US <br />Provisional (PRV) 62/732,885<br />Filed on 2018-09-18<br />Status: Abandoned 147166377 E-181-2018-2 E-181-2018-2-PCT-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) PCT COMB Patent Cooperation Treaty PCT/US2019/043357 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/043357<br />Filed on 2019-07-25<br />Status: Expired 147166378 E-181-2018-2 E-181-2018-2-CN-02 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) National Stage China ZL201980062917.5 201980062917.5 Issued China <br />National Stage 201980062917.5<br />Filed on 2019-07-25<br />Status: Issued 147166379 E-181-2018-2 E-181-2018-2-EP-03 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) National Stage European Patent 19750204.0 Pending European Patent <br />National Stage 19750204.0<br />Filed on 2019-07-25<br />Status: Pending 147166380 E-181-2018-2 E-181-2018-2-US-04 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) National Stage US 17/262,379 Pending US <br />National Stage 17/262,379<br />Filed on 2021-01-22<br />Status: Pending 147166381 E-181-2018-2 E-181-2018-2-HK-05 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) EP Hong Kong 62021043492.9 Pending Hong Kong <br />European patent (EP) 62021043492.9<br />Filed on 2021-12-02<br />Status: Pending 147173124 Benzophenanthridine Derivatives 147173126 Benzophenanthridinone 147173127 Camptothecin 147173129 Dihydrobenzophenanthridine 147173130 IRINOTECAN 147173131 Oxynitidine 147173132 Pommier 147173133 Tdp1 147173134 TOP1 147173136 Topoisomerase 1B 147173138 Topotecan 147173140 Tyrosyl-DNA Phosphodiesterase 1 TAB-4075 147157357 RNASEH-Assisted Detection Assay for RNA NCI Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing Dipak Poria, G Esta Sterneck <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.</p> <h2>Description of Technology:</h2> <p>Several viral epidemics &ndash; such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 &ndash; have profoundly impacted global human health. Early identification of infected and/or infectious persons and isolating them from the population are some of the most effective and evident measures to prevent human-to-human spreading. In addition, areas with low resources and infrastructure may benefit from this technique for the detection of any viral or non-viral pathogens.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a technology that describes an RNase-H-assisted detection assay for RNA (RADAR) that is rapid, inexpensive and highly sequence-specific.&nbsp; The assay is capable of detecting any RNA of interest, including cellular or viral RNA in a sequence-specific manner. The assay uses a modified isothermal rolling circle amplification (RCA) method that utilizes RNase H and a labeled RNA reporter molecule for the specific detection of a target RNA. The technology can detect viral RNA in approximately 2.5 hours and does not require expensive thermocyclers. Furthermore, the technology circumvents potential supply bottlenecks associated with other techniques that require enzymes other than DNA ligase, DNA polymerase, and RNaseH. Mode of detection of the amplified product is flexible depending on the nature of the label on the RNA reporter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic test for viral infection or any specific pathogen-derived RNA</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid readout from isolated RNA of less than three hours&nbsp;</li> <li>May have the potential for point-of-care application</li> <li>Employs only three enzymes, which are relatively thermostable&nbsp;</li> <li>Does not require expensive and sophisticated thermocyclers</li> <li>Reagents are all commercially available and relatively low-cost</li> </ul> 2020-11-30 2026-04-24 2020-11-30 2026-04-24 2020-11-30 COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-11-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163427 Sterneck, G Esta NIH - NCI NCI Sterneck, G Esta (NCI) 1 147163428 Poria, Dipak NIH - NCI NCI Poria, Dipak (NCI) 2 147163427 Sterneck, G Esta NIH - NCI NCI Sterneck, G Esta (NCI) 1 147163428 Poria, Dipak NIH - NCI NCI Poria, Dipak (NCI) 2 147158186 RNaseH-assisted Detection Assay For RNA (RADAR) E-193-2020-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4075] RNASEH-Assisted Detection Assay for RNA&body=Please send me information about technology [TAB-4075] RNASEH-Assisted Detection Assay for RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4075] RNASEH-Assisted Detection Assay for RNA&body=Please send me information about technology [TAB-4075] RNASEH-Assisted Detection Assay for RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161176 E-193-2020-0 E-193-2020-0-US-01 RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR) PRV US 63/077,123 Abandoned US <br />Provisional (PRV) 63/077,123<br />Filed on 2020-09-11<br />Status: Abandoned 147166349 E-193-2020-0 E-193-2020-0-PCT-02 RNASE H-ASSISTED DETECTION ASSAY FOR RNA PCT Patent Cooperation Treaty PCT/US2021/049588 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/049588<br />Filed on 2021-09-09<br />Status: Expired 147173424 COVID 147173425 COVID-19 147173426 INFLUENZA 147173428 Poria 147173429 RNA 147173431 RNASEH 147173432 SARS-CoV2 147173434 Sterneck 147173436 Viral RNA TAB-4338 147157629 Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Francisco Battiti, Alessandro Bonifazi, Sophe Cemaj, Amy Newman <h2>Description of Technology:</h2> <p>Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially difficult.&nbsp;</p> <p>The inventors at the National Institute on Aging (NIDA) have recently synthesized a new generation of D3R selective agonists by applying a well-established bitopic molecular approach. Inventors were able to combine a primary pharmacophore (PP) with a secondary pharmacophore (SP) to generate compounds with high D3R subtype affinity and selectivity (e.g., compound 53). All newly synthesized compounds were tested in radioligand competition binding studies for D2-like receptor affinities (D2R, D3R, and D4R). Compound 53 and its eutomer, 53a were further evaluated for metabolic stability in rat liver microsomes and metabolite identification to confirm their applicability to future in vivo studies.&nbsp;</p> <p>The molecules could not only serve as a tools for studying D3R dopaminergic signaling but have the potential to become a pharmacological treatment of neurodegenerative disorders associated with dopaminergic dysregulation. The characterization of these D3R specific agonists including compound 53 and 53a is further described in the listed manuscript (PMID: 31257877) and claimed in the referenced patent application below. The inventors have future plans to develop these compounds as molecular tools which will be appealing to a large group of scientists working in molecular biology, pharmacology, and computational sciences directed toward dopamine D3R and their multi-therapeutic potential. The syntheses and in vitro characterization are completed. Potential application as therapeutics is also a collaboration interest of the inventors.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>New molecular tools for the discovery of, and research into, D3R physiology</li> <li>Therapeutic use for neurodegenerative disorders such as Parkinson&rsquo;s Disease and Restless Legs Syndrome</li> <li>Neurological and neuropsychiatric disorders associated with dopamine dysregulation</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The agonists have unique high D3R affinity and selectivity over D2R</li> <li>Potentially fewer side effects due to high selectivity toward D3R</li> <li>Broad range of clinical applications for the treatment neurological and neuropsychiatric disorders associated with dopamine dysregulation</li> </ul> 2020-10-27 2026-04-24 2020-10-27 2026-04-24 2020-10-27 D3R agonists, Dopamine, Newman, Parkinson’s Disease, Restless Legs Syndrome, RLS, small molecule False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-10-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162030 Battiti FO, et al. The significance of chirality in drug design and synthesis of bitopic ligands as d3 receptor (d3r) selective agonists https://pubmed.ncbi.nlm.nih.gov/31257877/ <a href="https://pubmed.ncbi.nlm.nih.gov/31257877/">Battiti FO, et al. The significance of chirality in drug design and synthesis of bitopic ligands as d3 receptor (d3r) selective agonists</a> 147164363 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147164366 Bonifazi, Alessandro NIH - NIDA NIDA Bonifazi, Alessandro (NIDA) 2 147164364 Battiti, Francisco NIH - NIDA NIDA Battiti, Francisco (NIDA) 3 147164365 Cemaj, Sophe NIH - NIDA Cemaj, Sophe 4 147164363 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147164366 Bonifazi, Alessandro NIH - NIDA NIDA Bonifazi, Alessandro (NIDA) 2 147164364 Battiti, Francisco NIH - NIDA NIDA Battiti, Francisco (NIDA) 3 147164365 Cemaj, Sophe NIH - NIDA Cemaj, Sophe 4 147157933 Novel Opotically Active Dopamine D3 Receptor Selective Agonists E-077-2019-0 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use&body=Please send me information about technology [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use&body=Please send me information about technology [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147161004 E-077-2019-0 E-077-2019-0-US-01 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF PRV US 62/833,023 Abandoned US <br />Provisional (PRV) 62/833,023<br />Filed on 2019-04-12<br />Status: Abandoned 147168275 E-077-2019-0 E-077-2019-0-PCT-02 Novel Opotically Active Dopamine D3 Receptor Selective Agonists PCT Patent Cooperation Treaty PCT/US2020/027903 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/027903<br />Filed on 2020-04-13<br />Status: Expired 147168276 E-077-2019-0 E-077-2019-0-AU-03 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage Australia 2020270992 2020270992 Issued Australia <br />National Stage 2020270992<br />Filed on 2020-04-13<br />Status: Issued 147168277 E-077-2019-0 E-077-2019-0-CA-04 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage Canada 3136151 Pending Canada <br />National Stage 3136151<br />Filed on 2020-04-13<br />Status: Pending 147168278 E-077-2019-0 E-077-2019-0-EP-05 Novel Opotically Active Dopamine D3 Receptor Selective Agonists National Stage European Patent 20724970.7 Pending European Patent <br />National Stage 20724970.7<br />Filed on 2020-04-13<br />Status: Pending 147168279 E-077-2019-0 E-077-2019-0-US-06 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage US 12,479,838 17/602,504 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479838 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479838">12,479,838</a><br />Filed on 2021-10-08<br />Status: Issued 147170855 D3R agonists 147170856 Dopamine 147170857 Newman 147170859 Parkinson’s Disease 147170861 Restless Legs Syndrome 147170863 RLS 147170864 small molecule TAB-4166 147157449 Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants NICHD Collaboration, Dermatology, Licensing, Materials Available, Medical Devices, Non-Medical Devices Collaboration Dermatology Licensing Materials Available Medical Devices Non-Medical Devices Peter Basser, Ferenc Horkay <h2>Description of Technology:</h2> <p style="margin-left:5.45pt">Gel materials, particularly hydrogels, typically lose their mechanical strength and stiffness as they swell. This property &nbsp;limits their use in both biological (e.g., cartilage and ECM repair) and non-biological (e.g., sealant) applications. Innovative materials in both medical and non-medical application areas are sorely needed.</p> <p style="margin-left:5.45pt">Recent innovations in this space, from the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (NICHD), include self-reinforcing composite hydrogels. These composite materials comprise novel combinations of solvents, swellable crosslinked polymer particles, and crosslinked polymer networks or matrices, which confine them. Exemplary solvents include water&nbsp;and organic solvents, silicone fluids and oils and others known in the art. Exemplary swellable crosslinked microgel polymer particles could comprise hyaluronic acid (HA) or other proteoglycans, polyethylene glycol, dextran particles, a poly(acrylic acid), a poly(methacrylic acid), polystyrene sulfonate, polyvinylpyrrolidone (PVP), polyacrylamide, or combinations thereof. Exemplary confining polymer networks or matrices in which these microgel polymer particles are incorporated can include polyvinyl alcohol (PVA) and its copolymers (e.g., polyvinyl alcohol-polyvinyl acetate copolymer, polyvinyl alcohol &ndash; polyvinyl acetal copolymer, polyvinyl alcohol &ndash; polyvinyl butyral copolymer) and other matrices or networks such as cellulose derivatives (e.g., methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose). Tests of the innovative gels developed by NICHD scientists demonstrate that these gels have properties similar to, e.g., human cartilage &ndash; including load-bearing ability and demonstrating high self-reinforcement. The special properties of these gels also render them suitable for drug release to the intestines and other organs.</p> <p style="margin-left:5.45pt">Researchers at NICHD welcome a wide variety of collaborative and licensing relationships. Possibilities include a cooperative research and development agreement (CRADA). The NICHD and NCI technology transfer center welcome non-exclusive or exclusive license agreements. They are eager to transfer rights in these technologies &nbsp;&nbsp;to responsible commercial partners who will diligently move therapeutics and other applications towards commercialization.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cartilage repair Intervertebral disc repair</li> <li>Drug delivery vehicle</li> <li>Breast implants and tissue expanders</li> <li>Commercial or industrial sealants</li> <li>Underwater (naval) or commercial sealant technology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly self-reinforcing as compared to traditional gel materials Wide variety of potential clinical and industrial applications</li> <li>Fracture resistant, like rip-stop nylon</li> </ul> 2020-10-27 2026-04-24 2021-12-01 2026-04-24 2020-10-27 Basser, Cartilage, Composite, Drug Delivery, Gel, Horkay, Hydrogels, IMPLANTS, MATRIX, polymer, sealants, Tissue, Tissue Repair False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-01 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161866 Horkay F, et al. Composite Hydrogel Model of Cartilage Predicts Its Load-Bearing Ability. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228937/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228937/">Horkay F, et al. Composite Hydrogel Model of Cartilage Predicts Its Load-Bearing Ability.</a> 147163751 Horkay, Ferenc NIH - NICHD NICHD Horkay, Ferenc (NICHD) 1 147163750 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163751 Horkay, Ferenc NIH - NICHD NICHD Horkay, Ferenc (NICHD) 1 147163750 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147157792 Composite Cartilage-like Load Bearing Hydrogel Systems E-014-2019-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants&body=Please send me information about technology [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants&body=Please send me information about technology [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160901 E-014-2019-0 E-014-2019-0-US-02 COMPOSITE GELS AND METHODS OF USE THEREOF ORD US 12,083,246 16/783,494 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083246 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083246">12,083,246</a><br />Filed on 2020-02-06<br />Status: Issued 147167050 E-014-2019-0 E-014-2019-0-US-01 COMPOSITE GELS AND METHODS OF USE THEREOF PRV US 62/802,885 Abandoned US <br />Provisional (PRV) 62/802,885<br />Filed on 2019-02-08<br />Status: Abandoned 147169510 Basser 147169511 Cartilage 147169512 Composite 147169513 Drug Delivery 147169514 Gel 147169516 Horkay 147169517 Hydrogels 147169518 IMPLANTS 147169519 MATRIX 147169520 polymer 147169522 sealants 147169523 Tissue 147169525 Tissue Repair TAB-4020 147157301 Use of Acetalax for Treatment of Triple Negative Breast Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Matthew Garnett, Augustin Luna, Yves Pommier, Vinodh Rajapakse, William Reinhold <h2>Summary:</h2> <p>NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).</p> <h2>Description of Technology:</h2> <p>Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually.&nbsp; Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However, TNBC readily becomes resistant to chemotherapy, and those with TNBC are more likely to have a recurrence or die within five years compared to those with other breast cancer types. Therefore, there is a need for safer and more effective TNBC treatments to improve patient outcomes.</p> <p>Investigators from the National Cancer Institute (NCI) and collaborating institutions have identified the compound acetalax (oxyphenisatin acetate) as a promising potential therapy for TNBC. Strikingly, acetalax&rsquo;s cytotoxic effect checked first against ~178 FDA-approved or clinical trial oncology drugs on the three TNBC against the NCI-60 panel of cancer cell lines &ndash; subsequently followed up using the 22 different TNBC cell lines checked against 15 oncology drugs &ndash; were significantly most cytotoxic.<br /> Acetalax&rsquo;s efficacy in vivo has been investigated using a TNBC patient-derived xenograft (PDX) mouse model. Untreated PDX mice exhibited a tumor volume doubling rate of approximately 7-8 days whereas acetalax-treated mice tumor volumes decreased to undetectable levels in approximately 13 days.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A therapeutic for Triple Negative Breast Cancer</li> <li>Potential therapeutic for recalcitrant or estrogen-dependent cancers</li> <li>Potential applicability to breast (non-Triple Negative), ovarian, pancreatic, sarcoma, and uterine cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Repurposed, previously approved FDA drug for a novel use as a therapeutic for TNBC and other cancers</li> <li>Repurposed, previously approved drugs can have an expedited approval process due in part to pre-existing safety data</li> </ul> 2020-09-25 2026-04-24 2020-09-25 2026-04-24 2020-09-25 Acetalax, Oxyphenisatin Acetate, Pommier, TNBC, Triple Negative Breast Cancer, Uterine Cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162411 Rajapakse VN, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. https://pubmed.ncbi.nlm.nih.gov/30553813/ <a href="https://pubmed.ncbi.nlm.nih.gov/30553813/">Rajapakse VN, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.</a> 147163245 Reinhold, William NIH - NCI NCI Reinhold, William (NCI) 1 147163248 Garnett, Matthew The Wellcome Trust Sanger Institute Garnett, Matthew 2 147163246 Rajapakse, Vinodh NIH - NCI NCI Rajapakse, Vinodh (NCI) 3 147163244 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 4 147163247 Luna, Augustin Harvard Medical School Luna, Augustin 5 147163245 Reinhold, William NIH - NCI NCI Reinhold, William (NCI) 1 147163248 Garnett, Matthew The Wellcome Trust Sanger Institute Garnett, Matthew 2 147163246 Rajapakse, Vinodh NIH - NCI NCI Rajapakse, Vinodh (NCI) 3 147163244 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 4 147163247 Luna, Augustin Harvard Medical School Luna, Augustin 5 147157846 Use Of Acetalax For Treatment Of Triple Negative Breast Cancer. E-041-2018-0 Filing authorized Harvard Medical School, NCI, The Wellcome Trust Sanger Institute 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer&body=Please send me information about technology [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer&body=Please send me information about technology [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147160946 E-041-2018-0 E-041-2018-0-US-01 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER PRV US 62/627,926 Abandoned US <br />Provisional (PRV) 62/627,926<br />Filed on 2018-02-08<br />Status: Abandoned 147166039 E-041-2018-0 E-041-2018-0-PCT-02 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER PCT Patent Cooperation Treaty PCT/US2019/017239 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/017239<br />Filed on 2019-02-08<br />Status: Expired 147166040 E-041-2018-0 E-041-2018-0-EP-03 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER National Stage European Patent 3749302 19707221.8 Issued European Patent <br />National Stage 19707221.8<br />Filed on 2019-02-08<br />Status: Issued 147166041 E-041-2018-0 E-041-2018-0-US-04 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER National Stage US 16/967,472 Pending US <br />National Stage 16/967,472<br />Filed on 2020-08-05<br />Status: Pending 147170058 Acetalax 147170060 Oxyphenisatin Acetate 147170061 Pommier 147170063 TNBC 147170065 Triple Negative Breast Cancer 147170067 Uterine Cancer TAB-4326 147157617 Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg, James Yang, Rami Yoseph <h2>Summary:</h2> <p>NCI seeks commercial partners to co-develop and/or license a&nbsp;novel method to identify neoantigen reactive T cells and TCRs.</p> <h2>Description of Technology:</h2> <p>Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (&ldquo;neoantigens&rdquo;). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies more broadly, is the identification and isolation of these mutation specific TILs and TCRs. Only a fraction of TILs in a given patient is known to be tumor reactive, while the majority are not useful for cell therapy. The current procedures for isolating neoantigen reactive TILs and TCRs are time consuming, labor-intensive, and lack sensitivity and specificity.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method to identify neoantigen reactive T cells and TCRs, isolated from fresh tumors of common epithelial cancers. This method does not require tumor cells to be grown or propagated in vitro. By using a single cell, transcriptome-based approach and barcoded antibodies (CITE-seq), neoantigen reactive T cells can be clustered within tSNE (t-Distributed Stochastic Neighbor Embedding) plots. Using genetic markers that are highly expressed in such clusters, a transcriptomic gene signature, called &ldquo;NeoTCR Signature&rdquo;, has been developed. This NeoTCR Signature can be used to identify a very high frequency of previously unknown T-cell clones and TCRs that recognize neoantigens from the autologous tumor. Critically, identification and isolation of the neoantigen-reactive TCR can now occur in a few days, in stark contrast to the 6-8 weeks required for current methods. This rapid determination of the neoantigen reactive TCR sequences can be useful for translating this information into TCR-engineered T-cell populations for immunotherapy. This technique can also identify T-cells with specificities for new neoantigens not presently identifiable by conventional screening methods.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized cell therapy to treat cancer patients</li> <li>Immune monitoring of other immunotherapies</li> <li>Developing treatment against chronic infections which are expected to have similar T-cell dysfunction signatures (e.g. HIV, HCV, TB, etc.)</li> <li>Research tool to identify mutation-specific TCRs</li> <li>Prognostic testing for presence of tumor-relevant TILs</li> <li>Prospective isolation of cell population ideal for introduction of stem-like factors for cell therapy</li> <li>Biomarkers in immunotherapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely applicable to treat different types of cancer</li> <li>Significantly reduces the expensive and time-consuming procedures of tumor cell culture, propagation, and screening in vitro</li> <li>High specificity and sensitivity eliminate off-target effects</li> <li>Patient-specificity to improve efficacy of ACT or TCR therapy</li> </ul> 2020-09-03 2026-04-24 2022-01-19 2026-04-24 2020-09-03 act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-067-2017 E-229-2014 E-233-2014 147164323 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164318 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164321 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 3 147164320 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164319 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147164322 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 6 147164317 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 7 147164323 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164318 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164321 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 3 147164320 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164319 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147164322 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 6 147164317 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 7 147157897 Method For Rapid Isolation Of Neoantigen-reactive T-cell Receptors In Human Cancers By Single-cell Analysis For Immunotherapy E-061-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)&body=Please send me information about technology [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)&body=Please send me information about technology [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160978 E-061-2020-0 E-061-2020-0-US-01 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PRV US 62/992,701 Abandoned US <br />Provisional (PRV) 62/992,701<br />Filed on 2020-03-20<br />Status: Abandoned 147168179 E-061-2020-0 E-061-2020-0-PCT-02 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2021/023240 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/023240<br />Filed on 2021-03-19<br />Status: Expired 147168180 E-061-2020-0 E-061-2020-0-AU-03 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Australia 2021237717 Pending Australia <br />National Stage 2021237717<br />Filed on 2022-09-28<br />Status: Pending 147168181 E-061-2020-0 E-061-2020-0-CA-04 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Canada 3171559 Pending Canada <br />National Stage 3171559<br />Filed on 2022-09-13<br />Status: Pending 147168182 E-061-2020-0 E-061-2020-0-CN-05 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage China 202180022592.5 Pending China <br />National Stage 202180022592.5<br />Filed on 2021-03-19<br />Status: Pending 147168183 E-061-2020-0 E-061-2020-0-EP-06 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage European Patent 21718712.9 Pending European Patent <br />National Stage 21718712.9<br />Filed on 2022-10-11<br />Status: Pending 147168184 E-061-2020-0 E-061-2020-0-JP-07 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Japan 2022-556459 Abandoned Japan <br />National Stage 2022-556459<br />Filed on 2022-09-16<br />Status: Abandoned 147168185 E-061-2020-0 E-061-2020-0-KR-08 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage South Korea 10-2022-7036214 Pending South Korea <br />National Stage 10-2022-7036214<br />Filed on 2022-10-18<br />Status: Pending 147168186 E-061-2020-0 E-061-2020-0-US-09 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage US 17/912,315 Pending US <br />National Stage 17/912,315<br />Filed on 2022-09-16<br />Status: Pending 147168187 E-061-2020-0 E-061-2020-0-IL-10 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Israel 296629 Pending Israel <br />National Stage 296629<br />Filed on 2022-09-19<br />Status: Pending 147170537 act 147170538 Adoptive Cell Transfer 147170539 Immunotherapy 147170540 Neoantigen 147170541 Rosenberg 147170542 T Cell Receptor 147170543 TCR 147170544 TIL 147170545 tumor 147170547 Tumor Infiltrating Lymphocyte TAB-4145 147157428 Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Amy Copeland, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg, Rami Yoseph <h2>Summary:</h2> <p>NCI seeks commercial partners to co-develop and/or license&nbsp;a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL).</p> <h2>Description of Technology:</h2> <p>Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and time consuming. The success of these procedures is limited and differs between patients and histologies. Isolation of neoantigen reactive TCRs have historically been challenging due to very low precursor frequencies of these T-cells as well as lack of technical advances that can determine phenotypic markers of these cells from the blood.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL) of cancer patients.&nbsp; This method allows direct isolation of T cells from the blood, based on a distinct T cell gene signature; thus, it does not require tumor cells to be gown or propagated in vitro. In this method, peptide-HLA tetramers (pHLA) are used to isolate neoantigen reactive T cells based on patient specific information on major histocompatibility complex and tumor specific mutations. By taking advantage of the unique genetic signatures of neoantigen specific T cells, this method not only generates accurate scoring of single T cells from tumors, but also facilitates identification and reconstruction of unknown TCRs for immunotherapy. Additionally, these gene signatures can be used to identify TCRs from chronic infections (such as HIV).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized cell therapy to treat cancer patients</li> <li>Testing for the presence of tumor-relevant T cells in the blood of cancer patients</li> <li>Isolation of cell populations ideal for introduction of stem-like factors for cell therapy</li> <li>Biomarkers for cancer immunotherapy</li> <li>Developing treatment against chronic infections which are expected to have similar T-cell dysfunction signatures (e.g. HIV, HCV, TB, etc.)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely applicable to treat different types of cancer</li> <li>Eliminates the expensive and time-consuming procedures of tumor cell culture, propagation, and screening in vitro</li> <li>High specificity and sensitivity significantly reduce off-target effects</li> <li>Patient-specificity to improve efficacy of ACT or TCR therapy</li> <li>Rapid and scalable method of isolating neoantigen-specific TCRs</li> </ul> 2020-09-03 2026-04-24 2020-09-03 2026-04-24 2020-09-03 act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-061-2020 E-067-2017 E-229-2014 E-233-2014 147163676 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 1 147163675 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147163677 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 3 147163678 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 4 147163679 Copeland, Amy NIH - NCI NCI Copeland, Amy (NCI) 5 147163674 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 6 147163676 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 1 147163675 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147163677 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 3 147163678 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 4 147163679 Copeland, Amy NIH - NCI NCI Copeland, Amy (NCI) 5 147163674 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 6 147157991 NeoBlood TCR: Prospective Isolation Of Neoantigen-reactive T-cell Receptors From Peripheral Blood By Single-cell Analysis For Immunotherapy Of Cancer Patients E-102-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients&body=Please send me information about technology [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients&body=Please send me information about technology [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161041 E-102-2020-0 E-102-2020-0-US-01 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PRV US 62/992,715 Abandoned US <br />Provisional (PRV) 62/992,715<br />Filed on 2020-03-20<br />Status: Abandoned 147166908 E-102-2020-0 E-102-2020-0-PCT-02 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2021/023225 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/023225<br />Filed on 2021-03-19<br />Status: Expired 147166909 E-102-2020-0 E-102-2020-0-AU-03 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Australia 2021239379 Pending Australia <br />National Stage 2021239379<br />Filed on 2022-09-23<br />Status: Pending 147166910 E-102-2020-0 E-102-2020-0-CA-04 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Canada 3171583 Pending Canada <br />National Stage 3171583<br />Filed on 2022-09-13<br />Status: Pending 147166911 E-102-2020-0 E-102-2020-0-CN-05 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage China 202180030252.7 Pending China <br />National Stage 202180030252.7<br />Filed on 2021-03-19<br />Status: Pending 147166912 E-102-2020-0 E-102-2020-0-EP-06 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage European Patent 21718376.3 Pending European Patent <br />National Stage 21718376.3<br />Filed on 2022-10-19<br />Status: Pending 147166913 E-102-2020-0 E-102-2020-0-JP-07 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Japan 2022-556460 Pending Japan <br />National Stage 2022-556460<br />Filed on 2022-09-16<br />Status: Pending 147166914 E-102-2020-0 E-102-2020-0-KR-08 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage South Korea 10-2022-7036226 Pending South Korea <br />National Stage 10-2022-7036226<br />Filed on 2022-10-18<br />Status: Pending 147166915 E-102-2020-0 E-102-2020-0-US-09 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage US 17/906,524 Pending US <br />National Stage 17/906,524<br />Filed on 2022-09-16<br />Status: Pending 147166916 E-102-2020-0 E-102-2020-0-IL-10 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Israel 296608 Pending Israel <br />National Stage 296608<br />Filed on 2022-09-19<br />Status: Pending 147171462 act 147171463 Adoptive Cell Transfer 147171464 Immunotherapy 147171465 Neoantigen 147171466 Rosenberg 147171468 T Cell Receptors 147171469 TCRs 147171470 TILS 147171472 Tumor Infiltrating Lymphocytes TAB-3944 147157224 Margaric Acid Decreases PIEZO2 Mediated Pain NCCIH Collaboration, Dermatology, Licensing, Neurology, Therapeutics Collaboration Dermatology Licensing Neurology Therapeutics Alexander Chesler, Julio Cordero-Morales, Luis Romero, Valeria Vasquez <h2>Summary:</h2> <p>The National Center for Complimentary and Integrative Health (NCCIH) seeks licensees and/or commercial partners to develop topical formulations of margaric acid to treat allodynia, neuropathy, and pain caused by chronic inflammation.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Some existing therapies for treatment of pain are administered systematically and have significant side effects, such as addiction and drowsiness. Alternative therapy that does not impair normal touch function could be used to treat pain caused by mechanical injury or chronic inflammation. Administration of margaric acid was shown to ameliorate pain in mouse models of pain. In vitro data shows that margaric acid counteracts PIEZO2 (Piezo-type mechanosensitive ion channel component 2) potentiation evoked by bradykinin (i.e. a peptide that promotes inflammation) by reducing the mechanocurrents up to non-inflammatory levels. Margaric acid seems to be specific to target mechanical pain as it does not significantly alter the electric excitability of mice dorsal root ganglia neurons or human iPSC-derived neurons. It mainly decreases action potential firing evoked by mechanical stimulation.</p> <p>&nbsp;</p> <p><img alt="E-081-2020 - PIEZO2 channel under different physiological conditions" src="https://nih.technologypublisher.com/files/sites/e-081-2020_-_piezo2_channel_under_different_physiological_conditions2.png" style="float:left; height:467px; width:700px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <h2>&nbsp;</h2> <h2>&nbsp;</h2> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of pain caused by mechanical injury</li> <li>Treatment of pain caused by chronic inflammation (e.g., rheumatoid arthritis)</li> <li>Treatment of allodynia</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Not addictive</li> <li>Topical application</li> <li>Fewer side effects</li> </ul> 2020-09-03 2026-04-24 2020-09-03 2026-04-24 2020-09-03 ALLODYNIA, Chesler, Chronic Inflammation, fatty acid, Margaric Acid, migraine, National Center for Complimentary and Integrative Health, NCCIH, Neuropathy, Pain, PIEZO2, Vásquez False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162417 Romero LO, et al. A dietary fatty acid counteracts neuronal mechanical sensitization https://pubmed.ncbi.nlm.nih.gov/32561714/ <a href="https://pubmed.ncbi.nlm.nih.gov/32561714/">Romero LO, et al. A dietary fatty acid counteracts neuronal mechanical sensitization</a> 147162963 Chesler, Alexander NIH - NCCIH NICHD Chesler, Alexander (NICHD) 1 147162964 Vasquez, Valeria University of Tennessee Health Science Center Vasquez, Valeria 2 147162965 Cordero-Morales, Julio University of Tennessee Health Science Center Cordero-Morales, Julio 3 147162966 Romero, Luis University of Tennessee Health Science Center Romero, Luis 4 147162963 Chesler, Alexander NIH - NCCIH NICHD Chesler, Alexander (NICHD) 1 147162964 Vasquez, Valeria University of Tennessee Health Science Center Vasquez, Valeria 2 147162965 Cordero-Morales, Julio University of Tennessee Health Science Center Cordero-Morales, Julio 3 147162966 Romero, Luis University of Tennessee Health Science Center Romero, Luis 4 147157946 MARGARIC ACID DECREASES PIEZO2-MEDIATED MECHANICAL ALLODYNIA E-081-2020-0 Filing authorized National Center for Complementary and Integrative Health (NCCIH), University of Tennessee Health Science Center 91800717 Hubbs, Alan hubbsa@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America Technology Transfer Center hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain&body=Please send me information about technology [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Hubbs, Alan<br><a href="mailto:hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain&body=Please send me information about technology [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">hubbsa@mail.nih.gov</a><br> 147161010 E-081-2020-0 E-081-2020-0-US-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN PRV US 62/976,014 Abandoned US <br />Provisional (PRV) 62/976,014<br />Filed on 2020-02-13<br />Status: Abandoned 147165468 E-081-2020-0 E-081-2020-0-PCT-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN PCT Patent Cooperation Treaty PCT/US2021/017780 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/017780<br />Filed on 2021-02-12<br />Status: Expired 147165469 E-081-2020-0 E-081-2020-0-JP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Japan 7729824 2022-548411 Issued Japan <br />National Stage 2022-548411<br />Filed on 2022-08-08<br />Status: Issued 147165470 E-081-2020-0 E-081-2020-0-CA-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN National Stage Canada 3167629 Pending Canada <br />National Stage 3167629<br />Filed on 2022-08-10<br />Status: Pending 147165471 E-081-2020-0 E-081-2020-0-AU-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Australia 2021220883 Pending Australia <br />National Stage 2021220883<br />Filed on 2021-02-12<br />Status: Pending 147165472 E-081-2020-0 E-081-2020-0-CN-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage China 202180015900.1 Pending China <br />National Stage 202180015900.1<br />Filed on 2021-02-12<br />Status: Pending 147165473 E-081-2020-0 E-081-2020-0-NZ-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN National Stage New Zealand 790763 Pending New Zealand <br />National Stage 790763<br />Filed on 2022-07-28<br />Status: Pending 147165474 E-081-2020-0 E-081-2020-0-KR-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage South Korea 10-2022-7031665 Pending South Korea <br />National Stage 10-2022-7031665<br />Filed on 2022-09-13<br />Status: Pending 147165475 E-081-2020-0 E-081-2020-0-MX-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Mexico 431664 MX/a/2022/009914 Issued Mexico <br />National Stage MX/a/2022/009914<br />Filed on 2021-02-12<br />Status: Issued 147165476 E-081-2020-0 E-081-2020-0-EP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage European Patent 21710729.1 Pending European Patent <br />National Stage 21710729.1<br />Filed on 2021-02-12<br />Status: Pending 147171000 ALLODYNIA 147171002 Chesler 147171004 Chronic Inflammation 147171005 fatty acid 147171007 Margaric Acid 147171008 migraine 147171010 National Center for Complimentary and Integrative Health 147171012 NCCIH 147171013 Neuropathy 147171014 Pain 147171016 PIEZO2 147171018 Vásquez TAB-4195 147157480 Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease NIA Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Bira Arya, Ioana Bodogai, Purevdorj Olkhanud <h2>Description of Technology:</h2> <p>The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.</p> <p>Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis.</p> <p>Researchers from the <a href="https://www.nia.nih.gov/" rel="nofollow" target="_blank">National Institute on Aging</a> (NIA), NIH, have developed methods for the generation of tBregs, and for using tBregs to produce Tregs, and methods that inactivate or deplete tBregs. These methods have significant therapeutic value in the combat with cancer immune escape and metastasis, and in the control of harmful autoimmune diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Production of cellular cancer vaccines</li> <li>Treatments for immune-mediated disorders</li> <li>Treatments for cancer</li> <li>Treatments for chronic viral infections</li> </ul> 2016-02-16 2026-04-24 2020-08-13 2026-04-24 2020-08-30 IMMUNOTHERAPEUTIC, Immunotherapy, suppressive regulatory B cells, tBregs False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163863 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147163864 Olkhanud, Purevdorj NIH - NIA NCI Olkhanud, Purevdorj (NCI) 2 147163865 Bodogai, Ioana NIH - NIA NIA Bodogai, Ioana (NIA) 3 147163863 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147163864 Olkhanud, Purevdorj NIH - NIA NCI Olkhanud, Purevdorj (NCI) 2 147163865 Bodogai, Ioana NIH - NIA NIA Bodogai, Ioana (NIA) 3 147157989 Cancer-induced Regulatory B Cells (tBregs) Are Efficient Suppressors Of Immune Cellular Responses E-101-2010-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease&body=Please send me information about technology [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease&body=Please send me information about technology [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147167278 E-101-2010-0 E-101-2010-0-US-01 REGULATORY B CELLS (tBREGS) AND THEIR USE PRV US 61/302,074 Abandoned US <br />Provisional (PRV) 61/302,074<br />Filed on 2010-02-05<br />Status: Abandoned 147167279 E-101-2010-0 E-101-2010-0-PCT-02 Regulatory B Cells (tBregs) And Their Use PCT Patent Cooperation Treaty PCT/US2011/023789 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/023789<br />Filed on 2011-02-04<br />Status: Expired 147167280 E-101-2010-0 E-101-2010-0-US-03 Regulatory B Cells (TBregs) And Their Use National Stage US 9,228,171 13/577,226 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228171 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228171">9,228,171</a><br />Filed on 2012-08-03<br />Status: Issued 147167281 E-101-2010-0 E-101-2010-0-US-04 Regulatory B Cells (tBregs) And Their Uses CON US 9,657,269 14/952,768 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657269 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657269">9,657,269</a><br />Filed on 2015-11-25<br />Status: Issued 147171451 IMMUNOTHERAPEUTIC 147171452 Immunotherapy 147171454 suppressive regulatory B cells 147171455 tBregs TAB-3857 147157136 Use of Cucurbitacins and Withanolides for the Treatment of Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Nancy Booth, Alan Brooks, Karen Erickson, Kirk Gustafson, Curtis Henrich, Thomas Sayers <h2>Description of Technology:</h2> <p>Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL &quot;death receptors&quot;. These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).&nbsp;</p> <p>The protein TRAIL has a very interesting characteristic that it can preferentially cause death of cancer cells whereas normal non-transformed cells are unaffected.&nbsp; Thus use of TRAIL or agonist antibodies to its so-called &quot;death receptors&quot; has been a current focus in cancer therapy.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Use of the compounds with known TRAIL or agonist antibodies such as Mapatumumab or in combination with immunotherapeutic approaches for the treatment of cancer.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Cucurbitacins and withanolides can be successfully developed in combination with known TRAIL agonist have the potential of new cancer combination therapies without major toxicities.</li> </ul> 2016-02-16 2026-04-24 2020-08-13 2026-04-24 2020-08-29 cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162452 Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. https://www.ncbi.nlm.nih.gov/pubmed/19089423 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19089423">Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.</a> 147162634 Sayers, Thomas NIH - NCI Leidos Sayers, Thomas (Leidos) 1 147162635 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 2 147162636 Erickson, Karen NIH - NCI Erickson, Karen 3 147162638 Brooks, Alan NIH - NCI Leidos Brooks, Alan (Leidos) 4 147162637 Henrich, Curtis NIH - NCI Henrich, Curtis 5 147162639 Booth, Nancy NIH - NCI Booth, Nancy 6 147162634 Sayers, Thomas NIH - NCI Leidos Sayers, Thomas (Leidos) 1 147162635 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 2 147162636 Erickson, Karen NIH - NCI Erickson, Karen 3 147162638 Brooks, Alan NIH - NCI Leidos Brooks, Alan (Leidos) 4 147162637 Henrich, Curtis NIH - NCI Henrich, Curtis 5 147162639 Booth, Nancy NIH - NCI Booth, Nancy 6 147157869 Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL E-050-2010-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer&body=Please send me information about technology [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer&body=Please send me information about technology [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160966 E-050-2010-0 E-050-2010-0-US-01 Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL PRV US 61/287,139 Abandoned US <br />Provisional (PRV) 61/287,139<br />Filed on 2009-12-16<br />Status: Abandoned 147164857 E-050-2010-0 E-050-2010-0-PCT-02 Method of Sensitizing Cancer Cells To The Cytotoxic Effects Of Death Receptor Ligands In Cancer Treatment PCT Patent Cooperation Treaty PCT/US2010/060821 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/060821<br />Filed on 2010-12-16<br />Status: Expired 147164858 E-050-2010-0 E-050-2010-0-US-03 METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF DEATH RECEPTOR LIGANDS IN CANCER TREATMENT National Stage US 9,238,069 13/516,514 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238069 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238069">9,238,069</a><br />Filed on 2012-10-26<br />Status: Issued 147170305 cucurbitacin 147170306 Immunotherapy 147170308 mapatumamab 147170309 TRAIL 147170311 withanolide TAB-4181 147157466 Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Jeffery Brender, Murali Cherukuri, Shun Kishimoto, Hellmut Merkle, James Mitchell, Jeeva Munasinghe, Kazutoshi Yamamoto <h2>Summary:</h2> <p>The scientists seek co-development parties and/or licensees for a method for measuring low-abundance metabolites in vivo.</p> <h2>Description of Technology:</h2> <p>Accurate measurement of low metabolite concentrations produced by medically important enzymes is commonly obscured by noise during magnetic resonance imaging (MRI). Measuring the turnover rate of low-level metabolites can directly quantify the activity of enzymes of interest, including possible drug targets in cancer and other diseases. Noise can cause the in vivo signal to fall below the limit of detection. A variety of denoising methods have been proposed to enhance spectroscopic peaks, but still fall short for the detection of low-intensity signals. Dynamic nuclear polarization (DNP) is one method that has been critical for boosting weak signals. DNP must be performed near zero absolute temperature, requiring high operating costs. Measurements are limited to imaging immediately after tracer injection, limiting the range of injectable tracers that can be used in vivo.&nbsp;</p> <p>To address these issues, scientists at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) have invented a unique method for measuring low-abundance metabolites in vivo which does not rely on frequency or spatial domains &ndash; but instead works in the kinetic domain. Data processing structure is simpler. True weak spectroscopic peaks can be more easily distinguished from noise. This technology improves the signal-to-noise ratio by an order of magnitude or more and has already been tested in vivo. The denoising software enhances low-metabolic signal without the need for DNP, which was previously thought impossible. The method makes MRI more informative for determining the metabolic activity of key enzymes in serious pathologies, is more dynamic in the range of tracers that can be used, and is generally less expensive. This software is also highly adaptable as it can be added as a plug-in to already existing MRI processing software.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Plug-in software adaptable for use with current MRI-processing software</li> <li>MRIs for clinical or research purposes</li> <li>Ancillary invention of X-nuclei leg coil which improves signal-to-noise ratio and is compatible with software</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Unique method for measuring low-abundance metabolites in vivo which does not rely on frequency or spatial domains</li> <li>Significant enhancement of raw signal and differentiation when detecting pyruvic acid metabolism to lactate</li> </ul> 2020-08-24 2026-04-24 2020-08-24 2026-04-24 2020-08-24 13C imaging, Brender, Denoising, DNP, Dynamic Nuclear Polarization, Glucose Metabolism, Low Metabolite Concentration, Magnetic Resonance Imaging, Metabolic Enzymes, MRI, Software Plugin, SPECTROSCOPIC False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-24 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161913 Brender JR, et al. Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization. https://doi.org/10.1038/s41598-019-38981-1 <a href="https://doi.org/10.1038/s41598-019-38981-1">Brender JR, et al. Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization.</a> 147161951 Kishimoto S, et al. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice https://pubmed.ncbi.nlm.nih.gov/31408004/ <a href="https://pubmed.ncbi.nlm.nih.gov/31408004/">Kishimoto S, et al. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice</a> 147162338 Brender J, et al. PET by MRI: Glucose Imaging by 13C-MRS without Dynamic Nuclear Polarization by Noise Suppression through Tensor Decomposition Rank Reduction. https://www.biorxiv.org/content/10.1101/265793v1.full <a href="https://www.biorxiv.org/content/10.1101/265793v1.full">Brender J, et al. PET by MRI: Glucose Imaging by 13C-MRS without Dynamic Nuclear Polarization by Noise Suppression through Tensor Decomposition Rank Reduction.</a> 147163802 Brender, Jeffery NIH - NCI NCI Brender, Jeffery (NCI) 1 147163803 Yamamoto, Kazutoshi NIH - NCI NCI Yamamoto, Kazutoshi (NCI) 2 147163804 Munasinghe, Jeeva NIH - NCI NINDS Munasinghe, Jeeva (NINDS) 3 147163805 Kishimoto, Shun NIH - NCI NCI Kishimoto, Shun (NCI) 4 147163801 Merkle, Hellmut NIH - NINDS NINDS Merkle, Hellmut (NINDS) 5 147163800 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 6 147163799 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 7 147163802 Brender, Jeffery NIH - NCI NCI Brender, Jeffery (NCI) 1 147163803 Yamamoto, Kazutoshi NIH - NCI NCI Yamamoto, Kazutoshi (NCI) 2 147163804 Munasinghe, Jeeva NIH - NCI NINDS Munasinghe, Jeeva (NINDS) 3 147163805 Kishimoto, Shun NIH - NCI NCI Kishimoto, Shun (NCI) 4 147163801 Merkle, Hellmut NIH - NINDS NINDS Merkle, Hellmut (NINDS) 5 147163800 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 6 147163799 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 7 147157904 Denoising Of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations In The Kinetic Domain E-063-2017-0 Filing authorized NCI, NINDS 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain&body=Please send me information about technology [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain&body=Please send me information about technology [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147167173 E-063-2017-0 E-063-2017-0-US-01 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN PRV US 62/459,008 Abandoned US <br />Provisional (PRV) 62/459,008<br />Filed on 2017-02-14<br />Status: Abandoned 147167174 E-063-2017-0 E-063-2017-0-PCT-02 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN PCT Patent Cooperation Treaty PCT/US2018/018217 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/018217<br />Filed on 2018-02-14<br />Status: Expired 147167175 E-063-2017-0 E-063-2017-0-JP-06 DENOISING OF DYNAMIC MAGNETIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Japan 7142017 2019-543765 Issued Japan <br />National Stage 2019-543765<br />Filed on 2018-02-14<br />Status: Issued 147167176 E-063-2017-0 E-063-2017-0-AU-03 DENOISING OF DYNAMIC MAGNETIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Australia 2018221015 2018221015 Issued Australia <br />National Stage 2018221015<br />Filed on 2019-08-13<br />Status: Issued 147167177 E-063-2017-0 E-063-2017-0-CA-04 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Canada 3053157 3053157 Issued Canada <br />National Stage 3053157<br />Filed on 2018-02-14<br />Status: Issued 147167178 E-063-2017-0 E-063-2017-0-EP-05 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage European Patent 3583436 18707581.7 Issued European Patent <br />National Stage 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167179 E-063-2017-0 E-063-2017-0-US-07 Denoising Of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations In The Kinetic Domain National Stage US 16/485,772 Pending US <br />National Stage 16/485,772<br />Filed on 2019-08-13<br />Status: Pending 147167180 E-063-2017-0 E-063-2017-0-US-08 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN CON US 12,270,881 17/576,283 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270881 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270881">12,270,881</a><br />Filed on 2022-01-14<br />Status: Issued 147167181 E-063-2017-0 E-063-2017-0-DE-09 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP Germany 3583436 18707581.7 Issued Germany <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167182 E-063-2017-0 E-063-2017-0-FR-10 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP France 3583436 18707581.7 Issued France <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167183 E-063-2017-0 E-063-2017-0-GB-11 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP United Kingdom 3583436 18707581.7 Issued United Kingdom <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147170598 13C imaging 147170600 Brender 147170601 Denoising 147170603 DNP 147170605 Dynamic Nuclear Polarization 147170607 Glucose Metabolism 147170609 Low Metabolite Concentration 147170610 Magnetic Resonance Imaging 147170612 Metabolic Enzymes 147170613 MRI 147170615 Software Plugin 147170616 SPECTROSCOPIC TAB-3990 147157271 T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Christian Hinrichs, Kazusa Ishii <h2>Summary:</h2> <p>NCI seeks parties interested in licensing&nbsp;to further develop&nbsp;a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias.</p> <h2>Description of Technology:</h2> <p>CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include cancer cells becoming resistant to the therapy. Resistance mechanisms to the existing CD20 therapies include loss of target antigen expression from the cell surface, loss of antibody epitope, or modulation of antibody epitope &ndash; all of which make the malignant cells &ldquo;invisible&rdquo; to antibodies. Importantly, these resistance mechanisms do not affect TCR-mediated target recognition. Epitopes for TCRs are short fragments of peptides that are processed intracellularly and presented in the context of major histocompatibility complex. Thus, TCRs can recognize and kill leukemia and lymphoma that are no longer &ldquo;visible&rdquo; to existing antibodies.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have developed a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias. These novel TCRs can recognize and exert cell killing against CD20-derived epitopes even when the target protein escapes surface expression and remains in a sub-cellular compartment, such as endoplasmic reticulum or cytoplasm. These characteristics of the novel anti-CD20 TCRs allow them to overcome known resistance mechanisms associated with B-cell malignancies, making them an attractive therapy over other current CD20 therapeutics on the market.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>The TCRs can be used as a therapeutic against B-cell malignancies such as non-Hodgkin&rsquo;s lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia</li> <li>The TCRs can be used for treatment in: <ul> <li>CD20-expressing malignancies, even if the CD20 antigen escapes the surface of the tumor cells and resides within intracellular compartments or is only partially expressed</li> <li>CD20-expressing malignancies, even if the diseases are resistant to existing anti-CD20 antibodies through resistance to antibody-specific cytotoxicity mechanisms (such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity)&nbsp;</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The novel TCRs can recognize and exert cell killing against CD20-derived epitopes even when the target protein escapes surface expression and remains in a sub-cellular compartment, which are current limitations of CAR-T cell therapy and anti-CD20 monoclonal antibodies</li> <li>The novel anti-CD20 TCRs&nbsp;can specifically recognize and exert tumor-cell killing in a target-antigen-restricted manner, when CD20 expression is low, or when CD20 is expressed intracellularly</li> <li>In in vitro experiments, T cells engineered to express anti-CD20 TCR recognize and mediate cytotoxicity against cells lines that are both CD20+ and HLA-A2+ and exhibit high functional activity</li> <li>CD20 targeting TCRs are available for immediate clinical validation</li> </ul> 2020-08-19 2026-04-24 2021-03-23 2026-04-24 2020-08-19 Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163144 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147163143 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147163144 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147163143 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147158086 Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD20 Epitope E-152-2020-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias&body=Please send me information about technology [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias&body=Please send me information about technology [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147165752 E-152-2020-0 E-152-2020-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 PRV US 63/043,520 Abandoned US <br />Provisional (PRV) 63/043,520<br />Filed on 2020-06-24<br />Status: Abandoned 147165753 E-152-2020-0 E-152-2020-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 PCT Patent Cooperation Treaty PCT/US2021/038649 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/038649<br />Filed on 2021-06-23<br />Status: Expired 147165754 E-152-2020-0 E-152-2020-0-US-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 National Stage US 18/012,056 Pending US <br />National Stage 18/012,056<br />Filed on 2022-12-21<br />Status: Pending 147172428 Acute Lymphoblastic Leukemia 147172429 ALL 147172430 CD20 147172431 Chronic lymphocytic leukemia 147172432 CLL 147172433 Hinrichs 147172434 Ishii 147172435 NHL 147172436 Non-Hodgkin’s Lymphoma 147172438 Resistant B-lymphoid malignancies 147172439 T-Cell Receptor 147172440 TCR TAB-4411 147157706 Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Suja Hiriyanna, Kamil Kruczek, Anand Swaroop, Zhijian Wu <h2>Description of Technology:</h2> <p>Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially restored expression of visual opsins and other phototransduction genes as revealed by immunohistochemistry and single cell RNA-sequencing. Retinal organoids from iPSCs of a second dominant CRX-LCA patient carrying a K88N mutation also revealed loss of expression of opsins and phototransduction genes as a common phenotype, which could be alleviated by AAV-mediated overexpression of CRX.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Early onset blindness, including Leber congenital amaurosis</li> <li>Gene therapy of CRX retinopathies; i.e., patients with a mutation in the CRX gene</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Promising commercial potential given that there are no current treatments for CRX-retinopathies&nbsp;</li> <li>Gene therapy by delivering CRX should restore photoreceptor structure and function</li> <li>Existing commercial interest and an established regulatory path for directly administered gene therapy targeting an ophthalmic disease caused by mutations in a specific gene: In 2017, Luxturna (voretigene neparvovec-rzyl) was FDA approved for an inherited form of vision loss (confirmed biallelic RPE65 mutation-associated retinal dystrophy) that may result in blindness</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 AAV, Adeno-associated Virus, Cone-rod Dystrophy, CRD, GENE THERAPY, LCA, Leber Congenital Amaurosis, Lentivirus, NEI, rare disease, Retinitis Pigmentosa, Retinopathies, RP, Swaroop False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164644 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164647 Kruczek, Kamil NIH - NEI NEI Kruczek, Kamil (NEI) 2 147164645 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 3 147164646 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 4 147164644 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164647 Kruczek, Kamil NIH - NEI NEI Kruczek, Kamil (NEI) 2 147164645 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 3 147164646 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 4 147157778 Gene Therapy For Treatment Of CRX-associated Retinopathies E-008-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160891 E-008-2020-0 E-008-2020-0-US-01 Gene Therapy For Treatment Of CRX-associated Retinopathies PRV US 62/962,732 Abandoned US <br />Provisional (PRV) 62/962,732<br />Filed on 2020-01-17<br />Status: Abandoned 147168764 E-008-2020-0 E-008-2020-0-PCT-02 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES PCT Patent Cooperation Treaty PCT/US2021/013733 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013733<br />Filed on 2021-01-15<br />Status: Expired 147168765 E-008-2020-0 E-008-2020-0-US-03 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage US 17/789,729 Pending US <br />National Stage 17/789,729<br />Filed on 2022-06-28<br />Status: Pending 147168766 E-008-2020-0 E-008-2020-0-AU-04 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Australia 2021208631 Pending Australia <br />National Stage 2021208631<br />Filed on 2021-01-15<br />Status: Pending 147168767 E-008-2020-0 E-008-2020-0-CA-05 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Canada 3165922 Pending Canada <br />National Stage 3165922<br />Filed on 2021-01-15<br />Status: Pending 147168768 E-008-2020-0 E-008-2020-0-EP-06 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage European Patent 21705324.8 Pending European Patent <br />National Stage 21705324.8<br />Filed on 2021-01-15<br />Status: Pending 147168769 E-008-2020-0 E-008-2020-0-JP-07 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Japan 7703543 2022-540642 Issued Japan <br />National Stage 2022-540642<br />Filed on 2021-01-15<br />Status: Issued 147169363 AAV 147169364 Adeno-associated Virus 147169366 Cone-rod Dystrophy 147169368 CRD 147169369 GENE THERAPY 147169370 LCA 147169372 Leber Congenital Amaurosis 147169373 Lentivirus 147169375 NEI 147169376 rare disease 147169378 Retinitis Pigmentosa 147169379 Retinopathies 147169381 RP 147169383 Swaroop TAB-4342 147157634 CD206 Small Molecule Modulators, Their Use and Methods for Preparation NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bolormaa Baljinnyam, Raul Calvo, Xin Hu, Juan Marugan, Udo Rudloff, Noel Southall <h2>Summary:</h2> <p>The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers.</p> <h2>Description of Technology:</h2> <p>Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis &ndash; it is often asymptomatic in early stages &ndash; and a poor response to conventional chemotherapy and radiotherapy. One of the major immune cell types present in the PDA microenvironment is a subset of macrophages commonly termed tumor-associated macrophages (TAM). TAMs originate, in part, from circulating monocytes upon activation by CCL2, a chemotactic chemokine secreted and then recruited to the tumor microenvironment by cytokines expressed by PDA cells.</p> <p>TAMs consist primarily of polarized M2 macrophages which promote tumor growth by secreting immunosuppressive factors that block effector T-cell activation. TAMs express scavenger receptors such as CD206 which facilitate tumor angiogenesis and migration. CD206 is a member of the large C-type lectin receptor family and not found on other TAM population like undifferentiated M0 or M1-like macrophages. CD206high expression and infiltration with CD206high macrophages has been associated with poor clinical outcomes in pancreatic cancer and other solid organ cancers. Current anti-macrophage therapy generally inhibits activation or the recruitment of macrophages (CCL2/CCR2), which lacks specificity towards M2-like macrophages, agonism of M1 signaling via CD40 ligation, or blockade of the CD47-SIRP &lsquo;do-not-eat&rsquo; cancer phagocytosis checkpoint.</p> <p>Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and induces M2-to-M1 reprogramming, cancer cell phagocytosis and M2 cell death. The anti-CD206 small molecule was identified through structure-based pharmacophore modeling and in silico screening of the anti-cancer peptide, RP-182 (NIH Reference Number: E-242-2015.) The activity of this CD206 small molecule modulator was confirmed in vitro and in vivo across a number of different solid organ cancer models. In addition to its reprogramming function to a M1 mechanism, a selective reduced cell viability was observed in human CD206high M2-like macrophages derived from healthy volunteers compared with M1 control macrophages. This new small molecule immunomodulator will be the first-in-class that will have application in selectively targeting M2 macrophages &ndash; a pro-tumor immune cell population &ndash; and the reprogramming of M2 macrophages towards a M1 phenotype (anti-tumor cell population) for the treatment of pancreatic cancer. The small molecule candidate has high oral bioavailability, a large therapeutic window, favorable pharmacokinetics, and limited off-target effects.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of cancers associated with high expression of CD206 including pancreatic, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, and melanoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First-in-class small molecule targeting CD206 for oncology indication</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients</li> <li>High unmet needs and commercial opportunity for pancreatic cancer</li> </ul> 2020-08-17 2026-04-24 2021-05-20 2026-04-24 2020-08-17 CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-242-2015 147164385 Rudloff, Udo NIH - NCI NCI Rudloff, Udo (NCI) 1 147164384 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 2 147164386 Hu, Xin NIH - NCATS NCATS Hu, Xin (NCATS) 3 147164387 Calvo, Raul NIH - NCATS NCATS Calvo, Raul (NCATS) 4 147164383 Southall, Noel NIH - NCATS NCATS Southall, Noel (NCATS) 5 147164382 Baljinnyam, Bolormaa NIH - NCATS NCATS Baljinnyam, Bolormaa (NCATS) 6 147164385 Rudloff, Udo NIH - NCI NCI Rudloff, Udo (NCI) 1 147164384 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 2 147164386 Hu, Xin NIH - NCATS NCATS Hu, Xin (NCATS) 3 147164387 Calvo, Raul NIH - NCATS NCATS Calvo, Raul (NCATS) 4 147164383 Southall, Noel NIH - NCATS NCATS Southall, Noel (NCATS) 5 147164382 Baljinnyam, Bolormaa NIH - NCATS NCATS Baljinnyam, Bolormaa (NCATS) 6 147157996 Small Molecules With Selective Activity Against The M2 Phenotype Of Macrophages E-105-2019-0 Filing authorized NCATS - NCGC, NCATS - NCGC, NCI, NIH - NCATS, NIH - NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation&body=Please send me information about technology [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation&body=Please send me information about technology [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147161046 E-105-2019-0 E-105-2019-0-US-01 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION PRV US 62/950,488 Abandoned US <br />Provisional (PRV) 62/950,488<br />Filed on 2019-12-19<br />Status: Abandoned 147168315 E-105-2019-0 E-105-2019-0-PCT-02 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION PCT Patent Cooperation Treaty PCT/US2020/065238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/065238<br />Filed on 2020-12-16<br />Status: Expired 147168316 E-105-2019-0 E-105-2019-0-CA-04 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Canada 3165339 Pending Canada <br />National Stage 3165339<br />Filed on 2020-12-16<br />Status: Pending 147168317 E-105-2019-0 E-105-2019-0-CN-05 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage China ZL202080096478.2 202080096478.2 Issued China <br />National Stage 202080096478.2<br />Filed on 2022-08-30<br />Status: Issued 147168318 E-105-2019-0 E-105-2019-0-EP-06 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage European Patent 20842083.6 Pending European Patent <br />National Stage 20842083.6<br />Filed on 2020-12-16<br />Status: Pending 147168319 E-105-2019-0 E-105-2019-0-JP-07 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Japan 7801223 2022-537672 Issued Japan <br />National Stage 2022-537672<br />Filed on 2020-12-16<br />Status: Issued 147168320 E-105-2019-0 E-105-2019-0-US-08 CD206 Modulators Their Use and Methods for Preparation National Stage US 17/787,313 Pending US <br />National Stage 17/787,313<br />Filed on 2022-06-18<br />Status: Pending 147168321 E-105-2019-0 E-105-2019-0-AU-03 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Australia 2020404978 Pending Australia <br />National Stage 2020404978<br />Filed on 2020-12-16<br />Status: Pending 147171505 CD206 147171507 M1 Macrophage 147171509 M2 Macrophage 147171510 Pancreatic Cancer 147171512 Pancreatic Ductal Adenocarcinoma 147171513 PDA 147171515 Rudloff 147171516 TAM 147171518 Tumor-Associated Macrophages TAB-4281 147157569 High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Dan Li, Brad St. Croix, Ruixue Wang <h2>Summary:</h2> <p>The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.&nbsp;</p> <h2>Description of Technology:</h2> <p>CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) &ndash; making it an ideal target for cancer therapy.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 single domain antibodies (also known as nanobodies) from novel camel and rabbit single domain (VHH) libraries by phage display.&nbsp;</p> <p>Nanobodies are the smallest known antigen-binding fragments of antibodies. Due to their small size, high solubility, thermal stability, refolding capacity, and relatively easy tissue penetration, they have great potential as medical applications and research tools. These antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). The CARs using the RWB12, RWC4 and RWG8 antibodies have shown potent killing in various CD276-expressing tumor cell models, strongly supporting that these candidates may be further developed as therapeutics.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Numerous solid tumors &ndash; including, but not limited to: pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma)&nbsp;</li> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Diagnostic agent for detection and monitoring levels of mesothelin expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Antibodies with high CD276 binding specificity should result in less non-specific cell killing (off-target toxicity) and lower potential side-effects</li> <li>Similarity of camel and human VH sequences suggests humanization of these antibodies is not necessary, and that the product is ready for immediate clinical testing</li> <li>Relative ease of Tissue Penetration for targeting Solid Tumors</li> <li>CARs using the A101 and G8 antibodies available for immediate testing</li> <li>B7-H3 antagonist</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164144 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164145 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 2 147164147 Wang, Ruixue NIH - NCI NCI Wang, Ruixue (NCI) 3 147164146 Li, Dan NCI - CCR NCI Li, Dan (NCI) 4 147164144 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164145 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 2 147164147 Wang, Ruixue NIH - NCI NCI Wang, Ruixue (NCI) 3 147164146 Li, Dan NCI - CCR NCI Li, Dan (NCI) 4 147158171 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors E-185-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors&body=Please send me information about technology [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors&body=Please send me information about technology [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161165 E-185-2019-0 E-185-2019-0-US-01 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PRV US 62/924,498 Abandoned US <br />Provisional (PRV) 62/924,498<br />Filed on 2019-10-22<br />Status: Abandoned 147167851 E-185-2019-0 E-185-2019-0-PCT-02 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PCT Patent Cooperation Treaty PCT/US2020/056601 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/056601<br />Filed on 2020-10-21<br />Status: Expired 147167852 E-185-2019-0 E-185-2019-0-AU-03 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Australia 2020370125 Pending Australia <br />National Stage 2020370125<br />Filed on 2020-10-21<br />Status: Pending 147167853 E-185-2019-0 E-185-2019-0-CA-04 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Canada 3156761 Pending Canada <br />National Stage 3156761<br />Filed on 2020-10-21<br />Status: Pending 147167854 E-185-2019-0 E-185-2019-0-CN-05 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage China ZL202080074414.2 202080074414.2 Issued China <br />National Stage 202080074414.2<br />Filed on 2020-10-21<br />Status: Issued 147167855 E-185-2019-0 E-185-2019-0-EP-06 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage European Patent 20804404.0 Pending European Patent <br />National Stage 20804404.0<br />Filed on 2020-10-21<br />Status: Pending 147167856 E-185-2019-0 E-185-2019-0-JP-07 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Japan 7690468 2022-523456 Issued Japan <br />National Stage 2022-523456<br />Filed on 2020-10-21<br />Status: Issued 147167857 E-185-2019-0 E-185-2019-0-US-08 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage US 12,552,865 17/770,940 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552865 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552865">12,552,865</a><br />Filed on 2022-04-21<br />Status: Issued 147173275 ADC 147173276 Antibody-drug Conjugate 147173277 B7-H3 147173278 BREAST CANCER 147173279 CAR 147173280 CD276 147173281 chimeric antigen receptor 147173282 COLON CANCER 147173283 Glioma 147173284 HO 147173285 lung cancer 147173286 Nanobodies 147173287 Neuroblastoma 147173288 OVARIAN CANCER 147173289 Pancreatic Cancer 147173290 solid tumors TAB-3899 147157179 Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Christine Alewine, Norman Collins, Theresa Guerin, Serguei Kozlov, Theresa O'Sullivan, Jerome Schlomer, Xianyu Zhang <h2>Summary:</h2> <p>The NCI Laboratory of Molecular Biology is seeking parties interested in licensing&nbsp;a genetically engineered&nbsp;mouse model expressing hMSLN in the thyroid gland for commercialization in the field of cancer therapeutics and research targeting mesothelin-expressing tumors.</p> <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is an antigen highly expressed in several human cancers including mesotheliomas, ovarian cancers and pancreatic cancers. As such, human MSLN (hMSLN) is a target for many anti-cancer drugs. Most therapeutics targeting hMSLN do not recognize the mouse isoform of MSLN (mMSLN) and therefore cannot be tested in mouse cancer models.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have developed a mouse model wherein mice are genetically engineered to express hMSLN in the thyroid gland under the transcriptional control of a thyroid-specific (Tpo) gene promoter. Due to the tolerance to the hMSLN isoform, these mice are efficient recipients of cancer cell lines engineered to express hMSLN. These mice allow the testing of cancer therapeutics targeted against hMSLN in a fully immunocompetent animal background. In addition, these mice can be used to investigate on-target, off-tumor toxicity caused by hMSLN-directed therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research, diagnostics, or therapeutics involving the target, mesothelin, such as in human mesotheliomas, ovarian cancers, pancreatic cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The humanized mice have expression of human mesothelin (hMSLN) that is localized to the thyroid. The Bl6/TPO mice are efficient recipients of cancer cells lines that express hMSLN</li> <li>Endogenous expression of hMSLN in mice allows for the unique ability to test therapies that target human mesothelin, including studies off-target toxicity</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 Alewine, Bl6/TPO, Cancer Animal Model, hMSLN, Humanized Mice, MESOTHELIN, MSLN, Murine Model, THYROID False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162190 Zhang X, et al. Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics. https://cancerres.aacrjournals.org/content/79/13_Supplement/268 <a href="https://cancerres.aacrjournals.org/content/79/13_Supplement/268">Zhang X, et al. Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics.</a> 147162791 Alewine, Christine NIH - NCI NCI Alewine, Christine (NCI) 1 147162792 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 2 147162796 Zhang, Xianyu NIH - NCI NCI Zhang, Xianyu (NCI) 3 147162794 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 4 147162790 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 5 147162795 Collins, Norman NIH - NCI NCI Collins, Norman (NCI) 6 147162793 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 7 147162791 Alewine, Christine NIH - NCI NCI Alewine, Christine (NCI) 1 147162792 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 2 147162796 Zhang, Xianyu NIH - NCI NCI Zhang, Xianyu (NCI) 3 147162794 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 4 147162790 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 5 147162795 Collins, Norman NIH - NCI NCI Collins, Norman (NCI) 6 147162793 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 7 147157978 C57BI6 Mice With Thyroid Specific Expression Of Human Mesothelin E-096-2020-0 Research Material NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice&body=Please send me information about technology [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice&body=Please send me information about technology [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147171332 Alewine 147171334 Bl6/TPO 147171336 Cancer Animal Model 147171338 hMSLN 147171340 Humanized Mice 147171341 MESOTHELIN 147171342 MSLN 147171344 Murine Model 147171345 THYROID TAB-4256 147157543 Antisense Oligonucleotides against Cancer Cell Migration and Invasion NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Stavroula Mili <h2>Summary:</h2> <p>NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.</p> <h2>Description of Technology:</h2> <p>Advanced stage cancers are typically marked by metastases of the primary cancer to secondary sites such as lungs, liver, and bones. Such metastatic cancers result in strikingly low 5-year survival rates, underscoring the need for novel therapeutics. For example, bone metastasis of primary breast cancer has a 5-year survival rate of 13%, lung cancer only 1%. There is a need for targeted therapy options specific to metastases. One approach to targeting metastases is to reduce cancer cell migration and invasion.</p> <p>Several mRNAs become localized to subcellular destinations during the metastatic process. These mRNAs may play roles in cell and organelle development &ndash; either through corresponding increases in encoded protein concentration or through dynamic interactions with the extracellular environment. Their activities may be modulated via antisense oligonucleotides. One example is the mRNA localization at the protrusions extended by mesenchymal migrating cells, partially under control of the adenomatous polyposis coli (APC) tumor suppressor. Regulation of the mRNAs localized to these protrusions may be usurped to target cancer cell migration and invasion and, ultimately, metastasis. RAB13 and NET1 are especially promising mRNA targets as they are overexpressed in multiple cancer types and contributory to cell motility in vitro.</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology, have shown that mRNA localization at protrusive regions of migrating cells depends on specific signals within the 3&rsquo;-untranslated regions of these mRNAs. These signals may be modulated by antisense oligonucleotides as a novel mechanism to target cancer metastasis. The inventors have designed chemically modified antisense oligonucleotides against RAB13 and NET1, delivered these into cancer cells, and observed inhibition of cell migration and invasion in two-dimensional and three-dimensional in vitro assays. These oligonucleotides specifically target RNAs at protrusions without broadly affecting expression of encoded proteins, so they are expected to have minimal effects on non-migrating cells. In vivo studies with xenograft tumor models are currently taking place to optimize delivery of the oligonucleotides.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Metastatic cancer therapeutic</li> <li>Targeted cancer therapeutic</li> <li>Cardiovascular and neurodegenerative diseases, as well as genetic disorders</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Regulatory approval pathway exists following FDA/EMA approval of the first antisense-based molecule (Tegsedi&trade;) in 2018&nbsp;</li> <li>Targeting cancer metastasis and inhibition of cell movement through antisense oligonucleotides is a novel approach</li> <li>Antisense oligonucleotides specifically target RNAs at cell protrusions without broadly affecting cellular protein expression</li> <li>Antisense oligonucleotides can be highly specific, permitting induction at advanced stages of cancer growth &ndash; as compared with chemotherapy</li> </ul> 2020-07-21 2026-04-24 2020-07-21 2026-04-24 2020-07-21 Antisense, APC, CANCER, Invasion, Metastasis, MIGRATION, Mili, Net1, OLIGO, oligonucleotide, Oncology, Rab13, RNA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162220 Moissoglu K, et al. Translational regulation of protrusion-localized RNAs involves silencing and clustering after transport. https://pubmed.ncbi.nlm.nih.gov/31290739/ <a href="https://pubmed.ncbi.nlm.nih.gov/31290739/">Moissoglu K, et al. Translational regulation of protrusion-localized RNAs involves silencing and clustering after transport.</a> 147162297 Moissoglu K, et al. Local RNA translation controls cell migration and Rab GTPase function. https://www.biorxiv.org/content/10.1101/2020.05.19.104463v1 <a href="https://www.biorxiv.org/content/10.1101/2020.05.19.104463v1">Moissoglu K, et al. Local RNA translation controls cell migration and Rab GTPase function.</a> 147162373 Mili S, et al. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions. https://pubmed.ncbi.nlm.nih.gov/18451862/ <a href="https://pubmed.ncbi.nlm.nih.gov/18451862/">Mili S, et al. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions.</a> 147164065 Mili, Stavroula NIH - NCI NCI Mili, Stavroula (NCI) 1 147164065 Mili, Stavroula NIH - NCI NCI Mili, Stavroula (NCI) 1 147157847 Antisense Oligos That Block Cancer Cell Migration And Invasion E-041-2020-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion&body=Please send me information about technology [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion&body=Please send me information about technology [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160947 E-041-2020-0 E-041-2020-0-US-01 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER PRV US 62/966,204 Abandoned US <br />Provisional (PRV) 62/966,204<br />Filed on 2020-01-27<br />Status: Abandoned 147167709 E-041-2020-0 E-041-2020-0-PCT-02 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER PCT Patent Cooperation Treaty PCT/US2021/015053 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/015053<br />Filed on 2021-01-26<br />Status: Expired 147167710 E-041-2020-0 E-041-2020-0-US-03 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER National Stage US 12,503,695 17/792,507 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12503695 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12503695">12,503,695</a><br />Filed on 2022-07-13<br />Status: Issued 147170068 Antisense 147170069 APC 147170070 CANCER 147170071 Invasion 147170072 Metastasis 147170073 MIGRATION 147170075 Mili 147170077 Net1 147170078 OLIGO 147170079 oligonucleotide 147170080 Oncology 147170082 Rab13 147170083 RNA TAB-4155 147157438 Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment NCI Collaboration, Endocrinology, Licensing, Oncology, Therapeutics Collaboration Endocrinology Licensing Oncology Therapeutics Nicholas Aboreden, William Figg, Berkley Gryder, Adegboyega Oyelere, Eric Raftery, Subhasish Tapadar <h2>Description of Technology:</h2> <p>Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy, radiation therapy, and importantly androgen-deprivation therapy (ADT). Prostate cancer is dependent on androgen hormones, such as testosterone, for sustaining and promoting growth. Androgen hormones bind to the Androgen receptor (AR), causing AR localization to the nucleus where a complex is formed that regulates the transcription of critical genes. ADT is accomplished through administering an antagonist to the AR that blocks androgen ligands, or by castration (physical or chemical) to reduce the amount of testosterone. However, the disease frequently advances to castration resistant prostate cancer (CRPC), becoming resistant to these therapies by overexpressing AR. Additional anti-androgens have been developed, though these have had limited improvements in patient outcomes and are not effective against the refractory forms of prostate cancer.&nbsp;</p> <p>Recently, antiandrogenic diaryl thiohydantoin compounds have been shown to be more promising prostate cancer therapeutics. These compounds have shown success in clinical trials, though still with only mild improvement of patient outcomes. Therefore, more potent forms of these compounds are needed for improved therapies. Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin derived heterocyclic compounds with improved efficacy as shown by in vitro and in vivo studies. These compounds include, most importantly, Androgen Receptor Inverse Agonists (ARIA), but also agonists and antagonists of the AR.&nbsp; &nbsp;</p> <p>NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for: <ul> <li>Early and advanced stages of prostate cancer</li> <li>Androgen receptor-positive breast cancer and other androgen receptor-positive solid tumors</li> <li>Androgen deficiency disorders</li> <li>Hyperandrogenism</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased potency compared with current prostate cancer therapeutic compounds</li> <li>Potency in disease models that are non-responsive to current prostate cancer therapeutics</li> <li>Potential to treat both early stage and advance stage prostate cancer</li> <li>Potential to treat a range of androgen receptor-positive solid tumors</li> <li>Other clinical trials with similar approaches provides promising human safety data</li> </ul> 2020-07-07 2026-04-24 2020-07-07 2026-04-24 2020-07-07 Androgen Deficiency Disorders, Androgen dysfunctional Disorders, Androgen Receptor, Androgen Receptor Inverse Agonists, Anti-androgens, AR, ARIA, BREAST CANCER, Georgia Institute of Technology, GIT, Gryder, Hyperandrogenism, PROSTATE CANCER False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163711 Gryder, Berkley NIH - NCI NCI Gryder, Berkley (NCI) 1 147163712 Oyelere, Adegboyega Georgia Institute of Technology Oyelere, Adegboyega 2 147163713 Raftery, Eric Georgia Institute of Technology Raftery, Eric 3 147163714 Tapadar, Subhasish Georgia Institute of Technology Tapadar, Subhasish 4 147163715 Aboreden, Nicholas NIH - NCI NCI Aboreden, Nicholas (NCI) 5 147163710 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147163711 Gryder, Berkley NIH - NCI NCI Gryder, Berkley (NCI) 1 147163712 Oyelere, Adegboyega Georgia Institute of Technology Oyelere, Adegboyega 2 147163713 Raftery, Eric Georgia Institute of Technology Raftery, Eric 3 147163714 Tapadar, Subhasish Georgia Institute of Technology Tapadar, Subhasish 4 147163715 Aboreden, Nicholas NIH - NCI NCI Aboreden, Nicholas (NCI) 5 147163710 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147158131 Aryl Hydantoin Heterocycles And Methods Of Making And Using Thereof E-169-2018-0 Filing authorized Georgia Institute of Technology, National Cancer Institute (NCI), NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment&body=Please send me information about technology [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment&body=Please send me information about technology [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161140 E-169-2018-0 E-169-2018-0-US-01 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE PRV US 62/963,959 Abandoned US <br />Provisional (PRV) 62/963,959<br />Filed on 2020-01-21<br />Status: Abandoned 147166960 E-169-2018-0 E-169-2018-0-PCT-02 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2021/014176 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/014176<br />Filed on 2021-01-20<br />Status: Expired 147166961 E-169-2018-0 E-169-2018-0-AU-03 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage Australia 2021209875 Pending Australia <br />National Stage 2021209875<br />Filed on 2022-07-14<br />Status: Pending 147166962 E-169-2018-0 E-169-2018-0-CA-04 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage Canada 3165120 Pending Canada <br />National Stage 3165120<br />Filed on 2022-07-18<br />Status: Pending 147166963 E-169-2018-0 E-169-2018-0-EP-05 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage European Patent 21705753.8 Pending European Patent <br />National Stage 21705753.8<br />Filed on 2022-08-16<br />Status: Pending 147166964 E-169-2018-0 E-169-2018-0-US-06 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage US 17/794,212 Pending US <br />National Stage 17/794,212<br />Filed on 2022-07-20<br />Status: Pending 147172873 Androgen Deficiency Disorders 147172875 Androgen dysfunctional Disorders 147172877 Androgen Receptor 147172879 Androgen Receptor Inverse Agonists 147172881 Anti-androgens 147172882 AR 147172884 ARIA 147172885 BREAST CANCER 147172887 Georgia Institute of Technology 147172889 GIT 147172891 Gryder 147172893 Hyperandrogenism 147172894 PROSTATE CANCER TAB-4032 147157313 Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus NCI Immunology, Licensing, Research Materials Immunology Licensing Research Materials Amanda (Declined Roy Aloia, Alan Rein <h2>Description of Technology:</h2> <p>Gammaretroviral vectors were the first viral gene-therapy vectors to enter clinical trials and remain in use. One potential hazard associated with the use of such vectors is the presence of replication-competent retroviruses (RCR) in the vector preparations &ndash; either as a result of: 1) recombination events between the plasmids used for vector production, 2) interactions between the plasmids and endogenous retroviral sequences in the packaging cell lines, or 3) as a result of contamination in the laboratory. RCRs are potentially pathogenic and shown to induce malignancy in mice and non-human primates. Therefore, it is critical that vector preparations be rigorously tested to exclude the presence of RCRs given that the Food and Drug Administration (FDA) requires all vector preparations be screened for RCRs.</p> <p>At present, the FDA recommends RCR testing by inoculating an aliquot of each vector preparation into a permissive cell line and passaging the cells for at least three weeks (i.e., amplification phase). Cell-free media from the amplification phase can then be analyzed by a variety of methods to demonstrate the presence or absence of RCRs.</p> <p>Scientists at the National Cancer Institute (NCI) have developed a new research method for the detection of RCRs in gammaretrovirus-based gene-therapy products and the cell lines used to make them. The assay uses one of a series of DERSE (Detector of Exogenous Retroviral Sequence Elements) plasmids, stably maintained in a cell line permissive for the retrovirus of interest. Utilizing the unique reverse-transcription step of the retroviral infection cycle, a functional reporter gene is formed in the DERSE cell culture only after infection with an RCR. The DERSE assay can be constructed, potentially, to detect any RCR and can use any reporter gene.</p> <p>This invention is available for licensing.</p> <p><img alt="E-125-2020 - Schematic of inGluc-MLV-DERSE assay" src="https://nih.technologypublisher.com/files/sites/e-125-2020_-_schematic_of_ingluc-mlv-derse_assay2.jpg" style="float:left; height:489px; width:450px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Figure: Schematic of inGluc-MLV-DERSE assay</strong></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>The inG<em>luc</em>-MLV-DERSE plasmid consists of a Gaussia Luciferase (G<em>luc</em>) sequence oriented in a reverse direction with respect to flanking MLV non-coding sequences. Within the non-coding G<em>luc</em> sequence is an intron that is oriented in a forward direction relative to the viral non-coding regions (and can be spliced by the host cell). The plasmid is maintained in 293mCAT1 cells. In the absence of RCR, only minus-strand, spliced G<em>luc</em> sequences are present in the cell. An RCR that infects the DERSE cell can package the RNA containing the minus-strand G<em>luc</em> sequence. In the next round of infection reverse transcription of the encapsidated RNA produces a double-stranded DNA containing an uninterrupted G<em>luc</em> gene. This gene is an intact, coding G<em>luc</em> sequence that is subsequently integrated into the DNA of, and expressed by, the newly infected cell. Expression of G<em>luc</em> is under the control of the cytomegalovirus (CMV) promoter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Laboratory tool to investigate molecular mechanisms of retroviral replication</li> <li>Research tool to screen gene therapy regimens</li> <li>Manufacturing tool to screen viral vector preparations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Provides reliable results in roughly half the time of traditional methods for detecting replication-competent retrovirus (RCR)</li> <li>Overcomes the inhibitory effect of excess gene-therapy vector in the detection of RCRs</li> <li>Does not require the identification of foci</li> <li>Useful for screening both gene-therapy products and the packaging cell lines used for vector production</li> <li>Enhanced detection sensitivity as the indicating reporter is only formed in cells infected with replication-competent retrovirus&nbsp;</li> </ul> 2020-07-07 2026-04-24 2020-07-07 2026-04-24 2020-07-07 Cell line, Gammaretrovirus, Gaussia Luciferase, GENE THERAPY, PLASMID, RCR, Rein, Replication-Competent Retrovirus, Vector Preparation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162154 Aloia AL, et al. A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay. https://pubmed.ncbi.nlm.nih.gov/22402321/ <a href="https://pubmed.ncbi.nlm.nih.gov/22402321/">Aloia AL, et al. A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.</a> 147163285 Rein, Alan NIH - NCI Leidos Rein, Alan (Leidos) 1 147163286 Aloia, Amanda (Declined Royalty) NIH - NCI Aloia, Amanda (Declined Royalty) 2 147163285 Rein, Alan NIH - NCI Leidos Rein, Alan (Leidos) 1 147163286 Aloia, Amanda (Declined Royalty) NIH - NCI Aloia, Amanda (Declined Royalty) 2 147158032 Reporter For Detection And Quantitation Of Replication-Competent Gammaretrovirus E-125-2020-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus&body=Please send me information about technology [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus&body=Please send me information about technology [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147171916 Cell line 147171917 Gammaretrovirus 147171919 Gaussia Luciferase 147171920 GENE THERAPY 147171921 PLASMID 147171923 RCR 147171925 Rein 147171927 Replication-Competent Retrovirus 147171929 Vector Preparation TAB-4323 147157614 Mouse Embryo Culture Chamber and Imaging System and Methods of Use NEI Collaboration, Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology, Reproductive Health Collaboration Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Reproductive Health Vijay Kumar Kalaskar <h2>Description of Technology:</h2> <p>The culture of mouse embryos <em>ex utero</em> and continuous monitoring and imaging of embryos as they develop have applications in drug testing, genetic studies, and basic research on embryonic development. However, the embryo culture systems currently available for post-implantation embryos include rolling bottle culture systems, which do not permit imaging of the developing embryos and do not support the long-term survival and development of embryos <em>ex utero</em>. Current culture systems for pre-implantation stage embryos, including microfluidic culture systems, are suitable for short-term culture of very early stage embryos &ndash; such as fertilized zygotes. However, they are not suitable for the culture and survival of post-implantation stage embryos. Similarly, the cell culture systems currently available (e.g., slides, multi-well plates, and microfluidic chambers) may allow for imaging of single-dimensional structures such as cells, but cannot be used for culturing or imaging three-dimensional structures such as embryos. Therefore, there is a need for a system that provides long-term embryo culturing combined with imaging. Such a system could support long-term culture while allowing for continuous imaging of the developing embryos.</p> <p>Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, an embryo culturing and imaging system, and a method of culturing and imaging an embryo. The chamber allows for the continuous imaging of the embryo for the culture period. This invention is available for licensing and co-development.</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-042-2020_mouse_embryo_culture_imaging_multi-chamber_system2.png" style="height:450px; width:800px" /></p> <p><strong>Figure: Mouse embryo culture imaging multi-chamber system</strong>. The multi-chamber mouse embryo culture imaging system consists of multiple embryo culture chambers connected to a common medium and gas (95% O<sub>2</sub>/5% CO<sub>2</sub>) source. Culture medium (and serum/blood) flows through the peristaltic pump into the culture chamber (blood/serum flows through internal sub-chamber) submerging the embryos and passes through the outlets to recirculate. Gas flow through the chambers can be monitored as it passes through the water trap and adjusted by a flow meter. The inlet shows enlarged view of the culture chamber with a microscope objective lens for imaging and a removable chamber lid. Mouse embryos are cultured on specialized platform with pores and elevations to provide minimal contact with the surface and allow free flow of medium in all directions. The serum/blood flowing through the internal sub-chamber baths the mouse placenta/yolk sac simulating placental blood supply.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Drug screening for teratogenic and developmental effects with temporal and spatial evaluation on different organ systems during embryonic growth</li> <li>Substituting cell-culture and organoid based culture systems as direct testing or studies on mammalian embryos (e.g., mouse embryos)</li> <li>Genetic screening for developmental defects with direct visualization of the embryonic development&nbsp;</li> <li>Drug development and evaluation of molecules regardless of whether they cross the placental barrier</li> <li>Visualization of the developing organ systems and tissues at the embryonic level</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The internal sub-chamber simulates placental blood supply through which blood/serum can be supplied to developing embryos</li> <li>The unique design of the stage/platform on which the embryo rests enables maximum exposure of the body surface area to the circulating medium and oxygen permits appropriate development and survival of the embryos long-term</li> <li>The embryo culture chamber enables continuous imaging of developing embryos during culture</li> <li>Development of specific organ systems, such as eye, lungs, heart, liver, etc., can be monitored and imaged</li> <li>Temporal and spatial distribution of pharmacological molecules (e.g., molecules/proteins tagged with fluorescent markers) in different organ systems and their effect on a specific organ or whole-body development can be monitored and studied</li> <li>The blood/serum supply through the internal sub-chamber simulates placental blood supply and can be used to treat embryos with specific drugs/molecules while the litter mates serve as controls for studying the effect of specific molecules on organ system development</li> <li>Long-term or complete ex utero development of post-implantation stage embryos provides access to developing mammalian embryos for pharmacological manipulation and research studies</li> </ul> 2020-06-30 2026-04-24 2020-06-30 2026-04-24 2020-06-30 Culture Chamber, Embryo Development, Embryonic, FETAL, GENE THERAPY, IMAGING, In Vitro Drug Toxicology, Kalaskar, National Eye Institute, NEI, Organ System Therapy False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164308 Kalaskar, Vijay Kumar NIH - NEI NEI Kalaskar, Vijay Kumar (NEI) 1 147164308 Kalaskar, Vijay Kumar NIH - NEI NEI Kalaskar, Vijay Kumar (NEI) 1 147157849 Mouse Embryo Culture Imaging Chamber E-042-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use&body=Please send me information about technology [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use&body=Please send me information about technology [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160949 E-042-2020-0 E-042-2020-0-US-01 MOUSE EMBRYO CULTURE IMAGING CHAMBER AND METHODS THEREOF PRV US 62/968,474 Abandoned US <br />Provisional (PRV) 62/968,474<br />Filed on 2020-01-31<br />Status: Abandoned 147170091 Culture Chamber 147170093 Embryo Development 147170094 Embryonic 147170095 FETAL 147170096 GENE THERAPY 147170097 IMAGING 147170099 In Vitro Drug Toxicology 147170101 Kalaskar 147170103 National Eye Institute 147170104 NEI 147170106 Organ System Therapy TAB-4352 147157645 Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Luca Gattinoni, Dalton Hermans, Warren Leonard, Leonard Neckers <h2>Description of Technology:</h2> <p>Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual&#39;s adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells. Altering metabolic pathways is one way to affect the actions of T cells, and different cellular subtypes vary in how they produce and expend energy. T cell metabolism can be altered by several factors, including cytokine stimulation and by inhibiting lactate dehydrogenase (LDH), which mediates the final step in glycolytic metabolic pathway.</p> <p>Researchers at the National Cancer Institute (NCI) and the National Heart Lung and Blood Institute (NHLBI) have discovered that preconditioning T cells with LDH inhibitors during in vitro culture with cytokines improves efficacy of these cells once adoptively transferred to a mouse model of melanoma. This was accomplished by investigating the role of metabolic programming in the developmental differences induced by interleukin-21 (IL-21), a cytokine with known antitumor activity. IL-21 alone promoted stem cell memory T cells (TSCM) expansion, and this was enhanced when combined with an LDH inhibitor. This resulted in a more profound antitumor responses and prolonged host survival. Studies revealed that inhibition of LDH activity prior to adoptive transfer of CD8+ T cells promoted maintainence of the cells in a more T stem-cell like state. Combining IL-21 with the LDH inhibitor also prevented the induction of several immune checkpoints/exhaustion molecules known to limit in vivo antitumor responses &ndash; including PD-1, TIM-3, LAG3 and 2B4. Results are similar for LDH inhibition of human and murine CD8+ T cells in vitro, underscoring the potential therapeutic benefits of preconditioning with LDH inhibition before ACTimmunotherapy.&nbsp;&nbsp;</p> <p>The NCI seeks research co-development partners and/or licensees for clinical evaluation of this invention.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A strategy to improve ACT immunotherapies to treat and/or prevent the recurrence of a variety of human cancers</li> <li>Use of this preconditioning method in a variety of ACT therapies, including TIL, TCR, and CAR therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved host survival in a murine model, suggesting treatment benefit in human trials&nbsp;</li> <li>A mechanism for enhancing robustness of adoptive T cells</li> </ul> 2020-06-25 2026-04-24 2020-06-25 2026-04-24 2020-06-25 act, Adoptive T Cell Therapy, CAR T Cells, CD8+ T Cells, Gattinoni, Interleukin-21, Lactate Dehydrogenase Inhibitor, LDH, Neckers, Preconditioning, TCR-engineered T Cells, TILS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-190-2016 E-244-2014 147161882 Hermans A, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. https://pubmed.ncbi.nlm.nih.gov/32123114/ <a href="https://pubmed.ncbi.nlm.nih.gov/32123114/">Hermans A, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity.</a> 147164420 Leonard, Warren NIH - NHLBI NHLBI Leonard, Warren (NHLBI) 1 147164421 Hermans, Dalton NIH - NHLBI NHLBI Hermans, Dalton (NHLBI) 2 147164422 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147164419 Neckers, Leonard NIH - NCI NCI Neckers, Leonard (NCI) 4 147164420 Leonard, Warren NIH - NHLBI NHLBI Leonard, Warren (NHLBI) 1 147164421 Hermans, Dalton NIH - NHLBI NHLBI Hermans, Dalton (NHLBI) 2 147164422 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147164419 Neckers, Leonard NIH - NCI NCI Neckers, Leonard (NCI) 4 147158034 Inhibition Of T Cell Lactate Dehydrogenase (LDH) Ex Vivo Promotes Enhanced Anti-tumor Efficacy In A Model Of Adoptive Cell Therapy E-126-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy&body=Please send me information about technology [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy&body=Please send me information about technology [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161074 E-126-2019-0 E-126-2019-0-US-01 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PRV US 62/883,927 Abandoned US <br />Provisional (PRV) 62/883,927<br />Filed on 2019-08-07<br />Status: Abandoned 147168390 E-126-2019-0 E-126-2019-0-PCT-02 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PCT Patent Cooperation Treaty PCT/US2020/045100 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/045100<br />Filed on 2020-08-06<br />Status: Expired 147168391 E-126-2019-0 E-126-2019-0-US-03 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY National Stage US 12,558,424 17/633,414 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12558424 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12558424">12,558,424</a><br />Filed on 2022-02-07<br />Status: Issued 147171947 act 147171949 Adoptive T Cell Therapy 147171951 CAR T Cells 147171953 CD8+ T Cells 147171954 Gattinoni 147171955 Interleukin-21 147171957 Lactate Dehydrogenase Inhibitor 147171958 LDH 147171960 Neckers 147171962 Preconditioning 147171964 TCR-engineered T Cells 147171965 TILS TAB-4275 147157563 Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yang Feng, Steven Seaman, Brad St. Croix <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors.</p> <h2>Description of Technology:</h2> <p>Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of normal, healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to selectively target pathological angiogenesis without impacting physiological angiogenesis. In fact, CD276-directed therapeutic antibodies may have a higher degree of specificity for tumor vessels than current antiangiogenic agents that cannot distinguish physiological and pathological angiogenesis. Moreover, CD276 protein is also frequently overexpressed on tumor cells. The ability to target the vasculature as well as tumor cells directly makes CD276 a potentially ideal dual-compartment therapeutic target.</p> <p>Researchers at the National Cancer Institute (NCI) have created a potent antibody-drug conjugate (ADC) with an improved therapeutic index that selectively reacts with a broad variety of tumor types.&nbsp; The lead ADC, m276-PBD-SL, targets CD276 for the treatment of cancer. The m276 antibody used to develop this ADC is fully-human and recognizes mouse, non-human primate, and human CD276 with similar affinity &ndash; unlike all other CD276 antibodies described to date. This ADC contains mutations to prevent inappropriate interaction of the ADC with endogenous immunoglobulin receptors present on cells of the immune system. These mutations prevent the potentially harmful killing of normal cells and minimize off-target toxicity. The ADC also contains a mutation which allows site-directed conjugation of the payload to the antibody. Payload attachment at this specific site prevents the premature release of the warhead from the antibody, increasing the stability of the ADC in the circulation and preventing non-specific toxicity. This ADC is the only one that combines all these critical features with a potent optimized warhead and an optimally targeted pan anti-cancer fully-human antibody against CD276. These advantages can be leveraged to facilitate preclinical ADC studies and may be a better reflection of what a human clinical response would be, may facilitate GMP scale-up, may facilitate preclinical testing in multiple species using the same clinical-grade product, and may facilitate earlier toxicity assessments due to the multiple cross-species reactivity of the fully-human CD276 antibody.&nbsp; &nbsp; &nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for various solid cancer including, but not limited to, lung, breast, colon, endometrial, renal, and ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Simultaneously targets both tumor cells and tumor vasculature</li> <li>Potentially superior adverse events mitigation over existing anti-angiogenic agents due to the differential expression of CD276 on tumor versus normal vasculature</li> <li>Fully human antibodies are less likely to be recognized and cleared by the immune system upon repeated administration&nbsp; &nbsp;</li> <li>Cross-reactive with mouse, rat, and monkey CD276 making preclinical studies easier and more informative</li> <li>Antibody mutations block inappropriate killing of Fc-receptor-bearing normal cells to minimize off-target toxicity</li> <li>The mutation in the Fc domain creates a superior site-directed conjugation attachment site for the drug payload to the warhead by increasing solubility of the ADC and preventing premature shedding of the drug in serum</li> </ul> 2020-06-17 2026-04-24 2021-06-10 2026-04-24 2020-06-17 ADC, antibody drug conjugate, B7-H3, CD276, Immunotherapy, Monoclonal Antibody, St. Croix False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-104-2013 E-250-2014 147164128 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147164129 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147164130 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 3 147164128 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147164129 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147164130 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 3 147158076 Development Of Next Generation ADCs Against CD276 E-145-2019-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276&body=Please send me information about technology [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276&body=Please send me information about technology [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161104 E-145-2019-0 E-145-2019-0-US-01 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF PRV US 62/947,135 Abandoned US <br />Provisional (PRV) 62/947,135<br />Filed on 2019-12-12<br />Status: Abandoned 147167816 E-145-2019-0 E-145-2019-0-PCT-02 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/063732 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/063732<br />Filed on 2020-12-08<br />Status: Expired 147167817 E-145-2019-0 E-145-2019-0-AU-03 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Australia 2020402752 Pending Australia <br />National Stage 2020402752<br />Filed on 2020-12-08<br />Status: Pending 147167818 E-145-2019-0 E-145-2019-0-CA-04 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Canada 3161573 Pending Canada <br />National Stage 3161573<br />Filed on 2020-12-08<br />Status: Pending 147167819 E-145-2019-0 E-145-2019-0-EP-05 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage European Patent 20834060.4 Pending European Patent <br />National Stage 20834060.4<br />Filed on 2020-12-08<br />Status: Pending 147167820 E-145-2019-0 E-145-2019-0-JP-06 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Japan 7679380 2022-535127 Issued Japan <br />National Stage 2022-535127<br />Filed on 2020-12-08<br />Status: Issued 147167821 E-145-2019-0 E-145-2019-0-US-07 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage US 17/783,171 Pending US <br />National Stage 17/783,171<br />Filed on 2022-06-07<br />Status: Pending 147172319 ADC 147172320 antibody drug conjugate 147172321 B7-H3 147172322 CD276 147172323 Immunotherapy 147172324 Monoclonal Antibody 147172325 St. Croix TAB-4186 147157471 Mitotic Figures Electronic Counting Application for Surgical Pathology NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Stephen Hewitt, Munish Puri, Robert Simpson <h2>Summary:</h2> <p>The National Cancer Institute (NCI) Laboratory of Cancer Biology and Genetics is seeking parties interested in licensing and /or co-development research collaboration of a software application for commercialization in quantitative and digital pathology fields.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Cancer diagnosis depends on the assessment of patient biopsies to determine tumor type, grading, and stage of malignancy. Pathologists visually review specimens and count mitotic figures (MF) in a variety of cancer types to help gauge aggressiveness, guide treatment, and inform patient prognosis. Current technology for recording MF counts in surgical pathology is lacking in objectivity, and enumeration of MF by microscopy can be error prone. In particular, a lack of systematic means for recording contributes to recognized variability. Cell counting instruments have been employed in the field as an attempt to address these issues. However, these instruments were not designed to assess the mitotic activity index for tumor grading, and they do not record MF microscopy field-of-view by field-of-view, do not function to sum the counts, and do not export data for inclusion in a pathology report.</p> <p>This discovery provides a software application for the electronic recording, summation, and transcription of clinical data obtained during surgical pathology examination of patient tissues. This invention will enable standardization across diagnostic centers which will permit harmonization of MF counting by electronic means. Through standardization enabled by the application, interobserver variance in MF counting can be reduced and transcription errors eliminated, enhancing the accuracy of mitotic index generation that will improve patient care.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Quantitative Pathology&nbsp;</li> <li>Digital Pathology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Systematic recordings of observation</li> <li>Objective counts</li> <li>Standard protocol for recording mitotic counts</li> <li>Graphical User Interface in MATLAB</li> </ul> 2020-06-17 2026-04-24 2020-06-17 2026-04-24 2020-06-17 cell proliferation, COUNTING, ELECTRONIC, MATLAB, Matrix Laboratory, MF, MICROSCOPY, Mitotic Figures, PATHOLOGY, Simpson, SURGICAL False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-038-2019 147162267 Wei BR, et al. Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis. https://pubmed.ncbi.nlm.nih.gov/31321298/ <a href="https://pubmed.ncbi.nlm.nih.gov/31321298/">Wei BR, et al. Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis.</a> 147163824 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163823 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 2 147163822 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 3 147163824 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163823 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 2 147163822 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 3 147157983 Electronic Counting Application For Surgical Pathology E-097-2019-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology&body=Please send me information about technology [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology&body=Please send me information about technology [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147171373 cell proliferation 147171374 COUNTING 147171375 ELECTRONIC 147171376 MATLAB 147171378 Matrix Laboratory 147171379 MF 147171380 MICROSCOPY 147171382 Mitotic Figures 147171383 PATHOLOGY 147171384 Simpson 147171385 SURGICAL TAB-4108 147157390 Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Stephen Hewitt, Shelley Hoover, Munish Puri, Robert Simpson <h2>Summary:</h2> <p>The National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow" target="_blank">Laboratories of Pathology</a> and <a href="https://ccr.cancer.gov/Laboratory-of-Cancer-Biology-and-Genetics" rel="nofollow" target="_blank">Cancer Biology and Genetics</a> are seeking parties interested in licensing and/or partnering in co-development research of a software tool for commercialization in the field of clinical immunohistochemistry quantification.</p> <h2>Description of Technology:</h2> <p>Cancer diagnosis is based on the assessment of patient biopsies to determine the tumor type, grade, and stage of malignancy. The proliferative potential of tumors correlates to their growth and metastasis. Visually identifying and quantifying mitotic figures (MF) in cancer biopsy tissue can be used as a surrogate for proliferative activity in tumors. The manual examination and quantification of stained tissue sections to determine tumor areas with the greatest number of MF, known as mitotic hotspots (HS), is subjective because the current method of assessment is based on the skill of the examining pathologist. In addition, the method used to determine HS is tedious, time-consuming, and error prone due to inter- and intra-observer variability. A newly developed technology addresses the issue of standardizing the assessment of tumor cell proliferation, yielding a diagnostic tool improves medical decision making and diagnostic precision.</p> <p>This software tool identifies all tumor cell proliferating areas, maps foci in relation to the tumor tissue, and quantifies the proliferating cells for grading purposes. It provides MF metrics as a surrogate for tumor proliferative activity while also providing topographic information on HS locations. This new technology is a major improvement over current methods that use visual inspection and counting, which can result in the inclusion of erroneous findings during cancer grading. The software uses a computational approach by processing digital whole slide images (WSI) to render image grid tiles to extract immunolabeled MF and map the HS&rsquo;s topographically to the tissue section of the WSI. This technology has demonstrated highly reproducibility unaffected by diagnostic skill level or work-fatigue. The automated approach represents a technology that requires minimal computational operations on image tile-based processing &ndash; while providing low complexity and enhancements in determining HS.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Clinical immunohistochemistry quantification for improved cancer diagnosis</li> <li>Analytic software for improved cancer diagnosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Computation approach to process whole slide images</li> <li>High reproducibility, unaffected by diagnostic skill level or fatigue</li> <li>Low complexity and enhancements in determining mitotic hotspots</li> </ul> 2020-06-17 2026-04-24 2020-06-17 2026-04-24 2020-06-17 Cancer Biopsy, diagnostic, Hewitt, HS, IHC, Immunohistochemistry, MF, Mitotic Figure, Mitotic Hotspots, Simpson, Tissue Histopathology False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-097-2019 147161947 Puri M, et al. Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support. https://pubmed.ncbi.nlm.nih.gov/30915258/ <a href="https://pubmed.ncbi.nlm.nih.gov/30915258/">Puri M, et al. Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support.</a> 147163537 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163535 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 2 147163538 Hoover, Shelley NCI - CCR NCI Hoover, Shelley (NCI) 3 147163536 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 4 147163537 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163535 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 2 147163538 Hoover, Shelley NCI - CCR NCI Hoover, Shelley (NCI) 3 147163536 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 4 147157839 Automated Cancer Diagnostic Tool For Detecting, Quantifying And Mapping Mitotically-active Proliferative Cells In Tumor Tissue Histopathology Whole-slide Images E-038-2019-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images&body=Please send me information about technology [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images&body=Please send me information about technology [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147169983 Cancer Biopsy 147169984 diagnostic 147169986 Hewitt 147169988 HS 147169989 IHC 147169990 Immunohistochemistry 147169992 MF 147169994 Mitotic Figure 147169996 Mitotic Hotspots 147169998 Simpson 147170000 Tissue Histopathology TAB-4413 147157708 Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers NCI Collaboration, Licensing, Neurology, Oncology, Therapeutics Collaboration Licensing Neurology Oncology Therapeutics Robert Hawley, Javed Khan, Megan Peach, Girma Woldemichael <h2>Description of Technology:</h2> <p>Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and makes up 3% of all childhood cancers. Aveloar Rhabdomyosarcoma is the most aggressive subtype and is primarily established through a chromosomal translocation resulting in the fusion protein PAX3-FOXO1. Despite aggressive therapy, the 5-year survival rate for patients with high risk or recurrent Fusion Positive RMS (FP-RMS) is low (~30% and ~17%, respectively). Therefore, new therapies targeting the PAX3-FOXO1 oncogenic driver are urgently needed.&nbsp;&nbsp;</p> <p>To identify inhibitors of PAX3-FOXO1, scientists at the National Cancer Institute (NCI) developed a novel cell-based reporter assay of PAX3-FOXO1 activity. Using this system NCI scientists screened a 62,643 small molecule chemical library and found compounds with unknown function that disrupt PAX3-FOXO1 activity. Further studies of these compounds showed that they were inhibitors of histone lysine demethylases (KDMs), with enhanced selectivity for KDM3B. Treatment of RMS cell lines with these compounds resulted in cytotoxicity and apoptosis, highlighting their potential as therapeutics for RMS. These compounds were also found to be cytotoxic to other sarcoma cell lines, such as Ewing&rsquo;s sarcoma and osteosarcoma. Screening of the NCI-60 cancer cell panel with one of these compounds resulted in growth inhibition of a range of cancer cell types, including leukemias, CNS cancers, melanoma, prostate cancer, colon cancer, ovarian cancers, breast cancers, and renal caners. In the case of renal cancer, treatment resulted in growth inhibition followed by cell death. Thus, these compounds may be effective therapeutics for a variety of cancers outside of RMS.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for Rhabdomyosarcoma and other cancers &ndash; including, but perhaps not limited to: <ul> <li>breast cancer</li> <li>melanoma</li> <li>leukemias</li> <li>prostate cancer</li> <li>colon cancer</li> <li>renal cancer</li> </ul> </li> <li>Therapeutic for diseases involving aberrant histone lysine methylation, such as neurodevelopmental disorders&nbsp;&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First-in-class inhibitors of the histone lysine demethylase KDM3B</li> <li>The ability of the compounds to target multiple histone demethylases (KDMs) has two main advantages: 1) may upregulate myogenesis and apoptosis, while at the same time downregulating PAX3-FOXO1 oncogenic targets, and 2) may reduce the frequency of acquired drug resistance resulting from the acquisition of mutations in a single therapeutic KDM target&nbsp;&nbsp;</li> </ul> 2020-06-08 2026-04-24 2022-05-11 2026-04-24 2020-06-08 Histone Lysine Demethylases, KDM3B, KDM3B inhibitors, KDMs, Khan, Lysine Demethylase 3B, PAX3-FOXO1, Rhabdomyosarcoma, RMS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-05-11 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164652 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147164653 Hawley, Robert NIH - NCI Hawley, Robert 2 147164654 Peach, Megan NIH - NCI Leidos Peach, Megan (Leidos) 3 147164655 Woldemichael, Girma NIH - NCI Leidos Woldemichael, Girma (Leidos) 4 147164652 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147164653 Hawley, Robert NIH - NCI Hawley, Robert 2 147164654 Peach, Megan NIH - NCI Leidos Peach, Megan (Leidos) 3 147164655 Woldemichael, Girma NIH - NCI Leidos Woldemichael, Girma (Leidos) 4 147157810 Identification Of A Novel Inhibitor Of The Jumonji Family Of Histone Lysine Demethylases That Disrupts The PAX3-FOXO1 Oncogenic Circuitry In Alveolar Rhabdomyosarcoma E-023-2019-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers&body=Please send me information about technology [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers&body=Please send me information about technology [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147160918 E-023-2019-0 E-023-2019-0-US-01 INHIBITORS OF HISTONE DEMETHYLASES PRV US 62/936,722 Abandoned US <br />Provisional (PRV) 62/936,722<br />Filed on 2019-11-18<br />Status: Abandoned 147168776 E-023-2019-0 E-023-2019-0-PCT-02 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS PCT Patent Cooperation Treaty PCT/US2020/060955 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/060955<br />Filed on 2020-11-18<br />Status: Expired 147168777 E-023-2019-0 E-023-2019-0-CA-03 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage Canada 3158557 Pending Canada <br />National Stage 3158557<br />Filed on 2022-05-16<br />Status: Pending 147168778 E-023-2019-0 E-023-2019-0-EP-04 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage European Patent 4061366 20824760.1 Issued European Patent <br />National Stage 20824760.1<br />Filed on 2022-06-17<br />Status: Issued 147168779 E-023-2019-0 E-023-2019-0-US-05 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage US 17/777,552 Pending US <br />National Stage 17/777,552<br />Filed on 2022-05-17<br />Status: Pending 147169672 Histone Lysine Demethylases 147169674 KDM3B 147169676 KDM3B inhibitors 147169678 KDMs 147169680 Khan 147169682 Lysine Demethylase 3B 147169683 PAX3-FOXO1 147169684 Rhabdomyosarcoma 147169686 RMS TAB-4260 147157547 Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bruce Shapiro, Paul Zakrevsky <h2>Summary:</h2> <p>The NCI is looking for innovative companies interested in co-developing and/or licensing a&nbsp;novel nucleic-based therapy based on the conditional activation strategy.</p> <h2>Description of Technology:</h2> <p>Gene therapy research has yielded FDA-approved treatments for an array of diseases. However, challenges facing nucleic-acid based therapeutics include non-specific delivery and degradation of the nanoparticles. NCI investigators have developed a solution to address these challenges in their novel nucleic-based therapy based on the conditional activation strategy.&nbsp;</p> <p>The inducible activation nucleic acid hybrid switch overcomes the drawbacks of current technologies through its unique design. The implementation of nucleic acid logic elements in these constructs circumvents off-target effects. The functional oligonucleotide constructs would only be generated and activated in environments denoted by the presence or absence of a specific cognate RNA trigger, ensuring context-sensitive function. The systems were also optimized to be resistant to nuclease degradation yet inexpensive for commercial production. Furthermore, this collection of logic-based systems can accommodate different trigger/target sequence pairs, enhancing its diversity of application, and serves as a novel paradigm for conditionally regulated therapeutics against cancer, genetic disorders, or infectious diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer</li> <li>Infectious diseases</li> <li>Genetic disorders&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Resistant to nuclease degradation</li> <li>Specificity of action based on environmental context, minimizing off-target effects</li> <li>Amenable to alterations to accommodate different trigger/target sequence pairs without the need for sequence overlap or similarities&nbsp;</li> <li>A set of context sensitive drugs that separate diagnosis (disease state &ndash; e.g. over or under expression of particular genes) from the therapeutic state (targeting specific genes &ndash; e.g. Dicer substrate RNAs that induce apoptosis)</li> </ul> 2020-05-01 2026-04-24 2021-04-06 2026-04-24 2020-05-01 Conditional Activation, Functional RNA, Gene silencing, In Silico Design, Nanoparticle, Nucleic Acid Therapeutic, RNA, RNA Logic, Shapiro False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2012 E-059-2009 E-075-2018 E-078-2016 E-156-2014 E-277-2016 E-765-2013 147162029 Zakrevsky P, et al. A Suite of Therapeutically-Inspired Nucleic Acid Logic Systems for Conditional Generation of Single-Stranded and Double-Stranded Oligonucleotides. https://www.ncbi.nlm.nih.gov/pubmed/30991728 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30991728">Zakrevsky P, et al. A Suite of Therapeutically-Inspired Nucleic Acid Logic Systems for Conditional Generation of Single-Stranded and Double-Stranded Oligonucleotides.</a> 147164086 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147164087 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147164086 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147164087 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147157911 Inducible Activation Nucleic Acid Hybrid Switch E-065-2019-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides&body=Please send me information about technology [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides&body=Please send me information about technology [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147160986 E-065-2019-0 E-065-2019-0-US-01 HYBRID NUCLEIC ACID SWITCHES PRV US 62/832,171 Abandoned US <br />Provisional (PRV) 62/832,171<br />Filed on 2019-04-10<br />Status: Abandoned 147167725 E-065-2019-0 E-065-2019-0-PCT-02 HYBRID NUCLEIC ACID SWITCHES PCT Patent Cooperation Treaty PCT/US2020/027637 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/027637<br />Filed on 2020-04-10<br />Status: Expired 147167726 E-065-2019-0 E-065-2019-0-US-03 HYBRID NUCLEIC ACID SWITCHES National Stage US 17/602,204 Pending US <br />National Stage 17/602,204<br />Filed on 2021-10-07<br />Status: Pending 147170647 Conditional Activation 147170649 Functional RNA 147170650 Gene silencing 147170652 In Silico Design 147170653 Nanoparticle 147170655 Nucleic Acid Therapeutic 147170656 RNA 147170658 RNA Logic 147170660 Shapiro TAB-4349 147157642 Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Research Materials Collaboration Ear Nose & Throat Licensing Ophthalmology Research Materials Yu Holly Chen, Milton English, Hiroko Shimada-Ishii, Anand Swaroop <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.</p> <h2>Description of Technology:</h2> <p>Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent stem cells (iPS) cells were derived from patients with LCA and unaffected relatives.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Screening for agents to treat patients with CEP290-associated ciliopathies such as retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Extensive characterization, including use in making 3-D retinal organoids and optic cup organoids</li> <li>Complement studies with model organisms and examine retinal dystrophies relevant to humans</li> </ul> 2020-04-30 2026-04-24 2020-04-30 2026-04-24 2020-04-30 Anosmia, Cell therapy, Ciliopathies, Congenital Blindness, Drug Development, GENE THERAPY, hearing loss, iPS, National Eye Institute, NEI, Pluripotent Stem Cells, Primary Cilia, Retina, Retinal degeneration, Swaroop, VISION False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-164-2014 147162306 Shimada H, el al. In vitro modeling using ciliopathy patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations https://www.ncbi.nlm.nih.gov/pubmed/28700940 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28700940">Shimada H, el al. In vitro modeling using ciliopathy patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations</a> 147164412 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164414 Shimada-Ishii, Hiroko NIH - NEI Shimada-Ishii, Hiroko 2 147164413 Chen, Yu Holly NIH - NEI NEI Chen, Yu Holly (NEI) 3 147164415 English, Milton NIH - NEI NHGRI English, Milton (NHGRI) 4 147164412 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164414 Shimada-Ishii, Hiroko NIH - NEI Shimada-Ishii, Hiroko 2 147164413 Chen, Yu Holly NIH - NEI NEI Chen, Yu Holly (NEI) 3 147164415 English, Milton NIH - NEI NHGRI English, Milton (NHGRI) 4 147157988 Induced Pluripotent Stem Cells Derived From Patients With CEP290-associated Ciliopathies For Disease Modeling And Development And Relatives Of The Patients E-100-2020-0 Closed National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members&body=Please send me information about technology [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members&body=Please send me information about technology [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147171432 Anosmia 147171433 Cell therapy 147171434 Ciliopathies 147171436 Congenital Blindness 147171437 Drug Development 147171438 GENE THERAPY 147171439 hearing loss 147171440 iPS 147171441 National Eye Institute 147171442 NEI 147171444 Pluripotent Stem Cells 147171446 Primary Cilia 147171447 Retina 147171448 Retinal degeneration 147171449 Swaroop 147171450 VISION TAB-5098 166964729 Neutralizing Monoclonal Antibodies Against West Nile Virus NIAID Antibodies, Application, Diagnostics, ResearchProducts, TherapeuticArea, Virus/Bacteria Antibodies Application Diagnostics ResearchProducts TherapeuticArea Virus/Bacteria Katherine Burgomaster, Ananda Chowdhury, Parker Dabbs, Daniel Douek, Kimberly Dowd, David Gordon, Dror Harats, Yaniv Lustig, Yael Ottolenghi, Theodore Pierson, Chaim Schramm, Leonid Serebryannyy, Sarah Smith (Kerscher), Laura Vanblargan, Lu Wang, Yuxiang Wang <p>&nbsp; &nbsp; &nbsp; &nbsp;West Nile virus (WNV) is a mosquito-borne flavivirus that can cause fever and, in some cases, severe neurologic disease. There is no approved human vaccine or specific antiviral treatment for WNV.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Researchers at NIAID&#39;s Vaccine Research Center (VRC), working with collaborators at Sheba Medical Center under the PREMISE program, identified five new human monoclonal antibodies that potently neutralize WNV. These antibodies bind the viral envelope (E) protein, with data indicating recognition of E dimers or quaternary epitopes on the virion.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The invention includes compositions comprising the antibodies alone or in combination, nucleic acids encoding them, vectors and host cells for production, and methods for preventing, treating, or detecting WNV infection. The antibodies may be formulated for therapeutic administration, including emergency-use settings, and may also support diagnostic and research applications.</p> <ul> <li> Shown to strongly neutralize WNV at low concentrations in laboratory cell-based studies </li> <li> Novel antibodies with distinct molecular features not previously reported in scientific literature </li> <li> Human monoclonal antibodies targeting E dimer or quaternary epitopes on the WNV virion </li> <li> Potential applications in WNV treatment, diagnostics, and surveillance </li> <li> Collaboration may help speed development to support WNV outbreak response </li> </ul> <ul> <li> Prevention or treatment antibodies for WNV, including use alone or in combination </li> <li> Antibodies that strongly target the WNV E protein </li> <li> Potential treatments for WNV outbreak response and prevention in high-risk populations </li> <li> Genetic and cell-engineering tools for antibody production and product development </li> <li> Antibodies for WNV detection, surveillance, and research tests </li> <li> Potential intravenous treatments for patients with WNV </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128, or bbailey@mail.nih.gov. 2026-04-23 2026-04-24 2026-04-24 2026-04-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-021-2026-0 166964944 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 166964948 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 2 166964953 Chowdhury, Ananda NIAID - VRC Chowdhury, Ananda 3 166964965 Dabbs, Parker NIAID - VRC Dabbs, Parker 4 166965179 Wang, Lu NIAID - VRC Wang, Lu 5 166966485 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 6 166966491 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 7 166966503 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 8 166966531 Vanblargan, Laura National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Vanblargan, Laura (NIAID) 9 166966539 Burgomaster, Katherine NIAID - VRC NIAID Burgomaster, Katherine (NIAID) 10 166966613 Gordon, David National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gordon, David (NIAID) 11 166966628 Wang, Yuxiang NIAID - VRC Wang, Yuxiang 12 166966639 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 13 166966661 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 14 166966666 Harats, Dror Sheba Medical Center Harats, Dror 15 166967476 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 16 166964944 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 166964948 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 2 166964953 Chowdhury, Ananda NIAID - VRC Chowdhury, Ananda 3 166964965 Dabbs, Parker NIAID - VRC Dabbs, Parker 4 166965179 Wang, Lu NIAID - VRC Wang, Lu 5 166966485 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 6 166966491 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 7 166966503 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 8 166966531 Vanblargan, Laura National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Vanblargan, Laura (NIAID) 9 166966539 Burgomaster, Katherine NIAID - VRC NIAID Burgomaster, Katherine (NIAID) 10 166966613 Gordon, David National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gordon, David (NIAID) 11 166966628 Wang, Yuxiang NIAID - VRC Wang, Yuxiang 12 166966639 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 13 166966661 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 14 166966666 Harats, Dror Sheba Medical Center Harats, Dror 15 166967476 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 16 166964734 Neutralizing antibodies against West Nile Virus E-200-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIAID - VRC, NIAID - VRC, Sheba Medical Center, The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus.">bbailey@mail.nih.gov</a><br> 166964739 E-200-2024-0 E-200-2024-0-US-01 WEST NILE VIRUS NEUTRALIZING MONOCLONAL ANTIBODIES PRV US 63/677,612 Expired US <br />Provisional (PRV) 63/677,612<br />Filed on 2024-07-31<br />Status: Expired 166964740 E-200-2024-0 E-200-2024-0-PC-01 WEST NILE VIRUS NEUTRALIZING MONOCLONAL ANTIBODIES PCT Patent Cooperation Treaty PCT/US2025/039922 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/039922<br />Filed on 2025-07-30<br />Status: Pending TAB-3947 147157227 EGFRvIII Antibodies for the Treatment of Human Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Antonella Antignani, David Fitzgerald, Eric Ho, Robert Sarnovsky <h2>Summary:</h2> <p>The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.</p> <h2>Description of Technology:</h2> <p>Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.&nbsp;</p> <p>Inventors from the National Cancer Institute (NCI) have isolated seven mouse monoclonal antibodies that bind to the human EGFRvIII but not wildtype EGFR. These EGFRvIII antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Significantly, RITs using one of the antibodies (40H3) have shown potent killing in breast cancer cells and in epidermoid cancer cells, strongly supporting that the antibodies may be further developed as therapeutics. The 40H3 antibody is also able to bind to EGFR when overexpressed as seen in various cancers, and thus has broad therapeutic potential.&nbsp; &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety in ADCs, RITs, and CARs</li> <li>Diagnostic agent for detection and monitoring levels of EGFRvIII expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The EGFRvIII antibodies with high EGFRvIII binding specificity will result in less non-specific cell killing and lower potential side effects&nbsp;</li> <li>RITs using the 40H3 antibody are available for immediate testing&nbsp;</li> <li>40H3 can also bind EGFR when over-expressed from amplified EGFR, which is specific to various cancers&nbsp;&nbsp;</li> </ul> 2020-04-28 2026-04-24 2021-03-29 2026-04-24 2020-04-28 ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, EGFR, EGFRvIII, Epidermal Growth Factor Receptor, Epidermal growth factor receptor variant III, FitzGerald, Recombinant Immunotoxins, RITs False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-29 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162975 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 147162976 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 147162977 Ho, Eric NIH - NCI NCI Ho, Eric (NCI) 3 147162978 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 4 147162975 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 147162976 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 147162977 Ho, Eric NIH - NCI NCI Ho, Eric (NCI) 3 147162978 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 4 147157993 Monoclonal Antibodies To Cancer-expressed EGFR E-103-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer&body=Please send me information about technology [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer&body=Please send me information about technology [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161043 E-103-2019-0 E-103-2019-0-US-01 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE PRV US 62/869,956 Abandoned US <br />Provisional (PRV) 62/869,956<br />Filed on 2019-07-02<br />Status: Abandoned 147165483 E-103-2019-0 E-103-2019-0-PCT-02 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE PCT Patent Cooperation Treaty PCT/US2020/040544 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/040544<br />Filed on 2020-07-01<br />Status: Expired 147165484 E-103-2019-0 E-103-2019-0-AU-03 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Australia 2020299382 Pending Australia <br />National Stage 2020299382<br />Filed on 2020-07-01<br />Status: Pending 147165485 E-103-2019-0 E-103-2019-0-CA-04 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Canada 3142833 Pending Canada <br />National Stage 3142833<br />Filed on 2020-07-01<br />Status: Pending 147165486 E-103-2019-0 E-103-2019-0-CN-05 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage China ZL202080055447.2 202080055447.2 Issued China <br />National Stage 202080055447.2<br />Filed on 2020-07-01<br />Status: Issued 147165487 E-103-2019-0 E-103-2019-0-EP-06 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage European Patent 20745396.0 Pending European Patent <br />National Stage 20745396.0<br />Filed on 2020-07-01<br />Status: Pending 147165488 E-103-2019-0 E-103-2019-0-US-07 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage US 12,565,532 17/623,370 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12565532 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12565532">12,565,532</a><br />Filed on 2021-12-28<br />Status: Issued 147165489 E-103-2019-0 E-103-2019-0-IL-08 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Israel 289488 Abandoned Israel <br />National Stage 289488<br />Filed on 2020-07-01<br />Status: Abandoned 147165490 E-103-2019-0 E-103-2019-0-IN-09 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage India 202217002368 Pending India <br />National Stage 202217002368<br />Filed on 2020-07-01<br />Status: Pending 147165491 E-103-2019-0 E-103-2019-0-JP-10 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Japan 7815099 2022-500090 Issued Japan <br />National Stage 2022-500090<br />Filed on 2020-07-01<br />Status: Issued 147165492 E-103-2019-0 E-103-2019-0-KR-11 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage South Korea 10-2022-7003667 Abandoned South Korea <br />National Stage 10-2022-7003667<br />Filed on 2020-07-01<br />Status: Abandoned 147165493 E-103-2019-0 E-103-2019-0-MX-12 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Mexico MX/a/2022/000174 Pending Mexico <br />National Stage MX/a/2022/000174<br />Filed on 2020-07-01<br />Status: Pending 147165495 E-103-2019-0 E-103-2019-0-SG-14 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Singapore 11202114486Y Abandoned Singapore <br />National Stage 11202114486Y<br />Filed on 2020-07-01<br />Status: Abandoned 147165496 E-103-2019-0 E-103-2019-0-EA-15 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Eurasian Patent 202290208 Pending Eurasian Patent <br />National Stage 202290208<br />Filed on 2020-07-01<br />Status: Pending 147165497 E-103-2019-0 E-103-2019-0-HK-16 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE CN Hong Kong 62022061195.3 Pending Hong Kong <br />China Patent (CN) 62022061195.3<br />Filed on 2022-09-26<br />Status: Pending 147171479 ADC 147171480 Antibody-drug Conjugate 147171481 CAR 147171482 chimeric antigen receptor 147171483 EGFR 147171484 EGFRvIII 147171485 Epidermal Growth Factor Receptor 147171487 Epidermal growth factor receptor variant III 147171489 FitzGerald 147171490 Recombinant Immunotoxins 147171491 RITs TAB-4375 147157669 Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Caroline Andrews, Julie Hixon, Wenqing Li, Stephen Miller, Joel Schneider, Steven Tau, Scott Walsh, Yuji Yamada <h2>Description of Technology:</h2> <p>Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells. The porosity of the mesh-like network contributes to enhanced protection and controlled release of therapeutics compared with the rapid clearance and degradation of some proteins observed using conventional drug-delivery methods. Although all hydrogel platforms provide spatial and temporal control over the release of therapeutics, the current standard requires designing a unique hydrogel for a select therapeutic agent for a specific application. This one therapeutic agent-one gel model adds significant research and regulatory burden.</p> <p>To address this, researchers at the National Cancer Institute (NCI) developed a novel syringe-injectable/sprayable hydrogel platform that can deliver a variety of different therapeutic agents. This hydrogel can be used to deliver small molecules, peptides, proteins, nucleic acids, nanoparticles, or cells.&nbsp; Further, this hydrogel has been engineered to be compatible with a protein delivery platform invented at the NCI. This tunable combination system enables the release of different kinds of proteins based on the electrostatic interaction between the fusion sequence engineered directly at the amino- or carboxy-terminus of proteins and the anionic fibrillar network of the hydrogel AcVES3. In a proof-of-concept study, NCI researchers have delivered a cytokine protein, IL-7, a therapeutic agent critical for improving T cell development for immunotherapy in cancer, sepsis, and HIV-infected patients. Administration of a single dose of IL-7 encapsulated within AcVES3 was shown to exhibit comparable development of T cell populations compared to soluble IL-7 added every 3 days in vitro and to daily subcutaneous IL-7 injections for greater than 30 days in vivo. Thus, this hydrogel platform can reduce the amount of protein needed to attain desired endpoints and potentially reduce patient burden for targeted therapies.</p> <p>Furthermore, the AcVES3 platform can be used to culture cells in 2D and 3D environments and deliver these cells as potential therapeutic agents. NCI researchers conducted murine studies to culture and deliver fluorescently labeled human dermal fibroblasts encapsulated in AcVES3-RGDV hydrogel at high cellular concentrations. Stem and cancer cells can be also be grown within the 3D AcVES3 hydrogel environment; instead of the commonly used murine-derived Matrigel reagent and subsequently these cells may be injected in vivo, even into larger scale animal models such as non-human primates. These proof-of-concept studies suggest that the AcVES3 platform can be used to encapsulate an appropriate number of cells of interest over time in vivo for therapeutic applications. Overall, the AcVES3 platform is a promising hydrogel system that is applicable for numerous non-clinical and clinical applications.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer &ndash; especially those involving therapeutic whole cells &ndash; such as stem cells, T cells, CAR T cells for cancer therapy and/or fibroblasts</li> <li>Sepsis &ndash; especially when boosting T cell levels is effective</li> <li>HIV</li> <li>Autoimmune disorders &ndash; especially to modulate T cell populations</li> <li>Transplantation</li> <li>Delivering viruses for gene therapy or oncolytic viruses for cancer therapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rate-controlled release of therapeutic drugs including small molecules, nucleic acids, peptides, proteins, or nanoparticles: therapeutic drugs encapsulated in the anionic hydrogel platform&nbsp;</li> <li>Rate-controlled release of therapeutic whole cells: such as stem cells, T cells, CAR T cells for cancer therapy and/or fibroblasts</li> <li>T cell enhancer for in vitro and in clinical setting: stimulating T cells in cultures, essential in adoptive T cell therapy, cancer and HIV-immunotherapy, boosting T cell levels in sepsis patients, and modulating T cell populations in autoimmune diseases</li> <li>Delivers locally or systemically a variety of different therapeutic drugs including small molecule, peptides, proteins, nucleic acids, nanoparticles, or cells</li> <li>Reduces the amount of drugs or cells needed to attain desirable clinical results&nbsp;</li> <li>Reduces the patient burden from multiple injections and travel time to the clinic</li> <li>Offers targeted syringe or catheter injectable delivery or sprayable delivery</li> <li>Is a tunable delivery platform that can attenuate peptide or protein release rate within hydrogel</li> </ul> 2020-04-20 2026-04-24 2020-04-20 2026-04-24 2020-04-20 DEVICE, IL-7, Nanoparticle, Peptide, Peptide-based Hydrogel, Protein, Schneider, small molecule, T Cell Enhancer, Whole Cell Delivery System False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161969 Yamada Y, et al. Design of a peptide-based electronegative hydrogel for the direct encapsulation, 3D culturing, in vivo syringe-based delivery, and long-term tissue engraftment of cells. https://www.ncbi.nlm.nih.gov/pubmed/?term=31448901 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31448901">Yamada Y, et al. Design of a peptide-based electronegative hydrogel for the direct encapsulation, 3D culturing, in vivo syringe-based delivery, and long-term tissue engraftment of cells.</a> 147162356 Miller SE, et al. Electrostatically driven guanidinium interaction domains that control hydrogel-mediated protein delivery in vivo. https://www.ncbi.nlm.nih.gov/pubmed/?term=31807676 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31807676">Miller SE, et al. Electrostatically driven guanidinium interaction domains that control hydrogel-mediated protein delivery in vivo.</a> 147164499 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147164500 Miller, Stephen NIH - NCI NCI Miller, Stephen (NCI) 2 147164501 Yamada, Yuji NIH - NCI NCI Yamada, Yuji (NCI) 3 147164502 Tau, Steven NIH - NCI NCI Tau, Steven (NCI) 4 147164503 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 6 147164504 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 7 147164506 Andrews, Caroline NIH - NCI NCI Andrews, Caroline (NCI) 8 147164505 Walsh, Scott NIH - NCI NCI Walsh, Scott (NCI) 9 147164499 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147164500 Miller, Stephen NIH - NCI NCI Miller, Stephen (NCI) 2 147164501 Yamada, Yuji NIH - NCI NCI Yamada, Yuji (NCI) 3 147164502 Tau, Steven NIH - NCI NCI Tau, Steven (NCI) 4 147164503 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 6 147164504 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 7 147164506 Andrews, Caroline NIH - NCI NCI Andrews, Caroline (NCI) 8 147164505 Walsh, Scott NIH - NCI NCI Walsh, Scott (NCI) 9 147158178 Controlling The Rate Of Protein Release From Peptide Hydrogels Using Engineered Electrostatic Interactions E-188-2017-0 Filing authorized NCI 147162556 Controlling The Rate Of Protein Release From Peptide Hydrogels Using Engineered Electrostatic Interactions E-188-2017-1 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics&body=Please send me information about technology [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics&body=Please send me information about technology [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161170 E-188-2017-1 E-188-2017-1-PCT-01 PEPTIDE HYDROGELS AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2017/066893 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/066893<br />Filed on 2017-12-17<br />Status: Expired 147168524 E-188-2017-1 E-188-2017-1-US-02 PEPTIDE HYDROGELS AND USE THEREOF National Stage US 11,661,439 16/954,492 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11661439 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11661439">11,661,439</a><br />Filed on 2020-06-16<br />Status: Issued 147173348 DEVICE 147173349 IL-7 147173350 Nanoparticle 147173351 Peptide 147173353 Peptide-based Hydrogel 147173354 Protein 147173355 Schneider 147173356 small molecule 147173358 T Cell Enhancer 147173360 Whole Cell Delivery System TAB-4350 147157643 A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Ramiro Iglesias-Bartolome, Yao Yuan <h2>Summary:</h2> <p>The NCI Laboratory of Cellular and Molecular Biology seeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.</p> <h2>Description of Technology:</h2> <p>The Hippo signaling pathway regulates a multitude of biological processes including cell proliferation, apoptosis, differentiation, tissue homeostasis, and stem cell functions. This axis has been recently listed as one of the top 10 signaling pathways altered in human cancer. Its role in modulating cell growth and proliferation is mediated by the activation of Yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding domain (TAZ). Under low cell density conditions, YAP1/TAZ translocate to the nucleus, bind to various transcription factors including TEA domain (TEAD) family of transcription factors, and drive the expression of genes associated with cell proliferation and differentiation. If hyperactivated due to disruptions in the Hippo pathway, this upregulation in gene transcription leads to uncontrolled cell growth, transformation, and cancer development.</p> <p>Research into the Hippo pathway is limited due to technical difficulties in the precise study of the transcriptional networks downstream of YAP1 and TAZ. For example, simultaneous downregulation of YAP1 and TAZ is needed to observe an effect on cancer progression. Furthermore, there are numerous effectors to the Hippo pathway, not limited to transcription factors. To overcome these difficulties, researchers at the National Cancer Institute (NCI) have developed a genetically encoded, fluorescently labeled peptide inhibitor of YAP1/TAZ which specifically targets its interactions with TEADs (named TEAD-inhibitor or TEADi). TEADi consists of various TEAD binding domains, including those of YAP1 and TAZ, modified for efficient inhibition. Using this inhibitor, NCI researchers have studied the functions of the Hippo pathway in the epidermis and in squamous cell carcinoma.&nbsp;NCI is continuing to develop this inhibitor to improve its stability and potency.</p> <p>Considering that the Hippo pathway constitutes one of the top signaling pathways altered in human cancer, disruption of YAP1/TAZ-TEAD complexes has become a main target to suppress oncogenic activity. TEADi can be used to dissect the TEAD-dependent and independent roles of YAP1/TAZ signaling and aid in the discovery of improved targeting strategies for this pathway. In conclusion, TEADi is a valuable research tool for studying YAP1/TAZ and the Hippo pathway in cancer and other pathologies, with improved advantages that include rapid and simple inhibition of TEAD transcription and specific blockage of nuclear events mediated by both YAP1 and TAZ without affecting structural or cytoplasmic functions of these proteins. NCI is continuing to develop this inhibitor to improve its stability and potency.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>TEADi DNA construct to study Hippo signaling pathway in different pathologies and cellular systems.</li> <li>TEADi DNA construct to selectively shut off Hippo signaling pathway for broader research purposes</li> <li>Delivery of TEADi DNA construct using lentivirus, adenovirus (AV), or adeno-associated virus (AAV) for broad research purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid and simple inhibition of specific effectors of a signaling pathway frequently disrupted in cancer</li> <li>Inhibition of both YAP1 and TAZ factors that regulate the Hippo pathway</li> <li>Inhibition of YAP/TAZ interaction with a specific family of transcription factors</li> <li>Green fluorescent protein (GFP) label for easy tracking</li> <li>Nuclear localization signal to target hyperactivated YAP/TAZ</li> </ul> 2020-04-02 2026-04-24 2021-03-10 2026-04-24 2020-04-02 Cancer Progression, Hippo Signaling Pathway, Iglesias-Bartolome, Peptide Inhibitor, TAZ, TEAD, YAP1, Yes-Associated Protein 1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162268 Yuan Y, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity. https://pubmed.ncbi.nlm.nih.gov/32193376/ <a href="https://pubmed.ncbi.nlm.nih.gov/32193376/">Yuan Y, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.</a> 147162421 Yuan Y, et al. YAP1-TAZ/TEAD transcriptional networks restrain differentiation downstream of oncogenic Hedgehog-SMO activity. https://www.biorxiv.org/content/10.1101/2020.12.28.424593v1 <a href="https://www.biorxiv.org/content/10.1101/2020.12.28.424593v1">Yuan Y, et al. YAP1-TAZ/TEAD transcriptional networks restrain differentiation downstream of oncogenic Hedgehog-SMO activity.</a> 147164417 Iglesias-Bartolome, Ramiro NIH - NCI NCI Iglesias-Bartolome, Ramiro (NCI) 1 147164416 Yuan, Yao NIH - NCI Yuan, Yao 2 147164417 Iglesias-Bartolome, Ramiro NIH - NCI NCI Iglesias-Bartolome, Ramiro (NCI) 1 147164416 Yuan, Yao NIH - NCI Yuan, Yao 2 147158004 Peptide Inhibitors Of YAP1/TAZ-TEAD E-108-2019-0 Closed NCI 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer&body=Please send me information about technology [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer&body=Please send me information about technology [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">pragnesh.mistry@nih.gov</a><br> 147171585 Cancer Progression 147171587 Hippo Signaling Pathway 147171589 Iglesias-Bartolome 147171590 Peptide Inhibitor 147171592 TAZ 147171594 TEAD 147171596 YAP1 147171598 Yes-Associated Protein 1 TAB-4157 147157440 T-Cell Therapy Against Patient-Specific Cancer Mutations NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Eric Tran <h2>Description of Technology:</h2> <p>Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.</p> <p>Scientists at the <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow" target="_blank">National Cancer Institute&#39;s Surgery Branch</a> developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encoding all of the mutations expressed by a patient&#39;s tumor, the inventors identified T cells that recognized the immunogenic mutations from the same patient. These mutation-reactive T cells have the potential to eliminate the cancer cells while sparing normal tissues since normal tissues do not express the mutations. The mutation-reactive T cells were expanded <em>in vitro</em>, and then infused as a highly pure population back into the same patient. The patient experienced tumor regression when treated with this approach.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized immunotherapy with mutation-reactive T cells for mediating tumor regression in patients with immunogenic mutations;</li> <li>Mutation-reactive T cell therapy especially beneficial for cancer patients refractory to other therapies;</li> <li>A research tool to identify patient-specific immunogenic mutations in the tumor.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>This patient-specific therapy has the potential application to most epithelial cancers, which account for about 90% of cancer deaths in the United States;</li> <li>Personalized mutation-specific T cells recognize mutations harboring tumor cells only and spare normal tissues. This therapy has no tissue toxicities comparing to traditional chemotherapy and radiotherapy;</li> <li>The infusion of a highly pure population of these mutation-specific T cells may maximize therapy and result in regression of all target lesions.</li> </ul> 2020-02-03 2026-04-24 2020-02-03 2026-04-24 2020-02-03 Cholangiocarcinoma, Immunogenic, Rosenberg, T-cell, Tran False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-02-03 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161972 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/25046408 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25046408">Tran E, et al.</a> 147162359 Robbins P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23644516 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23644516">Robbins P, et al.</a> 147162397 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/24812403 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24812403">Tran E, et al.</a> 162585338 Per discussions with A. Burke Per discussions with A. Burke 147163723 Tran, Eric NIH - NCI Tran, Eric 1 147163724 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163722 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163721 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147163723 Tran, Eric NIH - NCI Tran, Eric 1 147163724 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163722 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163721 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147158242 A Genomics-based Method For Developing Personalized Adoptive Cell Therapies For Cancer By Targeting Tumor-specific Mutations E-229-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147166976 E-229-2014-0 E-229-2014-0-PCT-01 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation PCT Patent Cooperation Treaty PCT/US2014/058805 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/058805<br />Filed on 2014-10-02<br />Status: Expired 147166977 E-229-2014-0 E-229-2014-0-AU-02 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Australia 2014407540 2014407540 Issued Australia <br />National Stage 2014407540<br />Filed on 2014-10-02<br />Status: Issued 147166978 E-229-2014-0 E-229-2014-0-CA-03 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Canada 2963364 Pending Canada <br />National Stage 2963364<br />Filed on 2014-10-02<br />Status: Pending 147166979 E-229-2014-0 E-229-2014-0-CN-04 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage China 201480082922.X Abandoned China <br />National Stage 201480082922.X<br />Filed on 2014-10-02<br />Status: Abandoned 147166980 E-229-2014-0 E-229-2014-0-EP-05 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage European Patent 14790878.4 Abandoned European Patent <br />National Stage 14790878.4<br />Filed on 2014-10-02<br />Status: Abandoned 147166981 E-229-2014-0 E-229-2014-0-JP-06 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Japan 6599450 2017-517677 Issued Japan <br />National Stage 2017-517677<br />Filed on 2014-10-02<br />Status: Issued 147166982 E-229-2014-0 E-229-2014-0-US-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION National Stage US 10,973,894 15/515,055 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10973894 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10973894">10,973,894</a><br />Filed on 2014-10-02<br />Status: Issued 147166983 E-229-2014-0 E-229-2014-0-JP-08 METHODS FOR ISOLATING T CELLS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS DIV Japan 6878544 2019-182421 Issued Japan <br />Divisional (DIV) 2019-182421<br />Filed on 2019-10-02<br />Status: Issued 147166984 E-229-2014-0 E-229-2014-0-EP-09 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation DIV European Patent 20212578.7 Pending European Patent <br />Divisional (DIV) 20212578.7<br />Filed on 2020-12-08<br />Status: Pending 147166985 E-229-2014-0 E-229-2014-0-US-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION CON US 12,171,818 17/195,072 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12171818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12171818">12,171,818</a><br />Filed on 2021-03-08<br />Status: Issued 147166986 E-229-2014-0 E-229-2014-0-AU-11 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation DIV Australia 2021202223 2021202223 Issued Australia <br />Divisional (DIV) 2021202223<br />Filed on 2021-04-13<br />Status: Issued 147166987 E-229-2014-0 E-229-2014-0-JP-12 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR CANCER SPECIFIC MUTATIONS DIV Japan 7096397 2021-076293 Issued Japan <br />Divisional (DIV) 2021-076293<br />Filed on 2021-04-28<br />Status: Issued 147166988 E-229-2014-0 E-229-2014-0-JP-13 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR CANCER SPECIFIC MUTATIONS DIV Japan 7340144 2022-101099 Issued Japan <br />Divisional (DIV) 2022-101099<br />Filed on 2022-06-23<br />Status: Issued 147173986 Cholangiocarcinoma 147173987 Immunogenic 147173988 Rosenberg 147173989 T-cell 147173991 Tran TAB-4373 147157667 A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Jinping Liu, Wei Tang, Xin Wei Wang <h2>Summary:</h2> <p>NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.</p> <h2>Description of Technology:</h2> <p>Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions of Americans and possibly billions in the world are considered at risk for developing liver cancer. Individuals are considered at risk for developing liver cancer if they have underlying chronic liver diseases such as fibrosis and cirrhosis which in turn may be caused by viral infections and inflammation. However, this risk greatly varies among individuals and the current methods for early detection and surveillance are inadequate.</p> <p>Scientists at the National Cancer Institute&rsquo;s (NCI) Laboratory of Human Carcinogenesis established a biomarker signature of viral infection that can predict HCC among at-risk individuals up to 7 years prior to their clinical diagnosis. This viral exposure signature has been identified through serological profiling of individuals from a case-control study and validated in a cohort of at-risk individuals who were followed up to 20 years for the development of HCC. The specificity and sensitivity of this biomarker signature is superior to current available methods of diagnosis such as alpha-fetoprotein screening.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic assay for early detection and surveillance of HCC</li> <li>Companion diagnostics for HCC therapeutic development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The large market for hepatocellular carcinoma is in need of improved diagnostics</li> <li>Detection of cancer patients from at-risk individuals up to 7 years prior to clinical diagnosis</li> <li>Potential competitive cost, easy to implement</li> <li>Serological profiling allows easy access to patient samples</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-024-2009 E-101-2016 147164491 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164493 Liu, Jinping NIH - NCI NCI Liu, Jinping (NCI) 2 147164492 Tang, Wei NIH - NCI NCI Tang, Wei (NCI) 3 147164491 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164493 Liu, Jinping NIH - NCI NCI Liu, Jinping (NCI) 2 147164492 Tang, Wei NIH - NCI NCI Tang, Wei (NCI) 3 147158147 A Viral Exposure Defines Nature Defines Early Onset Hepatocellular Carcinoma E-174-2019-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma&body=Please send me information about technology [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma&body=Please send me information about technology [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161150 E-174-2019-0 E-174-2019-0-PCT-02 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PCT Patent Cooperation Treaty PCT/US2020/055077 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/055077<br />Filed on 2020-10-09<br />Status: Expired 147168515 E-174-2019-0 E-174-2019-0-US-01 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PRV US 62/914,138 Abandoned US <br />Provisional (PRV) 62/914,138<br />Filed on 2019-10-11<br />Status: Abandoned 147168516 E-174-2019-0 E-174-2019-0-CN-03 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA National Stage China ZL202080071446.7 202080071446.7 Issued China <br />National Stage 202080071446.7<br />Filed on 2020-10-09<br />Status: Issued 147168517 E-174-2019-0 E-174-2019-0-US-04 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA National Stage US 12,571,796 17/766,015 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12571796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12571796">12,571,796</a><br />Filed on 2022-04-01<br />Status: Issued 147173045 Biomarker 147173046 HCC 147173047 hepatocellular carcinoma 147173048 Liver cancer 147173049 viral infection 147173050 Wang TAB-4200 147157485 A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer NCI Licensing, Neurology, Oncology, Research Materials Licensing Neurology Oncology Research Materials Rajaa El Meskini, Michelle Gumprecht, Alan Kulaga, Anthony Lacovelli, Zoe Ohler, Terry Van Dyke <h2>Description of Technology:</h2> <p>Current therapies for glioblastoma multiforme (GBM), the highest grade malignant brain tumor, are mostly ineffective, and better preclinical model systems are needed to increase the successful translation of drug discovery efforts into the clinic. Scientists at the National Cancer Institute (NCI) have developed and characterized an orthotopic genetically engineered mouse (GEM)-derived model of GBM that closely recapitulates various human GBM subtypes and is useful for preclinical evaluation of candidate therapeutics. The GEM-derived GBM model harbors perturbations in the receptor tyrosine kinase (RTK), phosphoinositide 3-kinase (PI3K) and retinoblastoma (RB) tumor suppressor networks and develops spontaneous p53 aberrations upon induction of the constitutively active mutant KRASG12D and deletion of phosphatase and tensin homolog (PTEN) alleles; the orthotopically implanted mice are referred to as &lsquo;TRP&rsquo; mice. The TRP mice develop high grade GBM that are histologically similar to human GBM within weeks allowing the creation of large preclinical cohorts that are tractable for therapeutic evaluation.&nbsp;</p> <p><strong>Figure:&nbsp;Orthotopic GBM model characterization&nbsp;</strong></p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image_for_e-264-20141.png" style="height:551px; width:600px" /></p> <p>(A) Tumor cells were isolated from TRP grade IV astrocytoma and cultured for several passages prior to intracranial injection into syngeneic mouse brains, or cells were implanted directly. (B) Both methods resulted in grade IV astrocyomas. Orthotopic tumors have large numbers of variably sized irregular blood vessels (*). Enlarged images of areas labeled X and Y are shown in panel C. (C) Orthotopic GBMs feature necrotic foci (N in region labeled X) in central regions that are lined by pseudopalisading tumor cells (P). The invasive tumor cells often track along adjacent small blood vessels (arrows in region labeled Y), as well as diffusely invading through the recipient&rsquo;s neuropil. Two images are shown for each marker stain; in the second, invasion is indicated by &lsquo;I&rsquo; where orthotopic tumors contain foci of extensive invasion into the adjacent recipient normal brain. Tumor cells express variable levels of T121 with increased levels at the invasive edge highlighting individual invading tumor cells (T121 and T121/I). GFAP expression is heterogeneous with greater numbers of negative cells at the periphery (GFAP and GFAP/I). Nestin expression is also greater at the invasive front (Nestin and Nestin/I). Most tumor cells express Olig-2 (Olig-2 and Olig-2/I) and Sox-2 (Sox-2 and Sox-2/I).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tractable mouse model of human glioblastoma multiforme for preclinical evaluation of GBM therapies&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid preclinical evaluation of therapeutics. Primary cells from the GEM-GBM injected orthotopically into immune competent syngeneic mice brains induce grade IV tumors within 2 to 3 weeks.</li> <li>The GEM-GBM model represents a range of GBM cell types, recapitulating the heterogeneous cell population found in human GBM.&nbsp;</li> <li>GBM tumors are distinct and measurable on MRI scans and DCE-MRI properties have been described</li> <li>Superior to human cell xenograft models: syngeneic immunocompetent model allows for the evaluation of checkpoint inhibitors and other immunotherapeutic drugs.</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 Brain Cancer, GBM, GEM, Genetically Engineered Mouse, Meskini, mouse model, Multiforme, Ohler Weaver, Orthotopic Glioblastoma False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162437 El Meskini R, et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283649/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283649/">El Meskini R, et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.</a> 147163886 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 1 147163887 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 2 147163888 Lacovelli, Anthony NIH - NCI Leidos Lacovelli, Anthony (Leidos) 3 147163889 Kulaga, Alan NIH - NCI Leidos Kulaga, Alan (Leidos) 4 147163890 Gumprecht, Michelle NIH - NCI Leidos Gumprecht, Michelle (Leidos) 5 147163885 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147163886 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 1 147163887 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 2 147163888 Lacovelli, Anthony NIH - NCI Leidos Lacovelli, Anthony (Leidos) 3 147163889 Kulaga, Alan NIH - NCI Leidos Kulaga, Alan (Leidos) 4 147163890 Gumprecht, Michelle NIH - NCI Leidos Gumprecht, Michelle (Leidos) 5 147163885 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147158266 A Preclinical Orthotopic Model For Glioblastoma Multiforme That Represents Key Pathways Aberrant In Human Brain Cancer E-246-2014-0 Research Material NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer&body=Please send me information about technology [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer&body=Please send me information about technology [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147174184 Brain Cancer 147174185 GBM 147174186 GEM 147174187 Genetically Engineered Mouse 147174189 Meskini 147174190 mouse model 147174191 Multiforme 147174192 Ohler Weaver 147174194 Orthotopic Glioblastoma TAB-4175 147157460 Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Description of Technology:</h2> <p>Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology have derived a cell line, A2780, from a patient with metastatic ovarian adenocarcinoma who was not exposed to any anti-cancer agents before tumor extraction. This cell line forms tumors in nude mice and can be used to evaluate the effects of anti-cancer agents on ovarian cancer. Furthermore, cisplatin- (A2780CIS) and adriamycin- resistant (A2780ADR) derivatives have been developed by chronic exposure of the parental cell line to cisplatin and adriamycin, respectively. These lines show cross-resistance to other agents such as melphalan, vinblastine or irradiation, and can be used to study the molecular basis of drug resistance in ovarian cancer.&nbsp;</p> <p>NCI is seeking parties to non-exclusively license these ovarian cancer cell lines.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for drug screen and related preclinical studies of ovarian cancer therapeutics</li> <li>Research tool for mechanistic studies of ovarian cancer such as the basis of drug resistance</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized ovarian cancer cell lines</li> <li>Parental A2780 may be used to generate other drug-resistant cell lines through exposure to low concentrations of other agents</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 A2780, Aaronson, adriamycin, CISPLATIN, drug resistance, IRRADIATION, Melphalan, OVARIAN CANCER, VINBLASTINE False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161944 Westin EH, et al. Differential expression of the amv gene in human hematopoietic cells. https://www.ncbi.nlm.nih.gov/pubmed/6954533 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6954533">Westin EH, et al. Differential expression of the amv gene in human hematopoietic cells.</a> 147162331 Beaufort CM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. https://www.ncbi.nlm.nih.gov/pubmed/25230021 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25230021">Beaufort CM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.</a> 147162369 Eva A, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. https://www.ncbi.nlm.nih.gov/pubmed/6173755 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6173755">Eva A, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells.</a> 147163782 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163783 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147163782 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163783 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147157800 Parental A2780 Ovarian Cancer Cell Line And Derivative Cisplatin-resistant And Adriamycin-resistant A2780 Cell Lines E-018-2020-0 Research Material NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines&body=Please send me information about technology [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines&body=Please send me information about technology [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147169600 A2780 147169602 Aaronson 147169603 adriamycin 147169604 CISPLATIN 147169605 drug resistance 147169606 IRRADIATION 147169608 Melphalan 147169609 OVARIAN CANCER 147169610 VINBLASTINE TAB-4116 147157398 A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Simone Difilippantonio, Lionel Feigenbaum, Deborah Householder, Philip Martin, Zoe Ohler, Terry Van Dyke <h2>Description of Technology:</h2> <p>Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse (GEM) model of human EGFR-driven tumor model (hEGFR-TL) that recapitulates the discrete lung tumor nodules similar to those found in human lung tumor morphology. Individual tumor nodules can be easily measured by live animal imaging and the nodules can be harvested and isolated from surrounding lung tissue post-treatment, making this a more tractable model for human non-small cell lung adenocarcinoma. The lungs express an EGFR transgene that harbors two mutations (&lsquo;L858R&rsquo; and &lsquo;T790M&rsquo;) which render the lung tumors resistant to first generation EGFR inhibitors and are useful for evaluating drugs targeting resistant tumors.</p> <p>&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image_for_e-041-20145.png" /></p> <h2>Potential Commercial Applications:</h2> <ul> <li>Preclinical in vivo screen of therapeutics targeting tumor kinase inhibitors such as EGFR-mediated lung tumors, and identification of new biomarkers in this pathway&nbsp;</li> <li>Evaluation of novel therapeutics in inducible models of EGFR-driven drug resistant lung adenocarcinoma</li> <li>Dermatology Research</li> <li>Immunology, Inflammation and Autoimmunity Research</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Lung tumor development and response to drugs can be monitored by MRI or CT scanning</li> <li>Contain a human EGFR transgene (either TRE-EGFR-L858R or TRE-EGFR-L858R-T790M models are available) and an activating transgene (CCSP-rtTA) to direct expression of mutant EGFR to the Clara cells</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 EGFR, Epidermal Growth Factor Receptor, GEM, Genetically Engineered Mouse, Lung adenocarcinoma, lung cancer, mouse model, Ohler Weaver, respiratory False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162258 Nakamura Y, et al., Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335921/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335921/">Nakamura Y, et al., Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer.</a> 147163562 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163561 Feigenbaum, Lionel NIH - NCI Leidos Feigenbaum, Lionel (Leidos) 2 147163565 Householder, Deborah NIH - NCI NCI Householder, Deborah (NCI) 3 147163566 Martin, Philip NIH - NCI Martin, Philip 4 147163564 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 5 147163563 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147163562 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163561 Feigenbaum, Lionel NIH - NCI Leidos Feigenbaum, Lionel (Leidos) 2 147163565 Householder, Deborah NIH - NCI NCI Householder, Deborah (NCI) 3 147163566 Martin, Philip NIH - NCI Martin, Philip 4 147163564 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 5 147163563 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147157845 A New Model For Mutant EGFR-driven Lung Adenocarcinoma That Develops Nodular, Discrete Tumors Useful For Preclinical Evaluation And Biomarker Discovery E-041-2014-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma&body=Please send me information about technology [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma&body=Please send me information about technology [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147170045 EGFR 147170047 Epidermal Growth Factor Receptor 147170049 GEM 147170051 Genetically Engineered Mouse 147170052 Lung adenocarcinoma 147170053 lung cancer 147170054 mouse model 147170056 Ohler Weaver 147170057 respiratory TAB-3968 147157248 Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Rita Braziel, Wing Chan, James Cook, Jan Delabie, Kai Fu, Randy Gascoyne, Timothy Greiner, Elias Guerri, Elias Guerri, Elias Guerri, Elaine Jaffe, Anja Mottok, German Ott, Lisa Rimsza, Andreas Rosenwald, David Scott, Erlend Smeland, Joo Song, Louis Staudt, Christian Steidl, Dennis Weisenburger, George Wright <h2>Description of Technology:</h2> <p>Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL. The diagnostic uncertainty of PMBCL can result in delayed and/or inappropriate treatment, serious harm, and even death of the patient, so there is a need to more precisely diagnose PMBCL.&nbsp;&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a gene expression-based assay comprising a set of 58 nucleic acid probes that measure the abundance of selected mRNA species using the Nanostring platform. This assay can be used successfully to better distinguish PMBCL from DLBCL and applied to further classify DLBCL into well-established cell-of-origin subtypes. This test can be applied by clinicians to support the pathological diagnosis of PMBCL, and therefore identify a group of patients whose tumors are characterized by a distinct underlying biology.&nbsp;&nbsp;</p> <p>The NCI seeks licensees and/or co-development partners to develop this technology toward commercialization.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnosis of PMBCL</li> <li>Distinguishing PMBCL from DLBCL</li> <li>The invention could be used: <ul> <li>in the near term as a clinical tool in the initial diagnostic evaluation of suspected PMBCL, which is required in the WHO guidelines for diagnosis of hematologic malignancies</li> <li>as an entry criterion for clinical trials in order to include those patients for which the efficacy of a given treatment likely depends on the molecular subtype of their disease&nbsp;</li> </ul> </li> <li>Targeted therapies appropriate for each DLBCL subtype</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easy to integrate into current clinical practice of cancer diagnosis as the assay can be performed using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies</li> <li>Superior prognostic ability over traditional histopathological diagnosis</li> </ul> 2020-01-15 2026-04-24 2020-01-15 2026-04-24 2020-01-15 assay, Diffuse Large B Cell Lymphoma, DLBCL, FFPE, Formalin-fixed, GENE EXPRESSION, paraffin-embedded biopsies, PMBCL, Primary Mediastinal Large B Cell Lymphoma, Staudt False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-01-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162044 Mottok A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. https://www.ncbi.nlm.nih.gov/pubmed/30257882 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30257882">Mottok A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.</a> 147162200 Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. https://www.ncbi.nlm.nih.gov/pubmed/31292115 <a href="https://www.ncbi.nlm.nih.gov/pubmed/31292115">Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.</a> 147163052 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147163055 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 2 147163056 Scott, David BC Cancer Scott, David 3 147163053 Wright, George NIH - NCI NCI Wright, George (NCI) 4 147163057 Mottok, Anja BC Cancer Mottok, Anja 5 147163058 Steidl, Christian BC Cancer Steidl, Christian 6 147163054 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 7 147163065 Gascoyne, Randy BC Cancer Gascoyne, Randy 8 147163073 Guerri, Elias Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Guerri, Elias 9 147163072 Guerri, Elias Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Guerri, Elias 10 147163069 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 11 147163059 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 12 147163063 Fu, Kai University of Nebraska Medical Center Fu, Kai 13 147163061 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 14 147163066 Smeland, Erlend Oslo University Hospital Smeland, Erlend 15 147163067 Delabie, Jan Oslo University Hospital Delabie, Jan 16 147163068 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 17 147163060 Chan, Wing City of Hope National Medical Center Chan, Wing 18 147163071 Song, Joo City of Hope National Medical Center Song, Joo 19 147163062 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147163064 Ott, German Robert Bosch Stiftung Ott, German 21 147163070 Cook, James Cleveland Clinic Foundation Cook, James 22 147163052 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147163055 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 2 147163056 Scott, David BC Cancer Scott, David 3 147163053 Wright, George NIH - NCI NCI Wright, George (NCI) 4 147163057 Mottok, Anja BC Cancer Mottok, Anja 5 147163058 Steidl, Christian BC Cancer Steidl, Christian 6 147163054 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 7 147163065 Gascoyne, Randy BC Cancer Gascoyne, Randy 8 147163073 Guerri, Elias Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Guerri, Elias 9 147163072 Guerri, Elias Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Guerri, Elias 10 147163069 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 11 147163059 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 12 147163063 Fu, Kai University of Nebraska Medical Center Fu, Kai 13 147163061 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 14 147163066 Smeland, Erlend Oslo University Hospital Smeland, Erlend 15 147163067 Delabie, Jan Oslo University Hospital Delabie, Jan 16 147163068 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 17 147163060 Chan, Wing City of Hope National Medical Center Chan, Wing 18 147163071 Song, Joo City of Hope National Medical Center Song, Joo 19 147163062 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147163064 Ott, German Robert Bosch Stiftung Ott, German 21 147163070 Cook, James Cleveland Clinic Foundation Cook, James 22 147158141 Molecular Classification Of Primary Mediastinal Large B Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Tissue Specimens E-172-2017-0 Filing authorized BC Cancer, Mayo Clinic, Arizona, NCI 147162546 Molecular Classification Of Primary Mediastinal Large B Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Tissue Specimens E-172-2017-1 Filing authorized BC Cancer, City of Hope National Medical Center, Cleveland Clinic Foundation, Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic of Barcelona [Hospital Clinico de Barcelona], Mayo Clinic, Arizona, NCI, Oregon Health and Science University (OHSU), Oslo University Hospital, Robert Bosch Stiftung, University of Barcelona [Universitat de Barcelona], University of Nebraska Medical Center, University Of Wurzburg 83707317 Bhattacharya, Ramona ramona.bhattacharya@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens&body=Please send me information about technology [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bhattacharya, Ramona<br><a href="mailto:ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens&body=Please send me information about technology [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ramona.bhattacharya@nih.gov</a><br> 147161145 E-172-2017-0 E-172-2017-0-US-01 METHOD FOR DETERMINING LYMPHOMA TYPE PRV US 62/519,728 Abandoned US <br />Provisional (PRV) 62/519,728<br />Filed on 2017-06-14<br />Status: Abandoned 147165605 E-172-2017-1 E-172-2017-1-PCT-01 METHOD FOR DETERMINING LYMPHOMA TYPE PCT Patent Cooperation Treaty PCT/US2018/036084 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/036084<br />Filed on 2018-06-05<br />Status: Expired 147165606 E-172-2017-1 E-172-2017-1-EP-02 METHOD FOR DETERMINING LYMPHOMA TYPE National Stage European Patent 3638814 18733500.5 Issued European Patent <br />National Stage 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165607 E-172-2017-1 E-172-2017-1-US-03 METHOD FOR DETERMINING LYMPHOMA TYPE CIP US 11,646,099 16/713,528 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11646099 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11646099">11,646,099</a><br />Filed on 2019-12-13<br />Status: Issued 147165609 E-172-2017-1 E-172-2017-1-FR-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP France 3638814 18733500.5 Issued France <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165610 E-172-2017-1 E-172-2017-1-DE-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP Germany 3638814 18733500.5 Issued Germany <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165611 E-172-2017-1 E-172-2017-1-GB-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP United Kingdom 3638814 18733500.5 Issued United Kingdom <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147172976 assay 147172977 Diffuse Large B Cell Lymphoma 147172978 DLBCL 147172979 FFPE 147172980 Formalin-fixed 147172981 GENE EXPRESSION 147172983 paraffin-embedded biopsies 147172985 PMBCL 147172987 Primary Mediastinal Large B Cell Lymphoma 147172988 Staudt TAB-4242 147157529 Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a) NICHD Collaboration, Endocrinology, Licensing, Nephrology, Therapeutics Collaboration Endocrinology Licensing Nephrology Therapeutics Barry Byrne, Janice Chou <h2>Summary:</h2> <p>NICHD is seeking licensees for development&nbsp;of&nbsp;an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).</p> <h2>Description of Technology:</h2> <p>GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect of long-term remission in patients with GSD-Ia.</p> <p>Researchers at the NIH <a href="https://www.nichd.nih.gov/Pages/index.aspx" rel="nofollow" target="_blank">National Institute for Child Health and Human Development</a>&nbsp;developed adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).This technology describes new AAV vectors for the delivery of corrective genes that express modified human G6Pase-alpha proteins, directed by the tissue-specific human G6PC promoter/enhancer.</p> <p>The NICHD inventor is also interested in the mechanisms by which GSD-1a may lead to hepatic malignancy and a collaboration project may be considered.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gene therapy vector for the delivery of a corrective gene to treat of GSD-Ia.</li> <li>Useful in development of a combined pharmaceutical plus gene therapy approach to treat adult GSD-1a patients at risk of hepatocellular carcinoma.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Protein coding sequences are modified from the wildtype human sequence for enhanced enzymatic activity.</li> </ul> 2021-04-30 2026-04-24 2021-04-30 2026-04-24 2021-04-30 Chou, GSD-1a, hepatic malignancy, hyperlipidemia, hypoglycemia, National Institute of Child Health and Human Development, NICHD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-30 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2015 147161903 Lee YM et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 2012 Nov;56(5):1719-29. https://pubmed.ncbi.nlm.nih.gov/22422504/ <a href="https://pubmed.ncbi.nlm.nih.gov/22422504/">Lee YM et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 2012 Nov;56(5):1719-29.</a> 147162291 Lee YM, et al. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab. 2013 Nov;110(3):275-80. https://pubmed.ncbi.nlm.nih.gov/23856420/ <a href="https://pubmed.ncbi.nlm.nih.gov/23856420/">Lee YM, et al. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab. 2013 Nov;110(3):275-80.</a> 147164018 Chou, Janice NICHD NICHD Chou, Janice (NICHD) 1 147164019 Byrne, Barry University of Florida Byrne, Barry 2 147164018 Chou, Janice NICHD NICHD Chou, Janice (NICHD) 1 147164019 Byrne, Barry University of Florida Byrne, Barry 2 147158357 The Enhancer Elements Upstream Of The Human G6PC Minimal Promoter Are Necessary For Efficient Hepatic G6PC Expression E-552-2013-0 Filing authorized NICHD, University of Florida 91800717 Hubbs, Alan hubbsa@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America Technology Transfer Center hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)&body=Please send me information about technology [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Hubbs, Alan<br><a href="mailto:hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)&body=Please send me information about technology [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">hubbsa@mail.nih.gov</a><br> 147161278 E-552-2013-0 E-552-2013-0-US-13 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE CON US 10,113,183 15/493,622 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10113183 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10113183">10,113,183</a><br />Filed on 2017-04-21<br />Status: Issued 147167619 E-552-2013-0 E-552-2013-0-US-01 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PRV US 61/908,861 Abandoned US <br />Provisional (PRV) 61/908,861<br />Filed on 2013-11-26<br />Status: Abandoned 147167620 E-552-2013-0 E-552-2013-0-PCT-02 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PCT Patent Cooperation Treaty PCT/US2014/067415 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/067415<br />Filed on 2014-11-25<br />Status: Expired 147167621 E-552-2013-0 E-552-2013-0-AU-03 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Australia 2014354839 2014354839 Issued Australia <br />National Stage 2014354839<br />Filed on 2014-11-25<br />Status: Issued 147167622 E-552-2013-0 E-552-2013-0-BR-04 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Brazil BR112016011997-5 BR112016011997-5 Issued Brazil <br />National Stage BR112016011997-5<br />Filed on 2014-11-25<br />Status: Issued 147167623 E-552-2013-0 E-552-2013-0-CA-05 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Canada 2930872 2930872 Issued Canada <br />National Stage 2930872<br />Filed on 2014-11-25<br />Status: Issued 147167624 E-552-2013-0 E-552-2013-0-CN-06 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage China ZL201480074046.6 201480074046.6 Issued China <br />National Stage 201480074046.6<br />Filed on 2014-11-25<br />Status: Issued 147167625 E-552-2013-0 E-552-2013-0-CO-07 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Colombia 33396 16162610 Abandoned Colombia <br />National Stage 16162610<br />Filed on 2016-06-21<br />Status: Abandoned 147167626 E-552-2013-0 E-552-2013-0-EP-08 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage European Patent 3074510 14812375.5 Issued European Patent <br />National Stage 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167627 E-552-2013-0 E-552-2013-0-IL-09 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Israel 245659 245659 Issued Israel <br />National Stage 245659<br />Filed on 2016-05-16<br />Status: Issued 147167628 E-552-2013-0 E-552-2013-0-JP-10 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Japan 6649265 2016-554828 Issued Japan <br />National Stage 2016-554828<br />Filed on 2014-11-25<br />Status: Issued 147167629 E-552-2013-0 E-552-2013-0-MX-11 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Mexico 375360 MX/a/2016/006774 Issued Mexico <br />National Stage MX/a/2016/006774<br />Filed on 2014-11-25<br />Status: Issued 147167630 E-552-2013-0 E-552-2013-0-US-12 Adeno-Associated Virus Vectors for Treatment of Glycogen Storage Disease National Stage US 9,644,216 15/038,979 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644216 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644216">9,644,216</a><br />Filed on 2016-05-24<br />Status: Issued 147167631 E-552-2013-0 E-552-2013-0-EP-14 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE DIV European Patent 3415620 18186594.0 Issued European Patent <br />Divisional (DIV) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167632 E-552-2013-0 E-552-2013-0-BE-15 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Belgium 3074510 14812375.5 Issued Belgium <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167633 E-552-2013-0 E-552-2013-0-CH-16 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Switzerland 3074510 14812375.5 Issued Switzerland <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167634 E-552-2013-0 E-552-2013-0-DE-17 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Germany 3074510 14812375.5 Issued Germany <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167635 E-552-2013-0 E-552-2013-0-ES-18 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Spain 3074510 14812375.5 Issued Spain <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167636 E-552-2013-0 E-552-2013-0-FR-19 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP France 3074510 14812375.5 Issued France <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167637 E-552-2013-0 E-552-2013-0-GB-20 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP United Kingdom 3074510 14812375.5 Issued United Kingdom <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167638 E-552-2013-0 E-552-2013-0-IT-21 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Italy 3074510 14812375.5 Issued Italy <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167639 E-552-2013-0 E-552-2013-0-NL-22 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP The Netherlands 3074510 14812375.5 Issued The Netherlands <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167640 E-552-2013-0 E-552-2013-0-SE-23 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Sweden 3074510 14812375.5 Issued Sweden <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167641 E-552-2013-0 E-552-2013-0-US-24 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE CON US 11,060,110 16/148,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060110 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060110">11,060,110</a><br />Filed on 2018-10-01<br />Status: Issued 147167642 E-552-2013-0 E-552-2013-0-DE-25 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Germany 3415620 18186594.0 Issued Germany <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167643 E-552-2013-0 E-552-2013-0-FR-26 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP France 3415620 18186594.0 Issued France <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167644 E-552-2013-0 E-552-2013-0-GB-27 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP United Kingdom 3415620 18186594.0 Issued United Kingdom <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147174903 Chou 147174905 GSD-1a 147174906 hepatic malignancy 147174907 hyperlipidemia 147174908 hypoglycemia 147174909 National Institute of Child Health and Human Development 147174910 NICHD TAB-4224 147157509 Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Diana Blithe, Pranab Gupta, Bashir Kaskar, Min Lee, Ming-Teh Lin <h2>Summary:</h2> <p>NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.</p> <h2>Description of Technology:</h2> <p>The options for male contraceptives are limited. Research is ongoing to develop a male contraceptive based on hormonal activity. Testosterone is one of the hormones necessary in producing sperm.&nbsp; Testosterone is absolutely required as a hormone for male fertility. Derivatives of testosterone for male contraceptives currently in clinical trials are associated with estrogenic deficiency. This deficiency can cause several issues including, but not limited to, bone density loss, risk of obesity, cardiovascular disease, and/or ineffective carbohydrate or lipid metabolism.&nbsp;</p> <p>Researchers at the <em>Eunice Kennedy Shriver </em>National Institute of Child Health and Human Development (NICHD) have developed a new chemical entity and related embodiments of the following formula:&nbsp;</p> <p><img alt=" This invention discloses embodiments of the above compound, or a pharmaceutically acceptable salt, a prodrug, a solvate, or a tautomer thereof" src="https://nih.technologypublisher.com/files/sites/formula_1_for_e-141-2019_compound1.png" style="border-style:solid; border-width:1px; float:left; height:213px; width:300px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Formula 1.</strong> This invention discloses embodiments of the above compound, or a pharmaceutically acceptable salt, a prodrug, a solvate, or a tautomer thereof.&nbsp;&nbsp;</p> <p>Disclosed monomeric compounds and embodiments exhibit androgenic activity. Disclosed oligomeric compounds can provide control of receptor activation or deactivation and/or treatment through the coupling of steroidal-based compounds to one another or with therapeutic agents. Depending on the type and length between the compounds that form the oligomer, the rate at which each component of the oligomer release can be controlled as in &lsquo;time release&rsquo;. The appropriate dosage would depend on a variety of factors defined during further development.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Contraceptive use by humans, particularly male, and animals</li> <li>Compounds used as endocrine therapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Significant, unmet medical need given few current options for male contraceptives&nbsp;</li> <li>Timed release of active ingredients</li> </ul> 2021-02-09 2026-04-24 2021-02-09 2026-04-24 2021-02-09 Blithe, CONTRACEPTIVE, Estrogenic Activity, Eunice Kennedy Shriver National Institute of Child Health an, Lee, Male Contraceptive, MONOMERIC, NCE, New Chemical Entity, NICHD, OLIGOMERIC False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163965 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147163961 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147163963 Gupta, Pranab Ash Stevens, LLC Gupta, Pranab 3 147163962 Kaskar, Bashir Ash Stevens, LLC Kaskar, Bashir 4 147163964 Lin, Ming-Teh Ash Stevens, LLC Lin, Ming-Teh 5 147163965 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147163961 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147163963 Gupta, Pranab Ash Stevens, LLC Gupta, Pranab 3 147163962 Kaskar, Bashir Ash Stevens, LLC Kaskar, Bashir 4 147163964 Lin, Ming-Teh Ash Stevens, LLC Lin, Ming-Teh 5 147158072 Novel Substituted Steroid Hormones E-141-2019-0 Filing authorized Ash Stevens, LLC, NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics&body=Please send me information about technology [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics&body=Please send me information about technology [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147167510 E-141-2019-0 E-141-2019-0-US-01 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME PRV US 63/037,952 Abandoned US <br />Provisional (PRV) 63/037,952<br />Filed on 2020-06-11<br />Status: Abandoned 147167511 E-141-2019-0 E-141-2019-0-PCT-02 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2021/036809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/036809<br />Filed on 2021-06-10<br />Status: Expired 147167512 E-141-2019-0 E-141-2019-0-CA-03 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage Canada 3184810 Pending Canada <br />National Stage 3184810<br />Filed on 2021-06-10<br />Status: Pending 147167516 E-141-2019-0 E-141-2019-0-US-07 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage US 18/009,571 Pending US <br />National Stage 18/009,571<br />Filed on 2022-12-09<br />Status: Pending 147167517 E-141-2019-0 E-141-2019-0-EP-08 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage European Patent 21745474.3 Pending European Patent <br />National Stage 21745474.3<br />Filed on 2021-06-10<br />Status: Pending 147172272 Blithe 147172273 CONTRACEPTIVE 147172275 Estrogenic Activity 147172276 Eunice Kennedy Shriver National Institute of Child Health an 147172277 Lee 147172279 Male Contraceptive 147172280 MONOMERIC 147172282 NCE 147172284 New Chemical Entity 147172285 NICHD 147172286 OLIGOMERIC TAB-3996 147157277 Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease NICHD Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Yong Cheng, Yoke Peng Loh <h2>Summary:</h2> <p>The NICHD is seeking licensees&nbsp;for development&nbsp;of Carboxypeptidase E (CPE)&nbsp;as a therapy for MCI or AD.</p> <h2>Description of Technology:</h2> <p>There is no known cure for Alzheimer&rsquo;s disease, a brain disorder that severely affects memory, thinking, learning, and organizing skills. It eventually decreases a person&rsquo;s ability to carry out simple, daily activities. It is predicted that over 14 million Americans will develop Alzheimer&rsquo;s without effective treatment options. Mild cognitive impairment (MCI) is a stage prior to Alzheimer&rsquo;s when memory problems become noticeable. A patient&rsquo;s ability to function and live independently remain intact as the brain compensates for disease-related changes. Disease symptoms worsen over a period that may progress over 10 years. In some people, MCI can hold steady at this stage. However, people with MCI are at high risk for progressing to dementia. Alzheimer&rsquo;s disease is the most common form of dementia.</p> <p>MCI is associated with neurological cell death in the hippocampus. The technology from the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (NICHD), describes that direct administration of an adenovirus carrying the Carboxypeptidase E (CPE) gene to the hippocampus results in overexpression of the CPE protein in an experimental mouse model of AD. CPE protein overexpression averts neurological cell death in the hippocampus. Treated mice do not develop memory impairment. This technology was effective in mice with normal expression of brain-derived neurotrophic factor (BNDF). It may be applicable to a wider range of patients, including those with BNDF deficiency and no deficiency of BNDF expression. Further, this technology may provide for a combination therapy with CPE and BNDF to treat AD.</p> <p>This technology protects neurons prior to the appearance of cell damage due to accumulation of intracellular tau-containing neurofibrillary tangles and extracellular &beta;-amyloid (A&beta;) deposits in the brain.</p> <p>The use of CPE as an early intervention in the initial diagnosis of MCI may stabilize the neurological condition of patients and avoid progression of AD in a large population of aging patients.</p> <p>There is also opportunity for preclinical co-development of the technology with the NICHD laboratory of Dr. Peng Loh.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of patients: <ul> <li>Diagnosed with mild cognitive impairment (MCI)</li> <li>Diagnosed with neurologic damage to the hippocampus</li> <li>With early signs of Alzheimer&rsquo;s Disease (AD)</li> </ul> </li> <li>Combination therapy with Brain-Derived Neurotrophic Factor (BDNF)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Halt the progression from MCI to AD</li> <li>Combination therapy with CPE and BNDF</li> <li>Neuroprotective prior to the appearance of cell damage</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for Carboxypeptidase E (CPE) to Treat Mild Cognitive Impairment and Alzheimer Disease 2021-12-21 2026-04-24 2021-12-21 2026-04-24 2021-12-21 “Cognitive impairment”, Ad, Alzheimer’s Disease, BNDF, brain, Brain-Derived Neurotrophic Factor, Carboxypeptidase E, CPE, Hippocampus, LOH, MCI, MEMORY, Mild Cognitive Impairment, NEURODEGENERATION, NEUROTROPHIC False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161932 Xiao L, et.al. Neurotrophic factor-α1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF. https://pubmed.ncbi.nlm.nih.gov/33414376/ <a href="https://pubmed.ncbi.nlm.nih.gov/33414376/">Xiao L, et.al. Neurotrophic factor-α1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF.</a> 147163162 Loh, Yoke Peng NIH - NICHD NICHD Loh, Yoke Peng (NICHD) 1 147163163 Cheng, Yong Minzu University of China Cheng, Yong 2 147163162 Loh, Yoke Peng NIH - NICHD NICHD Loh, Yoke Peng (NICHD) 1 147163163 Cheng, Yong Minzu University of China Cheng, Yong 2 147158202 Use Of Neurotrophic Factor-alpha1/Carboxypeptidase E To Treat Alzheimer Disease E-200-2021-0 Filing authorized Minzu University of China, NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease&body=Please send me information about technology [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease&body=Please send me information about technology [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161187 E-200-2021-0 E-200-2021-0-US-01 Use of Carboxypeptidase E / Neurotrophic Factor-Alpha 1 to Treat Neurodegenerative Disease PRV US 63/273,312 Abandoned US <br />Provisional (PRV) 63/273,312<br />Filed on 2021-10-29<br />Status: Abandoned 147165788 E-200-2021-0 E-200-2021-0-PCT-02 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE PCT Patent Cooperation Treaty PCT/US2022/078713 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/078713<br />Filed on 2022-10-26<br />Status: Expired 147173562 “Cognitive impairment” 147173563 Ad 147173564 Alzheimer’s Disease 147173566 BNDF 147173567 brain 147173569 Brain-Derived Neurotrophic Factor 147173571 Carboxypeptidase E 147173573 CPE 147173575 Hippocampus 147173576 LOH 147173578 MCI 147173579 MEMORY 147173581 Mild Cognitive Impairment 147173582 NEURODEGENERATION 147173583 NEUROTROPHIC TAB-4418 147157713 Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis NIA Collaboration, Endocrinology, Licensing, Therapeutics Collaboration Endocrinology Licensing Therapeutics Josephine Earley, Luigi Ferrucci, Qing Rong Liu, Pingbo Zhang, Min Zhu <h2>Summary:</h2> <p>The NIA seeks co-development partners and/or licensees for the further development of C&alpha;-peptide as a therapeutic that inhibits islet amyloidosis.</p> <h2>Description of Technology:</h2> <p>Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide (IAPP) fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Mounting evidence suggests that islet amyloidosis plays a causative role in the development and progression of &szlig;-cell dysfunction in T2DM. Currently, approved therapies for T2DM modulate the production of or sensitivity to insulin, but do not specifically target islet amyloidosis. Thus, there is an unmet need to develop new diabetes treatments that inhibit islet amyloidosis. Additionally, any therapy preventing IAPP amyloidosis may prevent other potential amyloidogenic peptides from forming amyloid and amyloid plaques.</p> <p>Insulin C-peptide, co-secreted from secretory granules within pancreatic &beta;-cells alongside mature insulin and IAPP, plays a key role in keeping insulin and IAPP non-aggregated by charge-based interactions. Researchers at the NIA uncovered a novel variant of the C-peptide, named C&alpha;- peptide, having 19 amino acids and lacking -sheet and hairpin motifs present in the middle portion of the conventional 31 amino acid length C-peptide. The newly discovered C&alpha;-peptide derives from a novel proinsulin of 74 amino acids and inhibits IAPP amyloid fibrillation more efficiently than conventional C-peptide. There is an opportunity for C&alpha;-peptide derivatives to be developed as a therapeutic inhibiting islet amyloidosis. Researchers also identified decreased levels of processed C&alpha;-peptide in T2DM pancreatic islets compared with control islets. This finding reveals the potential for C&alpha;-peptide as a clinical diagnostic marker for islet dysfunction and, potentially, neurodegenerative diseases.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapy for type 2 diabetes</li> <li>Therapy for preventing amyloidosis by mutated transthyretin, therapy for primary (AL) amyloidosis, therapy for Amyloid &szlig;40 and 42</li> <li>Therapy for amyloidogenic diseases, including Alzheimer&rsquo;s disease and Parkinson disease</li> <li>Clinical diagnostic marker for type 1 and type 2 diabetes</li> <li>Clinical diagnostic marker for neurodegenerative diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Peptides inhibit islet amyloidosis</li> <li>Peptides lack the amyloidogenic domain</li> <li>Potential for synergistic use with existing diabetes treatments</li> <li>Potential market applications for neurodegenerative diseases</li> </ul> 2021-08-25 2026-04-24 2021-08-27 2026-04-24 2021-08-26 Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164673 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147164675 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147164676 Zhang, Pingbo Johns Hopkins University Zhang, Pingbo 3 147164672 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 4 147164674 Ferrucci, Luigi NIH - NIA NIA Ferrucci, Luigi (NIA) 5 147164673 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147164675 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147164676 Zhang, Pingbo Johns Hopkins University Zhang, Pingbo 3 147164672 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 4 147164674 Ferrucci, Luigi NIH - NIA NIA Ferrucci, Luigi (NIA) 5 147157902 Novel Human Insulin Ca-peptide As An Antagonist For Islet And Brain Amyloidosis E-062-2021-0 Filing authorized Johns Hopkins University, National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis&body=Please send me information about technology [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis&body=Please send me information about technology [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147160981 E-062-2021-0 E-062-2021-0-US-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE PRV US 63/178,083 Abandoned US <br />Provisional (PRV) 63/178,083<br />Filed on 2021-04-22<br />Status: Abandoned 147168802 E-062-2021-0 E-062-2021-0-PCT-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2022/025764 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/025764<br />Filed on 2022-04-21<br />Status: Expired 147168803 E-062-2021-0 E-062-2021-0-US-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE National Stage US 18/287,630 Pending US <br />National Stage 18/287,630<br />Filed on 2023-10-19<br />Status: Pending 147168804 E-062-2021-0 E-062-2021-0-EP-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE National Stage European Patent 22722061.3 Pending European Patent <br />National Stage 22722061.3<br />Filed on 2023-11-10<br />Status: Pending 147170577 Alzheimer’s Disease 147170578 Amyloidosis 147170580 C-peptide 147170581 DIABETES 147170583 Egan 147170584 insulin 147170586 Islet Amyloid Polypeptide 147170588 Liu 147170589 National Institute on Aging 147170590 NIA TAB-4380 147157674 AT-3 Mouse Breast Tumor Cell Line NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Scott Abrams, Jeffrey Schlom <h2>Summary:</h2> <p>NCI is seeking licensees for the AT-3 mouse breast tumor cell line.</p> <h2>Description of Technology:</h2> <p>Tumor cell lines are important tools for the study of cancer. However, most tumor cell lines available today do not mimic physiological tumor development, progression, and host immune responses. Autochthonous tumors include spontaneously occurring tumors and chemical, viral, or physical carcinogen-induced tumors. They are considered to model human tumors more closely than transplanted tumors. Autochthonous tumors can be generated de novo in a model organism of interest and are thought to resemble physiological human tumor conditions. There is therefore a need for development of cell lines from autochthonous tumor models that recapitulate physiological tumor conditions to provide relevant tools for studying tumor development and progression, and host immune responses to cancers.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a mouse breast tumor cell line, AT-3, derived from cells of the primary mammary gland carcinoma of the MTAG model. The MTAG&nbsp; mouse model was developed using the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter to specifically target the polyomavirus middle T antigen (Ag) expression in the mammary gland tissue of B6 mice. This strategy resulted in the generation of transgenic mice with autochthonous mammary carcinomas, with eventual metastatic spread to the lungs that occurs over an approximate 6-month life span. The AT-3 cell line has further been used to study tumor-specific immune dysfunction in the B6 mouse background.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Breast cancer research</li> <li>Anti-breast cancer drug screening</li> <li>Development of other mouse models for breast cancer research</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Orthotopic growth</li> <li>Tumor histology devoid of transplantation introduced changes</li> <li>Metastasis via lymphatic and vascular vessels surrounding and within the primary tumor&nbsp;</li> <li>AT-3 cells were isolated from an autochthonous mouse mammary tumor from the MTAG mouse model</li> <li>Mammary tumor development and progression in MTAG mice closely mimic breast cancer development and progression in humans</li> <li>AT-3 cell line is a physiologically relevant tool for study of breast cancer in humans</li> </ul> 2021-09-23 2026-04-24 2021-09-23 2026-04-24 2021-09-23 AT-3, Autochthonous Tumor, Autologous Tumor Cell Line, BREAST CANCER, In Vitro Animal Model, Mouse, Murine, Schlom False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162360 Stewart TJ &amp; Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. https://pubmed.ncbi.nlm.nih.gov/17709499/ <a href="https://pubmed.ncbi.nlm.nih.gov/17709499/">Stewart TJ &amp; Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth.</a> 147164516 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164517 Abrams, Scott NIH - NCI NCI Abrams, Scott (NCI) 2 147164516 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164517 Abrams, Scott NIH - NCI NCI Abrams, Scott (NCI) 2 147158257 AT-3 Mouse Breast Tumor Cell Line E-240-2016-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4380] AT-3 Mouse Breast Tumor Cell Line&body=Please send me information about technology [TAB-4380] AT-3 Mouse Breast Tumor Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4380] AT-3 Mouse Breast Tumor Cell Line&body=Please send me information about technology [TAB-4380] AT-3 Mouse Breast Tumor Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147174122 AT-3 147174124 Autochthonous Tumor 147174126 Autologous Tumor Cell Line 147174127 BREAST CANCER 147174129 In Vitro Animal Model 147174130 Mouse 147174131 Murine 147174132 Schlom TAB-4365 147157659 Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection NCI Collaboration, Immunology, Infectious Disease, Licensing, Vaccines Collaboration Immunology Infectious Disease Licensing Vaccines Jay Berzofsky, Yongjun Sui <h2>Summary:</h2> <p>Inventors are seeking licensing and/or co-development research collaborations&nbsp; for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.</p> <h2>Description of Technology:</h2> <p>The Corona virus disease, 2019 (COVID-19) pandemic is a worldwide public health crisis with over 153 million confirmed cases and 3.2 million deaths as of April 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein, which has two portions, S1 that binds the cell and S2 that is involved in viral entry via fusion with the cell membrane. There are several vaccines available for COVID-19 patients that directly target SARS-CoV-2 by systemic immunization.</p> <p>Investigators at NCI have designed a unique adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is generated as a subunit vaccine with spike protein S1 used for an intramuscular (IM) primed vaccine followed by intranasal boosted mucosal vaccine in rhesus macaques. The mucosal vaccines are administered intranasally and adjuvanted with the combination of TLR agonists CpG and Poly I:C and cytokine IL-15 incorporated in PLGA or DOTAP nanoparticles. The IM-alum-only vaccine induced robust binding and neutralizing antibody and persistent cellular immunity systemically and mucosally, while IN boosting with nanoparticles including IL-15 and TLR agonists elicited weaker T-cell and antibody responses, but higher dimeric IgA and IFNa, enhancing the effect of systemic immunization. Studies conducted by the inventors showed that the mucosal vaccine induced robust humoral and cellular as well as trained innate immunity in the vaccinated macaques, and cleared virus from the nasal mucosa more effectively, which should reduce forward transmission.</p> <p>Overall, the results demonstrated that the mucosal vaccine could protect against respiratory SARS-CoV-2 exposure and may enhance systemic vaccines, and thus is a good candidate for a SARS-CoV-2 vaccine.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adjuvanted mucosal subunit vaccines (as single agents)&nbsp;</li> <li>Vaccine composition (s)</li> <li>Co-administration to enhance the effect of systemic immunization</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Stimulates both systemic and mucosal immunity;&nbsp; induces&nbsp; both humoral and cellular immunity, as well as trained innate immunity</li> <li>Leads to more effective virus clearance from the upper respiratory tract from which it could spread.</li> <li>Stimulated sustained immune response</li> <li>Protects against SARS-CoV-2 variants</li> <li>Intranasal administration avoids painful injection&nbsp;</li> <li>Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates.</li> </ul> 2021-11-04 2026-04-24 2022-02-09 2026-04-24 2021-11-09 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162454 Yongjun Sui et al., Protection against SARS-CoV-2 infection by mucosal vaccine in rhesus macaques. https://pubmed.ncbi.nlm.nih.gov/33908897/ <a href="https://pubmed.ncbi.nlm.nih.gov/33908897/">Yongjun Sui et al., Protection against SARS-CoV-2 infection by mucosal vaccine in rhesus macaques.</a> 147164454 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147164455 Sui, Yongjun NCI - CCR Sui, Yongjun 2 147164454 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147164455 Sui, Yongjun NCI - CCR Sui, Yongjun 2 147157906 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection E-064-2021-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection&body=Please send me information about technology [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection&body=Please send me information about technology [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160984 E-064-2021-0 E-064-2021-0-US-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection PRV US 63/146,279 Abandoned US <br />Provisional (PRV) 63/146,279<br />Filed on 2021-02-05<br />Status: Abandoned 147168461 E-064-2021-0 E-064-2021-0-PCT-03 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection PCT Patent Cooperation Treaty PCT/US2022/015349 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/015349<br />Filed on 2022-02-04<br />Status: Expired 147168462 E-064-2021-0 E-064-2021-0-US-02 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection National Stage US 18/275,925 Pending US <br />National Stage 18/275,925<br />Filed on 2023-08-04<br />Status: Pending 147168463 E-064-2021-0 E-064-2021-0-EP-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection National Stage European Patent 22705675.1 Pending European Patent <br />National Stage 22705675.1<br />Filed on 2023-08-30<br />Status: Pending TAB-4346 147157639 Human and Improved Murine Monoclonal Antibodies Against CD22 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Ira Pastan, Xiaodong Xiao <h2>Summary:</h2> <p>Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.</p> <h2>Description of Technology:</h2> <p>CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown promise in clinical trials. However, all monoclonal anti-CD22 antibodies used in clinical trials are of murine origin. This is problematic because they have the potential of causing immunogenic reactions when used repeatedly in patients to achieve higher efficacy.</p> <p>NCI scientists isolated two human monoclonal anti-CD22 Fab antibodies; m972 and m971 with 2nM and 20nM affinities respectively. These two human anti-CD22 monoclonal antibodies are better alternatives for cancer immunotherapy over current humanized murine antibodies as they overcome the problem of immune reactivity. They also developed a murine anti-CD22 monoclonal antibody M973 with better affinity and solubility than its parent antibody HA22 and could have improved efficacy in cancer immunotherapy than the murine monoclonal anti-CD22 antibodies currently in use.&nbsp; The m971 binder has also been incorporated into chimeric antigen receptors (CARs) with positive results which are covered under NIH Reference Number E-291-2012 and other related filings.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Monoclonal antibody therapeutic against B-cell lymphomas and other CD22-positive cancers</li> <li>Diagnostic tool for detection of CD22-positive cancers</li> <li>Delivery of drugs, toxins and liposomes to CD22-positive cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Fully human monoclonal antibodies overcome the problem of immune reactivity to murine antibodies</li> <li>Improved monoclonal antibodies have better affinity and solubility than current antibodies</li> </ul> 2021-06-04 2026-04-24 2021-06-04 2026-04-24 2021-06-04 antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-017-2017 E-106-2015 E-161-2018 E-291-2012 147162148 Xiao X, et al. Identification and characterization of fully human anti-CD22 monoclonal antibody. https://pubmed.ncbi.nlm.nih.gov/20065646/ <a href="https://pubmed.ncbi.nlm.nih.gov/20065646/">Xiao X, et al. Identification and characterization of fully human anti-CD22 monoclonal antibody.</a> 147164404 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164405 Xiao, Xiaodong NIH - NCI Xiao, Xiaodong 2 147164403 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147164404 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164405 Xiao, Xiaodong NIH - NCI Xiao, Xiaodong 2 147164403 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147157941 Human And Improved Murine Monoclonal Antibodies Against CD22 E-080-2008-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22&body=Please send me information about technology [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22&body=Please send me information about technology [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147168358 E-080-2008-0 E-080-2008-0-US-01 Human Monoclonal Antibodies Specific For CD22 PRV US 61/042,329 Abandoned US <br />Provisional (PRV) 61/042,329<br />Filed on 2008-04-04<br />Status: Abandoned 147168359 E-080-2008-0 E-080-2008-0-PCT-02 Human And Improved Murine Monoclonal Antibodies Against CD22 PCT Patent Cooperation Treaty PCT/US2009/039080 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/039080<br />Filed on 2009-04-01<br />Status: Expired 147168360 E-080-2008-0 E-080-2008-0-US-03 Human Monoclonal Antibodies Sepcific for CD22 National Stage US 8,591,889 12/934,214 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8591889 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8591889">8,591,889</a><br />Filed on 2010-09-23<br />Status: Issued 147168361 E-080-2008-0 E-080-2008-0-US-04 Human Monoclonal Antibodies Specific For CD22 DIV US 9,279,019 13/959,061 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9279019 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9279019">9,279,019</a><br />Filed on 2013-08-05<br />Status: Issued 147168362 E-080-2008-0 E-080-2008-0-US-05 Human Monoclonal Antibodies Specific for CD22 DIV US 9,598,492 15/012,023 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598492 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598492">9,598,492</a><br />Filed on 2016-02-01<br />Status: Issued 147168363 E-080-2008-0 E-080-2008-0-US-06 Human Monoclonal Antibodies Specific for CD22 CON US 10,494,435 15/424,238 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10494435 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10494435">10,494,435</a><br />Filed on 2017-02-03<br />Status: Issued 147170938 antibodies 147170939 ANTIGEN 147170940 B-CELL 147170942 B-Cell Lymphoma 147170943 Bcl 147170944 CANCER 147170945 CD22 147170947 Chronic Lymphoblastic Leukemia 147170948 CLL 147170949 Dimitrov 147170950 Hairy cell leukemia 147170952 HCL 147170953 Human 147170954 monoclonal 147170955 NHL 147170957 non-Hodgkins lymphoma 147170958 Oncology TAB-4330 147157621 Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics James McMahon, Toshiyuki Mori, Barry O'Keefe <h2>Description of Technology:</h2> <p>This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).&nbsp; Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.&nbsp;</p> <p>Issued patents: <a href="https://patents.google.com/patent/US8088729B2/en?oq=US+8%2c088%2c729" rel="nofollow" target="_blank">US 8,088,729</a>&nbsp;(Jan. 3, 2012) and foreign rights in&nbsp;France, Germany, Ireland, United Kingdom, Switzerland (all granted)</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Microbicide that can prevent viral transmission</li> <li>Therapeutic against enveloped virus-mediated diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly Potent Broad-Spectrum Antiviral Lectin</li> <li>Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.</li> </ul> 2021-07-07 2026-04-24 2021-07-07 2026-04-24 2021-07-07 Anti-Viral, Corona virus, Ebola, Griffithsin, INFLUENZA, O’Keefe, SARS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-07-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-106-2003 147162255 Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture https://pubmed.ncbi.nlm.nih.gov/16300962/ <a href="https://pubmed.ncbi.nlm.nih.gov/16300962/">Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</a> 147162408 Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. https://pubmed.ncbi.nlm.nih.gov/15613479/ <a href="https://pubmed.ncbi.nlm.nih.gov/15613479/">Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.</a> 147164332 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164331 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147164333 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 3 147164332 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164331 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147164333 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 3 147157812 Antiviral Activity Of Griffithsin Against SARS And HCV E-025-2006-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use&body=Please send me information about technology [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use&body=Please send me information about technology [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168226 E-025-2006-0 E-025-2006-0-US-01 Antiviral Activity Of Griffithsin Against SARS And HCV PRV US 60/741,403 Abandoned US <br />Provisional (PRV) 60/741,403<br />Filed on 2005-12-01<br />Status: Abandoned 147168227 E-025-2006-0 E-025-2006-0-PCT-02 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use PCT Patent Cooperation Treaty PCT/US2006/045930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/045930<br />Filed on 2006-12-01<br />Status: Expired 147168228 E-025-2006-0 E-025-2006-0-US-03 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use National Stage US 8,088,729 12/095,697 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088729">8,088,729</a><br />Filed on 2008-05-30<br />Status: Issued 147168229 E-025-2006-0 E-025-2006-0-EP-04 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use National Stage European Patent 1976596 06838737.2 Issued European Patent <br />National Stage 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168230 E-025-2006-0 E-025-2006-0-EP-05 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use DIV European Patent 10014894.9 Abandoned European Patent <br />Divisional (DIV) 10014894.9<br />Filed on 2006-12-01<br />Status: Abandoned 147168231 E-025-2006-0 E-025-2006-0-EP-06 Anti-Viral Griffithsin Compounds, Compositions, and Methods DIV European Patent 2314349 10014895.6 Abandoned European Patent <br />Divisional (DIV) 10014895.6<br />Filed on 2006-12-01<br />Status: Abandoned 147168232 E-025-2006-0 E-025-2006-0-EP-07 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use DIV European Patent 10014893.1 Abandoned European Patent <br />Divisional (DIV) 10014893.1<br />Filed on 2006-12-01<br />Status: Abandoned 147168233 E-025-2006-0 E-025-2006-0-FR-08 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP France 1976596 06838737.2 Issued France <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168234 E-025-2006-0 E-025-2006-0-DE-09 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Germany 1976596 06838737.2 Issued Germany <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168235 E-025-2006-0 E-025-2006-0-IE-10 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Ireland 1976596 06838737.2 Issued Ireland <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168236 E-025-2006-0 E-025-2006-0-GB-11 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP United Kingdom 1976596 06838737.2 Issued United Kingdom <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168237 E-025-2006-0 E-025-2006-0-CH-12 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Switzerland 1976596 06838737.2 Issued Switzerland <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147169695 Anti-Viral 147169697 Corona virus 147169698 Ebola 147169699 Griffithsin 147169700 INFLUENZA 147169702 O’Keefe 147169703 SARS TAB-4307 147157597 High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics S M Rafiqul Islam, Takuya Maeda, Nicholas Restifo, Raul Sakoda, Naritaka Tamaoki <h2>Summary:</h2> <p>NCI seeks proposals from parties interested in licensing an&nbsp;improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers (e.g., melanoma), current methods used to produce cancer-reactive T cells require significant time and may not adequately identify the desired TCRs which bind cancer targets.</p> <p>Researchers at the National Cancer Institute (NCI) Surgery Branch have developed a method which allows for the identification of TCRs from bulk populations of TIL. This method generates induced pluripotent stem cell (iPSC) lines inheriting tumor antigen-specific TCRs from minor populations of TIL, not routinely achievable by other conventional approaches. Additionally, the method can generate previously unidentified tumor antigen-specific iPSC lines without pre-generating tumor antigen-specific T cell lines. This novel method is an improvement in the generation of tumor antigen-specific TCR inherited iPSC lines.</p> <h2>&nbsp;Potential Commercial Applications:</h2> <ul> <li>Therapeutics for a wide range of liquid and solid cancers</li> <li>iPSC lines inheriting tumor antigen-specific TCRs from minor populations of TIL not routinely achievable by other conventional approaches</li> <li>Improved and expedited cell therapy manufacturing, including: <ul> <li>Identification and reprogramming of bulk, polyclonal TIL populations with a high frequency of inherited tumor antigen-specific TCRs</li> <li>Method to identify, clone, and transduce tumor and neoantigen-specific TCRs from a bulk, polyclonal TIL population by genomic DNA sequencing</li> <li>Identification of tumor-reactive TCRs without having to identify their TCR alpha and TCR beta recombination patterns by bioinformatics and algorithm predictions</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>iPSC lines inheriting tumor antigen-specific TCRs from minor populations of TIL not routinely achievable by other conventional approaches</li> <li>Production of several TIL-derived iPSC (TIL-iPSC) with multiple different and novel tumor antigen-specific TCRs</li> <li>iPSC can be expanded without restrictions, and TCR sequencing and identification can be achieved with minimal error by genomic DNA based TCR sequencing</li> <li>Improved generation of tumor antigen-specific TIL for T cell rejuvenation purposes and subsequent TIL-iPSC-derived immunotherapy</li> </ul> 2021-04-28 2026-04-24 2021-04-28 2026-04-24 2021-04-28 act, adoptive cell therapy, ANTIGEN-SPECIFIC, Cancer Targets, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Restifo, Rosenberg, T Cell Receptors, TCR, TIL, Tumor Infiltrated Lymphocytes False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-28 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-091-2019 147162230 Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30449714/ <a href="https://pubmed.ncbi.nlm.nih.gov/30449714/">Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy.</a> 147162345 Vizcardo R, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. https://pubmed.ncbi.nlm.nih.gov/23290135/ <a href="https://pubmed.ncbi.nlm.nih.gov/23290135/">Vizcardo R, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells.</a> 147162383 Maeda T, et al. Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. https://pubmed.ncbi.nlm.nih.gov/27872100/ <a href="https://pubmed.ncbi.nlm.nih.gov/27872100/">Maeda T, et al. Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity.</a> 147164245 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164246 Islam, S M Rafiqul NIH - NCI NCI Islam, S M Rafiqul (NCI) 2 147164244 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 3 147164247 Maeda, Takuya NIH - NCI NCI Maeda, Takuya (NCI) 4 147164243 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 5 147164245 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164246 Islam, S M Rafiqul NIH - NCI NCI Islam, S M Rafiqul (NCI) 2 147164244 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 3 147164247 Maeda, Takuya NIH - NCI NCI Maeda, Takuya (NCI) 4 147164243 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 5 147158008 High-throughput Generation Of IPSC Carrying Antigen Specific TCRs From Tumor Infiltrated Lymphocytes E-109-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes&body=Please send me information about technology [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes&body=Please send me information about technology [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161056 E-109-2020-0 E-109-2020-0-US-01 HIGH-THROUGHPUT GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PRV US 63/068,458 Abandoned US <br />Provisional (PRV) 63/068,458<br />Filed on 2020-08-21<br />Status: Abandoned 147168060 E-109-2020-0 E-109-2020-0-PCT-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PCT Patent Cooperation Treaty PCT/US2021/046969 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/046969<br />Filed on 2021-08-20<br />Status: Expired 147168061 E-109-2020-0 E-109-2020-0-JP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage Japan 2023-512482 Pending Japan <br />National Stage 2023-512482<br />Filed on 2023-02-20<br />Status: Pending 147168062 E-109-2020-0 E-109-2020-0-US-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage US 18/020,823 Pending US <br />National Stage 18/020,823<br />Filed on 2023-02-10<br />Status: Pending 147168063 E-109-2020-0 E-109-2020-0-EP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage European Patent 21769306.8 Pending European Patent <br />National Stage 21769306.8<br />Filed on 2023-03-08<br />Status: Pending 147171635 act 147171636 adoptive cell therapy 147171637 ANTIGEN-SPECIFIC 147171639 Cancer Targets 147171640 Immunotherapy 147171642 Induced Pluripotent Stem Cells 147171643 iPSC 147171644 Restifo 147171645 Rosenberg 147171646 T Cell Receptors 147171647 TCR 147171648 TIL 147171650 Tumor Infiltrated Lymphocytes TAB-4283 147157572 Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Alan Bermingham, Kirk Gustafson, Lauren Krumpe, Christophe Marchand, Barry O'Keefe, Yves Pommier, Johan Rosengren, Ingrid Schroeder, Brice Wilson <h2>Summary:</h2> <p>NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents.</p> <h2>Description of Technology:</h2> <p>Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors such as camptothecin, rinotecan, and topotecan are widely used anti-cancer agents that work by stabilizing the TOP1-DNA cleavage complex. Stabilization causes irreversible double-strand DNA breaks, eventually leading to the death of replicating cancer cells. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that plays a role in allowing cells to escape from TOP1 inhibitor-induced cell death by catalyzing the clearance of TOP1-DNA complexes. This activity led researchers to consider TDP1 a molecular target for the sensitization of replicating cancer cells to camptothecin and related chemotherapeutic agents.</p> <p>Scientists at the National Cancer Institute (NCI) discovered recifin, a unique cysteine-rich cyclic peptide that inhibits the human protein tyrosyl-DNA phosphodiesterase 1 (TDP1). The peptide was isolated from a natural source, the sponge Axinella sp. The three-dimensional structure of recifin was determined by NMR and found to represent a completely new structural class unlike previously published cyclic peptides. Recifin inhibits TDP1 via an allosteric mechanism of inhibition and is the first identified allosteric inhibitor of this protein. TDP1 is important for cancer chemotherapy because its inhibition can restore cancer-cell sensitivity to clinically-used topoisomerase inhibitors.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for various solid cancers previously chemoresistant to some degree &ndash; such as small cell lung and ovarian cancer&nbsp;</li> <li>Development of new chemosensitizing agents: inhibition of tyrosyl-DNA phosphodiesterase 1 (TDP1), an important DNA repair enzyme in humans and a promising inhibition target&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Numerous commercialization and/or sub-licensing opportunities due to wide range of relevant cancers.</li> <li>First-in-class drug; Recifin is the first member of a new family of cyclic peptides that inhibits the enzyme tyrosyl-DNA phosphodiesterase 1 (TDP1)</li> <li>First-in-class with effective and safe chemosensitizer to TOP1 inhibitors&nbsp;</li> <li>Potential for improved clinical responses</li> <li>TDP1 inhibitors can sensitize cancer cells to chemotherapeutic agents &ndash; including topotecan and irinotecan</li> <li>Recifin is stable to protease digestion</li> <li>Scale-up manufacturing: recifin analogues could be created with simple, automated peptide synthesis&nbsp;</li> <li>Sensitizing cells to topoisomerase I (TOP1) inhibitors, including topotecan, irinotecan and related chemotherapeutic agents</li> </ul> 2021-11-04 2026-04-24 2021-11-05 2026-04-24 2021-11-04 CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162473 Bermingham A, et al. Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1) https://pubmed.ncbi.nlm.nih.gov/28697309/ <a href="https://pubmed.ncbi.nlm.nih.gov/28697309/">Bermingham A, et al. Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1)</a> 147164154 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164155 Krumpe, Lauren NCI - FCRDC (Leidos) NCI Krumpe, Lauren (NCI) 2 147164159 Rosengren, Johan The University of Queensland Rosengren, Johan 3 147164157 Schroeder, Ingrid NIH - NCI Leidos Schroeder, Ingrid (Leidos) 4 147164158 Bermingham, Alan Revolution Medicines, Inc. Bermingham, Alan 5 147164153 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 6 147164152 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 7 147164156 Wilson, Brice NIH - NCI NCI Wilson, Brice (NCI) 8 147164151 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 9 147164154 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164155 Krumpe, Lauren NCI - FCRDC (Leidos) NCI Krumpe, Lauren (NCI) 2 147164159 Rosengren, Johan The University of Queensland Rosengren, Johan 3 147164157 Schroeder, Ingrid NIH - NCI Leidos Schroeder, Ingrid (Leidos) 4 147164158 Bermingham, Alan Revolution Medicines, Inc. Bermingham, Alan 5 147164153 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 6 147164152 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 7 147164156 Wilson, Brice NIH - NCI NCI Wilson, Brice (NCI) 8 147164151 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 9 147158203 Recifin, The First Of A Novel Class Of Bioactive Peptides E-202-2020-0 Filing authorized NCI, Revolution Medicines, Inc., The University of Queensland 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues&body=Please send me information about technology [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues&body=Please send me information about technology [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147167870 E-202-2020-0 E-202-2020-0-US-01 TYROSYL-LOCK PEPTIDES PRV US 63/115,418 Abandoned US <br />Provisional (PRV) 63/115,418<br />Filed on 2020-11-18<br />Status: Abandoned 147167871 E-202-2020-0 E-202-2020-0-PCT-02 TYROSYL-LOCK PEPTIDES PCT Patent Cooperation Treaty PCT/US2021/059764 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059764<br />Filed on 2021-11-17<br />Status: Expired 147167872 E-202-2020-0 E-202-2020-0-CA-01 TYROSYL-LOCK PEPTIDES National Stage Canada 3199368 Pending Canada <br />National Stage 3199368<br />Filed on 2023-05-17<br />Status: Pending 147167873 E-202-2020-0 E-202-2020-0-AU-01 TYROSYL-LOCK PEPTIDES National Stage Australia 2021385049 Pending Australia <br />National Stage 2021385049<br />Filed on 2023-05-23<br />Status: Pending 147167874 E-202-2020-0 E-202-2020-0-US-02 TYROSYL-LOCK PEPTIDES National Stage US 18/037,379 Pending US <br />National Stage 18/037,379<br />Filed on 2023-05-17<br />Status: Pending 147167875 E-202-2020-0 E-202-2020-0-EP-01 TYROSYL-LOCK PEPTIDES National Stage European Patent 21840215.4 Pending European Patent <br />National Stage 21840215.4<br />Filed on 2023-06-16<br />Status: Pending 147173584 CANCER 147173586 Chemosensitizing Agents 147173587 CHEMOTHERAPY 147173588 Cyclic Peptide 147173590 Irinotecan TOP1 147173591 O’Keefe 147173592 Recifin 147173593 Tdp1 147173595 Topoisomerase 1 inhibitors 147173596 Topotecan 147173598 Tyrosyl-DNA Phosphodiesterase 1 Inhibitors TAB-4269 147157557 HIV-1 IN Mutant in a Single Round Vector NCI Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Stephen Hughes, Steven Smith <h2>Summary:</h2> <p>The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a&nbsp;collection of single-round vectors containing mutations in HIV-1 IN or RT.</p> <h2>Description of Technology:</h2> <p>Antiretroviral therapy (ART) has changed the prognosis of HIV-1 infection to a chronic illness that, in most cases, can be managed or controlled. Integrase strand transfer inhibitors (INSTIs) and reverse transcription inhibitors are essential components of ART drug cocktails. In compliant individuals, ART has been found to block viral replication completely. Additionally, blocking viral replication can prevent the emergence of drug resistance.</p> <p>Researchers at the Retroviral Replication Laboratory of the National Cancer Institute have introduced mutations into the nucleotides encoding the integrase (IN) or reverse transcriptase (RT) of a replication-defective variant of the pNL4.3 HIV-1 vector. The result is a collection of single-round vectors containing mutations in HIV-1 IN or RT. These mutants can be used in single round-infection assays to evaluate potential anti-HIV drugs. The vector collection contains over 140 mutations or a combination of mutations and has been thoroughly tested and validated. This collection is a good research surrogate as the included vectors are safer versions of HIV-1 viruses when compared to those found in patients.</p> <p>Parties interested in licensing the technology should submit an application for licensing and seek detailed information from the Licensing and Patenting Manager indicated below.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Screening assays to test the efficacy of potential INSTIs or RT anti-HIV drugs</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Collections make from replication-defective variant of the pNL4.3 HIV-1 vector</li> <li>Over 140 mutation or combination of mutations in collection</li> </ul> 2021-11-04 2026-04-24 2021-11-04 2026-04-24 2021-11-04 Anti-HIV Drugs, HIV, Hughes, INSTIs, Integrase Strand Transfer Inhibitors, pNL4.3, Reverse Transcriptase, RT, Single-Round Vectors, Smith False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162075 Smith SJ, et al. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. https://pubmed.ncbi.nlm.nih.gov/33572956/ <a href="https://pubmed.ncbi.nlm.nih.gov/33572956/">Smith SJ, et al. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.</a> 147164115 Smith, Steven NCI - CCR Smith, Steven 1 147164114 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 2 147164115 Smith, Steven NCI - CCR Smith, Steven 1 147164114 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 2 147158016 HIV-1 IN Mutants In A Single Round Vector E-114-2021-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4269] HIV-1 IN Mutant in a Single Round Vector&body=Please send me information about technology [TAB-4269] HIV-1 IN Mutant in a Single Round Vector.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4269] HIV-1 IN Mutant in a Single Round Vector&body=Please send me information about technology [TAB-4269] HIV-1 IN Mutant in a Single Round Vector.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147171717 Anti-HIV Drugs 147171718 HIV 147171720 Hughes 147171721 INSTIs 147171723 Integrase Strand Transfer Inhibitors 147171725 pNL4.3 147171727 Reverse Transcriptase 147171728 RT 147171730 Single-Round Vectors 147171732 Smith TAB-4223 147157508 Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Crystal Mackall, Rimas Orentas, Ira Pastan, Nirali Shah <h2>Description of Technology:</h2> <p>Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.&nbsp; Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.&nbsp; Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.&nbsp; This promising new therapeutic approach is known as adoptive cell therapy.<br /> &nbsp;<br /> CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma.&nbsp; Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins.&nbsp; This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of diseases associated with increased or preferential expression of CD22</li> <li>Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, potentially resulting in fewer non-specific side-effects and healthier patients</li> <li>Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream&nbsp;</li> <li>Expression of CD22 only on mature cells avoids stem cell elimination during treatment</li> </ul> 2021-06-02 2026-04-24 2021-06-02 2026-04-24 2021-06-02 Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-02 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-017-2017 E-080-2008 E-106-2015 E-161-2018 147161901 Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial https://pubmed.ncbi.nlm.nih.gov/32286905/ <a href="https://pubmed.ncbi.nlm.nih.gov/32286905/">Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial</a> 147163959 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 0 147163960 Shah, Nirali NIH - NCI NCI Shah, Nirali (NCI) 1 147163956 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163958 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163957 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147163960 Shah, Nirali NIH - NCI NCI Shah, Nirali (NCI) 1 147163959 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 0 147163956 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163958 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163957 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147158326 High Activity Chimeric Antigen Receptor For CD22 E-291-2012-0 Filing authorized NCI 147162599 M971 CAR Research Material E-291-2012-1 Research Material NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers&body=Please send me information about technology [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers&body=Please send me information about technology [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161263 E-291-2012-0 E-291-2012-0-US-01 M971 Chimeric Antigen Receptors PRV US 61/717,960 Abandoned US <br />Provisional (PRV) 61/717,960<br />Filed on 2012-10-24<br />Status: Abandoned 147167485 E-291-2012-0 E-291-2012-0-PCT-02 M971 Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US2013/060332 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/060332<br />Filed on 2013-09-18<br />Status: Expired 147167486 E-291-2012-0 E-291-2012-0-AU-03 M971 Chimeric Antigen Receptors National Stage Australia 2013335180 2013335180 Issued Australia <br />National Stage 2013335180<br />Filed on 2013-09-18<br />Status: Issued 147167487 E-291-2012-0 E-291-2012-0-BR-04 M971 Chimeric Antigen Receptors National Stage Brazil BR112015009003-6 BR112015009003-6 Issued Brazil <br />National Stage BR112015009003-6<br />Filed on 2015-04-22<br />Status: Issued 147167488 E-291-2012-0 E-291-2012-0-CA-05 M971 Chimeric Antigen Receptors National Stage Canada 2889055 2889055 Issued Canada <br />National Stage 2889055<br />Filed on 2013-09-18<br />Status: Issued 147167489 E-291-2012-0 E-291-2012-0-CN-06 M971 Chimeric Antigen Receptors National Stage China ZL201380061387.5 201380061387.5 Issued China <br />National Stage 201380061387.5<br />Filed on 2015-05-25<br />Status: Issued 147167490 E-291-2012-0 E-291-2012-0-EP-07 M971 Chimeric Antigen Receptors National Stage European Patent 2912061 13773468.7 Issued European Patent <br />National Stage 13773468.7<br />Filed on 2013-09-18<br />Status: Issued 147167491 E-291-2012-0 E-291-2012-0-IN-08 M971 Chimeric Antigen Receptors National Stage India 385803 2344/CHENP/2015 Issued India <br />National Stage 2344/CHENP/2015<br />Filed on 2013-09-18<br />Status: Issued 147167492 E-291-2012-0 E-291-2012-0-JP-09 M971 Chimeric Antigen Receptors National Stage Japan 6338252 2015-539602 Issued Japan <br />National Stage 2015-539602<br />Filed on 2013-09-18<br />Status: Issued 147167493 E-291-2012-0 E-291-2012-0-RU-10 M971 Chimeric Antigen Receptors National Stage Russia 2658485 2015117237 Issued Russia <br />National Stage 2015117237<br />Filed on 2015-05-07<br />Status: Issued 147167494 E-291-2012-0 E-291-2012-0-US-11 M971 Chimeric Antigen Receptors National Stage US 10,072,078 14/437,889 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072078 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072078">10,072,078</a><br />Filed on 2015-04-23<br />Status: Issued 147167495 E-291-2012-0 E-291-2012-0-HK-12 M971 Chimeric Antigen Receptors National Stage Hong Kong HK1213922B 16101891.0 Issued Hong Kong <br />National Stage 16101891.0<br />Filed on 2016-02-19<br />Status: Issued 147167496 E-291-2012-0 E-291-2012-0-RU-13 M971 Chimeric Antigen Receptors DIV Russia 2770411 2018116582 Issued Russia <br />Divisional (DIV) 2018116582<br />Filed on 2018-05-04<br />Status: Issued 147167497 E-291-2012-0 E-291-2012-0-JP-14 M971 Chimeric Antigen Receptors DIV Japan 6643394 2018-088908 Issued Japan <br />Divisional (DIV) 2018-088908<br />Filed on 2018-05-02<br />Status: Issued 147167499 E-291-2012-0 E-291-2012-0-AU-16 M971 Chimeric Antigen Receptors DIV Australia 2018204257 2018204257 Issued Australia <br />Divisional (DIV) 2018204257<br />Filed on 2018-06-14<br />Status: Issued 147167500 E-291-2012-0 E-291-2012-0-US-17 M971 CHIMERIC ANTIGEN RECEPTORS DIV US 10,703,816 16/107,271 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703816 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703816">10,703,816</a><br />Filed on 2018-08-21<br />Status: Issued 147167501 E-291-2012-0 E-291-2012-0-DE-18 M971 Chimeric Antigen Receptors EP Germany 2912061 13773468.7 Issued Germany <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167502 E-291-2012-0 E-291-2012-0-ES-19 M971 Chimeric Antigen Receptors EP Spain 2912061 13773468.7 Issued Spain <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167503 E-291-2012-0 E-291-2012-0-FR-20 M971 Chimeric Antigen Receptors EP France 2912061 13773468.7 Issued France <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167504 E-291-2012-0 E-291-2012-0-GB-21 M971 Chimeric Antigen Receptors EP United Kingdom 2912061 13773468.7 Issued United Kingdom <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167505 E-291-2012-0 E-291-2012-0-IT-22 M971 Chimeric Antigen Receptors EP Italy 2912061 13773468.7 Issued Italy <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167506 E-291-2012-0 E-291-2012-0-CN-23 M971 Chimeric Antigen Receptors DIV China ZL201910500128.7 201910500128.7 Issued China <br />Divisional (DIV) 201910500128.7<br />Filed on 2019-06-11<br />Status: Issued 147167507 E-291-2012-0 E-291-2012-0-US-24 M971 CHIMERIC ANTIGEN RECEPTORS DIV US 11,807,682 16/869,792 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11807682 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11807682">11,807,682</a><br />Filed on 2020-05-08<br />Status: Issued 147174692 Acute Lymphoblastic Leukemia 147174693 adoptive cell therapy 147174694 ALL 147174695 B-CELL 147174696 CD22 147174697 Chimeric antigen receptors (CARs) 147174698 Chronic lymphocytic leukemia 147174699 CLL 147174700 Dimitrov 147174701 Hairy cell leukemia 147174702 HCL 147174703 Immunotherapy 147174704 pediatric TAB-4216 147157501 New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Celeste Alverez, Kenneth Jacobson, Kyung Lee, Jung-Eun Park <h2>Summary:</h2> <p>The National Institutes of Health is seeking commercial partners to co-develop and/or license a&nbsp;heterocyclic scaffold for development of&nbsp;therapeutics against Plk1-dependent cancers.</p> <h2>Description of Technology:</h2> <p>Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family, plays a critical role in regulating mitosis and cell cycle progression. Aberrant expression of Plk1 has been observed in a variety of human cancers, and it is known to be associated with tumorigenesis as well as poor prognosis in cancer patients. Unlike normal cells, some cancer cells are dependent on augmented Plk1 levels to remain viable and are killed when Plk1 function is attenuated. Although Plk1 has proven to be an attractive target in cancer treatment, currently available Plk1 inhibitors have shown limited efficacy with significant dose-limiting toxicity and non-specificity in various preclinical or clinical trials. Thus, there remains an unmet need to develop anti-cancer drugs that are highly specific against Plk1 and have better clinical outcomes.</p> <p>Scientists at the National Institutes of Health have identified a new heterocyclic scaffold with unique structural and chemical features that can be leveraged for anti-Plk1 drug discovery. This triazoloquinazolinone scaffold can be used to synthesize various S-methyl prodrugs that effectively inhibit the functionally essential, polo-box domain (PBD) of Plk1 without affecting its related Plk2 and Plk3 PBDs. These prodrugs effectively arrest mitotic progression and cell proliferation in cell-based assays. Low molecular weight and moderate hydrophobicity of these prodrugs increase their availability in intracellular compartments. Promising chemical features of these compounds could offer a new avenue for developing therapeutics against Plk1-dependent cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anticancer therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially superior toxicity profile while maintaining specificity</li> <li>Inhibition of Plk1-driven cellular proliferation</li> <li>PBD-directed inhibitors show selectivity advantages over classical inhibitors of Plk1</li> <li>Exhibit specific anti-Plk1 PBD activity in both in vitro biochemical and cell-based assays without affecting Plk2 and Plk3 PBDs</li> <li>Anticipated not to be chemically reactive unlike many of the current inhibitors of Plk1 PBD that contain electrophilic groups</li> <li>Exhibit &ge;10-fold higher inhibitory activity than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT</li> <li>Low molecular weight and moderate hydrophobicity of these molecules increases their anti-cancer activity in intracellular compartments</li> </ul> 2021-05-05 2026-04-24 2021-05-05 2026-04-24 2021-05-05 CANCER, cell cycle, Heterocyclic Scaffold, Lee, mitosis, Oncology, PBD, plk1, Polo-Box Domain, Polo-Like Kinase 1, PRODRUGS, Triazoloquinazolinone False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-094-2013 E-178-2017 E-179-2017 E-181-2009 E-186-2015 E-254-2016 147161893 Alverez CN, et al. Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1. https://pubmed.ncbi.nlm.nih.gov/33175530/ <a href="https://pubmed.ncbi.nlm.nih.gov/33175530/">Alverez CN, et al. Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1.</a> 147163939 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 1 147163938 Jacobson, Kenneth NIH - NIDDK NIDDK Jacobson, Kenneth (NIDDK) 2 147163941 Alverez, Celeste NIH - NCI NCI Alverez, Celeste (NCI) 3 147163940 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147163939 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 1 147163938 Jacobson, Kenneth NIH - NIDDK NIDDK Jacobson, Kenneth (NIDDK) 2 147163941 Alverez, Celeste NIH - NCI NCI Alverez, Celeste (NCI) 3 147163940 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147158216 Development Of New Heterocyclic Scaffold-based Prodrugs Against The Polo-box Domain Of Polo-like Kinase 1 E-211-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer&body=Please send me information about technology [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer&body=Please send me information about technology [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161197 E-211-2020-0 E-211-2020-0-US-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PRV US 63/082,813 Abandoned US <br />Provisional (PRV) 63/082,813<br />Filed on 2020-09-24<br />Status: Abandoned 147167463 E-211-2020-0 E-211-2020-0-PCT-02 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PCT Patent Cooperation Treaty PCT/US2021/052054 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/052054<br />Filed on 2021-09-24<br />Status: Expired 147167464 E-211-2020-0 E-211-2020-0-AU-01 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage Australia 2021350736 Pending Australia <br />National Stage 2021350736<br />Filed on 2023-04-18<br />Status: Pending 147167465 E-211-2020-0 E-211-2020-0-US-02 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage US 18/028,463 Pending US <br />National Stage 18/028,463<br />Filed on 2023-03-24<br />Status: Pending 147167466 E-211-2020-0 E-211-2020-0-CA-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER National Stage Canada 3193855 Pending Canada <br />National Stage 3193855<br />Filed on 2023-03-24<br />Status: Pending 147167467 E-211-2020-0 E-211-2020-0-EP-01 PLK1 POLO DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage European Patent 21795110.2 Pending European Patent <br />National Stage 21795110.2<br />Filed on 2023-04-19<br />Status: Pending 147173725 CANCER 147173726 cell cycle 147173728 Heterocyclic Scaffold 147173729 Lee 147173730 mitosis 147173731 Oncology 147173732 PBD 147173733 plk1 147173735 Polo-Box Domain 147173737 Polo-Like Kinase 1 147173738 PRODRUGS 147173740 Triazoloquinazolinone TAB-4184 147157469 Automated Digital Pathology Device for High-Throughput Demand NCI Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Anthony Cappadona, Young-Wan Moon, Zhengping (Ping) Zhuang <h2>Summary:</h2> <p>The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.</p> <h2>Description of Technology:</h2> <p>Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This resulted in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of the techniques used in processing of pathology samples and acquisition of digital images to make them amenable with high-throughput approaches like AI analysis.</p> <p>National Cancer Institute inventors are developing an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing (e.g., sectioning, fixing, and staining) with optical scanning and digital image acquisition. This streamlines the entire process enabling high-throughput preparation of large volumes of samples and data for subsequent AI analysis. As a result of automation, the device saves time, minimizes errors, and reduces wasting reagents and supplies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Biopsy sample processing in pathology labs, hospitals, research labs</li> <li>Applicable to diagnoses of various disease indications, including cancer and infectious diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Facilitates processing and imaging of large volumes of pathology samples</li> <li>Automation saves time, increases reproducibility, and minimizes errors</li> <li>Compatible with high-throughput processes, e.g., AI analysis of digital pathology images and 3D reconstruction</li> </ul> 2021-09-23 2026-04-24 2021-09-23 2026-04-24 2021-09-23 AI, Artificial Intelligence, AUTOMATION, Digital Pathology, High-throughput, Histology, IMAGING, Zhuang False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-23 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163813 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147163814 Moon, Young-Wan AIPATec, Inc. Moon, Young-Wan 2 147163815 Cappadona, Anthony NCI - CCR NCI Cappadona, Anthony (NCI) 3 147163813 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147163814 Moon, Young-Wan AIPATec, Inc. Moon, Young-Wan 2 147163815 Cappadona, Anthony NCI - CCR NCI Cappadona, Anthony (NCI) 3 147157951 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand E-084-2019-0 Filing authorized AIPATec, Inc., NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand&body=Please send me information about technology [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand&body=Please send me information about technology [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147167192 E-084-2019-0 E-084-2019-0-US-01 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand PRV US 62/820,604 Abandoned US <br />Provisional (PRV) 62/820,604<br />Filed on 2019-03-19<br />Status: Abandoned 147167193 E-084-2019-0 E-084-2019-0-PCT-02 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING PCT Patent Cooperation Treaty PCT/US2020/023644 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/023644<br />Filed on 2020-03-19<br />Status: Expired 147167194 E-084-2019-0 E-084-2019-0-EP-03 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand National Stage European Patent 20772823.9 Pending European Patent <br />National Stage 20772823.9<br />Filed on 2020-03-19<br />Status: Pending 147167195 E-084-2019-0 E-084-2019-0-JP-04 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage Japan 7680363 2021-555576 Issued Japan <br />National Stage 2021-555576<br />Filed on 2021-09-14<br />Status: Issued 147167196 E-084-2019-0 E-084-2019-0-US-05 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage US 17/440,368 Pending US <br />National Stage 17/440,368<br />Filed on 2021-09-17<br />Status: Pending 147167197 E-084-2019-0 E-084-2019-0-CN-06 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand National Stage China ZL202080023309.6 202080023309.6 Issued China <br />National Stage 202080023309.6<br />Filed on 2020-03-19<br />Status: Issued 147167198 E-084-2019-0 E-084-2019-0-KR-07 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage South Korea 10-2021-7033539 Pending South Korea <br />National Stage 10-2021-7033539<br />Filed on 2021-10-18<br />Status: Pending 147171081 AI 147171082 Artificial Intelligence 147171083 AUTOMATION 147171084 Digital Pathology 147171085 High-throughput 147171086 Histology 147171087 IMAGING 147171088 Zhuang TAB-4183 147157468 Size-dependent brain distribution of macromolecular drug delivery platform NCI Collaboration, Licensing, Neurology, Oncology Collaboration Licensing Neurology Oncology Stephan Stern, David Stevens <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for&nbsp;a selective polylysine succinylated (PLS) drug delivery platform.</p> <h2>Description of Technology:</h2> <p>The blood brain barrier (BBB) is a specialized endothelium that prevents the uptake of substances from the systemic circulation into the central nervous system. This barrier, while protecting the sensitive physiological environment of the brain, is also a major impediment in administering therapeutics that need to pass through the BBB. A drug delivery platform that could deliver therapeutic agents directly to the brain is needed, and could have wide ranging significance in a variety of psychiatric, oncology, infectious, and neurodegenerative diseases. Currently, there are no approved formulations that can effectively increase drug exposure to the brain, and this remains an unmet clinical need.</p> <p>&nbsp;Investigators in the Nanotechnology Characterization Laboratory at the National Cancer Institute (NCI) have developed a selective polylysine succinylated (PLS) drug delivery platform, which can pass through the BBB by scavenger receptor A1 (SR-A1)- mediated transcytosis, and also target SR-A1 expressing cells, such as macrophages, monocytes, mast cells, and dendritic cells. This PLS polymer has an anionic backbone, containing pendant carboxylic acids that facilitate conjugation of therapeutic agent having a free alcohol moiety via hydrolysable ester bonds. Thus, the PLS platform has tremendous versatility in delivering a wide variety of therapeutic cargos to the brain. In addition to small molecules, other classes of therapeutic drugs that can be conjugated to the PLS polymer include nucleic acids and peptides. In addition to delivering therapeutic agents, this technology can also be used for imaging applications by conjugating imaging agents to the PLS polymer. This technology is a variant of the PLS drug delivery platform previously developed by the inventors (NIH Reference # E-097-2017).&nbsp;&nbsp;</p> <p>Through in vivo mice fluorescent studies, the inventors have shown greater brain distribution with 10k and 25k PLS polymers in comparison to a larger, 62.5k polymer. This polymer platform has tremendous potential to increase drug delivery to the brain and lymphatic system, as well as stabilize metabolically labile drugs. It offers a novel therapeutic strategy for treating brain cancers and other neurological disorders. It also brings a novel imaging approach for diagnostic purposes.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of brain cancer</li> <li>Treatment of neurological disorders representing significant unmet medical needs; e.g., Alzheimer&rsquo;s disease, depression and epilepsy</li> <li>Treatment of infectious diseases</li> <li>Imaging of the central nervous system</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Currently no efficient, general drug delivery system to cross the blood-brain barrier; this invention would be the first-to-market</li> <li>Several go-to-market opportunities; this technology could be used to treat psychiatric, oncology, infectious disease and neurodegenerative-related diseases</li> <li>Would overcome the major factor limiting the future growth of neurotherapeutics</li> </ul> 2021-02-09 2026-04-24 2022-10-04 2026-04-24 2021-02-09 BBB, Blood-brain Barrier, Brain Cancer, Controlled Drug Release, Drug Delivery Platform, Neurological Disorders, Stern False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-097-2017 147161875 Frederick National Laboratory web article entitled &ldquo;Novel prodrug platform enables drug delivery to lymphatic system&rdquo; https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-delivery-lymphatic-system <a href="https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-delivery-lymphatic-system">Frederick National Laboratory web article entitled &ldquo;Novel prodrug platform enables drug delivery to lymphatic system&rdquo;</a> 147161991 Stephan T. Stern et al., &ldquo;Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV&rdquo;, corresponding to NIH Ref. E-097-20172. https://pubmed.ncbi.nlm.nih.gov/32841040/ <a href="https://pubmed.ncbi.nlm.nih.gov/32841040/">Stephan T. Stern et al., &ldquo;Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV&rdquo;, corresponding to NIH Ref. E-097-20172.</a> 147163811 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 1 147163812 Stevens, David NIH - NCI Stevens, David 2 147163811 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 1 147163812 Stevens, David NIH - NCI Stevens, David 2 147157936 Size-dependent Brain Distribution Of Macromolecular Drug Delivery Platform E-078-2020-0 Filing authorized NCI, NIH - NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform&body=Please send me information about technology [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform&body=Please send me information about technology [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161007 E-078-2020-0 E-078-2020-0-US-01 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM PRV US 63/037,058 Abandoned US <br />Provisional (PRV) 63/037,058<br />Filed on 2020-06-10<br />Status: Abandoned 147167186 E-078-2020-0 E-078-2020-0-PCT-02 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM PCT Patent Cooperation Treaty PCT/US2021/036548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/036548<br />Filed on 2021-06-09<br />Status: Expired 147167187 E-078-2020-0 E-078-2020-0-AU-03 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage Australia 2021289443 Pending Australia <br />National Stage 2021289443<br />Filed on 2021-06-09<br />Status: Pending 147167188 E-078-2020-0 E-078-2020-0-CA-04 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage Canada 3186654 Pending Canada <br />National Stage 3186654<br />Filed on 2021-06-09<br />Status: Pending 147167189 E-078-2020-0 E-078-2020-0-EP-05 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage European Patent 21822452.5 Pending European Patent <br />National Stage 21822452.5<br />Filed on 2023-01-05<br />Status: Pending 147167190 E-078-2020-0 E-078-2020-0-US-06 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage US 18/009,710 Pending US <br />National Stage 18/009,710<br />Filed on 2022-12-09<br />Status: Pending 147170873 BBB 147170875 Blood-brain Barrier 147170877 Brain Cancer 147170879 Controlled Drug Release 147170881 Drug Delivery Platform 147170883 Neurological Disorders 147170884 Stern TAB-4136 147157418 IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Jessica Hong <h2>Description of Technology:</h2> <p>Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.</p> <p>Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain and the transmembrane domain. Hinge changes in CAR design can achieve the threshold of antigen density required for optimal CAR-T cell activity. Significantly, the optimized GPC1-IgG4 hinge CARs have shown rapid and complete tumor regression in mouse models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapeutic applications for the treatment of pancreatic adenocarcinoma &ndash; a significant unmet medical need</li> <li>Immunotherapeutic applications for the treatment of several GPC1-positive malignancies &ndash; including uterine cervical cancer, colorectal cancer, liver cancer, glioma, lung cancer, head and neck cancer, thyroid cancer, endometrial cancer, breast cancer and ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>GPC1-targeted CAR T cells demonstrated potent antitumor efficacy in a peritoneal dissemination xenograft mouse model.</li> <li>Recombinant receptors providing both antigen-binding and T-cell&ndash;activating functions&nbsp;</li> <li>Likely successful targeting and lower toxicity due to high affinity of the GPC1 nanobody fragment</li> <li>Incorporation of the IgG4 hinge sequence increases the potency of the nanobody based CARs against pancreatic cancer&nbsp;</li> <li>CARs using the IgG4 hinge domain are available for immediate testing</li> <li>Potential immunotherapy for several cancer types with few treatment options &ndash; including pancreatic adenocarcinoma and uterine cervical cancer&nbsp;</li> </ul> 2021-08-18 2026-04-24 2021-08-18 2026-04-24 2021-08-18 cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2019 147163647 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163648 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163647 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163648 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147158003 IgG4 Hinge Containing Chimeric Antigen Receptors For Treating Solid Tumors E-107-2020-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors&body=Please send me information about technology [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors&body=Please send me information about technology [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161052 E-107-2020-0 E-107-2020-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PRV US 63/065,388 Abandoned US <br />Provisional (PRV) 63/065,388<br />Filed on 2020-08-13<br />Status: Abandoned 147166868 E-107-2020-0 E-107-2020-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PCT Patent Cooperation Treaty PCT/US2021/045305 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045305<br />Filed on 2021-08-10<br />Status: Expired 147166869 E-107-2020-0 E-107-2020-0-CN-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage China 202180070402.7 Pending China <br />National Stage 202180070402.7<br />Filed on 2023-04-13<br />Status: Pending 147166870 E-107-2020-0 E-107-2020-0-US-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage US 18/020,191 Pending US <br />National Stage 18/020,191<br />Filed on 2023-02-07<br />Status: Pending 147166871 E-107-2020-0 E-107-2020-0-EP-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage European Patent 21762956.7 Pending European Patent <br />National Stage 21762956.7<br />Filed on 2023-02-08<br />Status: Pending 147171570 cancer therapeutic 147171571 CAR 147171572 chimeric antigen receptor 147171573 Glypican-1 147171575 GPC-1 147171576 Hinge 147171577 HO 147171578 IgG4 147171580 Immunoglobulin subclass 4 147171581 NANOBODY 147171582 Pancreatic Cancer 147171583 Single Domain Antibody TAB-4135 147157417 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jay Berzofsky, Kaddy Camara, Amy Howell, Lise Pasquet, Masaki Terabe <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2</p> <h2>Description of Technology:</h2> <p>Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2 switches immune specificity to activate type I NKT cells, triggering a potent IFN-&gamma;&ndash;mediated Th1 response. This novel mechanism significantly reduces lung metastases in preclinical models and positions C24:2 as a promising candidate for next-generation cancer immunotherapy.</p> <p>The structure and synthesis procedure of C24:2 are described in Patent Cooperation Treaty PCT/US2019/023890 which corresponds to E-100-2018 and for which Dr. Jay Berzofsky is the lead inventor. .</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic agent for lung metastases from different types of cancers</li> <li>Immunomodulator for type I NKT cell</li> <li>Combination therapy with checkpoint inhibitors or cancer vaccines</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses a high unmet need: No effective therapies currently exist for lung metastases.</li> <li>First-in-class approach: Exploits a unique mechanism based on antigen processing and NKT cell subtype switching.</li> <li>Broad cancer applicability: Effective against metastases from diverse tumor types.</li> <li>Combination potential: May synergize with approved checkpoint inhibitors to boost patient outcomes</li> </ul> The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2. 2021-02-24 2026-04-24 2021-02-24 2026-04-24 2021-02-24 3-o-sulfo-galactosylceramide Analogs, Berzofsky, C24:2, Immunotherapy, lung cancer, Metastasis, Natural Killer cells, NKT cells, Sulfatide Analogs, T Cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-034-2010 164128544 Nishio et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. (PMID 38127463) https://pubmed.ncbi.nlm.nih.gov/38127463/ <a href="https://pubmed.ncbi.nlm.nih.gov/38127463/">Nishio et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. (PMID 38127463)</a> 147163644 Pasquet, Lise NIH - NCI Pasquet, Lise 1 147163642 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163645 Howell, Amy University of Connecticut Howell, Amy 3 147163643 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163646 Camara, Kaddy University of Connecticut Camara, Kaddy 5 147163644 Pasquet, Lise NIH - NCI Pasquet, Lise 1 147163642 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163645 Howell, Amy University of Connecticut Howell, Amy 3 147163643 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163646 Camara, Kaddy University of Connecticut Camara, Kaddy 5 147157987 C24:2 Activates The Regulatory Type II NKT Cells And Limits The Development Of Lung Metastasis E-100-2018-0 Filing authorized NCI, University of Connecticut 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases&body=Please send me information about technology [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases&body=Please send me information about technology [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147161038 E-100-2018-0 E-100-2018-0-US-01 ACTIVATORS OF TYPE II NKT CELLS AND METHODS OF USE THEREOF PRV US 62/648,167 Abandoned US <br />Provisional (PRV) 62/648,167<br />Filed on 2018-03-26<br />Status: Abandoned 147166864 E-100-2018-0 E-100-2018-0-PCT-02 ACTIVATORS OF TYPE II NKT CELLS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2019/023890 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/023890<br />Filed on 2019-03-25<br />Status: Expired 147166865 E-100-2018-0 E-100-2018-0-EP-03 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF National Stage European Patent 19716658.0 Pending European Patent <br />National Stage 19716658.0<br />Filed on 2020-10-07<br />Status: Pending 147166866 E-100-2018-0 E-100-2018-0-US-04 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF National Stage US 12,268,700 17/041,604 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12268700 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12268700">12,268,700</a><br />Filed on 2020-09-25<br />Status: Issued 147171417 3-o-sulfo-galactosylceramide Analogs 147171419 Berzofsky 147171420 C24:2 147171421 Immunotherapy 147171422 lung cancer 147171423 Metastasis 147171425 Natural Killer cells 147171427 NKT cells 147171429 Sulfatide Analogs 147171430 T Cells TAB-4133 147157415 CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles NCI Collaboration, Immunology, Licensing, Oncology, Research Materials Collaboration Immunology Licensing Oncology Research Materials Peng Jiang <h2>Description of Technology:</h2> <p>Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. However, systematic profiling of cytokine signaling activities has remained challenging due to the short half-lives of cytokines, and the pleiotropic functions and redundancy of cytokine activities within specific cellular contexts. The redundancy and pleiotropy in cytokine activities are not fully captured by most immunological assays such as the enzyme-linked immunosorbent assay (ELISA) and Luminex xMAP, which only measures the cytokine release level that could be transient and do not reflect target signaling activities. On the other hand, existing databases of cytokine signaling targets cover only a small fraction of cytokines, leaving most cytokine-induced target changes unexplored.&nbsp;</p> <p>Researchers at National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig) that uses transcriptome data to model the cytokine signaling activity and regulatory cascade in human inflammatory processes. To build the CytoSig platform, the Framework for Data Curation (FDC) was created to couple large-scale automatic data processing with natural language processing functions to assist expert annotations of metadata to analyze RNA-sequencing (RNA-seq) and MicroArray big-data resources. CytoSig includes an initial set of 20,591 curated human cytokine, chemokine, and growth factor response experiments, and can reliably predict the activity of 43 cytokines in both tissues and single cells based on the transcriptional effect of cytokine target genes. CytoSig, an excellent tool for leveraging the big-data resource in public domains to predict clinical outcome of anticancer therapies that inhibit cytokine signaling, is available for co-development and/or licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Predicting cytokine target activities from bulk transcriptomic data available from large-scale cohorts and single-cell RNA-seq data</li> <li>Identifying new immunological functions of cytokines and candidate therapeutic targets in inflammatory diseases</li> <li>Predicting the clinical outcome of therapies that inhibit cytokine signaling in human inflammatory diseases and cancer.</li> <li>Framework for Data Curation (FDC) can be used by data scientists to accelerate data curation projects</li> <li>Applicable to cancers, infectious diseases, and inflammation</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li style="margin-left:9pt">Integrative framework that leverages the big-data resource in public domains to identify candidate therapeutic targets</li> <li style="margin-left:9pt">Higher cytokine coverage compared to existing databases</li> <li style="margin-left:9pt">CytoSig predictions had better associations with the clinical outcome than other metrics, such as ligand or receptor expression and gene-set signatures</li> <li style="margin-left:9pt">Offers particular advantages in analyzing single-cell data because it is not affected by the absence of cytokine-producing cells or zero read counts for ligand or receptor genes</li> </ul> 2021-11-17 2026-04-24 2021-11-17 2026-04-24 2021-11-17 Big-data Integration, Cancer Immunotherapy, CDSS, Clinical Decision Support System, Cytokine Signaling, Infectious Disease, Inflammation, Jiang, Target Discovery, Transcriptomic Profiles False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-11-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161877 Jiang P, et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. https://pubmed.ncbi.nlm.nih.gov/34594031/ <a href="https://pubmed.ncbi.nlm.nih.gov/34594031/">Jiang P, et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels.</a> 147163639 Jiang, Peng NCI - DCTD NCI Jiang, Peng (NCI) 1 147163639 Jiang, Peng NCI - DCTD NCI Jiang, Peng (NCI) 1 147157955 CellSig: A Data-driven Predictive Model Of Cytokine Signaling And Regulatory Activity E-086-2021-0 Research Material NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles&body=Please send me information about technology [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles&body=Please send me information about technology [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171118 Big-data Integration 147171119 Cancer Immunotherapy 147171121 CDSS 147171123 Clinical Decision Support System 147171125 Cytokine Signaling 147171126 Infectious Disease 147171127 Inflammation 147171129 Jiang 147171131 Target Discovery 147171133 Transcriptomic Profiles TAB-4072 147157354 Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Shar-yin Huang, Brianna Mitchell, Yves Pommier <h2>Summary:</h2> <p>The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains.</p> <h2>Description of Technology:</h2> <p>Topoisomerase poisons, such as quinolone antibiotics, are widely used as anticancer drugs and antibiotics. Quinolone antibiotics act by trapping prokaryotic type IIA topoisomerases (DNA gyrase and TOPO IV), resulting in irreversible topoisomerase cleavage complexes. However, current U.S. Food and Drug Administration (FDA) guidance reserves the use of quinolones for the most serious bacterial infections due to their associated side effects and to limit the occurrence of drug-resistant bacterial strains. Resistance to available antibiotics in pathogenic bacteria is a global challenge as the number of drug-resistant strains increased dramatically each year.&nbsp;</p> <p>Combination of antibiotics with antibiotic adjuvants offers a productive strategy to address the widespread emergence of antibiotic-resistant strains. Exonuclease VII (ExoVII) repairs quinolone-induced DNA damage by excising the tyrosyl-DNA linkage between DNA and trapped DNA gyrase, an essential prokaryotic type II A topoisomerase. Consequently, inactivation of ExoVII results in hypersensitivity to quinolones. Researchers at the NCI have discovered ExoVII inhibitors that synergize with the antimicrobial activity of the quinolone antibiotic ciprofloxacin. These inhibitors present strong potential as antibiotic adjuvants increasing the potency of quinolones &ndash; particularly against quinolone-resistant bacterial strains. In addition, the combination of ExoVII inhibitors with quinolones may allow dose reduction &ndash; potentially decreasing side-effects.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Antibiotic adjuvant in combination with ciprofloxacin and other quinolone antibiotics&nbsp;</li> <li>Antibiotic adjuvant in combination with other topoisomerase poisons&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>ExoVII inhibitor increases the efficacy of quinolone antibiotics, allowing dose reduction for quinolones and potentially decrease side-effects and be well-tolerated</li> <li>Potentially overcome bacterial resistance to quinolones&nbsp;</li> <li>Lack of inhibitory activity against human tyrosyl-DNA phosphodiesterase (TDP) suggests that inhibitors targeting prokaryotic ExoVII might decrease side-effects and be well-tolerated</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of ExoVII inhibitors and quinolones as a novel treatment for bacterial infections. 2021-05-07 2026-04-24 2021-05-07 2026-04-24 2021-05-12 Antibacterial, Antibiotic Adjuvants, Antibiotic Resistance, DNA gyrase, Exonuclease VII, ExoVII, Infection, Pommier, Quinolone, TOPO IV, Topoisomerase Poisons False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162122 Huang SN, et al. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. https://advances.sciencemag.org/content/7/10/eabe0384 <a href="https://advances.sciencemag.org/content/7/10/eabe0384">Huang SN, et al. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes.</a> 147163421 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 1 147163422 Huang, Shar-yin NIH - NCI NCI Huang, Shar-yin (NCI) 2 147163423 Mitchell, Brianna NIH - NCI NCI Mitchell, Brianna (NCI) 3 147163421 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 1 147163422 Huang, Shar-yin NIH - NCI NCI Huang, Shar-yin (NCI) 2 147163423 Mitchell, Brianna NIH - NCI NCI Mitchell, Brianna (NCI) 3 147158139 Isoquinolinedione Derivatives Specifically Inhibit Exonuclease VII And Synergizes With Quinolones As Antimicrobials E-171-2020-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection&body=Please send me information about technology [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection&body=Please send me information about technology [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147166338 E-171-2020-0 E-171-2020-0-US-01 EXO VII INHIBITOR AND QUINOLONE ANTIBIOTIC COMBINATION USEFUL FOR TREATING BACTERIAL INFECTION PRV US 63/129,271 Abandoned US <br />Provisional (PRV) 63/129,271<br />Filed on 2020-12-22<br />Status: Abandoned 147166339 E-171-2020-0 E-171-2020-0-PCT-02 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection PCT Patent Cooperation Treaty PCT/US2021/064996 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/064996<br />Filed on 2021-12-22<br />Status: Expired 147166340 E-171-2020-0 E-171-2020-0-CA-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage Canada 3205044 Pending Canada <br />National Stage 3205044<br />Filed on 2023-06-12<br />Status: Pending 147166341 E-171-2020-0 E-171-2020-0-AU-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage Australia 2021409956 Pending Australia <br />National Stage 2021409956<br />Filed on 2023-06-25<br />Status: Pending 147166342 E-171-2020-0 E-171-2020-0-CN-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage China 202180086835.1 Pending China <br />National Stage 202180086835.1<br />Filed on 2023-06-21<br />Status: Pending 147166343 E-171-2020-0 E-171-2020-0-US-02 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage US 18/268,603 Pending US <br />National Stage 18/268,603<br />Filed on 2023-06-20<br />Status: Pending 147166344 E-171-2020-0 E-171-2020-0-EP-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage European Patent 21851911.4 Pending European Patent <br />National Stage 21851911.4<br />Filed on 2023-05-16<br />Status: Pending 147172955 Antibacterial 147172957 Antibiotic Adjuvants 147172959 Antibiotic Resistance 147172961 DNA gyrase 147172963 Exonuclease VII 147172965 ExoVII 147172966 Infection 147172967 Pommier 147172969 Quinolone 147172971 TOPO IV 147172973 Topoisomerase Poisons TAB-4070 147157352 Human Synovial Sarcoma Cell Line A2243 NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Summary:</h2> <p>NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.</p> <h2>Description of Technology:</h2> <p>Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes misregulation of downstream gene expression, leading to tumor formation.</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology (LCMB), have derived a cell line, A2243, from a patient with human synovial sarcoma. This cell line forms tumors in nude mice. The A2243 cell line has been used to characterize the abnormal karyotype associated with synovial sarcoma. Additionally, the A2243 cell line has been used to discover the gene involved in recurrent chromosomal translocation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for drug screening efforts</li> <li>Research tool for identifying general and specific chromosomal translocations in synovial sarcoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized cell line for a rare human cancer: synovial sarcoma</li> </ul> Available for licensing 2021-05-19 2026-04-24 2021-05-25 2026-04-24 2021-05-25 A2243, Aaronson, Chromosomal Translocation, CONNECTIVE TISSUE, Drug Screening, Human Cell Line, Mesenchymal Cells, Rare Cancer, SSX, Synovial sarcoma, SYT, tumor formation False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-25 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162236 Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. https://pubmed.ncbi.nlm.nih.gov/7951320/ <a href="https://pubmed.ncbi.nlm.nih.gov/7951320/">Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.</a> 147163413 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163414 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147163413 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163414 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147158107 Human Synovial Sarcoma Cell Line A2243 E-160-2005-0 Research Material NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4070] Human Synovial Sarcoma Cell Line A2243&body=Please send me information about technology [TAB-4070] Human Synovial Sarcoma Cell Line A2243.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4070] Human Synovial Sarcoma Cell Line A2243&body=Please send me information about technology [TAB-4070] Human Synovial Sarcoma Cell Line A2243.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147172626 A2243 147172627 Aaronson 147172629 Chromosomal Translocation 147172630 CONNECTIVE TISSUE 147172631 Drug Screening 147172633 Human Cell Line 147172635 Mesenchymal Cells 147172637 Rare Cancer 147172639 SSX 147172640 Synovial sarcoma 147172642 SYT 147172643 tumor formation TAB-4059 147157341 Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Michael Diprima, Nathalie Jores, Denis Kudlinzki, Harald Schwalbe, Giovanna Tosato, Alix Troster <h2>Description of Technology:</h2> <p>Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells. Furthermore, colorectal cancers express the EphrinB2 ligand and its Eph receptors at significantly higher levels than numerous other cancer types. Colorectal cancer patients with the highest levels of EphrinB2 expression in their tumor have a lower probability of survival than those with the lowest levels.</p> <p>The NCI investigators found that a small-molecule inhibitor of the Eph kinase, NVP-BHG712 and its regioisomer NVP-Iso, reduce human colorectal cancer cell growth <em>in vitro</em> and tumor growth in mice. Proof-of-concept data demonstrate inhibition of the Eph tyrosine kinase inhibits the growth of human colorectal carcinomas. Eph signaling sustains colorectal carcinoma cell survival and growth and that inhibition of the phosphotyrosine‐dependent Eph signaling is effective at blocking this prosurvival function. Several derivatives of these prototype compounds have been synthesized and tested for inhibition of the Eph tyrosine kinase activity. Two of these new derivatives have promising biochemical and functional profiles.&nbsp; These small molecule inhibitors have the potential to be developed as a therapeutic for colorectal cancers, other types of Eph-growth dependent tumors, and diseases where the Eph kinase plays a pathogenic role.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics for colorectal cancer</li> <li>Therapeutics for other Eph growth-dependent cancers, including breast, lung, prostate, and brain</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Differs in targeting selectivity from many other tyrosine kinase inhibitors</li> <li>Distinct mechanism of action from Regorafenib, the only existing receptor tyrosine inhibitor approved to treat metastatic colorectal cancer; Regorafenib is a multi-targeted tyrosine kinase inhibitor developed to inhibit VEGF-dependent tumor angiogenesis</li> <li>Promising combination therapy when used with other tyrosine kinase inhibitors and antibodies &ndash; such as Cetuximab (approved for metastatic colorectal cancer)</li> <li>Overcome resistance to EGFR or BRAF treatment in various tumor types; attributed to EphA2 kinase activity</li> </ul> 2021-12-14 2026-04-24 2021-12-14 2026-04-24 2021-12-14 colorectal cancer, Eph Kinase Inhibitors, Eph-related cancers, Ephrin, NVP-BHG712, Regioisomer NVP-Iso, small molecule, solid tumors, Tosato, Tyrosine kinase inhibitors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162046 Diprima M, et al. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. https://pubmed.ncbi.nlm.nih.gov/31545551/ <a href="https://pubmed.ncbi.nlm.nih.gov/31545551/">Diprima M, et al. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.</a> 147163376 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147163377 Diprima, Michael NIH - NCI NCI Diprima, Michael (NCI) 2 147163378 Schwalbe, Harald J.W. Goethe University, Frankfurt Schwalbe, Harald 3 147163379 Troster, Alix J.W. Goethe University, Frankfurt Troster, Alix 4 147163380 Jores, Nathalie J.W. Goethe University, Frankfurt Jores, Nathalie 5 147163381 Kudlinzki, Denis German Cancer Research Center [Deutsches Krebsforschungszentrum] Kudlinzki, Denis 6 147163376 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147163377 Diprima, Michael NIH - NCI NCI Diprima, Michael (NCI) 2 147163378 Schwalbe, Harald J.W. Goethe University, Frankfurt Schwalbe, Harald 3 147163379 Troster, Alix J.W. Goethe University, Frankfurt Troster, Alix 4 147163380 Jores, Nathalie J.W. Goethe University, Frankfurt Jores, Nathalie 5 147163381 Kudlinzki, Denis German Cancer Research Center [Deutsches Krebsforschungszentrum] Kudlinzki, Denis 6 147158164 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-0 Filing authorized NCI 147162554 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-1 Filing authorized J.W. Goethe University, Frankfurt, NCI 147162555 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-2 Filing authorized German Cancer Research Center [Deutsches Krebsforschungszentrum], J.W. Goethe University, Frankfurt, NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors&body=Please send me information about technology [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors&body=Please send me information about technology [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161160 E-182-2019-2 E-182-2019-2-PCT-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PCT COMB Patent Cooperation Treaty PCT/US2020/050439 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/050439<br />Filed on 2020-09-11<br />Status: Expired 147166252 E-182-2019-0 E-182-2019-0-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PRV US 62/900,240 Abandoned US <br />Provisional (PRV) 62/900,240<br />Filed on 2019-09-13<br />Status: Abandoned 147166254 E-182-2019-1 E-182-2019-1-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PRV US 63/070,739 Abandoned US <br />Provisional (PRV) 63/070,739<br />Filed on 2020-08-26<br />Status: Abandoned 147166257 E-182-2019-2 E-182-2019-2-CA-03 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage Canada 3153096 Pending Canada <br />National Stage 3153096<br />Filed on 2020-09-11<br />Status: Pending 147166259 E-182-2019-2 E-182-2019-2-EP-05 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage European Patent 20785624.6 Pending European Patent <br />National Stage 20785624.6<br />Filed on 2020-09-11<br />Status: Pending 147166261 E-182-2019-2 E-182-2019-2-US-07 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage US 12,486,270 17/692,978 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12486270 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12486270">12,486,270</a><br />Filed on 2022-03-11<br />Status: Issued 147173183 colorectal cancer 147173185 Eph Kinase Inhibitors 147173187 Eph-related cancers 147173188 Ephrin 147173190 NVP-BHG712 147173192 Regioisomer NVP-Iso 147173193 small molecule 147173194 solid tumors 147173195 Tosato 147173197 Tyrosine kinase inhibitors TAB-4031 147157312 Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Kenneth Cowan <h2>Summary:</h2> <p>NCI is seeking parties to non-exclusively license the ADR-RES cell line.</p> <h2>Description of Technology:</h2> <p>Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.</p> <p>Researchers at the National Cancer Institute (NCI) have derived an Adriamycin-resistant cell line, NCI/ADR-RES, from human ovarian cancer cells. The parental cell line is OVCAR-8, obtained from a high-grade ovarian serous adenocarcinoma. NCI/ADR-RES is resistant to Adriamycin and found to express high levels of the Multi-Drug Resistance 1 (MDR1) protein &ndash; also known as P-glycoprotein. The cell line was extensively characterized and proven useful in identifying compounds subject to multi-drug resistance. NCI/ADR-RES was deposited into the Division of Cancer Treatment and Diagnosis (DCTD) Developmental Therapeutics Program (DTP) Tumor Repository and added to the NCI-60 Human Tumor Cell Lines Screen, along with parental OVCAR-8. Molecular characterization data are publicly available on the DTP website.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool to study the multi-drug resistance phenomenon in cancer</li> <li>Research tool to study Adriamycin resistance in ovarian cancer</li> <li>Research tool to study the overexpression of MDR1 (P-glycoprotein) in cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Extensively characterized and documented human ovarian adenocarcinoma cell line</li> <li>Part of the NCI anti-cancer drug screen human cell line panel (NCI-60 Human Tumor Cell Lines Screen)</li> <li>Molecular characterization data are publicly available</li> </ul> 2021-06-04 2026-04-24 2021-06-04 2026-04-24 2021-06-04 ADENOCARCINOMA, Adriamycin-resistant, Cell line, Cowan, MCF-7/ADR-RES, MDR1, Multi-Drug Resistance, NCI/ADR-RES, OVARIAN CANCER, OVCAR-8, P-GLYCOPROTEIN False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161881 Scudiero DA, et al. Cell line designation change: multidrug-resistant cell line in the NCI anti-cancer screen. https://pubmed.ncbi.nlm.nih.gov/9625176/ <a href="https://pubmed.ncbi.nlm.nih.gov/9625176/">Scudiero DA, et al. Cell line designation change: multidrug-resistant cell line in the NCI anti-cancer screen.</a> 147162269 Batist G, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. https://pubmed.ncbi.nlm.nih.gov/3782078/ <a href="https://pubmed.ncbi.nlm.nih.gov/3782078/">Batist G, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.</a> 147162422 Vert A, et al. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. https://pubmed.ncbi.nlm.nih.gov/29379303/ <a href="https://pubmed.ncbi.nlm.nih.gov/29379303/">Vert A, et al. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance.</a> 147163284 Cowan, Kenneth NIH - NCI NCI Cowan, Kenneth (NCI) 1 147163284 Cowan, Kenneth NIH - NCI NCI Cowan, Kenneth (NCI) 1 147158018 ADR-RES (adriamycin-resistant Cell Line) Cell Line E-115-2021-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES&body=Please send me information about technology [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES&body=Please send me information about technology [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147171738 ADENOCARCINOMA 147171739 Adriamycin-resistant 147171740 Cell line 147171742 Cowan 147171744 MCF-7/ADR-RES 147171745 MDR1 147171747 Multi-Drug Resistance 147171749 NCI/ADR-RES 147171750 OVARIAN CANCER 147171752 OVCAR-8 147171753 P-GLYCOPROTEIN TAB-3966 147157246 Immunogens for Use in a High Efficacy HIV Vaccine NCI Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Manuel Becerra-Flores, Massimiliano Bissa, Timothy Cardozo, Genoveffa Franchini, Giacomo Gorini, Isabela Silva De Castro <h2>Summary:</h2> <p>The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.</p> <h2>Description of Technology:</h2> <p>Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting protection and alleviate the need to depend heavily on prevention methods that require continued access and adherence. Immunization with the genetically engineered versions of HIV surface glycoprotein gp120, along with env, gag, pol, has been a promising approach that needs improved efficacy (currently at ~30%).&nbsp;</p> <p>Researchers at NCI have previously shown the levels and avidity of antibodies against variable envelope region 2 (V2) of gp120 correlate with protection of young macaques against the closely related simian immunodeficiency virus (SIV), while antibodies against V1 have an opposing effect on immunity. To improve the current HIV vaccine efforts, they deleted the V1 region from gp120, while preserving the V2 folded conformation, in a collaboration with researchers at NYU. They demonstrated increased antigenicity of V2 upon V1 deletion, as well as increased binding to soluble CD4 receptors. They further observed higher V2 responses in macaques with V1-deleted gp120 immunogen. Using SIV as a model, they could increase vaccine efficacy to nearly 70%.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Human immunodeficiency virus (HIV) vaccine</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior vaccine efficacy up to 70% using the closely related SIV as a model</li> <li>Increased antibody recognition of V2 via V1-deleted gp120 immunogens, previously associated with protection from SIV</li> <li>Increased V2 responses (in macaques, elicited via V1-deleted gp120 immunogens)</li> </ul> 2021-05-25 2026-04-24 2021-06-16 2026-04-24 2021-06-16 AIDS, Franchini, GLYCOPROTEIN, gp120, HIV, Human Immunodeficiency Virus, V1, V2, Vaccine, Variable Envelope Region False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-062-2014 E-157-2000 147161964 Silva de Castro I, et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. https://doi.org/10.1016/j.isci.2021.102047 <a href="https://doi.org/10.1016/j.isci.2021.102047">Silva de Castro I, et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.</a> 147162351 Vaccari M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. https://www.ncbi.nlm.nih.gov/pubmed/27239761 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27239761">Vaccari M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.</a> 147162389 Gordon SN, et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition. https://www.ncbi.nlm.nih.gov/pubmed/27591322 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27591322">Gordon SN, et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition.</a> 147163043 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147163045 Cardozo, Timothy New York University School of Medicine Cardozo, Timothy 2 147163046 Silva De Castro, Isabela NCI - CCR Silva De Castro, Isabela 3 147163047 Gorini, Giacomo NIH - NCI Gorini, Giacomo 4 147163044 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 147163048 Becerra-Flores, Manuel NIH - New York University School of Medicine Becerra-Flores, Manuel 6 147163043 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147163045 Cardozo, Timothy New York University School of Medicine Cardozo, Timothy 2 147163046 Silva De Castro, Isabela NCI - CCR Silva De Castro, Isabela 3 147163047 Gorini, Giacomo NIH - NCI Gorini, Giacomo 4 147163044 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 147163048 Becerra-Flores, Manuel NIH - New York University School of Medicine Becerra-Flores, Manuel 6 147158109 Delta V1/V2a Gp120 Immunogens To Augment Protective V2 Responses E-160-2018-0 Filing authorized NCI, New York University School of Medicine 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine&body=Please send me information about technology [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine&body=Please send me information about technology [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147165586 E-160-2018-0 E-160-2018-0-US-01 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION PRV US 62/748,905 Abandoned US <br />Provisional (PRV) 62/748,905<br />Filed on 2018-10-22<br />Status: Abandoned 147165587 E-160-2018-0 E-160-2018-0-PCT-02 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION PCT Patent Cooperation Treaty PCT/US2019/057268 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/057268<br />Filed on 2019-10-21<br />Status: Expired 147165588 E-160-2018-0 E-160-2018-0-AU-03 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage Australia 2019368218 2019368218 Issued Australia <br />National Stage 2019368218<br />Filed on 2019-10-21<br />Status: Issued 147165589 E-160-2018-0 E-160-2018-0-CA-04 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage Canada 3117390 Pending Canada <br />National Stage 3117390<br />Filed on 2019-10-21<br />Status: Pending 147165590 E-160-2018-0 E-160-2018-0-EP-05 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage European Patent 19804901.7 Pending European Patent <br />National Stage 19804901.7<br />Filed on 2019-10-21<br />Status: Pending 147165591 E-160-2018-0 E-160-2018-0-US-06 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage US 12,162,910 17/285,453 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162910 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162910">12,162,910</a><br />Filed on 2021-04-14<br />Status: Issued 147172646 AIDS 147172647 Franchini 147172648 GLYCOPROTEIN 147172649 gp120 147172650 HIV 147172651 Human Immunodeficiency Virus 147172652 V1 147172653 V2 147172654 Vaccine 147172656 Variable Envelope Region TAB-3963 147157243 SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation NCI Cardiology, Endocrinology, Immunology, Licensing, Neurology, Oncology, Research Materials Cardiology Endocrinology Immunology Licensing Neurology Oncology Research Materials Caroline Hill, Sushil Rane, Lalage Wakefield, Yu-an Yang <h2>Description of Technology:</h2> <p>The Transforming Growth Factor Beta (TGF-&szlig;) ligands (i.e., TGF-&szlig;1, -&szlig;2, -&szlig;3) are key regulatory proteins in animal physiology. Disruption of normal TGF-&szlig; signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-&szlig; activates TGF-&szlig; receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression and contribute to tumorigenesis.&nbsp; Reliable animal models are essential for the study of TGF-&szlig; signaling. A previously developed animal model for TGF-&szlig; signaling utilizes a luciferase expression system under the control of SMAD protein responsive promoter elements (Lin et al., 2005, J. Immunol). The luciferase-based reporter mouse requires administering luciferin for bioluminescence detection. Another previously developed model is a SMAD protein-responsive, green fluorescent protein (GFP)-based reporter mouse (Neptune et al., 2003, Nat. Genet.); however, the model is no longer available. Thus, there remains a need for novel reporter animal models to study TGF-&szlig; signaling.</p> <p>NCI investigators designed an enhanced GFP (eGFP)-based reporter construct that is more sensitive to SMAD3 activation than other existing reporter constructs. Expression of eGFP is driven by an artificial enhancer element consisting of six repeats of a strong SMAD3 binding element. This reporter was greater than ten times more sensitive in vitro than the CAGA12-based reporter, another commonly used construct to detect TGF-&szlig; signaling.&nbsp; Using CRISPR/Cas9 technology, the inventors knocked this reporter construct into the Rosa26 locus, a ubiquitously expressed gene in most cells of the mouse. This strategy allows identification of tissues and cells in which signaling of TGF-&beta;s are endogenously active during normal development, tissue homeostasis, and disease.</p> <p>The mouse model is currently undergoing further validation using genetic and pharmacological approaches. It is available for licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of oncology therapeutics</li> <li>Developing of fibrosis therapeutics</li> <li>Pre-clinical in vivo model to study TGF-&beta; signaling and pathway antagonists</li> <li>Pre-clinical model for TGF-&beta;/SMAD3 disease states</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No requirement for luciferin injections</li> <li>Higher sensitivity for SMAD3 activation than other reporters</li> </ul> 2021-12-14 2026-04-24 2021-12-14 2026-04-24 2021-12-14 Animal Model, CANCER, EGFP, Fibrosis, Wakefield, mothers against decapentaplegic homolog 3, Oncology, Reporter Mouse, SMAD3, TGF-ß, Transforming Growth Factor Beta False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162000 Yang Y, et al. A new TGF-ß pathway reporter mouse for analysis of TGF-β signaling in normal homeostasis and cancer. https://cancerres.aacrjournals.org/content/80/16_Supplement/1645 <a href="https://cancerres.aacrjournals.org/content/80/16_Supplement/1645">Yang Y, et al. A new TGF-ß pathway reporter mouse for analysis of TGF-β signaling in normal homeostasis and cancer.</a> 147163033 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147163034 Yang, Yu-an NIH - NCI NCI Yang, Yu-an (NCI) 2 147163035 Rane, Sushil NIH - NIDDK NIDDK Rane, Sushil (NIDDK) 3 147163036 Hill, Caroline The Francis Crick Institute Hill, Caroline 4 147163033 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147163034 Yang, Yu-an NIH - NCI NCI Yang, Yu-an (NCI) 2 147163035 Rane, Sushil NIH - NIDDK NIDDK Rane, Sushil (NIDDK) 3 147163036 Hill, Caroline The Francis Crick Institute Hill, Caroline 4 147158061 Smad3 Reporter Mouse For Assessing TGF-ß/activin Pathway Activation E-136-2019-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI, The Francis Crick Institute 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation&body=Please send me information about technology [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation&body=Please send me information about technology [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147172187 Animal Model 147172188 CANCER 147172189 EGFP 147172191 Fibrosis, Wakefield 147172193 mothers against decapentaplegic homolog 3 147172194 Oncology 147172196 Reporter Mouse 147172197 SMAD3 147172199 TGF-ß 147172201 Transforming Growth Factor Beta TAB-3940 147157220 CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples NCI Collaboration, Immunology, Licensing, Research Materials Collaboration Immunology Licensing Research Materials Joo Lee, Sushant Patkar, Eytan Ruppin, Alejandro Schaffer, Kun Wang <h2>Description of Technology:</h2> <p>The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities. However, the use of FACS is limited to simultaneously measuring the expression of a few protein markers, whereas the use of single-cell RNAseq has been limited due to cost and scarcity of fresh tumor biopsies. In contrast, bulk tumor gene expression from preserved biopsies accompanied by clinical outcome metadata is abundant. Several algorithms have shown promise in accurately reconstructing cell-type-specific gene expression profiles from bulk gene expression.&nbsp;&nbsp;</p> <p>Researchers at National Cancer Institute (NCI) have developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a transcriptomics computation tool that can confidently estimate cell type abundance and deconvolve cell-type-specific gene expression profiles of individual cancer patients from bulk gene expression measurements. A complementary, second software tool LIRICS (LIgand-Receptor Interaction between Cell Subsets) prioritizes clinically relevant ligand-receptor interactions between cell types from the deconvolved data. These tools uncovered TME ligand-receptor interactions associated with improved patient survival and high sensitivity to immune checkpoint blockade therapy. These excellent tools for understanding the TME can inform diagnosis and treatment strategies. They are available for co-development or licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of improved immune checkpoint blockade therapies against cancer</li> <li>Development of improved therapies against cancer involving the TME</li> <li>Improved determination and analysis of cell-type abundance and cell-type-specific gene expression from bulk gene expression&nbsp;</li> <li>Identifying cell-cell and ligand-receptor interactions within complex tissues, including the TME&nbsp;</li> <li>Identifying cell type specific biomarkers, drug targets and drug repurposing opportunities to improve diagnosis and clinical outcome</li> <li>Applicable non-cancerous disease, including preeclampsia, pregnancy-related complications, autoimmune disorders, ageing and neurodegenerative disorders.&nbsp; &nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Higher gene coverage for all cell types than existing related technologies</li> <li>Improved predictive accuracy of patient response to therapy&nbsp;</li> <li>Built-in confidence ranking system to compare prediction accuracies</li> </ul> 2021-11-04 2026-04-24 2021-11-04 2026-04-24 2021-11-04 Cell-cell Interaction, CODEFACS, Deconvolution, GENE EXPRESSION, Immunotherapy, Ligand-Receptor Interaction, LIRICS, Ruppin, TME, Tumor Microenvironment False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162939 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147162940 Wang, Kun NIH - NCI NCI Wang, Kun (NCI) 2 147162941 Patkar, Sushant NIH - NCI NCI Patkar, Sushant (NCI) 3 147162942 Lee, Joo NIH - NCI Lee, Joo 4 147162943 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 5 147162939 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147162940 Wang, Kun NIH - NCI NCI Wang, Kun (NCI) 2 147162941 Patkar, Sushant NIH - NCI NCI Patkar, Sushant (NCI) 3 147162942 Lee, Joo NIH - NCI Lee, Joo 4 147162943 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 5 147157857 The COOEFACS And LIRICS Pipelines For Bulk Expression Deconvolution E-044-2020-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples&body=Please send me information about technology [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples&body=Please send me information about technology [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160956 E-044-2020-0 E-044-2020-0-PCT-02 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DECONVOLVING BULK GENE EXPRESSION PCT Patent Cooperation Treaty PCT/US2020/062238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/062238<br />Filed on 2020-11-25<br />Status: Expired 147165449 E-044-2020-0 E-044-2020-0-US-01 CODEFACS AND LIRICS PIPELINES FOR BULK EXPRESSION DECONVOLUTION PRV US 62/940,755 Abandoned US <br />Provisional (PRV) 62/940,755<br />Filed on 2019-11-26<br />Status: Abandoned 147165450 E-044-2020-0 E-044-2020-0-US-03 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DE-CONVOLVING BULK GENE EXPRESSION National Stage US 17/780,356 Abandoned US <br />National Stage 17/780,356<br />Filed on 2022-05-26<br />Status: Abandoned 147170168 Cell-cell Interaction 147170170 CODEFACS 147170171 Deconvolution 147170172 GENE EXPRESSION 147170173 Immunotherapy 147170175 Ligand-Receptor Interaction 147170176 LIRICS 147170178 Ruppin 147170180 TME 147170182 Tumor Microenvironment TAB-3922 147157202 HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Gabriel Ivey, Almin Latani, Paul Robbins, Steven Rosenberg <h2>Summary:</h2> <p>The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.</p> <h2>Description of Technology:</h2> <p>Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated NRAS is an important candidate for targeted therapies, including cellular immunotherapy.&nbsp;</p> <p>National Cancer Institute scientists developed a T-cell receptor (TCR) specific for NRAS Q61K for use in adoptive cell transfer (ACT) T-cell immunotherapy against melanoma. T cells reactive to NRAS Q61K were screened and isolated from tumor infiltrating lymphocytes of a melanoma patient with this mutation and the human leukocyte antigen (HLA) phenotype of A*01:01. TCR alpha and beta chains from the isolated T cells were then cloned to construct the NRAS Q61K-specific TCR. This TCR can be used to develop T-cell therapies against melanoma. Due to the similarities between different RAS isoforms (NRAS, KRAS, HRAS), the TCR could also be used to target other cancers exhibiting RAS Q61K mutations, such as colorectal, prostate, pancreatic and thyroid cancers in patients with the HLA-A*01:01 phenotype.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Use in adoptive cell transfer T-cell therapy against melanoma and other cancers</li> <li>Solid tumors without target antigens as surface proteins</li> <li>Diagnostic tool for NRAS Q61K tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential for lower toxicity as NRAS Q61K is not present in healthy individuals</li> <li>Highly expressed target antigen for melanoma indication</li> <li>HLA-A*01:01 occurs in high frequency in Caucasian populations, therefore the TCR may benefit many patients&nbsp;</li> <li>Intracellular proteins TCRs target can be tumor-specific</li> <li>Redirects the immune system against tumors</li> <li>TCRs potentially target more antigens than Chimeric Antigen Receptors (CARs) since both surface and intracellular proteins can be presented as peptides on MHC molecules</li> </ul> 2021-09-24 2026-04-24 2021-09-24 2026-04-24 2021-09-24 act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-24 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162874 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 1 147162873 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162875 Ivey, Gabriel Georgetown University Ivey, Gabriel 3 147162876 Latani, Almin NCI - CCR NCI Latani, Almin (NCI) 4 147162874 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 1 147162873 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162875 Ivey, Gabriel Georgetown University Ivey, Gabriel 3 147162876 Latani, Almin NCI - CCR NCI Latani, Almin (NCI) 4 147158181 HLA-A*01:01 Restricted Human T Cell Receptor Recognizing The NRAS Q61K Hotspot Mutation E-191-2019-0 Filing authorized Georgetown University, NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation&body=Please send me information about technology [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation&body=Please send me information about technology [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161172 E-191-2019-0 E-191-2019-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION PRV US 63/177,570 Abandoned US <br />Provisional (PRV) 63/177,570<br />Filed on 2021-04-21<br />Status: Abandoned 147165283 E-191-2019-0 E-191-2019-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION PCT Patent Cooperation Treaty PCT/US2022/025177 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/025177<br />Filed on 2022-04-18<br />Status: Expired 147173375 act 147173376 Adoptive Cell Transfer 147173377 HLA 147173378 Human Leukocyte Antigen 147173379 immuno-oncology 147173380 Immunotherapy 147173382 Neuroblastoma Rat Sarcoma Viral Oncogene 147173383 NRAS 147173385 Robbins 147173386 Rosenberg 147173387 T-Cell Receptor 147173388 TCR TAB-3893 147157173 T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Gregoire Altan-Bonnet, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg <h2>Summary:</h2> <p>The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not fully elucidated, the phenotype of the adoptively transferred cell is known to be a key determinant of treatment efficacy.</p> <p>Researchers at National Cancer Institute&rsquo;s (NCI) Surgery Branch have now determined that the CD3<sup>+</sup>CD39<sup>-</sup>CD69<sup>-</sup> subpopulation of T cells are highly associated with complete disease response following ACT. Leveraging over 30 years of ACT clinical data and associated biological materials, NCI researchers immune-profiled archived infusion products and correlated cell phenotypes with therapeutic outcomes. Clustering of clinically significant markers helped in determining the candidate profile. Validation of the markers in other patients and other cancer settings is ongoing.</p> <p>The inventive method could be used to engineer relevant cell therapy products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectious diseases. The method could further be used to develop gene expression signatures to either screen prospective patients or genetically engineer better therapies. In addition to its application in ACT, the &ldquo;response&rdquo; immunoprofile may be applicable to immunotherapy regimens more generally, including checkpoint blockade therapies, immune modulators, and T-cell receptor (TCR) or chimeric antigen receptor (CAR) therapies.</p> <p>Related technologies are available.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Companion diagnostic to support cell therapy and utility products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectious diseases&nbsp;</li> <li>Generation of gene expression signatures to prospectively screen patients or to engineer better ACT and TCR-based treatments</li> <li>Immunoprofiling patients before and after ACT, checkpoint blockade, immunomodulator, and TCR/CAR therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Method to screen adoptive T-cell therapy (ACT) patients to predetermine therapy efficiency</li> <li>Method to increase the efficacy of ACT therapies</li> </ul> 2021-05-25 2026-04-24 2021-07-13 2026-04-24 2021-07-13 act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-07-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-022-2017 147162043 Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. https://pubmed.ncbi.nlm.nih.gov/33303615/ <a href="https://pubmed.ncbi.nlm.nih.gov/33303615/">Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.</a> 147162770 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147162773 Altan-Bonnet, Gregoire NIH - NCI NCI Altan-Bonnet, Gregoire (NCI) 2 147162774 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 3 147162771 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 4 147162772 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 5 147162770 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147162773 Altan-Bonnet, Gregoire NIH - NCI NCI Altan-Bonnet, Gregoire (NCI) 2 147162774 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 3 147162771 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 4 147162772 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 5 147158126 T-cell Phenotypes Associated With Clinical Response To Adoptive Immunotherapy E-167-2019-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy&body=Please send me information about technology [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy&body=Please send me information about technology [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161136 E-167-2019-0 E-167-2019-0-US-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PRV US 63/075,536 Abandoned US <br />Provisional (PRV) 63/075,536<br />Filed on 2020-09-08<br />Status: Abandoned 147165093 E-167-2019-0 E-167-2019-0-PCT-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PCT Patent Cooperation Treaty PCT/US2021/049387 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/049387<br />Filed on 2021-09-08<br />Status: Expired 147165094 E-167-2019-0 E-167-2019-0-JP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Japan 7869197 2023-515322 Issued Japan <br />National Stage 2023-515322<br />Filed on 2023-03-07<br />Status: Issued 147165095 E-167-2019-0 E-167-2019-0-CA-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Canada 3191211 Pending Canada <br />National Stage 3191211<br />Filed on 2023-02-28<br />Status: Pending 147165096 E-167-2019-0 E-167-2019-0-AU-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Australia 2021341969 Pending Australia <br />National Stage 2021341969<br />Filed on 2023-02-21<br />Status: Pending 147165097 E-167-2019-0 E-167-2019-0-CN-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage China 202180074998.8 Pending China <br />National Stage 202180074998.8<br />Filed on 2023-05-05<br />Status: Pending 147165098 E-167-2019-0 E-167-2019-0-US-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage US 18/024,430 Pending US <br />National Stage 18/024,430<br />Filed on 2023-03-02<br />Status: Pending 147165099 E-167-2019-0 E-167-2019-0-EP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage European Patent 4211228 21787116.9 Issued European Patent <br />National Stage 21787116.9<br />Filed on 2023-03-28<br />Status: Issued 147172814 act 147172815 Adoptive T Cell Therapy 147172817 Cancer Immunotherapies 147172818 CAR 147172820 CD-39 Receptor 147172822 CD3-Receptor 147172824 CD-69 Receptor 147172825 chimeric antigen receptor 147172827 Lowery 147172828 Rosenberg 147172829 T Cell Receptor 147172830 TCR 147172831 TILS 147172833 Tumor-Infiltrating T-Lymphocytes TAB-3882 147157162 Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19 NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Mitchell Ho, Jessica Hong <h2>Summary:</h2> <p>The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.</p> <h2>Description of Technology:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. There are few therapeutics available for COVID-19 patients that directly target SARS-CoV-2.</p> <p>Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-RBD single domain antibodies (also called &lsquo;nanobodies&rsquo;) from camel single domain (VHH) phage display libraries. RBD is an ideal target as it is the key virus-host contact region required for viral entry and infection. There are 3 lead nanobodies, 7A3, 1B5, and 2F7, which were found to be the most potent RBD-ACE2 blockers. Interestingly, the 1B5 nanobody can cross react with the S protein of the previous 2002-2003 SARs-CoV coronavirus. This indicates that this nanobody targets a conserved region of the S protein and may be useful for treatments against other coronavirus variants that may emerge.&nbsp;</p> <p>Nanobodies are the smallest known antigen-binding fragments of antibodies and have several advantages. Due to their small size, high solubility, thermal stability, refolding capacity, and relatively easy tissue penetration, they have great potential as medical applications and research tools. These nanobodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). Due to their small size and high stability, the nanobodies may have the ability to be administered by an inhaler making them uniquely attractive therapeutics for respiratory infections such as COVID-19.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neutralizing nanobodies</li> <li>Nanobody-Fc fusion proteins as standard antibody therapy</li> <li>Antibody-drug conjugates (ADCs)</li> <li>Immunotoxins</li> <li>Diagnostic reagents (in vivo virus imaging)</li> <li>CARs (CAR T, NK, and macrophage)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The nanobodies directly target the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein, which blocks the virus-host contact region required for viral entry and infection</li> <li>Due to their small size and high stability, the nanobodies may be administered by an inhaler making them ideal for respiratory infections such as COVID-19</li> </ul> 2021-04-05 2026-04-24 2021-04-05 2026-04-24 2021-04-05 ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162716 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162717 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147162716 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162717 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147158277 Single Domain Antibodies Targeting SARS-SoV-2 E-253-2020-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19&body=Please send me information about technology [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19&body=Please send me information about technology [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161233 E-253-2020-0 E-253-2020-0-US-01 Single Domain Antibodies Targeting SARS-CoV-2 PRV US 63/105,769 Abandoned US <br />Provisional (PRV) 63/105,769<br />Filed on 2020-10-26<br />Status: Abandoned 147165031 E-253-2020-0 E-253-2020-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/056548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/056548<br />Filed on 2021-10-26<br />Status: Expired 147165032 E-253-2020-0 E-253-2020-0-US-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF National Stage US 18/033,656 Pending US <br />National Stage 18/033,656<br />Filed on 2023-04-25<br />Status: Pending 147174284 ANTIBODY 147174285 antigen-binding fragment 147174286 CORONAVIRUS 147174287 COVID-19 147174288 HO 147174289 NANOBODY 147174290 respiratory INFECTION 147174292 S Protein 147174293 SARS-CoV-2 147174294 spike protein TAB-3877 147157157 An Anti-Viral Polypeptide: Griffithsin NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Michael Boyd, Toshiyuki Mori, Barry O'Keefe <h2>Summary:</h2> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.</p> <h2>Description of Technology:</h2> <p>Virus entry into a susceptible host cell is the first step in the formation of all viral diseases. Controlling viral infections by disrupting viral entry is advantageous for antibody-mediated neutralization by the host&rsquo;s immune system and as a preventive and therapeutic antiviral strategy. Plant-derived carbohydrate-binding proteins (lectins) have emerged as a new class of antiviral biologics by taking advantage of a unique glycosylation pattern only found on the surface of viruses.</p> <p>This technology describes the lectin, Griffithsin (GRFT), isolated from red algae. GRFT shows significant broad-spectrum anti-viral activity making it a promising agent for use as a general microbicide that can prevent viral transmission and as a therapeutic against enveloped virus-mediated diseases.&nbsp; The patent rights for this technology cover the sequence of the GRFT polypeptide as well as several GRFT variants mutated to render them glycosylation-resistant. The patent rights also cover GRFT conjugates, compositions, nucleic acids, vectors, host cells, antibodies and methods of their production and methods of use.&nbsp; The broad spectrum anti-viral activity of GRFT has been attributed to its ability to inhibit viral binding, fusion and entry into the host cells by binding to viral envelope gp120.&nbsp; GRFT has potential as a therapeutic or prophylactic for retroviral infections including HIV-1 and HIV-2 as well as FIV, SIV, MLV, BLV, equine infectious virus, avian sarcoma viruses, and HTLV. In addition, Griffithsin could be used in combination with other anti-viral agents to treat patients who have drug-resistant virus.</p> <p>A related NCI invention, reference number <a href="https://techtransfer.cancer.gov/available-technologies?abstract=TAB-4330" target="_blank">E-025-2006</a>, further covers the use of Griffithsin against viral infection including Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.</p> <p>Issued patents include&nbsp;<a href="https://patents.google.com/patent/US7884178B2/en?oq=11%2f569%2c813" rel="nofollow" target="_blank">US 7,884,178</a>,&nbsp;<a href="https://patents.google.com/patent/US8394764B2/en?oq=US+8%2c394%2c764+" rel="nofollow" target="_blank">US 8,394,764</a>, with foreign rights in Canada, Australia, Japan, Israel, New Zealand, South Africa, France, Germany, Ireland, Switzerland, United Kingdom (all granted).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Microbicide that can prevent viral transmission</li> <li>Therapeutic against enveloped virus-mediated diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly Potent Broad-Spectrum Antiviral Lectin</li> <li>Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses</li> </ul> 2021-07-08 2026-04-24 2021-07-08 2026-04-24 2021-07-08 Griffithsin, O'Keefe, SARS, Severe acute respiratory syndrome False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-07-08 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-025-2006 147162113 Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. https://pubmed.ncbi.nlm.nih.gov/15613479 <a href="https://pubmed.ncbi.nlm.nih.gov/15613479">Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.</a> 147162460 Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture https://pubmed.ncbi.nlm.nih.gov/16300962/ <a href="https://pubmed.ncbi.nlm.nih.gov/16300962/">Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</a> 147162700 Boyd, Michael NIH - NCI Boyd, Michael 1 147162702 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 2 147162701 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 3 147162700 Boyd, Michael NIH - NCI Boyd, Michael 1 147162702 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 2 147162701 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 3 147157998 Griffithsin, Sertulavirin And Related Proteins, Peptides, Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, Host Cells, Methods Of Production And Methods Of Using E-106-2003-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3877] An Anti-Viral Polypeptide: Griffithsin&body=Please send me information about technology [TAB-3877] An Anti-Viral Polypeptide: Griffithsin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3877] An Anti-Viral Polypeptide: Griffithsin&body=Please send me information about technology [TAB-3877] An Anti-Viral Polypeptide: Griffithsin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161048 E-106-2003-0 E-106-2003-0-US-03 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Use National Stage US 7,884,178 11/569,813 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7884178 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7884178">7,884,178</a><br />Filed on 2006-11-30<br />Status: Issued 147164988 E-106-2003-0 E-106-2003-0-US-01 Griffithsins and Related conjucages, Fusion Proteins, Nucleic Acids, Vectors, Host Cells, Compositions, Antibodies and Methods of Using Griffithsins PRV US 60/576,056 Abandoned US <br />Provisional (PRV) 60/576,056<br />Filed on 2004-06-01<br />Status: Abandoned 147164990 E-106-2003-0 E-106-2003-0-PCT-02 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use PCT Patent Cooperation Treaty PCT/US2005/018778 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/018778<br />Filed on 2005-05-27<br />Status: Expired 147164991 E-106-2003-0 E-106-2003-0-CA-04 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Canada 2567728 2567728 Expired Canada <br />National Stage 2567728<br />Filed on 2010-03-09<br />Status: Expired 147164992 E-106-2003-0 E-106-2003-0-AU-05 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Australia 2005250429 2005250429 Expired Australia <br />National Stage 2005250429<br />Filed on 2005-05-27<br />Status: Expired 147164993 E-106-2003-0 E-106-2003-0-EP-06 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage European Patent 1740605 05804849.7 Expired European Patent <br />National Stage 05804849.7<br />Filed on 2005-05-27<br />Status: Expired 147164994 E-106-2003-0 E-106-2003-0-JP-07 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Japan 4776620 2007-515398 Expired Japan <br />National Stage 2007-515398<br />Filed on 2005-05-27<br />Status: Expired 147164995 E-106-2003-0 E-106-2003-0-IL-08 GRIFFITHSIN AND GLYCOSYLATION-RESISTANT VARIANTS THEREOF HAVING ANTI-VIRAL ACTIVITY AND RELATED METHODS National Stage Israel 179236 179236 Expired Israel <br />National Stage 179236<br />Filed on 2006-11-13<br />Status: Expired 147164996 E-106-2003-0 E-106-2003-0-NZ-09 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage New Zealand 551375 551375 Expired New Zealand <br />National Stage 551375<br />Filed on 2006-11-17<br />Status: Expired 147164997 E-106-2003-0 E-106-2003-0-ZA-10 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage South Africa 2006/09573 2006/09573 Expired South Africa <br />National Stage 2006/09573<br />Filed on 2006-11-17<br />Status: Expired 147164998 E-106-2003-0 E-106-2003-0-EP-11 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use DIV European Patent 5804849.7 Administratively Closed European Patent <br />Divisional (DIV) 5804849.7<br />Filed on 2005-05-27<br />Status: Administratively Closed 147164999 E-106-2003-0 E-106-2003-0-US-12 Griffithsin, Glycosylation-Resistant Griffithsin, And Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods Of Production And Methods Of Use DIV US 8,394,764 13/022,289 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394764 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394764">8,394,764</a><br />Filed on 2011-02-07<br />Status: Expired 147165000 E-106-2003-0 E-106-2003-0-FR-13 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP France 1740605 05804849.7 Expired France <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165001 E-106-2003-0 E-106-2003-0-DE-14 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Germany 1740605 05804849.7 Expired Germany <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165002 E-106-2003-0 E-106-2003-0-IE-15 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Ireland 1740605 05804849.7 Expired Ireland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165003 E-106-2003-0 E-106-2003-0-CH-16 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Switzerland 1740605 05804849.7 Expired Switzerland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165004 E-106-2003-0 E-106-2003-0-GB-17 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP United Kingdom 1740605 05804849.7 Expired United Kingdom <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165005 E-106-2003-0 E-106-2003-0-CH-18 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Switzerland 1740605 05804849.7 Expired Switzerland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165006 E-106-2003-0 E-106-2003-0-DE-19 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Germany 1740605 05804849.7 Expired Germany <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165007 E-106-2003-0 E-106-2003-0-FR-20 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP France 1740605 05804849.7 Expired France <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165008 E-106-2003-0 E-106-2003-0-GB-21 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP United Kingdom 1740605 05804849.7 Expired United Kingdom <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165009 E-106-2003-0 E-106-2003-0-IE-22 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Ireland 1740605 05804849.7 Expired Ireland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147171529 Griffithsin 147171531 O'Keefe 147171532 SARS 147171533 Severe acute respiratory syndrome TAB-4897 152954990 T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools NCI Diagnostics, Licensing, Oncology, Research Materials Diagnostics Licensing Oncology Research Materials Catherine Ade, Matthew Sporn, Zhiya Yu <h2>Summary:</h2> <p>The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.&nbsp;</p> <h2>Description of Technology:</h2> <p>Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS) when used in conjunction with elution of peptides bound to a specific Human Leukocyte Antigen (HLA) allele. Using MS in this context can demonstrate which oncogene derived neoepitopes are presented by common HLA alleles, and can provide the data necessary to rapidly develop TCRs against the desired antigens.&nbsp;</p> <p>Using the MS approach, inventors at the National Cancer Institute (NCI) have identified neoepitopes derived from a mutated isoform of Epithelial Growth Factor Receptor (EGFR) presented by HLA A*11:01 across multiple biological replicates. From this MS data, the inventors were able to successfully isolate murine TCRs that specifically recognize HLA A*11:01 restricted neoepitopes targeting EGFR L858R. According to various cancer genome databases, EGFR L858R is highly prevalent in lung adenocarcinoma, non-small cell lung carcinoma, and nonsquamous non-small cell lung carcinoma, making this driver mutation an excellent target to develop off-the-shelf cellular therapies. While the clinical potential of these TCRs has not been explored, they are valuable research materials to identify HLA-A*11:01 EGFR L858R reactive T cells in various sources including patients and animal models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research use</li> <li>In vitro diagnostic use</li> <li>The TCRs may be used as positive controls to identify HLA-A*11:01 EGFR L858R reactive T cells from different sources such as patients or animal models</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>TCRs recognize the common EGFR L858R driver mutation in the context of HLA-A*11:01&nbsp;</li> <li>EGFR mutations are highly prevalent in lung cancers, especially lung adenocarcinoma, non-small cell lung cancer and non-squamous non-small cell lung cancer</li> <li>The prevalence of EGFR L858R substitutions, relative to the overall EGFR mutation population, ranges from 27.7% to 41.1% in non-small cell lung cancer patients</li> <li>HLA-A*11:01 allele frequency is particularly high (up to 60%) in Asian and Oceanian populations</li> <li>This research has validated the effectiveness of using mass spectrometry to detect amino acid sequences on specific HLA complexes&nbsp;<br /> &nbsp;</li> </ul> The NCI seeks licensees for T Cell Receptors (TCRs) targeting Epidermal Growth Factor Receptor (EGFR) L858 mutation for use as research tools. 2024-02-16 2026-04-24 2026-04-24 2024-02-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-098-2018 152960967 Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652) https://pubmed.ncbi.nlm.nih.gov/37758652/ <a href="https://pubmed.ncbi.nlm.nih.gov/37758652/">Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652)</a> 152956517 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152956539 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 2 152956564 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 3 152956517 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152956539 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 2 152956564 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 3 152954993 Identification and cloning of EGFR L858R/A11_mTCR1, EGFR L858R/A11_mTCR4, and EGFR L858R/A11_mTCR9, three T cell receptors targeting EGFR L858R mutation on HLA-A1101+ tumor cells E-251-2023-0 Under Review NCI - CCR, NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools&body=Please send me information about technology [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools&body=Please send me information about technology [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-3960 147157240 Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho, Jessica Hong <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.</p> <h2>Description of Technology:</h2> <p>Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD and the ACE2 receptor, is critical in neutralizing the virus. However, the S2 subunit, is also critical for viral infection and entry into human cells. The S2 subunit is highly conserved across many coronaviruses, however, there are currently no effective antibodies targeting this S2 subunit.</p> <p>The inventors isolated the J1B4 camel VHH nanobody, a potent S2 binder that can neutralize all the known variants of SARS-CoV-2, including omicron. The J1B4 VHH can be engineered with other COVID binders to create multi-specific drugs to treat current COVID-19 infections as well as future SARS-like viral infections. This technology presents a promising novel treatment for SARS-CoV-2 infection by using the anti-S2 nanobodies alone or in combination with anti-S1/RBD nanobodies.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 infections</li> <li>Multi-specific antibody therapy</li> <li>Delivery of nanoparticles</li> <li>Diagnostic reagents for in vivo virus imaging</li> <li>Antiviral nanobody nasal spray</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No currently available therapeutic antibodies targeting the S2 subunit of SARS-CoV-2</li> <li>Potential treatment for current and future SARS-CoV-2 infections</li> <li>Use of nanobodies suitable for developing non-invasive treatments, such as an intranasal spray</li> </ul> 2023-06-28 2026-04-24 2023-06-27 2026-04-24 2023-06-28 ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-06-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-204-2021 E-253-2020 147163025 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163024 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163023 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 147163022 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 4 147163025 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163024 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163023 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 147163022 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 4 147158041 Camel VHH nanobodies bind the S2 subunit of SARS-CoV-2 and broadly neutralize variants including omicron E-129-2023-0 Filing authorized Laboratory of Molecular Biology, NCI - CCR, NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron&body=Please send me information about technology [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron&body=Please send me information about technology [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161078 E-129-2023-0 E-129-2023-0-US-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PRV US 63/501,772 Expired US <br />Provisional (PRV) 63/501,772<br />Filed on 2023-05-12<br />Status: Expired 163804438 E-129-2023-0 E-129-2023-0-PC-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2024/028832 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/028832<br />Filed on 2024-05-10<br />Status: Expired 164238034 E-129-2023-0 E-129-2023-0-US-02 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF National Stage US 19/482,967 Pending US <br />National Stage 19/482,967<br />Filed on 2025-11-10<br />Status: Pending 147172022 ANTIBODY 147172024 Camel Nanobody 147172025 CORONAVIRUS 147172026 COVID-19 147172027 HO 147172028 Infectious Diseases 147172029 Nanobodies 147172030 Pandemic 147172031 SARS-CoV-2 147172032 therapeutic 147172033 Vaccine TAB-3938 147157218 T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Christian Hinrichs, Kazusa Ishii <h2>Description of Technology:</h2> <p>CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T&rsquo;s &ndash; including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.</p> <p>Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.</p> <p>NCI seeks parties interested in licensing and/or collaborations to further develop this technology.</p> <h2>Potential Commercial Applications:</h2> <p>Therapeutic against B-cell malignancies such as non-Hodgkin&rsquo;s lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia&nbsp;<br /> Therapeutic for:</p> <ul> <li>CD22-expressing malignancies, even if the CD22 antigen escapes the surface of the tumor cells and resides within intracellular compartments or is only partially expressed</li> <li>CD22-expressing malignancies, even if the diseases are resistant to existing anti CD22 antibodies through resistance to antibody-specific cytotoxicity mechanisms (such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity).</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Established market need and regulatory path &ndash; following Accelerated Approval of Inotuzumab ozogamicin in 2017.</li> <li>T cells expressing the CD22 TCR (CD22 TCR-T cells) mediate dose-dependent anti-tumor activity in leukemia and lymphoma models in vivo.</li> <li>CD22 TCR-T cells, but not T cells expressing a comparable CAR (CD22 CAR-T cells), clear leukemia at clinically-relevant doses and without causing systemic cytokine elevation.</li> <li>CD22 TCR-T cells are not cross-reactive against other human proteins.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope 2023-04-04 2026-04-24 2023-04-04 2026-04-24 2023-04-04 Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-152-2020 147162937 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147162936 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147162937 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147162936 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147157825 Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD22 Epitope E-029-2021-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160930 E-029-2021-0 E-029-2021-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 PCT Patent Cooperation Treaty PCT/US2022/016561 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/016561<br />Filed on 2022-02-16<br />Status: Expired 147165424 E-029-2021-0 E-029-2021-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 PRV US 63/149,795 Abandoned US <br />Provisional (PRV) 63/149,795<br />Filed on 2021-02-16<br />Status: Abandoned 147165425 E-029-2021-0 E-029-2021-0-CA-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage Canada 3207989 Pending Canada <br />National Stage 3207989<br />Filed on 2023-08-10<br />Status: Pending 147165426 E-029-2021-0 E-029-2021-0-US-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage US 18/277,521 Pending US <br />National Stage 18/277,521<br />Filed on 2023-08-16<br />Status: Pending 147165427 E-029-2021-0 E-029-2021-0-EP-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage European Patent 22709092.5 Pending European Patent <br />National Stage 22709092.5<br />Filed on 2023-09-13<br />Status: Pending 147169834 Acute Lymphoblastic Leukemia 147169835 ALL 147169836 B cells 147169837 CD22 147169839 Cellular Immunotherapy 147169840 Chronic lymphocytic leukemia 147169841 CLL 147169842 Hinrichs 147169844 Ishii 147169846 NHL 147169847 Non-Hodgkin’s Lymphoma 147169849 Relapsed / refractory B-Lymphoid Malignancies 147169851 T-Cell Receptor 147169852 TCR TAB-4319 147157609 Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain NICHD Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics John Davies, Guillaume Gaud, Christian Hinrichs, Paul Love <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies.&nbsp; An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.&nbsp;</p> <h2>Description of Technology:</h2> <p>Immunotherapy is a cutting-edge new category of treatment that aims to harness and, in some cases, modify the patient&rsquo;s own immune cells to improve their ability to cure diseases. It can be an effective approach for a variety of conditions, ranging from cancer to inflammatory diseases.&nbsp; However, a number of obstacles to the overall success of immunotherapy still exist.&nbsp; For example, reactivity against a target antigen can be attenuated or the lifespan of the &ldquo;modified&rdquo; immune cells can be too short. In cancer, some tumor cells could express antigen with very low reactivity, thus remaining undetected by &ldquo;classical&rdquo; immune cells.&nbsp; &nbsp;Despite considerable research in the field of immunotherapy, there still exists a need for improved methods and products.</p> <p>This technology describes the method of enhancing an antigen-specific immune response in a subject. This is accomplished through the modification of a CD3 subunit chain or related non-CD3 subunit chain which functions to transduce signals through immune receptors &ndash; such as the T cell antigen receptor. The specific subunit chain modifications are comprised of one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapy treatment for cancer</li> <li>Immunotherapy treatment for autoimmune diseases</li> <li>Immunotherapy treatment for infectious diseases</li> <li>Autologous cell therapy with pharmaceutical compositions comprising novel cell populations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly enhanced target antigen reactivity</li> <li>Highly enhanced functional avidity&nbsp;</li> <li>Cutting-edge therapeutic platform applicable to the treatment of multiple classes of diseases</li> </ul> 2022-02-15 2026-04-23 2022-02-15 2026-04-23 2022-02-15 CD3, Davies, Eunice Kennedy Shriver National Institute of Child Health an, Gaud, Hinrichs, Immuno-receptor Tyrosine-based Activation Motif, Immunotherapy, ITAM, Love, National Cancer Institute, Nci, NICHD, T Cell Receptor, TCR, Zeta Chain False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164287 Love, Paul NIH - NICHD NICHD Love, Paul (NICHD) 1 147164289 Gaud, Guillaume NIH - NICHD NICHD Gaud, Guillaume (NICHD) 2 147164288 Hinrichs, Christian NIH - NCI Hinrichs, Christian 3 147164290 Davies, John NIH - NCI NCI Davies, John (NCI) 4 147164287 Love, Paul NIH - NICHD NICHD Love, Paul (NICHD) 1 147164289 Gaud, Guillaume NIH - NICHD NICHD Gaud, Guillaume (NICHD) 2 147164288 Hinrichs, Christian NIH - NCI Hinrichs, Christian 3 147164290 Davies, John NIH - NCI NCI Davies, John (NCI) 4 147157785 Enhanced Tumor Reactivity Of T Cells Expressing T Cell Antigen Receptors Containing A Mutant Non-signaling CD3zeta Chain E-010-2021-0 Filing authorized NCI, NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain&body=Please send me information about technology [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain&body=Please send me information about technology [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160895 E-010-2021-0 E-010-2021-0-US-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PRV US 63/113,428 Abandoned US <br />Provisional (PRV) 63/113,428<br />Filed on 2020-11-13<br />Status: Abandoned 147168135 E-010-2021-0 E-010-2021-0-PCT-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PCT Patent Cooperation Treaty PCT/US2021/059109 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059109<br />Filed on 2021-11-12<br />Status: Expired 147168136 E-010-2021-0 E-010-2021-0-US-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN National Stage US 18/036,112 Pending US <br />National Stage 18/036,112<br />Filed on 2023-05-09<br />Status: Pending 147168137 E-010-2021-0 E-010-2021-0-EP-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN National Stage European Patent 21824143.8 Pending European Patent <br />National Stage 21824143.8<br />Filed on 2023-03-30<br />Status: Pending 147169426 CD3 147169428 Davies 147169429 Eunice Kennedy Shriver National Institute of Child Health an 147169431 Gaud 147169433 Hinrichs 147169435 Immuno-receptor Tyrosine-based Activation Motif 147169436 Immunotherapy 147169438 ITAM 147169440 Love 147169442 National Cancer Institute 147169443 Nci 147169444 NICHD 147169446 T Cell Receptor 147169447 TCR 147169449 Zeta Chain TAB-4228 147157513 Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts NICHD Collaboration, Diagnostics, Immunology, Licensing, Oncology Collaboration Diagnostics Immunology Licensing Oncology Peter Basser, Michal Komlosh, Magdoom Mohamed Kulam Najmudeen <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution MR imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, or in other applications.</p> <h2>Description of Technology:</h2> <p>Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Clinically, several neuropathologies such as cancer and stroke, are associated with changes in tissue microstructure. Diffusion tensor imaging (DTI), which models diffusion anisotropy, is an ideal imaging modality to elucidate these changes. However, DTI provides a mean diffusion tensor averaged over the entire MRI voxel. This has limitations when applied to heterogeneous neural tissue. Although some of these could be overcome by increased spatial resolution, this comes at the cost of reduced signal-to-noise ratio (SNR) and increased scan time. The SNR limitation makes it impractical to resolve individual neuronal soma and axons whose size range between 0.1-60 &micro;m. Multiple pulsed field gradient (mPFG) methods can resolve microscopic features several orders of magnitude smaller than the typical MRI voxel size &ndash; for example, plant cell size and pore diameters in phantoms &ndash; using lower gradient strengths compared to single PFG methods.</p> <p>This technology describes methods and apparatus to measure and map the diffusion tensor distribution (DTD) in neural tissue or other specimens. Efficient and translatable methods of performing mPFG MRI experiments in a single spin echo sequence to generate b-matrices of ranks one, two, or three, without concomitant gradient field artifacts are disclosed. The disclosed approaches and signal inversion framework captures features of heterogeneity and anisotropy in the spinal cord or other specimens. The disclosed stains may have utility in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neuro or whole-body MRI suites for disease assessment in neural or other tissues.</li> <li>Detection of microscopic anisotropy and heterogeneity within neural tissue (including the spinal cord)</li> <li>Assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior non-invasive measurement and mapping of nervous tissue microstructure</li> <li>Better time efficiency relative to other multiple pulsed field gradient (mPFG) techniques</li> <li>Well-defined diffusion timing parameters for q-space MRI analysis</li> <li>Reduction of concomitant gradient field artifacts</li> </ul> 2022-02-11 2026-04-23 2022-02-10 2026-04-23 2022-02-10 Basser, Diffusion Tensor Distribution MR Imaging, DTI, Eunice Kennedy Shriver National Institute of Child Health an, Komlosh, Magnetic Resonance Imaging, mPFG, MRI, Multi-Pulsed Field Gradient, Najmudeen, NICHD False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-10 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163976 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163977 Komlosh, Michal Henry M. Jackson Foundation (HJF) NICHD Komlosh, Michal (NICHD) 2 147163978 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 3 147163976 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163977 Komlosh, Michal Henry M. Jackson Foundation (HJF) NICHD Komlosh, Michal (NICHD) 2 147163978 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 3 147158136 Time Efficient Multi-pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts E-170-2020-0 Filing authorized Henry M. Jackson Foundation (HJF), NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts&body=Please send me information about technology [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts&body=Please send me information about technology [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161143 E-170-2020-0 E-170-2020-0-US-01 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS PRV US 63/055,150 Abandoned US <br />Provisional (PRV) 63/055,150<br />Filed on 2020-07-22<br />Status: Abandoned 147167537 E-170-2020-0 E-170-2020-0-PCT-02 Time Efficient Multi-pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts PCT Patent Cooperation Treaty PCT/US2021/040929 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040929<br />Filed on 2021-07-08<br />Status: Expired 147167538 E-170-2020-0 E-170-2020-0-US-03 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS National Stage US 12,493,092 18/017,150 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12493092 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12493092">12,493,092</a><br />Filed on 2023-01-20<br />Status: Issued 147172929 Basser 147172931 Diffusion Tensor Distribution MR Imaging 147172932 DTI 147172933 Eunice Kennedy Shriver National Institute of Child Health an 147172935 Komlosh 147172936 Magnetic Resonance Imaging 147172937 mPFG 147172938 MRI 147172940 Multi-Pulsed Field Gradient 147172941 Najmudeen 147172942 NICHD TAB-4168 147157452 Tamperless Tensor Elastography Imaging NICHD Collaboration, Diagnostics, Licensing, Neurology, Oncology Collaboration Diagnostics Licensing Neurology Oncology Peter Basser, Magdoom Mohamed Kulam Najmudeen <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamper-less tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.</p> <h2>Description of Technology:</h2> <p>Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Several neuropathologies &ndash; such as cancer and stroke &ndash; are associated with changes in tissue microstructure. Changes in material properties, such as stiffness, represent a sensitive measure of<br /> underlying changes in tissue architecture, organization, and microstructure. Elastography techniques used to map material stiffness typically involves measuring displacement resulting from shear waves of known frequency imposed on the material by an external actuator or tamper. Material stiffness is estimated from measured displacement by inverting a model relating the material&rsquo;s strain to its stress. A minimal description of a constitutive law relating the stress and strain in the anisotropic material requires a rank-4 anisotropic elasticity tensor (E-tensor). The E-tensor has a number of free parameters ranging from 2 to 21 depending on the degree of material symmetry &ndash; instead of the 1-parameter isotropic scalar shear modulus used in conventional methods. Reconstructing the full E-tensor from a single mechanical excitation is an ill-posed inverse problem since the number of unknowns typically exceeds the number of available equations.</p> <p>The disclosure describes elastography methods permitting measurement of small physiological tissue displacements using spin echo MRI, ultrasound, or other techniques. It allows reconstruction of a full rank-4 anisotropic elasticity tensor (E-tensor). It includes strategies that denoise the measured displacement field using physically motivated compatibility conditions. Also, it includes a family of new intrinsic, invariant stains or parameters to characterize different features of the measured E-tensor. The disclosed E-tensor estimation pipelines are evaluated using simulated 3D displacement data in the presence of noise which confirm the applicability of the disclosed approaches. With the selected E-tensor and associated stains, physiological disorders &ndash; such as Alzheimer&rsquo;s disease and traumatic brain injury (TBI) &ndash; is more readily detected versus conventional methods not utilizing the full E-tensor.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neuro or whole-body MRI suites for disease assessment and diagnosis in neural and other tissues</li> <li>Assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications</li> <li>Brain tissue stiffness atlas to design head gear which minimizes impact</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior non-invasive measurement and mapping of nervous tissue microstructure</li> <li>Produces estimates of a full rank-4 elasticity tensors (E-tensors) using suitable constraints</li> <li>Incorporates intrinsic deformation of the tissue caused by physiological motion, such as from cardiac pulsation and/or respiratory motion, rather than reliance on external tampers</li> </ul> 2022-04-01 2026-04-23 2022-04-01 2026-04-23 2022-04-01 Alzheimer’s Disease, Anisotropy, Basse, brain, CANCER, Elasticity Tensor, Elastography, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, Najmudeen, NICHD, TBI, TRAUMA, Traumatic Brain Injury False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-04-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-170-2020 147163754 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163755 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 2 147163754 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163755 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 2 147157824 MR Viscoelasticity Tensor MRI Of The Brain And Other Tissue E-028-2020-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4168] Tamperless Tensor Elastography Imaging&body=Please send me information about technology [TAB-4168] Tamperless Tensor Elastography Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4168] Tamperless Tensor Elastography Imaging&body=Please send me information about technology [TAB-4168] Tamperless Tensor Elastography Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160929 E-028-2020-0 E-028-2020-0-US-01 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING PRV US 63/192,920 Abandoned US <br />Provisional (PRV) 63/192,920<br />Filed on 2021-05-25<br />Status: Abandoned 147167062 E-028-2020-0 E-028-2020-0-PCT-02 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING PCT Patent Cooperation Treaty PCT/US2022/030846 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/030846<br />Filed on 2022-05-25<br />Status: Administratively Closed 147169816 Alzheimer’s Disease 147169817 Anisotropy 147169819 Basse 147169820 brain 147169821 CANCER 147169823 Elasticity Tensor 147169824 Elastography 147169825 Eunice Kennedy Shriver National Institute of Child Health an 147169826 Magnetic Resonance Imaging 147169827 MRI 147169829 Najmudeen 147169830 NICHD 147169831 TBI 147169832 TRAUMA 147169833 Traumatic Brain Injury TAB-4016 147157297 Therapeutics Against Pathogenic Coronaviruses NICHD Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Arup Chakraborty, Melvin DePamphilis, Matthew Frieman <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this technology.</p> <h2>Description of Technology:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available that specifically target SARS-CoV-2. Middle East respiratory syndrome coronavirus (MERS-CoV) is less understood than SARS-CoV-2. MERS-CoV patients have a 65% long-term survival rate, according the World Health Organization (WHO).</p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development discovered that PIKfyve phosphatidyl linositol kinase inhibitors exhibit therapeutic potential in preventing infection of mammalian cells by pathogenic coronaviruses. It does so by disrupting membrane trafficking to treat coronavirus infection and replication. These compounds are effective at concentrations 100-1000X less than those toxic to uninfected cells. The technology is for use in treating coronavirus infections in humans, particularly infections caused by SARS-CoV-2, SARS-CoV or MER-CoV.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 or SARS-CoV</li> <li>Treatment of MER-CoV</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Effective against SARS-CoV-2, SARS-CoV, and MER-CoV</li> <li>Disrupts membrane trafficking to treat coronavirus infection and replication</li> <li>Promising safety profile</li> </ul> 2022-04-01 2026-04-23 2022-04-01 2026-04-23 2022-03-31 CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-04-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163227 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147163228 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 2 147163229 Chakraborty, Arup NIH - NICHD NICHD Chakraborty, Arup (NICHD) 3 147163227 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147163228 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 2 147163229 Chakraborty, Arup NIH - NICHD NICHD Chakraborty, Arup (NICHD) 3 147157782 Therapeutics Against Pathogenic Coronaviruses SARS-CoV-2, MERS-CoV And SARS-CoV E-009-2021-0 Filing authorized NICHD, University of Maryland 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4016] Therapeutics Against Pathogenic Coronaviruses&body=Please send me information about technology [TAB-4016] Therapeutics Against Pathogenic Coronaviruses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4016] Therapeutics Against Pathogenic Coronaviruses&body=Please send me information about technology [TAB-4016] Therapeutics Against Pathogenic Coronaviruses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147160892 E-009-2021-0 E-009-2021-0-US-01 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PRV US 63/119,522 Abandoned US <br />Provisional (PRV) 63/119,522<br />Filed on 2020-11-30<br />Status: Abandoned 147166008 E-009-2021-0 E-009-2021-0-PCT-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PCT Patent Cooperation Treaty PCT/US2021/060122 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/060122<br />Filed on 2021-11-19<br />Status: Expired 147166009 E-009-2021-0 E-009-2021-0-US-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES National Stage US 18/028,490 Abandoned US <br />National Stage 18/028,490<br />Filed on 2023-03-24<br />Status: Abandoned 147169405 CORONAVIRUS 147169406 COVID-19 147169407 Depamphilis 147169408 Eunice Kennedy Shriver National Institute of Child Health an 147169409 Infectious Diseases 147169411 MER-CoV 147169412 NICHD 147169414 PIKfyve Phosphatidyl Linositol Kinase Inhibitors 147169415 SARS-CoV 147169416 SARS-CoV-2 147169417 virus TAB-3969 147157249 Nandrolone 17 Beta-Carbonates NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Richard Blye, Hyun Kim, Min Lee <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.</p> <h2>Description of Technology:</h2> <p><img alt="" src="/sites/ttc/files/pictures/e-181-2004-0-us-07_abstract_image.docx" />The available options for male contraceptives are limited. Androgens are administered as part of hormone-based male contraception and have also been used in the treatment of hypogonadism and hormone replacement therapy HRT. Many synthetic androgens require an oil-based delivery vehicle and have limited durations of action.</p> <div>This technology describes androgenic compounds and pharmaceutical compositions thereof for use in a number of diseases or conditions, most notably as a potential male contraceptive, and as an androgenic agent suppressing the release of hormones such as the luteinizing hormone. Additional potential therapeutic areas include hypogonadism, osteoporosis, and anemia.&nbsp;</div> <div>Since 2016, NICHD has been testing the following lead compound as a male contraceptive in Phase I clinical trials:</div> <div> <p>Safety and pharmacokinetics of oral single-dose, 28 day repeat-dose, and dose escalation study of 11-MNTDC in healthy men have been conducted.&nbsp; The drug was well tolerated without serious adverse events.&nbsp; Daily oral dose of 11&beta;-MNTDC for 28 days in healthy men showed markedly suppressed serum gonadotropins and T concentrations without serious adverse effects.&nbsp; NICHD is planning another Phase I trial to test 11&beta;-MNTDC via intramuscular injection.&nbsp;</p> <p>&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-181-2004-0-us-07_abstract_image4.png" /></p> </div> <h2>Potential Commercial Applications:</h2> <ul> <li>Male contraceptive</li> <li>Treatment of hormonal diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Significant market need for male contraceptive</li> <li>Clinical-stage asset</li> <li>No adverse events in a Phase I dose-escalation study</li> <li>Intramuscular (IM) injection</li> </ul> 2022-09-13 2026-04-23 2026-04-23 2022-09-13 19-nortestosterone, Androgenic Compounds, Blye, Male Contraceptive, Nandrolone, National Institute of Child Health and Human Development, NICHD False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162240 Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial https://pubmed.ncbi.nlm.nih.gov/34153318/ <a href="https://pubmed.ncbi.nlm.nih.gov/34153318/">Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial</a> 147162355 Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men. https://pubmed.ncbi.nlm.nih.gov/30252057/ <a href="https://pubmed.ncbi.nlm.nih.gov/30252057/">Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.</a> 147162393 Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. https://pubmed.ncbi.nlm.nih.gov/31976519/#:~:text=Conclusion%3A%20Daily%20oral%2011%CE%B2%2DMNTDC,a%20potential%20male%20oral%20contraceptive. <a href="https://pubmed.ncbi.nlm.nih.gov/31976519/#:~:text=Conclusion%3A%20Daily%20oral%2011%CE%B2%2DMNTDC,a%20potential%20male%20oral%20contraceptive.">Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.</a> 147163075 Blye, Richard NIH - NICHD NICHD Blye, Richard (NICHD) 1 147163074 Kim, Hyun NIH - NICHD Kim, Hyun 2 147163076 Lee, Min NICHD NICHD Lee, Min (NICHD) 3 147163075 Blye, Richard NIH - NICHD NICHD Blye, Richard (NICHD) 1 147163074 Kim, Hyun NIH - NICHD Kim, Hyun 2 147163076 Lee, Min NICHD NICHD Lee, Min (NICHD) 3 147158157 Preparation And Use Of Androgenic Compounds E-181-2004-0 Filing authorized NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3969] Nandrolone 17 Beta-Carbonates&body=Please send me information about technology [TAB-3969] Nandrolone 17 Beta-Carbonates.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3969] Nandrolone 17 Beta-Carbonates&body=Please send me information about technology [TAB-3969] Nandrolone 17 Beta-Carbonates.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147165613 E-181-2004-0 E-181-2004-0-US-01 Preparation And Use Of Androgenic Compounds PRV US 60/650,376 Abandoned US <br />Provisional (PRV) 60/650,376<br />Filed on 2005-02-04<br />Status: Abandoned 147165614 E-181-2004-0 E-181-2004-0-PCT-02 NANDROLONE 17B-CARBONATES PCT Patent Cooperation Treaty PCT/US2006/02436 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/02436<br />Filed on 2006-01-24<br />Status: Expired 147165615 E-181-2004-0 E-181-2004-0-AU-03 NANDROLONE 17 BETA-CARBONATES National Stage Australia 2006211907 2006211907 Abandoned Australia <br />National Stage 2006211907<br />Filed on 2006-01-24<br />Status: Abandoned 147165616 E-181-2004-0 E-181-2004-0-CA-04 NANDROLONE 17 BETA-CARBONATES National Stage Canada 2596884 2596884 Abandoned Canada <br />National Stage 2596884<br />Filed on 2006-01-24<br />Status: Abandoned 147165617 E-181-2004-0 E-181-2004-0-EP-05 NANDROLONE 17 BETA-CARBONATES National Stage European Patent 1846434 06719336.7 Abandoned European Patent <br />National Stage 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165618 E-181-2004-0 E-181-2004-0-JP-06 NANDROLONE 17 BETA-CARBONATES National Stage Japan 5227593 2007-554134 Abandoned Japan <br />National Stage 2007-554134<br />Filed on 2006-01-24<br />Status: Abandoned 147165619 E-181-2004-0 E-181-2004-0-US-07 NANDROLONE 17B-CARBONATES National Stage US 7,820,642 11/815,532 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820642 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820642">7,820,642</a><br />Filed on 2007-08-03<br />Status: Issued 147165620 E-181-2004-0 E-181-2004-0-DE-08 NANDROLONE 17 BETA-CARBONATES EP Germany 1846434 06719336.7 Abandoned Germany <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165621 E-181-2004-0 E-181-2004-0-FR-09 NANDROLONE 17 BETA-CARBONATES EP France 1846434 06719336.7 Abandoned France <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165622 E-181-2004-0 E-181-2004-0-GB-10 NANDROLONE 17 BETA-CARBONATES EP United Kingdom 1846434 06719336.7 Abandoned United Kingdom <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147173106 19-nortestosterone 147173108 Androgenic Compounds 147173110 Blye 147173111 Male Contraceptive 147173113 Nandrolone 147173114 National Institute of Child Health and Human Development 147173115 NICHD TAB-3870 147157149 La Protein as a Novel Regulator of Osteoclastogenesis NICHD Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics Leonid Chernomordik, Evgenia Leikina, Jarred Whitlock <h2>Summary:</h2> <p>NICHD seeks co-development partners and/or licensees for the further development of methods to target the La protein for the regulation of osteoclast fusion and osteoclastogenesis.</p> <h2>Description of Technology:</h2> <p>Millions of patients in the United States are afflicted by a host of bone diseases caused by osteoclast (specialized calls arising from the macrophage/monocyte lineage) dysfunction. Diseases include Paget&rsquo;s disease, osteoporosis, fibrous dysplasia and osteolytic bone metastasis. The current standard of care for these diseases uses broad-spectrum therapies that either coat the skeletal system or inhibit osteoclast development in an effort to modulate osteoclastogenesis. New therapies are needed that specifically target osteoclast fusion &ndash; allowing patients to forgo the off-target side effects caused by existing, broad-spectrum therapies.</p> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) discovered that the Lupus autoantigen (La) protein is a master regulator of osteoclast fusion and osteoclastogenesis., The resorptive capacity of osteoclasts and the ability of osteoclasts to remodel bone can be modulated by :(1) administering an effective amount of a La protein or (2) an agent that modulates La protein expression or activity. This specific approach to regulating osteoclast fusion and osteoclastogenesis should bypass the off-target side effects associated with current therapies. It represents a major opportunity to improve the lives of millions who suffer from numerous bone diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics targeting La protein to treat all the most common types of bone disease &ndash; including but not limited to: <ul> <li>Osteoporosis</li> <li>Paget&rsquo;s disease</li> <li>Fibrous dysplasia</li> <li>Osteolytic bone metastasis</li> </ul> </li> <li>Therapeutics targeting La protein for relieving symptoms associated with: <ul> <li>Rheumatoid arthritis</li> <li>Metastatic bone disease</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Technology addresses most major forms of &ndash; and therefore the largest addressable markets for &ndash; bone disease</li> <li>Enables precise modulation of osteoclast fusion and function</li> <li>Potential to prevent off-target side-effects associated with current therapies</li> </ul> 2022-07-07 2026-04-23 2022-07-06 2026-04-23 2022-07-07 Chernomordik, La Protein, Lupus Autoantigen Protein, National Institute of Child Health and Human Development, NICHD, Osteoclast Fusion, Osteoclastogenesis False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-06 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162677 Chernomordik, Leonid NIH - NICHD NICHD Chernomordik, Leonid (NICHD) 1 147162676 Leikina, Evgenia NICHD Leikina, Evgenia (NICHD) 2 147162678 Whitlock, Jarred NICHD NICHD Whitlock, Jarred (NICHD) 3 147162677 Chernomordik, Leonid NIH - NICHD NICHD Chernomordik, Leonid (NICHD) 1 147162676 Leikina, Evgenia NICHD Leikina, Evgenia (NICHD) 2 147162678 Whitlock, Jarred NICHD NICHD Whitlock, Jarred (NICHD) 3 147157887 La Protein As A Novel Regulator Of Osteoclastogenesis E-058-2021-0 Filing authorized Division of Intramural Research, NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis&body=Please send me information about technology [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis&body=Please send me information about technology [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147164935 E-058-2021-0 E-058-2021-0-US-01 La Protein As A Novel Regulator Of Osteoclastogenesis PRV US 63/155,896 Abandoned US <br />Provisional (PRV) 63/155,896<br />Filed on 2021-03-03<br />Status: Abandoned 147164936 E-058-2021-0 E-058-2021-0-PCT-02 La Protein As A Novel Regulator Of Osteoclastogenesis PCT Patent Cooperation Treaty PCT/US2022/018639 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/018639<br />Filed on 2022-03-03<br />Status: Expired 147170454 Chernomordik 147170456 La Protein 147170458 Lupus Autoantigen Protein 147170460 National Institute of Child Health and Human Development 147170461 NICHD 147170463 Osteoclast Fusion 147170464 Osteoclastogenesis TAB-4377 147157671 Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease NIA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Madhav Thambisetty <h2>Summary:</h2> <p>The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer&rsquo;s disease.</p> <h2>Description of Technology:</h2> <p>There are no effective treatments for Alzheimer&rsquo;s disease (AD), a progressive brain disease that slowly destroys a person&rsquo;s memory, cognitive skills and ability to carry out the simplest tasks. AD affects more than 5 million individuals in the United States and ranks as the sixth leading cause of death. The &epsilon;4 allele of the apolipoprotein-E (APOE) gene is the strongest genetic risk factor for sporadic or late-onset AD. Heterozygous carriers of the &epsilon;4 allele are at three-to-four times greater risk; homozygous carriers are at ten times greater risk. In fact, APOE &epsilon;4 carriers accumulate AD neuropathology early in adulthood with earlier age onset of AD compared with &epsilon;4 non-carriers.</p> <p>Researchers at the National Institute on Aging (NIA) identified a brain proteomic signature comprised of 25 proteins that may drive the risk for developing AD in young APOE &epsilon;4 carriers. NIA researchers further identified compounds that target proteins in this AD proteomic signature and rescue molecular abnormalities associated with AD. Specifically, the STAT3 inhibitors TTI-101 and hydroxychloroquine rescued three specific AD phenotypes in cell culture-based phenotypic screens: (1) lipopolysaccharide (LPS)-induced neuroinflammation; (2) tau phosphorylation; and (3) A&beta; secretion/A&beta; clearance. Dasatinib, a YES1/FYN inhibitor, lowered tau phosphorylation. These findings reveal that TT1-101, hydroxychloroquine and Dasatinib &ndash; among other approved and experimental drugs &ndash; may be repurposed to treat AD.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A therapeutic for patients with Alzheimer&rsquo;s disease</li> <li>A therapeutic for APOE &epsilon;4 carriers with Alzheimer&rsquo;s disease&nbsp;</li> <li>A therapeutic for APOE &epsilon;4 carriers with early signs of Alzheimer&rsquo;s disease</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Prevent the development and progression of Alzheimer&rsquo;s disease in high-risk <em>APOE</em> &epsilon;4 carriers</li> <li>Expedited approval process due in part to pre-existing safety data for repurposed drugs</li> </ul> 2022-02-11 2026-04-23 2022-02-23 2026-04-23 2022-02-11 Alzheimer’s Disease, ApoE, Apolipoprotein-E, Aβ, FYN, National Institute on Aging, Neuroinflammation, NIA, STAT3, Tau Phosphorylation, Thambisetty, YES1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162048 Roberts JA, et al. A brain proteomic signature of incipient Alzheimer&rsquo;s disease in young APOE ε4 carriers identifies novel drug targets. https://pubmed.ncbi.nlm.nih.gov/34757788/ <a href="https://pubmed.ncbi.nlm.nih.gov/34757788/">Roberts JA, et al. A brain proteomic signature of incipient Alzheimer&rsquo;s disease in young APOE ε4 carriers identifies novel drug targets.</a> 147164508 Thambisetty, Madhav National Institute on Aging (NIH/NIA) NIA Thambisetty, Madhav (NIA) 1 147164508 Thambisetty, Madhav National Institute on Aging (NIH/NIA) NIA Thambisetty, Madhav (NIA) 1 147158210 C188-9 (STAT3 Inhibitor) And Dasatinib (Scr Family Tyrosine Kinases YES1 And FYN Inhibitor) Are Novel Disease-modifying Treatments For Alzheimer's Disease E-207-2021-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease&body=Please send me information about technology [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease&body=Please send me information about technology [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147161194 E-207-2021-0 E-207-2021-0-US-01 COMPOUNDS AND MOLECULAR TARGETS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE PRV US 63/253,992 Abandoned US <br />Provisional (PRV) 63/253,992<br />Filed on 2021-10-08<br />Status: Abandoned 147168527 E-207-2021-0 E-207-2021-0-PCT-02 COMPOUNDS AND MOLECULAR TARGETS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE PCT Patent Cooperation Treaty PCT/US2022/046018 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/046018<br />Filed on 2022-10-07<br />Status: Expired 147173670 Alzheimer’s Disease 147173671 ApoE 147173673 Apolipoprotein-E 147173675 Aβ 147173676 FYN 147173677 National Institute on Aging 147173678 Neuroinflammation 147173679 NIA 147173680 STAT3 147173682 Tau Phosphorylation 147173684 Thambisetty 147173685 YES1 TAB-4042 147157323 Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method NEI Collaboration, Diagnostics, Infectious Disease, Licensing, Oncology Collaboration Diagnostics Infectious Disease Licensing Oncology Bin Guan, Robert Hufnagel <h2>Summary:</h2> <p>Inventors at the National Eye Institute are seeking&nbsp;research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method, (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.</p> <h2>Description of Technology:</h2> <p>DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab in a universal transport medium during transport to testing site, RNA extraction, and analysis of the extracted RNA sample. Collected patient samples &ndash; in addition to the possible presence of SARS-CoV-2 &ndash; also contain inhibitors for downstream enzymatic reactions, RNA degrading enzymes (e.g., RNase), and magnesium and calcium ions required for RNase activity. Active RNase in the patient sample reduces the amount of SARS-CoV-2 RNA in the sample; so the RNA needs to be extracted for analysis.&nbsp;<br /> &nbsp;<br /> Researchers at the National Institutes of Health&rsquo;s National Eye Institute (NEI) developed a novel improved sample preparation method that eliminates the need for an RNA extraction step from the currently used method of detecting SARS-CoV-2. NEI researchers discovered that incorporation of a chelating agent into the RT-qPCR heating step ties up the magnesium and calcium ions needed for RNase activity &ndash; thereby increasing the amount of RNA produced for analysis. The new procedure also simultaneously removes potential inhibitors of RT-qPCR and inactivates SARS-CoV-2 infectivity. This removal improves workflow safety and eliminates the need for a BSL-2 testing facility. This is a versatile and safe method for RNA preparation for a variety of patient samples beyond SARS-CoV-2. It is suitable for standard clinical collection and testing on high throughput platforms for both DNA and RNA.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Improved COVID-19 diagnostic test</li> <li>Improved DNA or RNA-based diagnostic test for additional infectious diseases</li> <li>Safer preparation of patient samples</li> <li>Reagent kits for biomarker profiles and inherited diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved workflow safety</li> <li>Removes potential inhibitors of RT-qPCR</li> <li>Inactivates SARS-CoV-2 infectivity</li> <li>Increased RNA production for analysis</li> <li>Eliminates the need for an RNA extraction step</li> </ul> 2022-01-21 2026-04-23 2022-01-26 2026-04-23 2022-01-20 Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-26 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162086 Guan B, et al. Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA 1 preparation method. https://pubmed.ncbi.nlm.nih.gov/33532808/ <a href="https://pubmed.ncbi.nlm.nih.gov/33532808/">Guan B, et al. Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA 1 preparation method.</a> 147163310 Guan, Bin NIH - NEI NEI Guan, Bin (NEI) 1 147163311 Hufnagel, Robert NIH - NEI NEI Hufnagel, Robert (NEI) 2 147163310 Guan, Bin NIH - NEI NEI Guan, Bin (NEI) 1 147163311 Hufnagel, Robert NIH - NEI NEI Hufnagel, Robert (NEI) 2 147158191 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method E-195-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method&body=Please send me information about technology [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method&body=Please send me information about technology [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161180 E-195-2020-0 E-195-2020-0-US-01 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PRV US 63/065,931 Abandoned US <br />Provisional (PRV) 63/065,931<br />Filed on 2020-08-14<br />Status: Abandoned 147166165 E-195-2020-0 E-195-2020-0-PCT-03 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PCT Patent Cooperation Treaty PCT/US2021/045675 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045675<br />Filed on 2021-08-12<br />Status: Expired 147166166 E-195-2020-0 E-195-2020-0-US-03 SAMPLE PREPARATION AND VIRAL DETECTION METHODS National Stage US 12,637,705 18/041,295 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12637705 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12637705">12,637,705</a><br />Filed on 2023-02-10<br />Status: Issued 147173470 Biomarker 147173472 Chelating Resin 147173474 Chelex Resin 147173475 COVID 147173476 COVID-19 147173478 DNA/RNA diagnostic test 147173480 Extraction-free Detection 147173481 Infectious Diseases 147173482 SARS-CoV-2 147173483 virus TAB-4406 147157701 High Efficacy Vaccine and Microbicide Combination For Use Against HIV NCI Collaboration, Immunology, Infectious Disease, Licensing, Vaccines Collaboration Immunology Infectious Disease Licensing Vaccines Daniel Appella, Ettore Appella, Massimiliano Bissa, Genoveffa Franchini, Sabrina Helmold Hait, Lisa Marie Jenkins, Mohammed Rahman, Marjorie Robert-Guroff, Isabela Silva De Castro <h2>Summary:</h2> <p>NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.&nbsp;</p> <h2>Description of Technology:</h2> <p>Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant virus strains insensitive to treatment and with toxic effects following long-term usage. In addition, access to ARVs is limited in certain regions, particularly in sub-Saharan Africa &ndash; where the HIV epidemic continues unabated and disproportionately affects women and adolescent girls. There is a global health need for development of alternative approaches providing long-term protection from the virus, such as vaccines.</p> <p>Researchers at the National Cancer Institute (NCI) previously demonstrated the efficacy of envelope glycoprotein 120 (gp120) variable region 1 (V1)-deleted simian immunodeficiency virus (SIV) vaccines against the highly pathogenic SIVmac251, which recapitulates human AIDS in animals. These SIV envelope V1-deleted vaccines increased the antigenicity of the envelope glycoprotein variable region 2 (V2) and were 65% effective in preventing vaginal SIVmac251 infection in the macaque animal model. However, the vaccine regimen was ineffective in about one third of animals. Therefore, the inventors added the SAMT-247 microbicide that disrupts the folded structure of the viral nucleocapsid protein NCp7 by interfering with zinc coordination in the protein. This resulted in the production of immature viral particles. Following 14 weekly exposures to SIVmac251, 80% of macaques vaccinated and treated with SAMT-247 remained uninfected &ndash; reducing infection risk &gt;90%. SAMT-247 was administered 4 hours before each challenge exposure and dramatically augmented vaccine-induced protection via increased NK cytotoxicity, increased monocyte efferocytosis, and decreased T-cell activation (figure below).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of next generation HIV vaccines</li> <li>Prevention of HIV infection and AIDS</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased vaccine efficacy of up to 80%&nbsp;</li> <li>Combination treatment &ndash; vaccine and SAMT-247 microbicide &ndash; significantly reducing risk of SIV infection</li> <li>SAMT-247 microbicide is not toxic to human cervical tissue</li> <li>SAMT-247 microbicide remains effective in cervical mucus</li> </ul> 2022-10-21 2026-04-23 2022-10-21 2026-04-23 2022-10-21 Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-160-2018 E-329-2000 147162336 Halt SH et al. An SAMT-247 microbicide provides potent protection against intravaginal Simian Immunodeficiency virus infection of Rhesus Macaques, whereas an added vaccine component elicits mixed outcomes. https://pubmed.ncbi.nlm.nih.gov/32393514/ <a href="https://pubmed.ncbi.nlm.nih.gov/32393514/">Halt SH et al. An SAMT-247 microbicide provides potent protection against intravaginal Simian Immunodeficiency virus infection of Rhesus Macaques, whereas an added vaccine component elicits mixed outcomes.</a> 147162374 Silva de Castro I et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. https://pubmed.ncbi.nlm.nih.gov/33554060/ <a href="https://pubmed.ncbi.nlm.nih.gov/33554060/">Silva de Castro I et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.</a> 147164617 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164616 Robert-Guroff, Marjorie NIH - NCI Robert-Guroff, Marjorie 2 147164619 Appella, Daniel NIH - NIDDK NIDDK Appella, Daniel (NIDDK) 3 147164622 Helmold Hait, Sabrina NIH - NCI NCI Helmold Hait, Sabrina (NCI) 4 147164623 Rahman, Mohammed NIH - NCI NCI Rahman, Mohammed (NCI) 5 147164620 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 6 147164618 Appella, Ettore NIH - NCI NCI Appella, Ettore (NCI) 7 147164624 Jenkins, Lisa Marie NIH - NCI NCI Jenkins, Lisa Marie (NCI) 8 147164621 Silva De Castro, Isabela NIH - NCI Silva De Castro, Isabela 9 147164617 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164616 Robert-Guroff, Marjorie NIH - NCI Robert-Guroff, Marjorie 2 147164619 Appella, Daniel NIH - NIDDK NIDDK Appella, Daniel (NIDDK) 3 147164622 Helmold Hait, Sabrina NIH - NCI NCI Helmold Hait, Sabrina (NCI) 4 147164623 Rahman, Mohammed NIH - NCI NCI Rahman, Mohammed (NCI) 5 147164620 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 6 147164618 Appella, Ettore NIH - NCI NCI Appella, Ettore (NCI) 7 147164624 Jenkins, Lisa Marie NIH - NCI NCI Jenkins, Lisa Marie (NCI) 8 147164621 Silva De Castro, Isabela NIH - NCI Silva De Castro, Isabela 9 147157867 DNA/ALVAC-SIV/gp120?V1/Alum Vaccination And SAMT-247 Microbicide Synergize In Protecting Female Rhesus Macaques From SIV Acquisition E-048-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV&body=Please send me information about technology [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV&body=Please send me information about technology [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160964 E-048-2021-0 E-048-2021-0-US-01 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION PRV US 63/228,707 Abandoned US <br />Provisional (PRV) 63/228,707<br />Filed on 2021-08-03<br />Status: Abandoned 147168752 E-048-2021-0 E-048-2021-0-PCT-02 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION PCT Patent Cooperation Treaty PCT/US2022/074432 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/074432<br />Filed on 2022-08-02<br />Status: Administratively Closed 147170277 Acquired Immuno-Deficiency Syndrome 147170278 ADCC 147170279 AIDS 147170281 Antibody-dependent Cellular Cytotoxicity 147170283 Efferocytosis 147170285 Envelope Glycoprotein 120 147170287 Envelope Variable Region 147170289 Franchini 147170290 gp120 147170291 HIV 147170292 Human Immunodeficiency Virus 147170293 Microbicide 147170294 SAMT-247 147170295 V1 147170296 Vaccine TAB-4389 147157683 T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Sri Krishna, Shoshana Levi, Frank Lowery, Shirley Nah, Paul Robbins, Steven Rosenberg, Rami Yoseph <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.</p> <h2>Description of Technology:</h2> <p>Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition for a variety of cancers, including melanoma and pancreatic cancers. Despite the high frequency of CDKN2A mutations in cancer, there have been no successful therapies targeting these mutations to date. Adoptive cell therapy, a promising form of immunotherapy, offers a potential form of targeted therapy for cancers with CDKN2A mutations.</p> <p>Researchers at the National Cancer Institute (NCI) have developed seven novel human T cell receptors (TCRs) targeting CDKN2A. These TCRs may be used in adoptive cell therapy to treat cancers driven by CDKN2A mutations by targeting neoantigens expressed only by cancer cells. More specifically, the TCRs target neoantigens driven by frameshifts and those driven by nonsynonymous mutations that result in a proline to leucine in position 114 in the CDKN2A gene. Together, these account for 53% of CDKN2A mutations. The TCRs are restricted by some of the most common HLA alleles including HLA A*03:01, HLA A*11:01 and HLA A*02:01, which have an approximate frequency of 8%, 7%, and 40% respectively within the United States population. Thus, these TCRs allow for engineering TCR-based therapies resulting in specific elimination of tumor cells with the indicated CDKN2A mutations present in a diverse group of cancer patients.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Autologous TCR-engineered T cell therapy for cancer patients with CDKN2A mutations</li> <li>Off-the-shelf, allogeneic TCR-engineered T cell therapy for cancer patients with CDKN2A mutations</li> <li>Combination immunotherapies using TCR-engineered T cells alongside other immunotherapies targeting common driver mutations or patient specific mutations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No approved therapies targeting CDKN2A</li> <li>Targeted therapy against CDKN2A mutations with therapeutic potential for a wide variety of cancers</li> <li>Targets neoantigens presented by common HLA alleles making the therapy potentially effective for a broad cancer patient population</li> <li>CDKN2A mutations not present in healthy cells</li> </ul> 2022-11-22 2026-04-23 2022-11-22 2026-04-23 2022-11-22 adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-22 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 E-237-2017 147164554 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164555 Levi, Shoshana NCI - CCR NCI Levi, Shoshana (NCI) 2 147164551 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147164550 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164556 Nah, Shirley NCI - CCR NCI Nah, Shirley (NCI) 5 147164552 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 6 147164553 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 7 147164554 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164555 Levi, Shoshana NCI - CCR NCI Levi, Shoshana (NCI) 2 147164551 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147164550 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164556 Nah, Shirley NCI - CCR NCI Nah, Shirley (NCI) 5 147164552 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 6 147164553 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 7 147158209 T Cell Receptors Targeting Mutations In CDKN2A For Cancer Immunotherapy E-206-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy&body=Please send me information about technology [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy&body=Please send me information about technology [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161193 E-206-2022-0 E-206-2022-0-US-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PRV US 63/381,591 Expired US <br />Provisional (PRV) 63/381,591<br />Filed on 2022-10-31<br />Status: Expired 159507026 E-206-2022-0 E-206-2022-0-PC-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PCT Patent Cooperation Treaty PCT/US2023/078190 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/078190<br />Filed on 2023-10-30<br />Status: Expired 147173659 adoptive cell therapy 147173660 CDKN2A 147173662 cyclin dependent kinase inhibitor 2A 147173663 Immunotherapy 147173664 Krishna 147173665 MELANOMA 147173666 Neoantigen 147173667 Rosenberg 147173668 T Cell Receptor 147173669 TCR TAB-4359 147157652 Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials <h2>Summary:</h2> <p>The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene.&nbsp;</p> <h2>Description:</h2> <p>The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+ T cells, also known as &ldquo;helper&rdquo; T cells, are critical for long-term immunity against pathogens as well as for promoting CD8+ &ldquo;effector&rdquo; T cell and effective B cell responses. ThPOK is needed for the development and functional fitness of CD4+ T cells as well as multiple aspects of the immune response to infection. As such, ThPOK offers a potential target for immune regulation. For example, increasing the activity of ThPOK may enhance the efficacy of immunization strategies against infections or cancer; diseases associated with CD4+ T cell deficiency. Alternatively, inhibitors of ThPOK could offer new ways to interfere with CD4+ T cell activity, offering therapeutic benefit in inflammatory or autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.</p> <p>Researchers at the National Cancer Institute (NCI) developed mouse alleles carrying germline and conditional deletions of the Zbtb7b gene. These alleles were used to generate mice which demonstrate the Zbtb7b gene is essential for CD4+ T cell development and function. These mice can be used to study the function of ThPOK and the role of CD4+ T cells in the immune system. In addition to generating mice that are homozygous for the Zbtb7b gene deletion, the researchers generated mice that can be beneficial as experimental controls. One such mouse line is heterozygous for the Zbtb7b gene deletion; it carries one wild-type allele and one knockout allele. The other mouse line appears wild-type phenotypically but contains a &ldquo;floxed&rdquo; version of the Zbtb7b gene flanked by LoxP sites. It may be used to generate additional conditional deletions for the temporal and spatial regulation of gene expression. Given the importance of CD4+ T cells for the immune system, these mice are applicable to preclinical studies regarding a wide variety of human disorders.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool to study the role of CD4+ T cells in immune response</li> <li>Drug screening and evaluation</li> <li>Develop ThPOK inhibitors which could be relevant for inflammatory or autoimmune diseases</li> <li>Develop ThPOK activators which could enhance the efficacy of immunization strategies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Investigate the function of CD4+ T cells in vivo</li> <li>Investigate the role of the Zbtb7b gene and its protein product ThPOK in vivo</li> <li>Control the expression of the Zbtb7b gene through alleles carrying conditional deletions and/or the floxed allele</li> </ul> 2022-12-06 2026-04-23 2022-12-06 2026-04-23 2022-12-06 Autoimmunity, Bosselut, CANCER, CD4, cKrox, Helper T Cell, Infection, LYMPHOCYTE, Memory T Cell, Oncology, ThPOK, transgenic mice, Zbtb7b, Zinc Finger Transcription Factor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161894 Vacchio MS, et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells. https://pubmed.ncbi.nlm.nih.gov/25129370/ <a href="https://pubmed.ncbi.nlm.nih.gov/25129370/">Vacchio MS, et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells.</a> 147162010 Ciucci T, et al. The emergence and functional fitness of memory CD4+ T cells require the transcription factor Thpok. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503975/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503975/">Ciucci T, et al. The emergence and functional fitness of memory CD4+ T cells require the transcription factor Thpok.</a> 147162282 Vacchio MS, et al. A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf expression to orchestrate T follicular helper differentiation. https://pubmed.ncbi.nlm.nih.gov/31422869/ <a href="https://pubmed.ncbi.nlm.nih.gov/31422869/">Vacchio MS, et al. A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf expression to orchestrate T follicular helper differentiation.</a> 155750779 Mice, Organs And Mouse Alleles Carrying Germline And Conditional Deletions Of The Zbtb7b Gene E-226-2022-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene&body=Please send me information about technology [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene&body=Please send me information about technology [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147173916 Autoimmunity 147173918 Bosselut 147173919 CANCER 147173920 CD4 147173922 cKrox 147173924 Helper T Cell 147173925 Infection 147173926 LYMPHOCYTE 147173928 Memory T Cell 147173929 Oncology 147173931 ThPOK 147173932 transgenic mice 147173933 Zbtb7b 147173935 Zinc Finger Transcription Factor TAB-4357 147157650 Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho <h2>Description:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of RBD and the ACE2 receptor on human cells is the first of the two critical steps for neutralization of the virus. However, the S2 subunit of the spike is also critical for viral infection and entry into human cells. It is highly conserved across many coronaviruses, including other SARS-CoV-2 like viruses. To date there are no antibodies targeting the S2 subunit.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 infections</li> <li>&nbsp;Standard antibody therapy</li> <li>&nbsp;Delivery of nanoparticles</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Currently, only one antibody treatment received FDA-issued emergency use authorization for COVID-19 treatment.</li> <li>Currently, no antibodies targeting the S2 subunit of SARS-CoV-2.</li> <li>Potential to treat current and future SARS-CoV-2 infections.</li> <li>Nanobodies are attractive candidates for intranasal spray therapy due to their small size, high affinity and high stability</li> <li>Nanobody characteristics which could be a more effective treatment for the respiratory disease</li> <li>Does not require intravenous administration</li> </ul> 2022-09-14 2026-04-23 2022-09-14 2026-04-23 2022-09-14 : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-09-14 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164435 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164436 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147164437 Buffington, Jesse NCI - CCR NCI Buffington, Jesse (NCI) 3 147164435 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164436 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147164437 Buffington, Jesse NCI - CCR NCI Buffington, Jesse (NCI) 3 147158204 Single Domain Antibodies Targeting The S2 Subunit Of SARS-CoV-2 Spike Protein E-204-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein&body=Please send me information about technology [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein&body=Please send me information about technology [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161188 E-204-2021-0 E-204-2021-0-US-01 Single Domain Antibodies Targeting The S2 Subunit Of SARS-CoV-2 Spike Protein PRV US 63/271,854 Abandoned US <br />Provisional (PRV) 63/271,854<br />Filed on 2021-10-26<br />Status: Abandoned 147168408 E-204-2021-0 E-204-2021-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN PCT Patent Cooperation Treaty PCT/US2022/078632 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/078632<br />Filed on 2022-10-25<br />Status: Expired 147173600 : COVID-19 147173601 ANTIBODY 147173602 Camel Nanobody 147173603 CORONAVIRUS 147173604 HO 147173605 Infectious Diseases 147173606 Nanobodies 147173607 Pandemic 147173608 SARS-CoV-2 147173610 Shark Nanobody 147173611 therapeutic 147173612 Vaccine TAB-4322 147157613 Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Tapan Bera, Mitchell Ho, Xiu Fen Liu, Masanori Onda, Ira Pastan <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time. Indeed, the shed portion of MSLN can act as a decoy for these antibodies, further limiting them from reaching and destroying tumor cells.</p> <p>Scientists at NCI&nbsp;previously developed MAB15B6, an antibody that specifically binds&nbsp;to the unshed region of MSLN and blocks MSLN shedding. Building on this discovery, the inventors made specific modifications to CARs which utilize humanized MAB15B6.&nbsp; T cells expressing these enhanced CARs are very active in blocking tumor progression in xenograph models. As a result, these CAR-T cells represent an excellent therapeutic candidate for patients who have not responded to other MSLN-targeted therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of MSLN-positive malignancies such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, pancreatic and gastric cancers</li> <li>Therapeutic Use as a targeting moiety for CARs, antibody-drug conjugates (ADCs), immunotoxins (RITs), bispecific antibodies, etc.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The inventors have made specific improvements to immunoconjugates which utilize MAB15B6 that significantly enhance the ability of these immunoconjugates to exert a therapeutic effect</li> <li>Specific binding to the unshed portion of MSLN allow the antibodies and CAR-T cells to maintain contact with the cancer cells for a longer duration to exert a therapeutic effect</li> <li>More effective in blocking tumor progression compared to currently available anti-MSLN antibodies</li> </ul> 2022-01-25 2026-04-23 2022-02-24 2026-04-23 2022-01-25 ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-106-2017 147162063 Awuah P, et al. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins. https://pubmed.ncbi.nlm.nih.gov/27196771/ <a href="https://pubmed.ncbi.nlm.nih.gov/27196771/">Awuah P, et al. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins.</a> 147164303 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164305 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 2 147164304 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164306 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 4 147164307 Ho, Mitchell NCI - CCR NCI Ho, Mitchell (NCI) 5 147164303 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164305 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 2 147164304 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164306 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 4 147164307 Ho, Mitchell NCI - CCR NCI Ho, Mitchell (NCI) 5 147157833 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE E-033-2022-0 Filing authorized NCI, NCI - CCR, NIH - NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent&body=Please send me information about technology [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent&body=Please send me information about technology [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147160936 E-033-2022-0 E-033-2022-0-US-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS PRV US 63/290,761 Expired US <br />Provisional (PRV) 63/290,761<br />Filed on 2021-12-17<br />Status: Expired 147168153 E-033-2022-0 E-033-2022-0-PCT-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS PCT Patent Cooperation Treaty PCT/US2022/081766 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/081766<br />Filed on 2022-12-16<br />Status: Expired 163272656 E-033-2022-0 E-033-2022-0-CA-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage Canada 3240254 Pending Canada <br />National Stage 3240254<br />Filed on 2024-06-06<br />Status: Pending 163272692 E-033-2022-0 E-033-2022-0-AU-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage Australia 2022416639 Pending Australia <br />National Stage 2022416639<br />Filed on 2024-06-18<br />Status: Pending 163272697 E-033-2022-0 E-033-2022-0-EP-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage European Patent 22854336.9 Pending European Patent <br />National Stage 22854336.9<br />Filed on 2024-05-17<br />Status: Pending 163272702 E-033-2022-0 E-033-2022-0-US-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage US 18/710,726 Pending US <br />National Stage 18/710,726<br />Filed on 2024-05-16<br />Status: Pending 147169935 ANTIBODY 147169937 Bispecific T-cell engager 147169938 BITE 147169939 CANCER 147169940 CAR 147169941 chimeric antigen receptor 147169942 diagnostic 147169943 Immunotherapy 147169944 MESOTHELIN 147169945 Mesothelioma 147169947 Pastan 147169948 therapeutic TAB-4321 147157612 Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Rosandra Kaplan, Nan Li, Rosa Nguyen, Carol Thiele Galetto <h2>Description of Technology:</h2> <p>Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed. Glypican-2 (GPC2) is a cell surface protein that is highly expressed in neuroblastomas and other cancers, including medulloblastoma, retinoblastoma, small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas, which makes GPC2 an attractive candidate for targeted therapy in solid tumors.&nbsp;</p> <p>Researchers at the National Cancer Institute&rsquo;s (NCI) Center for Cancer Research have developed a novel Chimeric Antigen Receptor (CAR) specific for GPC2 that includes a potent anti-GPC2 antibody CT3 and a CD28 hinge and transmembrane domains.&nbsp; CT3 has been shown to specifically target GPC2-expressing neuroblastoma, medulloblastoma, and retinoblastoma cell lines. CT3.28H.BB&zeta; CAR T cells were shown to be more potent against neuroblastoma cells than the previous anti-GPC2 CAR T cells in vitro and in vivo. These preclinical data suggest that CT3.28H.BB&zeta; CAR T cells may be further developed as therapeutics for patients with neuroblastoma and other GPC2-positive cancers. Incorporation of the CD28 hinge and transmembrane domains increases the potency of the CT3 CARs against neuroblastoma cells.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapeutic treatments of GPC2-positive pediatric malignancies, including neuroblastoma, medulloblastoma, retinoblastoma, and a subset of acute lymphocytic leukemias</li> <li>Immunotherapeutic treatments of GPC2-positive adult cancers, including small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas</li> <li>CT3.28H.BB&zeta; CAR available for immediate testing</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>CT3 antibody with high GPC2 binding specificity leading to&nbsp; successful targeting</li> <li>CT3 antibody with high GPC2 binding specificity leading to lower potential side-effects</li> <li>Increased potency against neuroblastoma&nbsp;</li> <li>Potential immunotherapy for several GPC2-positive cancer types with few treatment options&nbsp;</li> </ul> 2022-12-13 2026-04-23 2022-12-13 2026-04-23 2022-12-12 CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-198-2018 147164299 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164298 Thiele Galetto, Carol NIH - NCI NCI Thiele Galetto, Carol (NCI) 2 147164300 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147164302 Nguyen, Rosa NCI - CCR NCI Nguyen, Rosa (NCI) 4 147164301 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 5 147164299 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164298 Thiele Galetto, Carol NIH - NCI NCI Thiele Galetto, Carol (NCI) 2 147164300 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147164302 Nguyen, Rosa NCI - CCR NCI Nguyen, Rosa (NCI) 4 147164301 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 5 147157817 CD28 Hinge And Transmembrane Containing Chimeric Antigen Receptors Targeting GPC2 For Treating Neuroblastoma E-025-2022-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma&body=Please send me information about technology [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma&body=Please send me information about technology [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147168150 E-025-2022-0 E-025-2022-0-US-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PRV US 63/310,456 Expired US <br />Provisional (PRV) 63/310,456<br />Filed on 2022-02-15<br />Status: Expired 147168151 E-025-2022-0 E-025-2022-0-PC-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2023/062525 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/062525<br />Filed on 2023-02-14<br />Status: Expired 159504791 E-025-2022-0 E-025-2022-0-EP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage European Patent 23710624.0 Pending European Patent <br />National Stage 23710624.0<br />Filed on 2024-08-13<br />Status: Pending 159504796 E-025-2022-0 E-025-2022-0-US-02 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage US 18/837,367 Pending US <br />National Stage 18/837,367<br />Filed on 2024-08-09<br />Status: Pending 159504801 E-025-2022-0 E-025-2022-0-CN-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage China 202380034151.6 Pending China <br />National Stage 202380034151.6<br />Filed on 2024-10-14<br />Status: Pending 159504806 E-025-2022-0 E-025-2022-0-AU-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage Australia 2023221836 Pending Australia <br />National Stage 2023221836<br />Filed on 2024-07-23<br />Status: Pending 159504816 E-025-2022-0 E-025-2022-0-JP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage Japan 2024-547534 Pending Japan <br />National Stage 2024-547534<br />Filed on 2024-08-09<br />Status: Pending 147169735 CAR 147169736 chimeric antigen receptor 147169738 Glypican 2 147169739 GPC2 147169740 HO 147169741 Immunotherapy 147169742 Medulloblastoma 147169743 Neuroblastoma 147169744 Retinoblastoma 147169746 Small-Cell Lung Cancers TAB-4318 147157608 Automatic System and Method for Tissue Sectioning, Staining, and Scanning NCI Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Young-Wan Moon, Zhengping (Ping) Zhuang <h2>Summary:</h2> <p>The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.</p> <h2>Description of Technology:</h2> <p>Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This results in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of techniques used in processing of pathology samples and acquisition of digital images to make them amenable with high-throughput approaches such as AI analysis.</p> <p>National Cancer Institute inventors developed an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing (e.g., sectioning, fixing, and staining) with optical scanning and digital image acquisition. This invention, related to another technology, E-084-2019, is updated to include a coated tape for holding and carrying sample sections as an alternative to a carrier film. The tape carries sequentially cut sample slices into a staining cassette where the slices are simultaneously stained directly on the tape. The tape carrying the stained samples are then fed into the imaging unit. This streamlines the entire process enabling high-throughput preparation of large volumes of samples and data for subsequent AI analysis. As a result of automation, the device saves time, minimizes errors, and reduces wasting reagents and supplies. Automation is expected to reduce sample processing time ten-fold.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Biopsy sample processing in hospitals, pathology labs, research labs</li> <li>Diagnostics for various disease indications, including cancer and infectious diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Facilitates processing and imaging of large volumes of pathology samples</li> <li>Automation is expected to reduce sample processing time ten-fold</li> <li>Automation increases reproducibility and minimizes errors</li> <li>Compatible with high-throughput processes, e.g., AI analysis of digital pathology images and 3D reconstruction</li> <li>Mounting and processing all sections of a sample on the same tape allows for an easier, more streamlined staining/imaging process</li> <li>Staining cassette is customizable</li> </ul> 2022-09-12 2026-04-23 2026-04-23 2022-12-13 AI, Artificial Intelligence, AUTOMATION, Digital Pathology, High-throughput, Histology, IMAGING, Zhuang False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164285 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147164286 Moon, Young-Wan MicroVizual Inc. Moon, Young-Wan 2 147164285 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147164286 Moon, Young-Wan MicroVizual Inc. Moon, Young-Wan 2 147157769 Automatic System And Method For Tissue Sectioning, Staining, And Scanning E-003-2022-0 Filing authorized MicroVizual Inc., NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning&body=Please send me information about technology [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning&body=Please send me information about technology [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147160883 E-003-2022-0 E-003-2022-0-US-01 Automatic System And Method For Tissue Sectioning, Staining, And Scanning PRV US 63/254,743 Abandoned US <br />Provisional (PRV) 63/254,743<br />Filed on 2021-10-12<br />Status: Abandoned 147168133 E-003-2022-0 E-003-2022-0-PCT-02 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING PCT Patent Cooperation Treaty PCT/US2022/046406 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/046406<br />Filed on 2022-10-12<br />Status: Expired 147169270 AI 147169272 Artificial Intelligence 147169273 AUTOMATION 147169275 Digital Pathology 147169276 High-throughput 147169277 Histology 147169278 IMAGING 147169279 Zhuang TAB-4305 147157595 PIM-Targeted PROTACs NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics John Brognard, Dawid Mehlich, Venkatareddy Sabbasani, Rolf Swenson, Pedro Torres-Ayuso, Noel Warfel <h2>Description of Technology:</h2> <p>Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers &ndash; including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical trials, all ultimately increased PIM1-3 protein levels and developed intrinsic resistance.&nbsp;</p> <p>Researchers at the National Institutes of Health (NIH) developed multiple PIM kinase-targeting proteolysis-targeting chimeras (PROTACs) that lead to PIM1 degradation in a prostate cancer cell model and increased chemo-sensitization. The targeting of PIM kinases for degradation provides superior catalytic inhibition as these compounds target pro-tumorigenic functions of the PIM kinases, which are not linked to kinase activity. Additionally, these PROTACs prevent the onset of resistance due to increased expression of PIM kinases that occur from catalytic inhibition. They represent unique opportunities as novel anti-cancer therapies. This is a continuation of the PROTAC technologies being developed by the NIH team of Brognard and Swenson.</p> <p>The inventors welcome licensing and co-development interests to further develop and commercialize the technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A novel anti-cancer therapy to target the PIM kinases</li> <li>A PIM targeting PROTACs for the treatments of prostate, breast, and colon cancers, among others</li> <li>A PIM targeting moiety for additional targeted therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Compound target pro-tumorigenic functions of the PIM kinases that are not linked to kinase activity</li> <li>Prevention of the onset of resistance due to increased expression of PIM kinases that occurs from catalytic inhibition</li> <li>Increased chemo-sensitivity</li> <li>Compared to small molecule inhibitors, PROTACs: <ul> <li>show promise overcoming tumor resistance</li> <li>address and degrade undruggable targets</li> <li>offer novel, rapid and reversible chemical knockout capabilities</li> </ul> </li> </ul> 2022-07-07 2026-04-23 2023-01-09 2026-04-23 2022-07-07 anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-01-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164235 Brognard, John NIH - NCI NCI Brognard, John (NCI) 1 147164236 Swenson, Rolf NIH - NHLBI NHLBI Swenson, Rolf (NHLBI) 2 147164237 Torres-Ayuso, Pedro NIH - NCI NCI Torres-Ayuso, Pedro (NCI) 3 147164238 Sabbasani, Venkatareddy NIH - NHLBI NHLBI Sabbasani, Venkatareddy (NHLBI) 4 147164239 Mehlich, Dawid NIH - NCI NCI Mehlich, Dawid (NCI) 5 147164240 Warfel, Noel University of Arizona Warfel, Noel 6 147164235 Brognard, John NIH - NCI NCI Brognard, John (NCI) 1 147164236 Swenson, Rolf NIH - NHLBI NHLBI Swenson, Rolf (NHLBI) 2 147164237 Torres-Ayuso, Pedro NIH - NCI NCI Torres-Ayuso, Pedro (NCI) 3 147164238 Sabbasani, Venkatareddy NIH - NHLBI NHLBI Sabbasani, Venkatareddy (NHLBI) 4 147164239 Mehlich, Dawid NIH - NCI NCI Mehlich, Dawid (NCI) 5 147164240 Warfel, Noel University of Arizona Warfel, Noel 6 147157976 PIM Kinase Developed PROTACs Target PIM Kinases For Degradation And Promote Cancer Cell Death E-094-2022-0 Filing authorized NCI, NCI - CCR, Polish Academy of Sciences, University of Arizona 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4305] PIM-Targeted PROTACs&body=Please send me information about technology [TAB-4305] PIM-Targeted PROTACs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4305] PIM-Targeted PROTACs&body=Please send me information about technology [TAB-4305] PIM-Targeted PROTACs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161032 E-094-2022-0 E-094-2022-0-US-01 PIM-TARGETED PROTACS AND METHODS OF USE PRV US 63/341,757 Expired US <br />Provisional (PRV) 63/341,757<br />Filed on 2022-05-13<br />Status: Expired 147168048 E-094-2022-0 E-094-2022-0-PC-01 PIM-TARGETED PROTACS WITH PIM-BINDING MOIETIES SGI-1776, AZD-1208 OR PIM-447, AND A E3 UBIQUITIN LIGASE BINDING MOIETY FOR THE TREATMENT OF CANCER PCT Patent Cooperation Treaty PCT/US2023/022017 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/022017<br />Filed on 2023-05-12<br />Status: Expired 147171302 anti-cancer 147171304 Brognard 147171306 Chemotherapy Resistance 147171307 Kinase 147171308 PIM 147171310 PIM kinase-targeting proteolysis-targeting chimeras 147171311 PROTACs 147171312 solid tumors 147171314 Swenson 147171315 THERAPY TAB-5088 165166556 DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Ziedulla Abdullaev, Kenneth Aldape, Elaine Jaffe, Antonios Papanicolau-Sengos, Stefania Pittaluga, Mark Raffeld, Omkar Singh, Rustamzhon Turakulov <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen.</p> <p>This technology encompasses a DNA methylation&ndash;based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By identifying disease-specific methylation signatures, the approach reduces interobserver variability and enhances diagnostic confidence. The central nervous system (CNS) classifier is built from a curated reference set of 16,567 methylation profiles and organizes tumors into 22 families and 133 clinically relevant diagnostic classes, including 21 newly developed methylation classes not represented in other existing tools. Across multiple independent validation cohorts (n = 5,875), the classifier demonstrated robust performance, and in a clinical-impact analysis of 1,204 NIH validation cases, methylation profiling materially influenced final diagnosis in 74.4% of cases by refining, increasing precision, or reclassifying. The CNS classifier was deployed as a user-facing software tool, MethylScape Analysis, which streamlines methylation-based classification workflows for CNS tumors (https://methylscape.ccr.cancer.gov/). The development of multiple specialized classifiers supports a more granular understanding of tumor biology and&nbsp; informed clinical decision-making.</p> <h2>Description of Technology:</h2> <p>Accurate CNS tumor classification can be challenging when tumors show overlapping histology, limited tissue or atypical features. A meaningful fraction of cases remains unclassified or assigned with limited confidence with current molecular tools. These diagnostic ambiguities directly affect subtype and grade assignment which, in turn, influence treatment planning, prognosis, and clinical trial eligibility. Variability across observers and institutions can lead to additional testing, delays, and inconsistent diagnoses.</p> <p>The NCI/Bethesda classifier addresses this gap using DNA methylation patterns as a robust molecular fingerprint. It applies a stratified machine learning framework to extend diagnostic coverage and improve assignment confidence for CNS tumors. The classifier was developed from a rigorously curated reference set of over 16k methylation profiles, structured into 22 tumor families and 133 clinically relevant diagnostic classes and includes 21 recently developed methylation classes not represented in existing tools. The approach has been validated across multiple independent cohorts (n = 5,875) and supports deployment through MethylScape, a public web-based portal that streamlines classifier execution for broad accessibility. In an NIH validation cohort analysis of 1,204 high-confidence matches with pre-methylation diagnoses available, methylation profiling confirmed the initial diagnosis in 25.6% of cases while driving clinically meaningful diagnostic evolution in the remainder, including refined diagnosis (subtyping) in 14.6%, new diagnosis with increased precision in 54.7%, and substantial diagnostic reclassification in 5.0%&mdash;changes that are expected to affect patient management in the reclassification subset.</p> <p>Renal neoplasms present a parallel diagnostic challenge due to morphologic and molecular heterogeneity, overlapping microscopic features, and interobserver variability. As a result, a subset of cases are unclassifiable even after immunohistochemical, mutation and cytogenetic workups. To address this, the Kidney Classifier component of this platform leverages genome-wide DNA methylation profiling (feasible on formalin-fixed paraffin-embedded tissue using robust array-based methods). It was developed through examination of methylation signatures from over 2,000 renal neoplasms, identifying 23 coherent methylation groups that correlate with known tumor types and reveal clinically relevant novel subtypes. A machine learning classifier trained on 1,284 samples was externally tested on 287 renal neoplasms, demonstrating &gt;90% concordance between expected neoplasm type and high-score methylation-based classification, with discordant cases highlighting opportunities for diagnostic reclassification and improved precision in challenging renal tumor evaluations.</p> <p>Licensing and collaboration opportunities include commercial development of methylation-based diagnostic tests and/or software-enabled classification solutions for clinical laboratories, reference labs, and diagnostic companies. Partners may engage in external validation (retrospective and prospective), assay standardization, integration into pathology workflows and reporting systems, and extension of classifier coverage to additional tumor types and multi-institutional datasets. Consistent with consensus recommendations for complementary classifiers, the inventors are also interested in collaborations that: (1) operationalize multi-classifier strategies (concordant/complementary prediction to increase confidence; (2) leverage discordance to trigger orthogonal follow-up) and (3) accelerate clinical translation through scalable deployment models- including CLIA laboratory workflows and regulated diagnostic pathways.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Molecular classification and diagnosis of CNS and kidney tumors, including difficult-to-classify and low-confidence cases</li> <li>Diagnostic subtyping aligned to WHO-guided entities</li> <li>Reference-lab and hospital-lab deployment</li> <li>Clinical trial stratification and translational research cohort harmonization</li> <li>Multi-classifier diagnostic decision support</li> <li>Cancer treatment development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Developed from a rigorously curated, large reference set of methylation profiles</li> <li>Clinically relevant CNS diagnostic</li> <li>CNS tumor methylation classes not represented in existing tools, expanding diagnostic coverage</li> <li>Clinical-impact analysis creating superior diagnostic precision</li> <li>Superior classifier for kidney cancer</li> <li>Superior classifiers for multiple solid, difficult-to-diagnose tumors</li> <li>Integrative into clinical workflows, improving diagnostic practices and enhancing patient care</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations to further develop and possibly expand the classification capabilities of the software. 2025-12-12 2026-04-23 2026-04-23 2026-04-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 166817637 Singh O., et.al. Robust DNA Methylation-Based Diagnosis and Classification for Central Nervous 1 System Tumors, submitted Singh O., et.al. Robust DNA Methylation-Based Diagnosis and Classification for Central Nervous 1 System Tumors, submitted 166817672 Aldape K., et.al. cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv. 2025 Jan 3;7(1):vdae228. PMID: 39902391 https://pubmed.ncbi.nlm.nih.gov/39902391/ <a href="https://pubmed.ncbi.nlm.nih.gov/39902391/">Aldape K., et.al. cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv. 2025 Jan 3;7(1):vdae228. PMID: 39902391</a> 166817702 Papanicolau-Sengos A., et.al., Mod Pathol. 2025 Nov;38(11):100884, PMID: 40939817 https://pubmed.ncbi.nlm.nih.gov/40939817/ <a href="https://pubmed.ncbi.nlm.nih.gov/40939817/">Papanicolau-Sengos A., et.al., Mod Pathol. 2025 Nov;38(11):100884, PMID: 40939817</a> 165166621 Aldape, Kenneth Laboratory of Pathology NCI Aldape, Kenneth (NCI) 1 165166625 Abdullaev, Ziedulla National Cancer Institute (NCI) NCI Abdullaev, Ziedulla (NCI) 2 165166629 Turakulov, Rustamzhon Laboratory of Pathology Turakulov, Rustamzhon 3 165166639 Pittaluga, Stefania National Cancer Institute (NCI) NCI Pittaluga, Stefania (NCI) 4 165166643 Raffeld, Mark National Cancer Institute (NCI) NCI Raffeld, Mark (NCI) 5 165166647 Jaffe, Elaine NCI - CCR NCI Jaffe, Elaine (NCI) 6 165166651 Singh, Omkar National Cancer Institute (NCI) NCI Singh, Omkar (NCI) 7 165166699 Papanicolau-Sengos, Antonios Laboratory of Pathology NCI Papanicolau-Sengos, Antonios (NCI) 8 165166621 Aldape, Kenneth Laboratory of Pathology NCI Aldape, Kenneth (NCI) 1 165166625 Abdullaev, Ziedulla National Cancer Institute (NCI) NCI Abdullaev, Ziedulla (NCI) 2 165166629 Turakulov, Rustamzhon Laboratory of Pathology Turakulov, Rustamzhon 3 165166639 Pittaluga, Stefania National Cancer Institute (NCI) NCI Pittaluga, Stefania (NCI) 4 165166643 Raffeld, Mark National Cancer Institute (NCI) NCI Raffeld, Mark (NCI) 5 165166647 Jaffe, Elaine NCI - CCR NCI Jaffe, Elaine (NCI) 6 165166651 Singh, Omkar National Cancer Institute (NCI) NCI Singh, Omkar (NCI) 7 165166699 Papanicolau-Sengos, Antonios Laboratory of Pathology NCI Papanicolau-Sengos, Antonios (NCI) 8 165166559 DNA methylation-based cancer diagnostics for tumors of the central nervous system, kidney and hematopoietic system E-105-2023-0 Filing authorized Laboratory of Pathology, National Cancer Institute (NCI), NCI - CCR 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification&body=Please send me information about technology [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification&body=Please send me information about technology [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">greenejaime@mail.nih.gov</a><br> 165166607 E-105-2023-0 E-105-2023-0-US-01 DNA methylation-based cancer diagnostics ORD US 18/499,833 Pending US <br />Ordinary Patent (ORD) 18/499,833<br />Filed on 2023-11-01<br />Status: Pending TAB-4285 147157574 Molecular Nanotags for Detection of Single Molecules NCI Collaboration, Endocrinology, Infectious Disease, Licensing, Oncology, Research Materials Collaboration Endocrinology Infectious Disease Licensing Oncology Research Materials Jennifer Jones, William Telford <h2>Description of Technology:</h2> <p>Biological nanoparticles, like extracellular vesicles (EVs), possess unique biological characteristics making them attractive therapeutic agents, targets, or disease biomarkers. However, their use is hindered by the lack of tools available to accurately detect, sort, and analyze. Flow cytometers are used to sort and study individual cells. But, they are unable to detect and sort nanomaterials smaller than 200 nanometers with single epitope sensitivity.</p> <p>Researchers at the National Cancer Institute (NCI) developed a new class of nanoscale molecular tags (nanotags) allowing the detection and sorting of single biological nanoparticle using conventional flow cytometers. Otherwise, using standard methods such as fluorescently labeled antibodies, very few epitopes are detected. These nanotags are composed of materials with high refractive indices, high optical absorption, and remarkable spectral scattering properties. These properties allow both low epitope number determination and spectral phenotyping of biological nanoparticles &ndash; such as EVs, lipoproteins, RNA-protein complexes and other circulating submicron particles with significant biomedical applications.</p> <p>The NCI seeks commercial partners to co-develop and/or license this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for studying structure and function of biological nanoparticles</li> <li>Diagnostic tool for detection of clinical biomarkers&nbsp;</li> <li>Tool for characterization of industrial and environmental nanoparticles</li> <li>Biodefense</li> <li>Industrial sectors</li> <li>Environmental applications</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Detect, sort and analyze nanomaterials &lt;200 nanometers with single epitope sensitivity&nbsp;</li> <li>Enumeration of the number of labeled molecules beyond the capabilities of current flow cytometric labels and instruments</li> <li>Improved detection above background noise</li> <li>Improved signal:noise ratio&nbsp;</li> </ul> 2022-01-21 2026-04-23 2022-01-21 2026-04-23 2022-01-20 Biological Nanoparticle, Biomarker, EVs, Extracellular Vesicles, flow cytometer, Jones, Nanoscale Molecular Tags, Nanotags False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-01-21 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-008-2018 E-105-2018 147162245 Welsh JA, et al. Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111846/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111846/">Welsh JA, et al. Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry.</a> 147164164 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164165 Telford, William NIH - NCI NCI Telford, William (NCI) 2 147164164 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164165 Telford, William NIH - NCI NCI Telford, William (NCI) 2 147158254 Single Molecule Detection With NanoFACS E-238-2015-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4285] Molecular Nanotags for Detection of Single Molecules&body=Please send me information about technology [TAB-4285] Molecular Nanotags for Detection of Single Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4285] Molecular Nanotags for Detection of Single Molecules&body=Please send me information about technology [TAB-4285] Molecular Nanotags for Detection of Single Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161219 E-238-2015-0 E-238-2015-0-US-01 MOLECULAR NANOTAGS PRV US 62/411,324 Abandoned US <br />Provisional (PRV) 62/411,324<br />Filed on 2016-10-21<br />Status: Abandoned 147167884 E-238-2015-0 E-238-2015-0-PCT-02 MOLECULAR NANOTAGS PCT Patent Cooperation Treaty PCT/US2017/057928 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/057928<br />Filed on 2017-10-23<br />Status: Expired 147167885 E-238-2015-0 E-238-2015-0-AU-03 MOLECULAR NANOTAGS National Stage Australia 2017345814 2017345814 Issued Australia <br />National Stage 2017345814<br />Filed on 2017-10-23<br />Status: Issued 147167886 E-238-2015-0 E-238-2015-0-CA-04 MOLECULAR NANOTAGS National Stage Canada 3041059 3041059 Issued Canada <br />National Stage 3041059<br />Filed on 2017-10-23<br />Status: Issued 147167887 E-238-2015-0 E-238-2015-0-CN-05 MOLECULAR NANOTAGS National Stage China ZL201780079138.7 201780079138.7 Issued China <br />National Stage 201780079138.7<br />Filed on 2017-10-23<br />Status: Issued 147167888 E-238-2015-0 E-238-2015-0-EP-06 MOLECULAR NANOTAGS National Stage European Patent 3529205 17809073.4 Issued European Patent <br />National Stage 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167889 E-238-2015-0 E-238-2015-0-JP-07 MOLECULAR NANOTAGS National Stage Japan 7492826 2019-521089 Issued Japan <br />National Stage 2019-521089<br />Filed on 2017-10-23<br />Status: Issued 147167890 E-238-2015-0 E-238-2015-0-US-08 MOLECULAR NANOTAGS National Stage US 11,536,719 16/342,345 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11536719 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11536719">11,536,719</a><br />Filed on 2019-04-16<br />Status: Issued 147167891 E-238-2015-0 E-238-2015-0-HK-09 MOLECULAR NANOTAGS CN Hong Kong HK40013934B 62020003242.8 Issued Hong Kong <br />China Patent (CN) 62020003242.8<br />Filed on 2020-02-24<br />Status: Issued 147167892 E-238-2015-0 E-238-2015-0-DE-10 MOLECULAR NANOTAGS EP Germany 3529205 17809073.4 Issued Germany <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167893 E-238-2015-0 E-238-2015-0-FR-11 MOLECULAR NANOTAGS EP France 3529205 17809073.4 Issued France <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167894 E-238-2015-0 E-238-2015-0-GB-12 MOLECULAR NANOTAGS EP United Kingdom 3529205 17809073.4 Issued United Kingdom <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147174079 Biological Nanoparticle 147174080 Biomarker 147174081 EVs 147174082 Extracellular Vesicles 147174083 flow cytometer 147174084 Jones 147174086 Nanoscale Molecular Tags 147174088 Nanotags TAB-4284 147157573 Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants NCI Cardiology, Collaboration, Endocrinology, Immunology, Licensing, Oncology, Research Materials Cardiology Collaboration Endocrinology Immunology Licensing Oncology Research Materials Jay Berzofsky, Jennifer Jones, Katherine McKinnon, Joshua Welsh <h2>Description of Technology:</h2> <p>Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanometer-sized membranous vesicles that can carry different types of cargos, such as proteins, nucleic acids and metabolites. EVs are produced and released by most cell types. They act as biological mediators for intercellular communication via delivery of their cargos. This unique ability spurred translational research interest for targeted delivery of therapeutic molecules to treat a wide range of diseases. EVs also contain interesting information of their specific cellular origin. Thus, EVs can reveal nature, severity, and prognosis of a various pathophysiologic disease states. Such characteristics also make them a reliable and stable source of biomarkers, accessible in several body fluids. However, their small size makes it difficult to isolate EVs by using standard purification methods commonly used for isolating cells and platelets. Currently available techniques for EV isolation, are non-scalable, labor intensive, time consuming, and ineffective in removing contaminants.</p> <p>Researchers at the National Cancer Institute (NCI) developed a chromatographic EV purification technology using a custom-made &ldquo;mixed mode&rdquo; resin. The resin combines Capto Core-type resin with other affinity-based beads for depletion of unwanted contaminants smaller than 700 MDa &ndash; such as proteins, nucleic acids, or other molecules. This Exo-Clean technology is both broadly applicable for biofluid processing and scalable for high-throughput screening (i.e., compatible with robotic 96- or 384- well format). This technology is also suitable for large-scale GMP production of therapeutic exosome and other EV analogue-based therapeutics.&nbsp;</p> <p>Unique biophysical features of this technology could offer a new avenue for developing EV based clinical biomarkers, and therapeutics. The NCI seeks commercial partners to co-develop and/or license this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for studying structure and function of EVs</li> <li>EV-based clinical biomarkers for detecting various pathological conditions</li> <li>Therapeutic exosome and other EV analogue-based therapeutics for targeted drug delivery</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Efficient in removing proteins and various labels from EV preparations</li> <li>Scalable for high-throughput screening</li> <li>Amenable to a wide range of preparation scales and formats</li> </ul> 2022-01-19 2026-04-23 2022-01-19 2026-04-23 2022-01-18 Affinity, Biomarkers, CHROMATOGRAPHIC, EVs, Exo-Clean, Exosomes, Extracellular Vesicles, High-throughput, Jones, Microvesicles, purification, Resin False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162321 Welsh JA, et al. A simple, high-throughput method of protein and label removal from extracellular vesicle samples. https://pubmed.ncbi.nlm.nih.gov/33544111/ <a href="https://pubmed.ncbi.nlm.nih.gov/33544111/">Welsh JA, et al. A simple, high-throughput method of protein and label removal from extracellular vesicle samples.</a> 147164161 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164160 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147164163 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 3 147164162 McKinnon, Katherine NIH - NCI NCI McKinnon, Katherine (NCI) 4 147164161 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164160 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147164163 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 3 147164162 McKinnon, Katherine NIH - NCI NCI McKinnon, Katherine (NCI) 4 147158238 Exo-Clean Method For Removing Proteins And Various Labels From Extracellular Vesicle And Exosome Preparations E-227-2017-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants&body=Please send me information about technology [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants&body=Please send me information about technology [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161208 E-227-2017-0 E-227-2017-0-US-01 EXO-CLEAN METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PRV US 62/612,040 Abandoned US <br />Provisional (PRV) 62/612,040<br />Filed on 2017-12-29<br />Status: Abandoned 147167877 E-227-2017-0 E-227-2017-0-PCT-02 METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PCT Patent Cooperation Treaty PCT/US2018/067913 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/067913<br />Filed on 2018-12-28<br />Status: Expired 147167878 E-227-2017-0 E-227-2017-0-EP-03 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION National Stage European Patent 3731947 18847175.9 Issued European Patent <br />National Stage 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167879 E-227-2017-0 E-227-2017-0-US-04 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION National Stage US 12,083,448 16/959,071 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083448 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083448">12,083,448</a><br />Filed on 2020-06-29<br />Status: Issued 147167880 E-227-2017-0 E-227-2017-0-FR-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP France 3731947 18847175.9 Issued France <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167881 E-227-2017-0 E-227-2017-0-DE-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP Germany 3731947 18847175.9 Issued Germany <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167882 E-227-2017-0 E-227-2017-0-GB-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP United Kingdom 3731947 18847175.9 Issued United Kingdom <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147173949 Affinity 147173950 Biomarkers 147173951 CHROMATOGRAPHIC 147173953 EVs 147173954 Exo-Clean 147173955 Exosomes 147173956 Extracellular Vesicles 147173957 High-throughput 147173958 Jones 147173959 Microvesicles 147173960 purification 147173961 Resin TAB-4271 147157559 Bacteriophage Based-Vaccine System NCI Collaboration, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Infectious Disease Licensing Oncology Vaccines Sankar Adhya, Donald Court, Xintian Li, Manoj Rajaure <h2>Summary:</h2> <p>Researchers at NCI seek licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.</p> <h2>Description of Technology:</h2> <p>Vaccines have become one of the most important tools in the fight against cancers and infectious diseases. However, some vaccines have shown limitations due to their high cost and low immune responses. To overcome these limitations, bacteriophages were proposed for the development of more cost-effective, immunogenic vaccines. Phages have shown a strong ability to activate induced&nbsp;and adaptive immune systems. The genome of these viral particles can be engineered, and their surface proteins can be exploited for antigen display.</p> <p>Researchers at National Cancer Institute (NCI) developed an engineered bacteriophage lambda () vector for displaying antigens as a vaccine in the treatment of cancer and infectious diseases. In this technology, a nucleic acid sequence encoding a fusion protein linked to a heterologous antigen is inserted into a native gene D locus adjacent to gene E in the bacteriophage lambda genome. The researchers have also constructed several phages in the &lambda; prophage vector system to display different fusion proteins as candidate vaccines representing several human diseases like human Chronic Lymphocyte Leukemia disease and malaria.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Vaccine in the treatment of cancer and other infectious diseases</li> <li>Method for rapid production of bioengineered bacteriophage lambda for vaccine development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel way to generate multivalent vaccine antigens against various cancers and infectious diseases&nbsp;</li> <li>Inexpensive to produce compared with competing technologies</li> <li>Can stimulate induced&nbsp;immune and therefore potentially act as a natural adjuvant</li> <li>Can be stored and shipped at ambient temperatures</li> </ul> 2022-08-16 2026-04-23 2022-11-30 2026-04-23 2022-08-16 Adhya, Bacteriophage Engineering, Bacteriophage Genetics, CANCER VACCINE, Infectious Diseases, Lambda Vector, Phage Therapy, Recombineering, Vaccine False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164119 Adhya, Sankar NIH - NCI NCI Adhya, Sankar (NCI) 1 147164118 Court, Donald NIH - NCI NCI Court, Donald (NCI) 2 147164120 Li, Xintian NIH - NCI NCI Li, Xintian (NCI) 3 147164121 Rajaure, Manoj NIH - NCI NCI Rajaure, Manoj (NCI) 4 147164119 Adhya, Sankar NIH - NCI NCI Adhya, Sankar (NCI) 1 147164118 Court, Donald NIH - NCI NCI Court, Donald (NCI) 2 147164120 Li, Xintian NIH - NCI NCI Li, Xintian (NCI) 3 147164121 Rajaure, Manoj NIH - NCI NCI Rajaure, Manoj (NCI) 4 147158014 Bacteriophage Based-Vaccine System E-113-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4271] Bacteriophage Based-Vaccine System&body=Please send me information about technology [TAB-4271] Bacteriophage Based-Vaccine System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4271] Bacteriophage Based-Vaccine System&body=Please send me information about technology [TAB-4271] Bacteriophage Based-Vaccine System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161061 E-113-2021-0 E-113-2021-0-US-01 BACTERIOPHAGE LAMBDA-VACCINE SYSTEM PRV US 63/289,018 Expired US <br />Provisional (PRV) 63/289,018<br />Filed on 2021-12-13<br />Status: Expired 147167807 E-113-2021-0 E-113-2021-0-PCT-02 vBacteriophage Based-Vaccine System PCT Patent Cooperation Treaty PCT/US2022/081383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/081383<br />Filed on 2022-12-12<br />Status: Expired 147171697 Adhya 147171699 Bacteriophage Engineering 147171701 Bacteriophage Genetics 147171702 CANCER VACCINE 147171703 Infectious Diseases 147171705 Lambda Vector 147171707 Phage Therapy 147171708 Recombineering 147171709 Vaccine TAB-4257 147157544 Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Sri Krishna, Steven Rosenberg, Zhiya Yu <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer.</p> <h2>Description of Technology:</h2> <p>Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy and prevents a sustained immune response.&nbsp;<br /> Researchers at the National Cancer Institute (NCI) have developed a combination immunotherapy to rescue the function of exhausted, neoantigen-specific T cells and, thus, enhance ACT. The method involves concurrent administration of neoantigen-specific T cells alongside a vaccine targeting the same neoantigens. The antitumor effect of this combination immunotherapy is superior to that mediated by the vaccine or by ACT alone, as measured in vivo by overall survival and tumor regression. Patient T cells genetically engineered with a neoantigen-specific T-cell receptor (TCR) can also be synergistically enhanced when used alongside a vaccine targeting the same antigen in this combination immunotherapy. This combined immunotherapy approach has broad therapeutic potential in a wide range of metastatic cancers, particularly those that are not responsive to traditional treatment methods.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A variety of human cancers potentially amenable to the synergistic combination therapy of adoptive cell therapy (ACT) and tumor vaccine to treat&nbsp;</li> <li>Cell therapies for which the ACT component can employ isolated exhausted, neoantigen-specific T cells or T cells transduced with a neoantigen-specific TCR&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Synergistic, instead of additive, effect observed with this combination therapy based on available in vivo data</li> <li>Increased efficacy of exhausted, neoantigen-specific T cells</li> <li>Reduced toxicity compared to non-tumor specific immunotherapies&nbsp;</li> <li>T cells and vaccine can target either patient-specific somatic mutations or common driver mutations</li> <li>Broad clinical applications, including solid tumors (which traditional ACT methods have struggled to effectively treat)&nbsp;</li> </ul> 2022-08-17 2026-04-23 2022-08-17 2026-04-23 2022-08-17 act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-059-2013 E-061-2020 E-067-2017 E-085-2013 E-102-2020 E-229-2014 E-233-2014 E-280-2016 147164069 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164068 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147164067 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 147164066 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164069 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164068 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147164067 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 147164066 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147157863 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer E-046-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer&body=Please send me information about technology [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer&body=Please send me information about technology [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160960 E-046-2022-0 E-046-2022-0-US-01 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer PRV US 63/295,762 Expired US <br />Provisional (PRV) 63/295,762<br />Filed on 2021-12-31<br />Status: Expired 147167712 E-046-2022-0 E-046-2022-0-PCT-02 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER PCT Patent Cooperation Treaty PCT/US2022/082579 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/082579<br />Filed on 2022-12-29<br />Status: Expired 147170250 act 147170251 Adoptive Cell Transfer 147170252 Immunotherapy 147170254 Krishna 147170255 Neoantigen 147170256 Rosenberg 147170257 T-Cell Receptor 147170258 TCR 147170259 Vaccine TAB-4213 147157498 Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs) NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials <h2>Summary:</h2> <p>The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs.</p> <h2>Description of Technology:</h2> <p>Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens that are expressed by tumor cells but not by healthy tissues. Current methods to identify such T cells involve extracting autologous antigen presenting cells (APCs) from patients in an expensive, laborious, and time-consuming process. In addition, the quantity and quality of extracted APCs varies significantly between patients, necessitating a novel, standardized approach.<br /> Researchers at the National Cancer Institute (NCI) developed a library of cell lines to identify T cells that specifically target tumor cells, thus eliminating the need for autologous APCs. These cell lines stably express tumor-specific antigens at a high level in the tandem minigene (TMG) format. The antigens expressed arise from mutations in the RAS or p53 genes. These mutations are also referred to as &ldquo;hotspot&rdquo; driver mutations because they are shared among many cancer patients and are the most commonly mutated genes in solid tumors. The cells also stably and highly express Class-I or Class-II human leukocyte antigens (HLAs) of interest, allowing for determination of HLA restriction. These cell lines offer a versatile, quick, and cost-effective method to identify, isolate, and expand tumor-reactive T cells.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Rapid identification, isolation, and expansion of mutated RAS or p53-reactive TILs or TCR-engineered T cells</li> <li>Validation of mutated RAS or p53-reactive TILs or TCR-engineered T cells&nbsp;</li> <li>Determination of HLA restriction of mutated RAS or p53-reactive TILs or TCR-engineered T cells</li> <li>Identification of T cell reactivities in infectious diseases (ex. Influenza, COVID-19)</li> <li>Identification of T cell reactivities in immunological disorders&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Universal APCs</li> <li>Replace the expensive, laborious, and time-consuming process of extracting/preparing autologous APCs</li> <li>Express tumor-specific antigens in the tandem minigene (TMG) format, allowing the cell lines to cover multiple different RAS or p53 mutations&nbsp;</li> <li>Express hotspot driver mutations, granting applicability to a broad range of cancer patients</li> </ul> 2022-10-14 2026-04-23 2022-10-13 2026-04-23 2022-10-13 act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 155750792 Cell Lines Constitutively Expressing Tandem Minigenes (TMGs) Of Hotspot Mutations And Human Leukocyte Antigens (HLA) E-182-2022-0 Research Material NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)&body=Please send me information about technology [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)&body=Please send me information about technology [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147173198 act 147173199 adoptive cell therapy 147173200 Antigen Presenting Cells 147173201 APC 147173202 cell lines 147173203 HLA 147173204 Human Leukocyte Antigen 147173205 Immunotherapy 147173206 KRAS 147173208 Levin 147173209 p53 147173210 Rosenberg 147173211 T Cell Receptor 147173212 TCR 147173213 TIL 147173214 Tumor Infiltrating Lymphocytes 147173216 Tumor-Specific Antigen TAB-4201 147157486 Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terrence Burke, Evgeny Kiselev, George Lountos, Yves Pommier, David Waugh, Xue Zhao <h2>Summary:</h2> <p>The NCI seeks proposals from parties interested in licensing and/or co-development for commercializing the use of TDP1 inhibitors as part of a potent and selective anti-cancer combination therapy.</p> <h2>Description of Technology:</h2> <p>Topoisomerase 1 (TOP1) is an essential enzyme that plays a critical role in DNA transcription and replication. TOP1 inhibitors are a known class of anti-cancer agents that work to interrupt DNA replication in cancer cells, causing cell death. Since the discovery of the TOP1 inhibitor camptothecin (CPT) from plant extracts more than 60 years ago, two CPT analogs (irinotecan and topotecan) were approved by the FDA for cancer treatment. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme involved in DNA repair created when TOP1 is inhibited. As a result, targeting TDP1 is considered a potential therapeutic approach to enhance and possibly synergize the potency of TOP1 inhibitors. While TOP1 inhibitors are widely used to treat solid tumors &ndash; such as colon, lung, ovarian and certain pediatric cancers &ndash; there are currently no drugs targeting TDP1. Many TDP1 inhibitors may potentially have mechanisms of action that are promiscuous and non-specific. Researchers at the NCI developed a series of novel compounds selectively targeting the catalytic domain of TDP1. These small molecules show low micromolar potency against TDP1. X-ray structures of TDP1 bound to some of the small molecules elucidated their catalytic binding modes. The compounds developed at the NCI show selectivity for TDP1 over TDP2.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Combination therapy with TOP1 inhibitors for cancer treatment</li> <li>Incorporation into Proteolysis Targeting Chimeric or Antibody-Drug Conjugate therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Irreversible inhibition of TDP1</li> <li>Selectivity for TDP1 over TDP2</li> <li>Small molecules capable of accessing and binding to the catalytic machinery to cause cancer cell death</li> <li>Currently, no FDA-approved TDP1 inhibitors</li> </ul> 2022-12-04 2026-04-23 2022-12-04 2026-04-23 2022-12-04 Burke, CANCER, solid tumor, Tdp1, TOP1, Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1, Zhao False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162324 Zhao, X.Z. et al. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites https://pubmed.ncbi.nlm.nih.gov/34163656/ <a href="https://pubmed.ncbi.nlm.nih.gov/34163656/">Zhao, X.Z. et al. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites</a> 147163894 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163895 Lountos, George NIH - NCI NCI Lountos, George (NCI) 2 147163896 Kiselev, Evgeny NIH - NCI NCI Kiselev, Evgeny (NCI) 3 147163892 Waugh, David NIH - NCI NCI Waugh, David (NCI) 4 147163891 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 5 147163893 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 6 147163894 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163895 Lountos, George NIH - NCI NCI Lountos, George (NCI) 2 147163896 Kiselev, Evgeny NIH - NCI NCI Kiselev, Evgeny (NCI) 3 147163892 Waugh, David NIH - NCI NCI Waugh, David (NCI) 4 147163891 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 5 147163893 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 6 147158282 Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors Derived From A Small Molecule Microarray (SMM) Screen E-256-2020-0 Filing authorized NCI, NIH - NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors&body=Please send me information about technology [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors&body=Please send me information about technology [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161235 E-256-2020-0 E-256-2020-0-US-01 IMIDAZO[1,2-a]PYRAZINE AND IMIDAZO[1,2-a]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS PRV US 63/141,634 Abandoned US <br />Provisional (PRV) 63/141,634<br />Filed on 2021-01-26<br />Status: Abandoned 147167316 E-256-2020-0 E-256-2020-0-PCT-04 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS PCT Patent Cooperation Treaty PCT/US2022/013946 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/013946<br />Filed on 2022-01-26<br />Status: Expired 147167317 E-256-2020-0 E-256-2020-0-US-04 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS National Stage US 18/262,779 Pending US <br />National Stage 18/262,779<br />Filed on 2023-07-25<br />Status: Pending 147167318 E-256-2020-0 E-256-2020-0-EP-01 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS National Stage European Patent 22705222.2 Pending European Patent <br />National Stage 22705222.2<br />Filed on 2023-08-08<br />Status: Pending 147174325 Burke 147174326 CANCER 147174327 solid tumor 147174328 Tdp1 147174329 TOP1 147174331 Topoisomerase 1 147174332 Tyrosyl-DNA Phosphodiesterase 1 147174334 Zhao TAB-4197 147157482 T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Catherine Ade, Kenichi Hanada, Matthew Sporn, James Yang, Zhiya Yu <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation.</p> <h2>Description of Technology:</h2> <p>BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the BRAF gene allow cells to continuously divide, leading to the development of cancer. A substitution of glutamic acid for valine at amino acid number 600 (designated V600E) accounts for 90% of BRAF mutations and is a driver of many cancers. The V600E mutation is present in ~3% of all cancer cases, representing a patient population of 540,000 patients per year. Though While the V600E mutation is found in a wide variety of cancers, it ishas a particularly high prevalentce in metastatic melanoma, colorectal cancer, thyroid cancer, and lung cancer. Many of these cancers are aggressive and the V600E mutation is commonly recognized as a poor prognostic factor. Therapies for these cancers are often nonspecific or limited by acquired resistance, necessitating novel therapeutic approaches specifically targeting the BRAF V600E mutation.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have identified two T cell receptors (TCRs) that target the BRAF V600E mutation. These TCRs specifically recognize tumor cells expressing the BRAF V600E mutation when presented by HLA-A*0301 molecules. The TCRs were identified by first using mass spectrometric analysis to isolate a short peptide derived from the BRAF V600E mutated protein that binds to HLA-A*0301. Transgenic mice harboring the HLA-A*0301 allele were then immunized with the peptide to obtain T cells recognizing the BRAF V600E mutation. The two TCRs were isolated from these T cells and tested in vitro for efficacy. Genetically engineered human T cells transduced with the TCRs were specifically reactive against multiple human tumor cell lines harboring the BRAF V600E mutation. These encouraging preclinical results suggest the potential for the TCRs to be used in a therapeutic approach such as T-cell therapy against cancers with the BRAF V600E mutation. Given the broad distribution of the V600E mutation across cancers, the TCRs are also an attractive candidate for allogeneic T-cell therapy among cancer patients with the HLA-A*0301 allele.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy for cancers expressing the BRAF V600E mutation</li> <li>&ldquo;Off-the-shelf&rdquo; allogenic cell therapy for BRAF V600E mutated cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential for therapeutic efficacy against many cancers, given the high prevalence and broad distribution of the BRAF V600E mutation among cancer patients</li> <li>Therapies for BRAF V600E mutation-relevant cancers are often nonspecific or limited by acquired resistance</li> <li>T cells engineered with the TCRs are cytotoxic to tumor cells as the BRAF V600E mutation is not present in healthy tissues</li> <li>Efficacy against solid tumors</li> </ul> 2022-11-21 2026-04-23 2022-11-21 2026-04-23 2022-11-21 BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 E-237-2017 147163872 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 1 147163873 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 2 147163874 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 147163871 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147163870 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147163872 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 1 147163873 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 2 147163874 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 147163871 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147163870 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147158219 Murine T Cell Receptors Targeting Human BRAF V600E Mutation On HLA-A*0301+ Tumor Cells E-213-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy&body=Please send me information about technology [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy&body=Please send me information about technology [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161199 E-213-2022-0 E-213-2022-0-US-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PRV US 63/381,587 Expired US <br />Provisional (PRV) 63/381,587<br />Filed on 2022-10-31<br />Status: Expired 159504232 E-213-2022-0 E-213-2022-0-PC-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PCT Patent Cooperation Treaty PCT/US2023/078156 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/078156<br />Filed on 2023-10-30<br />Status: Expired 147173777 BRAF 147173779 B-Raf kinase 147173781 B-Raf Proto-Oncogene 147173783 HLA-A*0301 restriction 147173784 Immunotherapy 147173785 Rosenberg 147173786 serine-threonine kinase 147173787 T Cell Receptor 147173788 T cell therapy 147173789 TCR 147173791 V600E mutation 147173793 Yang 147173795 Yu TAB-4140 147157423 Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20 NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics James Kochenderfer, Norris Lam <h2>Description of Technology:</h2> <p>Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after anti-CD19 CAR T-cell therapy. Relapse and non-response are likely due to diminished CD19 expression after anti-CD19 therapy and low expression of CD19 in some lymphomas.&nbsp;</p> <p>To overcome the limitations of the CD19 CAR T therapy, inventors developed an improved CAR targeting both CD19 and CD20. CARs targeting both CD19 and CD20 showed greater efficacy than the CD19 targeting CAR by itself. The structure of the CD20 binder in some of these CAR constructs is optimized to reduce death of CAR-expressing T cells and to promote retention of CAR expression. Also, these constructs are optimized to reduce retroviral recombination events.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of CD19-positive malignancies such as diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia</li> <li>Treatment of CD20-positive malignancies such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma</li> <li>Treatment of autoimmune diseases via B cell depletion</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Constructs optimized to reduce retroviral recombination events</li> <li>Bicistronic expression vector allows for more efficient targeting of two antigens versus two separate vectors</li> <li>Bicistronic construct targeting both CD19 and CD20 increases the durability of response often&nbsp;limited by diminished expression of CD19 on tumor cell surfaces after anti-CD19 therapy</li> </ul> 2022-01-19 2026-04-23 2022-01-20 2026-04-23 2022-01-19 act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-205-2018 147163659 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163660 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147163659 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163660 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147157912 Nucleotide Optimized Fully-human CAR Constructs Targeting CD19-CD20 E-065-2021-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160987 E-065-2021-0 E-065-2021-0-US-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF PRV US 63/165,195 Abandoned US <br />Provisional (PRV) 63/165,195<br />Filed on 2021-03-24<br />Status: Abandoned 147166882 E-065-2021-0 E-065-2021-0-PCT-02 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2022/021545 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/021545<br />Filed on 2022-03-23<br />Status: Expired 147170661 act 147170662 adoptive cell therapy 147170663 Autoimmune 147170665 B Cell Malignancies 147170666 BICISTRONIC 147170667 CAR 147170668 CD19 147170669 CD20 147170670 chimeric antigen receptor 147170672 Kochenderfer 147170673 Leukemia 147170674 lymphoma 147170675 Monospecific TAB-4126 147157408 T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Christian Hinrichs, Steven Rosenberg <h2>Summary:</h2> <p>The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E7-targeting TCR with therapeutic potential for HPV-positive conditions.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain &ndash; an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E7 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E7 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E711-19. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR. An ongoing Phase I/II clinical trial is investigating the efficacy of the E7-targeting TCR in treating HPV-positive malignancies.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy against HPV-positive cancers</li> <li>Treatment of HPV-related infections and premalignant conditions</li> <li>Prevention of HPV-related infections and premalignant conditions</li> <li>Detection of HPV-infected or transformed cells for diagnostic purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach&nbsp;</li> <li>FDA approval of another first-in-class TCR therapeutic decreases regulatory risk</li> <li>High avidity for the HPV-specific E7 oncoprotein</li> <li>Specifically recognize HLA-A*02-positive HPV-16 cancer cells</li> <li>TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a TCR with high-avidity recognition of the E7 oncoprotein to treat HPV-positive malignancies. 2022-07-06 2026-04-23 2022-07-08 2026-04-23 2022-07-08 act, adoptive cell therapy, Cervical cancer, E7, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-08 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-495-2013 147161890 Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer. https://pubmed.ncbi.nlm.nih.gov/24329789/ <a href="https://pubmed.ncbi.nlm.nih.gov/24329789/">Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer.</a> 147162006 Nagarsheth NB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. https://pubmed.ncbi.nlm.nih.gov/33558725/ <a href="https://pubmed.ncbi.nlm.nih.gov/33558725/">Nagarsheth NB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.</a> 147163607 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147163606 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147163607 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147163606 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158151 T-cell Receptor Targeting An HLA-A2-restricted Epitope Of Human Papillomavirus-16 E7 E-176-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein&body=Please send me information about technology [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein&body=Please send me information about technology [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147166721 E-176-2014-0 E-176-2014-0-US-01 Anti-Human Papillomavirus-16 E7 T Cell Receptors PRV US 62/004,335 Abandoned US <br />Provisional (PRV) 62/004,335<br />Filed on 2014-05-29<br />Status: Abandoned 147166722 E-176-2014-0 E-176-2014-0-PCT-02 Anti-Human Papillomavirus 16 E7 T Cell Receptors PCT Patent Cooperation Treaty PCT/US2015/033129 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/033129<br />Filed on 2015-05-29<br />Status: Expired 147166723 E-176-2014-0 E-176-2014-0-CA-05 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Canada 2950192 Pending Canada <br />National Stage 2950192<br />Filed on 2015-05-29<br />Status: Pending 147166724 E-176-2014-0 E-176-2014-0-AU-03 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Australia 2015266818 2015266818 Issued Australia <br />National Stage 2015266818<br />Filed on 2015-05-29<br />Status: Issued 147166725 E-176-2014-0 E-176-2014-0-BR-04 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Brazil BR112016027805-4 BR112016027805-4 Issued Brazil <br />National Stage BR112016027805-4<br />Filed on 2015-05-29<br />Status: Issued 147166726 E-176-2014-0 E-176-2014-0-CN-06 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage China ZL201580031789.X 201580031789.X Issued China <br />National Stage 201580031789.X<br />Filed on 2015-05-29<br />Status: Issued 147166727 E-176-2014-0 E-176-2014-0-EP-07 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage European Patent 3149031 15729004.0 Issued European Patent <br />National Stage 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166728 E-176-2014-0 E-176-2014-0-IL-08 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Israel 248797 248797 Issued Israel <br />National Stage 248797<br />Filed on 2016-11-07<br />Status: Issued 147166729 E-176-2014-0 E-176-2014-0-JP-09 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Japan 6742991 2017-515021 Issued Japan <br />National Stage 2017-515021<br />Filed on 2015-05-29<br />Status: Issued 147166730 E-176-2014-0 E-176-2014-0-KR-10 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage South Korea 10-2445667 10-2016-7033189 Issued South Korea <br />National Stage 10-2016-7033189<br />Filed on 2016-11-28<br />Status: Issued 147166731 E-176-2014-0 E-176-2014-0-MX-11 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Mexico 375379 MX/a/2016/015383 Issued Mexico <br />National Stage MX/a/2016/015383<br />Filed on 2015-05-29<br />Status: Issued 147166732 E-176-2014-0 E-176-2014-0-SA-12 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Saudi Arabia 7456 516380394 Issued Saudi Arabia <br />National Stage 516380394<br />Filed on 2015-05-29<br />Status: Issued 147166733 E-176-2014-0 E-176-2014-0-US-13 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS National Stage US 10,174,098 15/313,673 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10174098 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10174098">10,174,098</a><br />Filed on 2016-11-23<br />Status: Issued 147166734 E-176-2014-0 E-176-2014-0-HK-14 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Hong Kong HK1236203B 17109823.5 Issued Hong Kong <br />European patent (EP) 17109823.5<br />Filed on 2017-09-27<br />Status: Issued 147166735 E-176-2014-0 E-176-2014-0-US-15 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV US 10,870,687 16/205,631 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10870687 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10870687">10,870,687</a><br />Filed on 2018-11-30<br />Status: Issued 147166736 E-176-2014-0 E-176-2014-0-EP-16 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV European Patent 3689900 19217074.4 Issued European Patent <br />Divisional (DIV) 19217074.4<br />Filed on 2019-12-17<br />Status: Issued 147166737 E-176-2014-0 E-176-2014-0-AU-17 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2019283892 2019283892 Issued Australia <br />Divisional (DIV) 2019283892<br />Filed on 2019-12-18<br />Status: Issued 147166738 E-176-2014-0 E-176-2014-0-AL-18 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Albania 3149031 15729004.0 Issued Albania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166739 E-176-2014-0 E-176-2014-0-AT-19 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Austria 3149031 15729004.0 Issued Austria <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166740 E-176-2014-0 E-176-2014-0-BE-20 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Belgium 3149031 15729004.0 Issued Belgium <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166741 E-176-2014-0 E-176-2014-0-BG-21 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Bulgaria 3149031 15729004.0 Issued Bulgaria <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166742 E-176-2014-0 E-176-2014-0-CH-22 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Switzerland 3149031 15729004.0 Issued Switzerland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166743 E-176-2014-0 E-176-2014-0-CY-23 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Cyprus 3149031 15729004.0 Issued Cyprus <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166744 E-176-2014-0 E-176-2014-0-CZ-24 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Czech Republic 3149031 15729004.0 Issued Czech Republic <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166745 E-176-2014-0 E-176-2014-0-DE-25 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Germany 3149031 15729004.0 Issued Germany <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166746 E-176-2014-0 E-176-2014-0-DK-26 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Denmark 3149031 15729004.0 Issued Denmark <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166747 E-176-2014-0 E-176-2014-0-EE-27 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Estonia 3149031 15729004.0 Issued Estonia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166748 E-176-2014-0 E-176-2014-0-ES-28 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Spain 3149031 15729004.0 Issued Spain <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166749 E-176-2014-0 E-176-2014-0-FI-29 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Finland 3149031 15729004.0 Issued Finland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166750 E-176-2014-0 E-176-2014-0-FR-30 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP France 3149031 15729004.0 Issued France <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166751 E-176-2014-0 E-176-2014-0-GB-31 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP United Kingdom 3149031 15729004.0 Issued United Kingdom <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166752 E-176-2014-0 E-176-2014-0-GR-32 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Greece 3149031 15729004.0 Issued Greece <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166753 E-176-2014-0 E-176-2014-0-HR-33 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Croatia 3149031 15729004.0 Issued Croatia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166754 E-176-2014-0 E-176-2014-0-HU-34 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Hungary 3149031 15729004.0 Issued Hungary <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166755 E-176-2014-0 E-176-2014-0-IE-35 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Ireland 3149031 15729004.0 Issued Ireland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166756 E-176-2014-0 E-176-2014-0-IS-36 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Iceland 3149031 15729004.0 Issued Iceland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166757 E-176-2014-0 E-176-2014-0-IT-37 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Italy 3149031 15729004.0 Issued Italy <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166758 E-176-2014-0 E-176-2014-0-LT-38 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Lithuania 3149031 15729004.0 Issued Lithuania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166759 E-176-2014-0 E-176-2014-0-LU-39 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Luxembourg 3149031 15729004.0 Issued Luxembourg <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166760 E-176-2014-0 E-176-2014-0-LV-40 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Latvia 3149031 15729004.0 Issued Latvia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166761 E-176-2014-0 E-176-2014-0-MK-41 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP North Macedonia 3149031 15729004.0 Issued North Macedonia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166762 E-176-2014-0 E-176-2014-0-MT-42 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Malta 3149031 15729004.0 Issued Malta <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166763 E-176-2014-0 E-176-2014-0-NL-43 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP The Netherlands 3149031 15729004.0 Issued The Netherlands <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166764 E-176-2014-0 E-176-2014-0-NO-44 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Norway 3149031 15729004.0 Issued Norway <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166765 E-176-2014-0 E-176-2014-0-PL-45 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Poland 3149031 15729004.0 Issued Poland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166766 E-176-2014-0 E-176-2014-0-PT-46 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Portugal 3149031 15729004.0 Issued Portugal <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166767 E-176-2014-0 E-176-2014-0-RO-47 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Romania 3149031 15729004.0 Issued Romania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166768 E-176-2014-0 E-176-2014-0-SE-48 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Sweden 3149031 15729004.0 Issued Sweden <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166769 E-176-2014-0 E-176-2014-0-SI-49 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Slovenia 3149031 15729004.0 Issued Slovenia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166770 E-176-2014-0 E-176-2014-0-SK-50 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Slovakia 3149031 15729004.0 Issued Slovakia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166771 E-176-2014-0 E-176-2014-0-SM-51 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP San Marino 3149031 15729004.0 Issued San Marino <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166772 E-176-2014-0 E-176-2014-0-TR-52 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Turkey 3149031 15729004.0 Issued Turkey <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166773 E-176-2014-0 E-176-2014-0-JP-53 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T-CELL RECEPTOR DIV Japan 6997267 2020-127833 Issued Japan <br />Divisional (DIV) 2020-127833<br />Filed on 2020-07-29<br />Status: Issued 147166774 E-176-2014-0 E-176-2014-0-SA-54 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Saudi Arabia 520412601 Abandoned Saudi Arabia <br />Divisional (DIV) 520412601<br />Filed on 2020-08-06<br />Status: Abandoned 147166775 E-176-2014-0 E-176-2014-0-HK-55 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS EP Hong Kong HK40030123B 42020020661.3 Issued Hong Kong <br />European patent (EP) 42020020661.3<br />Filed on 2020-11-24<br />Status: Issued 147166776 E-176-2014-0 E-176-2014-0-MX-56 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Mexico 432750 MX/a/2020/010035 Issued Mexico <br />Divisional (DIV) MX/a/2020/010035<br />Filed on 2020-09-24<br />Status: Issued 147166777 E-176-2014-0 E-176-2014-0-US-57 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS CON US 11,434,272 17/101,360 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434272 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434272">11,434,272</a><br />Filed on 2020-11-23<br />Status: Issued 147166778 E-176-2014-0 E-176-2014-0-AU-58 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2021202227 2021202227 Issued Australia <br />Divisional (DIV) 2021202227<br />Filed on 2021-04-13<br />Status: Issued 147166779 E-176-2014-0 E-176-2014-0-CN-59 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV China ZL202110399056.9 202110399056.9 Issued China <br />Divisional (DIV) 202110399056.9<br />Filed on 2021-04-14<br />Status: Issued 147166780 E-176-2014-0 E-176-2014-0-IL-60 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Israel 282518 282518 Issued Israel <br />Divisional (DIV) 282518<br />Filed on 2021-04-21<br />Status: Issued 147166782 E-176-2014-0 E-176-2014-0-HK-62 Anti-Human Papillomavirus 16 E7 T Cell Receptors CN Hong Kong HK40056926B 42022046605.6 Issued Hong Kong <br />China Patent (CN) 42022046605.6<br />Filed on 2022-01-19<br />Status: Issued 147166783 E-176-2014-0 E-176-2014-0-JP-63 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV Japan 7291196 2021-203953 Issued Japan <br />Divisional (DIV) 2021-203953<br />Filed on 2021-12-16<br />Status: Issued 147166784 E-176-2014-0 E-176-2014-0-IL-64 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Israel 290655 290655 Issued Israel <br />Divisional (DIV) 290655<br />Filed on 2022-02-16<br />Status: Issued 147166785 E-176-2014-0 E-176-2014-0-US-65 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS CON US 12,534,508 17/816,496 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12534508 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12534508">12,534,508</a><br />Filed on 2022-08-01<br />Status: Issued 147166786 E-176-2014-0 E-176-2014-0-KR-66 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV South Korea 10-2618267 10-2022-7032043 Issued South Korea <br />Divisional (DIV) 10-2022-7032043<br />Filed on 2022-09-15<br />Status: Issued 147166787 E-176-2014-0 E-176-2014-0-AU-01 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2023200608 2023200608 Issued Australia <br />Divisional (DIV) 2023200608<br />Filed on 2023-02-06<br />Status: Issued 147166788 E-176-2014-0 E-176-2014-0-JP-01 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV Japan 7535158 2023-091878 Issued Japan <br />Divisional (DIV) 2023-091878<br />Filed on 2023-06-02<br />Status: Issued 147173065 act 147173066 adoptive cell therapy 147173067 Cervical cancer 147173068 E7 147173070 HLA-A*02 147173071 HPV 147173072 Human Papillomavirus 147173074 Major Histocompatibility Complex 147173075 MALIGNANCY 147173076 MHC 147173077 ONCOPROTEIN 147173078 Rosenberg 147173079 T Cell Receptor 147173080 TCR TAB-4115 147157397 Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Seham Ebrahim, Weiye Wang, Roberto Weigert <h2>Summary:</h2> <p>NCI is seeking licensees for mouse lines with fluorescently labeled membrane proteins regulating cellular motility and cancer progression.</p> <h2>Description of Technology:</h2> <p>Cell motility and membrane trafficking play important roles in regulating cell division, cell migration, cell death and autophagy. Impairment of these processes can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. There is therefore a need for development of animal models for studying the roles of these proteins in cancer and their responses to drug treatment in vivo.</p> <p>Researchers at the National Cancer Institute (NCI) have developed mouse lines with fluorescently labelled membrane proteins regulating cellular motility and membrane trafficking. These transgenic mouse lines were created by insertion of fluorescent proteins to tag Myosin IIA, Septin 2, Septin 7, Septin 9 and Rab25. They facilitate the study of cell motility and membrane trafficking proteins and their activity during tumor progression in live animal models.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer research</li> <li>Live animal imaging cancer studies</li> <li>Live animal imaging cancer drug screening</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Use of neon-Green and pTag-RFP tagging provides a superior means of imaging in vivo over other fluorescent proteins</li> <li>These mouse lines facilitate live animal imaging studies of cell motility and membrane trafficking proteins</li> <li>The first available mouse lines for live animal imaging of Septin 2, Septin 7, Septin 9 and Rab25 in vivo</li> </ul> Researchers at the NCI seek licensing for mouse lines with fluorescently labelled membrane proteins regulating cellular motility and cancer progression 2022-02-03 2026-04-23 2022-02-03 2026-04-23 2022-02-03 Cellular Motility, Florescent Labels, Membrane Trafficking, Mouse Lines, Rab25, Septin 2, Septin 7, Septin 9, Weigert False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163558 Weigert, Roberto NIH - NCI NCI Weigert, Roberto (NCI) 1 147163560 Wang, Weiye NCI - CCR NCI Wang, Weiye (NCI) 2 147163559 Ebrahim, Seham NCI - CCR NCI Ebrahim, Seham (NCI) 3 147163558 Weigert, Roberto NIH - NCI NCI Weigert, Roberto (NCI) 1 147163560 Wang, Weiye NCI - CCR NCI Wang, Weiye (NCI) 2 147163559 Ebrahim, Seham NCI - CCR NCI Ebrahim, Seham (NCI) 3 147157829 Mouse Lines With Fluorescently Labeled Membrane Proteins (Septins, Myosin IIA, Rab25) Regulating Cellular Motility And Membrane Trafficking E-031-2022-0 Research Material NCI 147188440 Watson, Shana shana.watson@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America shana.watson@nih.gov?subject=Web Inquiry on [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking&body=Please send me information about technology [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Watson, Shana<br><a href="mailto:shana.watson@nih.gov?subject=Web Inquiry on [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking&body=Please send me information about technology [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">shana.watson@nih.gov</a><br> 147169887 Cellular Motility 147169889 Florescent Labels 147169891 Membrane Trafficking 147169893 Mouse Lines 147169894 Rab25 147169896 Septin 2 147169898 Septin 7 147169900 Septin 9 147169902 Weigert TAB-4043 147157325 IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Aarti Kolluri, Nan Li <h2>Summary:</h2> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for developing new nanobody-based CAR and/or antibody-T-cell receptor therapies for treating liver cancer.</p> <h2>Description of Technology:</h2> <p>Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates for curative-intent treatment. As a result, alternative treatments are needed. Chimeric antigen receptor (CAR) T cell therapy is a promising alternative approach selectively targets targeting tumors via tumor-specific antigens. However, to date, no effective CAR T cell therapy exists for HCC.</p> <p>Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for glypican-3 (GPC3) that include short Immunoglobulin subclass 4 (IgG4) and CD28 based hinge domains and the HN3 human single-domain antibody (also called nanobody). The specific HN3 nanobody-IgG4H-CD28TM CAR included in this invention was much more potent both in in vitro cell models and in vivo mouse models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of liver cancer, whose worldwide incidence is increasing in direct relation to the spread of hepatitis C virus infection.</li> <li>Chimeric antigen receptor (CAR) and/or antibody-T-cell receptor cancer therapies.&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic effectiveness of CAR T therapies for the vast majority patients with HCC without impactful treatment options</li> <li>New nanobody-based CAR immunotherapy in preclinical in vivo studies has a greater decrease in tumor size compared with other CAR formats</li> <li>Nanobodies&rsquo; lack of a light chain, making them much smaller and more flexible than standard antibodies, allows: (1) binding in different modes than typical antibodies, (2) coverage of more chemical space and (3) binding to epitopes otherwise inaccessible.&nbsp;&nbsp;</li> <li>Nanobodies can be readily genetically engineered for additional functionality and, consequently, paths to market.&nbsp;&nbsp;</li> </ul> 2022-07-06 2026-04-23 2022-07-06 2026-04-23 2022-07-06 ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-016-2018 E-130-2011 147162126 Dan Li, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology vol. 158,8 (2020): 2250-2265.e20. doi:10.1053/j.gastro.2020.02.011 https://pubmed.ncbi.nlm.nih.gov/32060001/ <a href="https://pubmed.ncbi.nlm.nih.gov/32060001/">Dan Li, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology vol. 158,8 (2020): 2250-2265.e20. doi:10.1053/j.gastro.2020.02.011</a> 147163312 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163314 Kolluri, Aarti NCI - CCR NCI Kolluri, Aarti (NCI) 2 147163313 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147163312 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163314 Kolluri, Aarti NCI - CCR NCI Kolluri, Aarti (NCI) 2 147163313 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147158207 IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 For Treating Liver Cancer E-205-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer&body=Please send me information about technology [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer&body=Please send me information about technology [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161191 E-205-2021-0 E-205-2021-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF PRV US 63/277,287 Abandoned US <br />Provisional (PRV) 63/277,287<br />Filed on 2021-11-09<br />Status: Abandoned 147166168 E-205-2021-0 E-205-2021-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2022/079554 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/079554<br />Filed on 2022-11-09<br />Status: Expired 147173628 ANTIBODY 147173629 cancer therapeutic 147173631 Chimeric antigen receptors (CARs) 147173633 Glypican-3 (GPC3) 147173635 Hepatocellular Carcinoma (HCC) 147173636 HO 147173637 IgG4 147173638 Liver cancer 147173639 Macrophage 147173640 NANOBODY 147173642 Natural Killer (NK) Cell 147173643 T cell 147173644 therapeutic TAB-3933 147157213 T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Christian Hinrichs, Steven Rosenberg <h2>Summary:</h2> <p>The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E6-targeting TCR with therapeutic potential for HPV-positive conditions.</p> <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain &ndash; an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E6 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E6 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E629-38. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy against HPV-positive cancers</li> <li>Treatment of HPV-related infections and premalignant conditions</li> <li>Prevention of HPV-related infections and premalignant conditions</li> <li>Detection of HPV-infected or transformed cells for diagnostic purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach&nbsp;</li> <li>FDA approval of another first-in-class TCR therapeutic decreases regulatory risk</li> <li>High avidity for the HPV-specific E6 oncoprotein</li> <li>Specifically recognize HLA-A*02-positive HPV-16 cancer cells</li> <li>TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells&nbsp;</li> </ul> 2022-07-08 2026-04-23 2022-09-29 2026-04-23 2022-07-08 act, adoptive cell therapy, Cervical cancer, E6, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-09-29 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-176-2014 147162097 Doran SL, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus&ndash;Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. https://pubmed.ncbi.nlm.nih.gov/?term=31408414 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=31408414">Doran SL, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus&ndash;Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.</a> 147162175 Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer. https://pubmed.ncbi.nlm.nih.gov/24329789/ <a href="https://pubmed.ncbi.nlm.nih.gov/24329789/">Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer.</a> 147162920 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162919 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162920 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162919 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158355 T Cell Receptor Targeting An HLA-A2 Restricted Epitope Of Human Papillomavirus-16 E6 E-495-2013-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein&body=Please send me information about technology [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein&body=Please send me information about technology [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147165363 E-495-2013-0 E-495-2013-0-US-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors PRV US 61/846,167 Abandoned US <br />Provisional (PRV) 61/846,167<br />Filed on 2013-07-15<br />Status: Abandoned 147165364 E-495-2013-0 E-495-2013-0-PCT-02 Anti-Human Papillomavirus 16 E6 T Cell Receptors PCT Patent Cooperation Treaty PCT/US2014/046480 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/046480<br />Filed on 2014-07-14<br />Status: Expired 147165365 E-495-2013-0 E-495-2013-0-JP-07 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Japan 6628719 2016-527006 Issued Japan <br />National Stage 2016-527006<br />Filed on 2016-01-15<br />Status: Issued 147165366 E-495-2013-0 E-495-2013-0-AU-03 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Australia 2014290288 2014290288 Issued Australia <br />National Stage 2014290288<br />Filed on 2014-07-14<br />Status: Issued 147165367 E-495-2013-0 E-495-2013-0-CA-04 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Canada 2918216 2918216 Issued Canada <br />National Stage 2918216<br />Filed on 2014-07-14<br />Status: Issued 147165368 E-495-2013-0 E-495-2013-0-CN-05 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage China ZL201480044286.1 201480044286.1 Issued China <br />National Stage 201480044286.1<br />Filed on 2016-02-04<br />Status: Issued 147165369 E-495-2013-0 E-495-2013-0-EP-06 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage European Patent 3022223 14748353.1 Issued European Patent <br />National Stage 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165370 E-495-2013-0 E-495-2013-0-US-08 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage US 9,822,162 14/905,108 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9822162 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9822162">9,822,162</a><br />Filed on 2016-01-14<br />Status: Issued 147165371 E-495-2013-0 E-495-2013-0-US-09 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 10,329,339 15/786,966 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329339">10,329,339</a><br />Filed on 2017-10-18<br />Status: Issued 147165372 E-495-2013-0 E-495-2013-0-EP-10 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV European Patent 3572423 19180239.6 Issued European Patent <br />Divisional (DIV) 19180239.6<br />Filed on 2019-06-14<br />Status: Issued 147165373 E-495-2013-0 E-495-2013-0-US-11 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 10,913,785 16/408,939 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913785 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913785">10,913,785</a><br />Filed on 2019-05-10<br />Status: Issued 147165374 E-495-2013-0 E-495-2013-0-DE-12 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Germany 3022223 14748353.1 Issued Germany <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165375 E-495-2013-0 E-495-2013-0-ES-13 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Spain 3022223 14748353.1 Issued Spain <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165376 E-495-2013-0 E-495-2013-0-FR-14 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP France 3022223 14748353.1 Issued France <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165377 E-495-2013-0 E-495-2013-0-GB-15 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP United Kingdom 3022223 14748353.1 Issued United Kingdom <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165378 E-495-2013-0 E-495-2013-0-IE-16 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Ireland 3022223 14748353.1 Issued Ireland <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165379 E-495-2013-0 E-495-2013-0-IT-17 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Italy 3022223 14748353.1 Issued Italy <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165380 E-495-2013-0 E-495-2013-0-CN-18 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS DIV China ZL201910649441.7 201910649441.7 Issued China <br />Divisional (DIV) 201910649441.7<br />Filed on 2019-07-18<br />Status: Issued 147165381 E-495-2013-0 E-495-2013-0-JP-19 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan 6959970 2019-219105 Issued Japan <br />Divisional (DIV) 2019-219105<br />Filed on 2019-12-03<br />Status: Issued 147165382 E-495-2013-0 E-495-2013-0-HK-20 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Hong Kong HK40018191B 42020008016.6 Issued Hong Kong <br />European patent (EP) 42020008016.6<br />Filed on 2020-05-25<br />Status: Issued 147165383 E-495-2013-0 E-495-2013-0-HK-21 Anti-Human Papillomavirus 16 E6 T Cell Receptors CN Hong Kong HK40016948B 42020007152.0 Issued Hong Kong <br />China Patent (CN) 42020007152.0<br />Filed on 2020-05-09<br />Status: Issued 147165384 E-495-2013-0 E-495-2013-0-US-22 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 11,697,676 17/142,486 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11697676 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11697676">11,697,676</a><br />Filed on 2021-01-06<br />Status: Issued 147165385 E-495-2013-0 E-495-2013-0-JP-23 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan 7223822 2021-166407 Issued Japan <br />Divisional (DIV) 2021-166407<br />Filed on 2021-10-08<br />Status: Issued 147165386 E-495-2013-0 E-495-2013-0-JP-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan Administratively Closed Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 147165387 E-495-2013-0 E-495-2013-0-US-02 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 12,187,779 18/323,493 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12187779 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12187779">12,187,779</a><br />Filed on 2023-05-25<br />Status: Issued 147174883 act 147174884 adoptive cell therapy 147174885 Cervical cancer 147174886 E6 147174887 HLA-A*02 147174888 HPV 147174889 Human Papillomavirus 147174890 Major Histocompatibility Complex 147174891 MALIGNANCY 147174892 MHC 147174893 ONCOPROTEIN 147174894 Rosenberg 147174895 T Cell Receptor 147174896 TCR TAB-3935 147157215 Optical Configuration Methods for Spectral Scatter Flow Cytometry NCI Cardiology, Collaboration, Immunology, Infectious Disease, Licensing, Research Materials Cardiology Collaboration Immunology Infectious Disease Licensing Research Materials Jay Berzofsky, Jennifer Jones, Ariel ("Ari") Rosner, William Telford, Joshua Welsh <h2>Summary:</h2> <p>The inventors are constructing a prototype system and seek licensing or co-development opportunities from commercial flow cytometry platforms to optimize the invention for use in combination with their proprietary platforms.</p> <h2>Description of Technology:</h2> <p>Multi-parameter flow cytometry has been extensively used in multiple disciplines of biological discoveries, including immunology and cancer research. However, the disadvantage of traditional flow cytometry platforms using excitation lasers and fluorescence detectors is spectral overlap when using multiple dyes on the same biological sample. Metaethical compensation of spectral overlap could only be effective to a certain degree. Mass cytometry is advantageous compared to flow cytometry but is pricey and requires highly skilled operators.&nbsp;</p> <p>The inventors from the National Cancer Institute (NCI) developed a new flow cytometry protype using molecular NanoTags. NanoTags are nano-sized cytometric labels detectable individually or quantitatively enumerated based on their intrinsic light scattering or fluorescence properties. They are modularly designed to embody distinctive light scattering, fluorescence, and epitope specificity properties. Because NanoTags are modular, they can be comprised of different nanomaterials &ndash; each with identifiable and distinctive light scattering spectral properties across a wide range of wavelengths. Using the unique property of NanoTags, the inventors have tested three unique configurations. Configuration #1, &ldquo;Spectral Scatter Cytometer,&rdquo; is designed for full spectral scatter flow cytometry and would implement a supercontinuum white laser providing illumination at all UV-visible wavelengths. Configuration #2, &ldquo;Co-linear Laser Alignment,&rdquo; involves the co-linear alignment of at least two monochromatic lasers onto the core stream of standard flow cytometry.&nbsp; Configuration #3, &ldquo;Spatially Separated Lasers with Slit Apertures,&rdquo; involves a white-light laser, with its wavelengths spatially separated or part of standard, multi-monochromatic laser flow cytometry. Configuration #3 has the potential of being built to stand alone or add on to existing flow cytometers, providing high-throughput sample characterization with improved resolution.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>High-throughput sample characterization with flow cytometry</li> <li>Adaptable for other cytometric and microfluidic systems for enhanced detection</li> <li>Next generation cytometers&rsquo; configuration</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Enables single molecule detection in flow cytometry</li> <li>Identifying, quantifying and separating different subsets of extracellular vesicles and viruses</li> <li>Enable enhanced development of biomarkers, diagnostic and imaging products</li> </ul> 2022-01-21 2026-04-23 2022-01-21 2026-04-23 2022-01-21 flow cytometry, High-throughput Characterization, Jones, Molecular NanoTag, Multispectral Detection, Optical Configuration False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-21 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-238-2015 147162926 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147162928 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 2 147162927 Telford, William NIH - NCI NCI Telford, William (NCI) 3 147162924 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147162925 Rosner, Ariel ("Ari") NIH - NCI Rosner, Ariel ("Ari") 5 147162926 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147162928 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 2 147162927 Telford, William NIH - NCI NCI Telford, William (NCI) 3 147162924 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147162925 Rosner, Ariel ("Ari") NIH - NCI Rosner, Ariel ("Ari") 5 147157777 Optical Configuration Device And Methods For Spectral Scatter Cytometry E-008-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry&body=Please send me information about technology [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry&body=Please send me information about technology [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160890 E-008-2018-0 E-008-2018-0-US-07 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage US 10,876,955 16/756,420 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876955 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876955">10,876,955</a><br />Filed on 2020-04-15<br />Status: Issued 147165396 E-008-2018-0 E-008-2018-0-US-01 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PRV US 62/575,988 Abandoned US <br />Provisional (PRV) 62/575,988<br />Filed on 2017-10-23<br />Status: Abandoned 147165397 E-008-2018-0 E-008-2018-0-PCT-02 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PCT Patent Cooperation Treaty PCT/US2018/057128 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/057128<br />Filed on 2018-10-23<br />Status: Expired 147165398 E-008-2018-0 E-008-2018-0-CN-03 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage China ZL201880069066.2 201880069066.2 Issued China <br />National Stage 201880069066.2<br />Filed on 2018-10-23<br />Status: Issued 147165399 E-008-2018-0 E-008-2018-0-EP-04 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage European Patent 3701246 18808559.1 Issued European Patent <br />National Stage 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165400 E-008-2018-0 E-008-2018-0-JP-05 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage Japan 6788148 2020-522670 Issued Japan <br />National Stage 2020-522670<br />Filed on 2020-04-21<br />Status: Issued 147165401 E-008-2018-0 E-008-2018-0-KR-06 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage South Korea 10-2182575 10-2020-7011517 Issued South Korea <br />National Stage 10-2020-7011517<br />Filed on 2020-04-21<br />Status: Issued 147165402 E-008-2018-0 E-008-2018-0-DE-08 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP Germany 3701246 18808559.1 Issued Germany <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165403 E-008-2018-0 E-008-2018-0-FR-09 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP France 3701246 18808559.1 Issued France <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165404 E-008-2018-0 E-008-2018-0-GB-10 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP United Kingdom 3701246 18808559.1 Issued United Kingdom <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165405 E-008-2018-0 E-008-2018-0-NL-11 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP The Netherlands 3701246 18808559.1 Issued The Netherlands <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147169352 flow cytometry 147169354 High-throughput Characterization 147169356 Jones 147169358 Molecular NanoTag 147169360 Multispectral Detection 147169362 Optical Configuration TAB-3957 147157237 Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Jay Berzofsky, Jennifer Jones, Joshua Welsh <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for a biomarker analysis software for high-throughput diagnostic multiplex data.</p> <h2>Description of Technology:</h2> <p>Extracellular vesicles (EVs) are lipid bilayer-enclosed particles that are released from cells. EVs may contain proteins derived from their cells of origin with the potential as diagnostic biomarkers indicating the state of the cells when released. However, due to their small size (50-1000nm), the methods currently used to phenotype EVs have limited sensitivity and scale. A need exists for development of novel technologies improving EV detection and phenotyping.</p> <p>National Cancer Institute (NCI) scientists have developed a software package to perform high-throughput multi-dimensional analysis of EVs. The software utilizes a multiplex bead-based approach, coupled with secondary markers, clinical data, and -omics data. This technology provides a mechanism for high-throughput, semi-automated multidimensional data analysis for potential diagnostic and prognostic outcomes. The inventors used the software to identify and visualize a broad range of EV subsets, while also indirectly measuring specific EV populations. Exploratory studies confirmed strong correlations of liquid biopsy EV repertoires with tumor burden and responses to treatment. Furthermore, this software allows a scalable method of using EVs as biomarkers in a highly multiplexed fashion. When coupled with other clinical data, it is a useful means of diagnostic and/or prognostic outcomes.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Software package for high-throughput screening of extracellular vesicles as diagnostic and prognostic markers in personalized medicine.</li> <li>Can be utilized as software interface for other multiplex assays</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Allows for high-throughput, multiplexed and semi-automated analysis of extracellular vesicles and cargo protein.</li> <li>Utilizes secondary markers, clinical data and -omics data to provide diagnostic and/or prognostic determinations.</li> </ul> 2022-02-23 2026-04-23 2022-02-23 2026-04-23 2022-02-23 Berzofsky, Biomarker, EV, Extracellular Vesicles, High-throughput, Jones, Lipid Bilayer-Enclosed Particles, software False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-23 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161957 Welsh JA et al. MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. https://doi.org/10.1016/j.crmeth.2021.100136 <a href="https://doi.org/10.1016/j.crmeth.2021.100136">Welsh JA et al. MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.</a> 147163014 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 1 147163013 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 2 147163012 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 3 147163014 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 1 147163013 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 2 147163012 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 3 147157995 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data E-105-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data&body=Please send me information about technology [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data&body=Please send me information about technology [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161045 E-105-2018-0 E-105-2018-0-US-01 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data PRV US 62/650,162 Abandoned US <br />Provisional (PRV) 62/650,162<br />Filed on 2018-03-29<br />Status: Abandoned 147165544 E-105-2018-0 E-105-2018-0-PCT-02 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data PCT Patent Cooperation Treaty PCT/US2019/024975 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/024975<br />Filed on 2019-03-29<br />Status: Expired 147165545 E-105-2018-0 E-105-2018-0-AU-03 BIOMARKER ANALYSIS FOR HIGH-THROUGHPUT DIAGNOSTIC MULTIPLEX DATA National Stage Australia 2019245402 Pending Australia <br />National Stage 2019245402<br />Filed on 2019-03-29<br />Status: Pending 147165546 E-105-2018-0 E-105-2018-0-CA-04 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage Canada 3095485 3095485 Issued Canada <br />National Stage 3095485<br />Filed on 2020-09-28<br />Status: Issued 147165547 E-105-2018-0 E-105-2018-0-EP-05 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage European Patent 3775897 19717657.1 Issued European Patent <br />National Stage 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 147165548 E-105-2018-0 E-105-2018-0-US-06 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage US 17/042,765 Abandoned US <br />National Stage 17/042,765<br />Filed on 2020-09-28<br />Status: Abandoned 159504200 E-105-2018-0 E-105-2018-0-ES-07 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Spain 3775897 19717657.1 Issued Spain <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504634 E-105-2018-0 E-105-2018-0-FR-08 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP France 3775897 19717657.1 Issued France <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504645 E-105-2018-0 E-105-2018-0-DK-09 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Denmark 3775897 19717657.1 Issued Denmark <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504650 E-105-2018-0 E-105-2018-0-IT-10 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Italy 3775897 19717657.1 Issued Italy <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504661 E-105-2018-0 E-105-2018-0-DE-11 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Germany 3775897 19717657.1 Issued Germany <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504666 E-105-2018-0 E-105-2018-0-NL-14 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP The Netherlands 3775897 19717657.1 Issued The Netherlands <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504671 E-105-2018-0 E-105-2018-0-CH-13 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Switzerland 3775897 19717657.1 Issued Switzerland <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504683 E-105-2018-0 E-105-2018-0-GB-12 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP United Kingdom 3775897 19717657.1 Issued United Kingdom <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 147171496 Berzofsky 147171497 Biomarker 147171498 EV 147171499 Extracellular Vesicles 147171500 High-throughput 147171501 Jones 147171503 Lipid Bilayer-Enclosed Particles 147171504 software TAB-4029 147157310 Nanobodies Neutralizing Lassa Virus NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Sao "Crystal" Cheung, Zhijian Duan, Jason Gorman, Mitchell Ho, Peter Kwong, Yaping Sun <h2>Summary:</h2> <p>Researchers at the National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus.</p> <h2>Description of Technology:</h2> <p>Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) &ndash; highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC). LASV poses a severe public health threat with infections expanding outside the traditional endemic areas and no LHF- specific vaccines or therapies.</p> <p>Researchers at NCI&rsquo;s Laboratory of Molecular Biology, in collaboration with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, developed and isolated six nanobodies with high binding affinity for the LASV envelop protein. Nanobodies are the smallest known antigen-binding fragments of antibodies. They have great potential as research tools and in medical applications due to their (1) small size, (2) high solubility, (3) thermal stability, (4) refolding capacity, and (5) relatively easy tissue penetration,.&nbsp;</p> <p>The nanobodies D5 and C3 show the most potent neutralizing activities. These nanobodies neutralized LASV Josiah pseduotyped virus when prepared in a bivalent IgG2a format as human IgG Fc-fusion. Overall, it is evident that the nanobodies can be used and developed into therapeutics that that neutralize Lassa virus.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics against Lassa virus infection</li> <li>Lassa virus diagnostics (in vivo virus imaging)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No LSV-specific vaccines or treatments</li> <li>First stabilized, soluble LASV glycoprotein trimer</li> <li>Nanobodies with high affinity for the LASV GPC trimer</li> <li>Nanobodies compete with 4 different groups of human neutralizing antibodies</li> <li>Nanobodies neutralize LASV when prepared in a human IgG Fc-fusion</li> </ul> 2022-04-12 2026-04-23 2022-04-12 2026-04-23 2022-04-12 antibodies, diagnostic, HO, LASSA, Lassa Hemorrhagic Fever, LHF, Nanobodies, Neutralizing, virus False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-04-12 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163277 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163276 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 2 147163280 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 3 147163281 Sun, Yaping NCI - CCR NCI Sun, Yaping (NCI) 4 147163279 Cheung, Sao "Crystal" NIH - NIAID NIAID Cheung, Sao "Crystal" (NIAID) 5 147163278 Gorman, Jason NIH - NIAID NIAID Gorman, Jason (NIAID) 6 147163277 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163276 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 2 147163280 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 3 147163281 Sun, Yaping NCI - CCR NCI Sun, Yaping (NCI) 4 147163279 Cheung, Sao "Crystal" NIH - NIAID NIAID Cheung, Sao "Crystal" (NIAID) 5 147163278 Gorman, Jason NIH - NIAID NIAID Gorman, Jason (NIAID) 6 147157986 Nanobodies Neutralizing Lassa Virus E-099-2021-0 Filing authorized NCI, NIAID 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4029] Nanobodies Neutralizing Lassa Virus&body=Please send me information about technology [TAB-4029] Nanobodies Neutralizing Lassa Virus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4029] Nanobodies Neutralizing Lassa Virus&body=Please send me information about technology [TAB-4029] Nanobodies Neutralizing Lassa Virus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161037 E-099-2021-0 E-099-2021-0-US-01 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE PRV US 63/181,519 Abandoned US <br />Provisional (PRV) 63/181,519<br />Filed on 2021-04-29<br />Status: Abandoned 147166111 E-099-2021-0 E-099-2021-0-PCT-02 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2022/027082 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/027082<br />Filed on 2022-04-29<br />Status: Expired 147171405 antibodies 147171406 diagnostic 147171407 HO 147171408 LASSA 147171410 Lassa Hemorrhagic Fever 147171412 LHF 147171413 Nanobodies 147171414 Neutralizing 147171415 virus TAB-3568 114097423 Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways NCI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Trevor Broadt, Xiaoyi Yang <h2>Description of Technology:</h2> <p>This technology includes a method of analyzing the potency of membrane transporter protein-based drugs acting on intracellular antioxidant and redox response pathways (and associated apoptosis pathways), wherein the drug delivery and activity is lipid associated. The present invention is a cell-based bioassay for measuring the bioactivity of drug substance and formulated drug product by determining the drug&#39;s dose-dependent inhibitory effects on 4 hydroxynonenal (4-HNE)-induced antioxidant response element (ARE) activity. The present invention covers use of HEK293 ARE-Luc Stable cell line as the detection system, high-throughput 96-well format, drug dilution approach, enclosure of negative controls with non-relevant heterologous proteins, use of the stimulator 4-HNE, and the optimal measurement time points with the ARE luciferase reporter gene. This is also an effective method to make liposome-drug substance mixtures for assembly of drug substance proteins into cellular membranes by using premade empty liposomes as a drug delivery system.</p> This method standardizes the analysis of the potency of RLIP76-based drug substance and drug product in a dose-dependent manner during the manufacturing process, release, and stability monitoring of RLIP76 and similar molecules. Applications include potency analysis of drug substance and drug product of membrane transporter protein-based drugs, such as RLIP76, acting on antioxidant and redox response pathways during the process, release, and stability monitoring. 2022-08-01 2026-04-23 2026-04-23 2022-08-01 ACTING, ANTIOXIDANT, APOPTOSIS, assay, DRUGS, MEMBRANE, PATHWAYS, POTENCY, Protein-based, Redox, RESPONSE, TRANSPORTER, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110830 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114110829 Yang, Xiaoyi NCI - CCR Leidos Yang, Xiaoyi (Leidos) 1 114110829 Yang, Xiaoyi NCI - CCR Leidos Yang, Xiaoyi (Leidos) 1 114110830 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114102677 Potency Assay For Membrane Transporter Protein-based Drugs Acting On Antioxidant, Redox, And Apoptosis Response Pathways E-225-2018-0 Filing authorized NCI 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways&body=Please send me information about technology [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways&body=Please send me information about technology [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways.">sury.vepa@nih.gov</a><br> 114128772 VPXXXX 114128773 WIXXXX 114128774 WKXXXX 114153251 POTENCY 114153252 assay 114153253 MEMBRANE 114153254 TRANSPORTER 114153255 Protein-based 114153256 DRUGS 114153257 ACTING 114153258 ANTIOXIDANT 114153259 Redox 114153260 APOPTOSIS 114153261 RESPONSE 114153262 PATHWAYS TAB-3897 147157177 National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program NCI Infectious Disease, Licensing, Neurology, Oncology, Software / Apps Infectious Disease Licensing Neurology Oncology Software / Apps <h2>Description of Technology:</h2> <p>About half of the per capita dose of radiation due to medical exposures is provided by computed tomography (CT) examinations. Approximately 80 million CTs are performed annually in the United States. CT scans most commonly look for internal bleeding or clots, abscesses due to infection, tumors and internal structures. Although CT provides great patient benefit, concerns exist about potential associated risks from radiation doses &ndash; especially in pediatric patients more sensitive to radiation. Better understanding of the magnitude of radiation dose delivered during CT examinations is crucial to estimate risks and make an informed clinical decisions. However, calculating organ radiation doses to be delivered to patients is complicated.</p> <p>To address these challenges, Dr. Choonsik Lee from the NCI developed a novel computer program with a graphical user interface (GUI) to interactively estimate radiation dose to the organs of patients undergoing CT examinations. The computer program provides radiation dose to 30 different radiosensitive organs and tissues in the human body by using data entered by users. These data include patient characteristics (age and sex) and CT scan data (scanner model and technical parameters). The calculation algorithm in the program is based on multiple datasets with international standard, human anatomy, and dosimetry data. Potential users of this computer program would include radiologists, clinical/research medical physicists, physicians, epidemiologists and other medical professionals.</p> <p>The NCI dosimetry system for Computed Tomography (NCICT) successfully converts existing CT scanner output &ndash; very simple to obtain &ndash; into organ radiation doses. NCICT makes it possible for vendors to incorporate this software program into their patient dose-monitoring systems. The NCI seeks licensees interested in estimating radiation doses and potential risks to the organs of CT patients</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Radiation dose calculations for computed tomography examinations</li> <li>Components can be incorporated with NCIDose software into a commercial platform: NCICT program, computational human phantom series (human anatomy models, electronic files), CT scanner simulation model, and organ dose library (tabulated numbers)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easily implemented within the existing commercial solutions</li> <li>Estimates organ doses for pediatric and adult patients with various body sizes and pregnant women</li> <li>Runs on standard Windows, Macintosh, and LINUX operating systems</li> </ul> Researchers at the NCI seek licensing for a novel computer program that converts existing CT scan output into organ radiation doses. 2023-05-14 2026-04-23 2023-05-14 2026-04-23 2023-05-14 • Computed Tomography, CT, CT Examination, Dosimetry, Lee, NCI dosimetry system for Computed Tomography, NCICT, Radiation, Radiation Dosing False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-05-14 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-125-2019 E-127-2023 147162303 Lee C, et al. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans https://pubmed.ncbi.nlm.nih.gov/26609995/ <a href="https://pubmed.ncbi.nlm.nih.gov/26609995/">Lee C, et al. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans</a> 155750673 National Cancer Institute Dosimetry System For Computed Tomography (NCICT) Computer Program E-082-2016-0 Research Material NCI, University of Florida 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program&body=Please send me information about technology [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program&body=Please send me information about technology [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171020 • Computed Tomography 147171021 CT 147171023 CT Examination 147171024 Dosimetry 147171026 Lee 147171028 NCI dosimetry system for Computed Tomography 147171029 NCICT 147171030 Radiation 147171032 Radiation Dosing TAB-4471 151021571 A Wearable Device for Monitoring Pregnancy Health NICHD Application, Collaboration, Licensing, Medical Devices, Reproductive Health Application Collaboration Licensing Medical Devices Reproductive Health George Downey, Amir Gandjbakhche, Kosar Khaksari, Alireza Khaligh, Thien Nguyen, Soongho Park, Zeyu Zhang <h2>Summary:&nbsp;</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Observing the placenta during pregnancy offers a look into the utero fetal environment. Monitoring placental oxygenation level and maternal physiological signals can be useful to assess mother and fetus well-being during pregnancy. Additionally, fetal movement has long served as a measure for well-being and nervous system development helping identify adverse pregnancy outcomes. Identification of complications during pregnancy can allow for earlier interventions, including medications to reduce risk of perinatal mortality and maternal gene therapy. Current non-invasive techniques on available are considered expensive, bulky, and do not offer continuous monitoring of fetal physiological signals and placental oxygenation. There is an unmet need for a convenient way for mothers to safely monitor their pregnancy remotely.&nbsp;</p> <p>Researchers created a wearable, wireless device and protocol for continuously monitoring the placental oxygenation levels, multiple physiological signals and movement activities of a fetus and mother. The device includes a compact control board, flexible near-infrared spectroscopy (NIRS) probe and multiple accelerator probes. A classification algorithm based on Monte-Carlo simulations of multiple layers model computes oxygen saturation of the placenta. There is one or more accelerator probes attached to different body parts of the mother to detect mother movement activities and to eliminate the effect of mother movement on fetal movement. The overall data acquisition rate of this device is 10 Hz or more. With this acquisition rate, the output of the device contains extra physiological signal such as maternal respiratory and cardiac functions, and fetal cardiac functions.&nbsp;</p> <p>The NICHD seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Low cost and flexible method of continuously monitoring pregnancy health</li> <li>Early identification of adverse outcomes such as reduced uteroplacental perfusion and stillbirth</li> <li>Potential for device to be applied in general health monitoring or sleep monitoring&nbsp;</li> <li>Daily measurement results may be collected by a cellphone and uploaded to cloud for patient&rsquo;s healthcare provider to remotely review and provide health suggestions</li> </ul> <h2>Competitive Advantage:</h2> <ul> <li>Wearable and non-invasive placenta and fetal monitoring device</li> <li>Capable of 24/7 monitoring of mother and fetal well-being</li> <li>Low power consumption&nbsp;</li> <li>Monitors both maternal and fetal multiple physiological signals and movement activities</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for clinical validation and to further develop the technology. 2023-10-25 2026-04-23 2026-04-23 2023-11-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 151545526 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 1 151545616 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 2 151021496 Zhang, Zeyu AmpX Technologies, Inc. Zhang, Zeyu 3 151021500 Park, Soongho NICHD NICHD Park, Soongho (NICHD) 4 151021646 Downey, George AmpX Technologies, Inc. Downey, George 5 151021650 Khaligh, Alireza AmpX Technologies, Inc. Khaligh, Alireza 6 151587921 Khaksari, Kosar NICHD Khaksari, Kosar 7 151545526 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 1 151545616 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 2 151021496 Zhang, Zeyu AmpX Technologies, Inc. Zhang, Zeyu 3 151021500 Park, Soongho NICHD NICHD Park, Soongho (NICHD) 4 151021646 Downey, George AmpX Technologies, Inc. Downey, George 5 151021650 Khaligh, Alireza AmpX Technologies, Inc. Khaligh, Alireza 6 151587921 Khaksari, Kosar NICHD Khaksari, Kosar 7 151021574 A System And Protocol For Monitoring Pregnancy Health E-198-2022-0 Filing authorized AmpX Technologies, Inc., NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4471] A Wearable Device for Monitoring Pregnancy Health&body=Please send me information about technology [TAB-4471] A Wearable Device for Monitoring Pregnancy Health.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4471] A Wearable Device for Monitoring Pregnancy Health&body=Please send me information about technology [TAB-4471] A Wearable Device for Monitoring Pregnancy Health.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 151390934 E-198-2022-0 E-198-2022-0-US-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH PRV US 63/451,066 Expired US <br />Provisional (PRV) 63/451,066<br />Filed on 2023-03-09<br />Status: Expired 157405584 E-198-2022-0 E-198-2022-0-PC-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH PCT Patent Cooperation Treaty PCT/US2024/019168 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/019168<br />Filed on 2024-03-08<br />Status: Expired TAB-4472 151021715 A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Hanbing Lu, Qinglei Meng, Hieu Nguyen, Yihong Yang <h2>Summary:&nbsp;</h2> <p>The National Institute on Drug Abuse (NIDA) seeks research co-development partners and/or licensees for a high-powered electronic device and coil that delivers Transcranial Magnetic Stimulation (TMS) pulses as well as the software that controls the device for treating treatment resistant depression, substance use disorders and other CNS disorders.</p> <h2>Description of Technology:&nbsp;</h2> <p>Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique recently cleared by the FDA as a therapy for treatment-resistant major depression, obsessive-compulsive disorder (OCD) and nicotine addiction. Stimulation is produced by passing a brief, strong electric current through a coil placed in close proximity to the patient&rsquo;s head. The coil generates an electric field inside the patient&rsquo;s brain, exciting or inhibiting a targeted region. Repetitive high-frequency TMS at 10 Hz (rTMS) was the first protocol cleared by FDA for depression treatment, while Intermittent Theta Burst Stimulation (iTBS) is a newer protocol recently cleared by the FDA. The rTMS protocol requires 37.5 min per treatment session compared with only 190 seconds for iTBS &ndash; making iTBS much more tolerable to a patient. The therapeutic efficacy between these two protocols is non-distinguishable. However, given the high voltages and currents required in iTBS (e.g., 50 Hz instead of 10 Hz), it is more challenging to implement. In addition, clinical efficacy of TMS treatment overall has been relatively modest, with only about one-third of the patients responding well to the treatment. Enhancing TMS treatment efficacy is of great medical value and broad interest.</p> <p>Researchers at NIDA developed a novel TMS paradigm to enhance the effects of TMS treatment and, in addition, the machine to realize this paradigm. The invention allows specifying a variable number of pulses in each burst (e.g., up to 6 pulses per burst) and having an inter-burst interval of 200 ms (e.g., 5 Hz). The paradigm is based on iTBS but deliveries 6 pulses fixed per burst instead of 3. Thus, the number of TMS pulses delivered is effectively doubled in the same amount of time. Data from in vivo experiments using an awake rat model suggest that, compared with conventional iTBS protocol, this novel TMS paradigm enhance TMS after-effects by up to 92% versus conventional methods. This technology has the potential to greatly improve clinical outcomes of TMS treatment of depression and other neurological and/or psychiatric disorders.</p> <p>The National Institute on Drug Abuse (NIDA) seeks research co-development partners and/or licensees to further develop and commercialize this technology.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Enhanced TMS therapeutic for treatment resistant depression (MDD)</li> <li>Enhanced TMS therapeutic for treatment resistant obsessive-compulsive disorder (OCD)</li> <li>Enhanced TMS therapeutic for treatment resistant nicotine addiction</li> </ul> <h2>Competitive Advantage:</h2> <ul> <li>Novel TMS paradigm that can improve the outcome of TMS treatment</li> <li>The machine to deliver this paradigm has already been developed</li> <li>This technology delivers the high frequency pulses needed for TMS operations which occur at high current and high voltage (3000 Amperes and 2000 volts), which requires special expertise and is highly valuable</li> <li>This technology provides a new coil design, cooling, and fabrication strategy, and there is a need for new TMS coil development</li> <li>Prototypes have been developed for the technology and successfully validated in a rat modelc</li> </ul> Researchers at the NIDA seek licensing and/or co-development research collaborations for a high-powered electronic device and coil that delivers TMS pulses as well as the software that controls the device for treating treatment resistant depression and other CNS disorders. 2023-10-25 2026-04-23 2026-04-23 2023-10-26 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 151037341 Meng Q, Nguyen H, Vrana A, Baldwin S, Li CQ, Giles A, Wang J, Yang Y, Lu H. A high-density theta burst paradigm enhances the aftereffects of transcranial magnetic stimulation: Evidence from focal stimulation of rat motor cortex. Brain Stimulation. 2022;15(3):833-842. doi: 10.1016/j.brs.2022.05.017. PMID: 35636708 https://pubmed.ncbi.nlm.nih.gov/35636708/ <a href="https://pubmed.ncbi.nlm.nih.gov/35636708/">Meng Q, Nguyen H, Vrana A, Baldwin S, Li CQ, Giles A, Wang J, Yang Y, Lu H. A high-density theta burst paradigm enhances the aftereffects of transcranial magnetic stimulation: Evidence from focal stimulation of rat motor cortex. Brain Stimulation. 2022;15(3):833-842. doi: 10.1016/j.brs.2022.05.017. PMID: 35636708</a> 151037155 Lu, Hanbing NIDA - Biomedical Research Center NIDA Lu, Hanbing (NIDA) 1 151037163 Meng, Qinglei NIDA - Biomedical Research Center Meng, Qinglei 2 151037318 Nguyen, Hieu NIDA - Biomedical Research Center Nguyen, Hieu 3 151037326 Yang, Yihong NIDA - Biomedical Research Center NIDA Yang, Yihong (NIDA) 4 151037155 Lu, Hanbing NIDA - Biomedical Research Center NIDA Lu, Hanbing (NIDA) 1 151037163 Meng, Qinglei NIDA - Biomedical Research Center Meng, Qinglei 2 151037318 Nguyen, Hieu NIDA - Biomedical Research Center Nguyen, Hieu 3 151037326 Yang, Yihong NIDA - Biomedical Research Center NIDA Yang, Yihong (NIDA) 4 151021718 A Protocol To Enhance Therapeutic Effects Of Transcranial Magnetic Stimulation And The Methods To Realize It E-183-2021-0 Filing authorized National Institute on Drug Abuse (NIDA) 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It&body=Please send me information about technology [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It&body=Please send me information about technology [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 151037347 E-183-2021-0 E-183-2021-0-US-01 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION PRV US 63/286,229 Expired US <br />Provisional (PRV) 63/286,229<br />Filed on 2021-12-06<br />Status: Expired 151037354 E-183-2021-0 E-183-2021-0-US-02 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION ORD US 18/076,071 Pending US <br />Ordinary Patent (ORD) 18/076,071<br />Filed on 2022-12-06<br />Status: Pending TAB-5010 158185969 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation NICHD Collaboration, Infectious Disease, Licensing, Medical Devices, Neurology, Respiratory Collaboration Infectious Disease Licensing Medical Devices Neurology Respiratory Amir Gandjbakhche, Brian Hill, Thien Nguyen, Soongho Park <h2>Summary:</h2> <p>The National Institute of Child Health and Human Development (NICHD) seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation.</p> <h2>Description of Technology:&nbsp;</h2> <p>Tissue oxygen saturation (StO2) is an important parameter to assess oxygen delivery and uptake. Hypoxia, a term used to indicate inadequate StO2, is often seen in patients with cardiac problems, respiratory infections or pulmonary diseases. Prolonged hypoxia can damage vital organs such as the brain, lungs, and heart, and can be fatal. Currently available tissue oximeters to monitor StO2 are expensive and cumbersome.&nbsp;</p> <p>The National Institute of Child Health and Human Development (NICHD) has developed a novel method, which uses a single source-detector separation to calculate StO2. With this technique, a simple tissue oximeter can be made with just a LED and a photodetector, which enables the development of a miniaturized device. As a result, it can be used independently or implemented on existing technologies to measure StO2 without any hardware modifications. It can be applied in wearable devices, implantable medicines or endoscopies to measure tissue oxygenation in different tissues such as muscle, brain, spinal cord, internal organs, fetus and placenta.&nbsp;</p> <p>The NICHD seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Miniaturized tissue oximeter for implantation or endoscopy</li> <li>Measure tissue oxygen saturation</li> <li>Multilayer tissue oximeter</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Simpler and more compact as it only requires a single light source such as LED and a single photodetector such as a photodetector to build a tissue oximeter</li> <li>Multilayer measurement</li> <li>Implementation with existing technologies without any hardware modifications</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation. 2024-09-13 2026-04-23 2026-04-23 2024-09-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 158186553 Nguyen, T., et al. Application of the Single Source—Detector Separation Algorithm in Wearable Neuroimaging Devices: A Step toward Miniaturized Biosensor for Hypoxia Detection. (PMID 38671806) https://pubmed.ncbi.nlm.nih.gov/38671806/ <a href="https://pubmed.ncbi.nlm.nih.gov/38671806/">Nguyen, T., et al. Application of the Single Source—Detector Separation Algorithm in Wearable Neuroimaging Devices: A Step toward Miniaturized Biosensor for Hypoxia Detection. (PMID 38671806)</a> 166884104 Nguyen, T., et al. Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation Using Continuous Wave Near-infrared Spectroscopy. (DOI 10.1109/OJEMB.2023.3246929) Nguyen, T., et al. Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation Using Continuous Wave Near-infrared Spectroscopy. (DOI 10.1109/OJEMB.2023.3246929) 158186011 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 1 158186023 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 2 158434152 Park, Soongho National Heart and Lung Institute (Imperial College London; ICKL) [GB] NICHD Park, Soongho (NICHD) 3 158186178 Hill, Brian NICHD NICHD Hill, Brian (NICHD) 4 158186011 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 1 158186023 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 2 158434152 Park, Soongho National Heart and Lung Institute (Imperial College London; ICKL) [GB] NICHD Park, Soongho (NICHD) 3 158186178 Hill, Brian NICHD NICHD Hill, Brian (NICHD) 4 158185972 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation E-037-2023-0 Filing authorized NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation&body=Please send me information about technology [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation&body=Please send me information about technology [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 162828523 E-037-2023-0 E-037-2023-0-US-01 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation PRV US 63/434,827 Expired US <br />Provisional (PRV) 63/434,827<br />Filed on 2022-12-22<br />Status: Expired 162828524 E-037-2023-0 E-037-2023-0-PC-01 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation PCT Patent Cooperation Treaty PCT/US2023/085725 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/085725<br />Filed on 2023-12-22<br />Status: Expired 162828525 E-037-2023-0 E-037-2023-0-US-02 SINGLE SOURCE-DETECTOR SEPARATION APPROACH TO CALCULATE TISSUE OXYGEN SATURATION National Stage US 19/140,070 Pending US <br />National Stage 19/140,070<br />Filed on 2025-06-17<br />Status: Pending TAB-5093 166506999 Neutralizing Antibodies Against West Nile Virus NIAID Application, Diagnostics, ResearchProducts, TherapeuticArea, Vaccines, Virus/Bacteria Application Diagnostics ResearchProducts TherapeuticArea Vaccines Virus/Bacteria Daniel Douek, Kimberly Dowd, Dror Harats, Yaniv Lustig, Yael Ottolenghi, Theodore Pierson, Gili Regev-Yochay <p>&nbsp; &nbsp; &nbsp; &nbsp;West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Researchers at NIAID&rsquo;s Vaccine Research Center (VRC), together with collaborators at Sheba Medical Center and the Israeli Ministry of Health, have identified and characterized seven new fully human monoclonal antibodies that bind to the WNV envelope (E) protein&mdash;the main surface protein the virus uses to enter cells. In laboratory studies, these antibodies (AIS-196, AIS-204, AIS-259, AIS-260, AIS-261, AIS-262, and AIS-265) strongly blocked WNV infection, and several also showed protective effects in a mouse model.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The invention includes the antibody sequences and tools needed to produce them, supporting development of full-length antibody therapies or smaller antibody fragments. These antibodies could help prevent WNV disease in people at higher risk or treat infection early, either individually or in combination. Modified versions are also included that may extend how long the antibodies remain active in the body or adjust how they interact with the immune system. The antibodies may also be useful in laboratory tests for WNV diagnosis, surveillance, and research.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <ul> <li> An antibody-based approach for WNV prevention or treatment, given the lack of an approved human vaccine, specific antiviral treatment, or licensed antibody therapy </li> <li> Strong virus-neutralizing activity </li> <li> Fully human antibodies, which are less likely to cause anti-drug immune responses than non-human or humanized antibodies </li> <li> Engineered versions that may last longer in the body and tune immune activity to improve safety and effectiveness </li> <li> High-quality antibodies that support WNV prevention or treatment and can also be used in diagnostic tests, public health surveillance, and research </li> </ul> <ul> <li> Prevention or treatment antibodies for WNV, especially for people at higher risk of severe disease or after a known exposure </li> <li> Fully human antibodies that strongly neutralize virus infection by targeting its key surface E protein </li> <li> Flexible formats for different uses, including full-length antibodies or antibody fragments, and the option to use a single antibody or a combination (“cocktail") </li> <li> Engineered versions designed to last longer in the body and tune immune functions for safety and performance </li> <li> High-quality antibodies for WNV testing and surveillance, supporting laboratory detection, public health monitoring, and research </li> <li> Neutralizing antibodies as components of delivery systems for prophylactic or therapeutic applications </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128, or bbailey@mail.nih.gov. 2026-03-19 2026-04-23 2026-04-23 2026-04-22 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2024-0 166507438 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 1 166507460 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 2 166507484 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 3 166507488 Harats, Dror Sheba Medical Center Harats, Dror 4 166507496 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 5 166507500 Regev-Yochay, Gili The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Regev-Yochay, Gili 6 166507516 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 7 166507438 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 1 166507460 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 2 166507484 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 3 166507488 Harats, Dror Sheba Medical Center Harats, Dror 4 166507496 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 5 166507500 Regev-Yochay, Gili The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Regev-Yochay, Gili 6 166507516 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 7 166507002 Neutralizing antibodies against West Nile virus E-021-2026-0 Filing authorized Israel Ministry of Health [IL], National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - VRC, Sheba Medical Center, The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5093] Neutralizing Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5093] Neutralizing Antibodies Against West Nile Virus. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5093] Neutralizing Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5093] Neutralizing Antibodies Against West Nile Virus.">bbailey@mail.nih.gov</a><br> 166507058 E-021-2026-0 E-021-2026-0-US-01 Neutralizing antibodies against West Nile Virus PRV US 63/991,485 Pending US <br />Provisional (PRV) 63/991,485<br />Filed on 2026-02-26<br />Status: Pending TAB-5071 163810508 Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof NCI Collaboration, Diagnostics, Infectious Disease, Licensing, Oncology, Pulmonology Collaboration Diagnostics Infectious Disease Licensing Oncology Pulmonology Clint Allen, Scott Norberg, Xiaolin Wu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).</p> <h2>Description of Technology:</h2> <p>Recurrent respiratory papillomatosis (RRP), caused by chronic infection with human papillomavirus (HPV) types 6 and 11, is a rare but potentially fatal disease characterized by the growth of papillomas throughout the respiratory tract. While HPV 6/11 infections are common, affecting approximately 40% of U.S. adults, a subset of patients can develop a range of conditions from benign papillomas to dysplasia and invasive cancers. Current treatment for RRP typically involves repetitive surgical intervention or laser ablation to alleviate symptoms, which carries significant procedural risks. A recent breakthrough with a therapeutic HPV vaccine demonstrated that 51% of patients avoided surgery for at least a year, with some experiencing durable remission. However, there remains no reliable diagnostic tool to confirm viral clearance or guide systemic therapy decisions.</p> <p>Researchers at the NCI and FNLCR have developed a novel hybridization-based next-generation sequencing (NGS) liquid biopsy method to detect circulating cell-free HPV 6 and 11 DNA in the plasma of patients with RRP. This innovative approach uses the established relevance of circulating viral DNA as a valuable biomarker for disease monitoring and therapeutic decision-making in other virally-associated conditions. The method is designed to target multiple regions across the entire HPV 6 and 11 genomes. It employs a pull-down DNA technology to enhance coverage &ndash; overcoming limitations of fixed-primer PCR for small cell-free DNA fragments. While low-risk HPV-associated diseases like RRP exhibit less tumor cell turnover compared to advanced cancers, the inherent high vascularity of papillomas may facilitate the release of viral DNA into peripheral blood. This method offers a non-invasive, sensitive and potentially prognostic tool to aid in (1) diagnosis, (2) monitoring progression and (3) guiding systemic therapies such as HPV vaccination or predicting severity &ndash; including pulmonary risk.</p> <p>Investigators at the NCI and FNLCR continue to evaluate circulating HPV 6 and 11 DNA in patients previously treated in clinical trials to further assess its prognostic and predictive capabilities. This technology presents a compelling opportunity for commercial development and seamless integration into existing diagnostic platforms. NCI and FNLCR offer licensing and collaborative development opportunities to advance this critical diagnostic and prognostic tool for RRP.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Liquid biopsy diagnostic for RRP confirmation</li> <li>Monitoring RRP disease progression</li> <li>Prognostic test for RRP severity, especially pulmonary disease</li> <li>Companion diagnostic to guide systemic RRP therapies</li> <li>HPV 6/11 detection assay for anogenital condyloma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Non-invasive, sensitive and potentially prognostic and diagnostic tool</li> <li>Reduces the need for, and risk from, repeat surgical procedures</li> <li>Detects disease even with a Derkay score of 0 (minimal laryngeal involvement)</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for Recurrent Respiratory Papillomatosis (RRP). 2025-08-21 2025-08-21 2026-04-20 2025-08-21 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163810747 Norberg SM, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. (PMID 39855244) https://pubmed.ncbi.nlm.nih.gov/39855244/ <a href="https://pubmed.ncbi.nlm.nih.gov/39855244/">Norberg SM, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. (PMID 39855244)</a> 163810649 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163810679 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163810697 Wu, Xiaolin NIH - NCI Leidos Wu, Xiaolin (Leidos) 3 163810649 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163810679 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163810697 Wu, Xiaolin NIH - NCI Leidos Wu, Xiaolin (Leidos) 3 163922749 Method of detecting circulating cell-free HPV 6 and 11 DNA in patients afflicted with disease caused by chronic HPV 6 or 11 infection and use thereof (LBR# 25-004) (LBR Greater Rights Requested) E-019-2025-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof&body=Please send me information about technology [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof&body=Please send me information about technology [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 163922754 E-019-2025-0 E-019-2025-0-US-01 METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIES PRV US 63/803,323 Expired US <br />Provisional (PRV) 63/803,323<br />Filed on 2025-05-09<br />Status: Expired 166910976 E-019-2025-0 E-019-2025-0-PC-01 METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIES PCT Patent Cooperation Treaty PCT/US2026/027273 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/027273<br />Filed on 2026-05-08<br />Status: Pending TAB-5092 166395418 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics S. Patricia Becerra, Alexandra Bernardo-Colon, Burchelle Blackman, Natarajan Raju, Rolf Swenson, Carolyn Woodroofe <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases.</p> <h2>Description of Technology:</h2> <p>Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) that is estimated to affect 1 in 4,000 people in the United States and worldwide. Over 100,000 people in the US, and 1.5 million people worldwide suffer from RP. RP leads to progressive photoreceptor cell degeneration and ultimately vision loss, with more than 90 genes implicated in molecular pathways towards photoreceptor cell death. Due to this high heterogeneity, therapeutic approaches targeting specific genes generally benefit few patients, while for most forms of RP few or no medical options are available.</p> <p>Peptide drug development has made great progress recently thanks to new production, modification, and analytical technologies. Solutions of chemically synthesized bioactive peptides have unique advantages over mixed formulations. They are free of inactive ingredients that cause secondary effects. Structural biology and recombinant biologics aid in peptide design to modify amino acids, enhancing target affinity, specificity, and regulating bioactivity, as well as improving the solubility and stability of peptide drugs. Peptides can diffuse better than biologics (proteins, antibodies) with better penetrability. Compared with biologics, therapeutic peptides have demonstrably less immunogenicity and lower production costs.</p> <p>This technology optimizes synthetic peptides that are soluble, stable, and protect the retina. A series of peptides derived from the neurotrophic region of PEDF 17-mer (human sequence 98-114 amino acids, N- and C-terminus uncapped) is designed and synthesized. They have a series of truncations from the amino and carboxy ends, and internal region, as well as isosteric amino acid replacements, and amino terminal additions such as capping (X) and amidation (Y) to prevent exopeptidases from degrading the peptide. The peptides are optimized to protect photoreceptors and other retinal cells against death and degeneration. They optimized for solubility, stability, efficacy, in protecting the retina at the structural, morphological and functional level. The peptides can be tested in vitro, ex vivo, in cells and in vivo using models of retinal degeneration. The peptides can be used as eyedrops in vivo.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Potential simple and effective treatment for inherited eye diseases contributing to Retinitis Pigmentosa (RP) and macular degenerations, such as AMD and geographic atrophy</li> <li>Prevent disease progression by protecting degenerating photoreceptors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Chemically synthesized bioactive peptide solutions are free of inactive ingredients that cause secondary effects as compared to mixed formulations</li> <li>Enhanced target affinity, specificity, bioactivity, as well as in improved solubility, and stability</li> <li>Peptides can diffuse better than biologics (proteins, antibodies) with better penetrability</li> <li>Compared to biologics, therapeutic peptides have demonstrably less immunogenicity and lower production costs</li> <li>Eye drop formulation is accessible to more patients and provides an easy administration route</li> <li>PEDF formulation mimics the natural protective process lost in patients with inherited eye diseases, contributing to RP</li> </ul> The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. 2026-03-11 2026-03-11 2026-04-17 2026-03-11 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2023 166395672 Bernardo-Colon A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996) https://pubmed.ncbi.nlm.nih.gov/40118996/ <a href="https://pubmed.ncbi.nlm.nih.gov/40118996/">Bernardo-Colon A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996)</a> 166395675 Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127) https://pubmed.ncbi.nlm.nih.gov/33008127/ <a href="https://pubmed.ncbi.nlm.nih.gov/33008127/">Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127)</a> 166395678 Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815) https://pubmed.ncbi.nlm.nih.gov/30980815/ <a href="https://pubmed.ncbi.nlm.nih.gov/30980815/">Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815)</a> 166395684 Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116) https://pubmed.ncbi.nlm.nih.gov/26304116/ <a href="https://pubmed.ncbi.nlm.nih.gov/26304116/">Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116)</a> 166395566 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166395574 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 166395593 Raju, Natarajan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Raju, Natarajan (NHLBI) 3 166395604 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 4 166395611 Woodroofe, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Woodroofe, Carolyn (NHLBI) 5 166395635 Blackman, Burchelle National Heart, Lung, and Blood Institute (NHLBI) NHLBI Blackman, Burchelle (NHLBI) 6 166395566 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166395574 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 166395593 Raju, Natarajan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Raju, Natarajan (NHLBI) 3 166395604 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 4 166395611 Woodroofe, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Woodroofe, Carolyn (NHLBI) 5 166395635 Blackman, Burchelle National Heart, Lung, and Blood Institute (NHLBI) NHLBI Blackman, Burchelle (NHLBI) 6 166395421 Photoreceptor-protective Peptides based on truncated PEDF E-156-2023-0 Filing authorized National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE&body=Please send me information about technology [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE&body=Please send me information about technology [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166395426 E-156-2023-0 E-156-2023-0-US-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE PRV US 63/604,026 Expired US <br />Provisional (PRV) 63/604,026<br />Filed on 2023-11-29<br />Status: Expired 166395427 E-156-2023-0 E-156-2023-0-PC-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2024/057784 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/057784<br />Filed on 2024-11-27<br />Status: Expired 166895073 E-156-2023-0 E-156-2023-0-JP-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Japan 2026-531738 Pending Japan <br />National Stage 2026-531738<br />Filed on 2026-05-27<br />Status: Pending 166895169 E-156-2023-0 E-156-2023-0-CA-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Canada 3313052 Pending Canada <br />National Stage 3313052<br />Filed on 2026-05-28<br />Status: Pending 166895224 E-156-2023-0 E-156-2023-0-AU-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Australia 2024388722 Pending Australia <br />National Stage 2024388722<br />Filed on 2026-06-03<br />Status: Pending 166895361 E-156-2023-0 E-156-2023-0-US-02 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage US 19/590,855 Pending US <br />National Stage 19/590,855<br />Filed on 2026-05-27<br />Status: Pending 166895416 E-156-2023-0 E-156-2023-0-EP-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-5029 159051371 NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes NCI Collaboration, Immunology, Licensing, Oncology, ResearchProducts Collaboration Immunology Licensing Oncology ResearchProducts Sanghyun (Peter) Kim, Noam Levin, Lior Levy, Steven Rosenberg <h2>Summary:</h2> <p>&nbsp;The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.</p> <h2>Description of Technology:&nbsp;</h2> <p>Somatic mutations are spontaneous changes in the DNA sequence of somatic cells which drive the development of most cancers. These somatic mutations may also create neoantigens, newly formed antigens that can be recognized by T cells. Adoptive cell transfer (ACT) and T cell receptor- (TCR-) engineered T cell therapies (TCR-T) can be used to target cells expressing these neoantigens and treat cancer patients. Traditionally, TCR-T or tumor infiltrating lymphocyte (TIL) cell therapy products utilize an in vitro expansion step in their manufacture called a rapid expansion protocol (REP). However, recent evidence suggests that conventional REPs reduce the frequency of neoantigen-reactive T cells in the final product, which may diminish treatment efficacy.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a method to identify and selectively expand neoantigen-specific T cells, including TCR-T and TIL-based products. This method, termed &ldquo;NeoExpand,&rdquo; promotes the selective growth of neoantigen-reactive T cells and, additionally, enables the sensitive identification of novel neoantigen-reactive TCRs.</p> <p>The NCI seeks co-development partners and/or licensees. As &ldquo;NeoExpand&rdquo; provides a novel method of identify and selectively expanding neoantigen-specific T cells, this technology may be particularly appealing to companies developing cell therapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Manufacturing method for ACT products</li> <li>Manufacturing method for TCR-T products</li> <li>Discovery engine for the isolation of neoantigen-specific TCRs</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increase the efficacy of immunotherapies treating cancer</li> <li>Identify neoantigen-specific T cells</li> <li>Selectively expand neoantigen-specific T cells</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a method to identify and selectively expand neoantigen-specific T cells. 2024-11-12 2026-04-16 2026-04-16 2024-11-12 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 159081648 Wölfl M, et al. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. (PMID 24675735) https://pubmed.ncbi.nlm.nih.gov/24675735/ <a href="https://pubmed.ncbi.nlm.nih.gov/24675735/">Wölfl M, et al. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. (PMID 24675735)</a> 159081651 Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. (PMID 30683863) https://pubmed.ncbi.nlm.nih.gov/30683863/ <a href="https://pubmed.ncbi.nlm.nih.gov/30683863/">Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. (PMID 30683863)</a> 159081940 Levin N, et al. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. (PMID 34168045) https://pubmed.ncbi.nlm.nih.gov/34168045/ <a href="https://pubmed.ncbi.nlm.nih.gov/34168045/">Levin N, et al. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. (PMID 34168045)</a> 159051713 Levin, Noam National Cancer Institute (NCI) NCI Levin, Noam (NCI) 1 159051753 Kim, Sanghyun (Peter) Surgery Branch NCI Kim, Sanghyun (Peter) (NCI) 2 159051764 Levy, Lior NCI Levy, Lior (NCI) 3 159051780 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 4 159051713 Levin, Noam National Cancer Institute (NCI) NCI Levin, Noam (NCI) 1 159051753 Kim, Sanghyun (Peter) Surgery Branch NCI Kim, Sanghyun (Peter) (NCI) 2 159051764 Levy, Lior NCI Levy, Lior (NCI) 3 159051780 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 4 159051374 NeoExpansion - Method to identify and selectively expand neoantigen-specific T cells, including T cell receptor-engineered T cells and tumor infiltrating lymphocytes. E-101-2024-0 Filing authorized NCI - CCR, NIH - NCI, Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes&body=Please send me information about technology [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes&body=Please send me information about technology [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 159502980 E-101-2024-0 E-101-2024-0-US-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS . PRV US 63/572,693 Expired US <br />Provisional (PRV) 63/572,693<br />Filed on 2024-04-01<br />Status: Expired 162827652 E-101-2024-0 E-101-2024-0-PC-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS PCT Patent Cooperation Treaty PCT/US2025/022247 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/022247<br />Filed on 2025-03-31<br />Status: Pending TAB-4995 157267387 Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration NEI Collaboration, Diagnostics, Ear, Nose, & Throat, Licensing Collaboration Diagnostics Ear Nose & Throat Licensing Elvira Agron, Qingyu Chen, Emily Chew, Tiarnan Keenan, Zhiyong Lu, Wai Wong <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration.</p> <h2>Description of Technology:&nbsp;</h2> <p>In 2024, an estimated 200 million people worldwide suffer from age-related macular degeneration (AMD); projected to affect ~288 million people by 2040. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.</p> <p>Reticular pseudodrusen (RPD) is an AMD disease feature recently discovered to confer greatly increased risk of progression to late AMD. However, RPD is often very difficult to detect on clinical examination or on color fundus photography (CFP). Detection usually requires specialized imaging (especially fundus autofluorescence) and highly expert grading typically available at few specialized centers. For these reasons, RPD have not been incorporated into AMD risk classification systems.</p> <p>We used Artificial Intelligence (AI) to predict the risk of progression to late AMD using over 80,000 images from almost 3300 participants from the Age-Related Eye Disease Studies AREDS and AREDS2. Using independent test data, our deep learning algorithm produced 5% higher prognostic accuracy compared to existing clinical standards. The predictive accuracy of the new approach was 5% higher than that of the two traditional approaches ((i) AREDS Simplified Severity Scale, and (ii) the Casey AMD online calculator). Our approach can make predictions over a wide range of time intervals (1-12 years), and separately for the two subtypes of late AMD (geographic and neovascular AMD). In contrast, the AREDS Simplified Severity Scale can make predictions at one fixed interval only (5 years), and for late AMD only (not separately by subtype). By separating the deep learning extraction of retinal features from the survival analysis, the final predictions are more explainable and biologically plausible, and error analysis is possible. By contrast, end-to-end &lsquo;black-box&rsquo; deep learning approaches are less transparent and may be more susceptible to failure<br /> A fully automated device that contains this novel image processing method has also been developed.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic tool predicting risk of AMD</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely available via device&nbsp;</li> <li>Fully automated analysis of the CFP and no requirement for human grading of the CFP, either by retinal specialists or by reading center experts</li> <li>More predictive, accurate approach compared using the same test set of AREDS and AREDS2 participants&nbsp;</li> <li>Predictive over a wide range of time intervals (1-12 years) and separately for the two subtypes of late AMD (geographic and neovascular AMD)&nbsp;</li> <li>Two-step method separates the deep learning extraction of retinal features from the survival analysis</li> <li>Two-step method produces final predictions that are more explainable and biologically plausible</li> <li>Error analysis&nbsp;</li> <li>Our approach has the advantage of not requiring genetic information to provide a high level of predictive accuracy<br /> &nbsp;</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157267554 Keenan, et al. Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus Autofluorescence Images or Color Fundus Photographs in AREDS2. (PMID 32447042) https://pubmed.ncbi.nlm.nih.gov/32447042/ <a href="https://pubmed.ncbi.nlm.nih.gov/32447042/">Keenan, et al. Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus Autofluorescence Images or Color Fundus Photographs in AREDS2. (PMID 32447042)</a> 166884053 Peng, et al. Predicting risk of late age-related macular degeneration using deep learning. (PMID 32904246) https://pubmed.ncbi.nlm.nih.gov/32904246/ <a href="https://pubmed.ncbi.nlm.nih.gov/32904246/">Peng, et al. Predicting risk of late age-related macular degeneration using deep learning. (PMID 32904246)</a> 166884056 Chen, et al. Multimodal, multitask, multiattention (M3) deep learning detection of reticular pseudodrusen: Toward automated and accessible classification of age-related macular degeneration. (PMID 33792724) https://pubmed.ncbi.nlm.nih.gov/33792724/ <a href="https://pubmed.ncbi.nlm.nih.gov/33792724/">Chen, et al. Multimodal, multitask, multiattention (M3) deep learning detection of reticular pseudodrusen: Toward automated and accessible classification of age-related macular degeneration. (PMID 33792724)</a> 157267522 Chew, Emily National Eye Institute (NEI) NEI Chew, Emily (NEI) 1 157267526 Lu, Zhiyong NLM NLM Lu, Zhiyong (NLM) 2 157267530 Keenan, Tiarnan National Eye Institute (NEI) NEI Keenan, Tiarnan (NEI) 3 157267534 Wong, Wai National Eye Institute (NEI) NEI Wong, Wai (NEI) 4 157267542 Chen, Qingyu NLM NLM Chen, Qingyu (NLM) 5 157267546 Agron, Elvira National Eye Institute (NEI) NEI Agron, Elvira (NEI) 6 157267522 Chew, Emily National Eye Institute (NEI) NEI Chew, Emily (NEI) 1 157267526 Lu, Zhiyong NLM NLM Lu, Zhiyong (NLM) 2 157267530 Keenan, Tiarnan National Eye Institute (NEI) NEI Keenan, Tiarnan (NEI) 3 157267534 Wong, Wai National Eye Institute (NEI) NEI Wong, Wai (NEI) 4 157267542 Chen, Qingyu NLM NLM Chen, Qingyu (NLM) 5 157267546 Agron, Elvira National Eye Institute (NEI) NEI Agron, Elvira (NEI) 6 157267390 Method And System Of Building A Data-base And Models For Determining The Presence Of Reticular Pseudodrusen (RPD) Associated With Age-Related Macular Degeneration (AMD) Using Fundus Autofluorescence And/or Color Fundus Photos E-057-2020-0 Filing authorized National Eye Institute (NEI), NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157267585 E-057-2020-0 E-057-2020-0-US-01 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PRV US 62/978,070 Abandoned US <br />Provisional (PRV) 62/978,070<br />Filed on 2020-02-18<br />Status: Abandoned 164119882 E-057-2020-0 E-057-2020-0-PCT-02 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PCT Patent Cooperation Treaty PCT/US2021/018589 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/018589<br />Filed on 2021-02-18<br />Status: Expired 164119883 E-057-2020-0 E-057-2020-0-AU-03 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage Australia 2021224660 Pending Australia <br />National Stage 2021224660<br />Filed on 2021-02-18<br />Status: Pending 164119884 E-057-2020-0 E-057-2020-0-CA-04 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage Canada 3177173 Pending Canada <br />National Stage 3177173<br />Filed on 2021-02-18<br />Status: Pending 164119885 E-057-2020-0 E-057-2020-0-EP-05 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage European Patent 21711144.2 Pending European Patent <br />National Stage 21711144.2<br />Filed on 2021-02-18<br />Status: Pending 164119886 E-057-2020-0 E-057-2020-0-US-06 Method and Systems for Predicting Rates of Progression of Age-Related Macular Degeneration National Stage US 17/904,573 Pending US <br />National Stage 17/904,573<br />Filed on 2022-08-18<br />Status: Pending TAB-4061 147157343 Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation NIA Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Josephine Earley, Qing Rong Liu, Min Zhu <h2>Description of Technology:</h2> <p>Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer&rsquo;s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-&beta; is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to &beta;-cell dysfunction. A hallmark feature of T2DM is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques and cause apoptosis of -cells of islets.&nbsp;</p> <p>Researchers at NIA used a bioinformatic and molecular biological approaches to identify two novel islet amyloid polypeptide isoforms: IAPP&beta;, encoding an elongated propeptide of the conventional IAPP and a non-aggregating IAPP&gamma;, which is processed to an unrelated mature IAPP25 instead of IAPP37. They developed a quantitative selective reaction monitoring (SRM) proteomic assay that determined the isoform peptide levels in human clinical plasma and CSF from individuals with early AD were significantly reduced. Further, mature IAPP25 derived from IAPP&gamma; isoform inhibited fibrillation of IAPP37 and amyloid-&beta; efficiently in vitro.</p> <p>The novel IAPP&beta; and IAPP&gamma; isoforms could potentially be developed as peptidyl therapeutics to counteract with amyloid forming IAPP37 and amyloid-&beta; in treatments of diabetes and Alzheimer&rsquo;s disease. These isoforms could also serve as blood-based biomarkers for Alzheimer&rsquo;s disease. The NIA seeks co-development partners and/or licensees for the further development of these therapeutics and biomarkers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapy for amyloid diseases, including type 2 diabetes mellitus, Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease</li> <li>Potential to be developed as peptidyl therapeutics&nbsp;</li> <li>Clinical diagnostic blood-derived biomarkers for AD</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Peptide based anti-amyloid medicine</li> <li>Potential market applications for neurodegenerative diseases</li> </ul> The National Institute on Aging (NIA) seeks licensing and/or co-development research collaboration partners for the further development of islet amyloid polypeptide (IAPP) diagnostic biomarkers and peptidyl therapeutics for amyloid related diseases. 2023-04-27 2026-04-16 2023-04-27 2026-04-16 2023-04-27 Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162280 Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer&rsquo;s Disease and Inhibitors of Amyloid Formation. https://pubmed.ncbi.nlm.nih.gov/36671553/ <a href="https://pubmed.ncbi.nlm.nih.gov/36671553/">Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer&rsquo;s Disease and Inhibitors of Amyloid Formation.</a> 147163385 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147163386 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147163384 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 3 147163385 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147163386 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147163384 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 3 147158195 Novel Islet Amyloid Polypeptide (IAPP ) And Soluble IAPP Polypeptides, Inhibitor Of Amyloid And Biomarkers Of AD E-197-2022-0 Filing authorized National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation&body=Please send me information about technology [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation&body=Please send me information about technology [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161183 E-197-2022-0 E-197-2022-0-US-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PRV US 63/417,582 Expired US <br />Provisional (PRV) 63/417,582<br />Filed on 2022-10-19<br />Status: Expired 147166277 E-197-2022-0 E-197-2022-0-PC-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2023/077173 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/077173<br />Filed on 2023-10-18<br />Status: Expired 147173506 Ad 147173508 Age-Associated Disease 147173509 Alzheimer’s Disease 147173510 Amyloidosis 147173512 Amyloids 147173513 Biomarkers 147173514 DIABETES 147173515 IAPP 147173517 Islet Amyloid Polypeptide Isoforms 147173518 Liu 147173519 National Institute on Aging 147173520 NIA 147173521 PEPTIDYL TAB-4403 147157698 Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases NIA Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Bira Arya, Dolgor Bataar, Kouji Matsushima <h2>Description of Technology:</h2> <p>Cancer is one of the leading causes of death in United States and it is estimated that there will be more than half a million deaths caused by cancer in 2009.&nbsp; A major drawback of the current chemotherapy-based therapeutics is the cytotoxic side-effects associated with them.&nbsp; Thus there is a dire need to develop new therapeutic strategies with fewer side-effects.&nbsp; Immunotherapy has taken a lead among the new therapeutic approaches.&nbsp; Enhancing the innate immune response of an individual has been a key approach for the treatment against different diseases such as cancer and infectious diseases.</p> <p>This technology involves the generation of novel chemoattractant toxins that deplete the T regulatory cells (Treg) or other immunosuppressive or hyperactivated cells locally.&nbsp; Treg controls activation of immune responses by suppressing the induction of adaptive immune responses, particularly T cell responses.&nbsp; Immunosuppressive cells such as tumor infiltrating macrophages, regulatory T cells, regulatory B cells, or NKT and other cells down regulate antitumor immune responses.&nbsp; The chemoattractant toxins consist of a toxin moiety fused with a chemokine receptor ligand, such as chemokines and various chemoattractants, that enables specific targeting and delivery to the regulatory cells. This technology is advantageous over the more harmful antibodies and chemicals that are currently used for the systemic depletion of regulatory cells.&nbsp; The current technology can be used therapeutically in a variety of ways.&nbsp; They can be used together with vaccines to increase efficacy of the vaccine for the treatment of cancer, and can be used to locally deplete Treg, Bregs, or other immuno suppressive cells to induce cytolytic cell responses at the tumor site or to eliminate chronic infectious diseases such as HIV and tuberculosis.</p> <p>Development Status:&nbsp;<br /> The technology is currently in the pre-clinical stage of development.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>New chemoattractant-based toxins targeted towards Treg cells.</li> <li>New chemoattractant-based toxins targeted towards immunosuppressive B cells, NKT and macrophages.</li> <li>New chemoattractant based toxins targeted towards local depletion of hyperactivated CD4 T cells to treat autoimmune diseases.</li> <li>Chemoattractant-based toxins depleting Treg cells or other immunosuppressive cells causing enhanced vaccine immune responses.</li> <li>Novel immunotherapy by increasing vaccine efficacy against cancer and infectious diseases.</li> </ul> 2016-02-16 2026-04-16 2017-11-20 2026-04-16 2023-04-06 2016-03-07 AIDS/HIV, Chemoattractant toxins, Immune Diseases, immunosuppressant, T regulatory (Treg) cells, TUBERCULOSIS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162023 R Schiavo et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006 Jun 15; 107(12):4597-4605. http://www.ncbi.nlm.nih.gov/pubmed/16514063?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16514063?dopt">R Schiavo et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006 Jun 15; 107(12):4597-4605.</a> 147162062 D Baatar, P Olkhanud, D Newton, K Sumitomo, A Biragyn. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007 Aug 1;179(3):1996-2004. http://www.ncbi.nlm.nih.gov/pubmed/17641067?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17641067?dopt">D Baatar, P Olkhanud, D Newton, K Sumitomo, A Biragyn. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007 Aug 1;179(3):1996-2004.</a> 147162140 M Coscia, A Biragyn. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004 Jun; 14(3):209-218. http://www.ncbi.nlm.nih.gov/pubmed/15246057?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15246057?dopt">M Coscia, A Biragyn. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004 Jun; 14(3):209-218.</a> 147162179 D Baatar, P Olkhanud, K Sumitomo, D Taub, R Gress, A Biragyn. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007 Apr 15;178(8):4891-4900. http://www.ncbi.nlm.nih.gov/pubmed/17404270?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17404270?dopt">D Baatar, P Olkhanud, K Sumitomo, D Taub, R Gress, A Biragyn. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007 Apr 15;178(8):4891-4900.</a> 147164607 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164606 Matsushima, Kouji University of Tokyo Matsushima, Kouji 2 147164608 Bataar, Dolgor NIH - NIA NIA Bataar, Dolgor (NIA) 3 147164607 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164606 Matsushima, Kouji University of Tokyo Matsushima, Kouji 2 147164608 Bataar, Dolgor NIH - NIA NIA Bataar, Dolgor (NIA) 3 147157819 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases E-027-2005-0 Filing authorized National Institute on Aging (NIH/NIA), University of Tokyo 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases&body=Please send me information about technology [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases&body=Please send me information about technology [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147168726 E-027-2005-0 E-027-2005-0-US-01 METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE PRV US 60/722,675 Abandoned US <br />Provisional (PRV) 60/722,675<br />Filed on 2005-09-30<br />Status: Abandoned 147168727 E-027-2005-0 E-027-2005-0-PCT-02 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases PCT Patent Cooperation Treaty PCT/US2006/038195 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/038195<br />Filed on 2006-09-28<br />Status: Expired 147168728 E-027-2005-0 E-027-2005-0-AU-03 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage Australia 2006297126 Abandoned Australia <br />National Stage 2006297126<br />Filed on 2006-09-28<br />Status: Abandoned 147168729 E-027-2005-0 E-027-2005-0-CA-04 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage Canada 2624662 Abandoned Canada <br />National Stage 2624662<br />Filed on 2006-09-28<br />Status: Abandoned 147168730 E-027-2005-0 E-027-2005-0-EP-05 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage European Patent 06825277.4 Abandoned European Patent <br />National Stage 06825277.4<br />Filed on 2006-09-28<br />Status: Abandoned 147168731 E-027-2005-0 E-027-2005-0-US-06 METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE National Stage US 8,795,674 11/992,880 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8795674 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8795674">8,795,674</a><br />Filed on 2008-03-28<br />Status: Issued 147168732 E-027-2005-0 E-027-2005-0-EP-07 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases DIV European Patent 6825277.4 Administratively Closed European Patent <br />Divisional (DIV) 6825277.4<br />Filed on 2006-09-28<br />Status: Administratively Closed 147168733 E-027-2005-0 E-027-2005-0-US-08 Methods and Compositions for Modulating Immune Tolerance DIV US 9,605,044 14/313,481 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9605044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9605044">9,605,044</a><br />Filed on 2014-06-24<br />Status: Issued 147168734 E-027-2005-0 E-027-2005-0-US-09 Methods and Compositions for Modulating Immune Tolerance DIV US 10,300,115 15/404,189 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300115 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300115">10,300,115</a><br />Filed on 2017-01-11<br />Status: Issued 147169754 AIDS/HIV 147169756 Chemoattractant toxins 147169758 Immune Diseases 147169759 immunosuppressant 147169761 T regulatory (Treg) cells 147169762 TUBERCULOSIS TAB-4205 147157490 Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders NIDA Gastroenterology, Licensing, Research Materials Gastroenterology Licensing Research Materials Jianjing Cao, George Cyriac, Peter Grundt, Robert Luedtke, Amy Newman <h2>Summary:</h2> <p>The National Institute on Drug Abuse&#39;s Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands.</p> <h2>Description of Technology:</h2> <p>The dopamine D3 receptor subtype is a member of the dopamine D2 subclass of receptors.&nbsp; These receptors have been implicated in a number of CNS disorders, including psychostimulant abuse, psychosis and Parkinson&#39;s disease.&nbsp; Compounds that bind with high affinity and selectivity to D3 receptors can not only provide important tools with which to study the structure and function of this receptor subtype, but may also have therapeutic potential in the treatment of numerous psychiatric and neurologic disorders.&nbsp;</p> <p>The 4-phenylpiperazine derivatives are an important class of dopamine D3 selective ligands.&nbsp; However, due to their highly lipophilic nature, these compounds suffer from solubility problems in aqueous media and reduced bioavailability.&nbsp; To address this problem, a process was designed to introduce functionality into the carbon chain linker of these compounds.&nbsp; Compared to currently available dopamine D3 receptor ligands, the resulting compounds show improved pharmacological properties and D3 selectivities but due to their more hydrophilic nature, these derivatives are predicted to have improved water solubility and bioavailability.</p> <p>R&amp;D Status: Pre-clinical discovery</p> <p>Further R&amp;D Needed:</p> <ul> <li>Evaluate selected compounds in animal models of drug abuse, psychosis, obesity and Parkinson&#39;&#39;s disease</li> <li>Design and synthesize novel, functionalized analogs using both classical and computational drug design to improve D3 receptor affinity and selectivity</li> <li>Evaluate compounds for binding in D3 and D2 receptor expressing cell lines and in in vitro functional assays</li> <li>Correlate in vitro binding affinities with in vivo function in rats and monkeys and evaluate compounds in knockout mice models</li> <li>Pursue PET and SPECT imaging agents by radiolabel of D3 ligands and evaluation in rats and non-human primates.</li> </ul> <p>IP Status:&nbsp; PCT Application PCT/US2007/071412 filed 6/17/2007</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics for a variety of psychiatric and neurologic disorders</li> <li>Research tools to study D3 receptor structure and function</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved pharmacological properties and selectivity over existing dopamine D3 receptor ligands.</li> <li>Hydrophilic nature likely to lead to improved water solubility and bioavailability</li> </ul> 2016-02-16 2026-04-16 2017-11-20 2026-04-16 2023-04-06 2019-09-26 False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163907 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163909 Grundt, Peter NIH - NIDA NIDA Grundt, Peter (NIDA) 2 147163910 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163908 Luedtke, Robert University of North Texas Health Science Center Luedtke, Robert 4 147163911 Cyriac, George NIH - NIDA Cyriac, George 5 147163907 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163909 Grundt, Peter NIH - NIDA NIDA Grundt, Peter (NIDA) 2 147163910 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163908 Luedtke, Robert University of North Texas Health Science Center Luedtke, Robert 4 147163911 Cyriac, George NIH - NIDA Cyriac, George 5 147158037 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands With Drug Abuse Therapeutic Potential E-128-2006-0 Filing authorized National Institute on Drug Abuse (NIDA), University of North Texas Health Science Center 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders&body=Please send me information about technology [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders&body=Please send me information about technology [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147167344 E-128-2006-0 E-128-2006-0-PCT-01 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use PCT Patent Cooperation Treaty PCT/US2007/071412 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/071412<br />Filed on 2007-06-15<br />Status: Expired 147167345 E-128-2006-0 E-128-2006-0-US-02 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands And Methods of Use National Stage US 8,748,608 12/664,668 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8748608 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8748608">8,748,608</a><br />Filed on 2010-06-25<br />Status: Issued 147167346 E-128-2006-0 E-128-2006-0-AU-03 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use National Stage Australia 2007354861 2007354861 Issued Australia <br />National Stage 2007354861<br />Filed on 2007-06-15<br />Status: Issued 147167347 E-128-2006-0 E-128-2006-0-CA-04 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use National Stage Canada 2690789 2690789 Issued Canada <br />National Stage 2690789<br />Filed on 2012-03-20<br />Status: Issued 147167348 E-128-2006-0 E-128-2006-0-US-05 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands And Methods of Use DIV US 14/266,076 Abandoned US <br />Divisional (DIV) 14/266,076<br />Filed on 2014-04-30<br />Status: Abandoned TAB-4211 147157496 Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Zhijian Duan, Christian Hinrichs, Mitchell Ho <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer death in women ages 20 to 39. Engineered T cell receptor (TCR) therapy has been effective in some patients with HPV16 E6 expressing cancers, however, there continues to be a need for more therapies targeting HPV16 E6, when current treatment options fail.&nbsp;</p> <p>NCI inventors have identified two nanobodies (F5 and G9) against MHC/E6 by phage display technologies from the lab&rsquo;s multiple dromedary camel VHH single domain libraries. F5 and G9 could recognize the MHC/E6 complex more specifically over the control nanobodies. CAR T cells using the F5 nanobody as the binding domain showed specific killing of the target tumor cells in mouse models. These nanobodies could potentially treat cancers associated with the expression of HPV16 E6.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, TCRs, RITs, ADCs, immunocytokines and bispecific antibodies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>These anti- HPV E6/E7 nanobodies have an advantage, due to their small size, to potentially bind to epitopes unavailable to more conventional antibodies or TCRs</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes 2023-04-03 2026-04-16 2023-04-03 2026-04-16 2023-04-03 adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163925 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163927 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147163926 Hinrichs, Christian NIH - Rutgers Cancer Institute of New Jersey Hinrichs, Christian 3 147163925 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163927 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147163926 Hinrichs, Christian NIH - Rutgers Cancer Institute of New Jersey Hinrichs, Christian 3 147158133 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes E-169-2022-0 Filing authorized NCI, Rutgers Cancer Institute of New Jersey 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes&body=Please send me information about technology [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes&body=Please send me information about technology [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147167370 E-169-2022-0 E-169-2022-0-US-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PRV US 63/374,307 Expired US <br />Provisional (PRV) 63/374,307<br />Filed on 2022-09-01<br />Status: Expired 147167371 E-169-2022-0 E-169-2022-0-PC-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PCT Patent Cooperation Treaty PCT/US2023/073144 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/073144<br />Filed on 2023-08-30<br />Status: Expired 147172911 adoptive cell therapy 147172912 HO 147172913 HPV16 147172914 Immunotherapy 147172915 NANOBODY 147172916 T Cell Receptor TAB-4088 147157370 High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources NCI Collaboration, Diagnostics, Endocrinology, Licensing Collaboration Diagnostics Endocrinology Licensing <h2>Description of Technology:</h2> <p>There is growing awareness that a wide variety of synthetic and natural compounds that may be present in water sources, such as streams, wells, and ground water, may lead to adverse health effects, including increased cancer risk. Even low concentrations of these compounds are of concern, as they may have biological effects at concentrations of parts per billion or less. In particular, the presence of endocrine disrupting chemicals (EDCs) in the environment is under examination for potential adverse effects on human health, such as immune suppression, impaired fertility, and increased incidence of cancer, diabetes, and obesity. However, these compounds are often laborious and difficult to measure and thus are not commonly monitored. In addition, even if such compounds are detected, only the known compound itself is typically measured, neglecting its metabolites which are more likely to be found in water samples and retain endocrine disrupting activity.&nbsp;</p> <p>Inventors at the NCI&rsquo;s Laboratory of Receptor Biology and Gene Expression have developed a novel assay methodology for detecting EDCs in contaminated water. The assay utilizes fluorescently labeled nuclear steroid receptor constructs in a high-throughput, mammalian cell-based format. Detection and measurements are based on translocation of the fluorescent marker from the cytoplasm to the nucleus in the presence of a ligand that interacts with a specific steroid receptor. Overall, this assay has the capability to detect very low concentrations of EDCs in water or other liquid samples. The inventors have demonstrated proof of concept for this technology by testing for the presence of Glucocorticoid Receptor (GR), Androgen Receptor (AR), Estrogen Receptor (ER), Aryl hydrocarbon receptor (AhR), Progesterone Receptor (PR), and Thyroid Hormone Receptor (TR) activity in water samples. For example, NCI scientists screened water samples collected from 14 states in the US and found AR activity in 35% of samples, as well as previously unrecognized glucocorticoid (GC) activity in 27% of the samples. In particular, the compound androst-4-en-3,6-dione was identified in one of the samples. AR-dependent nuclear translocation and transcriptional activation was also confirmed for two AR-responsive genes, NKX3.1 and RHOU. Moreover, NKX3.1 is a homeobox gene frequently deleted in prostate cancers, and RHOU is implicated in epidermal growth factor receptor signaling and cell migration.&nbsp;</p> <p>A product or service based on this technology could fulfill an unmet need for a high-throughput, rapid method for screening multiple water samples for contaminants with potential endocrine-disrupting activity. The NCI is seeking co-development partners and/or licensees for this technology as a product or service for detecting and screening for endocrine disrupting chemicals in water samples.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Water source testing</li> <li>Wastewater testing</li> <li>Drug ligand screening for agonistic and antagonistic activity</li> <li>Research tool to detect known and orphan receptor activity</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High-throughput and rapid testing&nbsp;</li> <li>High sensitivity and selectivity</li> <li>Readily adaptable for use with a variety of endocrine receptor targets</li> <li>Can detect many EDC variants modified in the environment or other compounds that may act and interfere like EDCs&nbsp;</li> <li>Does not require a priori knowledge of the ligand chemical structure&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a product or service for detecting and screening for endocrine disrupting chemicals (EDCs) in samples from water sources and/or wastewater. 2023-03-02 2026-04-16 2023-03-13 2026-04-16 2023-03-02 EDC detection, EDCs, Endocrine disrupting chemicals, Endocrine disruption screening, Endocrine receptor ligand screening, Hager, Hormone receptor activity, Stavreva, Wastewater, Water sources False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-03-13 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161899 Bruno NE, et al. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. https://pubmed.ncbi.nlm.nih.gov/33510451/ <a href="https://pubmed.ncbi.nlm.nih.gov/33510451/">Bruno NE, et al. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.</a> 147162015 Stavreva DA, et al. Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants. https://pubmed.ncbi.nlm.nih.gov/27528272/ <a href="https://pubmed.ncbi.nlm.nih.gov/27528272/">Stavreva DA, et al. Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants.</a> 147162054 Jones RR, et al. Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays. https://pubmed.ncbi.nlm.nih.gov/32018941/ <a href="https://pubmed.ncbi.nlm.nih.gov/32018941/">Jones RR, et al. Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays.</a> 147162093 Stavreva DA, et al. Prevalent contamination of U.S. water sources with biologically active steroids. https://pubmed.ncbi.nlm.nih.gov/23226835/ <a href="https://pubmed.ncbi.nlm.nih.gov/23226835/">Stavreva DA, et al. Prevalent contamination of U.S. water sources with biologically active steroids.</a> 147162171 Paul-Friedman K, et al. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. https://pubmed.ncbi.nlm.nih.gov/31566444/ <a href="https://pubmed.ncbi.nlm.nih.gov/31566444/">Paul-Friedman K, et al. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library.</a> 147162249 Varticovski L, et al. Endocrine disruptors of sex hormone activities. https://pubmed.ncbi.nlm.nih.gov/34339825/ <a href="https://pubmed.ncbi.nlm.nih.gov/34339825/">Varticovski L, et al. Endocrine disruptors of sex hormone activities.</a> 147162287 Bradley PM, et al. Juxtaposition of intensive agriculture, vulnerable aquifers, and mixed chemical/microbial exposures in private-well tap water in northeast Iowa. https://pubmed.ncbi.nlm.nih.gov/36657670/ <a href="https://pubmed.ncbi.nlm.nih.gov/36657670/">Bradley PM, et al. Juxtaposition of intensive agriculture, vulnerable aquifers, and mixed chemical/microbial exposures in private-well tap water in northeast Iowa.</a> 147162326 Stavreva DA, et al. Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays. https://pubmed.ncbi.nlm.nih.gov/33592464/ <a href="https://pubmed.ncbi.nlm.nih.gov/33592464/">Stavreva DA, et al. Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays.</a> 147162440 Lynch C, et al. Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. https://pubmed.ncbi.nlm.nih.gov/28478275/ <a href="https://pubmed.ncbi.nlm.nih.gov/28478275/">Lynch C, et al. Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.</a> 155750804 A Living Cell Fluorescence Assay For Detection And Monitoring Of Endocrine Disrupting Chemicals In Water Sources E-269-2011-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources&body=Please send me information about technology [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources&body=Please send me information about technology [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 155750809 E-269-2011-0 E-269-2011-0-US-01 Kits For Detecting And Monitoring Endocrine Disrupting Chemicals (EDCs) PRV US 61/656,473 Abandoned US <br />Provisional (PRV) 61/656,473<br />Filed on 2012-06-06<br />Status: Abandoned 155750810 E-269-2011-0 E-269-2011-0-PCT-02 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) PCT Patent Cooperation Treaty PCT/US2013/044569 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/044569<br />Filed on 2013-06-06<br />Status: Expired 155750811 E-269-2011-0 E-269-2011-0-US-03 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) ORD US 9,040,248 13/912,071 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040248 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040248">9,040,248</a><br />Filed on 2013-06-06<br />Status: Issued 155750812 E-269-2011-0 E-269-2011-0-EP-04 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage European Patent 13730754.2 Abandoned European Patent <br />National Stage 13730754.2<br />Filed on 2013-06-06<br />Status: Abandoned 155750813 E-269-2011-0 E-269-2011-0-JP-05 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage Japan 6388575 2015-516223 Issued Japan <br />National Stage 2015-516223<br />Filed on 2014-12-05<br />Status: Issued 155750814 E-269-2011-0 E-269-2011-0-US-06 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage US 14/405,696 Abandoned US <br />National Stage 14/405,696<br />Filed on 2014-12-04<br />Status: Abandoned 155750815 E-269-2011-0 E-269-2011-0-US-07 METHODS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) CON US 9,921,211 14/693,511 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9921211 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9921211">9,921,211</a><br />Filed on 2015-04-22<br />Status: Issued 155750816 E-269-2011-0 E-269-2011-0-JP-08 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) DIV Japan 6546311 2018-057959 Issued Japan <br />Divisional (DIV) 2018-057959<br />Filed on 2018-03-26<br />Status: Issued 147174481 EDC detection 147174483 EDCs 147174485 Endocrine disrupting chemicals 147174487 Endocrine disruption screening 147174489 Endocrine receptor ligand screening 147174491 Hager 147174493 Hormone receptor activity 147174495 Stavreva 147174497 Wastewater 147174499 Water sources TAB-4117 147157399 Method for HLA LOH Detection in Liquid Biopsies NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology James Gulley, Cem Sievers, Andrew Sinkoe <h2>Description of Technology:</h2> <p>Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers, and other modalities. Dozens of therapies in this category were developed with many in clinical trials. The resistance mechanism noted here, HLA LOH, causes these therapies to fail. Therefore, it is beneficial to know before treating a patient whether their cancer&rsquo;s genome has undergone HLA LOH. There is currently no HLA LOH detection method with widespread use in the market and, furthermore, no non-invasive HLA LOH detection test available. Approximately 17% of all cancer patients undergo HLA LOH (Montesion et al., Cancer Discovery, 2021) and would therefore be less likely to respond to TCR-based immunotherapies, making a test for HLA LOH crucial for attaining better patient outcomes.</p> <p>The inventors at the National Cancer Institute (NCI) a developed a non-invasive test for HLA LOH detection in liquid biopsies from blood. As a companion diagnostic (CDx), this HLA LOH detection method allows for improved patient selection. It determines patients unlikely to benefit prior to immunotherapy and thus, can avoid the toxicity, costs, and prevent delay in effective therapy.&nbsp;</p> <p>This is an application of precision oncology. For HLA LOH detection, treatment decisions can be based in part on the HLA LOH status of the patient&rsquo;s cancer, and a patient&rsquo;s treatment course is tailored to give the patient rapid access to more effective therapy. Because the test is non-invasive, determining HLA LOH status does not require surgery. This dramatically increases patient comfort, improves their experience and decreases healthcare costs. An additional benefit is that the patient will not undergo unnecessary treatments that could cause toxicities.&nbsp;</p> <p>The Center for Immuno-Oncology at the NCI is primarily looking for collaborators to co-develop this technology with the inventor. As a companion diagnostic, it will be paired with immunotherapies, to select patients who are most likely to achieve treatment benefit. The inventors seek co-development partners who developed immunotherapies that function via TCR-based mechanisms. The goal is to conduct clinical trials for the diagnostic concomitantly with the drug. The end-result of the trial will be determination of how accurately the diagnostic predicts efficacy of the drug. A companion diagnostic can increase the market potential of therapeutics by allowing them to be used as a first-line treatment. The companion diagnostic can be co-developed and/or co-marketed with a drug at any stage of the drug&rsquo;s regulatory approval process, from Phase I to FDA-approved. The next step for the diagnostic is a Phase I clinical trial, with possible IDE exemption. The companion diagnostic may also be a candidate for College of American Pathologists (CAP) accreditation and, more stringently, Clinical Laboratory Improvement Amendments (CLIA) designation while the clinical trials are being conducted.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Companion diagnostic for TCR-based immunotherapies in experimental clinical trials</li> <li>Companion diagnostic for TCR-based immunotherapies FDA-approved clinical practice</li> <li>Research use in labs studying/developing new pre-clinical therapeutic candidates</li> <li>Research use in basic research labs studying immunotherapy resistance mechanisms, antigen processing and presentation and basic immunology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Mean overall survival (mOS) in TMB-(tumor mutational burden-)low, HLA-intact patients is twice as high as in patients with TMB-low and HLA LOH, which creates an opportunity to benefit patients by treating them with Pembrolizumab despite their TMB-low status (Montesion et al., Cancer Discovery, 2021); therefore HLA LOH as a biomarker may complement TMB-low for improved patient selection</li> <li>Non-invasive test not requiring surgical removal of solid tumor tissue</li> <li>Allows patient-tailored treatment utilizing a wide range of TCR-based immunotherapies</li> <li>Potential improvement in patient survival</li> <li>Potential time and money savings for patients, insurance companies, oncologists, and immunotherapy manufacturers by facilitating the selection of a precision treatment course for each patient</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a companion diagnostic (CDx) that detects HLA LOH and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies. 2023-03-01 2026-04-16 2026-04-16 2023-03-01 Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163568 Sinkoe, Andrew NCI - CCR NCI Sinkoe, Andrew (NCI) 1 147163567 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 147163569 Sievers, Cem National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Sievers, Cem (NCI) 3 147163568 Sinkoe, Andrew NCI - CCR NCI Sinkoe, Andrew (NCI) 1 147163567 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 147163569 Sievers, Cem National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Sievers, Cem (NCI) 3 147157861 Method Of HLA LOH Detection In Liquid Biopsies E-045-2022-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies&body=Please send me information about technology [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies&body=Please send me information about technology [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160958 E-045-2022-0 E-045-2022-0-US-01 METHOD OF HLA LOH DETECTION IN LIQUID BIOPSIES PRV US 63/299,672 Expired US <br />Provisional (PRV) 63/299,672<br />Filed on 2022-01-14<br />Status: Expired 147166647 E-045-2022-0 E-045-2022-0-PCT-02 Method of HLA loss Heterozygosity Detection in Liquid Biopsies PCT Patent Cooperation Treaty PCT/US2023/060664 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/060664<br />Filed on 2023-01-13<br />Status: Expired 162755006 E-045-2022-0 E-045-2022-0-US-02 METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES National Stage US 18/729,138 Pending US <br />National Stage 18/729,138<br />Filed on 2024-07-15<br />Status: Pending 162755007 E-045-2022-0 E-045-2022-0-EP-01 Method of HLA loss Heterozygosity Detection in Liquid Biopsies National Stage European Patent 23705845.8 Pending European Patent <br />National Stage 23705845.8<br />Filed on 2024-08-08<br />Status: Pending 147170222 Companion Diagnostic 147170223 Gulley 147170224 HLA 147170225 Human Leukocyte Antigen 147170226 ICI 147170227 Immune Checkpoint Inhibition 147170228 Immunotherapy 147170229 LOH 147170230 Loss of Heterozygosity 147170231 Sinkoe 147170232 T cell therapy TAB-3896 147157176 A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Jeffrey Gildersleeve, Joel Temme <h2>Description of Technology:</h2> <p>Biofilms are complex microbial communities, surface attached and held together by self-produced polymer matrices.&nbsp; These matrices are mainly composed of polysaccharides, secreted proteins and nucleic acids.&nbsp; Poly-N-acetyl glucosamine (PNAG) is a highly conserved surface polysaccharide expressed by a range of bacterial, fungal and protozoan microorganisms. It is associated with microbial biofilm formation.&nbsp; Partial deacetylation of PNAG (dPNAG) is critical for the function of PNAG in biofilm formation and required for the structural development and integrity of biofilm.&nbsp; Antibodies to PNAG and/or dPNAG have significant potential as broad-spectrum therapeutics for a range of bacterial and fungal infections.&nbsp; Research suggests that dPNAG is a better target than PNAG for antibody-based therapeutics; however, identification of dPNAG antibodies has been challenging.&nbsp;&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) identified a human antibody, denoted TG10, that selectively binds to dPNAG with potential as a novel antimicrobial agent.&nbsp; F598, a human IgG1 monoclonal antibody (mAb) which binds to both PNAG and dPNAG, is in active development as a potential antimicrobial agent in clinical trials.&nbsp; The novel antibody TG10 binds to a different location on the biofilm and shows synergistic effects when administered in combination with F598.&nbsp; The TG10 antibody has been tested both in vitro and in vivo and shows good efficacy both alone and in combination with F598.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic use against multiple microbial pathogens, either alone or in combination with other anti-PNAG/dPNAG agents</li> <li>Prophylactic use to prevent high-risk infections&nbsp;&nbsp;</li> <li>Diagnostic imaging (using labeled form of TG10)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Possible combinatorial or synergistic effect on existing dPNAG or PNAG antibodies.&nbsp;</li> <li>Binds to a different location on dPNAG than the known dPNAG antibody F598&nbsp;</li> <li>Suggestion that combination therapy with TG10 and F598 is superior to either as mono-therapy</li> <li>F598 already used in human clinical trials; existing safety data could facilitate regulatory process of a combination therapy</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of an anti-deacetylated poly-N-acetyl glucosamine (dPNAG) antibody for use as an antimicrobial agent. 2023-03-01 2026-04-16 2026-04-16 2023-03-01 ANTIMICROBIAL, Biofilm, Deacetyleated Poly-N-Acetyl Glucosamine, dPNAG, Gildersleeve, Mab, Monoclonal Antibody, TG10 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162108 Temme JS, et al. Microarray-guided evaluation of the frequency, B-cell origins, and selectivity of human glycan-binding antibodies reveals new insights and novel antibodies. https://pubmed.ncbi.nlm.nih.gov/29786478/ <a href="https://pubmed.ncbi.nlm.nih.gov/29786478/">Temme JS, et al. Microarray-guided evaluation of the frequency, B-cell origins, and selectivity of human glycan-binding antibodies reveals new insights and novel antibodies.</a> 147162783 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162784 Temme, Joel NCI - CCR NCI Temme, Joel (NCI) 2 147162783 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162784 Temme, Joel NCI - CCR NCI Temme, Joel (NCI) 2 147157931 Human Monoclonal Antibody To Pathogen Associated Carbohydrate, Deacetylated-PNAG E-075-2022-0 Filing authorized Michigan State University, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent&body=Please send me information about technology [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent&body=Please send me information about technology [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161002 E-075-2022-0 E-075-2022-0-US-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PRV US 63/319,090 Expired US <br />Provisional (PRV) 63/319,090<br />Filed on 2022-03-11<br />Status: Expired 147165119 E-075-2022-0 E-075-2022-0-PC-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PCT Patent Cooperation Treaty PCT/US2023/064047 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/064047<br />Filed on 2023-03-09<br />Status: Expired 147170833 ANTIMICROBIAL 147170834 Biofilm 147170836 Deacetyleated Poly-N-Acetyl Glucosamine 147170838 dPNAG 147170839 Gildersleeve 147170840 Mab 147170841 Monoclonal Antibody 147170843 TG10 TAB-4054 147157336 Methods of Determining Homeostatic Perturbations NICHD Collaboration, Diagnostics, Licensing, Neurology, Oncology Collaboration Diagnostics Licensing Neurology Oncology Peter Basser, Teddy Cai, Rea Ravin, Nathan Williamson <h2><strong>Description of Technology:</strong></h2> <p>Biological homeostasis is a state of steady internal, physical, and chemical conditions maintained by a living organism observed at the cellular level.&nbsp; Biological homeostasis can vary in order to alter the cellular physical and chemical conditions. Thus, it acts as a mechanism to define the physiological state of cellular activity; for instance resting states or active states (e.g., intensive physical or mental activity or intensive physical or mental stimulation).&nbsp; Deviations or perturbations from biological homeostasis, even at the cellular level, can be caused by pathological conditions such as diseases within the organism.&nbsp; Such deviations result in physical and chemical conditions that feedback to prolong pathological states as part of an injury or disease.&nbsp; In the extreme case, cell death can be characterized by a complete loss of homeostasis.&nbsp; In these ways, states of biological homeostasis are linked to physiological and pathological activities occurring at various levels of the organism (e.g., organelle, cell, tissue, organ).&nbsp; States of biological homeostasis can be difficult to detect using conventional analytical techniques.</p> <p>The disclosed technology consists of methods to determine a homeostatic steady-state of a biological entity.&nbsp; Also disclosed are methods to use Nuclear Magnetic Resonance (NMR) or Magnetic Resonance Imaging (MRI) to quantify a water exchange rate between at least two compartments in a biological system, to characterize physiological water transport, and methods for non-invasively measuring transmembrane exchange rates of endogenous water in a biological system under steady-state or non-steady-state conditions in near-real time.</p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners further to develop methods and/or assays arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this diagnostic in the area of neurology or another suitable field.</p> <h2><strong>Potential Commercial Applications:</strong></h2> <ul> <li><span style="tab-stops:list .5in">Diagnosis of benign tumors capable of immune stimulation (&ldquo;hot&rdquo;)</span></li> <li><span style="tab-stops:list .5in">Diagnosis of abnormal central nervous system (CNS) states (ex: those caused by stroke, brain aneurysm, traumatic brain injury, migraine aura, and seizure)</span></li> <li><span style="tab-stops:list .5in">Determining the physiological or functional activity state of the central nervous system (CNS) (e.g. sleep, wake, intense stimulation)</span></li> <li><span style="tab-stops:list .5in">Evaluating CNS therapeutics and their mechanism of action</span></li> </ul> <h2><strong>Competitive Advantages:</strong></h2> <ul> <li><span style="tab-stops:list .5in">Absolute measurement&mdash;can directly detect the homeostatic state&mdash;does not require a relative reading.&nbsp;</span></li> <li><span style="tab-stops:list .5in">Uses endogenous water&mdash;does not require a tracer or contrast agent</span></li> <li><span style="tab-stops:list .5in">Less invasive than the current state of the art methods to measure spreading depolarization</span></li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for methods to determine homeostatic perturbations. 2023-01-21 2026-04-16 2023-01-22 2026-04-16 2023-01-23 Basser, Biomarkers, Central Nervous System, CNS, functional imaging, HOMEOSTASIS, Magnetic Resonance Imaging, MRI, NICHD, NMR, Nuclear Magnetic Resonance, r, Steady-state, The Eunice Kennedy Shriver National Institute of Child Healt False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-01-22 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161885 Cai TX, et al. Disentangling the effects of restriction and exchange with diffusion exchange spectroscopy https://doi.org/10.3389/fphy.2022.805793 <a href="https://doi.org/10.3389/fphy.2022.805793">Cai TX, et al. Disentangling the effects of restriction and exchange with diffusion exchange spectroscopy</a> 147162001 Cai TX, et al. Rapid detection of the presence of diffusion exchange https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xGKhQ3sAAAAJ&sortby=pubdate&citation_for_view=xGKhQ3sAAAAJ:_FxGoFyzp5QC <a href="https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xGKhQ3sAAAAJ&sortby=pubdate&citation_for_view=xGKhQ3sAAAAJ:_FxGoFyzp5QC">Cai TX, et al. Rapid detection of the presence of diffusion exchange</a> 147162273 Williamson NH, Magnetic resonance measurements of cellular and sub-cellular membrane structures in live and fixed neural tissue https://pubmed.ncbi.nlm.nih.gov/31829935 <a href="https://pubmed.ncbi.nlm.nih.gov/31829935">Williamson NH, Magnetic resonance measurements of cellular and sub-cellular membrane structures in live and fixed neural tissue</a> 147163350 Ravin, Rea NIH - Celoptics, Inc. NIBIB Ravin, Rea (NIBIB) 1 147163351 Williamson, Nathan NIGMS NIGMS Williamson, Nathan (NIGMS) 2 147163352 Cai, Teddy NICHD NICHD Cai, Teddy (NICHD) 3 147163349 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 4 147163350 Ravin, Rea NIH - Celoptics, Inc. NIBIB Ravin, Rea (NIBIB) 1 147163351 Williamson, Nathan NIGMS NIGMS Williamson, Nathan (NIGMS) 2 147163352 Cai, Teddy NICHD NICHD Cai, Teddy (NICHD) 3 147163349 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 4 147158084 Magnetic Resonance Method Of Measuring Water Exchange For Identifying Brain Physiology And Pathology E-151-2021-0 Filing authorized Celoptics, Inc., NICHD, NIGMS 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4054] Methods of Determining Homeostatic Perturbations&body=Please send me information about technology [TAB-4054] Methods of Determining Homeostatic Perturbations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4054] Methods of Determining Homeostatic Perturbations&body=Please send me information about technology [TAB-4054] Methods of Determining Homeostatic Perturbations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147166229 E-151-2021-0 E-151-2021-0-US-01 Magnetic Resonance Method Of Measuring Water Exchange For Identifying Brain Physiology And Pathology PRV US 63/277,881 Abandoned US <br />Provisional (PRV) 63/277,881<br />Filed on 2021-11-10<br />Status: Abandoned 147166230 E-151-2021-0 E-151-2021-0-PCT-02 NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC PERTURBATIONS PCT Patent Cooperation Treaty PCT/US2022/049542 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/049542<br />Filed on 2022-11-10<br />Status: Expired 147172398 Basser 147172399 Biomarkers 147172400 Central Nervous System 147172401 CNS 147172403 functional imaging 147172404 HOMEOSTASIS 147172405 Magnetic Resonance Imaging 147172406 MRI 147172407 NICHD 147172408 NMR 147172410 Nuclear Magnetic Resonance 147172411 r 147172412 Steady-state 147172414 The Eunice Kennedy Shriver National Institute of Child Healt TAB-5024 158742599 Immunotherapy Delivery System to Improve Organ Transplantation Outcomes NCI Cardiology, Collaboration, Immunology, Nephrology, Therapeutics Cardiology Collaboration Immunology Nephrology Therapeutics Xiomara Calderon-Colon, Alexander Komin, Monessha Nambiar, Julia Patrone, Giorgio Raimondi, Joel Schneider, Olivia Tiburzi <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Value Proposition</p> <ul> <li>Novel Therapy: &nbsp;Hydro(LNp), is a new therapeutic application to improve outcomes for organ transplant recipients</li> <li>Broad Scope: Potential to adapt for applications beyond transplantation, such as cancer, autoimmunity, and regenerative medicine</li> <li>Convenient Delivery: Hydro(LNp) is a two-phase delivery system to increase effectiveness in regulating transplant rejection</li> </ul> <p>Transplantation becomes the only therapeutic option after end-stage organ diseases and other devastating tissue loss. However, transplanted patients need to receive high doses of multi-drug immunosuppressive therapy for the rest of their life to prevent rejection. This current standard of care often entails dangerous side effects &ndash;including nephrotoxicity, cardiovascular disease, diabetes, and higher predisposition to infections and cancer. Therefore, there is an unmet need to identify a safer and effective treatment plan for transplant recipients.</p> <p>Researchers from the National Cancer Institute (NCI), Johns Hopkins University (JHU) and Johns Hopkins Applied Physics Laboratory (JH-APL) have identified that concomitant inhibition of the JAK/STAT pathway (via small molecule inhibitors) and of a key costimulatory pathway (via the biologic CTLA4-Ig) improves the control of the immune response to a transplant. As a combination therapy, they create &ldquo;Enhanced Costimulation Blockade,&rdquo; generating positive results without many rejection episodes or side effects. The multidisciplinary team of researchers engineered a dual component delivery system called Hydro(LNp), which delivers JAK inhibitors (JAKi) in a dual form: (1) microcrystalline drug deposits in the hydrogel and (2) lipid nanoparticles encapsulated drug. This product can be injected near the transplant site. The microcrystalline drug is released locally, while the lipid nanoparticle (LNp) carry it to the specific distal sites where the immune response against the transplant is initiated. The net result is a localized synergy with CTLA4-Ig effectively preventing graft rejection.&nbsp;</p> <p>This technology could positively impact transplantation-control of immune response to prevent transplant rejection. An autoimmunity-based therapeutic that inhibits JAK signaling could bring therapeutic benefit to autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. Cancers with a dysregulated JAK/STAT pathway could also be treated with this technology.</p> <p>This technology is co-owned by JHU and The National Institutes of Health (NIH), and was co-developed by NCI, JHU and JH-APL. The summary of the technology was provided by Johns Hopkins Technology Ventures (JHTV) and <a href="https://profiles.hopkinsmedicine.org/provider/giorgio-raimondi/2777419" target="_blank">Dr. Giorgio Raimondi</a>. The technology is cross-listed on<a href="https://jhu.technologypublisher.com/technology/47435" target="_blank"> JHTV&rsquo;s website Tech Publisher</a>. The &nbsp;Hydro(LNp) is as a modification of an earlier NCI-JHU co-owned technology (NIH Ref. No.&nbsp; E-123-2018) which is cross-listed as <a href="https://jhu.technologypublisher.com/technology/47435" target="_blank">Case ID:15347 on Tech Publisher</a>.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Prevent transplant rejection</li> <li>Autoimmunity diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease</li> <li>Cancer therapeutic&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Drug delivery method that extends the half-life of tofacitinib</li> <li>Provide continuous, rate-controlled, localized and targeted release of tofacitinib</li> <li>Treat autoimmunity or prevent transplant rejection when combined with CTLA4-Ig, an immunosuppressive agent, for Enhanced Costimulation Blockade</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of this delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 2024-10-23 2026-04-16 2026-04-16 2024-11-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-123-2018 162763644 Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. PMID: 32812339 https://doi.org/10.1002/smll.202002791 <a href="https://doi.org/10.1002/smll.202002791">Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. PMID: 32812339</a> 158990771 Raimondi, Giorgio Johns Hopkins School of Medicine Raimondi, Giorgio 1 158990775 Schneider, Joel NCI Schneider, Joel (NCI) 2 158990779 Patrone, Julia Patrone, Julia 3 159081976 Komin, Alexander Johns Hopkins University Komin, Alexander 4 159081980 Nambiar, Monessha National Cancer Institute (NCI) NCI Nambiar, Monessha (NCI) 5 159081984 Calderon-Colon, Xiomara Calderon-Colon, Xiomara 6 159081988 Tiburzi, Olivia Tiburzi, Olivia 7 158990771 Raimondi, Giorgio Johns Hopkins School of Medicine Raimondi, Giorgio 1 158990775 Schneider, Joel NCI Schneider, Joel (NCI) 2 158990779 Patrone, Julia Patrone, Julia 3 159081976 Komin, Alexander Johns Hopkins University Komin, Alexander 4 159081980 Nambiar, Monessha National Cancer Institute (NCI) NCI Nambiar, Monessha (NCI) 5 159081984 Calderon-Colon, Xiomara Calderon-Colon, Xiomara 6 159081988 Tiburzi, Olivia Tiburzi, Olivia 7 158742602 Dual-component Therapeutic Platform For Localized And Inflammation Triggered Immune Targeted Delivery Of Immunotherapies E-121-2022-0 Filing authorized Johns Hopkins School of Medicine, Johns Hopkins University, Johns Hopkins University, NCI, NIH - NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes&body=Please send me information about technology [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes&body=Please send me information about technology [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 159502867 E-121-2022-0 E-121-2022-0-US-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS PRV US 63/350,315 Expired US <br />Provisional (PRV) 63/350,315<br />Filed on 2022-06-08<br />Status: Expired 159502872 E-121-2022-0 E-121-2022-0-PC-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS PCT Patent Cooperation Treaty PCT/US2023/068139 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/068139<br />Filed on 2023-06-08<br />Status: Expired 159502877 E-121-2022-0 E-121-2022-0-US-02 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS National Stage US 18/872,676 Pending US <br />National Stage 18/872,676<br />Filed on 2024-12-06<br />Status: Pending TAB-5028 158934494 HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K NCI Collaboration, Immunology, Licensing, Oncology, TherapeuticArea, Therapeutics Collaboration Immunology Licensing Oncology TherapeuticArea Therapeutics S M Rafiqul Islam, Frank Lowery, Maria Parkhurst, Steven Rosenberg, Samantha Seitter, NIkolaos Zacharakis <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01.</p> <h2>Description of Technology:</h2> <p>Phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha gene, also known as PIK3CA, makes a subunit of the PIK3 enzyme with various cellular functions. Mutations in the PIK3CA can result in the growth of cells through overactivation of the PIK3 enzyme and are associated with the development of several forms of cancers. Indeed, PIK3CA mutation is the third most common mutation in epithelial cancers. Previous studies attempted to inhibit the activity of mutant PIK3CA using both small molecules and monoclonal antibodies. However, these studies showed limited in vivo efficacy in treating tumors with mutant PIK3CA.</p> <p>The National Cancer Institute (NCI) has developed novel, HLA-class II-restrcited T cell receptors (TCRs) to target two of the most common PIK3CA &ldquo;hotspot&rdquo; mutations: E545K and N345K. Two TCRs against N345K are restricted by the common HLA-DPA1*01:03:01 and HLA-DPB1*04:01:01, found in about 85% of the US Caucasian population. The TCR against E545K is rectricted by the common HLA-DRB1*04:01, found in about 17-20% of US Caucasian population. Given the frequency of PIK3CA mutations in various common cancers, these inventions have the potential to benefit a wide range of cancer patients. Targeted therapy against PIK3CA mutations represents therapeutic potential for various types of cancer. Further, as PIK3CA mutations are not present in healthy tissue, this approach could produce fewer off-target effects and a more promising safety profile.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>TCR-engineered cell therapy products for cancers expressing PIK3CA mutations &ndash; including, but not limited to: <ul> <li>breast&nbsp;</li> <li>endometrial</li> <li>bladder</li> <li>colorectal carcinoma</li> <li>head and neck squamous cell carcinoma</li> </ul> </li> <li>Soluble TCR-fusion proteins</li> <li>Combination immunotherapies using ACT alongside other immunotherapies targeting PIK3CA mutations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Targeted therapy</li> <li>Potentially fewer and less severe off-target effects</li> <li>Potentially more promising safety profile</li> <li>Therapeutic potential for various types of cancer</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for T cell receptors (TCRs) targeting PIK3CA mutations to treat patients with tumors expressing these mutations such as metastatic epithelial cancers. 2024-11-01 2026-04-16 2026-04-16 2024-11-06 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-206-2022 158934581 Fusco N, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. (PMID 33842357) https://pubmed.ncbi.nlm.nih.gov/33842357/ <a href="https://pubmed.ncbi.nlm.nih.gov/33842357/">Fusco N, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. (PMID 33842357)</a> 158990386 Martínex-Sáez, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. (PMID 32404150) https://pubmed.ncbi.nlm.nih.gov/32404150/ <a href="https://pubmed.ncbi.nlm.nih.gov/32404150/">Martínex-Sáez, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. (PMID 32404150)</a> 158990393 Krop IE, et al. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. (PMID 35138919) https://pubmed.ncbi.nlm.nih.gov/35138919/ <a href="https://pubmed.ncbi.nlm.nih.gov/35138919/">Krop IE, et al. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. (PMID 35138919)</a> 158934542 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 158934546 Zacharakis, NIkolaos National Cancer Institute (NCI) NCI Zacharakis, NIkolaos (NCI) 2 158934550 Islam, S M Rafiqul NCI Islam, S M Rafiqul (NCI) 3 158934554 Seitter, Samantha Seitter, Samantha 4 158934558 Parkhurst, Maria NCI Parkhurst, Maria (NCI) 5 158934562 Lowery, Frank NCI Lowery, Frank (NCI) 6 158934542 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 158934546 Zacharakis, NIkolaos National Cancer Institute (NCI) NCI Zacharakis, NIkolaos (NCI) 2 158934550 Islam, S M Rafiqul NCI Islam, S M Rafiqul (NCI) 3 158934554 Seitter, Samantha Seitter, Samantha 4 158934558 Parkhurst, Maria NCI Parkhurst, Maria (NCI) 5 158934562 Lowery, Frank NCI Lowery, Frank (NCI) 6 158934497 HLA-class II-restricted T cell receptors for PIK3CA “hotspot” mutations, E545K and N345K. E-076-2024-0 Filing authorized Inova Health System, NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K&body=Please send me information about technology [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K&body=Please send me information about technology [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 159503000 E-076-2024-0 E-076-2024-0-US-01 T CELL RECEPTORS TARGETING E545K OR N345K MUTATION IN PIK3CA PRV US 63/565,764 Expired US <br />Provisional (PRV) 63/565,764<br />Filed on 2024-03-15<br />Status: Expired TAB-5025 158743710 Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof NCI Cardiology, Collaboration, Immunology, Licensing, Nephrology, Therapeutics Cardiology Collaboration Immunology Licensing Nephrology Therapeutics Poulami Majumder, Giorgio Raimondi, Joel Schneider <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a hydrogel-based delivery system for the local administration of tofacitinib to improve transplant outcomes.</p> <h2>Description of Technology:&nbsp;</h2> <p>More than 1 million tissue transplantations are performed each year. Organ transplantation therapies are typically combined with immunosuppressive agents to reduce the risk of allograft rejection and enhance transplant survival. Currently, immunosuppressive drugs are administered systemically and have several dose-limiting side effects, including impairment of renal function, hypertension, and lymphatic malignancies. Therefore, there is an unmet need to identify a safer, more effective treatment plan for transplant recipients.<br /> &nbsp;<br /> A multidisciplinary team of researchers from the National Cancer Institute (NCI) and <a href="https://www.hopkinsmedicine.org/plastic-reconstructive-surgery/research/vca-lab" target="_blank">Johns Hopkins University (JHU)</a> developed a peptide hydrogel containing a crystalized form of an immunosuppressive small molecule.&nbsp;<br /> This novel formulation can be syringe-injected to the site of transplantation during surgery, allowing for localized, sustained delivery of immunosuppressive agents &ndash; improving transplant outcomes while reducing off-target toxicities. As proof of concept, a hydrogel containing a potent JAK inhibitor, tofacitinib, was injected directly to the grafting site using a mouse model of heterotopic heart transplantation. A single, local application of the tofacitinib hydrogel, combined with systemic administration of CTLA4-Ig, a common immunosuppressant, significantly prolonged graft survival of the transplanted heart. This technology could positively impact transplantation-control of immune response to prevent transplant rejection. An autoimmunity-based therapeutic that inhibits JAK signaling could bring therapeutic benefit to autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. Cancers with a dysregulated JAK/STAT pathway could also be treated with this technology.</p> <p>This technology is co-owned and was co-developed by JHU and The National Institutes of Health (NIH). The summary of the technology was provided by Johns Hopkins Technology Ventures (JHTV) and is cross-listed on <a href="https://jhu.technologypublisher.com/technology/47435" target="_blank">JHTV&rsquo;s Tech Publisher website Case ID C15347</a>. There is a modified, related, co-owned technology (E-121-2022) which is cross listed on <a href="https://jhu.technologypublisher.com/technology/55093" target="_blank">JHTV&rsquo;s Tech Publisher website Case ID C17351</a>.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Prevent transplant rejection</li> <li>Autoimmunity diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease</li> <li>Cancer therapeutic</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Drug delivery method that extends the half-life of tofacitinib</li> <li>Provide continuous, rate-controlled, localized and targeted release of tofacitinib</li> <li>Treat autoimmunity or prevent transplant rejection when combined with CTLA4-Ig, an immunosuppressive agent, for Enhanced Costimulation Blockade&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of this delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 2024-10-23 2026-04-16 2026-04-16 2024-11-06 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-121-2022 158990415 Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. (PMID: 32812339). https://pubmed.ncbi.nlm.nih.gov/32812339/ <a href="https://pubmed.ncbi.nlm.nih.gov/32812339/">Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. (PMID: 32812339).</a> 158990403 Raimondi, Giorgio Raimondi, Giorgio 1 158990407 Schneider, Joel National Cancer Institute (NCI) NCI Schneider, Joel (NCI) 2 158990411 Majumder, Poulami NCI Majumder, Poulami (NCI) 3 158990403 Raimondi, Giorgio Raimondi, Giorgio 1 158990407 Schneider, Joel National Cancer Institute (NCI) NCI Schneider, Joel (NCI) 2 158990411 Majumder, Poulami NCI Majumder, Poulami (NCI) 3 158743713 Hydrogel Delivery Platform To Deliver Immunosuppressive Drugs E-123-2018-0 Filing authorized Johns Hopkins School of Medicine, NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof&body=Please send me information about technology [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof&body=Please send me information about technology [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 159503047 E-123-2018-0 E-123-2018-0-US-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF PRV US 62/666,471 Abandoned US <br />Provisional (PRV) 62/666,471<br />Filed on 2018-05-03<br />Status: Abandoned 159503058 E-123-2018-0 E-123-2018-0-PCT-02 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2019/030656 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/030656<br />Filed on 2019-05-03<br />Status: Expired 159503063 E-123-2018-0 E-123-2018-0-EP-03 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF National Stage European Patent 3787664 19724994.9 Abandoned European Patent <br />National Stage 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503068 E-123-2018-0 E-123-2018-0-US-04 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF National Stage US 12,527,870 17/051,574 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12527870 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12527870">12,527,870</a><br />Filed on 2020-10-29<br />Status: Issued 159503073 E-123-2018-0 E-123-2018-0-FR-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP France 3787664 19724994.9 Abandoned France <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503078 E-123-2018-0 E-123-2018-0-DE-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP Germany 3787664 19724994.9 Abandoned Germany <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503083 E-123-2018-0 E-123-2018-0-GB-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP United Kingdom 3787664 19724994.9 Abandoned United Kingdom <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned TAB-5023 158678127 Machine Learning Model for the Prioritization of Cancer Neoepitopes NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Jared Gartner, Paul Robbins, Steven Rosenberg <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.</p> <h2>Description of Technology:&nbsp;</h2> <p>Success in immunotherapy is often attributable to the reactivity of patient T-cells to specific mutated peptide(s) found in the patient&rsquo;s tumor known as neoepitopes. In the development of patient-specific immunotherapies, there is no consistent standard for prioritizing such neoepitopes. Current models arrive at a ranked list of potential candidates by removing epitopes based on pre-determined criteria which might lead to the elimination of known reactive neoepitopes.&nbsp;</p> <p>Identification, prioritization and targeting of patient neoepitopes are crucial for developing effective, personalized treatments. Ranking or prioritizing neoepitopes is especially important when trying to construct a cancer vaccine that will elicit a therapeutically beneficialn immune response. Accordingly, scientists at the National Cancer Institute (NCI) have created a novel approach to identify and prioritize patient neoantigens. This model uses a training dataset of known neoantigens from patient screening and determines features of importance to epitope recognition using both reactive and non-reactive epitopes. The machine learning algorithm scores epitopes for their likelihood of reactivity and provides a stable, reproducible method to prioritize epitopes that can be used anywhere in the world.&nbsp;<br /> &nbsp;<br /> The National Cancer Institute (NCI) seeks licensees for this machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Oncology</li> <li>Prioritization of neoantigens for the development of effective personalized therapies</li> <li>Cancer vaccines</li> <li>TIL and T-cell receptor therapies</li> <li>Research use</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Model is trained using a dataset of verified neoantigens from patient tumor data&nbsp;</li> <li>Model is unbiased because it does not use prior assumptions about what features a neoepitope should have</li> <li>Uses two models (MMP and NMER model) aswhich is a more reproducible approach than using a single model</li> <li>Particularly useful for prioritizing epitopes for patients with large numbers of mutations</li> </ul> The NCI seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy. 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158678146 Gartner JJ, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. (PMID: 34927080) https://pubmed.ncbi.nlm.nih.gov/34927080/ <a href="https://pubmed.ncbi.nlm.nih.gov/34927080/">Gartner JJ, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. (PMID: 34927080)</a> 158678134 Gartner, Jared NCI Gartner, Jared (NCI) 1 158678138 Robbins, Paul NCI Robbins, Paul (NCI) 2 158678142 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 3 158678134 Gartner, Jared NCI Gartner, Jared (NCI) 1 158678138 Robbins, Paul NCI Robbins, Paul (NCI) 2 158678142 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 3 158678130 Development of a model for ranking candidate HLA class I neoantigens based upon datasets of known neoepitopes E-022-2024-0 Closed NIH - NCI, Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes&body=Please send me information about technology [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes&body=Please send me information about technology [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-5022 158677893 Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Pradip Bajgain, Yang Feng, Brad St. Croix <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use.</p> <h2>Description of Technology:</h2> <p>Chimeric antigen receptor (CAR)-T cell therapy has been successful in leukemia but its use for the treatment of solid tumors has been challenging. &nbsp;CD276, also known as B7-H3, is a surface tumor marker highly expressed in the vasculature and surface of solid tumors. This strong expression in both areas of solid tumors makes CD276 a promising target for cancer therapies such as CARs.</p> <p>This technology comprises of a panel of five fully human antibodies (Y868, Y422, Y111, Y117, and YE5) against CD276 that can be incorporated into immunotherapies. &nbsp;The CARs generated using these antibodies were evaluated and compared to other known CD276-targeting CARs in development. &nbsp;One of the CARs showed a more durable anti-tumor response superior to all others tested, including those known in the literature. &nbsp;CARs generated from this set are effective against Panc1 pancreatic tumor models. One CAR in particular showing high efficacy in the HPAC pancreatic tumor model which was resistant to all other CARs. &nbsp;In addition to CARs, the antibodies developed under this invention could potentially be used in other antibody-based therapeutics targeting CD276 including other cell therapies such as CAR NK-cell therapies. &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>CAR T-Cell therapy for treatment of pancreatic cancer</li> <li>CAR T-Cell or NK cell therapy for treatment of several solid tumors&nbsp;</li> <li>Antibody based therapeutics such as antibody drug conjugates (ADCs) for the treatment of solid tumors&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High efficacy against tumors resistant to other CARs</li> <li>CD276 target is highly expressed on many solid tumor types</li> <li>Fully human antibody potentially less immunogenic than those derived from mouse</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of antibody-based therapeutics targeting CD276 for the treatment of solid tumors. 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158678102 Feng et al. Engineering CD276/B7-H3-targeting antibody-drug conjugates with enhanced cancer-eradicating capability (PMID 38019654) Seaman et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. (PMID 28399408) https://pubmed.ncbi.nlm.nih.gov/38019654/ <a href="https://pubmed.ncbi.nlm.nih.gov/38019654/">Feng et al. Engineering CD276/B7-H3-targeting antibody-drug conjugates with enhanced cancer-eradicating capability (PMID 38019654) Seaman et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. (PMID 28399408)</a> 158677900 St. Croix, Brad NCI St. Croix, Brad (NCI) 1 158678094 Bajgain, Pradip National Cancer Institute (NCI) NCI Bajgain, Pradip (NCI) 2 158678098 Feng, Yang NCI Feng, Yang (NCI) 3 158677900 St. Croix, Brad NCI St. Croix, Brad (NCI) 1 158678094 Bajgain, Pradip National Cancer Institute (NCI) NCI Bajgain, Pradip (NCI) 2 158678098 Feng, Yang NCI Feng, Yang (NCI) 3 158677896 Fully Human Chimeric Antigen Receptors against CD276 for the treatment of solid tumors E-125-2023-0 Filing authorized Mouse Cancer Genetics Program 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors&body=Please send me information about technology [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors&body=Please send me information about technology [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 159502484 E-125-2023-0 E-125-2023-0-US-01 Fully Human Chimeric Antigen Receptors against CD276 for the treatment of solid tumors PRV US 63/514,596 Expired US <br />Provisional (PRV) 63/514,596<br />Filed on 2023-07-20<br />Status: Expired 159502489 E-125-2023-0 E-125-2023-0-PC-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS PCT Patent Cooperation Treaty PCT/US2024/037349 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/037349<br />Filed on 2024-07-10<br />Status: Expired 165318378 E-125-2023-0 E-125-2023-0-CA-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage Canada 3299104 Pending Canada <br />National Stage 3299104<br />Filed on 2026-01-19<br />Status: Pending 165318413 E-125-2023-0 E-125-2023-0-AU-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage Australia 2024295016 Pending Australia <br />National Stage 2024295016<br />Filed on 2026-01-15<br />Status: Pending 165318575 E-125-2023-0 E-125-2023-0-US-02 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage US 19/503,627 Pending US <br />National Stage 19/503,627<br />Filed on 2026-01-20<br />Status: Pending 165318610 E-125-2023-0 E-125-2023-0-EP-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage European Patent 24749087.3 Pending European Patent <br />National Stage 24749087.3<br />Filed on 2026-02-04<br />Status: Pending TAB-5021 158677813 Novel Kinase Inhibitory Thiazines NCI Application, Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Application Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h2>Description of Technology:</h2> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.), showed broad potential applicability to numerous kinases of importance including, but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>The original cohort of compounds, including the pharmaceutical compositions of the natural products Aplithianine A and Aplithianine B, as well as a range of synthetic derivatives are described in NIH Technology Ref # E-044-2022.&nbsp;</p> <p>This technology (NIH Ref # E-202-2023) describes the Second Cohort of compounds that comprise the same chemical scaffold of the broadest generic formula in the Original Family but represent a patentably distinct, subgenus formula. This Second Cohort of compounds shares the same chemical scaffold as aplithianine but have been optimized through extensive medicinal chemistry efforts to increase binding affinity to the oncogenic fusion kinase called DNAJB1-PRKACA (PKADJ) and its wild-type counterpart protein kinase A (PKA). These new compounds, like the Original Family compounds, compete with ATP for binding on these kinases and other related kinases (namely, protein kinase G, cdc2-like kinases (CLK) 1 &amp; 2, and the DYRK family of kinases). However, the compounds described in this Second Cohort exhibit improved low nanomolar binding affinity and high activity in secondary assays.&nbsp;</p> <p>A Third Cohort of compounds, namely the Reverse Thiazine Kinase inhibitors, are described in NIH Ref # E-162-2024. They are also structurally related to, but patentably distinct from the compounds described in the patent filings for the Original Family and Second Cohort.&nbsp;</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-471.png" style="height:1676px; width:1218px" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting &nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gastric cancer</li> <li>Ultra-rare adolescent liver cancer</li> <li>Solid cancers susceptible to kinase inhibitors</li> <li>Cushing&rsquo;s Disease</li> <li>Transplantation</li> <li>Diabetic neuropathic pain</li> <li>Malaria</li> <li>Protozoa infection&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Applicability to numerous clinically relevant kinases, including: <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> </li> <li>Applicable to a range of kinases, but are not promiscuous inhibitors</li> <li>Broad potential commercial applicability for several blockbuster indications, including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li>No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> <p>&nbsp;</p> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-044-2022 E-162-2024 158677854 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 https://pubmed.ncbi.nlm.nih.gov/37082750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37082750/">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750</a> 162874682 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072 https://pubmed.ncbi.nlm.nih.gov/37843072/ <a href="https://pubmed.ncbi.nlm.nih.gov/37843072/">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072</a> 158677820 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158677824 Du, Lin NCI Du, Lin (NCI) 2 158677828 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677832 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677838 Moore, William NCI Moore, William (NCI) 5 158677842 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677846 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677850 Li, Ning Leidos Li, Ning (Leidos) 8 158677820 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158677824 Du, Lin NCI Du, Lin (NCI) 2 158677828 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677832 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677838 Moore, William NCI Moore, William (NCI) 5 158677842 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677846 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677850 Li, Ning Leidos Li, Ning (Leidos) 8 158677816 Novel Kinase Inhibitory Thiazines E-202-2023-0 Filing authorized National Cancer Institute (NCI), NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5021] Novel Kinase Inhibitory Thiazines&body=Please send me information about technology [TAB-5021] Novel Kinase Inhibitory Thiazines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5021] Novel Kinase Inhibitory Thiazines&body=Please send me information about technology [TAB-5021] Novel Kinase Inhibitory Thiazines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503095 E-202-2023-0 E-202-2023-0-US-01 KINASE INHIBITORS PRV US 63/527,274 Expired US <br />Provisional (PRV) 63/527,274<br />Filed on 2023-07-17<br />Status: Expired 159503100 E-202-2023-0 E-202-2023-0-PC-01 KINASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2024/038376 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/038376<br />Filed on 2024-07-17<br />Status: Expired TAB-5020 158677380 Reverse Thiazine Kinase Inhibitors NCI Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h3>Summary:</h3> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h3>Description of Technology:</h3> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.) showed broad potential applicability to numerous kinases of importance including but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>This Technology (NIH Ref # <strong>E-162-2024</strong>) describes a Third Cohort of compounds, namely the Reverse Thiazine Kinase inhibitors &ndash; structurally related to, but patentably distinct from &ndash; compounds described in the patent filings for the Original Family and Second Cohort. This Third Cohort of reverse thiazine compounds were created based on the initial activity determination and structural interactions for the aplithianine kinase inhibitors (described in the Original Family) and the DNAJ-PKA fusion protein. These Third Cohort compounds are a new structural class of Ser/Thr kinase (i.e. PKA) inhibitors related to the aplithianine class of kinase inhibitors but differ in both their chemical structures and mode of binding into the ATP binding pocket of kinases. They show potent and improved biochemical inhibition, reduction of the phosphorylation of the PKA substrate CREB, and the ability to reduce the viability of cancer cells. Computational modeling predicted enhanced binding affinity of these reverse thiazines with the DNAJ-PKA fusion protein. Consistent with this hypothesis-driven modeling effort, the reverse thiazines show improved potency and cellular activity over the compounds described in the Original Family and Second Cohort patent families</p> <p>Original Cohort of compounds, including the pharmaceutical compositions of the natural products Aplithianine A and Aplithianine B, as well as a range of synthetic derivatives are described in NIH Technology Ref # E-044-2022.&nbsp;</p> <p>The Second Cohort of compounds are covered in (NIH Ref # E-202-2023). This Second Cohort comprises the same chemical scaffold of the broadest generic formula in the Original Family but represents a patentably distinct, subgenus formula. This Second Cohort of compounds shares the same chemical scaffold as aplithianine but have been optimized through extensive medicinal chemistry efforts to increase binding affinity to the oncogenic fusion kinase called DNAJB1-PRKACA (PKADJ) and its wild-type counterpart protein kinase A (PKA).</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-471.png" style="height:1676px; width:1218px" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that, while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date, there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting&nbsp;&nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h3>Potential Commercial Applications:</h3> <ul> <li style="margin-left: 8px;"><span style="font-family:Times New Roman,serif">Gastric Cancer</span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Ultra-rare, adolescent liver cancer</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Solid cancers susceptible to kinase inhibitors</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Cushing&rsquo;s Disease</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Transplantation</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Diabetic neuropathic pain</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Malaria</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Protozoa infection </span></span></li> </ul> <h3 style="margin-left:8px">Competitive Advantages:</h3> <ul> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Applicability to numerous clinically relevant kinases, including:</span></span> <ul> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Wild type protein kinase A (PKA)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Protein kinase G (PKG)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Ccdc2-like kinases (CLK) 1 &amp; 2</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">DYRK family of kinases</span></span></li> </ul> </li> <li style="margin-left: 8px;">Applicable to range of kinases, but are not promiscuous kinase inhibitors</li> <li style="margin-left: 8px;">Broad potential commercial applicability for several blockbuster indications, including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li style="margin-left: 8px;">No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-044-2022 E-202-2023 158677441 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 https://pubmed.ncbi.nlm.nih.gov/37082750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37082750/">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750</a> 166884134 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072 https://pubmed.ncbi.nlm.nih.gov/37843072/ <a href="https://pubmed.ncbi.nlm.nih.gov/37843072/">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072</a> 158677389 O'Keefe, Barry NCI O'Keefe, Barry (NCI) 1 158677393 Du, Lin NCI - CCR NCI Du, Lin (NCI) 2 158677397 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677401 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677405 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158677413 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677417 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677421 Li, Ning Leidos Li, Ning (Leidos) 8 158677389 O'Keefe, Barry NCI O'Keefe, Barry (NCI) 1 158677393 Du, Lin NCI - CCR NCI Du, Lin (NCI) 2 158677397 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677401 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677405 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158677413 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677417 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677421 Li, Ning Leidos Li, Ning (Leidos) 8 158677383 Reverse Thiazine Kinase Inhibitors E-162-2024-0 Filing authorized National Cancer Institute (NCI), NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5020] Reverse Thiazine Kinase Inhibitors&body=Please send me information about technology [TAB-5020] Reverse Thiazine Kinase Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5020] Reverse Thiazine Kinase Inhibitors&body=Please send me information about technology [TAB-5020] Reverse Thiazine Kinase Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503194 E-162-2024-0 E-162-2024-0-US-01 Reverse Thiazine Kinase Inhibitors PRV US 63/672,577 Expired US <br />Provisional (PRV) 63/672,577<br />Filed on 2024-07-17<br />Status: Expired TAB-5019 158672233 Novel Kinase Inhibitory Aplithianines NCI Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h3>Summary:</h3> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h3>Description of Technology:</h3> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.), showed broad potential applicability to numerous kinases of importance including but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>This Technology describes the Original Family of compounds filed. Subsequent to this filing, two additional cohorts of related, but patentably distinct Cohorts of compounds have been filed under NIH Ref # &nbsp;<strong>E-202-2023</strong> and <strong>E-164-2024</strong>. Both the Second and the Third Cohorts comprise the same chemical scaffold of the broadest generic formula of this Original Family but represent patentably distinct subgenus formulas.&nbsp;</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-47.png" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting &nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gastric cancer</li> <li>Ultra-rare adolescent liver cancer</li> <li>Solid cancers susceptible to kinase inhibitors</li> <li>Cushing&rsquo;s Disease</li> <li>Transplantation</li> <li>Diabetic neuropathic pain</li> <li>Malaria</li> <li>Protozoa infection&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Applicability to numerous clinically relevant kinases, including: <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> </li> <li>Applicable to a range of kinases, but are not promiscuous kinase inhibitors</li> <li>Broad potential commercial applicability for several blockbuster indications including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li>No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-202-2023 E-162-2024 158672505 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 3708275 : O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 <a href=": O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 3708275</a> 158849587 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 3784307 : O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 37843072 <a href=": O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 37843072">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 3784307</a> 158672259 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158848379 Du, Lin Molecular Targets Program NCI Du, Lin (NCI) 2 158672267 Wilson, Brice NCI Wilson, Brice (NCI) 3 158672273 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 4 158672277 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158672346 Wang, Dongdong National Cancer Institute (NCI) NCI Wang, Dongdong (NCI) 6 158672350 Martinez Fiesco, Juliana National Cancer Institute (NCI) Martinez Fiesco, Juliana 7 158672377 Li, Ning Leidos Li, Ning (Leidos) 8 158672259 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158848379 Du, Lin Molecular Targets Program NCI Du, Lin (NCI) 2 158672267 Wilson, Brice NCI Wilson, Brice (NCI) 3 158672273 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 4 158672277 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158672346 Wang, Dongdong National Cancer Institute (NCI) NCI Wang, Dongdong (NCI) 6 158672350 Martinez Fiesco, Juliana National Cancer Institute (NCI) Martinez Fiesco, Juliana 7 158672377 Li, Ning Leidos Li, Ning (Leidos) 8 158672236 Novel Kinase Inhibitory Aplithianines E-044-2022-0 Filing authorized NCI, NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5019] Novel Kinase Inhibitory Aplithianines&body=Please send me information about technology [TAB-5019] Novel Kinase Inhibitory Aplithianines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5019] Novel Kinase Inhibitory Aplithianines&body=Please send me information about technology [TAB-5019] Novel Kinase Inhibitory Aplithianines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503214 E-044-2022-0 E-044-2022-0-US-01 KINASE INHIBITORS PRV US 63/389,937 Expired US <br />Provisional (PRV) 63/389,937<br />Filed on 2022-07-17<br />Status: Expired 159503219 E-044-2022-0 E-044-2022-0-PCT-01 KINASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2023/070304 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/070304<br />Filed on 2023-07-17<br />Status: Expired 159503239 E-044-2022-0 E-044-2022-0-IN-01 KINASE INHIBITORS National Stage India 202547012577 Pending India <br />National Stage 202547012577<br />Filed on 2025-02-14<br />Status: Pending 159503244 E-044-2022-0 E-044-2022-0-JP-01 KINASE INHIBITORS National Stage Japan 2025-502384 Pending Japan <br />National Stage 2025-502384<br />Filed on 2025-01-16<br />Status: Pending 159503249 E-044-2022-0 E-044-2022-0-CN-01 KINASE INHIBITORS National Stage China 202380062947.2 Pending China <br />National Stage 202380062947.2<br />Filed on 2025-02-28<br />Status: Pending 159503254 E-044-2022-0 E-044-2022-0-US-02 KINASE INHIBITORS National Stage US 18/995,318 Pending US <br />National Stage 18/995,318<br />Filed on 2025-01-16<br />Status: Pending 159503259 E-044-2022-0 E-044-2022-0-EP-01 KINASE INHIBITORS National Stage European Patent 23755549.5 Pending European Patent <br />National Stage 23755549.5<br />Filed on 2025-02-04<br />Status: Pending TAB-5007 158185662 Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies NCI Collaboration, Diagnostics, Immunology, Oncology Collaboration Diagnostics Immunology Oncology James Gulley, Scott Norberg, Andrew Sinkoe, Xiaolin Wu <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-&gamma; response pathways.</p> <h2>Description of Technology:&nbsp;</h2> <p>Immunotherapy is an effective cancer treatment utilizing T cells to recognize and eliminate cancer cells. Antigen processing and presentation machinery (APM) and interferon-&gamma; (IFN) response pathways play an important role for T cells to target cancer cells. To evade immunotherapy, cancer cells can develop somatic mutations in genes important for APM and IFN.&nbsp;<br /> Liquid biopsy is a non-invasive tool that can diagnose and monitor cancer by analyzing circulating tumor DNA (ctDNA). The ability to detect somatic mutations and predict response to immunotherapies using liquid biopsy would be critical to provide more personalized cancer treatment. However, currently marketed liquid biopsies cannot predict response to cellular immunotherapies. As a result, patients with relapsed or recurrent disease lose valuable time and resources on ineffective treatments.</p> <p>The inventors at the National Cancer Institute (NCI) developed a novel method to detect somatic mutations from liquid biopsy samples. Combined with NCI&rsquo;s method to detect loss of heterozygosity in HLA genes &ndash; another mechanism for immunotherapy evasion &ndash; this invention allows for improved patient selection and non-invasive prediction of response. This novel precision medicine method will allow patient-tailored treatment by targeting treatment based on genetic mutations and prediction of immunotherapy response. This invention could potentially deliver better patient satisfaction, lower healthcare costs and better outcomes.</p> <p>The Center for Immuno-Oncology at the NCI is looking for co-development partners and/or licensees. As a companion diagnostic for immunotherapies, this invention will be used to select optimal patients and monitor efficacy of treatments &ndash; such as TCR-T cell therapy. There are no liquid biopsy assays on the market designed as companion diagnostic for cellular immunotherapy &ndash; such as TCR-T cell therapy. Therefore, this technology may be particularly appealing to co-development partners who are developing proprietary cellular immunotherapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Companion diagnostic for cellular immunotherapies</li> <li>Companion diagnostic for monitoring the effectiveness of TCR-based immunotherapies</li> <li>Companion diagnostic for T cell-based immunotherapies, including certain immune checkpoint inhibitors&nbsp;</li> <li>Research use in labs studying/developing new pre-clinical therapeutic candidates</li> <li>Research use in basic research labs studying immunotherapy resistance mechanisms, antigen processing and presentation, interferon-&gamma; response pathways, mutations in cancer cells, basic immunology and basic oncology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First method to predict response to immunotherapies by detecting damaging mutations using liquid biopsy samples</li> <li>Non-invasive test not requiring surgery</li> <li>Easy to administer</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a liquid biopsy analysis method capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. 2024-09-13 2026-04-16 2026-04-16 2024-09-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-045-2022-0 158185678 Norberg, Scott Center for Immuno-Oncology NCI Norberg, Scott (NCI) 1 158185693 Sinkoe, Andrew Sesh Incorporated NCI Sinkoe, Andrew (NCI) 2 158185700 Wu, Xiaolin Genomics Laboratory Leidos Wu, Xiaolin (Leidos) 3 158185717 Gulley, James NCI - CCR NCI Gulley, James (NCI) 4 158185678 Norberg, Scott Center for Immuno-Oncology NCI Norberg, Scott (NCI) 1 158185693 Sinkoe, Andrew Sesh Incorporated NCI Sinkoe, Andrew (NCI) 2 158185700 Wu, Xiaolin Genomics Laboratory Leidos Wu, Xiaolin (Leidos) 3 158185717 Gulley, James NCI - CCR NCI Gulley, James (NCI) 4 158185670 Method of detecting damaging mutations in immune related genes by liquid biopsy Leidos EIR # 23-018 E-027-2024-0 Filing authorized National Cancer Institute (NCI), NCI - FCRDC (Leidos) 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies&body=Please send me information about technology [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies&body=Please send me information about technology [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 159502811 E-027-2024-0 E-027-2024-0-US-01 METHODS OF DETECTING LOSS OF HETEROZYGOSITY AND DAMAGING MUTATIONS IN IMMUNERELATED GENES IN LIQUID BIOPSIES PRV US 63/572,760 Expired US <br />Provisional (PRV) 63/572,760<br />Filed on 2024-04-01<br />Status: Expired TAB-4999 157682678 Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Neurology, Therapeutics Collaboration Ear Nose & Throat Licensing Neurology Therapeutics Wei Li, Jingxing Ou, Tantai Zhao <h2>Description of Technology:</h2> <p>Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS injuries by mediating the immune response and increasing inflammation at the site of injury.&nbsp;</p> <p>Scientists at the National Eye Institute (NEI) have discovered a novel method of reducing neuronal death by using Dimethyl Malonate (DMM), a compound that inhibits the activity of succinate dehydrogenase (SDH). Using DMM on an optic nerve crush model in ground squirrels, DMM helped reduce the pro-inflammatory response of microglia via decreasing succinate levels or reducing the SDH activity. In the same model, treatment also improved the retinal function compared to controls. Additionally, administering DMM after optic crush injury reduced the microglia response and promoted neural protection against axonal injury.&nbsp;</p> <p>This method of treats immune-mediated disorders using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase in patients. It inhibits activation of microglial cells by using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase in cells. It prevents the activation of astrocytes in a system comprising of microglial cells and astrocytes using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase. Overall, these results show the promise of DMM for protecting neurodegeneration due to neural injury and possibly other neurodegenerative disorders.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Ophthalmic diseases, such as glaucoma</li> <li>Neurodegenative diseases, such as multiple sclerosis</li> <li>Acute neural injuries</li> </ul> <h2><strong>Competitive Advantages:&nbsp;</strong></h2> <ul> <li>Dimethyl Malonate (DMM) is inexpensive and readily available &ndash; reducing manufacturing costs</li> <li>Address significant, unmet medical needs since few, if any, treatments exist for neural injuries and neurodegeneration</li> <li>Mutation independent method for treating neurodegeneration</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a novel method of treating neural injury and neurodegeneration via immune-metabolic regulation. 2024-08-08 2026-04-16 2026-04-16 2024-08-23 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158013913 Li, Wei National Eye Institute (NEI) Li, Wei 1 158013991 Ou, Jingxing National Sun Yat-Sen University NEI Ou, Jingxing (NEI) 2 158014042 Zhao, Tantai Zhao, Tantai 3 158013913 Li, Wei National Eye Institute (NEI) Li, Wei 1 158013991 Ou, Jingxing National Sun Yat-Sen University NEI Ou, Jingxing (NEI) 2 158014042 Zhao, Tantai Zhao, Tantai 3 157682681 Metabolic Regulation Of Mitochondria To Inhibit Inflammatory Microglia In Treatment Of Axonal Injury And Neurodegenerations E-077-2018-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration&body=Please send me information about technology [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration&body=Please send me information about technology [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157851175 E-077-2018-0 E-077-2018-0-CN-03 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS National Stage China 201980061762.3 Pending China <br />National Stage 201980061762.3<br />Filed on 2019-08-21<br />Status: Pending 157915564 E-077-2018-0 E-077-2018-0-US-01 Metabolic Regulation Of Mitochondria To Inhibit Inflammatory Microglia In Treatment Of Axonal Injury And Neurodegenerations PRV US 62/720,612 Abandoned US <br />Provisional (PRV) 62/720,612<br />Filed on 2018-08-21<br />Status: Abandoned 157915565 E-077-2018-0 E-077-2018-0-PCT-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS PCT Patent Cooperation Treaty PCT/US2019/047504 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/047504<br />Filed on 2019-08-21<br />Status: Expired 157915566 E-077-2018-0 E-077-2018-0-US-04 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS National Stage US 12,011,426 17/268,203 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011426 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011426">12,011,426</a><br />Filed on 2021-02-12<br />Status: Issued 157915567 E-077-2018-0 E-077-2018-0-US-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS CON US 18/664,615 Abandoned US <br />Continuation (CON) 18/664,615<br />Filed on 2024-05-15<br />Status: Abandoned TAB-4998 157594389 Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Therapeutics Collaboration Ear Nose & Throat Licensing Therapeutics Yu Holly Chen, Wenwei Huang, Zhiji Luo, Anupam Mondal, Samantha Papal, Anand Swaroop, Manju Swaroop, Gregory Tawa, Wei Zheng <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.</p> <h2>Description of Technology:&nbsp;</h2> <p>Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.&nbsp;</p> <p>RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.</p> <p>By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.</p> <p>Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.&nbsp;</p> <p>These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Therapeutic to treat Leber congenital amaurosis</li> <li>Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration</li> <li>Therapeutic to treat AMD</li> <li>Therapeutic to treat mutation-independent ocular diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Less time-consuming, costly and labor intensive versus the development of individualized gene therapies</li> <li>Small molecules are scalable with cost-effective manufacturing</li> <li>Small molecules are highly penetrant with easy routes of administration</li> <li>Small molecules can be delivered via eye drops or as intra-vitreal injection</li> <li>Less intrusive and easy administration route</li> <li>Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection<br /> &nbsp;</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration. 2024-08-02 2026-04-16 2026-04-16 2024-08-05 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157619396 Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211) https://pubmed.ncbi.nlm.nih.gov/36975211/ <a href="https://pubmed.ncbi.nlm.nih.gov/36975211/">Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)</a> 157594396 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 1 157594400 Chen, Yu Holly National Eye Institute (NEI) NEI Chen, Yu Holly (NEI) 2 157594408 Papal, Samantha National Eye Institute (NEI) NEI Papal, Samantha (NEI) 3 157594416 Mondal, Anupam National Eye Institute (NEI) NEI Mondal, Anupam (NEI) 4 157594424 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 5 157594428 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 6 157594432 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 7 157594436 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 8 157594443 Luo, Zhiji Zhiji, Luo Luo, Zhiji 9 157594396 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 1 157594400 Chen, Yu Holly National Eye Institute (NEI) NEI Chen, Yu Holly (NEI) 2 157594408 Papal, Samantha National Eye Institute (NEI) NEI Papal, Samantha (NEI) 3 157594416 Mondal, Anupam National Eye Institute (NEI) NEI Mondal, Anupam (NEI) 4 157594424 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 5 157594428 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 6 157594432 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 7 157594436 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 8 157594443 Luo, Zhiji Zhiji, Luo Luo, Zhiji 9 157594392 Small Molecule Drug Candidates And Disease-associated Signature Genes For Therapeutic Interventions In Retinal Degeneration E-071-2020-0 Filing authorized National Eye Institute (NEI), NCATS - NCGC 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157595034 E-071-2020-0 E-071-2020-0-US-01 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME PRV US 63/047,858 Abandoned US <br />Provisional (PRV) 63/047,858<br />Filed on 2020-07-02<br />Status: Abandoned 157595066 E-071-2020-0 E-071-2020-0-PCT-02 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2021/040157 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040157<br />Filed on 2021-07-01<br />Status: Expired 164119845 E-071-2020-0 E-071-2020-0-AU-04 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage Australia 2021300425 Pending Australia <br />National Stage 2021300425<br />Filed on 2022-12-08<br />Status: Pending 164119846 E-071-2020-0 E-071-2020-0-CA-05 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME National Stage Canada 3186586 Pending Canada <br />National Stage 3186586<br />Filed on 2021-07-01<br />Status: Pending 164119847 E-071-2020-0 E-071-2020-0-EP-06 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage European Patent 21751672.3 Pending European Patent <br />National Stage 21751672.3<br />Filed on 2021-07-01<br />Status: Pending 164119848 E-071-2020-0 E-071-2020-0-JP-07 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME National Stage Japan 2022-581456 Pending Japan <br />National Stage 2022-581456<br />Filed on 2022-12-28<br />Status: Pending 164119849 E-071-2020-0 E-071-2020-0-US-08 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage US 18/014,045 Pending US <br />National Stage 18/014,045<br />Filed on 2022-12-30<br />Status: Pending 165783069 E-071-2020-0 E-071-2020-0-JP-01 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME DIV Japan 2026-019246 Pending Japan <br />Divisional (DIV) 2026-019246<br />Filed on 2026-02-09<br />Status: Pending TAB-4993 157247834 Improved Methods For Cryopreservation Of Cells, Tissues, And Organs NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Research Materials Application Collaboration Ear Nose & Throat Licensing Research Materials Lihao Ge, Guanghui Jin, Wei Li, Kiyoharu Miyagishima, Jingxing Ou <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for novel methods of cryopreserving cells, tissues, and organs via FOXO1 activation and other mechanisms.</p> <h2>Description of Technology:&nbsp;</h2> <p>The cornea is a critical part of the eye that helps prevent debris from entering and refracts light for proper vision. Corneal disorders such as keratoconus, Fuchs dystrophy, and infectious keratitis require corneal transplantation to restore vision. Approximately 185,000 corneal transplants are performed annually worldwide to treat corneal disorders. Corneas for those transplants are supplied by donor eyes that are stored at eye banks in select countries.&nbsp;</p> <p>Currently, Optisol-GS&trade; is the corneal preservation solution that is most widely used to store donated corneas at eye banks. Per National Eye Institute (NEI) guidelines, corneas preserved in Optisol-GS&trade; have a 12-day shelf life. With the high demand for corneal transplantations worldwide, a 12-day shelf life cannot meet the requirement for long term cryogenic storage of corneas at large eye banks.&nbsp;</p> <p>Scientists at the NEI have developed improved methods for cryopreservation of cells, tissues, and organs (with focus of corneal tissue/cells) that increases cold storage shelf life 2.5 times longer than current market products.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Corneal biobanks</li> <li>Transplantation to remedy a wide range of corneal disorders</li> <li>Improved method of cryopreserving corneal cells and other cell types</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior corneal shelf life: 16-day compared to 12-day maximum shelf-life of current market products&nbsp;</li> <li>Better meets requirement for larger eye bank cryopreservation</li> <li>95% endothelial cell survival after 4 weeks in cold storage</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for improved methods of cryopreservation of cells, tissues, and organs via FOXO1 activation. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True discovery (LeadID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-073-2018 157266800 Ou, Jingxing National Eye Institute (NEI) NEI Ou, Jingxing (NEI) 1 157266831 Miyagishima, Kiyoharu National Eye Institute (NEI) NEI Miyagishima, Kiyoharu (NEI) 2 157266888 Jin, Guanghui Sun Yat-sen University Jin, Guanghui 3 157266928 Li, Wei National Eye Institute (NEI) NEI Li, Wei (NEI) 4 157266932 Ge, Lihao NINDS NINDS Ge, Lihao (NINDS) 5 157266800 Ou, Jingxing National Eye Institute (NEI) NEI Ou, Jingxing (NEI) 1 157266831 Miyagishima, Kiyoharu National Eye Institute (NEI) NEI Miyagishima, Kiyoharu (NEI) 2 157266888 Jin, Guanghui Sun Yat-sen University Jin, Guanghui 3 157266928 Li, Wei National Eye Institute (NEI) NEI Li, Wei (NEI) 4 157266932 Ge, Lihao NINDS NINDS Ge, Lihao (NINDS) 5 157247837 Regulations Of FOXO1A Pathway Protect Cells, Tissues, And Organs Against Stresses And Insults E-013-2021-0 Filing authorized National Eye Institute (NEI), NINDS, Sun Yat-sen University 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs&body=Please send me information about technology [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs&body=Please send me information about technology [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157266992 E-013-2021-0 E-013-2021-0-US-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage US 18/258,125 Pending US <br />National Stage 18/258,125<br />Filed on 2023-06-16<br />Status: Pending 157267002 E-013-2021-0 E-013-2021-0-CA-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage Canada 3202729 Pending Canada <br />National Stage 3202729<br />Filed on 2023-06-19<br />Status: Pending 157267007 E-013-2021-0 E-013-2021-0-AU-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE ENVIRONMENT National Stage Australia 2021400321 Abandoned Australia <br />National Stage 2021400321<br />Filed on 2023-06-23<br />Status: Abandoned 157267018 E-013-2021-0 E-013-2021-0-CN-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage China 202180094031.6 Pending China <br />National Stage 202180094031.6<br />Filed on 2023-08-17<br />Status: Pending 157267084 E-013-2021-0 E-013-2021-0-EP-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE ENVIRONMENT National Stage European Patent 21844141.8 Pending European Patent <br />National Stage 21844141.8<br />Filed on 2023-07-17<br />Status: Pending 164119806 E-013-2021-0 E-013-2021-0-PCT-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE PCT Patent Cooperation Treaty PCT/US2021/064086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/064086<br />Filed on 2021-12-17<br />Status: Expired 164119807 E-013-2021-0 E-013-2021-0-CN-01 PREPARATION METHOD AND APPLICATION OF CELL, TISSUE OR ORGAN COLD PRESERVATION LIQUID ORD China ZL202011500962.5 202011500962.5 Issued China <br />Ordinary Patent (ORD) 202011500962.5<br />Filed on 2020-12-17<br />Status: Issued TAB-4992 157246749 Using Artificial Intelligence To Diagnose Uveitis NEI Collaboration, Diagnostics, Ear, Nose, & Throat, Licensing Collaboration Diagnostics Ear Nose & Throat Licensing Jongwoo Kim, Shilpa Kodati, Nam Nguyen <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can identify retinal vasculitis using color fundus images.</p> <h2>Description of Technology:&nbsp;</h2> <p>Uveitis is caused by inflammation in the eye that can cause pain and reduce vision. The rate of uveitis in the United States is 1 in every 200 people with eye-related irritation. Permanent symptoms such as vision loss can occur if untreated. Therefore, early detection is crucial.&nbsp;</p> <p>In certain uveitis cases, fluorescein angiography (FA) is essential for the diagnosis and management due to its ability to display retinal vascular leakage (RVL). Although proven to be critical in diagnosing and assessing severity, FA is invasive and side effects have been reported. Additionally, the procedure is time-consuming and imposes economic burdens to patients, physicians and payors.&nbsp;</p> <p>Scientists at the NEI have developed a deep learning tool to non-invasively detect RVL using ultrawide-field color fundus photos. This algorithm identifies fundus images with and without RVL with high accuracy (79%) and sensitivity (85%). Compared to the current gold standard of assessing RVL (clinician interpretation), this deep learning tool provides an improved method of detecting RVL for patients with uveitis.</p> <h2>Potential Commercial Applications:</h2> <p>&bull; Diagnostic tool to predict uveitis&nbsp;<br /> &bull; Add-on to current color fundus imaging modalities</p> <h2>Competitive Advantages:</h2> <p>&bull; Greater accuracy and sensitivity versus current gold standard to assess RVL (clinician assessment)<br /> &bull; Deep learning tool to assess RVL<br /> &bull; Deep learning to assess ultrawide-field color fundus images and assess RVL</p> Researchers at the NEI seek licensing and/or co-development research collaborations for a deep learning algorithm that can identify retinal vasculitis using color fundus images. 2024-07-22 2026-04-16 2026-04-16 2024-07-23 False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157246892 Young LH, et al. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept. (PMID 35877095). https://pubmed.ncbi.nlm.nih.gov/35877095/ <a href="https://pubmed.ncbi.nlm.nih.gov/35877095/">Young LH, et al. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept. (PMID 35877095).</a> 157246764 Kodati, Shilpa University of Michigan NEI Kodati, Shilpa (NEI) 1 157246768 Kim, Jongwoo NLM Kim, Jongwoo 2 157246772 Nguyen, Nam National Eye Institute (NEI) Nguyen, Nam 3 157246764 Kodati, Shilpa University of Michigan NEI Kodati, Shilpa (NEI) 1 157246768 Kim, Jongwoo NLM Kim, Jongwoo 2 157246772 Nguyen, Nam National Eye Institute (NEI) Nguyen, Nam 3 157246752 Deep Learning To Detect Retinal Vasculitis On Ultrawide-Field Color Fundus Photos E-005-2023-0 Filing authorized National Eye Institute (NEI), NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis&body=Please send me information about technology [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis&body=Please send me information about technology [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157246801 E-005-2023-0 E-005-2023-0-US-01 Deep Learning to Detect Retinal Vasculitis on Color Fundus Photos of Patients with Uveitis PRV US 63/482,676 Expired US <br />Provisional (PRV) 63/482,676<br />Filed on 2023-02-01<br />Status: Expired 159507671 E-005-2023-0 E-005-2023-0-PC-01 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS PCT Patent Cooperation Treaty PCT/US2024/013833 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/013833<br />Filed on 2024-01-31<br />Status: Expired 164119786 E-005-2023-0 E-005-2023-0-US-02 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS National Stage US 19/153,124 Pending US <br />National Stage 19/153,124<br />Filed on 2025-08-01<br />Status: Pending 164119787 E-005-2023-0 E-005-2023-0-EP-01 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS National Stage European Patent 24710954.9 Pending European Patent <br />National Stage 24710954.9<br />Filed on 2025-08-12<br />Status: Pending TAB-4991 157206100 TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Rare/Neglected Diseases, Therapeutics Application Collaboration Ear Nose & Throat Licensing Ophthalmology Rare/Neglected Diseases Therapeutics Brian Brooks, Aman George <h2>Summary:</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair, skin and eyes. The absence of pigmentation is caused by insufficient melanin production &ndash; an important pigment providing normal black color to important eye tissues such as the iris and retinal pigment epithelium. Lack of melanin in the eye results in abnormal development and impaired vision. Individuals diagnosed with OCA1, the most common type if albinism worldwide (1:40,000 people), is caused by mutations in the TYROSINASE (TYR) gene. OCA1A patients suffer complete loss of melanin caused by inactivity of the TYROSINASE enzyme. Currently, there is no treatment.&nbsp;&nbsp;</p> <p>Scientist at the National Eye Institute (NEI) have developed a gene therapy method for inducing pigmentation in human subjects who have OCA1A by administering the normal copy of human Tyrosinase via an adeno-associated viral (AAV) vector. Experiments in albino rat eyes showed that the AAV-Tyr construct localized to the tissue of interest (retinal pigment epithelium or RPE) and increased melanin production. Introducing the AAV-Tyr construct in OCA1A patient derived RPE also showed increased pigment density, demonstrating the construct&rsquo;s therapeutic potential to increase melanin production in vivo and in affected patient cells.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gene therapy for OCA1A</li> <li>Therapy for other TYROSINASE enzyme deficient eye disease</li> <li>Platform for AAV gene therapy for retinal pigment epithelium cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses medical need with no treatment options</li> <li>Low damage to eye</li> <li>Potential one-time injection</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. 2024-07-19 2026-04-16 2026-04-16 2024-07-19 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157206257 Brooks, Brian National Eye Institute (NEI) NEI Brooks, Brian (NEI) 1 157206261 George, Aman Ophthalmic Genetics Visual Function Branch NEI George, Aman (NEI) 2 157206257 Brooks, Brian National Eye Institute (NEI) NEI Brooks, Brian (NEI) 1 157206261 George, Aman Ophthalmic Genetics Visual Function Branch NEI George, Aman (NEI) 2 157206103 TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A E-116-2023-0 Filing authorized National Eye Institute (NEI), Ophthalmic Genetics Visual Function Branch 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A&body=Please send me information about technology [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A&body=Please send me information about technology [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157206338 E-116-2023-0 E-116-2023-0-US-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PRV US 63/468,748 Expired US <br />Provisional (PRV) 63/468,748<br />Filed on 2023-05-24<br />Status: Expired 157206461 E-116-2023-0 E-116-2023-0-PC-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PCT Patent Cooperation Treaty PCT/US2024/031101 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/031101<br />Filed on 2024-05-24<br />Status: Expired 164119766 E-116-2023-0 E-116-2023-0-US-02 Method for inducing pigmentation in human subjects who have Oculocutaneous albinism type 1A (OCA1A) or other clinically-defined pigmentation related condition due to a loss-of-function mutation in the gene encoding the TYROSINASE enzyme, the method comprises of administering to the patients a nucleic acid of human TYROSINASE cDNA using an adeno-associated viral vector. PRV US Administratively Closed US <br />Provisional (PRV) None<br />Filed on None<br />Status: Administratively Closed 164725054 E-116-2023-0 E-116-2023-0-CA-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage Canada 3293242 Pending Canada <br />National Stage 3293242<br />Filed on 2025-11-21<br />Status: Pending 164725184 E-116-2023-0 E-116-2023-0-US-03 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage US 19/486,763 Pending US <br />National Stage 19/486,763<br />Filed on 2025-11-21<br />Status: Pending 164725219 E-116-2023-0 E-116-2023-0-EP-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage European Patent 24734696.8 Pending European Patent <br />National Stage 24734696.8<br />Filed on 2025-12-16<br />Status: Pending TAB-4982 155467337 Fluorinated MU-Opioid Receptor Agonists NIDA Application, Collaboration, Immunology, Licensing, Neurology, Radiology, Therapeutics Application Collaboration Immunology Licensing Neurology Radiology Therapeutics Michael Baumann, Juan Gomez, Michael ("Mike") Michaelides, Kenner Rice, Agnieszka Sulima <h2>Summary:&nbsp;</h2> <p>Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds.</p> <h2>Description of Technology:&nbsp;</h2> <p>Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come with debilitating side effects. These include addiction, respiratory distress, hyperalgesia, and constipation. Therefore, there is a need for alternatives with lower adverse effects.</p> <p>Investigators at NIDA have identified a novel fluorinated mu-opioid receptor agonist, Fluornitrazene (FNZ), a derivative of Etonitazene, that shows potent antinociceptive effects with low adverse effects. This compound does not accumulate in the brain or cause hyperalgesia. It has higher potency than morphine and fentanyl, but with fewer adverse effects. These characteristics make it and any derivatives useful as potential pain medications or anesthetics, and as therapeutics for treating opioid addiction or opioid use disorder. Compared to fentanyl, FNZ has greater potency and efficacy for the G protein activation pathway of the MOR and a lower incidence of respiratory depression in rats. This suggests that FNZ may be a better alternative to fentanyl in clinical use.</p> <p>Investigators seek co-development opportunities through cooperative research and development agreement (CRADA) collaborations. This technology is also available for development under a license.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Pain prevention or pain management</li> <li>Anesthetic&nbsp;</li> <li>Opioid addiction or opioid use disorder</li> <li>PET agonist radiotracer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Reduced time in brain</li> <li>High potency</li> <li>MOR Selective</li> <li>No known hyperalgesia or tolerance</li> <li>Reduced side effects &ndash; such as respiratory depression&nbsp;</li> </ul> Researchers at the NIDA seek licensing and/or co-development research collaborations for research collaboration. 2024-04-17 2026-04-16 2026-04-16 2024-04-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 155467354 Michaelides, Michael ("Mike") NIDA - Biomedical Research Center NIDA Michaelides, Michael ("Mike") (NIDA) 1 155467358 Gomez, Juan NIDA - Biomedical Research Center NIDA Gomez, Juan (NIDA) 2 155467362 Rice, Kenner National Institute on Drug Abuse (NIDA) Rice, Kenner 3 155467366 Sulima, Agnieszka NIDA - Biomedical Research Center NIDA Sulima, Agnieszka (NIDA) 4 155467370 Baumann, Michael NIDA - Biomedical Research Center NIDA Baumann, Michael (NIDA) 5 155467354 Michaelides, Michael ("Mike") NIDA - Biomedical Research Center NIDA Michaelides, Michael ("Mike") (NIDA) 1 155467358 Gomez, Juan NIDA - Biomedical Research Center NIDA Gomez, Juan (NIDA) 2 155467362 Rice, Kenner National Institute on Drug Abuse (NIDA) Rice, Kenner 3 155467366 Sulima, Agnieszka NIDA - Biomedical Research Center NIDA Sulima, Agnieszka (NIDA) 4 155467370 Baumann, Michael NIDA - Biomedical Research Center NIDA Baumann, Michael (NIDA) 5 155467340 Selective and potent biased mu opioid receptor agonist with low adverse effects E-053-2023-0 Filing authorized NIDA - Biomedical Research Center 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4982] Fluorinated MU-Opioid Receptor Agonists&body=Please send me information about technology [TAB-4982] Fluorinated MU-Opioid Receptor Agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4982] Fluorinated MU-Opioid Receptor Agonists&body=Please send me information about technology [TAB-4982] Fluorinated MU-Opioid Receptor Agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 155467380 E-053-2023-0 E-053-2023-0-US-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PRV US 63/452,879 Expired US <br />Provisional (PRV) 63/452,879<br />Filed on 2023-03-17<br />Status: Expired 155467385 E-053-2023-0 E-053-2023-0-PCT-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PCT Patent Cooperation Treaty PCT/US2023/082355 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/082355<br />Filed on 2023-12-04<br />Status: Expired TAB-4828 152146471 T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use NCI Application, Licensing, Research Materials, TherapeuticArea Application Licensing Research Materials TherapeuticArea Catherine Ade, Kenichi Hanada, Matthew Sporn, James Yang, Zhiya Yu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research.</p> <h2>Description of Technology:</h2> <p>Tumor-specific mutated proteins can create immunogenic, mutation-containing &ldquo;neoepitopes&rdquo; which are attractive targets for adoptive T-cell therapies. There has been major interest in the field in targeting common shared mutations in driver genes, such as KRAS, using off-the-shelf T-cell receptors (TCRs) engineered into autologous lymphocytes. However, identifying the neoepitopes to pursue as therapeutics is a complex and challenging process. One method to demonstrate whether an epitope is presented at the cell surface is to elute peptides bound to a specific human leukocyte antigen (HLA) allele and analyze them by mass spectrometry (MS). These MS data can then be prospectively applied to isolate TCRs specific to the neoepitope.</p> <p>Using this MS methodology, investigators at the Surgery Branch have identified TCRs that can recognize the G13D substitution mutation of KRAS in the context of HLA-A11:01. Importantly, the G13D mutation of KRAS is an attractive target for adoptive cell therapy as it is highly mutated in cancers (e.g., KRAS is found to be mutated in 45% of all colorectal carcinoma patients, and about 16% of these patients have the G13D mutation). Furthermore, approximately 15% of the US population has the HLA-A11:01 allele.</p> <p>This is the first known report of HLA-A11:01-restricted TCRs that can recognize KRAS G13D. The identified TCRs have high specificity and immunogenicity for the G13D mutation and can recognize processed and presented antigen on the surface of cells. While these TCRs are not effective as therapeutics, they would be useful for identification of other KRAS G13D reactive TCRs in patient and animal models.</p> <p>The National Cancer Institute (NCI) seeks licensees for T Cell Receptors (TCRs) targeting the KRAS G13D mutation for potential use in research.</p> <h2>Potential Commercial Applications&nbsp;</h2> <ul> <li>Research use</li> <li>Diagnostic use</li> <li>Use as positive controls to identify other HLA-A11:01 KRAS G13D reactive T cells from different patient and/or animal models</li> <li>Use as negative controls in other research applications</li> </ul> <h2>Competitive Advantages</h2> <ul> <li>The KRAS G13D TCRs are highly specific and immunogenic</li> <li>&nbsp;G13D is a common mutation of the KRAS driver gene in cancers, making it an attractive target for immunotherapy</li> <li>The HLA-A11:01 allele is present in about 15% of the US population and up to 60% of the Asian and Oceanian populations</li> <li>The results indicate that Mass Spectrometry is an effective and accurate way to detect antigens on specific HLA complexes</li> </ul> The NCI seeks licensees for T Cell Receptors (TCRs) targeting KRAS mutation G13D for use as a research tool. 2024-01-11 2026-04-16 2026-04-16 2024-01-16 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 152204876 Publications: Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652) https://pubmed.ncbi.nlm.nih.gov/37758652/ <a href="https://pubmed.ncbi.nlm.nih.gov/37758652/">Publications: Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652)</a> 152199868 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152199916 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 2 152200031 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 152200061 Yang, James NCI - CCR NCI Yang, James (NCI) 4 152200083 Hanada, Kenichi NCI - CCR NCI Hanada, Kenichi (NCI) 5 152199868 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152199916 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 2 152200031 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 152200061 Yang, James NCI - CCR NCI Yang, James (NCI) 4 152200083 Hanada, Kenichi NCI - CCR NCI Hanada, Kenichi (NCI) 5 152146474 Identification and cloning of KRAS G13D/A11_mTCR3 and KRAS G13D/A11_mTCR7, two T cell receptors targeting the KRAS G13D mutation on HLA-A1101+ cells E-006-2024-0 Closed NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use&body=Please send me information about technology [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use&body=Please send me information about technology [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-5091 166130102 Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics S. Patricia Becerra, Alexandra Bernardo-Colon, Andrea Bighinati, Valeria Marigo <h2>Summary:&nbsp;&nbsp;</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.&nbsp;</p> <h2>Description of Technology:&nbsp;&nbsp;</h2> <p>Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) &ndash; estimated to affect 1 in 4,000 people worldwide. Over 100,000 people in the US and 1.5 million people worldwide suffer from RP. This disease leads to progressive photoreceptor cell degeneration and, ultimately, vision loss. More than 90 genes are implicated in molecular pathways towards photoreceptor cell death. Due to this high heterogeneity, therapeutic approaches targeting specific genes generally benefit few patients. For most forms of RP, few or no medical options are available. Thus, there remains a need to identify new and more effective treatments for RP and other inherited retinal degenerations. Mutation-independent strategies to protect photoreceptors against continued damage and degradation are appealing approaches.&nbsp;&nbsp;</p> <p>To delay photoreceptor degeneration, we propose using neurotrophic molecules as a mutation-independent approach using pigment epithelium-derived factor (PEDF). PEDF is a multifunctional member of the serine proteinase inhibitor (serpin) family with neurotrophic and antiangiogenic properties in the retina. Researchers at the NEI developed a peptide of 17 amino acid residues (17-mer) from the receptor-binding domain of PEDF. It contains amino acid substitution at position 105 from a histidine to an alanine (PEDF 17-mer[H105A]). H105A exhibits a highly potent protective effect on photoreceptors using in vivo mouse models of RP.&nbsp;&nbsp;</p> <p>The technology encompasses two delivery approaches for this proprietary peptide: (1) an eyedrop formulation and/or (2) an Adeno-Associated Vector 2 (AAV2). A sustained delivery system delivers the 17-mer [H105A] to treat or prevent photoreceptor degradation and vision loss in patients with IRDs (e.g., retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, Stargardt-like macular degeneration or maculopathy) or age-related macular degenerations (AMD). The technology is available for licensing and co-development.&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;&nbsp;</h2> <ul> <li>Minimally invasive therapy to prevent photoreceptor degeneration in retinal disorders (IRDs and AMD)&nbsp;</li> <li>Retinitis Pigmentosa (RP), macular degeneration, and other related diseases&nbsp;</li> <li>AAV2 vectors for delivery of genes to retinal cells both preventative and therapeutic&nbsp;</li> <li>Prevent disease progression to late-stage RP&nbsp;</li> </ul> <h2>Competitive Advantages:&nbsp;</h2> <ul> <li>Favorable safety profile&nbsp;</li> <li>Large addressable market given applications to IRDs and AMD (USD 13.7 billion in 2023 and an estimated compound annual growth rate (CAGR) of 9.6% from 2024 to 2032&nbsp;</li> <li>Partially established regulatory path, as their AAV2 vector is identical to Luxturna, an FDA-approved therapy for retinal dystrophy&nbsp;</li> <li>Superior diffusion and penetrability than biologics&nbsp;</li> <li>Demonstrably less immunogenicity and lower production costs than biologics&nbsp;</li> <li>Eye drop formulation has larger addressable market&nbsp;</li> <li>Eye drop formulation provides easy administration route&nbsp;&nbsp;</li> <li>Broad-spectrum therapeutic approach:&nbsp;&nbsp; <ul> <li>PEDF mimics the natural protective process lost in patients with inherited eye diseases&nbsp;</li> <li>Protective effects on photoreceptors are independent of the gene mutations causing degeneration&nbsp;</li> </ul> </li> <li>Chemically synthesized bioactive peptide solutions are free of inactive ingredients, causing fewer secondary effects than mixed formulations&nbsp;</li> </ul> Researchers at the ​NEI​ seek ​licensing and/or co-development research collaborations ​ for the development of an AVV2-based delivery system or an eyedrop formulation to deliver a PEDF peptide as a gene-agnostic approach to treating inherited retinal diseases. 2026-02-23 2026-03-24 2026-04-14 2026-03-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-156-2023 166427821 Bernardo-Colón A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996) https://pubmed.ncbi.nlm.nih.gov/40118996/ <a href="https://pubmed.ncbi.nlm.nih.gov/40118996/">Bernardo-Colón A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996)</a> 166427825 Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127) https://pubmed.ncbi.nlm.nih.gov/33008127/ <a href="https://pubmed.ncbi.nlm.nih.gov/33008127/">Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127)</a> 166427828 Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815) https://pubmed.ncbi.nlm.nih.gov/30980815/ <a href="https://pubmed.ncbi.nlm.nih.gov/30980815/">Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815)</a> 166427831 Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116) https://pubmed.ncbi.nlm.nih.gov/26304116/ <a href="https://pubmed.ncbi.nlm.nih.gov/26304116/">Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116)</a> 166427764 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166427768 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 2 166427772 Marigo, Valeria University of Modena and Reggio Emilia Marigo, Valeria 3 166427779 Bighinati, Andrea University of Modena and Reggio Emilia Bighinati, Andrea 4 166427764 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166427768 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 2 166427772 Marigo, Valeria University of Modena and Reggio Emilia Marigo, Valeria 3 166427779 Bighinati, Andrea University of Modena and Reggio Emilia Bighinati, Andrea 4 166130105 In Vivo Assay For Drug Discovery And Detection Of Photoreceptor Survival Factors: Discovery Of The PEDF Peptide 17- mer[H105A] E-028-2023-0 Filing authorized National Eye Institute (NEI), University of Modena and Reggio Emilia, University of Modena and Reggio Emilia 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration&body=Please send me information about technology [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration&body=Please send me information about technology [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166130110 E-028-2023-0 E-028-2023-0-US-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION PRV US 63/430,251 Expired US <br />Provisional (PRV) 63/430,251<br />Filed on 2022-12-05<br />Status: Expired 166130111 E-028-2023-0 E-028-2023-0-PC-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION PCT Patent Cooperation Treaty PCT/US2023/064947 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/064947<br />Filed on 2023-03-24<br />Status: Expired 166130112 E-028-2023-0 E-028-2023-0-JP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Japan 2025-555099 Pending Japan <br />National Stage 2025-555099<br />Filed on 2025-06-04<br />Status: Pending 166130113 E-028-2023-0 E-028-2023-0-CA-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Canada 3275801 Pending Canada <br />National Stage 3275801<br />Filed on 2025-06-03<br />Status: Pending 166130114 E-028-2023-0 E-028-2023-0-AU-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Australia 2023390868 Pending Australia <br />National Stage 2023390868<br />Filed on 2025-06-05<br />Status: Pending 166130115 E-028-2023-0 E-028-2023-0-US-02 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage US 19/135,668 Pending US <br />National Stage 19/135,668<br />Filed on 2025-06-04<br />Status: Pending 166130116 E-028-2023-0 E-028-2023-0-EP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage European Patent 23720018.3 Pending European Patent <br />National Stage 23720018.3<br />Filed on 2025-07-01<br />Status: Pending 166849971 E-028-2023-0 E-028-2023-0-HK-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION EP Hong Kong 62026121881.7 Pending Hong Kong <br />European patent (EP) 62026121881.7<br />Filed on 2026-04-15<br />Status: Pending TAB-5096 166779508 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio CDC Collaboration Sought, Diagnostics, Endocrinology, Geriatrics, Hematology, Obstetrics/Neo-Natal, Reproductive Health, Research Materials, TherapeuticArea, Urology Collaboration Sought Diagnostics Endocrinology Geriatrics Hematology Obstetrics/Neo-Natal Reproductive Health Research Materials TherapeuticArea Urology Ashley Ribera, Hubert Vesper, Hui Zhou <p>CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.</p> <p>&nbsp;Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.&nbsp;&nbsp;</p> <ul> <li> Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings. </li> <li> Public Health: Use of the dialysis microplate to provide dialysis testing services for customers. </li> </ul> <ul> <li> Diagnostics: Meets the criteria of American National Standards Institute (ANSI). </li> <li> Research Materials. </li> </ul> The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov. 2026-04-08 2026-04-10 2026-04-10 2026-04-10 False True Clinical Assay Development Stage True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 166779738 Ribera, Ashley Battelle Memorial Institute CDC Ribera, Ashley (CDC) 1 166779783 Zhou, Hui CDC - DIR CDC Zhou, Hui (CDC) 2 166779790 Vesper, Hubert CDC - DIR CDC Vesper, Hubert (CDC) 3 166779738 Ribera, Ashley Battelle Memorial Institute CDC Ribera, Ashley (CDC) 1 166779783 Zhou, Hui CDC - DIR CDC Zhou, Hui (CDC) 2 166779790 Vesper, Hubert CDC - DIR CDC Vesper, Hubert (CDC) 3 166779511 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio E-101-2023-0 Filing authorized CDC - DIR 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.">dawn.taylor-mulneix@nih.gov</a><br> 166779516 E-101-2023-0 E-101-2023-0-US-01 MULTI-WELL DIALYSIS MICROPLATE PRV US 63/551,965 Expired US <br />Provisional (PRV) 63/551,965<br />Filed on 2024-02-09<br />Status: Expired 166779517 E-101-2023-0 E-101-2023-0-PC-01 MULTI-WELL DIALYSIS MICROPLATE PCT Patent Cooperation Treaty PCT/US2025/014980 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/014980<br />Filed on 2025-02-07<br />Status: Pending TAB-5097 166811027 Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Catherine Ade, Kenichi Hanada, Vid Leko, Aidan Pursley, James Yang, Zhiya Yu <h2>Summary:&nbsp;</h2> <p>The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.</p> <h2>Description of Technology:&nbsp;</h2> <p>Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis and a 5-year survival rate of ~33%. Current treatments, including intensive chemotherapy and stem cell transplantation, are not suitable for all patients and can cause significant toxicities, including low blood cell counts, infection and graft-versus-host disease. Therefore, there is a need for safer and more effective treatments.&nbsp;</p> <p>This specific invention concerns the isolation of two highly specific T cell receptors (TCRs), known as TCR6 and TCR7, recognizing a neoepitope, AVEEVSLRK. The neoepitope is derived from mutant Nucleophosmin 1 (NPM1) and presented in the context of HLA-A*11:01. Pre-clinical results for these TCRs revealed robust and specific cytotoxicity against a leukemia cell line and several patient-derived AML samples expressing the NPM1 mutation and HLA-A*11:01. Furthermore, they showed no cross-reactivity to normal peripheral blood mononuclear cells, structurally similar peptides or unrelated HLA alleles. These results suggest these novel TCRs represent a potential adoptive T cell therapy for the treatment of AML.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Acute myeloid leukemia patients expressing HLA-A*11:01.&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly specific targeting of mutant NPM1</li> <li>Minimed off-target effects with enhanced safety profile</li> <li>&bull;Significant unmet medical need for AML patients</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. 2026-04-10 2026-04-10 2026-04-10 2026-04-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 166811280 https://ashpublications.org/blood/article/146/Supplement%201/4132/555170/T-cell-receptors-targeting-mutant-NPM1-for https://ashpublications.org/blood/article/146/Supplement%201/4132/555170/T-cell-receptors-targeting-mutant-NPM1-for 166811062 Leko, Vid NIH - NCI NCI Leko, Vid (NCI) 1 166811066 Pursley, Aidan NIH - NCI NCI Pursley, Aidan (NCI) 2 166811070 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 166811074 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 166811086 Ade, Catherine NIH - NCI NCI Ade, Catherine (NCI) 5 166811092 Yang, James NIH - NCI NCI Yang, James (NCI) 6 166811062 Leko, Vid NIH - NCI NCI Leko, Vid (NCI) 1 166811066 Pursley, Aidan NIH - NCI NCI Pursley, Aidan (NCI) 2 166811070 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 166811074 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 166811086 Ade, Catherine NIH - NCI NCI Ade, Catherine (NCI) 5 166811092 Yang, James NIH - NCI NCI Yang, James (NCI) 6 166811031 NPM1 mutation-specific T cell receptors for treatment of HLA-A*11:01-positive acute myeloid leukemia E-200-2025-0 Filing authorized NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia&body=Please send me information about technology [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia&body=Please send me information about technology [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 166811036 E-200-2025-0 E-200-2025-0-US-01 NUCLEOPHOSMIN 1 MUTATION-SPECIFIC T CELL RECEPTORS PRV US 63/908,266 Pending US <br />Provisional (PRV) 63/908,266<br />Filed on 2025-10-30<br />Status: Pending TAB-5073 163873358 Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Lauren Cutmore, James Kochenderfer <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the &gamma;&delta; T-Cell Receptor.</p> <h2>Description of Technology:</h2> <p>T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha beta) and gd (gamma delta). T cells expressing the gd TCR are detected at lower frequencies compared with T cells expressing the ab TCR. gd T cells make up 0.3-10% of peripheral blood T cells. The gd TCR is expressed on the cell surface of several aggressive cancers, including &ndash; but not limited to &ndash; hepatosplenic T-cell lymphoma, primary cutaneous gd T-cell lymphoma and T-cell acute lymphoblastic leukemia (T-ALL). These cancers carry poor prognosis as they are often resistant to chemotherapy. In addition, to their roles in cancer development, gd T cells may also play role in autoimmune diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis and myositis. There is evidence that gd T cells are involved in initiation or persistence of these autoimmune diseases. To this end, new treatment options are needed for gd T-cell malignancies and autoimmune diseases.</p> <p>Researchers at the National Cancer Institute (NCI) have developed several CARs targeting the gd TCR. These CARs can specifically bind to and immunologically recognize human gd TCR. Binding of the CAR to the gd TCR elicits an immune response that allows for killing of cells expressing this TCR.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of &gamma;&delta; T cell cancers <ul> <li>hepatosplenic T-cell lymphoma</li> <li>primary cutaneous gd T-cell lymphoma</li> <li>T-ALL</li> </ul> </li> <li>Treatment of &gamma;&delta; T cell autoimmune diseases <ul> <li>psoriasis</li> <li>rheumatoid arthritis</li> <li>multiple sclerosis</li> <li>myositis</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Promising new treatment option for several major market opportunities, including gd T cell malignancies and autoimmune diseases</li> <li>Promising new treatment option for patients resistant to chemotherapy</li> <li>In vivo proof-of-concept studies completed</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor, and if applicable, CARs that target the αβ T-Cell Receptor, too. 2025-08-25 2025-08-25 2026-04-08 2025-08-25 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163873535 Kochenderfer JN, et al. Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor. https://doi.org/10.1182/blood-2024-204126 <a href="https://doi.org/10.1182/blood-2024-204126">Kochenderfer JN, et al. Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor.</a> 163873409 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 163873416 Cutmore, Lauren NIH - NCI NCI Cutmore, Lauren (NCI) 2 163873409 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 163873416 Cutmore, Lauren NIH - NCI NCI Cutmore, Lauren (NCI) 2 163873361 Development of chimeric antigen receptors targeting the gamma-delta T-cell receptor E-214-2024-0 Filing authorized NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor&body=Please send me information about technology [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor&body=Please send me information about technology [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 163873366 E-214-2024-0 E-214-2024-0-US-01 CHIMERIC ANTIGEN RECEPTORS TARGETING THE GAMMA DELTA T CELL RECEPTOR PRV US 63/678,625 Expired US <br />Provisional (PRV) 63/678,625<br />Filed on 2024-08-02<br />Status: Expired 163873367 E-214-2024-0 E-214-2024-0-PC-01 CHIMERIC ANTIGEN RECEPTORS TARGETING THE GAMMA DELTA T CELL RECEPTOR PCT Patent Cooperation Treaty PCT/US2025/040252 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/040252<br />Filed on 2025-08-01<br />Status: Pending TAB-5056 162401133 Oral Iron-Chelator Therapy for Treating Developmental Stuttering NINDS Licensing, Neurology, Psychiatry/Mental Health, Therapeutics Licensing Neurology Psychiatry/Mental Health Therapeutics Shahriar SheikhBahaei <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology discloses the use of small-molecule iron chelators&mdash;drugs that bind and remove excess iron&mdash;for the oral treatment of developmental stuttering in children and adults. Mouse models carrying human stuttering mutations show both elevated striatal iron and impaired vocalization; daily low-dose deferiprone reverses these speech-like deficits while normalizing brain-iron MRI signals. Because exemplary chelators deferiprone, deferasirox, and deferoxamine are already marketed for other indications, their safety, dosing, and manufacturing are well characterized, enabling a streamlined regulatory path. The approach offers the first disease-targeted pharmacologic option for a disorder currently managed only by speech therapy.</span></span></span></p> <ul> <li>First-in-class, mechanism-based therapy for stuttering, addressing a $3 B underserved global market with no approved drugs.</li> <li>Repurposes FDA-approved iron chelators, leveraging extensive safety data and oral formulations for rapid Phase II entry and lower development risk.</li> <li>Quantifiable biomarker (MRI R2* brain-iron signal) enables patient stratification and objective efficacy read-outs, enhancing trial efficiency and market differentiation.</li> </ul> <ul> <li>Stand-alone or adjunctive pharmacotherapy for persistent developmental stuttering in pediatric and adult populations.</li> <li>MRI-guided precision treatment platform for speech-motor disorders linked to basal-ganglia iron dysregulation.</li> <li>Expansion into related neurodevelopmental or movement disorders where excess neural iron contributes to pathophysiology.</li> </ul> 2025-05-13 2025-07-31 2026-04-08 2025-06-13 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162401172 SheikhBahaei, Shahriar Stony Brook University SheikhBahaei, Shahriar 1 162401172 SheikhBahaei, Shahriar Stony Brook University SheikhBahaei, Shahriar 1 162401136 Iron Chelators as potential therapeutics for stuttering E-186-2023-0 Filing authorized NIH - NINDS 162927805 Iron Chelators as potential therapeutics for stuttering E-186-2023-1 Filing authorized NIH - NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering&body=Please send me information about technology [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering&body=Please send me information about technology [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering.">susan.ano@nih.gov</a><br> 162401141 E-186-2023-0 E-186-2023-0-US-01 Use of Iron Chelators for Treating Stuttering PRV US 63/510,794 Expired US <br />Provisional (PRV) 63/510,794<br />Filed on 2023-06-28<br />Status: Expired 162401143 E-186-2023-1 E-186-2023-1-PC-01 Use of Iron Chelators for Treating Stuttering PCT Patent Cooperation Treaty PCT/US2024/036062 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/036062<br />Filed on 2024-06-28<br />Status: Expired 164857199 E-186-2023-1 E-186-2023-1-US-01 Uses of Iron Chelators for Treating Stuttering National Stage US 19/496,195 Pending US <br />National Stage 19/496,195<br />Filed on 2025-12-22<br />Status: Pending 164857219 E-186-2023-1 E-186-2023-1-EP-01 Uses of Iron Chelators for Treating Stuttering National Stage European Patent 24742436.9 Pending European Patent <br />National Stage 24742436.9<br />Filed on 2026-01-05<br />Status: Pending TAB-3363 114097266 Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Dennis Bagarozzi, Jason Goldstein, Madhavan Nallani Padmanabha Zika virus infection during pregnancy can cause microcephaly and other severe birth defects. The CDC Zika MAC-ELISA (IgM antibody capture enzyme-linked immunosorbent assay) currently used for diagnosis detects antibodies produced to fight a Zika virus infection. However, reactivity of flavivirus antibodies (from exposure to other mosquito-borne infections such as dengue or West Nile virus) can complicate the interpretation of these results. <br /><br /> CDC and partner researchers have developed six monoclonal antibodies (mAbs) from hybridoma technology with high sensitivity to the Zika virus (ZIKV) pre-membrane/envelope (ENV) protein and limited cross-reactivity to other flaviviruses, notably dengue virus. Multiple methods such as indirect ELISA, bio-layer interferometry (BLI), immunoblotting, immunofluorescence, and plaque reduction neutralization tests (PRNTs) were used to validate the data. Additionally, ZIKV pre-membrane/envelope protein is a candidate biomarker for diagnosis during active infection vs. serological tests (based on identification of IgM and/or IgG) after clearance of infection. The technology can be used for immunoassay development and immunodiagnostic reagents for clinical sample and tissue confirmation of ZIKV. The mAbs also offer improved differentiation between ZIKV and related flaviviruses. <ul> <li>May be used for diagnosis during active Zika virus infection vs. serological tests (based on identification of IgM and/or IgG) after clearance of infection</li> <li>Offers higher sensitivity than many commercial and academic mAbs available to detect ZIKV</li> <li>Limited cross-reactivity with other flaviviruses</li> <li>High affinity mAbs (bind more quickly to the antigen and with a stronger bond)</li> </ul> <ul> <li>Engineering of mAbs for commercial diagnostic applications</li> <li>Clinical diagnostic assay to detect active Zika virus infection</li> <li>Multiple platforms such as immunoassay, lateral flow diagnostics, and nanotechnology device capable of interfacing with smartphone/digital technology</li> <li>ENV protein target is a valid target for diagnostic development with the understanding that a sufficient viral load needs to be present</li> <li>These mAbs may serve in a competition serological assay for dengue (or other closely related flaviviruses) where clinical IgG/IgM that do not compete with these ZIKV-specific mAbs for r-Env or VLP, can exclude a previous ZIKV infection</li> <li>Immunodiagnostic reagents for confirmation of Zika virus in clinical samples (e.g., serum, saliva and/or urine) or tissue</li> <li>Differentiation between Zika and related flaviviruses such as dengue, yellow fever or West Nile viruses</li> <li>Can be useful in more generalized diagnostic assay development to detect all flaviviruses</li> <li>Research tool, monitoring and public health surveillance</li> <li>Antiviral efficacy testing in animal models</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2025-04-24 2026-04-02 2019-02-22 antibodies, Development, Diagnostics, monoclonal, NCEZID, NCEZID-DSR, Novel, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, YBXXXX, Zika False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-286-2016-0 E-341-2013-0 E-341-2013-1 E-081-2017-0 E-107-2016-1 114110009 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114110011 Nallani Padmanabha, Madhavan ACM Biolabs Private Limited Nallani Padmanabha, Madhavan 0 114110010 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114110010 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114110009 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114110011 Nallani Padmanabha, Madhavan ACM Biolabs Private Limited Nallani Padmanabha, Madhavan 0 114102510 Development Of Zika Virus Monoclonal Antibodies For Research, Development And Novel Diagnostics E-030-2017-0 Research Material ACM Biolabs Private Limited, Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research&body=Please send me information about technology [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research&body=Please send me information about technology [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research.">benjamin.hurley@nih.gov</a><br> 114168845 E-030-2017-0 E-030-2017-0-US-01 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ZIKA VIRUS INFECTION PRV US 62/622,521 Abandoned US <br />Provisional (PRV) 62/622,521<br />Filed on 2018-01-26<br />Status: Abandoned 114128232 YBXXXX 114128233 VLXXXX 114128234 WBXXXX 114128235 WFXXXX 114128236 WIXXXX 114128237 XAXXXX 114151572 Development 114151573 Zika 114151574 virus 114151575 monoclonal 114151576 antibodies 114151577 Novel 114151578 Diagnostics 114151579 NCEZID 114151580 NCEZID-DSR TAB-5058 162672189 First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02) NCATS Cardiology, Dermatology, Geriatrics, Oncology, Pulmonology, Reproductive Health, Research Materials, Therapeutics Cardiology Dermatology Geriatrics Oncology Pulmonology Reproductive Health Research Materials Therapeutics Alexander Agoulnik, Irina Agoulnik, Ana Cabrera, Mark Henderson, Wenwei Huang, Joshua Hutcheson, Jiankang Jiang, Abhijeet Kapoor, Bing Li, Juan Marugan, Khalida Shamim, Noel Southall, Kenneth Wilson, Wenjuan Ye <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">NCATS in collaboration with Florida International University (FIU) and </span></span>University of South Florida<span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous <span style="color:black">cancers, fibrotic, and vascular disorders</span>.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast <span style="color:black">cancer, solid tumors, atherosclerosis, and liver fibrosis</span>. </span></span></p> <ul><li>First and only small molecule agonists of RXFP1</li><li>Potent and highly selective</li><li>Bioavailable with excellent exposure</li><li>Easy to synthesize and scale-up</li></ul> <ul><li>Vascular health</li><li>Fibrotic diseases</li><li>Cancers</li><li>Human reproductive health</li></ul> Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules. Licensing Contact: Jasmine Kalsi, M.S. Email: jasmine.kalsi@nih.gov Telephone: 301.435.0129 2025-05-29 2025-05-30 2026-04-01 2025-05-29 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 162672380 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 162672384 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 2 162672393 Wilson, Kenneth National Center for Advancing Translational Sciences Wilson, Kenneth 3 162672397 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 4 162672401 Ye, Wenjuan NCATS - NCGC NCATS Ye, Wenjuan (NCATS) 5 162672410 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 6 162672414 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 7 162672418 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 8 162672422 Li, Bing National Center for Advancing Translational Sciences Li, Bing 9 162672458 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 10 162672621 Kapoor, Abhijeet Florida International University (FIU) Kapoor, Abhijeet 11 162672761 Hutcheson, Joshua Florida International University (FIU) Hutcheson, Joshua 12 162672791 Cabrera, Ana Florida International University (FIU) Cabrera, Ana 13 162672896 Agoulnik, Irina Florida International University (FIU) Agoulnik, Irina 14 162672380 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 162672384 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 2 162672393 Wilson, Kenneth National Center for Advancing Translational Sciences Wilson, Kenneth 3 162672397 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 4 162672401 Ye, Wenjuan NCATS - NCGC NCATS Ye, Wenjuan (NCATS) 5 162672410 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 6 162672414 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 7 162672418 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 8 162672422 Li, Bing National Center for Advancing Translational Sciences Li, Bing 9 162672458 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 10 162672621 Kapoor, Abhijeet Florida International University (FIU) Kapoor, Abhijeet 11 162672761 Hutcheson, Joshua Florida International University (FIU) Hutcheson, Joshua 12 162672791 Cabrera, Ana Florida International University (FIU) Cabrera, Ana 13 162672896 Agoulnik, Irina Florida International University (FIU) Agoulnik, Irina 14 162672192 NCGC00846044 is a novel functionally selective RXFP1 agonist with exceptional properties E-145-2024-0 Filing authorized Florida International University (FIU), National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, NCATS - NCGC, NCATS - NCGC, NCATS - TRND, University of South Florida 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02). Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).">jasmine.kalsi@nih.gov</a><br> 162672197 E-145-2024-0 E-145-2024-0-US-01 RFXP1 AGONISTS PRV US 63/757,235 Expired US <br />Provisional (PRV) 63/757,235<br />Filed on 2025-02-11<br />Status: Expired 162672198 E-145-2024-0 E-145-2024-0-US-02 RFXP1 AGONISTS PRV US 63/780,976 Expired US <br />Provisional (PRV) 63/780,976<br />Filed on 2025-03-31<br />Status: Expired 166692346 E-145-2024-0 E-145-2024-0-PC-01 RFXP1 AGONISTS PCT Patent Cooperation Treaty PCT/US2026/021648 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/021648<br />Filed on 2026-03-31<br />Status: Pending TAB-4989 156774528 Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Infectious Disease Licensing Research Materials Cherelle Dacon, Joshua Tan <p>Malaria is one of the worlds deadliest infectious diseases, causing an estimated 249 million cases and 608,000 deaths annually, with children in the regions of Africa and South Asia being most vulnerable. Approx 2,000 cases of malaria are reported in the United States each year, by travelers from malaria-risk countries. Malaria is a mosquito-borne parasitic disease transmitted through the bite of infected female mosquitoes, which introduces Plasmodium sporozoites into the bloodstream of the human host. There are five Plasmodium parasite species that cause malaria in humans, of which, the vast majority of life-threatening cases are caused by infection with Plasmodium falciparum parasites. Researchers at NIAID have developed 11 human monoclonal antibodies that bind to a unique site on the circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites that is not targeted by any known monoclonal antibodies. These antibodies do not bind to recombinant forms of CSP and as such bind to a processed or post-translational form of the protein processed by the sporozoites. In vivo studies have shown several of these antibodies can substantially reduce liver parasite burden in a mouse model of malaria. These antibodies can work cooperatively with known antibodies that target the repeat region of CSP. Some of these novel antibodies have shown enhanced protection in an animal model when combined with known protective monoclonal antibodies against sporozoites, suggesting that together they may form an effective cocktail to prevent malaria.</p> <ul> <li>These antibodies bind to a unique site on the circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites that is distinct from the targets of pre-existing mAbs.</li> <li>These monoclonal antibodies can be used alone or in combination with existing antibodies.</li> </ul> <ul> <li>Prophylactic and preventative treatment against malaria.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include: (a) testing developability of these antibodies (e.g., biophysical characteristics, cross-reactivity, pharmacokinetics, toxicity), (b) pre-clinical model assessment, and (c) human clinical trials. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189, or dawn.taylor-mulneix@nih.gov. 2024-06-26 2025-05-29 2026-03-30 2024-06-27 False False <ul> <li>Pre-Clinical</li> </ul> True 37470483 Website Abstract E-212-2022-0 156774781 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156774785 Dacon, Cherelle National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dacon, Cherelle (NIAID) 2 156774781 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156774785 Dacon, Cherelle National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dacon, Cherelle (NIAID) 2 156774531 Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites E-212-2022-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites&body=Please send me information about technology [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites&body=Please send me information about technology [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4509 151706142 High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis NHLBI Diagnostics, Licensing, Medical Devices, Research Materials Diagnostics Licensing Medical Devices Research Materials Alan Koretsky, Nikorn Pothayee, Deepak Sail, Rolf Swenson <p>This technology includes a peptide containing alternating Alanine and Lys(DOTA-Gd) residues can be used to increase the MRI relaxivity of a peptide. The low molecular weight construct can be appended to proteins, antibodies and peptides to increase MRI signals. This approach offers advantages over previous dendrimeric constructs. The increased MRI signal may allow effective neuronal tracing of peptides that when misfolded and transported from the gut to the brain may lead to inflammation and serious diseases including Alzheimer&rsquo;s (A-beta), Parkinson&rsquo;s Disease, Lewey Body Dementia, and Multiple Systems atrophy (alpha synuclein), Creutzfeld-Jakob disease, and Amyotrophic lateral sclerosis.</p> Multivalent chelated Gd can be efficiently constructed on a peptide scaffold, with substantial increase in relaxivity (i.e., higher MRI signal), with minimum molecular weight increase and can be efficiently added to proteins, antibodies, and proteins for targeted MRI applications in disease diagnosis. For use in diagnostic MRI applications. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2026-03-26 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706190 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151706194 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 2 151706198 Pothayee, Nikorn NINDS NINDS Pothayee, Nikorn (NINDS) 3 151706203 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 4 151706190 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151706194 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 2 151706198 Pothayee, Nikorn NINDS NINDS Pothayee, Nikorn (NINDS) 3 151706203 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 4 151706145 High Relaxivity Mulitivalent Gadolinium On A Peptide Scaffold E-146-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NINDS 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis&body=Please send me information about technology [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis&body=Please send me information about technology [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis.">malabika.ghosh@nih.gov</a><br> 157755246 E-146-2019-0 E-146-2019-0-US-01 HIGH RELAXIVITY MULITIVALENT GADOLINIUM ON A PEPTIDE SCAFFOLD PRV US 62/873,272 Abandoned US <br />Provisional (PRV) 62/873,272<br />Filed on 2019-07-12<br />Status: Abandoned TAB-2905 114097066 LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders NIAID Cardiology, Dental, Endocrinology, Immunology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Immunology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Atsushi Kitani, Warren Strober, Tetsuya Takagawa Use of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing inflammatory disorders of the gastrointestinal tract.<br /><br /> LRRK2 is a kinase encoded by a gene that contains a non-coding polymorphism (SNP). LRRK2 has been associated with and is a risk factor for inflammatory bowel disease. NIH inventors have shown that human cells expressing this SNP have increased levels of LRRK2 and, correspondingly, mice with increased levels of LRRK2 exhibit more severe Dextran Sulfate colitis. In various studies of the role of LRRK2 in cell signaling, NIH inventors have shown that increased levels of LRRK2 lead to increased pro-inflammatory cytokine secretion. Also, an inhibitor of LRRK2 is shown to abrogate the pro-inflammatory activity of LRRK2 both <em>in vitro</em> and <em>in vivo</em>. <ul> <li>A LRRK2 inhibitor would be a unique form of anti-inflammatory therapy that will complement or compete with an array of cytokines in primary treatment for lBD.</li> <li>A LRRK2 inhibitor would provide a much needed alternate mode of therapy.</li> </ul> <ul> <li>Treatment for or prevention of Intestinal Bowel Disorders.</li> </ul> 2022-03-08 2026-03-26 2026-03-26 2015-01-26 COLITIS, Crohn's, Disease, IB3XXX, inhibitor, LRRK2, TREAT, Ulcerative, VPXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108958 Takagawa, Tetsuya NIAID - DIR NIAID Takagawa, Tetsuya (NIAID) 0 114108959 Kitani, Atsushi NIAID - DIR NIAID Kitani, Atsushi (NIAID) 0 114108957 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114108957 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114108958 Takagawa, Tetsuya NIAID - DIR NIAID Takagawa, Tetsuya (NIAID) 0 114108959 Kitani, Atsushi NIAID - DIR NIAID Kitani, Atsushi (NIAID) 0 114102240 Use Of LRRK2 Inhibitor To Treat Ulcerative Colitis And Crohn's Disease E-070-2014-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders&body=Please send me information about technology [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders&body=Please send me information about technology [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders.">polung.yang@nih.gov</a><br> 114161781 E-070-2014-0 E-070-2014-0-US-03 Treatment or Prevention of an Intestinal Disease or Disorder National Stage US 10,058,559 15/311,405 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058559 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058559">10,058,559</a><br />Filed on 2016-11-15<br />Status: Issued 114167061 E-070-2014-0 E-070-2014-0-PCT-02 Treatment or Prevention of an Intestinal Disease or Disorder PCT Patent Cooperation Treaty PCT/US2015/031200 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/031200<br />Filed on 2015-05-15<br />Status: Expired 114168055 E-070-2014-0 E-070-2014-0-US-01 TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER PRV US 61/993,637 Abandoned US <br />Provisional (PRV) 61/993,637<br />Filed on 2014-05-15<br />Status: Abandoned 114126812 IB3XXX 114126813 VPXXXX 114126814 WKXXXX 114126815 XEXXXX 114126816 YAXXXX 114126817 YBXXXX 114126818 YCXXXX 114148050 LRRK2 114148051 inhibitor 114148052 TREAT 114148053 Ulcerative 114148054 COLITIS 114148055 Disease 114148056 Crohn's TAB-1758 114095987 Muramyl Dipeptide as a Therapeutic Agent for Inflammation NIAID Collaboration, Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Immunology Licensing Research Materials Therapeutics Warren Strober The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation of NOD2 by MDP negatively regulates the activity of TLR2, and thus reduces inflammation. <br><br> The inventors have demonstrated that administration of MDP prevents the development of experimental colitis in mice. They have also determined that MDP reduces pro-inflammatory cytokine production from multiple Toll-like receptors, and that this reduction arises from the induction of IFN regulatory factor 4 (IRF4). The technology includes methods of treating or preventing inflammation associated with an autoimmune disorder, particularly inflammatory bowel disease, via administration of muramyl peptide; also included are methods of reducing symptoms characteristic of inflammation via administration of muramyl peptide. This technology has potential as an anti-inflammatory therapy for autoimmune or other inflammation-associated diseases, particularly inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The NIAID Laboratory of Host Defenses, Mucosal Immunity Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact either Rosemary Walsh or Charles Rainwater at 301-496-2644 for more information. This technology is available for exclusive or non-exclusive licensing. 2022-03-08 2026-03-26 2026-03-26 2008-05-01 Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis False True <i>In vivo</i> data are available in an experimental colitis mouse model, and <i>in vitro</i> data supporting mechanism of action also are available. <i>In vivo</i> data are available in an experimental colitis mouse model, and <i>in vitro</i> data supporting mechanism of action also are available. True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170513 T Watanabe et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559. http://www.ncbi.nlm.nih.gov/pubmed/18188453?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18188453?dopt">T Watanabe et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559.</a> 114106058 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114106058 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114100985 Adminstration Of Muramyl Dipeptide (MDP) For The Treatment Of Inflammatory Bowel Disease (IBD) E-110-2006-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation&body=Please send me information about technology [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation&body=Please send me information about technology [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation.">polung.yang@nih.gov</a><br> 114164239 E-110-2006-0 E-110-2006-0-PCT-02 USE OF MURAMYL DIPEPTIDE (MDP) FOR TREATING INFLAMMATION PCT Patent Cooperation Treaty PCT/US2007/086117 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/086117<br />Filed on 2007-11-30<br />Status: Expired 114164444 E-110-2006-0 E-110-2006-0-US-01 USES OF MURAMYL DIPEPTIDE COMPOSITIONS FOR TREATING AND PREVENTING INFLAMMATION PRV US 60/872,384 Abandoned US <br />Provisional (PRV) 60/872,384<br />Filed on 2006-12-01<br />Status: Abandoned 114165302 E-110-2006-0 E-110-2006-0-US-03 Use Of Muramyl Dipeptide (MDP) For Treating Inflammation National Stage US 8,603,978 12/516,633 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603978 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603978">8,603,978</a><br />Filed on 2009-05-28<br />Status: Issued 114118678 IB3XXX 114118679 IBXXXX 114118680 IXXXXX 114120845 BBXXXX 114121282 BCXXXX 114130858 Ulcerative Colitis 114130859 Muramyl 114130860 Dipeptide 114130861 MDP 114130862 Crohn's disease 114130863 inflammatory bowel disease 114130864 INFLAMMATORY 114130865 BOWEL 114130866 inflammatory disease 114130867 IBD 114130868 Autoimmune 114130869 AUTOIMMUNE DISEASE 114130870 Autoimmune disorder 114130871 Autoimmunity 114130872 peptidoglycan 114130873 NOD2 114130874 TLR 114130875 TLR2 114130876 Toll-like 114130877 Toll-like receptors 114130878 Inflammation 114130879 INTERLEUKIN-12 114130880 INTERLEUKIN 114130881 IL-12 114130882 IRF4 114156529 Inflammatory bowel disease 1 114158348 Crohn disease; Inflammatory bowel disease 1 TAB-1364 114095691 Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules NIAID Diagnostics, Immunology, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Immunology Licensing Reproductive Health Research Materials Therapeutics Vaccines Stefan Fichtner-Feigl, Koji Kawakami, Atsushi Kitani, Peter Mannon, Jan Preiss, Raj Puri, Warren Strober Ulcerative colitis (UC) is a chronic inflammatory disease of the colorectum and affects approximately 400,000 people in the United States. The cause of UC is not known, although an abnormal immunological response to bacterial antigens in the gut microflora is thought to be involved. Present treatments for UC include anti-inflammatory therapy using aminosalicylates or corticosteroids, as well as immunomodulators and diet. However, 25-40% of ulcerative colitis patients must eventually have their colons removed due to massive bleeding, severe illness, rupture of the colon, risk of cancer or due to side effects of corticosteroids and novel treatments are still actively being sought. NIH scientists and their collaborators have used a mouse model of experimental colitis (oxazolone colitis, OC) to show that IL-13, a Th2 cytokine, is a significant pathologic factor in OC and that neutralizing IL-13 in these animals effectively prevents colitis.<br /><br /> OC is a colitis induced by intrarectal administration of a relatively low dose of the haptenating agent oxazolone subsequent to skin sensitization with oxazolone. A highly reproducible and chronic colonic inflammation is obtained that is histologically similar to human ulcerative colitis. Studies show that Natural Killer T (NKT) cells, rather than conventional CD4+T cells, mediate oxazolone colitis and are the source of IL-13 as well as being activated by CD1- expressing intestinal epithelial cells. Tissue removed from ulcerative colitis patients were also shown to contain increased numbers of nonclassical NKT cells that produce markedly increased amounts of IL-13 and that in keeping with epithelial damage being a key factor in UC, these NKT cells are cytotoxic for epithelial cells. Building on their previous work, scientists at NIAID and FDA have shown that an Il-13 chimeric fusion protein linked to an effector molecule was able to prevent colitis in a mouse model of ulcerative colitis.<br /><br /> Available for licensing are methods for treating or preventing the inflammatory response of IBD by inhibiting the binding of IL-13 to IL-13 receptors on NKT cells. Additionally, these mutant and chimeric Il-13 molecules are able to block the chronic inflammatory response that results in fibrosis as seen in Crohn's disease. Preventing the inflammatory response of colitis by either modulating or blocking IL-13 and NKT cell activity continues to be an effective therapeutic approach in animal models of colitis with implications for the treatment of human ulcerative colitis and for the treatment of fibrosis associated with Crohn's disease. 2022-03-08 2026-03-26 2026-03-26 2006-06-01 Crohn disease; Inflammatory bowel disease 1, IB3XXX, IB6XXX, IBXXXX, Inflammatory bowel disease 1, IXXXXX False True True NIHTT 37470483 Website Abstract E-131-2002-0 114171191 Heller F, et al. http://www.ncbi.nlm.nih.gov/pubmed/12433369 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12433369">Heller F, et al.</a> 114171192 Fuss IJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/15146247 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15146247">Fuss IJ, et al.</a> 114105505 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105506 Mannon, Peter NIAID Mannon, Peter (NIAID) 0 114105507 Preiss, Jan Preiss, Jan 0 114105508 Puri, Raj FDA Puri, Raj (FDA) 0 114105509 Kawakami, Koji FDA Kawakami, Koji (FDA) 0 114105510 Fichtner-Feigl, Stefan Fichtner-Feigl, Stefan 0 114105511 Kitani, Atsushi NIAID Kitani, Atsushi (NIAID) 0 114105505 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105506 Mannon, Peter NIAID Mannon, Peter (NIAID) 0 114105507 Preiss, Jan Preiss, Jan 0 114105508 Puri, Raj FDA Puri, Raj (FDA) 0 114105509 Kawakami, Koji FDA Kawakami, Koji (FDA) 0 114105510 Fichtner-Feigl, Stefan Fichtner-Feigl, Stefan 0 114105511 Kitani, Atsushi NIAID Kitani, Atsushi (NIAID) 0 114100606 Treatment And Prevention Of Inflammatory Bowel Disease (IBD) Using Mutant And Chimeric IL-13 Molecules E-003-2005-0 Filing authorized FDA, NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules&body=Please send me information about technology [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules&body=Please send me information about technology [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules.">polung.yang@nih.gov</a><br> 114163448 E-003-2005-0 E-003-2005-0-US-01 Treatment and prevention of IBD using Mutant and Chimeric Il-13 Molecules PRV US 60/671,624 Abandoned US <br />Provisional (PRV) 60/671,624<br />Filed on 2005-04-15<br />Status: Abandoned 114163451 E-003-2005-0 E-003-2005-0-US-03 Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells National Stage US 9,072,716 11/918,711 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9072716 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9072716">9,072,716</a><br />Filed on 2008-11-10<br />Status: Expired 114166207 E-003-2005-0 E-003-2005-0-PCT-02 Methods of Treating and Preventing Inflammatory Bowel Disease Involving IL-13 and NKT Cells PCT Patent Cooperation Treaty PCT/US2006/014393 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/014393<br />Filed on 2006-04-14<br />Status: Expired 114117242 IB3XXX 114117243 IB6XXX 114117244 IBXXXX 114117246 IXXXXX 114156177 Inflammatory bowel disease 1 114158182 Crohn disease; Inflammatory bowel disease 1 TAB-5095 166536297 Gene Editing for ALPK1 p.Thr237Met NIAID Application, Collaboration Sought, Rare/Neglected Diseases, ResearchProducts, TherapeuticArea Application Collaboration Sought Rare/Neglected Diseases ResearchProducts TherapeuticArea Uimook Choi, Christina Kozycki, Colin Sweeney <p>ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient&rsquo;s DNA. This method uses a base editor combined with a guide RNA to safely and efficiently convert the pathogenic thymine of the mutation back to cytosine. In laboratory tests, this gene editing technology successfully repaired the mutation in patient-derived affected cells with high accuracy and no side effects.</p> <p>This therapy could be delivered directly to the eye or salivary glands, or patient cells could be corrected outside the body and then returned to the patient, offering hope for personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.</p> <ul> <li>Highly accurate tool that directly repairs the faulty gene that causes ROSAH syndrome, while avoiding unwanted changes elsewhere in DNA</li> <li>Corrects the mutation in most patient cells with few or no mistakes</li> <li>Can be delivered directly to affected areas (e.g., eye or salivary glands) or can treat patient cells outside the body</li> <li>Custom therapy for people with the ALPK1 mutation</li> <li>Effective in cells that don’t divide, unlike older gene editing methods</li> </ul> <ul> <li>Personalized therapy for individuals with disease secondary to the ALPK1 p.Thr237Met genetic variant</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Area of specific interest includes human clinical trials. For collaboration opportunities, please contact David Yang at 240-695-6406, or David.Yang@niaid.nih.gov. 2026-03-23 2026-03-26 2026-03-26 2026-03-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 166536410 Kozycki, Christina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kozycki, Christina (NIAID) 1 166536424 Sweeney, Colin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sweeney, Colin (NIAID) 2 166538687 Choi, Uimook National Institute of Allergy and Infectious Diseases (NIAID/NIH) Choi, Uimook 3 166536410 Kozycki, Christina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kozycki, Christina (NIAID) 1 166536424 Sweeney, Colin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sweeney, Colin (NIAID) 2 166538687 Choi, Uimook National Institute of Allergy and Infectious Diseases (NIAID/NIH) Choi, Uimook 3 166536300 Gene editing for ALPK1 p.Thr237Met E-044-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-5095] Gene Editing for ALPK1 p.Thr237Met&body=Please send me information about technology [TAB-5095] Gene Editing for ALPK1 p.Thr237Met. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-5095] Gene Editing for ALPK1 p.Thr237Met&body=Please send me information about technology [TAB-5095] Gene Editing for ALPK1 p.Thr237Met.">polung.yang@nih.gov</a><br> 166536305 E-044-2024-0 E-044-2024-0-US-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME PRV US 63/733,836 Expired US <br />Provisional (PRV) 63/733,836<br />Filed on 2024-12-13<br />Status: Expired 166536306 E-044-2024-0 E-044-2024-0-PC-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME PCT Patent Cooperation Treaty PCT/US2025/059432 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/059432<br />Filed on 2025-12-12<br />Status: Pending TAB-4568 151739556 Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use NIAMS Human Cell Lines, Materials Available, Neurology, Research Materials Human Cell Lines Materials Available Neurology Research Materials Nasir Malik, Mahendra Rao, Xianmin Zeng <p>This technology includes an innovative method for differentiating astrocytes from neural stem cells (NSCs). The process involves using Life Technologies StemPro embryonic stem cell serum-free medium to initially guide NSCs towards a neuronal lineage. Over a period of 28-35 days, as the cells are continually passaged, neurons gradually die off, leading to the proliferation of astrocytes. By the end of this differentiation protocol, approximately 70% of the cells exhibit markers characteristic of mature astrocytes, specifically GFAP. Additionally, this method allows for the astrocytes to be frozen at early stages and later thawed to continue their differentiation into the astrocyte lineage. This technology stands out from previous methods by significantly enhancing the efficiency and speed of astrocyte derivation. The potential applications of this technology are extensive, including facilitating research into astrocyte development mechanisms and providing a scalable way to produce astrocytes for potential clinical applications in cellular replacement therapies for brain and spinal cord injuries.</p> This astrocyte differentiation technology offers a competitive advantage by enabling the efficient and rapid generation of mature astrocytes, surpassing previous methods in both speed and efficacy. The technology holds promise for advancing research in astrocyte development and could be pivotal in cellular replacement therapies for treating brain and spinal cord injuries. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2026-03-25 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739563 Malik, Nasir NINDS NINDS Malik, Nasir (NINDS) 1 151739567 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739571 Zeng, Xianmin Buck Institute for Research on Aging [US] Zeng, Xianmin 3 151739563 Malik, Nasir NINDS NINDS Malik, Nasir (NINDS) 1 151739567 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739571 Zeng, Xianmin Buck Institute for Research on Aging [US] Zeng, Xianmin 3 151739559 Astrocyte Differentiation Of Neural Stem Cells With StemPro Embryonic Stem Cell Serum Free Medium E-612-2013-0 Research Material Buck Institute for Research on Aging [US], NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use&body=Please send me information about technology [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use&body=Please send me information about technology [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use.">vlado.knezevic@nih.gov</a><br> TAB-5057 162516862 Synergistic Interactions for Improved Cancer Treatment NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Barbara Felber, Sevasti Karaliota, George Pavlakis, Dimitrios Stellas <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.</p> <h2>Description of Technology:</h2> <p>Immunotherapy has emerged as a promising treatment strategy for many types of cancer. However, a major challenge is &ldquo;exhausted&rdquo; tumor-infiltrating immune cells, which lose their ability to effectively eliminate cancer cells. To address this issue, researchers are exploring ways to reverse immune exhaustion and improve treatment outcomes. One potential approach involves interleukin-15 (IL-15), a cytokine that promotes the growth and killing ability of tumor-specific CD8+ T cells and NK cells. IL-15, either alone or in combination with other agents, has shown some promise in clinical trials. However, its use is hindered by toxicity at effective doses. Therefore, there is a critical need for safer and more effective combinations to improve patient outcomes.</p> <p>Inventors at the National Cancer Institute previously developed heterodimeric IL-15 (hetIL-15), composed of IL-15 and IL-15 receptor alpha (NIH Reference # E-254-2005, E-257-2009, E-141-2008, E-054-2013, and E-070-2015). The inventors now demonstrate novel combinations of hetIL-15 with other active agents to enhance the metabolic fitness of intratumoral lymphocytes to provide therapeutic improvement. Specifically, the combination of hetIL-15 and Fenofibrate, a cholesterol-lowering drug, increased cytotoxic T cell activity and provided an almost complete eradication of triple negative breast cancer tumors, including metastatic lesions. &nbsp;Similar results occurred in a mouse pancreatic cancer model. Using a mouse orthotopic breast cancer model, hetIL-15 combined with quizartinib &ndash; a potent Fms-like tyrosine kinase 3 (Flt3) inhibitor &ndash; resulted in a significant tumor growth delay and complete eradication of tumors in 50% of mice after 16 days of treatment. Additionally, the inventors constructed a fusion protein of IL-15 and IL-12 that controls metastatic disease in a mouse melanoma model.&nbsp; These novel combinations would be particularly useful for the treatment of triple negative breast or pancreatic cancer.</p> <p>The National Cancer Institute seeks parties interested in collaborative research and/or licensees to further develop this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for triple negative breast cancer</li> <li>Treatment for pancreatic cancer</li> <li>Treatment of solid tumors for which cellular immunotherapy outcomes are diminished due to T or NK cell exhaustion</li> <li>Treatment of solid tumors for which IL-15-based therapy is diminished due to toxicity at clinically relevant doses</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel combination showing improved therapeutic potential in several solid cancers, including breast cancer and melanoma</li> <li>Combination of hetIL-15 with agents already approved (Fenofibrate, Flt-3) decreases regulatory risk and thus expedites commercialization</li> <li>Overcoming IL-15 toxicity at clinically relevant doses</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for translating hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy, into a therapeutic for the treatment of cancer. 2025-05-19 2025-06-27 2026-03-19 2025-06-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-254-2005 E-257-2009 E-141-2008 E-054-2013 E-070-2015 162518109 Karaliota S, et al. "Tumor eradication by het IL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population." (PMID: 37178117) https://pubmed.ncbi.nlm.nih.gov/37178117/ <a href="https://pubmed.ncbi.nlm.nih.gov/37178117/">Karaliota S, et al. "Tumor eradication by het IL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population." (PMID: 37178117)</a> 162518219 Bergamaschi C, et al. Heterodimeric "IL-15 in cancer immunotherapy." (PMID: 33671252) https://pubmed.ncbi.nlm.nih.gov/33671252/ <a href="https://pubmed.ncbi.nlm.nih.gov/33671252/">Bergamaschi C, et al. Heterodimeric "IL-15 in cancer immunotherapy." (PMID: 33671252)</a> 162518307 Conlon K, et al. "Phase Ⅰ study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist in adult patients with metastatic or unresectable solid tumors." (PMID: 34799399 https://pubmed.ncbi.nlm.nih.gov/34799399/ <a href="https://pubmed.ncbi.nlm.nih.gov/34799399/">Conlon K, et al. "Phase Ⅰ study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist in adult patients with metastatic or unresectable solid tumors." (PMID: 34799399</a> 162516976 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 162517000 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 162517016 Karaliota, Sevasti NIH - Leidos Leidos Karaliota, Sevasti (Leidos) 3 162517106 Stellas, Dimitrios NIH - NCI NCI Stellas, Dimitrios (NCI) 4 162516976 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 162517000 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 162517016 Karaliota, Sevasti NIH - Leidos Leidos Karaliota, Sevasti (Leidos) 3 162517106 Stellas, Dimitrios NIH - NCI NCI Stellas, Dimitrios (NCI) 4 162516865 Synergistic Interactions For Improved Cancer Treatment E-174-2022-0 Filing authorized Leidos Biomedical Research, Inc, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-5057] Synergistic Interactions for Improved Cancer Treatment&body=Please send me information about technology [TAB-5057] Synergistic Interactions for Improved Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-5057] Synergistic Interactions for Improved Cancer Treatment&body=Please send me information about technology [TAB-5057] Synergistic Interactions for Improved Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">rose.freel@nih.gov</a><br> 162516871 E-174-2022-0 E-174-2022-0-US-01 Synergistic Interactions For Improved Cancer Treatment PRV US 63/398,450 Expired US <br />Provisional (PRV) 63/398,450<br />Filed on 2022-08-16<br />Status: Expired 162516872 E-174-2022-0 E-174-2022-0-PC-01 Synergistic Interactions For Improved Cancer Treatment PCT Patent Cooperation Treaty PCT/US2023/072333 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/072333<br />Filed on 2023-08-16<br />Status: Expired 162516873 E-174-2022-0 E-174-2022-0-US-02 Synergistic Interactions For Improved Cancer Treatment National Stage US 19/101,938 Pending US <br />National Stage 19/101,938<br />Filed on 2025-02-07<br />Status: Pending 162516874 E-174-2022-0 E-174-2022-0-EP-01 Synergistic Interactions For Improved Cancer Treatment National Stage European Patent 23768747.0 Pending European Patent <br />National Stage 23768747.0<br />Filed on 2025-01-29<br />Status: Pending TAB-4445 147157740 Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds NEI Collaboration, Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology Collaboration Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Juan Amaral, Kapil Bharti, Steven Charles, Vladimir Khristov, Arvydas Maminishkis <p>Medical clamps currently available are not efficient nor are they sufficiently precise in closure and alignment of the edges of an incision or wound. Many available designs are difficult to use and handle, especially in situations where repeated opening and closure of an incision or wound is required. The functional short-comings of existing clamp designs may result in surgical complications, such as excess loss of fluids and pressure and hemostasis during some procedures. These functional deficiencies may increase the difficulty and expense of a surgery or altogether limit the ability to perform some procedures. </p> <p>This clamp design is functionally superior in its ease of use and capability to precisely keep in alignment incision or wound margins during repeated opening and closure.  As a result, a surgeon using this clamp is able to quickly open or close an incision or wound, as needed. This ability is a critical attribute where there is need to insert instruments, sometimes repeatedly, through an incision or wound. These superior functionalities reduce potential for fluid loss, which is especially critical in procedures such as intraocular surgeries where maintaining fluid balance avoids serious complications. Excessive loss of intraocular fluid balance during surgery can result in collapse of the eye, hemorrhage, and retinal detachment. This clamp design may improve outcomes of many surgeries and potentially enable new procedures presently too risky to undertake with current clamp devices. </p> <p>This invention is available for licensing and/or collaborative development partnerships.</p> <h2>Competitive Advantages:</h2> <ul><li>Maintains more precise alignment of the wound margins</li> <li>Permits easy reopening and entry into the incision or wound and repeated closure</li> <li>Reduces fluid loss from wound or incision, helps maintain hemostasis</li> <li>Guides and controls placement and depth of sutures</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Intraocular surgeries requiring incision in sclera</li> <li>Rapid closure of traumatic wounds</li> </ul> 2017-02-17 2025-04-22 2018-02-17 2026-03-18 2017-02-21 CLAMP, ocular surgery, sclera incision closure False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-251-2012 147164764 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147164765 Charles, Steven NIH - NEI NEI Charles, Steven (NEI) 2 147164762 Amaral, Juan NIH - NEI NEI Amaral, Juan (NEI) 3 147164761 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147164763 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 5 147164764 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147164765 Charles, Steven NIH - NEI NEI Charles, Steven (NEI) 2 147164762 Amaral, Juan NIH - NEI NEI Amaral, Juan (NEI) 3 147164761 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147164763 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 5 147158331 A Surgical Clamp To Gate Large Scleral Surgery Port And Suture Alignment Tool E-293-2016-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds&body=Please send me information about technology [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds&body=Please send me information about technology [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147168964 E-293-2016-0 E-293-2016-0-US-01 Tissue Clamp and Implantation Method PRV US 62/419,804 Abandoned US <br />Provisional (PRV) 62/419,804<br />Filed on 2016-11-09<br />Status: Abandoned 147168965 E-293-2016-0 E-293-2016-0-PCT-02 TISSUE CLAMP AND IMPLANTATION METHOD PCT Patent Cooperation Treaty PCT/US2017/060672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060672<br />Filed on 2017-11-08<br />Status: Expired 147168966 E-293-2016-0 E-293-2016-0-US-03 TISSUE CLAMP AND IMPLANTATION METHOD National Stage US 11,717,298 16/348,855 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11717298 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11717298">11,717,298</a><br />Filed on 2019-05-09<br />Status: Issued 147168967 E-293-2016-0 E-293-2016-0-AU-04 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Australia 2017359336 2017359336 Issued Australia <br />National Stage 2017359336<br />Filed on 2019-05-03<br />Status: Issued 147168968 E-293-2016-0 E-293-2016-0-CA-05 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Canada 3043174 Pending Canada <br />National Stage 3043174<br />Filed on 2017-11-08<br />Status: Pending 147168969 E-293-2016-0 E-293-2016-0-EP-06 TISSUE CLAMP AND IMPLANTATION METHOD National Stage European Patent 17801272.0 Pending European Patent <br />National Stage 17801272.0<br />Filed on 2017-11-08<br />Status: Pending 147168970 E-293-2016-0 E-293-2016-0-JP-07 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Japan 7069192 2019-545900 Issued Japan <br />National Stage 2019-545900<br />Filed on 2017-11-08<br />Status: Issued 147168971 E-293-2016-0 E-293-2016-0-JP-08 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 7417655 2022-075904 Issued Japan <br />Divisional (DIV) 2022-075904<br />Filed on 2022-05-02<br />Status: Issued 147168972 E-293-2016-0 E-293-2016-0-US-02 TISSUE CLAMP AND IMPLANTATION METHOD DIV US 12,605,156 18/226,043 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12605156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12605156">12,605,156</a><br />Filed on 2023-07-25<br />Status: Issued 147168973 E-293-2016-0 E-293-2016-0-AU-01 TISSUE CLAMP AND IMPLANTATION METHOD DIV Australia 2023203954 2023203954 Issued Australia <br />Divisional (DIV) 2023203954<br />Filed on 2023-06-22<br />Status: Issued 163972577 E-293-2016-0 E-293-2016-0-JP-09 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 7642109 2024-000617 Issued Japan <br />Divisional (DIV) 2024-000617<br />Filed on 2024-01-05<br />Status: Issued 163972579 E-293-2016-0 E-293-2016-0-JP-01 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan Administratively Closed Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 163972580 E-293-2016-0 E-293-2016-0-JP-10 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 2025-027718 Pending Japan <br />Divisional (DIV) 2025-027718<br />Filed on 2025-02-25<br />Status: Pending 164039358 E-293-2016-0 E-293-2016-0-AU-02 TISSUE CLAMP AND IMPLANTATION METHOD DIV Australia 2025283670 Pending Australia <br />Divisional (DIV) 2025283670<br />Filed on 2025-12-22<br />Status: Pending 166474398 E-293-2016-0 E-293-2016-0-US-04 TISSUE CLAMP AND IMPLANTATION METHOD CON US 19/638,763 Pending US <br />Continuation (CON) 19/638,763<br />Filed on 2026-04-03<br />Status: Pending 147174735 CLAMP 147174737 ocular surgery 147174739 sclera incision closure TAB-5083 164393859 Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jeffrey Schlom, Kwong-Yok Tsang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types.</p> <h2>Description of Technology:</h2> <p>Many human carcinomas and hematologic malignancies overexpress mucin 1 (MUC1), a transmembrane glycoprotein composed of heterodimers formed by a large, N-terminal subunit (MUC1-N) and a smaller, C-terminal subunit (MUC1-C). In tumors, the MUC-1 heterodimer becomes abnormally hypoglycosylated &ndash; leading to the exposure of antigenic epitopes to the immune system. Aberrant MUC1 expression, and in particular its MUC1-C subunit, has been associated with poor prognosis and correlates with cancer metastasis &ndash; further establishing MUC1 as a target for cancer therapy.</p> <p>Inventors at the National Cancer Institute have identified epitopes of MUC1-C and enhancer agonist peptides that can activate cytotoxic T lymphocytes. These epitopes and enhancers may be suitable to develop into immunotherapies, such as cancer vaccines against various malignancies. In particular, the agonist peptides are expected to further enhance responses in patients when used in vaccines or T-cell therapy. The epitopes span the human leukocyte antigen HLA-A24 allele and facilitate recognition of MUC1-C in the context of HLA-A24.</p> <p>This technology is available for collaboration and licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of MUC1-expressing cancers</li> <li>Cancer vaccine compositions</li> <li>MUC1-targeting epitopes and agonists</li> <li>Activation of cytotoxic T cell response as an enhanced cancer treatment</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Agonist epitopes can be incorporated into various vaccine platforms</li> <li>Agonist epitopes can be used for the ex vivo generation of human T cells</li> <li>Epitopes span the HLA-A24 allele and facilitate recognition and killing of human tumor cells in an MHC-restricted manner</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for agonist epitopes of the MUC1-C oncoprotein. 2025-09-29 2025-09-29 2026-03-17 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 164394007 Jochems C, et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (PMID 24233342) https://pubmed.ncbi.nlm.nih.gov/24233342/ <a href="https://pubmed.ncbi.nlm.nih.gov/24233342/">Jochems C, et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (PMID 24233342)</a> 164393890 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393911 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 164393890 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393911 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 164393862 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein E-520-2013-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein&body=Please send me information about technology [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein&body=Please send me information about technology [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> 164411756 E-520-2013-0 E-520-2013-0-US-01 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein PRV US 61/894,482 Abandoned US <br />Provisional (PRV) 61/894,482<br />Filed on 2013-10-23<br />Status: Abandoned 164411761 E-520-2013-0 E-520-2013-0-PCT-02 HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use PCT Patent Cooperation Treaty PCT/US2014/061723 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/061723<br />Filed on 2014-10-22<br />Status: Expired 164412485 E-520-2013-0 E-520-2013-0-US-02 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 11,732,017 17/240,260 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11732017 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11732017">11,732,017</a><br />Filed on 2021-04-26<br />Status: Issued 164412490 E-520-2013-0 E-520-2013-0-US-03 HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE CON US 12,325,731 18/344,242 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12325731 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12325731">12,325,731</a><br />Filed on 2023-06-29<br />Status: Issued 164412495 E-520-2013-0 E-520-2013-0-US-07 HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein and Compositions and Methods of Use National Stage US 10,035,832 15/031,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035832 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035832">10,035,832</a><br />Filed on 2016-04-22<br />Status: Issued 164412622 E-520-2013-0 E-520-2013-0-US-18 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 10,508,141 16/034,654 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508141 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508141">10,508,141</a><br />Filed on 2018-07-13<br />Status: Issued 164412777 E-520-2013-0 E-520-2013-0-US-19 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 11,155,588 16/715,038 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155588">11,155,588</a><br />Filed on 2019-12-16<br />Status: Issued 166454591 E-520-2013-0 E-520-2013-0-CA-01 HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use DIV Canada 3205348 Pending Canada <br />Divisional (DIV) 3205348<br />Filed on 2023-06-30<br />Status: Pending TAB-3828 143328687 Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants NIAID Kevina Birungi-Huff, Sabrina Bush, Man Chen, Nicole Doria-Rose, Daniel Douek, Richard Koup, John Mascola, John Misasi, Maryam Musayev, Chaim Schramm, Wei Shi, Nancy Sullivan, Lingshu Wang, Eun Yang, Yi Zhang <p>&nbsp; &nbsp; &nbsp; &nbsp;Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.<br /> &nbsp; &nbsp; &nbsp; &nbsp;Scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified multiple antibodies that ultra-potently neutralize SARS-CoV-2, including the highly transmissible BA.4, BA.5, BQ.1.1 and XBB subvariants of Omicron, as shown in a pseudovirus neutralization assay. &nbsp;These antibodies target several epitopes in the receptor binding domain of the spike protein that are not impacted by spike mutations that knockout binding to other therapeutic antibodies, including, K417N, N439K, N440K, K444T, V445P, G446S, L452R, Y453F, N460K, S477N, E484A/K, F486S/V and Q498R. &nbsp;Several of the antibodies are able to simultaneously bind to the spike protein and are compatible for use in combination therapies.&nbsp;<br /> &nbsp; &nbsp; &nbsp; This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404.<br /> &nbsp;</p> <ul> <li>Ultra-potent neutralization of currently identified SARS-CoV-2 variants including Omicron subvariants BQ.1.1 and XBB</li> <li>Mechanism of Action – Some antibodies directly bind to and block ACE2 receptor binding to the SARS CoV-2 spike protein </li> </ul> <ul> <li>Treatment of SARS-CoV-2 infection</li> </ul> 2023-01-31 2026-03-13 2026-03-13 2023-01-25 False False Preclinical Research True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144856488 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144856504 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144856514 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144856519 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144856550 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144856554 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144856562 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144856694 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144856761 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144856798 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144856823 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144856855 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144856968 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144857042 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144857200 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 144856488 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144856504 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144856514 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144856519 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144856550 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144856554 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144856562 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144856694 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144856761 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144856798 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144856823 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144856855 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144856968 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144857042 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144857200 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 143328697 Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants E-024-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID, NIAID - VRC, NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants.">bbailey@mail.nih.gov</a><br> TAB-4148 147157431 Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics James Doroshow, Tafazzai Hossain, Jaimo Lu, Prabhakar Risbood, Krishnendu Roy <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for the further development of a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.</p> <h2>Description of Technology:</h2> <p>Diverse human cancers like colorectal, pancreatic, ovarian, melanoma, and pre-cancers express NADPH oxidases (NOX) at high levels. Reactive oxygen species (ROS) produced from metabolic reactions catalyzed by NOX in tumors are essential to the tumor&rsquo;s growth and play a key role in inflammation-related conditions. Though drugs that inhibit ROS production by NOX could be effective against a variety of human cancers and chronic inflammation-related conditions, these types of drugs are not widely available.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have discovered a family of novel analogs of diphenylene iodonium (DPI) and di-thienyl-iodonium (DTI) as inhibitors of NOX and other flavin dehydrogenases for the treatment and prevention of cancer and chronic inflammation-related conditions. Several of these inhibitors displayed in vitro potency that were superior to their parent molecules and were effective in inhibiting cell growth, ROS production, NOX1 mRNA expression, and NOX isoform activity in multiple cancer cell lines, including those representing acute lymphocytic leukemia, chronic myelogenous leukemia, myeloma, large cell immunoblastic lymphoma, non-small cell lung cancer, colon, melanoma, and renal cancer. In vivo validation of parent molecules DPI and DTI using human colon cancer xenografted mice yielded a statistically significant reduction in the average rate of tumor growth in mice administered either DPI or DTI compared to control mice.</p> <p>The National Cancer Institute (NCI) seeks licensees for the further development of these novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anti-cancer therapeutic for tumors that overexpress NOXs or depend on ROS to proliferate, such as colorectal, pancreatic, and ovarian cancers</li> <li>Therapeutic for chronic inflammatory conditions, such as diabetes, neuropathies, chronic pancreatitis, and inflammatory bowel disease</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased potency which may facilitate lower dosing concentrations needed</li> <li>Optimized specificity and selectivity which may lessen risk of off-target effects</li> <li>Potential to be first-in-class drug</li> </ul> Researchers at the NCI seek licensing for the further development a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions. 2021-04-14 2026-02-23 2026-02-23 2026-03-09 2021-04-14 Diphenylene Iodonium, Di-thienyl-iodonium, Doroshow, DPI, DTI, Flavin Dehydrogenases, NADPH oxidases, NOX, Pre-cancerous Lesions, Reactive Oxygen Species, ROS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161921 Lu J, et al. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. (PMID 28709950) https://pubmed.ncbi.nlm.nih.gov/28709950/ <a href="https://pubmed.ncbi.nlm.nih.gov/28709950/">Lu J, et al. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. (PMID 28709950)</a> 147161959 Doroshow JH, et al. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer and xenografts. (PMID 23314043) https://pubmed.ncbi.nlm.nih.gov/23314043/ <a href="https://pubmed.ncbi.nlm.nih.gov/23314043/">Doroshow JH, et al. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer and xenografts. (PMID 23314043)</a> 147162346 Doroshow JH, et al. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. (PMID 22305747) https://pubmed.ncbi.nlm.nih.gov/22305747/ <a href="https://pubmed.ncbi.nlm.nih.gov/22305747/">Doroshow JH, et al. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. (PMID 22305747)</a> 147163689 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 1 147163688 Risbood, Prabhakar NIH - NCI NCI Risbood, Prabhakar (NCI) 2 147163691 Lu, Jaimo NIH - NCI NCI Lu, Jaimo (NCI) 3 147163690 Roy, Krishnendu NIH - NCI NCI Roy, Krishnendu (NCI) 4 147163692 Hossain, Tafazzai Starks Associates, Inc. Hossain, Tafazzai 5 147163689 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 1 147163688 Risbood, Prabhakar NIH - NCI NCI Risbood, Prabhakar (NCI) 2 147163691 Lu, Jaimo NIH - NCI NCI Lu, Jaimo (NCI) 3 147163690 Roy, Krishnendu NIH - NCI NCI Roy, Krishnendu (NCI) 4 147163692 Hossain, Tafazzai Starks Associates, Inc. Hossain, Tafazzai 5 147158021 Development Of Analogs Of Diphenylene Iodonium And Di-thienyl-iodonium As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases For The Treatment And Prevention Of Cancer And Inflammation-related Conditions E-116-2014-0 Filing authorized NCI, Starks Associates, Inc. 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions&body=Please send me information about technology [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions&body=Please send me information about technology [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147166923 E-116-2014-0 E-116-2014-0-US-01 Iodonium Analogs As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases; Formulations Thereof; And Uses Thereof PRV US 61/976,362 Abandoned US <br />Provisional (PRV) 61/976,362<br />Filed on 2014-04-07<br />Status: Abandoned 147166924 E-116-2014-0 E-116-2014-0-PCT-02 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2015/024445 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/024445<br />Filed on 2015-04-06<br />Status: Expired 147166925 E-116-2014-0 E-116-2014-0-EP-03 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF National Stage European Patent 3129102 15717363.4 Issued European Patent <br />National Stage 15717363.4<br />Filed on 2015-04-06<br />Status: Issued 147166926 E-116-2014-0 E-116-2014-0-US-04 Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases; Formulations Thereof; and Uses Thereof National Stage US 10,131,659 15/302,566 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10131659 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10131659">10,131,659</a><br />Filed on 2016-10-07<br />Status: Issued 147166927 E-116-2014-0 E-116-2014-0-US-05 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF CON US 10,738,047 16/160,599 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738047 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738047">10,738,047</a><br />Filed on 2018-10-15<br />Status: Issued 147171769 Diphenylene Iodonium 147171770 Di-thienyl-iodonium 147171772 Doroshow 147171774 DPI 147171776 DTI 147171778 Flavin Dehydrogenases 147171780 NADPH oxidases 147171782 NOX 147171784 Pre-cancerous Lesions 147171785 Reactive Oxygen Species 147171786 ROS TAB-3176 114097126 Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA NIAID Licensing, Research Materials Licensing Research Materials Philip Murphy A plasmid encodes human CC chemokine receptor CX3CR1/CMKBRL1 as described in DNA Cell Biol. 1995 Aug;14(8):673-80, and developed in the laboratory of Philip M. Murphy at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-257) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cc, CC-CMKBRL1, cDNA, Chemokine, Human, PLASMID, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114171740 Combadiere C, et al. https://www.ncbi.nlm.nih.gov/pubmed/7646814 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7646814">Combadiere C, et al.</a> 114107759 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107759 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114101477 Human CC Chemokine Receptor CC-CMKBRL1 cDNA B-037-1995-6 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA&body=Please send me information about technology [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA&body=Please send me information about technology [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114126810 WIXXXX 114149570 Human 114149571 cc 114149572 Chemokine 114149573 RECEPTOR 114149574 CC-CMKBRL1 114149575 cDNA 114149576 PLASMID 114149598 RM TAB-3177 114097119 CXCR1 - Human IL-8 Receptor cDNA NIAID Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics Sunil Ahuja, Philip Murphy A plasmid encodes human interleukin-8 (IL-8) receptor CXCR1. IL-8 is a chemo-attractant cytokine that attracts and activates neutrophils in inflammatory regions. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-006) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 CB3AXX, CC1XXX, cDNA, CXCRI, Hu, Human, IL-8, IL-8A, Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Subtype, WIXXXX False True True NIHTT 37470483 Website Abstract 114107016 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114107758 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107758 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107016 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114102339 CXCRI (Hu IL-8A) - Human IL-8 (A Subtype) Receptor cDNA B-004-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA&body=Please send me information about technology [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA&body=Please send me information about technology [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127493 CB3AXX 114127494 CC1XXX 114127495 WIXXXX 114149577 CXCRI 114149578 Hu 114149579 IL-8A 114149580 Human 114149581 IL-8 114149582 Subtype 114149583 RECEPTOR 114149584 cDNA 114149585 Listed LPM Ano as of 4/15/2015 114149586 Pre LPM working set 20150418 114149587 Post LPM Assignment Set 20150420 114149588 PLASMID 114149599 RM TAB-3183 114097117 Human CCR3 cDNA NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Sunil Ahuja, Christophe Combadiere, Philip Murphy, James Pease A plasmid encodes human C-C motif chemokine receptor 3 (CCR3). It may contribute to the accumulation and activation of eosinophil and other inflammatory cells in the allergic airway. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-196) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 4, CCR3, CCR3;, cDNA, Cell, DA4AXX, DE4-CCR3, Expressing, Human, Line, Listed LPM Ano as of 4/15/2015, Murine, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109426 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109427 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109428 Pease, James NIAID - DIR Pease, James 0 114109425 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109425 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109426 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109427 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109428 Pease, James NIAID - DIR Pease, James 0 114102345 cDNA for human CCR3; cDNA for murine CCR3; and cell line expressing human CCR3 (4 DE4-CCR3 cell line) B-009-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3183] Human CCR3 cDNA&body=Please send me information about technology [TAB-3183] Human CCR3 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3183] Human CCR3 cDNA&body=Please send me information about technology [TAB-3183] Human CCR3 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127507 DA4AXX 114127508 VLXXXX 114127509 WIXXXX 114149652 cDNA 114149653 Human 114149654 CCR3; 114149655 Murine 114149656 Cell 114149657 Line 114149658 Expressing 114149659 CCR3 114149660 4 114149661 DE4-CCR3 114149662 Listed LPM Ano as of 4/15/2015 114149663 Pre LPM working set 20150418 114149664 Post LPM Assignment Set 20150420 114149665 PLASMID 114149666 RM TAB-3182 114097116 Human CCR2 cDNA NIAID Licensing, Research Materials Licensing Research Materials Sunil Ahuja, Christophe Combadiere, Philip Murphy, James Pease A plasmid encodes human C-C chemokine receptor type 2 (CCR2). CCR2 play important roles in the recruitment of monocytes/macrophages and T cells. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-195) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cc, CCR2, cDNA, Cell, Chemokine, Cloning, EOSINOPHIL, Expression, FUNCTIONAL, Human, Including, line., Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109422 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109423 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109424 Pease, James NIAID - DIR Pease, James 0 114109421 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109421 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109422 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109423 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109424 Pease, James NIAID - DIR Pease, James 0 114102344 CCR2 Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, including cDNA and cell line. B-008-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3182] Human CCR2 cDNA&body=Please send me information about technology [TAB-3182] Human CCR2 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3182] Human CCR2 cDNA&body=Please send me information about technology [TAB-3182] Human CCR2 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127506 WIXXXX 114149634 CCR2 114149635 Cloning 114149636 FUNCTIONAL 114149637 Expression 114149638 Human 114149639 EOSINOPHIL 114149640 cc 114149641 Chemokine 114149642 RECEPTOR 114149643 Including 114149644 cDNA 114149645 Cell 114149646 line. 114149647 Listed LPM Ano as of 4/15/2015 114149648 Pre LPM working set 20150418 114149649 Post LPM Assignment Set 20150420 114149650 PLASMID 114149651 RM TAB-3180 114097113 Human FPRL1 / FPR2 cDNA NIAID Licensing, Neurology, Research Materials Licensing Neurology Research Materials Philip Murphy A plasmid encodes human formyl peptide receptor-like 1 (FPRL1/FPR2). <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-017) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cDNA, FPRL1, Human, Listed LPM Ano as of 4/15/2015, NC3XXX, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109412 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109412 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102342 Human FPRL1 Receptor cDNA B-008-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3180] Human FPRL1 / FPR2 cDNA&body=Please send me information about technology [TAB-3180] Human FPRL1 / FPR2 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3180] Human FPRL1 / FPR2 cDNA&body=Please send me information about technology [TAB-3180] Human FPRL1 / FPR2 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127500 NC3XXX 114127501 WIXXXX 114127502 VEXXXX 114149609 Human 114149610 FPRL1 114149611 RECEPTOR 114149612 cDNA 114149613 Listed LPM Ano as of 4/15/2015 114149614 Pre LPM working set 20150418 114149615 Post LPM Assignment Set 20150420 114149616 PLASMID 114149617 RM TAB-3179 114097112 Human fMLP Receptor / FPR cDNA NIAID Licensing, Neurology, Research Materials Licensing Neurology Research Materials Philip Murphy A plasmid encodes human fMLP receptor. Formyl peptide receptor (FPR, fMLP receptor) is a G protein-coupled receptor and mediates anti-inflammatory reactions in human neutrophils and other tissues. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-013) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cDNA, FMLP, Human, Listed LPM Ano as of 4/15/2015, NC3XXX, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109411 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109411 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102341 Human FMLP Receptor cDNA B-007-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3179] Human fMLP Receptor / FPR cDNA&body=Please send me information about technology [TAB-3179] Human fMLP Receptor / FPR cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3179] Human fMLP Receptor / FPR cDNA&body=Please send me information about technology [TAB-3179] Human fMLP Receptor / FPR cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127497 NC3XXX 114127498 VEXXXX 114127499 WIXXXX 114149600 Human 114149601 FMLP 114149602 RECEPTOR 114149603 cDNA 114149604 Listed LPM Ano as of 4/15/2015 114149605 Pre LPM working set 20150418 114149606 Post LPM Assignment Set 20150420 114149607 PLASMID 114149608 RM TAB-2917 114097074 CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells NIAID Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Ji-Liang Gao, Qian Liu, Harry Malech, David McDermott, Philip Murphy, Marie Siwiki Methods of enhancing engraftment of donor hematopoietic stem cells (HSCs) by reducing expression or activity of CXCR4 in HSCs is described. HSC are the only cells in the bone marrow that are both pluripotent and long lived. Bone marrow transplantation (BMT) using HSC is an increasingly common medical therapy for severe hematologic cancers and primary hematologic immunodeficiencies. However, for significant HSC engraftment to occur there must usually be pre-transplant conditioning with either irradiation or chemotherapy or both. The technology described herein shows that it is possible to replace HSC without the need for pre-transplant conditioning regimen. It is known that the chemokine receptor CXCR4 plays a critical role in HSC homing to the bone marrow and in HSC quiescence. The inventors have identified a patient in which one copy of CXCR4 had been deleted in a somatic mutation of an HSC and this cell had clonally repopulated the bone marrow. This led to experiments in mice where the inventors clearly demonstrated in a bone marrow transplantation model, that donor cells with a single copy of the Cxcr4 gene repopulate recipient mice much faster and last much longer than donor cells having two copies of the Cxcr4 gene. This technology which shows that HSCs with one copy of the CXCR4 gene have a durable selective advantage in bone marrow repopulation can solve the problem frequently encountered in gene therapy, i.e., the short-lived nature of gene-corrected cells, by utilizing recently discovered gene editing methods that can be used to delete one copy of CXCR4 gene in gene-corrected cells. <ul> <li>This technology potentially facilitates HSC transplantation without the need of radiation or chemotherapy conditioning.</li> <li>This technology may uniquely overcome a major hurdle limiting all gene therapy applications, namely the failure to correct the gene defect over a long time.</li> </ul> <ul> <li>Improvement of engraftment in gene therapy protocols and in HSC transplantation.</li> <li>Improved bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.</li> </ul> 2022-03-08 2026-03-02 2026-03-02 2015-03-20 Cell, COPY, CXCR4, Durably, ENGRAFTMENT, Enhanced, hematopoietic, ONE, SILENCING, Stem, VCXXXX, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172239 McDermott DH, et al. http://www.ncbi.nlm.nih.gov/pubmed/25662009 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25662009">McDermott DH, et al.</a> 114108986 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114108987 McDermott, David NIAID - DIR NIAID McDermott, David (NIAID) 0 114108988 Siwiki, Marie NIAID - DIR NIAID Siwiki, Marie (NIAID) 0 114108989 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 0 114108990 Liu, Qian NIAID - DIR NIAID Liu, Qian (NIAID) 0 114108985 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 1 114108985 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 1 114108986 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114108987 McDermott, David NIAID - DIR NIAID McDermott, David (NIAID) 0 114108988 Siwiki, Marie NIAID - DIR NIAID Siwiki, Marie (NIAID) 0 114108989 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 0 114108990 Liu, Qian NIAID - DIR NIAID Liu, Qian (NIAID) 0 114102255 Hematopoietic Stem Cell Engraftment Can Be Durably Enhanced By Silencing One Copy Of CXCR4 E-173-2014-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells&body=Please send me information about technology [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells&body=Please send me information about technology [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells.">dawn.taylor-mulneix@nih.gov</a><br> 114162342 E-173-2014-0 E-173-2014-0-US-03 Reducing CXCR4 Expression and/or Function to Enchance Engraftment of Hematopoietic Stem Cells National Stage US 11,278,572 15/324,219 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11278572 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11278572">11,278,572</a><br />Filed on 2017-01-05<br />Status: Issued 114168101 E-173-2014-0 E-173-2014-0-US-01 REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS PRV US 62/026,138 Abandoned US <br />Provisional (PRV) 62/026,138<br />Filed on 2014-07-18<br />Status: Abandoned 114168173 E-173-2014-0 E-173-2014-0-PCT-02 REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS PCT Patent Cooperation Treaty PCT/US2015/040954 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/040954<br />Filed on 2015-07-17<br />Status: Expired 114126882 VCXXXX 114126883 VPXXXX 114126884 WJXXXX 114126885 XEXXXX 114126886 YAXXXX 114126887 YBXXXX 114126888 YCXXXX 114148130 hematopoietic 114148131 Stem 114148132 Cell 114148133 ENGRAFTMENT 114148134 Durably 114148135 Enhanced 114148136 SILENCING 114148137 ONE 114148138 COPY 114148139 CXCR4 TAB-2173 114096388 Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies NIAID Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics Joshua Farber, Hongwei Zhang This technology describes monoclonal antibodies against mouse chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (Mig). CXCL9 is a secreted protein that functions to attract white cells and increased expression of CXCL9 has been linked to several diseases. The inventors at the NIH generated over 100 anti-mouse CXCL9 antibodies from a CLXL9/Mig knockout mouse and further characterized several antibodies to show neutralization of CXCL9. As such, these antibodies could be used to measure concentrations of mouse CLXL9 in laboratory samples and block the activity of CXCL9 in injected mice. These antibodies are suitable for ELISA and Western blot. The antibodies have not been tested in flow cytometry or immunohistochemistry, but may also be useful for these applications. Can be used in mice without eliciting endogenous antibodies reacting against the injected anti-CXCL9. <ul> <li>ELISA assays for detection and measurement of CXCL9.</li> <li>Neutralization of CXCL9 activity in mouse models and <i>in vitro</i> assays to study the role of CXCL9 in immune response and disease.</li> </ul> Research Tool -- Patent protection is not being pursued for this technology. Available for licensing. 2022-03-08 2026-03-02 2026-03-02 2010-10-12 antibodies, Anti-mouse, AXXXXX, CCXXXX, CXCL9, CXXXXX, IA3XXX, IAXXXX, IDXXXX, IXXXXX, MIG, monoclonal, Mouse False True The technology is currently in the pre-clinical stage of development. True NIHTT 37470483 Website Abstract 114107011 Zhang, Hongwei NIAID - DIR NIAID Zhang, Hongwei (NIAID) 0 114107010 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114107010 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114107011 Zhang, Hongwei NIAID - DIR NIAID Zhang, Hongwei (NIAID) 0 114101474 Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies E-198-2009-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies&body=Please send me information about technology [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies&body=Please send me information about technology [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies.">dawn.taylor-mulneix@nih.gov</a><br> 114121620 AXXXXX 114121621 CXXXXX 114121622 CCXXXX 114121623 IA3XXX 114121624 IDXXXX 114121625 IXXXXX 114121626 IAXXXX 114140577 CXCL9 114140578 Anti-mouse 114140579 Mouse 114140580 MIG 114140581 monoclonal 114140582 antibodies TAB-1973 114096193 A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry NIAID Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Edward Berger, Bertrand Saunier, Miriam Triyatni HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vaccine is yet available. The difficulty in developing HCV vaccines is largely due to the broad sequence-diversity displayed by HCV, the frequent occurrence of viral mutations within immunogenic epitopes in vivo, and the lack of proper standard/definition for viral neutralization. <br><br> One alternative strategy in HCV-vaccine or drug development comprises measuring viral entry, the first step in viral infection. Such measurements are limited by the available screening systems, in that, HCV pseudo-typed retroviral particles have a different envelope conformation and contain foreign components that are likely to interfere with the measured HCV entry. Moreover, HCV lab strain requires intensive replication for its in vitro production, resulting in numerous mutations that impede development of convenient screening tools. <br><br> The inventors have developed a system for generating infectious HCV particles and HCV-like particles (HCV-LP) suitable for a qualitative single-cycle entry assay, completely independent of HCV replication. To adapt this system as a single assay to study HCV-LP entry, HCV non-structural genes were replaced with a heterologous gene that upon viral-entry triggers firefly luciferase and EGFP expressions in target as well as non-permissive cells. The pretreatment of HCV-replication permissive HuH-7.5 cells with siRNA targeting HCV candidate receptors inhibited viral entry. These new systems enable production of authentic HCV infectious particles as well as HCV-LPs suitable for single-cycle entry assays adaptable to high throughput screening. <ul> <li>These systems do not use pseudo-typed HCV particles, i.e. no foreign proteins present in the virus particles.</li> <li>Particle production in the producing cells is independent of HCV RNA replication, hence avoids the occurrence of adaptive mutations that could be detrimental for virus particle's infectivity or could alter tags or nucleotide sequences incorporated in the viral genome.</li> <li>These systems are not specifically dedicated to HCV of a particular genotype, i.e. they can be used to generate HCV particles of various genotypes without requiring the use of chimeras.</li> </ul> <ul> <li>Screening a library expressed in non-permissive cells for identifying new HCV candidate receptor(s) or entry molecule(s).</li> <li>Testing drugs or compounds inhibiting HCV particle entry or viral genome uncoating, or neutralizing antibodies in target cells.</li> <li>Testing drugs or compounds that inhibit virus assembly, maturation and/or egress, or genome packaging, in producer cells.</li> <li>Incorporating a 'tag' in the genome of various HCV genotypes to more conveniently study virus spreading and dissemination in an organ, tissue and/or small animal model.</li> <li>Enhancing immune response in patients: one way to trigger high level anti-HCV immunity is by isolating antigen-presenting cells from patients and incubating them with HCV particles produced with this system using replication-defective viral genome (with or without an immunogenic tag and/or in combination with other viral epitopes) and eventually re-inject their primed cells to the patients.</li> </ul> The NIAID OTD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a novel system for producing infectious HCV virions and developing a reporter system for studying HCV entry. Please contact Michael Piziali at 301-496-2644 for more information. Available for licensing. 2022-03-08 2026-03-02 2026-03-02 2009-06-23 AC4XXX, ACXXXX, AXXXXX, BBXXXX, Biotechnology, C, DB4BXX, DB4XXX, DBXXXX, Development, DXXXXX, Entry., Flavivirus-based, HCV, HCV:, Hepatitis, Hepatitis A, Hepatitis D, Hepatitis E, INFECTIOUS, Novel, Patent Category - Biotechnology, production, REPORTER, STUDYING, System, Virion, VIRIONS, virus False True <ul> <li>Proof of concept.</li> <li>Preliminary tools and techniques for screening strategies.</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114106656 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114106658 Triyatni, Miriam NIAID - DIR NIAID Triyatni, Miriam (NIAID) 0 114106657 Saunier, Bertrand NIAID - DIR NIAID Saunier, Bertrand (NIAID) 1 114106657 Saunier, Bertrand NIAID - DIR NIAID Saunier, Bertrand (NIAID) 1 114106656 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114106658 Triyatni, Miriam NIAID - DIR NIAID Triyatni, Miriam (NIAID) 0 114101244 A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry. E-005-2009-0 Filing authorized NIAID 114101356 A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry. E-005-2009-1 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry&body=Please send me information about technology [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry&body=Please send me information about technology [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry.">dawn.taylor-mulneix@nih.gov</a><br> 114165297 E-005-2009-0 E-005-2009-0-US-01 Flavivirus-Based System for Production of Hepatitis C Virus (HCV) PRV US 61/195,088 Abandoned US <br />Provisional (PRV) 61/195,088<br />Filed on 2008-10-03<br />Status: Abandoned 114165746 E-005-2009-1 E-005-2009-1-PCT-01 Flavivirus-Based System For Production Of Hepatitis C Virus (HCV) PCT COMB Patent Cooperation Treaty PCT/US09/58598 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US09/58598<br />Filed on 2009-09-28<br />Status: Expired 114166394 E-005-2009-1 E-005-2009-1-US-02 Flavivirus-based System For Production Of Hepatitis C Virus (HCV) National Stage US 9,052,321 13/122,154 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9052321 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9052321">9,052,321</a><br />Filed on 2011-04-01<br />Status: Issued 114120343 DB4BXX 114120344 AC4XXX 114120345 DXXXXX 114120346 DBXXXX 114120347 DB4XXX 114120348 AXXXXX 114120349 ACXXXX 114121306 BBXXXX 114138031 Novel 114138032 Flavivirus-based 114138033 System 114138034 production 114138035 Hepatitis 114138036 C 114138037 virus 114138038 HCV: 114138039 INFECTIOUS 114138040 VIRIONS 114138041 Development 114138042 REPORTER 114138043 STUDYING 114138044 HCV 114138045 Virion 114138046 Entry. 114138047 Patent Category - Biotechnology 114138048 Biotechnology 114156816 Hepatitis D 114156817 Hepatitis A 114156818 Hepatitis E TAB-1574 114095842 Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor) NIAID Animal Models, Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics Animal Models Collaboration Consumer Products Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Ji-Liang Gao, Philip Murphy The present research tool is a knockout mouse model (FPR<sup>-/-</sup>) that lacks the high affinity N-formylpeptide receptor (FPR), created by targeted gene disruption.<br /><br /> N-formylpeptides derive from bacterial and mitochondrial proteins, and bind to specific receptors on mammalian phagocytes. Since binding induces chemotaxis and activation of phagocytes in vitro, it has been postulated that N-formylpeptide receptor signaling in vivo may be important in antibacterial host defense, although direct proof has been lacking. The inventors have found that FPR<sup>-/-</sup> mice have no obvious developmental defects and do not develop spontaneous infection when derived in specific pathogen-free conditions. This suggests that, under these conditions, FPR is dispensable. However, when challenged with L. monocytogenes, FPR-deficient mice have accelerated mortality and increased bacterial burden in liver and spleen early after infection, which suggests a role for FPR in host defense, specifically through regulation of innate immunity. <ul> <li>FPR knock out mouse can be used as antibacterial host defense model and innate immunity studies.</li> </ul> The Laboratory of Molecular Immunology, NIAID, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize FPR knockout mice. Please contact Philip Murphy, M.D. at Tel: 301-496-8616 and/or <a href="mailto:pmm@nih.gov">pmm@nih.gov</a> for more information. Research Tool -- Patent protection is not being pursued for this technology. (IC Reference No. 2007-087) This technology is not patented. The mouse model will be transferred through a Biological Materials License. 2022-03-08 2026-03-02 2026-03-02 2007-07-01 BAXXXX, CHEMOATTRACTANT, DDXXXX, DEFICIENT, DEXXXX, DXXXXX, Formyl, FPR, GENETICALLY, knockout mice, Mice, MXXXXX, Peptide, RECEPTOR, RM, WIXXXX False True The technology is a research tool. The technology is a research tool. True NIHTT 37470483 Website Abstract 114170379 Gao JL, et al. https://www.ncbi.nlm.nih.gov/pubmed/9989980 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9989980">Gao JL, et al.</a> 114105774 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114105775 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114105775 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114105774 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114100812 Mice Genetically Deficient In The Chemoattractant Receptor FPR (formyl Peptide Receptor E-258-2007-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)&body=Please send me information about technology [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor). Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)&body=Please send me information about technology [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor).">dawn.taylor-mulneix@nih.gov</a><br> 114117961 DDXXXX 114117962 DEXXXX 114117963 DXXXXX 114117964 MXXXXX 114121200 BAXXXX 114127368 WIXXXX 114135649 Mice 114135650 GENETICALLY 114135651 DEFICIENT 114135652 CHEMOATTRACTANT 114135653 RECEPTOR 114135654 FPR 114135655 Formyl 114135656 Peptide 114149419 RM 114149420 knockout mice TAB-788 114095125 Mouse Lacking the Chemokine Receptor CX3CR1 NIAID Diagnostics, Licensing, Materials Available, Oncology, Research Materials Diagnostics Licensing Materials Available Oncology Research Materials Ji-Liang Gao, Philip Murphy This mouse has been generated by targeted gene disruption. The mouse provides a model to investigate the function of the chemokine receptor CX3CR1, which is a proinflammatory receptor for the leukocyte chemoattractant CX3CL1 (aka fractalkine). As an example, the mouse is in use in the study of atherosclerosis. Further, the mouse may serve as a model study the role of the immune system during infection with pathogens as well as other immunologically mediated diseases and responses to tumors. Research Tool -- patent protection is not being pursued for this technology Available for licensing under a biological materials license. 2022-03-08 2026-03-02 2026-03-02 2003-11-01 CA1AXX, CA1XXX, CAXXXX, CXXXXX, RXXXXX False True True NIHTT 37470483 Website Abstract 114169937 C Combadière et al. Decreased atheroscelerotic lesion formation in CX3R1/apolipoprotein E double knockout mice. http://www.ncbi.nlm.nih.gov/pubmed/12600915?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/12600915?dopt">C Combadière et al. Decreased atheroscelerotic lesion formation in CX3R1/apolipoprotein E double knockout mice.</a> 114104506 Murphy, Philip NIAID Murphy, Philip (NIAID) 0 114104507 Gao, Ji-Liang NIAID Gao, Ji-Liang (NIAID) 0 114104506 Murphy, Philip NIAID Murphy, Philip (NIAID) 0 114104507 Gao, Ji-Liang NIAID Gao, Ji-Liang (NIAID) 0 114099957 Mouse Lacking The Chemokine Receptor CX3CR1, Due To Targeted Gene Disruption E-216-2003-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1&body=Please send me information about technology [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1&body=Please send me information about technology [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1.">dawn.taylor-mulneix@nih.gov</a><br> 114114682 CA1AXX 114114683 CAXXXX 114114684 CXXXXX 114114685 RXXXXX 114120914 CA1XXX TAB-3184 114094368 Mouse CCR1 cDNA NIAID Licensing, Research Materials Licensing Research Materials Ji-Liang Gao, Philip Murphy A plasmid encodes mouse C-C motif chemokine receptor 1 (CCR1). CCR1 plays an important role in host protection from inflammatory response, and susceptibility to virus and parasite. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-025) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 CCR1, cDNA, Encoding, Listed LPM Ano as of 4/15/2015, Mouse, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109430 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114109429 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109429 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109430 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114102346 cDNA Encoding the Mouse CCR1 Receptor B-012-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3184] Mouse CCR1 cDNA&body=Please send me information about technology [TAB-3184] Mouse CCR1 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3184] Mouse CCR1 cDNA&body=Please send me information about technology [TAB-3184] Mouse CCR1 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127510 WIXXXX 114149667 cDNA 114149668 Encoding 114149669 Mouse 114149670 CCR1 114149671 RECEPTOR 114149672 Listed LPM Ano as of 4/15/2015 114149673 Pre LPM working set 20150418 114149674 Post LPM Assignment Set 20150420 114149675 PLASMID 114149676 RM TAB-3178 114094359 Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA NIAID Licensing, Research Materials Licensing Research Materials Philip Murphy A plasmid encodes human monocyte chemoattractant protein-1 (MCP-1/CCL2). MCP-1/CCL2 is a chemokine that regulate migration and infiltration of monocytes/macrophages. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-007) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 1, Human, Listed LPM Ano as of 4/15/2015, MCP, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, Subtype, WIXXXX False True True NIHTT 37470483 Website Abstract 114107015 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107015 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102340 Human MCP 1 (A Subtype) B-005-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA&body=Please send me information about technology [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA&body=Please send me information about technology [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127496 WIXXXX 114149589 Human 114149590 MCP 114149591 1 114149592 Subtype 114149593 Listed LPM Ano as of 4/15/2015 114149594 Pre LPM working set 20150418 114149595 Post LPM Assignment Set 20150420 114149596 PLASMID 114149597 RM TAB-4239 147157524 ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology William Bonner, Jiuping ("Jay") Ji, Christophe Redon, Yiping Zhang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.</p> <h2>Description of Technology:</h2> <p>Exposure to ionizing radiation or agents that induce DNA double-stranded breaks (DSBs) can result in severe damage to cell and/or tissues, including cell death.&nbsp;This can lead to illness (i.e., acute radiation syndrome, cancer, etc.) or even death.&nbsp; Identifying the amount of exposure to a DNA DSB-causing agent can be useful in monitoring, determining the need for further testing, and avoidance or modification of certain medical interventions and/or types of medical treatments. DNA damage caused by DSBs can be identified and quantified&nbsp;in situ&nbsp;by detecting phosphorylated histone protein &gamma;-H2AX (gamma-H2AX) foci which is formed at DSBs.&nbsp;However, existing methods of analyzing &gamma;-H2AX are laborious, low-throughput, and prone to variability.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have developed a novel, high-throughput ELISA-based biodosimeter to measure DNA damage. This biodosimeter simultaneously quantifies the amount of &gamma;-H2AX and total H2AX and results in a percent &gamma;-H2AX, which is a normalized value representative of the amount of DNA damage. Overall, this biodosimeter provides users with flexibility of input sample type (ex. cells, tissues, blood) and high-throughput, less laborious option to precisely measure DNA damage. It provides reliable, dose-dependent measurement outputs that are independent of variability in cell number, cell viability, cell lysis efficiency, and laboratory operator. Additionally, the biodosimeter is both sensitive and specific, having a 100-fold quantitative range with sensitivity of 5 pM for &gamma;-H2AX and 50 pM for H2AX.</p> <p>NCI is seeking co-development partners and/or licensees to further develop this novel ELISA-based biodosimeter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Assay for measuring DNA damage by a variety of causes (ex. ionizing radiation, environmental agents, chemotherapeutic agents, etc.)</li> <li>Biodosimeter to monitor cancer drug treatment course</li> <li>High-throughput screening of new drugs targeting DNA metabolism</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Quantitative</li> <li>High sensitivity and selectivity</li> <li>Can be used on varying sample types (ex. cells, blood, and or tissues)</li> <li>Has internal controls for reliable measurements</li> <li>High-throughput and less laborious than other methods for assaying &gamma;H2AX levels</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of a novel ELISA-based biodosimeter. 2016-02-16 2026-02-23 2026-02-23 2026-02-23 2016-09-12 and environmental agents, chemotherapeutic agents, DNA damage, ionizing radiation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 166121280 Ji J, et al. Phosphorylated Fraction of H2AX as a Measurement for DNA Damage in Cancer Cells and Potential Applications of a Novel Assay. (PMID: 28158293) https://pubmed.ncbi.nlm.nih.gov/28158293/ <a href="https://pubmed.ncbi.nlm.nih.gov/28158293/">Ji J, et al. Phosphorylated Fraction of H2AX as a Measurement for DNA Damage in Cancer Cells and Potential Applications of a Novel Assay. (PMID: 28158293)</a> 147164009 Redon, Christophe NIH - NCI NCI Redon, Christophe (NCI) 1 147164010 Zhang, Yiping NIH - NCI Leidos Zhang, Yiping (Leidos) 2 147164008 Bonner, William NIH - NCI NCI Bonner, William (NCI) 3 147164011 Ji, Jiuping ("Jay") NIH - NCI Leidos Ji, Jiuping ("Jay") (Leidos) 4 147164009 Redon, Christophe NIH - NCI NCI Redon, Christophe (NCI) 1 147164010 Zhang, Yiping NIH - NCI Leidos Zhang, Yiping (Leidos) 2 147164008 Bonner, William NIH - NCI NCI Bonner, William (NCI) 3 147164011 Ji, Jiuping ("Jay") NIH - NCI Leidos Ji, Jiuping ("Jay") (Leidos) 4 147158309 ELISA Biodosimeter Based On Gamma-H2AX To H2AX Ratios E-276-2014-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage&body=Please send me information about technology [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage&body=Please send me information about technology [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147167592 E-276-2014-0 E-276-2014-0-US-01 Methods and Kits for Measuring and Quantifying DNA Double-Stranded Breaks Using Gamma-H2AX and H2AX PRV US 62/110,764 Abandoned US <br />Provisional (PRV) 62/110,764<br />Filed on 2015-02-02<br />Status: Abandoned 147167593 E-276-2014-0 E-276-2014-0-PCT-02 Methods and Kits For Measuring and Quantifying DNA Double-Stranded Breaks Using Gamma-H2AX and H2AX PCT Patent Cooperation Treaty PCT/US2016/016000 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/016000<br />Filed on 2016-02-01<br />Status: Expired 147167594 E-276-2014-0 E-276-2014-0-US-03 METHODS AND KITS FOR MEASURING AND QUANTIFYING DNA DOUBLE-STRANDED BREAKS USING GAMMA-H2AX AND H2AX National Stage US 10,809,268 15/545,402 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10809268 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10809268">10,809,268</a><br />Filed on 2017-07-21<br />Status: Issued 147174553 and environmental agents 147174555 chemotherapeutic agents 147174556 DNA damage 147174558 ionizing radiation TAB-4214 147157499 Surgical Tool for Sub-retinal Tissue Implantation NEI Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Arvydas Maminishkis <p>The accurate placement of transplanted tissue at a precise position in the retina is difficult but critical for a successful implementation of an ocular surgical intervention.&nbsp;</p> <p>Researchers at the <a href="https://www.nei.nih.gov/" rel="nofollow">National Eye Institute</a> (NEI) developed a surgical tool (see image below)&nbsp;designed to place tissue patches, such as sheets of tissue, onto the retina in a precise and controlled fashion. The tissue for transplantation remains enshrouded in an internal channel until it is accurately delivered to the site of transplant by fluid pressure from a hydrostatic pump.&nbsp; The curved design of the tool matches the curvature of the human eye, and the ease of operation minimizes surgical damage to the eye during placement of the tissue. The secure and precise operation of the tool and delivery of the tissue to the transplantation site maximizes the therapeutic effectiveness. The researchers demonstrated that this tool can be used, with or without modification, to deliver small implantable devices into the retina.&nbsp;</p> <p>This tool is manufactured as a disposable prototype. It is available for licensing and the NEI is open to discussion on potential additional uses of the tool. For example, it is currently being used for autologous iPSC tissue transplant, and can be licensed for this field of use.</p> <p><img alt=" A handheld surgical device/tool designed for intra-ocular delivery and placement of single layer transplant retina tissue to the retina or sub retina. The device is an improvement over similar device as its curved design that matches the curvature of the human eye, making it easier operate and minimizes damage to the eye during placement. " height="150" src="https://nih.technologypublisher.com/files/sites/e-192-2014_image_surgical_tool_for_sub-retinal_delivery_of_rpe_implants4.png" width="732" /></p> <h2>Competitive Advantages:</h2> <p>&bull; Precision of operation for surgeon (no extra moving parts)&nbsp;<br /> &bull; Tool consists of separate disposable parts&nbsp;<br /> &bull; Ease of operation, controlled delivery&nbsp;<br /> &bull; Minimized damage to the eye and transplanted tissue&nbsp;<br /> &bull; Only tool available that can deliver tissue into the sub-retinal space</p> <h2>Commercial Applications:</h2> <p>&bull; Ocular tissue transplantation;<br /> &bull; Delivery of small devices or extended release drug pellets into sub-retinal space</p> 2018-02-16 2025-04-22 2018-07-19 2026-02-18 2018-02-16 EYE, Intra-Ocular, Maminishkis, National Eye Institute, NEI, sub-retinal, surgical tool, tissue placement retina False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-293-2016 147163934 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 1 147163934 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 1 147158184 Surgical Tool For Soft Ocular Tissue Transplantation E-192-2014-0 Filing authorized National Eye Institute (NEI) 147162558 Surgical Tool For Soft Ocular Tissue Transplantation E-192-2014-1 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation&body=Please send me information about technology [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation&body=Please send me information about technology [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147167432 E-192-2014-0 E-192-2014-0-US-01 Surgical Tool and Method for Ocular Tissue Transplantation PRV US 62/023,289 Abandoned US <br />Provisional (PRV) 62/023,289<br />Filed on 2014-07-11<br />Status: Abandoned 147167434 E-192-2014-1 E-192-2014-1-PCT-01 Surgical Tool and Method for Ocular Tissue Transplantation PCT COMB Patent Cooperation Treaty PCT/US2015/039932 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/039932<br />Filed on 2015-07-10<br />Status: Expired 147167435 E-192-2014-1 E-192-2014-1-US-02 Surgical Tool For Soft Ocular Tissue Transplantation National Stage US 10,729,579 15/325,584 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10729579 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10729579">10,729,579</a><br />Filed on 2017-01-11<br />Status: Issued 147167436 E-192-2014-1 E-192-2014-1-AU-03 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Australia 2015287692 Abandoned Australia <br />National Stage 2015287692<br />Filed on 2015-07-10<br />Status: Abandoned 147167437 E-192-2014-1 E-192-2014-1-CA-04 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Canada 2954762 2954762 Issued Canada <br />National Stage 2954762<br />Filed on 2015-07-10<br />Status: Issued 147167438 E-192-2014-1 E-192-2014-1-EP-05 Surgical Tool and Method for Ocular Tissue Transplantation National Stage European Patent 3166550 15741462.4 Issued European Patent <br />National Stage 15741462.4<br />Filed on 2017-02-07<br />Status: Issued 147167439 E-192-2014-1 E-192-2014-1-IN-06 Surgical Tool and Method for Ocular Tissue Transplantation National Stage India 478178 201717003244 Issued India <br />National Stage 201717003244<br />Filed on 2015-07-10<br />Status: Issued 147167440 E-192-2014-1 E-192-2014-1-JP-07 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Japan 6794343 2017-501212 Issued Japan <br />National Stage 2017-501212<br />Filed on 2017-01-10<br />Status: Issued 147167441 E-192-2014-1 E-192-2014-1-US-08 Surgical Tool And Method For Soft Ocular Tissue Transplantation CON US 11,723,799 16/910,388 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11723799 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11723799">11,723,799</a><br />Filed on 2020-06-24<br />Status: Issued 147167442 E-192-2014-1 E-192-2014-1-AU-09 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2020202248 2020202248 Issued Australia <br />Divisional (DIV) 2020202248<br />Filed on 2020-03-30<br />Status: Issued 147167443 E-192-2014-1 E-192-2014-1-EP-10 Surgical Tool and Method for Ocular Tissue Transplantation DIV European Patent 23215832.9 Pending European Patent <br />Divisional (DIV) 23215832.9<br />Filed on 2023-12-12<br />Status: Pending 147167444 E-192-2014-1 E-192-2014-1-AU-11 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2022203098 2022203098 Issued Australia <br />Divisional (DIV) 2022203098<br />Filed on 2022-05-09<br />Status: Issued 147167445 E-192-2014-1 E-192-2014-1-CH-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Switzerland 3166550 15741462.4 Issued Switzerland <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167446 E-192-2014-1 E-192-2014-1-DE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Germany 3166550 15741462.4 Issued Germany <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167447 E-192-2014-1 E-192-2014-1-ES-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Spain 3166550 15741462.4 Issued Spain <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167448 E-192-2014-1 E-192-2014-1-DK-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Denmark 3166550 15741462.4 Issued Denmark <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167449 E-192-2014-1 E-192-2014-1-GB-01 Surgical Tool and Method for Ocular Tissue Transplantation EP United Kingdom 3166550 15741462.4 Issued United Kingdom <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167450 E-192-2014-1 E-192-2014-1-FR-01 Surgical Tool and Method for Ocular Tissue Transplantation EP France 3166550 15741462.4 Issued France <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167451 E-192-2014-1 E-192-2014-1-IE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Ireland 3166550 15741462.4 Issued Ireland <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167452 E-192-2014-1 E-192-2014-1-SE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Sweden 3166550 15741462.4 Issued Sweden <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167453 E-192-2014-1 E-192-2014-1-NL-01 Surgical Tool and Method for Ocular Tissue Transplantation EP The Netherlands 3166550 15741462.4 Issued The Netherlands <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167454 E-192-2014-1 E-192-2014-1-US-01 Surgical Tool And Method For Soft Ocular Tissue Transplantation CON US 18/233,654 Pending US <br />Continuation (CON) 18/233,654<br />Filed on 2023-08-14<br />Status: Pending 164119644 E-192-2014-1 E-192-2014-1-IT-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Italy 3166550 15741462.4 Issued Italy <br />European patent (EP) 15741462.4<br />Filed on 2017-02-07<br />Status: Issued 164119645 E-192-2014-1 E-192-2014-1-AU-12 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2024259653 Pending Australia <br />Divisional (DIV) 2024259653<br />Filed on 2024-10-31<br />Status: Pending 166059827 E-192-2014-1 E-192-2014-1-US-03 SURGICAL TOOL AND METHOD FOR SOFT OCULAR TISSUE TRANSPLANTATION CON US 19/543.817 Pending US <br />Continuation (CON) 19/543.817<br />Filed on 2026-02-18<br />Status: Pending 147173406 EYE 147173407 Intra-Ocular 147173409 Maminishkis 147173410 National Eye Institute 147173411 NEI 147173413 sub-retinal 147173415 surgical tool 147173417 tissue placement retina TAB-5089 165621401 Real-time AI System for Echocardiography Analysis and Quantification NLM Cardiology, Collaboration, Diagnostics, Software / Apps Cardiology Collaboration Diagnostics Software / Apps Ghada Alzamzmi, Sameer Antani, Li-Yueh Hsu, Sivarama Krishnan Rajaraman, Vandana Sachdev <h2>Summary:</h2> <p>We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.</p> <h2>Description of Technology:</h2> <p>Scientists have developed an artificial intelligence (AI) system to automatically extract predictive biomarkers from echocardiography. This AI system takes an echocardiography study as input and produces predictive biomarkers as output in real-time. It performs several automated image analysis tasks including echocardiography quality (quality for the acquired echo clips) assessment, echocardiography view retrieval (e.g., 2D four chamber or parasternal long axis view, Doppler), echocardiography cardiac region segmentation (e.g. inferior vena cava) and cardiac biomarker quantification (e.g. right atrial pressure). This system is:</p> <ol> <li>efficient (in terms of time and space)</li> <li>robust (can handle missing data)</li> <li>interpretable (can provide human-understandable insights)</li> </ol> <p>Such features allow its use in embedded devices for real-world clinical practice and point of care testing. This technology can be used to assist the diagnosis of a wide range of common cardiac diseases as well as to evaluate cardiac function in minority populations such as sickle cell disease patients.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cardiologists in clinical practice, to: <ul> <li>streamline cross-functional workflows</li> <li>obtain temporal biomarkers of a full study in a single run</li> </ul> </li> <li>Cardiology researchers, to: <ul> <li>Enable systematic comparison across millions of echocardiograms</li> <li>rapidly analyze cardiac data across hospitals and research centers</li> <li>perform analysis and quantification for pattern detection, verification, and informed hypothesis testing</li> </ul> </li> <li>Perform diagnosis and assessment of wide range of cardiac diseases including coronary artery disease, heart failure, and cardiopulmonary complications in sickle cell disease patients</li> <li>Once converted into a software application, can be installed in bedside and handheld ultrasound devices to extract imaging biomarkers</li> <li>Can combine the extracted imaging biomarkers with non-imaging biomarkers (e.g., lab tests, age)</li> <li>Applicable to other clinical fields; e.g., endocrinology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Real-time medical imaging <ul> <li>No comparable system in the market that performs a series of medical image tasks in real-time to extract predictive imaging biomarkers from different echo types and views including Doppler, M-model, and B-mode (A2C, A4C, PLAX, IVC, etc.)</li> </ul> </li> <li>Enhance efficiency and save time &ndash; hours to minutes or seconds</li> <li>Enable deeper analysis of a patient&rsquo;s condition</li> <li>Enables the streamlining of tedious clinical tasks (e.g., image analysis tasks and visual biomarkers observation), potentially saving hours of physicians&rsquo; time</li> <li>Reduced costs to payers and patients resulting from decreased physician time</li> <li>Reproducible and precise image analysis anywhere</li> <li>Enables unprecedented portability and standardized access to care &mdash; including visual analytics, predictive biomarker calculation, diagnosis, assessment, and prognosis</li> </ul> Researchers at the NLM are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. 2026-01-14 2026-02-18 2026-02-18 2026-02-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406769 Prototype 52406769 NCI 37470483 Website Abstract 165622365 Zamzmia G, et al. Evaluation of An Artificial Intelligence-Based System for Echocardiographic Estimation of Right Atrial Pressure, International Journal of Cardiovascular Imaging, DOI: 10.1007/s10554-023-02941-8, September 2023. Zamzmia G, et al. Evaluation of An Artificial Intelligence-Based System for Echocardiographic Estimation of Right Atrial Pressure, International Journal of Cardiovascular Imaging, DOI: 10.1007/s10554-023-02941-8, September 2023. 165622368 Zamzmi G, et al. Real-time echocardiography image analysis and quantification of cardiac indices. Medical image analysis, 80, 102438. (2022). https://doi.org/10.1016/j.media.2022.102438 Zamzmi G, et al. Real-time echocardiography image analysis and quantification of cardiac indices. Medical image analysis, 80, 102438. (2022). https://doi.org/10.1016/j.media.2022.102438 165622371 Zamzmi G, et al. Open-world active learning for echocardiography view classification. Medical Imaging 2022: Computer-Aided Diagnosis. Vol. 12033. SPIE, 2022. DOI: https://doi.org/10.1117/12.2612578 Zamzmi G, et al. Open-world active learning for echocardiography view classification. Medical Imaging 2022: Computer-Aided Diagnosis. Vol. 12033. SPIE, 2022. DOI: https://doi.org/10.1117/12.2612578 165622504 Zamzmi G, et al. Fully automated spectral envelope and peak velocity detection from Doppler echocardiography images. Medical Imaging 2020: Computer-Aided Diagnosis. Vol. 11314G. SPIE, 2020. DOI: https://doi.org/10.1117/12.2551183 Zamzmi G, et al. Fully automated spectral envelope and peak velocity detection from Doppler echocardiography images. Medical Imaging 2020: Computer-Aided Diagnosis. Vol. 11314G. SPIE, 2020. DOI: https://doi.org/10.1117/12.2551183 166059633 Zamzmi G, Hsu LY, Li W, Sachdev V, Antani S. Echo doppler flow classification and goodness assessment with convolutional neural networks. 2019 18th IEEE International Conference On Machine Learning And Applications (ICMLA), 2019. DOI: https://doi.org/10.1109/ICMLA.2019.00283 Zamzmi G, Hsu LY, Li W, Sachdev V, Antani S. Echo doppler flow classification and goodness assessment with convolutional neural networks. 2019 18th IEEE International Conference On Machine Learning And Applications (ICMLA), 2019. DOI: https://doi.org/10.1109/ICMLA.2019.00283 165621507 Alzamzmi, Ghada NIH - NLM Alzamzmi, Ghada 1 165621532 Antani, Sameer NIH - NLM NLM Antani, Sameer (NLM) 2 165621551 Hsu, Li-Yueh NIH - CC NHLBI Hsu, Li-Yueh (NHLBI) 3 165622134 Sachdev, Vandana NIH - NHLBI NHLBI Sachdev, Vandana (NHLBI) 4 165622149 Rajaraman, Sivarama Krishnan NIH - NLM NLM Rajaraman, Sivarama Krishnan (NLM) 5 165621507 Alzamzmi, Ghada NIH - NLM Alzamzmi, Ghada 1 165621532 Antani, Sameer NIH - NLM NLM Antani, Sameer (NLM) 2 165621551 Hsu, Li-Yueh NIH - CC NHLBI Hsu, Li-Yueh (NHLBI) 3 165622134 Sachdev, Vandana NIH - NHLBI NHLBI Sachdev, Vandana (NHLBI) 4 165622149 Rajaraman, Sivarama Krishnan NIH - NLM NLM Rajaraman, Sivarama Krishnan (NLM) 5 165621416 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NLM 166060406 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-1 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NIH - NLM, NLM 166060441 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-2 Filing authorized NIH - CC, NIH - NHLBI, NIH - NLM, NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification&body=Please send me information about technology [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification&body=Please send me information about technology [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166060412 E-111-2022-1 E-111-2022-1-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM PRV US 63/458,054 Expired US <br />Provisional (PRV) 63/458,054<br />Filed on 2023-04-07<br />Status: Expired 166060445 E-111-2022-2 E-111-2022-2-PC-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM PCT COMB Patent Cooperation Treaty PCT/US2023/024902 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2023/024902<br />Filed on 2023-06-09<br />Status: Expired 166060446 E-111-2022-2 E-111-2022-2-JP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Japan 2024-572228 Abandoned Japan <br />National Stage 2024-572228<br />Filed on 2024-12-06<br />Status: Abandoned 166060447 E-111-2022-2 E-111-2022-2-CA-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Canada 3258628 Abandoned Canada <br />National Stage 3258628<br />Filed on 2024-12-06<br />Status: Abandoned 166060448 E-111-2022-2 E-111-2022-2-IL-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Israel 317482 Abandoned Israel <br />National Stage 317482<br />Filed on 2024-12-05<br />Status: Abandoned 166060450 E-111-2022-2 E-111-2022-2-CN-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage China 202380055216.5 Abandoned China <br />National Stage 202380055216.5<br />Filed on 2025-01-21<br />Status: Abandoned 166060455 E-111-2022-2 E-111-2022-2-KR-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage South Korea 10-2025-7000599 Abandoned South Korea <br />National Stage 10-2025-7000599<br />Filed on 2025-01-08<br />Status: Abandoned 166060458 E-111-2022-2 E-111-2022-2-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage US 18/872,402 Pending US <br />National Stage 18/872,402<br />Filed on 2024-12-06<br />Status: Pending 166060459 E-111-2022-2 E-111-2022-2-EP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage European Patent 23738969.7 Pending European Patent <br />National Stage 23738969.7<br />Filed on 2024-12-18<br />Status: Pending TAB-3446 114097317 Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants NIAID Licensing Licensing Daniel Douek, Amy Henry, Peter Kwong, John Mascola, John Misasi, Amarendra ("Amar") Pegu, Mario Roederer, Wei Shi, Nancy Sullivan, Lingshu Wang, Eun Yang, Yi Zhang, Tongqing Zhou Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.<br /><br /> Scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases discovered and characterized a group of human monoclonal antibodies that target unique epitopes on the receptor binding domain of SARS-CoV-2 spike protein. These antibodies ultra-potently neutralize >12 variants of SARS-CoV-2, including P1, B.1.429, B.1.1.7 and B.1.351, as shown in a pseudovirus neutralization assay. These antibodies target 3 distinct epitopes in the receptor binding domain of the spike protein and function by blocking ACE2 binding. These antibodies are not impacted by spike mutations that knockout binding to other therapeutic antibodies, including E484K, N439K, Y453F, L452R and K417N. Several antibodies are able to simultaneously bind to the spike protein and are compatible for use in combination therapies. In in vitro assays, these combinations were shown to decrease the appearance of escape mutants suggesting the potential to mitigate resistance development when used as combination therapy.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Ultra-potent neutralization of currently identified SARS-CoV-2 variants</li> <li>Combinations show the potential to mitigate resistance</li> <li>Mechanism of Action – These antibodies bind to block ACE2 receptor binding to the SARS CoV-2 spike protein</li> </ul> <ul> <li>Treatment of SARS-CoV-2 infection</li> </ul> 2022-03-08 2025-08-13 2026-02-09 2021-05-27 antibodies, Coronaviruses, Protein, SARS-CoV-2, spike, Targeting False True True NIHTT 37470483 Website Abstract 114172608 Wang L, et al. https://pubmed.ncbi.nlm.nih.gov/33655252/ <a href="https://pubmed.ncbi.nlm.nih.gov/33655252/">Wang L, et al.</a> 114110215 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 0 114110216 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114110218 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 0 114110219 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110220 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110221 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114110222 Henry, Amy NIAID - DIR NIAID Henry, Amy (NIAID) 0 114110223 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 0 114110224 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114110225 Roederer, Mario NIAID - VRC NIAID Roederer, Mario (NIAID) 0 114110226 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 0 114110227 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 0 114110214 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 114110214 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 114110215 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 0 114110216 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114110218 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 0 114110219 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110220 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110221 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114110222 Henry, Amy NIAID - DIR NIAID Henry, Amy (NIAID) 0 114110223 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 0 114110224 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114110225 Roederer, Mario NIAID - VRC NIAID Roederer, Mario (NIAID) 0 114110226 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 0 114110227 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 0 114102568 Antibodies Targeting The Spike Protein Of Coronaviruses E-037-2021-0 Filing authorized NIAID 160390377 Antibodies Targeting The Spike Protein Of Coronaviruses E-037-2021-1 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants.">bbailey@mail.nih.gov</a><br> 114169124 E-037-2021-0 E-037-2021-0-US-01 Antibodies Targeting The Spike Protein Of Coronaviruses PRV US 63/147,419 Abandoned US <br />Provisional (PRV) 63/147,419<br />Filed on 2021-02-09<br />Status: Abandoned 114169200 E-037-2021-1 E-037-2021-1-PCT-01 Antibodies Targeting The Spike Protein Of Coronaviruses PCT Patent Cooperation Treaty PCT/US2022/015341 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/015341<br />Filed on 2022-02-04<br />Status: Expired 160390382 E-037-2021-1 E-037-2021-1-IN-09 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage India 202317048889 Pending India <br />National Stage 202317048889<br />Filed on 2023-07-20<br />Status: Pending 160390383 E-037-2021-1 E-037-2021-1-JP-10 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Japan 2023-547766 Pending Japan <br />National Stage 2023-547766<br />Filed on 2023-08-08<br />Status: Pending 160390384 E-037-2021-1 E-037-2021-1-CA-04 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Canada 3209136 Pending Canada <br />National Stage 3209136<br />Filed on 2023-07-21<br />Status: Pending 160390385 E-037-2021-1 E-037-2021-1-AU-02 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Australia 2022221297 Pending Australia <br />National Stage 2022221297<br />Filed on 2023-07-17<br />Status: Pending 160390386 E-037-2021-1 E-037-2021-1-IL-08 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Israel 304955 Pending Israel <br />National Stage 304955<br />Filed on 2023-08-03<br />Status: Pending 160390387 E-037-2021-1 E-037-2021-1-CN-06 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage China 202280027556.2 Pending China <br />National Stage 202280027556.2<br />Filed on 2023-10-09<br />Status: Pending 160390388 E-037-2021-1 E-037-2021-1-CL-05 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Chile 202302326 Pending Chile <br />National Stage 202302326<br />Filed on 2022-02-04<br />Status: Pending 160390389 E-037-2021-1 E-037-2021-1-BR-03 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Brazil BR112023015424-3 Pending Brazil <br />National Stage BR112023015424-3<br />Filed on 2023-07-31<br />Status: Pending 160390390 E-037-2021-1 E-037-2021-1-KR-11 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage South Korea 10-2023-7030836 Pending South Korea <br />National Stage 10-2023-7030836<br />Filed on 2023-09-08<br />Status: Pending 160390391 E-037-2021-1 E-037-2021-1-MX-12 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Mexico MX/a/2023/009244 Pending Mexico <br />National Stage MX/a/2023/009244<br />Filed on 2023-08-07<br />Status: Pending 160390392 E-037-2021-1 E-037-2021-1-US-01 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage US 18/263,995 Pending US <br />National Stage 18/263,995<br />Filed on 2023-08-02<br />Status: Pending 160390393 E-037-2021-1 E-037-2021-1-EP-07 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage European Patent 22705961.5 Pending European Patent <br />National Stage 22705961.5<br />Filed on 2023-08-22<br />Status: Pending 165573219 E-037-2021-1 E-037-2021-1-JP-13 Antibodies Targeting The Spike Protein Of Coronaviruses DIV Japan In Preparation Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 165938906 E-037-2021-1 E-037-2021-1-CL-14 Antibodies Targeting The Spike Protein Of Coronaviruses DIV Chile In Preparation Chile <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 114152177 antibodies 114152178 Targeting 114152179 spike 114152180 Protein 114152181 Coronaviruses 114152182 SARS-CoV-2 TAB-3289 114097216 Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin NIAID Licensing, Research Materials Licensing Research Materials Richard Davey, Thomas Nutman Reagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-034) 2022-03-08 2026-02-06 2026-02-06 2018-06-07 antibodies, BASIC, CATIONIC, EOSINOPHIL, Eosinophil-Derived, Eosionophil, Human, Listed LPM Fenn as of 4/15/2015, MAJOR, monoclonal, Neurotoxin, PEROXIDASE, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109741 Davey, Richard NIAID - DIR NIAID Davey, Richard (NIAID) 0 114109740 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109740 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109741 Davey, Richard NIAID - DIR NIAID Davey, Richard (NIAID) 0 114102450 Polyclonal And Monoclonal Antibodies To Human Eosinophil Major Basic Protein, Eosionophil Peroxidase, Eosinophil Cationic Protein, And Eosinophil-Derived Neurotoxin E-286-2014-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin&body=Please send me information about technology [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin&body=Please send me information about technology [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin.">jonathan.motley@nih.gov</a><br> 114127949 WIXXXX 114150931 polyclonal 114150932 monoclonal 114150933 antibodies 114150934 Human 114150935 EOSINOPHIL 114150936 MAJOR 114150937 BASIC 114150938 Protein 114150939 Eosionophil 114150940 PEROXIDASE 114150941 CATIONIC 114150942 Eosinophil-Derived 114150943 Neurotoxin 114150944 Listed LPM Fenn as of 4/15/2015 114150945 Pre LPM working set 20150418 114150946 Post LPM Assignment Set 20150420 114150969 RM TAB-3282 114094375 Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays NIAID Infectious Disease, Licensing, Materials Available, Research Materials Infectious Disease Licensing Materials Available Research Materials Sasi Bennuru, Papa Drame, Thomas Nutman Loa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-012) 2022-03-08 2026-02-06 2026-02-06 2018-06-07 ANTIGENS, IMMUNOASSAYS, Listed LPM Fenn as of 4/15/2015, Loa, Microfilariae, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, QUANTITATIVE, RM, VQXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109728 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109729 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114109727 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109727 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109728 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109729 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114102444 Antigens For Use In Loa Loa Microfilariae Quantitative Immunoassays E-230-2014-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays&body=Please send me information about technology [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays&body=Please send me information about technology [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays.">jonathan.motley@nih.gov</a><br> 114127927 VQXXXX 114127928 WIXXXX 114150844 IMMUNOASSAYS 114150845 QUANTITATIVE 114150846 Microfilariae 114150847 Loa 114150848 ANTIGENS 114150849 Listed LPM Fenn as of 4/15/2015 114150850 Pre LPM working set 20150418 114150851 Post LPM Assignment Set 20150420 114150852 RM TAB-3273 114097197 Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Amy Klion, Thomas Nutman A Loa loa specific antigen that can be used as the basis of an immunoassay for the diagnosis of Loa loa infection. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2015-035) 2022-03-08 2026-02-06 2026-02-06 2018-06-07 Immunodiagnosis, LL-SXP1, Loa, RM, VQXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114108380 Klion, Amy NIAID - DIR NIAID Klion, Amy (NIAID) 0 114108381 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108381 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108380 Klion, Amy NIAID - DIR NIAID Klion, Amy (NIAID) 0 114102026 LL-SXP1 For The Immunodiagnosis Of Loa Loa E-003-2016-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa&body=Please send me information about technology [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa&body=Please send me information about technology [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa.">jonathan.motley@nih.gov</a><br> 114127910 VQXXXX 114127911 WIXXXX 114150747 LL-SXP1 114150748 Immunodiagnosis 114150749 Loa 114150750 RM TAB-3120 114095716 Compositions and Methods for Detecting Loa loa NIAID Collaboration Collaboration Sasi Bennuru, Papa Drame, Thomas Nutman <em>Loa loa</em> is a filarial nematode estimated to infect 3-13 million people in Central and Western Africa. In parts of Africa, mass administration of ivermectin is common for onchocerciasis and lymphatic filariasis control. However, some individuals infected with <em>Loa loa</em> microfilariae in high densities are known to experience post-ivermectin severe adverse events, such as encephalopathy, coma, or even death. Therefore, diagnostic tools that can accurately identify and differentiate <em>Loa loa</em> microfilariae from other filarial infections are needed. Microscopic evaluation of blood samples is the only current diagnostic method used to detect <em>Loa loa</em> microfilaremia in endemic areas, and is impractical for widespread screening. Molecular based assays are useful and are quantitative, but require the use of sophisticated instrumentation.<br /><br /> The inventors analyzed samples from <em>Loa loa</em> infected patients and uninfected controls, and have identified <em>Loa loa</em> microfilaria-specific antigens. The pending application claims a variety of means of detecting these antigens. <ul> <li>Highly specific to <em>Loa loa</em> microfilariae</li> <li>Highly sensitive</li> <li>Both diagnostic and quantitative</li> <li>Works with blood, urine, or saliva sample</li> </ul> <ul> <li>Diagnostics</li> <ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. 2022-03-08 2026-02-06 2026-02-06 2021-10-29 2021-10-15 ANTIGENS, Diagnostics, Listed LPM Fenn as of 4/15/2015, Loa, Microfilariae, Post LPM Assignment Set 20150420, Pre LPM working set 20150418 False True True NIHTT 37470483 Website Abstract 114172305 Drame PM, et al. http://www.ncbi.nlm.nih.gov/pubmed/26884435 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26884435">Drame PM, et al.</a> 114109197 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109198 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114109199 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109199 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109197 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109198 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114101814 Antigens For Use In Loa Loa Microfilariae Diagnostics E-140-2015-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3120] Compositions and Methods for Detecting Loa loa&body=Please send me information about technology [TAB-3120] Compositions and Methods for Detecting Loa loa. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3120] Compositions and Methods for Detecting Loa loa&body=Please send me information about technology [TAB-3120] Compositions and Methods for Detecting Loa loa.">jonathan.motley@nih.gov</a><br> 114159997 E-140-2015-0 E-140-2015-0-PCT-02 COMPOSITIONS AND METHODS FOR DETECTING LOA LOA PCT Patent Cooperation Treaty PCT/US2016/029673 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/029673<br />Filed on 2016-04-28<br />Status: Expired 114164219 E-140-2015-0 E-140-2015-0-US-01 Compositions and Methods for Detecting Loa Loa PRV US 62/153,654 Abandoned US <br />Provisional (PRV) 62/153,654<br />Filed on 2015-04-28<br />Status: Abandoned 114168013 E-140-2015-0 E-140-2015-0-US-03 COMPOSITIONS AND METHODS FOR DETECTING LOA LOA National Stage US 10,598,655 15/569,507 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10598655 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10598655">10,598,655</a><br />Filed on 2017-10-26<br />Status: Issued 114148919 Post LPM Assignment Set 20150420 114148920 Pre LPM working set 20150418 114148921 Listed LPM Fenn as of 4/15/2015 114148922 Diagnostics 114148923 Microfilariae 114148924 Loa 114148925 ANTIGENS TAB-2669 114096853 Recombinant NIE Antigen from Strongyloides stercoralis NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Franklin Neva, Thomas Nutman, Ravi Varatharajalu <em>Strongyloides stercoralis</em> is an intestinal nematode endemic that affects an estimated 30 to 100 million people worldwide. Many of these individuals may be asymptomatic for decades. The present invention discloses a NIE recombinant antigen that can be used in improved assays and diagnostics for <em>S. stercoralis</em> infection. The NIE antigen is the only one that is non-cross-reactive with sera from humans with other related filaria infections. The NIE antigen can be utilized as a skin test antigen for immediate hypersensitivity as well as for use in ELISA or other assays. <ul> <li>Only non-cross-reactive <em>Strongyloides antigen</em></li> <li>Use in a variety of formats</li> </ul> <ul> <li>Assays and diagnostics for <em>S. stercoralis</em> infection</li> </ul> Research Material – Patent protection is not being pursued for this technology. 2022-03-08 2026-02-06 2026-02-06 2013-11-13 ANTIGEN, DA2XXX, DAXXXX, DDXXXX, DXXXXX, recombinant, S., SS-NIE, Stercoralis False True <ul> <li>Prototype</li> <li>Pilot</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114170606 Krolewiecki AJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/20739501 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20739501">Krolewiecki AJ, et al.</a> 114171927 Ramanathan R, et al. http://www.ncbi.nlm.nih.gov/pubmed/18558872 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18558872">Ramanathan R, et al.</a> 114171928 Ravi V, et al. http://www.ncbi.nlm.nih.gov/pubmed/15891128 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15891128">Ravi V, et al.</a> 114171929 Ravi V, et al. http://www.ncbi.nlm.nih.gov/pubmed/12467975 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12467975">Ravi V, et al.</a> 114108215 Varatharajalu, Ravi George Washington University Varatharajalu, Ravi 0 114108216 Neva, Franklin NIAID - DIR Neva, Franklin 0 114108214 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108214 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108215 Varatharajalu, Ravi George Washington University Varatharajalu, Ravi 0 114108216 Neva, Franklin NIAID - DIR Neva, Franklin 0 114101980 SS-NIE, Recombinant Antigen From S. Stercoralis E-081-2012-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis&body=Please send me information about technology [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis&body=Please send me information about technology [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis.">jonathan.motley@nih.gov</a><br> 114123868 DA2XXX 114123869 DDXXXX 114123870 DXXXXX 114123871 DAXXXX 114145285 ANTIGEN 114145286 recombinant 114145287 SS-NIE 114145288 Stercoralis 114145289 S. TAB-2133 114096351 Novel Antigen for Use as Vaccine Against Nematode Infection NIAID Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Therapeutics Vaccines David Abraham, Thomas Nutman This invention describes a new vaccine against <i>Strongyoides stercoralis</i>, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with <i>S. stercoralis</i> infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses <i>S. stercoralis</i> immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen. In addition, sera from immunized mice have also been used to effectively protect naive mice from infection.<br><br> The invention may also have potential use in diminishing allergic responses, as <i>Strongyoides stercoralis</i> infection has been shown to reduce the murine response to allergens. Consequently, SsIR may be used to immunize individuals and reduce the allergic response. The antigen may also be used to identify homologous antigens from other parasitic nematodes that may be important for vaccine development. <ul> <li>Vaccines against <i>S. stercoralis</i> infection</li> <li>Discovery and use of other anti-parasitic antigens for vaccines</li> <li>Potential for allergy therapy</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. Available for licensing 2022-03-08 2026-02-06 2026-02-06 2021-10-29 2021-10-15 Against, ANTIGEN, DB2XXX, DBXXXX, DC2XXX, DCXXXX, DXXXXX, Immunorcaclive, Infection, Patent Category - Biotechnology, Protection, S., SslR, Stercaralis, Stercoralis, STRONGYLOIDES, Vaccine False True Early stage True NIHTT 37470483 Website Abstract 114106930 Abraham, David Thomas Jefferson University Abraham, David 0 114106929 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114106929 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114106930 Abraham, David Thomas Jefferson University Abraham, David 0 114101434 S. Stercoralis Immunoreactive Antigen (SslR) As A Vaccine For Protection Against Strongyloides Stercoralis Infection E-084-2010-0 Filing authorized NIAID, Thomas Jefferson University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection&body=Please send me information about technology [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection&body=Please send me information about technology [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection.">jonathan.motley@nih.gov</a><br> 114163890 E-084-2010-0 E-084-2010-0-US-03 Vaccine And Methods Of Use Against Strongyloides Stercoralis Infection National Stage US 9,056,068 13/575,987 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9056068 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9056068">9,056,068</a><br />Filed on 2012-08-15<br />Status: Issued 114166098 E-084-2010-0 E-084-2010-0-US-01 Human Monoclonal Antibodies That Bind Insulin-like Growth Factor (IGF) I and II PRV US 61/301,426 Abandoned US <br />Provisional (PRV) 61/301,426<br />Filed on 2010-02-04<br />Status: Abandoned 114166313 E-084-2010-0 E-084-2010-0-PCT-02 Vaccine And Methods of Use Against Strongyloides Stercoralis Infection PCT Patent Cooperation Treaty PCT/US2011/023320 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/023320<br />Filed on 2011-02-01<br />Status: Expired 114121411 DC2XXX 114121412 DB2XXX 114121413 DXXXXX 114121414 DCXXXX 114121415 DBXXXX 114140150 S. 114140151 Stercoralis 114140152 Immunorcaclive 114140153 ANTIGEN 114140154 SslR 114140155 Vaccine 114140156 Protection 114140157 Against 114140158 STRONGYLOIDES 114140159 Stercaralis 114140160 Infection 114140161 Patent Category - Biotechnology TAB-1996 114096216 Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21 NIAID Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Thomas Wynn This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R monoclonal antibodies or the sequestration of IL-21 by soluble IL-21R or anti-IL-21 monoclonal antibodies has been demonstrated to reduce TH2 immune responses associated with fibrosis in animal models.<br /><br /> The causes of chronic tissue fibrosis are diverse and the market for a therapeutic that targets fibrosis is large. Fibrosis is associated with diverse causes which include: genetic diseases (such as cystic fibrosis); autoimmune diseases (such as scleroderma); chronic viral infections (such as hepatitis), parasitic infections (such as schistosomiasis); and occupational exposures to causative agents (such as asbestosis). Additionally, many cases of tissue fibrosis are idiopathic. <ul> <li>The treatment or amelioration of tissue fibrosis.</li> </ul> International rights available. Available for licensing. 2022-03-08 2026-02-06 2026-02-06 2009-07-29 Asbestosis, CB1AXX, CB1XXX, CB6XXX, CBXXXX, CXXXXX, Cystic fibrosis, DEFICIENCY, FIBROSIS, Hepatitis A, Hepatitis D, Hepatitis E, IL-21, Immunity, Inflammmation, Patent Category - Biotechnology, RECEPTOR, REDUCES, SCHISTOSOMIASIS, Schistosomiasis (Schistosoma sp.), Scleroderma, Scleroderma, systemic, Tissue, TYPE-2 False True True NIHTT 37470483 Website Abstract 114170892 Pesce J, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. https://www.ncbi.nlm.nih.gov/pubmed/16778988 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16778988">Pesce J, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation.</a> 114106709 Wynn, Thomas NIAID - DIR NIAID Wynn, Thomas (NIAID) 0 114106709 Wynn, Thomas NIAID - DIR NIAID Wynn, Thomas (NIAID) 0 114101279 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis E-250-2005-0 Filing authorized Genetics Institute, Inc., NIAID, Wyeth 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21&body=Please send me information about technology [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21&body=Please send me information about technology [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21.">jonathan.motley@nih.gov</a><br> 114162892 E-250-2005-0 E-250-2005-0-US-01 Methods and Compositions for treating and preventing fibrosis (Wyeth Ref.: AM101991L1) PRV US 60/671,374 Abandoned US <br />Provisional (PRV) 60/671,374<br />Filed on 2005-04-14<br />Status: Abandoned 114165410 E-250-2005-0 E-250-2005-0-US-02 METHODS FOR TREATING AND PREVENTING FIBROSIS ORD US 7,910,105 11/402,885 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7910105 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7910105">7,910,105</a><br />Filed on 2006-04-13<br />Status: Expired 114165411 E-250-2005-0 E-250-2005-0-PCT-03 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS PCT Patent Cooperation Treaty PCT/US2006/013829 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/013829<br />Filed on 2006-04-13<br />Status: Expired 114166366 E-250-2005-0 E-250-2005-0-US-44 Methods For Treating And Preventing Fibrosis DIV US 13/030,840 Abandoned US <br />Divisional (DIV) 13/030,840<br />Filed on 2011-02-18<br />Status: Abandoned 114120508 CB6XXX 114120509 CB1AXX 114120510 CXXXXX 114120511 CBXXXX 114120512 CB1XXX 114138414 IL-21 114138415 RECEPTOR 114138416 DEFICIENCY 114138417 REDUCES 114138418 TYPE-2 114138419 Immunity 114138420 Inflammmation 114138421 Tissue 114138422 FIBROSIS 114138423 Patent Category - Biotechnology 114156859 Hepatitis D 114156860 Scleroderma, systemic 114156861 Hepatitis A 114156862 Asbestosis 114156863 Cystic fibrosis 114156864 Hepatitis E 114156865 SCHISTOSOMIASIS 114157883 Schistosomiasis (Schistosoma sp.) 114158517 Scleroderma TAB-5090 165796379 Humanized 40H3 Antibody NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Antonella Antignani, David Fitzgerald, Robert Sarnovsky <h2>Summary:</h2> <p>The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.</p> <h2>Description of Technology:</h2> <p>Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have previously isolated a mouse monoclonal antibody that binds to the human EGFRvIII &ndash; but not wildtype EGFR known as the 40H3 antibody (NCI Ref: E-103-2019). To improve the 40H3 antibody&rsquo;s suitability for the clinic, the inventors humanized the antibody through the generation of multiple variants with distinct sequences. The inventors produced about 14 humanized candidates of the 40H3 antibody. Significantly, CAR Ts using one of the antibodies (A10) showed potent killing of cancer cells in various pre-clinical models overexpressing EGFR. The pre-clinical results obtained to date suggest that the A10 antibody is a promising candidate for development as various therapeutics for the treatment of EGFRvIII-expressing cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer therapeutic against numerous EGFRvIII-expressing tumor types &ndash; including, but not limited to, lung cancer, head and neck cancer and GBM.</li> <li>Therapeutic applications of the unconjugated antibodies</li> <li>Use of the unconjugated antibodies as a targeting moiety in antibody-drug conjugates (ADCs), radio-immunotherapies (RITs) and chimeric antigen receptors (CARs)</li> <li>Diagnostic agent for detection and monitoring levels of EGFRvIII-expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Less non-specific cell killing using humanized EGFRvIII antibodies with high EGFRvIII binding specificity will result in fewer and lower grade potential side effects</li> <li>Therapeutic development against various common and rare cancers represent many paths to market and out-licensing opportunities</li> <li><span style="font-size:12pt"><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-family:&quot;Times New Roman&quot;,serif">CAR Ts using the A10 antibody are available for immediate testing</span></span></span></span></li> <li><span style="font-size:12pt"><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-family:&quot;Times New Roman&quot;,serif">A10 binding EGFR when over-expressed from amplified EGFR is specific to various cancers&nbsp;&nbsp;</span></span></span></span></li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for monoclonal antibodies that specifically target cancer-expressed EGFR. 2026-01-28 2026-02-05 2026-02-05 2026-02-05 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-103-2019 165796614 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 165796640 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 165796655 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 3 165796614 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 165796640 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 165796655 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 3 165796382 Humanization of the monoclonal antibody, 40H3: generation of improved variants E-188-2023-0 Filing authorized Laboratory of Molecular Biology, National Cancer Institute (NCI), NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5090] Humanized 40H3 Antibody&body=Please send me information about technology [TAB-5090] Humanized 40H3 Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5090] Humanized 40H3 Antibody&body=Please send me information about technology [TAB-5090] Humanized 40H3 Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 165796387 E-188-2023-0 E-188-2023-0-US-01 HUMANIZED 40H3 ANTIBODY PRV US 63/525,493 Expired US <br />Provisional (PRV) 63/525,493<br />Filed on 2023-07-07<br />Status: Expired 165796388 E-188-2023-0 E-188-2023-0-PC-01 HUMANIZED 40H3 ANTIBODY PCT Patent Cooperation Treaty PCT/US2024/037091 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/037091<br />Filed on 2024-07-08<br />Status: Expired 165796389 E-188-2023-0 E-188-2023-0-JP-01 HUMANIZED 40H3 ANTIBODY National Stage Japan 2026-500043 Pending Japan <br />National Stage 2026-500043<br />Filed on 2026-01-05<br />Status: Pending 165796390 E-188-2023-0 E-188-2023-0-CA-01 HUMANIZED 40H3 ANTIBODY National Stage Canada 3297257 Pending Canada <br />National Stage 3297257<br />Filed on 2025-12-30<br />Status: Pending 165796391 E-188-2023-0 E-188-2023-0-AU-01 HUMANIZED 40H3 ANTIBODY National Stage Australia 2024296940 Pending Australia <br />National Stage 2024296940<br />Filed on 2026-01-13<br />Status: Pending 165796392 E-188-2023-0 E-188-2023-0-CN-01 HUMANIZED 40H3 ANTIBODY National Stage China 202480057586.7 Pending China <br />National Stage 202480057586.7<br />Filed on 2026-04-01<br />Status: Pending 165796393 E-188-2023-0 E-188-2023-0-US-02 HUMANIZED 40H3 ANTIBODY National Stage US 19/497,173 Pending US <br />National Stage 19/497,173<br />Filed on 2025-12-24<br />Status: Pending 165796394 E-188-2023-0 E-188-2023-0-EP-01 HUMANIZED 40H3 ANTIBODY National Stage European Patent 24748511.3 Pending European Patent <br />National Stage 24748511.3<br />Filed on 2026-01-27<br />Status: Pending TAB-4590 151763295 Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity NIDCD Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Lisa Cunningham, Katharine Fernandez, Nicle Schmitt <p>This technology includes the use of atorvastatin, a medication to manage hypercholesterolemia, as a method to protect patients receiving cisplatin from hearing loss. Cisplatin chemotherapy is indicated in various cancer types in adults and children and is known to cause hearing loss. A patient on atorvastatin during chemotherapy is 46% less likely to acquire a significant cisplatin-induced hearing loss relative to a non-statin user. Atorvastatin is an FDA-approved medication routinely prescribed and well-tolerated clinically. The quality of life in cisplatin-treated cancer patients may be dramatically improved by using atorvastatin to protect their hearing during cisplatin-based chemotherapy.</p> Currently, there is no FDA-approved clinical treatment to prevent hearing loss in patients receiving cisplatin as part of their cancer chemotherapy. Atorvastatin has a good safety profile, oral administration is non-invasive; significant side effects are rare, and statins do not reduce survival rates in cisplatin-treated patients. Atorvastatin could be rapidly translated into clinical practice to protect the hearing of cancer patients undergoing cisplatin therapy. 2023-12-12 2024-08-12 2026-01-30 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151763348 Fernandez K, et al. https://pubmed.ncbi.nlm.nih.gov/33393488/ <a href="https://pubmed.ncbi.nlm.nih.gov/33393488/">Fernandez K, et al.</a> 151763310 Cunningham, Lisa National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cunningham, Lisa (NIDCD) 1 151763320 Schmitt, Nicle Schmitt, Nicle 2 151763336 Fernandez, Katharine National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Fernandez, Katharine (NIDCD) 3 151763310 Cunningham, Lisa National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cunningham, Lisa (NIDCD) 1 151763320 Schmitt, Nicle Schmitt, Nicle 2 151763336 Fernandez, Katharine National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Fernandez, Katharine (NIDCD) 3 151763301 Concurrent Use Of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity E-029-2020-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity&body=Please send me information about technology [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity&body=Please send me information about technology [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity.">shmilovm@nih.gov</a><br> 157762794 E-029-2020-0 E-029-2020-0-US-01 Use of Statins to Treat or Prevent Drug Induced Hearing Loss PRV US 62/966,794 Abandoned US <br />Provisional (PRV) 62/966,794<br />Filed on 2020-01-28<br />Status: Abandoned 157762799 E-029-2020-0 E-029-2020-0-PCT-02 USE OF STATINS TO TREAT OR PREVENT DRUG INDUCED HEARING LOSS PCT Patent Cooperation Treaty PCT/U2021/014918 Expired Patent Cooperation Treaty <br />(PCT) PCT/U2021/014918<br />Filed on 2021-01-25<br />Status: Expired 157762804 E-029-2020-0 E-029-2020-0-EP-03 USE OF STATINS TO TREAT OR PREVENT DRUG INDUCED HEARING LOSS National Stage European Patent 21705831.2 Abandoned European Patent <br />National Stage 21705831.2<br />Filed on 2021-01-25<br />Status: Abandoned 157762809 E-029-2020-0 E-029-2020-0-US-04 USE OF STATINS TO TREAT OR PREVENT DRUG-INDUCED HEARING LOSS National Stage US 17/791,239 Abandoned US <br />National Stage 17/791,239<br />Filed on 2022-07-07<br />Status: Abandoned TAB-5004 158054566 PET Imaging Agents for Fungal Infections NHLBI Collaboration, Diagnostics, Licensing Collaboration Diagnostics Licensing Falguni Bhattacharyya, Dima Hammoud, Swati Shah, Rolf Swenson, Peter Williamson, Xiang Zhang <p><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Available for licensing and commercial development are patent rights covering PET imaging agents, methods of their synthesis, and their uses in imaging specific fungal infections. &nbsp;Fungal infections remain a global health problem resulting in over 1.5 million annual deaths.&nbsp; Immunocompromised patients, especially those undergoing cancer treatments or transplantation, are particularly vulnerable and the fungus, <em>Aspergillus fumigatus, </em>is of particular concern.&nbsp; To date, no fungal-<em>specific</em> imaging agents are available&mdash;existing imaging agents cannot discern fungal pathogens from bacteria or viruses and generally cannot differentiate between infection and inflammation. One naturally-occurring disaccharide, cellobiose, is selectively hydrolyzed by <em>Aspergillus fumigatus</em> and not by bacteria or human cells. &nbsp;The fluorinated version of the disaccharide, <sup>18</sup>F-Fluorodeoxycellobiose ([18F]-FCB), has been synthesized and tested. [18F]-FCB is particularly useful as it is not metabolized by human enzymes and hydrolyzed only by fungal beta-glucosidases. &nbsp;Both in vitro and in vivo testing in animal models (see publications below) of different infections and inflammation confirmed radioactivity accumulation only in live pathogenic fungi.&nbsp; Imaging with [18F]-FCB in mice infected with Aspergillus, for example, &nbsp;showed that the imaging agent can detect whether there has been a response to antifungal therapy.&nbsp; One major advantage is that synthesis of [18F]-FCB is simple and efficient using readily commercially available reagents. &nbsp;&nbsp;The radiolabeled agent can then be administered intravenously, and imaging performed 90-120 minutes after injection.&nbsp; A radiosynthesis kit has also been developed and can be used at ambient temperature to produce [18F]-FCB from a commercially acquired kit in less than two hours without the need for a cyclotron.</span></span></p> <ul> <li>Imaging of live infections</li> </ul> 2024-09-04 2025-08-13 2026-01-29 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 158056239 Hammoud, Dima Radiology and Imaging Sciences CC Hammoud, Dima (CC) 1 158056738 Shah, Swati Clinical Center (CC) Shah, Swati 2 158057071 Williamson, Peter NIAID - DIR NIAID Williamson, Peter (NIAID) 3 158057105 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 4 158057174 Zhang, Xiang National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhang, Xiang (NHLBI) 5 158057735 Bhattacharyya, Falguni National Heart, Lung, and Blood Institute (NHLBI) NHLBI Bhattacharyya, Falguni (NHLBI) 6 158056239 Hammoud, Dima Radiology and Imaging Sciences CC Hammoud, Dima (CC) 1 158056738 Shah, Swati Clinical Center (CC) Shah, Swati 2 158057071 Williamson, Peter NIAID - DIR NIAID Williamson, Peter (NIAID) 3 158057105 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 4 158057174 Zhang, Xiang National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhang, Xiang (NHLBI) 5 158057735 Bhattacharyya, Falguni National Heart, Lung, and Blood Institute (NHLBI) NHLBI Bhattacharyya, Falguni (NHLBI) 6 158054574 Radiolabeled Sugars For Imaging Of Fungal Infections E-163-2019-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NIAID 158054579 Enzymatic Radiosynthesis of 2-deoxy 2-{18F] fluorocellobiose E-080-2023-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI) 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5004] PET Imaging Agents for Fungal Infections&body=Please send me information about technology [TAB-5004] PET Imaging Agents for Fungal Infections. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5004] PET Imaging Agents for Fungal Infections&body=Please send me information about technology [TAB-5004] PET Imaging Agents for Fungal Infections.">malabika.ghosh@nih.gov</a><br> 158054584 E-080-2023-0 E-080-2023-0-US-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE PRV US 63/492,302 Expired US <br />Provisional (PRV) 63/492,302<br />Filed on 2023-03-27<br />Status: Expired 158054585 E-080-2023-0 E-080-2023-0-PC-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE PCT Patent Cooperation Treaty PCT/US2024/021440 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/021440<br />Filed on 2024-03-26<br />Status: Expired 163509665 E-080-2023-0 E-080-2023-0-US-02 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE National Stage US 19/167,752 Pending US <br />National Stage 19/167,752<br />Filed on 2025-09-22<br />Status: Pending 163509710 E-080-2023-0 E-080-2023-0-EP-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE National Stage European Patent 24721311.9 Pending European Patent <br />National Stage 24721311.9<br />Filed on 2025-09-18<br />Status: Pending 165818912 E-080-2023-0 E-080-2023-0-HK-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE National Stage Hong Kong In Preparation Hong Kong <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-3817 114097664 Lymphatic Filariasis Biomarkers for Detection and Surveillance NIAID Sasi Bennuru, Thomas Nutman Lymphatic filariasis (elephantiasis; LF) is a neglected tropical disease that affects over 120 million people throughout the tropics and sub­tropics of Asia, Africa, the Western Pacific, and parts of the Caribbean and South America. LF results from infection with the filarial parasites Wuchereria bancrofti or Brugia malayi. Current methods of confirming active infection by W. bancrofti or B. malayi include microscopy and immunoassays using serum/plasma extracted from the patient. However, the sensitivity of microscopy detection varies among patients, and immunoassays show cross-reactivity with antibodies directed towards other parasites, such as Onchocerca volvulus or Loa loa whose geographic distribution can overlap with the LF-causing filarial parasites. <br /><br /> This new technology addresses the limitations of cross-reactivity through the detection of a single antigen, Wb5B, selected due to a lack of homologs in other filarial parasites that infect humans. Preliminary data indicates that Wb5B is immunogenic, highly specific (>99%), and accurate (>90%) for the detection of W. bancrofti infection in sera from humans and other mammalian sources. The antigen can be isolated in soluble form for integration in a variety of diagnostic assay formats. <ul> <li>Increased specificity compared to available diagnostics</li> <li>Differentiation from other parasites with similar geographic footprints</li> </ul> <ul> <li>Diagnostics for W. bancrofti infection</li> <li>Surveillance for W. bancrofti prevalence</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Theodoric Mattes at <a href="mailto: theodoric.mattes@nih.gov."> theodoric.mattes@nih.gov.</a>or 240-627-3827. 2022-09-28 2026-01-22 2026-01-22 2022-09-28 2IXXXX, 2XXXXX, Biomarkers, Detection, Filariasis, Lymphatic, Surveillance False False True NIHTT 37470483 Website Abstract E-281-2010-0 114111637 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114111638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114111638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114111637 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114102914 Lymphatic Filariasis Biomarkers For Detection And Surveillance E-093-2022-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance&body=Please send me information about technology [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance&body=Please send me information about technology [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance.">jonathan.motley@nih.gov</a><br> 114169653 E-093-2022-0 E-093-2022-0-US-01 COMPOSITIONS AND METHODS FOR DETECTING LYMPHATIC FILARIASIS PRV US 63/347,794 Expired US <br />Provisional (PRV) 63/347,794<br />Filed on 2022-06-01<br />Status: Expired 114129707 2IXXXX 114129710 2XXXXX 114155636 Filariasis 114155637 Lymphatic 114155638 Biomarkers 114155639 Detection 114155640 Surveillance TAB-3343 114097258 Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level. NIAID Collaboration Collaboration Daniel Barber, Keith Kauffman, Michelle Sallin <em>Mycobacterium tuberculosis</em> (Mtb) infection continues to be the leading cause of death due to a single infectious agent and poses significant global health challenges. Past research has shown that CD4 T cells are essential for resistance to Mtb infection, and for decades it has been thought that IFN(?) production is the primary mechanism of CD4 T cell-mediated protection. <br /><br /> NIAID researchers have discovered that the expression of TNF superfamily molecule CD153 (TNSF8) is required for control of the pulmonary Mtb infection by CD4 T cells. The results have shown that, in Mtb infected mice, CD153 expression is highest on Ag-specific Th1 cells in the lung tissue parenchyma. On the contrary, CD153 deficient mice have developed high pulmonary bacterial loads and succumb early to Mtb infection. In Mtb infected non-human primates, CD153 expression is much higher on Ag-specific CD4 T cells in the airways compared to the blood, and the frequency of Mtb-specific CD153-expressing CD4 T cells inversely correlates with bacterial loads in granulomas. Further, in Mtb infected humans, CD153 defines a subset of highly polyfunctional Mtb-specific CD4 T cells that are much more abundant in individuals with controlled latent Mtb infection compared to those with active TB. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future. <ul> <li>Ability to be used as a target for Mtb diagnostics and therapeutics</li> </ul> <ul> <li><em>Mycobacterium tuberculosis</em> diagnostic that measures the production of CD153 as an indicator of the disease and its severity </li> <li>A companion diagnostic can be used to determine the effectiveness of a vaccine against a <em>Mycobacterium tuberculosis</em> infection in a subject</li> <li>Therapeutic use to treat <em>Mycobacterium tuberculosis</em> in a subject</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. 2022-03-08 2026-01-22 2026-01-22 2021-11-02 CD153/CD30, Diagnosis, PATHWAY, Targeting, treatment, TUBERCULOSIS False True True NIHTT 37470483 Website Abstract 114172546 Sallin, Michelle A., et al. https://www.ncbi.nlm.nih.gov/pubmed/30202016 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30202016">Sallin, Michelle A., et al.</a> 114109964 Sallin, Michelle NIAID - DIR NIA Sallin, Michelle (NIA) 0 114109965 Kauffman, Keith NIAID - DIR NIAID Kauffman, Keith (NIAID) 0 114109963 Barber, Daniel NIAID - DIR NIAID Barber, Daniel (NIAID) 1 114109963 Barber, Daniel NIAID - DIR NIAID Barber, Daniel (NIAID) 1 114109964 Sallin, Michelle NIAID - DIR NIA Sallin, Michelle (NIA) 0 114109965 Kauffman, Keith NIAID - DIR NIAID Kauffman, Keith (NIAID) 0 114102501 Targeting The CD153/CD30 Pathway For The Treatment And Diagnosis Of Tuberculosis E-085-2018-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.&body=Please send me information about technology [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.&body=Please send me information about technology [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level..">jonathan.motley@nih.gov</a><br> 114168784 E-085-2018-0 E-085-2018-0-US-01 CD153 AND MYCOBACTERIUM TUBERCULOSIS INFECTION PRV US 62/633,816 Abandoned US <br />Provisional (PRV) 62/633,816<br />Filed on 2018-02-22<br />Status: Abandoned 114168847 E-085-2018-0 E-085-2018-0-PCT-02 CD153 AND/OR CD30 IN INFECTION PCT Patent Cooperation Treaty PCT/US2019/019164 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/019164<br />Filed on 2019-02-22<br />Status: Expired 114169048 E-085-2018-0 E-085-2018-0-US-04 CD153 AND/OR CD30 IN INFECTION National Stage US 16/971,144 Abandoned US <br />National Stage 16/971,144<br />Filed on 2020-08-19<br />Status: Abandoned 114151500 CD153/CD30 114151501 PATHWAY 114151502 treatment 114151503 Diagnosis 114151504 TUBERCULOSIS 114151505 Targeting TAB-4830 152187485 Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs NIAID Hector Garcia-Garcia, Siddhartha Mahanty, Theodore Nash, Thomas Nutman, Elise O'Connell <p>The pork tapeworm, Taenia solium, is endemic in most of Asia, Latin America, and Sub-Saharan Africa. The risk of infection is increased in regions where pigs are raised in closed proximity to humans, with migration from endemic regions being directly proportional to the prevalence of infection in high-income countries. Human infection by T. solium occurs following oral ingestion of eggs passed in human feces from an infected carrier. The larvae can travel anywhere in the human body. Neurocysticercosis (NCC) occurs when the larvae traverse the blood-brain barrier and penetrate the central nervous system. Diagnosis of NCC is typically made through radiological imaging studies (such as computed tomography or magnetic resonance imaging) to visualize the morphology, stage, and location of the cysts.</p> <p>Investigators at NIAID have developed the recombinant IgG monoclonal antibody known as TsG10, which can target T. solium circulating antigens. An expression vector to produce TsG10 is available for expression in mammalian cell lines. The resulting construct allows for a scalable, repeatable, and broadly accessible production of monoclonal antibodies for both human and veterinary use. The TsG10 monoclonal antibodies are adaptable for plate-based diagnostic assays like ELISAs, to support a diagnosis of NCC.</p> <ul> <li>Detection of active T. solium infection</li> <li>Scalable and repeatable production of a monoclonal antibody targeting T. solium</li> <li>Materials available for development or licensing</li> </ul> <ul> <li>Plate-based diagnostic immunoassays, both human and veterinary, for the detection of T. solium circulating antigen</li> <li>Production of TsG10 recombinant monoclonal antibodies</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Theodoric Mattes at 240–627–3827, or theodoric.mattes@nih.gov. 2024-01-16 2026-01-22 2026-01-22 2023-12-11 FOOD, HEALTH, Livestock, Monoclonal Antibody, pork, SOLIUM, TAENIA, tapeworm False False Research material True 37470483 Website Abstract 152187658 Nutman, Thomas National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nutman, Thomas (NIAID) 1 152187733 O'Connell, Elise National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID O'Connell, Elise (NIAID) 2 152187764 Nash, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nash, Theodore (NIAID) 3 152187788 Mahanty, Siddhartha National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Mahanty, Siddhartha (NIAID) 4 152187855 Garcia-Garcia, Hector MedStar Health Research Institute Inc Garcia-Garcia, Hector 5 152187658 Nutman, Thomas National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nutman, Thomas (NIAID) 1 152187733 O'Connell, Elise National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID O'Connell, Elise (NIAID) 2 152187764 Nash, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nash, Theodore (NIAID) 3 152187788 Mahanty, Siddhartha National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Mahanty, Siddhartha (NIAID) 4 152187855 Garcia-Garcia, Hector MedStar Health Research Institute Inc Garcia-Garcia, Hector 5 152187567 Recombinant IgG Monoclonal Antibody-based Detection Of Taenia Antigen In Humans And Pigs E-043-2022-0 Research Material NIAID, University of Melbourne 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs&body=Please send me information about technology [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs&body=Please send me information about technology [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs.">jonathan.motley@nih.gov</a><br> 152205568 TAENIA 152205572 SOLIUM 152205595 Monoclonal Antibody 152205691 pork 152205698 tapeworm 152205707 FOOD 152205718 Livestock 152205728 HEALTH TAB-4829 152173053 Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission NIAID J. P. Dubey, Michael Grigg, Lukes Julius, Viviana Pszenny, Aline Sardinha da Silva <p>Toxoplasma gondii is the zoonotic causative agent of toxoplasmosis, a disease of significant concern for pregnant persons and livestock. A member of the phylum Apicomplexa, Toxoplasma gondii can infect almost any cell type found in mammals and birds. There are multiple transmission pathways, including consumption of undercooked meat from infected animals, consumption of unwashed plants, contaminated water supplies, blood transfers, and congenital transfer. Felines are considered the definitive host of Toxoplasma gondii. Direct or indirect transmission can occur via contact with the stool of infected felines.</p> <p>Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), the U.S. Department of Agriculture (USDA), and the University of South Bohemia (Česke; Budějovice, Czechia) have demonstrated that T. gondii strains lacking expression of either the intracellular transport protein IFT88 or the CYS-6-type surface antigen SRS15B prevent the formation of oocysts and have potential for broad immunity to T. gondii. The inventors propose that mass inoculation of felines, specifically wild or feral felines, with a live vaccine developed from these strains could result in a significant reduction in oocyst production and environment contamination, reducing further infection in a geographical area. It is also proposed that loss of IFT88 or SRS15B homologs in other Apicomplexa parasites, like Neospora, Sarcocystis, or Cryptosporidium could have a similar impact.</p> <ul> <li>100% blocked Toxoplasma gondii oocyst shedding in felines</li> <li>Detectable seroconversion protective against future Toxoplasma gondii infection</li> <li>Scalable production strain with predictable inactivation of IFT88 or SRS15B gene</li> <li>Materials available for development or licensing</li> </ul> <ul> <li>Live vaccine for felines against Toxoplasma gondii infection</li> <li>Reduction in environmental Toxoplasma gondii oocysts</li> </ul> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. 2024-01-12 2026-01-22 2026-01-22 2023-12-11 FELINE, Live-Attenuated, TOXOPLASMA, Toxoplasmosis, Vaccine, VETERINARY False False Pre-Clinical True 37470483 Website Abstract E-118-2023-1 E-118-2023-2 152173134 Grigg, Michael National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Grigg, Michael (NIAID) 1 152173144 Sardinha da Silva, Aline National Institute of Allergy and Infectious Diseases (NIAID/NIH) Sardinha da Silva, Aline 2 152173153 Pszenny, Viviana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pszenny, Viviana (NIAID) 3 152173157 Dubey, J. P. US Department of Agriculture (USDA) Dubey, J. P. 4 152173172 Julius, Lukes University of South Bohemia in Ceské Budejovice Julius, Lukes 5 152173134 Grigg, Michael National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Grigg, Michael (NIAID) 1 152173144 Sardinha da Silva, Aline National Institute of Allergy and Infectious Diseases (NIAID/NIH) Sardinha da Silva, Aline 2 152173153 Pszenny, Viviana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pszenny, Viviana (NIAID) 3 152173157 Dubey, J. P. US Department of Agriculture (USDA) Dubey, J. P. 4 152173172 Julius, Lukes University of South Bohemia in Ceské Budejovice Julius, Lukes 5 152173064 IFT88-Based Vaccine for cats to block Toxoplasma gondii oocyst shedding and transmission E-118-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), US Department of Agriculture (USDA) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission&body=Please send me information about technology [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission&body=Please send me information about technology [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission.">jonathan.motley@nih.gov</a><br> 152175187 TOXOPLASMA 152175273 Toxoplasmosis 152175309 FELINE 152175405 Vaccine 152175409 Live-Attenuated 152175423 VETERINARY TAB-4047 147157329 Devices for Improved Tissue Cryopreservation and Recovery NEI Collaboration, Dermatology, Ear, Nose, & Throat, Immunology, Licensing, Materials Available, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology Collaboration Dermatology Ear Nose & Throat Immunology Licensing Materials Available Medical Devices Non-Medical Devices Oncology Ophthalmology Kapil Bharti, Vladimir Khristov, Arvydas Maminishkis <p><strong>Problem:</strong> Cryopreservation is a process where living biological materials like cells, tissues, and cell therapies (which are susceptible to damage caused by unregulated chemical kinetics) are preserved by cooling to very low temperatures in the presence of specific cryopreservation media that protects the biological material from damage. In order to be used, the biological material ideally should be thawed in a controlled manner that minimizes damage and desirably brings the material back to a viable state. While this is not a problem for single cell suspensions, cryopreservation and efficient revival of sheets or layers of tissues and three-dimensional tissue constructs, is inefficient. Layers of tissue and three-dimensional tissue constructs can suffer damage from tensional stresses experienced during expansion and contractions that occur during freezing and thawing. Several other problems exist with conventional cryopreservation: 1) Uneven physical changes within the tissue during cooling or warming can cause damage to the tissue, 2) Conventional cryopreservation media can be toxic to the tissues in a non-frozen state and can render the tissues not suitable for later recovery, culturing, and transplantation in engineered cell and other tissue therapies, and 3) The sterility of the tissue during the thawing process is usually compromised.</p> <p><strong>Technical Solution:</strong> The technology developed by researchers at the <a href="https://nei.nih.gov/" target="_blank" rel="nofollow">National Eye Institute</a> (NEI) is a closed recovery device consisting of three chambers that allow for the separation of media and frozen tissue until it is time to defrost the tissue. The top portion is a media chamber controlled by a valve/lumen. The middle chamber houses the frozen tissue and the bottom chamber is a waste receptacle. The recovery device can be placed in a regulator apparatus that facilitates thawing and warming of the frozen tissue/cryopreservation media inside the tissue container.</p> <p><strong>Collaboration Opportunity:</strong> The inventor is interested in building other versions of the prototype device and testing them for performance. A collaboration or license interest is sought.  </p> <h2>Competitive Advantages:</h2> <ul><li>Current cryopreservation containers are less successful with confluent cells and need a large volume of toxic cryopreservation media, which hampers subsequent cell recovery and culturing. A cryopreservation/defrost system that uses minimal volume of cryopreservation media and conducts automated cell thawing and recovery for cell monolayers and 3D tissues can be useful in many clinical applications, such as transplantation.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Transport, Storage and Recovery of cells, tissues for <em>in vitro</em> culture</li> <li><em>In vivo</em> experiments including cell therapy transplantation</li> </ul> 2017-04-14 2025-04-22 2020-04-13 2026-01-21 2017-04-14 Cell recovery, Cell thawing, Cell therapy, Cryopreservation, Defrost, National Eye Institute, NEI, Tissue transplant False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163328 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147163326 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 2 147163327 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 3 147163328 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147163326 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 2 147163327 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 3 147157974 A Self-contained Cryopreservation And Recovery Device For Tissue Storage, Shipping And Recovery E-094-2016-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery&body=Please send me information about technology [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery&body=Please send me information about technology [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161030 E-094-2016-0 E-094-2016-0-US-01 Devices for Tissue Cryopreservation and Recovery PRV US 62/453,148 Abandoned US <br />Provisional (PRV) 62/453,148<br />Filed on 2017-02-01<br />Status: Abandoned 147166192 E-094-2016-0 E-094-2016-0-PCT-02 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY PCT Patent Cooperation Treaty PCT/US2018/016101 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/016101<br />Filed on 2018-01-31<br />Status: Expired 147166193 E-094-2016-0 E-094-2016-0-US-03 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage US 11,819,020 16/478,093 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11819020 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11819020">11,819,020</a><br />Filed on 2019-07-15<br />Status: Issued 147166194 E-094-2016-0 E-094-2016-0-AU-04 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage Australia 2018214954 2018214954 Issued Australia <br />National Stage 2018214954<br />Filed on 2018-01-31<br />Status: Issued 147166195 E-094-2016-0 E-094-2016-0-CA-05 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage Canada 3048523 Pending Canada <br />National Stage 3048523<br />Filed on 2018-01-31<br />Status: Pending 147166196 E-094-2016-0 E-094-2016-0-EP-06 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage European Patent 3576527 18704773.3 Issued European Patent <br />National Stage 18704773.3<br />Filed on 2019-07-30<br />Status: Issued 147166197 E-094-2016-0 E-094-2016-0-JP-07 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage Japan 2019-538157 Abandoned Japan <br />National Stage 2019-538157<br />Filed on 2018-01-31<br />Status: Abandoned 147166198 E-094-2016-0 E-094-2016-0-JP-01 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY DIV Japan 7824913 2023-127909 Issued Japan <br />Divisional (DIV) 2023-127909<br />Filed on 2023-08-04<br />Status: Issued 164118969 E-094-2016-0 E-094-2016-0-JP-02 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY DIV Japan 7812356 2023-127908 Issued Japan <br />Divisional (DIV) 2023-127908<br />Filed on 2023-08-04<br />Status: Issued 165688005 E-094-2016-0 E-094-2016-0-JP-03 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY DIV Japan In Preparation Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 147171282 Cell recovery 147171284 Cell thawing 147171285 Cell therapy 147171286 Cryopreservation 147171288 Defrost 147171289 National Eye Institute 147171290 NEI 147171292 Tissue transplant TAB-4498 151704860 A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients NHLBI Computational models/software, Licensing, Research Materials, Software / Apps Computational models/software Licensing Research Materials Software / Apps Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Sunil Patil <p>This technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. Motion of this water due to ultrasound vibrations, convection, and circulation between sonications causes diffuse artifacts in images, which can compromise clinical outcomes. PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures.</p> The proposed solution: <ul> <li>does not require any additional hardware, materials, or changes in clinical setup</li> <li>can easily be incorporated into the existing product pulse sequences, and therefore adds no additional cost for implementation</li> <li>does not impact image acquisition time under most practical circumstances</li> </ul> Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-01-16 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704868 Patil, Sunil Siemens Medical USA Patil, Sunil 1 151704872 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 2 151704876 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 3 151704880 Bhat, Himanshu Siemens Medical Solutions USA Inc. Bhat, Himanshu 4 151704868 Patil, Sunil Siemens Medical USA Patil, Sunil 1 151704872 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 2 151704876 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 3 151704880 Bhat, Himanshu Siemens Medical Solutions USA Inc. Bhat, Himanshu 4 151704863 A Method To Remove Fluid-motion Related Artifacts In Magnetic Resonance Thermometry Images Using Magnetic Field Gradients E-113-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Medical Solutions USA Inc., Siemens Medical Solutions USA, Inc. 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients.">shmilovm@nih.gov</a><br> TAB-4496 151704475 A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry NHLBI Computational models/software, Licensing, Software / Apps Computational models/software Licensing Software / Apps Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Rainer Schneider <p>This technology includes a novel Principal Component Analysis (PCA) based approach to correct motion related B0 changes in PRF thermometry. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. PRF thermometry relies on phase difference between the acquired images, and therefore motion related baseline changes in organs of interest and background adversely affect the accuracy of temperature difference estimates, even when registration-based motion correction is performed to correct for displacements.</p> PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures. Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. Used in MRI clinical imaging to provide substantial reduction in bias and variance due to motion related baseline changes. 2023-12-07 2024-08-12 2026-01-16 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704566 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704570 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704583 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704587 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704566 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704570 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704583 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704587 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704478 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry E-112-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Healthineers AG, Siemens Medical Solutions USA Inc. 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry&body=Please send me information about technology [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry&body=Please send me information about technology [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry.">shmilovm@nih.gov</a><br> 157754912 E-112-2019-0 E-112-2019-0-US-01 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry PRV US 62/840,006 Abandoned US <br />Provisional (PRV) 62/840,006<br />Filed on 2019-04-29<br />Status: Abandoned 157754917 E-112-2019-0 E-112-2019-0-US-02 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry ORD US 11,301,997 16/849,313 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11301997 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11301997">11,301,997</a><br />Filed on 2020-04-15<br />Status: Issued TAB-4495 151704426 A Method to Guide Protocol Development for Magnetic Resonance Thermometry NHLBI Computational models/software, Licensing, Medical Devices, Research Equipment Computational models/software Licensing Medical Devices Research Equipment Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Rainer Schneider <p>This technology includes tools to guide optimization of thermometry imaging/post-processing protocols. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue.</p> <ul> <li>The invention is based on well-established principles of MR physics and statistics, and therefore results in reliable predictions</li> <li>No competing solutions present in the literature</li> <li>Given the immense utility of the features proposed in this invention, this will become a must-have feature on commercial MR Thermometry related products</li> </ul> PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures. Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-01-16 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704433 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704437 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704441 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704450 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704433 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704437 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704441 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704450 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704429 A Method To Guide Protocol Development For Magnetic Resonance Thermometry E-111-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Healthineers AG, Siemens Medical Solutions USA Inc. 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry&body=Please send me information about technology [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry&body=Please send me information about technology [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry.">pragnesh.mistry@nih.gov</a><br> 157754893 E-111-2019-0 E-111-2019-0-US-01 A Method To Guide Protocol Development For Magnetic Resonance Thermometry ORD US 11,176,717 16/583,596 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11176717 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11176717">11,176,717</a><br />Filed on 2019-09-26<br />Status: Issued TAB-4152 147157435 Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders NIA Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Gregory Keyes, Christopher Ramsden <p>The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:</p> <ul><li>increased activity</li> <li>lower toxicity</li> <li>greater stability</li> <li>longer half-life</li> </ul><p>These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.  </p> <p>NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.  In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.</p> <h2>Competitive Advantages:</h2> <ul><li>Ability to readily cross the blood-brain barrier</li> <li>Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain</li> <li>Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038</li> <li>Proof-of-concept in rat model</li> </ul> <h2>Commercial Applications:</h2> <p><strong>Therapies to treat:</strong></p> <ul><li>Autoimmune disorders</li> <li>Inflammation</li> <li>Pain-related disorders</li> <li>Itching and/or skin disorders</li> </ul> 2018-04-25 2026-01-14 2022-03-23 2026-01-14 2018-04-25 Autoimmune, Inflammation, National Institute on Aging (NIA), Pain, Ramsden False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162157 Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch. https://www.ncbi.nlm.nih.gov/pubmed/28831021 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28831021">Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.</a> 147163703 Ramsden, Christopher NIH - NIA NIA Ramsden, Christopher (NIA) 1 147163704 Keyes, Gregory NIH - NIA NIA Keyes, Gregory (NIA) 2 147163703 Ramsden, Christopher NIH - NIA NIA Ramsden, Christopher (NIA) 1 147163704 Keyes, Gregory NIH - NIA NIA Keyes, Gregory (NIA) 2 147158083 Synthesis And Use Of Endogenous Lipid Mediators, Their Stable Analogs, And Small Molecule Pharmacophores Containing The Same Active Moieties As The Endogenous Compounds, To Regulate Inflammation, Neuronal Activation, Nociceptive And Pruriceptive Sens E-151-2017-0 Filing authorized National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147166939 E-151-2017-0 E-151-2017-0-US-01 FATTY ACID DERIVATIVES AND THEIR USE PRV US 62/529,846 Abandoned US <br />Provisional (PRV) 62/529,846<br />Filed on 2017-07-07<br />Status: Abandoned 147166940 E-151-2017-0 E-151-2017-0-PCT-02 FATTY ACID DERIVATIVES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2018/041086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/041086<br />Filed on 2018-07-06<br />Status: Expired 147166941 E-151-2017-0 E-151-2017-0-AU-03 FATTY ACID DERIVATIVES AND THEIR USE National Stage Australia 2018297192 2018297192 Issued Australia <br />National Stage 2018297192<br />Filed on 2018-07-06<br />Status: Issued 147166942 E-151-2017-0 E-151-2017-0-CA-04 FATTY ACID DERIVATIVES AND THEIR USE National Stage Canada 3064132 3064132 Issued Canada <br />National Stage 3064132<br />Filed on 2018-07-06<br />Status: Issued 147166943 E-151-2017-0 E-151-2017-0-CN-05 FATTY ACID DERIVATIVES AND THEIR USE National Stage China 201880045287.6 Abandoned China <br />National Stage 201880045287.6<br />Filed on 2018-07-06<br />Status: Abandoned 147166944 E-151-2017-0 E-151-2017-0-EP-06 FATTY ACID DERIVATIVES AND THEIR USE National Stage European Patent 3649115 18746415.1 Issued European Patent <br />National Stage 18746415.1<br />Filed on 2018-07-06<br />Status: Issued 147166945 E-151-2017-0 E-151-2017-0-JP-07 FATTY ACID DERIVATIVES AND THEIR USE National Stage Japan 7234151 2019-572570 Issued Japan <br />National Stage 2019-572570<br />Filed on 2018-07-06<br />Status: Issued 147166946 E-151-2017-0 E-151-2017-0-KR-08 FATTY ACID DERIVATIVES AND THEIR USE National Stage South Korea 10-2725883 10-2020-7003568 Issued South Korea <br />National Stage 10-2020-7003568<br />Filed on 2020-02-06<br />Status: Issued 147166947 E-151-2017-0 E-151-2017-0-MX-09 FATTY ACID DERIVATIVES AND THEIR USE National Stage Mexico 391168 MX/a/2019/015730 Issued Mexico <br />National Stage MX/a/2019/015730<br />Filed on 2018-07-06<br />Status: Issued 147166948 E-151-2017-0 E-151-2017-0-US-10 FATTY ACID DERIVATIVES AND THEIR USE National Stage US 11,555,021 16/622,697 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555021 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555021">11,555,021</a><br />Filed on 2019-12-30<br />Status: Issued 147166949 E-151-2017-0 E-151-2017-0-HK-11 FATTY ACID DERIVATIVES AND THEIR USE National Stage Hong Kong 62020007841.3 Pending Hong Kong <br />National Stage 62020007841.3<br />Filed on 2018-07-06<br />Status: Pending 147166950 E-151-2017-0 E-151-2017-0-US-12 FATTY ACID DERIVATIVES AND THEIR USE DIV US 12,479,812 17/718,965 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479812 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479812">12,479,812</a><br />Filed on 2022-04-12<br />Status: Issued 147172391 Autoimmune 147172392 Inflammation 147172394 National Institute on Aging (NIA) 147172395 Pain 147172397 Ramsden TAB-2215 114096425 A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner) NHLBI Collaboration, Licensing Collaboration Licensing Mark Knepper <p style="font-size:16px">The invention offered for licensing is a computer program called &quot;NHLBI AbDesigner&quot; that allows the user to input a unique identifier for an individual mammalian protein to be analyzed in order to find out what short peptides in its amino sequence would most likely result in a strong immunogenic response when injected into a research animal. The software displays standard predictors of immunogenicity and antigenicity in easy-to-view heat maps and also allows users to choose peptides most likely to elicit antibodies that are specific to said protein. The computer code is written in Java and would be made available in the form of .jar files.<br /> <br /> For additional information please refer to:&nbsp;<a href="http://esbl.nhlbi.nih.gov/AbDesigner/" target="_blank">https://esbl.nhlbi.nih.gov/AbDesigner/</a>.&nbsp;</p> <ul> <li>This program allows the user to identify tradeoffs in the decision making process by aligning various types of information with the amino acid sequence, constituting an improvement over present ad hoc methods of accumulating and relating different type of information regarding immunogenicity, uniqueness of sequences, conservation of sequences, and presence of post-translational modifications.</li> </ul> <ul> <li>Design and production of antibodies for research or therapeutic purposes</li> <li>Bioinformatic analysis of protein structure and functions</li> <li>Analysis and interpretation of proteomic data</li> </ul> The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Brian Bailey, Ph.D. at 301-594-4094 or <a href="mailto:bbailey@mail.nih.gov">bbailey@mail.nih.gov</a> for more information. Software -- Patent protection is not being pursued for this technology. Available for licensing. 2022-03-08 2026-01-14 2026-01-14 2011-01-20 AbDesigner, ACXXXX, Along, antibodies, AXXXXX, CALLED, computer, INDIVIDUAL, NHLBI, OPTIMAL, Peptide-directed, PREDICTS, Primary, production, Program, proteins, sequence, Sites, That False True Fully developed True NIHTT 37470483 Website Abstract 114172477 Pisitkun T, et al. https://www.ncbi.nlm.nih.gov/pubmed/21956165 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21956165">Pisitkun T, et al.</a> 114107091 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114107091 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114101520 A Computer Program Called "NHLBI AbDesigner" That Predicts Optimal Sites Along The Primary Sequence Of Individual Proteins For Production Of Peptide-directed Antibodies E-251-2010-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner)&body=Please send me information about technology [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner)&body=Please send me information about technology [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner).">shmilovm@nih.gov</a><br> 114121808 ACXXXX 114121809 AXXXXX 114141000 computer 114141001 Program 114141002 CALLED 114141003 NHLBI 114141004 AbDesigner 114141005 That 114141006 PREDICTS 114141007 OPTIMAL 114141008 Sites 114141009 Along 114141010 Primary 114141011 sequence 114141012 INDIVIDUAL 114141013 proteins 114141014 production 114141015 Peptide-directed 114141016 antibodies TAB-4443 147157738 Polypeptides for Stimulation of Immune Response (Adjuvants) NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Michael Bustin, Joost Oppenheim, De Yang <p>HMGN polypeptides belong to the high mobility group (HMG) family of chromosomal binding peptides. HMGN polypeptides typically function inside the cell nucleus to bind to DNA and nucleosomes and regulate the transcription of various genes. HMGN polypeptides also can be released by peripheral blood mononuclear cells. However, the extracellular release of a HMGN polypeptide initiates activation of the immune system. Therefore, it has potential use as a biological therapeutic for stimulating an immune response. Therefore, HMGN has potential use as a clinically effective immunoadjuvant for use in vaccines against tumors and many intracellular pathogens.</p> <p>Researchers at the National Cancer Institute, Laboratory of Cancer Immunometabolism&nbsp;developed compositions and methods for using HMGN and its derivatives as immunoadjuvants with microbial or tumor antigens. HMGN can be fused to an antigen gene to produce recombinant fusion proteins or can be administered as a DNA vaccine. Alternatively, HMGN could be exploited as a drug target to treat parasitic infections, inflammatory or autoimmune diseases. The technoloogy has shown effectiveness and high potency in several different mouse xenograft models.</p> <h2>Competitive Advantages:</h2> <ul> <li>Expected to have diminished adverse effects compared to currently available technologies</li> <li>Enables dendritic cells to induce enduring cellular immunity</li> <li>More selective for Th-1 type immunity allowing for a more controlled immune response.</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Immunostimulatory adjuvant to increase efficacy of vaccinations against microbes or cancer</li> <li>Attractant or activator of dendritic cells</li> <li>HMGN antagonists to suppress inflammatory immune response</li> </ul> 2016-02-16 2026-01-14 2018-07-13 2026-01-14 2016-08-30 Autoimmune, HMGN, immune response, immunoadjuvant, POLYPEPTIDES, Vaccine Adjuvant False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-069-2016 147161891 Yang D, et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. http://www.ncbi.nlm.nih.gov/pubmed/22184635 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22184635">Yang D, et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses.</a> 147164757 Yang, De NIH - NCI Leidos Yang, De (Leidos) 1 147164756 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 2 147164758 Bustin, Michael NIH - NCI NCI Bustin, Michael (NCI) 3 147164757 Yang, De NIH - NCI Leidos Yang, De (Leidos) 1 147164756 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 2 147164758 Bustin, Michael NIH - NCI NCI Bustin, Michael (NCI) 3 147158169 High-Mobility Group N1 Protein (HMGN1) Is An Immune Enhancer E-185-2008-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants)&body=Please send me information about technology [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants)&body=Please send me information about technology [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168952 E-185-2008-0 E-185-2008-0-US-01 HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS PRV US 61/083,781 Abandoned US <br />Provisional (PRV) 61/083,781<br />Filed on 2008-07-25<br />Status: Abandoned 147168953 E-185-2008-0 E-185-2008-0-US-02 HMGN Polypeptides As Immune Enhancers And HMGN Antagonists As Immune Suppressants ORD US 8,227,417 12/509,088 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8227417 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8227417">8,227,417</a><br />Filed on 2009-07-24<br />Status: Issued 147168954 E-185-2008-0 E-185-2008-0-US-03 HMGN Polypeptides As Immune Enhancers And HMGN Antagonists As Immune Suppressants CON US 9,567,566 13/533,492 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9567566 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9567566">9,567,566</a><br />Filed on 2012-06-26<br />Status: Issued 147168955 E-185-2008-0 E-185-2008-0-US-04 HMGN Polypeptides as Immune Enhancers and HMGN Antagonists as Immune Suppressants DIV US 15/191,000 Abandoned US <br />Divisional (DIV) 15/191,000<br />Filed on 2016-06-23<br />Status: Abandoned 147173266 Autoimmune 147173267 HMGN 147173268 immune response 147173270 immunoadjuvant 147173271 POLYPEPTIDES 147173272 Vaccine Adjuvant TAB-3779 114097630 Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function NIDCR Antibodies, Immunology, Research Materials Antibodies Immunology Research Materials Steven Akiyama, Kenneth Yamada, Susan Yamada <p>This technology includes a rat monoclonal antibody termed mAb11 was generated against the human alpha-5 integrin subunit and can provide immunological characterizations without disrupting integrin adhesive function. It permits characterization of its localization even if the receptor is bound to its fibronectin ligand. The&nbsp;antibody is commercially available from Millipore Sigma.</p> Because it is a rat monoclonal antibody, it permits co-staining using a mouse monoclonal antibody using indirect immunofluorescence. Antibody characterization of the alpha-5/beta-1 integrin receptor for fibronectin. Available for non-exclusive licensing 2022-11-30 2024-12-26 2026-01-12 2022-11-30 2022-08-01 Against, Alpha-5, ANTIBODY, DISRUPT, DOES, FUNCTION, Human, INTEGRIN, monoclonal, That, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172949 Miyamoto S, Akiyama S, et al. https://pubmed.ncbi.nlm.nih.gov/7846531/ <a href="https://pubmed.ncbi.nlm.nih.gov/7846531/">Miyamoto S, Akiyama S, et al.</a> 114172950 Miyamoto S, Teramoto H, et al. https://pubmed.ncbi.nlm.nih.gov/7593197/ <a href="https://pubmed.ncbi.nlm.nih.gov/7593197/">Miyamoto S, Teramoto H, et al.</a> 114111543 Akiyama, Steven Akiyama, Steven 0 114111544 Yamada, Susan NIDCR NIDCR Yamada, Susan (NIDCR) 0 114111542 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 1 114111542 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 1 114111543 Akiyama, Steven Akiyama, Steven 0 114111544 Yamada, Susan NIDCR NIDCR Yamada, Susan (NIDCR) 0 114102882 Monoclonal Antibody Against Human Alpha-5 Integrin That Does Not Disrupt Function E-016-2017-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function&body=Please send me information about technology [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function&body=Please send me information about technology [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function.">vlado.knezevic@nih.gov</a><br> 114129576 WIXXXX 114129577 XAXXXX 114155352 monoclonal 114155353 ANTIBODY 114155354 Against 114155355 Human 114155356 Alpha-5 114155357 INTEGRIN 114155358 That 114155359 DOES 114155360 DISRUPT 114155361 FUNCTION TAB-2113 114096330 Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease NIDCR Diagnostics, Infectious Disease Diagnostics Infectious Disease Peter Burbelo, Michael Iadarola, Adriana Marques This technology is for compositions and methods for diagnosis of Lyme disease. Currently, Lyme disease is diagnosed by clinical exam and a history of exposure to endemic regions. Although, laboratory tests may aid diagnosis, the best tests currently available are slow and labor intensive and require understanding of the test, and infection stage. A two-step antibody based test process is currently the recommended laboratory test. The first step is either an enzyme immunoassay (EIA), or an indirect immunofluorescence assay (IFA). If the first step is positive, a “Western blot” test is then performed. Because early intervention is critical to prevent neurological, rheumatological and cardiac damage from advanced infection, more sensitive, specific, simpler, high-throughput format laboratory diagnostics are needed. This technology uses a novel synthetic gene (VOVO) in a highly sensitive, specific and high-throughput Luciferase Immunoprecipitation Systems (LIPS) format. LIPS screening using VOVO offers an efficient and qualitative approach for serological screening of antibodies in Lyme disease in human and veterinary applications. <ul> <li>Higher efficiencies, High-throughput Format Qualitative</li> </ul> <ul> <li>Diagnostic for Lyme disease in human and veterinary applications.</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2026-01-12 2010-05-21 ANTIBODY, Borreliosis, DAXXXX, Detection, Disease, DXXXXX, Highly, Listed LPM Fenn as of 4/15/2015, LYME, Lyme Disease, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, QUANTITATIVE, SENSITIVE, SIMPLE, VJXXXX, WBXXXX False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> </ul> True NIHTT 37470483 Website Abstract 114171078 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/20392886 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20392886">Burbelo PD, et al.</a> 114107710 Marques, Adriana NIAID - DIR NIAID Marques, Adriana (NIAID) 0 114107711 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114107712 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114107712 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114107710 Marques, Adriana NIAID - DIR NIAID Marques, Adriana (NIAID) 0 114107711 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114101809 Simple, Quantitative, And Highly Sensitive Antibody Detection For Lyme Disease E-036-2010-1 Filing authorized NIAID, NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease&body=Please send me information about technology [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease&body=Please send me information about technology [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease.">ediz.yonter@nih.gov</a><br> 114166902 E-036-2010-1 E-036-2010-1-US-04 Compositions and Methods for Screening For Lyme Disease DIV US 9,310,367 14/562,068 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9310367 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9310367">9,310,367</a><br />Filed on 2014-12-05<br />Status: Issued 114166903 E-036-2010-1 E-036-2010-1-US-03 Compositions and Methods for Screening for Lyme Disease National Stage US 8,926,989 13/583,472 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8926989 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8926989">8,926,989</a><br />Filed on 2012-09-07<br />Status: Issued 114121095 DAXXXX 114121096 DXXXXX 114127839 VJXXXX 114127840 WBXXXX 114139885 SIMPLE 114139886 QUANTITATIVE 114139887 Highly 114139888 SENSITIVE 114139889 ANTIBODY 114139890 Detection 114139891 LYME 114139892 Disease 114139893 Patent Category - Biotechnology 114143466 Listed LPM Fenn as of 4/15/2015 114143467 Pre LPM working set 20150418 114143468 Post LPM Assignment Set 20150420 114157051 Borreliosis 114158619 Lyme Disease TAB-2003 114096223 Antigen Mixtures for Serological Detection of HHV-8 Infection NIDCR Diagnostics, Infectious Disease, Research Materials Diagnostics Infectious Disease Research Materials Peter Burbelo, Michael Iadarola, Joseph Kovacs This invention describes a highly specific and sensitive serological test for human herpesvirus 8 (HHV-8) infection that uses the Luciferase Immunoprecipitation System (LIPS). A mixture of four virus-specific antigens, including K8.1, v-cyclin, ORF65 and LANA, was shown to provide more robust detection of HHV-8 infection than traditional methods due its ability to detect very low viral loads. In addition, one of the antigens, v-cyclin, was identified as a new serological marker for HHV-8 infection, and its similarity to a known human oncogene, cyclin-D, raises the possibility of its use as a diagnostic tool for detecting cancer.<br /><br /> This test is more sensitive and amenable to a high-throughput format than other conventional tests for HHV-8 infection such as Immunofluorescent Assays, Western Blots, ELISAs and PCR based approaches. It simplifies data collection and analysis and allows for more rapid clinical output. Validation tests on patient sera samples using this 4-antigen mixture has shown 100% sensitivity and specificity compared to 94% for ELISAs.<br /><br /> The test can be incorporated into routine screening panels for rapid screening of HHV-8 infection, and may be potentially adapted for use as a diagnostic tool for detecting cancer. A successful embodiment of the test can be incorporated into routine blood screening panels, and may lead a reduced risk of transfusion-transmitted HHV-8 infection in patients. It may also be useful for detecting HHV-8 induced cancer in HIV infected patients. <ul> <li>Rapid and efficient serological screening of HHV-8 infection</li> <li>Cancer diagnostics</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2026-01-12 2009-08-14 ANTIGEN, DA4XXX, DAXXXX, DDXXXX, DXXXXX, HERPES, HERPESVIRUS-8, HHV-8, Infection, MIXTURES, Patent Category - Biotechnology, screening, SEROLOGICAL False True Early Stage True NIHTT 37470483 Website Abstract 114170907 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/19261774 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19261774">Burbelo PD, et al.</a> 114106720 Kovacs, Joseph Clinical Center (CC) CC Kovacs, Joseph (CC) 0 114106721 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114105581 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114105581 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114106720 Kovacs, Joseph Clinical Center (CC) CC Kovacs, Joseph (CC) 0 114106721 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114101286 Serological Screening For HHV-8 Infection Using Antigen Mixtures E-063-2009-0 Filing authorized Clinical Center (CC), NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection&body=Please send me information about technology [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection&body=Please send me information about technology [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection.">ediz.yonter@nih.gov</a><br> 114166537 E-063-2009-0 E-063-2009-0-US-03 Serological Screening For HHV-8 Infection Using Antigen Mixtures National Stage US 8,951,723 13/201,317 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951723 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951723">8,951,723</a><br />Filed on 2011-08-12<br />Status: Issued 114120551 DA4XXX 114120552 DDXXXX 114120553 DXXXXX 114120554 DAXXXX 114138493 SEROLOGICAL 114138494 screening 114138495 HHV-8 114138496 Infection 114138497 ANTIGEN 114138498 MIXTURES 114138499 HERPES 114138500 HERPESVIRUS-8 114138501 Patent Category - Biotechnology TAB-1697 114095925 Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers NIDCR Research Equipment, Research Materials Research Equipment Research Materials Andrew Doyle, Kenneth Yamada Available for licensure and commercial development is a micro-photoablation (µPA) method used as a micro-patterning technique to attach ECM proteins or other biological molecules to specified locations. Advantages of this photolytic technique are that it: (a) is stampless, (b) allows for flexible pattern generation to the submicron level, (c) allows for live cell fluorescence imaging, retains cell viability, and (d) allows the use of multiple proteins. The technique has demonstrated experimentally that micropatterning with live cell fluorescence imaging can be used to precisely visualize studying distinct cell-ECM interactions. <br><br> Applications of microlithography techniques into the study of cell biology aid in resolving cellular function as regulated by the interaction of cells with the extracellular matrix. Currently many techniques have used micro-contact patterning (µCP) to apply ECM proteins in distinct localized patterns. These techniques require the fabrication of silicone-based stamps to either "ink" proteins directly or indirectly onto a gold coated surface, limiting the user to a specified stamp shape and size. To bypass the necessity of a physical stamp the current technique provides submicron sized spots using a tunable multiphoton laser coupled to a confocal microscope to photo ablate hydrophilic poly vinyl alcohol (PVA) macro-molecular thin films. Through controlled photo ablation, PVA layers are locally removed allowing deposition of ECM proteins into distinct patterns. The use of ROI's produces a "virtual mask" that can be created in any shape or pattern and are easily modified. Unlike µCP techniques, micro-photoablation (µPA) allows live cell imaging of multiple fluorophores and is possible even with total internal reflection fluorescence (TIRF) microscopy. Therefore, micro-photo ablation (µPA) allows kinetic quantification of ECM-cell interactions. This technique that uses a macro-molecular thin film together with localized photo ablation allows the versatility to create protein spots of any size or shape easily on the same cover slip. Furthermore, this process can be repeated multiple times to directly conjugate different proteins to the same local region allowing the investigation of how single cells probe their surroundings to discern different ECM proteins. <ul> <li>Cellular interactions</li> <li>Protein visualization</li> <li>Diagnostics</li> </ul> Available for licensing. 2022-03-08 2024-10-28 2026-01-12 2007-12-01 AA2XXX, AA3AXX, AA3XXX, AAXXXX, AC3XXX, ACXXXX, AXXXXX, CELL-BINDING, Cellular Interactions, Extracellular, INTERACTION, INTERACTIONS, Micropatterning, Microphoto-ablation, Polyvinyl, PVA False True True NIHTT 37470483 Website Abstract 114170452 CM Cheng, PR LeDuc. Micropatterning polyvinyl alcohol as a biomimetic material through soft lithography with cell culture. Mol Biosyst. 2006 Jun;2(6-7):299-303. http://www.ncbi.nlm.nih.gov/pubmed/16880948?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16880948?dopt">CM Cheng, PR LeDuc. Micropatterning polyvinyl alcohol as a biomimetic material through soft lithography with cell culture. Mol Biosyst. 2006 Jun;2(6-7):299-303.</a> 114170453 T Matsuda, T Sugawara. Development of surface photochemical modification method for micropatterning of cultured cells. J Biomed Mater Res. 1995 Jun;29(6):749-756. http://www.ncbi.nlm.nih.gov/pubmed/7593012?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/7593012?dopt">T Matsuda, T Sugawara. Development of surface photochemical modification method for micropatterning of cultured cells. J Biomed Mater Res. 1995 Jun;29(6):749-756.</a> 114105943 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 0 114105944 Doyle, Andrew NIDCR NIDCR Doyle, Andrew (NIDCR) 1 114105944 Doyle, Andrew NIDCR NIDCR Doyle, Andrew (NIDCR) 1 114105943 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 0 114100915 Micropatterning Of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly(vinyl Alcohol) (PVA) Monolayers E-001-2008-0 Filing authorized National Institute of Standards and Technology, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers&body=Please send me information about technology [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers&body=Please send me information about technology [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers.">vlado.knezevic@nih.gov</a><br> 114162393 E-001-2008-0 E-001-2008-0-US-02 Micropatterning Of Biological Molecules Using Laser Ablation ORD US 8,048,641 12/249,824 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8048641 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8048641">8,048,641</a><br />Filed on 2008-10-10<br />Status: Issued 114118397 AA3AXX 114118398 AAXXXX 114118399 ACXXXX 114118400 AXXXXX 114118950 AA2XXX 114118951 AA3XXX 114118952 AC3XXX 114131732 Micropatterning 114131733 Extracellular 114131734 Cellular Interactions 114131735 INTERACTION 114131736 Microphoto-ablation 114131737 INTERACTIONS 114131738 CELL-BINDING 114131739 PVA 114131740 Polyvinyl TAB-2955 114096791 WNT1-Induced Secreted Protein-1 Knockout Mouse Model NIDCR Cardiology, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Azusa Maeda, Mitsuaki Ono, Marian Young <p>WNT1-induced secreted protein-1 (WISP1) is expressed at high levels in osteoblasts and their precursors. WIPS1 plays an important role in various aspects of bone formation. Scientists at the NIH generated <em>Wisp1</em>-deficient (<em>Wisp1<sup>-/-</sup></em>) mice. Deletion of <em>Wisp1</em> resulted in a decrease in bone mineral density, total bone volume, bone thickness, and biomechanical strength. <em>Wisp1</em> knockout mouse model can be used to study the molecular mechanisms of bone turnover and patho/physiology of tissues that express WISP1.&nbsp;The animal is only available from MMRRC.</p> <ul> <li>To study the molecular mechanisms of bone formation and osteodifferentiation.</li> <li>To study the patho/physiology of tissues that express WISP1, including cartilage during osteoarthritis, healing skin, and other soft tissues including lung, pancreas, and heart.</li> </ul> Research Tool - Patent protection is not being pursued for this technology. Available for non-exclusive licensing 2022-03-08 2024-12-26 2026-01-12 2015-08-03 DEFICIENT, Generation, Mice, OSTEOGENESIS, VAXXXX, VPXXXX, WISP1, WIXXXX, XCXXXX, XEXXXX, YCXXXX False True In vivo data available (animal) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171853 Maeda A, et al. http://www.ncbi.nlm.nih.gov/pubmed/25864198 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25864198">Maeda A, et al.</a> 114103327 Maeda, Azusa Okayama University Graduate School of Medicine Maeda, Azusa 0 114103431 Ono, Mitsuaki Okayama University Graduate School of Medicine Ono, Mitsuaki 0 114104352 Young, Marian NIDCR NIDCR Young, Marian (NIDCR) 1 114104352 Young, Marian NIDCR NIDCR Young, Marian (NIDCR) 1 114103327 Maeda, Azusa Okayama University Graduate School of Medicine Maeda, Azusa 0 114103431 Ono, Mitsuaki Okayama University Graduate School of Medicine Ono, Mitsuaki 0 114101914 Generation Of WISP1 Deficient Mice For The Study Of Osteogenesis E-234-2015-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model&body=Please send me information about technology [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model&body=Please send me information about technology [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model.">vlado.knezevic@nih.gov</a><br> 114121483 VAXXXX 114121484 VPXXXX 114123343 WIXXXX 114123344 XCXXXX 114123345 XEXXXX 114123346 YCXXXX 114139045 Generation 114139046 WISP1 114139047 DEFICIENT 114139048 Mice 114139049 OSTEOGENESIS TAB-3794 114097644 In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract NIDCR Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Kelly Ten Hagen, Liping Zhang This technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled cell proliferation and the up-regulation of conserved signaling pathways (JAK/STAT). Specifically, this mutant could be used to screen for compounds that either: 1) act to minimize damage to the epithelial cells in vivo; 2) stop uncontrolled cell proliferation in vivo; 3) rescue the abnormal up-regulation of conserved signaling pathways in vivo; and/or 4) act as a synthetic mucous membrane or mucin mimetic in vivo. Preliminary results suggest that this mutant can provide a great read-out for compounds that suffice in restoring the functional properties of the mucous membrane and therefore could be of potential use in treating patients that suffer from a compromised mucous lining. <ul><li>It is a complete in vivo system, with intact, functional organs comprised of all the appropriately differentiated cell types</li> <li>Drosophila larvae are inexpensive to grow and maintain</li> <li>Large numbers of larvae can be easily generated to perform screening of many compounds</li></ul> Screen for compounds to be used in the treatment of oral cavity and digestive tract disorders. 2022-11-30 2024-12-26 2026-01-12 2022-11-30 2022-08-03 FUNCTIONS, IDENTIFY, Inhibitors, Interrogate, Jak/STAT, MEMBRANES, MIMETICS, Mucin/glycan, Mucous, System, Vivo, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172954 Zhang L, Syed Z, et al. https://pubmed.ncbi.nlm.nih.gov/24799692/ <a href="https://pubmed.ncbi.nlm.nih.gov/24799692/">Zhang L, Syed Z, et al.</a> 114172955 Kuraishi T, Binggeli O, et al. https://pubmed.ncbi.nlm.nih.gov/21896728/ <a href="https://pubmed.ncbi.nlm.nih.gov/21896728/">Kuraishi T, Binggeli O, et al.</a> 114111588 Zhang, Liping NIDCR NIDCR Zhang, Liping (NIDCR) 0 114111589 Ten Hagen, Kelly NIDCR NIDCR Ten Hagen, Kelly (NIDCR) 1 114111589 Ten Hagen, Kelly NIDCR NIDCR Ten Hagen, Kelly (NIDCR) 1 114111588 Zhang, Liping NIDCR NIDCR Zhang, Liping (NIDCR) 0 114102896 In Vivo System To Interrogate The Functions Of Mucous Membranes And Identify Mucin/glycan Mimetics And JAK/STAT Inhibitors E-148-2016-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract&body=Please send me information about technology [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract&body=Please send me information about technology [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract.">vlado.knezevic@nih.gov</a><br> 114129625 VPXXXX 114129626 WIXXXX 114129627 XEXXXX 114155478 Vivo 114155479 System 114155480 Interrogate 114155481 FUNCTIONS 114155482 Mucous 114155483 MEMBRANES 114155484 IDENTIFY 114155485 Mucin/glycan 114155486 MIMETICS 114155487 Jak/STAT 114155488 Inhibitors TAB-2966 114094544 Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins NIDCR Antibodies, Cardiology, Diagnostics, Endocrinology, Geriatrics, Immunology, Oncology, Research Materials Antibodies Cardiology Diagnostics Endocrinology Geriatrics Immunology Oncology Research Materials Larry Fisher <p>The extracellular matrix (ECM) is composed of a group of proteins that regulate many cellular functions, such as cell shape, adhesion, migration, proliferation, and differentiation. Deregulation of ECM protein production or function contributes to many pathological conditions, including asthma, chronic obstructive pulmonary disease, arthrosclerosis, and cancer. Scientists at the NIH have developed antisera against various ECM components such as proteoglycan, sialoprotein, collagen, etc.. These antisera can be used as research tools to study the biology of extracellular matrix molecules. The resource is only available from KeraFAST and Millipore Sigma.</p> <ul> <li>Studying the biology of extracellular matrix molecules.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2026-01-12 2015-08-10 ANIMAL, Antisera, Human, Listed LPM Maddox as of 4/15/2015, Matricellular, MATRIX, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, proteins, rabbit, RXXXXX, SECRETED, VARIOUS, VAXXXX, VCXXXX, VDXXXX, VGXXXX, VIXXXX, WIXXXX, XAXXXX, XCXXXX, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109055 Fisher, Larry NIDCR NIDCR Fisher, Larry (NIDCR) 1 114109055 Fisher, Larry NIDCR NIDCR Fisher, Larry (NIDCR) 1 114101876 Rabbit Polyclonal Antisera To Human And Various Animal Matrix, Matricellular And Other Secreted Proteins E-135-2008-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins&body=Please send me information about technology [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins&body=Please send me information about technology [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins.">vlado.knezevic@nih.gov</a><br> 114127088 RXXXXX 114127089 VAXXXX 114127090 VCXXXX 114127091 VDXXXX 114127092 VGXXXX 114127093 VIXXXX 114127094 WIXXXX 114127095 XAXXXX 114127096 XCXXXX 114127097 YAXXXX 114148430 rabbit 114148431 polyclonal 114148432 Antisera 114148433 Human 114148434 VARIOUS 114148435 ANIMAL 114148436 MATRIX 114148437 Matricellular 114148438 SECRETED 114148439 proteins 114148440 Listed LPM Maddox as of 4/15/2015 114148441 Pre LPM working set 20150418 114148442 Post LPM Assignment Set 20150420 TAB-736 114095072 Postnatal Stem Cells and Uses Thereof NIDCR Dental, Diagnostics, Licensing, Therapeutics Dental Diagnostics Licensing Therapeutics Pamela Robey, Songtao Shi Many individuals with ongoing and severe dental problems are faced with the prospect of permanent tooth loss. Examples of such dental problems include: dentinal degradation due to chronic dental disease (caries or periodontal); mouth injury; or through surgical removal, such as with tumors associated with the jaw. For many, a technology that offers a possible alternative to artificial dentures by designing and transplanting a set of living teeth fashioned from an individual's own pulp cells would greatly improve their quality of life.<br /><br /> The NIH announces a new technology wherein human postnatal deciduous dental pulp stem cells commonly known as "baby teeth", are used to create dentin and have been shown to differentiate into cells of specialized function such as neural cells, adipocytes, and odontoblasts. It is believed that these cells could be manipulated to repair damaged teeth, induce the regeneration of bone, and treat neural injury or disease. 2022-03-08 2024-10-28 2026-01-12 2005-07-01 TB2XXX, TBXXXX, TCXXXX, TXXXXX False True True NIHTT 37470483 Website Abstract 114169909 Miura M, et al. http://www.ncbi.nlm.nih.gov/pubmed/12716973 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12716973">Miura M, et al.</a> 114104426 Shi, Songtao Shi, Songtao 0 114104427 Robey, Pamela NIDCR Robey, Pamela (NIDCR) 0 114104426 Shi, Songtao Shi, Songtao 0 114104427 Robey, Pamela NIDCR Robey, Pamela (NIDCR) 0 114099893 Isolation Of Multipotent Post-Natal Stem Cells From Exfoliated Human Primary (Baby) Teeth E-018-2003-0 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-736] Postnatal Stem Cells and Uses Thereof&body=Please send me information about technology [TAB-736] Postnatal Stem Cells and Uses Thereof. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-736] Postnatal Stem Cells and Uses Thereof&body=Please send me information about technology [TAB-736] Postnatal Stem Cells and Uses Thereof.">vlado.knezevic@nih.gov</a><br> 114161793 E-018-2003-0 E-018-2003-0-US-02 Postnatal Stem Cells And Uses Thereof National Stage US 9,175,264 10/553,633 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175264 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175264">9,175,264</a><br />Filed on 2006-11-07<br />Status: Issued 114114477 TB2XXX 114114478 TBXXXX 114114479 TCXXXX 114114480 TXXXXX TAB-2808 114096988 Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus NIDDK Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Shanshan (Melissa) He, Zongyi Hu, Tsanyang (Jake) Liang, Wei Zheng The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Thus, there is still the need for additional new therapeutics against HCV.<br /><br /> The subject technology are small molecule compounds identified using a novel cell-based high throughput assay of HCV infection. The compounds are antihistamines that show potent antiviral properties against HCV. One advantage of these compounds is that they are already on the market for the treatment of allergic reactions and, thus, have been used extensively in humans and have excellent safety profiles with known pharmaceutical properties. The subject technology can also potentially be used in combination with other HCV therapeutics. <ul> <li>These compounds are already on the market and, thus, have known safety profiles and pharmaceutical properties.</li> </ul> <ul> <li>Prevention or treatment of HCV infection.</li> <ul> 2022-03-08 2025-08-13 2026-01-12 2017-04-18 Analogs, C, Chlorcyclizine, DB4BXX, Hepatitis, RELATED, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108685 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108686 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114107484 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107484 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114108684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108685 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108686 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114101692 Use Of Chlorcyclizine And Its Related Analogs In Treatment Of Hepatitis C E-011-2014-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus.">vlado.knezevic@nih.gov</a><br> 114161387 E-011-2014-0 E-011-2014-0-PCT-02 Heterocyclic Compounds and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2014/066680 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/066680<br />Filed on 2014-11-20<br />Status: Expired 114166359 E-011-2014-0 E-011-2014-0-US-08 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer National Stage US 15/039,781 Abandoned US <br />National Stage 15/039,781<br />Filed on 2016-05-26<br />Status: Abandoned 114167748 E-011-2014-0 E-011-2014-0-US-01 Heterocyclic Compounds and Methods of Use Thereof PRV US 61/909,414 Abandoned US <br />Provisional (PRV) 61/909,414<br />Filed on 2013-11-27<br />Status: Abandoned 114125940 DB4BXX 114125941 VLXXXX 114125942 WKXXXX 114125943 YAXXXX 114125944 YBXXXX 114147147 Chlorcyclizine 114147148 RELATED 114147149 Analogs 114147150 treatment 114147151 Hepatitis 114147152 C TAB-2421 114096623 MUP-tTA Mouse Model for Liver Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Tsanyang (Jake) Liang Tetracycline-responsive transcriptional activator driven by the liver-specific mouse major urinary protein promoter (MUP-tTA). <br /><br /> The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain (Tet-Off). Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as the mouse major urinary protein (MUP) promoter determined that the tetracycline-regulated transcriptional activator (tTA) would be expressed specifically in liver. To study the effect of the transcription activator on a target gene (for example, beta-galactosidase, LacZ) specifically in liver, MUP-tTA mice would be mated with transgenic mice in which the TAg Target gene was controlled by the E.Coli Tetracycline Operator (Tet-O). The Tet technology may require a separate license. Mouse model to study liver function. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2026-01-12 2017-04-17 IDXXXX, IXXXXX, Mouse, MUP-tTA False True Pre-clinical True NIHTT 37470483 Website Abstract 114171566 Manickan E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11278564 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11278564">Manickan E, et al.</a> 114107524 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107524 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114101723 MUP-tTA Mouse E-126-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies.">vlado.knezevic@nih.gov</a><br> 114122723 IXXXXX 114122724 IDXXXX 114142906 MUP-tTA 114142907 Mouse TAB-2420 114096622 Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Tsanyang (Jake) Liang Tetracycline-responsive transcriptional activator driven by the liver-specific mouse albumin promoter (Alb-tTA). <br /><br /> The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain. Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as mouse albumin determined that the tetracycline-regulated transcriptional activator (tTA) would be expressed specifically in liver. To study the effect of the transcription activator on a target gene (for example, Simian Virus 40 (SV4) large tumor (T) antigen (TAg)) specifically in liver, Alb-tTA mice were mated with transgenic mice in which the Target gene (TAg) was controlled by the E.Coli Tetracycline Operator (Tet-O). In this example, TAg was expressed in hepatocytes in the absence of Tetracycline, leading to hepatoma formation. When the mice were treated with tetracycline, TAg was not expressed and hepatomas did not form. Mouse model to liver function. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2026-01-12 2017-04-18 Alb-tTA, IDXXXX, IXXXXX, Mouse, TgAlb1-tTa3123Lng False True Pre-clinical True NIHTT 37470483 Website Abstract 114171565 Manickan E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11278564 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11278564">Manickan E, et al.</a> 114107523 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107523 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114101722 Alb-tTA (Tg(Alb1-tTa)3123Lng) Mouse E-125-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies.">vlado.knezevic@nih.gov</a><br> 114122721 IXXXXX 114122722 IDXXXX 114142903 Alb-tTA 114142904 TgAlb1-tTa3123Lng 114142905 Mouse TAB-3726 114097578 Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures NIDDK Medical Devices, Non-Medical Devices, Research Materials Medical Devices Non-Medical Devices Research Materials Poorni Adika, Mritunjay Pandey, William Simonds, Jianhua Zhang This technology includes a semi-automatic and affordable protein purification system that produces purified proteins with yields and purities comparable to an automatic protein purification system for less than 10% of its cost, which can be used for studying protein structure and function, as well as antibody purifications and drug screenings. Additionally, the new system is flexible and customizable for use with both custom-made and commercial pre-made resin columns with either gravity flow or low-pressure configurations. Using a prototype, we have successfully performed one-step purification of different twin-strep tagged protein complexes overexpressed in mammalian cells and obtained proteins with more than 90% purity. This easy-to-use and user-friendly system can facilitate the affinity purification of any protein in both large and small scales. Therefore, this new system shares the advantages of both automatic and manual systems at a fraction of the cost, and therefore could be a better alternative for the protein purification systems currently available. Compared to existing protein purification systems, this innovation has the following unique features: <ul> <li>Significantly reduces the hands-on time compared to the regular gravity flow method</li> <li>Very low cost compared to automatic method</li> <li>Simple to use</li> <li>Semi-automatic</li> <li>Compatible with both premade and custom-made columns</li> <li>Flexible in column size and capacity</li> <li>Controlled flow rate and more reproducible results as compared to regular gravity flow method</li> </ul> The novel protein purification system can be used: <ul> <li>For purification of polyclonal, monoclonal antibodies</li> <li>For purification of proteins</li> <li>For separation of other materials using gravity flow mechanisms</li> <li>For use with existing and commercially available columns and custom-made columns</li> </ul> 2022-11-30 2026-01-12 2026-01-12 2022-11-30 Affordable, Development, Efficient, Protein, purification, System, WIXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114111403 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 0 114111404 Pandey, Mritunjay National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pandey, Mritunjay 0 114111405 Adika, Poorni National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Adika, Poorni (NIDDK) 0 114111406 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 1 114111406 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 1 114111403 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 0 114111404 Pandey, Mritunjay National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pandey, Mritunjay 0 114111405 Adika, Poorni National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Adika, Poorni (NIDDK) 0 114102830 Development Of An Efficient And Affordable Protein Purification System E-011-2018-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures &body=Please send me information about technology [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures . Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures &body=Please send me information about technology [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures .">vlado.knezevic@nih.gov</a><br> 114129410 WIXXXX 114129411 XDXXXX 114154848 Development 114154849 Efficient 114154850 Affordable 114154851 Protein 114154852 purification 114154853 System TAB-5076 164222822 Innovative Antibody Conjugates for Targeted Therapeutics NIBIB Diagnostics, Immunology, Oncology, Therapeutics Diagnostics Immunology Oncology Therapeutics Devon Hartigan, Katharina Maisel, Kaitlyn Sadtler <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">This cutting-edge technology leverages innovative conjugated antibodies to transform the way diseases are treated. By engineering antibodies to deliver therapeutic agents directly to specific cells, this approach offers a powerful combination of precision, potency, and safety.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Unlike traditional therapies that often impact healthy tissues and cause significant side effects, these conjugated antibodies provide highly targeted delivery, ensuring that treatment is concentrated where it is needed most. This next-generation strategy addresses the critical limitations of conventional treatments by improving both accuracy in targeting disease mechanisms and overall treatment outcomes.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The technology&rsquo;s versatility makes it especially impactful in oncology, where eliminating tumor cells without harming surrounding tissue is paramount, and in autoimmune disorders, where precise modulation of immune activity can dramatically improve patient quality of life. With its potential to reshape multiple therapeutic landscapes, this innovation represents a new frontier in targeted medicine.</span></span></p> <ul> <li>Enhanced targeting capabilities leading to improved therapeutic outcomes.</li> <li>Reduced side effects compared to conventional treatments due to localized drug delivery.</li> <li>Potential for broad applications across various therapeutic areas, including oncology and autoimmune diseases.</li> </ul> <ul> <li>Targeted cancer therapies using engineered antibodies.</li> <li>Autoimmune disease treatments with reduced systemic effects.</li> <li>Diagnostic imaging agents for precise disease localization.</li> </ul> 2025-09-22 2025-09-22 2026-01-02 2025-09-22 False True True 52406768 Discovery 52406768 37470483 Website Abstract 164222874 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 1 164222853 Hartigan, Devon Hartigan, Devon 2 164222849 Maisel, Katharina Maisel, Katharina 3 164222874 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 1 164222853 Hartigan, Devon Hartigan, Devon 2 164222849 Maisel, Katharina Maisel, Katharina 3 164222825 A thermo-sensitive hydrogel for in situ delivery of Amphotericin B to fungal infection sites E-078-2024-0 Filing authorized NIBIB, NIBIB, University of Maryland 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics&body=Please send me information about technology [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics&body=Please send me information about technology [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics.">vlado.knezevic@nih.gov</a><br> 164222831 E-078-2024-0 E-078-2024-0-PC-01 THERMO-SENSITIVE ANTI-FUNGAL HYDROGEL COMPOSITIONS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2025/017838 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/017838<br />Filed on 2025-02-28<br />Status: Pending TAB-5077 164223314 Innovative Antibody Conjugates for Targeted Therapy NIBIB Diagnostics, Immunology, Oncology, Therapeutics Diagnostics Immunology Oncology Therapeutics Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Kaitlyn Sadtler <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">This advanced technology introduces innovative antibody conjugates that redefine the possibilities of targeted therapy. By coupling therapeutic agents to engineered antibodies with highly specific binding sites, these conjugates deliver treatments directly to diseased cells while sparing healthy tissues. The result is a powerful increase in treatment efficacy, accompanied by a meaningful reduction in side effects.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Designed with cutting-edge engineering techniques, the platform offers exceptional versatility, enabling adaptation across a wide range of therapeutic areas. Its greatest potential lies in oncology, where precision targeting is critical for destroying tumor cells while preserving patient health, and in immunology, where carefully modulating immune responses can transform chronic disease management.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">By uniting precision targeting, enhanced safety, and broad therapeutic applicability, this technology represents a major step forward in the evolution of targeted therapies, offering new hope for improved patient outcomes and more effective treatments.</span></span></p> <ul> <li>High specificity and reduced off-target effects, leading to improved patient safety.</li> <li>Versatile applications across multiple therapeutic areas, including oncology and immunology.</li> <li>Potential for rapid development and commercialization due to established engineering techniques.</li> </ul> <ul> <li>Targeted cancer therapies using engineered immune cells.</li> <li>Diagnostic imaging agents for precise disease detection.</li> <li>Therapeutic agents for autoimmune diseases.</li> </ul> 2025-09-22 2025-09-22 2026-01-02 2025-09-22 False True True 52406768 Discovery 52406768 37470483 Website Abstract 164223425 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 1 164223416 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 2 164223458 Fathi, Parinaz Fathi, Parinaz 3 164223504 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 4 164223425 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 1 164223416 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 2 164223458 Fathi, Parinaz Fathi, Parinaz 3 164223504 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 4 164223317 Microfluidic Devices For Evaluating Fibrosis In Material Implantation And Cancer E-118-2022-0 Filing authorized NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy&body=Please send me information about technology [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy&body=Please send me information about technology [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy.">vlado.knezevic@nih.gov</a><br> 164223328 E-118-2022-0 E-118-2022-0-US-02 MICROFLUIDIC DEVICES FOR EVALUATING FIBROSIS IN MATERIAL IMPLANTATION AND CANCER National Stage US 18/859,345 Pending US <br />National Stage 18/859,345<br />Filed on 2024-10-23<br />Status: Pending 164223329 E-118-2022-0 E-118-2022-0-EP-01 MICROFLUIDIC DEVICES FOR EVALUATING FIBROSIS IN MATERIAL IMPLANTATION AND CANCER National Stage European Patent 23726232.4 Pending European Patent <br />National Stage 23726232.4<br />Filed on 2024-10-25<br />Status: Pending TAB-5079 164223742 Advanced Biodegradable Polymers for Medical Devices NIBIB Human Cell Lines, Medical Devices, Therapeutics Human Cell Lines Medical Devices Therapeutics Ravi Lokwani, Kaitlyn Sadtler <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">This breakthrough technology features advanced biodegradable polymers engineered specifically for medical device applications. Designed to safely degrade within the body, these polymers eliminate the need for surgical removal, significantly reducing the risk of long-term complications and enhancing overall patient safety.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The polymers&rsquo; controlled degradation rates provide unmatched versatility, allowing them to be tailored for a wide range of clinical uses&mdash;from temporary implants to drug-delivery systems. Beyond patient care, the technology also addresses a growing global need for sustainable healthcare solutions, reducing medical waste and lessening environmental impact.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">By combining safety, precision, and sustainability, this innovation represents a major step forward in next-generation medical device design. It sets a new standard for solutions that improve patient outcomes while contributing to a more environmentally responsible future.</span></span></p> <ul> <li>Biodegradable materials reduce the need for invasive follow-up surgeries.</li> <li>Customizable degradation rates tailored to specific medical applications.</li> <li>Environmentally friendly, addressing growing concerns about medical waste.</li> </ul> <ul> <li>Implantable devices such as stents and orthopedic implants.</li> <li>Drug delivery systems that dissolve after releasing medication.</li> <li>Wound care products that promote healing while degrading safely in the body.</li> </ul> 2025-09-22 2025-09-22 2026-01-02 2025-09-22 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 164223794 Sadtler, Kaitlyn NIBIB Sadtler, Kaitlyn (NIBIB) 1 164223789 Lokwani, Ravi NIBIB NIBIB Lokwani, Ravi (NIBIB) 2 164223794 Sadtler, Kaitlyn NIBIB Sadtler, Kaitlyn (NIBIB) 1 164223789 Lokwani, Ravi NIBIB NIBIB Lokwani, Ravi (NIBIB) 2 164223745 Modulation Of Antigen Presentation In Immune Responses To Medical Devices And Regenerative Therapeutics E-139-2022-2 Filing authorized NIBIB, NIH - NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5079] Advanced Biodegradable Polymers for Medical Devices&body=Please send me information about technology [TAB-5079] Advanced Biodegradable Polymers for Medical Devices. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5079] Advanced Biodegradable Polymers for Medical Devices&body=Please send me information about technology [TAB-5079] Advanced Biodegradable Polymers for Medical Devices.">vlado.knezevic@nih.gov</a><br> 164223753 E-139-2022-2 E-139-2022-2-US-01 METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING National Stage US 18/992,393 Pending US <br />National Stage 18/992,393<br />Filed on 2025-01-08<br />Status: Pending 164223754 E-139-2022-2 E-139-2022-2-EP-01 METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING National Stage European Patent 23750873.4 Pending European Patent <br />National Stage 23750873.4<br />Filed on 2025-01-08<br />Status: Pending TAB-4579 151757285 Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging NIBIB Antibodies, Licensing, Oncology, Therapeutics Antibodies Licensing Oncology Therapeutics Xiaoyuan (Shawn) Chen, Orit Jacobson weiss <p>This technology includes anti-PSMA antibody labeled with 177Lu, which has shown to be an effective treatment for prostate cancer. Several small molecules targeting PSMA were also evaluated in prostate cancer patients labeled with betta emitters such as 177Lu. The most common one is 177Lu-PSMA-617 which is under clinical evaluation in many countries. Usual treatment in patients in most clinical trials was composed of up to 3 cycles of 177Lu-PSMA-617. The limited data available suggest partial response rates of up to 70%&ndash;80% that was limited to as few as several weeks in some of the patients. Encouragingly, only stage 1 -2 hematologic toxicities and sporadically mild xerostomia and fatigue were reported as side effects.</p> Our modification of small molecule-based radiotherapy attaches an albumin binding domain based on the structure of Evans blue that results in significantly increased blood half-life, increased tumor uptake, and more effective anti-tumor radiotherapy. This may improve therapy of patients with PSMA-positive tumors and the general design may be applicable to other therapeutic small molecules. This product will be of use in nuclear imaging and radiotherapy of PSMA-positive tumors, and the EB derivative can be used for increasing the blood half-life of small molecules targeting PSMA. We are seeking statements of capability or interest from parties interested in collaborative research to further developr, evaluate, or commercialize this technology. 2023-12-12 2025-08-13 2026-01-02 2024-03-27 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 151757299 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151757313 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151757299 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151757313 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151757288 Evans Blue Modified Small Molecule Based Prostate-specific Membrane Antigen (PSMA) Radiotherapy E-054-2018-0 Filing authorized NIBIB 83709191 Carranza, Mario carranzam@mail.nih.gov
United States of America Office of Technology Transfer and Development carranzam@mail.nih.gov?subject=Web Inquiry on [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging&body=Please send me information about technology [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging. Carranza, Mario<br><a href="mailto:carranzam@mail.nih.gov?subject=Web Inquiry on [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging&body=Please send me information about technology [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging.">carranzam@mail.nih.gov</a><br> 157762470 E-054-2018-0 E-054-2018-0-CN-03 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage China ZL201980014834.9 201980014834.9 Issued China <br />National Stage 201980014834.9<br />Filed on 2019-02-22<br />Status: Issued 157762475 E-054-2018-0 E-054-2018-0-EP-04 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage European Patent 3755321 19756548.4 Issued European Patent <br />National Stage 19756548.4<br />Filed on 2019-02-22<br />Status: Issued 157762480 E-054-2018-0 E-054-2018-0-IL-05 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Israel 276653 276653 Issued Israel <br />National Stage 276653<br />Filed on 2020-08-11<br />Status: Issued 157762485 E-054-2018-0 E-054-2018-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING National Stage US 12,161,733 16/969,673 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12161733 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12161733">12,161,733</a><br />Filed on 2020-08-13<br />Status: Issued 157762495 E-054-2018-0 E-054-2018-0-AU-08 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Australia 2019225154 2019225154 Issued Australia <br />National Stage 2019225154<br />Filed on 2019-02-22<br />Status: Issued 157762500 E-054-2018-0 E-054-2018-0-CA-09 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Canada 3090812 Pending Canada <br />National Stage 3090812<br />Filed on 2019-02-22<br />Status: Pending 157762505 E-054-2018-0 E-054-2018-0-JP-10 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Japan 7449864 2020-543529 Issued Japan <br />National Stage 2020-543529<br />Filed on 2019-02-22<br />Status: Issued 157762510 E-054-2018-0 E-054-2018-0-KR-11 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage South Korea 10-2902487 10-2020-7027109 Issued South Korea <br />National Stage 10-2020-7027109<br />Filed on 2020-09-18<br />Status: Issued 157762515 E-054-2018-0 E-054-2018-0-HK-12 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER CN Hong Kong HK40029571B 62020019110.9 Issued Hong Kong <br />China Patent (CN) 62020019110.9<br />Filed on 2019-02-22<br />Status: Issued 157762520 E-054-2018-0 E-054-2018-0-CN-01 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER DIV China 202410872371.2 Pending China <br />Divisional (DIV) 202410872371.2<br />Filed on 2024-07-01<br />Status: Pending 157762525 E-054-2018-0 E-054-2018-0-MO-01 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER CN Macao J/008699 J/008699 Issued Macao <br />China Patent (CN) J/008699<br />Filed on 2024-09-27<br />Status: Issued TAB-4581 151758960 Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation NIBIB Licensing, Medical Devices, Research Equipment Licensing Medical Devices Research Equipment John Kakareka, George Patterson, Thomas Pohida, Peter Schuck, Huaying Zhao <p>This technology includes improvements in the fluorescence scanner to increase efficiency. This method works by eliminating the need to radially slide the optical assembly during scanning, instead using a galvanometric mirror deflecting a laser beam to different positions in the sample. This allows the scanner to be incorporated into existing commercial analytical ultracentrifugation (AUC) systems with minimal modifications. A further improvement designed to increase detection efficiency is the use of plano-convex windows replacing planar windows in the sample cell assembly, which can help focus excitation and emitted fluorescence. Ensuing spatial inhomogeneities of beam angles and excitation intensities and detection efficiencies are accounted for in the mathematical analysis.</p> Invention improves detection limits for fluorescence. The fluorescence detectors could be manufactured to retrofit existing preparative ultracentrifuges or AUC instruments as well as be incorporated into the design of new instruments. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-12 2026-01-02 2026-01-02 2024-03-27 False True True 52406769 Prototype 52406769 37470483 Website Abstract 151759125 Schuck, Peter NIBIB NIBIB Schuck, Peter (NIBIB) 1 151759288 Pohida, Thomas Center for Information Technology (CIT) CIT Pohida, Thomas (CIT) 2 151759355 Patterson, George NIBIB NIBIB Patterson, George (NIBIB) 3 151759403 Zhao, Huaying NIBIB NIBIB Zhao, Huaying (NIBIB) 4 151759420 Kakareka, John NIBIB NIBIB Kakareka, John (NIBIB) 5 151759125 Schuck, Peter NIBIB NIBIB Schuck, Peter (NIBIB) 1 151759288 Pohida, Thomas Center for Information Technology (CIT) CIT Pohida, Thomas (CIT) 2 151759355 Patterson, George NIBIB NIBIB Patterson, George (NIBIB) 3 151759403 Zhao, Huaying NIBIB NIBIB Zhao, Huaying (NIBIB) 4 151759420 Kakareka, John NIBIB NIBIB Kakareka, John (NIBIB) 5 151758963 Fluorescence Scanning System For Analytical Ultracentrifugation E-076-2020-0 Filing authorized CIT, NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation&body=Please send me information about technology [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation&body=Please send me information about technology [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation.">vlado.knezevic@nih.gov</a><br> TAB-5063 163191393 Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling NIBIB Collaboration, Diagnostics, Endocrinology, Human Cell Lines, Immunology, Licensing, Medical Devices, Metabolic Disease, Oncology, Research Equipment, Research Materials, Therapeutics Collaboration Diagnostics Endocrinology Human Cell Lines Immunology Licensing Medical Devices Metabolic Disease Oncology Research Equipment Research Materials Therapeutics Madison Daminato, Parinaz Fathi, Parnika Kant, Nicole Morgan, Anagha Rama Varma, Paniz Rezvan Sangsari, Kaitlyn Sadtler <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a micro-engineered &ldquo;thyroid-on-a-chip&rdquo; that combines human thyroid organoids with integrated micro-vasculature to replicate the gland&rsquo;s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform yields more physiologically relevant data than conventional static cultures or animal surrogates. Its modular design accommodates cells from individual patients, helping clinicians predict therapeutic response and tailor treatment for thyroid cancers and autoimmune disorders. In pharmaceutical R&amp;D, the chip shortens pre-clinical timelines by providing actionable efficacy and toxicity read-outs within days. Overall, the system offers a high-fidelity bridge between benchtop discovery and clinical decision-making, addressing an unmet need for robust human thyroid models.</span></span></span></p> <ul> <li>First thyroid model to incorporate functional micro-vasculature, closely mirroring in-vivo hemodynamics and hormone exchange.</li> <li>Allows insertion of primary patient cells, enabling personalized therapy selection and reducing costly late-stage clinical failures.</li> <li>Generates predictive efficacy and safety data in days, cutting pre-clinical study time and animal use.</li> </ul> <ul> <li>Patient-specific screening of small-molecule, biologic, or radiotherapeutic candidates for thyroid cancer and autoimmune thyroiditis.</li> <li>Investigating thyroid-immune interactions to identify new immunomodulatory drug targets.</li> <li>High-throughput endocrine toxicity testing for pipeline compounds and environmental chemicals.</li> </ul> 2025-07-03 2026-01-02 2026-01-02 2025-07-03 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 163191536 Rama Varma, Anagha NIH - NIBIB NIBIB Rama Varma, Anagha (NIBIB) 1 163191540 Kant, Parnika NIH - NIBIB NIBIB Kant, Parnika (NIBIB) 2 163191551 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 3 163191563 Fathi, Parinaz NIBIB Fathi, Parinaz 4 163191572 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 5 163191576 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 6 163191583 Daminato, Madison NIH - NIBIB NIBIB Daminato, Madison (NIBIB) 7 163191536 Rama Varma, Anagha NIH - NIBIB NIBIB Rama Varma, Anagha (NIBIB) 1 163191540 Kant, Parnika NIH - NIBIB NIBIB Kant, Parnika (NIBIB) 2 163191551 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 3 163191563 Fathi, Parinaz NIBIB Fathi, Parinaz 4 163191572 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 5 163191576 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 6 163191583 Daminato, Madison NIH - NIBIB NIBIB Daminato, Madison (NIBIB) 7 163191396 Vascularized Thyroid on-a-chip E-076-2025-0 Filing authorized NIBIB, NIH - NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling&body=Please send me information about technology [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling&body=Please send me information about technology [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling.">vlado.knezevic@nih.gov</a><br> 163191402 E-076-2025-0 E-076-2025-0-US-01 VASCULARIZED THYROID-ON-A-CHIP PRV US 63/802,302 Expired US <br />Provisional (PRV) 63/802,302<br />Filed on 2025-05-08<br />Status: Expired 163191403 E-076-2025-0 E-076-2025-0-US-02 VASCULARIZED THYROID-ON-A-CHIP ORD US 19/247,851 Pending US <br />Ordinary Patent (ORD) 19/247,851<br />Filed on 2025-06-24<br />Status: Pending TAB-4085 147157367 Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials John Greiner, Jeffrey Schlom <p>Bladder cancer is the fifth most common cancer in the United States and one of the costliest cancers to treat. Compared to other cancer types, bladder cancer has been understudied, and there is a need for informative mouse bladder cancer models that resemble the clinical situation and allow for evaluation of chemotherapeutic or immunotherapeutic agents. The orthotopic murine bladder cancer model MB49 resembles non-muscle invasive, nonmetastatic urothelial carcinomas and provides an opportunity to study the anti-tumor effects of immune cell checkpoint inhibitors. Moreover, successful tumor cell implantation of MB49 cells fails in ~25% of the animals due to low tumor- take rates. Thus, there is also a need for methods that assess tumor- take rates in orthotopic bladder tumor models.    </p> <p>Researchers at the National Cancer Institute (NCI) have developed a MB49-luciferase cell line that allows for intravital imaging to evaluate anti-cancer agents in bladder cancer. Furthermore, the MB49-luciferase cell line is helpful in assessing the tumor- take to select mice for treatments groups based on equivalent tumor burden. The inventors have demonstrated in vivo that MB49-luciferase bladder tumors are highly positive for the expression of programmed death-ligand 1 (PD-L1). </p> <p>The <a href="https://ccr.cancer.gov/Laboratory-of-Tumor-Immunology-and-Biology" rel="nofollow">National Cancer Institute, Laboratory of Tumor Immunology and Biology</a>, is seeking <br /> statements of capability or interest from parties interested in licensing this research material to evaluate anti-cancer agents in bladder cancer. </p> <h2>Competitive Advantages:</h2> <ul><li>Bioluminescence allows for assessment of tumor progression after treatment with anti-cancer agents </li> <li>Intravital imaging is helpful in assessing early tumor-take and the amount of radiance can be used to select mice accurately for treatment groups based on equivalent tumor burden</li> <li>Intravital imaging also allows for temporal assessment of tumor growth in real time</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Use in preclinical studies to evaluate anti-cancer agents in bladder cancer</li> </ul> 2018-11-08 2025-04-22 2018-11-08 2025-12-30 2018-11-08 Bioluminescence, Bladder cancer, LUCIFERASE, MB49, Schlom False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-11-08 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-132-2011 147162322 Vandeveer A, et al. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor https://www.ncbi.nlm.nih.gov/pubmed/26921031 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26921031">Vandeveer A, et al. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor</a> 147163463 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163464 Greiner, John NIH - NCI NCI Greiner, John (NCI) 2 147163463 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163464 Greiner, John NIH - NCI NCI Greiner, John (NCI) 2 147158253 MB49-luciferase Cell Line E-237-2018-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression&body=Please send me information about technology [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression&body=Please send me information about technology [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147174072 Bioluminescence 147174073 Bladder cancer 147174074 LUCIFERASE 147174076 MB49 147174077 Schlom TAB-4180 147157465 Brachyury-directed Vaccine for the Prevention or Treatment of Cancers NCI Collaboration, Immunology, Licensing, Oncology, Vaccines Collaboration Immunology Licensing Oncology Vaccines Claudia Palena, Jeffrey Schlom <p>Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers.</p> <p>Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that a therapeutic vaccine derived from this technology would be broadly applicable for the treatment of cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Treatment targets invasive and metastatic tumor cells which are the primary cause of cancer-related mortality.</li> <li>Vaccine can eliminate cancer stem cells which are resistant to conventional therapies</li> <li>Compatible with the clinically-proven TRICOM cancer vaccine platform</li> <li>Available (Optimized) for use with non-pox, non-yeast vectors including: adenovirus, lentivirus, etc., and for use with protein- or peptide-based vaccines</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Preventative cancer vaccine for patients with precancerous lesions of the breast, colon or prostate.</li> <li>Therapeutic cancer vaccine for the treatment of disseminated and late-stage tumors.</li> <li>Vaccine component of a multi-modal cancer therapy</li> </ul> 2017-10-06 2025-04-22 2018-03-20 2025-12-30 2017-10-06 Brachyury, CANCER VACCINE, Immunotherapy, T-CELLS, Transcription factor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-20 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162222 R.I. Fernando et al. https://www.ncbi.nlm.nih.gov/pubmed/20071775 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20071775">R.I. Fernando et al.</a> 147162375 C. Palena et al. https://www.ncbi.nlm.nih.gov/pubmed/17438107 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17438107">C. Palena et al.</a> 147163797 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163798 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 2 147163797 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163798 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 2 147157880 The Development And Use Of Vaccines (Non-Yeast, Non-Poxvirus Based) For The Prevention And/or Therapy Of Human Cancer E-055-2011-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers&body=Please send me information about technology [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers&body=Please send me information about technology [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147167163 E-055-2011-0 E-055-2011-0-US-05 BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE DIV US 11,357,839 16/107,559 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11357839 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11357839">11,357,839</a><br />Filed on 2018-08-21<br />Status: Issued 147167171 E-055-2011-0 E-055-2011-0-US-13 BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE DIV US 17/833,383 Pending US <br />Divisional (DIV) 17/833,383<br />Filed on 2022-06-06<br />Status: Pending 147170396 Brachyury 147170397 CANCER VACCINE 147170398 Immunotherapy 147170399 T-CELLS 147170400 Transcription factor TAB-4384 147157678 Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Jeffrey Schlom, Kwong-Yok Tsang <p>Human papillomavirus (HPV) has been associated with the cause of several cancer types, including cervical, anal, and head and neck cancers. There has been great success in preventing HPV infections with the development of prophylactic HPV vaccines, Gardasil and Cervarix. However, these vaccines have only been shown to prevent HPV infection and not treat those already infected with HPV. These vaccines elicit antibody responses to late HPV genes, and thus would not be effective in treating established tumors. To date, no therapeutic HPV vaccine has been approved by the FDA, and there is an unmet need for therapeutic vaccines for the treatment of cervical, anal, and head and neck cancers. </p> <p>One approach in the development of HPV therapeutic vaccines is the use of agonist epitopes that would elicit enhanced cytotoxic T-lymphocyte (CTL) responses capable of lysing human tumor cells expressing native HPV epitopes. Researchers at the National Cancer Institute (NCI) have identified three agonist epitopes that target early HPV genes responsible for maintaining the malignant phenotype. Moreover, these agonist epitopes generate CTLs capable of lysing carcinoma cells expressing the native HPV epitope. </p> <p>The NCI, Center for Cancer Research, is seeking statements of capability or interest from parties interested in licensing and/or collaborative research to further develop, evaluate, or commercialize the HPV agonist epitopes for the development of a therapeutic vaccine.</p> <h2>Competitive Advantages:</h2> <ul><li>Gardasil and Cervarix are prophylactic HPV vaccines and are not used to treat HPV-infected individuals. This technology could be used to develop the first therapeutic vaccine for HPV </li> <li>HPV agonist epitopes target early HPV genes that are responsible for maintenance of the malignant phenotype. Gardasil and Cervarix target late genes and would not be effective in treating established tumors</li> <li>HPV agonist epitopes activate HPV-specific CTLs that lyse tumor cells and control tumor growth/rejection </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Development of HPV therapeutic vaccines for the treatment of cervical, anal, and head and neck cancers </li> <li>For cancer immunotherapy targeting HPV-mediated cancers or use as a combination therapy with immune checkpoint inhibitors, other immune modulators and/or chemotherapy, radiation therapy, and other modes of therapy such as the use of small molecule-targeted therapeutics</li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-12-30 2018-10-12 Agonist Epitope, CTL, Cytotoxic T Lymphocytes, HPV, Human Papillomavirus, Schlom, Therapeutic Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-001-2012 147161888 Tsang KY, et al. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. https://www.ncbi.nlm.nih.gov/pubmed/28389098 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28389098">Tsang KY, et al. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.</a> 147164531 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164532 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 147164531 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164532 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 147158130 Development Of Agonist Epitopes Of The Human Papillomavirus ( HPV) E-169-2016-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine&body=Please send me information about technology [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine&body=Please send me information about technology [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147161139 E-169-2016-0 E-169-2016-0-US-01 Development Of Agonist Epitopes Of The Human Papillomavirus PRV US 62/497,064 Abandoned US <br />Provisional (PRV) 62/497,064<br />Filed on 2016-11-07<br />Status: Abandoned 147168558 E-169-2016-0 E-169-2016-0-PCT-02 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS PCT Patent Cooperation Treaty PCT/US2017/060109 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060109<br />Filed on 2017-11-06<br />Status: Expired 147168559 E-169-2016-0 E-169-2016-0-AU-03 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage Australia 2017355564 2017355564 Issued Australia <br />National Stage 2017355564<br />Filed on 2019-05-06<br />Status: Issued 147168560 E-169-2016-0 E-169-2016-0-CA-04 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage Canada 3042703 3042703 Issued Canada <br />National Stage 3042703<br />Filed on 2017-11-06<br />Status: Issued 147168561 E-169-2016-0 E-169-2016-0-EP-05 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage European Patent 3535284 17 808 241.8 Issued European Patent <br />National Stage 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168562 E-169-2016-0 E-169-2016-0-US-06 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage US 11,311,613 16/347,764 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11311613 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11311613">11,311,613</a><br />Filed on 2019-05-06<br />Status: Issued 147168563 E-169-2016-0 E-169-2016-0-CH-07 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Switzerland 3535284 17 808 241.8 Issued Switzerland <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168564 E-169-2016-0 E-169-2016-0-DE-08 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Germany 3535284 17 808 241.8 Issued Germany <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168565 E-169-2016-0 E-169-2016-0-ES-09 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Spain 3535284 17 808 241.8 Issued Spain <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168566 E-169-2016-0 E-169-2016-0-FR-10 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP France 3535284 17 808 241.8 Issued France <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168567 E-169-2016-0 E-169-2016-0-GB-11 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP United Kingdom 3535284 17 808 241.8 Issued United Kingdom <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168568 E-169-2016-0 E-169-2016-0-IE-12 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Ireland 3535284 17 808 241.8 Issued Ireland <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168569 E-169-2016-0 E-169-2016-0-IT-13 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Italy 3535284 17 808 241.8 Issued Italy <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168570 E-169-2016-0 E-169-2016-0-NL-14 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP The Netherlands 3535284 17 808 241.8 Issued The Netherlands <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147172862 Agonist Epitope 147172863 CTL 147172865 Cytotoxic T Lymphocytes 147172866 HPV 147172868 Human Papillomavirus 147172869 Schlom 147172871 Therapeutic Vaccine TAB-4551 151737494 Treatment of Periodontal Disease via ENPPI Inhibition NIAMS Collaboration, Collaboration Sought, Dental, Therapeutics Collaboration Collaboration Sought Dental Therapeutics Demetrios Braddock, Emily Chu, Brian Foster, Francisco Nociti, Martha Somerman, Vivek Thumbigere-Math <p>This technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization. Research indicates that the balance between inorganic phosphate (Pi) and PPi (Pi/PPi ratio) significantly influences cementum formation, a crucial tissue for dental health. Notably, cementum production can be considerably enhanced, by over ten times, when PPi levels are reduced. This has been observed in both murine models and humans with impaired ENPP1 function. Since ENPP1 is the primary extracellular source of PPi, its inhibition creates a favorable environment for increased cementum production, offering a promising avenue for treating periodontal diseases.</p> Current therapies for treating periodontal disease, such as dental hygiene, antibiotics, and teeth replacement via surgery, do not have predictable outcomes and do not demonstrate reliable cementum regeneration. Use for periodontal regeneration and beyond for other disorders, conditions, trauma related to mineralized tissues. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. Technology is also available for non-exclusive or exclusive licensing 2023-12-11 2024-12-31 2025-12-30 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151737504 Braddock, Demetrios Yale University Braddock, Demetrios 1 151737508 Somerman, Martha NIDCR NIDCR Somerman, Martha (NIDCR) 2 151737524 Chu, Emily NIAMS Chu, Emily 3 151737536 Thumbigere-Math, Vivek University of Maryland, Baltimore NIAMS Thumbigere-Math, Vivek (NIAMS) 4 151737540 Foster, Brian NIAMS Foster, Brian 5 151737545 Nociti, Francisco State University of Campinas Nociti, Francisco 6 151737504 Braddock, Demetrios Yale University Braddock, Demetrios 1 151737508 Somerman, Martha NIDCR NIDCR Somerman, Martha (NIDCR) 2 151737524 Chu, Emily NIAMS Chu, Emily 3 151737536 Thumbigere-Math, Vivek University of Maryland, Baltimore NIAMS Thumbigere-Math, Vivek (NIAMS) 4 151737540 Foster, Brian NIAMS Foster, Brian 5 151737545 Nociti, Francisco State University of Campinas Nociti, Francisco 6 151737497 Method Of Treating Periodontal Disease Via ENPPl Inhibition E-024-2018-0 Filing authorized NIAMS, Yale University 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition&body=Please send me information about technology [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition&body=Please send me information about technology [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition.">ediz.yonter@nih.gov</a><br> 157760390 E-024-2018-0 E-024-2018-0-EP-04 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING AND/OR PREVENTING PERIODONTAL DISEASE National Stage European Patent 18816451.1 Pending European Patent <br />National Stage 18816451.1<br />Filed on 2018-11-27<br />Status: Pending TAB-5075 163996507 Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology NCI Collaboration, Licensing, Medical Devices, Oncology, Research Materials Collaboration Licensing Medical Devices Oncology Research Materials Stephen Adler, Peter Choyke, Noriko Sato <h2>Summary:</h2> <p>The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.</p> <h2>Description of Technology:</h2> <p>This technology includes an automated cell radiolabeling device that utilizes acoustophoresis microfluidic technology. The device streamlines the radiolabeling process by integrating cell washing and concentrating steps, which enhances reproducibility and standardization. This innovation simplifies the GMP (Good Manufacturing Practice) compliance for radiolabeling cells intended for human use. It also addresses the limitations of current manual methods that rely on centrifugation. The result is a benchtop system designed for clinical radio-pharmacies, ensuring efficient and reliable cell preparation for diagnostic and therapeutic applications.</p> <p><a href="https://cbiit.webex.com/recordingservice/sites/cbiit/recording/f287687265fd103cbf9de650e0bf904c/playback" target="_blank">Automated Acoustophoresis Device to Radio-Label &amp; Isolate Cells for Immunotherapy and Isolated Cells for Immunotherapy Treatment</a></p> <h2>Potential Commercial Applications:</h2> <ul> <li>Clinical radio-pharmacies for radiolabeled cell diagnostics</li> <li>Research institutions focused on cellular therapies and diagnostics</li> <li>Pharmaceutical companies developing radiolabeled therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Fully automated process reduces manual intervention, increasing efficiency and consistency</li> <li>Micron-scale acoustophoresis technology enhances reproducibility and standardization of cell radiolabeling</li> <li>Streamlined GMP compliance simplifies regulatory processes for clinical applications</li> <li>Benchtop system</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for an automated acoustophoresis device to radio-label and isolate cells. 2025-09-04 2025-12-15 2025-12-15 2025-12-08 False False True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 165083181 Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure. https://jnm.snmjournals.org/content/63/supplement_2/2755 <a href="https://jnm.snmjournals.org/content/63/supplement_2/2755">Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure.</a> 163996723 Adler, Stephen NCI - FCRDC (Leidos) Leidos Adler, Stephen (Leidos) 1 163996730 Sato, Noriko National Cancer Institute (NCI) NCI Sato, Noriko (NCI) 2 163996736 Choyke, Peter National Cancer Institute (NCI) NCI Choyke, Peter (NCI) 3 163996723 Adler, Stephen NCI - FCRDC (Leidos) Leidos Adler, Stephen (Leidos) 1 163996730 Sato, Noriko National Cancer Institute (NCI) NCI Sato, Noriko (NCI) 2 163996736 Choyke, Peter National Cancer Institute (NCI) NCI Choyke, Peter (NCI) 3 163996510 Novel Device For Cell Radiolabeling Using Acoustophoresis Micro-fluidic Technology E-096-2021-0 Filing authorized NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology&body=Please send me information about technology [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology&body=Please send me information about technology [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 163996515 E-096-2021-0 E-096-2021-0-US-01 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS PRV US 63/191,103 Abandoned US <br />Provisional (PRV) 63/191,103<br />Filed on 2021-05-20<br />Status: Abandoned 163996516 E-096-2021-0 E-096-2021-0-PCT-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS PCT Patent Cooperation Treaty PCT/US2022/028819 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/028819<br />Filed on 2022-05-11<br />Status: Expired 163996517 E-096-2021-0 E-096-2021-0-US-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS National Stage US 18/290,442 Pending US <br />National Stage 18/290,442<br />Filed on 2023-11-13<br />Status: Pending TAB-5032 159360802 Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins NHLBI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Xiuxiu Lu, Kylie Walters <p>Summary:</p> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers.</p> <p><br /> Description of Technology:</p> <p>Over 35,000 new cases of multiple myeloma are diagnosed each year in the US. Standard of care and experimental therapies include monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors and corticosteroids. While these therapies can be effective, a majority of patients experience relapse within four years. New proteasome-targeting drugs are needed to improve current myeloma treatments.</p> <p>Proteasome inhibitors function by interfering with a cell&rsquo;s normal protein recycling process and induce apoptosis via multiple mechanisms. FDA-approved proteasome inhibitors exist with indications for the treatment of liquid cancers, specifically multiple myeloma and mantle-cell lymphoma. However, these drugs can induce dose-limiting toxicities. It is hypothesized that targeting ubiquitin receptors upstream of the 20S proteasome may lead to less toxic therapies, such as targeting the 19S proteasome regulatory region associated within ubiquitin receptor Rpn13.</p> <p>Inventors at the NCI have generated three small molecules, XL44, XL69, XL80 that target ubiquitin receptor hRpn13. hRpn13Pru is produced in certain cancer cell types. XL44, XL69, and XL80 deplete it reliably without fusion to a known ligand related to ubiquitination complexes, suggesting a glue-like mechanism of depletion. XL44 induces apoptosis in a hRpn13-dependent manner, but can restrict cell viability independently of hRpn13, specifically via depletion of KEN box proteins. Early in vivo studies show reduced tumor size in xenograft multiple myeloma models. The inventors have developed an oral formulation.</p> <h2>Potential Commercial Applications:</h2> <p>* Multiple Myeloma therapeutic</p> <p>* Mantle Cell therapeutic</p> <h2><br /> Competitive Advantages:</h2> <p>* Oral formulation</p> <p>* Lower toxicity than currently approved proteasome inhibitors</p> Researchers at the NCI seek licensing and/or co-development research collaborations for three small molecules that inhibit hRpn13 as a cancer therapeutic 2024-11-27 2025-12-11 2025-12-11 2024-11-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 159360845 Osei-Amponsa, V. et al “hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4 and transcription factor NF-kB p50” PMID: 38151017. https://pubmed.ncbi.nlm.nih.gov/38151017/ <a href="https://pubmed.ncbi.nlm.nih.gov/38151017/">Osei-Amponsa, V. et al “hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4 and transcription factor NF-kB p50” PMID: 38151017.</a> 159360959 Lu, X., Chandravanshi, et al. “A structure-based designed small molecule depletes hRpn13Pru and a select group of KEN box proteins” PMID 38509117 https://pubmed.ncbi.nlm.nih.gov/38509117/ <a href="https://pubmed.ncbi.nlm.nih.gov/38509117/">Lu, X., Chandravanshi, et al. “A structure-based designed small molecule depletes hRpn13Pru and a select group of KEN box proteins” PMID 38509117</a> 159360809 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 1 159360813 Lu, Xiuxiu NCI Lu, Xiuxiu (NCI) 2 159360809 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 1 159360813 Lu, Xiuxiu NCI Lu, Xiuxiu (NCI) 2 159360805 A degrader molecule for an hRpn13 naturally generated fragment that includes the Pru domain, PCLAF, RRM2 and other KEN box containing proteins E-138-2023-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NIH - NCI, NIH - NHLBI, Structural Biophysics Laboratory 153929528 Ghosh, Malabika malabika.ghosh@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins&body=Please send me information about technology [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins&body=Please send me information about technology [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">malabika.ghosh@nih.gov</a><br> 159502829 E-138-2023-0 E-138-2023-0-US-01 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS PRV US 63/539,663 Expired US <br />Provisional (PRV) 63/539,663<br />Filed on 2023-09-21<br />Status: Expired 159502834 E-138-2023-0 E-138-2023-0-PC-01 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS PCT Patent Cooperation Treaty PCT/US2024/047709 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/047709<br />Filed on 2024-09-20<br />Status: Expired TAB-5067 163489281 A conserved viral peptide for use in cancer immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Man Hsin Hung, Lichun Ma, Xin Wei Wang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment.</p> <h2>Description of Technology:</h2> <p>Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic liver diseases, such as hepatitis and cirrhosis. HCC is a leading cause of cancer-related death worldwide and its global incidence and mortality rate continues to rise. The current methods for early detection, surveillance and treatment are suboptimal due to complex etiologies and intricate tumor biology.</p> <p>Through serological profiling across three independent cohorts, researchers at the National Cancer Institute (NCI) have identified a common epitope (CE1) shared among protective viral antigens enriched in healthy individuals compared to HCC patients. A synthetic CE1 peptide was demonstrated to have utility in eliciting a T cell response to HCC cells and can be developed as an immunotherapy for HCC, such as a CE1-based HCC vaccine. Currently, as there are limited therapeutic options for HCC patients, novel treatments would offer tremendous commercial and public health benefits.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>HCC prevention and treatment</li> <li>Predictive biomarker for HCC risk <ul> <li>Serological response test</li> <li>Patient stratification for CE1-based therapy</li> <li>Monitoring the efficacy of the CE1-based vaccine</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>VirScan data support that this peptide correlates with better outcomes in HCC and breast cancer</li> <li>CE1 peptide shows an immunomodulatory effect; immunomodulators are a promising approach to cancer treatment</li> <li>CE1 peptide is biologically active in inducing T cell cytolytic activity</li> <li>HCC cell killing in an HLA-specific manner &nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for viral peptide (CE1)-based therapeutics for HCC prevention and treatment 2025-07-28 2025-08-21 2025-11-19 2025-07-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-171-2022 E-174-2019 163489749 Ma L, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. (PMID: 40345802) https://pubmed.ncbi.nlm.nih.gov/40345802/ <a href="https://pubmed.ncbi.nlm.nih.gov/40345802/">Ma L, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. (PMID: 40345802)</a> 163489378 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 163489408 Ma, Lichun NIH - NCI Ma, Lichun 2 163489418 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 3 163489378 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 163489408 Ma, Lichun NIH - NCI Ma, Lichun 2 163489418 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 3 163489284 A conserved viral peptide for use in cancer immunotherapy E-023-2024-0 Filing authorized NIH - NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-5067] A conserved viral peptide for use in cancer immunotherapy&body=Please send me information about technology [TAB-5067] A conserved viral peptide for use in cancer immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-5067] A conserved viral peptide for use in cancer immunotherapy&body=Please send me information about technology [TAB-5067] A conserved viral peptide for use in cancer immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">changke@mail.nih.gov</a><br> 163489289 E-023-2024-0 E-023-2024-0-US-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA PRV US 63/735,040 Expired US <br />Provisional (PRV) 63/735,040<br />Filed on 2024-12-17<br />Status: Expired 164898215 E-023-2024-0 E-023-2024-0-PC-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE EARLY INTERVENTION AND TREATMENT OF LIVER CANCER PCT Patent Cooperation Treaty PCT/US2025/059785 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/059785<br />Filed on 2025-12-16<br />Status: Pending TAB-4543 151736665 Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair NHLBI Cardiology, Licensing, Medical Devices, Research Equipment, Research Materials Cardiology Licensing Medical Devices Research Equipment Research Materials Ozgur Kocaturk, Robert Lederman, Toby Rogers, Merdim Sonmez <p>This technology includes a device to close a hole in the wall of a large blood vessel or cardiac chamber from the inside out, delivered over a guidewire and through a catheter or sheath. First, the proximal portion deploys within the vessel or chamber and is advanced over a guidewire to oppose the wall and seal the hole. Second, the distal portion self-assembles outside the vessel or chamber upon withdrawal of the guidewire. Deployment of the distal portion anchors the device securely in place.</p> There are currently no commercially available devices to close holes in the wall of large blood vessels or cardiac chambers, and has the potential to enable novel procedures that are not possible currently because of a lack of custom closure device. This device could become a critical tool to have available in every interventional catheterization laboratory. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736678 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 1 151736684 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736690 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736743 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 4 151736678 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 1 151736684 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736690 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736743 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 4 151736668 Endo-cameral Closure Device E-273-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair&body=Please send me information about technology [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair&body=Please send me information about technology [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair.">shmilovm@nih.gov</a><br> 157756297 E-273-2015-0 E-273-2015-0-US-01 Endo-cameral Closure Device PRV US 62/236,734 Abandoned US <br />Provisional (PRV) 62/236,734<br />Filed on 2015-10-02<br />Status: Abandoned 157756302 E-273-2015-0 E-273-2015-0-PCT-02 Endo-cameral Closure Device PCT Patent Cooperation Treaty PCT/US2016/054961 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/054961<br />Filed on 2016-09-30<br />Status: Expired 157756307 E-273-2015-0 E-273-2015-0-EP-03 Endo-cameral Closure Device National Stage European Patent 3355802 16852768.7 Issued European Patent <br />National Stage 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756312 E-273-2015-0 E-273-2015-0-US-04 Endo-cameral Closure Device National Stage US 10,603,021 15/761,923 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10603021 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10603021">10,603,021</a><br />Filed on 2018-03-21<br />Status: Issued 157756317 E-273-2015-0 E-273-2015-0-CH-05 Endo-cameral Closure Device EP Switzerland 3355802 16852768.7 Issued Switzerland <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756322 E-273-2015-0 E-273-2015-0-DE-06 Endo-cameral Closure Device EP Germany 3355802 16852768.7 Issued Germany <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756327 E-273-2015-0 E-273-2015-0-FR-07 Endo-cameral Closure Device EP France 3355802 16852768.7 Issued France <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756332 E-273-2015-0 E-273-2015-0-GB-08 Endo-cameral Closure Device EP United Kingdom 3355802 16852768.7 Issued United Kingdom <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756337 E-273-2015-0 E-273-2015-0-IE-09 Endo-cameral Closure Device EP Ireland 3355802 16852768.7 Issued Ireland <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued TAB-4527 151719871 Annuloplasty Procedures, Related Devices and Methods NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Nasser Raffie, Toby Rogers <p>This technology includes design enhancements to transcatheter mitral cerclage annuloplasty. They include a device to convert from crossing guidewire to tension element, refinements to the tension element which incorporates a coronary artery protection device, a target/capture/snare device, a wishbone locking device, and a cutting device.</p> These refinements represent years of iterative technology development and reflect the near-final design of the device. Improved procedures for repairing heart valves. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151719878 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151719882 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151719886 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151719878 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151719882 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151719886 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151719874 Annuloplasty Procedures, Related Devices And Methods E-201-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4527] Annuloplasty Procedures, Related Devices and Methods&body=Please send me information about technology [TAB-4527] Annuloplasty Procedures, Related Devices and Methods. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4527] Annuloplasty Procedures, Related Devices and Methods&body=Please send me information about technology [TAB-4527] Annuloplasty Procedures, Related Devices and Methods.">pragnesh.mistry@nih.gov</a><br> 157755883 E-201-2016-0 E-201-2016-0-US-01 Annuloplasty Procedures, Related Devices And Methods PRV US 62/332,754 Abandoned US <br />Provisional (PRV) 62/332,754<br />Filed on 2016-05-06<br />Status: Abandoned 157755888 E-201-2016-0 E-201-2016-0-PCT-02 Annuloplasty Procedures, Related Devices And Methods PCT Patent Cooperation Treaty PCT/US2017/031543 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/031543<br />Filed on 2017-05-08<br />Status: Expired 157755893 E-201-2016-0 E-201-2016-0-US-03 Annuloplasty Procedures, Related Devices And Methods CIP US 10,433,962 15/796,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10433962 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10433962">10,433,962</a><br />Filed on 2017-10-27<br />Status: Issued 157755898 E-201-2016-0 E-201-2016-0-EP-04 Annuloplasty Procedures, Related Devices And Methods National Stage European Patent 3451973 17793543.4 Issued European Patent <br />National Stage 17793543.4<br />Filed on 2018-11-26<br />Status: Issued 157755903 E-201-2016-0 E-201-2016-0-JP-05 Annuloplasty Procedures, Related Devices And Methods National Stage Japan 7097351 2019-510584 Issued Japan <br />National Stage 2019-510584<br />Filed on 2018-06-11<br />Status: Issued 157755908 E-201-2016-0 E-201-2016-0-KR-06 Annuloplasty Procedures, Related Devices And Methods National Stage South Korea 10-2416646 10-2018-7035352 Issued South Korea <br />National Stage 10-2018-7035352<br />Filed on 2018-12-05<br />Status: Issued TAB-4521 151719298 Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Toby Rogers <p>This technology includes a pair of subsystems for a novel transcatheter bicuspid valve (frame and leaflets) intended for implantation in the mitral position. It is simple, it overcomes key limitations to transcatheter bicuspid mitral valve implants, and it overcomes key limitations to transcatheter tricuspid mitral valve implants.</p> This is novel, useful, non-obvious, clinically attractive, and commercially attractive despite the large number of investigational transcatheter mitral valve implantation devices currently under commercial development. This can be developed into a novel transcatheter mitral valve implant. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2025-08-13 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151719305 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151719309 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151719305 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151719309 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151719301 Novel Bicuspid Transcatheter Heart Valve Frame And Leaflets E-191-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation&body=Please send me information about technology [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation&body=Please send me information about technology [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation.">shmilovm@nih.gov</a><br> 157755587 E-191-2020-0 E-191-2020-0-US-01 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT PRV US 63/054,623 Abandoned US <br />Provisional (PRV) 63/054,623<br />Filed on 2020-07-21<br />Status: Abandoned 157755592 E-191-2020-0 E-191-2020-0-PCT-02 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT PCT Patent Cooperation Treaty PCT/US2021/042380 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/042380<br />Filed on 2021-07-20<br />Status: Expired 157755597 E-191-2020-0 E-191-2020-0-CN-03 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage China 202180059611.1 Pending China <br />National Stage 202180059611.1<br />Filed on 2023-01-28<br />Status: Pending 157755602 E-191-2020-0 E-191-2020-0-EP-04 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage European Patent 21845838.8 Pending European Patent <br />National Stage 21845838.8<br />Filed on 2023-01-17<br />Status: Pending 157755607 E-191-2020-0 E-191-2020-0-IL-05 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage Israel 299776 Pending Israel <br />National Stage 299776<br />Filed on 2021-07-20<br />Status: Pending 157755632 E-191-2020-0 E-191-2020-0-US-06 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage US 18/006,331 Pending US <br />National Stage 18/006,331<br />Filed on 2023-01-20<br />Status: Pending TAB-4502 151705244 Device for Closure of Transvascular or Transcameral Access Ports NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Nasser Raffie, Toby Rogers <p>This technology includes a novel method to access the arterial circulation to allow introduction of large devices, such as transcatheter aortic valve replacement, percutaneous left ventricular assist devices, and thoracic aortic endografts. It also can be used in most labeled and off-label applications of Amplatzer nitinol occluder devices to occlude intracardiac holes and to allow non-surgical direct access to the heart. This new disclosure adds additional design features that have been tested in vivo. These include a new compression member design that enhances wall apposition and hemostasis, a new delivery cable design, alternative endoluminal limb designs. The new design allows flexible deliver and recovery but is designed to avoid inadvertent pull-through. The disclosed invention has already been built and reduced to practice in an animal model.</p> The unique features of the device which are not available in commercial devices marketed for the occlusion of congenital heart and vascular defects include: <ul> <li>New compression member design that enforces flattening of the nitinol endoluminal disks</li> <li>Wing-shaped endoluminal disks to enhance disk stiffness</li> <li>Flexible delivery cable that still allows continuous central guidewire access</li> <li>Beveled marker sheath catheter design to accommodate oblique delivery angles</li> </ul> Method and device to access arterial circulation to allow introduction of devices in various cardiac procedures. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705251 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151705255 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151705259 Raffie, Nasser Mehr Medical Raffie, Nasser 3 151705251 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151705255 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151705259 Raffie, Nasser Mehr Medical Raffie, Nasser 3 151705247 Device For Closure Of Transvascular Or Transcameral Access Ports E-124-2014-0 Filing authorized Mehr Medical, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports.">shmilovm@nih.gov</a><br> 157755053 E-124-2014-0 E-124-2014-0-US-01 Device For Closure Of Transvascular Or Transcameral Access Ports PRV US 61/971,458 Abandoned US <br />Provisional (PRV) 61/971,458<br />Filed on 2014-03-27<br />Status: Abandoned TAB-4485 151645196 Device for Closure of Transvascular or Transcameral Access Ports NHLBI Cardiology, Licensing, Medical Devices, Research Equipment, Research Materials Cardiology Licensing Medical Devices Research Equipment Research Materials Ozgur Kocaturk, Robert Lederman, Nasser Raffie, Kanishka Ratnayaka, Toby Rogers <p>This technology includes part of transcatheter aortic valve replacement and to enable non-surgical thoracic aortic aneurysm endograft repair. The invention enables a completely new way to access the arterial circulation to allow introduction of large devices, such as transcatheter aortic valve replacement, percutaneous left ventricular assist devices, and thoracic aortic endografts. It also can be used in most labeled and off-label applications of Amplatzer (AGA Medical, St Jude) nitinol occluder devices to occlude intracardiac holes and to allow non-surgical direct access to the heart. This invention has been applied, using marketed devices off-label, in 15 patients.</p> The unique features of the device which are not available in commercial devices marketed for the occlusion of congenital heart and vascular defects include: <ul> <li>Multiple disks, especially the favored three-disc embodiment with intra-aortic, extra-aortic, and venous disks</li> <li>Billowed nitinol disk, especially in the preferred embodiment of the extra-aortic disk, occupies space to achieve hemostasis on the aortic rent</li> <li>Tether mechanism for independent control of multiple disks during deployment</li> </ul> Permanent medical implant for use as part of transcatheter aortic valve replacement and to enable non-surgical thoracic aortic aneurysm endograft repair. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2025-11-19 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151645204 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151645208 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 2 151645212 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151645216 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151645224 Raffie, Nasser Mehr Medical Raffie, Nasser 5 151645204 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151645208 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 2 151645212 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151645216 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151645224 Raffie, Nasser Mehr Medical Raffie, Nasser 5 151645199 Device For Closure Of Transvascular Or Transcameral Access Ports E-068-2014-0 Filing authorized Mehr Medical, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports.">shmilovm@nih.gov</a><br> 157754290 E-068-2014-0 E-068-2014-0-US-01 Device For Closure Of Transvascular Or Transcameral Access Ports PRV US 61/910,346 Abandoned US <br />Provisional (PRV) 61/910,346<br />Filed on 2013-11-30<br />Status: Abandoned TAB-3520 114097380 Systemic CRISPR Therapy for the Treatment of Inherited Diseases NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Dongsheng Duan, Chady Hakim, Nalinda Wasala, Youngping Yue This technology includes novel systemic adeno-associated virus (AAV)-mediated CRISPR gene therapy technology. While some diseases (e.g., retinal diseases) can be treated through local gene transfer, many diseases such as Duchenne Muscular Dystrophy (DMD) require systemic therapy. The CRISPR technology has two components, the Cas9 endonuclease, and the gRNA. To explore systemic CRISPR therapy, we co-delivered the AAV.Cas9 and AAV.gRNA vector to mdx mice, a mouse DMD model. Direct delivery to muscle yielded efficient gene correction. Through detailed analysis of gene editing at the protein and transcript level and detailed profiling of the two AAV CRISPR vectors, we identified preferential loss of the gRNA vector as the barrier to systemic AAV CRISPR therapy. Increasing gRNA vector dose successfully overcome this hurdle and resulted in correction in both heart and skeletal muscle. Importantly, modified CRISPR therapy significantly enhanced skeletal muscle and cardiac function. The patent illustrates the development of this novel systemic AAV CRISPR gene therapy technology, which can be applied to treat many inherited diseases. The modified CRISPR gene therapy technology has achieved efficient body wide skeletal muscle and heart CRISPR editing and function improvement which opens the door to treat many inherited diseases by systemic AAV CRISPR therapy. Further clinical work using novel systemic adeno-associated virus (AAV)-mediated CRISPR could establish this invention as a treatment of inherited diseases, such as Duchenne Muscular Dystrophy. 2022-08-01 2025-08-13 2025-11-14 2022-08-01 2022-03-30 CRISPR, SYSTEMIC, THERAPY, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114110536 Hakim, Chady NCATS - NCGC NCATS Hakim, Chady (NCATS) 0 114110537 Wasala, Nalinda University of Missouri Wasala, Nalinda 0 114110538 Yue, Youngping University of Missouri Yue, Youngping 0 114110535 Duan, Dongsheng University of Missouri Duan, Dongsheng 1 114110535 Duan, Dongsheng University of Missouri Duan, Dongsheng 1 114110536 Hakim, Chady NCATS - NCGC NCATS Hakim, Chady (NCATS) 0 114110537 Wasala, Nalinda University of Missouri Wasala, Nalinda 0 114110538 Yue, Youngping University of Missouri Yue, Youngping 0 114102632 Systemic CRISPR Therapy E-193-2018-0 Filing authorized NCATS - NCGC, University of Missouri 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases&body=Please send me information about technology [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases&body=Please send me information about technology [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases.">rebecca.erwin-cohen@nih.gov</a><br> 114169301 E-193-2018-0 E-193-2018-0-US-01 Systemic CRISPR Therapy PRV US 62/661,391 Abandoned US <br />Provisional (PRV) 62/661,391<br />Filed on 2018-04-23<br />Status: Abandoned 114169302 E-193-2018-0 E-193-2018-0-PCT-02 Improved CRISPR Therapy PCT Patent Cooperation Treaty PCT/US2019/028635 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/028635<br />Filed on 2019-04-23<br />Status: Expired 114128663 VPXXXX 114128664 WIXXXX 114152806 SYSTEMIC 114152807 CRISPR 114152808 THERAPY TAB-4534 151721981 Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development NIAID Human Cell Lines, Infectious Disease, Research Materials, ResearchProducts Human Cell Lines Infectious Disease Research Materials ResearchProducts Suzanne Emerson, Hanh Nguyen, Udana Torian <p>The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly valuable for virological research focused on Hepatitis E Virus.</p> The S10-3 cells, derived from the Huh-7 cell line, offer a significant competitive advantage in Hepatitis E Virus research due to their enhanced efficiency in transfection and infection processes. The S10-3 cell line, with its heightened transfection and infection capabilities, holds potential for groundbreaking advances in the study and development of treatments and vaccines for Hepatitis E Virus. 2023-12-10 2025-08-13 2025-11-14 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151722002 Emerson, S. https://pubmed.ncbi.nlm.nih.gov/16928762/ <a href="https://pubmed.ncbi.nlm.nih.gov/16928762/">Emerson, S.</a> 151721990 Emerson, Suzanne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Emerson, Suzanne (NIAID) 1 151721994 Nguyen, Hanh National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nguyen, Hanh (NIAID) 2 151721998 Torian, Udana NIAID Torian, Udana (NIAID) 3 151721990 Emerson, Suzanne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Emerson, Suzanne (NIAID) 1 151721994 Nguyen, Hanh National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nguyen, Hanh (NIAID) 2 151721998 Torian, Udana NIAID Torian, Udana (NIAID) 3 151721984 Huh-7 Cell Line Derived S10-3 Cells For Hepatitis E Virus Infection Studies E-218-2018-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development.">elizabeth.pitts@nih.gov</a><br> TAB-5061 162910291 Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties NCATS Licensing, Materials Available, Neurology, Psychiatry/Mental Health, Therapeutics Licensing Materials Available Neurology Psychiatry/Mental Health Therapeutics Catherine Chen, Xin Hu, Wenwei Huang, Xiuli Huang, Amy Newman, Elias Padilha, Philip Sanderson, Pranav Shah, Khalida Shamim, Xin Xu, Wei Zheng <p>One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists that have potential to target and treat Parkinson&rsquo;s disease, Schizophrenia, Depression, and substance-use disorders including opioid addiction. Important features of these novel chemical compounds are that they exhibit favorable drug-like properties that are likely to make them successful drug candidates, and have reduced human ether-&agrave;-gogo-related gene (hERG) liability and effect on potassium channels, which suggests that the compounds may perform better as Dopamine D3 receptor agonists due to a lower propensity to create cardiac arrythmias.<br /> The novel compounds comprise potent and highly selective Dopamine D3 receptor effectors, inclusive of antagonists and agonists, with alleviated hERG liability and desirable pharmacokinetic properties.<br /> &nbsp;</p> <ul> <li>Superior potency and affinity for Dopamine D3 receptors</li> <li>Limited off-target effects due to brain-specific expression of D3 receptors and superior selectivity of compounds for D3 over D2</li> <li>Lead compounds exhibit 50-100 times greater selectivity for Dopamine D3 over D2 receptors</li> <li>Reduced hERG liability</li> <li>High D3R occupancy</li> <li>Ability to cross the Blood Brain Barrier with excellent brain penetration and low P-Glycoprotein efflux</li> <li>Early-stage invention with IND-enabling data including toxicity study data, in vivo studies</li> </ul> <ul> <li>Parkinson’s disease</li> <li>Schizophrenia</li> <li>Depression</li> <li>Substance use disorders</li> </ul> 2025-06-12 2025-06-13 2025-11-14 2025-06-13 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-053-2016 E-042-2022 162910318 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 1 162910322 Huang, Wenwei NCATS Huang, Wenwei (NCATS) 2 162910326 Zheng, Wei NCATS Zheng, Wei (NCATS) 3 162910332 Chen, Catherine NCATS - TRND Chen, Catherine 4 162910336 Huang, Xiuli NCATS - TRND NCATS Huang, Xiuli (NCATS) 5 162910340 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 6 162910344 Xu, Xin NCATS Xu, Xin (NCATS) 7 162910393 Shah, Pranav NCATS Shah, Pranav (NCATS) 8 162910397 Padilha, Elias NCATS Padilha, Elias (NCATS) 9 162910401 Sanderson, Philip National Center for Advancing Translational Sciences NCATS Sanderson, Philip (NCATS) 10 162910405 Newman, Amy National Institute on Drug Abuse (NIDA) NIDA Newman, Amy (NIDA) 11 162910318 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 1 162910322 Huang, Wenwei NCATS Huang, Wenwei (NCATS) 2 162910326 Zheng, Wei NCATS Zheng, Wei (NCATS) 3 162910332 Chen, Catherine NCATS - TRND Chen, Catherine 4 162910336 Huang, Xiuli NCATS - TRND NCATS Huang, Xiuli (NCATS) 5 162910340 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 6 162910344 Xu, Xin NCATS Xu, Xin (NCATS) 7 162910393 Shah, Pranav NCATS Shah, Pranav (NCATS) 8 162910397 Padilha, Elias NCATS Padilha, Elias (NCATS) 9 162910401 Sanderson, Philip National Center for Advancing Translational Sciences NCATS Sanderson, Philip (NCATS) 10 162910405 Newman, Amy National Institute on Drug Abuse (NIDA) NIDA Newman, Amy (NIDA) 11 162910294 Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties E-097-2023-0 Filing authorized NIH - NCATS, NIH - NIDA 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties&body=Please send me information about technology [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties&body=Please send me information about technology [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties.">rebecca.erwin-cohen@nih.gov</a><br> 162910298 E-097-2023-0 E-097-2023-0-US-01 POTENT AND SELECTIVE D3 ANTAGONISTS PRV US 63/511,452 Expired US <br />Provisional (PRV) 63/511,452<br />Filed on 2023-06-30<br />Status: Expired 162910300 E-097-2023-0 E-097-2023-0-PC-01 POTENT AND SELECTIVE DOPAMINE D3 ANTAGONISTS PCT Patent Cooperation Treaty PCT/US2024/036149 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/036149<br />Filed on 2024-06-28<br />Status: Expired TAB-5069 163660392 Chimeric VLP vaccines to Prevent HTLV-1 Infection NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Massimiliano Bissa, Genoveffa Franchini, Cynthia Masison, Ramona Moles, Sarkis Sarkis <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection.</p> <h2>Description of Technology:</h2> <p>There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult T-cell leukemia/lymphoma (ATLL) and Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP). Existing interventions are limited to behavioral prevention, leaving millions at risk, especially in underserved global regions. A safe and effective vaccine is urgently needed to fill this critical public health gap.</p> <p>This invention is a nucleic acid-based vaccine that generates virus-like particles (VLPs) in the body using HTLV-1 Env and gag proteins to trigger a protective immune response against HTLV-1 infection. With no approved vaccines available and millions at risk&mdash;particularly in underserved regions&mdash;this first-of-its-kind solution addresses a critical public health need. It offers broad protection across HTLV-1 subtypes and is currently being tested in non-human primates, with strong potential for future clinical development and commercial interest.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>HTLV-1 Infection</li> <li>Adult T-cell leukemia/lymphoma (ATLL)</li> <li>Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No approved HTLV-1 vaccines</li> <li>Preventative vaccine to reduce healthcare costs and economic burden of treating people developing related diseases</li> </ul> The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of a nucleic acid-based vaccine for use as a preventative to human T-lymphotrophic virus-1 (HTLV-1) infection. 2025-08-12 2025-08-12 2025-11-10 2025-08-12 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163660868 Franchini G, et al. HTLV-1 and HTLV-2: Pathogenesis and role of viral proteins. Viruses. 2022;14(10):2084. https://doi.org/10.3390/v14102084 <a href="https://doi.org/10.3390/v14102084">Franchini G, et al. HTLV-1 and HTLV-2: Pathogenesis and role of viral proteins. Viruses. 2022;14(10):2084.</a> 163660611 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 163660616 Sarkis, Sarkis NIH - NCI Sarkis, Sarkis 2 163660620 Moles, Ramona NIH - NCI NCI Moles, Ramona (NCI) 3 163660649 Masison, Cynthia NIH - NCI NCI Masison, Cynthia (NCI) 4 163660654 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 163660611 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 163660616 Sarkis, Sarkis NIH - NCI Sarkis, Sarkis 2 163660620 Moles, Ramona NIH - NCI NCI Moles, Ramona (NCI) 3 163660649 Masison, Cynthia NIH - NCI NCI Masison, Cynthia (NCI) 4 163660654 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 163660395 Chimeric VLP Vaccines To Prevent HTLV-1 Infection E-126-2022-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection&body=Please send me information about technology [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection&body=Please send me information about technology [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> 163660555 E-126-2022-0 E-126-2022-0-US-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 PRV US 63/340,400 Expired US <br />Provisional (PRV) 63/340,400<br />Filed on 2022-05-10<br />Status: Expired 163660556 E-126-2022-0 E-126-2022-0-PC-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 PCT Patent Cooperation Treaty PCT/US2023/066839 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/066839<br />Filed on 2023-05-10<br />Status: Expired 163660557 E-126-2022-0 E-126-2022-0-AU-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage Australia 2023268543 Pending Australia <br />National Stage 2023268543<br />Filed on 2024-11-14<br />Status: Pending 163660558 E-126-2022-0 E-126-2022-0-IN-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage India 202417088469 Pending India <br />National Stage 202417088469<br />Filed on 2024-11-15<br />Status: Pending 163660559 E-126-2022-0 E-126-2022-0-US-02 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage US 18/864,213 Pending US <br />National Stage 18/864,213<br />Filed on 2024-11-08<br />Status: Pending TAB-4566 151739492 Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking NIAMS Human Cell Lines, Materials Available, Neurology, Research Materials Human Cell Lines Materials Available Neurology Research Materials Nasir Malik, Mahendra Rao <p>This technology involves neural stem cells (NSCs) derived from pluripotent stem cells (PSCs) that can differentiate into neurons and glia. The key feature of this technology is the CY2 EEF1A1 GFP iPSC line, which includes a green fluorescent protein (GFP) expressed under the EEF1A1 promoter, leading to its ubiquitous expression in cells. This characteristic makes the NSCs and the neural cells differentiated from this line exhibit green fluorescence. Such cells, when transplanted into animal models like mice and rats, can be easily tracked due to their fluorescence. This tracking is critical for assessing whether these cells have successfully integrated into the host&#39;s nervous system and are functioning properly. The primary advantage of this technology is that the GFP expression allows for easier tracking of the transplanted cells in comparison to most other NSC lines which lack such fluorescent reporters. This technology has potential applications in studying the integration and functionality of transplanted neurons and astrocytes in animal models, providing significant insights into neural cell behavior and treatment efficacy.</p> The competitive advantage of this technology lies in its unique ability to track transplanted neural stem cells easily in animal models, thanks to the ubiquitous expression of green fluorescent protein, a feature not commonly found in other NSC lines. This technology has potential applications in neurological research and therapy, particularly in studying the integration and functionality of transplanted neurons and astrocytes in animal models, enhancing our understanding of neural cell behavior and treatment possibilities. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-11-10 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739499 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739503 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739499 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739503 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739495 Neural Stem Cells From An IPSC Line Ubiquitously Expressing Green Fluorescent Protein E-610-2013-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking&body=Please send me information about technology [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking&body=Please send me information about technology [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking.">vlado.knezevic@nih.gov</a><br> TAB-4565 151739338 A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development NIAMS Human Cell Lines, Materials Available, Metabolic Disease, Neurology, Research Materials Human Cell Lines Materials Available Metabolic Disease Neurology Research Materials Nasir Malik <p>This technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells. Their ability to differentiate into various central nervous system cell types is vital for understanding NPC&#39;s underlying causes. Additionally, these NSCs are uniquely positioned for high-throughput drug screening, with the potential to identify novel compounds for treating NPC. This technology is particularly groundbreaking as it represents the first reported NSC line from an NPC patient, offering significant opportunities for novel discoveries in the disease&#39;s study.</p> This neural stem cell technology represents a unique and groundbreaking advancement, offering unprecedented opportunities for in-depth study of the disease and the potential discovery of novel treatments through high-throughput drug screening. The differentiated neural stem cells can be used to study the mechanisms underlying Niemann Pick C disease and employing these cells in high-throughput drug screening to identify novel treatment options for this neurodegenerative disorder. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-11-10 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739345 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739345 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739341 A Neural Stem Line (NSC) From A Neiman Pick (NPC) Type 1 Patient E-609-2013-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development&body=Please send me information about technology [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development&body=Please send me information about technology [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development.">vlado.knezevic@nih.gov</a><br> TAB-4483 151644902 A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer NHLBI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Xiuxiu Lu, Venkatareddy Sabbasani, Rolf Swenson, Nadya Tarasova, Kylie Walters <p>This technology includes a new chemical scaffold (with lead compound XL5) against hRpn13 that induces apoptosis, which may have clinical efficacy against cancer. The structure of XL5-conjugated hRpn13 guided the design of XL5-PROTAC degrader compounds that exhibit greater efficacy than previous hRpn13-targeting compounds, as evaluated by selectivity for hRpn13, induction of apoptosis, and loss of cell viability. In cells, XL5-PROTACs revealed the presence of a truncated hRpn13 product that binds to proteasomes and is selectively degraded by XL5-PROTACs. The presence of this truncated hRpn13 protein correlates with induction of apoptosis by XL5-PROTACs, providing a previously unknown mechanism of action for hRpn13 targeting.</p> A next generation of hRpn13-targeting molecules that include degraders has been generated with superior efficacy compared to all previous generation molecules. These reagents and the structure-function assays provide insights into further optimization possibilities and set the stage for clinical trials. Moreover, the mechanism of action for hRpn13 targeting has now been revealed by using these molecules and defined to be a previously unknown Rpn13 species. In the near term, this chemical scaffold against hRpn13 can be used to 1) interrogate hRpn13 function in cells and 2) further development of hRpn13-targeting molecules for clinical application. In the long-term, this chemical scaffold and derived PROTACs or AUTACs may be clinically effective. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2025-08-13 2025-10-29 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151645039 Sabbasani, Venkatareddy National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sabbasani, Venkatareddy (NHLBI) 1 151645043 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 2 151645047 Lu, Xiuxiu Structural Biophysics Laboratory NCI Lu, Xiuxiu (NCI) 3 151645051 Tarasova, Nadya Cancer Innovation Laboratory NCI Tarasova, Nadya (NCI) 4 151645055 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 5 151645039 Sabbasani, Venkatareddy National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sabbasani, Venkatareddy (NHLBI) 1 151645043 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 2 151645047 Lu, Xiuxiu Structural Biophysics Laboratory NCI Lu, Xiuxiu (NCI) 3 151645051 Tarasova, Nadya Cancer Innovation Laboratory NCI Tarasova, Nadya (NCI) 4 151645055 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 5 151644905 A New Molecular Scaffold For Targeting HRpn13 E-056-2021-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer&body=Please send me information about technology [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer&body=Please send me information about technology [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer.">malabika.ghosh@nih.gov</a><br> 157754219 E-056-2021-0 E-056-2021-0-US-01 A New Molecular Scaffold For Targeting HRpn13 PRV US 63/143,398 Abandoned US <br />Provisional (PRV) 63/143,398<br />Filed on 2021-01-29<br />Status: Abandoned 157754225 E-056-2021-0 E-056-2021-0-PCT-02 A New Molecular Scaffold For Targeting HRpn13 PCT Patent Cooperation Treaty PCT/US2022/014199 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/014199<br />Filed on 2022-01-28<br />Status: Expired 157754233 E-056-2021-0 E-056-2021-0-CA-01 A New Molecular Scaffold For Targeting HRpn13 National Stage Canada 3209597 Abandoned Canada <br />National Stage 3209597<br />Filed on 2022-01-28<br />Status: Abandoned 157754241 E-056-2021-0 E-056-2021-0-AU-01 A New Molecular Scaffold For Targeting HRpn13 National Stage Australia 2022212029 Abandoned Australia <br />National Stage 2022212029<br />Filed on 2022-01-28<br />Status: Abandoned 157754246 E-056-2021-0 E-056-2021-0-CN-01 A New Molecular Scaffold For Targeting HRpn13 National Stage China 202280022424.0 Abandoned China <br />National Stage 202280022424.0<br />Filed on 2023-09-18<br />Status: Abandoned 157754251 E-056-2021-0 E-056-2021-0-US-02 A New Molecular Scaffold For Targeting HRpn13 National Stage US 18/262,941 Pending US <br />National Stage 18/262,941<br />Filed on 2023-07-26<br />Status: Pending 157754256 E-056-2021-0 E-056-2021-0-EP-01 A New Molecular Scaffold For Targeting HRpn13 National Stage European Patent 22704672.9 Pending European Patent <br />National Stage 22704672.9<br />Filed on 2022-01-28<br />Status: Pending 157754261 E-056-2021-0 E-056-2021-0-IL-01 A New Molecular Scaffold For Targeting HRpn13 National Stage Israel 304725 Abandoned Israel <br />National Stage 304725<br />Filed on 2023-07-25<br />Status: Abandoned TAB-5037 159557783 Immunotherapy for Treating HER2-Positive Breast Cancer NIAID Angela DeVico, Ethan Shevach <p><span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family:&quot;Calibri&quot;,sans-serif">This technology includes a novel immunotherapy approach designed to target HER2-positive breast cancer cells. It leverages a specific mechanism to enhance the immune system&#39;s ability to identify and destroy these cancer cells. The technology demonstrated significant potential in pre-clinical in vivo studies, suggesting it could improve treatment outcomes for patients with HER2-positive breast cancer</span></span></span></p> This immunotherapy offers a targeted approach that specifically addresses HER2-positive cancer cells, potentially reducing side effects compared to conventional treatments. Additionally, its mechanism enhances the immune response, which may lead to better efficacy in eliminating cancer cells. This technology could be applied in developing new treatment protocols for HER2-positive breast cancer, particularly for patients who have not responded well to existing therapies. It also holds potential as a combination therapy, enhancing the effectiveness of current treatment regimens. 2024-12-10 2024-12-10 2025-10-28 2024-12-10 False False True 37470483 Website Abstract 159557809 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159557821 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159557809 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159557821 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159557786 Generation Of Ikzf2 Floxed X Foxp3Cre Mice E-248-2017-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer&body=Please send me information about technology [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer&body=Please send me information about technology [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer.">yogikala.prabhu@nih.gov</a><br> TAB-5036 159553715 Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice NIAID Angela DeVico, Ethan Shevach <p><span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family:&quot;Calibri&quot;,sans-serif">This technology includes the development of transgenic mice with a targeted gene mutation that flanks exon 8 of the Ikzf2 (Helios) gene using loxP sites. These Ikzf2 fl/fl (floxed) mice allow researchers to selectively delete the Ikzf2 gene in specific tissues or cells by crossing them with mice that express Cre recombinase under tissue-specific promoters. This approach provides a powerful tool for studying the role of the Helios gene in specific cells, which can be particularly useful in immunological research</span></span></span></p> This technology allows for precise gene deletion in targeted tissues or cells, avoiding the complications of whole-organism gene knockout. It offers a significant advantage in studying cell-specific functions without systemic effects. The technology can be applied in the research of immunological functions, particularly in understanding the role of the Helios gene in immune cells. Additionally, it has potential applications in developing targeted therapies that require precise genetic modifications in specific cell types. 2024-12-10 2024-12-10 2025-10-28 2024-12-10 False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 159553849 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159553923 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159553849 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159553923 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159553718 Generation Of Ikzf2 Floxed Mice E-241-2017-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice&body=Please send me information about technology [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice&body=Please send me information about technology [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice.">yogikala.prabhu@nih.gov</a><br> TAB-4928 153551276 A Key Advancement for Human Norovirus Research and Reverse Genetics NIAID Collaboration, Human Cell Lines, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics, Vaccines Collaboration Human Cell Lines Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Vaccines Carlos Sandoval-Jaime, Stanislav Sosnovtsev <p>The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which is essential for driving transcription from T7 promoters. This capability opens up new possibilities for studying human noroviruses, which cannot be propagated in cell culture, and may facilitate the development of a reverse genetics system for these viruses. Overall, the HEK293T/T7 cell line represents a significant advancement in virology research and offers a valuable tool for researchers studying virus-host interactions and developing therapeutics or vaccines.</p> The HEK293T/T7 cell line offers several competitive advantages over existing technologies. Firstly, it is the first stable HEK293T cell line expressing T7 polymerase, filling a gap in available tools for researchers. This novel cell line provides a platform for developing reverse genetics systems for viruses, such as human noroviruses, which cannot be propagated in conventional cell culture. Secondly, the expression of functional T7 RNA polymerase in HEK293T cells has been confirmed, demonstrating its utility in driving transcription from T7 promoters. This feature is crucial for studying virus-host interactions and developing therapeutics or vaccines against viruses. Lastly, the compatibility of HEK293T cells with existing methodologies for recombinant protein expression enhances the versatility and usability of the HEK293T/T7 cell line in various research applications. Overall, these competitive advantages position the HEK293T/T7 cell line as a valuable and innovative tool for virology research. The HEK293T/T7 cell line has a wide range of potential applications in virology research and beyond. One key application is in the study of human noroviruses, where the cell line can facilitate the development of reverse genetics systems. This could lead to a better understanding of norovirus-host interactions and the development of novel therapeutics or vaccines. Additionally, the HEK293T/T7 cell line could be used in other virus research, where the T7 polymerase-driven transcription system is beneficial, such as in studying other viruses that are difficult to propagate in cell culture. Beyond virology, the HEK293T/T7 cell line's compatibility with existing methodologies for recombinant protein expression opens up possibilities for use in protein production and other biotechnology applications. Overall, the HEK293T/T7 cell line has the potential to significantly advance research in virology and related fields. 2024-03-04 2024-12-10 2025-10-27 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153551392 Sandoval-Jaime, Carlos National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sandoval-Jaime, Carlos (NIAID) 1 153551414 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 2 153551392 Sandoval-Jaime, Carlos National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sandoval-Jaime, Carlos (NIAID) 1 153551414 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 2 153551279 Human Embryonic Kidney Cell Line (designated HEK293T/T7 Constitutively Expressing The Phage T7 RNA Polymerase E-122-2013-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics&body=Please send me information about technology [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics&body=Please send me information about technology [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics.">peter.soukas@nih.gov</a><br> TAB-4591 151763432 Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer NIDCD Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Zhong Chen, Hui Cheng, Anthony Saleh, Carter Van Waes <p>This technology includes a method to identify potentially therapeutic microRNAs in cancer, particularly squamous cell carcinoma of the head and neck (HNSCC). This approach first utilizes a large and publicly available expression dataset, which is then validated by a smaller independent dataset to determine deregulated microRNAs expression. These results are then intersected with in vitro functional anti-proliferative screening data to select for microRNAs that play a functional tumor suppressive role and likely serve as therapeutic targets. Utilizing the recently published data from 279 tumor specimens, this analysis strategy identified 9 potentially therapeutic microRNAs, four of which were members of the miR-30-5p family. To further validate its role in tumor suppression, several classical oncogenes centering on Receptor tyrosine kinase (RTK) signaling as novel targets of miR-30 and display regulation both in vitro and in vivo were identified. Finally, its validity as a therapeutic target is supported by showing strong tumor growth delay for a synthetic miR-30a-5p mimic in a xenograft tumor model of HNSCC.</p> The greatest advantage of such a therapeutic would be the ability to target and repress multiple driving oncogenic pathways simultaneously, reducing the chances of resistance. Agents to be used in the treatment of cancer, either alone or in combination with chemotherapy/radiation, in addition to a companion diagnostic test. 2023-12-12 2024-08-12 2025-10-22 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151763442 Van Waes, Carter National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Van Waes, Carter (NIDCD) 1 151763449 Saleh, Anthony miRecule, Inc. NIDCD Saleh, Anthony (NIDCD) 2 151763453 Cheng, Hui National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cheng, Hui (NIDCD) 3 151763457 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 4 151763442 Van Waes, Carter National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Van Waes, Carter (NIDCD) 1 151763449 Saleh, Anthony miRecule, Inc. NIDCD Saleh, Anthony (NIDCD) 2 151763453 Cheng, Hui National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cheng, Hui (NIDCD) 3 151763457 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 4 151763435 Functions And Targets Of Therapeutic MicroRNAs To Treat Cancer E-043-2016-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer&body=Please send me information about technology [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer&body=Please send me information about technology [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer.">shmilovm@nih.gov</a><br> 157762820 E-043-2016-0 E-043-2016-0-US-01 MICRORNAS AND METHODS OF THEIR USE PRV US 62/304,844 Abandoned US <br />Provisional (PRV) 62/304,844<br />Filed on 2016-03-07<br />Status: Abandoned 157762825 E-043-2016-0 E-043-2016-0-PCT-02 MICRORNAS AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2017/021178 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/021178<br />Filed on 2017-03-07<br />Status: Expired 157762830 E-043-2016-0 E-043-2016-0-CN-03 MICRORNAS AND METHODS OF THEIR USE National Stage China ZL201780027750.X 201780027750.X Issued China <br />National Stage 201780027750.X<br />Filed on 2017-03-07<br />Status: Issued 157762835 E-043-2016-0 E-043-2016-0-EP-04 MICRORNAS AND METHODS OF THEIR USE National Stage European Patent 3426781 17712348.6 Issued European Patent <br />National Stage 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762840 E-043-2016-0 E-043-2016-0-IN-05 MICRORNAS AND METHODS OF THEIR USE National Stage India 201817037296 Abandoned India <br />National Stage 201817037296<br />Filed on 2018-10-03<br />Status: Abandoned 157762845 E-043-2016-0 E-043-2016-0-JP-06 MICRORNAS AND METHODS OF THEIR USE National Stage Japan 2018-547943 Pending Japan <br />National Stage 2018-547943<br />Filed on 2017-03-07<br />Status: Pending 157762850 E-043-2016-0 E-043-2016-0-US-07 MICRORNAS AND METHODS OF THEIR USE National Stage US 11,655,469 16/082,852 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11655469 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11655469">11,655,469</a><br />Filed on 2018-09-06<br />Status: Issued 157762855 E-043-2016-0 E-043-2016-0-US-02 MICRORNAS AND METHODS OF THEIR USE DIV US 18/301,040 Abandoned US <br />Divisional (DIV) 18/301,040<br />Filed on 2023-04-14<br />Status: Abandoned 157762860 E-043-2016-0 E-043-2016-0-EP-01 MICRORNAS AND METHODS OF THEIR USE DIV European Patent Administratively Closed European Patent <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 157762865 E-043-2016-0 E-043-2016-0-CN-08 MICRORNAS AND METHODS OF THEIR USE DIV China 202410174429.6 Abandoned China <br />Divisional (DIV) 202410174429.6<br />Filed on 2024-02-07<br />Status: Abandoned 157762870 E-043-2016-0 E-043-2016-0-CN-09 MICRORNAS AND METHODS OF THEIR USE DIV China 202410174426.2 Abandoned China <br />Divisional (DIV) 202410174426.2<br />Filed on 2024-02-07<br />Status: Abandoned 157762875 E-043-2016-0 E-043-2016-0-ES-01 MICRORNAS AND METHODS OF THEIR USE EP Spain 3426781 17712348.6 Issued Spain <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762880 E-043-2016-0 E-043-2016-0-FR-01 MICRORNAS AND METHODS OF THEIR USE EP France 3426781 17712348.6 Issued France <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762885 E-043-2016-0 E-043-2016-0-IT-01 MICRORNAS AND METHODS OF THEIR USE EP Italy 3426781 17712348.6 Issued Italy <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762890 E-043-2016-0 E-043-2016-0-DE-01 MICRORNAS AND METHODS OF THEIR USE EP Germany 3426781 17712348.6 Issued Germany <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762895 E-043-2016-0 E-043-2016-0-DK-01 MICRORNAS AND METHODS OF THEIR USE EP Denmark 3426781 17712348.6 Issued Denmark <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762900 E-043-2016-0 E-043-2016-0-BE-01 MICRORNAS AND METHODS OF THEIR USE EP Belgium 3426781 17712348.6 Issued Belgium <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762905 E-043-2016-0 E-043-2016-0-GB-01 MICRORNAS AND METHODS OF THEIR USE EP United Kingdom 3426781 17712348.6 Issued United Kingdom <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762910 E-043-2016-0 E-043-2016-0-IE-01 MICRORNAS AND METHODS OF THEIR USE EP Ireland 3426781 17712348.6 Issued Ireland <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762915 E-043-2016-0 E-043-2016-0-SE-01 MICRORNAS AND METHODS OF THEIR USE EP Sweden 3426781 17712348.6 Issued Sweden <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762920 E-043-2016-0 E-043-2016-0-NO-01 MICRORNAS AND METHODS OF THEIR USE EP Norway 3426781 17712348.6 Issued Norway <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762925 E-043-2016-0 E-043-2016-0-NL-01 MICRORNAS AND METHODS OF THEIR USE EP The Netherlands 3426781 17712348.6 Issued The Netherlands <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued TAB-4548 151737163 Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer NHLBI Antibodies, Licensing, Oncology, Therapeutics Antibodies Licensing Oncology Therapeutics Margaret Lindorfer, Christoph Rader, Martin Skarzynski, Ronald Taylor, Berengere Vire, Adrian Wiestner <p>This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects. This invention is a novel therapeutic concept to enhance the efficacy of therapeutic antibodies and the specific mAbs to achieve this goal. In a &quot;one-two punch&quot; approach, administration of a first tumor antigen-specific mAb that kills some but not all tumor cells is followed by an anti-C3d mAb that targets the C3d deposited on the tumor cells.</p> Novel therapeutic method and approach, which can enhance mAb-dependent tumor cell kill in an additive or even synergistic way. Therapy for multiple forms of cancer. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-10-20 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151737171 Skarzynski, Martin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Skarzynski, Martin (NHLBI) 1 151737179 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 2 151737183 Lindorfer, Margaret University of Virginia School of Medicine Lindorfer, Margaret 3 151737191 Taylor, Ronald University of Colorado Taylor, Ronald 4 151737206 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 5 151737210 Vire, Berengere National Heart, Lung, and Blood Institute (NHLBI) Vire, Berengere 6 151737171 Skarzynski, Martin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Skarzynski, Martin (NHLBI) 1 151737179 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 2 151737183 Lindorfer, Margaret University of Virginia School of Medicine Lindorfer, Margaret 3 151737191 Taylor, Ronald University of Colorado Taylor, Ronald 4 151737206 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 5 151737210 Vire, Berengere National Heart, Lung, and Blood Institute (NHLBI) Vire, Berengere 6 151737166 Antibody Targeting Of Cell Surface Deposited Complement Protein C3 E-758-2013-0 Filing authorized EraMiondi R&D, National Heart, Lung, and Blood Institute (NHLBI), NCI, University of Virginia School of Medicine 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer&body=Please send me information about technology [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer&body=Please send me information about technology [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer.">vidita.choudhry@nih.gov</a><br> 157756613 E-758-2013-0 E-758-2013-0-US-01 Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof PRV US 61/924,967 Abandoned US <br />Provisional (PRV) 61/924,967<br />Filed on 2014-01-08<br />Status: Abandoned TAB-4530 151720340 Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer NHLBI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Sivasubramanian Baskar, Christoph Rader, Adrian Wiestner <p>This technology includes the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to be used to treat cancer. CD19/CD3 bispecific antibodies (bsAbs) can be used to recruit endogenous T cells against CD19+ tumor cells via the formation of cytolytic synapses. lbrutinib, a BTK inhibitor, has been shown to normalize T cell dysfunction characteristic of CLL. We show that achieved significantly more killing of ibrutinib-treated CLL cells compared to treatment-naive CLL cells after 3 days of exposure (56.85% versus -3.29% mean specific-killing, p = 0.002), and after 7 days of exposure.</p> The invention describes a new form of immunotherapy: the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to recruit T cell attack on tumor cells. Our data provide evidence for a superior treatment response of the combined modality. Combination therapy of bispecific antibodies in malignancies in combination with kinase inhibitors. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-10-20 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151720373 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 151720377 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 2 151720381 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 3 151720373 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 151720377 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 2 151720381 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 3 151720343 Enhancing Activity Of Bispecific Antibodies In Combination With Ibrutinib E-212-2017-0 Research Material National Heart, Lung, and Blood Institute (NHLBI), NCI, The Scripps Research Institute, Scripps Florida 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer&body=Please send me information about technology [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer&body=Please send me information about technology [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer.">vidita.choudhry@nih.gov</a><br> TAB-4545 151736902 Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Stuart MacDonald, Nasser Raffie, Kanishka Ratnayaka <p>This technology includes a catheter-delivered endograft designed to treat congenital heart disease without surgery. The specific surgical procedure averted is cavopulmonary bypass graft. The key innovations are features to effect distal end-to-side anastomosis and proximal end-to-end anastomosis without surgery. The system operates under X-ray and MRI guidance.</p> Transcatheter endografts have long been proposed and frequently have failed, however, this successful, simple transcatheter endograft anastomosis based on unique strut and flange design. This endograft is specifically designed for congenital heart disease and may have applications for other bypass graft alternatives such as portal, visceral, and peripheral vascular such as carotid-subclavian to support thoracic aortic endograft. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-10-14 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736909 MacDonald, Stuart Transmural Systems, LLC MacDonald, Stuart 1 151736914 Raffie, Nasser Mehr Medical Raffie, Nasser 2 151736918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736922 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151736909 MacDonald, Stuart Transmural Systems, LLC MacDonald, Stuart 1 151736914 Raffie, Nasser Mehr Medical Raffie, Nasser 2 151736918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736922 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151736905 Device, Prosthesis And Delivery Systems, Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft E-287-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease&body=Please send me information about technology [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease&body=Please send me information about technology [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease.">shmilovm@nih.gov</a><br> 157756522 E-287-2015-0 E-287-2015-0-US-01 Device, Prosthesis And Delivery Systems, Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft PRV US 62/219,118 Abandoned US <br />Provisional (PRV) 62/219,118<br />Filed on 2015-09-15<br />Status: Abandoned 157756537 E-287-2015-0 E-287-2015-0-US-02 Devices And Methods For Effectuating Percutaneous Glenn And Fontan Procedures ORD US 10,426,482 15/267,075 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10426482 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10426482">10,426,482</a><br />Filed on 2016-09-15<br />Status: Issued 157756542 E-287-2015-0 E-287-2015-0-US-03 DEVICES AND METHODS FOR EFFECTUATING PERCUTANEOUS GLENN AND FONTAN PROCEDURES CON US 11,179,156 16/399,670 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11179156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11179156">11,179,156</a><br />Filed on 2019-04-30<br />Status: Issued TAB-4489 151702933 Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Nasser Raffie <p>This technology includes a guidewire purpose-built for delivery of bulky transcatheter heart valves (THV). Conventional THV guidewires are rigid and have a distal tip shaped like a pigtail to prevent apical ventricular perforation. This invention is a 3-dimensional helical or antihelical curve that can protect against apical perforation, possibly better, and that allows subtle 3-mensional deflection to aid the operator in achieving coaxiality or overcoming delivery obstacles such as calcific spicules.</p> This simple device modification can ease and speed delivery of transcatheter heart valves over conventional designs. Guidewire for use during transcatheter heart valve procedures. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-10-14 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151702940 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151702954 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151702940 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151702954 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151702936 HELICAL GUIDEWIRES AND RELATED SYSTEMS E-078-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures&body=Please send me information about technology [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures&body=Please send me information about technology [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures.">shmilovm@nih.gov</a><br> 157754455 E-078-2019-0 E-078-2019-0-US-01 HELICAL GUIDEWIRES AND RELATED SYSTEMS PRV US 62/651,692 Abandoned US <br />Provisional (PRV) 62/651,692<br />Filed on 2018-04-02<br />Status: Abandoned 157754460 E-078-2019-0 E-078-2019-0-PCT-02 HELICAL GUIDEWIRES AND RELATED SYSTEMS PCT Patent Cooperation Treaty PCT/US2019/025383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/025383<br />Filed on 2019-04-02<br />Status: Expired 157754465 E-078-2019-0 E-078-2019-0-US-03 HELICAL GUIDEWIRES AND RELATED SYSTEMS ORD US 17/038,095 Abandoned US <br />Ordinary Patent (ORD) 17/038,095<br />Filed on 2020-09-30<br />Status: Abandoned TAB-5087 164409186 Acyloxyacyl Hydrolase (AOAH) and Methods of Use NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Lanqi Gong, Peng Jiang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of AOAH as a cancer immunotherapy.</p> <h2>Description of Technology:</h2> <p>Immune CheckPoint Inhibitors (ICIs) and T-cell based therapies are part of the emerging immunology-based therapies being used to treat cancers.&nbsp; However, the efficacy of ICI therapies can be limited and a substantial portion of patients develop resistance or tolerance to treatment.&nbsp; T-cell based cancer immunotherapies have only been approved for hematological cancers. They are suboptimal in solid tumor cancers due to physical barriers and the immuno-suppressive tumor microenvironment.&nbsp; Thus, additional therapies and strategies are needed to improve efficacy and expand the types of cancer amendable to treatment.</p> <p>Scientists at the National Cancer Institute have identified a secreted lipase, Acyloxyacyl Hydrolase (AOAH), produced by cells such as macrophages and dendritic cells that can potentiate immunotherapies in murine tumor models.&nbsp; The protein sensitizes T cell receptors to weak antigens and protects dendritic cells through depleting immunosuppressive arachidonyl phoshatidylcholines and oxidized derivatives.&nbsp; Thus, the protein can potentially enhance the efficacy and types of cancers treated by ICI based and T-cell based immunotherapies.</p> <p>The National Cancer Institute is seeking collaborators and/or licensees to develop this technology as a cancer immunotherapy.</p> <h2>Potential Commercial Applications:&nbsp; &nbsp;</h2> <ul> <li>Cancer immunotherapy</li> <li>Combination therapy with ICIs or T-cell based therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel therapeutic entity</li> <li>Potentially improved efficacy</li> <li>Increased types of addressable cancers</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of AOAH as an immunotherapy for cancer treatment. 2025-09-30 2025-09-30 2025-09-30 2025-09-30 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 164409372 Gong L et al. Cancer Immunology Data Engine Reveals Secreted AOAH as a Potential Immunotherapy. (PMID 40730154) https://pubmed.ncbi.nlm.nih.gov/40730154/ <a href="https://pubmed.ncbi.nlm.nih.gov/40730154/">Gong L et al. Cancer Immunology Data Engine Reveals Secreted AOAH as a Potential Immunotherapy. (PMID 40730154)</a> 164409292 Jiang, Peng NIH - NCI NCI Jiang, Peng (NCI) 1 164409296 Gong, Lanqi NIH - NCI NCI Gong, Lanqi (NCI) 2 164409292 Jiang, Peng NIH - NCI NCI Jiang, Peng (NCI) 1 164409296 Gong, Lanqi NIH - NCI NCI Gong, Lanqi (NCI) 2 164409189 Big data-driven discovery and development of AOAH as new immunotherapy E-038-2024-0 Filing authorized NIH - NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use&body=Please send me information about technology [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use&body=Please send me information about technology [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">changke@mail.nih.gov</a><br> 164409194 E-038-2024-0 E-038-2024-0-US-01 ACYLOXYACYL HYDROLASE AND METHODS OF USE PRV US 63/717,036 Expired US <br />Provisional (PRV) 63/717,036<br />Filed on 2024-11-06<br />Status: Expired 164409195 E-038-2024-0 E-038-2024-0-PC-01 ACYLOXYACYL HYDROLASE AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2025/053940 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/053940<br />Filed on 2025-11-04<br />Status: Pending TAB-5086 164407714 Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Peter Choyke, Daiki Hara, Hisataka Kobayashi, Hideo Takakura <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) for use in near-infrared photoimmunotherapy (NIR-PIT) in the treatment of cancer.</p> <h2>Description of Technology:</h2> <p>Near-infrared photoimmunotherapy (NIR-PIT) is a method of treating cancers that utilizes an antibody-photoabsorber conjugate (APC), which is activated by near-infrared light to kill cells. The antibody binds to the appropriate cell surface antigen and a photo-activatable compound induces lethal damage to the cell membrane after NIR-light exposure. NIR-light exposure induces highly selective, necrotic cancer cell death within minutes without damage to adjoining cells.</p> <p>Researchers at the National Cancer Institute (NCI) and Kansai Medical University (KMU) have developed the current invention which is a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) as alternatives to the current IRDye700DX. This series of IR702HKTs have modified linkers that improve the efficacy of cellular cytotoxicity of IR702HKT bound to target cancer cells. Additionally, appropriate modifications improved in vivo stability of these new APCs and required less energetic therapeutic light exposure, which should improve clinical therapeutic efficacy and safety of NIR-PIT.</p> <p>The inventors are open to co-development partners and/or licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer treatment</li> <li>Cancer diagnosis</li> <li>Cancer imaging</li> <li>Treatment against viral, fungus, parasite, or bacterial infection</li> <li>Age-related macular degeneration and lymphangioma, via depletion of abnormal vessels</li> <li>Improved metabolic and physical function, via targeting of senile senescent cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved in vivo stability</li> <li>Improved cytotoxicity against APC-bound target cells by the same light exposure</li> <li>Reduced therapeutic light exposure clinical therapeutic efficacy and safety, compared to current photo-absorbing silicon-phthalocyanine derivatives</li> <li>Improved synthesis yields</li> </ul> Researchers at the NCI seek licensing for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) as alternatives to the current IRDye700DX. 2025-09-30 2025-09-30 2025-09-30 2025-09-30 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-137-2024-1 164407776 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 1 164407780 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 2 164407791 Takakura, Hideo Kansai Medical University Takakura, Hideo 3 164407795 Hara, Daiki Kansai Medical University Hara, Daiki 4 164407776 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 1 164407780 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 2 164407791 Takakura, Hideo Kansai Medical University Takakura, Hideo 3 164407795 Hara, Daiki Kansai Medical University Hara, Daiki 4 164407717 Photoabsorbing Dyes (IR702HKTs) for Near Infrared PhotoImmuno Therapy (NIR-PIT) E-137-2024-0 Filing authorized Kansai Medical University, Molecular Imaging Branch 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same&body=Please send me information about technology [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same&body=Please send me information about technology [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 164407722 E-137-2024-0 E-137-2024-0-US-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PRV US 63/690,585 Expired US <br />Provisional (PRV) 63/690,585<br />Filed on 2024-09-04<br />Status: Expired 164407723 E-137-2024-0 E-137-2024-0-PC-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2025/044361 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/044361<br />Filed on 2025-09-03<br />Status: Pending TAB-5082 164393007 Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1 NCI Collaboration, Immunology, Licensing, Oncology, Vaccines Collaboration Immunology Licensing Oncology Vaccines Renee Donahue, Duane Hamilton, Claudia Palena, Jeffrey Schlom <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas.</p> <h2>Description of Technology:</h2> <p>Human Endogenous Retroviruses (HERVs), remnants of ancient retroviral germline infections that comprise ~8% of the human genome, represent a promising yet underexplored frontier in targeted cancer therapy. Although typically epigenetically silenced in normal adult tissues, select HERV components, including RNAs and envelope proteins, are frequently overexpressed in various carcinomas due to epigenetic dysregulation &ndash; a hallmark of cancer. The challenge lies in identifying specific, highly immunogenic HERV targets that elicit potent anti-tumor immune responses without triggering autoimmunity. Addressing this need is critical to advancing broadly applicable cancer immunotherapies.</p> <p>Inventors at the NCI have developed and characterized a novel cancer immunotherapy platform targeting ERVMER34-1, a specific HERV envelope protein that is highly expressed across multiple human carcinomas while exhibiting minimal expression in normal tissues. Using transcriptomic and proteomic datasets, the team confirmed the tumor-selective expression profile of ERVMER34-1. To improve safety and specificity, they engineered an artificial antigen-presenting cell line to express the full-length ERVMER34-1 protein, HLA-A2 and CD80 to facilitate efficient priming and expansion of ERVMER34-1-reactive CD8+ T cells. To therapeutically target ERVMER34-1, they modified the ERVMER34-1 protein by removing the signal peptide, cleavage site, predicted immunosuppressive domain, transmembrane domain and a 170-amino acid region homologous to human proteins. These modifications prevent surface trafficking, antigen shedding, immune dampening, and off-target reactivity. This modified sequence was incorporated into a recombinant adenoviral vector as a therapeutic cancer vaccine. In preclinical murine models (e.g., MC38 colon cancer, EMT6 breast cancer), vaccination with this construct alone or in combination with immune checkpoint blockade or an IL-15 superagonist elicited robust, multifunctional CD4⁺ and CD8⁺ T cell responses. Those enhanced T cell responses induced tumor clearance, increased intratumoral lymphocyte infiltration, broadened neoantigen spreading and prolonged tumor control. ERVMER34-1-reactive T cells could be expanded from both healthy donor and cancer patient Peripheral Blood Mononuclear Cells (PBMCs) and demonstrated specific cytolytic activity against ERVMER34-1⁺ human carcinoma cell lines in vitro. To support peptide-based approaches, researchers developed an overlapping 15-mer peptide library spanning the modified ERVMER34-1 protein sequence. These peptides elicited strong, polyfunctional T cell responses in vitro &ndash; including both CD4⁺ and HLA-A2-restricted CD8⁺ T cell activation, enabling precise epitope mapping and facilitating future peptide vaccine design and adoptive T cell receptor (TCR)-based therapies.</p> <p>The NCI invites industry partners and translational researchers to collaborate on or license this pioneering HERV ERVMER34-1 protein targeted vaccine technology. With promising preclinical data, this technology addresses a critical gap in the cancer vaccine landscape. It offers a unique opportunity to advance a novel therapeutic targeting widespread carcinomas, opening a substantial market for cancer treatment.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Peptide-based therapeutic cancer vaccines</li> <li>Adenoviral vector-based therapeutic cancer vaccines</li> <li>Liposome- or nanoparticle-formulated therapeutic cancer vaccines</li> <li>Artificial Antigen-Presenting Cell platforms expressing ERVMER34-1 with HLA-A2 and CD80 to expand antigen-specific T cells for adoptive cell therapies</li> <li>Adoptive T cell therapies using ERVMER34-1-specific TCRs isolated from PBMCs or engineered T cells redirected against shared HERV antigens</li> <li>Combination immunotherapies pairing the ERVMER34-1 vaccine with checkpoint inhibitors and/or epigenetic modifiers to boost response breadth and tumor infiltration</li> <li>Cytokine or immuno-cytokine-enhanced combination regimens incorporating immune-oncology agents to amplify tumor-specific T cell activation</li> <li>Companion diagnostic tools to identify ERVMER34-1-expressing tumors for patient selection and treatment stratification</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Broad tumor coverage across ~62% of carcinomas</li> <li>Minimal expression in normal tissues reduces toxicity risk and expands market potential</li> <li>Engineered antigen design in vaccine eliminates immunosuppressive and off-target domains, improving safety and therapeutic precision</li> <li>Elicits potent, multifunctional T cell responses with cytokine production and broad epitope recognition, enhancing anti-tumor efficacy</li> <li>Selectively clears tumor cells based on ERVMER34-1 expression, enabling precise targeting across variable antigen levels</li> <li>Demonstrates remarkable synergistic efficacy with immune checkpoint inhibitors, achieving ~89% tumor clearance in established large tumors in mouse models</li> <li>Exhibits synergistic interaction with cytokine agonists such as N-803 (Anktiva), significantly enhancing neoepitope-reactive T cell responses and improving tumor control in combination therapies</li> <li>Potential for use in combination with epigenetic modulators to enhance expression of targeted antigen in human carcinomas</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. 2025-09-29 2025-09-29 2025-09-29 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-056-2023 164393294 Maldonado MDM, et al. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control (PMID: 40360436) https://pubmed.ncbi.nlm.nih.gov/40360436/ <a href="https://pubmed.ncbi.nlm.nih.gov/40360436/">Maldonado MDM, et al. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control (PMID: 40360436)</a> 164393297 Gracia-Hernandez M, et al. Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer (PMID: 40387511) https://pubmed.ncbi.nlm.nih.gov/40387511/ <a href="https://pubmed.ncbi.nlm.nih.gov/40387511/">Gracia-Hernandez M, et al. Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer (PMID: 40387511)</a> 164393132 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393153 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 164393157 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 3 164393178 Donahue, Renee NIH - NCI NCI Donahue, Renee (NCI) 4 164393132 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393153 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 164393157 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 3 164393178 Donahue, Renee NIH - NCI NCI Donahue, Renee (NCI) 4 164393010 Identification Of Novel Human Immunogenic Epitopes Of HEMO And HHLA2 Human Endogenous Retroviruses (HERVs) E-159-2019-0 Filing authorized Chan Soon-Shiong Institute of Molecular Medicine at Windber, MDR Global Systems, LLC, NCI, NIH - NCI, Uniformed Services University of the Health Sciences 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1&body=Please send me information about technology [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1&body=Please send me information about technology [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> 164393022 E-159-2019-0 E-159-2019-0-US-01 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVs) PRV US 62/963,872 Abandoned US <br />Provisional (PRV) 62/963,872<br />Filed on 2020-01-21<br />Status: Abandoned 164393023 E-159-2019-0 E-159-2019-0-PCT-02 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) PCT Patent Cooperation Treaty PCT/US2021/014335 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/014335<br />Filed on 2021-01-21<br />Status: Expired 164393024 E-159-2019-0 E-159-2019-0-CA-03 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage Canada 3165251 Pending Canada <br />National Stage 3165251<br />Filed on 2022-07-19<br />Status: Pending 164393025 E-159-2019-0 E-159-2019-0-AU-04 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage Australia 2021210915 Pending Australia <br />National Stage 2021210915<br />Filed on 2022-08-18<br />Status: Pending 164393026 E-159-2019-0 E-159-2019-0-EP-05 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage European Patent 21705769.4 Pending European Patent <br />National Stage 21705769.4<br />Filed on 2022-08-18<br />Status: Pending 164393027 E-159-2019-0 E-159-2019-0-US-06 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage US 17/793,753 Pending US <br />National Stage 17/793,753<br />Filed on 2022-07-19<br />Status: Pending 164393028 E-159-2019-0 E-159-2019-0-HK-07 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) EP Hong Kong 62023070659.5 Pending Hong Kong <br />European patent (EP) 62023070659.5<br />Filed on 2023-03-27<br />Status: Pending TAB-5081 164388769 Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2 NICHD Licensing, Rare/Neglected Diseases, Research Materials Licensing Rare/Neglected Diseases Research Materials Bjorn Knollmann, Karl Pfeifer <h2>Summary:</h2> <p>&nbsp;The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291 and https://www.jax.org/strain/036290.</p> <h2>Description of Technology:</h2> <p>Cardiac calsequestrin (Casq2) plays an essential role in maintaining cardiac Ca2+ homeostasis. Human CASQ2 mutations are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare familial arrhythmogenic disorder within a group of diseases characterized as Sudden Arrhythmic Death.</p> <p>The inventors have generated Casq2Flox and Casq2RevFlox mouse strains that model CPVT. The two novel strains successfully phenocopy aspects of CPVT, including stress-induced arrhythmias and reduced basal heart rates. The strains allow investigators to determine the importance of Casq2 gene function in specific tissues and at specific developmental time points. They also allow investigators to determine the efficacy of gene therapy and to address key mechanism questions. The materials are validated and fully functional.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Study of Casq2 function</li> <li>Study of calcium storage in cardiac muscle and CPVT</li> <li>Determining the efficacy of gene therapy for CPVT</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Only available conditional and reverse conditional loss-of-function alleles in mouse Casq2</li> <li>Allows the study of Casq2 gene function in specific tissues and at specific developmental points</li> </ul> NICHD seeks licensing for further developing or utilizing these Casq2 mouse strains. 2025-09-29 2025-09-29 2025-09-29 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract 164390469 Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (PMID 16932808) https://pubmed.ncbi.nlm.nih.gov/16932808/ <a href="https://pubmed.ncbi.nlm.nih.gov/16932808/">Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (PMID 16932808)</a> 164390478 Flores DJ, et al. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype. (PMID 29452352) https://pubmed.ncbi.nlm.nih.gov/29452352/ <a href="https://pubmed.ncbi.nlm.nih.gov/29452352/">Flores DJ, et al. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype. (PMID 29452352)</a> 164390525 Blackwell DJ, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. (PMID 34990403) https://pubmed.ncbi.nlm.nih.gov/34990403/ <a href="https://pubmed.ncbi.nlm.nih.gov/34990403/">Blackwell DJ, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. (PMID 34990403)</a> 164388829 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 1 164388840 Knollmann, Bjorn Vanderbilt University Knollmann, Bjorn 2 164388829 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 1 164388840 Knollmann, Bjorn Vanderbilt University Knollmann, Bjorn 2 164388772 Generating conditional and reverse conditional loss-of-function alleles in mouse Casq2 E-128-2024-0 Research Material NIH - NICHD, Vanderbilt University 83746064 Whitman, Nathan nathan.whitman@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2&body=Please send me information about technology [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitman, Nathan<br><a href="mailto:nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2&body=Please send me information about technology [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">nathan.whitman@nih.gov</a><br> TAB-3345 114097260 Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection NIAID Collaboration Collaboration Wei Bu, Jeffrey Cohen, Michael Joyce, Masaru Kanekiyo According to the World Health Organization, over 90% of the worldwide population is infected with Epstein-Barr virus by adulthood. In most cases, the disease accompanying initial infection is subclinical though some individuals who are infected as adolescents or adults do experience infectious mononucleosis. However, once infected, individuals carry latent EBV for their remaining lifespan. In such individuals, immune suppression can result in reactivation of the EBV and consequently, EBV-associated lymphoproliferative disease. Currently, there is no prophylactic to prevent primary EBV infection and additional therapeutics would be useful to treat EBV-associated B-cell driven lymphoproliferative disease.<br /><br /> Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1). The antibodies target epitopes on either the gp350 surface glycoprotein of EBV or the gH/gL heterodimer. In vitro experiments have demonstrated that the antibodies effectively inhibit EBV infection of B cells and epithelial cells as well as cell-to-cell fusion of cells expressing the viral proteins gH/gL. <ul> <li>No EBV therapeutics or prophylactics currently exist</li> </ul><< <ul> <li>Treatment of individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases</li> <li>Prevention of primary EBV infection in individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Epstein-Barr monoclonal antibody technologies. For collaboration opportunities, please contact Peter Soukas, J.D., 301-594-8730; <ahref="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a> 2022-03-08 2025-09-29 2025-09-29 2018-11-05 Against, antibodies, B, both, Cells, Epithelial, EPSTEIN-BARR, Fusion, Infection, INHIBIT, Neutralize, Neutralizing, POTENT, That, Their, virus False True True NIHTT 37470483 Website Abstract 114109972 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109973 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114109974 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114109971 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 114109971 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 114109972 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109973 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114109974 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114102503 Potent Neutralizing Antibodies Against Epstein-Barr Virus And Their Use E-001-2017-0 Filing authorized NIAID 114102504 Potent Neutralizing Antibodies Against Epstein-Barr Virus And Their Use E-001-2017-1 Filing authorized NIAID 114102505 Epstein-Barr Virus Antibodies That Neutralize Virus Infection In Both Epithelial Cells And B Cells And Inhibit Fusion E-079-2018-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection&body=Please send me information about technology [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection&body=Please send me information about technology [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection.">maryann.puglielli@nih.gov</a><br> 114168791 E-001-2017-0 E-001-2017-0-US-01 Antibodies and Methods for the Diagnosis and Treatment of Epstein Barr Virus Infection PRV US 62/490,023 Abandoned US <br />Provisional (PRV) 62/490,023<br />Filed on 2017-04-25<br />Status: Abandoned 114168792 E-001-2017-1 E-001-2017-1-PCT-01 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION PCT COMB Patent Cooperation Treaty PCT/US2018/029463 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2018/029463<br />Filed on 2018-04-25<br />Status: Expired 114168793 E-079-2018-0 E-079-2018-0-US-01 Antibodies and Methods for the Diagnosis, Prevention, and Treatment of Epstein Barr Virus Infection PRV US 62/665,977 Abandoned US <br />Provisional (PRV) 62/665,977<br />Filed on 2018-05-02<br />Status: Abandoned 114168876 E-079-2018-0 E-079-2018-0-PCT-01 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION PCT COMB Patent Cooperation Treaty PCT/US2019/030431 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/030431<br />Filed on 2019-05-02<br />Status: Expired 114168925 E-001-2017-1 E-001-2017-1-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION National Stage US 11,236,151 16/608,386 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236151">11,236,151</a><br />Filed on 2019-10-25<br />Status: Issued 114169067 E-079-2018-0 E-079-2018-0-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION National Stage US 12,084,489 17/052,470 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12084489 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12084489">12,084,489</a><br />Filed on 2020-11-02<br />Status: Issued 114169178 E-001-2017-1 E-001-2017-1-US-04 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION DIV US 11,926,656 17/553,139 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11926656 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11926656">11,926,656</a><br />Filed on 2021-12-16<br />Status: Issued 114151522 Against 114151523 antibodies 114151524 Neutralizing 114151525 POTENT 114151526 Their 114151527 EPSTEIN-BARR 114151528 virus 114151529 That 114151530 Neutralize 114151531 Infection 114151532 both 114151533 Epithelial 114151534 Cells 114151535 B 114151536 INHIBIT 114151537 Fusion TAB-2321 114096515 Diagnostic Assays and Methods of Use for Detection of Filarial Infection NIAID Collaboration, Diagnostics, Infectious Disease Collaboration Diagnostics Infectious Disease Peter Burbelo, Doran Fink, Joseph Kubofcik, Thomas Nutman The effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult <em>Wuchereria bancrofti</em> (Wb) antigen in blood, but shows variable efficacy due to the complex life cycle of the parasites and cross reactivity with other organisms. This variability may hinder effective lymphatic filariasis elimination efforts. This new technology improves available detection methods through use of an isolated immunoreactive antigen, Wb123, from infective stage larvae (L3) Wb; which results in specific detection early in the infective cycle with reduced cross reactivity. This technology may see wide application in testing and surveillance of lymphatic filariasis as part of the effort to eliminate the disease worldwide. <ul> <li>Improved detection of early stage lymphatic filariasis</li> </ul> <ul> <li>Diagnostics testing</li> <li>Infectious disease monitoring</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. 2022-03-08 2025-09-29 2025-09-29 2021-10-29 2021-08-16 Bancrofitan, Bancrofti, CONTROL, DA2XXX, DAXXXX, DXXXXX, Filariasis, FOLLOWING, Immunodiagnosis, Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi), MOLECULE, Programs, Specific, Successful, Surveillance, Wuchereria False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> </ul> True NIHTT 37470483 Website Abstract E-084-2010-0 E-014-2011-0 114171412 Senbagavalli P, et al. https://www.ncbi.nlm.nih.gov/pubmed/21734131 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21734131">Senbagavalli P, et al.</a> 114171413 Bennuru S, et al. https://www.ncbi.nlm.nih.gov/pubmed/21606368 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21606368">Bennuru S, et al.</a> 114171414 Steel C, et al. https://www.ncbi.nlm.nih.gov/pubmed/21559422 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21559422">Steel C, et al.</a> 114171415 Fink DL, et al. https://www.ncbi.nlm.nih.gov/pubmed/20980560 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20980560">Fink DL, et al.</a> 114171416 Bennuru S, et al. https://www.ncbi.nlm.nih.gov/pubmed/20889885 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20889885">Bennuru S, et al.</a> 114107309 Fink, Doran NIAID - DIR NIAID Fink, Doran (NIAID) 0 114107311 Kubofcik, Joseph NIAID - DIR NIAID Kubofcik, Joseph (NIAID) 0 114107312 Burbelo, Peter NIDCR Burbelo, Peter (NIDCR) 0 114107310 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114107310 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114107309 Fink, Doran NIAID - DIR NIAID Fink, Doran (NIAID) 0 114107311 Kubofcik, Joseph NIAID - DIR NIAID Kubofcik, Joseph (NIAID) 0 114107312 Burbelo, Peter NIDCR Burbelo, Peter (NIDCR) 0 114101629 Wuchereria Bancrofti Specific Molecule For The Immunodiagnosis Of Bancrofitan Filariasis And For Surveillance Following Successful Control Programs E-281-2010-0 Filing authorized NIAID, NIDCR 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection&body=Please send me information about technology [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection&body=Please send me information about technology [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection.">jonathan.motley@nih.gov</a><br> 114163154 E-281-2010-0 E-281-2010-0-PCT-02 DIAGNOSTIC ASSAYS AND METHODS OF USE FOR DETECTION OF FILARIAL INFECTION PCT Patent Cooperation Treaty PCT/US2011/58561 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/58561<br />Filed on 2011-10-31<br />Status: Expired 114166523 E-281-2010-0 E-281-2010-0-US-01 Diagnostic Assays And Methods Of Use For Detection Of Filarial Infection PRV US 61/410,239 Abandoned US <br />Provisional (PRV) 61/410,239<br />Filed on 2010-11-04<br />Status: Abandoned 114167058 E-281-2010-0 E-281-2010-0-US-03 Diagnostic Assays and Methods of Use for Detection of Filarial Infection National Stage US 9,068,993 13/882,850 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9068993 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9068993">9,068,993</a><br />Filed on 2013-06-13<br />Status: Issued 114122301 DA2XXX 114122302 DXXXXX 114122303 DAXXXX 114141989 Wuchereria 114141990 Bancrofti 114141991 Specific 114141992 MOLECULE 114141993 Immunodiagnosis 114141994 Bancrofitan 114141995 Filariasis 114141996 Surveillance 114141997 FOLLOWING 114141998 Successful 114141999 CONTROL 114142000 Programs 114157965 Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi) TAB-2813 114096991 Novel Dopamine D2 Receptor Antagonists and Methods of Their Use NINDS Collaboration, Neurology, Psychiatry/Mental Health, Research Materials, Therapeutics Collaboration Neurology Psychiatry/Mental Health Research Materials Therapeutics Marc Ferrer-Alegre, R Benjamin Free, Juan Marugan, David Sibley, Noel Southall, Jingbo Xiao Investigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA approved antipsychotic agents are antagonists of this receptor. Unfortunately, most agents that act as antagonists of D2 DAR are problematic, either they are less efficacious than desired or cause multiple adverse effects. Thus, it is desirable to develop a class of novel therapeutic agents with high selectivity for the D2 DAR. This invention describes dihydrobenzo[b,f][1,4]thiazepine-8-carboxamide compounds, methods of making these compounds, methods of characterizing their in vitro activity, demonstration of in vivo activity in animals, as well as methods of using these compounds to treat central nervous system (CNS) related disorders. <ul> <li>Highly selective</li> </ul> <ul> <li>Antipsychotic agent</li> <li>Treatment for schizophrenia, Tourette's syndrome, depression</li> <li>Alternative therapy for disorders currently treated with non-selective D2 antagonists</li> </ul> The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Novel Dopamine D2 Receptor Antagonists and Methods of Their Use. For collaboration opportunities, please contact Susan Ano at <a href="mailto:susan.ano@nih.gov">susan.ano@nih.gov</a>. 2022-03-08 2024-10-28 2025-09-23 2015-04-09 Agents, ANTAGONISTS, ANTIPSYCHOTIC, D2, Dopamine, Human, NB2BXX, NB2XXX, Potential, RECEPTOR, SELECTIVE, VEXXXX, VNXXXX, WIXXXX, WKXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170781 Xiao J, et al. https://www.ncbi.nlm.nih.gov/pubmed/24666157 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24666157">Xiao J, et al.</a> 114172244 Xiao J, et al. https://www.ncbi.nlm.nih.gov/pubmed/24260782 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24260782">Xiao J, et al.</a> 164235772 responded 23Sept with copy of issued US patent and a link to the license application. responded 23Sept with copy of issued US patent and a link to the license application. 114108698 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114108699 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114108700 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114108701 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108703 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114108702 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114108702 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114108698 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114108699 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114108700 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114108701 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108703 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114102146 Selective Human D2 Dopamine Receptor Antagonists As Potential Antipsychotic Agents E-030-2013-0 Filing authorized NCATS - NCGC, NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use&body=Please send me information about technology [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use&body=Please send me information about technology [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use.">susan.ano@nih.gov</a><br> 114161129 E-030-2013-0 E-030-2013-0-US-04 11-OXO-10,11-Dihydrodibenzo[B,F][1,4]Thiazepine S-Oxide Derivatives And Their Use As Dopamine D2 Receptor Antagonists National Stage US 9,550,742 14/908,271 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9550742 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9550742">9,550,742</a><br />Filed on 2014-07-29<br />Status: Issued 114167778 E-030-2013-0 E-030-2013-0-US-01 Selective Dopamine D2 Receptor Antagonists And Methods Of Their Use PRV US 61/859,532 Abandoned US <br />Provisional (PRV) 61/859,532<br />Filed on 2013-07-29<br />Status: Abandoned 114167909 E-030-2013-0 E-030-2013-0-PCT-02 Selective Human D2 Dopamine Receptor Antagonists And Methods Of Their Use PCT Patent Cooperation Treaty PCT/US2014/048619 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/048619<br />Filed on 2014-07-29<br />Status: Expired 114125977 VEXXXX 114125978 VNXXXX 114125979 WIXXXX 114125980 WKXXXX 114125981 NB2XXX 114125982 NB2BXX 114125983 YBXXXX 114125984 YCXXXX 114147215 SELECTIVE 114147216 Human 114147217 D2 114147218 Dopamine 114147219 RECEPTOR 114147220 ANTAGONISTS 114147221 Potential 114147222 ANTIPSYCHOTIC 114147223 Agents TAB-4227 147157512 Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages NEI Cardiology, Collaboration, Ear, Nose, & Throat, Licensing, Nephrology, Ophthalmology, Research Materials Cardiology Collaboration Ear Nose & Throat Licensing Nephrology Ophthalmology Research Materials Wei Li, Kiyoharu Miyagishima, Jingxing Ou <p>Researchers at the National Eye Institute (NEI) have discovered an invention describing a composition and method(s) of using such composition for preserving viability of cells, tissues, or organs at a low temperature (around 4&ordm;C). Current cold storage solutions or methods for cells, tissues, and organs are suboptimal due to irreversible damage to cold-sensitive tissue or organ transplants that need a longer term of storage for facilitating clinical practices. In addition to mitigating this damage, the new method may be potentially used in therapeutic hypothermia for protecting neural injury or trauma, or for enhancing neuronal survival from axonal damage and degeneration.&nbsp;</p> <p>The invented composition, which was inspired by the inventors&rsquo; hibernation mechanism studies using their ground squirrel induced pluripotent stem (iPSC) cells, contains a mitochondrial uncoupling agent that reduces mitochondrial oxidation and thus protects tissues or organs from cold stress. The invention can be either used alone or may supplement other types of preservation reagents. The new composition represents an improved one as compared with currently available commercial preservation products for certain tissue types, such as Optisol&trade;-GS corneal storage solution or CoStorSol&reg; cold storage solution that is the current standard for liver and kidney transplantation.</p> <p>The NEI inventors seek licensees and/or to collaborate with commercial partners to develop the new composition into preservation products that can be used in research or variable clinical practices such as therapeutic hypothermia, transplantation, and physical neural injuries.&nbsp;</p> <p>The&nbsp;figure below shows pretreatments with the invented storage solution preserved cellular morphology and functions of retinal ganglion cells following 4-h cold storage:</p> <p><img alt=" pretreatments with the invented storage solution preserved cellular morphology and functions of retinal ganglion cells following 4-h cold storage" height="504" src="https://nih.technologypublisher.com/files/sites/e-165-2017_image_1_03.jpg" width="344" /></p> <p>The&nbsp;figure below shows pretreatments with the mitochondrial inhibitor Bam15 and/or protease inhibitors (Pi) preserved microtubule morphology following 24-h cold storage and 2-h rewarming, and reduced cell apoptosis following 72-h cold storage:</p> <p><img alt=" This Figure shows pretreatments with the mitochondrial inhibitor Bam15 and/or protease inhibitors (Pi) preserved microtubule morphology following 24-h cold storage and 2-h rewarming, and reduced cell apoptosis following 72-h cold storage. " height="623" src="https://nih.technologypublisher.com/files/sites/e-165-2017_image_22.jpg" width="600" /></p> <p>&nbsp;</p> <h2>Competitive Advantages:</h2> <ul> <li>This invented cold storage solution employs newly discovered mechanism for preserving cell or tissue viability under cold stress, thus improving preservation efficacy&nbsp;</li> <li>This new cold storage solution represents a better choice owing to its innovative concept in preservation, compared with current commercially available products, for enhanced preservation efficacy and prolonged storage of cold-sensitive cells, tissues, or organs, which include primary neural tissues, hepatocytes, kidneys retinas, etc.</li> <li>This new solution can be used as supplements into other current research- or clinical-grade of reagents for a variety of applications that demand induced cold tolerance&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Preservation storage solutions for extended preservation of cold-sensitive tissues or organs for research or medical procedures</li> <li>Medical product(s) that can be used in therapeutic hypothermia for treating neural injury or trauma</li> <li>Medical product(s) that can be used for directly treating neural injury or trauma&nbsp;&nbsp;</li> </ul> 2018-10-12 2025-05-15 2018-10-12 2025-09-15 2018-10-12 Cold Storage, Cold-sensitive, Hypothermia, lysosome, Mitochondria, National Eye Institute, NEI, neural injury, Ou, Protein Degradation, TRANSPLANTATION False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-059-2017 147162390 Ou J, et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications. https://www.ncbi.nlm.nih.gov/pubmed/29576452 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29576452">Ou J, et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications.</a> 147163974 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163973 Li, Wei NIH - NCI NCI Li, Wei (NCI) 2 147163975 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 3 147163974 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163973 Li, Wei NIH - NCI NCI Li, Wei (NCI) 2 147163975 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 3 147158120 Strategies To Protect Mammalian Neural Tissue Against Cold And Potentially Other Metabolic Stresses E-165-2017-0 Filing authorized National Eye Institute (NEI), NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages&body=Please send me information about technology [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages&body=Please send me information about technology [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161132 E-165-2017-0 E-165-2017-0-PCT-02 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES PCT Patent Cooperation Treaty PCT/US2018/047064 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/047064<br />Filed on 2018-08-20<br />Status: Expired 147167532 E-165-2017-0 E-165-2017-0-US-01 Compositions and Methods To Protect Mammalian Tissue Against Cold And Other Metabolic Stresses PRV US 62/547,945 Abandoned US <br />Provisional (PRV) 62/547,945<br />Filed on 2017-08-21<br />Status: Abandoned 147167533 E-165-2017-0 E-165-2017-0-CN-03 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES National Stage China ZL201880068155.5 201880068155.5 Issued China <br />National Stage 201880068155.5<br />Filed on 2018-08-20<br />Status: Issued 147167534 E-165-2017-0 E-165-2017-0-US-04 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES National Stage US 11,547,708 16/636,945 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11547708 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11547708">11,547,708</a><br />Filed on 2020-02-06<br />Status: Issued 147167535 E-165-2017-0 E-165-2017-0-US-05 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES DIV US 12,383,554 18/058,064 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12383554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12383554">12,383,554</a><br />Filed on 2022-11-22<br />Status: Issued 147172753 Cold Storage 147172755 Cold-sensitive 147172757 Hypothermia 147172758 lysosome 147172759 Mitochondria 147172760 National Eye Institute 147172761 NEI 147172762 neural injury 147172764 Ou 147172766 Protein Degradation 147172767 TRANSPLANTATION TAB-4119 147157401 Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel NEI Licensing, Neurology, Research Materials Licensing Neurology Research Materials Wei Li, Barbara Mallon, Jingxing Ou <p>The limited choice in cell types available for in vitro studies has become an obstacle in hibernation research.&nbsp;</p> <p>Researchers at the National Eye Institute for the first time have successfully established iPSC line(s) from a mammalian hibernator, which can be potentially used to generate various cell types and tissue models for in-depth mechanistic studies of hibernation and coldness tolerance in vitro.&nbsp;</p> <p>Hibernation-specific features make this line a unique platform and valuable tool for inspiring novel pharmacological strategies. For example, they can be used to bestow cold adaptability to target cells and organs derived from non-hibernating mammals, as well as translating cold-adaptive strategies into humans in clinical applications, such as neural injury or other diseases that involve cold intolerance.</p> <p><img alt="Compared with human iPSC-derived neurons, GS iPSC-derived neurons are not susceptible to cold stress treatment." height="707" src="https://nih.technologypublisher.com/files/sites/e-059-2017_image_for_lynne_huang4.png" style="float:right" width="500" /></p> <h2>Competitive Advantages:</h2> <ul> <li>The first iPSC line established from small hibernators like ground squirrel</li> <li>Potential in generating various cell types and tissue models for in-depth mechanistic studies of hibernation and coldness tolerance in vitro</li> <li>Unique benefits in studying hibernation mechanism and cold-adaptive strategies&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Research tool for studying hibernation and cold adaptability and disease modeling</li> <li>Drug screening platform for neuronal injuries or other diseases</li> </ul> 2018-06-20 2025-05-15 2021-01-26 2025-09-15 2018-06-20 cellular stress, coldness, hibernation, Induced Pluripotent Stem Cell (iPSC), Li, neural injury, Squirrel False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162028 J. Ou et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications https://www.ncbi.nlm.nih.gov/pubmed/29576452 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29576452">J. Ou et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications</a> 147163573 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163575 Mallon, Barbara NIH - NINDS NINDS Mallon, Barbara (NINDS) 2 147163574 Li, Wei NIH - NEI NEI Li, Wei (NEI) 3 147163573 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163575 Mallon, Barbara NIH - NINDS NINDS Mallon, Barbara (NINDS) 2 147163574 Li, Wei NIH - NEI NEI Li, Wei (NEI) 3 147157893 Establishment Of Induced Pluripotent Stem Cells From The Thirteen-lined Ground Squirrel E-059-2017-0 Research Material National Eye Institute (NEI), NINDS 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel&body=Please send me information about technology [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel&body=Please send me information about technology [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147170492 cellular stress 147170494 coldness 147170496 hibernation 147170498 Induced Pluripotent Stem Cell (iPSC) 147170500 Li 147170502 neural injury 147170503 Squirrel TAB-3959 147157239 Interleukin 24 (IL-24) to treat inflammatory diseases NEI Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Rachel Caspi, Wai Po Chong, Mary Mattapallil, Reiko Yamane <p>Proinflammatory T-helper 17 cells (Th17) play important roles in host immune defense against infection, but uncontrolled activation of these cells, known as the Th17 response, may cause autoimmune and autoinflammatory diseases (uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn&rsquo;s disease) through the effects of Th17 lineage cytokines (such as, IL-17F, IL-22 and GM-CSF). Importantly, IL-17A (a proinflammatory cytokine) represses other Th17 lineage cytokines by upregulating the regulatory cytokine IL-24. Loss of this regulatory pathway due to IL-17A neutralization, and consequent upregulation of the other Th17 cytokines, may result in reduced efficacy of anti-IL-17A therapy. The inventors suggest that targeting the Th17 lineage cytokines as a class, by augmenting IL-24 may be a better approach for controlling the Th17 response than targeting IL-17A alone, which is currently under development by pharmaceutical companies. For instance, the current strategy to suppress Th17 activity [use of Secukinumab (Cosentyx)] has had only limited success in treating some autoimmune diseases, possibly because reducing IL-17A permits upregulation of other Th17-related proinflammatory cytokines through an intermediate step involving reduced IL-24. Researchers at the National Eye Institute (NEI) have developed a new strategy of using IL-24 to target the whole Th17 lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases.&nbsp;</p> <p><img alt="IL-17A represses other Th17 lineage cytokines in an autocrine (and paracrine?) fashion via IL-24" height="291" src="https://nih.technologypublisher.com/files/sites/e-119-2017_il-17a_image1.png" width="389" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Monotherapy of IL-17A targeting alone is insufficient in some diseases</li> <li>May avoid patients&rsquo; exposure to infections that are possible when targeting both IL-23 and IL-12 combination therapy or STAT3 blockade &ndash; as either can be broadly suppressive&nbsp;</li> <li>This approach is designed to bring other members of the Th17 pathway back to normal, rather than massively inhibiting them, while targeting its most proinflammatory member IL-17A; the approach augments the naturally produced regulatory cytokine, IL-24, which becomes deficient due to IL-17 neutralization <ul> <li>Side effects of IL-24 augmentation/normalization are likely to be minimal</li> </ul> </li> <li>Local treatment to augment IL-24 in the eye reduces inflammation and may reduce systemic side effects&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Potential therapeutic drugs for Th17-relevant inflammatory diseases such as uveitis, arthritis, and multiple sclerosis etc.</li> <li>Potential therapeutic drugs for regulating the Th-17 response in various inflammatory conditions&nbsp;</li> </ul> 2018-07-19 2025-04-22 2018-07-19 2025-09-15 2018-07-19 Caspi, Crohn’s disease, IL-24, inflammatory disease, interleukin 24, Multiple sclerosis, National Eye Institute, NEI, proinflammatory T-helper 17 cell, RHEUMATOID ARTHRITIS, Th17, uveitis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163018 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147163020 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147163019 Yamane, Reiko NIH - NEI NEI Yamane, Reiko (NEI) 3 147163021 Chong, Wai Po Sun Yat-sen University Chong, Wai Po 4 147163018 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147163020 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147163019 Yamane, Reiko NIH - NEI NEI Yamane, Reiko (NEI) 3 147163021 Chong, Wai Po Sun Yat-sen University Chong, Wai Po 4 147158027 Interleukin 24 Limits Expression Of Tissue Specific Autoimmune Disease By Controlling Th17 Lineage Cytokines E-119-2017-0 Filing authorized National Eye Institute (NEI), Sun Yat-sen University 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases&body=Please send me information about technology [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases&body=Please send me information about technology [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147161069 E-119-2017-0 E-119-2017-0-US-03 IL-24 TO TREAT INFLAMMATORY DISEASES ORD US 10,512,671 15/957,019 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10512671 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10512671">10,512,671</a><br />Filed on 2018-04-19<br />Status: Issued 147165565 E-119-2017-0 E-119-2017-0-US-01 IL-24 TO TREAT INFLAMMATORY DISEASES PRV US 62/487,223 Abandoned US <br />Provisional (PRV) 62/487,223<br />Filed on 2017-04-19<br />Status: Abandoned 147171836 Caspi 147171838 Crohn’s disease 147171840 IL-24 147171841 inflammatory disease 147171843 interleukin 24 147171844 Multiple sclerosis 147171845 National Eye Institute 147171846 NEI 147171848 proinflammatory T-helper 17 cell 147171849 RHEUMATOID ARTHRITIS 147171850 Th17 147171851 uveitis TAB-3855 147157134 Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases NEI Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Charles Egwuagu, Ren-Wi Wang, Chengrong Yu <p>Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown.  Given that Bregs are a very rare B-cell, identifying factors that promote their development would allow in vivo modulation of Breg levels and ex-vivo production of large amounts of antigen-specific Bregs to use in immunotherapy for auto-inflammatory diseases.<br />  <br /> Researchers at NEI's <a href="https://www.nei.nih.gov/research/research-labs-and-branches/laboratory-retinal-cell-and-molecular-biology" rel="nofollow">Molecular Immunology Section</a> developed a method for the <em>ex-vivo</em> production of Breg. The method of production involves treating isolated primary B-cells or B-cell lines with IL-35 to induce their conversion into IL-10, producing Breg. Using this method, B-regulatory cells can be produced in large quantity and used in a Breg-based therapy against autoimmune diseases including, but not limited to, uveitis and sarcoidosis. <em>In vivo</em> animal data are available.</p> <h2>Competitive Advantages:</h2> <ul><li>There is no known biological or chemical agent that can induce Bregs <em>ex-vivo</em></li> <li>This method produces large quantities of Bregs and can therefore aid in Breg-based therapy</li> <li>Pre-clinical mouse model data available that uses the Bregs to treat experimental autoimmune uveitis (EAU)</li> </ul> <h2>Commercial Applications:</h2> <ul><li><em>In vivo</em> modulation of Breg levels</li> <li>Supplement the low population of Breg in a patient suffering from an autoimmune disease where it is known that B-regulatory cell populations are severely reduced (i.e. uveitis)</li> <li>Use in immunotherapy for the treatment of other autoimmune diseases such as multiple sclerosis, sarcoidosis, colitis, and arthritis.</li> </ul> 2016-02-16 2025-04-22 2020-04-13 2025-09-15 2016-08-29 ARTHRITIS, B-CELL, COLITIS, EYE, Multiple sclerosis, sarcoidosis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162296 Q. Ding et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. http://www.ncbi.nlm.nih.gov/pubmed/21821911 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21821911">Q. Ding et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.</a> 147162410 N. Carter et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. http://www.ncbi.nlm.nih.gov/pubmed/21464089 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21464089">N. Carter et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.</a> 147162627 Egwuagu, Charles NIH - NEI NEI Egwuagu, Charles (NEI) 1 147162629 Wang, Ren-Wi NIH - NEI Wang, Ren-Wi 2 147162628 Yu, Chengrong NIH - NEI NEI Yu, Chengrong (NEI) 3 147162627 Egwuagu, Charles NIH - NEI NEI Egwuagu, Charles (NEI) 1 147162629 Wang, Ren-Wi NIH - NEI Wang, Ren-Wi 2 147162628 Yu, Chengrong NIH - NEI NEI Yu, Chengrong (NEI) 3 147157837 Production Of Regulatory B (Breg) Cells By A Genetically Engineered Heterodimeric Interleukin-35 Cytokine:IL-35-induced Bregs As Immunotherapy For Autoimmune Diseases E-036-2012-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases&body=Please send me information about technology [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases&body=Please send me information about technology [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147160939 E-036-2012-0 E-036-2012-0-US-01 Methods of Producing And Using Regulatory B Cells PRV US 61/637,915 Abandoned US <br />Provisional (PRV) 61/637,915<br />Filed on 2012-04-25<br />Status: Abandoned 147164846 E-036-2012-0 E-036-2012-0-PCT-02 Methods of Producing and Using Regulatory B-Cells PCT Patent Cooperation Treaty PCT/US2013/036175 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/036175<br />Filed on 2013-04-11<br />Status: Expired 147164847 E-036-2012-0 E-036-2012-0-AU-03 Methods of Producing and Using Regulatory B-Cells National Stage Australia 2013252771 2013252771 Issued Australia <br />National Stage 2013252771<br />Filed on 2013-04-11<br />Status: Issued 147164848 E-036-2012-0 E-036-2012-0-CA-04 Methods of Producing and Using Regulatory B-Cells National Stage Canada 2871499 2871499 Issued Canada <br />National Stage 2871499<br />Filed on 2013-04-11<br />Status: Issued 147164849 E-036-2012-0 E-036-2012-0-EP-05 Methods of Producing and Using Regulatory B-Cells National Stage European Patent 2841562 13718448.7 Issued European Patent <br />National Stage 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147164850 E-036-2012-0 E-036-2012-0-JP-06 Methods of Producing and Using Regulatory B-Cells National Stage Japan 6258922 2015-509008 Issued Japan <br />National Stage 2015-509008<br />Filed on 2014-10-24<br />Status: Issued 147164851 E-036-2012-0 E-036-2012-0-US-07 Methods of Producing and Using Regulatory B-Cells National Stage US 9,629,897 14/396,475 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629897 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629897">9,629,897</a><br />Filed on 2014-10-23<br />Status: Issued 147164852 E-036-2012-0 E-036-2012-0-DE-08 Methods of Producing and Using Regulatory B-Cells EP Germany 2841562 13718448.7 Issued Germany <br />European patent (EP) 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147164853 E-036-2012-0 E-036-2012-0-FR-09 Methods of Producing and Using Regulatory B-Cells EP France 2841562 13718448.7 Issued France <br />European patent (EP) 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147164854 E-036-2012-0 E-036-2012-0-GB-10 Methods of Producing and Using Regulatory B-Cells EP United Kingdom 2841562 13718448.7 Issued United Kingdom <br />European patent (EP) 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147169970 ARTHRITIS 147169971 B-CELL 147169972 COLITIS 147169973 EYE 147169974 Multiple sclerosis 147169976 sarcoidosis TAB-3875 147157155 Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration NEI Collaboration, Ear, Nose, & Throat, Immunology, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Immunology Licensing Ophthalmology Therapeutics Rachel Caspi, Mary Mattapallil, Zhijian Wu <p>Interleukin (IL)-34 is a homodimer that is produced mainly by keratinocytes, neuronal cells and regulatory T cells (Tregs). It is believed to play important roles in chronic inflammation and the homeostasis of microglia. Currently, there is no effective treatment for many types of retinal degeneration. An improved treatment of autoimmune uveitis is also needed, as current uveitis treatment primarily uses steroidal anti-inflammation medication, which may produce significant unwanted side effects in long-term use. The inventors at the National Eye Institute (NEI) found that various retinal degeneration and uveitis models in mice with congenital mutations affecting vision have varying degrees of IL-34 deficiency in their intraocular environment. This suggests that IL-34 may be essential in modulating autoimmune uveitis and retinal degeneration. Therefore, Adeno-associated Virus (AAV) AAV8-IL-34-mediated gene therapy or other extended delivery methods of IL-34 protein to the eyes of patients with uveitis or retinal degeneration is a promising strategy for reducing retinal damage caused by ocular inflammation or degeneration and counteracting vision loss. AAV8 is a promising delivery method, as it preferentially infects retinal cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Abrogates the need for chronic steroid use in uveitis, diminishing the risk of side effects from long-term use </li> <li>AAV8 preferentially infects retinal cells; therefore, it could be a good choice for IL-34 gene therapy of uveitis for improved efficacy </li> <li>Potential platform approach to the more than 200 inherited retinal dystrophies (IRDs) associated with progressive retinal degeneration. </li> <li>A regulatory path to approval now exists: the first FDA-approved gene therapy, voretigene neparvovec (Luxturna; Spark Therapeutics) was already approved by FDA and the European Medicines Agency (EMA) in November 2018. </li> <li>IRDs are strong candidates for gene therapy when causative mutations have been identified and, to some degree, the eye is an immune-privileged space. </li> <li>In clinical trials, no significant immune reactivity or systemic adverse events have been associated with the AAV as gene delivery vehicle.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>New therapeutic approach for uveitis and retinal degenerative diseases.</li> </ul> 2019-06-28 2025-04-22 2019-06-28 2025-09-15 2019-06-28 AAV Vector, Caspi, GENE THERAPY, IL-34, inflammatory disease, Inherited Retinal Dystrophies, Interleukin 34, National Eye Institute, NEI, NEURODEGENERATION, Photoreceptor Death, Retinal degeneration, Retinal Inflammation, uveitis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-06-28 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 162585908 per emails with M. Baxter. per emails with M. Baxter. 147162695 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147162696 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147162697 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 3 147162695 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147162696 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147162697 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 3 147157966 AAV8 Mediated Intra-Ocular Delivery Of Interleukin-34 For Treating Inflammation Of Neural Retina E-091-2018-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration&body=Please send me information about technology [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration&body=Please send me information about technology [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147164963 E-091-2018-0 E-091-2018-0-US-01 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION PRV US 62/637,592 Abandoned US <br />Provisional (PRV) 62/637,592<br />Filed on 2018-03-02<br />Status: Abandoned 147164964 E-091-2018-0 E-091-2018-0-PCT-02 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION PCT Patent Cooperation Treaty PCT/US2019/020341 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/020341<br />Filed on 2019-03-01<br />Status: Expired 147164965 E-091-2018-0 E-091-2018-0-CA-03 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage Canada 3091810 Pending Canada <br />National Stage 3091810<br />Filed on 2019-03-01<br />Status: Pending 147164966 E-091-2018-0 E-091-2018-0-EP-04 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage European Patent 3758736 19711759.1 Issued European Patent <br />National Stage 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 147164967 E-091-2018-0 E-091-2018-0-JP-05 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage Japan 7356994 2020-545170 Issued Japan <br />National Stage 2020-545170<br />Filed on 2019-03-01<br />Status: Issued 147164968 E-091-2018-0 E-091-2018-0-US-06 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage US 16/971,288 Pending US <br />National Stage 16/971,288<br />Filed on 2020-08-19<br />Status: Pending 164119432 E-091-2018-0 E-091-2018-0-FR-07 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION EP France 3758736 19711759.1 Issued France <br />European patent (EP) 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 164119433 E-091-2018-0 E-091-2018-0-DE-08 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION EP Germany 3758736 19711759.1 Issued Germany <br />European patent (EP) 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 164119434 E-091-2018-0 E-091-2018-0-GB-09 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION EP United Kingdom 3758736 19711759.1 Issued United Kingdom <br />European patent (EP) 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 147171185 AAV Vector 147171187 Caspi 147171188 GENE THERAPY 147171190 IL-34 147171191 inflammatory disease 147171193 Inherited Retinal Dystrophies 147171195 Interleukin 34 147171196 National Eye Institute 147171197 NEI 147171198 NEURODEGENERATION 147171200 Photoreceptor Death 147171201 Retinal degeneration 147171203 Retinal Inflammation 147171204 uveitis TAB-3911 147157191 Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Research Materials Collaboration Ear Nose & Throat Licensing Ophthalmology Research Materials Kapil Bharti, Kapil Bharti, Janine Davis, Marc Ferrer-Alegre, Arvydas Maminishkis, Sheldon Miller <p>The retinal pigment epithelial cells (RPE) make up a polarized monolayer in the vertebrate eye that separates the neural retina from the choroid, and performs a crucial role in retinal physiology by forming a blood-retinal barrier and closely interacting with photoreceptors to maintain visual function.  Many ophthalmic diseases, such as age-related macular degeneration, are associated with a degeneration or deterioration of the RPE. </p> <p>Researchers at NEI have developed high efficiency methods for producing retinal pigment epithelial cells (RPE) from induced pluripotent stem cells (iPSCs).  The iPSCs are produced from somatic cells, including retinal pigment epithelial cells, such as fetal RPE.  These methods involve producing embryoid bodies from human iPSCs, culturing the embryoid bodies using specific media to induce differentiation into RPE and growing the differentiated RPE cells in a defined media to generate human RPE cells.  The investigators also developed methods for detecting RPE cells and authenticating RPE cells; determining agents that can affect the production of RPE cells from an iPSC; and identifying an agent that can increase RPE survival in response to a proteo toxic insult or stress.  These novel methods and RPE cells can be useful for both pre-clinical and clinical studies involving RPE.</p> <h2>Competitive Advantages:</h2> <ul><li>These methods dramatically increase the efficiency of iPSC differentiation into RPE and produce superior quality RPE</li> <li>The RPE cells produced using these methods are fully authenticated</li> <li>These novel methods provide ways to perform high throughput screens with RPE cells</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Production of RPE cells for use in screening for novel ocular therapeutics and for identifying toxic side effects of drugs</li> <li>The RPE cells produced with these methods could be used in novel cell-based therapies</li> <li>In a research setting, these cells could be used to study the pathophysiology of RPE</li> </ul> 2016-02-16 2025-04-22 2018-07-19 2025-09-15 2016-08-31 Age-related Macular Degeneration, AMD, DIFFERENTIATION, retinal pigment epithelial cells, STEM CELLS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162832 Bharti, Kapil NIH - NINDS NEI Bharti, Kapil (NEI) 0 147162834 Bharti, Kapil NIH - NINDS NINDS Bharti, Kapil (NINDS) 1 147162831 Davis, Janine NIH - NEI NEI Davis, Janine (NEI) 2 147162829 Miller, Sheldon NIH - NEI NEI Miller, Sheldon (NEI) 3 147162830 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147162833 Ferrer-Alegre, Marc NIH - NCATS NCATS Ferrer-Alegre, Marc (NCATS) 5 147162834 Bharti, Kapil NIH - NINDS NINDS Bharti, Kapil (NINDS) 1 147162832 Bharti, Kapil NIH - NINDS NEI Bharti, Kapil (NEI) 0 147162831 Davis, Janine NIH - NEI NEI Davis, Janine (NEI) 2 147162829 Miller, Sheldon NIH - NEI NEI Miller, Sheldon (NEI) 3 147162830 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147162833 Ferrer-Alegre, Marc NIH - NCATS NCATS Ferrer-Alegre, Marc (NCATS) 5 147158275 Methods For Authenticating Fully-differentiated And Functional RPE Cells From IPS Cells E-251-2012-0 Filing authorized National Eye Institute (NEI), NCATS - NCGC, NCATS - NCGC, NINDS 147162579 Methods Of Performing High Throughput And Multiplex Screenings With IPS Cell Derived RPE E-251-2012-1 Filing authorized NCATS - NCGC, NINDS 147162580 Use Of Fetal Human RPE Derived IPS Cells For Generating Authentic RPE Cells With High Efficiency E-251-2012-2 Filing authorized National Eye Institute (NEI) 147162581 GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) E-251-2012-3 Filing authorized National Eye Institute (NEI), NINDS 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells&body=Please send me information about technology [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells&body=Please send me information about technology [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147165192 E-251-2012-3 E-251-2012-3-US-01 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM (IPS) CELLS PRV US 61/759,988 Abandoned US <br />Provisional (PRV) 61/759,988<br />Filed on 2013-02-01<br />Status: Abandoned 147165193 E-251-2012-3 E-251-2012-3-PCT-02 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) PCT Patent Cooperation Treaty PCT/US2014/014160 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/014160<br />Filed on 2014-01-31<br />Status: Expired 147165194 E-251-2012-3 E-251-2012-3-US-03 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage US 14/764,959 Abandoned US <br />National Stage 14/764,959<br />Filed on 2015-07-30<br />Status: Abandoned 147165195 E-251-2012-3 E-251-2012-3-EP-04 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage European Patent 2951290 14705645.1 Issued European Patent <br />National Stage 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165196 E-251-2012-3 E-251-2012-3-CA-05 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage Canada 2899865 2899865 Issued Canada <br />National Stage 2899865<br />Filed on 2014-01-31<br />Status: Issued 147165197 E-251-2012-3 E-251-2012-3-AU-06 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage Australia 2014212230 2014212230 Issued Australia <br />National Stage 2014212230<br />Filed on 2014-01-31<br />Status: Issued 147165198 E-251-2012-3 E-251-2012-3-JP-07 Method For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage Japan 6426110 2015-556170 Issued Japan <br />National Stage 2015-556170<br />Filed on 2014-01-31<br />Status: Issued 147165199 E-251-2012-3 E-251-2012-3-DK-08 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Denmark 2951290 14705645.1 Issued Denmark <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165200 E-251-2012-3 E-251-2012-3-FI-09 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Finland 2951290 14705645.1 Issued Finland <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165201 E-251-2012-3 E-251-2012-3-FR-10 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP France 2951290 14705645.1 Issued France <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165202 E-251-2012-3 E-251-2012-3-DE-11 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Germany 2951290 14705645.1 Issued Germany <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165203 E-251-2012-3 E-251-2012-3-IE-12 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Ireland 2951290 14705645.1 Issued Ireland <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165204 E-251-2012-3 E-251-2012-3-NL-13 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP The Netherlands 2951290 14705645.1 Issued The Netherlands <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165205 E-251-2012-3 E-251-2012-3-GB-14 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP United Kingdom 2951290 14705645.1 Issued United Kingdom <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165206 E-251-2012-3 E-251-2012-3-EP-15 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) DIV European Patent 17197785.3 Abandoned European Patent <br />Divisional (DIV) 17197785.3<br />Filed on 2014-01-31<br />Status: Abandoned 147165207 E-251-2012-3 E-251-2012-3-US-16 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) CON US 10,480,031 15/969,686 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10480031 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10480031">10,480,031</a><br />Filed on 2018-05-02<br />Status: Issued 147165208 E-251-2012-3 E-251-2012-3-JP-17 Method For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) DIV Japan 2018-200003 Abandoned Japan <br />Divisional (DIV) 2018-200003<br />Filed on 2014-01-31<br />Status: Abandoned 147165209 E-251-2012-3 E-251-2012-3-US-18 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) DIV US 11,441,184 16/586,656 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11441184 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11441184">11,441,184</a><br />Filed on 2019-09-27<br />Status: Issued 147165210 E-251-2012-3 E-251-2012-3-AU-19 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) DIV Australia 2019236596 Abandoned Australia <br />Divisional (DIV) 2019236596<br />Filed on 2019-09-23<br />Status: Abandoned 147165211 E-251-2012-3 E-251-2012-3-US-20 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) DIV US 17/812,915 Pending US <br />Divisional (DIV) 17/812,915<br />Filed on 2022-07-15<br />Status: Pending 147174272 Age-related Macular Degeneration 147174273 AMD 147174274 DIFFERENTIATION 147174276 retinal pigment epithelial cells 147174277 STEM CELLS TAB-3951 147157231 Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Wenxin Ma, Xu Wang, Wai Wong, Lian Zhao <p>Retinal degeneration is a deteriorative condition of the human retina caused by the progressive and eventual death of photoreceptor cells. To date, no effective treatment for genetically inherited or age-associated retinal degeneration, which includes a large patient population worldwide, is available. Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more SERMs compounds, which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation. Commercial entities who are interested in developing new drugs for ocular disorders are being actively sought for co-developing this technology as collaborative partners or licensing it for commercialization.</p> <h2>Competitive Advantages:</h2> <ul><li>There is currently no treatment for the “dry” form (geographic atrophy form) of AMD, in which the degeneration of photoreceptors results in vision loss <ul><li>Chemical drugs, with a well-characterized safety profile (like SERMs), that can neuroprotect photoreceptors, may be an effective therapy for those types of AMD</li> </ul></li> <li>There is currently no treatment for RP. Although gene therapy of RP is under active commercial development, this may not be broadly applicable to RP patients with diverse genetic causes for their condition <ul><li>Microglial contribution to degeneration is shared in multiple genetic causes of RP, and the inhibition of this contribution (likely by SERMs) may be suitable to a broad spectrum of affected patients</li> <li>Chemical compounds, like SERMs may be more advantageous than RP gene therapy in many aspects such as safety and administration</li> </ul></li> </ul> <h2>Commercial Applications:</h2> <ul><li>Potential therapeutic drug(s) for retinal degenerative diseases such as RP, AMD etc.</li> <li>Potential therapeutic drug(s) for treating retinal degenerative conditions featuring photoreceptor death</li> </ul> 2017-06-22 2025-05-15 2020-04-13 2025-09-15 2017-06-22 Age-Related Degeneration, AMD, Estrogen-receptor, Microglial Inhibition, National Eye Institute, NEI, Photoreceptor, Retinal degeneration, Retinitis Pigmentosa, RP False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161961 Wang X, et al. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration. https://www.ncbi.nlm.nih.gov/pubmed/28235894 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28235894">Wang X, et al. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration.</a> 147162348 Brookshire B. Researchers stumble onto a new role for breast cancer drug. https://www.sciencenews.org/article/researchers-stumble-new-role-breast-cancer-drug <a href="https://www.sciencenews.org/article/researchers-stumble-new-role-breast-cancer-drug">Brookshire B. Researchers stumble onto a new role for breast cancer drug.</a> 147162993 Wong, Wai NIH - NEI NEI Wong, Wai (NEI) 1 147162994 Zhao, Lian NIH - NEI NEI Zhao, Lian (NEI) 2 147162995 Wang, Xu NIH - NEI Wang, Xu 3 147162996 Ma, Wenxin NIH - NEI NEI Ma, Wenxin (NEI) 4 147162993 Wong, Wai NIH - NEI NEI Wong, Wai (NEI) 1 147162994 Zhao, Lian NIH - NEI NEI Zhao, Lian (NEI) 2 147162995 Wang, Xu NIH - NEI Wang, Xu 3 147162996 Ma, Wenxin NIH - NEI NEI Ma, Wenxin (NEI) 4 147158055 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration E-134-2016-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration&body=Please send me information about technology [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration&body=Please send me information about technology [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161089 E-134-2016-0 E-134-2016-0-US-01 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration PRV US 62/377,439 Abandoned US <br />Provisional (PRV) 62/377,439<br />Filed on 2016-08-19<br />Status: Abandoned 147165512 E-134-2016-0 E-134-2016-0-PCT-02 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration PCT Patent Cooperation Treaty PCT/US2017/046359 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/046359<br />Filed on 2017-08-10<br />Status: Expired 147165513 E-134-2016-0 E-134-2016-0-AU-03 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage Australia 2017312499 2017312499 Issued Australia <br />National Stage 2017312499<br />Filed on 2019-01-16<br />Status: Issued 147165514 E-134-2016-0 E-134-2016-0-CA-04 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage Canada 3032153 3032153 Issued Canada <br />National Stage 3032153<br />Filed on 2017-08-10<br />Status: Issued 147165515 E-134-2016-0 E-134-2016-0-EP-05 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage European Patent 3484463 17757972.9 Issued European Patent <br />National Stage 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165516 E-134-2016-0 E-134-2016-0-JP-06 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage Japan 7100019 2019-508935 Issued Japan <br />National Stage 2019-508935<br />Filed on 2017-08-10<br />Status: Issued 147165517 E-134-2016-0 E-134-2016-0-US-07 SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION National Stage US 11,040,019 16/325,678 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11040019 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11040019">11,040,019</a><br />Filed on 2019-02-14<br />Status: Issued 147165518 E-134-2016-0 E-134-2016-0-CH-08 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP Switzerland 3484463 17757972.9 Issued Switzerland <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165519 E-134-2016-0 E-134-2016-0-DE-09 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP Germany 3484463 17757972.9 Issued Germany <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165520 E-134-2016-0 E-134-2016-0-FR-10 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP France 3484463 17757972.9 Issued France <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165521 E-134-2016-0 E-134-2016-0-GB-11 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP United Kingdom 3484463 17757972.9 Issued United Kingdom <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147172137 Age-Related Degeneration 147172138 AMD 147172139 Estrogen-receptor 147172141 Microglial Inhibition 147172142 National Eye Institute 147172143 NEI 147172144 Photoreceptor 147172145 Retinal degeneration 147172146 Retinitis Pigmentosa 147172147 RP TAB-3958 147157238 Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics David Adams, Brian Brooks, William Gahl <p>Albinism (also called achromia, achromasia, or achromatosis) is a congenital disorder characterized by the complete or partial absence of pigment in the skin, hair and eyes due to absence or defect in any one of a number of proteins involved in the production of melanin.  Certain forms of albinism are known to be due to mutations in tyrosine metabolism.  In oculocutaneous albinism (OCA), pigment is lacking in the eyes, skin and hair.  In ocular albinism, only the eyes lack pigment.  Patients with albinism experience varying degrees of vision loss associated with foveal hypoplasia, nystagmus, photophobia and/or glare sensitivity, refractive errors, and abnormal decussation of ganglion cell axons at the optic chiasm.  Current treatment options for vision problems caused by albinism are limited to correction of refractive errors and amblyopia, low vision aids, and (in some cases) extraocular muscle surgery.</p> <p> Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1.  The drug blocks the normal degradation pathway of tyrosine thus allowing greater circulating plasma levels of tyrosine.  NEI investigators identified administration of NTBC to subjects (e.g., mice or humans) with certain forms of albinism, can result in increased circulating tyrosine levels, an increase in tyrosinase activity, and, subsequently, increased pigmentation. Co-development research agreements with companies are sought to advance this treatment to humans.</p> <h2>Competitive Advantages:</h2> <ul><li>Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1</li> </ul> 2016-02-16 2025-05-15 2021-06-08 2025-09-15 2017-08-30 achromasia, achromatosis, achromia, Albinism, Nitisinone, Ocular disorders, pigmentation False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-08 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162114 Adams DR et al. One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B. JCI Insight. 2019 Jan 24;4(2):e124387. doi: 10.1172/jci.insight.124387. Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/30674731/ <a href="https://pubmed.ncbi.nlm.nih.gov/30674731/">Adams DR et al. One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B. JCI Insight. 2019 Jan 24;4(2):e124387. doi: 10.1172/jci.insight.124387. Epub ahead of print.</a> 147162461 Brooks, B.P. Nitisinone for Type 1B Oculocutaneous Albinism. ClinicalTrials.gov Identifier: NCT01838655 Brooks, B.P. Nitisinone for Type 1B Oculocutaneous Albinism. ClinicalTrials.gov Identifier: NCT01838655 147163016 Brooks, Brian NIH - NEI NEI Brooks, Brian (NEI) 1 147163015 Gahl, William NIH - NHGRI NHGRI Gahl, William (NHGRI) 2 147163017 Adams, David NIH - NHGRI NHGRI Adams, David (NHGRI) 3 147163016 Brooks, Brian NIH - NEI NEI Brooks, Brian (NEI) 1 147163015 Gahl, William NIH - NHGRI NHGRI Gahl, William (NHGRI) 2 147163017 Adams, David NIH - NHGRI NHGRI Adams, David (NHGRI) 3 147158011 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Cosmetic Tanning E-113-2010-0 Filing authorized National Eye Institute (NEI), National Human Genome Research Institute (NHGRI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation&body=Please send me information about technology [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation&body=Please send me information about technology [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147165550 E-113-2010-0 E-113-2010-0-US-01 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Cosmetic Tanning PRV US 61/308,771 Abandoned US <br />Provisional (PRV) 61/308,771<br />Filed on 2010-02-26<br />Status: Abandoned 147165551 E-113-2010-0 E-113-2010-0-PCT-02 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation PCT Patent Cooperation Treaty PCT/US2011/026260 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/026260<br />Filed on 2011-02-25<br />Status: Expired 147165552 E-113-2010-0 E-113-2010-0-AU-03 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation National Stage Australia 2011220475 2011220475 Issued Australia <br />National Stage 2011220475<br />Filed on 2011-02-25<br />Status: Issued 147165553 E-113-2010-0 E-113-2010-0-CA-04 Nitisinone For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation National Stage Canada 2791245 2791245 Issued Canada <br />National Stage 2791245<br />Filed on 2016-02-23<br />Status: Issued 147165554 E-113-2010-0 E-113-2010-0-EP-05 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation National Stage European Patent 2538936 11706137.4 Issued European Patent <br />National Stage 11706137.4<br />Filed on 2011-02-25<br />Status: Issued 147165555 E-113-2010-0 E-113-2010-0-US-06 Nitisinone For Treatment Of Oculocutaneious/Ocular Albinism And For Increasing Pigmentation National Stage US 8,822,540 13/580,452 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822540 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822540">8,822,540</a><br />Filed on 2012-09-06<br />Status: Issued 147165556 E-113-2010-0 E-113-2010-0-US-07 Nitisinone For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation CON US 9,364,448 14/471,142 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9364448 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9364448">9,364,448</a><br />Filed on 2014-08-28<br />Status: Issued 147165557 E-113-2010-0 E-113-2010-0-CH-08 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Switzerland 2538936 11706137.4 Issued Switzerland <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165558 E-113-2010-0 E-113-2010-0-DE-09 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Germany 2538936 11706137.4 Issued Germany <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165559 E-113-2010-0 E-113-2010-0-ES-10 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Spain 2538936 11706137.4 Issued Spain <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165560 E-113-2010-0 E-113-2010-0-FR-11 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP France 2538936 11706137.4 Issued France <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165561 E-113-2010-0 E-113-2010-0-GB-12 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP United Kingdom 2538936 11706137.4 Issued United Kingdom <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165562 E-113-2010-0 E-113-2010-0-IT-13 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Italy 2538936 11706137.4 Issued Italy <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165563 E-113-2010-0 E-113-2010-0-SE-14 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Sweden 2538936 11706137.4 Issued Sweden <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147171657 achromasia 147171659 achromatosis 147171661 achromia 147171662 Albinism 147171663 Nitisinone 147171665 Ocular disorders 147171666 pigmentation TAB-3983 147157264 Metformin for the Treatment of Age-related Retinal Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Karla Barbosa-Sabenero, Kapil Bharti, Justin Chang, Katharina Clore-Gronenborn, Balendu Jha, Kiyoharu Miyagishima, Fnu Ruchi <p>Retinal Degenerations (RD) are the leading cause of blindness in the United States. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt’s disease, retinitis pigmentosa, choroideremia, Late-Onset Retinal Degeneration (L-ORD), and Age-related Macular Degeneration (AMD). The RPE as a layer of cells in the back of the eye. Therefore, it is essential to maintain the health and integrity of retinal photoreceptors. RPE dysfunction and degeneration leads to photoreceptor cell death and vision loss, a common factor among several forms of RD.</p> <p>To resolve these challenges, researchers at the National Eye Institute (NEI) generated iPS cells from two L-ORD patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. They then differentiated all iPS cells into authenticated RPE cells. A comparative analysis of RPE differentiated from these iPS cells showed sub-RPE deposits and increased VEGF secretion; two of the shared characteristics of different RDs including AMD. Interestingly, the baseline activity of AMP-protein Kinase (AMPK) – a nutrient and energy sensor that maintains energy homeostasis – was changed: in L-ORD patient-derived RPE cells, the lowered baseline intracellular calcium would likely affect lysosomal function. Thus, the reduced AMPK activity leads to lower autophagy in L-ORD patient RPE cells. Researchers at the NEI have shown that: (i) native CTRP5 activates AMPK; and (ii) Metformin, as an FDA-approved drug currently used for the treatment of diabetes, activates AMPK, reduce VEGF secretion, and corrects baseline calcium levels in patient RPE cells.</p> <p>The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration. </p> <h2>Competitive Advantages:</h2> <ul><li>Metformin provides an upstream therapy that rescues metabolic dysfunction and decline associated with aging, thereby potentially delaying the onset of retinal disease</li> <li>L-ORD patient RPE cells demonstrate reduced AMPK activity (leading to lower autophagy), increased VEGF secretion, and unbalanced calcium levels. Metformin might be able to correct/prevent vision loss of L-ORD patients (and possibly others with retinal degenerations) through its activation of AMPK, reduction of VEGF secretion, and correction of baseline calcium levels (as demonstrated in L-ORD patient RPE cells) </li> </ul> <h2>Commercial Applications:</h2> <p>Treatment for retinal diseases:</p> <ul><li>Age-related Macular Degeneration (AMD)</li> <li>Late-onset retinal degeneration (L-ORD)</li> <li>Stargardt’s disease</li> <li>Retinitis pigmentosa</li> <li>Choroideremia</li> </ul> 2019-05-15 2025-04-22 2019-05-15 2025-09-15 2019-05-15 Age-related Macular Degeneration, AMD, Bharti, choroideremia, iPS cells, Late-Onset Retinal Degeneration, L-ORD, Metformin, RD, Retinal degeneration, Retinal Pigment Epithelium, Retinitis Pigmentosa, RPE, Stargardt’s disease False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-05-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-094-2016 E-192-2014 E-212-2015 E-251-2012 E-293-2016 147163115 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163116 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 2 147163118 Ruchi, Fnu NIH - NEI NEI Ruchi, Fnu (NEI) 2 147163119 Chang, Justin NIH - NEI NEI Chang, Justin (NEI) 2 147163117 Clore-Gronenborn, Katharina NIH - NEI Clore-Gronenborn, Katharina 3 147163120 Jha, Balendu NIH - NEI NEI Jha, Balendu (NEI) 3 147163121 Barbosa-Sabenero, Karla NIH - NEI NEI Barbosa-Sabenero, Karla (NEI) 3 147163115 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163116 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 2 147163118 Ruchi, Fnu NIH - NEI NEI Ruchi, Fnu (NEI) 2 147163119 Chang, Justin NIH - NEI NEI Chang, Justin (NEI) 2 147163117 Clore-Gronenborn, Katharina NIH - NEI Clore-Gronenborn, Katharina 3 147163120 Jha, Balendu NIH - NEI NEI Jha, Balendu (NEI) 3 147163121 Barbosa-Sabenero, Karla NIH - NEI NEI Barbosa-Sabenero, Karla (NEI) 3 147158239 Metformin For The Treatment Of Age-related Retinal Degeneration E-227-2018-0 Filing authorized Clinical Center (CC), National Eye Institute (NEI), NIH - NEI 147162569 L-745,870, Riluzole, Acadesine (INN), And Aminocaproic Acid For The Treatment Of Agerelated, Inherited Retinal Degenerations, And Proliferative Vitreoretinopathy E-227-2018-1 Filing authorized National Eye Institute (NEI), NIH - NEI 147162570 Therapeutics To Maintain Retinal Pigment Epithelium (RPE) Healthy Phenotype In RPE-associated Disorders E-227-2018-2 Filing authorized National Eye Institute (NEI), NIH - NEI 147162571 NOX4 - A Druggable Target To Treat Retinal Degeneration And Metastatice Cancers E-227-2018-3 Filing authorized National Eye Institute (NEI), NIH - NEI 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration&body=Please send me information about technology [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration&body=Please send me information about technology [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147165707 E-227-2018-0 E-227-2018-0-US-01 Metformin For The Treatment Of Age-related Retinal Degeneration PRV US 62/899,899 Abandoned US <br />Provisional (PRV) 62/899,899<br />Filed on 2019-09-13<br />Status: Abandoned 147165708 E-227-2018-0 E-227-2018-0-PCT-02 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION PCT Patent Cooperation Treaty PCT/US2020/050540 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/050540<br />Filed on 2020-09-11<br />Status: Expired 147165709 E-227-2018-0 E-227-2018-0-AU-03 Druggable Target to Treat Retinal Degeneration National Stage Australia 2020346064 Pending Australia <br />National Stage 2020346064<br />Filed on 2022-03-24<br />Status: Pending 147165710 E-227-2018-0 E-227-2018-0-BR-04 Druggable Taraget to Treat Retinal Degeneration National Stage Brazil BR112022004515-8 Pending Brazil <br />National Stage BR112022004515-8<br />Filed on 2022-03-11<br />Status: Pending 147165711 E-227-2018-0 E-227-2018-0-CA-05 Druggable Taraget to Treat Retinal Degeneration National Stage Canada 3151011 Pending Canada <br />National Stage 3151011<br />Filed on 2022-03-11<br />Status: Pending 147165712 E-227-2018-0 E-227-2018-0-CN-06 Druggable Taraget to Treat Retinal Degeneration National Stage China 202080075532.5 Pending China <br />National Stage 202080075532.5<br />Filed on 2022-04-27<br />Status: Pending 147165713 E-227-2018-0 E-227-2018-0-EP-07 Druggable Taraget to Treat Retinal Degeneration National Stage European Patent 20780525.0 Pending European Patent <br />National Stage 20780525.0<br />Filed on 2022-03-31<br />Status: Pending 147165714 E-227-2018-0 E-227-2018-0-ID-08 Druggable Taraget to Treat Retinal Degeneration National Stage Indonesia P-00202204386 Pending Indonesia <br />National Stage P-00202204386<br />Filed on 2022-04-13<br />Status: Pending 147165715 E-227-2018-0 E-227-2018-0-IN-09 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION National Stage India 202247021119 Pending India <br />National Stage 202247021119<br />Filed on 2022-04-08<br />Status: Pending 147165716 E-227-2018-0 E-227-2018-0-JP-10 Druggable Taraget to Treat Retinal Degeneration National Stage Japan 2022-516237 Pending Japan <br />National Stage 2022-516237<br />Filed on 2022-03-11<br />Status: Pending 147165717 E-227-2018-0 E-227-2018-0-KR-11 Druggable Taraget to Treat Retinal Degeneration National Stage South Korea 10-2022-7012050 Pending South Korea <br />National Stage 10-2022-7012050<br />Filed on 2022-04-12<br />Status: Pending 147165718 E-227-2018-0 E-227-2018-0-MX-12 Druggable Taraget to Treat Retinal Degeneration National Stage Mexico MX/a/2022/003027 Pending Mexico <br />National Stage MX/a/2022/003027<br />Filed on 2022-03-11<br />Status: Pending 147165719 E-227-2018-0 E-227-2018-0-US-13 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION National Stage US 17/642,610 Pending US <br />National Stage 17/642,610<br />Filed on 2022-03-11<br />Status: Pending 147165720 E-227-2018-0 E-227-2018-0-ZA-14 Druggable Target to Treat Retinal Degeneration National Stage South Africa 2022/03100 Pending South Africa <br />National Stage 2022/03100<br />Filed on 2022-03-15<br />Status: Pending 147173963 Age-related Macular Degeneration 147173964 AMD 147173965 Bharti 147173967 choroideremia 147173968 iPS cells 147173970 Late-Onset Retinal Degeneration 147173972 L-ORD 147173973 Metformin 147173975 RD 147173976 Retinal degeneration 147173978 Retinal Pigment Epithelium 147173979 Retinitis Pigmentosa 147173980 RPE 147173982 Stargardt’s disease TAB-3997 147157278 Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Kapil Bharti <p>The retinal pigment epithelium (RPE) is a cell monolayer with specialized functions crucial to maintaining the metabolic environment and chemistry of the sub-retinal and choroidal layers in the eye. Damage or disease causing RPE cell loss leads to progressive photoreceptor damage and impaired vision. Loss of RPE is observed in many of the most prevalent cases of vision loss, including age related macular degeneration (AMD) and Best disease. Retinal degenerative diseases linked to loss of RPE result in a substantial economic, social, and healthcare burden for individuals and governments worldwide.</p> <p>Currently, no Food and Drug Administration (FDA) approved treatments exist for AMD. Importantly, AMD vision loss is linked to RPE cell atrophy; thus, transplant and replacement of the lost RPE with healthy and functional RPE cells might be a treatment for AMD and other retina diseases. Healthy functional RPE can be grown/differentiated from induced pluripotent stem cells. A graft of such RPE cells may potentially be implanted into the eye of AMD patients to restore vision or prevent vision loss.  However, methods for producing RPE cells for human therapy must be consistent, scalable and reliable. Generation and differentiation of clinical grade RPE under good laboratory practice (GLP) and good manufacturing practices (GMP) is critical for generating cells suitable for regulatory approval studies and for development of RPE cells for transplantation therapies. </p> <p>Researchers at the National Eye Institute (NEI),  and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) have developed a novel invention that includes a procedure/method to consistently produce clinical grade RPE cells from human induced pluripotent stem cells (iPSC). The RPE cells produced may be used for advancing transplantation therapy for AMD and other retinal degenerative diseases associated with the loss of RPE. </p> <h2>Competitive Advantages:</h2> <ul><li>Clinical-grade process </li> <li>RPE cells for therapeutics or modeling</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Producing RPE cells for commercial or research purposes</li> </ul> 2018-08-14 2025-04-22 2018-08-14 2025-09-15 2018-08-14 Age Related Macular Degeneration, AMD, Best Disease, Bharti, Human Induced Pluripotent Stem Cells, Human Retinal Pigment Epithelial Cells, IPSCS, National Eye Institute, National Institute of Arthritis and Muscoskeletal and Skin D, NEI, NIAMS, Photoreceptor, Retinal Degenerative Diseases, RPE, STEM CELLS, Vision Loss False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162281 Miyagishimaa K, et al. In Pursuit of Authenticity: iPS Cell-derived RPE for Clinical Applications. https://www.ncbi.nlm.nih.gov/pubmed/27400791 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27400791">Miyagishimaa K, et al. In Pursuit of Authenticity: iPS Cell-derived RPE for Clinical Applications.</a> 147162434 Miyagishimaa K, et al. A basis for comparison: sensitive authentication of stem cell derived RPE using physiological responses of intact RPE monolayers. https://www.ncbi.nlm.nih.gov/pubmed/28286868 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28286868">Miyagishimaa K, et al. A basis for comparison: sensitive authentication of stem cell derived RPE using physiological responses of intact RPE monolayers.</a> 147163164 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163164 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147158218 An Efficient, Reproducible, And GMP-compatible And Commercially Scalable Stem Cell To RPE Differentiation Protocol E-212-2015-0 Filing authorized FUJIFILM Cellular Dynamics, Inc., National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells&body=Please send me information about technology [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells&body=Please send me information about technology [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161198 E-212-2015-0 E-212-2015-0-US-01 Method for Reproducible Differentiation of Clinical-Grade Retinal Pigment Epithelium Cells PRV US 62/215,579 Abandoned US <br />Provisional (PRV) 62/215,579<br />Filed on 2015-09-08<br />Status: Abandoned 147165790 E-212-2015-0 E-212-2015-0-PCT-02 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS PCT Patent Cooperation Treaty PCT/US2016/050543 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/050543<br />Filed on 2016-09-07<br />Status: Expired 147165791 E-212-2015-0 E-212-2015-0-AU-03 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage Australia 2016321170 2016321170 Issued Australia <br />National Stage 2016321170<br />Filed on 2018-03-21<br />Status: Issued 147165792 E-212-2015-0 E-212-2015-0-CA-04 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage Canada 2997952 Pending Canada <br />National Stage 2997952<br />Filed on 2016-09-07<br />Status: Pending 147165793 E-212-2015-0 E-212-2015-0-EP-05 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage European Patent 3347456 16766444.0 Issued European Patent <br />National Stage 16766444.0<br />Filed on 2016-09-07<br />Status: Issued 147165794 E-212-2015-0 E-212-2015-0-JP-06 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage Japan 6983762 2018-512373 Issued Japan <br />National Stage 2018-512373<br />Filed on 2018-03-07<br />Status: Issued 147165795 E-212-2015-0 E-212-2015-0-US-07 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage US 15/758,314 Abandoned US <br />National Stage 15/758,314<br />Filed on 2018-03-07<br />Status: Abandoned 147165796 E-212-2015-0 E-212-2015-0-US-08 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS CON US 12,065,671 16/931,003 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12065671 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12065671">12,065,671</a><br />Filed on 2020-07-16<br />Status: Issued 147165797 E-212-2015-0 E-212-2015-0-JP-09 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS DIV Japan 2021-128087 Pending Japan <br />Divisional (DIV) 2021-128087<br />Filed on 2021-08-04<br />Status: Pending 164119154 E-212-2015-0 E-212-2015-0-US-02 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS CON US 18/769,320 Pending US <br />Continuation (CON) 18/769,320<br />Filed on 2024-07-10<br />Status: Pending 147173756 Age Related Macular Degeneration 147173757 AMD 147173759 Best Disease 147173760 Bharti 147173762 Human Induced Pluripotent Stem Cells 147173764 Human Retinal Pigment Epithelial Cells 147173765 IPSCS 147173766 National Eye Institute 147173768 National Institute of Arthritis and Muscoskeletal and Skin D 147173769 NEI 147173770 NIAMS 147173771 Photoreceptor 147173773 Retinal Degenerative Diseases 147173774 RPE 147173775 STEM CELLS 147173776 Vision Loss TAB-4014 147157295 Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics NEI Cardiology, Collaboration, Dermatology, Licensing, Oncology, Software / Apps Cardiology Collaboration Dermatology Licensing Oncology Software / Apps Kapil Bharti, Nathan Hotaling, Nicholas Schaub, Carl Simon <p>Many biological and clinical procedures require functional validation of a desired cell type. Current techniques to validate rely on various assays and methods, such as staining with dyes, antibodies, and nucleic acid probes, to assess stem cell health, death, proliferation, and functionality. These techniques potentially destroy stem cells and risk contaminating cells and cultures by exposing them to the environment; they are low-throughput and difficult to scale-up. Therefore, there is a significant need for potentially less invasive, scalable, higher throughput methods of validation, while maintaining quality and accuracy.</p> <p>Trained biologists can often recognize cells and phenotypic cell function based on cell appearance under a microscope. Applying machine learning to perform similar visual analysis may have many advantages. Computer-automated, image-based validation of a cell’s function does not require exposing the cells to the environment, thus significantly reducing the chance of cell contamination or destruction. Furthermore, such technology could be more inexpensive to implement than other validation or quality controls. It even has potential for high throughput use, to be scaled up, for many applications in research, manufacturing, and cell therapeutics settings. </p> <p>Scientists at the National Cancer Institute (NCI) and National Institute of Standards and Technology (NIST) have developed an image-based machine learning system that is able to validate functional cell phenotypes. The system may be trained to automatically recognize image features that correlate to a desired cell-type or properties for research, diagnostic, and therapeutic purposes. Learned models based on multiple visual characteristics may be developed using this system. The system has been shown to accurately recognize retinal pigment epithelial (RPE), with validated physiological function. It may also be trained to recognize numerous other cells such as embryonic stem cells (ESC), induced pluripotent stem cells (IPSC), neural stem cells (NSC), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and cancer stem cells (CSC). This novel technology may have applications for cell therapies &amp; transplants, (including those that are stem cell-derived), and for validation, quality control, and cell diagnostics in many areas. </p> <h2>Competitive Advantages:</h2> <ul><li>Least invasive means of identifying cell qualities</li> <li>Inexpensive means of performing cell diagnostics</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Stem cell therapies</li> <li>Validation</li> <li>Quality control</li> <li>Cell diagnostic </li> <li>Clinical diagnostic </li> </ul> 2018-08-14 2025-04-22 2018-08-14 2025-09-15 2018-08-14 Bharti, Cell therapy, Cell Validation, Less Invasive Diagnostics, Machine Learning, Neural Networks, QUALITY CONTROL, Stem Cell Diagnostics, Stem Cell Therapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163218 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163220 Schaub, Nicholas National Institute of Standards and Technology Schaub, Nicholas 2 147163221 Simon, Carl National Institute of Standards and Technology Simon, Carl 3 147163219 Hotaling, Nathan NIH - NEI NEI Hotaling, Nathan (NEI) 4 147163218 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163220 Schaub, Nicholas National Institute of Standards and Technology Schaub, Nicholas 2 147163221 Simon, Carl National Institute of Standards and Technology Simon, Carl 3 147163219 Hotaling, Nathan NIH - NEI NEI Hotaling, Nathan (NEI) 4 147157886 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) Fro Use In Cell Therapy And Tissue Engineered Products E-058-2018-0 Filing authorized National Eye Institute (NEI), National Institute of Standards and Technology 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics&body=Please send me information about technology [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics&body=Please send me information about technology [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160975 E-058-2018-0 E-058-2018-0-US-01 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY AND DIAGNOSTICS PRV US 62/644,175 Abandoned US <br />Provisional (PRV) 62/644,175<br />Filed on 2018-03-16<br />Status: Abandoned 147165984 E-058-2018-0 E-058-2018-0-PCT-02 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS PCT Patent Cooperation Treaty PCT/US2019/022611 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/022611<br />Filed on 2019-03-15<br />Status: Expired 147165985 E-058-2018-0 E-058-2018-0-US-03 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products National Stage US 11,531,844 16/981,531 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11531844 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11531844">11,531,844</a><br />Filed on 2020-09-16<br />Status: Issued 147165986 E-058-2018-0 E-058-2018-0-AU-04 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage Australia 2019236297 2019236297 Issued Australia <br />National Stage 2019236297<br />Filed on 2020-09-16<br />Status: Issued 147165987 E-058-2018-0 E-058-2018-0-CA-05 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage Canada 3094078 3094078 Issued Canada <br />National Stage 3094078<br />Filed on 2019-03-15<br />Status: Issued 147165988 E-058-2018-0 E-058-2018-0-EP-06 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage European Patent 19714930.5 Pending European Patent <br />National Stage 19714930.5<br />Filed on 2019-03-15<br />Status: Pending 147165989 E-058-2018-0 E-058-2018-0-JP-07 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage Japan 7659394 2020-549687 Issued Japan <br />National Stage 2020-549687<br />Filed on 2020-09-15<br />Status: Issued 147165990 E-058-2018-0 E-058-2018-0-US-08 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES (2-D CELLS AND 3-D TISSUES) FOR USE IN CELL THERAPY AND TISSUE ENGINEERED PRODUCTS CON US 12,020,494 17/983,963 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12020494 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12020494">12,020,494</a><br />Filed on 2022-11-09<br />Status: Issued 164118996 E-058-2018-0 E-058-2018-0-US-09 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products CON US 18/662,788 Pending US <br />Continuation (CON) 18/662,788<br />Filed on 2024-05-13<br />Status: Pending 164118997 E-058-2018-0 E-058-2018-0-AU-10 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS DIV Australia 2024227758 Pending Australia <br />Divisional (DIV) 2024227758<br />Filed on 2024-10-30<br />Status: Pending 164118998 E-058-2018-0 E-058-2018-0-JP-01 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS DIV Japan 2025-055757 Pending Japan <br />Divisional (DIV) 2025-055757<br />Filed on 2025-03-28<br />Status: Pending 164118999 E-058-2018-0 E-058-2018-0-CA-01 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS DIV Canada 3279009 Pending Canada <br />Divisional (DIV) 3279009<br />Filed on 2025-07-03<br />Status: Pending 147170438 Bharti 147170439 Cell therapy 147170441 Cell Validation 147170443 Less Invasive Diagnostics 147170445 Machine Learning 147170447 Neural Networks 147170448 QUALITY CONTROL 147170450 Stem Cell Diagnostics 147170452 Stem Cell Therapy TAB-4093 147157375 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Kapil Bharti, Russell Quinn, Min Jae Song <p>Degeneration of retinal tissues occurs in many ocular disorders resulting in the loss of vision. Dysfunction and/or loss of Retinal Pigment Epithelium Cells (RPE) and disruption of the associated blood retinal barrier (BRB) tissue structures are linked with many ocular diseases and conditions including: age-related macular degeneration (AMD), Best disease, and retinitis pigmentosa. Engineered tissue structures that are able to replicate the function of lost BRB structures may restore lost vision and provide insight into new treatments and mechanisms of the underlying conditions. </p> <p>Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The layers of BRB structures are printed as “bio-ink” (a specified formulation of cells that may be mixed with other biomaterials). The formulation of the bio-inks in each layer can be controlled. For example, induced pluripotent stem cells can be differentiated into RPE cells and endothelial cells, fibroblasts and pericytes. These differentiated cells may be used to formulate the desired composition for each bio-ink. Each formulated bio-ink layer may then be printed in a precise, user-defined, spatial and temporally-controlled pattern to build a 3D tissue architecture. Through this process, a 3D printed tissue architecture, similar in structure and function to natural BRB tissues, may be created.  The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system. </p> <p>The NEI is seeking partners for commercial licensing &amp; development and for possible collaborative research related to the development of this technology. </p> <h2>Competitive Advantages:</h2> <ul><li>No current in vitro model of human BRB diseases</li> <li>No current effective therapy to restore BRB tissue lost in human BRB disorders</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cell based therapy </li> <li>Develop a human model for disease &amp; drug target testing, and identification</li> </ul> 2018-08-16 2025-04-22 2020-04-13 2025-09-15 2018-08-16 3D bio-printing, Bharti, Blood Retinal Barrier Disorder, BRB, Cell therapy, in Vitro Human Blood Retinal Barrier Model, Ocular cell therapy scaffold, Retinal disorder, Retinal Pigment Epithelium Cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163480 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163481 Song, Min Jae NIH - NEI NCATS Song, Min Jae (NCATS) 2 147163482 Quinn, Russell NIH - NEI NEI Quinn, Russell (NEI) 3 147163480 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163481 Song, Min Jae NIH - NEI NCATS Song, Min Jae (NCATS) 2 147163482 Quinn, Russell NIH - NEI NEI Quinn, Russell (NEI) 3 147157770 3D Vascularized Human Ocular Tissue For Cell Therapy And Drug Discovery And A Manufacturing Process To Develop A 3D Vascularized Human Ocular Tissue That Can Be Used For Cell Therapy, Drug Discovery, And Drug Testing E-004-2017-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160884 E-004-2017-0 E-004-2017-0-US-01 3D Vascularized Human Ocular Tissue For Cell Therapy And Drug Discovery PRV US 62/419,835 Abandoned US <br />Provisional (PRV) 62/419,835<br />Filed on 2016-11-09<br />Status: Abandoned 147166433 E-004-2017-0 E-004-2017-0-PCT-02 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY PCT Patent Cooperation Treaty PCT/US2017/060666 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060666<br />Filed on 2017-11-08<br />Status: Expired 147166434 E-004-2017-0 E-004-2017-0-US-03 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage US 11,458,225 16/347,939 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11458225 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11458225">11,458,225</a><br />Filed on 2019-05-07<br />Status: Issued 147166435 E-004-2017-0 E-004-2017-0-AU-04 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage Australia 2017359330 2017359330 Issued Australia <br />National Stage 2017359330<br />Filed on 2017-11-08<br />Status: Issued 147166436 E-004-2017-0 E-004-2017-0-CA-05 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage Canada 3043194 3043194 Issued Canada <br />National Stage 3043194<br />Filed on 2017-11-08<br />Status: Issued 147166437 E-004-2017-0 E-004-2017-0-EP-06 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage European Patent 3538168 17801270.4 Issued European Patent <br />National Stage 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 147166438 E-004-2017-0 E-004-2017-0-JP-07 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage Japan 7222900 2019-545899 Issued Japan <br />National Stage 2019-545899<br />Filed on 2017-11-08<br />Status: Issued 147166439 E-004-2017-0 E-004-2017-0-US-08 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY DIV US 17/894,773 Pending US <br />Divisional (DIV) 17/894,773<br />Filed on 2022-08-24<br />Status: Pending 147166440 E-004-2017-0 E-004-2017-0-JP-01 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY DIV Japan 7565022 2023-015034 Issued Japan <br />Divisional (DIV) 2023-015034<br />Filed on 2023-02-03<br />Status: Issued 164118816 E-004-2017-0 E-004-2017-0-FR-09 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY EP France 3538168 17801270.4 Issued France <br />European patent (EP) 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 164118817 E-004-2017-0 E-004-2017-0-DE-10 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY EP Germany 3538168 17801270.4 Issued Germany <br />European patent (EP) 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 164118818 E-004-2017-0 E-004-2017-0-GB-11 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY EP United Kingdom 3538168 17801270.4 Issued United Kingdom <br />European patent (EP) 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 147169281 3D bio-printing 147169283 Bharti 147169285 Blood Retinal Barrier Disorder 147169286 BRB 147169288 Cell therapy 147169290 in Vitro Human Blood Retinal Barrier Model 147169292 Ocular cell therapy scaffold 147169294 Retinal disorder 147169296 Retinal Pigment Epithelium Cells TAB-4110 147157392 RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Suja Hiriyanna, Tiansen Li, Suddhasil Mookherjee, Anand Swaroop, Zhijian Wu <p>X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.</p> <p>This technology is poised to advance RPGR or RP2 gene therapy to clinical stage using AAV8 or AAV9 vector carrying human full-length RPGR or RP2-coding sequence.  The investigators have performed a wide dose range study over 18-months and found it to preserve rod and/or cone function as evidenced by ERG and/or OCT, optomotor tests. Morphologically, the treatment preserved rod and cone viability, and corrected mistrafficking of cone opsin and/or rhodopsin. The therapeutic effect was also achieved in advanced disease stage. The broad treatment window and long-lasting therapeutic effects make the RPGR and RP2 gene therapy attractive for clinical development.</p> <p>This technology is available for licensing, or the NEI research team will entertain potential collaborations that will advance this technology through the remaining preclinical stage toward IND development under a CRADA or a license combined with a CRADA project.</p> <blockquote><p><em>This patented treatment of albinism has not been approved by the U.S. Food and Drug Administration (FDA), and currently there is no active clinical trial to assess this albinism therapy benefit. However, if you are interested in participating in a future or upcoming NIH clinical trial on albinism, please contact NIH clinical coordinator, Ms. Ellaine Galindez-Balut (<a href="mailto:ellaine.galindez-balut@nih.gov">ellaine.galindez-balut@nih.gov</a>), for helpful information. Thank you.</em></p> </blockquote> <h2>Competitive Advantages:</h2> <ul><li>Pre-clinical dose efficacy study done </li> <li>RPGR and RP2 available in both AAV-8 and AAV-9 vectors. </li> <li>Preclinical data to show that treatment at advanced age also shows remarkable preservation of retinal structure and function.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Use in gene therapy to prevent or cure XLRP</li> <li>Preserving cone and/or rod function, restoring ERG and protein in the retina, increasing photoreceptor numbers, decrease in retinal detachments </li> <li>Improving quality of life, visual acuity, ability to drive and independent living</li> </ul> 2018-06-01 2025-05-15 2018-06-01 2025-09-15 2018-06-01 GENE THERAPY, hereditary ocular disease, Pigmentosa, Retina, Wu False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-01 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-162-2016 E-164-2014 147162027 Wu Z, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration https://www.ncbi.nlm.nih.gov/pubmed/25877300 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25877300">Wu Z, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration</a> 147162066 Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2. https://www.ncbi.nlm.nih.gov/pubmed/25422369 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25422369">Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2.</a> 147162105 Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration https://www.ncbi.nlm.nih.gov/pubmed/23745007 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23745007">Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration</a> 147162183 Mookherjee S, et al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy https://www.ncbi.nlm.nih.gov/pubmed/26358772 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26358772">Mookherjee S, et al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy</a> 147163543 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 1 147163540 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 2 147163544 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 147163542 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 4 147163541 Li, Tiansen NIH - NEI NEI Li, Tiansen (NEI) 5 147163543 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 1 147163540 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 2 147163544 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 147163542 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 4 147163541 Li, Tiansen NIH - NEI NEI Li, Tiansen (NEI) 5 147157871 Novel Gene Therapy Vectors For Treating X-linked Retinitis Pigmentosa Caused Bymutations In RPGR And/or RP2 Genes E-050-2015-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa&body=Please send me information about technology [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa&body=Please send me information about technology [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147166581 E-050-2015-0 E-050-2015-0-US-01 RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa PRV US 62/131,661 Abandoned US <br />Provisional (PRV) 62/131,661<br />Filed on 2015-03-11<br />Status: Abandoned 147166583 E-050-2015-0 E-050-2015-0-PCT-03 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa PCT Patent Cooperation Treaty PCT/US2016/022072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/022072<br />Filed on 2016-03-11<br />Status: Expired 147166584 E-050-2015-0 E-050-2015-0-AU-04 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Australia 2016228751 2016228751 Issued Australia <br />National Stage 2016228751<br />Filed on 2016-03-11<br />Status: Issued 147166585 E-050-2015-0 E-050-2015-0-CA-05 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Canada 2979229 Pending Canada <br />National Stage 2979229<br />Filed on 2016-03-11<br />Status: Pending 147166586 E-050-2015-0 E-050-2015-0-EP-06 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage European Patent 3268481 16762623.3 Issued European Patent <br />National Stage 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166587 E-050-2015-0 E-050-2015-0-JP-07 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Japan 6935049 2017-547425 Issued Japan <br />National Stage 2017-547425<br />Filed on 2017-09-08<br />Status: Issued 147166588 E-050-2015-0 E-050-2015-0-US-08 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA National Stage US 10,646,588 15/556,746 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10646588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10646588">10,646,588</a><br />Filed on 2017-09-08<br />Status: Issued 147166589 E-050-2015-0 E-050-2015-0-US-09 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA DIV US 11,617,801 16/854,605 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11617801 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11617801">11,617,801</a><br />Filed on 2020-04-21<br />Status: Issued 147166590 E-050-2015-0 E-050-2015-0-DE-10 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Germany 3268481 16762623.3 Issued Germany <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166591 E-050-2015-0 E-050-2015-0-FR-11 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP France 3268481 16762623.3 Issued France <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166592 E-050-2015-0 E-050-2015-0-GB-12 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP United Kingdom 3268481 16762623.3 Issued United Kingdom <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166593 E-050-2015-0 E-050-2015-0-EP-13 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa DIV European Patent 3719134 20176667.2 Issued European Patent <br />Divisional (DIV) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 147166594 E-050-2015-0 E-050-2015-0-JP-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa DIV Japan 2020-167984 Abandoned Japan <br />Divisional (DIV) 2020-167984<br />Filed on 2020-10-02<br />Status: Abandoned 164118779 E-050-2015-0 E-050-2015-0-FR-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP France 3719134 20176667.2 Issued France <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118780 E-050-2015-0 E-050-2015-0-IT-15 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Italy 3719134 20176667.2 Issued Italy <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118781 E-050-2015-0 E-050-2015-0-DE-16 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Germany 3719134 20176667.2 Issued Germany <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118782 E-050-2015-0 E-050-2015-0-GB-17 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP United Kingdom 3719134 20176667.2 Issued United Kingdom <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 147170314 GENE THERAPY 147170316 hereditary ocular disease 147170317 Pigmentosa 147170318 Retina 147170320 Wu TAB-4162 147157445 Methods and Compositions for Treating Genetically Linked Diseases of the Eye NEI Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Ear Nose & Throat Licensing Ophthalmology Therapeutics Ronald Bush, Peter Colosi, Paul Sieving, Yong Zeng <p>X-linked retinoschisis (XLRS) is an inherited, monogenetic ocular disease caused by mutations in the retinoschisin (RS1) gene, resulting in the development of cystic cavities throughout the retina and leading to juvenile macular degeneration. Approximately 1:15,000 males in the US are affected, classifying the condition as an orphan indication. </p> <p>The National Eye Institute (NEI) has developed a tissue-specific gene therapy approach based upon adeno-associated virus (AAV) mediated delivery of the full coding sequence for human retinoschisin to retinal cells under the control of a retinoschisin promoter.  Delivery and expression of AAV-RS1 is a novel invention for the restoration of RS1 expression in those suffering from XLRS, presenting a potential cure to an untreatable disease.  Restoration of both structure and function was demonstrated in a preclinical mouse model. A single site Phase I/IIa clinical trial of AAV-RS1 using GMP-grade material is in progress at the NIH/NEI.  </p> <p>This technology will be of interest and value to licensors or co-development partners capable of evaluating the clinical and regulatory path, apply its regulatory, manufacturing, and clinical expertise in gene therapy. The licensors/collaborator will identify an optimal course toward regulatory approval in the US and other countries. Ideally, the collaborator will participate in conducting aPhase II/III multicenter trial including U.S. and European trial sites – will the submission of a BLA or comparable application for marketing approval in the US as well as relevant global markets.</p> <h2>Competitive Advantages:</h2> <ul><li>Clinical-stage asset</li> <li>No FDA approved drug or therapy is available for XLRS</li> <li>The XLRS gene replacement strategy is applicable to all XLRS causative gene defects</li> <li>The use of a low-seroprevalence, non-pathogenic AAV8 vector favors efficacy in a high percentage of the patient population</li> <li>The use of a tissue specific promoter limits non-specific gene expression</li> <li>Demonstrated GMP manufacturing process</li> <li>Eligible for Orphan Drug Status</li> </ul> <h2>Commercial Applications:</h2> <p>Potentially curative therapy for XLRS regardless of genetic background or causative XLRS genetic defect.</p> 2018-07-27 2025-05-15 2020-08-13 2025-09-15 2018-07-27 Clinical, EYE, GENE THERAPY, ophthalmological, Orphan Indication, Sieving, XLRS False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162134 Bush RA, et al. Preclinical Dose Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function. https://www.ncbi.nlm.nih.gov/pubmed/27036983 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27036983">Bush RA, et al. Preclinical Dose Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function.</a> 147162212 Zeng Y, et al. Retinal Structure and Gene Therapy Outcome in Retinoschisin-Deficient Mice Assessed by Spectral-Domain Optical Coherence Tomography. https://www.ncbi.nlm.nih.gov/pubmed/27409484 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27409484">Zeng Y, et al. Retinal Structure and Gene Therapy Outcome in Retinoschisin-Deficient Mice Assessed by Spectral-Domain Optical Coherence Tomography.</a> 147162481 Marangoni D, et al. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice. https://www.ncbi.nlm.nih.gov/pubmed/27626041 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27626041">Marangoni D, et al. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice.</a> 147163738 Sieving, Paul NIH - NIDCD Sieving, Paul 1 147163741 Bush, Ronald NIH - NIDCD NEI Bush, Ronald (NEI) 2 147163740 Zeng, Yong NIH - NIDCD NEI Zeng, Yong (NEI) 3 147163739 Colosi, Peter NIH - NEI NEI Colosi, Peter (NEI) 4 147163738 Sieving, Paul NIH - NIDCD Sieving, Paul 1 147163741 Bush, Ronald NIH - NIDCD NEI Bush, Ronald (NEI) 2 147163740 Zeng, Yong NIH - NIDCD NEI Zeng, Yong (NEI) 3 147163739 Colosi, Peter NIH - NEI NEI Colosi, Peter (NEI) 4 147158321 A Method For Treating X-linked Rentinosisis Lntravitreal Injection Of An AAV Retinoschismin Vector E-284-2012-0 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 147162592 A Method For Treating X-linked Rentinosisis Lntravitreal Injection Of An AAV Retinoschismin Vector E-284-2012-1 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 147162593 A Method For Treating X-linked Rentinosisis Lntravitreal Injection Of An AAV Retinoschismin Vector E-284-2012-2 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye&body=Please send me information about technology [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye&body=Please send me information about technology [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147167015 E-284-2012-0 E-284-2012-0-US-01 Methods And Compositions For Treating Genetically Linked Diseases Of The Eye PRV US 61/765,654 Abandoned US <br />Provisional (PRV) 61/765,654<br />Filed on 2013-02-15<br />Status: Abandoned 147167017 E-284-2012-1 E-284-2012-1-US-01 Methods And Compositions For Treating Genetically Linked Diseases Of The Eye PRV US 61/815,636 Abandoned US <br />Provisional (PRV) 61/815,636<br />Filed on 2013-04-24<br />Status: Abandoned 147167019 E-284-2012-2 E-284-2012-2-PCT-01 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE PCT COMB Patent Cooperation Treaty PCT/US2014/016389 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/016389<br />Filed on 2014-02-14<br />Status: Expired 147167020 E-284-2012-2 E-284-2012-2-AU-02 Methods and Compositions for Treating Genetically Linked Diseases of the Eye National Stage Australia 2014216160 2014216160 Issued Australia <br />National Stage 2014216160<br />Filed on 2014-02-14<br />Status: Issued 147167021 E-284-2012-2 E-284-2012-2-CA-03 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE National Stage Canada 2900231 2900231 Issued Canada <br />National Stage 2900231<br />Filed on 2014-02-14<br />Status: Issued 147167022 E-284-2012-2 E-284-2012-2-JP-04 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE National Stage Japan 6449175 2015-558144 Issued Japan <br />National Stage 2015-558144<br />Filed on 2015-08-13<br />Status: Issued 147167023 E-284-2012-2 E-284-2012-2-US-05 Methods and Compositions for Treating Genetically Linked Diseases of the Eye National Stage US 9,873,893 14/766,842 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9873893 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9873893">9,873,893</a><br />Filed on 2015-08-10<br />Status: Issued 147167024 E-284-2012-2 E-284-2012-2-EP-06 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS National Stage European Patent 2956174 14708176.4 Issued European Patent <br />National Stage 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 147167025 E-284-2012-2 E-284-2012-2-US-07 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE CON US 10,350,306 15/876,821 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10350306 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10350306">10,350,306</a><br />Filed on 2018-01-22<br />Status: Issued 147167026 E-284-2012-2 E-284-2012-2-PCT-08 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE PCT Patent Cooperation Treaty PCT/US2019/014418 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/014418<br />Filed on 2019-01-21<br />Status: Expired 147167027 E-284-2012-2 E-284-2012-2-US-09 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE National Stage US 16/956,976 Abandoned US <br />National Stage 16/956,976<br />Filed on 2020-06-22<br />Status: Abandoned 164118742 E-284-2012-2 E-284-2012-2-FR-01 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS EP France 2956174 14708176.4 Issued France <br />European patent (EP) 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 164118743 E-284-2012-2 E-284-2012-2-DE-01 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS EP Germany 2956174 14708176.4 Issued Germany <br />European patent (EP) 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 164118744 E-284-2012-2 E-284-2012-2-GB-01 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS EP United Kingdom 2956174 14708176.4 Issued United Kingdom <br />European patent (EP) 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 147174656 Clinical 147174657 EYE 147174658 GENE THERAPY 147174660 ophthalmological 147174661 Orphan Indication 147174662 Sieving 147174663 XLRS TAB-4170 147157454 Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Benjamin Mead, Stanislav Tomarev <p>Glaucoma is one of the world’s leading causes of irreversible blindness. There is no cure and vision lost from glaucoma cannot be restored. Glaucoma is associated with fluid build-up in the eye resulting in an increased intraocular pressure (IOP). The pressure may cause damage to the optic nerve and lead to progressive degeneration of retinal ganglion cells (RGC) and vision loss. Currently, available treatments for glaucoma delay progression by reducing IOP, but no therapies exist to directly protect RGC from degradation and loss. </p> <p>Scientists at the National Eye Institute (NEI) have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal stem cells (BMSC).  BMSC‐derived exosome administration for glaucoma may confer a significant neuroprotective effect for RGC and prevent vision loss. Isolated exosomes have several immediate advantages for clinical translation compared to potential whole-cell (stem cell) therapies for glaucoma. Isolation and purification of BMSC‐derived exosomes, or their therapeutically active components, is relatively simple via centrifugation. BMSC‐derived exosomes are stable, and once isolated, can be stored at 4C for months to years. Prior clinical trials of BMSC‐derived exosomes administered systemically have shown a positive safety profile. These exosomes are immunologically inert and, due to their small size and stability, are also easy to dose &amp; deliver and will also readily diffuse from the vitreous into the retinal cell layers.  Significant therapeutic- neuroprotective effects for isolated BMSC‐derived exosomes have been shown in in vitro and in vivo glaucoma models. BMSC‐derived exosomes are a promising potential cell‐free therapy for glaucoma and degenerative ocular diseases associated with loss of RGC.</p> <h2>Competitive Advantages:</h2> <ul><li>More inexpensive than bone marrow-derived mesenchymal stem cells (BMSC)</li> <li>Safer than BMSC</li> <li>BMSC and BMSC exomes represent the only known treatments for protecting RGC</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic to treat glaucoma</li> <li>Therapeutic to treat degenerative ocular diseases associated with loss of retinal ganglion cells (RGC)</li> </ul> 2018-08-16 2025-04-22 2018-08-16 2025-09-15 2018-08-16 Degenerative Ocular Disease, Exosomes, GLAUCOMA, National Eye Institute, NEI, Neuroprotection, Retinal Ganglion Cell Loss, RGC, Tomarev, Vector Encoding miRNA, Vision Loss False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162065 Mead B, et al. Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes Promote Survival of Retinal Ganglion Cells Through miRNA-Dependent Mechanisms. https://www.ncbi.nlm.nih.gov/pubmed/28198592 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28198592">Mead B, et al. Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes Promote Survival of Retinal Ganglion Cells Through miRNA-Dependent Mechanisms.</a> 147163762 Tomarev, Stanislav NIH - NEI NEI Tomarev, Stanislav (NEI) 1 147163763 Mead, Benjamin NIH - NEI NEI Mead, Benjamin (NEI) 2 147163762 Tomarev, Stanislav NIH - NEI NEI Tomarev, Stanislav (NEI) 1 147163763 Mead, Benjamin NIH - NEI NEI Mead, Benjamin (NEI) 2 147157856 Bone Marrow Mesenchymal Stem Cell (BMSC)-derived Exosomes For The Treatment Of Glaucoma E-044-2018-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma&body=Please send me information about technology [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma&body=Please send me information about technology [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160955 E-044-2018-0 E-044-2018-0-US-01 BMSC DERIVED EXOSOMES AND MIRNA TO TREAT GLAUCOMA PRV US 62/622,032 Abandoned US <br />Provisional (PRV) 62/622,032<br />Filed on 2018-01-25<br />Status: Abandoned 147167075 E-044-2018-0 E-044-2018-0-US-02 EXOSOMES AND MIRNA TO TREAT GLAUCOMA ORD US 11,058,729 16/257,026 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11058729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11058729">11,058,729</a><br />Filed on 2019-01-24<br />Status: Issued 147167076 E-044-2018-0 E-044-2018-0-US-03 EXOSOMES AND MIRNA TO TREAT GLAUCOMA DIV US 11,806,369 17/341,057 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11806369 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11806369">11,806,369</a><br />Filed on 2021-06-07<br />Status: Issued 147170151 Degenerative Ocular Disease 147170152 Exosomes 147170153 GLAUCOMA 147170154 National Eye Institute 147170155 NEI 147170156 Neuroprotection 147170158 Retinal Ganglion Cell Loss 147170160 RGC 147170162 Tomarev 147170164 Vector Encoding miRNA 147170166 Vision Loss TAB-4834 152366631 Soluble Antigen-Based ELISA for the Detection of B. malayi Infections NIAID Collaboration, Diagnostics, Licensing, Therapeutics Collaboration Diagnostics Licensing Therapeutics Thomas Nutman <p>The technology presented is a breakthrough in the diagnosis of lymphatic filariasis, specifically targeting the B. malayi pathogen. It encompasses a novel soluble antigen extract used in both IgG and IgG4-based ELISA tests, aimed at detecting the presence of the filarial infection. This innovation serves as a cornerstone for a CLIA-certified reference test, established and utilized in Dr. Nutman&#39;s laboratory since the late 1980s. It offers a significant advancement in the field, particularly beneficial for remote areas where traditional PCR methods are challenging to implement, thereby facilitating more accessible point-of-care diagnostics for B. malayi infection.</p> The ELISA test for B. malayi provides a fast, cost-effective, and highly accurate diagnosis of lymphatic filariasis, outperforming traditional methods with its ease of use in field conditions and proven reliability, streamlining disease management in resource-limited settings. The ELISA technology for B. malayi has vast potential applications including widespread field diagnostics in endemic regions, integration into routine health screenings, and use in epidemiological surveillance programs. It also holds promise for facilitating ongoing research in filarial diseases and could be adapted for mass drug administration monitoring, enhancing global efforts to control and eventually eliminate lymphatic filariasis. 2024-01-24 2025-09-05 2025-09-05 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152366638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 152366638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 152366634 Soluble Brugia Malayi Adult Antigen For Use In Immunoassays E-009-2014-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections&body=Please send me information about technology [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections&body=Please send me information about technology [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections.">jonathan.motley@nih.gov</a><br> TAB-5072 163822312 Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s) NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Clint Allen, Ke Bai, Zulmarie Franco, Scott Norberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections.</p> <h2>Description of Technology:</h2> <p>Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused by chronic infection with human papillomavirus (HPV) types 6 or 11. These conditions lead to the development of papillomatous growths in different regions of the body &ndash; RRP affects the upper aerodigestive tract, while condylomas involve the anogenital area. In RRP, growths in the aerodigestive tract can cause dysphonia, dyspnea, and, in severe cases, airway obstruction, which may lead to recurrent pneumonia or respiratory failure.</p> <p>Current treatment for RRP primarily involves repeated surgical debulking or laser ablation to manage symptoms. However, the virus often persists in a latent state, resulting in continual papilloma regrowth. The need for frequent procedures exposes patients to cumulative anesthetic and surgical risks, emotional distress, and significantly diminished quality of life. Despite progress in localized treatments such as surgery and laser ablation, there are no approved systemic therapies for chronic HPV 6 or 11-related conditions. This highlights a clear unmet need for effective, curative therapy options.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel adoptive cell therapy approach to target conditions driven by HPV types 6 or 11. They have successfully identified and preferentially expanded HPV 6 and/or 11-specific T cells from papilloma tissue obtained from patients with RRP. These papilloma-infiltrating lymphocytes (PILs) have demonstrated the ability to eliminate papillomatous tissue. This T cell manufacturing method holds promise for developing cell-based therapies for chronic HPV 6/11-related conditions, including RRP and potentially anogenital condyloma. Notably, the ability to isolate and expand antigen-specific lymphocytes from non-cancerous growths represents an exciting advancement in the field of adoptive cell therapy &ndash; potentially paving the way for treating a broader range of non-malignant diseases.</p> <p>This technology is available for licensing and offers a compelling opportunity for companies developing next-generation immunotherapies. The Center for Immuno-Oncology and the Surgical Oncology Program of the NCI, Center for Cancer Research are actively seeking industry partners to support the clinical development and commercialization of this approach. It is particularly well-suited for biotech firms focused on T cell therapies or addressing HPV-related diseases. Strategic collaboration could accelerate market entry and unlock significant value in an area with high unmet medical need.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapy for chronic HPV-related conditions such as recurrent respiratory papillomatosis (RRP) and anogenital condyloma.</li> <li>Development of personalized T cell therapies targeting HPV 6 or HPV 11 infections.</li> <li>Generation of T cell receptor (TCR) libraries for research and therapeutic purposes.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Selective expansion of T cells with high specificity for HPV 6 or HPV 11 antigens.</li> <li>Potential to treat both non-cancerous and cancerous HPV-related conditions.</li> <li>Ability to produce oligoclonal T cell populations, increasing the efficacy of the therapy.</li> <li>Methodology applicable to both therapeutic and preventative treatments for chronic HPV infections.</li> <li>Drug development for RRP may qualify for regulatory incentives due to the rarity of the disease.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for papilloma-infiltrating lymphocytes (PIL) in treatment for chronic HPV6/11-associated diseases 2025-08-21 2025-08-21 2025-09-04 2025-08-21 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163822392 Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. 163822341 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163822345 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163822349 Franco, Zulmarie NIH - NCI NCI Franco, Zulmarie (NCI) 3 163822353 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 4 163822341 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163822345 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163822349 Franco, Zulmarie NIH - NCI NCI Franco, Zulmarie (NCI) 3 163822353 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 4 163822315 Method of Manufacturing Papilloma Infiltrating Lymphocyte Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s) E-143-2024-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)&body=Please send me information about technology [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)&body=Please send me information about technology [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 163822320 E-143-2024-0 E-143-2024-0-US-01 METHODS OF PREPARING CELL THERAPY PRODUCTS FOR THE TREATMENT OF CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS 6 OR 11 INFECTION PRV US 63/709,683 Expired US <br />Provisional (PRV) 63/709,683<br />Filed on 2024-10-21<br />Status: Expired 164010270 E-143-2024-0 E-143-2024-0-PC-01 METHODS OF PREPARING CELL THERAPY PRODUCTS FOR THE TREATMENT OF CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS 6 OR 11 INFECTION PCT Patent Cooperation Treaty PCT/US2025/051640 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/051640<br />Filed on 2025-10-20<br />Status: Pending TAB-5074 163873661 Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Drew Deniger, Steven Feldman, Steven Rosenberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.</p> <h2>Description of Technology:</h2> <p>TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers. Contemporary gene engineering techniques permit both the targeted integration of the exogenous receptor(s) and further genetic manipulation of the host cells to enhance persistence and performance following adoptive transfer (e.g., through disruption of immune checkpoints such as CISH or PD1). However, these techniques often suffer from low transduction efficiencies and may result in the generation of infusion products with sub-optimal percentages of targeted cells.</p> <p>NCI scientists designed a new method that enables the selective expansion of T lymphocytes, under GMP conditions, that have been engineered to stably express a murine-human hybrid TCR. These hybrid TCRs consist of human variable regions and murine constant regions. The inventive approach uses irradiated feeder cells and an anti-mouse TCR beta constant region antibody (e.g., H57) to provide stimulation, enabling the specific activation and expansion of T cells transduced with the hybrid TCRs. Critically, replacement of the OKT3 activating antibody from the standard rapid expansion protocol with one specific for the TCR murine constant region prevents the outgrowth of non-transduced cells. Consequently, the new method produces a cell population highly enriched for the desired engineered cells.</p> <p>NCI seeks to market this method, which is analogous to an antigen-specific stimulation of the T cell, to companies interested in developing personalized ACT.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Enables the GMP production of personalized T cell therapy products targeting tumor specific mutations with a high percentage of engineered cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic benefit due to enhanced persistence and performance following adoptive T cell transfer</li> <li>Increased therapeutic benefit due to improved surface expression of the therapeutic TCR &alpha;&beta; <ul> <li>TCR alpha/beta chains substantially eliminate the risk of mis-pairing with the endogenous alpha/beta chain sequences expressed by the host cell</li> </ul> </li> <li>Improved manufacturing since the population is highly enriched for the desired engineered cells <ul> <li>Greatly increases the frequency of tumor-specific T cells following expansion, exceeding what is achieved using alternative methods to generate mutation- or tumor-specific T cells</li> </ul> </li> </ul> <p>&nbsp;</p> Researchers at the NCI seek licensing for TCR-engineered T cells that will facilitate the ACT process. 2025-08-25 2025-08-25 2025-08-25 2025-08-25 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159140 Clinical Phase II 72159140 NCI 37470483 Website Abstract 163873915 Parkhurst M, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. (PMID 38992) https://pubmed.ncbi.nlm.nih.gov/38992/ <a href="https://pubmed.ncbi.nlm.nih.gov/38992/">Parkhurst M, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. (PMID 38992)</a> 163873942 Kim SP, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. (PMID 35749374) https://pubmed.ncbi.nlm.nih.gov/35749374/ <a href="https://pubmed.ncbi.nlm.nih.gov/35749374/">Kim SP, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. (PMID 35749374)</a> 163873951 Lowery FL, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. (PMID 35113651) https://pubmed.ncbi.nlm.nih.gov/35113651/ <a href="https://pubmed.ncbi.nlm.nih.gov/35113651/">Lowery FL, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. (PMID 35113651)</a> 163873866 Feldman, Steven NIH - NCI Feldman, Steven 1 163873878 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 163873886 Deniger, Drew NIH - NCI Deniger, Drew 3 163873866 Feldman, Steven NIH - NCI Feldman, Steven 1 163873878 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 163873886 Deniger, Drew NIH - NCI Deniger, Drew 3 163873664 Sorting And/or Selective Expansion Of T Lymphocytes For Use In Adoptive Cell Immunotherapy. E-182-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy&body=Please send me information about technology [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy&body=Please send me information about technology [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 163873669 E-182-2017-0 E-182-2017-0-US-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PRV US 62/568,339 Abandoned US <br />Provisional (PRV) 62/568,339<br />Filed on 2017-10-05<br />Status: Abandoned 163873670 E-182-2017-0 E-182-2017-0-PCT-02 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PCT Patent Cooperation Treaty PCT/US2018/052432 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/052432<br />Filed on 2018-09-24<br />Status: Expired 163873710 E-182-2017-0 E-182-2017-0-AU-03 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Australia 2018345400 2018345400 Issued Australia <br />National Stage 2018345400<br />Filed on 2018-09-24<br />Status: Issued 163873711 E-182-2017-0 E-182-2017-0-CA-04 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Canada 3077595 Pending Canada <br />National Stage 3077595<br />Filed on 2018-09-24<br />Status: Pending 163873712 E-182-2017-0 E-182-2017-0-CN-05 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage China ZL201880076862.9 201880076862.9 Issued China <br />National Stage 201880076862.9<br />Filed on 2018-09-24<br />Status: Issued 163873713 E-182-2017-0 E-182-2017-0-EP-06 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage European Patent 3692140 18786145.5 Issued European Patent <br />National Stage 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873714 E-182-2017-0 E-182-2017-0-IL-07 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Israel 273698 273698 Issued Israel <br />National Stage 273698<br />Filed on 2020-03-30<br />Status: Issued 163873715 E-182-2017-0 E-182-2017-0-JP-08 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Japan 7867764 2020-519092 Issued Japan <br />National Stage 2020-519092<br />Filed on 2020-04-02<br />Status: Issued 163873716 E-182-2017-0 E-182-2017-0-KR-09 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage South Korea 10-2757789 10-2020-7012314 Issued South Korea <br />National Stage 10-2020-7012314<br />Filed on 2020-04-28<br />Status: Issued 163873717 E-182-2017-0 E-182-2017-0-SG-10 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Singapore 11202003112Q Abandoned Singapore <br />National Stage 11202003112Q<br />Filed on 2018-09-24<br />Status: Abandoned 163873718 E-182-2017-0 E-182-2017-0-US-11 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage US 12,227,554 16/652,948 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12227554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12227554">12,227,554</a><br />Filed on 2020-04-01<br />Status: Issued 163873719 E-182-2017-0 E-182-2017-0-HK-12 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Hong Kong HK40031098B 62020020943.0 Issued Hong Kong <br />European patent (EP) 62020020943.0<br />Filed on 2020-11-26<br />Status: Issued 163873720 E-182-2017-0 E-182-2017-0-EP-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV European Patent 23185846.5 Pending European Patent <br />Divisional (DIV) 23185846.5<br />Filed on 2023-07-17<br />Status: Pending 163873721 E-182-2017-0 E-182-2017-0-ES-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Spain 3692140 18786145.5 Issued Spain <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873722 E-182-2017-0 E-182-2017-0-FI-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Finland 3692140 18786145.5 Issued Finland <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873723 E-182-2017-0 E-182-2017-0-FR-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP France 3692140 18786145.5 Issued France <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873724 E-182-2017-0 E-182-2017-0-IT-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Italy 3692140 18786145.5 Issued Italy <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873725 E-182-2017-0 E-182-2017-0-DE-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Germany 3692140 18786145.5 Issued Germany <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873726 E-182-2017-0 E-182-2017-0-GB-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP United Kingdom 3692140 18786145.5 Issued United Kingdom <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873727 E-182-2017-0 E-182-2017-0-CH-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Switzerland 3692140 18786145.5 Issued Switzerland <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873728 E-182-2017-0 E-182-2017-0-NO-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Norway 3692140 18786145.5 Issued Norway <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873729 E-182-2017-0 E-182-2017-0-SG-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV Singapore 10202302822Q Pending Singapore <br />Divisional (DIV) 10202302822Q<br />Filed on 2023-10-03<br />Status: Pending 163873730 E-182-2017-0 E-182-2017-0-JP-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV Japan 7747724 2023-220106 Issued Japan <br />Divisional (DIV) 2023-220106<br />Filed on 2023-12-26<br />Status: Issued TAB-5065 163297774 Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1 NICHD Immunology, Oncology, Therapeutics Immunology Oncology Therapeutics Avik Dutta, Paul Love <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.</p> <h2>Description of Technology:</h2> <p>Cellular immunotherapy holds much promise for the treatment of cancer. However, certain cellular therapies have limited success because of immunosuppression in the tumor microenvironment. Thus, there is an unmet need for improved methods of cellular immunotherapy.</p> <p>T cells constitutively express inhibitory molecules that limit the activation response to antigens by the T cell antigen receptor (TCR). Among these are the transmembrane adapter proteins SIT1, LAX 1 and TRA T1. These appear to tonically associate with the TCR and inhibit signal transduction. Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified SIT1, LAX 1 and TRA T1 as potential targets for T-cell immunotherapy. Mouse models have demonstrated that deletion of SIT1, LAX1 and TRA T1 &ndash; or expression of nonfunctional mutant versions of these proteins in mouse T cells &ndash; enhances TCR signaling and significantly increases T cell cytotoxicity against tumor cells. Experiments confirming these results in human T cells are currently underway. This discovery provides a new therapeutic approach to greatly improve clinical outcomes of T-cell immunotherapy in treating cancers. It also holds potential to treat infectious diseases or autoimmune diseases</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for cancer</li> <li>Treatment for infectious diseases</li> <li>Treatment for autoimmune diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially superior therapeutic benefit in cancer by: <ul> <li>Enhancing tumoricidal activity of T-cell immunotherapy</li> <li>Overcoming immunosuppression in the tumor microenvironment</li> </ul> </li> <li>Potentially superior therapeutic benefit in infectious diseases by enhancing immune responses to pathogens</li> <li>Potentially superior therapeutic benefit in autoimmune disease by enhancing the generation or function of antigen-specific regulator T cells (Tregs)</li> </ul> Researchers at the NICHD seek licensing for further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. 2025-07-14 2025-08-21 2025-08-21 2025-07-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163298026 Love, Paul NICHD NICHD Love, Paul (NICHD) 1 163298037 Dutta, Avik NICHD NICHD Dutta, Avik (NICHD) 2 163298026 Love, Paul NICHD NICHD Love, Paul (NICHD) 1 163298037 Dutta, Avik NICHD NICHD Dutta, Avik (NICHD) 2 163297777 Enhanced tumor of T cells lacking SIT1, LAX1 or TRAT1 E-004-2024-0 Filing authorized NIH - NICHD 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1&body=Please send me information about technology [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1&body=Please send me information about technology [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">darackn@mail.nih.gov</a><br> 163363211 E-004-2024-0 E-004-2024-0-US-01 Enhanced Tumor Reactivity of T cells lacking SIT1, LAX1 or TRAT1 PRV US 63/625,354 Expired US <br />Provisional (PRV) 63/625,354<br />Filed on 2024-01-26<br />Status: Expired 163363216 E-004-2024-0 E-004-2024-0-PC-01 Enhanced Tumor Reactivity of T cells lacking SIT1, LAX1 or TRAT1 PCT Patent Cooperation Treaty PCT/US2025/013054 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/013054<br />Filed on 2025-01-24<br />Status: Pending TAB-5066 163312519 Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jay Berzofsky, Shweta Tiwary <h2>Summary:</h2> <p>The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI&rsquo;s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven lipid imbalances and other immunosuppressive factors reducing vaccine effectiveness. To address this issue, NCI has generated dendritic cells in the presence of omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) and their derivatives, or specialized pro-resolving lipid mediators, to restore and enhance the dendritic cells&rsquo; antigen-presenting function and anti-tumor efficacy. This approach could significantly improve the potency of DC-based cancer vaccines, offering a promising strategy to overcome a major limitation in current cancer immunotherapies. NCI is actively continuing development of this technology and seeks licensing and/or collaboration partners to support further preclinical validation and potential clinical translation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer immunotherapy</li> <li>Development of human DC vaccines</li> <li>Formulations involving omega-3 fatty acids or pro-resolving lipids</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Production of DCs with enhanced antigen-presenting function, anti-tumor efficacy and potency</li> <li>Significant tumor reduction and improved survival compared in animals compared with wild-type DCs</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines by using omega-3 fatty acids or pro-resolving lipid mediators. 2025-07-15 2025-08-21 2025-08-21 2025-07-15 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163312808 Tiwary, S., "Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment." https://doi.org/10.4049/jimmunol.210.Supp.172.18 <a href="https://doi.org/10.4049/jimmunol.210.Supp.172.18">Tiwary, S., "Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment."</a> 163312813 Tiwary, S., K. Hsu, K. C. Goldfarbmuren, Z. Xia, and J. A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. Cancer Immunology Research, in press. Tiwary, S., K. Hsu, K. C. Goldfarbmuren, Z. Xia, and J. A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. Cancer Immunology Research, in press. 163312555 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 163312567 Tiwary, Shweta NIH - NCI Tiwary, Shweta 2 163312555 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 163312567 Tiwary, Shweta NIH - NCI Tiwary, Shweta 2 163312522 Improving the efficacy of dendric cell-based cancer vaccines by DHA treatment E-231-2023-0 Filing authorized NIH - NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy&body=Please send me information about technology [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy&body=Please send me information about technology [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> 163312527 E-231-2023-0 E-231-2023-0-US-01 COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELL-BASED VACCINES WITH ENHANCED EFFICACY PRV US 63/586,629 Expired US <br />Provisional (PRV) 63/586,629<br />Filed on 2023-09-29<br />Status: Expired 163312528 E-231-2023-0 E-231-2023-0-PC-01 COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELL-BASED VACCINES WITH ENHANCED EFFICACY PCT Patent Cooperation Treaty PCT/US2024/049057 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/049057<br />Filed on 2024-09-27<br />Status: Expired TAB-5033 160688466 Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Lin-kun An, Yves Pommier <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in further developing this family of oxynitidine derivatives as tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors and radiosensitizers for the treatment of cancer.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that promotes the repair of DNA damage caused by common anti-cancer interventions, such as ionizing radiation (IR) and topoisomerase 1 (TOP1) chemotherapy. This enzyme plays a critical role in repairing the trapped DNA cleavage complexes induced by clinically used TOP1 chemotherapy (such as irinotecan and topotecan). TDP1 also plays a regulatory role in non-homologous end joining (NHEJ) in the repair of DNA double-strand breaks and damage caused by ionizing radiation. In both cases, this leads to a diminished therapeutic effect of the intervention and is a limitation of radiotherapy and the use of TOP1 chemotherapies. TDP1 deficiency can help overcome this limitation by preventing the TDP1 DNA repair activity. As such, TDP1 is a promising target for novel anti-cancer and radiosensitizing agents. Although there are reported TDP1 inhibitors to enhance chemotherapy agents, such as TOP1 inhibitors, there are no reported TDP1 inhibitors as radiosensitizers. Additionally, there are no FDA-approved TDP1 inhibitors for cancer treatment or as a radiosensitizing agent.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) and their collaborators have identified a family of oxynitidine derivatives that inhibit TDP1 while enhancing the effects of ionizing radiation. In vitro, these compounds have been demonstrated to be potent TDP1 inhibitors that target, stabilize, and increase the formation of DNA cleavage complexes in various cancers &ndash; including colorectal cancer (CRC). Additionally, these compounds exhibited a strong radiosensitizing effect in vitro and in vivo in a dose-dependent-manner in CRC. The compounds, in combination with IR, reduced intracellular NHEJ, inhibited tumor growth and reduced tumor weight. These results underscore the potential use of this family of oxynitidine derivatives as therapeutic radiosensitizers and TDP1 inhibitors. &nbsp;</p> <p>The NCI is seeking co-development research opportunities and/or potential licensees to further advance these oxynitidine derivatives as novel inhibitors of TDP1 and radiosensitizers for the treatment of cancer.</p> <h2><br /> Potential Commercial Applications:&nbsp;</h2> <ul> <li>TDP1 inhibitors for treating various cancers</li> <li>Radiosensitizing agent&nbsp;</li> <li>Combination drug treatment to boost anti-tumor potency</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Can be used synergistically with TOP1 inhibitors to increase effectiveness</li> <li>Few reported clinical trials</li> <li>No FDA approved TDP1 inhibitors&nbsp;</li> <li>Potential for first-in-class therapeutic/radiosensitizer&nbsp;</li> <li>Can be used synergistically with ionizing radiation to increase effectiveness&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of a family of oxynitidine derivatives as tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors and radiosensitizers for the treatment of cancer. 2025-02-21 2025-08-21 2025-08-21 2025-03-14 False False True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 160722928 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 160722940 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 160722928 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 160722940 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 160688469 Oxynitidine derivatives as tyrosyl DNA phosphodiesterase inhibitors and radiosensitizers E-075-2024-0 Filing authorized NIH - NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers&body=Please send me information about technology [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers&body=Please send me information about technology [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 162827534 E-075-2024-0 E-075-2024-0-US-01 OXYNITIDINE DERIVATIVES USEFUL AS TYROSYL-DNA PHOSPHODIESTERASE INHIBITORS AND RADIOSENSITIZERS PRV US 63/674,198 Expired US <br />Provisional (PRV) 63/674,198<br />Filed on 2024-07-22<br />Status: Expired 162827539 E-075-2024-0 E-075-2024-0-PC-01 OXYNITIDINE DERIVATIVES USEFUL AS TYROSYL-DNA PHOSPHODIESTERASE INHIBITORS AND RADIOSENSITIZERS PCT Patent Cooperation Treaty PCT/US2025/038739 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/038739<br />Filed on 2025-07-22<br />Status: Pending TAB-5068 163496618 T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials Clint Allen, Scott Norberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 &nbsp;in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma.</p> <h2>Description of Technology:</h2> <p>Chronic infections with low-risk HPV types 6 and 11 can lead to such diseases as recurrent respiratory papillomatosis and anogenital condyloma. Such diseases can lower quality of life considerably, expose patients to repeated invasive procedures (such as surgery) and are often recurrent and unresponsive to standard treatments. There are few targeted treatments in development against these diseases. Therefore, there may be a need for reliable research tools to test the potency of targeted treatments, particularly immunotherapies, prior to the product&rsquo;s release for patient use.</p> <p><br /> The researchers at the National Cancer Institute (NCI) identified a novel T cell receptor (TCR) specific for an antigen derived from HPV6 E2, restricted to HLA-B55. This TCR was reconstructed with a mouse constant region for tracking in donor T cells and may be used in potency testing and release assays of vaccines and other immunotherapies that target HPV6.</p> <p>The NCI seeks licensees for the research-use TCR and the panel of Cos7 cells. This invention offers a unique opportunity for developing new TCR-based therapies and validation tools for HPV-related diseases.</p> <h2>Potential Commercial Applications: &nbsp;</h2> <ul> <li>Research materials to support therapeutic or diagnostic development against HPV-related diseases</li> <li>Potency testing and other release assays of HPV 6-containing immunotherapy products</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Unique TCR and cell line panel to validate T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma</li> <li>Superior tools &ndash; together or separately &ndash; in release assays for HPV 6-targeting immunotherapy products</li> <li>Unique tools for lot release assays for low- or high-risk HPV-targeting immunotherapy products</li> <li>Unique tools for lot release, stability and comparability studies</li> </ul> Researchers at the NCI seek licensing for this invention that comprises a novel T cell receptor (TCR) targeting HPV6 E2 in the context of HLA-B55 and a panel of Cos7 cells expressing different Class I human leukocyte antigen (HLA) proteins, that may be used in development of validation and potency assays for vaccines and other therapies designed to induce HPV6-specific T cell responses. 2025-07-28 2025-08-21 2025-08-21 2025-07-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163496887 Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. 163496740 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 163496774 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 163496740 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 163496774 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 163496621 Discovery of a T cell receptor targeting an antigen derived from HPV6 E2 and a panel of Cos7 cells expressing different HLA class I proteins E-010-2024-0 Research Material NIH - NCI 142435134 Sherwani, Zehra zehra.sherwani@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America zehra.sherwani@nih.gov?subject=Web Inquiry on [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies&body=Please send me information about technology [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Sherwani, Zehra<br><a href="mailto:zehra.sherwani@nih.gov?subject=Web Inquiry on [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies&body=Please send me information about technology [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">zehra.sherwani@nih.gov</a><br> TAB-5070 163753648 C8166-45 Cells NCI Infectious Disease, Licensing, Oncology, Research Materials Infectious Disease Licensing Oncology Research Materials Genoveffa Franchini, Robert Gallo, V Kalyanaraman, Phillip Markham, Syed Salahuddin, Flossie Wong-Staal <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.</p> <h2>Description of Technology: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h2> <p>Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus reported and is recognized as an etiological agent of adult T-cell leukemia (ATL). However, only a small percentage of individuals develop symptomatic ATL which carries a poor prognosis. The latency period can last for decades and universal screening for HTLV-1 infection has ceased. Thus, the C8166-45 cell line is a necessary component for understanding the mechanisms of HTLV-1 infection and improving clinical outcomes.</p> <p>NCI researchers derived C8166-45 by cocultivation or fusion of umbilical cord blood lymphocyte with T-cells cultures from leukemia-lymphoma patients. It is highly permissive to HIV-1 infection and characterized for its suitability in replication-competent lentiviral (RCL) assays to assess its safety for gene therapy products, such as lentiviral vectors. This cell line is highly useful in studying viral protein interactions, immortalization of human T-cells, and HIV replication.</p> <p>NCI is seeking parties to non-exclusively license the C8166-45 cell line.</p> <h2>Potential Commercial: &nbsp;</h2> <ul> <li>Investigation of HTLV pathogenesis and replication</li> <li>Studies of virus-induced T-cell transformation</li> <li>Studies of HTLV expression regulation by human T-cells</li> <li>Studies of HIV replication</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Contains a low amount of viral proteins</li> <li>Does not release detectable virus particles</li> <li>Suitable for testing RCL assay sensitivity</li> </ul> The NCI seeks licensing for the C8166-45 cell line. 2025-08-19 2025-08-21 2025-08-21 2025-08-19 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159134 Analytical Assay Performance Stage 72159134 NCI 37470483 Website Abstract 163753705 DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327) https://pubmed.ncbi.nlm.nih.gov/25240327/ <a href="https://pubmed.ncbi.nlm.nih.gov/25240327/">DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327)</a> 163753890 Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453) https://pubmed.ncbi.nlm.nih.gov/6412453/ <a href="https://pubmed.ncbi.nlm.nih.gov/6412453/">Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453)</a> 163753898 Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045) https://pubmed.ncbi.nlm.nih.gov/28970045/ <a href="https://pubmed.ncbi.nlm.nih.gov/28970045/">Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045)</a> 163753789 Franchini, Genoveffa NCI - CCR NCI Franchini, Genoveffa (NCI) 1 163753806 Salahuddin, Syed NIH - NCI Salahuddin, Syed 2 163753818 Wong-Staal, Flossie NIH - NCI Wong-Staal, Flossie 3 163753838 Gallo, Robert NIH - NCI NCI Gallo, Robert (NCI) 4 163753857 Markham, Phillip NIH - NCI Markham, Phillip 5 163753861 Kalyanaraman, V NIH - NCI Kalyanaraman, V 6 163753789 Franchini, Genoveffa NCI - CCR NCI Franchini, Genoveffa (NCI) 1 163753806 Salahuddin, Syed NIH - NCI Salahuddin, Syed 2 163753818 Wong-Staal, Flossie NIH - NCI Wong-Staal, Flossie 3 163753838 Gallo, Robert NIH - NCI NCI Gallo, Robert (NCI) 4 163753857 Markham, Phillip NIH - NCI Markham, Phillip 5 163753861 Kalyanaraman, V NIH - NCI Kalyanaraman, V 6 163753654 C8166-45 Cell Line (NIH AIDS Reagent Repository Catalog No. 404) E-272-2007-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5070] C8166-45 Cells&body=Please send me information about technology [TAB-5070] C8166-45 Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5070] C8166-45 Cells&body=Please send me information about technology [TAB-5070] C8166-45 Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> TAB-3591 114097445 Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction NCATS Endocrinology, Neurology, Research Materials, Therapeutics Endocrinology Neurology Research Materials Therapeutics Marc Ferrer-Alegre, Mark Henderson, Xin Hu, Daniel Jansen, David Kim, Juan Marugan, Noel Southall This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein pathway promotes production and secretion of multiple hormones, including insulin, growth hormone, and IGF1. Activation of the beta-arrestin-2 pathway stimulates dopamine production and may mediate addictive behaviors. Work with non-selective antagonists in models has indicated good in vivo efficacy results for treating addictive disorders. However, long term exposure to this type of antagonist triggers multiple undesirable side effects due to their capacity to inhibit production of numerous hormones. A select antagonist has the potential to have positive therapeutic effects without the side effects. This technology describes a novel selective GHSR1a Ghrelin receptor inhibitor. Further optimization work could be used to produce a molecule with the selective beta-arrestin activity and improved oral bioavailability, increase CNS exposure and half-life. 2022-08-01 2024-10-28 2025-08-19 2022-08-01 2022-05-06 ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110934 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110935 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110936 Jansen, Daniel FDA Jansen, Daniel 0 114110937 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114110938 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110939 Kim, David NCATS - NCGC NCATS Kim, David (NCATS) 0 114110933 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110933 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110934 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110935 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110936 Jansen, Daniel FDA Jansen, Daniel 0 114110937 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114110938 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110939 Kim, David NCATS - NCGC NCATS Kim, David (NCATS) 0 114102699 NCG00538279 Is A Novel Funtionally Selective Ghrelin Receptor Ligand For The Treatment Of Food And Chemical Addiction E-082-2021-0 Under Review FDA, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction&body=Please send me information about technology [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction&body=Please send me information about technology [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction.">ami.gadhia@nih.gov</a><br> 114128856 VEXXXX 114128857 VGXXXX 114128858 WIXXXX 114128859 WKXXXX 114128860 XEXXXX 114153467 NCG00538279 114153468 Novel 114153469 Funtionally 114153470 SELECTIVE 114153471 Ghrelin 114153472 RECEPTOR 114153473 LIGAND 114153474 treatment 114153475 FOOD 114153476 Chemical 114153477 ADDICTION TAB-3945 147157225 New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Karen Hathcock, Nicole McNeil Ford, Hesed Padilla-Nash, Karl Ried <p>The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.</p> <p> Investigators at the NIH have created a collection of 45 mouse epithelial cancer cell lines derived from six organs: bladder, cervix, colon, lung, kidney, and mammary glands.  These cells lines were obtained from spontaneously transformed primary cell cultures without genetic, viral or chemical manipulation so they can serve as mouse models for studying the natural process of oncogenesis. </p> <p> The cell lines were characterized cytogenetically during their transformation from normal to spontaneously immortalization and were found to recapitulate many of the changes observed in human cancer cells such as the deregulation of oncogenes (Myc, Mdm2) and tumor suppressor genes (Cdnk4a/Ink4a/p16, Rb).</p> <p> Carcinomas that arise from the epithelial cells lining organs lead to the most common cancers in humans.  However, research on cellular transformation has largely relied on fibroblast cells which are not of epithelial origin and therefore, may not reflect the changes that lead to epithelial oncogenesis.  The availability of these mouse epithelial cancer cell lines should allow for a more accurate analysis of this process.</p> <h2>Competitive Advantages:</h2> <ul><li>Cytogenetically defined epithelial cell lines from mouse that model human carcinomas</li> <li>Spontaneously transformed primary cell cultures were generated from isogenic mouse strain that has a low propensity for epithelial tumors in vivo therefore, not involving other mouse strains potentially influencing the genetic background.</li> <li>These cell lines were generated without viral, chemical or genetic manipulation and thus can serve as mouse models for studying the natural process of oncogenesis and as mouse models of human cancers.</li> <li>Genomically defined colon, bladder, and kidney cell lines showing oncogene deregulation (i.e. Mdm2 and Myc overexpression)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>These cell lines serve as "ideal" murine tumor models as they show evidence of progression, permitting analysis of the genetic and biological changes observed in the equivalent human carcinomas and associated with tumor progression. Their tumor histology is comparable to human cancers.</li> <li>The cell lines have unique properties that make them suitable for study of the following:</li> <li>Unlimited replicative potential</li> <li>Exhibit tumorigenic potential and EMT (Epithelial Mesencymal Transition</li> <li>Exhibit high degree of chromosome instability (chromosome rearrangements, amplifications) in regions orthologous to those altered in human cancers</li> <li>Use in mapping mouse genes homologous to human cancer genes and for the study of the effects of deregulation of cancer associated genes, through silencing or overexpression.</li> <li>For use in gene expression studies of tumor progression, comparing profiles to human cancers involving the same tissue types</li> <li>Use as experimental controls in the analysis of oncogene signaling pathways</li> <li>Use in the studying telomerase pathway regulation (200-fold expression difference between cell lines)</li> <li>Use of mouse as model of epithelial carcinomas and specifically cancers of the bladder, cervix, colon, lung, mammarys and kidney cancers</li> <li>These mouse models serve as vehicles to test the efficacy of new therapies, targeting specific targets associated with the transformation of six different mouse epithelial tissues.</li> <li>Use for discovering drugs that alter the tumorigenic potential, invasiveness, and the Epithelial-Mesenchymal Transition state</li> </ul> 2016-02-16 2025-08-19 2018-03-09 2025-08-19 2016-07-25 Mouse Epithelial Cancer Cell Lines, Research Tools False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162969 Padilla-Nash, Hesed NIH - NCI NCI Padilla-Nash, Hesed (NCI) 1 147162968 Ried, Karl NIH - NCI NCI Ried, Karl (NCI) 2 147162967 Hathcock, Karen NIH - NCI NCI Hathcock, Karen (NCI) 3 147162970 McNeil Ford, Nicole NIH - NCI NCI McNeil Ford, Nicole (NCI) 4 147162969 Padilla-Nash, Hesed NIH - NCI NCI Padilla-Nash, Hesed (NCI) 1 147162968 Ried, Karl NIH - NCI NCI Ried, Karl (NCI) 2 147162967 Hathcock, Karen NIH - NCI NCI Hathcock, Karen (NCI) 3 147162970 McNeil Ford, Nicole NIH - NCI NCI McNeil Ford, Nicole (NCI) 4 147157961 Collection Of 45 Transformed Murine Epithelial Cell Lines Derived From Six Organs: Bladder, Cervix, Colon, Lime, Kidney And Mammary Glands E-089-2010-0 Research Material NCI 83657698 Specialist (ALS), Admin. Licensing nihott@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines&body=Please send me information about technology [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Specialist (ALS), Admin. Licensing<br><a href="mailto:nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines&body=Please send me information about technology [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nihott@mail.nih.gov</a><br> 147171161 Mouse Epithelial Cancer Cell Lines 147171162 Research Tools TAB-3987 147157268 GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Jeffrey Green, Hosein Kouros-Mehr <p>GATA-3 is a transcription factor that is highly expressed in normal cells of the mammary luminal epithelium. GATA-3 plays a regulatory role in determining the fate of cells in the mammary gland. Disruption of GATA-3 expression leads to defects in the development of mammary cells, including an inability to differentiate properly into the correct cell type. GATA-3 function is also disrupted in various breast cancer models indicating that GATA-3 has tumor suppressive properties in normal cells. Mammary cell differentiation during a cell's development and lifespan helps determine the progression, severity, and clinical outcome of disease for a breast cancer patient. Low or limited mammary GATA-3 expression is correlated with larger tumors, an increased likelihood of tumor-positive lymph nodes, and therefore predicts an overall poorer clinical outcome compared to patients with higher GATA-3 expression. Researchers at the National Cancer Institute, Laboratory of Cancer Biology and Genetics believe that a better understanding of GATA-3 function and dysregulated during the onset and progression of breast cancer will lead to new strategies in diagnosing and treating the disease. They are seeking statements of capability or interest from parties interested in collaborative research to co- develop, evaluate, or commercialize a research tool for the diagnosis or treatment of breast cancer. </p> <h2>Competitive Advantages:</h2> <ul><li>Useful for in vitro and in vivo assays</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Possible identification of new targets for breast cancer therapy</li> </ul> 2016-02-16 2025-08-19 2020-04-07 2025-08-19 2016-08-11 BREAST CANCER, diagnostic, GATA-3 expression, prognostic False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162347 H. Kouros-Mehr et al. GATA-3 and the regulation of the mammary luminal cell fate. http://www.ncbi.nlm.nih.gov/pubmed/18358709 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18358709">H. Kouros-Mehr et al. GATA-3 and the regulation of the mammary luminal cell fate.</a> 147163134 Kouros-Mehr, Hosein NIH - NCI Kouros-Mehr, Hosein 1 147163133 Green, Jeffrey NIH - NCI NCI Green, Jeffrey (NCI) 2 147163134 Kouros-Mehr, Hosein NIH - NCI Kouros-Mehr, Hosein 1 147163133 Green, Jeffrey NIH - NCI NCI Green, Jeffrey (NCI) 2 147158038 GATA-3 Reporter Plasmid E-128-2009-0 Research Material NCI 83657698 Specialist (ALS), Admin. Licensing nihott@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer&body=Please send me information about technology [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Specialist (ALS), Admin. Licensing<br><a href="mailto:nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer&body=Please send me information about technology [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nihott@mail.nih.gov</a><br> 147171998 BREAST CANCER 147171999 diagnostic 147172001 GATA-3 expression 147172002 prognostic TAB-5034 159362020 Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization NHLBI Murali Cherukuri, Jessica Ettedgui-Benjamini, Rolf Swenson <p>Hyperpolarized magnetic resonance imaging (MRI) is an emerging molecular imaging method for metabolic imaging for detecting cancer, cardiovascular disease, stroke, and traumatic brain injury and monitoring therapy with no Gadolinium or Iron. Available for licensing and commercial development is a patent estate covering a perfluorinated single amplification by reversible exchange (SABRE) catalyst for generating MRI agents that includes a d-block element and a perfluorinated ligand hyperpolarized substrate comprising a 1/2 spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration. The invention also provides methods for separating a hyperpolarized substrate from the SABRE catalyst and/or hyperpolarized SABRE catalyst complex containing a heavy metal. These changes can be observed in patients in real time with a specialized MRI approach called hyperpolarization. By transiently changing the nuclear spin of naturally occurring intermediates in cellular energy production, the metabolic fate can be observed with greater than 10,000-fold sensitivity. Current methods of hyperpolarization require expensive machines with limited throughput.</p> <ul> <li>High Sensitivity: Over 10,000-fold sensitivity improvement.</li> <li>Cost Efficiency: Avoids expensive hyperpolarization machines.</li> <li>Metal-Free Imaging: No gadolinium or iron required.</li> <li>Real-Time Monitoring: Enables immediate observation of metabolic changes.</li> </ul> <ul> <li>MRI imaging</li> <li>Hyperpolarization</li> <li>Infusion Device for imaging reagents</li> <li>Cancer diagnostics</li> <li>Cardiovascular disease diagnostics</li> </ul> 2024-11-27 2025-08-19 2025-08-19 2024-12-03 False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 159422126 Ettedgui J, 2024 https://pubmed.ncbi.nlm.nih.gov/38154120/ <a href="https://pubmed.ncbi.nlm.nih.gov/38154120/">Ettedgui J, 2024</a> 159422129 Hong D, 2023 https://pubmed.ncbi.nlm.nih.gov/38024238/ <a href="https://pubmed.ncbi.nlm.nih.gov/38024238/">Hong D, 2023</a> 159422144 Schmidt AB, 2022 https://pubmed.ncbi.nlm.nih.gov/36379005/ <a href="https://pubmed.ncbi.nlm.nih.gov/36379005/">Schmidt AB, 2022</a> 159422158 Adelabu I, 2022 https://pubmed.ncbi.nlm.nih.gov/36136056/ <a href="https://pubmed.ncbi.nlm.nih.gov/36136056/">Adelabu I, 2022</a> 159422206 Adelabu I, 2022 https://pubmed.ncbi.nlm.nih.gov/34813142/ <a href="https://pubmed.ncbi.nlm.nih.gov/34813142/">Adelabu I, 2022</a> 159422221 AbuSalim JE, 2021 https://pubmed.ncbi.nlm.nih.gov/34554724/ <a href="https://pubmed.ncbi.nlm.nih.gov/34554724/">AbuSalim JE, 2021</a> 159422229 Miura N, 2021 https://pubmed.ncbi.nlm.nih.gov/34263489/ <a href="https://pubmed.ncbi.nlm.nih.gov/34263489/">Miura N, 2021</a> 159422271 Chapman B, 2021 https://pubmed.ncbi.nlm.nih.gov/34102835/ <a href="https://pubmed.ncbi.nlm.nih.gov/34102835/">Chapman B, 2021</a> 159422274 Yamamoto K, 2021 https://pubmed.ncbi.nlm.nih.gov/34108512/ <a href="https://pubmed.ncbi.nlm.nih.gov/34108512/">Yamamoto K, 2021</a> 159422074 Ettedgui-Benjamini, Jessica National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ettedgui-Benjamini, Jessica (NHLBI) 1 159422090 Swenson, Rolf NHLBI Swenson, Rolf (NHLBI) 2 159422096 Cherukuri, Murali NCI Cherukuri, Murali (NCI) 3 159422074 Ettedgui-Benjamini, Jessica National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ettedgui-Benjamini, Jessica (NHLBI) 1 159422090 Swenson, Rolf NHLBI Swenson, Rolf (NHLBI) 2 159422096 Cherukuri, Murali NCI Cherukuri, Murali (NCI) 3 159362025 Synthesis Of Iridium SABRE Catalysts Containing Heavy Perfluorinated Carbon Chains For Its Facile Removal And Delivery Of Metal-free Hyperpolarized Contrast Agents Such As Pyruvate E-036-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362038 Preparation Of Deuterated 12C, 13C-ketoglutarate (1-13C-3-D2-4-D-512C Ketoglutarate) And Methods To Hyperpolarization Using SABRE-Signal Amplification By Reversible Exchange E-035-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362045 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN E-039-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 159362213 INFUSION DEVICE FOR THE USE OF HYPERPOLARIZED MRI PROBES PREPARED BY FLUOROUS CATALYZED SABRE E-052-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362336 Real-time Monitoring Of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine E-069-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362413 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging E-070-2020-0 Filing authorized National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI), Radiation Biology Branch 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization&body=Please send me information about technology [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization&body=Please send me information about technology [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization.">shmilovm@nih.gov</a><br> 159362050 E-039-2022-0 E-039-2022-0-US-01 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PRV US 63/203,591 Abandoned US <br />Provisional (PRV) 63/203,591<br />Filed on 2021-07-27<br />Status: Abandoned 159362051 E-039-2022-0 E-039-2022-0-PCT-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PCT Patent Cooperation Treaty PCT/US2022/074122 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/074122<br />Filed on 2022-07-26<br />Status: Expired 159362052 E-039-2022-0 E-039-2022-0-US-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN National Stage US 12,566,228 18/291,681 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566228 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566228">12,566,228</a><br />Filed on 2024-01-24<br />Status: Issued 159362079 E-035-2022-0 E-035-2022-0-US-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PRV US 63/303,190 Expired US <br />Provisional (PRV) 63/303,190<br />Filed on 2022-01-26<br />Status: Expired 159362080 E-035-2022-0 E-035-2022-0-PCT-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PCT Patent Cooperation Treaty PCT/US2023/011640 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/011640<br />Filed on 2023-01-26<br />Status: Expired 159362081 E-035-2022-0 E-035-2022-0-JP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Japan 2024-544466 Abandoned Japan <br />National Stage 2024-544466<br />Filed on 2024-07-25<br />Status: Abandoned 159362082 E-035-2022-0 E-035-2022-0-CA-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Canada 3243219 Pending Canada <br />National Stage 3243219<br />Filed on 2024-07-23<br />Status: Pending 159362083 E-035-2022-0 E-035-2022-0-IL-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Israel 314428 Pending Israel <br />National Stage 314428<br />Filed on 2024-07-22<br />Status: Pending 159362084 E-035-2022-0 E-035-2022-0-CN-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage China 202380026889.8 Abandoned China <br />National Stage 202380026889.8<br />Filed on 2024-09-11<br />Status: Abandoned 159362085 E-035-2022-0 E-035-2022-0-US-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage US 18/833,627 Pending US <br />National Stage 18/833,627<br />Filed on 2024-07-26<br />Status: Pending 159362086 E-035-2022-0 E-035-2022-0-EP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage European Patent 23707534.6 Pending European Patent <br />National Stage 23707534.6<br />Filed on 2024-07-23<br />Status: Pending 159362087 E-035-2022-0 E-035-2022-0-HK-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) EP Hong Kong Administratively Closed Hong Kong <br />European patent (EP) None<br />Filed on None<br />Status: Administratively Closed 159362218 E-052-2022-0 E-052-2022-0-US-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PRV US 63/328,556 Expired US <br />Provisional (PRV) 63/328,556<br />Filed on 2022-04-07<br />Status: Expired 159362219 E-052-2022-0 E-052-2022-0-PC-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PCT Patent Cooperation Treaty PCT/US2023/017895 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/017895<br />Filed on 2023-04-07<br />Status: Expired 159362220 E-052-2022-0 E-052-2022-0-JP-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Japan 2024-559257 Abandoned Japan <br />National Stage 2024-559257<br />Filed on 2024-10-04<br />Status: Abandoned 159362221 E-052-2022-0 E-052-2022-0-CA-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Canada 3246953 Pending Canada <br />National Stage 3246953<br />Filed on 2024-09-26<br />Status: Pending 159362222 E-052-2022-0 E-052-2022-0-IL-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Israel 315942 Pending Israel <br />National Stage 315942<br />Filed on 2024-09-26<br />Status: Pending 159362223 E-052-2022-0 E-052-2022-0-CN-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage China 202380040403.6 Abandoned China <br />National Stage 202380040403.6<br />Filed on 2024-11-14<br />Status: Abandoned 159362224 E-052-2022-0 E-052-2022-0-US-02 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage US 18/854,462 Pending US <br />National Stage 18/854,462<br />Filed on 2024-10-04<br />Status: Pending 159362225 E-052-2022-0 E-052-2022-0-EP-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage European Patent 23721501.7 Pending European Patent <br />National Stage 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 159362341 E-069-2020-0 E-069-2020-0-US-01 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PRV US 62/961,855 Abandoned US <br />Provisional (PRV) 62/961,855<br />Filed on 2020-01-16<br />Status: Abandoned 159362342 E-069-2020-0 E-069-2020-0-PCT-02 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PCT Patent Cooperation Treaty PCT/US2021/013634 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013634<br />Filed on 2021-01-15<br />Status: Expired 159362343 E-069-2020-0 E-069-2020-0-EP-03 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage European Patent 21741034.9 Pending European Patent <br />National Stage 21741034.9<br />Filed on 2021-01-15<br />Status: Pending 159362344 E-069-2020-0 E-069-2020-0-IL-04 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage Israel 294365 Pending Israel <br />National Stage 294365<br />Filed on 2022-06-28<br />Status: Pending 159362345 E-069-2020-0 E-069-2020-0-US-05 REAL-TIME MONITORING OF INVIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage US 17/793,083 Pending US <br />National Stage 17/793,083<br />Filed on 2022-07-15<br />Status: Pending 159362418 E-070-2020-0 E-070-2020-0-US-01 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging PRV US 62/962,473 Abandoned US <br />Provisional (PRV) 62/962,473<br />Filed on 2020-01-17<br />Status: Abandoned 159362419 E-070-2020-0 E-070-2020-0-PCT-02 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING PCT Patent Cooperation Treaty PCT/US2021/013658 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013658<br />Filed on 2021-01-15<br />Status: Expired 159362420 E-070-2020-0 E-070-2020-0-EP-03 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING National Stage European Patent 21741941.5 Pending European Patent <br />National Stage 21741941.5<br />Filed on 2021-01-15<br />Status: Pending 159362421 E-070-2020-0 E-070-2020-0-IL-04 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage Israel 294464 Pending Israel <br />National Stage 294464<br />Filed on 2022-07-03<br />Status: Pending 159362422 E-070-2020-0 E-070-2020-0-US-05 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage US 17/793,089 Pending US <br />National Stage 17/793,089<br />Filed on 2022-07-15<br />Status: Pending 160031297 E-052-2022-0 E-052-2022-0-HK-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES CN Hong Kong 62025104551.9 Abandoned Hong Kong <br />China Patent (CN) 62025104551.9<br />Filed on 2025-03-11<br />Status: Abandoned TAB-946 114095280 Haplotypes of Human Bitter Taste Receptor Genes NIDCD Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Dennis Drayna, Un-kyung Kim Bitter taste has evolved in mammals as a crucial, important warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter, and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is very large and more than two dozen members of the T2R bitter taste receptor family have been identified. Individuals are now known to be genetically predisposed to respond or not to respond to the bitter taste of a number of substances. For example, large individual differences in the perception of bitterness have been well documented in compounds as different as nicotine, thiocyanates such as those found in cruciferous vegetables, and many bitter beta-glucopyranosides. This may have broad implications for nutritional status and tobacco use and common allelic variants of a member of the T2R bitter taste receptor gene family have been shown to underlie variation in the ability to taste phenylthiocarbamide (PTC) [Science (2003) 299, 1221-1225; HHS Ref No: E-169-2001/0]. <br><br> Scientists at the NIDCD have extended these results to other bitter taste receptors and have sequenced 22 of the 24 known T2R genes in a series of populations worldwide, including Northern Europeans, Hungarians, Japanese, Cameroonians, Pygmies and South American Indians and the present invention includes these isolated sequences and their variants. This includes a total of 127 SNPs and 103 different protein coding haplotypes, including those defined for the PTC Receptor (T2R38) [E-169-2001/0]. The inventors showed that 77% of the SNPs identified caused an amino acid substitution in the encoded receptor protein, giving rise to a very high degree of receptor protein variation in the population (Kim et al. (2005) Human Mutation 26, 199-204). The frequencies of these different haplotypes have been shown to differ in different populations which will aid in population-specific studies, such as those targeting differences in taste perception between Europeans and Asians, for example. <br><br> The invention available for licensing includes these novel SNPs and haplotypes and methods of use, which can be used to better identify and characterize different groups of individuals within and between populations that vary in the their bitter taste abilities. This is important to the food and flavoring industry, for example, where these variants can be used to aid in the development of a variety of taste improvements in foods and orally administered medications. 2022-03-08 2025-08-13 2025-08-15 2006-02-01 AC4XXX, ACXXXX, AXXXXX, Bitter, bitter taste, Chromosome 22 ring, flavor evaluation, Haplotypes, Human, ICXXXX, IXXXXX, population genetics, R 22, RECEPTOR, SNPs, TASTE, taste masking, taste receptors, VARIANTS False True True NIHTT 37470483 Website Abstract E-099-2005-0 E-169-2001-0 114104798 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114104797 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104797 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104798 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114100142 Human Bitter Taste Receptor Variants E-222-2003-1 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes&body=Please send me information about technology [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes&body=Please send me information about technology [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes.">shmilovm@nih.gov</a><br> 114162357 E-222-2003-1 E-222-2003-1-US-02 Variants of Human Taste Receptor Genes National Stage US 7,579,453 10/561,487 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7579453 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7579453">7,579,453</a><br />Filed on 2005-12-19<br />Status: Expired 114165430 E-222-2003-1 E-222-2003-1-US-06 Variants of Human Taste Receptor Genes CON US 8,309,701 12/534,505 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8309701 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8309701">8,309,701</a><br />Filed on 2009-08-03<br />Status: Expired 114166899 E-222-2003-1 E-222-2003-1-US-07 Variants Of Human Taste Receptor Genes DIV US 9,783,590 13/674,637 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783590 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783590">9,783,590</a><br />Filed on 2012-11-12<br />Status: Expired 114168038 E-222-2003-1 E-222-2003-1-PCT-01 Human Bitter Taste Receptor Variants PCT COMB Patent Cooperation Treaty PCT/US2004/019489 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2004/019489<br />Filed on 2004-06-18<br />Status: Expired 114114574 AXXXXX 114115079 AC4XXX 114115425 ICXXXX 114115426 IXXXXX 114115576 ACXXXX 114136339 Human 114136340 Bitter 114136341 TASTE 114136342 RECEPTOR 114136343 VARIANTS 114136344 bitter taste 114136345 flavor evaluation 114136346 Haplotypes 114136347 population genetics 114136348 taste masking 114136349 SNPs 114136350 taste receptors 114157837 Chromosome 22 ring 114159041 R 22 TAB-910 114095244 Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12) NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Vaccines Lisbeth Kim Green, Stanislav Sosnovtsev The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.<br /><br /> Because the noroviruses cannot be propagated by any means in the laboratory, an important strategy in their study is the development of molecular biology-based tools. This invention reports the development of recombinant baculoviruses carrying the capsid gene from several caliciviruses associated with human disease. Growth of these baculovirus recombinants in insect cells results in the expression of virus-like particles (VLPs) that are antigenically indistinguishable from the native calicivirus particle. These VLPs can be purified in large quantities for use as diagnostic reagents and potential vaccine candidates. The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize norovirus VLP antigens. Please contact Kim Y. Green at <a href="mailto:kgreen@niaid.nih.gov">kgreen@niaid.nih.gov</a> for more information. Research Material --Patent protection is not being pursued for this technology Research Material -- Patent protection is not being pursued for these technologies The materials embodied in this invention are available nonexclusively through a biological materials license. 2022-03-08 2025-08-13 2025-08-15 2008-06-01 Baculoviruses, CALICIVIRUS, CAPSID, Construction, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Hawaii, MD145-12, Mountain, Norovirus, SHIELD, Snow, STRAINS, TORONTO, VP1 False True True NIHTT 37470483 Website Abstract E-283-2003-0 E-214-2003-0 E-212-2003-0 114169964 Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. https://www.ncbi.nlm.nih.gov/pubmed/11807686 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11807686">Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly.</a> 114104726 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104728 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114104728 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114104726 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114100102 Construction Of Recombinant Baculoviruses Carrying The Gene Encoding The Major Capsid Protein, VP1, From Calicivirus Strains (including, But Not Limited To, Norovirus Strains, Toronto, Hawaii, Desert Shield, Snow Mountain And MD145-12) E-198-2003-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12). Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12).">elizabeth.pitts@nih.gov</a><br> 114115252 DA4BXX 114115253 DB4BXX 114115254 DC5BXX 114115255 DDXXXX 114115256 DAXXXX 114115257 DBXXXX 114115258 DCXXXX 114115259 DXXXXX 114119609 DA4XXX 114119610 DB4XXX 114119611 DC5XXX 114130371 Construction 114130372 Baculoviruses 114130373 CAPSID 114130374 VP1 114130375 CALICIVIRUS 114130376 STRAINS 114130377 Norovirus 114130378 TORONTO 114130379 Hawaii 114130380 SHIELD 114130381 Snow 114130382 Mountain 114130383 MD145-12 TAB-878 114095212 Method and Apparatus for Bioweapon Decontamination ORS Licensing Licensing Deborah Wilson It is in the interest of the public health and national security that the Public Health Service find a licensee for the commercial development and rapid dissemination of the apparatus and method of this invention. <p>The apparatus enables the decontamination of articles contaminated with bioweapons, more particularly sporolated bioweapons of which anthrax (Bacillus anthracis) is of notable concern. The system includes enclosing the article to be decontaminated in a humidified environment thus enhancing the susceptibility of spores to decontamination gases such as chlorine dioxide. Vacuum sealing the chamber and exposing the contaminated article to decontamination gases kills 100% of the spores.</p> 2022-03-08 2025-08-13 2025-08-15 2004-03-01 AB3FXX, AB3XXX, ABXXXX, AE1XXX, AE2BXX, AE2XXX, AEXXXX, Anthrax, AXXXXX False True True NIHTT 37470483 Website Abstract 114104667 Wilson, Deborah ORS Wilson, Deborah (ORS) 0 114104667 Wilson, Deborah ORS Wilson, Deborah (ORS) 0 114100059 Deliberately Enhanced Bio-indicators: A Better Monitor For Decontamination Of Weaponized Bacteriologic Agents E-218-2003-0 Filing authorized CDG Research Corporation, ORS 83697013 Miller, Marguerite millermarg@mail.nih.gov
United States of America Technology Advancement Office millermarg@mail.nih.gov?subject=Web Inquiry on [TAB-878] Method and Apparatus for Bioweapon Decontamination&body=Please send me information about technology [TAB-878] Method and Apparatus for Bioweapon Decontamination. Miller, Marguerite<br><a href="mailto:millermarg@mail.nih.gov?subject=Web Inquiry on [TAB-878] Method and Apparatus for Bioweapon Decontamination&body=Please send me information about technology [TAB-878] Method and Apparatus for Bioweapon Decontamination.">millermarg@mail.nih.gov</a><br> 114159999 E-218-2003-0 E-218-2003-0-US-03 Method And Apparatus For Bioweapon Decontamination National Stage US 7,776,292 10/597,191 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7776292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7776292">7,776,292</a><br />Filed on 2006-07-14<br />Status: Abandoned 114163269 E-218-2003-0 E-218-2003-0-US-01 Method and Apparatus for Bioweapon Decontamination PRV US 60/537,457 Abandoned US <br />Provisional (PRV) 60/537,457<br />Filed on 2004-01-16<br />Status: Abandoned 114167595 E-218-2003-0 E-218-2003-0-PCT-02 Method And Apparatus For Decontamination PCT Patent Cooperation Treaty PCT/US2005/00766 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/00766<br />Filed on 2005-01-13<br />Status: Expired 114114933 ABXXXX 114114936 AXXXXX 114122942 AB3XXX 114122943 AB3FXX 114122944 AEXXXX 114122945 AE1XXX 114122946 AE2XXX 114122947 AE2BXX 114157781 Anthrax TAB-823 114095158 Phenylthiocarbamide (PTC) Taste Receptor NIDCD Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Dennis Drayna, Un-kyung Kim Bitter taste has evolved in mammals as a central warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is vast and more than two dozen members of the TAS2R bitter taste receptor gene family have been identified. How individuals are genetically predisposed to respond or not to respond to the bitter taste of substances like nicotine and certain foods like broccoli may have broad implications for nutritional status and tobacco use. Large individual differences in the taste perception of bitter compounds have been well documented, and phenylthiocarbamide (PTC), the subject of this invention by scientists at the NIH and the University of Utah, has been widely used for genetic and anthropological studies.<br /><br /> The PTC receptor encodes a novel member of the G protein-coupled TAS2R bitter taste receptor family. Three coding SNPs in this gene were identified as giving rise to five haplotypes which accounted for the bimodal distribution of PTC taste sensitivity worldwide. Distinct phenotypes are associated with distinct genotypes and SNPs such as these identifying variations in the PTC receptor would allow taste masking of bitter tasting compounds tailored to the population genetics profile of different groups and populations.<br /><br /> The invention available for licensing includes composition of matter claims for a bitter taste receptor for PTC, antibodies to the receptor and methods of detecting nucleic acid and amino acid sequences as well as modulators of such PTC taste receptors. The ability to taste PTC has been shown to be correlated with the ability to taste other bitter substances, many of which are toxic. Thus variation in PTC perception and knowledge of the genetic basis of these variants can be used to aid the development of a variety of taste improvements in foods and orally administered medications. 2022-03-08 2025-08-13 2025-08-15 2003-12-01 bitter taste, ICXXXX, IXXXXX, Phenylthiocarbamide, POLYMORPHISMS, PTC, RECEPTOR, SNPs, taste masking False True True NIHTT 37470483 Website Abstract E-222-2003-1 E-099-2005-0 114171648 Kim UK, et al. http://www.ncbi.nlm.nih.gov/pubmed/12595690 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12595690">Kim UK, et al.</a> 114104570 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114104571 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104571 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104570 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114099994 Phenylthiocarbamide (PTC) Taste Receptor E-169-2001-0 Filing authorized EM, National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor&body=Please send me information about technology [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor&body=Please send me information about technology [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor.">shmilovm@nih.gov</a><br> 114161145 E-169-2001-0 E-169-2001-0-US-01 Phenylthiocarbamide (PTC) Taste Receptor PRV US 60/306,991 Abandoned US <br />Provisional (PRV) 60/306,991<br />Filed on 2001-07-20<br />Status: Abandoned 114162024 E-169-2001-0 E-169-2001-0-US-07 Phenylthiocarbamide (PTC) Taste Receptor DIV US 7,666,601 11/871,131 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7666601 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7666601">7,666,601</a><br />Filed on 2007-10-11<br />Status: Expired 114164484 E-169-2001-0 E-169-2001-0-US-03 Phenylthiocarbamide (PTC) Taste Receptor National Stage US 7,314,725 10/484,525 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7314725 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7314725">7,314,725</a><br />Filed on 2004-01-20<br />Status: Expired 114165733 E-169-2001-0 E-169-2001-0-US-08 Phenylthiocarbamide (PTC) Taste Receptor CON US 8,148,082 12/690,286 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8148082 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8148082">8,148,082</a><br />Filed on 2010-01-20<br />Status: Expired 114167584 E-169-2001-0 E-169-2001-0-PCT-02 Phenylthiocarbamide (PTC) Taste Receptor PCT Patent Cooperation Treaty PCT/US2002/023172 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/023172<br />Filed on 2002-07-19<br />Status: Expired 114114830 ICXXXX 114114831 IXXXXX 114136351 Phenylthiocarbamide 114136352 PTC 114136353 bitter taste 114136354 RECEPTOR 114136355 SNPs 114136356 POLYMORPHISMS 114136357 taste masking TAB-776 114095112 Peptide Mimotope Candidates for Otitis Media Vaccine NIDCD Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases Vaccines Xinxing Gu This technology describes peptide mimotopes of lipooligosaccharides (LOS) from nontypeable <i>Haemophilus influenzae</i> (NTHi) and <i>Moraxella catarrhalis</i> that are suitable for developing novel vaccines against the respective pathogens, for which there are currently no licensed vaccines. The mimotopes not only immunologically mimic LOSs from NTHi and <i>M. catarrhalis</i> but will also bind to antibodies specific for the respective LOS. NTHi and <i>M. catarrhalis</i> are common pathogens that cause otitis media in children and lower respiratory tract infections in adults. The effectiveness of a vaccine could be increased by substitution of a LOS epitope with a peptide mimic. Preliminary experiments have shown that some of the mimic peptides conjugated to a carrier were as effective as their respective LOS-based vaccine in stimulating a humoral immune response in rabbits. A single consensus amino acid sequence was identified for <i>M. catarrhalis</i>, while four such sequences were identified for NTHi. Thus, the identified peptides are promising candidates for developing novel vaccines for NTHi or <i>M. catarrhalis</i>. Otitis media vaccine The NIDCD Vaccine Research Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Peptide vaccines derived from LOS of NTHi or M. catarrhalis. Please contact Marianne Lynch, a technology development specialist, at 301-594-4094 or <a href="mailto:lynchm2@mail.nih.gov">lynchm2@mail.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2007-07-01 BCXXXX, CANDIDATES, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, H. Influenzae, HAEMOPHILUS, HAEMOPHILUS INFLUENZ, Haemophilus influenzae, INFLUENZA, Lipoligosaccharide, MIMICING AGENT, Minotopes, NONTYPEABLE, OTITIS MEDIA, Peptide, Peptides, UAXXXX, Vaccine False True In vivo data available In vivo data available True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114104487 Gu, Xinxing National Institute on Deafness and Other Communication Disorders (NIDCD) NIAID Gu, Xinxing (NIAID) 1 114104487 Gu, Xinxing National Institute on Deafness and Other Communication Disorders (NIDCD) NIAID Gu, Xinxing (NIAID) 1 114099943 Development of Peptide Minotopes of Lipoligosaccharide From Nontypeable Haemophilus Influenza As Vaccine Candidates E-344-2002-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine&body=Please send me information about technology [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine&body=Please send me information about technology [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine.">shmilovm@nih.gov</a><br> 114161922 E-344-2002-0 E-344-2002-0-US-01 Peptide Minotopes of Lipoligosaccharide From Nontypeable Haemophilus Influenza As Vaccines PRV US 60/441,928 Abandoned US <br />Provisional (PRV) 60/441,928<br />Filed on 2003-01-22<br />Status: Abandoned 114162916 E-344-2002-0 E-344-2002-0-PCT-02 Peptide Mimotopes of Lipoligosaccharide From Nontypeable Haemophilus Influenza As Vaccines PCT Patent Cooperation Treaty PCT/US2004/001457 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/001457<br />Filed on 2004-01-21<br />Status: Expired 114164375 E-344-2002-0 E-344-2002-0-US-03 Peptide Mimotopes of Lipooligosaccharide from Nontypeable Haemophilus Influenzae as Vaccines National Stage US 7,514,529 11/187,419 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7514529 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7514529">7,514,529</a><br />Filed on 2005-07-22<br />Status: Expired 114114624 DC5BXX 114114625 DCXXXX 114114626 UAXXXX 114114627 DXXXXX 114119671 DC5XXX 114121248 BCXXXX 114135432 Vaccine 114135433 H. Influenzae 114135434 HAEMOPHILUS INFLUENZ 114135435 Peptides 114135436 MIMICING AGENT 114135437 OTITIS MEDIA 114135438 Development 114135439 Peptide 114135440 Minotopes 114135441 Lipoligosaccharide 114135442 NONTYPEABLE 114135443 HAEMOPHILUS 114135444 INFLUENZA 114135445 CANDIDATES 114157693 Haemophilus influenzae TAB-770 114095105 Variable Curve Catheter NHLBI Collaboration, Licensing Collaboration Licensing Parag Karmarkar, Robert Lederman The invention provides a deflectable tip guiding device, such as a catheter, that enables the operator to vary the radius of curvature of the tip of the catheter. This is a novel variation on the classic "fixed fulcrum" tip deflectors used in minimally invasive procedures in open surgical treatments. The described device permits a more comprehensive ability to navigate complex geometric pathways in patient's body and enables better access to target structures (e.g., to all endomyocardial walls from a transaortic approach). The guiding device can be made compatible with imaging methods like MRI. The described technology can be used as a platform for a variety of interventional devices for delivery of drugs, cells, energy, or sutures through complex trajectories of the body. The NHLBI Translational Medicine Branch Cardiovascular Intervention Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize technology for image-guided cardiovascular interventions. Please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2005-08-01 AA4XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114104479 Lederman, Robert NHLBI Lederman, Robert (NHLBI) 0 114104480 Karmarkar, Parag NHLBI Karmarkar, Parag (NHLBI) 0 114104479 Lederman, Robert NHLBI Lederman, Robert (NHLBI) 0 114104480 Karmarkar, Parag NHLBI Karmarkar, Parag (NHLBI) 0 114099933 Moving Fulcrum Deflectable-tip Having A Variable Radius Of Curvature For Minimally-invasive Diagnostic And Therapeutic Procedures E-035-2003-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-770] Variable Curve Catheter&body=Please send me information about technology [TAB-770] Variable Curve Catheter. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-770] Variable Curve Catheter&body=Please send me information about technology [TAB-770] Variable Curve Catheter.">shmilovm@nih.gov</a><br> 114161898 E-035-2003-0 E-035-2003-0-PCT-02 Variable Curve Catheter PCT Patent Cooperation Treaty PCT/US2003/036210 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/036210<br />Filed on 2003-11-14<br />Status: Expired 114161899 E-035-2003-0 E-035-2003-0-US-03 Variable Curve Catheter National Stage US 7,918,819 10/534,362 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7918819 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7918819">7,918,819</a><br />Filed on 2005-11-07<br />Status: Issued 114161900 E-035-2003-0 E-035-2003-0-US-01 Variable Curve Catheter PRV US 60/426,542 Abandoned US <br />Provisional (PRV) 60/426,542<br />Filed on 2002-11-15<br />Status: Abandoned 114114592 AA4XXX 114114593 AAXXXX 114114594 AXXXXX TAB-743 114095079 Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein NIAID Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Kuan-teh Jeang (Estate) NF-kB has been found to be important in immune responses, cell proliferation, apoptosis, and in organ development. Several years ago it was discovered that an IKKgamma/NEMO protein was essential as an adaptor molecule to mediate TNF-alpha, IL-1, and oncoprotein induced activation of NF-kB. Mutation in IKKgamma/NEMO also results in two human genetic diseases, Familial incontinentia pigmenti and hypohidrotic/anhidrotic ectodermal dysplasia. The NIH announces mouse monoclonal antibodies to IKKgamma/NEMO that are far superior to other immunological reagents. It is anticipated that the antibodies would have both research and diagnostic capabilities. 2022-03-08 2025-08-13 2025-08-15 2003-06-01 Ectodermal dysplasia, IAXXXX, IDXXXX, Incontinentia pigmenti, IXXXXX, Neurofibromatosis type 2, Neurofibromatosis type 3, NF 2, NF 3, RXXXXX False True True NIHTT 37470483 Website Abstract 114104437 Jeang (Estate), Kuan-teh NIAID Jeang (Estate), Kuan-teh (NIAID) 0 114104437 Jeang (Estate), Kuan-teh NIAID Jeang (Estate), Kuan-teh (NIAID) 0 114099900 Mouse Monoclonal Antibodies Against IKKgamma/NEMO Protein, A Factor Required For Proinflammatory Cytokines To Activate NF-kB E-118-2003-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein&body=Please send me information about technology [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein&body=Please send me information about technology [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein.">peter.tung@nih.gov</a><br> 114114502 IAXXXX 114114503 IDXXXX 114114504 IXXXXX 114114505 RXXXXX 114157643 Incontinentia pigmenti 114157644 Neurofibromatosis type 2 114157645 Neurofibromatosis type 3 114157646 Ectodermal dysplasia 114158924 NF 2 114158925 NF 3 TAB-671 114095007 Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4 NIAID Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Vaccines Joseph Blaney, Barry Falgout, Kathryn Hanley, Lewis Markoff, Brian Murphy, Stephen Whitehead The invention relates to a dengue virus tetravalent vaccine containing a common 30-nucleotide deletion (delta30) in the 3'-untranslated region (UTR) of the genome of dengue virus serotypes 1, 2, 3, and 4. The previously identified delta30 attenuating mutation, created in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from the 3'-UTR, is also capable of attenuating a wild-type strain of dengue virus type 1 (DEN1). Removal of 30 nucleotides from the DEN1 3'-UTR in a highly conserved region homologous to the DEN4 region encompassing the delta30 mutation yielded a recombinant virus attenuated in rhesus monkeys to a level similar to recombinant virus DEN4delta30. This established the transportability of the delta30 mutation and its attenuation phenotype to a dengue virus type other than DEN4. The effective transferability of the delta30 mutation establishes the usefulness of the delta30 mutation to attenuate and improve the safety of commercializable dengue virus vaccines of any serotype.<br /><br /> A tetravalent dengue virus vaccine containing dengue virus types 1, 2, 3, and 4 each attenuated by the delta30 mutation is being developed. The presence of the delta30 attenuating mutation in each virus component precludes the reversion to a wild-type virus by intertypic recombination. In addition, because of the inherent genetic stability of deletion mutations, the delta30 mutation represents an excellent alternative for use as a common mutation shared among each component of a tetravalent vaccine. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 3'-UTR, ANTIGENIC, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, Deletion, Deletion 7, DENGUE, Dengue (Flaviviridae), DXXXXX, Nucleotide, Tetravalent, UAXXXX, UBXXXX, Vaccine, Viruses False True True NIHTT 37470483 Website Abstract 114104300 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114104301 Markoff, Lewis FDA - CDER FDA Markoff, Lewis (FDA) 0 114104302 Falgout, Barry FDA - CDER FDA Falgout, Barry (FDA) 0 114104303 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104305 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 0 114104304 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104304 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104300 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114104301 Markoff, Lewis FDA - CDER FDA Markoff, Lewis (FDA) 0 114104302 Falgout, Barry FDA - CDER FDA Falgout, Barry (FDA) 0 114104303 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104305 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 0 114099816 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 E-089-2002-1 Filing authorized FDA, NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4&body=Please send me information about technology [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4&body=Please send me information about technology [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4.">ganelinaa@niaid.nih.gov</a><br> 114160994 E-089-2002-1 E-089-2002-1-US-09 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 CON US 8,075,903 12/398,043 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8075903 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8075903">8,075,903</a><br />Filed on 2009-03-04<br />Status: Expired 114162528 E-089-2002-1 E-089-2002-1-PCT-01 Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4, or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 PCT COMB Patent Cooperation Treaty PCT/US2003/013279 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2003/013279<br />Filed on 2003-04-25<br />Status: Expired 114164270 E-089-2002-1 E-089-2002-1-US-02 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 National Stage US 7,517,531 10/970,640 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7517531 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7517531">7,517,531</a><br />Filed on 2004-10-21<br />Status: Expired 114165277 E-089-2002-1 E-089-2002-1-US-45 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 DIV US 9,783,787 13/305,639 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783787 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783787">9,783,787</a><br />Filed on 2011-11-28<br />Status: Expired 114167086 E-089-2002-1 E-089-2002-1-US-47 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 REISSUE US RE46,631 13/896,384 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46631 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46631">RE46,631</a><br />Filed on 2013-05-17<br />Status: Expired 114167087 E-089-2002-1 E-089-2002-1-US-48 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 REISSUE US RE46641 13/896,388 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46641 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46641">RE46641</a><br />Filed on 2013-05-17<br />Status: Expired 114168376 E-089-2002-1 E-089-2002-1-US-51 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 DIV US 10,837,003 15/710,672 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10837003 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10837003">10,837,003</a><br />Filed on 2017-09-20<br />Status: Expired 114169052 E-089-2002-1 E-089-2002-1-US-89 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 DIV US 11,753,627 17/009,448 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11753627 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11753627">11,753,627</a><br />Filed on 2020-09-01<br />Status: Expired 114114250 UBXXXX 114114251 UAXXXX 114114252 DC5BXX 114114253 DC5XXX 114114254 DCXXXX 114114255 DB4BXX 114114256 DB4XXX 114114257 DBXXXX 114119292 DA4BXX 114119293 DA4XXX 114119294 DAXXXX 114119295 DXXXXX 114132880 DENGUE 114132881 Tetravalent 114132882 Vaccine 114132883 Nucleotide 114132884 Deletion 114132885 3'-UTR 114132886 ANTIGENIC 114132887 chimeric 114132888 Viruses 114157586 Chromosome 7, monosomy 114157907 Dengue (Flaviviridae) 114158893 Deletion 7 TAB-641 114094978 Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2 NIAID Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Diagnostics Immunology Licensing Research Materials Therapeutics Cem Akin, Arnold Kirshenbaum, Dean Metcalfe A human mast cell line LAD2 that more closely resembles normal in vivo and in vitro human mast cells by expressing functional FcepsilonRI receptors and responding to stem cell factor (SCF) with proliferation, as described in Leuk Res. 2003 Aug;27(8):677-82 and developed by the laboratory of Dr. Dean Metcalfe at the National Institute of Allergy and Infectious Diseases.  This cell line also releases mediators by cross-linking FcgammaRI (CD64) receptors and express FcgammaRII (CD32). <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material - Patent protection is no longer being pursued for this technology. (IC Reference No. 2001-022) 2022-03-08 2025-08-13 2025-08-15 2021-01-07 Cell line, IA3XXX, IAXXXX, IDXXXX, IXXXXX, Mast cell disease, Mastocytosis, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114170517 Kirshenbaum AS, et al. https://www.ncbi.nlm.nih.gov/pubmed/12801524 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12801524">Kirshenbaum AS, et al.</a> 114104232 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 0 114104233 Akin, Cem NIAID Akin, Cem (NIAID) 0 114104234 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 0 114104232 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 0 114104233 Akin, Cem NIAID Akin, Cem (NIAID) 0 114104234 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 0 114099780 Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LAD2 E-279-2001-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2&body=Please send me information about technology [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2&body=Please send me information about technology [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2.">yogikala.prabhu@nih.gov</a><br> 114164234 E-279-2001-0 E-279-2001-0-US-01 Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LAD2 PRV US 60/354,440 Abandoned US <br />Provisional (PRV) 60/354,440<br />Filed on 2002-02-04<br />Status: Abandoned 114164237 E-279-2001-0 E-279-2001-0-PCT-02 Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LADI PCT Patent Cooperation Treaty PCT/US03/02790 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US03/02790<br />Filed on 2003-01-29<br />Status: Abandoned 114114152 IA3XXX 114114153 IAXXXX 114114154 IDXXXX 114114155 IXXXXX 114127369 WIXXXX 114149421 RM 114149422 Cell line 114157561 Mast cell disease 114158879 Mastocytosis TAB-602 114094939 Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus NIAID Consumer Products, Diagnostics, Infectious Disease, Licensing, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Therapeutics Vaccines Joseph Blaney, Robert Chanock (Estate), Brian Murphy, Alexander Pletnev, Joseph Putnak, Stephen Whitehead West Nile virus (WNV) has recently emerged in the U.S. and is considered a significant emerging disease that has embedded itself over a considerable region of the U.S. WNV infections have been recorded in humans as well as in different animals. From 1999-2014, WNV killed 1,765 people in the U.S. and caused severe disease in more than 41,762 others. This project is part of NIAID's comprehensive emerging infectious disease program.<br /><br /> The methods and compositions of this invention provide a means for prevention of WNV infection by immunization with attenuated, immunogenic viral vaccines against WNV. The invention involves a chimeric virus form comprising parts of WNV and Dengue virus. Construction of the hybrids and their properties are described in detail in multiple publications. The WNV chimeric vaccine does not target the central nervous system, which would be the case in an infection with wild type WNV. Importantly, two successful Phase I clinical trials were recently carried out with the vaccine. The live attenuated WNV vaccine is safe, well-tolerated, and immunogenic in healthy adult volunteers. Furthermore, the vaccine virus may also be considered for use as a safe reagent handled at bio-safety level 2 facilities for WNV diagnosis and surveillance. <ul> <li>Low cost of manufacture</li> <li>Proven chimeric vaccine technology</li> <li>Phase I clinical data available</li> </ul> <ul> <li>Human West Nile vaccine</li> <li>Veterinary West Nile vaccine</li> <li>West Nile Virus diagnostics</li> <li>West Nile Virus therapeutics</li> </ul> Various international patents/applications issued/pending. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 Chimeras, DC5BXX, DC5XXX, DCXXXX, DENGUE, Dengue (Flaviviridae), DXXXXX, Live, Nile, Vaccine, virus, VLXXXX, VOXXXX, WAXXXX, WBXXXX, West, WEST NILE VIRUS, WMXXXX, WNXXXX, XKXXXX, YCXXXX, YDXXXX False True <ul> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114169736 Pletnev AG, et al. http://www.ncbi.nlm.nih.gov/pubmed/11880643 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11880643">Pletnev AG, et al.</a> 114172265 Pletnev AG, et al. http://www.ncbi.nlm.nih.gov/pubmed/14517072 <a href="http://www.ncbi.nlm.nih.gov/pubmed/14517072">Pletnev AG, et al.</a> 114172266 Hanley KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15815144 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15815144">Hanley KA, et al.</a> 114172267 Pletnev AG, et al. http://www.ncbi.nlm.nih.gov/pubmed/16831498 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16831498">Pletnev AG, et al.</a> 114172268 Durbin AP, et al. http://www.ncbi.nlm.nih.gov/pubmed/23968769 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23968769">Durbin AP, et al.</a> 114172269 Maximova OA, et al. http://www.ncbi.nlm.nih.gov/pubmed/24736001 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24736001">Maximova OA, et al.</a> 114103328 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114103329 Putnak, Joseph NIAID - DIR Putnak, Joseph 0 114109066 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114109067 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114109068 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 0 114104185 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114104185 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114103328 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114103329 Putnak, Joseph NIAID - DIR Putnak, Joseph 0 114109066 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114109067 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114109068 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 0 114099739 West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine E-357-2001-1 Filing authorized NIAID, Walter Reed National Military Medical Center (WRNMMC) 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus&body=Please send me information about technology [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus&body=Please send me information about technology [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus.">maryann.puglielli@nih.gov</a><br> 114161425 E-357-2001-1 E-357-2001-1-US-02 Construction of West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine to Prevent Disease Caused by West Nile Virus National Stage US 8,778,671 10/871,775 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8778671 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8778671">8,778,671</a><br />Filed on 2004-06-18<br />Status: Expired 114162527 E-357-2001-1 E-357-2001-1-PCT-01 Construction of West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine To Prevent Disease Caused by West Nile Virus PCT COMB Patent Cooperation Treaty PCT/US2003/000594 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2003/000594<br />Filed on 2003-01-09<br />Status: Expired 114167920 E-357-2001-1 E-357-2001-1-US-15 Construction of West Nile Virus and Dengue Virus Chimeras for Use in a Live Virus Vaccine to Prevent Disease Caused by West Nile Virus DIV US 10,058,602 14/305,572 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058602 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058602">10,058,602</a><br />Filed on 2014-06-16<br />Status: Expired 114168684 E-357-2001-1 E-357-2001-1-US-29 West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine DIV US 10,456,461 16/025,624 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10456461 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10456461">10,456,461</a><br />Filed on 2018-07-02<br />Status: Expired 114168927 E-357-2001-1 E-357-2001-1-US-33 CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS DIV US 10,869,920 16/596,175 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869920 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869920">10,869,920</a><br />Filed on 2019-10-08<br />Status: Expired 114169076 E-357-2001-1 E-357-2001-1-US-34 CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS DIV US 11,400,150 16/952,864 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11400150 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11400150">11,400,150</a><br />Filed on 2020-11-19<br />Status: Expired 114113994 DC5BXX 114113995 DCXXXX 114113996 DXXXXX 114119299 DC5XXX 114123347 VLXXXX 114126642 VOXXXX 114127155 WAXXXX 114127157 WBXXXX 114127158 WNXXXX 114127159 WMXXXX 114127160 XKXXXX 114127161 YCXXXX 114127162 YDXXXX 114132955 West 114132956 Nile 114132957 virus 114132958 DENGUE 114132959 Chimeras 114132960 Live 114132961 Vaccine 114157547 WEST NILE VIRUS 114157906 Dengue (Flaviviridae) TAB-587 114094926 Method and Apparatus to Improve an MRI Image NHLBI Licensing Licensing Peter Kellman, Elliot Mcveigh The invention is a method for improving image quality in MR imaging methods using the SENSE (SENSitivity Encoding) method, which is known to have degraded image quality due to numerical ill-conditioning (so called g-factor loss). The invention improves the numerical conditioning by means of an adaptive regularization (matrix conditioning), thereby improving image quality for a given scan time. This is accomplished by adaptively adjusting the regularization parameter for each pixel position to achieve a target ghost artifact suppression. In this manner, a higher degree of matrix conditioning is used in regions which have less artifact, thus improving the SNR in these regions. 2022-03-08 2025-08-13 2025-08-15 2002-03-01 AA3B1X, AA3BXX, AA3XXX, AAXXXX, ADXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114104146 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114104147 Mcveigh, Elliot Mcveigh, Elliot 0 114104146 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114104147 Mcveigh, Elliot Mcveigh, Elliot 0 114099724 A Method and Apparatus to improve an MRI Image E-361-2001-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-587] Method and Apparatus to Improve an MRI Image&body=Please send me information about technology [TAB-587] Method and Apparatus to Improve an MRI Image. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-587] Method and Apparatus to Improve an MRI Image&body=Please send me information about technology [TAB-587] Method and Apparatus to Improve an MRI Image.">vk5q@nih.gov</a><br> 114161383 E-361-2001-0 E-361-2001-0-US-10 A Method and Apparatus to improve an MRI Image National Stage US 7,154,268 10/492,897 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7154268 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7154268">7,154,268</a><br />Filed on 2004-04-15<br />Status: Abandoned 114165807 E-361-2001-0 E-361-2001-0-US-01 A Method and Apparatus to improve an MRI Image PRV US 60/348,005 Abandoned US <br />Provisional (PRV) 60/348,005<br />Filed on 2001-10-19<br />Status: Abandoned 114165824 E-361-2001-0 E-361-2001-0-PCT-02 A Method and Apparatus to Improve an MRI Image PCT Patent Cooperation Treaty PCT/US2002/033571 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/033571<br />Filed on 2002-10-17<br />Status: Expired 114113927 AA3B1X 114113928 AA3BXX 114113929 AA3XXX 114113930 AAXXXX 114113931 ADXXXX 114113932 AXXXXX TAB-562 114094900 Vaccination Strategies to Provide Protection Against the Ebola Virus NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Gary Nabel This invention describes a method for vaccination against Ebola virus. Outbreaks of hemorrhagic fever caused by the Ebola virus, particularly the Zaire subtype, are associated with high mortality rates. The virus is very contagious, and during an outbreak, presents a threat to anybody who comes into contact with an infected person. Because the virus progresses so rapidly and the mortality rate is so high, there is little opportunity to develop natural immunity, making vaccination a promising intervention. This invention relates to a vaccine strategy employing DNA and adenoviral vectors expressing proteins associated with the Ebola virus. This vaccine strategy, a DNA prime with an adenoviral boost, elicits a protective immune response in primates. A vaccine was designed to optimize expression by incorporating genes for two subtypes of the glycoprotein (Zaire and Sudan) and minimizes toxicity by eliminating the trans-membrane region. The specific genes identified may be used for gene-based or protein-based vaccines that will prevent Ebola infection. 2022-03-08 2025-08-13 2025-08-15 2002-02-01 DC5XXX, DCXXXX, DXXXXX, Hemorrhagic fever, Q fever False True True NIHTT 37470483 Website Abstract 114104096 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114104096 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114099701 Development of a Preventive Vaccine for Filovirus Infection in Primate E-241-2001-0 Filing authorized Centers for Disease Control and Prevention (CDC), NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus&body=Please send me information about technology [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus&body=Please send me information about technology [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus.">sabrina.hafiz@nih.gov</a><br> 114161324 E-241-2001-0 E-241-2001-0-US-01 Development of a Preventive Vaccine for Filovirus Infection in Primates PRV US 60/326,476 Abandoned US <br />Provisional (PRV) 60/326,476<br />Filed on 2001-10-01<br />Status: Abandoned 114161326 E-241-2001-0 E-241-2001-0-PCT-02 Development of a Preventive Vaccine for Filovirus Infection in Primates PCT Patent Cooperation Treaty PCT/US2002/030251 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/030251<br />Filed on 2002-09-24<br />Status: Expired 114161327 E-241-2001-0 E-241-2001-0-US-07 Development of a Preventive Vaccine for Filovirus Infection in Primates National Stage US 7,635,688 10/491,121 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635688 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635688">7,635,688</a><br />Filed on 2004-08-23<br />Status: Expired 114165656 E-241-2001-0 E-241-2001-0-US-08 Development of a Preventive Vaccine for Filovirus Infection in Primate DIV US 8,106,026 12/612,579 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106026 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106026">8,106,026</a><br />Filed on 2009-11-04<br />Status: Expired 114165658 E-241-2001-0 E-241-2001-0-US-09 Development of a Preventive Vaccine for Filovirus Infection in Primates DIV US 8,106,027 12/612,621 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106027 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106027">8,106,027</a><br />Filed on 2009-11-04<br />Status: Expired 114165660 E-241-2001-0 E-241-2001-0-US-10 Development of a Preventive Vaccine for Filovirus Infection in Primates DIV US 8,124,592 12/612,625 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8124592 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8124592">8,124,592</a><br />Filed on 2009-11-04<br />Status: Expired 114113819 DC5XXX 114113820 DCXXXX 114113821 DXXXXX 114157519 Q fever 114157520 Hemorrhagic fever TAB-560 114094898 Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Suzanne Emerson, Robert Purcell, Darren Schofield This invention claims antibodies and/or fragments thereof specific for hepatitis A virus (HAV) and the use of the antibodies in the diagnosis, prevention, and treatment of hepatitis A. Hepatitis A is the most common type of hepatitis reported in the United States, which reports an estimated 134,000 cases annually, and infects at least 1.4 million people worldwide each year. HAV is a positive sense RNA virus that is transmitted via the fecal-oral route, mainly through contaminated water supplies and food sources. HAV is thought to replicate in the oropharynx and epithelial lining of the intestines, where it initiates a transient viremia and subsequently infects the liver. Humoral immunity has been shown to provide an effective defense against Hepatitis A. Prior to the availability of the current inactivated virus vaccines, pooled human immune globulin preparations were routinely used to protect individuals traveling to areas of the world where HAV is endemic. Chimpanzees are susceptible to infection with HAV and can produce antibodies that neutralize the virus. Chimpanzee immunoglobulins are virtually identical to those of humans; thus, they have the same potential as human antibodies for clinical applications. The inventors have shown that the four chimpanzee monoclonal antibodies described in the patent application neutralized HAV strains HM-175, AGM-27, and the HM-175 VP3-070 mutant. Since only a single serotype of HAV has been identified, these antibodies are predicted to neutralize most, if not all, isolates of HAV. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 DB4BXX, DBXXXX, DCXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract 114104089 Schofield, Darren NIAID Schofield, Darren (NIAID) 0 114104090 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104091 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114104089 Schofield, Darren NIAID Schofield, Darren (NIAID) 0 114104090 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104091 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114099699 Anti-hepatitis A Virus Antibodies E-356-2001-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus&body=Please send me information about technology [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus&body=Please send me information about technology [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus.">maryann.puglielli@nih.gov</a><br> 114161073 E-356-2001-0 E-356-2001-0-US-05 Anti-Hepatitis A Virus Antibodies DIV US 7,635,476 11/789,377 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635476 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635476">7,635,476</a><br />Filed on 2007-04-23<br />Status: Abandoned 114161318 E-356-2001-0 E-356-2001-0-US-01 Four Chimpanzee Monoclonal Antibodies That Neutralize Hepatitis A Virus PRV US 60/339,109 Abandoned US <br />Provisional (PRV) 60/339,109<br />Filed on 2001-11-07<br />Status: Abandoned 114161320 E-356-2001-0 E-356-2001-0-PCT-02 Anti-Hepatitis A Virus Antibodies PCT Patent Cooperation Treaty PCT/US2002/036077 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/036077<br />Filed on 2002-11-07<br />Status: Expired 114161321 E-356-2001-0 E-356-2001-0-US-03 Anti-Hepatitis A Virus Antibodies National Stage US 7,282,205 10/494,676 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7282205 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7282205">7,282,205</a><br />Filed on 2004-05-04<br />Status: Abandoned 114113811 DB4BXX 114113812 DBXXXX 114113813 DCXXXX 114113814 DXXXXX 114157516 Hepatitis D 114157517 Hepatitis A 114157518 Hepatitis E TAB-553 114094891 TMC1, a Deafness-Related Gene NIDCD Collaboration, Diagnostics, Licensing, Rare/Neglected Diseases, Reproductive Health, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Licensing Rare/Neglected Diseases Reproductive Health Research Materials Therapeutics Vaccines Andrew Griffith Hearing loss is a common communication disorder affecting nearly 1 in 1,000 children in the United States alone, and nearly 50% of adults by the age of eighty. Hearing loss can be caused by environmental and disease-related factors; however, hearing loss due to genetic factors accounts for approximately 50% of cases. <br><br> The NIH announces the isolation of two novel genes involved in hearing; TMC1, short for transmembrane channel-like gene 1. The inventors have discovered that dominant and recessive mutations in TMC1 underlie two forms of hereditary deafness, known as DFNA36 and DFNB7/11. TMC1 encodes a protein required for normal function of the mammalian hair cell, which plays a critical role within the hearing pathway that detects sound in the inner ear. <br><br> The invention discloses TMC1 nucleic acids, vectors, and cells. Also disclosed are methods of detecting hearing loss, or a predisposition to hearing loss, due to a mutation in TMC1, as well as methods for identifying agents that interact with the TMC1 gene in a cell. Nucleic acids and methods of use for TMC2, a gene closely related to TMC1, are also disclosed. <ul> <li>Development of a genetic diagnostic test for hearing loss</li> <li>Development of pharmaceuticals to treat hearing loss</li> </ul> The NIDCD Otolaryngology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology as well as collaborate on further pre-clinical and clinical studies with the TMC2 gene mutations. Please contact Ms. Marianne Lynch at 301-402-5579 or via email at <a href="mailto:lynchm@nhlbi.nih.gov">lynchm@nhlbi.nih.gov</a> for more information. Available for non-exclusive licensing. 2022-03-08 2025-08-13 2025-08-15 2007-05-01 Hereditary deafness, IA6XXX, IAXXXX, IB6XXX, IBXXXX, IXXXXX, UAXXXX False True Early stage Early stage True NIHTT 37470483 Website Abstract 114169821 K Kurima et al. Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet. 2002 Mar;30(3):277-284. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11850618&query_hl=5&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11850618&query_hl=5&itool=pubmed_docsum">K Kurima et al. Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet. 2002 Mar;30(3):277-284.</a> 114104073 Griffith, Andrew NIDCD Griffith, Andrew (NIDCD) 0 114104073 Griffith, Andrew NIDCD Griffith, Andrew (NIDCD) 0 114099690 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness E-168-2001-0 National Institute on Deafness and Other Communication Disorders (NIDCD) 114099691 Transduction-1 And Transductin-2 And Applications To Hereditary Deafness E-168-2001-1 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-553] TMC1, a Deafness-Related Gene&body=Please send me information about technology [TAB-553] TMC1, a Deafness-Related Gene. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-553] TMC1, a Deafness-Related Gene&body=Please send me information about technology [TAB-553] TMC1, a Deafness-Related Gene.">shmilovm@nih.gov</a><br> 114161296 E-168-2001-0 E-168-2001-0-US-01 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness PRV US 60/323,275 Abandoned US <br />Provisional (PRV) 60/323,275<br />Filed on 2001-09-19<br />Status: Abandoned 114161297 E-168-2001-0 E-168-2001-0-PCT-02 Transductin-1 And Transductin-2 And Applications to Hereditary Deafness PCT Patent Cooperation Treaty PCT/US02/29614 Expired Patent Cooperation Treaty <br />(PCT) PCT/US02/29614<br />Filed on 2002-09-19<br />Status: Expired 114161299 E-168-2001-0 E-168-2001-0-US-03 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness National Stage US 7,192,705 10/487,887 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7192705 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7192705">7,192,705</a><br />Filed on 2004-02-26<br />Status: Abandoned 114161301 E-168-2001-0 E-168-2001-0-US-08 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness DIV US 7,659,115 11/615,250 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7659115 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7659115">7,659,115</a><br />Filed on 2006-12-22<br />Status: Expired 114162982 E-168-2001-1 E-168-2001-1-US-01 Transductin-1 And Transductin-2 And Applications To Hereditary Deafness CIP US 7,166,433 10/792,307 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7166433 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7166433">7,166,433</a><br />Filed on 2004-03-03<br />Status: Abandoned 114113778 IB6XXX 114113779 IA6XXX 114113780 IBXXXX 114113781 IAXXXX 114113782 IXXXXX 114113783 UAXXXX 114157504 Hereditary deafness TAB-538 114094876 Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination NIAID Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Suzanne Emerson, Robert Purcell Hepatitis E is endemic in many countries throughout the developing world, in particular on the continents of Africa and Asia. The disease generally affects young adults and has a very high mortality rate, up to 20%, in pregnant women. This invention relates to the identification of a neutralization site of hepatitis E virus (HEV) and neutralizing antibodies that react with it. The neutralization site is located on a polypeptide from the ORF2 gene (capsid gene) of HEV. This neutralization site was identified using a panel of chimpanzee monoclonal antibodies that are virtually identical to human antibodies. Since this neutralization site is conserved among genetically divergent strains of HEV, the neutralizing monoclonal antibodies may be useful in the diagnosis, treatment and/or prevention of hepatitis E. Furthermore, immunogens that encompass this neutralization site may be used in vaccination to effectively prevent, and/or reduce the incidence of HEV infection. Polypeptides containing this neutralization site may be useful in evaluating vaccine candidates for the production of neutralizing antibodies to HEV. The NIAID Laboratory of Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these antibodies or structures they interact with. For more information, please contact Robert H. Purcell, M.D., Co-chief, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bldg. 50, Rm. 6523, Bethesda, MD 20892-8009; Phone (301) 496-5090; Fax (301) 402-0524. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 DC5BXX, DCXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract 114169817 YH Zhou et al. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with HEV. Vaccine 2005 May 2;23(24):3157-3165. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15837215&query_hl=3&itool=pubmed_DocSum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15837215&query_hl=3&itool=pubmed_DocSum">YH Zhou et al. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with HEV. Vaccine 2005 May 2;23(24):3157-3165.</a> 114169818 DJ Schofield et al. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 2003 Dec 12;22(2):257-267. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14615154&query_hl=1&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14615154&query_hl=1&itool=pubmed_docsum">DJ Schofield et al. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 2003 Dec 12;22(2):257-267.</a> 114169819 YH Zhou et al. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1,2,3,and 4. Vaccine 2004 Jun 30;22(20):2578-2585. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15193383&query_hl=3&itool=pubmed_DocSum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15193383&query_hl=3&itool=pubmed_DocSum">YH Zhou et al. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1,2,3,and 4. Vaccine 2004 Jun 30;22(20):2578-2585.</a> 114104039 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104040 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114104039 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104040 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114099678 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of..... E-043-2000-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination&body=Please send me information about technology [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination&body=Please send me information about technology [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination.">maryann.puglielli@nih.gov</a><br> 114161260 E-043-2000-0 E-043-2000-0-US-04 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of Screening for Neutralizing Antibodies to Hepatitis E Virus National Stage US 6,930,176 10/148,737 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930176 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930176">6,930,176</a><br />Filed on 2003-01-27<br />Status: Abandoned 114161261 E-043-2000-0 E-043-2000-0-EP-03 Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination and in Methods of Screeening for Neutralizing Antibodies to Hepatitis E Virus National Stage European Patent 1235862 00982311.3 Abandoned European Patent <br />National Stage 00982311.3<br />Filed on 2000-11-30<br />Status: Abandoned 114161263 E-043-2000-0 E-043-2000-0-US-05 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of..... CON US 7,148,323 11/054,041 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7148323 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7148323">7,148,323</a><br />Filed on 2005-02-09<br />Status: Abandoned 114164339 E-043-2000-0 E-043-2000-0-US-01 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of..... PRV US 60/167,490 Abandoned US <br />Provisional (PRV) 60/167,490<br />Filed on 1999-12-01<br />Status: Abandoned 114165614 E-043-2000-0 E-043-2000-0-PCT-02 Major Neutralization Site of Hepatitis E Virus and Use of This Neutralization Site in Methods of Vaccination and in Methods of..... PCT Patent Cooperation Treaty PCT/US00/32614 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/32614<br />Filed on 2000-11-30<br />Status: Expired 114113717 DC5BXX 114113718 DCXXXX 114113719 DXXXXX 114157488 Hepatitis D 114157489 Hepatitis A 114157490 Hepatitis E TAB-535 114094873 Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses NIAID Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases Vaccines Joseph Blaney, Kathryn Hanley, Brian Murphy, Stephen Whitehead Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. This invention relates to dengue virus mutations that may contribute to the development of improved dengue vaccines. Site directed and random mutagenesis techniques were used to introduce mutations into the dengue virus genome and to assemble a collection of useful mutations for incorporation in recombinant live attenuated dengue virus vaccines. The resulting mutant viruses were screened for several valuable phenotypes, including temperature sensitivity in Vero cells or human liver cells, host cell restriction in mosquito cells or human liver cells, host cell adaptation for improved replication in Vero cells, and attenuation in mice or in mosquitoes. The genetic basis for each observed phenotype was determined by direct sequence analysis of the genome of the mutant virus. Mutations identified through these sequencing efforts have been further evaluated by re-introduction of the identified mutations, singly, or in combination, into recombinant dengue virus and characterization of the resulting recombinant virus for phenotypes. In this manner, a menu of attenuating and growth promoting mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccine candidates. The mutations promoting growth in Vero cells have usefulness for the production of live or inactivated dengue virus vaccines. The National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these vaccines. Please contact Dr. Brian Murphy at 301-594-1616 or <a href="mailto:bm25f@nih.gov">bm25f@nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 ATTENUATING, chimeric, DC5BXX, DC5XXX, DCXXXX, DENGUE, Dengue (Flaviviridae), Dengue Vaccine, Development, DXXXXX, Mutations, UAXXXX, UBXXXX, USEFUL, Viruses False True True NIHTT 37470483 Website Abstract 114104033 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114104034 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104035 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114104036 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104036 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104033 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114104034 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104035 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114099674 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES E-120-2001-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses&body=Please send me information about technology [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses&body=Please send me information about technology [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses.">ganelinaa@niaid.nih.gov</a><br> 114160995 E-120-2001-0 E-120-2001-0-US-13 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES CON US 8,039,003 12/396,376 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8039003 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8039003">8,039,003</a><br />Filed on 2009-03-02<br />Status: Expired 114161250 E-120-2001-0 E-120-2001-0-US-10 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 7,560,118 11/446,050 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7560118 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7560118">7,560,118</a><br />Filed on 2006-06-02<br />Status: Expired 114162529 E-120-2001-0 E-120-2001-0-PCT-02 Development of Mutations Useful For Attenuating Dengue Viruses And Chimeric PCT Patent Cooperation Treaty PCT/US2002/016308 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/016308<br />Filed on 2002-05-22<br />Status: Expired 114164261 E-120-2001-0 E-120-2001-0-US-04 Development of Mutations Useful For Attenuating Dengue Viruses And Chimeric Dengue Viruses National Stage US 7,226,602 10/719,547 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7226602 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7226602">7,226,602</a><br />Filed on 2003-11-21<br />Status: Expired 114164393 E-120-2001-0 E-120-2001-0-US-01 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES PRV US 60/293,049 Abandoned US <br />Provisional (PRV) 60/293,049<br />Filed on 2001-05-22<br />Status: Abandoned 114166539 E-120-2001-0 E-120-2001-0-US-18 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 8,632,782 13/240,849 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8632782 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8632782">8,632,782</a><br />Filed on 2011-09-22<br />Status: Expired 114167082 E-120-2001-0 E-120-2001-0-US-35 Attenuated Dengue Virus Comprising Mutations in the NS3 Gene REISSUE US RE045053 13/896,411 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45053 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45053">RE045053</a><br />Filed on 2013-05-17<br />Status: Expired 114167083 E-120-2001-0 E-120-2001-0-US-36 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES REISSUE US RE45016 13/896,396 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45016 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45016">RE45016</a><br />Filed on 2013-05-17<br />Status: Expired 114167084 E-120-2001-0 E-120-2001-0-US-37 Recombinant Attenuated Dengue Viruses Comprising A Deletion in the 3' Untranslated Region and Additional Attenuating Mutations Induced by Chemical Mutagenesis REISSUE US RE45,123 13/896,409 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45123 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45123">RE45,123</a><br />Filed on 2013-05-17<br />Status: Expired 114167714 E-120-2001-0 E-120-2001-0-US-38 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 9,707,287 14/096,424 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707287 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707287">9,707,287</a><br />Filed on 2013-12-04<br />Status: Expired 114168334 E-120-2001-0 E-120-2001-0-US-90 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 10,500,264 15/650,482 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10500264 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10500264">10,500,264</a><br />Filed on 2017-07-14<br />Status: Expired 114113706 DC5BXX 114113707 DCXXXX 114113708 UBXXXX 114113709 UAXXXX 114113710 DXXXXX 114119291 DC5XXX 114132872 Dengue Vaccine 114132873 Development 114132874 Mutations 114132875 USEFUL 114132876 ATTENUATING 114132877 DENGUE 114132878 Viruses 114132879 chimeric 114157905 Dengue (Flaviviridae) TAB-5045 162060508 Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder NIA Collaboration, Licensing, Neurology, Oncology, Therapeutics Collaboration Licensing Neurology Oncology Therapeutics Nigel Greig, Shih Chang Hsueh, Daniela Lecca, Weiming Luo, Michael Scerba, David Tweedie <h2>Summary:</h2> <p>The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders.</p> <h2>Description of Technology:</h2> <p>Numerous systemic, as well as neurological disorders, have a hallmark inflammatory element that can drive disease progression. However, the use of currently available anti-inflammatory agents have failed to demonstrate efficacy as potential treatment for systemic and neurological disorders in clinical trials.</p> <p>The immunomodulatory imide drug (IMiD) thalidomide exerts anti-inflammatory effects through inhibition of tumor necrosis factor-alpha (TNF-&alpha;), which is a master regulator of the inflammatory response.&nbsp; Researchers at the National Institute on Aging (NIA) have synthesized novel thalidomide analogs possessing potent anti-inflammatory actions but, importantly, hinder the cerebon binding that associated with the adverse teratogenic actions of classic IMiDs. This invention has potential to be developed as therapeutics for a variety of systemic and neurological disorders including inflammatory disorders, autoimmune disorders, viral infections, traumatic brain injury, neurodegenerative diseases and cancer.</p> <h2>Potential Commercial Applications:</h2> <p>Therapeutics for:</p> <ul> <li>neurodegenerative diseases</li> <li>inflammatory disorders</li> <li>autoimmune disorders</li> <li>viral infections</li> <li>cancer</li> </ul> <h2>Competitive Advantages over Clinically Available IMiDs:</h2> <ul> <li>More potent anti-inflammatory properties</li> <li>Potentially clinically safer than classic IMiDs by lower risk of fetal malformations</li> <li>Potential to treat a wide range of significant unmet medical needs</li> </ul> Researchers at the NIA seek licensing and/or co-development research collaborations for pre-clinical and clinical development of fluorophthalimides as anti-inflammatory therapeutics for systemic and neurodegenerative diseases 2025-04-25 2025-06-27 2025-08-15 2025-05-02 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-045-2012-0 E-208-2015-0 162062596 Lecca D, et al. Novel, thalidomidelike, noncereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. (PMID 36872339) https://pubmed.ncbi.nlm.nih.gov/36872339/ <a href="https://pubmed.ncbi.nlm.nih.gov/36872339/">Lecca D, et al. Novel, thalidomidelike, noncereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. (PMID 36872339)</a> 162061129 Greig, Nigel National Institute on Aging (NIH/NIA) NIA Greig, Nigel (NIA) 1 162061218 Luo, Weiming National Institute on Aging (NIH/NIA) NIA Luo, Weiming (NIA) 2 162061257 Tweedie, David National Institute on Aging (NIH/NIA) NIA Tweedie, David (NIA) 3 162061271 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 4 162061286 Lecca, Daniela National Institute on Aging (NIH/NIA) Lecca, Daniela 5 162061304 Hsueh, Shih Chang National Institute on Aging (NIH/NIA) Hsueh, Shih Chang 6 162061129 Greig, Nigel National Institute on Aging (NIH/NIA) NIA Greig, Nigel (NIA) 1 162061218 Luo, Weiming National Institute on Aging (NIH/NIA) NIA Luo, Weiming (NIA) 2 162061257 Tweedie, David National Institute on Aging (NIH/NIA) NIA Tweedie, David (NIA) 3 162061271 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 4 162061286 Lecca, Daniela National Institute on Aging (NIH/NIA) Lecca, Daniela 5 162061304 Hsueh, Shih Chang National Institute on Aging (NIH/NIA) Hsueh, Shih Chang 6 162060511 Flurorphthalimides As Anti-inflammatory Agents For Systemic And Neurodegenerative Disorders E-151-2022-0 Filing authorized National Institute on Aging (NIH/NIA) 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder&body=Please send me information about technology [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder&body=Please send me information about technology [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">geoffrey.ravilious@nih.gov</a><br> 162060598 E-151-2022-0 E-151-2022-0-US-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE PRV US 63/397,235 Expired US <br />Provisional (PRV) 63/397,235<br />Filed on 2022-08-11<br />Status: Expired 162060599 E-151-2022-0 E-151-2022-0-PC-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2023/029602 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/029602<br />Filed on 2023-08-07<br />Status: Expired 162060600 E-151-2022-0 E-151-2022-0-US-02 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION National Stage US 19/102,830 Pending US <br />National Stage 19/102,830<br />Filed on 2025-02-10<br />Status: Pending 162060601 E-151-2022-0 E-151-2022-0-EP-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION National Stage European Patent 23762066.1 Pending European Patent <br />National Stage 23762066.1<br />Filed on 2025-02-28<br />Status: Pending TAB-5038 159567984 Novel Antibody Test for Mycoplasma Detection NIAID Robert Purcell <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology is a novel antibody test designed for the detection of Mycoplasma antibodies, representing a significant advancement in Mycoplasma detection methods. This test offers a rapid and reliable means of diagnosing Mycoplasma infections, which is particularly valuable in research and clinical settings. Unlike existing tests, this innovative approach provides specificity and sensitivity in detecting Mycoplasma antibodies, ensuring accurate and timely diagnosis. The technology&#39;s development stage is currently at the prototype phase, indicating that it is undergoing initial testing and refinement to optimize its performance. Once fully developed, this antibody test has the potential to revolutionize Mycoplasma detection, improving research outcomes and patient care.</span></span></span></p> This novel antibody test for Mycoplasma detection offers several competitive advantages over existing methods. Firstly, it is the first of its kind, providing a unique solution to a previously unmet need in the field. Its specificity and sensitivity in detecting Mycoplasma antibodies surpass current standards, ensuring accurate and reliable results. Additionally, the test is designed to be rapid and easy to use, saving time and resources compared to traditional methods. Its innovative approach has the potential to significantly improve research and clinical outcomes related to Mycoplasma infections. As the technology advances towards commercialization, these competitive advantages position it as a game-changer in the field of Mycoplasma detection and diagnosis. The novel antibody test for Mycoplasma detection has a wide range of potential applications across various fields. In research settings, it can be used to screen cell cultures for Mycoplasma contamination, ensuring the integrity of experiments and the reliability of research outcomes. In clinical settings, the test can aid in the diagnosis of Mycoplasma infections, enabling healthcare providers to administer appropriate treatments promptly. Additionally, the test may find applications in veterinary medicine, agriculture, and environmental monitoring, where Mycoplasma contamination can have significant impacts. The test's versatility and reliability make it a valuable tool for a diverse range of applications, highlighting its potential to address key challenges in multiple industries. 2024-12-10 2025-08-13 2025-08-15 2024-12-10 False False True 52406769 Prototype 52406769 37470483 Website Abstract 159567997 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 1 159567997 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 1 159567987 Ureaplasma Urealyticum Mycoplasma Test E-198-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection.">elizabeth.pitts@nih.gov</a><br> TAB-497 114094835 Generalized MRI Artifact Reduction Using Array Processing Method NHLBI Licensing Licensing Peter Kellman, Elliot Mcveigh The invention is a phased array combining method for reducing artifacts in Magnetic Resonance (MR) imaging. The method uses a constrained optimization that optimizes signal-to-noise subject to the constraint of nulling ghost artifacts at known locations. The method is effective in reducing or canceling artifacts that arise in a wide variety of MR applications, including ghost artifacts from echo planar imaging and Gradient Recalled Echo with Echo Train (FGRE-ET) imaging used in cardiac or other rapid imaging applications. The strategy of using phase encode acquisition orders with distortion that results in ghosts, followed by applying this phased array ghost cancellation method has a number of benefits, including reduced blur and geometric distortion, reduced acquisition time (eliminating echo shifting), and reduced sensitivity to flow. 2022-03-08 2025-08-13 2025-08-15 2001-08-01 AAXXXX, ACXXXX, ADXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103962 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103963 Mcveigh, Elliot Mcveigh, Elliot 0 114103962 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103963 Mcveigh, Elliot Mcveigh, Elliot 0 114099637 Ghost Artifact Cancellation Using Phased Array Processing E-198-2000-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method&body=Please send me information about technology [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method&body=Please send me information about technology [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method.">vk5q@nih.gov</a><br> 114161156 E-198-2000-0 E-198-2000-0-AU-03 Ghost Artifact Cancellation Using Phased Array Processing National Stage Australia 2002247451 Abandoned Australia <br />National Stage 2002247451<br />Filed on 2002-03-28<br />Status: Abandoned 114164648 E-198-2000-0 E-198-2000-0-US-01 Ghost Artifact Cancellation Using Phased Array Processing ORD US 6,771,067 09/825,617 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6771067 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6771067">6,771,067</a><br />Filed on 2001-04-03<br />Status: Expired 114165813 E-198-2000-0 E-198-2000-0-PCT-02 Ghost Artifact Cancellation Using Phased Array Processing PCT Patent Cooperation Treaty PCT/US2002/009939 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/009939<br />Filed on 2002-03-28<br />Status: Expired 114113551 AAXXXX 114113552 ACXXXX 114113553 ADXXXX 114113554 AXXXXX TAB-4963 153986016 A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics NIAID Collaboration, Immunology, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Collaboration Immunology Infectious Disease Licensing Research Equipment Therapeutics Vaccines Ursula Buchholz <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome sequences into cDNA plasmids under a T7 RNA polymerase promoter, BSR T7/5 cells facilitate the transcription of RNA antigenomes and mRNA encoding RNP elements, leading to the assembly of infectious viruses. Notably, this system does not require helper viruses, and the cell line&#39;s permissiveness, attributed to the absence of a functional type 1 interferon response, makes it especially valuable for viruses replicating in the cytoplasm.</span></span></span></p> BSR T7/5 cells offer distinct competitive advantages over traditional methods for RNA virus recovery. Their efficiency in recovering RNA viruses from cDNA plasmids via reverse genetics surpasses that of other cell lines, particularly for members of the mononegavirales order. Unlike many existing approaches, the use of BSR T7/5 cells does not necessitate the presence of helper viruses, streamlining the recovery process. Additionally, the cell line's high permissiveness to RNA viruses, attributed to its lack of a functional type 1 interferon response, enhances the range of viruses that can be studied and recovered. These advantages make BSR T7/5 cells a superior choice for researchers seeking a reliable, efficient, and versatile platform for RNA virus recovery and study. The applications of BSR T7/5 cells extend across various fields, offering immense potential in virology, vaccine development, and antiviral drug discovery. Their ability to efficiently recover RNA viruses through reverse genetics makes them invaluable for studying viral pathogenesis, host-virus interactions, and viral evolution. In vaccine development, these cells can be instrumental in generating attenuated or modified viruses for vaccine candidates, particularly for viruses that replicate in the cytoplasm. Furthermore, BSR T7/5 cells hold promise in antiviral drug screening, allowing researchers to evaluate the efficacy of antiviral compounds against a wide range of RNA viruses. Overall, the versatility and reliability of BSR T7/5 cells make them a key tool for advancing our understanding of RNA viruses and developing strategies to combat them. 2024-03-25 2025-08-13 2025-08-15 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153986027 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 153986027 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 153986019 BSR T7/5 Cells: Baby Hamster Kidney (BHK-21) Cells Stably Expressing Phage T7 RNA Polymerase E-166-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics.">elizabeth.pitts@nih.gov</a><br> TAB-4912 153267820 DeePlexing – Extending Imaging Multiplexity Using Machine Learning NIAID Computational models/software, Dermatology, Immunology, Licensing, Radiology, Research Equipment, Software / Apps Computational models/software Dermatology Immunology Licensing Radiology Research Equipment Software / Apps Ronald Germain, Spencer Grant, Nishant Thakur, Abigail Wong-Rolle, Chen Zhao <p>Spatial proteomics and transcriptomics are fast-emerging fields with the potential to revolutionize various branches of biology. In the last five years, various multiplex immunofluorescence and immunohistochemistry imaging methods have been developed to stain 5-60 different protein markers in a given tissue. Nonetheless, most of these techniques are iterative and can image a maximum of 3-8 markers in a single cycle, resulting in processing time of several hours to days.</p> <p>Scientists at National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) have developed a new method - DeePlexing - that uses a deep learning algorithm to dramatically enhance the number of markers stained in a single imaging cycle. This is accomplished with no changes or upgrades to the imaging platform itself. In the DeePlexing method, multiple antibodies/probes are conjugated to the same fluorophores and later deconvolved computationally to retrieve the multichannel signal with high accuracy. In digital spatial profiling, DeePlexing enables the user to detect seven different protein markers in a single cycle using only three fluorophores and even quadruple the number of markers in a single round without compromising the quality of RNA and protein in the sample. For multiplex protein profiling, DeePlexing can potentially stain for up to 255 different protein markets with eight fluorophores and deconvolve the signal for each of the 255 markers computationally.</p> <ul> <li>Enhances the number of markers stained in a single imaging cycle</li> <li>Achieves this marker detection increase without compromising RNA or protein quality when that is part of the analytical pipeline</li> <li>Reduces the required processing time for multiplex imaging platforms</li> <li>Inexpensive and replicable</li> </ul> <ul> <li>Imaging platforms in spatial transcriptomics</li> <li>Multiplex protein spatial imaging</li> </ul> To license this technology, please contact Daniel Lee at 301-761-6327 or at <a href="mailto:daniel.lee5@nih.gov"> daniel.lee5@nih.gov</a>, and reference E-202-2021-0. 2024-02-23 2025-08-13 2025-08-15 2024-02-26 IMAGING, IMMUNOFLUORESCENCE, Immunohistochemistry, Methods, Multiplex False False True 52406769 Prototype 52406769 37470483 Website Abstract 153267958 Germain, Ronald NIH - NIAID NIAID Germain, Ronald (NIAID) 1 153267962 Grant, Spencer NIH - NIAID NIAID Grant, Spencer (NIAID) 2 153267981 Thakur, Nishant NIH - NIAID NIAID Thakur, Nishant (NIAID) 3 153267991 Zhao, Chen NCI - CCR NCI Zhao, Chen (NCI) 4 153268007 Wong-Rolle, Abigail NCI - CCR NCI Wong-Rolle, Abigail (NCI) 5 153267958 Germain, Ronald NIH - NIAID NIAID Germain, Ronald (NIAID) 1 153267962 Grant, Spencer NIH - NIAID NIAID Grant, Spencer (NIAID) 2 153267981 Thakur, Nishant NIH - NIAID NIAID Thakur, Nishant (NIAID) 3 153267991 Zhao, Chen NCI - CCR NCI Zhao, Chen (NCI) 4 153268007 Wong-Rolle, Abigail NCI - CCR NCI Wong-Rolle, Abigail (NCI) 5 153267823 DeePlexing - Extending Imaging Multiplexity Using Machine Learning E-202-2021-0 Research Material NCI, NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning&body=Please send me information about technology [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning&body=Please send me information about technology [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning.">yogikala.prabhu@nih.gov</a><br> 153303249 Multiplex 153303253 IMMUNOFLUORESCENCE 153303265 Immunohistochemistry 153303309 IMAGING 153303313 Methods TAB-4898 153000177 Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection NIAID Collaboration, Human Cell Lines, Immunology, Infectious Disease, Research Materials Collaboration Human Cell Lines Immunology Infectious Disease Research Materials Arnold Kirshenbaum, Dean Metcalfe <p>LAD2 and LADR cell lines are invaluable tools in mast cell research, offering insights into mastocytosis and immune responses. Derived from CD34+ cells, LAD2 cells have been extensively used for over 18 years, while LADR cells, a newer variant, exhibit enhanced characteristics such as larger size, increased granulation, and faster doubling time. Both cell lines release granular contents upon FceRI aggregation and can be infected with various strains of HIV. LADR cells, in particular, show greater expression of certain surface receptors and mRNA compared to LAD2 cells. Additionally, gene expression arrays highlight differences in signaling pathways and regulatory mechanisms between the two cell lines, providing a comprehensive platform for studying mast cell biology and related diseases.</p> <p>&nbsp;</p> The LAD2 and LADR cell lines offer several competitive advantages in mast cell research compared to other models. Firstly, their origin from a patient with aggressive mastocytosis provides a more clinically relevant model for studying mast cell biology and diseases. Secondly, the long-standing use and distribution of LAD2 cells worldwide demonstrate their reliability and reproducibility in experiments. The recent establishment of LADR cells further enhances this model by offering a variant with distinct characteristics, allowing for more diverse and comprehensive studies. Additionally, the ability of both cell lines to be infected with HIV strains provides a unique opportunity to study mast cell interactions with viral infections. Overall, the availability, reliability, and versatility of LAD2 and LADR cells make them highly competitive choices for researchers studying mast cells and related disorders. The LAD2 and LADR cell lines have a wide range of potential applications in mast cell research and beyond. Their ability to mimic mast cell behavior and responses makes them valuable tools for studying allergic reactions, inflammatory responses, and immune system modulation. These cell lines can be used to investigate the molecular mechanisms underlying mast cell activation, mediator release, and signaling pathways, leading to a better understanding of mast cell-related diseases such as mastocytosis, allergic disorders, and autoimmune conditions. Furthermore, their susceptibility to HIV infection opens up avenues for studying the interaction between mast cells and the virus, potentially uncovering new therapeutic targets for HIV treatment. The versatility and reliability of LAD2 and LADR cells make them promising candidates for various research applications in immunology, virology, and pharmacology. 2024-02-20 2025-08-13 2025-08-15 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153000418 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 1 153000434 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 2 153000418 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 1 153000434 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 2 153000180 LADR Human Mast Cell Line E-082-2020-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection&body=Please send me information about technology [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection&body=Please send me information about technology [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection.">yogikala.prabhu@nih.gov</a><br> TAB-4883 152844291 Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Therapeutics Vaccines Joseph Blaney, Zhaochun Chen, Robert Purcell <p>This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent and efficient production. While the in vitro results are promising, rigorous in vivo animal protection assays are necessary to confirm their effectiveness in providing protection against rabies, ultimately offering a promising solution to a disease that remains almost invariably fatal once clinical symptoms develop.</p> <p>&nbsp;</p> This technology's competitive advantages stem from its development of highly potent monoclonal antibodies (mAbs) for rabies prevention. These mAbs, such as F2 and G5a, offer superior protection compared to existing options. Additionally, their production through genetically engineered cell lines ensures a reliable supply, potentially addressing the global shortage of rabies immunoglobulin (RIG). By enhancing postexposure prophylaxis (PEP) when combined with rabies vaccines, this technology improves effectiveness and accessibility in regions with a high rabies incidence, making it a competitive solution in the fight against this deadly disease. These highly potent rabies-neutralizing monoclonal antibodies (mAbs) have diverse potential applications. They can enhance postexposure prophylaxis (PEP), improving survival rates for rabies-exposed individuals. Their utility extends to research, aiding in the study of rabies and the development of new treatments. With scalability and production efficiency, they are accessible tools for rabies control in regions facing shortages or high incidence rates, offering versatile solutions in the fight against rabies. 2024-02-12 2025-08-13 2025-08-15 2024-12-10 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152844341 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 152844357 Purcell, Robert NIAID Purcell, Robert (NIAID) 2 152844466 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 3 152844341 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 152844357 Purcell, Robert NIAID Purcell, Robert (NIAID) 2 152844466 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 3 152844294 Development Of Chimpanzee/Human Neutralizing Monoclonal Antibodies Against Rabies E-067-2014-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies&body=Please send me information about technology [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies&body=Please send me information about technology [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies.">elizabeth.pitts@nih.gov</a><br> TAB-4855 152461954 Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Mir Ali, Peter Burbelo, Jeffrey Cohen <p>The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.</p> The proposed high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection offers key competitive advantages. It provides quantitative results, enables efficient screening of numerous samples, and matches the sensitivity of the established FAMA test. While patent challenges may arise, this technology serves niche markets, like pregnant women and healthcare workers at higher risk of VZV exposure, making it a valuable tool for focused serological diagnosis and research. The high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection has versatile potential applications. It can be used for vaccine studies, epidemiological research, and clinical diagnostics, offering accurate results similar to the FAMA test. Despite potential patent challenges, it's well-suited for specialized purposes like assessing vaccine responses in pregnant women and screening high-risk healthcare workers. This makes it valuable in focused serological research and diagnostics. 2024-01-29 2025-08-13 2025-08-15 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152461962 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 152461980 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 2 152462067 Ali, Mir NIAID - DIR NIAID Ali, Mir (NIAID) 3 152461962 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 152461980 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 2 152462067 Ali, Mir NIAID - DIR NIAID Ali, Mir (NIAID) 3 152461957 Luciferase Immunoprecipitation Systems Assay To Detect Antibody To Varicella-Zoster Virus In Varicella Vaccine Recipients E-037-2014-0 Research Material NIAID, NIDCR 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients.">elizabeth.pitts@nih.gov</a><br> TAB-4852 152461108 Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2 NIAID Collaboration, Computational models/software, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Respiratory, Therapeutics Collaboration Computational models/software Diagnostics Infectious Disease Licensing Research Equipment Research Materials Respiratory Therapeutics Ursula Buchholz, Peter Collins, Cindy Luongo <p>In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery. Importantly, placing GFP in the first-gene position minimizes interference with the expression of key RSV interferon antagonist genes, maintaining the virus&#39;s functionality while enhancing the brightness and utility of the GFP marker. This technology offers valuable insights into RSV infection dynamics and facilitates high-throughput screening for potential therapeutic agents.</p> <p>&nbsp;</p> The incorporation of green fluorescent protein (GFP) into the first-gene position of Respiratory Syncytial Virus (RSV) strain A2 offers a competitive advantage by providing a highly sensitive and non-invasive method for monitoring RSV infection. This modification ensures a robust and bright signal for accurate tracking, while strategically minimizing interference with key RSV genes. Researchers can better study the virus and expedite drug discovery efforts with this enhanced technology. This technology has versatile potential applications. It aids in better understanding RSV infection, enabling high-throughput screening for antiviral compounds and vaccine development. Additionally, it has broader applications in respiratory virus research, offering insights into host interactions and potential treatments for various viral infections. 2024-01-29 2025-08-13 2025-08-15 2024-12-10 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152461118 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461125 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461129 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 3 152461118 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461125 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461129 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 3 152461111 Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) From An Added Gene In The Fifth-gene Position E-034-2014-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2.">elizabeth.pitts@nih.gov</a><br> TAB-4851 152460971 Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Plasmids/Vectors, Research Equipment, Respiratory Collaboration Diagnostics Infectious Disease Licensing Plasmids/Vectors Research Equipment Respiratory Stephanie Biacchesi, Ursula Buchholz, Peter Collins <p>The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral interventions.</p> The incorporation of enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers a competitive advantage by providing a precise and rapid method for monitoring virus infection. This technology enables real-time visualization, simplifies high-throughput screening for potential antiviral agents, and streamlines viral particle quantification through GFP-based assays. Its sensitivity and efficiency make it a valuable tool for advancing virology research and expediting antiviral drug discovery. Incorporating enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers versatile applications, including virology research for infection mechanisms, high-throughput drug screening, sensitive diagnostics, and vaccine development. 2024-01-29 2025-08-13 2025-08-15 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152460992 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461000 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461011 Biacchesi, Stephanie Institut national de la recherche agronomique (INRA) NIAID Biacchesi, Stephanie (NIAID) 3 152460992 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461000 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461011 Biacchesi, Stephanie Institut national de la recherche agronomique (INRA) NIAID Biacchesi, Stephanie (NIAID) 3 152460974 Human Metapneumovirus (HMPV) Expressing Green Fluorescent Protein (GFP) At The First Position (HMPV-GFP1) From An Added Gene E-033-2014-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening.">elizabeth.pitts@nih.gov</a><br> TAB-4847 152411254 Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Respiratory Collaboration Diagnostics Infectious Disease Licensing Research Equipment Research Materials Respiratory Peter Collins, Mark Peeples <p>The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuable tool for high-throughput screening of potential antiviral compounds. This technology offers a sensitive and efficient method for studying RSV infection and screening for inhibitors, facilitating both basic research and drug development efforts related to RSV.</p> <p>&nbsp;</p> This technology offers a competitive edge by enabling real-time monitoring of RSV infection through the use of GFP and Renilla luciferase markers, allowing for precise and sensitive assessments of viral replication. The engineered RSV strain's safety features, such as a mutated RSV G protein, enhance laboratory safety. These advantages streamline RSV research and drug development efforts, making it a powerful tool for studying the virus and screening potential inhibitors. This technology has diverse potential applications in RSV research and antiviral drug development. It enables rapid screening of antiviral compounds, facilitates the study of RSV infection dynamics, and aids in evaluating vaccines and therapies. The GFP and luciferase markers offer real-time monitoring for investigating RSV replication and pathogenesis. Overall, this versatile technology enhances our understanding of RSV and accelerates efforts to combat this respiratory virus. 2024-01-25 2025-08-13 2025-08-15 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152411274 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152411278 Peeples, Mark Nationwide Children's Hospital Peeples, Mark 2 152411274 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152411278 Peeples, Mark Nationwide Children's Hospital Peeples, Mark 2 152411257 Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) And Luciferase From Added Genes E-032-2014-0 Research Material Nationwide Children's Hospital, NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes.">elizabeth.pitts@nih.gov</a><br> TAB-4585 151762284 Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue NIBIB Diagnostics, Oncology, Research Equipment, Research Materials Diagnostics Oncology Research Equipment Research Materials Xiaoyuan (Shawn) Chen, Orit Jacobson weiss <p>This technology includes a newly designed, truncated Evans Blue (EB) form which allows labeling with metal isotopes for nuclear imaging and radiotherapy. Unlike previous designs, this new form of truncated EB confers site specific mono-labeling of desired molecules. The newly designed truncated EB form can be conjugated to various molecules including small molecules, peptides, proteins and aptamers to improve blood half-life and tumor uptake, and confer better imaging, therapy and radiotherapy. As a proof of concept, we chose to conjugate the new truncated EB to Arg-Gly-Asp (RGD) tripeptide, which binds to integrin avl33. lntegrin avl33 is a molecular marker for angiogenesis which is significantly upregulated in cancerous tissue and can be used as a target for therapy.</p> Compared to RGD alone, the EB-RGD has significantly higher half-life in the blood. Because RGD binding to avl33 induce peptide internalization into the cell, the higher half-life of EB-RGD in the blood result in about tenfold increase in peptide accumulation in target organ and low background. This product will be of use in nuclear imaging and radiotherapy of cancer as the EB derivative can be used for increasing the blood half-life of peptides and molecule. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-12 2025-08-13 2025-08-15 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151762350 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151762378 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151762350 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151762378 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151762287 Radiotherapy And Imaging Agent Based On Peptide Conjugated To Novel Evans Blue Derivatives With Long Half-life And High Accumulation In Target Tissue E-150-2016-0 Filing authorized NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue&body=Please send me information about technology [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue&body=Please send me information about technology [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue.">vlado.knezevic@nih.gov</a><br> 157762644 E-150-2016-0 E-150-2016-0-CN-03 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage China ZL201780029003.X 201780029003.X Issued China <br />National Stage 201780029003.X<br />Filed on 2018-11-09<br />Status: Issued 157762649 E-150-2016-0 E-150-2016-0-EP-04 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage European Patent 3455206 17796666.0 Issued European Patent <br />National Stage 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762654 E-150-2016-0 E-150-2016-0-JP-05 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage Japan 6946342 2018-558662 Issued Japan <br />National Stage 2018-558662<br />Filed on 2018-11-08<br />Status: Issued 157762659 E-150-2016-0 E-150-2016-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS National Stage US 10,696,631 16/099,488 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10696631 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10696631">10,696,631</a><br />Filed on 2018-11-07<br />Status: Issued 157762664 E-150-2016-0 E-150-2016-0-SG-07 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage Singapore 11201809982R 11201809982R Issued Singapore <br />National Stage 11201809982R<br />Filed on 2018-11-09<br />Status: Issued 157762669 E-150-2016-0 E-150-2016-0-CH-08 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Switzerland 3455206 17796666.0 Issued Switzerland <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762674 E-150-2016-0 E-150-2016-0-DE-09 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Germany 3455206 17796666.0 Issued Germany <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762679 E-150-2016-0 E-150-2016-0-FR-10 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP France 3455206 17796666.0 Issued France <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762684 E-150-2016-0 E-150-2016-0-GB-11 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP United Kingdom 3455206 17796666.0 Issued United Kingdom <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762689 E-150-2016-0 E-150-2016-0-IE-12 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Ireland 3455206 17796666.0 Issued Ireland <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762694 E-150-2016-0 E-150-2016-0-IT-13 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Italy 3455206 17796666.0 Issued Italy <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued TAB-4544 151736796 Segmented, Braided MRI Catheter for Cardiovascular Procedures NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Ozgur Kocaturk, Robert Lederman <p>This technology includes a catheter design to be used for cardiovascular procedures. This catheter has intrinsic freedom from MRI heating by segmenting and insulating the braiding material, yet that retains most of the mechanical properties of a braided catheter aligning the segment interruptions out-of-phase with each other.</p> A catheter is a fundamental tool for cardiovascular procedures, and this braided device is intrinsically safe by design, almost as strong as conventional braided catheters, and inexpensive to manufacture. This can be a valuable component of a suite of inventions for passive design catheters and guidewires that could together serve the basis of a product line or vendor. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736803 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736813 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736803 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736813 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736799 Segmented Braided MRI Catheter E-284-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures&body=Please send me information about technology [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures&body=Please send me information about technology [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures.">shmilovm@nih.gov</a><br> 157756491 E-284-2015-0 E-284-2015-0-US-01 Segmented Braided MRI Catheter PRV US 62/219,472 Abandoned US <br />Provisional (PRV) 62/219,472<br />Filed on 2015-09-16<br />Status: Abandoned 157756496 E-284-2015-0 E-284-2015-0-PCT-02 SEGMENTED MRI CATHETERS AND OTHER INTERVENTIONAL DEVICES PCT Patent Cooperation Treaty PCT/US2016/051600 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/051600<br />Filed on 2016-09-14<br />Status: Expired 157756501 E-284-2015-0 E-284-2015-0-EP-03 SEGMENTED MRI CATHETERS AND OTHER INTERVENTIONAL DEVICES National Stage European Patent 16847168.8 Abandoned European Patent <br />National Stage 16847168.8<br />Filed on 2016-09-14<br />Status: Abandoned 157756506 E-284-2015-0 E-284-2015-0-US-04 SEGMENTED MRI CATHETERS AND OTHER INTERVENTIONAL DEVICES National Stage US 10,835,710 15/755,186 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835710 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835710">10,835,710</a><br />Filed on 2018-02-26<br />Status: Issued TAB-4541 151736144 Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Burcu Basar, Ozgur Kocaturk, Robert Lederman <p>This technology includes a metallic guidewire that is suitable for MRI catheterization, because it is mechanically long but electrically consists of short conductive segments that cannot resonate during MRI. The invention consists of stiffness-matched non-conductive connectors or connections that are used along with short metallic segments. The embodiment reduced to practice has torquability and flexibility comparable to marketed metallic guidewires, yet is free from MRI heating.</p> The solution is novel, useful, and non-obvious as it solves the problem of heating during radiofrequency excitation without the complexity of detuning and decoupling electronic circuitry, and is mechanically suitable as a guidewire, yet it is immune to heating under MRI at specified field strengths. A guidewire is a fundamental tool for catheter procedures; an MRI guidewire is a fundamentally enabling tool for MRI catheter procedures. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736156 Basar, Burcu National Heart, Lung, and Blood Institute (NHLBI) NHLBI Basar, Burcu (NHLBI) 1 151736169 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151736185 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 3 151736156 Basar, Burcu National Heart, Lung, and Blood Institute (NHLBI) NHLBI Basar, Burcu (NHLBI) 1 151736169 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151736185 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 3 151736147 Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors E-253-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures&body=Please send me information about technology [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures&body=Please send me information about technology [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures.">shmilovm@nih.gov</a><br> 157756230 E-253-2014-0 E-253-2014-0-US-01 Segmented Metallic Guidewires PRV US 62/066,167 Abandoned US <br />Provisional (PRV) 62/066,167<br />Filed on 2014-10-20<br />Status: Abandoned 157756235 E-253-2014-0 E-253-2014-0-PCT-02 Segmented Metallic Guidewires PCT Patent Cooperation Treaty PCT/US2015/056266 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/056266<br />Filed on 2015-10-19<br />Status: Expired 157756240 E-253-2014-0 E-253-2014-0-EP-03 Segmented Metallic Guidewires National Stage European Patent 3209364 15787824.0 Issued European Patent <br />National Stage 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756245 E-253-2014-0 E-253-2014-0-US-04 Segmented Metallic Guidewires National Stage US 10,695,540 15/514,744 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695540 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695540">10,695,540</a><br />Filed on 2017-03-27<br />Status: Issued 157756250 E-253-2014-0 E-253-2014-0-CH-05 Segmented Metallic Guidewires EP Switzerland 3209364 15787824.0 Issued Switzerland <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756255 E-253-2014-0 E-253-2014-0-DE-06 Segmented Metallic Guidewires EP Germany 3209364 15787824.0 Issued Germany <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756260 E-253-2014-0 E-253-2014-0-FR-07 Segmented Metallic Guidewires EP France 3209364 15787824.0 Issued France <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756265 E-253-2014-0 E-253-2014-0-GB-08 Segmented Metallic Guidewires EP United Kingdom 3209364 15787824.0 Issued United Kingdom <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756270 E-253-2014-0 E-253-2014-0-IE-09 Segmented Metallic Guidewires EP Ireland 3209364 15787824.0 Issued Ireland <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued TAB-4540 151735998 Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection NHLBI Cardiology, Licensing, Medical Devices Cardiology Licensing Medical Devices Robert Lederman <p>This technology includes a novel transcatheter repair for functional mitral valve regurgitation, called mitral cerclage annuloplasty. This includes coronary artery protection for mitral cerclage annuloplasty against inside-out compression from subsequent transcatheter valve-in-ring mitral valve implantation, wherein the ring is created by the cerclage annuloplasty. Cerclage annuloplasty is to create a semi-rigid ring at the level of the mitral annulus. The purpose of this ring is to create a &ldquo;landing zone&rdquo; for a percutaneous mitral valve implant, which guides positioning of the percutaneous transcatheter mitral valve and also allows the valve to use outward compression against the cerclage annuloplasty for fixation. The value in this invention is that the arch not only protects the artery against compression from the outer surface of the annuloplasty but it also protects against compression from the heart surface of the coronary artery &lsquo;inside-out&rdquo;, when a transcatheter aortic valve is implanted in relation to or in tandem with the cerclage annuloplasty.</p> At present there is heavy market interest in transcatheter mitral valve implantation. To be used to repair functional mitral valve regurgitation. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736083 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736083 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736001 Expanded Claims For Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection E-249-2006-3 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection&body=Please send me information about technology [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection&body=Please send me information about technology [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection.">shmilovm@nih.gov</a><br> 157756204 E-249-2006-3 E-249-2006-3-US-01 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection Device CIP US 9,943,409 15/056,599 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9943409 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9943409">9,943,409</a><br />Filed on 2016-02-29<br />Status: Abandoned 157756209 E-249-2006-3 E-249-2006-3-PCT-02 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device PCT Patent Cooperation Treaty PCT/US2017/017367 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/017367<br />Filed on 2017-02-10<br />Status: Expired 157756214 E-249-2006-3 E-249-2006-3-US-09 Expanded Claims For Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection CON US 10,687,942 15/954,555 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10687942 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10687942">10,687,942</a><br />Filed on 2018-04-16<br />Status: Issued 157756219 E-249-2006-3 E-249-2006-3-US-10 Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection CON US 11,925,558 16/882,896 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11925558 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11925558">11,925,558</a><br />Filed on 2020-05-26<br />Status: Issued TAB-4535 151722135 Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery NIAID Human Cell Lines, Infectious Disease, Research Materials Human Cell Lines Infectious Disease Research Materials Ursula Buchholz, Peter Collins, Cyril Le Nouen, Joseph Marcotrigiano <p>This technology includes the NeurEx&reg; mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app&#39;s robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app&#39;s computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx&reg; enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.</p> This technology uniquely enables the high-yield production and purification of the RSV replication complex in human cells, paving the way for groundbreaking antiviral drug discovery and structural analysis of the virus. The technology holds promise for facilitating detailed structural studies of the RSV replication mechanism, advancing antiviral drug development, and potentially applying similar methods to other significant negative-sense RNA viruses like measles and ebola. 2023-12-10 2025-08-13 2025-08-15 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151722142 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 1 151722146 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 2 151722154 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 3 151722159 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 4 151722142 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 1 151722146 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 2 151722154 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 3 151722159 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 4 151722138 Generation Of A Human Cell Line That Constitutively Expresses Respiratory Syncytial Virus (RSV) Nucleocapsid (N), Phosphoprotein (P) And Polymerase (L) Proteins, And Purification Of The RSV Replication Complex E-235-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery.">elizabeth.pitts@nih.gov</a><br> TAB-4528 151719911 Devices and Methods for Cerclage of Luminal Systems NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Christopher Bruce, Robert Lederman <p>This technology includes a family of transcatheter endovenous intramyocardial tether (MIRTH) procedures to impose myocardial constraint on the LV (MIRTH), LV and RV (SCIMITAR), and cardiac resynchronization procedures. Included is a set of advanced cardiac treatment technologies that focus on minimally invasive procedures for heart patients. The main technology is the transcatheter endovenous intramyocardial tether (MIRTH) procedure, which is designed to apply physical constraint to the left ventricle (LV) of the heart. This method aims to aid in the treatment of certain heart conditions by altering the mechanical environment of the heart muscle. Additionally, the technology encompasses cardiac resynchronization procedures, which are used to improve the timing of the heart&#39;s contractions, particularly beneficial for patients with heart failure. Overall, these technologies represent a significant advancement in cardiac care, emphasizing less invasive methods to manage and treat complex heart conditions.</p> This technology is a minimally invasive approach, offering targeted myocardial constraint and cardiac resynchronization, potentially reducing recovery times and complications compared to more invasive heart treatments. Used for treating a range of cardiac conditions, including heart failure and ventricular dysfunction, by improving cardiac efficiency and synchronization through less invasive methods. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2025-08-13 2025-08-15 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151720113 Bruce, Christopher National Heart, Lung, and Blood Institute (NHLBI) Bruce, Christopher 2 151719918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151720113 Bruce, Christopher National Heart, Lung, and Blood Institute (NHLBI) Bruce, Christopher 2 151719914 Devices And Methods For Cerclage Of Luminal Systems (MIRTH Tranmural) E-206-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4528] Devices and Methods for Cerclage of Luminal Systems&body=Please send me information about technology [TAB-4528] Devices and Methods for Cerclage of Luminal Systems. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4528] Devices and Methods for Cerclage of Luminal Systems&body=Please send me information about technology [TAB-4528] Devices and Methods for Cerclage of Luminal Systems.">shmilovm@nih.gov</a><br> 157755920 E-206-2020-0 E-206-2020-0-US-01 Devices And Methods For Cerclage Of Luminal Systems PRV US 63/050,270 Abandoned US <br />Provisional (PRV) 63/050,270<br />Filed on 2020-07-10<br />Status: Abandoned 157755931 E-206-2020-0 E-206-2020-0-PCT-02 Devices And Methods For Cerclage Of Luminal Systems PCT Patent Cooperation Treaty PCT/US2021/041310 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/041310<br />Filed on 2021-07-12<br />Status: Expired 157755936 E-206-2020-0 E-206-2020-0-JP-01 Devices And Methods For Cerclage Of Luminal Systems National Stage Japan 2023-500441 Pending Japan <br />National Stage 2023-500441<br />Filed on 2023-01-05<br />Status: Pending 157755946 E-206-2020-0 E-206-2020-0-CA-01 Devices And Methods For Cerclage Of Lumenal Systems National Stage Canada 3184823 Pending Canada <br />National Stage 3184823<br />Filed on 2023-01-03<br />Status: Pending 157755951 E-206-2020-0 E-206-2020-0-AU-01 Devices And Methods For Cerclage Of Luminal Systems National Stage Australia 2021304368 Pending Australia <br />National Stage 2021304368<br />Filed on 2021-07-12<br />Status: Pending 157755956 E-206-2020-0 E-206-2020-0-IL-01 Devices And Methods For Cerclage Of Luminal Systems National Stage Israel 299587 Pending Israel <br />National Stage 299587<br />Filed on 2022-12-29<br />Status: Pending 157755961 E-206-2020-0 E-206-2020-0-CN-01 Devices And Methods For Cerclage Of Luminal Systems National Stage China 202180049654.1 Pending China <br />National Stage 202180049654.1<br />Filed on 2023-01-06<br />Status: Pending 157755966 E-206-2020-0 E-206-2020-0-EP-01 Devices And Methods For Cerclage Of Luminal Systems National Stage European Patent 21837310.8 Pending European Patent <br />National Stage 21837310.8<br />Filed on 2021-07-12<br />Status: Pending 157755971 E-206-2020-0 E-206-2020-0-US-02 DEVICES AND METHODS FOR CERCLAGE OF LUMENAL SYSTEMS CON US 18/151,601 Pending US <br />Continuation (CON) 18/151,601<br />Filed on 2023-01-09<br />Status: Pending TAB-4524 151719490 LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression NHLBI Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics John Brognard, Amy Funk, Carolyn Hitko, Katherine Nyswaner, Rolf Swenson <p>This technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway. In vivo preclinical cell line xenograft mouse model demonstrates that targeting LZK will suppress tumor growth. We also demonstrate that several additional compounds potently inhibit LZK and could serve as new therapeutic modalities.</p> We have discovered LZK as a novel therapeutic target in squamous cell carcinomas with amplified LZK; over 50% of HNSCC and LSCC patients have amplifications or gains in LZK. LZK inhibitors that serve as lead compounds could lead to new therapies for the treatment of LSCC and HNSCC and other cancers with amplified LZK that include prostate, ovarian and small cell lung cancer. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-08-15 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719498 Brognard, John National Cancer Institute (NCI) NCI Brognard, John (NCI) 1 151719620 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 151719624 Funk, Amy NCI - CCR NCI Funk, Amy (NCI) 3 151719628 Hitko, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hitko, Carolyn (NHLBI) 4 151719632 Nyswaner, Katherine NCI - CCR NCI Nyswaner, Katherine (NCI) 5 151719498 Brognard, John National Cancer Institute (NCI) NCI Brognard, John (NCI) 1 151719620 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 151719624 Funk, Amy NCI - CCR NCI Funk, Amy (NCI) 3 151719628 Hitko, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hitko, Carolyn (NHLBI) 4 151719632 Nyswaner, Katherine NCI - CCR NCI Nyswaner, Katherine (NCI) 5 151719493 DLK Inhibitors Can Be Repurposed To Target LZK And Suppress MYC Expression, Inhibit AKT Activation, And Promote Cancer Cell Death And Tumor Regression E-196-2020-0 Closed National Heart, Lung, and Blood Institute (NHLBI), NCI 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression&body=Please send me information about technology [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression&body=Please send me information about technology [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression.">shmilovm@nih.gov</a><br> TAB-4503 151705287 Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease NHLBI Licensing, Therapeutics Licensing Therapeutics Alan Remaley, Zhen-Dan Shi, Rolf Swenson, Zhihong Yang <p>This technology includes a new method to prepare very long chain fatty acids (VLCFA), which does not use the previously reported toxic mercury amalgam, for use as nutritional supplements, and as therapeutics for various diseases. The key coupling step involves an organocopper mediated coupling of the Grignard regent derived from the bromo alkyl tetraene with a bromoalkyl containing a protected alcohol. After the coupling the alcohol Is deprotected and oxidized to prepare the very long fatty acid. The synthetic approach is flexible and can be used to prepare the other VLCFA compounds. Similar methods are used in the chemical industry for preparation of fine chemicals and should allow the synthesis of large quantities of material.</p> This robust synthetic approach that can be used to prepare these VLCPUFAs that doesn’t include toxic mercury and can be conducted at large scales. Our product with significantly high purity could be used as nutritional formulas and supplements, and as therapeutics for various diseases, disorders, and conditions. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-08-15 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705373 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151705377 Shi, Zhen-Dan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Shi, Zhen-Dan (NHLBI) 2 151705381 Yang, Zhihong National Heart, Lung, and Blood Institute (NHLBI) Yang, Zhihong 3 151705386 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 4 151705373 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151705377 Shi, Zhen-Dan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Shi, Zhen-Dan (NHLBI) 2 151705381 Yang, Zhihong National Heart, Lung, and Blood Institute (NHLBI) Yang, Zhihong 3 151705386 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 4 151705369 Methods To Produce Very Long Chain Fatty Acids (VLCFA) E-126-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease&body=Please send me information about technology [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease&body=Please send me information about technology [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease.">malabika.ghosh@nih.gov</a><br> 157755067 E-126-2020-0 E-126-2020-0-US-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) PRV US 63/072,519 Abandoned US <br />Provisional (PRV) 63/072,519<br />Filed on 2020-08-31<br />Status: Abandoned 157755072 E-126-2020-0 E-126-2020-0-PCT-02 Methods To Produce Very Long Chain Fatty Acids (VLCFA) PCT Patent Cooperation Treaty PCT/US2021/048390 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/048390<br />Filed on 2021-08-31<br />Status: Expired 157755077 E-126-2020-0 E-126-2020-0-US-02 Methods To Produce Very Long Chain Fatty Acids (VLCFA) National Stage US 18/042,743 Pending US <br />National Stage 18/042,743<br />Filed on 2023-02-23<br />Status: Pending 157755082 E-126-2020-0 E-126-2020-0-IL-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) National Stage Israel 300768 Pending Israel <br />National Stage 300768<br />Filed on 2023-02-19<br />Status: Pending 157755087 E-126-2020-0 E-126-2020-0-EP-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) National Stage European Patent 21862955.8 Pending European Patent <br />National Stage 21862955.8<br />Filed on 2023-02-28<br />Status: Pending TAB-4488 151702582 Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Neal Fearnot, Shaun Gittard, William Havel, Jeremy Newkirk <p>This technology includes structures and methods for cinching a band around the heart for treating conditions including tricuspid valve regurgitation (TR). When positioned appropriately along the atrioventricular groove, the band is tightened around the heart which narrows the tricuspid annulus and relieves TR.</p> Method minimizes any risk of coronary compression (unintended compression of vessels to limit or prevent flow). To be used for the treatment of tricuspid valve regurgitation. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151702589 Havel, William Cook Medical Technologies LLC Havel, William 1 151702594 Fearnot, Neal Muffin Incorporated Fearnot, Neal 2 151702600 Newkirk, Jeremy Cook Medical Technologies LLC Newkirk, Jeremy 3 151702877 Gittard, Shaun Cook Medical Technologies LLC Gittard, Shaun 4 151702589 Havel, William Cook Medical Technologies LLC Havel, William 1 151702594 Fearnot, Neal Muffin Incorporated Fearnot, Neal 2 151702600 Newkirk, Jeremy Cook Medical Technologies LLC Newkirk, Jeremy 3 151702877 Gittard, Shaun Cook Medical Technologies LLC Gittard, Shaun 4 151702585 Systems And Methods For Applying Pressure To A Bodily Organ E-076-2021-0 Filing authorized Cook Medical Technologies LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation&body=Please send me information about technology [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation&body=Please send me information about technology [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation.">shmilovm@nih.gov</a><br> 157754411 E-076-2021-0 E-076-2021-0-US-01 Systems And Methods For Applying Pressure To A Bodily Organ PRV US 62/906,399 Abandoned US <br />Provisional (PRV) 62/906,399<br />Filed on 2019-09-26<br />Status: Abandoned 157754416 E-076-2021-0 E-076-2021-0-PCT-02 Systems And Methods For Applying Pressure To A Bodily Organ PCT Patent Cooperation Treaty PCT/US2020/052690 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/052690<br />Filed on 2020-09-25<br />Status: Expired 157754421 E-076-2021-0 E-076-2021-0-US-03 Systems And Methods For Applying Pressure To A Bodily Organ ORD US 12,213,881 17/032,283 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12213881 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12213881">12,213,881</a><br />Filed on 2020-09-25<br />Status: Issued TAB-4487 151702511 Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging NHLBI Computational models/software, Diagnostics, Licensing, Oncology, Research Equipment, Software / Apps Computational models/software Diagnostics Licensing Oncology Research Equipment Software / Apps Deepak Sail, Rolf Swenson <p>This technology includes 1-13C-ketoglutarate which can be used for imaging the conversion to hydroxyglutarate (HG) or Gln in cancer cells with an IDH1 mutations by hyperpolarized MRI. The ability to detect the status of IDH1 mutations is clinically prognostic for multiple cancers. These exciting observations are limited by two factors, the major one being that the natural abundance of 13C at position C5 overlaps with 1-13C-2-hydroxyglutarate peak, which limits the sensitivity of analysis and prevents simultaneous observations of HG and Gln formation. The other issue is that the ketoglutarate is not cell permeable. This invention provides a solution and enhances the utility of this imaging approach.</p> An improved hyperpolarized MRI tracer for prognostic imaging of cancer. Diagnostic imaging agent with potential for validating cancer treatment options. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-08-15 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151702518 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151702522 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 2 151702518 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151702522 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 2 151702514 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging E-070-2020-0 Filing authorized National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI), Radiation Biology Branch 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging&body=Please send me information about technology [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging&body=Please send me information about technology [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging.">malabika.ghosh@nih.gov</a><br> 157754378 E-070-2020-0 E-070-2020-0-US-01 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging PRV US 62/962,473 Abandoned US <br />Provisional (PRV) 62/962,473<br />Filed on 2020-01-17<br />Status: Abandoned 157754383 E-070-2020-0 E-070-2020-0-PCT-02 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING PCT Patent Cooperation Treaty PCT/US2021/013658 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013658<br />Filed on 2021-01-15<br />Status: Expired 157754388 E-070-2020-0 E-070-2020-0-EP-03 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING National Stage European Patent 21741941.5 Pending European Patent <br />National Stage 21741941.5<br />Filed on 2021-01-15<br />Status: Pending 157754393 E-070-2020-0 E-070-2020-0-IL-04 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage Israel 294464 Pending Israel <br />National Stage 294464<br />Filed on 2022-07-03<br />Status: Pending 157754398 E-070-2020-0 E-070-2020-0-US-05 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage US 17/793,089 Pending US <br />National Stage 17/793,089<br />Filed on 2022-07-15<br />Status: Pending TAB-4481 151644566 Compositions and Methods for Reducing Serum Triglycerides NHLBI Cardiology, Licensing, Research Materials, Therapeutics, Vaccines Cardiology Licensing Research Materials Therapeutics Vaccines Marcelo Amar, Bryce Chackerian, Alexandra Fowler, Alan Remaley <p>This technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown to induce the autoantibody against the target and to lower plasma triglycerides.</p> The vaccine strategy for lowering plasma triglycerides is novel and could represent a low-cost alternative to drug therapy. Development into a novel therapy for lowering plasma triglycerides. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151644600 Fowler, Alexandra University of New Mexico Fowler, Alexandra 1 151644608 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 2 151644612 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 3 151644616 Chackerian, Bryce University of New Mexico Health Science Center [US] Chackerian, Bryce 4 151644600 Fowler, Alexandra University of New Mexico Fowler, Alexandra 1 151644608 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 2 151644612 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 3 151644616 Chackerian, Bryce University of New Mexico Health Science Center [US] Chackerian, Bryce 4 151644569 Compositions And Methods For Reducing Serum Triglycerides E-054-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), University of New Mexico 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides&body=Please send me information about technology [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides&body=Please send me information about technology [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides.">malabika.ghosh@nih.gov</a><br> TAB-4474 151147722 Base-Covered HIV-1 Envelope Ectodomains and Their Use NIAID Cheng Cheng, Peter Kwong, John Mascola, Adam Olia, Reda Rawi, Yongping Yang, Tongqing Zhou <p>Researchers at the Vaccine Research Center (&ldquo;VRC&rdquo;) of the National Institute of Allergy and Infectious Diseases (&ldquo;NAID&rdquo;) continue to pursue a safe and effective HIV-1 vaccine to combat the HIV-1/AIDS pandemic. </p> <p><strong style="font-weight:bold"> To this end, researchers have engineered the soluble HIV-1 ectodomain trimer so that it is stabilized in its prefusion conformation by artificial disulfides, helix-disrupting prolines, and other structure-based alterations. However, mice and non-human primates immunized with these engineered soluble HIV-1 trimers produced a significant (>90% in some cases) immune response to the exposed trimer base.</strong></p> <p><strong style="font-weight:bold"> VRC researchers further modified the engineered prefusion soluble HIV-1 trimers by adding N-linked glycans to specific sites on the protein&rsquo;s base to block this immunodominant surface. They found that these N-linked glycans did reduce production of non-neutralizing antibodies directed to the trimer base. These soluble, glycan-masked prefusion HIV-1 trimers are envisioned as being a part of a heterologous prime-boost vaccine regimen.</strong></p> <p> This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as further development and evaluation under a research collaboration.</p> Currently, no licensed HIV vaccine exists <li>Vaccine for prevention of HIV-1 infection</li> <li>Therapeutic vaccine for treatment of HIV-1 infection</li> 2023-11-01 2025-08-13 2025-08-15 2023-11-07 False False Animal Studies True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151148328 Publications: Olia, et al. (2023) Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases. iScience 26, 107403, August 18, 2023. DOI: https://doi.org/10.1016/j.sci.2023.107403 Publications: Olia, et al. (2023) Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases. iScience 26, 107403, August 18, 2023. DOI: https://doi.org/10.1016/j.sci.2023.107403 151147900 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 1 151147916 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 2 151147922 Zhou, Tongqing NIH - NIAID NIAID Zhou, Tongqing (NIAID) 3 151147932 Olia, Adam NIH - NIAID NIAID Olia, Adam (NIAID) 4 151147936 Rawi, Reda NIAID - VRC NIAID Rawi, Reda (NIAID) 5 151147940 Yang, Yongping NIH - NIAID NIAID Yang, Yongping (NIAID) 6 151147987 Cheng, Cheng NIH - NIAID NIAID Cheng, Cheng (NIAID) 7 151147900 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 1 151147916 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 2 151147922 Zhou, Tongqing NIH - NIAID NIAID Zhou, Tongqing (NIAID) 3 151147932 Olia, Adam NIH - NIAID NIAID Olia, Adam (NIAID) 4 151147936 Rawi, Reda NIAID - VRC NIAID Rawi, Reda (NIAID) 5 151147940 Yang, Yongping NIH - NIAID NIAID Yang, Yongping (NIAID) 6 151147987 Cheng, Cheng NIH - NIAID NIAID Cheng, Cheng (NIAID) 7 151147726 Base-Covered Soluble HIV-1 Envelope Trimers E-079-2022-0 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use&body=Please send me information about technology [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use&body=Please send me information about technology [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use.">crainwater@mail.nih.gov</a><br> TAB-4452 147157747 CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders NICHD Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics Anil Mukherjee, Chinmoy Sarkar, Gary Zhongjian Zhang <p>Clinically known as Neuronal Ceroid-Lipofuscinoses (NCL), Batten disease, is a rare neuron killing disease and one of the lysosomal storage disorders (LSDs).  It is associated with a mutation or lack of palmitoyl-protein thioesterase-1 (PPT1) gene. It manifests very early in a child's life causing absence of brain activity as early as 4 years of age.</p> <p><a href="http://irp.nih.gov/pi/anil-mukherjee" target="_blank" rel="nofollow">Dr. Mukherje of NICHD</a> has discovered and developed N-t-BuHA, a chemical derivative of hydroxylamine that mimics the action of PPT1 enzyme.  Compared to hydroxylamine, N-t-BuHA has been shown to be non-toxic in mice expressing batten disease.  In addition, NtBuHA exhibited potent antioxidant property and extended the life of the diseased mice. NtBuHA has shown promising therapeutic potential to treat NCL-LSDs. </p> <h2>Competitive Advantages:</h2> <ul><li>First of its kind to treat INCL and other LSD</li> <li>Non-toxic dertivative therapeutic against thioesterase deficiency disorders</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Small molecule therapeutic for neuronal ceroid-lipfuscinoese</li> <li>Small molecule to treat or prevent thioesterase deficiency disorders.</li> </ul> 2016-02-16 2025-04-22 2018-11-09 2025-08-15 2016-08-30 lysosomal storage disorders (LSD), lysosome, Neuronal Ceroid-Lipofuscinoses (NCL), Non-toxic derivative of hydroxylamine, Palmitoyl-protein thioesterase False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-11-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161925 Sarkar, C., et al. http://www.ncbi.nlm.nih.gov/pubmed/24056696 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24056696">Sarkar, C., et al.</a> 147164786 Mukherjee, Anil NIH - NICHD NICHD Mukherjee, Anil (NICHD) 1 147164788 Sarkar, Chinmoy NIH - NICHD NICHD Sarkar, Chinmoy (NICHD) 2 147164787 Zhang, Gary Zhongjian NIH - NICHD NICHD Zhang, Gary Zhongjian (NICHD) 3 147164786 Mukherjee, Anil NIH - NICHD NICHD Mukherjee, Anil (NICHD) 1 147164788 Sarkar, Chinmoy NIH - NICHD NICHD Sarkar, Chinmoy (NICHD) 2 147164787 Zhang, Gary Zhongjian NIH - NICHD NICHD Zhang, Gary Zhongjian (NICHD) 3 147158095 Small Molecules (Derivatives Of Hydroxylamine) As Therapeutic Agents For Disorders Caused By Thioesterase Deficiency E-157-2011-0 Filing authorized NICHD 83746064 Whitman, Nathan nathan.whitman@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders&body=Please send me information about technology [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitman, Nathan<br><a href="mailto:nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders&body=Please send me information about technology [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nathan.whitman@nih.gov</a><br> 147161112 E-157-2011-0 E-157-2011-0-US-04 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders And Methods Of Using The Same National Stage US 9,629,816 14/110,393 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629816 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629816">9,629,816</a><br />Filed on 2013-10-07<br />Status: Issued 147168992 E-157-2011-0 E-157-2011-0-US-01 Small Molecule (Derivatives Of Hydroxylamine) Therapeutic Compounds Targeting Thioesterase Deficiency Disorders And Methods of Using The Same PRV US 61/473,692 Abandoned US <br />Provisional (PRV) 61/473,692<br />Filed on 2011-04-08<br />Status: Abandoned 147168993 E-157-2011-0 E-157-2011-0-PCT-02 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same PCT Patent Cooperation Treaty PCT/US2012/32772 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/32772<br />Filed on 2012-04-09<br />Status: Expired 147168994 E-157-2011-0 E-157-2011-0-EP-03 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same National Stage European Patent 2694047 12716889.6 Issued European Patent <br />National Stage 12716889.6<br />Filed on 2012-04-09<br />Status: Issued 147168995 E-157-2011-0 E-157-2011-0-US-05 SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME DIV US 15/458,234 Abandoned US <br />Divisional (DIV) 15/458,234<br />Filed on 2017-03-14<br />Status: Abandoned 147168996 E-157-2011-0 E-157-2011-0-US-06 SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME CON US 16/020,392 Abandoned US <br />Continuation (CON) 16/020,392<br />Filed on 2018-06-27<br />Status: Abandoned 147168997 E-157-2011-0 E-157-2011-0-DE-07 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Germany 2694047 12716889.6 Issued Germany <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147168998 E-157-2011-0 E-157-2011-0-DK-08 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Denmark 2694047 12716889.6 Issued Denmark <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147168999 E-157-2011-0 E-157-2011-0-FI-09 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Finland 2694047 12716889.6 Issued Finland <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147169000 E-157-2011-0 E-157-2011-0-GB-10 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP United Kingdom 2694047 12716889.6 Issued United Kingdom <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147169001 E-157-2011-0 E-157-2011-0-SE-11 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Sweden 2694047 12716889.6 Issued Sweden <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147172515 lysosomal storage disorders (LSD) 147172517 lysosome 147172519 Neuronal Ceroid-Lipofuscinoses (NCL) 147172521 Non-toxic derivative of hydroxylamine 147172523 Palmitoyl-protein thioesterase TAB-4438 147157733 T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Christian Hinrichs, Sanja Stevanovic <p>Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely by cancer cells and not normal tissues has been a major challenge for the development of T-cell based immunotherapies. Thus, it is essential to find novel target antigens differentially expressed in cancer versus normal tissues.</p> <p>Inventors at the National Cancer Institute (NCI) have developed a TCR that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) 52-60 epitope. KK-LC-1 antigen (encoded by the CT83 gene) is highly expressed by several common and aggressive epithelial tumor types. Importantly, KK-LC-1 is expressed at very low levels in normal tissues and not in those tissues vital for survival. This expression profile makes KK-LC-1</p> <p>an attractive target for T-cell based, anti-cancer therapies.</p> <p>This TCR may be used to genetically modify peripheral blood lymphocytes (T cells) from eligible patients. After expansion, these genetically modified T cells can be used to treat patients. It may also be possible to use portions of the KK-LC-1 TCR in chimeric proteins for cancer therapy and/or antigen detection assays. This technology is currently being evaluated in clinical trials at the NCI and at Rutgers Cancer Institute of New Jersey.</p> <p>NCI&rsquo;s Center for Immuno-Oncology seeks licensees and/or co-development partners for a T-cell immunotherapy that targets KK-LC-1 for use in the treatment of epithelial cancers.</p> <p>&nbsp;</p> <h2>Commercial Applications:</h2> <ul> <li>Therapeutic against several common and aggressive epithelial tumor types &ndash; such as ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Differential expression profile of KK-LC-1 suggests that therapy with a specific KK-LC-1 TCR could be cancer-specific and would not damage normal tissues</li> <li>The repertoire of targetable epithelial antigens for TCR-T cell therapy is larger than for CAR-T cells</li> <li>Increased sensitivity may improve tumor cell detection and killing versus CAR-T cells, due to lower epitope density required for activation</li> <li>Higher avidity and lower affinity could result in each TCR-T cell destroying numerous antigen-presenting cancer cells</li> <li>Thousands of cancer patients each year with otherwise untreatable disease may be eligible for immunotherapy with this TCR</li> </ul> <h2>&nbsp;</h2> <ul> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for T-cell immunotherapy that targets KK-LC-1 for use in the treatment of epithelial cancers. 2017-03-02 2025-04-22 2024-02-09 2025-08-15 2017-03-02 CT83, Immunotherapy, Kita-Kyushu Lung Cancer Antigen, KK-LC-1, T-Cell Receptor, TCR, Testis False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2024-02-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164742 Stevanovic, Sanja NIH - NCI NCI Stevanovic, Sanja (NCI) 1 147164741 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147164742 Stevanovic, Sanja NIH - NCI NCI Stevanovic, Sanja (NCI) 1 147164741 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147158090 T-cell Receptor Targeting The Cancer/testis Antigen KK-LC-1 E-153-2016-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors&body=Please send me information about technology [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors&body=Please send me information about technology [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147161109 E-153-2016-0 E-153-2016-0-US-01 Anti-KK-LC-1 T Cell Receptors PRV US 62/327,529 Abandoned US <br />Provisional (PRV) 62/327,529<br />Filed on 2016-04-26<br />Status: Abandoned 147168912 E-153-2016-0 E-153-2016-0-PCT-02 ANTI-KK-LC-1 T CELL RECEPTORS PCT Patent Cooperation Treaty PCT/US2017/027865 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/027865<br />Filed on 2017-04-17<br />Status: Expired 147168913 E-153-2016-0 E-153-2016-0-AU-03 ANTI-KK-LC-1 T CELL RECEPTORS National Stage Australia 2017258745 2017258745 Issued Australia <br />National Stage 2017258745<br />Filed on 2018-10-19<br />Status: Issued 147168914 E-153-2016-0 E-153-2016-0-CA-04 ANTI-KK-LC-1 T CELL RECEPTORS National Stage Canada 3021898 3021898 Issued Canada <br />National Stage 3021898<br />Filed on 2017-04-17<br />Status: Issued 147168915 E-153-2016-0 E-153-2016-0-EP-05 ANTI-KK-LC-1 T CELL RECEPTORS National Stage European Patent 3448882 17733120.4 Issued European Patent <br />National Stage 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168916 E-153-2016-0 E-153-2016-0-US-06 ANTI-KK-LC-1 T CELL RECEPTORS National Stage US 11,352,410 16/096,118 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352410 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352410">11,352,410</a><br />Filed on 2018-10-24<br />Status: Issued 147168917 E-153-2016-0 E-153-2016-0-CH-08 ANTI-KK-LC-1 T CELL RECEPTORS EP Switzerland 3448882 17733120.4 Issued Switzerland <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168918 E-153-2016-0 E-153-2016-0-DE-09 ANTI-KK-LC-1 T CELL RECEPTORS EP Germany 3448882 17733120.4 Issued Germany <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168919 E-153-2016-0 E-153-2016-0-BE-07 ANTI-KK-LC-1 T CELL RECEPTORS EP Belgium 3448882 17733120.4 Issued Belgium <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168920 E-153-2016-0 E-153-2016-0-DK-10 ANTI-KK-LC-1 T CELL RECEPTORS EP Denmark 3448882 17733120.4 Issued Denmark <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168921 E-153-2016-0 E-153-2016-0-ES-11 ANTI-KK-LC-1 T CELL RECEPTORS EP Spain 3448882 17733120.4 Issued Spain <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168922 E-153-2016-0 E-153-2016-0-FI-12 ANTI-KK-LC-1 T CELL RECEPTORS EP Finland 3448882 17733120.4 Issued Finland <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168923 E-153-2016-0 E-153-2016-0-FR-13 ANTI-KK-LC-1 T CELL RECEPTORS EP France 3448882 17733120.4 Issued France <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168924 E-153-2016-0 E-153-2016-0-GB-14 ANTI-KK-LC-1 T CELL RECEPTORS EP United Kingdom 3448882 17733120.4 Issued United Kingdom <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168925 E-153-2016-0 E-153-2016-0-IE-15 ANTI-KK-LC-1 T CELL RECEPTORS EP Ireland 3448882 17733120.4 Issued Ireland <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168926 E-153-2016-0 E-153-2016-0-IT-16 ANTI-KK-LC-1 T CELL RECEPTORS EP Italy 3448882 17733120.4 Issued Italy <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168927 E-153-2016-0 E-153-2016-0-NL-17 ANTI-KK-LC-1 T CELL RECEPTORS EP The Netherlands 3448882 17733120.4 Issued The Netherlands <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168928 E-153-2016-0 E-153-2016-0-NO-18 ANTI-KK-LC-1 T CELL RECEPTORS EP Norway 3448882 17733120.4 Issued Norway <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168929 E-153-2016-0 E-153-2016-0-SE-19 ANTI-KK-LC-1 T CELL RECEPTORS EP Sweden 3448882 17733120.4 Issued Sweden <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147172479 CT83 147172480 Immunotherapy 147172482 Kita-Kyushu Lung Cancer Antigen 147172483 KK-LC-1 147172484 T-Cell Receptor 147172485 TCR 147172486 Testis TAB-4408 147157703 Improved HIV Vaccines Through Ras Activation NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Mark Cameron, Melvin Doster, Slim Fourati, Genoveffa Franchini, Shari Gordon, Namal Liyanage, Rafick Sakaly, Luca Schifanella, Monica Vaccari <p>Researchers at the National Cancer Institute (NCI) have developed a new method of improving the efficacy of vaccines in patients with human immunodeficiency virus (HIV) by activating Ras. This method can be used to develop more efficacious vaccine compositions by activating Ras before, during, or after vaccination. Additionally, the researchers discovered that modulation of the Ras pathways could be a predictive biomarker of protection against HIV. This novel method has been shown to effectively stimulate the Ras pathway and to improve vaccine protection from Simian Immunodeficiency Virus (SIV), a HIV animal model, in chimpanzees.</p> <p>More than 30 million people are currently infected with HIV worldwide and it is estimated to increase by as much as 3 million new infections yearly. Although effective anti-retroviral therapies exist, millions still succumb to acquired immune deficiency syndrome (AIDS) every year, underscoring the need to develop new therapeutics to prevent the spread of this disease. Agents that have the potential to modulate immune response can improve the efficacy of vaccine candidates. Ras, a central regulatory molecule that can be easily activated, is a potential target because it affects both the innate and adaptive immune responses.</p> <p>The National Cancer Institute, Vaccine Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this method of improving HIV vaccine efficacy by activating the Ras pathway. </p> <h2>Competitive Advantages:</h2> <ul><li>Easy and affordable preparation</li> <li>Usable in combination with established vaccine compositions and treatments</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of HIV patients using vaccines in combination with Ras-activating agents</li> <li>Method to detect likelihood that an HIV vaccine composition will induce a protective immune response</li> </ul> 2018-08-01 2025-04-22 2018-08-01 2025-08-15 2018-08-01 Franchini, HIV, Human Immunodeficiency Virus, immune response, RAS, Ras Pathway Activation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-01 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162300 Van Rompay KK, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. https://www.ncbi.nlm.nih.gov/pubmed/15671796 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15671796">Van Rompay KK, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.</a> 147162414 Pegu P, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. https://www.ncbi.nlm.nih.gov/pubmed/23175374 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23175374">Pegu P, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.</a> 147164629 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164632 Sakaly, Rafick Vaccine & Gene Therapy Institute of Florida Sakaly, Rafick 2 147164633 Fourati, Slim Vaccine & Gene Therapy Institute of Florida Fourati, Slim 3 147164634 Cameron, Mark Vaccine & Gene Therapy Institute of Florida Cameron, Mark 4 147164631 Vaccari, Monica NIH - NCI NCI Vaccari, Monica (NCI) 5 147164635 Schifanella, Luca NCI - CCR NCI Schifanella, Luca (NCI) 6 147164630 Gordon, Shari NIH - NCI NCI Gordon, Shari (NCI) 7 147164636 Doster, Melvin NIH - NCI NCI Doster, Melvin (NCI) 8 147164637 Liyanage, Namal NIH - NCI Liyanage, Namal 9 147164629 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164632 Sakaly, Rafick Vaccine & Gene Therapy Institute of Florida Sakaly, Rafick 2 147164633 Fourati, Slim Vaccine & Gene Therapy Institute of Florida Fourati, Slim 3 147164634 Cameron, Mark Vaccine & Gene Therapy Institute of Florida Cameron, Mark 4 147164631 Vaccari, Monica NIH - NCI NCI Vaccari, Monica (NCI) 5 147164635 Schifanella, Luca NCI - CCR NCI Schifanella, Luca (NCI) 6 147164630 Gordon, Shari NIH - NCI NCI Gordon, Shari (NCI) 7 147164636 Doster, Melvin NIH - NCI NCI Doster, Melvin (NCI) 8 147164637 Liyanage, Namal NIH - NCI Liyanage, Namal 9 147157899 Modulation Of The RAS Pathways As A Biomarker Of Protection Against HIV And As A Means To Improve Vaccine Efficacy E-062-2014-0 Filing authorized NCI, Vaccine & Gene Therapy Institute of Florida 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4408] Improved HIV Vaccines Through Ras Activation&body=Please send me information about technology [TAB-4408] Improved HIV Vaccines Through Ras Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4408] Improved HIV Vaccines Through Ras Activation&body=Please send me information about technology [TAB-4408] Improved HIV Vaccines Through Ras Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160979 E-062-2014-0 E-062-2014-0-US-01 RAS Pathways As Markers Of Protection Against HIV And Means To Improve Vaccine Efficacy PRV US 61/925,154 Abandoned US <br />Provisional (PRV) 61/925,154<br />Filed on 2014-01-08<br />Status: Abandoned 147168756 E-062-2014-0 E-062-2014-0-PCT-02 RAS Pathways As Markers Of Protection Against HIV And Means To Improve Vaccine Efficacy PCT Patent Cooperation Treaty PCT/US2015/010664 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/010664<br />Filed on 2015-01-08<br />Status: Expired 147168757 E-062-2014-0 E-062-2014-0-US-03 RAS PATHWAYS AS MARKERS OF PROTECTION AGAINST HIV AND METHODS TO IMPROVE VACCINE EFFICACY National Stage US 10,398,772 15/110,400 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10398772 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10398772">10,398,772</a><br />Filed on 2016-07-07<br />Status: Issued 147170557 Franchini 147170558 HIV 147170559 Human Immunodeficiency Virus 147170560 immune response 147170561 RAS 147170563 Ras Pathway Activation TAB-4340 147157631 Natural product-based anti-cancer agents: aza-Englerin analogues NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics John Beutler, William Chain, Daniel Fash, William Figg, Zhenwu Li, Cody Peer, Joe Ramos, Florian Suizmaier, Ian Talisman <p>Chemotherapy resistance in a wide array of cancers is often associated with enhanced glucose uptake and dysregulation of the insulin signaling pathway.  Therapeutics capable of inhibiting insulin signaling would be valuable as a stand-alone treatment and for sensitizing resistant tumors to standard chemotherapy regiments.  Researchers at NCI’s <a href="https://ccr.cancer.gov/Genitourinary-Malignancies-Branch" rel="nofollow">Genitourinary Malignancies Branch</a><a href="http://irp.nih.gov/pi/william-figg" rel="nofollow"> </a>have synthesized and developed a series of Englerin-A analogues with potent anti-tumor activity that is linked to inhibition of the insulin pathway.</p> <p>The researchers have previously shown that Englerin A has potent activity <em>in vivo </em>using a renal carcinoma xenograft mouse model.  A new lead compound with specific activity against renal cell carcinoma, which can be synthesized to scale for <em>in vivo</em> studies, and improved oral bioavailability, has been identified. The NCI seeks partners interested in collaborative research to co-develop this therapeutic with an initial goal of preclinical evaluation leading to clinical testing.</p> <h2>Competitive Advantages:</h2> <ul><li>Novel compounds with potent and selective inhibitory effect on select cancer cells </li> <li>Parent compounds are effective in <em>in vivo</em> cancer models.</li> <li>Demonstrated bioavailability after oral administration (mouse model)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Chemotherapeutic for renal cell carcinoma, in addition to glucose dependent tumors. </li> <li>Treatment of diseases or conditions associated with insulin resistance</li> </ul> 2016-02-16 2025-08-13 2017-12-20 2025-08-15 2017-08-30 Ewing, Glycolytic, insulin, Resistance, Sarcoma False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-042-2012 E-064-2008 E-201-2012 147162033 Akee R, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=22280462 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22280462">Akee R, et al.</a> 147162111 Ratnayake R, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=19061394 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19061394">Ratnayake R, et al.</a> 147162189 Li Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=21476574 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21476574">Li Z, et al.</a> 147162458 Sourbier C, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=23352416 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23352416">Sourbier C, et al.</a> 147164373 Chain, William University of Hawaii at Manoa Chain, William 1 147164371 Beutler, John NIH - NCI NCI Beutler, John (NCI) 2 147164374 Ramos, Joe University of Hawaii at Manoa Ramos, Joe 3 147164378 Figg, William NIH - NCI NCI Figg, William (NCI) 3 147164375 Suizmaier, Florian University of Hawaii at Manoa Suizmaier, Florian 4 147164376 Li, Zhenwu Yale University Li, Zhenwu 5 147164377 Fash, Daniel University of Hawaii at Manoa Fash, Daniel 6 147164372 Talisman, Ian NIH - NCI Talisman, Ian 7 147164379 Peer, Cody NIH - NCI NCI Peer, Cody (NCI) 8 147164373 Chain, William University of Hawaii at Manoa Chain, William 1 147164371 Beutler, John NIH - NCI NCI Beutler, John (NCI) 2 147164374 Ramos, Joe University of Hawaii at Manoa Ramos, Joe 3 147164378 Figg, William NIH - NCI NCI Figg, William (NCI) 3 147164375 Suizmaier, Florian University of Hawaii at Manoa Suizmaier, Florian 4 147164376 Li, Zhenwu Yale University Li, Zhenwu 5 147164377 Fash, Daniel University of Hawaii at Manoa Fash, Daniel 6 147164372 Talisman, Ian NIH - NCI Talisman, Ian 7 147164379 Peer, Cody NIH - NCI NCI Peer, Cody (NCI) 8 147157964 Aza-englerin Analogues And Use In Cancer Therapy E-090-2014-0 Filing authorized NCI, University of Hawaii at Manoa, Yale University 147162521 Aza-englerin Analogues And Use In Cancer Therapy E-090-2014-1 Filing authorized NCI, University of Hawaii at Manoa, Yale University 147162522 Aza-englerin Analogues And Use In Cancer Therapy E-090-2014-2 Filing authorized NCI, University of Hawaii at Manoa, Yale University 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues&body=Please send me information about technology [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues&body=Please send me information about technology [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161021 E-090-2014-0 E-090-2014-0-US-01 Novel natural-product-based nitrogen-containing anti-cancer agents PRV US 61/936,285 Abandoned US <br />Provisional (PRV) 61/936,285<br />Filed on 2014-02-05<br />Status: Abandoned 147168290 E-090-2014-1 E-090-2014-1-US-01 AZA-EPOXY-GUAIANE DERIVATIVES AND TREATMENT OF CANCER PRV US 62/018,381 Abandoned US <br />Provisional (PRV) 62/018,381<br />Filed on 2014-06-27<br />Status: Abandoned 147168293 E-090-2014-2 E-090-2014-2-PCT-01 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer PCT COMB Patent Cooperation Treaty PCT/US2015/014601 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/014601<br />Filed on 2015-02-05<br />Status: Expired 147168294 E-090-2014-2 E-090-2014-2-AU-02 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage Australia 2015214189 2015214189 Issued Australia <br />National Stage 2015214189<br />Filed on 2015-02-05<br />Status: Issued 147168295 E-090-2014-2 E-090-2014-2-CA-03 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage Canada 2938971 2938971 Issued Canada <br />National Stage 2938971<br />Filed on 2015-02-05<br />Status: Issued 147168296 E-090-2014-2 E-090-2014-2-EP-04 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage European Patent 3102581 15705869.4 Issued European Patent <br />National Stage 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168297 E-090-2014-2 E-090-2014-2-US-05 Aza-Epoxy-Guaiane Derivatives and Treatment of Cancer National Stage US 9,676,788 15/116,887 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676788">9,676,788</a><br />Filed on 2015-02-05<br />Status: Issued 147168298 E-090-2014-2 E-090-2014-2-DE-06 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Germany 3102581 15705869.4 Issued Germany <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168299 E-090-2014-2 E-090-2014-2-ES-07 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Spain 3102581 15705869.4 Issued Spain <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168300 E-090-2014-2 E-090-2014-2-FR-08 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP France 3102581 15705869.4 Issued France <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168301 E-090-2014-2 E-090-2014-2-GB-09 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP United Kingdom 3102581 15705869.4 Issued United Kingdom <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168302 E-090-2014-2 E-090-2014-2-NO-10 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Norway 3102581 15705869.4 Issued Norway <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168303 E-090-2014-2 E-090-2014-2-SE-11 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Sweden 3102581 15705869.4 Issued Sweden <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147171175 Ewing 147171176 Glycolytic 147171177 insulin 147171178 Resistance 147171179 Sarcoma TAB-427 114094765 Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE) NHLBI Licensing Licensing Peter Kellman, Elliot Mcveigh The invention is an accelerated magnetic resonance imaging method developed to reduce the total imaging time for gated, segmented cine imaging or to increase the frame rate when imaging dynamic activity, such as heart motion or brain activity. The invention combines temporal filtering (e.g., the UNFOLD method) with a known spatial sensitivity encoding technique (SENSE or SMASH) to achieve a new technique that is the subject of the invention (TSENSE) having a higher degree of alias artifact rejection than could be obtained using either temporal or spatial filtering individually. The new technique tracks changing coil sensitivities over time, which may arise due to chest wall or other body motions, and provides time saving by eliminating a separate reference acquisition. The invention is thus a robust accelerated imaging method that tolerates body motion or change in scan plane without the need to reacquire additional reference images, and the method may be used to reconstruct the full field-of-view with a large temporal bandwidth. 2022-03-08 2025-08-13 2025-08-15 2001-02-01 AA3B1X, AA3BXX, AA3XXX, AAXXXX, AC2XXX, ACXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103803 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103804 Mcveigh, Elliot Mcveigh, Elliot 0 114103803 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103804 Mcveigh, Elliot Mcveigh, Elliot 0 114099569 Accelerated Magnetic Resonance Imaging E-200-2000-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE)&body=Please send me information about technology [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE). Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE)&body=Please send me information about technology [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE).">vk5q@nih.gov</a><br> 114164649 E-200-2000-0 E-200-2000-0-US-01 Accelerated Magnetic Resonance Imaging Using a Parallel Spatial Filter ORD US 6,556,009 09/735,263 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6556009 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6556009">6,556,009</a><br />Filed on 2000-12-11<br />Status: Expired 114165808 E-200-2000-0 E-200-2000-0-PCT-02 Accelerated Magnetic Resonance Imaging PCT Patent Cooperation Treaty PCT/US2001/046949 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/046949<br />Filed on 2001-12-05<br />Status: Expired 114113273 AA3B1X 114113274 AA3BXX 114113275 AA3XXX 114113276 AC2XXX 114113277 AAXXXX 114113278 ACXXXX 114113279 AXXXXX TAB-4111 147157393 Cancer Vaccines against POTE for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Jay Berzofsky, Yi-Hisang Huang, Ira Pastan, Masaki Terabe <p>POTE is a novel tumor antigen expressed in a variety of cancers including breast, prostate, colon, lung, ovary, and pancreas cancers.  POTE has limited expression in normal tissues and therefore a specific target for cancer treatments, including immunotherapy.  The researchers seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize immunogenic peptides. </p> <p>Antigen-specific cancer immunotherapy often relies on identification of epitopes expressed by cancer cells that can targeted by cytotoxic T cells (CTL).  However, the CTL repertoire against high-affinity cancer epitopes is often ineffective because cancer epitopes may share a similar structure to natural "self" antigens.  As a result, cancer cells are not recognized by CTLs and destroyed.  The enhanced POTE epitopes induce a stronger immune response than natural responses.  These modified epitopes are more effective at inducing CTL against POTE expressing cancer cells and have greater potential to serve as cancer vaccine targets.</p> <h2>Competitive Advantages:</h2> <h2>Commercial Applications:</h2> 2016-02-16 2025-04-22 2021-10-27 2025-08-15 2016-08-23 CANCER, immunogenic peptides, Immunotherapy, POTE, Vaccine False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-10-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163546 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147163548 Huang, Yi-Hisang NIH - NCI NCI Huang, Yi-Hisang (NCI) 2 147163547 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 3 147163545 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 4 147163546 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147163548 Huang, Yi-Hisang NIH - NCI NCI Huang, Yi-Hisang (NCI) 2 147163547 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 3 147163545 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 4 147157765 Modified POTE Peptide Vaccine Against Cancer Of The Prostate, Colon, Lung, Breast, Ovary And Pancreas E-003-2010-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors&body=Please send me information about technology [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors&body=Please send me information about technology [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160880 E-003-2010-0 E-003-2010-0-US-03 Immunogenic Pote Peptides And Methods Of Use National Stage US 8,871,902 13/610,421 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8871902 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8871902">8,871,902</a><br />Filed on 2012-09-11<br />Status: Issued 147166596 E-003-2010-0 E-003-2010-0-US-01 Modified POTE Peplide Vaccine Againsl Cancer Of The Prostate, Colon, Lung, Breast, Ovary And Pancreas PRV US 61/313,559 Abandoned US <br />Provisional (PRV) 61/313,559<br />Filed on 2010-03-12<br />Status: Abandoned 147166597 E-003-2010-0 E-003-2010-0-PCT-02 Immunogenic POTE Peptides And Methods of Use PCT Patent Cooperation Treaty PCT/US2011/027577 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/027577<br />Filed on 2011-03-08<br />Status: Expired 147166598 E-003-2010-0 E-003-2010-0-US-04 Immunogenic POTE Peptides And Methods Of Use DIV US 9,394,352 14/496,194 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394352 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394352">9,394,352</a><br />Filed on 2014-09-25<br />Status: Issued 147169216 CANCER 147169218 immunogenic peptides 147169219 Immunotherapy 147169220 POTE 147169221 Vaccine TAB-3936 147157216 Treatment of Prostate Cancer Using Anti-androgen Small Molecules NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Yeong Kim, Vineet Kumar, Sunmin Lee, Sanjay Malhotra, Jane Trepel Neckers <p>Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target androgen receptor signaling in both androgen-independent and androgen-sensitive androgen receptor activity, and androgen receptors that are resistant to the current antiandrogens available.  Unlike the currently available antiandrogens, the new small molecules induce androgen receptor degradation and cell death in prostate cancer cells. Further, these compounds and methods can also induce degradation of other steroid hormone receptors demonstrating the possibility of treating a wider range of cancers.</p> <h2>Competitive Advantages:</h2> <ul><li>First small molecule antiandrogen treatment</li> <li>Causes cell death, not just loss of function</li> <li>Potential to treat other cancers through degradation of other steroid hormone receptors</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Series of steroid receptor compounds that cause cancer cell death</li> <li>Method of using the compounds in cancer treatment</li> </ul> 2016-02-16 2025-04-22 2022-09-29 2025-08-15 2016-08-24 Antiandrogen, castrate resistant, CRPC, PROSTATE CANCER, small molecule, steroid hormone receptor. False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-09-29 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162929 Trepel Neckers, Jane NIH - NCI NCI Trepel Neckers, Jane (NCI) 1 147162931 Kim, Yeong NIH - NCI Kim, Yeong 2 147162930 Lee, Sunmin NIH - NCI NCI Lee, Sunmin (NCI) 3 147162933 Kumar, Vineet NIH - NCI Leidos Kumar, Vineet (Leidos) 4 147162932 Malhotra, Sanjay NIH - NCI Leidos Malhotra, Sanjay (Leidos) 5 147162929 Trepel Neckers, Jane NIH - NCI NCI Trepel Neckers, Jane (NCI) 1 147162931 Kim, Yeong NIH - NCI Kim, Yeong 2 147162930 Lee, Sunmin NIH - NCI NCI Lee, Sunmin (NCI) 3 147162933 Kumar, Vineet NIH - NCI Leidos Kumar, Vineet (Leidos) 4 147162932 Malhotra, Sanjay NIH - NCI Leidos Malhotra, Sanjay (Leidos) 5 147157793 A New Chemical Class Of Antiandrogen For The Treatment Of Castrate-resistant Prostate Cancer E-015-2011-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules&body=Please send me information about technology [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules&body=Please send me information about technology [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160902 E-015-2011-0 E-015-2011-0-US-01 A New Chemical Class Of Antiandrogen For The Treatment Of Castrate-resistant Prostate Cancer PRV US 61/497,129 Abandoned US <br />Provisional (PRV) 61/497,129<br />Filed on 2011-06-15<br />Status: Abandoned 147165407 E-015-2011-0 E-015-2011-0-PCT-02 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer. PCT Patent Cooperation Treaty PCT/US12/42753 Expired Patent Cooperation Treaty <br />(PCT) PCT/US12/42753<br />Filed on 2012-06-15<br />Status: Expired 147165408 E-015-2011-0 E-015-2011-0-AU-03 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer National Stage Australia 2012271403 2012271403 Abandoned Australia <br />National Stage 2012271403<br />Filed on 2012-06-15<br />Status: Abandoned 147165409 E-015-2011-0 E-015-2011-0-CA-04 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer National Stage Canada 2839301 2839301 Abandoned Canada <br />National Stage 2839301<br />Filed on 2012-06-15<br />Status: Abandoned 147165410 E-015-2011-0 E-015-2011-0-EP-05 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer National Stage European Patent 2721003 12800764.8 Abandoned European Patent <br />National Stage 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165411 E-015-2011-0 E-015-2011-0-US-06 Nuclear Receptor Modulators and Their Use for the Treatment and Prevention of Cancer National Stage US 10,071,945 14/126,178 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10071945 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10071945">10,071,945</a><br />Filed on 2014-02-07<br />Status: Issued 147165412 E-015-2011-0 E-015-2011-0-AU-07 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer DIV Australia 2017248517 2017248517 Abandoned Australia <br />Divisional (DIV) 2017248517<br />Filed on 2017-10-19<br />Status: Abandoned 147165413 E-015-2011-0 E-015-2011-0-EP-08 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer DIV European Patent 17211083.5 Abandoned European Patent <br />Divisional (DIV) 17211083.5<br />Filed on 2012-06-15<br />Status: Abandoned 147165414 E-015-2011-0 E-015-2011-0-DE-09 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer EP Germany 2721003 12800764.8 Abandoned Germany <br />European patent (EP) 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165415 E-015-2011-0 E-015-2011-0-FR-10 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer EP France 2721003 12800764.8 Abandoned France <br />European patent (EP) 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165416 E-015-2011-0 E-015-2011-0-GB-11 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer EP United Kingdom 2721003 12800764.8 Abandoned United Kingdom <br />European patent (EP) 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165417 E-015-2011-0 E-015-2011-0-US-12 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER DIV US 10,737,995 16/107,532 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10737995 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10737995">10,737,995</a><br />Filed on 2018-08-21<br />Status: Issued 147169526 Antiandrogen 147169528 castrate resistant 147169530 CRPC 147169531 PROSTATE CANCER 147169532 small molecule 147169534 steroid hormone receptor. TAB-3867 147157146 A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Miriam Anver, Donna Butcher, Jeffrey Gildersleeve, Qian Li, Zhitao Li <p>Cervical cancer is one of the most common cancers among women worldwide. Currently, physical descriptors such as tumor size and depth are the primary factors used for deciding the course of treatment. Despite significant efforts to identify prognostic biochemical markers or therapeutic targets to improve diagnosis and treatment, none have achieved routine clinical use. An example of one previously identified biomarker is the Tn antigen, a carbohydrate moiety composed of a GalNAc residue linked to serine or threonine. Previous studies examining Tn antigen levels present in cervical cancer tumors have produced conflicting results. The inventors discovered that this phenomenon is a direct result of using antibodies that are cross reactive to carbohydrates terminating in GalNAcal-3Gal or GalNAca1-6Gal. To precisely determine which carbohydrate antigen correlates with cervical cancer formation, the investigators produced a series of antibodies with high degrees of specificity for structurally distinct variants of the Tn antigen. The results show that relative to other carbohydrate antigens examined, GalNAca1-3Gal is expressed at high levels in squamous carcinomas of the cervix.  Importantly, expression levels of GalNAcal-3Gal have a statistically significant correlation with 5-year survival rates. </p> <p> Researchers at NCI developed antibodies with high specificity for GalNAca1-3Gal, which can be used to both diagnose cervical cancer and as a prognostic tool. In addition to cervical cancer, elevated GalNAc1-3Gal is present in a variety of other human carcinomas, including squamous cell carcinoma, esophageal cancer, laryngeal cancer, and skin cancer. </p> <h2>Competitive Advantages:</h2> <ul><li>Only monoclonal antibody known to bind the GalNAca1-3Gal antigen but no other closely related structures, including blood group A, the Forssman antigen, and the Tn antigen. </li> <li>Binds various human tumor samples via immunohistochemistry</li> <li>The antibody is a rabbit IgG. </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cervical cancer diagnostics and prognosis </li> <li>Research tool</li> <li>Immunohistochemical staining of a variety of carcinomas including cervical, larynx, and skin squamous cell carcinomas</li> </ul> 2018-02-16 2025-04-22 2018-02-16 2025-08-15 2018-02-16 ANTIBODY, CERVICAL, GaLNAc1-3Gal, Gildersleeve, Immunohistochemical staining, Larynx, Prognostic marker, SKIN, Squamous Cell False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-02-16 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162337 Qian Li, et al. GalNAcα1-3Gal, a New Prognostic Marker for Cervical Cancer. https://www.ncbi.nlm.nih.gov/pubmed/19585575 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19585575">Qian Li, et al. GalNAcα1-3Gal, a New Prognostic Marker for Cervical Cancer.</a> 147162667 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162668 Li, Zhitao NIH - NCI Li, Zhitao 2 147162669 Li, Qian NIH - NCI Li, Qian 3 147162666 Anver, Miriam NIH - NCI Leidos Anver, Miriam (Leidos) 4 147162670 Butcher, Donna Butcher, Donna 5 147162667 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162668 Li, Zhitao NIH - NCI Li, Zhitao 2 147162669 Li, Qian NIH - NCI Li, Qian 3 147162666 Anver, Miriam NIH - NCI Leidos Anver, Miriam (Leidos) 4 147162670 Butcher, Donna Butcher, Donna 5 147157884 Generation And Application Of Antibodies That Bind GaLNAc1-3Gal E-058-2009-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis&body=Please send me information about technology [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis&body=Please send me information about technology [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160974 E-058-2009-0 E-058-2009-0-US-02 Antibodies That Bind GaLNAc1-3Gal, Pharmaceutical Compositions and Methods Of Using Same ORD US 8,957,188 12/752,331 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8957188 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8957188">8,957,188</a><br />Filed on 2010-04-01<br />Status: Issued 147164890 E-058-2009-0 E-058-2009-0-US-01 Generation And Application Of Antibodies That Bind GaLNAc1-3Gal PRV US 61/165,675 Abandoned US <br />Provisional (PRV) 61/165,675<br />Filed on 2009-04-01<br />Status: Abandoned 147170419 ANTIBODY 147170420 CERVICAL 147170421 GaLNAc1-3Gal 147170423 Gildersleeve 147170425 Immunohistochemical staining 147170427 Larynx 147170429 Prognostic marker 147170430 SKIN 147170432 Squamous Cell TAB-3841 144873504 Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases NIDCR Application, Human Cell Lines, Human iPSC Lines, Immunology, Licensing, Research Materials, Therapeutics Application Human Cell Lines Human iPSC Lines Immunology Licensing Research Materials Therapeutics Stephen Gadomski, Pamela Robey <p>This technology includes a method for differentiating human induced pluripotent stem cells (hiPSCs) into stable chondrocytes, capable of producing cartilage, and their use in cartilage repair in human injury and degenerative diseases. In suspension culture, hiPSC aggregates demonstrate gene and protein expression patterns similar to articular cartilage. Transplantation of cells from the aggregates into a mouse/rat femoral articular cartilage defect leads to the formation of stable, hyaline-like cartilage that persists for up to 5 months in immunocompromised mice and rats, demonstrating that hiPSC could potentially be used to regenerate cartilage in humans with similar defects. A potential application includes the treatment of osteoarthritis (OA), a disease characterized by the permanent loss of articular cartilage that lines joint surfaces.</p> This technology has the potential to be used to repair a variety of sources of cartilage damage, including damage caused by injury, overuse, and disease. In addition, the method described here produces chondrocytes that are stable when transplanted in vivo, which can potentially effect long-term and significant healing. In vivo long-term transplantation of hIPSC-derived chondrocytes can potentially be used to treat: <ul> <li>Injuries: This technology could be used to treat cartilage damage caused by injuries such as sports injuries, falls, and car accidents.</li> <li>Overuse: This technology could be used to treat cartilage damage caused by overuse, such as in athletes and people who have physically demanding jobs. </li> <li>Diseases: This technology could be used to treat cartilage damage caused by diseases such as osteoarthritis, rheumatoid arthritis, and avascular necrosis. </li> </ul> 2023-04-13 2025-08-13 2025-08-15 2023-04-13 False True True 52406768 Discovery 52406768 37470483 Website Abstract 145042411 Robey, Pamela NIDCR NIDCR Robey, Pamela (NIDCR) 1 145042424 Gadomski, Stephen Gadomski, Stephen 2 145042411 Robey, Pamela NIDCR NIDCR Robey, Pamela (NIDCR) 1 145042424 Gadomski, Stephen Gadomski, Stephen 2 144875507 Generation of hiPSC-derived chondrospheroids that produce stable cartilage in vivo E-094-2023-0 Filing authorized NIDCR, NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases&body=Please send me information about technology [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases&body=Please send me information about technology [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases.">ediz.yonter@nih.gov</a><br> TAB-3839 144783752 Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine CDC Collaboration, Infectious Disease, Research Equipment, Vaccines Collaboration Infectious Disease Research Equipment Vaccines Cara Burns, Raymond (Ray) Campagnoli, Olen Kew, Jing Shaw <p>Polio is a&nbsp;disabling&nbsp;and&nbsp;potentially&nbsp;fatal infectious disease.&nbsp;Sabin Oral Poliovirus Vaccine (OPV) and Salk Inactivated Poliovirus Vaccine (IPV) have been crucial in the global poliovirus eradication efforts and substantial decrease in&nbsp;disease&nbsp;incidence&nbsp;rates.&nbsp;However,&nbsp;recent findings showed&nbsp;that&nbsp;Sabin OPV strains, due to their genetic instability,&nbsp;may revert to virulence and spread among communities, resulting in circulating vaccine-derived poliovirus (cVDPV).&nbsp;Salk IPV,&nbsp;which is made by inactivating live poliovirus,&nbsp;poses&nbsp;a&nbsp;potential threat of viral&nbsp;containment&nbsp;breach&nbsp;(spill/exposure)&nbsp;during&nbsp;the&nbsp;manufacturing process.&nbsp;Salk IPV&nbsp;is also limited by its inability to confer intestinal immunity, a factor that is&nbsp;crucial to stop fecal-oral viral transmission, especially in developing countries&nbsp;with poor sanitation and limited&nbsp;clean drinking water. A safer, genetically stable&nbsp;vaccine candidate is&nbsp;highly essential&nbsp;for the containment of poliovirus breach,&nbsp;whether&nbsp;it would occur&nbsp;during&nbsp;the&nbsp;manufacturing&nbsp;process&nbsp;or due to&nbsp;cVDPV&nbsp;spread, and in achieving complete eradication of the disease.</p> <p>CDC inventors discovered that replacing&nbsp;one or more natural (or native) codons in a pathogen with synonymous un-preferred codons can decrease&nbsp;replicative fitness&nbsp;of the pathogen, thereby&nbsp;attenuating&nbsp;(decreasing the virulence of)&nbsp;the&nbsp;pathogen.&nbsp;Building on this, CDC researchers&nbsp;applied&nbsp;the&nbsp;previously patented codon deoptimization&nbsp;(CD)&nbsp;technology to the Sabin oral poliovirus vaccine (OPV) strains&nbsp;to develop attenuated poliovirus strains with enhanced genetic stability. These attenuated strains were&nbsp;then&nbsp;used as seed strains&nbsp;for&nbsp;a&nbsp;new Sabin&nbsp;inactivated poliovirus vaccine (sIPV)&nbsp;that&nbsp;is more stable and has less likelihood of reverting back to virulence.&nbsp;These modified&nbsp;sIPV&nbsp;candidates,&nbsp;while antigenically equivalent to the currently used Sabin OPV, offer safer methods for vaccine manufacture and viral breach containment.&nbsp;Researchers produced CD seed strains of all three poliovirus serotypes&nbsp;for Sabin OPV.&nbsp;As&nbsp;polio eradication&nbsp;progresses, more&nbsp;poliovirus&nbsp;containment requirements may&nbsp;be enacted.&nbsp;</p> <ul> <li>Enhanced genetic stability</li> <li>Less likely to revert to virulence</li> <li>Antigenically equivalent to the currently used Sabin OPV</li> <li>Genetically distinct from novel OPV that is currently being used and alleviates some critical safety issues associated with using live attenuated vaccines</li> </ul> <ul> <li>Vaccine design and development for Sabin inactivated poliovirus (IPV) or other enterovirus vaccines</li> <li>Functional improvements for poliovirus vaccines or other enterovirus vaccines</li> <li>PV seed stocks</li> <li>Quality control in vaccine development</li> <li>Research tools</li> </ul> Collaborative Research Opportunity The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Codon Deoptimized Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine For collaboration opportunities, please contact: CDC Technology Transfer Office tto@cdc.gov 2023-04-06 2025-08-13 2025-08-15 2023-04-06 False False Pre-Clinical (in vivo (animal)) True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-328-2013-0 144784092 Burns CC, et al. PMID 19605476 https://pubmed.ncbi.nlm.nih.gov/19605476/ <a href="https://pubmed.ncbi.nlm.nih.gov/19605476/">Burns CC, et al. PMID 19605476</a> 144784118 Burns CC, et al. PMID 16537593 https://pubmed.ncbi.nlm.nih.gov/16537593/ <a href="https://pubmed.ncbi.nlm.nih.gov/16537593/">Burns CC, et al. PMID 16537593</a> 144784135 Bigouette JP, et al. PMID 34437527 https://pubmed.ncbi.nlm.nih.gov/34437527/ <a href="https://pubmed.ncbi.nlm.nih.gov/34437527/">Bigouette JP, et al. PMID 34437527</a> 144783785 Burns, Cara CDC - DIR CDC Burns, Cara (CDC) 1 144783807 Campagnoli, Raymond (Ray) CDC - DIR CDC Campagnoli, Raymond (Ray) (CDC) 2 144783858 Shaw, Jing CDC - DIR CDC Shaw, Jing (CDC) 3 144783867 Kew, Olen CDC - DIR CDC Kew, Olen (CDC) 4 144783785 Burns, Cara CDC - DIR CDC Burns, Cara (CDC) 1 144783807 Campagnoli, Raymond (Ray) CDC - DIR CDC Campagnoli, Raymond (Ray) (CDC) 2 144783858 Shaw, Jing CDC - DIR CDC Shaw, Jing (CDC) 3 144783867 Kew, Olen CDC - DIR CDC Kew, Olen (CDC) 4 144783755 Codon Deoptimized Poliovirus Seed Strains For Use In An Inactivated Poliovirus Vaccine E-004-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine&body=Please send me information about technology [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine&body=Please send me information about technology [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine.">jonathan.motley@nih.gov</a><br> TAB-3838 144746539 Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development CDC Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Shane Gansebom, Jason Wilson, Ian York <p>Influenza A and B viruses can cause seasonal flu epidemics ― commonly known as the &ldquo;flu season&rdquo; ― and infect the nose, throat, eyes, and lungs in humans. Typically, flu seasons that are dominated by influenza A (H3N2) virus activity have higher associated hospitalizations and deaths in at-risk groups, such as people ages 65 and older and young children. Influenza A (H3N2) virus can also cause respiratory disease in animals, such as canines and swine. </p> <p>CDC discovered a series of 17 hybridomas (murine B cell fused with an immortal myeloma that produces a specific monoclonal antibody (mAb)) that recognize neuraminidase (N2) from influenza A (H3N2) viruses. Researchers identified the hybridomas of murine origin with mAbs that recognize N2 from influenza A/Hong Kong/4801/2014. The technology has potential utility in diagnostic assays, surveillance, prophylaxis, therapeutic treatments, and research reagents. Additional testing is planned to better understand the technology&rsquo;s activities and potential. </p> <ul> <li>The newly identified mAbs may bind to regions on viral NA antigens in a manner that currently available antibodies do not</li> <li>The technology may have altered affinities or a broader range of subtype and strain specificity than existing antibodies</li> </ul> <ul> <li>Development or refinement of diagnostic assays for influenza A (H3N2)</li> <li>Controls or a reference reagent source for diagnostic assay validation</li> <li>Quality control/quality assurance testing for influenza A (H3N2) vaccine or therapeutic development</li> <li>Monitoring and public health surveillance</li> <li>Research tools</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development For collaboration opportunities, please contact: CDC Technology Transfer Office tto@cdc.gov 2023-04-04 2025-08-13 2025-08-15 2023-04-05 False False Early-stage True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2016-0 E-163-2018 E-095-2022 E-562-2013-0 E-563-2013-0 E-331-2013-0 E-274-2013-0 E-560-2013-0 E-129-2020-0 E-177-2022-0 E-144-2022-0 E-145-2022-0 E-026-2022-0 E-193-2021-0 144746990 Publications: Guo Z., et al. [PMID 30053389.] https://pubmed.ncbi.nlm.nih.gov/30053389/ <a href="https://pubmed.ncbi.nlm.nih.gov/30053389/">Publications: Guo Z., et al. [PMID 30053389.]</a> 144747104 Chen X., et al. [PMID 35255298.] https://pubmed.ncbi.nlm.nih.gov/35255298/ <a href="https://pubmed.ncbi.nlm.nih.gov/35255298/">Chen X., et al. [PMID 35255298.]</a> 144747109 Wilson J., et al. [PMID 28888111.] https://pubmed.ncbi.nlm.nih.gov/28888111/ <a href="https://pubmed.ncbi.nlm.nih.gov/28888111/">Wilson J., et al. [PMID 28888111.]</a> 144747114 Xuemin C., et al. [PMID 35255298.] https://pubmed.ncbi.nlm.nih.gov/35255298/ <a href="https://pubmed.ncbi.nlm.nih.gov/35255298/">Xuemin C., et al. [PMID 35255298.]</a> 144746621 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144746642 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144746727 Gansebom, Shane CDC - DIR CDC Gansebom, Shane (CDC) 3 144746621 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144746642 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144746727 Gansebom, Shane CDC - DIR CDC Gansebom, Shane (CDC) 3 144746542 Monoclonal Antibodies Recognizing Neuraminidase From Influenza A(H3N2) E-129-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development&body=Please send me information about technology [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development&body=Please send me information about technology [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development.">jonathan.motley@nih.gov</a><br> TAB-3837 144735510 Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development CDC Collaboration, Diagnostics, Therapeutics, Vaccines Collaboration Diagnostics Therapeutics Vaccines Zhu Guo, Wen-Pin Tzeng, Jason Wilson, Ian York <p>Human influenza A is one of two influenza virus types that cause seasonal epidemics of disease (known as flu season) almost every winter in the United States. Influenza A viruses are the only influenza viruses known to cause flu pandemics (i.e., global epidemics of flu disease). (<a href="https://www.cdc.gov/flu/about/viruses/types.htm">Source</a>.)</p> <p>CDC has discovered a series of human monoclonal antibodies (mAbs) that target hemagglutinin (HA), one of two proteins found on the surface of influenza A viruses. The mAbs are influenza virus subtype specific, broadly binding within a subtype, and broadly cross-reactive across influenza subtypes (group 1 and 2). CDC has obtained normal donor peripheral blood mononuclear cells (PBMCs) and purified B cells from a commercial source and sorted these cells based on influenza HA binding activity. The V(D)J genes of HA reactive B cells were then single-cell sequenced and cloned to produce recombinant mAbs for further characterization. </p> <p>CDC has screened the mAbs produced from these studies by ELISA to confirm antigen specificity and approximate breadth of reactivity. Some mAbs were tested for antiviral activity in HA inhibition assays and a small number were screened by bio-layer interferometry to determine their epitope binding profile. CDC ha additional protection studies in mouse and/or ferret models underway to understand the technology&rsquo;s potential to act as a prophylactic, therapeutic, and diagnostic.</p> <ul> <li> Each of the recombinant mAbs produced in these studies have unique sequences and therefore bind to influenza viruses in unique ways.</li> -<li>These mAbs do not exist as a commercial source. </li> -<li>This technology can be provided as an antibody or plasmid.</li> </ul> <ul> <li>Prevention of influenza A infection with hemagglutinin (HA) proteins</li> <li>Treatment of influenza A (HA) infection</li> <li>Diagnostic assays for detection and characterization of influenza A (HA) viruses</li> <li>Public health monitoring and surveillance</li> <li>Quality assurance and quality control for vaccine, therapeutic, or diagnostic development</li> <li>Research tools and diagnostic reagents</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development For collaboration opportunities, please contact: CDC Technology Transfer Office tto@cdc.gov 2023-04-04 2025-08-13 2025-08-15 2023-04-05 False False Early-stage Prototype True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2016-0 E-163-2018-0 E-129-2020-0 E-061-2016-0 E-177-2022-0 E-144-2022-0 E-145-2022-0 E-026-2022-0 E-193-2021-0 E-095-2022 E-562-2013-0 E-563-2013-0 E-331-2013-0 E-274-2013-0 E-560-2013-0 144736229 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144736294 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144736298 Tzeng, Wen-Pin CDC - DIR CDC Tzeng, Wen-Pin (CDC) 3 144736312 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 4 144736229 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144736294 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144736298 Tzeng, Wen-Pin CDC - DIR CDC Tzeng, Wen-Pin (CDC) 3 144736312 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 4 144735513 Human Monoclonal Antibodies That Recognize Influenza A Viruses E-095-2022-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development&body=Please send me information about technology [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development&body=Please send me information about technology [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development.">jonathan.motley@nih.gov</a><br> TAB-3836 144525520 Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures NHLBI Cardiology, Medical Devices Cardiology Medical Devices <p>This technology includes a device and method for maintaining access to a location in the body while reducing or eliminating the potential for pulling an access device (i.e., catheter) back through an opening, such as a cardiac procedure. An introducer sheath includes a distal indented portion and a balloon, so that once placed in a desired location through tissue, the balloon can be inflated to anchor the sheath against retraction. </p> Currently available devices do not have an anchoring feature particularly suitable to the sensitive tissues of the heart; this device is safer by preventing inadvertent pullback. Device to be used for interventional cardiac procedures or other procedures to prevent pullback. 2023-03-21 2025-08-13 2025-08-15 2024-03-20 False True True 52406768 Discovery 52406768 37470483 Website Abstract 144525538 Vascular Anchoring Introducer Sheath E-045-2018-0 Filing authorized Cook Medical Technologies LLC, National Heart, Lung, and Blood Institute (NHLBI), Rady Children's Hospital 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures&body=Please send me information about technology [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures&body=Please send me information about technology [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures.">shmilovm@nih.gov</a><br> 157753749 E-045-2018-0 E-045-2018-0-US-01 Vascular Anchoring Introducer Sheath PRV US 62/412,646 Abandoned US <br />Provisional (PRV) 62/412,646<br />Filed on 2016-10-25<br />Status: Abandoned 157753757 E-045-2018-0 E-045-2018-0-PCT-02 Vascular Anchoring Introducer Sheath PCT Patent Cooperation Treaty PCT/US2017/058245 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/058245<br />Filed on 2017-10-25<br />Status: Expired 157753762 E-045-2018-0 E-045-2018-0-CN-03 Vascular Anchoring Introducer Sheath National Stage China 201780080201.9 Pending China <br />National Stage 201780080201.9<br />Filed on 2017-10-25<br />Status: Pending 157753767 E-045-2018-0 E-045-2018-0-EP-04 Vascular Anchoring Introducer Sheath National Stage European Patent 3532146 17794615.9 Issued European Patent <br />National Stage 17794615.9<br />Filed on 2017-10-25<br />Status: Issued 157753772 E-045-2018-0 E-045-2018-0-JP-05 Vascular Anchoring Introducer Sheath National Stage Japan 7200447 2019-545881 Issued Japan <br />National Stage 2019-545881<br />Filed on 2019-04-25<br />Status: Issued 157753777 E-045-2018-0 E-045-2018-0-US-06 Vascular Anchoring Introducer Sheath National Stage US 11,071,535 16/394,182 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11071535 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11071535">11,071,535</a><br />Filed on 2019-04-25<br />Status: Issued 157753794 E-045-2018-0 E-045-2018-0-US-07 Vascular Anchoring Introducer Sheath DIV US 12,011,151 17/385,230 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011151">12,011,151</a><br />Filed on 2021-07-26<br />Status: Issued TAB-3833 144184928 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Vaccines Antibodies Collaboration Infectious Disease Licensing Vaccines Jesse Erasmus, Heinrich (Heinz) Feldmann, David Hawman <p>Crimean-Congo hemorrhagic fever (CCHF) is a deadly hemorrhagic fever having a high mortality rate. The disease results from infection of an individual by Crimean-Congo hemorrhagic fever virus (CCHFV), which is a tick-borne bunyavirus endemic in Southern and Eastern Europe, Africa, the Middle East, and Asia. Geographically, case distribution is consistent with the range of Hyalomma genus ticks, the main reservoir of CCHFV, and is likely to expand due to climate change. Humans may be infected from tick bites, through contact with infected animals or animal tissue. Nosocomial human-to-human transmission has also been described primarily for healthcare workers. Initial symptoms of CCHF include acute onset of a non-specific febrile illness consisting of sudden fever, myalgia, diarrhea, nausea, and vomiting. The hemorrhagic phase is characterized by large areas of severe bruising and uncontrolled bleeding throughout the body; among hospitalized patients, case fatality rates have ranged from 9-50%. Currently, there is no approved specific antiviral or vaccine for CCHFV infection.</p> <p>Scientists at NIAID in collaboration with HDT Bio have developed a replicating RNA (repRNA) vaccine based on Venezuelan Equine Encephalitis Virus replicon RNA expressing either the nucleoprotein (repNP) or the glycoprotein precursor (repGPC) from CCHFV alone or in combination. &nbsp;In mice, the repNP vaccine primarily elicited a robust but non-neutralizing antibody response while repGPC elicited primarily cellular immunity against epitopes in the CCHFV NSm and Gc proteins. Vaccination with repNP or repNP + repGPC resulted in protection against challenge with a heterologous strain of CCHFV in mice.</p> <ul> <li>Uses a cell-free system to express antigens thereby increasing safety of the vaccine</li> <li>RepRNA as a platform can drive high-level protein expression and mimics viral replication in a single round of replication resulting in a more robust immune response in comparison to DNA and mRNA platforms</li> </ul> <ul> <li>Prophylactic usage against CCHFV infections in normal or high-risk populations</li> <li>Therapeutic treatment, alone or in combination, in patients with CCHFV infection</li> <li>Assay development for surveillance, diagnostic, and prevention measures</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Maryann Puglielli at <a href=mailto:maryann.puglielli@nih.gov>maryann.puglielli@nih.gov</a> or 1-240-627-3723 2023-03-02 2025-08-13 2025-08-15 2023-03-29 False False Pre-clinical True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144206046 Leventhal, S. et al., EBioMedicine 82:104188 (2022), “Replicating RNA Vaccination Elicits an Unexpected Immune Response that Efficiently Protects Mice Against Lethal Crimean-Congo Hemorrhagic Fever Virus Challenge” Leventhal, S. et al., EBioMedicine 82:104188 (2022), “Replicating RNA Vaccination Elicits an Unexpected Immune Response that Efficiently Protects Mice Against Lethal Crimean-Congo Hemorrhagic Fever Virus Challenge” 144186769 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 144186838 Hawman, David NIAID - DIR NIAID Hawman, David (NIAID) 2 144186889 Erasmus, Jesse HDT Bio Corp. Erasmus, Jesse 3 144186769 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 144186838 Hawman, David NIAID - DIR NIAID Hawman, David (NIAID) 2 144186889 Erasmus, Jesse HDT Bio Corp. Erasmus, Jesse 3 144184931 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus E-103-2022-0 Filing authorized HDT Biocorp, NIAID, University of Washington 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus&body=Please send me information about technology [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus&body=Please send me information about technology [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus.">terrence.joyce@nih.gov</a><br> 144186591 E-103-2022-0 E-103-2022-0-US-01 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus PRV US 63/365,015 Expired US <br />Provisional (PRV) 63/365,015<br />Filed on 2022-05-19<br />Status: Expired 146131382 E-103-2022-0 E-103-2022-0-PC-01 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus PCT Patent Cooperation Treaty PCT/US2023/067226 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/067226<br />Filed on 2023-05-19<br />Status: Expired TAB-3825 114097671 Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging NHLBI Cardiology, Diagnostics, Medical Devices, Non-Medical Devices, Software / Apps Cardiology Diagnostics Medical Devices Non-Medical Devices Software / Apps Peter Kellman, Hui Xue This technology includes a technique to improves detection of myocardial scar compared with conventional bright-blood late gadolinium enhancement (LGE) techniques. Dark-blood late gadolinium enhancement (DB-LGE) improves tissue delineation with signal suppression of the blood pool based on T2-preparation pulse that is relatively independent from the blood flow velocities and improves scar detection in patients with known or suspected coronary artery disease. Improves the quality and speed of scanning by imaging multiple parameters in a single free-breathing scan. Improve CMR scanning of commercial CMR. 2022-11-06 2024-10-28 2025-08-15 2024-03-27 2022-11-06 Bright-blood, Cardiovascular, Dark-blood, Dark-bloodphase, ENHANCEMENT, Gadolinium, Imaging:, inversion, Late, LGE, Magnetic, PHASE, PSIR, RECOVERY, Resonance, SCAN, SENSITIVE, Single, VDXXXX, WBXXXX, XFXXXX False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114172981 Kellman P, et al. https://pubmed.ncbi.nlm.nih.gov/34743718/ <a href="https://pubmed.ncbi.nlm.nih.gov/34743718/">Kellman P, et al.</a> 114111668 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 0 114111667 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 1 114111667 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 1 114111668 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 0 114102923 Cardiovascular Magnetic Resonance Imaging: Single Scan Bright-blood And Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) E-025-2021-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging &body=Please send me information about technology [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging . Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging &body=Please send me information about technology [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging .">vk5q@nih.gov</a><br> 114169682 E-025-2021-0 E-025-2021-0-US-01 SYNTHETIC BRIGHT-BLOOD AND DARK-BLOOD PSIR LGE IMAGES ORD US 11,454,691 17/472,838 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11454691 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11454691">11,454,691</a><br />Filed on 2021-09-13<br />Status: Issued 114129747 VDXXXX 114129748 WBXXXX 114129749 XFXXXX 114155739 Cardiovascular 114155740 Magnetic 114155741 Resonance 114155742 Imaging: 114155743 Single 114155744 SCAN 114155745 Bright-blood 114155746 Dark-bloodphase 114155747 SENSITIVE 114155748 inversion 114155749 RECOVERY 114155750 PSIR 114155751 Late 114155752 Gadolinium 114155753 ENHANCEMENT 114155754 LGE 114155755 Dark-blood 114155756 PHASE TAB-3822 114097668 Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis NHLBI Cardiology, Consumer Products, Medical Devices, Non-Medical Devices Cardiology Consumer Products Medical Devices Non-Medical Devices Ozgur Kocaturk, Robert Lederman, Kanishka Ratnayaka, Toby Rogers This technology includes an interventional device to occlude the left atrial appendage to prevent thrombus formation. Atrial fibrillation is the most common cardiac arrhythmia and is associated with formation of thrombus in the left atrial appendage. Standard preventative treatment involves anticoagulation, which is not tolerated by all patients. Existing devices necessitate improvement because they need trans-septal puncture and anticoagulation to prevent thrombus or are prone to life-threatening complications. All existing devices can cause left atrial appendage perforation leading to cardiac tamponade, requiring urgent intervention. This device is designed to ligate and exclude the left atrial appendage from the left atrial cavity within the pericardial space. The left atrial appendage is then grasped with one limb of the device. The second limb deploys a suture and, using counter-traction between the two limbs, the suture is delivered to the base or neck of the left atrial appendage where it is tightened and secured. The suture is then cut, and the right atrial appendage puncture is sealed. The unique features of the device are: <ul><li>Two coaxial limbs with different purposes</li> <li>Application via a trans-auricular route</li> <li>An atraumatic grasper for the left atrial appendage</li> <li>A coaxial suture delivery system resembling the TRAIPTA device recently disclosed</li> <li>Counter traction between the two limbs allows complete external encirclement of the left atrial appendage at its ostium without risking appendage perforation rupture or avulsion</li></ul> Cardiac device to prevent thrombus formation. 2022-11-06 2025-08-13 2025-08-15 2024-03-20 Appendage, Atrial, Left, LIGATION, Listed LPM Shmilovich as of 4/15/2015, MECHANICAL, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Trans-auricular, VDXXXX, WMXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114172980 Bartus K, Han F, et al. https://pubmed.ncbi.nlm.nih.gov/23062528/ <a href="https://pubmed.ncbi.nlm.nih.gov/23062528/">Bartus K, Han F, et al.</a> 114111654 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114111655 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114111656 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114111653 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114111653 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114111654 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114111655 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114111656 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114102920 Trans-auricular Left Atrial Appendage Ligation E-018-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis &body=Please send me information about technology [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis . Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis &body=Please send me information about technology [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis .">shmilovm@nih.gov</a><br> 114169676 E-018-2014-0 E-018-2014-0-US-01 Trans-Auricular Left Atrial Appendage Ligation PRV US 61/896,048 Abandoned US <br />Provisional (PRV) 61/896,048<br />Filed on 2013-10-26<br />Status: Abandoned 114169677 E-018-2014-0 E-018-2014-0-PCT-02 Atrial Appendage Ligation PCT Patent Cooperation Treaty PCT/US2014/062364 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/062364<br />Filed on 2014-10-27<br />Status: Expired 114169678 E-018-2014-0 E-018-2014-0-US-04 ATRIAL APPENDAGE LIGATION National Stage US 10,575,851 15/030,574 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10575851 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10575851">10,575,851</a><br />Filed on 2016-04-19<br />Status: Issued 114129734 VDXXXX 114129735 WMXXXX 114129736 XDXXXX 114155700 Trans-auricular 114155701 Left 114155702 Atrial 114155703 Appendage 114155704 LIGATION 114155705 Listed LPM Shmilovich as of 4/15/2015 114155706 Pre LPM working set 20150418 114155707 Post LPM Assignment Set 20150420 114155708 MECHANICAL TAB-3773 114097624 Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules NIDDK Therapeutics Therapeutics Harris Bernstein, Janine Peterson, Giselle Roman-Hernandez This technology includes a plasmid (designated pJH114) that encodes all five subunits of the E. coli Bam (barrel assembly machine) complex under the control of an inducible promoter to be used in the study of the Bam and screen for therapeutic small molecules. The Bam (barrel assembly machine) complex is a highly conserved heterooligomer that catalyzes the integration of membrane proteins that have a beta barrel structure into the outer membrane of Gram-negative bacteria. Research suggests that this complex is essential for the viability of most, if not all bacteria in this class. An octahistidine tag was added to one of the subunits (BamE) to facilitate purification. The plasmid can be used to direct the synthesis of large amounts of all of the subunits simultaneously in E. coli. We have found that the proteins produced by this plasmid assemble into highly active complexes that are easily purified. This plasmid simplifies the production of intact Bam complexes and appears to yield a higher quality product. In academic laboratories this product can be used to study the function of the Bam complex using biochemical, biophysical and structural approaches. This product might also be used by academic or commercial entities to screen for compounds that inhibit Bam complex function. 2022-11-30 2025-08-13 2025-08-15 2022-11-30 ac5AXX, BAM, BamABCDE, Barn, COLI, COMPLEX, COMPONENTS, designated, E., ENCODES, Expression, Listed LPM Ano as of 4/15/2015, PJH114, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, WKXXXX False True True NIHTT 37470483 Website Abstract 114172938 Voulhoux R, Bos M, et al. https://pubmed.ncbi.nlm.nih.gov/12522254/ <a href="https://pubmed.ncbi.nlm.nih.gov/12522254/">Voulhoux R, Bos M, et al.</a> 114172939 Wu T, Malinverni J, et al. https://pubmed.ncbi.nlm.nih.gov/15851030/ <a href="https://pubmed.ncbi.nlm.nih.gov/15851030/">Wu T, Malinverni J, et al.</a> 114172940 Hagan C, Kim S, et al. https://pubmed.ncbi.nlm.nih.gov/20378773/ <a href="https://pubmed.ncbi.nlm.nih.gov/20378773/">Hagan C, Kim S, et al.</a> 114111528 Roman-Hernandez, Giselle National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Roman-Hernandez, Giselle 0 114111529 Peterson, Janine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Peterson, Janine (NIDDK) 0 114111527 Bernstein, Harris National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Bernstein, Harris (NIDDK) 1 114111527 Bernstein, Harris National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Bernstein, Harris (NIDDK) 1 114111528 Roman-Hernandez, Giselle National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Roman-Hernandez, Giselle 0 114111529 Peterson, Janine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Peterson, Janine (NIDDK) 0 114102876 Expression Plasmid Designated PJH114 That Encodes All Components Of The E. Coli Bam Complex (BamABCDE) E-288-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 91025239 Walsh, Rosemary rosemary.walsh@nih.gov
rosemary.walsh@nih.gov?subject=Web Inquiry on [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules&body=Please send me information about technology [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules. Walsh, Rosemary<br><a href="mailto:rosemary.walsh@nih.gov?subject=Web Inquiry on [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules&body=Please send me information about technology [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules.">rosemary.walsh@nih.gov</a><br> 114129559 ac5AXX 114129560 WKXXXX 114155273 Expression 114155274 PLASMID 114155275 PJH114 114155276 COLI 114155277 Barn 114155278 COMPLEX 114155279 BamABCDE 114155280 Listed LPM Ano as of 4/15/2015 114155281 Pre LPM working set 20150418 114155282 Post LPM Assignment Set 20150420 114155283 designated 114155284 That 114155285 ENCODES 114155286 COMPONENTS 114155287 E. 114155288 BAM TAB-3753 114097604 MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers NIDDK Antibodies, Immunology, Oncology, Research Materials, Therapeutics Antibodies Immunology Oncology Research Materials Therapeutics Kai Ge, Ji-Eun Lee This technology includes polyclonal antibodies against MLL3 (KMT2C), MLL4, PA1, UTX And PTIP for the development of treatments for development diseases and cancer. Enhancers play a central role in cell-type-specific gene expression and are marked by H3K4me1/2. Active enhancers are further marked by H3K27ac. However, the methyltransferases responsible for H3K4me1/2 on enhancers remain elusive. Furthermore, how these enzymes function on enhancers to regulate cell-type-specific gene expression is unclear. Our findings suggest that loss-of-function mutations in MLL3 and MLL4 would impair H3K4me1/2 on enhancers, which lead to defects in enhancer activation, cell-type-specific gene expression and cell differentiation. Such a mechanism may contribute to the pathogenesis of these developmental diseases and cancers. Using MLL3/4 KO human and mouse cells, we demonstrated that MLL3/4 are major mammalian H3K4me1/2 methyltransferases in vivo and partially redundant each other. Treatment of various developmental diseases and cancers. 2022-11-30 2025-08-13 2025-08-15 2022-11-30 2022-07-11 Activation, antibodies, DIFFERENTIATION, Di-methyltransferase, ENHANCER, H3K4, ID1XXX, KMT2C, Listed LPM Contreras as of 4/15/2015, MLL3, MLL4, Mono-, pa1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PTIP, Required, RESEARCH MATERIAL, UTX, VCXXXX, WIXXXX, WJXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172912 Lee J, Wang C, et al. https://pubmed.ncbi.nlm.nih.gov/24368734/ <a href="https://pubmed.ncbi.nlm.nih.gov/24368734/">Lee J, Wang C, et al.</a> 114111474 Lee, Ji-Eun National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Lee, Ji-Eun (NIDDK) 0 114111473 Ge, Kai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ge, Kai (NIDDK) 1 114111473 Ge, Kai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ge, Kai (NIDDK) 1 114111474 Lee, Ji-Eun National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Lee, Ji-Eun (NIDDK) 0 114102856 MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies E-114-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers&body=Please send me information about technology [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers&body=Please send me information about technology [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers.">shastrim@mail.nih.gov</a><br> 114129488 ID1XXX 114129489 VCXXXX 114129490 WIXXXX 114129491 WJXXXX 114129492 XAXXXX 114155042 antibodies 114155043 H3K4 114155044 Mono- 114155045 Di-methyltransferase 114155046 MLL4 114155047 Required 114155048 ENHANCER 114155049 Activation 114155050 DIFFERENTIATION 114155051 MLL3 114155052 pa1 114155053 UTX 114155054 PTIP 114155055 Listed LPM Contreras as of 4/15/2015 114155056 Pre LPM working set 20150418 114155057 Post LPM Assignment Set 20150420 114155058 RESEARCH MATERIAL 114155059 KMT2C TAB-3738 114097590 Method For Improving Insulin Sensitivity for the Treatment of Diabetes NIDDK Endocrinology, Therapeutics Endocrinology Therapeutics Arnold Newman, Lynnette Nieman, Andre Ulmann This technology includes the administration of the antiglucocorticoid mifepristone for the treatment of diabetes. Administration of mifepristone (50 mg orally every 6 hours) for one week improves hepatic and adipose insulin resistance in men and women with pre-diabetes or mild type 2 diabetes mellitus. This class of compounds has not been previously used for the treatment of insulin resistance, which is found in patients with prediabetes and diabetes type 2. Thus, it is a novel discovery that may have important therapeutic applications in the many patients with these disorders. Treatment of insulin resistance, type 2 diabetes. 2022-11-30 2025-08-13 2025-08-15 2022-11-30 2022-07-10 IMPROVING, insulin, Method, SENSITIVITY, VFXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111443 Ulmann, Andre CEMAG CARE Ulmann, Andre 0 114111444 Newman, Arnold Unit Cell Diamond Newman, Arnold 0 114111442 Nieman, Lynnette NICHD NICHD Nieman, Lynnette (NICHD) 1 114111442 Nieman, Lynnette NICHD NICHD Nieman, Lynnette (NICHD) 1 114111443 Ulmann, Andre CEMAG CARE Ulmann, Andre 0 114111444 Newman, Arnold Unit Cell Diamond Newman, Arnold 0 114102842 Method For Improving Insulin Sensitivity E-081-2019-0 Filing authorized Laboratorie HRA Pharma Corporation, NICHD, Unit Cell Diamond 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes&body=Please send me information about technology [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes&body=Please send me information about technology [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes.">tongb@niddk.nih.gov</a><br> 114169575 E-081-2019-0 E-081-2019-0-US-01 Method For Improving Insulin Sensitivity PRV US 62/919,496 Abandoned US <br />Provisional (PRV) 62/919,496<br />Filed on 2019-03-18<br />Status: Abandoned 114129450 VFXXXX 114129451 WKXXXX 114154942 Method 114154943 IMPROVING 114154944 insulin 114154945 SENSITIVITY TAB-3643 114097496 Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers NHGRI Diagnostics, Infectious Disease, Research Materials Diagnostics Infectious Disease Research Materials Heidi Kong, Lilia Mijares, Julia ("Julie") Segre This technology includes a catalog of commensal and pathogenic staphylococci from human skin for utilization as clinical molecular markers of skin conditions and infections. The study of microbial diversity of human skin in both healthy and disease states is important to develop tools to track infections, outbreaks, and multi-drug resistant organisms, particularly in atopic dermatitis, eczema and other microbial-associated infections. Commensal skin S. epidermidis have an open pan-genome and show considerable diversity between isolates. Previously unrecognized group of S. epidermidis strains have been characterized, which has the potential to be used as clinical molecular markers. This representative catalog of commensal and pathogenic staphylococci from the skin will also enable quantitative assessments of changes in staphylococcal burden during disease exacerbation, such as chronic relapsing atopic dermatitis or Methicillin-resistant Staphylococcus aureus (MRSA) infection. 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-18 Epidermidis, Human, ISOLATES, SAMPLES, SKIN, Staphylococcus, VJXXXX, WBXXXX, WIXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114172798 Conlan S, Mijares L, et al. https://pubmed.ncbi.nlm.nih.gov/22830599/ <a href="https://pubmed.ncbi.nlm.nih.gov/22830599/">Conlan S, Mijares L, et al.</a> 114111131 Mijares, Lilia University of Maryland, School of Medicine Mijares, Lilia 0 114111132 Kong, Heidi NIAMS - IRP NIAMS Kong, Heidi (NIAMS) 0 114111130 Segre, Julia ("Julie") National Human Genome Research Institute (NHGRI) NHGRI Segre, Julia ("Julie") (NHGRI) 1 114111130 Segre, Julia ("Julie") National Human Genome Research Institute (NHGRI) NHGRI Segre, Julia ("Julie") (NHGRI) 1 114111131 Mijares, Lilia University of Maryland, School of Medicine Mijares, Lilia 0 114111132 Kong, Heidi NIAMS - IRP NIAMS Kong, Heidi (NIAMS) 0 114102748 Staphylococcus Epidermidis Isolates From Human Skin Samples E-245-2020-0 Research Material National Human Genome Research Institute (NHGRI), NIAMS 83725487 Raghavan, Sangeetha sangeetha.raghavan@nih.gov
United States of America Technology Transfer Office sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers&body=Please send me information about technology [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers. Raghavan, Sangeetha<br><a href="mailto:sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers&body=Please send me information about technology [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers.">sangeetha.raghavan@nih.gov</a><br> 114129046 VJXXXX 114129047 WBXXXX 114129048 WIXXXX 114129049 XCXXXX 114153997 Staphylococcus 114153998 Epidermidis 114153999 ISOLATES 114154000 Human 114154001 SKIN 114154002 SAMPLES TAB-3639 114097492 Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis NHGRI Antibodies, Diagnostics, Immunology, Oncology, Research Materials Antibodies Diagnostics Immunology Oncology Research Materials David Azorsa, Javed Khan, Paul Meltzer This technology includes monoclonal antibody (mAb) that binds to the junction region of the PAX3-FOXO1 and PAX7-FOXO1 fusion protein for the diagnosis of Alveolar Rhabdomyosarcoma (ARMS). Specifically, two monoclonal antibodies (PFM.1 and PFM.2) have been isolated that recognize the 92kDa bands found uniquely to the pediatric striated muscle tumors of the type Alveolar Rhabdomyosarcoma (ARMS) carrying the characteristic t(2;13)(q35;q14) or t(1;13)(p36;q14) chromosomal translocations. This in-frame fusion protein is unique to the most common type of ARMS and acts as a potent transcriptional activator as the result of a decreased regulatory (of PAX3/7) sensitivity of the C-terminal domain of FOXO1. The mAbs recognize the ARMS fusion protein PAX3/7 FKHR on western analysis and do not recognize PAX3/7 or FOXO1 alone. The antibodies work by Westerns, Co-Immunoprecipitation, Chromatin Immunoprecipitation Sequencing (CHipSeq), and immunohistochemistry. Currently there is no recognized antibody capable of detecting the PAX3/7-FOXO1 fusion protein as a unique translocation product. To be utilized by pathologists for the diagnosis of ARMS. 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-12 antibodies, Fusion, monoclonal, Oncogene, PAX3-FOXO1, PAX7-FOXO1, RECOGNIZE, That, VCXXXX, WBXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172796 Gryder B, Yohe M, et al. https://pubmed.ncbi.nlm.nih.gov/28446439/ <a href="https://pubmed.ncbi.nlm.nih.gov/28446439/">Gryder B, Yohe M, et al.</a> 114111119 Meltzer, Paul NCI - CCR NCI Meltzer, Paul (NCI) 0 114111120 Azorsa, David University of Arizona College of Medicine - Phoenix Azorsa, David 0 114111118 Khan, Javed NCI - CCR NCI Khan, Javed (NCI) 1 114111118 Khan, Javed NCI - CCR NCI Khan, Javed (NCI) 1 114111119 Meltzer, Paul NCI - CCR NCI Meltzer, Paul (NCI) 0 114111120 Azorsa, David University of Arizona College of Medicine - Phoenix Azorsa, David 0 114102744 Monoclonal Antibodies That Recognize The Fusion Oncogene PAX3-FOXO1 And PAX7-FOXO1 E-213-2017-0 Research Material National Human Genome Research Institute (NHGRI) 83725487 Raghavan, Sangeetha sangeetha.raghavan@nih.gov
United States of America Technology Transfer Office sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis&body=Please send me information about technology [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis. Raghavan, Sangeetha<br><a href="mailto:sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis&body=Please send me information about technology [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis.">sangeetha.raghavan@nih.gov</a><br> 114129031 VCXXXX 114129032 WBXXXX 114129033 WIXXXX 114129034 XAXXXX 114153951 monoclonal 114153952 antibodies 114153953 That 114153954 RECOGNIZE 114153955 Fusion 114153956 Oncogene 114153957 PAX3-FOXO1 114153958 PAX7-FOXO1 TAB-3635 114097488 Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Therapeutics Ellen Sidransky, Barbara Stubblefield This technology includes two human fibroblast cell lines to be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1. Fibroblasts from various patients were collected, including those with genotype L444P/ recombinant allele (recNci1). Because this mutation is involved in neuronopathic Gaucher disease, it can be used for the study of neuronopathic forms of the disorder. These cell lines can be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-12 Cell, Fibroblast, Gaucher, Genotype, L44P/RecNci1, Lines, PATIENT, VPXXXX, WKXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172793 Weiss K, Gonzalez A, et al. https://pubmed.ncbi.nlm.nih.gov/25435509/ <a href="https://pubmed.ncbi.nlm.nih.gov/25435509/">Weiss K, Gonzalez A, et al.</a> 114111108 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114111107 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111107 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111108 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114102740 Fibroblast Cell Lines From A Patient With Gaucher Genotype L44P/RecNci1 E-062-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83718085 Surabian, Karen karen.surabian@nih.gov
United States of America Technology Transfer Office (TTO) karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment&body=Please send me information about technology [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment. Surabian, Karen<br><a href="mailto:karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment&body=Please send me information about technology [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment.">karen.surabian@nih.gov</a><br> 114129017 VPXXXX 114129018 WKXXXX 114129019 XHXXXX 114153915 Fibroblast 114153916 Cell 114153917 Lines 114153918 PATIENT 114153919 Gaucher 114153920 Genotype 114153921 L44P/RecNci1 TAB-3608 114097461 Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Ciprian Crainiceanu, Arthur Goldsmith, Daniel Reich, Colin Shea, Russell Shinohara, Elizabeth Sweeney Methylmalonic Acidemia (MMA) is a metabolic disorder characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. A significant portion of MMA cases stem from a deficiency in a key mitochondrial enzyme, methylmalonyl-CoA mutase (MUT), required to break down amino acids and lipids. Currently, there are no treatments for MMA and the disease is managed primarily with dietary restriction of amino acid precursors and liver-kidney transplantation in severe cases. <br /><r /> The present invention describes a synthetic codon-optimized MUT gene (co-MUT) that improves expression of human methylmalonyl-CoA mutase. A series of novel gene therapy vectors containing co-MUT rescued MMA mice from lethality and lowered levels of methylmalonic acid in the blood. Results of pre-clinical efficacy studies demonstrate a promising therapy for MMA and other renal-associated disorders. The co-MUT transgene could be used through non-viral and viral gene delivery. <ul> <li>The co-MUT transgene could be used to treat MMA patients.</li> <li>In addition, it could be used to produce MUT in vitro for MMA enzyme replacement therapy.</li> </ul> 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-11 Automatic, brain, Detection, IMAGING, Incidence, Lesion, Listed LPM Shmilovich as of 4/15/2015, Longitudinal, Magnetic, MULTIMODALITY, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Resonance, software, SuBLIME:, VPXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111032 Shea, Colin NINDS NINDS Shea, Colin (NINDS) 0 114111033 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114111034 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114111035 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114111036 Goldsmith, Arthur Johns Hopkins University Goldsmith, Arthur 0 114110560 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114110560 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114111032 Shea, Colin NINDS NINDS Shea, Colin (NINDS) 0 114111033 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114111034 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114111035 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114111036 Goldsmith, Arthur Johns Hopkins University Goldsmith, Arthur 0 152358172 A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) E-243-2012-1 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA).">eggerton.campbell@nih.gov</a><br> 114169325 E-043-2012-0 E-043-2012-0-US-03 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging National Stage US 9,607,392 14/362,354 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9607392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9607392">9,607,392</a><br />Filed on 2014-06-02<br />Status: Issued 114169326 E-043-2012-0 E-043-2012-0-PCT-02 SYSTEM AND METHOD OF AUTOMATICALLY DETECTING TISSUE ABNORMALITIES PCT Patent Cooperation Treaty PCT/US2012/067997 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/067997<br />Filed on 2012-12-05<br />Status: Expired 114169327 E-043-2012-0 E-043-2012-0-US-01 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging PRV US 61/630,101 Abandoned US <br />Provisional (PRV) 61/630,101<br />Filed on 2011-12-05<br />Status: Abandoned 152358237 E-243-2012-1 E-243-2012-1-US-01 Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) CIP US 9,944,918 15/070,787 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9944918 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9944918">9,944,918</a><br />Filed on 2016-03-15<br />Status: Issued 114128921 VPXXXX 114128922 WJXXXX 114128923 XEXXXX 114153600 SuBLIME: 114153601 Automatic 114153602 brain 114153603 Lesion 114153604 Incidence 114153605 Detection 114153606 MULTIMODALITY 114153607 Longitudinal 114153608 Magnetic 114153609 Resonance 114153610 IMAGING 114153611 Listed LPM Shmilovich as of 4/15/2015 114153612 Pre LPM working set 20150418 114153613 Post LPM Assignment Set 20150420 114153614 software TAB-3599 114097452 Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection NCATS Infectious Disease, Neurology, Research Materials, Therapeutics Infectious Disease Neurology Research Materials Therapeutics Ruili Huang, Wenwei Huang, Emily Lee, Guo-Li Ming, Hongjun Song, Hengli Tang, Zhexing Wen, Miao Xu, Cheng YiChen, Wei Zheng, Yi Zhou This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug discovery and development. Repurposing CDK inhibitors that have been used in clinical trials for other diseases for the treatment of Zika virus infection can reduce the long time course needed for new drug discovery and development. The group of identified CDK inhibitors could be used with an animal model to test for in vivo efficacy and to optimize the chemistry of the lead compounds. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 CDK, Infection, Inhibitors, Repurposing, treatment, VEXXXX, virus, VLXXXX, WIXXXX, WKXXXX, Zika False True True NIHTT 37470483 Website Abstract 114110983 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110984 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110985 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110986 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 0 114110987 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110988 YiChen, Cheng Florida State University Research Foundation, Inc. (FSURF) YiChen, Cheng 0 114110989 Zhou, Yi Florida State University Research Foundation, Inc. (FSURF) Zhou, Yi 0 114110990 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110991 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110992 Wen, Zhexing Johns Hopkins University Wen, Zhexing 0 114110982 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110982 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110983 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110984 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110985 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110986 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 0 114110987 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110988 YiChen, Cheng Florida State University Research Foundation, Inc. (FSURF) YiChen, Cheng 0 114110989 Zhou, Yi Florida State University Research Foundation, Inc. (FSURF) Zhou, Yi 0 114110990 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110991 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110992 Wen, Zhexing Johns Hopkins University Wen, Zhexing 0 114102706 Repurposing CDK Inhibitors For Treatment Of Zika Virus Infection E-202-2016-0 Filing authorized Florida State University Research Foundation, Inc. (FSURF), Johns Hopkins University, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169443 E-202-2016-0 E-202-2016-0-US-01 Compounds and Methods for Treatment and Prevention of Flavivirus Infection PRV US 62/363,238 Abandoned US <br />Provisional (PRV) 62/363,238<br />Filed on 2016-07-16<br />Status: Abandoned 114128885 VEXXXX 114128886 VLXXXX 114128887 WIXXXX 114128888 WKXXXX 114153519 Repurposing 114153520 CDK 114153521 Inhibitors 114153522 treatment 114153523 Zika 114153524 virus 114153525 Infection TAB-3598 114097451 Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) NCATS Endocrinology, Research Materials, Therapeutics Endocrinology Research Materials Therapeutics Asaf Alimardanov, Junfeng Huang, Wenwei Huang, Xiuli Huang, Jiankang Jiang, Arthur Lee, Philip Sanderson, Khalida Shamim, Gregory Tawa, Wei Zheng This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic endochondral ossification (HEO) postnatally, which leads to the formation of a second skeleton of heterotopic bone. Individuals with the classical features of FOP have the identical heterozygous activating mutation (R206H) in the gene encoding ACRV1 (also known as ALK2), a BMP type 1 receptor. There are no effective treatments for fibrodysplasia ossificans progressiva (FOP). Further clinical work could establish the novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP). Potent ALK2 inhibitors could conceivably be used prophylactic, acute or chronic therapy for patients with FOP as well as disorders associated with altered BMP signaling. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 ALK2, BMP, INHIBITING, Inhibitors, Methods, Novel, SIGNALING, VGXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172770 Yu PB, Deng DY, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/">Yu PB, Deng DY, et al.</a> 114172771 Hao J, Ho JN, et al. https://pubmed.ncbi.nlm.nih.gov/20020776/ <a href="https://pubmed.ncbi.nlm.nih.gov/20020776/">Hao J, Ho JN, et al.</a> 114172772 Cuny GD, Yu PB, et al. https://pubmed.ncbi.nlm.nih.gov/18621530/ <a href="https://pubmed.ncbi.nlm.nih.gov/18621530/">Cuny GD, Yu PB, et al.</a> 114172773 Sanvitale CE, Kerr G, et al. https://pubmed.ncbi.nlm.nih.gov/23646137/ <a href="https://pubmed.ncbi.nlm.nih.gov/23646137/">Sanvitale CE, Kerr G, et al.</a> 114110973 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110974 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110975 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110976 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110977 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114110978 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110979 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110980 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110981 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114110972 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110972 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110973 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110974 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110975 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110976 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110977 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114110978 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110979 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110980 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110981 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114102705 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling E-198-2016-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)&body=Please send me information about technology [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)&body=Please send me information about technology [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).">jasmine.kalsi@nih.gov</a><br> 114169439 E-198-2016-0 E-198-2016-0-US-01 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling PRV US 62/490,772 Abandoned US <br />Provisional (PRV) 62/490,772<br />Filed on 2017-04-27<br />Status: Abandoned 114169440 E-198-2016-0 E-198-2016-0-PCT-02 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling PCT Patent Cooperation Treaty PCT/US2018/029626 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/029626<br />Filed on 2018-04-26<br />Status: Expired 114169441 E-198-2016-0 E-198-2016-0-US-04 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling National Stage US 11,026,947 16/608,489 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11026947 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11026947">11,026,947</a><br />Filed on 2019-10-25<br />Status: Issued 114169442 E-198-2016-0 E-198-2016-0-US-08 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling CON US 11,654,147 17/340,589 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11654147 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11654147">11,654,147</a><br />Filed on 2021-06-07<br />Status: Issued 114128881 VGXXXX 114128882 WIXXXX 114128883 WKXXXX 114128884 XEXXXX 114153512 Novel 114153513 ALK2 114153514 Inhibitors 114153515 Methods 114153516 INHIBITING 114153517 BMP 114153518 SIGNALING TAB-3595 114097448 Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection NCATS Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics Ruili Huang, Wenwei Huang, Emily Lee, Hao Li, Khalida Shamim, Hengli Tang, Miao Xu, Shu Yang, Wei Zheng This technology includes the use of two related compounds, Emetine and Cephaeline, as a potent inhibitor of the Zika virus (ZIKV). Emetine and it's analog Cephaeline were identified in a high-throughput assay aimed at identifying anti-ZIKV compounds. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is a potent inhibitor of ZIKV infection in a live mouse model. These compounds were previously identified in an ipecac root crude extract which was used as a treatment for amoebic dysentery in addition to being used as an emetic agent, depending on dosage. While there has been some cardiotoxicity reported with high dosage of emetine, the effective IC50 observed in cell culture and mice is well below the toxic dosage. This is the first report of Emetine or Cephaeline as antiviral compounds in ZIKV infection. There are currently no known antiviral treatments against ZIKV infection. Current treatments for ZIKV are only supportive and not curative. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is a potent inhibitor of ZIKV infection in a live mouse model. Further clinical work may support the use of these compounds for therapeutic use. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 compounds, Emetine, Flavivirus, Infection, Prevention, treatment, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172768 Yang S, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/29872540/ <a href="https://pubmed.ncbi.nlm.nih.gov/29872540/">Yang S, Xu M, et al.</a> 114110955 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110956 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110957 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110958 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110959 Yang, Shu NCATS - TRND NCATS Yang, Shu (NCATS) 0 114110960 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110961 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110962 Li, Hao NCATS - TRND NCATS Li, Hao (NCATS) 0 114110954 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110954 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110955 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110956 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110957 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110958 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110959 Yang, Shu NCATS - TRND NCATS Yang, Shu (NCATS) 0 114110960 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110961 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110962 Li, Hao NCATS - TRND NCATS Li, Hao (NCATS) 0 114102702 EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION E-115-2018-0 Filing authorized Florida State University Research Foundation, Inc. (FSURF), NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection&body=Please send me information about technology [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection&body=Please send me information about technology [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169437 E-115-2018-0 E-115-2018-0-US-01 EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION PRV US 62/570,553 Abandoned US <br />Provisional (PRV) 62/570,553<br />Filed on 2017-10-10<br />Status: Abandoned 114128869 VLXXXX 114128870 WIXXXX 114128871 WKXXXX 114153496 Emetine 114153497 compounds 114153498 treatment 114153499 Prevention 114153500 Flavivirus 114153501 Infection TAB-3590 114097444 A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC) NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Zachary Caffall, Nicole Calakos, Joseph Rittiner This technology relates to the identification and use of a group of compounds that activate the AMP-activated protein kinase (AMPK) and also effectively reduce lysosomal cholesterol accumulation in patients with Niemann-Pick disease Type C (NPC). Clinical trials are currently underway to determine the efficacy of beta-cyclodextrin in treating patients with NPC. A potential mechanism has been proposed indicating that beta-cyclodextrin activated AMP-activated protein kinase, leading to restoration of autophagy in cells from NPC patients. A computer modeling was used to identify the group of compounds that bind and activate AMPK. Eight of the compounds were found to effectively reduce cholesterol accumulation in lysosomes of cells from NPC patients. The small molecule AMPK modulators can be optimized for better penetration of the blood-brain barrier. This is advantageous over beta-cyclodextrin, which is impermeable to the blood-brain barrier and needs to be directly injected into the central nervous system. In addition, the allosteric modulation of AMPK function by these compounds is more tolerable as a treatment because beta-cyclodextrin directly activates the AMPK alpha-subunit which can cause significant cytotoxicity. The group of compounds identified as AMPK activators can be further developed to improve potency and ability of blood-brain-barrier penetration as a new drug for the treatment of Niemann-Pick disease Type C. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 AMPK, C, Compositions, Disease, DISORDERS, Dystonia, Identifying, Methods, MODULATORS, Niemann, Pick, TREATING, treatment, TYPE, VEXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172766 Dai S, Dulcey AE, et al. https://pubmed.ncbi.nlm.nih.gov/28613987/ <a href="https://pubmed.ncbi.nlm.nih.gov/28613987/">Dai S, Dulcey AE, et al.</a> 114110931 Caffall, Zachary Duke University Caffall, Zachary 0 114110932 Rittiner, Joseph Duke University Rittiner, Joseph 0 114110930 Calakos, Nicole Duke University Calakos, Nicole 1 114110930 Calakos, Nicole Duke University Calakos, Nicole 1 114110931 Caffall, Zachary Duke University Caffall, Zachary 0 114110932 Rittiner, Joseph Duke University Rittiner, Joseph 0 114102698 Compositions And Methods For Identifying And Treating Dystonia Disorders E-060-2017-0 Filing authorized Duke University, NIH - NCATS 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC)&body=Please send me information about technology [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC). Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC)&body=Please send me information about technology [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC).">rebecca.erwin-cohen@nih.gov</a><br> 114169433 E-060-2017-0 E-060-2017-0-US-01 Compositions and Methods for Identifying and Treating Dystonia Disorders PRV US 62/234,127 Abandoned US <br />Provisional (PRV) 62/234,127<br />Filed on 2015-09-29<br />Status: Abandoned 114128852 VEXXXX 114128853 WIXXXX 114128854 WKXXXX 114128855 XEXXXX 114153453 AMPK 114153454 MODULATORS 114153455 treatment 114153456 Niemann 114153457 Pick 114153458 TYPE 114153459 C 114153460 Disease 114153461 Compositions 114153462 Methods 114153463 Identifying 114153464 TREATING 114153465 Dystonia 114153466 DISORDERS TAB-3587 114097442 Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis NCATS Consumer Products, Neurology Consumer Products Neurology Asaf Alimardanov, Mark Behnke, Scott David, Douglas (Doug) Fry, William Hoekstra, Christopher Yates This technology relates to the discovery and development of a practical, scalable, and commercially viable method for the synthesis of the novel antifungal VT-1129. Cryptococcal meningitis (CM) is a fungal infection that is particularly prevalent in immune-compromised patients and can be treated by VT-1129. CM has a current estimated patient population of 1-1.25 million, predominately in sub-Saharan Africa and the developing world. Several deficiencies and difficulties preclude large-scale preparation and manufacturing with previous processes, which include high cost and potential safety issues. The method described in this invention enables the practical and economical synthesis of VT-1129 at a large scale. This discovery has the following advantages over previous synthesis methods: 1) avoids using expensive chiral chromatography for separation and preparation of enantiomerically enriched aminoalcohols and derivatives 2) avoids using expensive chromatographic purification of intermediates 3) avoids using of cryogenic conditions in the process 4) avoids using unstable/explosive reagents 5) allows cost-efficient and scalable preparation applicable to commercial scale manufacturing The discovery described here can generally be used to prepare enantioenriched aminoalcohols that contain tertiary alcohol fragments, and their derivatives, including the novel antifungal VT-1129 used for treating cryptococcal meningitis. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Acid, Alcohol, Aminoalcohols, Benzenesulfonic, BSA., Co-crystal, Containing, Derivatives, Enantioenriched, Fragment, Including, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROCESS, Synthesis, Tertiary, THOSE, VEXXXX, VT-1129, WMXXXX False True True NIHTT 37470483 Website Abstract 114172760 Kolb HC et al. https://doi.org/10.1021/cr00032a009 <a href="https://doi.org/10.1021/cr00032a009">Kolb HC et al.</a> 114172761 Kitagawa O et al. https://doi.org/10.1246/CL.1989.389 <a href="https://doi.org/10.1246/CL.1989.389">Kitagawa O et al.</a> 114172762 Kurono N et al. https://doi.org/10.1002/ejoc.200901501 <a href="https://doi.org/10.1002/ejoc.200901501 ">Kurono N et al.</a> 114172763 Taguchi T et al. https://doi.org/10.1016/S0040-4039%2800%2985409-X <a href="https://doi.org/10.1016/S0040-4039%2800%2985409-X">Taguchi T et al.</a> 114172764 Wang X et al. https://doi.org/10.1016/S0040-4039%2800%2900741-3 <a href="https://doi.org/10.1016/S0040-4039%2800%2900741-3">Wang X et al.</a> 114110923 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110924 David, Scott Ricerca Biosciences, LLC David, Scott 0 114110925 Fry, Douglas (Doug) Ricerca Biosciences, LLC Fry, Douglas (Doug) 0 114110926 Hoekstra, William Mycovia Pharmaceuticals Inc. Hoekstra, William 0 114110927 Yates, Christopher Mycovia Pharmaceuticals Inc. Yates, Christopher 0 114110922 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110922 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110923 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110924 David, Scott Ricerca Biosciences, LLC David, Scott 0 114110925 Fry, Douglas (Doug) Ricerca Biosciences, LLC Fry, Douglas (Doug) 0 114110926 Hoekstra, William Mycovia Pharmaceuticals Inc. Hoekstra, William 0 114110927 Yates, Christopher Mycovia Pharmaceuticals Inc. Yates, Christopher 0 114102696 Process For Synthesis Of Enantioenriched Aminoalcohols Containing A Tertiary Alcohol Fragment, And Derivatives Of Those Aminoalcohols Including The Co-crystal Of VT-1129 With Benzenesulfonic Acid (BSA). E-046-2013-0 Filing authorized NCATS - NCGC, Ricerca Biosciences, LLC, Viamet Pharmaceuticals Inc. 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis&body=Please send me information about technology [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis&body=Please send me information about technology [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis.">jasmine.kalsi@nih.gov</a><br> 114169432 E-046-2013-0 E-046-2013-0-US-01 Process For Synthesis Of Enantioenriched Aminoalcohols Containing A Tertiary Alcohol Fragment, And Derivatives Of Those Aminoalcohols Including The Co-crystal Of VT-1129 With Benzenesulfonic Acid (BSA). PRV US 61/802,071 Abandoned US <br />Provisional (PRV) 61/802,071<br />Filed on 2013-03-15<br />Status: Abandoned 114128846 VEXXXX 114128847 WMXXXX 114153430 PROCESS 114153431 Synthesis 114153432 Enantioenriched 114153433 Aminoalcohols 114153434 Containing 114153435 Tertiary 114153436 Alcohol 114153437 Fragment 114153438 Derivatives 114153439 THOSE 114153440 Including 114153441 Co-crystal 114153442 VT-1129 114153443 Benzenesulfonic 114153444 Acid 114153445 BSA. 114153446 Listed LPM Nguyen-Antczak as of 4/15/2015 114153447 Pre LPM working set 20150418 114153448 Post LPM Assignment Set 20150420 TAB-3585 114097440 A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors NCATS Infectious Disease, Research Equipment, Research Materials, Therapeutics Infectious Disease Research Equipment Research Materials Therapeutics Ruili Huang, Laura Kramer, Hongmin Li, Zhong Li, Menghang Xia This invention includes a novel high-throughput assay to identify orthosteric inhibitors blocking the Zika virus NS2B-NS3 protease. Pathogenic flaviviruses, including Zika, require the NS2B-NS3 protease for viral replication. There is currently an unmet need for specific antiviral therapeutics against the Zika virus. Preliminary screening using the NCGC Pharmaceutical Collection library identified a group of drugs including temoporfin, erythrosin B, niclosamide, and nitazoxanide that can significantly inhibit the interactions between NS2B and NS3. The described assay is the first high-throughput method to aid in the identification of a flavivirus NS2B-NS3 protease inhibitor. The assay included in this invention can be used to identify novel compounds that inhibit the NS2B-NS3 interaction. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Activity, Antiflaviviral, Compositions, PHARMACEUTICAL, VLXXXX, WIXXXX, WKXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172757 Li Z, Brecher M, et al. https://pubmed.ncbi.nlm.nih.gov/28685770/ <a href="https://pubmed.ncbi.nlm.nih.gov/28685770/">Li Z, Brecher M, et al.</a> 114110911 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110912 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110914 Kramer, Laura Health Research Incorporated Kramer, Laura 0 114110915 Li, Zhong Health Research Incorporated Li, Zhong 0 114110913 Li, Hongmin Health Research Incorporated Li, Hongmin 1 114110913 Li, Hongmin Health Research Incorporated Li, Hongmin 1 114110911 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110912 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110914 Kramer, Laura Health Research Incorporated Kramer, Laura 0 114110915 Li, Zhong Health Research Incorporated Li, Zhong 0 114102694 Pharmaceutical Compositions With Antiflaviviral Activity E-043-2017-0 Filing authorized Health Research Incorporated, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors&body=Please send me information about technology [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors&body=Please send me information about technology [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors.">rebecca.erwin-cohen@nih.gov</a><br> 114169431 E-043-2017-0 E-043-2017-0-US-01 Pharmaceutical Compositions With Antiflaviviral Activity PRV US 62/353,887 Abandoned US <br />Provisional (PRV) 62/353,887<br />Filed on 2016-06-23<br />Status: Abandoned 114128839 VLXXXX 114128840 WIXXXX 114128841 WKXXXX 114128842 XHXXXX 114153421 PHARMACEUTICAL 114153422 Compositions 114153423 Antiflaviviral 114153424 Activity TAB-3582 114097437 Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1 NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Matthew Hall, Ross Holmes, Leonard Neckers, Daniel Urban, David Wood This technology includes the use of novel lactate dehydrogenase (LDH) inhibitors, including WO2018005807A1, for the treatment of primary hyperoxalurias (PHs). PHs are rare autosomal recessive disorders caused by overproduction of oxalate, leading to recurrent calcium oxalate kidney stone disease, and in some cases end-stage renal disease. One potential strategy to treat PHs is to reduce the production of oxalate by diminishing the activity of LDH, the proposed key enzyme responsible for converting glyoxylate to oxalate. Biochemical and cell-based assays were used to identify and characterize novel potent inhibitors of LDH that prevent the conversion of glyoxylate to oxalate. RNAi therapies targeting LDHA and GO enzymes are currently in clinical trials. Oral delivery of small molecule inhibitors of LDH would be more convenient than repetitive intravenous injections for patients. Small molecule inhibitors also have the advantage of being significantly cheaper to manufacture, thereby being more cost-effective for patients as well. Further clinical work could establish the identified small molecules, including WO2018005807A1, as the active pharmaceutical ingredient (API) for treatments for primary hyperoxalurias. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 DEHYDROGENASE, Hyperoxalurias, Inhibitors, LACTATE, MOLECULE, Primary, Small, TREATING, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110894 Urban, Daniel FDA Urban, Daniel (FDA) 0 114110895 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110896 Holmes, Ross University of Alabama Holmes, Ross 0 114110897 Wood, David University of Alabama Wood, David 0 114110893 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110893 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110894 Urban, Daniel FDA Urban, Daniel (FDA) 0 114110895 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110896 Holmes, Ross University of Alabama Holmes, Ross 0 114110897 Wood, David University of Alabama Wood, David 0 114102691 Treating Primary Hyperoxalurias With Small Molecule Lactate Dehydrogenase Inhibitors E-035-2020-0 Filing authorized NCATS - NCGC, NCI, University of Alabama 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1&body=Please send me information about technology [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1&body=Please send me information about technology [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1.">rebecca.erwin-cohen@nih.gov</a><br> 114169426 E-035-2020-0 E-035-2020-0-US-01 TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE PRV US 62/849,564 Abandoned US <br />Provisional (PRV) 62/849,564<br />Filed on 2019-05-17<br />Status: Abandoned 114128827 VPXXXX 114128828 WIXXXX 114128829 WKXXXX 114128830 XEXXXX 114153402 TREATING 114153403 Primary 114153404 Hyperoxalurias 114153405 Small 114153406 MOLECULE 114153407 LACTATE 114153408 DEHYDROGENASE 114153409 Inhibitors TAB-3580 114097434 Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia NCATS Neurology, Therapeutics Neurology Therapeutics Juan Marugan, Susan Slaugenhuapt This technology includes the creation and use of compounds, including kinetin derivatives, that improve mRNA splicing in a cell for the treatment of disorders associated with misspliced mRNA, including familial dysautonomia (FD). FD, the best-known and most common member of a group of congenital sensory and autonomic neuropathies, affects neuronal development and is associated with progressive neuronal degeneration. This disease is caused by mutations in the splicing of intron 20 of the IKMKAP gene that results in a unique pattern of tissue-specific exon skipping. There are no current treatments of familial dysautonomia (FD) and the kinetin derivatives described in this technology could be the first-in-class. Further clinical work with the mRNA splicing compounds may establish these therapeutics as definitive treatments for familial dysautonomia (FD). 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Derivatives, Kinetin, VEXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110885 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110884 Slaugenhuapt, Susan Massachusetts General Hospital Slaugenhuapt, Susan 1 114110884 Slaugenhuapt, Susan Massachusetts General Hospital Slaugenhuapt, Susan 1 114110885 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114102688 Kinetin Derivatives E-026-2016-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia&body=Please send me information about technology [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia&body=Please send me information about technology [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia.">jasmine.kalsi@nih.gov</a><br> 114169420 E-026-2016-0 E-026-2016-0-US-01 Compounds for Improving mRNA Splicing PRV US 62/104,547 Abandoned US <br />Provisional (PRV) 62/104,547<br />Filed on 2015-01-16<br />Status: Abandoned 114169421 E-026-2016-0 E-026-2016-0-PCT-03 Compounds for Improving MRNA Splicing PCT Patent Cooperation Treaty PCT/US2016/013553 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/013553<br />Filed on 2016-01-15<br />Status: Expired 114169422 E-026-2016-0 E-026-2016-0-US-10 Compounds for Improving mRNA Splicing National Stage US 10,676,475 15/543,826 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10676475 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10676475">10,676,475</a><br />Filed on 2017-07-14<br />Status: Issued 114169423 E-026-2016-0 E-026-2016-0-US-19 Compounds for Improving mRNA Splicing CON US 11,702,417 16/877,254 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11702417 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11702417">11,702,417</a><br />Filed on 2020-05-18<br />Status: Issued 114128819 VEXXXX 114128820 WKXXXX 114128821 XEXXXX 114153382 Kinetin 114153383 Derivatives TAB-3577 114097432 Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders NCATS Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Omar Ayyub, Adam Behrens, Gary Cunningham, Peter Kofinas, Juan Luque-Cabrera, Juan Marugan, Anton Simeonov, Marshall Summar This technology includes the development of devices capable of real-time evaluation of metabolite levels for the treatment of numerous metabolic disorders, including hyperammonemia and aminoacidopathies. Currently, the monitoring of metabolite levels is done in a hospital setting with specialized mass spectrometry instrumentation. As a consequence, susceptible patients who are undergoing a crisis need to visit the hospital for testing to determine if there is a metabolite disturbance. The development of a device, including an electrode with immobilized enzymes, could transform the care of these metabolite disorders similar to insulin detection and diabetes. The are no current sensors able to measure the proposed metabolites in real-time. The device included in this technology will allow the real-time evaluation of specific metabolite levels in blood. The device can be used for diagnosis, or for facilitating management, treatment, and follow-up care. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Detection, DEVICE, Listed LPM Tong as of 4/15/2015, MECHANICAL, METABOLITES, Metabolites., PLASMA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL, SENSOR, TIME, VPXXXX, WBXXXX, WFXXXX, WIXXXX, XCXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114110874 Behrens, Adam Behrens, Adam 0 114110875 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110876 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110877 Luque-Cabrera, Juan Luque-Cabrera, Juan 0 114110878 Cunningham, Gary Cunningham, Gary 0 114110879 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110880 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110873 Ayyub, Omar Ayyub, Omar 1 114110873 Ayyub, Omar Ayyub, Omar 1 114110874 Behrens, Adam Behrens, Adam 0 114110875 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110876 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110877 Luque-Cabrera, Juan Luque-Cabrera, Juan 0 114110878 Cunningham, Gary Cunningham, Gary 0 114110879 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110880 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102686 Sensor And Device For Real Time Detection Of Plasma Metabolites E-010-2013-0 Filing authorized Children's National Medical Center, NCATS - NCGC, University of Maryland 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders&body=Please send me information about technology [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders&body=Please send me information about technology [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders.">rebecca.erwin-cohen@nih.gov</a><br> 114169417 E-010-2013-0 E-010-2013-0-US-01 Point of Care Detection of Hyperammonemia and Aminoacidopathies PRV US 61/714,870 Expired US <br />Provisional (PRV) 61/714,870<br />Filed on 2012-10-17<br />Status: Expired 114169418 E-010-2013-0 E-010-2013-0-PCT-02 Sensor And Device For Real Time Detection Of Plasma Metabolites PCT Patent Cooperation Treaty PCT/US2013/065548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/065548<br />Filed on 2013-10-17<br />Status: Expired 114169419 E-010-2013-0 E-010-2013-0-US-06 Sensor And Device For Real Time Detection Of Plasma Metabolites National Stage US 10,392,646 14/436,844 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10392646 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10392646">10,392,646</a><br />Filed on 2015-04-17<br />Status: Issued 114128810 VPXXXX 114128811 WBXXXX 114128812 WFXXXX 114128813 WIXXXX 114128814 XCXXXX 114128815 XDXXXX 114153351 TIME 114153352 SENSOR 114153353 REAL 114153354 DEVICE 114153355 Detection 114153356 PLASMA 114153357 Metabolites. 114153358 METABOLITES 114153359 Listed LPM Tong as of 4/15/2015 114153360 Pre LPM working set 20150418 114153361 Post LPM Assignment Set 20150420 114153362 MECHANICAL TAB-3575 114097430 A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer NCATS Oncology, Therapeutics Oncology Therapeutics Ajit Jadhav, David Maloney, Jeffrey Strovel, Daniel Urban, Shyh-Ming Yang, Makoto Yoshioka This technology includes the design, synthesis, and use of a novel chemical series for multiple treatments, including for treating cancer. A series of substituted bicyclic heteroaryl small molecules were found to be a potent inhibitor of bromodomain-containing protein 4 (BRD4) for multiple uses, including cancer. A BRD4 inhibitor is in a class of drugs known as BET inhibitors that are used broadly as anti-inflammatories and as anti-cancer agents. The chemical series exhibited less hepatocyte toxicity compared to existing treatments. For example, the series also identified N-methyl 2-pyridone 1s as a great replacement for dimethylisoxazole, an existing BET inhibitor. The compounds identified in this chemical series have a novel composition and better drug-like properties. BRD4 has been identified as an important target, particularly for cancer. The chemical series has the potential to be used for a variety of indications including but not limited to cancer, diabetes, inflammation, and acute heart failure, and has a large market potential. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 BICYCLIC, Brd4, Bromodomain-containing, Heteroaryl, Inhibitors, Protein, Substituted, VCXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110860 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110861 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110862 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110863 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110865 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 0 114110864 Strovel, Jeffrey ConverGene, LLC Strovel, Jeffrey 1 114110864 Strovel, Jeffrey ConverGene, LLC Strovel, Jeffrey 1 114110860 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110861 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110862 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110863 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110865 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 0 114102684 Substituted Bicyclic Heteroaryl Inhibitors Of Bromodomain-containing Protein BRD4 E-004-2016-0 Filing authorized ConverGene, LLC, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer&body=Please send me information about technology [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer&body=Please send me information about technology [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer.">jasmine.kalsi@nih.gov</a><br> 114169413 E-004-2016-0 E-004-2016-0-US-01 Substituted Bicyclic Heteroaryl Inhibitors Of Bromodomain-containing Protein BRD4 PRV US 62/259,894 Abandoned US <br />Provisional (PRV) 62/259,894<br />Filed on 2015-11-25<br />Status: Abandoned 114169414 E-004-2016-0 E-004-2016-0-PCT-02 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2016/063485 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/063485<br />Filed on 2016-11-23<br />Status: Expired 114169415 E-004-2016-0 E-004-2016-0-US-08 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF National Stage US 10,508,106 15/779,353 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508106 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508106">10,508,106</a><br />Filed on 2018-05-25<br />Status: Issued 114128804 VCXXXX 114128805 WKXXXX 114128806 XEXXXX 114153340 Substituted 114153341 BICYCLIC 114153342 Heteroaryl 114153343 Inhibitors 114153344 Bromodomain-containing 114153345 Protein 114153346 Brd4 TAB-3564 114097419 Compounds for Niemann Pick C and Other Lysosomal Storage Disorders NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Raul Calvo, Frannie Chen, Seameen Dehdashti, Patricia Dranchak, Marc Ferrer-Alegre, Yiannis Ioannou, Juan Marugan, Samarjit Patnaik, Noel Southall, Mercedes Taylor, Wei Zheng This technology includes compounds that improve endoplasmic reticulum-lysosomal trafficking and normalizes the Niemann-Pick type C (NPC) phenotype in assays using NPC1 patient cells, which can be used for the treatment of NPC, other lysosomal storage disorders, and potentially other neurodegenerative disorders. NPC is a rare neurodegenerative lipidosis caused by mutations in NPC1 or NPC2 genes, and characterized by the accumulation of cholesterol and glycolipids in the late endosomes and lysosomes. Currently there is no FDA-approved treatment for this devastating neurodegenerative disease. Overexpression of such mutant NPC1 proteins has been shown to rescue the disease phenotype in vitro, suggesting that upregulation of endogenous NPC1 as a therapeutic strategy. The current treatment under study is administered directly into the brain, therefore the development of small molecules as a targeted and curative treatment with the ability to cross the blood brain barrier is of utmost importance. Small molecules can be used as tools in research and can be developed into drugs for Niemann Pick C disease, other lysosomal storage disorders, and potentially other neurodegenerative diseases, including Alzheimer's and Parkinson's. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 C, compounds, DISORDERS, Iysosomal, Listed LPM Vepa as of 4/15/2015, Niemann, Pick, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Storage, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172728 Gelsthorpe M, Baumann N, et al. https://pubmed.ncbi.nlm.nih.gov/18216017/ <a href="https://pubmed.ncbi.nlm.nih.gov/18216017/">Gelsthorpe M, Baumann N, et al.</a> 114172729 Millard E, Srivastava K, et al. https://pubmed.ncbi.nlm.nih.gov/10964915/ <a href="https://pubmed.ncbi.nlm.nih.gov/10964915/">Millard E, Srivastava K, et al.</a> 114110804 Taylor, Mercedes NCATS - NCGC NCATS Taylor, Mercedes (NCATS) 0 114110805 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110806 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110807 Chen, Frannie Icahn School of Medicine at Mount Sinai Chen, Frannie 0 114110808 Ioannou, Yiannis Icahn School of Medicine at Mount Sinai Ioannou, Yiannis 0 114110809 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110810 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110811 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110812 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110813 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110814 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 1 114110814 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 1 114110804 Taylor, Mercedes NCATS - NCGC NCATS Taylor, Mercedes (NCATS) 0 114110805 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110806 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110807 Chen, Frannie Icahn School of Medicine at Mount Sinai Chen, Frannie 0 114110808 Ioannou, Yiannis Icahn School of Medicine at Mount Sinai Ioannou, Yiannis 0 114110809 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110810 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110811 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110812 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110813 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114102673 Compounds For Niemann Pick C And Other Iysosomal Storage Disorders E-040-2015-0 Filing authorized Mount Sinai Medical Center, Mount Sinai Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders&body=Please send me information about technology [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders&body=Please send me information about technology [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders.">jasmine.kalsi@nih.gov</a><br> 114169393 E-040-2015-0 E-040-2015-0-US-07 Compounds For Niemann Pick C And Other Iysosomal Storage Disorders CON US 16/362,179 Abandoned US <br />Continuation (CON) 16/362,179<br />Filed on 2019-03-22<br />Status: Abandoned 114169394 E-040-2015-0 E-040-2015-0-US-03 BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS National Stage US 10,239,830 15/549,743 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10239830 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10239830">10,239,830</a><br />Filed on 2017-08-09<br />Status: Issued 114169395 E-040-2015-0 E-040-2015-0-PCT-02 BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS PCT Patent Cooperation Treaty PCT/US2016/017504 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/017504<br />Filed on 2016-02-11<br />Status: Expired 114169396 E-040-2015-0 E-040-2015-0-US-01 BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS PRV US 62/114,840 Abandoned US <br />Provisional (PRV) 62/114,840<br />Filed on 2015-02-11<br />Status: Abandoned 114128763 VPXXXX 114128764 WKXXXX 114153214 Post LPM Assignment Set 20150420 114153215 Pre LPM working set 20150418 114153216 Listed LPM Vepa as of 4/15/2015 114153217 DISORDERS 114153218 Storage 114153219 Iysosomal 114153220 C 114153221 Pick 114153222 Niemann 114153223 compounds TAB-3561 114097417 Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control NCATS Consumer Products, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Consumer Products Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Omar Ayyub, Adam Behrens, Juan Cabrera-Luque, Gary Cunningham, Peter Kofinas, Juan Marugan, Anton Simeonov, Marshall Summar This technology includes device and sensor selection for the detection of blood metabolites which can be used to diagnose and monitor diseases in real-time. Currently the monitoring of metabolite levels is performed with specialized mass spectrometry instrumentation, therefore patient quality-of-life and financial advantages exist to develop devices capable of detecting metabolites in real-time. Our invention deals with the reduction to practice of this concept, showing how to select the metabolite and immobilized enzymes, how to do the immobilization, how to attach the components to the electrode, how to make the measurement and develop a prototype. Further, our invention deals with selection of light source and light detection to quantitate the blue color produced, as well as specific design features of the portable meter to enable direct loading of small volume of whole blood, transport of the sample through the fluidic channels and chambers, and mixing of the reagents. Currently there are no sensors able to measure the proposed metabolites in real-time. This method and device will allow the real-time evaluation of the levels of a specific metabolite in blood, and it can be used as diagnostic tool, or for facilitating the management, treatment, and follow up of metabolic disorders. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Blood, Detection, DEVICE, Listed LPM Shmilovich as of 4/15/2015, MECHANICAL, METABOLITES, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL, SENSOR, TIME, WFXXXX, WIXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114110788 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110789 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110790 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110791 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110793 Behrens, Adam University of Maryland, College Park Behrens, Adam 0 114110794 Cabrera-Luque, Juan University of Maryland, College Park Cabrera-Luque, Juan 0 114110795 Cunningham, Gary Children's National Medical Center Cunningham, Gary 0 114110792 Ayyub, Omar University of Maryland, College Park Ayyub, Omar 1 114110792 Ayyub, Omar University of Maryland, College Park Ayyub, Omar 1 114110788 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110789 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110790 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110791 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110793 Behrens, Adam University of Maryland, College Park Behrens, Adam 0 114110794 Cabrera-Luque, Juan University of Maryland, College Park Cabrera-Luque, Juan 0 114110795 Cunningham, Gary Children's National Medical Center Cunningham, Gary 0 114102671 Sensor And Device For Real Time Detection Of Metabolites In Blood E-072-2015-0 Filing authorized Children's National Medical Center, NCATS - NCGC, University of Maryland 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control&body=Please send me information about technology [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control&body=Please send me information about technology [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control.">rebecca.erwin-cohen@nih.gov</a><br> 114169386 E-072-2015-0 E-072-2015-0-US-01 Sensor And Device For Real Time Detection Of Metabolites In Blood PRV US 61/872,149 Abandoned US <br />Provisional (PRV) 61/872,149<br />Filed on 2013-08-30<br />Status: Abandoned 114169387 E-072-2015-0 E-072-2015-0-PCT-02 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA PCT Patent Cooperation Treaty PCT/US2014/053756 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/053756<br />Filed on 2014-09-02<br />Status: Expired 114169388 E-072-2015-0 E-072-2015-0-US-15 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMIA National Stage US 9,952,199 14/915,602 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9952199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9952199">9,952,199</a><br />Filed on 2016-02-29<br />Status: Issued 114169389 E-072-2015-0 E-072-2015-0-US-17 Sensor And Device For Real Time Detection Of Metabolites In Blood DIV US 10,620,187 15/933,834 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10620187 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10620187">10,620,187</a><br />Filed on 2018-03-23<br />Status: Issued 114128758 WFXXXX 114128759 WIXXXX 114128760 XDXXXX 114153198 SENSOR 114153199 DEVICE 114153200 REAL 114153201 TIME 114153202 Detection 114153203 METABOLITES 114153204 Blood 114153205 Listed LPM Shmilovich as of 4/15/2015 114153206 Pre LPM working set 20150418 114153207 Post LPM Assignment Set 20150420 114153208 MECHANICAL TAB-3557 114097413 Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy NCATS Oncology, Therapeutics Oncology Therapeutics Matthew Boxer, Kyle Brimacombe, Michael Pacold, Jason Rohde, David Sabatini, Min Shen This technology includes a family of inhibitors of 3-phosphoglycerate dehydrogenase (PHGDH) which could be utilized as a treatment for cancer. These compounds are based on a carbiothioamide core and represent the first chemotype capable of inhibiting this enzyme. The compounds have in vitro IC50s of 1-5 uM and exhibit selective cytotoxicity towards PHGDH-overexpressing cell lines of ~10 uM. They exhibit at least an order of magnitude lower toxicity towards cell lines that do not express PHGDH. These compounds block flux through the serine synthesis pathway in PHGDH-overexpressing cells, and preliminarily appear to do the same in mice. First chemotype capable of inhibiting 3-phosphoglycerate dehydrogenase. Utilization as an anticancer therapy. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 3-phosphoglycerate, Aerobic glycolysis, Alpha-Ketoglutarate, CB5CXX, CB5EXX, DEHYDROGENASE, Inhibitors, Listed LPM McCue as of 4/15/2015, phgdh, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TCA cycle, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172726 Possemato R, Marks K, et al. https://pubmed.ncbi.nlm.nih.gov/21760589/ <a href="https://pubmed.ncbi.nlm.nih.gov/21760589/">Possemato R, Marks K, et al.</a> 114110756 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110757 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110758 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110759 Sabatini, David Whitehead Institute for Biomedical Research Sabatini, David 0 114110760 Pacold, Michael Whitehead Institute for Biomedical Research Pacold, Michael 0 114110755 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110755 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110756 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110757 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110758 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110759 Sabatini, David Whitehead Institute for Biomedical Research Sabatini, David 0 114110760 Pacold, Michael Whitehead Institute for Biomedical Research Pacold, Michael 0 114102667 Inhibitors Of 3-phosphoglycerate Dehydrogenase E-282-2014-0 Filing authorized Dana-Farber Cancer Institute, NCATS - NCGC, Whitehead Institute for Biomedical Research 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy&body=Please send me information about technology [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy&body=Please send me information about technology [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy.">rebecca.erwin-cohen@nih.gov</a><br> 114169381 E-282-2014-0 E-282-2014-0-US-01 Inhibitors Of 3-phosphoglycerate Dehydrogenase PRV US 62/103,990 Abandoned US <br />Provisional (PRV) 62/103,990<br />Filed on 2015-01-15<br />Status: Abandoned 114169382 E-282-2014-0 E-282-2014-0-PCT-02 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2016/013602 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/013602<br />Filed on 2016-01-15<br />Status: Expired 114169383 E-282-2014-0 E-282-2014-0-US-03 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF National Stage US 11,225,469 15/543,643 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11225469 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11225469">11,225,469</a><br />Filed on 2017-07-14<br />Status: Issued 114128744 CB5EXX 114128745 CB5CXX 114128746 VCXXXX 114128747 WKXXXX 114153160 Inhibitors 114153161 3-phosphoglycerate 114153162 DEHYDROGENASE 114153163 phgdh 114153164 Alpha-Ketoglutarate 114153165 TCA cycle 114153166 Aerobic glycolysis 114153167 Listed LPM McCue as of 4/15/2015 114153168 Pre LPM working set 20150418 114153169 Post LPM Assignment Set 20150420 TAB-3550 114097406 Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases NCATS Oncology, Therapeutics Oncology Therapeutics Shyh-Ming Yang, Makoto Yoshioka This technology includes a new chemical series of substituted bicyclic heteroaryl small molecules as potent bromodomain-containing protein BRD4 inhibitors used for the treatment of cancer and inflammatory diseases. The optimization led to compounds with good potency in enzymatic assay (< 100 nM) and in MV4-11 cell-based assay (< 1000 nM) as well as excellent early ADME properties. We also identified N-methyl 2 pyridone and N-methyl pyrrolopyridone are great replacements of di-methylisoxazole. This chemical series also exhibited good ADME profiles, including PK. From recent data indicated that the selected analogs also potently inhibited bromodomain of CBP/p300. The selected analogs demonstrated in vivo efficacy in cancer xenograft models and in inflammatory disease models. These compounds have novel composition and better drug-like properties, and also have the potential to be used for a variety of indications. BRD4 has been identified as an important target for a number of potential indications, particularly cancer and inflammatory diseases, as well as diabetes and acute heart failure. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 Bet, Bromodomain, ConverGene, Inhibitors, MOLECULE, Small, THEREOF, THEREOFULE, USES, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172719 Yang S, Yoshioka M, et al. https://pubmed.ncbi.nlm.nih.gov/30905542/ <a href="https://pubmed.ncbi.nlm.nih.gov/30905542/">Yang S, Yoshioka M, et al.</a> 114110695 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110694 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 1 114110694 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 1 114110695 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114102660 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF E-118-2019-0 Filing authorized ConverGene, LLC, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases&body=Please send me information about technology [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases&body=Please send me information about technology [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases.">jasmine.kalsi@nih.gov</a><br> 114169364 E-118-2019-0 E-118-2019-0-US-01 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF PRV US 62/838,083 Abandoned US <br />Provisional (PRV) 62/838,083<br />Filed on 2019-04-24<br />Status: Abandoned 114169365 E-118-2019-0 E-118-2019-0-PCT-02 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/022072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/022072<br />Filed on 2020-03-11<br />Status: Expired 114128723 VCXXXX 114128724 WKXXXX 114153099 USES 114153100 Inhibitors 114153101 Bromodomain 114153102 Bet 114153103 MOLECULE 114153104 Small 114153105 ConverGene 114153106 THEREOF 114153107 THEREOFULE TAB-3542 114097400 Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection NCATS Infectious Disease, Therapeutics Infectious Disease Therapeutics Ruili Huang, Wenwei Huang, Emily Lee, Guo-Li Ming, Hongjun Song, Hengli Tang, Menghang Xia, Miao Xu, Wei Zheng This technology includes a new Zika virus NS-1 assay which was used for a compound screen. Because the NS-1 protein is synthesized only in the Zika virus replication stage, the inhibition of NS-1 protein level by compounds determined in this NS-1 assay indicates the inhibition of Zika virus replication in human cells. A total of 256 compounds have been identified as active compounds that inhibited NS-1 production in human cells that have the potential to be developed as new therapeutics for the treatment of infection with Zika virus. Repositioning CDK inhibitor to treat infection with Zika virus can move to clinical trials quickly. Treatment of Zika virus infection. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 Infection, Inhibitors, NS-1, treatment, virus, VLXXXX, WKXXXX, Zika False True True NIHTT 37470483 Website Abstract 114110644 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110645 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110646 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110647 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110648 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110649 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110650 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110651 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110643 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110643 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110644 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110645 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110646 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110647 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110648 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110649 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110650 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110651 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114102653 Zika Virus NS-1 Inhibitors For Treatment Of Zika Virus Infection E-073-2017-0 Filing authorized Florida State University Research Foundation, Inc. (FSURF), Johns Hopkins University, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169354 E-073-2017-0 E-073-2017-0-US-01 Zika Virus NS-1 Inhibitors For Treatment Of Zika Virus Infection PRV US 62/430,107 Abandoned US <br />Provisional (PRV) 62/430,107<br />Filed on 2016-12-05<br />Status: Abandoned 114128707 VLXXXX 114128708 WKXXXX 114153026 Zika 114153027 virus 114153028 NS-1 114153029 Inhibitors 114153030 treatment 114153031 Infection TAB-3541 114097399 Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Raul Calvo, Marc Ferrer-Alegre, Xin Hu, Natalia Martinez, Juan Marugan, Noel Southall, Haoxing Xu, Lu Yu This technology includes a series of novel benzene-1,4-disulfonamides that activate TRPML1 receptor. The TRPML1 receptor is a lysosomal Ca2+ channel that has been shown to be involved in controlling lysosome functions, among then the maintenance of the integrity of the plasma membrane and the modulation of autophagosome-lysosome fusion. The improved ability of the receptor to deliver Ca2+ ions to the cytosol had been correlated with its capacity to modulate autophagy and lysosome exocytosis. Therapeutically, this activation alleviates many diseases involving lysosomal dysfunction, such as lysosomal storage disorders, and membrane repair, like in muscular dystrophies. First-in-class treatment for diseases with no cure and limited treatment options. Therapy for diseases involving lysosomal dysfunction (i.e., Gaucher’s Disease, Fabry Disease) and membrane repair (i.e., muscular dystrophies). 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 4-disulfonamide, Benzene-1, Derivatives, MODULATORS, PREPARATION, RECEPTOR, therapeutic, TRPML1, USEFUL, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110636 Yu, Lu University of Michigan Yu, Lu 0 114110637 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110638 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110639 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110640 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110641 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110642 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110635 Xu, Haoxing University of Michigan Xu, Haoxing 1 114110635 Xu, Haoxing University of Michigan Xu, Haoxing 1 114110636 Yu, Lu University of Michigan Yu, Lu 0 114110637 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110638 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110639 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110640 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110641 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110642 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114102652 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators E-084-2020-0 Filing authorized NCATS - NCGC, University of Michigan 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders&body=Please send me information about technology [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders&body=Please send me information about technology [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders.">jasmine.kalsi@nih.gov</a><br> 114169351 E-084-2020-0 E-084-2020-0-US-01 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PRV US 62/894,289 Abandoned US <br />Provisional (PRV) 62/894,289<br />Filed on 2019-08-30<br />Status: Abandoned 114169352 E-084-2020-0 E-084-2020-0-PCT-02 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PCT Patent Cooperation Treaty PCT/US2020/048482 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/048482<br />Filed on 2020-08-28<br />Status: Expired 114169353 E-084-2020-0 E-084-2020-0-US-03 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF National Stage US 17/638,929 Abandoned US <br />National Stage 17/638,929<br />Filed on 2020-08-28<br />Status: Abandoned 114128705 VPXXXX 114128706 WKXXXX 114153017 PREPARATION 114153018 Benzene-1 114153019 4-disulfonamide 114153020 Derivatives 114153021 USEFUL 114153022 therapeutic 114153023 TRPML1 114153024 RECEPTOR 114153025 MODULATORS TAB-3540 114097398 Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva NCATS Therapeutics Therapeutics Asaf Alimardanov, Kenneth Bloch, Gregory Cuny, Gurmit Grewal, Arthur Lee, John McKew, Randall Peterson, Min Shen, Xin Xu, Paul Yu This technology includes compounds which are selective inhibitors of anaplastic lymphoma kinases (ALK1, ALK2, ALK3 and ALK6), which inhibit these ALKs with low nanomolar potency. These compounds could be developed as a treatment of Fibrodysplasia ossificans progressiva (FOP) and other BMP-related diseases. FOP is a rare congenital disease with no current treatment options. Since the disease is driven by constitutively active ALK2, inhibition of ALK2 would be like hitting the Achilles’ heel of the disease and would potentially be an efficacious therapy for FOP patients. It has also been shown that inhibition of these ALKs is efficacious in animal disease models of anemia of inflammation. Compounds of this invention inhibit ALK2, as well as ALK1, ALK3 and ALK6, with nanomolar potency, both in enzyme and cell assays. <ul> <li>There are currently no effective treatments available for FOP</li> <li>Current BMP inhibitor in development is metabolized by Cyp enzymes and aldehyde oxidase and has the potential of generating an aniline-metabolite which could be potentially toxic and difficult to predict a safe and efficacious dose</li> </ul> A treatment for FOP and anemia of inflammation, as well as BMP driven diseases (certain cancers, cardio-vascular disease, inflammation, hematological disease and bone disorders). 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 5-a]pyrimidine, ALK, BMP, Bone, Derivatives, inhibition, Inhibitors, KINASES, Listed LPM Nguyen-Antczak as of 4/15/2015, MORPHOGENETIC, PATHWAY, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, proteins, Pyrazolo[1, SELECTIVE, SIGNALING, WKXXXX False True True NIHTT 37470483 Website Abstract 114172704 Yu P, Deng D, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/">Yu P, Deng D, et al.</a> 114172705 Hao J, Ho J, et al. https://pubmed.ncbi.nlm.nih.gov/20020776/ <a href="https://pubmed.ncbi.nlm.nih.gov/20020776/">Hao J, Ho J, et al.</a> 114172706 Cuny G, Yu P, et al. https://pubmed.ncbi.nlm.nih.gov/18621530/ <a href="https://pubmed.ncbi.nlm.nih.gov/18621530/">Cuny G, Yu P, et al.</a> 114110626 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110627 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110628 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110629 McKew, John NCATS - TRND McKew, John 0 114110630 Bloch, Kenneth Massachusetts General Hospital Bloch, Kenneth 0 114110631 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110632 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110633 Peterson, Randall Massachusetts General Hospital Peterson, Randall 0 114110634 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110625 Grewal, Gurmit NCATS - NCGC NCATS Grewal, Gurmit (NCATS) 1 114110625 Grewal, Gurmit NCATS - NCGC NCATS Grewal, Gurmit (NCATS) 1 114110626 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110627 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110628 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110629 McKew, John NCATS - TRND McKew, John 0 114110630 Bloch, Kenneth Massachusetts General Hospital Bloch, Kenneth 0 114110631 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110632 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110633 Peterson, Randall Massachusetts General Hospital Peterson, Randall 0 114110634 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114102651 Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of ALK Kinases For Inhibition Of The Bone Morphogenetic Proteins (BMP) Signaling Pathway E-299-2012-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva.">jasmine.kalsi@nih.gov</a><br> 114169346 E-299-2012-0 E-299-2012-0-US-01 Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of ALK Kinases For Inhibition Of The Bone Morphogenetic Proteins (BMP) Signaling Pathway PRV US 61/783,695 Abandoned US <br />Provisional (PRV) 61/783,695<br />Filed on 2013-03-14<br />Status: Abandoned 114169347 E-299-2012-0 E-299-2012-0-PCT-02 Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of ALK Kinases For Inhibition Of The Bone Morphogenetic Proteins (BMP) Signaling Pathway PCT Patent Cooperation Treaty PCT/US14/26042 Expired Patent Cooperation Treaty <br />(PCT) PCT/US14/26042<br />Filed on 2014-03-13<br />Status: Expired 114169348 E-299-2012-0 E-299-2012-0-US-05 BMP INHIBITORS AND METHODS OF USE THEREOF National Stage US 9,682,983 14/776,302 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9682983 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9682983">9,682,983</a><br />Filed on 2014-03-13<br />Status: Issued 114169349 E-299-2012-0 E-299-2012-0-US-06 BMP Inhibitors and Methods of Use Thereof CON US 10,017,516 15/598,540 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017516 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017516">10,017,516</a><br />Filed on 2017-05-18<br />Status: Issued 114169350 E-299-2012-0 E-299-2012-0-US-07 BMP Inhibitors and Methods of Use Thereof CON US 15/994,604 Abandoned US <br />Continuation (CON) 15/994,604<br />Filed on 2018-05-31<br />Status: Abandoned 114128704 WKXXXX 114153000 Pyrazolo[1 114153001 5-a]pyrimidine 114153002 Derivatives 114153003 SELECTIVE 114153004 Inhibitors 114153005 ALK 114153006 KINASES 114153007 inhibition 114153008 Bone 114153009 MORPHOGENETIC 114153010 proteins 114153011 BMP 114153012 SIGNALING 114153013 PATHWAY 114153014 Listed LPM Nguyen-Antczak as of 4/15/2015 114153015 Pre LPM working set 20150418 114153016 Post LPM Assignment Set 20150420 TAB-3536 114097394 Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs NCATS Antibodies, Cardiology, Dental, Endocrinology, Immunology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Antibodies Cardiology Dental Endocrinology Immunology Infectious Disease Oncology Ophthalmology Therapeutics Bonita Rup, Erik Wagner, Xin Xu This technology includes a strategy to generate antibodies of rabbit origin, both polyclonal and monoclonal, which have strong affinity to the TAT sequence and which enable specific immunocapture or immunodetection of TAT containing frataxin and analogs for quantitative or qualitative assays. In addition, antibodies that react with the FXN region have also been generated with this strategy. The HIV virus encoded a translational activator protein containing a 12 amino acid domain which permits transmembrane delivery of any therapeutic protein containing the sequence. Other anti-TAT antibodies are commercially available, but were found to be ineffective in immunocapturing TAT Frataxin, and are likely not to be directed to the same epitope as the 12 amino acid cell penetration sequence that we refer to as “TAT”. TAT-domain enhanced delivery of proteins or other biomolecules to the target sites has been used to enhance the efficacy of several therapeutics being currently developed. These biologics could involve antibodies, single chain variable regions (ScFv), or any derivative-sequence-containing-peptide, peptide mimetic, or protein containing the amino acid sequence which comprises the paratope of the TAT-binding monoclonal antibodies herein described could be the basis of a detection or quantitation mechanism for a TAT enhanced therapeutic. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 Analogs, antibodies, Anti-TAT, DETECTING, Domain, FXN, Generation, monoclonal, polyclonal, Protein, QUANTITATING, RELATED, Structurally, TAT, TATFrataxin, TAT-FXN, therapeutic, VPXXXX, WJXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114110603 Rup, Bonita Bonnie Rup Consulting LLC Rup, Bonita 0 114110604 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110602 Wagner, Erik NCATS - TRND NCATS Wagner, Erik (NCATS) 1 114110602 Wagner, Erik NCATS - TRND NCATS Wagner, Erik (NCATS) 1 114110603 Rup, Bonita Bonnie Rup Consulting LLC Rup, Bonita 0 114110604 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114102647 Generation Of Anti-TAT FXN Polyclonal And Monoclonal Antibodies To TAT Domain For Use In Quantitating Or Detecting TATFrataxin (TAT-FXN) And Its Structurally Related Therapeutic Protein Analogs E-176-2018-0 Filing authorized Bonnie Rup Consulting LLC, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs&body=Please send me information about technology [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs&body=Please send me information about technology [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs.">rebecca.erwin-cohen@nih.gov</a><br> 114169340 E-176-2018-0 E-176-2018-0-US-01 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF PRV US 62/970,662 Abandoned US <br />Provisional (PRV) 62/970,662<br />Filed on 2020-02-05<br />Status: Abandoned 114169341 E-176-2018-0 E-176-2018-0-PCT-02 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/016959 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/016959<br />Filed on 2021-02-05<br />Status: Expired 114128695 VPXXXX 114128696 WJXXXX 114128697 XAXXXX 114152962 Generation 114152963 Anti-TAT 114152964 FXN 114152965 polyclonal 114152966 monoclonal 114152967 antibodies 114152968 TAT 114152969 Domain 114152970 QUANTITATING 114152971 DETECTING 114152972 TATFrataxin 114152973 TAT-FXN 114152974 Structurally 114152975 RELATED 114152976 therapeutic 114152977 Protein 114152978 Analogs TAB-3517 114097377 Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers NCATS Oncology, Therapeutics Oncology Therapeutics Kyle Brimacombe, Plamen Christov, Chi Dang, Victor Darley-Usmar, Matthew Hall, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, David Maloney, William Moore, Bryan Mott, Leonard Neckers, Ganesha Rai Bantukallu, Anton Simeonov, Gary Sulikowski, Daniel Urban, Alex Waterson, Shyh-Ming Yang This technology includes LDHA inhibitors that have been synthesized and tested for the treatment of glycolytic cancers. These compounds may have improved activity over previous compounds. Currently there are no known high-quality inhibitors with demonstrated in vivo activity. These compounds are more potent than these prior art compound and have the potential for demonstrated in vivo activity as well. Further clinical work could establish these small molecule inhibitors of LDHA as a first-in-class/target therapy in oncology with a specific focus on glycolytic cancers. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-30 Inhibitors, LDHA, MOLECULE, Small, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110496 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110497 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110498 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110499 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110500 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110501 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110502 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110503 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110504 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110505 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110506 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110507 Dang, Chi University of Pennsylvania Dang, Chi 0 114110508 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110509 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 0 114110510 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110511 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110512 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110513 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114110495 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110495 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110496 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110497 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110498 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110499 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110500 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110501 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110502 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110503 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110504 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110505 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110506 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110507 Dang, Chi University of Pennsylvania Dang, Chi 0 114110508 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110509 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 0 114110510 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110511 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110512 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110513 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114102629 Small Molecule Inhibitors Of LDHA E-190-2016-0 Filing authorized NCATS - NCGC, NCI, University of Alabama at Birmingham, University of Pennsylvania, Vanderbilt University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers&body=Please send me information about technology [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers&body=Please send me information about technology [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers.">rebecca.erwin-cohen@nih.gov</a><br> 114169296 E-190-2016-0 E-190-2016-0-US-01 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PRV US 62/356,065 Abandoned US <br />Provisional (PRV) 62/356,065<br />Filed on 2016-06-29<br />Status: Abandoned 114169297 E-190-2016-0 E-190-2016-0-PCT-02 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2017/040021 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/040021<br />Filed on 2017-06-29<br />Status: Expired 114169298 E-190-2016-0 E-190-2016-0-US-08 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF National Stage US 10,954,228 16/313,727 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954228 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954228">10,954,228</a><br />Filed on 2018-12-27<br />Status: Issued 114128655 VCXXXX 114128657 WKXXXX 114152785 Small 114152786 MOLECULE 114152787 Inhibitors 114152788 LDHA TAB-3508 114097371 Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases NCATS Cardiology, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Jeffrey Baron, Youn Jee This technology includes a series of diphenylpropanamides as potent and selective RORgt inhibitors for the treatment of Th17-related autoimmune diseases. The retinoic acid-related orphan receptor RORgt plays an important role in the differentiation of thymocytes, lymphoid tissue inducer cells, and inflammatory T helper-expressing interleukin 17a (Th17) cells. Small molecule RORgt inhibitors may provide means to regulate Th17 mediated immune response. The novel molecules have potential to treat Th17-related autoimmune diseases. This invention may offer novel therapeutics for the treatment of Th17 autoimmune diseases. Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-16 assay, Benign, Biopsy, DISTINGUISH, dtx-ttcsite-08-2019, Fine, High-sensitivity, LEVELS, Listed LPM Campbell as of 4/15/2015, Malignant, MEASURE, Midkine, Needle, Nodules, Order, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THYROID, Tissue, VAXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172671 Solt L, Kumar N, et al. https://pubmed.ncbi.nlm.nih.gov/21499262/ <a href="https://pubmed.ncbi.nlm.nih.gov/21499262/">Solt L, Kumar N, et al.</a> 114172672 Huh J, Leung M, et al. https://pubmed.ncbi.nlm.nih.gov/21441909/ <a href="https://pubmed.ncbi.nlm.nih.gov/21441909/">Huh J, Leung M, et al.</a> 114110464 Jee, Youn NICHD NICHD Jee, Youn (NICHD) 0 114110465 Baron, Jeffrey NICHD NICHD Baron, Jeffrey (NICHD) 1 114110465 Baron, Jeffrey NICHD NICHD Baron, Jeffrey (NICHD) 1 114110464 Jee, Youn NICHD NICHD Jee, Youn (NICHD) 0 152357510 Preparation Of Arylpropanamides As RORgt Antagonists E-106-2013-0 Filing authorized NCATS - NCGC, New York University Medical Center, New York University School of Medicine 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases&body=Please send me information about technology [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases&body=Please send me information about technology [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases.">sury.vepa@nih.gov</a><br> 114169277 E-016-2013-0 E-016-2013-0-US-01 Assay To Measure Midkine Or Pleiotrophin Level For Diagnosing A Growth PRV US 61/728,624 Abandoned US <br />Provisional (PRV) 61/728,624<br />Filed on 2012-11-20<br />Status: Abandoned 114128634 VAXXXX 114128635 VPXXXX 114128636 WIXXXX 114128637 WKXXXX 114152719 High-sensitivity 114152720 assay 114152721 MEASURE 114152722 Midkine 114152723 LEVELS 114152724 Tissue 114152725 Fine 114152726 Needle 114152727 Biopsy 114152728 Order 114152729 DISTINGUISH 114152730 Benign 114152731 Malignant 114152732 THYROID 114152733 Nodules 114152734 Listed LPM Campbell as of 4/15/2015 114152735 Pre LPM working set 20150418 114152736 Post LPM Assignment Set 20150420 114152737 dtx-ttcsite-08-2019 TAB-3491 114097355 Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy NCATS Oncology, Therapeutics Oncology Therapeutics Kyle Brimacombe, Plamen Christov, Chi Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer Kouznetsova, David Maloney, William Moore, Bryan Mott, Leonard Neckers, Ganesha Rai Bantukallu, Anton Simeonov, Gary Sulikowski, Daniel Urban, Alex Waterson, Shyh-Ming Yang This technology includes a novel pyrazole-based compound NCGC00274266 (MLS000714501) that inhibits LDH-A with an IC50 of approximately 20 µM with low efficacy that can be used as an anti-cancer therapeutic. Structure-activity relationship studies on this compound led to hydroxypryazole-based compounds and discovery that the hydroxypyrazole compound and related analogs demonstrated a strong metal-dependent activity. These efforts have ultimately led to derivatives of compounds of NCGC00345087 which have abrogated the Zn++ requirement for LDH-A inhibition and exhibit low nanomolar potency and favorable ADME properties. Agents that target enzymes involved in cancer cell metabolism are important because of their potential to preferentially target cancer tissues over normal tissues. The compounds described represent some of the most potent and drug-like inhibitors of LDHA reported to date. These compounds will be used as anti-cancer agents, both as a single agent therapy and in combination with existing agents. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-02 BIOCHEMISTRY, CB5EXX, Glycolysis, Inhibitors, LACTATE, Listed LPM Nguyen-Antczak as of 4/15/2015, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110376 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110377 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110378 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110379 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110380 Kouznetsova, Jennifer NCATS - NCGC NCATS Kouznetsova, Jennifer (NCATS) 0 114110381 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110382 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110383 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110384 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110385 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110386 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110387 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110388 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114110389 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110390 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110391 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110392 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110393 Dang, Chi University of Pennsylvania Dang, Chi 0 114110375 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110375 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110376 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110377 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110378 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110379 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110380 Kouznetsova, Jennifer NCATS - NCGC NCATS Kouznetsova, Jennifer (NCATS) 0 114110381 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110382 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110383 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110384 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110385 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110386 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110387 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110388 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114110389 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110390 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110391 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110392 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110393 Dang, Chi University of Pennsylvania Dang, Chi 0 114102605 Small Molecule Inhibitors Of Lactate Dehydrogenase E-244-2014-0 Filing authorized NCATS - NCGC, NCI, University of Alabama at Birmingham, University of Pennsylvania, Vanderbilt University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy&body=Please send me information about technology [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy&body=Please send me information about technology [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy.">rebecca.erwin-cohen@nih.gov</a><br> 114169242 E-244-2014-0 E-244-2014-0-US-01 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PRV US 62/097,226 Abandoned US <br />Provisional (PRV) 62/097,226<br />Filed on 2014-12-29<br />Status: Abandoned 114169243 E-244-2014-0 E-244-2014-0-PCT-02 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2015/067895 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/067895<br />Filed on 2015-12-29<br />Status: Expired 114169244 E-244-2014-0 E-244-2014-0-US-08 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof National Stage US 10,351,532 15/540,893 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10351532 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10351532">10,351,532</a><br />Filed on 2017-06-29<br />Status: Issued 114169245 E-244-2014-0 E-244-2014-0-US-09 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF DIV US 10,961,200 16/455,848 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961200 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961200">10,961,200</a><br />Filed on 2019-06-28<br />Status: Issued 114169246 E-244-2014-0 E-244-2014-0-US-11 Small Molecule Inhibitors Of Lactate Dehydrogenase CON US 11,247,971 17/160,868 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11247971 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11247971">11,247,971</a><br />Filed on 2021-01-28<br />Status: Issued 114169247 E-244-2014-0 E-244-2014-0-US-32 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF CON US 11,897,845 17/572,359 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897845 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897845">11,897,845</a><br />Filed on 2022-01-10<br />Status: Issued 114128580 CB5EXX 114128581 VCXXXX 114128582 WKXXXX 114152604 Inhibitors 114152605 LACTATE 114152606 Patent Category - Chemistry 114152607 Glycolysis 114152608 BIOCHEMISTRY 114152609 Listed LPM Nguyen-Antczak as of 4/15/2015 114152610 Pre LPM working set 20150418 114152611 Post LPM Assignment Set 20150420 TAB-3490 114097354 Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Barry Coller, Wenwei Huang, Jiankang Jiang, Joshua McCoy, Min Shen, Craig Thomas This technology includes methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion, and/or aggregation. The present invention further relates to methods of treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery, peripheral vascular disease or thrombotic disorders resulting from atrial fibrillation or inflammation. Previous work with inhibitors of aIIbP3, particularly 2-ethyl-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyiimidin-5-one, has shown they are capable of inhibiting fibrinogen binding and platelet aggregation without inducing the binding of one or more integrin P3 LIBS-specific monoclonal antibodies (mAbs). Newly identified inhibitors of aIIbP3 are capable of inhibiting fibrinogen binding and platelet aggregation without inducing the binding of integrin P3 LIBS. Currently available agents are only available in parenteral form and cause adverse reactions (i.e., thrombocytopenia, hypotension). .This invention may offer a therapeutic option within IV bags, EpiPens and as therapy during surgery to avoid adverse clotting events. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-01 3, ALPHA, Beta, IIb, infarction, Inhibitors, INTERVENTION, Listed LPM Nguyen-Antczak as of 4/15/2015, MOLECULE, MYOCARDIAL, Post LPM Assignment Set 20150420, Potential, Pre LPM working set 20150418, RECEPTOR, Small, STROKE, therapeutic, VDXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172646 Luo B, Carman C, et al. https://pubmed.ncbi.nlm.nih.gov/17201681/ <a href="https://pubmed.ncbi.nlm.nih.gov/17201681/">Luo B, Carman C, et al.</a> 114172647 Coller B, Shattil S, et al. https://pubmed.ncbi.nlm.nih.gov/18840725/ <a href="https://pubmed.ncbi.nlm.nih.gov/18840725/">Coller B, Shattil S, et al.</a> 114172648 Gao C, Boylan B, et al. https://pubmed.ncbi.nlm.nih.gov/19197137/ <a href="https://pubmed.ncbi.nlm.nih.gov/19197137/">Gao C, Boylan B, et al.</a> 114172649 Blue R, Murcia M, et al. https://pubmed.ncbi.nlm.nih.gov/17978171/ <a href="https://pubmed.ncbi.nlm.nih.gov/17978171/">Blue R, Murcia M, et al.</a> 114172650 Blue R, Kowalska M, et al. https://pubmed.ncbi.nlm.nih.gov/19414864/ <a href="https://pubmed.ncbi.nlm.nih.gov/19414864/">Blue R, Kowalska M, et al.</a> 114172651 Zhu J, Zhu J, et al. https://pubmed.ncbi.nlm.nih.gov/20679525/ <a href="https://pubmed.ncbi.nlm.nih.gov/20679525/">Zhu J, Zhu J, et al.</a> 114110369 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114110370 Jiang, Jiankang National Human Genome Research Institute (NHGRI) NCATS Jiang, Jiankang (NCATS) 0 114110371 McCoy, Joshua Office of Research Services (ORS) McCoy, Joshua 0 114110372 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114110373 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110374 Coller, Barry The Rockefeller University Coller, Barry 1 114110374 Coller, Barry The Rockefeller University Coller, Barry 1 114110369 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114110370 Jiang, Jiankang National Human Genome Research Institute (NHGRI) NCATS Jiang, Jiankang (NCATS) 0 114110371 McCoy, Joshua Office of Research Services (ORS) McCoy, Joshua 0 114110372 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114110373 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114102604 Small Molecule Inhibitors Of Alpha IIb Beta 3 Receptor For Potential Therapeutic Intervention Within Myocardial Infarction And Stroke E-074-2012-0 Filing authorized NCATS - NCGC, The Rockefeller University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke&body=Please send me information about technology [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke&body=Please send me information about technology [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke.">rebecca.erwin-cohen@nih.gov</a><br> 114169239 E-074-2012-0 E-074-2012-0-US-01 Organic Compounds PRV US 61/587,030 Abandoned US <br />Provisional (PRV) 61/587,030<br />Filed on 2012-01-16<br />Status: Abandoned 114169240 E-074-2012-0 E-074-2012-0-PCT-02 Organic Compounds PCT Patent Cooperation Treaty PCT/US2013/021749 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/021749<br />Filed on 2013-01-16<br />Status: Expired 114169241 E-074-2012-0 E-074-2012-0-US-08 7-(PIPERAZIN-1-YL)-5H-[1,3,4]THIADIAZOLO[3,2-A]PYRIMIDIN-5-ONES FOR THE TREATMENT OF THROMBOTIC DISORDERS National Stage US 9,303,044 14/372,488 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9303044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9303044">9,303,044</a><br />Filed on 2014-07-16<br />Status: Issued 114128576 VDXXXX 114128577 VPXXXX 114128578 WIXXXX 114128579 WKXXXX 114152587 Small 114152588 MOLECULE 114152589 Inhibitors 114152590 ALPHA 114152591 IIb 114152592 Beta 114152593 3 114152594 RECEPTOR 114152595 Potential 114152596 therapeutic 114152597 INTERVENTION 114152598 MYOCARDIAL 114152599 infarction 114152600 STROKE 114152601 Listed LPM Nguyen-Antczak as of 4/15/2015 114152602 Pre LPM working set 20150418 114152603 Post LPM Assignment Set 20150420 TAB-3486 114097351 Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva NCATS Neurology, Oncology, Research Materials, Therapeutics Neurology Oncology Research Materials Therapeutics Xiuli Huang, Arthur Lee, John McKew, Paresma Patel, Philip Sanderson, Paul Yu, Wei Zheng This technology includes the use of a new class of molecules (nanomolar ALK2 inhibitor) to impede bone morphogenetic proteins (BMP) signaling for the treatment of Fibrodysplasia ossificans progressiva (FOP). FOP is a rare disease, characterized by malformation of the great (big) toes during embryonic development. Individuals with FOP have identical heterozygous activating mutation (R206H) in the gene encoding ACRV1 (also known as ALK2), a BMP type 1 receptor. This compound was created by replacing a quinoline moeity with a naphthalene moeity which gave rise to a class of molecules that are not susceptible to aldehyde oxidase (AO) metabolism, a major pathway for quinoline-containing molecules. Elimination of this metabolic pathway can have major benefits, such as increased systemic exposure, prevention of potential toxic effects of quinoline metabolites, and avoiding inter-subject variability based on AO polymorphism. This therapy is derived from a new, distinct class of compounds and would benefit those suffering from this disorder where there is currently no effective treatment available. A nanomolar ALK2 inhibitor could conceivably be used as prophylactic, acute, or chronic therapy for patients with FOP. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-23 1receptors, 5-a]pyrimidine, BMP, Derivatives, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, Naphthalene-containing, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Pyrazolo[1, SELECTIVE, TYPE, VCXXXX, VEXXXX, WIXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172643 Yu P, Deng D, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ [PMID 19029982] <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/ [PMID 19029982]">Yu P, Deng D, et al.</a> 114172644 Hao J, Ho J, et al. https://pubmed.ncbi.nlm.nih.gov/20020776 <a href="https://pubmed.ncbi.nlm.nih.gov/20020776">Hao J, Ho J, et al.</a> 114172645 Cuny G, Yu P, et al. https://pubmed.ncbi.nlm.nih.gov/18621530 <a href="https://pubmed.ncbi.nlm.nih.gov/18621530">Cuny G, Yu P, et al.</a> 114110356 McKew, John NCATS - TRND McKew, John 0 114110357 Patel, Paresma NCATS - TRND FDA Patel, Paresma (FDA) 0 114110358 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110359 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110360 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110361 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114110355 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110355 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110356 McKew, John NCATS - TRND McKew, John 0 114110357 Patel, Paresma NCATS - TRND FDA Patel, Paresma (FDA) 0 114110358 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110359 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110360 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110361 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114102601 Naphthalene-containing Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of BMP Type 1receptors E-208-2014-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva.">jasmine.kalsi@nih.gov</a><br> 114169232 E-208-2014-0 E-208-2014-0-US-01 Naphthalene-containing Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of BMP Type 1receptors PRV US 62/024,870 Abandoned US <br />Provisional (PRV) 62/024,870<br />Filed on 2014-07-15<br />Status: Abandoned 114169233 E-208-2014-0 E-208-2014-0-PCT-02 Compositions and Methods for Inhibiting BMP PCT Patent Cooperation Treaty PCT/US2015/040366 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/040366<br />Filed on 2015-07-14<br />Status: Expired 114169234 E-208-2014-0 E-208-2014-0-US-03 Compositions and Methods for Inhibiting BMP National Stage US 10,513,521 15/326,262 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10513521 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10513521">10,513,521</a><br />Filed on 2015-07-14<br />Status: Issued 114128568 WIXXXX 114128569 WKXXXX 114128570 YAXXXX 114128571 YBXXXX 114128889 VCXXXX 114128890 VEXXXX 114128891 XEXXXX 114152544 Naphthalene-containing 114152545 Pyrazolo[1 114152546 5-a]pyrimidine 114152547 Derivatives 114152548 SELECTIVE 114152549 Inhibitors 114152550 BMP 114152551 TYPE 114152552 1receptors 114152553 Listed LPM Nguyen-Antczak as of 4/15/2015 114152554 Pre LPM working set 20150418 114152555 Post LPM Assignment Set 20150420 TAB-3485 114097350 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Gregory Cuny, Arthur Lee, Agustin Mohedas, Paul Yu This technology includes the use of a new class of molecules (nanomolar ALK2 inhibitor) to impede bone morphogenetic proteins (BMP) signaling for the treatment of Fibrodysplasia ossificans progressiva (FOP). FOP is a rare disease, characterized by malformation of the great (big) toes during embryonic development. Individuals with FOP have an identical heterozygous activating mutation (R206H) in the gene encoding ACRV1 (also known as ALK2), a BMP type 1 receptor. This compound was created by replacing a quinoline moiety with a naphthalene moiety which gave rise to a class of molecules that are not susceptible to aldehyde oxidase (AO) metabolism, a major pathway for quinoline-containing molecules. Elimination of this metabolic pathway can have major benefits, such as increased systemic exposure, prevention of potential toxic effects of quinoline metabolites, and avoiding inter-subject variability based on AO polymorphism. This therapy is derived from a new, distinct class of compounds and would benefit those suffering from this disorder where there is currently no effective treatment available. A nanomolar ALK2 inhibitor to be used as a prophylactic, acute or chronic therapy for patients with FOP. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-22 2-SUBSTITUTED, BMP, INHIBITING, Listed LPM Nguyen-Antczak as of 4/15/2015, Methods, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PYRIDINES, SIGNALING, Their, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172639 Yu P, Deng D, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/">Yu P, Deng D, et al.</a> 114172640 Hao J, Ho J, et al. https://pubmed.ncbi.nlm.nih.gov/20020776 <a href="https://pubmed.ncbi.nlm.nih.gov/20020776">Hao J, Ho J, et al.</a> 114172641 Cuny G, Yu P, et al. https://pubmed.ncbi.nlm.nih.gov/18621530 <a href="https://pubmed.ncbi.nlm.nih.gov/18621530">Cuny G, Yu P, et al.</a> 114172642 Sanvitale C, Kerr G, et al. https://pubmed.ncbi.nlm.nih.gov/23646137 [PMID 23646137] <a href="https://pubmed.ncbi.nlm.nih.gov/23646137 [PMID 23646137]">Sanvitale C, Kerr G, et al.</a> 114110352 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110353 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110354 Mohedas, Agustin Massachusetts General Hospital Mohedas, Agustin 0 114110351 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110351 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110352 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110353 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110354 Mohedas, Agustin Massachusetts General Hospital Mohedas, Agustin 0 114102600 2-substituted Pyridines And Their Methods For Inhibiting BMP Signaling E-018-2015-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva.">jasmine.kalsi@nih.gov</a><br> 114169228 E-018-2015-0 E-018-2015-0-US-01 2-substituted Pyridines And Their Methods For Inhibiting BMP Signaling PRV US 62/058,377 Abandoned US <br />Provisional (PRV) 62/058,377<br />Filed on 2014-10-01<br />Status: Abandoned 114169229 E-018-2015-0 E-018-2015-0-PCT-02 COMPOSITIONS AND METHODS FOR INHIBITING BMP PCT Patent Cooperation Treaty PCT/US2015/053545 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/053545<br />Filed on 2015-10-01<br />Status: Expired 114169230 E-018-2015-0 E-018-2015-0-US-05 Compositions and Methods for Inhibiting BMP National Stage US 15/516,273 Abandoned US <br />National Stage 15/516,273<br />Filed on 2017-03-31<br />Status: Abandoned 114128564 VPXXXX 114128565 WKXXXX 114128566 WIXXXX 114128567 XEXXXX 114152534 2-SUBSTITUTED 114152535 PYRIDINES 114152536 Their 114152537 Methods 114152538 INHIBITING 114152539 BMP 114152540 SIGNALING 114152541 Listed LPM Nguyen-Antczak as of 4/15/2015 114152542 Pre LPM working set 20150418 114152543 Post LPM Assignment Set 20150420 TAB-3482 114097347 Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection NIAID Collaboration Collaboration Zhaochun Chen, Patrizia Farci, Paolo Lusso, Kamille West, Peng Zhang The ongoing COVID-19 pandemic, caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an immense public health, social, and economic burden. Variants of concern continue to emerge that have increased transmissibility, pathogenicity, or both and that reduce the effectiveness of current therapeutics and vaccines. Thus, there is a great need for broadly protective therapeutics.<br /><br /> This technology relates to two monoclonal antibodies targeting the spike protein of SARS-CoV-2 that between the two have picomolar activity against wild-type SARS-CoV-2 and the Alpha, Beta, Delta, and Omicron variants of concern. Additionally, one of the antibodies recognizes a highly-conserved epitope of the spike protein. Treatment with either monoclonal antibody before or after challenge with SARS-CoV-2 reduced symptoms and viral load in nasal turbinate and lung tissue in the golden Syrian hamster model. This monoclonal antibody technology has great potential to treat SARS-CoV-2 infections and may provide protection against future variants of concern.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. <ul> <li>Broad and potent neutralization of several variants of concern, including Omicron</li> </ul> <ul> <li>Treatment for SARS-CoV-2 infection</li> <li>Prophylaxis treatment to prevent or reduce SARS-CoV-2 infection</li> <li>Diagnostic for SARS-CoV-2 infection</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts, Ph.D., 240-669-5299; <a href="mailto:elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a>. 2022-04-21 2025-08-13 2025-08-15 2022-04-21 2022-02-28 antibodies, Cure, Disease, monoclonal, Prevent, SARS-CoV-2 False True True NIHTT 37470483 Website Abstract 114110337 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 0 114110338 West, Kamille Clinical Center (CC) CC West, Kamille (CC) 0 114110339 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 0 114110340 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 0 114110336 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114110336 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114110337 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 0 114110338 West, Kamille Clinical Center (CC) CC West, Kamille (CC) 0 114110339 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 0 114110340 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 0 114102597 Monoclonal Antibodies Specific For SARS-CoV-2 Spike Protein And Uses Thereof E-132-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC), Clinical Center (CC), NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection.">maryann.puglielli@nih.gov</a><br> 114169223 E-132-2021-0 E-132-2021-0-US-01_82723 Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein and Uses Thereof PRV US 63/296,380 Expired US <br />Provisional (PRV) 63/296,380<br />Filed on 2022-01-04<br />Status: Expired 114152517 antibodies 114152518 monoclonal 114152519 Prevent 114152520 Cure 114152521 SARS-CoV-2 114152522 Disease TAB-3479 114097345 A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies CC Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Research Materials Cardiology Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Research Materials Thomas Bulea, Diane Damiano, Andrew Gravunder, Ami Mankodi This invention relates to two devices that reliably, sensitively, and accurately measures force during handgrip contraction and subsequent relaxation. A delayed relaxation after a sustained and forceful handgrip is a cardinal symptom of myotonic dystrophies (DM). This delayed relaxation, handgrip myotonia, may be a therapeutic response biomarker in clinical trials. <br /><br /> The Hand Clasp Load Cell Device is an assembly of an upper piece to be held between the fingers and palm and a lower palmar piece embedded with force sensing transducers to measure grip strength and relaxation time. The accompanying software automates clinical assessment of hand strength and relaxation time, displays grip force in real-time and synchronizes data with verbal commands to also quantify reaction time. The Myotonia Relaxation Actuator consists of a servo-motor connected to a lever designed to track finger movements in addition to force measurements. Interactive software supports data collection, real-time synchronization, as well as a display of the force measurements and finger positions during handgrip and relaxation. <ul> <li>The combination of affordability, ease of use, and accuracy in measuring force during handgrip is unique in the market.</li> <li>The integrated software that automates clinical assessment of handgrip myotonia is also a unique feature.</li> <li>Portable set up is adaptable to any table surface and requires only a USB connection to any laptop and renders device attractive for a larger range of clinical settings.</li> </ul> The device can be used as a: <ul> <li>clinical assessment tool to quantify hand function biomarkers. The continuous force measurements may permit the assessment of other neurological disorders</li> <li>research device to affordably and accurately quantify grip force, thumb kinematics, and electromyography</li> </ul> <br /><br /> The real-time tracking of this device and associated software could be used in a virtual environment to be used in rehabilitation and non-medical fields. 2022-07-29 2025-08-13 2025-08-15 2022-02-08 Devices, Handgrip, MECHANICAL, Relaxometer, VEXXXX, VPXXXX, WBXXXX, WIXXXX, XCXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114172635 Moxley, RT, Logigian EL, et al. https://pubmed.ncbi.nlm.nih.gov/17587223/ <a href="https://pubmed.ncbi.nlm.nih.gov/17587223/">Moxley, RT, Logigian EL, et al.</a> 114110323 Gravunder, Andrew Clinical Center (CC) Gravunder, Andrew 0 114110324 Bulea, Thomas Clinical Center (CC) CC Bulea, Thomas (CC) 0 114110325 Damiano, Diane Clinical Center (CC) CC Damiano, Diane (CC) 0 114110322 Mankodi, Ami NINDS NINDS Mankodi, Ami (NINDS) 1 114110322 Mankodi, Ami NINDS NINDS Mankodi, Ami (NINDS) 1 114110323 Gravunder, Andrew Clinical Center (CC) Gravunder, Andrew 0 114110324 Bulea, Thomas Clinical Center (CC) CC Bulea, Thomas (CC) 0 114110325 Damiano, Diane Clinical Center (CC) CC Damiano, Diane (CC) 0 114102590 Handgrip Relaxometer Devices E-001-2019-1 Filing authorized Clinical Center (CC), NINDS 91828331 Beka, Lidia lidia.beka@nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies&body=Please send me information about technology [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies. Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies&body=Please send me information about technology [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies.">lidia.beka@nih.gov</a><br> 114169213 E-001-2019-1 E-001-2019-1-PCT-01 HANDGRIP RELAXOMETER SYSTEM PCT COMB Patent Cooperation Treaty PCT/US2020/018273 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/018273<br />Filed on 2020-02-14<br />Status: Expired 114169608 E-001-2019-1 E-001-2019-1-US-02 HANDGRIP RELAXOMETER SYSTEM National Stage US 17/430,891 Pending US <br />National Stage 17/430,891<br />Filed on 2021-08-13<br />Status: Pending 114128545 VEXXXX 114128546 VPXXXX 114128547 WBXXXX 114128548 WIXXXX 114128549 XCXXXX 114128550 XDXXXX 114152486 Handgrip 114152487 Relaxometer 114152488 Devices 114152489 MECHANICAL TAB-3473 114097338 A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells NCATS Neurology, Research Equipment, Research Materials Neurology Research Equipment Research Materials Vukasin Jovanovic, Anton Simeonov, Ilyas Singec This technology includes a robust and highly efficient protocol that differentiates induced pluripotent stem cells (iPSCs) exclusively into nociceptors (also called sensory neurons) under chemically defined conditions. The use of hPSCs, including hESCs and iPSCs, holds great promise for disease modeling, drug discovery, and cell therapy. However, efficient and highly reproducible protocols have not been developed for most cell types that are relevant and urgently needed for translational applications. Systematic testing of various cell culture conditions and simultaneous manipulation of specific cell signaling pathways has led to the ability to directly induce astrogliogenesis from iPSCs with over 95% efficiency in less than 30 days. These cells displayed astrocyte morphologies and expressed typical astrocyte markers such as GFAP, NF-IA, and S100-B. The protocol included in this technology is the most efficient and reproducible astrocyte differentiation protocol for human pluripotent stem cells. The protocol included in this invention will permit increased in vitro use of human astrocytes for basic research, drug discovery, disease modeling, and cell therapy. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 ASTROCYTE, Cells, DIFFERENTIATION, Efficient, Highly, Human, Pluripotent, PROTOCOL, Stem, VEXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract E-060-2019-0 E-022-2018-0 E-169-2019-0 114172631 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110301 Jovanovic, Vukasin NCATS - NCGC NCATS Jovanovic, Vukasin (NCATS) 0 114110302 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110300 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110300 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110301 Jovanovic, Vukasin NCATS - NCGC NCATS Jovanovic, Vukasin (NCATS) 0 114110302 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102588 A Highly Efficient Astrocyte Differentiation Protocol For Human Pluripotent Stem Cells E-168-2019-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells.">ami.gadhia@nih.gov</a><br> 114169209 E-168-2019-0 E-168-2019-0-US-01 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PRV US 62/979,429 Abandoned US <br />Provisional (PRV) 62/979,429<br />Filed on 2020-02-21<br />Status: Abandoned 114169210 E-168-2019-0 E-168-2019-0-PCT-02 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PCT Patent Cooperation Treaty PCT/US2021/018659 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/018659<br />Filed on 2021-02-19<br />Status: Expired 114169609 E-168-2019-0 E-168-2019-0-US-07 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS National Stage US 17/796,044 Pending US <br />National Stage 17/796,044<br />Filed on 2022-07-28<br />Status: Pending 114128521 VEXXXX 114128522 WIXXXX 114128523 XHXXXX 114152431 Highly 114152432 Efficient 114152433 ASTROCYTE 114152434 DIFFERENTIATION 114152435 PROTOCOL 114152436 Human 114152437 Pluripotent 114152438 Stem 114152439 Cells TAB-3472 114097337 A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells NCATS Neurology, Research Equipment, Research Materials Neurology Research Equipment Research Materials Tao Deng, Anton Simeonov, Ilyas Singec This technology includes a robust and highly efficient protocol that differentiates human pluripotent stem cells (hPSCs) exclusively into nociceptors (also called sensory neurons) under chemically defined conditions. The use of hPSCs, including hESCs and iPSCs, holds great promise for drug screening, disease modeling, toxicology, and regenerative medicine. However, efficient and highly reproducible protocols have not been developed for most cell types that are relevant and urgently needed for translational applications. Systematic testing of various cell culture conditions and simultaneous manipulation of specific cell signaling pathways allows the scalable production of large numbers of nociceptors, including the use of automated cell culture systems. The protocol included in this technology is the most efficient and reproducible nociceptor differentiation protocol for human pluripotent stem cells. The protocol included in this invention will permit increased in vitro work with human nocireceptors in areas such as pain and addiction research. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 Cells, DIFFERENTIATION, Efficient, Highly, Human, Nociceptor, Pluripotent, PROTOCOL, Stem, VEXXXX, VMXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract E-022-2018-0 E-168-2019-0 E-169-2019-0 114172629 Jayakar S, Shim J, et al. https://pubmed.ncbi.nlm.nih.gov/34757806/ <a href="https://pubmed.ncbi.nlm.nih.gov/34757806/">Jayakar S, Shim J, et al.</a> 114172632 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110298 Deng, Tao NCATS - NCGC NCATS Deng, Tao (NCATS) 0 114110299 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110297 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110297 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110298 Deng, Tao NCATS - NCGC NCATS Deng, Tao (NCATS) 0 114110299 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102587 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells E-060-2019-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells.">ami.gadhia@nih.gov</a><br> 114169207 E-060-2019-0 E-060-2019-0-US-01 ANOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PRV US 62/837,891 Abandoned US <br />Provisional (PRV) 62/837,891<br />Filed on 2019-04-24<br />Status: Abandoned 114169208 E-060-2019-0 E-060-2019-0-PCT-02 NOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PCT Patent Cooperation Treaty PCT/US2020/029721 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/029721<br />Filed on 2020-04-24<br />Status: Expired 114169547 E-060-2019-0 E-060-2019-0-US-03 NOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS National Stage US 17/605,876 Pending US <br />National Stage 17/605,876<br />Filed on 2021-10-22<br />Status: Pending 114128517 VEXXXX 114128518 VMXXXX 114128519 WIXXXX 114128520 XHXXXX 114152422 Highly 114152423 Efficient 114152424 Nociceptor 114152425 DIFFERENTIATION 114152426 PROTOCOL 114152427 Human 114152428 Pluripotent 114152429 Stem 114152430 Cells TAB-3471 114097336 Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Yu Chen, Anton Simeonov, Ilyas Singec This technology includes the use of the combination of the compounds Chroman-1 and Emricasan to achieve virtually 100% cell survival during human pluripotent stem cell passaging, cryopreservation/thawing, and differentiation in 2D and 3D cultures. Human pluripotent stem cells, including ESCs and iPSCs, are highly sensitive cells and undergo apoptosis during these routine procedures. A screening approach was used to identify the combination of the two compounds in this invention. The compounds allow dosing at a relatively low concentration, thus providing a cheaper iPSC growth media, stress-free environment, and minimization of off-target effects. The combination of the compounds Chroman-1 and Emricasan permit a higher cell survival rate for pluripotent and differentiating cells compared to commonly used procedures. This invention will significantly improve quality assurance, characterization, and application of pluripotent stem cells in both pre-clinical and clinical settings. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 Cell, Cells, Chroman-1, COMBINING, DIFFERENTIATION, Emricasan, Human, Improved, MOLECULES, Pluripotent, Small, Stem, SURVIVAL, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract E-060-2019-0 E-168-2019-0 E-169-2019-0 114172627 Watanabe K, Ueno M, et al. https://pubmed.ncbi.nlm.nih.gov/17529971/ <a href="https://pubmed.ncbi.nlm.nih.gov/17529971/">Watanabe K, Ueno M, et al.</a> 114172633 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110295 Chen, Yu NCATS - TRND NHGRI Chen, Yu (NHGRI) 0 114110296 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110294 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110294 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110295 Chen, Yu NCATS - TRND NHGRI Chen, Yu (NHGRI) 0 114110296 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102586 Improved Cell Survival And Differentiation Of Human Pluripotent Stem Cells By Combining Small Molecules Chroman-1 And Emricasan E-022-2018-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan&body=Please send me information about technology [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan&body=Please send me information about technology [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan.">ami.gadhia@nih.gov</a><br> 114169204 E-022-2018-0 E-022-2018-0-US-01 Improved Cell Survival And Differentiation Of Human Pluripotent Stem Cells By Combining Small Molecules Chroman-1 And Emricasan PRV US 62/744,395 Abandoned US <br />Provisional (PRV) 62/744,395<br />Filed on 2018-10-11<br />Status: Abandoned 114169205 E-022-2018-0 E-022-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR CELL CULTURE PCT Patent Cooperation Treaty PCT/US2019/055940 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/055940<br />Filed on 2019-10-11<br />Status: Expired 114169206 E-022-2018-0 E-022-2018-0-US-03 COMPOSITIONS AND METHODS FOR CELL CULTURE National Stage US 17/284,215 Pending US <br />National Stage 17/284,215<br />Filed on 2021-04-09<br />Status: Pending 114128515 VPXXXX 114128516 WIXXXX 114152409 Improved 114152410 Cell 114152411 SURVIVAL 114152412 DIFFERENTIATION 114152413 Human 114152414 Pluripotent 114152415 Stem 114152416 Cells 114152417 COMBINING 114152418 Small 114152419 MOLECULES 114152420 Chroman-1 114152421 Emricasan TAB-3469 114097334 Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Wei Zheng This technology includes the identification and use of a combination therapy consisting of human recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and the pharmacological chaperone compounds Ezetimibe and Pranlukast for the treatment of Mucopolysaccharidosis Type IVA (MPS IVA). MPS IVA is a rare disease caused by mutations in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Currently, hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are available for patients with MPS IVA. This technology includes the combinatorial use of hrGALNS and pharmacological chaperon compounds Ezetimibe and Pranlukast that have been found to have an additive/synergistic effect in reducing enlarged lysosomes in MPS IVA patient cells. The pharmacological chaperone compounds Ezetimibe and Pranlukast increase the activity of hrGALNS by a directly binding to it and stabilizing the protein structure. Therefore, these chaperone compounds can reduce the dose of hrGALNS needed for ERT when the two are used in a combination therapy. Further clinical work with the combination of hrGALNS and chaperones Ezetimibe and Pranlukast could establish these compounds as a treatment for Mucopolysaccharidosis Type IVA. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 CHAPERONES, Combination, hrGALNS, Human, IVA, Methods, Mucopolysaccharidosis, Nacetylgalactosamine6-sulfatase, PHARMACOLOGICAL, recombinant, THERAPY, treatment, TYPE, VPXXXX, WIXXXX, WJXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract E-032-2021-0 114110287 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110287 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114102584 Methods Of Combination Therapy For Treatment Of Mucopolysaccharidosis Type IVA Using Human Recombinant Nacetylgalactosamine 6-sulfatase (hrGALNS) And Pharmacological Chaperones E-229-2020-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA&body=Please send me information about technology [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA&body=Please send me information about technology [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA.">jasmine.kalsi@nih.gov</a><br> 114169549 E-229-2020-0 E-229-2020-0-PCT-02 Methods Of Combination Therapy For Treatment Of Mucopolysaccharidosis Type IVA Using Human Recombinant Nacetylgalactosamine 6-sulfatase (hrGALNS) And Pharmacological Chaperones PCT Patent Cooperation Treaty PCT/IB2021/055134 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2021/055134<br />Filed on 2021-06-10<br />Status: Expired 114128508 VPXXXX 114128509 WIXXXX 114128510 WJXXXX 114128511 WKXXXX 114152392 Methods 114152393 Combination 114152394 THERAPY 114152395 treatment 114152396 Mucopolysaccharidosis 114152397 TYPE 114152398 IVA 114152399 Human 114152400 recombinant 114152401 Nacetylgalactosamine6-sulfatase 114152402 hrGALNS 114152403 PHARMACOLOGICAL 114152404 CHAPERONES TAB-3468 114097333 Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection NCATS Infectious Disease, Licensing, Research Materials, Therapeutics Infectious Disease Licensing Research Materials Therapeutics Catherine Chen, Xin Hu, Wenwei Huang, Pranav Shah, Khalida Shamim, Amy Wang, Xin Xu, Wei Zheng This technology includes the identification and use of niclosamide analogs and prodrugs for the treatment of SARS-CoV-2 infection. In-vitro studies have found niclosamide, an old anthelminthic drug, to be potent and effective against Covid-19. But the broad antiviral effect of niclosamide is offset by the low solubility of the drug, leading to poor oral absorption. The niclosamide analogs and prodrugs included in this technology have better in vitro physicochemical properties. Also, these analogs were comparable to niclosamide in the in-vitro 3D models of SARS-CoV-2 infection. Pharmacokinetic studies of a prodrug conducted in mice and hamsters has shown better absorbtion of the active niclosamide, with higher concentrations of niclosamide in both plasma and lungs (the primary site of COVID-19 disease manifestation). The oral bio-availability of niclosamide is greatly enhanced with this prodrug. Despite poor solubility, niclosamide is showing promise for the treatment of COVID-19. The niclosamide analogs and prodrug included in this technology have increased solubility and oral absorption, making them suitable for further studies. Further clinical work could establish the niclosamide analogs and prodrug as new treatments for SARS-CoV-2 infection. 2022-03-08 2025-08-13 2025-08-15 2022-02-15 2022-02-04 Analogs, APPLICATION, INFECTIONS, Inhibitors, MOLECULE, Niclosamide, Pro-drugs, SARS-CoV-2, Small, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172628 Shamim K, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/33689873/ <a href="https://pubmed.ncbi.nlm.nih.gov/33689873/">Shamim K, Xu M, et al.</a> 114110280 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110281 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110282 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110283 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110284 Wang, Amy NCATS - TRND NCATS Wang, Amy (NCATS) 0 114110285 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110286 Shah, Pranav NCATS - TRND NCATS Shah, Pranav (NCATS) 0 114110279 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110279 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110280 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110281 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110282 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110283 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110284 Wang, Amy NCATS - TRND NCATS Wang, Amy (NCATS) 0 114110285 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110286 Shah, Pranav NCATS - TRND NCATS Shah, Pranav (NCATS) 0 114102583 Application Of Niclosamide Analogs And Pro-drugs As Small Molecule Inhibitors Of SARS-CoV-2 Infections E-234-2020-0 Filing authorized Florida State University, Florida State University College of Medicine, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169197 E-234-2020-0 E-234-2020-0-US-01 Small Molecule Inhibitors of SARS-CoV-2 PRV US 63/115,288 Abandoned US <br />Provisional (PRV) 63/115,288<br />Filed on 2020-11-18<br />Status: Abandoned 114169224 E-234-2020-0 E-234-2020-0-PCT-02 Small Molecule Inhibitors of Sars-Cov-2 Infections PCT Patent Cooperation Treaty PCT/US2021/059910 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059910<br />Filed on 2021-11-18<br />Status: Expired 114128505 VLXXXX 114128506 WKXXXX 114128507 WIXXXX 114152368 APPLICATION 114152384 Niclosamide 114152385 Analogs 114152386 Pro-drugs 114152387 Small 114152388 MOLECULE 114152389 Inhibitors 114152390 SARS-CoV-2 114152391 INFECTIONS TAB-3454 114097324 Mononegavirales Vectors Expressing Chimeric Antigens NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV—previously known as pneumonia virus of mice, PVM—of family Pneumovirida e) as a vaccine vector expressing the RSV fusion protein F, the most important protective antigen of RSV. MPV is not a human pathogen and is not restricted by immunity to common human viruses. MPV replicates in the superficial epithelial cells of the respiratory mucosa and is expected to be attenuated in humans based on the strong host range restriction observed in non-human primates. To generate these MPV/RSV vector vaccine candidates, the RSV F ORF was codon optimized, placed under the control of MPV transcription signals, and inserted at the first (rMPV-F1), third (rMPV29 F3), or fourth (rMPV-F4) gene position of a version of the MPV genome that contained a codon-pair optimized L polymerase gene. The recovered viruses replicated in vitro as efficiently as the empty vector, with stable expression of RSV F protein. Replication and immunogenicity of rMPV-F1 and rMPV-F3 were evaluated in rhesus macaques following administration by the combined intranasal and intratracheal routes. Both viruses replicated at low levels in the upper and lower respiratory tract, maintained stable RSV F expression, and induced similarly high levels of RSV-neutralizing serum antibodies that reached peak titers by fourteen (14) days post-vaccination. Thus, rMPV provides a highly attenuated yet immunogenic vector for the expression of RSV F protein, with potential application in RSV-naïve and RSV-experienced populations. RSV F was expressed in the wild-type form, but can readily be engineered to be stabilized in the highly immunogenic prefusion form, as has been done with parainfluenza virus vectors.<br /><br /> The invention relates to live, chimeric non-human Mononegavirales vectors that allow a cell to express at least one protein from at least one human pathogen as well as compositions comprising the vectors, methods and kits for eliciting an immune response in a host, and methods of making the vectors.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Multivalent live attenuated vaccines</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-496-2644; <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2021-07-15 Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus False True True NIHTT 37470483 Website Abstract 114110255 Brock, Linda NIAID - DIR NIAID Brock, Linda (NIAID) 0 114110256 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110257 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110254 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 1 114110254 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 1 114110255 Brock, Linda NIAID - DIR NIAID Brock, Linda (NIAID) 0 114110256 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110257 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114102574 Murine Pneumonia Virus (MPV) Expressing The Fusion F Protein Of Human Respiratory Syncytial Virus (RSV) From An Added Gene In Highly Attenuated And Immunogenic In Rhesus Macaques E-018-2018-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens&body=Please send me information about technology [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens&body=Please send me information about technology [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens.">ganelinaa@niaid.nih.gov</a><br> 114169142 E-018-2018-0 E-018-2018-0-US-01 CHIMERIC VECTORS PRV US 62/661,320 Abandoned US <br />Provisional (PRV) 62/661,320<br />Filed on 2018-04-23<br />Status: Abandoned 114169143 E-018-2018-0 E-018-2018-0-PCT-02 CHIMERIC VECTORS PCT Patent Cooperation Treaty PCT/US2019/028771 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/028771<br />Filed on 2019-04-23<br />Status: Expired 114169144 E-018-2018-0 E-018-2018-0-US-12 CHIMERIC VECTORS National Stage US 12,071,632 17/049,916 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071632 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071632">12,071,632</a><br />Filed on 2020-10-22<br />Status: Issued 114128481 DXXXXX 114128482 DCXXXX 114128483 DC5XXX 114128484 DC5BXX 114128485 DDXXXX 114128486 DD1XXX 114128487 DA4XXX 114128488 DA4BXX 114128489 DEXXXX 114152258 Murine 114152259 PNEUMONIA 114152260 virus 114152261 MPV 114152262 Expressing 114152263 Fusion 114152264 F 114152265 Protein 114152266 Human 114152267 respiratory 114152268 Syncytial 114152269 RSV 114152270 Added 114152271 Gene